DDI-MedLine.d78.s1.p0	fluoroquinolones	group	_	antibiotics	group	_	false	the druga are a rapidly growing class of drugb with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria .
DDI-MedLine.d80.s1.p1	progestin-only oral contraceptives	group	_	norgestrel	drug	_	false	in order to provide information for the appropriate package insert labeling of druga -lcb- drugn -rcb- in the us , a comprehensive review was made of drugb -lcb- # mg -rcb- and drugn -lcb- # mg -rcb- , with the clinical differences indicated where applicable .
DDI-MedLine.d80.s1.p2	progestin-only oral contraceptives	group	_	norethindrone	drug	_	false	in order to provide information for the appropriate package insert labeling of druga -lcb- drugn -rcb- in the us , a comprehensive review was made of drugn -lcb- # mg -rcb- and drugb -lcb- # mg -rcb- , with the clinical differences indicated where applicable .
DDI-MedLine.d80.s1.p3	POC	group	_	norgestrel	drug	_	false	in order to provide information for the appropriate package insert labeling of drugn -lcb- druga -rcb- in the us , a comprehensive review was made of drugb -lcb- # mg -rcb- and drugn -lcb- # mg -rcb- , with the clinical differences indicated where applicable .
DDI-MedLine.d80.s1.p4	POC	group	_	norethindrone	drug	_	false	in order to provide information for the appropriate package insert labeling of drugn -lcb- druga -rcb- in the us , a comprehensive review was made of drugn -lcb- # mg -rcb- and drugb -lcb- # mg -rcb- , with the clinical differences indicated where applicable .
DDI-MedLine.d80.s1.p5	norgestrel	drug	_	norethindrone	drug	_	false	in order to provide information for the appropriate package insert labeling of drugn -lcb- drugn -rcb- in the us , a comprehensive review was made of druga -lcb- # mg -rcb- and drugb -lcb- # mg -rcb- , with the clinical differences indicated where applicable .
DDI-MedLine.d84.s0.p0	Ganoderma lucidum extract	drug_n	_	antibiotics	group	_	false	antimicrobial activity of druga alone and in combination with some drugb .
DDI-MedLine.d84.s3.p0	GL	drug_n	_	antibiotics	group	_	false	to investigate the effects of antimicrobial combinations of druga with four kinds of drugb -lcb- drugn , drugn , drugn and drugn -rcb- , the fractional inhibitory concentration index -lcb- fici -rcb- was determined by checkerboard assay for each strain .
DDI-MedLine.d84.s3.p1	GL	drug_n	_	ampicillin	drug	_	false	to investigate the effects of antimicrobial combinations of druga with four kinds of drugn -lcb- drugb , drugn , drugn and drugn -rcb- , the fractional inhibitory concentration index -lcb- fici -rcb- was determined by checkerboard assay for each strain .
DDI-MedLine.d84.s3.p2	GL	drug_n	_	cefazolin	drug	_	false	to investigate the effects of antimicrobial combinations of druga with four kinds of drugn -lcb- drugn , drugb , drugn and drugn -rcb- , the fractional inhibitory concentration index -lcb- fici -rcb- was determined by checkerboard assay for each strain .
DDI-MedLine.d84.s3.p3	GL	drug_n	_	oxytetracycline	drug	_	false	to investigate the effects of antimicrobial combinations of druga with four kinds of drugn -lcb- drugn , drugn , drugb and drugn -rcb- , the fractional inhibitory concentration index -lcb- fici -rcb- was determined by checkerboard assay for each strain .
DDI-MedLine.d84.s3.p4	GL	drug_n	_	chloramphenicol	drug	_	false	to investigate the effects of antimicrobial combinations of druga with four kinds of drugn -lcb- drugn , drugn , drugn and drugb -rcb- , the fractional inhibitory concentration index -lcb- fici -rcb- was determined by checkerboard assay for each strain .
DDI-MedLine.d84.s4.p0	GL	drug_n	_	antibiotics	group	_	effect	the antimicrobial combinations of druga with four drugb resulted in additive effect in most instances , synergism in two instances , and antagonism in two instances .
DDI-MedLine.d84.s5.p0	GL	drug_n	_	cefazolin	drug	_	effect	synergism was observed when druga was combined with drugb against bacillus subtilis and klebsiella oxytoca .
DDI-MedLine.d13.s7.p0	amphetamine	drug	_	heroin	drug_n	_	false	on the basis of the estimated number of regular users of intravenous druga in ontario , the mortality rate in such users is at least four times as high as in the general population of the same age , and is comparable to that in alcoholics and drugb addicts .
DDI-MedLine.d13.s8.p0	alcohol	drug	_	amphetamine	drug	_	false	however , the absolute number of druga - related deaths is far greater than the number of deaths in drugb or drugn users .
DDI-MedLine.d13.s8.p1	alcohol	drug	_	heroin	drug_n	_	false	however , the absolute number of druga - related deaths is far greater than the number of deaths in drugn or drugb users .
DDI-MedLine.d13.s8.p2	amphetamine	drug	_	heroin	drug_n	_	false	however , the absolute number of drugn - related deaths is far greater than the number of deaths in druga or drugb users .
DDI-MedLine.d69.s0.p0	contortrostatin	drug_n	_	echistatin	drug_n	_	false	differential regulation of tyrosine phosphorylation in tumor cells by druga , a homodimeric disintegrin , and monomeric disintegrins drugb and drugn .
DDI-MedLine.d69.s0.p1	contortrostatin	drug_n	_	flavoridin	drug_n	_	false	differential regulation of tyrosine phosphorylation in tumor cells by druga , a homodimeric disintegrin , and monomeric disintegrins drugn and drugb .
DDI-MedLine.d69.s0.p2	echistatin	drug_n	_	flavoridin	drug_n	_	false	differential regulation of tyrosine phosphorylation in tumor cells by drugn , a homodimeric disintegrin , and monomeric disintegrins druga and drugb .
DDI-MedLine.d69.s1.p0	contortrostatin	drug_n	_	echistatin	drug_n	_	false	the homodimeric disintegrin druga was compared directly to the monomeric disintegrins drugb and drugn for the ability to affect protein tyrosine phosphorylation in tumor cells .
DDI-MedLine.d69.s1.p1	contortrostatin	drug_n	_	flavoridin	drug_n	_	false	the homodimeric disintegrin druga was compared directly to the monomeric disintegrins drugn and drugb for the ability to affect protein tyrosine phosphorylation in tumor cells .
DDI-MedLine.d69.s1.p2	echistatin	drug_n	_	flavoridin	drug_n	_	false	the homodimeric disintegrin drugn was compared directly to the monomeric disintegrins druga and drugb for the ability to affect protein tyrosine phosphorylation in tumor cells .
DDI-MedLine.d69.s3.p0	Echistatin	drug_n	_	contortrostatin	drug_n	_	effect	druga alone had no effect on tyrosine phosphorylation in t24 cells , but dose-dependently inhibits the effects of drugb when both are added simultaneously .
DDI-MedLine.d69.s5.p0	Flavoridin	drug_n	_	contortrostatin	drug_n	_	effect	druga alone was found to have no effect on cas , but can completely block drugb - induced phosphorylation of this protein in mda-mb-435 cells .
DDI-MedLine.d48.s3.p0	Diethyl pyrocarbonate	drug_n	_	toxin A	drug_n	_	false	druga , at ph # , was used to chemically modify exposed histidine residues on drugb .
DDI-MedLine.d48.s4.p0	toxin A	drug_n	_	diethyl pyrocarbonate	drug_n	_	false	modification of druga with drugb abolished both its cytotoxic activity and the ability of the toxin to bind zn-sepharose gel .
DDI-MedLine.d48.s5.p0	toxin A	drug_n	_	diethyl pyrocarbonate	drug_n	_	false	treatment of druga with -lsb- -lcb- 14 -rcb- c -rsb- - drugb revealed concentration dependent labelling of histidine residues on the toxin molecules .
DDI-MedLine.d48.s6.p0	diethyl pyrocarbonate	drug_n	_	hydroxylamine	drug_n	_	false	the effects of druga could be reversed by drugb treatment .
DDI-MedLine.d48.s11.p0	toxin A	drug_n	_	zinc	drug	_	false	exposed histidines on druga are available for drugb chelation , and these have been exploited in the development of a novel purification protocol for drugn using drugn - chelating chromatography .
DDI-MedLine.d48.s11.p2	toxin A	drug_n	_	zinc	drug	_	false	exposed histidines on druga are available for drugn chelation , and these have been exploited in the development of a novel purification protocol for drugn using drugb - chelating chromatography .
DDI-MedLine.d48.s11.p3	zinc	drug	_	toxin A	drug_n	_	false	exposed histidines on drugn are available for druga chelation , and these have been exploited in the development of a novel purification protocol for drugb using drugn - chelating chromatography .
DDI-MedLine.d48.s11.p5	toxin A	drug_n	_	zinc	drug	_	false	exposed histidines on drugn are available for drugn chelation , and these have been exploited in the development of a novel purification protocol for druga using drugb - chelating chromatography .
DDI-MedLine.d18.s0.p0	budesonide	drug	_	Survanta	brand	_	false	note : dissolution of aerosol particles of druga in drugb , a model drugn .
DDI-MedLine.d18.s0.p1	budesonide	drug	_	lung surfactant	group	_	false	note : dissolution of aerosol particles of druga in drugn , a model drugb .
DDI-MedLine.d18.s0.p2	Survanta	brand	_	lung surfactant	group	_	false	note : dissolution of aerosol particles of drugn in druga , a model drugb .
DDI-MedLine.d18.s1.p0	pulmonary surfactant	group	_	Survanta	brand	_	false	the effect of a druga extract from bovine lung , drugb , on the dissolution rate of aerosol particles of drugn was determined .
DDI-MedLine.d18.s1.p1	pulmonary surfactant	group	_	budesonide	drug	_	false	the effect of a druga extract from bovine lung , drugn , on the dissolution rate of aerosol particles of drugb was determined .
DDI-MedLine.d18.s1.p2	Survanta	brand	_	budesonide	drug	_	false	the effect of a drugn extract from bovine lung , druga , on the dissolution rate of aerosol particles of drugb was determined .
DDI-MedLine.d18.s2.p0	budesonide	drug	_	ethanol	drug	_	false	aerosol particles of druga were generated from an drugb solution , dried , and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments .
DDI-MedLine.d18.s6.p0	Survanta	brand	_	budesonide	drug	_	false	druga increased the extent of dissolution of drugb in proportion to the added concentration , which was also verified by equilibrium solubilization studies .
DDI-MedLine.d18.s7.p0	Survanta	brand	_	sodium dodecyl sulfate	drug_n	_	false	druga also increased rate of dissolution , in a manner similar to drugb .
DDI-MedLine.d18.s8.p1	budesonide	drug	_	Survanta	brand	_	false	analysis of the concentration of druga following ultracentrifugation indicated that there is rapid equilibration of drugn between the drugb and aqueous phase .
DDI-MedLine.d18.s8.p2	budesonide	drug	_	Survanta	brand	_	false	analysis of the concentration of drugn following ultracentrifugation indicated that there is rapid equilibration of druga between the drugb and aqueous phase .
DDI-MedLine.d62.s4.p0	METH	drug	_	SCH-23390	drug_n	_	effect	using in situ hybridization , we observed that druga caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist drugb but not by an drugn drugn .
DDI-MedLine.d62.s4.p1	METH	drug	_	atypical neuroleptic	group	_	false	using in situ hybridization , we observed that druga caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist drugn but not by an drugb drugn .
DDI-MedLine.d62.s4.p2	METH	drug	_	clozapine	drug	_	false	using in situ hybridization , we observed that druga caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist drugn but not by an drugn drugb .
DDI-MedLine.d62.s4.p3	SCH-23390	drug_n	_	atypical neuroleptic	group	_	false	using in situ hybridization , we observed that drugn caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist druga but not by an drugb drugn .
DDI-MedLine.d62.s4.p4	SCH-23390	drug_n	_	clozapine	drug	_	false	using in situ hybridization , we observed that drugn caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist druga but not by an drugn drugb .
DDI-MedLine.d62.s4.p5	atypical neuroleptic	group	_	clozapine	drug	_	false	using in situ hybridization , we observed that drugn caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist drugn but not by an druga drugb .
DDI-MedLine.d104.s0.p0	DCG-IV	drug_n	_	L-CCG-1	drug_n	_	false	the effects of druga and drugb upon drugn -lcb- drugn -rcb- - induced locomotion and behavioral changes in mice .
DDI-MedLine.d104.s0.p1	DCG-IV	drug_n	_	phencyclidine	drug_n	_	false	the effects of druga and drugn upon drugb -lcb- drugn -rcb- - induced locomotion and behavioral changes in mice .
DDI-MedLine.d104.s0.p2	DCG-IV	drug_n	_	PCP	drug_n	_	false	the effects of druga and drugn upon drugn -lcb- drugb -rcb- - induced locomotion and behavioral changes in mice .
DDI-MedLine.d104.s0.p3	L-CCG-1	drug_n	_	phencyclidine	drug_n	_	false	the effects of drugn and druga upon drugb -lcb- drugn -rcb- - induced locomotion and behavioral changes in mice .
DDI-MedLine.d104.s0.p4	L-CCG-1	drug_n	_	PCP	drug_n	_	false	the effects of drugn and druga upon drugn -lcb- drugb -rcb- - induced locomotion and behavioral changes in mice .
DDI-MedLine.d104.s3.p0	DCG-IV	drug_n	_	L-CCG-1	drug_n	_	false	then , the effects of metabotropic glutamate receptor -lcb- mglur -rcb- agonists , druga and drugb , on the above behavioral changes induced by drugn were found .
DDI-MedLine.d104.s3.p1	DCG-IV	drug_n	_	PCP	drug_n	_	false	then , the effects of metabotropic glutamate receptor -lcb- mglur -rcb- agonists , druga and drugn , on the above behavioral changes induced by drugb were found .
DDI-MedLine.d104.s3.p2	L-CCG-1	drug_n	_	PCP	drug_n	_	false	then , the effects of metabotropic glutamate receptor -lcb- mglur -rcb- agonists , drugn and druga , on the above behavioral changes induced by drugb were found .
DDI-MedLine.d104.s4.p0	DCG-IV	drug_n	_	PCP	drug_n	_	effect	the effects of druga were very strong and completely depressed the drugb - induced hyperlocomotion .
DDI-MedLine.d98.s0.p0	cocaine	drug	_	pentobarbital	drug	_	false	behavioral responses to repeated druga exposure in mice selectively bred for differential sensitivity to drugb .
DDI-MedLine.d98.s1.p0	pentobarbital	drug	_	cocaine	drug	_	false	mice from the 20th generation of three lines divergently selected for response to druga - induced sedation times -lsb- long-sedation time -lcb- lst -rcb- , short sedation time -lcb- sst -rcb- , and randomly bred control -lcb- rbc -rcb- -rsb- were used to study drugb - induced behavioral sensitization .
DDI-MedLine.d110.s0.p1	18-Methoxycoronaridine	drug_n	_	ibogaine	drug_n	_	false	druga -lcb- drugn -rcb- and drugb : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .
DDI-MedLine.d110.s0.p2	18-MC	drug_n	_	ibogaine	drug_n	_	false	drugn -lcb- druga -rcb- and drugb : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .
DDI-MedLine.d110.s2.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	like druga -lcb- 40 mg/kg -rcb- , drugb -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p1	ibogaine	drug_n	_	morphine	drug	_	false	like druga -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugb and drugn and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p2	ibogaine	drug_n	_	cocaine	drug	_	false	like druga -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugb and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p3	ibogaine	drug_n	_	ethanol	drug	_	false	like druga -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of drugb and drugn in rats ;
DDI-MedLine.d110.s2.p4	ibogaine	drug_n	_	nicotine	drug	_	false	like druga -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of drugn and drugb in rats ;
DDI-MedLine.d110.s2.p5	18-MC	drug_n	_	morphine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , druga -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugb and drugn and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p6	18-MC	drug_n	_	cocaine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , druga -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugb and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p7	18-MC	drug_n	_	ethanol	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , druga -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of drugb and drugn in rats ;
DDI-MedLine.d110.s2.p8	18-MC	drug_n	_	nicotine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , druga -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of drugn and drugb in rats ;
DDI-MedLine.d110.s2.p9	morphine	drug	_	cocaine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of druga and drugb and the oral self-administration of drugn and drugn in rats ;
DDI-MedLine.d110.s2.p10	morphine	drug	_	ethanol	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of druga and drugn and the oral self-administration of drugb and drugn in rats ;
DDI-MedLine.d110.s2.p11	morphine	drug	_	nicotine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of druga and drugn and the oral self-administration of drugn and drugb in rats ;
DDI-MedLine.d110.s2.p12	cocaine	drug	_	ethanol	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and druga and the oral self-administration of drugb and drugn in rats ;
DDI-MedLine.d110.s2.p13	cocaine	drug	_	nicotine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and druga and the oral self-administration of drugn and drugb in rats ;
DDI-MedLine.d110.s2.p14	ethanol	drug	_	nicotine	drug	_	false	like drugn -lcb- 40 mg/kg -rcb- , drugn -lcb- 40 mg/kg -rcb- decreases the intravenous self-administration of drugn and drugn and the oral self-administration of druga and drugb in rats ;
DDI-MedLine.d110.s3.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	unlike druga , drugb does not affect responding for a nondrug reinforcer -lcb- water -rcb- .
DDI-MedLine.d110.s4.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	both druga and drugb ameliorate drugn withdrawal signs .
DDI-MedLine.d110.s4.p1	ibogaine	drug_n	_	opioid	group	_	false	both druga and drugn ameliorate drugb withdrawal signs .
DDI-MedLine.d110.s4.p2	18-MC	drug_n	_	opioid	group	_	false	both drugn and druga ameliorate drugb withdrawal signs .
DDI-MedLine.d110.s5.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	both druga and drugb decrease extracellular levels of dopamine in the nucleus accumbens , but only drugn increases extracellular levels of serotonin in the nucleus accumbens .
DDI-MedLine.d110.s5.p2	18-MC	drug_n	_	ibogaine	drug_n	_	false	both drugn and druga decrease extracellular levels of dopamine in the nucleus accumbens , but only drugb increases extracellular levels of serotonin in the nucleus accumbens .
DDI-MedLine.d110.s6.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	both druga and drugb block drugn - induced and drugn - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s6.p1	ibogaine	drug_n	_	morphine	drug	_	effect	both druga and drugn block drugb - induced and drugn - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s6.p2	ibogaine	drug_n	_	nicotine	drug	_	effect	both druga and drugn block drugn - induced and drugb - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s6.p3	18-MC	drug_n	_	morphine	drug	_	effect	both drugn and druga block drugb - induced and drugn - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s6.p4	18-MC	drug_n	_	nicotine	drug	_	effect	both drugn and druga block drugn - induced and drugb - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s6.p5	morphine	drug	_	nicotine	drug	_	false	both drugn and drugn block druga - induced and drugb - induced dopamine release in the nucleus accumbens ;
DDI-MedLine.d110.s7.p0	ibogaine	drug_n	_	cocaine	drug	_	effect	only druga enhances drugb - induced increases in accumbal dopamine .
DDI-MedLine.d110.s8.p0	ibogaine	drug_n	_	18-MC	drug_n	_	false	both druga and drugb enhance the locomotor and/or stereotypic effects of stimulants .
DDI-MedLine.d110.s9.p0	Ibogaine	drug_n	_	18-MC	drug_n	_	false	druga attenuates , but drugb potentiates , the acute locomotor effects of drugn ;
DDI-MedLine.d110.s9.p1	Ibogaine	drug_n	_	morphine	drug	_	effect	druga attenuates , but drugn potentiates , the acute locomotor effects of drugb ;
DDI-MedLine.d110.s9.p2	18-MC	drug_n	_	morphine	drug	_	effect	drugn attenuates , but druga potentiates , the acute locomotor effects of drugb ;
DDI-MedLine.d110.s13.p0	Ibogaine	drug_n	_	18-MC	drug_n	_	false	druga , but not drugb , decreases heart rate at high doses .
DDI-MedLine.d110.s14.p0	18-MC	drug_n	_	ibogaine	drug_n	_	false	while druga and drugb have similar affinities for kappa opioid and possibly nicotinic receptors , drugn has much lower affinities than drugn for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .
DDI-MedLine.d110.s14.p2	18-MC	drug_n	_	ibogaine	drug_n	_	false	while druga and drugn have similar affinities for kappa opioid and possibly nicotinic receptors , drugn has much lower affinities than drugb for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .
DDI-MedLine.d110.s14.p3	ibogaine	drug_n	_	18-MC	drug_n	_	false	while drugn and druga have similar affinities for kappa opioid and possibly nicotinic receptors , drugb has much lower affinities than drugn for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .
DDI-MedLine.d110.s14.p5	18-MC	drug_n	_	ibogaine	drug_n	_	false	while drugn and drugn have similar affinities for kappa opioid and possibly nicotinic receptors , druga has much lower affinities than drugb for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .
DDI-MedLine.d110.s15.p0	18-MC	drug_n	_	ibogaine	drug_n	_	false	both druga and drugb are sequestered in fat and , like drugn , drugn probably has an active metabolite .
DDI-MedLine.d110.s15.p1	18-MC	drug_n	_	ibogaine	drug_n	_	false	both druga and drugn are sequestered in fat and , like drugb , drugn probably has an active metabolite .
DDI-MedLine.d110.s15.p4	ibogaine	drug_n	_	18-MC	drug_n	_	false	both drugn and druga are sequestered in fat and , like drugn , drugb probably has an active metabolite .
DDI-MedLine.d110.s15.p5	ibogaine	drug_n	_	18-MC	drug_n	_	false	both drugn and drugn are sequestered in fat and , like druga , drugb probably has an active metabolite .
DDI-MedLine.d110.s16.p0	18-MC	drug_n	_	ibogaine	drug_n	_	false	the data suggest that druga has a narrower spectrum of actions and will have a substantially greater therapeutic index than drugb .
DDI-MedLine.d106.s0.p0	warfarin	drug	_	sedatives	group	_	int	clinical implications of druga interactions with five drugb .
DDI-MedLine.d106.s1.p0	anticoagulant	group	_	phenobarbital	drug	_	false	the intensity , uniformity and time course of druga interference by drugb , drugn , drugn , drugn and drugn were systematically investigated in # patients receiving drugn therapy .
DDI-MedLine.d106.s1.p1	anticoagulant	group	_	secobarbital	drug	_	false	the intensity , uniformity and time course of druga interference by drugn , drugb , drugn , drugn and drugn were systematically investigated in # patients receiving drugn therapy .
DDI-MedLine.d106.s1.p2	anticoagulant	group	_	glutethimide	drug	_	false	the intensity , uniformity and time course of druga interference by drugn , drugn , drugb , drugn and drugn were systematically investigated in # patients receiving drugn therapy .
DDI-MedLine.d106.s1.p3	anticoagulant	group	_	chloral hydrate	drug	_	false	the intensity , uniformity and time course of druga interference by drugn , drugn , drugn , drugb and drugn were systematically investigated in # patients receiving drugn therapy .
DDI-MedLine.d106.s1.p4	anticoagulant	group	_	methaqualone	drug	_	false	the intensity , uniformity and time course of druga interference by drugn , drugn , drugn , drugn and drugb were systematically investigated in # patients receiving drugn therapy .
DDI-MedLine.d106.s1.p5	anticoagulant	group	_	coumarin	group	_	false	the intensity , uniformity and time course of druga interference by drugn , drugn , drugn , drugn and drugn were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s1.p10	phenobarbital	drug	_	coumarin	group	_	false	the intensity , uniformity and time course of drugn interference by druga , drugn , drugn , drugn and drugn were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s1.p14	secobarbital	drug	_	coumarin	group	_	false	the intensity , uniformity and time course of drugn interference by drugn , druga , drugn , drugn and drugn were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s1.p17	glutethimide	drug	_	coumarin	group	_	false	the intensity , uniformity and time course of drugn interference by drugn , drugn , druga , drugn and drugn were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s1.p19	chloral hydrate	drug	_	coumarin	group	_	false	the intensity , uniformity and time course of drugn interference by drugn , drugn , drugn , druga and drugn were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s1.p20	methaqualone	drug	_	coumarin	group	_	false	the intensity , uniformity and time course of drugn interference by drugn , drugn , drugn , drugn and druga were systematically investigated in # patients receiving drugb therapy .
DDI-MedLine.d106.s5.p0	chloral hydrate	drug	_	methaqualone	drug	_	false	there was no significant change in prothrombin test results during the trials of druga and drugb .
DDI-MedLine.d106.s6.p0	Barbiturates	group	_	glutethimide	drug	_	false	druga and drugb should not be administered to patients receiving drugn .
DDI-MedLine.d106.s6.p1	Barbiturates	group	_	coumarin drugs	group	_	advise	druga and drugn should not be administered to patients receiving drugb .
DDI-MedLine.d106.s6.p2	glutethimide	drug	_	coumarin drugs	group	_	advise	drugn and druga should not be administered to patients receiving drugb .
DDI-MedLine.d106.s8.p0	Chloral hydrate	drug	_	methaqualone	drug	_	false	druga and drugb interact pharmacologically with orally administered drugn , but the effect is not clinically significant .
DDI-MedLine.d106.s8.p1	Chloral hydrate	drug	_	anticoagulant agents	group	_	int	druga and drugn interact pharmacologically with orally administered drugb , but the effect is not clinically significant .
DDI-MedLine.d106.s8.p2	methaqualone	drug	_	anticoagulant agents	group	_	int	drugn and druga interact pharmacologically with orally administered drugb , but the effect is not clinically significant .
DDI-MedLine.d106.s9.p0	chloral hydrate	drug	_	methaqualone	drug	_	false	it is concluded that druga and drugb may be administered safely without additional caution in prothrombin test monitoring during oral drugn therapy .
DDI-MedLine.d106.s9.p1	chloral hydrate	drug	_	anticoagulant	group	_	false	it is concluded that druga and drugn may be administered safely without additional caution in prothrombin test monitoring during oral drugb therapy .
DDI-MedLine.d106.s9.p2	methaqualone	drug	_	anticoagulant	group	_	false	it is concluded that drugn and druga may be administered safely without additional caution in prothrombin test monitoring during oral drugb therapy .
DDI-MedLine.d127.s6.p0	thiazide diuretics	group	_	digoxin	drug	_	false	concomitantly given druga did not interfere with the absorption of a tablet of drugb .
DDI-MedLine.d135.s0.p0	clozapine	drug	_	phencyclidine	drug_n	_	false	combinations of druga and drugb : effects on drug discrimination and behavioral inhibition in rats .
DDI-MedLine.d135.s3.p0	atypical antipsychotic	group	_	clozapine	drug	_	false	in the present study , the druga drugb was tested in combination with an active dose of drugn in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates -lcb- drl -rcb- procedures .
DDI-MedLine.d135.s3.p1	atypical antipsychotic	group	_	PCP	drug_n	_	false	in the present study , the druga drugn was tested in combination with an active dose of drugb in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates -lcb- drl -rcb- procedures .
DDI-MedLine.d135.s3.p2	clozapine	drug	_	PCP	drug_n	_	false	in the present study , the drugn druga was tested in combination with an active dose of drugb in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates -lcb- drl -rcb- procedures .
DDI-MedLine.d135.s5.p0	clozapine	drug	_	PCP	drug_n	_	false	acute dosing with druga failed to alter the behavioral effects of drugb in either procedure even when tested up to doses that produced pharmacological effects alone .
DDI-MedLine.d135.s6.p0	clozapine	drug	_	PCP	drug_n	_	false	these results suggest that acute dosing with druga would not affect behaviors most closely associated with drugb intoxication .
DDI-MedLine.d135.s8.p0	antipsychotics	group	_	PCP	drug_n	_	false	since chronic dosing is required for therapeutic efficacy of druga , future studies should focus on investigation of chronic dosing effects of these drugs in combination with drugb .
DDI-MedLine.d95.s4.p0	Resveratrol	drug_n	_	noradrenaline	drug	_	false	druga -lcb- 5-35 micromol/l -rcb- induced concentration-dependent relaxation of mesenteric arteries preconstricted with drugb -lcb- 8 micromol/l -rcb- or drugn -lcb- 125 mmol/l -rcb- from both lean and dietary-obese rats .
DDI-MedLine.d95.s4.p1	Resveratrol	drug_n	_	KCl	drug	_	false	druga -lcb- 5-35 micromol/l -rcb- induced concentration-dependent relaxation of mesenteric arteries preconstricted with drugn -lcb- 8 micromol/l -rcb- or drugb -lcb- 125 mmol/l -rcb- from both lean and dietary-obese rats .
DDI-MedLine.d95.s4.p2	noradrenaline	drug	_	KCl	drug	_	false	drugn -lcb- 5-35 micromol/l -rcb- induced concentration-dependent relaxation of mesenteric arteries preconstricted with druga -lcb- 8 micromol/l -rcb- or drugb -lcb- 125 mmol/l -rcb- from both lean and dietary-obese rats .
DDI-MedLine.d95.s6.p0	L-NAME	drug_n	_	reseveratrol	drug_n	_	false	however , druga -lcb- 100 and # micromol/l -rcb- did not alter the effects of drugb on arteries from dietary-obese rats , giving superimposed concentration-responses curves .
DDI-MedLine.d95.s7.p0	Indomethacin	drug	_	resveratrol	drug_n	_	false	druga was also ineffective in altering drugb activity in arteries from both lean and dietary-obese rats .
DDI-MedLine.d95.s8.p0	noradrenaline	drug	_	resveratrol	drug_n	_	false	in druga - precontracted arteries from dietary-obese rats , responses to drugb were not attenuated by endothelial denudation , indicating an action independent of the endothelium .
DDI-MedLine.d79.s0.p1	indinavir	drug	_	didanosine	drug	_	false	if taken # hour before druga -lcb- drugn -rcb- , drugb does not affect drugn exposure , despite persistent buffering effects .
DDI-MedLine.d79.s0.p2	indinavir	drug	_	IDV	drug	_	false	if taken # hour before druga -lcb- drugn -rcb- , drugn does not affect drugb exposure , despite persistent buffering effects .
DDI-MedLine.d79.s0.p3	IDV	drug	_	didanosine	drug	_	false	if taken # hour before drugn -lcb- druga -rcb- , drugb does not affect drugn exposure , despite persistent buffering effects .
DDI-MedLine.d79.s0.p5	didanosine	drug	_	IDV	drug	_	false	if taken # hour before drugn -lcb- drugn -rcb- , druga does not affect drugb exposure , despite persistent buffering effects .
DDI-MedLine.d79.s1.p0	indinavir	drug	_	didanosine	drug	_	mechanism	concurrent administration of druga and drugb significantly reduces the level of exposure to drugn , but it is unclear how soon after drugn administration drugn may be given safely .
DDI-MedLine.d79.s1.p2	indinavir	drug	_	didanosine	drug	_	false	concurrent administration of druga and drugn significantly reduces the level of exposure to drugn , but it is unclear how soon after drugb administration drugn may be given safely .
DDI-MedLine.d79.s1.p4	didanosine	drug	_	indinavir	drug	_	false	concurrent administration of drugn and druga significantly reduces the level of exposure to drugb , but it is unclear how soon after drugn administration drugn may be given safely .
DDI-MedLine.d79.s1.p6	didanosine	drug	_	indinavir	drug	_	false	concurrent administration of drugn and druga significantly reduces the level of exposure to drugn , but it is unclear how soon after drugn administration drugb may be given safely .
DDI-MedLine.d79.s1.p7	indinavir	drug	_	didanosine	drug	_	false	concurrent administration of drugn and drugn significantly reduces the level of exposure to druga , but it is unclear how soon after drugb administration drugn may be given safely .
DDI-MedLine.d79.s1.p9	didanosine	drug	_	indinavir	drug	_	false	concurrent administration of drugn and drugn significantly reduces the level of exposure to drugn , but it is unclear how soon after druga administration drugb may be given safely .
DDI-MedLine.d79.s2.p2	indinavir	drug	_	didanosine	drug	_	false	we compared druga pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of drugn alone versus # mg of drugn administered # h after drugb administration .
DDI-MedLine.d79.s2.p4	indinavir	drug	_	didanosine	drug	_	false	we compared drugn pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of druga alone versus # mg of drugn administered # h after drugb administration .
DDI-MedLine.d79.s2.p5	indinavir	drug	_	didanosine	drug	_	false	we compared drugn pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of drugn alone versus # mg of druga administered # h after drugb administration .
DDI-MedLine.d79.s3.p0	indinavir	drug	_	didanosine	drug	_	mechanism	median gastric ph was significantly higher when druga was taken after drugb administration ;
DDI-MedLine.d79.s5.p0	Indinavir	drug	_	didanosine	drug	_	advise	druga may be taken with a light meal # h following the administration of # mg of drugb .
DDI-MedLine.d59.s4.p0	Cytochalasin D	drug_n	_	carbachol	drug	_	effect	druga at # microm preferentially blocked the secretory effect of drugb and its synergism with camp , whereas it had no effect on histamine - or camp-stimulated acid secretion within # min .
DDI-MedLine.d59.s5.p0	Cytochalasin D	drug_n	_	carbachol	drug	_	effect	druga inhibited the drugb - stimulated intracellular ca -lcb- 2 + -rcb- concentration -lcb- -lsb- ca -lcb- 2 + -rcb- -rsb- -lcb- i -rcb- -rcb- increase due to release from the ca -lcb- 2 + -rcb- store .
DDI-MedLine.d75.s3.p0	mu-selective opioids	group	_	delta(1)-selective opioids	group	_	false	the percentage of neurons hyperpolarized by druga , drugb , and drugn was significantly reduced when 1 % but not <
DDI-MedLine.d133.s0.p0	verapamil	drug	_	bombesin	drug_n	_	effect	suppression by druga of drugb - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drugn in wistar rats .
DDI-MedLine.d133.s0.p1	verapamil	drug	_	azoxymethane	drug_n	_	false	suppression by druga of drugn - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drugb in wistar rats .
DDI-MedLine.d133.s0.p2	bombesin	drug_n	_	azoxymethane	drug_n	_	false	suppression by drugn of druga - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drugb in wistar rats .
DDI-MedLine.d133.s1.p0	bombesin	drug_n	_	verapamil hydrochloride	drug	_	false	background : the effects of combined administration of druga and drugb -lcb- drugn -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p1	bombesin	drug_n	_	verapamil	drug	_	false	background : the effects of combined administration of druga and drugn -lcb- drugb -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p2	bombesin	drug_n	_	calcium channel blocker	group	_	false	background : the effects of combined administration of druga and drugn -lcb- drugn -rcb- , a drugb , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p3	bombesin	drug_n	_	azoxymethane	drug_n	_	false	background : the effects of combined administration of druga and drugn -lcb- drugn -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugb -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p4	bombesin	drug_n	_	AOM	drug_n	_	false	background : the effects of combined administration of druga and drugn -lcb- drugn -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugb -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p6	verapamil hydrochloride	drug	_	calcium channel blocker	group	_	false	background : the effects of combined administration of drugn and druga -lcb- drugn -rcb- , a drugb , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p7	verapamil hydrochloride	drug	_	azoxymethane	drug_n	_	false	background : the effects of combined administration of drugn and druga -lcb- drugn -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugb -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p8	verapamil hydrochloride	drug	_	AOM	drug_n	_	false	background : the effects of combined administration of drugn and druga -lcb- drugn -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugb -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p9	verapamil	drug	_	calcium channel blocker	group	_	false	background : the effects of combined administration of drugn and drugn -lcb- druga -rcb- , a drugb , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p10	verapamil	drug	_	azoxymethane	drug_n	_	false	background : the effects of combined administration of drugn and drugn -lcb- druga -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugb -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p11	verapamil	drug	_	AOM	drug_n	_	false	background : the effects of combined administration of drugn and drugn -lcb- druga -rcb- , a drugn , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugb -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p12	calcium channel blocker	group	_	azoxymethane	drug_n	_	false	background : the effects of combined administration of drugn and drugn -lcb- drugn -rcb- , a druga , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugb -lcb- drugn -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s1.p13	calcium channel blocker	group	_	AOM	drug_n	_	false	background : the effects of combined administration of drugn and drugn -lcb- drugn -rcb- , a druga , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drugn -lcb- drugb -rcb- and the labeling index of intestinal_cancer were investigated in male wistar rats .
DDI-MedLine.d133.s2.p0	AOM	drug_n	_	bombesin	drug_n	_	false	methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of druga -lcb- # mg/kg body weight -rcb- and subcutaneous injections of drugb -lcb- 40 microg/kg body weight -rcb- every other day , and from week 16 , intraperitoneal injections of drugn -lcb- 10 or # mg/kg body weight -rcb- every other day until the end fo the experiment in week 45 .
DDI-MedLine.d133.s2.p1	AOM	drug_n	_	verapamil	drug	_	false	methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of druga -lcb- # mg/kg body weight -rcb- and subcutaneous injections of drugn -lcb- 40 microg/kg body weight -rcb- every other day , and from week 16 , intraperitoneal injections of drugb -lcb- 10 or # mg/kg body weight -rcb- every other day until the end fo the experiment in week 45 .
DDI-MedLine.d133.s2.p2	bombesin	drug_n	_	verapamil	drug	_	false	methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of drugn -lcb- # mg/kg body weight -rcb- and subcutaneous injections of druga -lcb- 40 microg/kg body weight -rcb- every other day , and from week 16 , intraperitoneal injections of drugb -lcb- 10 or # mg/kg body weight -rcb- every other day until the end fo the experiment in week 45 .
DDI-MedLine.d133.s4.p0	verapamil	drug	_	bombesin	drug_n	_	false	although druga administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by drugb or on the location , histologic type , depth of involvement , labeling index , apoptotic index or tumor vascularity of intestinal cancers , it significantly decreased the incidence of cancer metastasis .
DDI-MedLine.d133.s5.p0	Verapamil	drug	_	bombesin	drug_n	_	effect	druga also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by drugb .
DDI-MedLine.d17.s0.p0	prostaglandin F2alpha	drug	_	oxytocin	drug	_	int	in vitro interaction of druga and drugb in placental vessels .
DDI-MedLine.d17.s1.p0	prostaglandin F2alpha	drug	_	oxytocin	drug	_	false	the interaction of druga and synthetic drugb on placental vessels was studied in vitro .
DDI-MedLine.d17.s3.p0	norepinephrine	drug	_	oxytocin	drug	_	false	in seven experiments reactions to druga and drugb were drugn .
DDI-MedLine.d17.s3.p1	norepinephrine	drug	_	PGF2alpha	drug	_	false	in seven experiments reactions to druga and drugn were drugb .
DDI-MedLine.d17.s3.p2	oxytocin	drug	_	PGF2alpha	drug	_	false	in seven experiments reactions to drugn and druga were drugb .
DDI-MedLine.d17.s4.p0	PGF2alpha	drug	_	oxytocin	drug	_	effect	druga produced significantly increased vasoconstriction after a single administration of drugb .
DDI-MedLine.d17.s9.p0	PGF2alpha	drug	_	oxytocin	drug	_	effect	there is thus an enhancement effect of druga upon the reaction of placental vessels to drugb in vitro .
DDI-MedLine.d36.s0.p0	Carbamazepine	drug	_	tricyclic antidepressant	group	_	false	druga overdose recognized by a drugb assay .
DDI-MedLine.d36.s2.p0	carbamazepine	drug	_	tricyclic antidepressant	group	_	effect	we report the case of an adolescent with altered consciousness caused by druga overdose with a positive drugb level to alert clinicians to the cross-reactivity of drugn with a toxicology screen for drugn .
DDI-MedLine.d36.s2.p2	carbamazepine	drug	_	tricyclic antidepressants	group	_	false	we report the case of an adolescent with altered consciousness caused by druga overdose with a positive drugn level to alert clinicians to the cross-reactivity of drugn with a toxicology screen for drugb .
DDI-MedLine.d36.s2.p3	tricyclic antidepressant	group	_	carbamazepine	drug	_	false	we report the case of an adolescent with altered consciousness caused by drugn overdose with a positive druga level to alert clinicians to the cross-reactivity of drugb with a toxicology screen for drugn .
DDI-MedLine.d36.s2.p5	carbamazepine	drug	_	tricyclic antidepressants	group	_	advise	we report the case of an adolescent with altered consciousness caused by drugn overdose with a positive drugn level to alert clinicians to the cross-reactivity of druga with a toxicology screen for drugb .
DDI-MedLine.d126.s0.p0	Cypermethrin	drug	_	vitamin E	drug	_	effect	druga - induced oxidative stress in rat brain and liver is prevented by drugb or drugn .
DDI-MedLine.d126.s0.p1	Cypermethrin	drug	_	allopurinol	drug	_	effect	druga - induced oxidative stress in rat brain and liver is prevented by drugn or drugb .
DDI-MedLine.d126.s0.p2	vitamin E	drug	_	allopurinol	drug	_	false	drugn - induced oxidative stress in rat brain and liver is prevented by druga or drugb .
DDI-MedLine.d126.s1.p0	cypermethrin	drug	_	Type II pyrethroid	drug_n	_	false	considering that the involvement of reactive oxygen species -lcb- ros -rcb- has been implicated in the toxicity of various pesticides , this study was designed to investigate the possibility of oxidative stress induction by druga , a drugb .
DDI-MedLine.d126.s6.p0	allopurinol	drug	_	Vitamin E	drug	_	false	pretreatment of rats with druga -lcb- 100 mg/kg , ip -rcb- or drugb -lcb- 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day -rcb- provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral drugn administration within # h.
DDI-MedLine.d126.s6.p1	allopurinol	drug	_	cypermethrin	drug	_	effect	pretreatment of rats with druga -lcb- 100 mg/kg , ip -rcb- or drugn -lcb- 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day -rcb- provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral drugb administration within # h.
DDI-MedLine.d126.s6.p2	Vitamin E	drug	_	cypermethrin	drug	_	effect	pretreatment of rats with drugn -lcb- 100 mg/kg , ip -rcb- or druga -lcb- 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day -rcb- provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral drugb administration within # h.
DDI-MedLine.d126.s7.p0	cypermethrin	drug	_	allopurinol	drug	_	effect	thus , the results suggest that druga exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by drugb and drugn .
DDI-MedLine.d126.s7.p1	cypermethrin	drug	_	Vitamin E	drug	_	effect	thus , the results suggest that druga exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by drugn and drugb .
DDI-MedLine.d126.s7.p2	allopurinol	drug	_	Vitamin E	drug	_	false	thus , the results suggest that drugn exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by druga and drugb .
DDI-MedLine.d58.s3.p0	ginsenosides	drug_n	_	selective Ca(2+) channel blockers	group	_	false	in this study we investigated the effect of druga on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their drugb drugn -lcb- l-type -rcb- , drugn -lcb- n-type -rcb- , or drugn -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p1	ginsenosides	drug_n	_	nimodipine	drug	_	false	in this study we investigated the effect of druga on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their drugn drugb -lcb- l-type -rcb- , drugn -lcb- n-type -rcb- , or drugn -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p2	ginsenosides	drug_n	_	omega-conotoxin GVIA	drug_n	_	false	in this study we investigated the effect of druga on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their drugn drugn -lcb- l-type -rcb- , drugb -lcb- n-type -rcb- , or drugn -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p3	ginsenosides	drug_n	_	omega-agatoxin IVA	drug_n	_	false	in this study we investigated the effect of druga on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their drugn drugn -lcb- l-type -rcb- , drugn -lcb- n-type -rcb- , or drugb -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p4	selective Ca(2+) channel blockers	group	_	nimodipine	drug	_	false	in this study we investigated the effect of drugn on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their druga drugb -lcb- l-type -rcb- , drugn -lcb- n-type -rcb- , or drugn -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p5	selective Ca(2+) channel blockers	group	_	omega-conotoxin GVIA	drug_n	_	false	in this study we investigated the effect of drugn on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their druga drugn -lcb- l-type -rcb- , drugb -lcb- n-type -rcb- , or drugn -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s3.p6	selective Ca(2+) channel blockers	group	_	omega-agatoxin IVA	drug_n	_	false	in this study we investigated the effect of drugn on high threshold voltage-dependent ca -lcb- 2 + -rcb- channel subtypes using their druga drugn -lcb- l-type -rcb- , drugn -lcb- n-type -rcb- , or drugb -lcb- p-type -rcb- in bovine chromaffin cells .
DDI-MedLine.d58.s6.p0	Nimodipine	drug	_	ginsenosides	drug_n	_	false	druga had no effect on drugb response .
DDI-MedLine.d58.s7.p0	ginsenosides	drug_n	_	omega-conotoxin GVIA	drug_n	_	false	these data suggest that druga are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugb - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p1	ginsenosides	drug_n	_	omega-agatoxin IVA	drug_n	_	false	these data suggest that druga are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an drugb - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p2	ginsenosides	drug_n	_	nimodipine	drug	_	false	these data suggest that druga are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugb / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p3	ginsenosides	drug_n	_	omega-conotoxin GVIA	drug_n	_	false	these data suggest that druga are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugn / drugb / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p4	ginsenosides	drug_n	_	omega-agatoxin VIA	drug_n	_	false	these data suggest that druga are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugb - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p5	omega-conotoxin GVIA	drug_n	_	omega-agatoxin IVA	drug_n	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an druga - sensitive -lcb- n-type -rcb- channel , an drugb - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p6	omega-conotoxin GVIA	drug_n	_	nimodipine	drug	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an druga - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugb / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p8	omega-conotoxin GVIA	drug_n	_	omega-agatoxin VIA	drug_n	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an druga - sensitive -lcb- n-type -rcb- channel , an drugn - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugb - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p9	omega-agatoxin IVA	drug_n	_	nimodipine	drug	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an druga - sensitive -lcb- p-type -rcb- channel and drugb / drugn / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p10	omega-agatoxin IVA	drug_n	_	omega-conotoxin GVIA	drug_n	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an druga - sensitive -lcb- p-type -rcb- channel and drugn / drugb / drugn - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s7.p11	omega-agatoxin IVA	drug_n	_	omega-agatoxin VIA	drug_n	_	false	these data suggest that drugn are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an drugn - sensitive -lcb- n-type -rcb- channel , an druga - sensitive -lcb- p-type -rcb- channel and drugn / drugn / drugb - resistant -lcb- presumptive q-type -rcb- channel .
DDI-MedLine.d58.s8.p0	ginsenosides	drug_n	_	ginseng	drug	_	false	thus , the selective regulation of voltage-dependent ca -lcb- 2 + -rcb- subtypes by druga in bovine chromaffin cell could be the cellular basis of antistress effects induced by drugb .
DDI-MedLine.d8.s0.p0	KRM-1648	drug_n	_	ofloxacin	drug	_	false	in vitro activity of druga , either singly or in combination with drugb , against mycobacterium ulcerans .
DDI-MedLine.d8.s1.p0	benzoxazinorifamycin	drug_n	_	KRM-1648	drug_n	_	false	the antimicrobial effect of a druga , drugb , either alone or in combination with drugn , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .
DDI-MedLine.d8.s1.p1	benzoxazinorifamycin	drug_n	_	ofloxacin	drug	_	false	the antimicrobial effect of a druga , drugn , either alone or in combination with drugb , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .
DDI-MedLine.d8.s1.p2	KRM-1648	drug_n	_	ofloxacin	drug	_	false	the antimicrobial effect of a drugn , druga , either alone or in combination with drugb , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .
DDI-MedLine.d8.s5.p0	rifampicin	drug	_	rifabutin	drug	_	false	ulcerans was between # and # mg/l , while corresponding values for druga and drugb were in the range of ## mg/l and ## mg/l respectively .
DDI-MedLine.d8.s6.p0	ofloxacin	drug	_	KRM-1648	drug_n	_	effect	when combined with druga , drugb exhibited strong synergistic activity while only additive effects were observed with the combination of drugn -lcb- or drugn -rcb- and drugn .
DDI-MedLine.d8.s6.p1	ofloxacin	drug	_	rifampicin	drug	_	false	when combined with druga , drugn exhibited strong synergistic activity while only additive effects were observed with the combination of drugb -lcb- or drugn -rcb- and drugn .
DDI-MedLine.d8.s6.p2	ofloxacin	drug	_	rifabutin	drug	_	false	when combined with druga , drugn exhibited strong synergistic activity while only additive effects were observed with the combination of drugn -lcb- or drugb -rcb- and drugn .
DDI-MedLine.d8.s6.p4	KRM-1648	drug_n	_	rifampicin	drug	_	false	when combined with drugn , druga exhibited strong synergistic activity while only additive effects were observed with the combination of drugb -lcb- or drugn -rcb- and drugn .
DDI-MedLine.d8.s6.p5	KRM-1648	drug_n	_	rifabutin	drug	_	false	when combined with drugn , druga exhibited strong synergistic activity while only additive effects were observed with the combination of drugn -lcb- or drugb -rcb- and drugn .
DDI-MedLine.d8.s6.p6	KRM-1648	drug_n	_	ofloxacin	drug	_	false	when combined with drugn , druga exhibited strong synergistic activity while only additive effects were observed with the combination of drugn -lcb- or drugn -rcb- and drugb .
DDI-MedLine.d8.s6.p8	rifampicin	drug	_	ofloxacin	drug	_	effect	when combined with drugn , drugn exhibited strong synergistic activity while only additive effects were observed with the combination of druga -lcb- or drugn -rcb- and drugb .
DDI-MedLine.d8.s6.p9	rifabutin	drug	_	ofloxacin	drug	_	effect	when combined with drugn , drugn exhibited strong synergistic activity while only additive effects were observed with the combination of drugn -lcb- or druga -rcb- and drugb .
DDI-MedLine.d114.s1.p1	ruthenium red	drug_n	_	inositol 1,4,5-trisphosphate	drug_n	_	false	the effects of druga -lcb- drugn -rcb- on drugb -lcb- drugn -rcb- - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .
DDI-MedLine.d114.s1.p2	ruthenium red	drug_n	_	InsP(3)	drug_n	_	false	the effects of druga -lcb- drugn -rcb- on drugn -lcb- drugb -rcb- - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .
DDI-MedLine.d114.s1.p3	RR	drug_n	_	inositol 1,4,5-trisphosphate	drug_n	_	false	the effects of drugn -lcb- druga -rcb- on drugb -lcb- drugn -rcb- - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .
DDI-MedLine.d114.s1.p4	RR	drug_n	_	InsP(3)	drug_n	_	false	the effects of drugn -lcb- druga -rcb- on drugn -lcb- drugb -rcb- - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .
DDI-MedLine.d114.s3.p0	InsP(3)	drug_n	_	RR	drug_n	_	effect	administering druga together with drugb -lcb- 100-500 microm -rcb- inhibited insp -lcb- 3 -rcb- - induced responses -lcb- both ca -lcb- 2 + -rcb- and current responses -rcb- in a dose-dependent fashion .
DDI-MedLine.d114.s4.p0	RR	drug_n	_	InsP(3)	drug_n	_	effect	pretreatment of megakaryocytes with extracellular druga -lcb- 50 microm -rcb- also inhibited drugb - induced responses .
DDI-MedLine.d114.s6.p0	RR	drug_n	_	InsP(3)	drug_n	_	false	in contrast , in isolated single pancreatic acinar cells , druga had no effect on drugb - induced responses .
DDI-MedLine.d114.s8.p0	RR	drug_n	_	InsP(3)	drug_n	_	false	in addition , we have shown that druga is a useful pharmacological tool with which to examine the drugb - mediated responses of megakaryocytes .
DDI-MedLine.d109.s0.p0	rofecoxib	drug	_	digoxin	drug	_	false	effect of druga on the pharmacokinetics of drugb in healthy volunteers .
DDI-MedLine.d109.s1.p0	rofecoxib	drug	_	digoxin	drug	_	false	the authors examined the effect of the cyclooxygenase-2 -lcb- cox-2 -rcb- inhibitor , druga , at steady state on the pharmacokinetics of drugb following a single dose in healthy subjects .
DDI-MedLine.d109.s7.p0	digoxin	drug	_	rofecoxib	drug	_	false	for druga auc -lcb- 0-infinity -rcb- , auc -lcb- 0-24 -rcb- , and cmax , the geometric mean ratios -lcb- 90 % confidence interval -rcb- for -lcb- drugb + drugn / placebo + drugn -rcb- were # -lcb- # , # -rcb- , # -lcb- # , # -rcb- , and # -lcb- # , # -rcb- , respectively .
DDI-MedLine.d109.s7.p3	rofecoxib	drug	_	digoxin	drug	_	false	for drugn auc -lcb- 0-infinity -rcb- , auc -lcb- 0-24 -rcb- , and cmax , the geometric mean ratios -lcb- 90 % confidence interval -rcb- for -lcb- druga + drugb / placebo + drugn -rcb- were # -lcb- # , # -rcb- , # -lcb- # , # -rcb- , and # -lcb- # , # -rcb- , respectively .
DDI-MedLine.d109.s9.p0	rofecoxib	drug	_	digoxin	drug	_	false	the harmonic mean elimination half-life was # and # hours for druga + drugb and placebo + drugn treatments , respectively .
DDI-MedLine.d109.s9.p1	rofecoxib	drug	_	digoxin	drug	_	false	the harmonic mean elimination half-life was # and # hours for druga + drugn and placebo + drugb treatments , respectively .
DDI-MedLine.d109.s11.p0	digoxin	drug	_	rofecoxib	drug	_	false	the mean -lcb- sd -rcb- cumulative urinary excretion of immunoreactive druga after concurrent treatment with drugb or placebo was # -lcb- + / - # -rcb- and # -lcb- + / - # -rcb- micrograms/120 hours , respectively .
DDI-MedLine.d109.s13.p0	Rofecoxib	drug	_	digoxin	drug	_	false	druga did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of drugb .
DDI-MedLine.d115.s0.p2	cyclophosphamide	drug	_	prednisone	drug	_	false	concomitant druga , drugn , drugn , and drugb chemotherapy plus drugn therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p3	cyclophosphamide	drug	_	highly active antiretroviral	group	_	false	concomitant druga , drugn , drugn , and drugn chemotherapy plus drugb therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p5	doxorubicin	drug	_	prednisone	drug	_	false	concomitant drugn , druga , drugn , and drugb chemotherapy plus drugn therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p6	doxorubicin	drug	_	highly active antiretroviral	group	_	false	concomitant drugn , druga , drugn , and drugn chemotherapy plus drugb therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p7	vincristine	drug	_	prednisone	drug	_	false	concomitant drugn , drugn , druga , and drugb chemotherapy plus drugn therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p8	vincristine	drug	_	highly active antiretroviral	group	_	false	concomitant drugn , drugn , druga , and drugn chemotherapy plus drugb therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s0.p9	prednisone	drug	_	highly active antiretroviral	group	_	false	concomitant drugn , drugn , drugn , and druga chemotherapy plus drugb therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .
DDI-MedLine.d115.s2.p2	cyclophosphamide	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugb -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p4	cyclophosphamide	drug	_	doxorubicin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugb , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p5	cyclophosphamide	drug	_	teniposide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugb , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p6	cyclophosphamide	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugb with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p7	cyclophosphamide	drug	_	vincristine	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugb plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p8	cyclophosphamide	drug	_	bleomycin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugb -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p9	cyclophosphamide	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the druga , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p11	doxorubicin	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugb -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p12	doxorubicin	drug	_	cyclophosphamide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugb , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p14	doxorubicin	drug	_	teniposide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugb , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p15	doxorubicin	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugb with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p16	doxorubicin	drug	_	vincristine	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugb plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p17	doxorubicin	drug	_	bleomycin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugb -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p18	doxorubicin	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , druga , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p19	vincristine	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugb -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p20	vincristine	drug	_	cyclophosphamide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugb , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p21	vincristine	drug	_	doxorubicin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugb , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p22	vincristine	drug	_	teniposide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugb , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p23	vincristine	drug	_	prednisone	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugb with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p25	vincristine	drug	_	bleomycin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugb -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p26	vincristine	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , druga , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p27	prednisone	drug	_	cyclophosphamide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugb , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p28	prednisone	drug	_	doxorubicin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugb , drugn , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p29	prednisone	drug	_	teniposide	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugb , and drugn with drugn plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p31	prednisone	drug	_	vincristine	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugb plus drugn -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p32	prednisone	drug	_	bleomycin	drug	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugb -rcb- without receiving drugn therapy .
DDI-MedLine.d115.s2.p33	prednisone	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and druga -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p39	cyclophosphamide	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , druga , drugn , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p44	doxorubicin	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , druga , drugn , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p48	teniposide	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , druga , and drugn with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p51	prednisone	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and druga with drugn plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p53	vincristine	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with druga plus drugn -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s2.p54	bleomycin	drug	_	antiretroviral	group	_	false	to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma -lcb- hiv-nhl -rcb- , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the drugn , drugn , drugn , and drugn -lcb- chop -rcb- chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen -lcb- i , e , , drugn , drugn , drugn , and drugn with drugn plus druga -rcb- without receiving drugb therapy .
DDI-MedLine.d115.s5.p0	Antiretroviral	group	_	reverse transcriptase inhibitors	group	_	false	druga regimens consisted of two drugb and one drugn .
DDI-MedLine.d115.s5.p1	Antiretroviral	group	_	protease inhibitor	group	_	false	druga regimens consisted of two drugn and one drugb .
DDI-MedLine.d115.s5.p2	reverse transcriptase inhibitors	group	_	protease inhibitor	group	_	false	drugn regimens consisted of two druga and one drugb .
DDI-MedLine.d115.s14.p0	antiretroviral drugs	group	_	antineoplastic drugs	group	_	advise	however , careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between druga and drugb .
DDI-MedLine.d21.s2.p0	antidepressant drugs	group	_	hypoglycemic agents	group	_	int	treatment with druga can directly interfere with blood glucose levels or may interact with drugb .
DDI-MedLine.d21.s9.p0	Imipramine	drug	_	clonazepam	drug	_	false	druga and drugb did not change fasting or overload glycemia .
DDI-MedLine.d21.s10.p0	Fluoxetine	drug	_	moclobemide	drug	_	false	druga and drugb increased blood drugn at different times after the glucose overload .
DDI-MedLine.d21.s10.p1	Fluoxetine	drug	_	glucose	drug	_	false	druga and drugn increased blood drugb at different times after the glucose overload .
DDI-MedLine.d21.s10.p2	moclobemide	drug	_	glucose	drug	_	false	drugn and druga increased blood drugb at different times after the glucose overload .
DDI-MedLine.d21.s11.p0	Sertraline	drug	_	glucose	drug	_	false	druga neutralized the increase of glycemia induced by oral drugb overload .
DDI-MedLine.d21.s13.p0	sertraline	drug	_	glucose	drug	_	false	again , druga neutralized the increase in glycemia after drugb overload both in diabetic and non-diabetic rats .
DDI-MedLine.d47.s0.p0	buforin II	drug_n	_	azithromycin	drug	_	false	activity of druga alone and in combination with drugb and drugn against cryptosporidium parvum in cell culture .
DDI-MedLine.d47.s0.p1	buforin II	drug_n	_	minocycline	drug	_	false	activity of druga alone and in combination with drugn and drugb against cryptosporidium parvum in cell culture .
DDI-MedLine.d47.s0.p2	azithromycin	drug	_	minocycline	drug	_	false	activity of drugn alone and in combination with druga and drugb against cryptosporidium parvum in cell culture .
DDI-MedLine.d47.s1.p0	buforin II	drug_n	_	azithromycin	drug	_	false	the in vitro anti-cryptosporidial activity of druga alone and in combination with drugb and drugn was investigated .
DDI-MedLine.d47.s1.p1	buforin II	drug_n	_	minocycline	drug	_	false	the in vitro anti-cryptosporidial activity of druga alone and in combination with drugn and drugb was investigated .
DDI-MedLine.d47.s1.p2	azithromycin	drug	_	minocycline	drug	_	false	the in vitro anti-cryptosporidial activity of drugn alone and in combination with druga and drugb was investigated .
DDI-MedLine.d47.s3.p0	azithromycin	drug	_	minocycline	drug	_	false	moreover , its activity was enhanced when it was combined with either druga or drugb with 90 % parasite reduction at the highest concentration tested .
DDI-MedLine.d47.s4.p0	Buforin II	drug_n	_	azithromycin	drug	_	effect	druga may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either drugb or drugn .
DDI-MedLine.d47.s4.p1	Buforin II	drug_n	_	minocycline	drug	_	effect	druga may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either drugn or drugb .
DDI-MedLine.d47.s4.p2	azithromycin	drug	_	minocycline	drug	_	false	drugn may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either druga or drugb .
DDI-MedLine.d112.s0.p0	dofetillide	drug	_	digoxin	drug	_	false	effect of druga on the pharmacokinetics of drugb .
DDI-MedLine.d112.s1.p0	dofetilide	drug	_	digoxin	drug	_	false	the effect of druga on the steady-state pharmacokinetics of drugb was evaluated in a randomized , double-blind study .
DDI-MedLine.d112.s2.p0	dofetilide	drug	_	digoxin	drug	_	false	five days of druga treatment did not significantly affect steady-state pharmacokinetic variables of drugb compared with placebo ;
DDI-MedLine.d112.s3.p0	dofetilide	drug	_	digoxin	drug	_	false	therefore , the use of druga does not necessitate an adjustment in drugb dose to maintain therapeutic digoxin levels .
DDI-MedLine.d19.s4.p0	anticonvulsant agents	group	_	phenobarbitone	drug	_	false	numerous drug interactions are possible with some druga , such as drugb and drugn , which affect hepatic microsomal enzyme systems .
DDI-MedLine.d19.s4.p1	anticonvulsant agents	group	_	phenytoin	drug	_	false	numerous drug interactions are possible with some druga , such as drugn and drugb , which affect hepatic microsomal enzyme systems .
DDI-MedLine.d19.s4.p2	phenobarbitone	drug	_	phenytoin	drug	_	false	numerous drug interactions are possible with some drugn , such as druga and drugb , which affect hepatic microsomal enzyme systems .
DDI-MedLine.d16.s0.p0	ketamine	drug	_	halothane	drug	_	int	interaction of druga and drugb in rats .
DDI-MedLine.d16.s1.p0	ketamine	drug	_	halothane	drug	_	false	the interaction of intramuscularly injected druga and its n-demethylated metabolite -lcb- metabolite i -rcb- with drugb was evaluated in rats .
DDI-MedLine.d16.s3.p0	halothane	drug	_	ketamine	drug	_	mechanism	however , druga anesthetic requirement -lcb- i , e , , mac -rcb- was depressed in a dose-dependent fashion as much as 56 % 1-2 hours and as much as 14 % 5-6 hours after injection of drugb , # mg/kg , im .
DDI-MedLine.d16.s5.p0	ketamine	drug	_	halothane	drug	_	mechanism	the half-life of druga in plasma and brain was longer in the presence of drugb than when drugn was given alone .
DDI-MedLine.d16.s5.p2	halothane	drug	_	ketamine	drug	_	false	the half-life of drugn in plasma and brain was longer in the presence of druga than when drugb was given alone .
DDI-MedLine.d16.s6.p0	ketamine	drug	_	halothane	drug	_	effect	it is concluded that druga is not a short-acting drug and that concomitant use with drugb would be expected to prolong further the duration of its action on the central nervous system .
DDI-MedLine.d116.s0.p0	Rifampin	drug	_	warfarin	drug	_	int	druga and drugb : a drug interaction .
DDI-MedLine.d116.s1.p0	warfarin	drug	_	rifampin	drug	_	int	the drug interaction between druga and drugb is not well known .
DDI-MedLine.d116.s2.p0	Rifampin	drug	_	warfarin	drug	_	mechanism	druga has been reported to increase the drugb requirements in human subjects ingesting these agents simultaneously .
DDI-MedLine.d116.s3.p0	rifampin	drug	_	warfarin	drug	_	mechanism	the concomitant administration of druga and drugb resulted in the need for an unusually high maintenance dose of drugn -lcb- 20 mg per day -rcb- in order to produce a therapeutic effect .
DDI-MedLine.d116.s3.p1	rifampin	drug	_	warfarin	drug	_	false	the concomitant administration of druga and drugn resulted in the need for an unusually high maintenance dose of drugb -lcb- 20 mg per day -rcb- in order to produce a therapeutic effect .
DDI-MedLine.d116.s4.p0	rifampin	drug	_	warfarin	drug	_	mechanism	withdrawal of druga decreased the drugb requirement by 50 % .
DDI-MedLine.d116.s5.p0	rifampin	drug	_	warfarin	drug	_	mechanism	this effect may be mediated by the ability of druga to induce microsomal enzymes and , thus , the catabolism of drugb .
DDI-MedLine.d116.s6.p0	rifampin	drug	_	warfarin	drug	_	effect	the effect of druga on the drugb requirement of our patient appeared to be maximal # to # days after the initiation of drugn and extended a similar length of time after drugn withdrawal .
DDI-MedLine.d116.s6.p3	warfarin	drug	_	rifampin	drug	_	false	the effect of drugn on the druga requirement of our patient appeared to be maximal # to # days after the initiation of drugb and extended a similar length of time after drugn withdrawal .
DDI-MedLine.d116.s6.p4	warfarin	drug	_	rifampin	drug	_	false	the effect of drugn on the druga requirement of our patient appeared to be maximal # to # days after the initiation of drugn and extended a similar length of time after drugb withdrawal .
DDI-MedLine.d76.s1.p1	sodium carboxymethylcellulose	drug_n	_	carboxymethylcellulose-cysteine	drug_n	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugb -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p2	sodium carboxymethylcellulose	drug_n	_	CMC-Cys	drug_n	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugn -lcb- drugb -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p3	sodium carboxymethylcellulose	drug_n	_	sodium fluorescein	drug	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugb -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p4	sodium carboxymethylcellulose	drug_n	_	NaFlu	drug	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugb -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p5	sodium carboxymethylcellulose	drug_n	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p6	sodium carboxymethylcellulose	drug_n	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of druga -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p7	NaCMC	drug_n	_	carboxymethylcellulose-cysteine	drug_n	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugb -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p8	NaCMC	drug_n	_	CMC-Cys	drug_n	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugn -lcb- drugb -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p9	NaCMC	drug_n	_	sodium fluorescein	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugb -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p10	NaCMC	drug_n	_	NaFlu	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugb -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p11	NaCMC	drug_n	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p12	NaCMC	drug_n	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- druga -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p14	carboxymethylcellulose-cysteine	drug_n	_	sodium fluorescein	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and druga -lcb- drugn -rcb- conjugates on the intestinal permeation of drugb -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p15	carboxymethylcellulose-cysteine	drug_n	_	NaFlu	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and druga -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugb -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p16	carboxymethylcellulose-cysteine	drug_n	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and druga -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p17	carboxymethylcellulose-cysteine	drug_n	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and druga -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p18	CMC-Cys	drug_n	_	sodium fluorescein	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- druga -rcb- conjugates on the intestinal permeation of drugb -lcb- drugn -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p19	CMC-Cys	drug_n	_	NaFlu	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- druga -rcb- conjugates on the intestinal permeation of drugn -lcb- drugb -rcb- and model peptide drugs , drugn and drugn .
DDI-MedLine.d76.s1.p20	CMC-Cys	drug_n	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- druga -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p21	CMC-Cys	drug_n	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- druga -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p23	sodium fluorescein	drug	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of druga -lcb- drugn -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p24	sodium fluorescein	drug	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of druga -lcb- drugn -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p25	NaFlu	drug	_	bacitracin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- druga -rcb- and model peptide drugs , drugb and drugn .
DDI-MedLine.d76.s1.p26	NaFlu	drug	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- druga -rcb- and model peptide drugs , drugn and drugb .
DDI-MedLine.d76.s1.p27	bacitracin	drug	_	insulin	drug	_	false	the purpose of this study was to evaluate the effect of drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- conjugates on the intestinal permeation of drugn -lcb- drugn -rcb- and model peptide drugs , druga and drugb .
DDI-MedLine.d76.s2.p0	Cysteine	drug	_	NaCMC	drug_n	_	false	druga was covalently linked to carbodiimide activated drugb .
DDI-MedLine.d76.s5.p0	NaCMC	drug_n	_	NaFlu	drug	_	false	unmodified druga -lcb- 1 % m/v -rcb- significantly improved the transport ratio -lcb- r = p -lcb- app -rcb- polymer / p -lcb- app -rcb- control -rcb- of drugb to # and 1 % -lcb- m/v -rcb- drugn conjugated with drugn further enhanced the permeation .
DDI-MedLine.d76.s5.p2	NaCMC	drug_n	_	cysteine	drug	_	false	unmodified druga -lcb- 1 % m/v -rcb- significantly improved the transport ratio -lcb- r = p -lcb- app -rcb- polymer / p -lcb- app -rcb- control -rcb- of drugn to # and 1 % -lcb- m/v -rcb- drugn conjugated with drugb further enhanced the permeation .
DDI-MedLine.d76.s5.p3	NaFlu	drug	_	NaCMC	drug_n	_	false	unmodified drugn -lcb- 1 % m/v -rcb- significantly improved the transport ratio -lcb- r = p -lcb- app -rcb- polymer / p -lcb- app -rcb- control -rcb- of druga to # and 1 % -lcb- m/v -rcb- drugb conjugated with drugn further enhanced the permeation .
DDI-MedLine.d76.s5.p4	NaFlu	drug	_	cysteine	drug	_	false	unmodified drugn -lcb- 1 % m/v -rcb- significantly improved the transport ratio -lcb- r = p -lcb- app -rcb- polymer / p -lcb- app -rcb- control -rcb- of druga to # and 1 % -lcb- m/v -rcb- drugn conjugated with drugb further enhanced the permeation .
DDI-MedLine.d76.s5.p5	NaCMC	drug_n	_	cysteine	drug	_	false	unmodified drugn -lcb- 1 % m/v -rcb- significantly improved the transport ratio -lcb- r = p -lcb- app -rcb- polymer / p -lcb- app -rcb- control -rcb- of drugn to # and 1 % -lcb- m/v -rcb- druga conjugated with drugb further enhanced the permeation .
DDI-MedLine.d76.s7.p0	CMC-Cys	drug_n	_	cysteine	drug	_	false	decreasing the concentration of druga , exhibiting # % -lcb- m/m -rcb- of immobilised drugb -lcb- cmc-cys # -rcb- from 1 % -lcb- m/v -rcb- to # % -lcb- m/v -rcb- decreased the r-value of drugn from # to # .
DDI-MedLine.d76.s7.p1	CMC-Cys	drug_n	_	NaFlu	drug	_	false	decreasing the concentration of druga , exhibiting # % -lcb- m/m -rcb- of immobilised drugn -lcb- cmc-cys # -rcb- from 1 % -lcb- m/v -rcb- to # % -lcb- m/v -rcb- decreased the r-value of drugb from # to # .
DDI-MedLine.d76.s7.p2	cysteine	drug	_	NaFlu	drug	_	false	decreasing the concentration of drugn , exhibiting # % -lcb- m/m -rcb- of immobilised druga -lcb- cmc-cys # -rcb- from 1 % -lcb- m/v -rcb- to # % -lcb- m/v -rcb- decreased the r-value of drugb from # to # .
DDI-MedLine.d76.s8.p0	NaCMC	drug_n	_	cysteine	drug	_	false	druga at 1 % -lcb- m/v -rcb- in the presence of free drugb had no significant effect on the r-value of drugn compared to drugn alone .
DDI-MedLine.d76.s8.p1	NaCMC	drug_n	_	NaFlu	drug	_	false	druga at 1 % -lcb- m/v -rcb- in the presence of free drugn had no significant effect on the r-value of drugb compared to drugn alone .
DDI-MedLine.d76.s8.p3	cysteine	drug	_	NaFlu	drug	_	false	drugn at 1 % -lcb- m/v -rcb- in the presence of free druga had no significant effect on the r-value of drugb compared to drugn alone .
DDI-MedLine.d76.s8.p4	cysteine	drug	_	NaCMC	drug_n	_	false	drugn at 1 % -lcb- m/v -rcb- in the presence of free druga had no significant effect on the r-value of drugn compared to drugb alone .
DDI-MedLine.d76.s8.p5	NaFlu	drug	_	NaCMC	drug_n	_	false	drugn at 1 % -lcb- m/v -rcb- in the presence of free drugn had no significant effect on the r-value of druga compared to drugb alone .
DDI-MedLine.d76.s9.p0	bacitracin	drug	_	insulin	drug	_	false	formulation of fluorescence labelled druga and drugb in unconjugated drugn -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugn # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s9.p1	bacitracin	drug	_	NaCMC	drug_n	_	false	formulation of fluorescence labelled druga and drugn in unconjugated drugb -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugn # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s9.p2	bacitracin	drug	_	CMC-Cys	drug_n	_	false	formulation of fluorescence labelled druga and drugn in unconjugated drugn -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugb # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s9.p3	insulin	drug	_	NaCMC	drug_n	_	false	formulation of fluorescence labelled drugn and druga in unconjugated drugb -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugn # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s9.p4	insulin	drug	_	CMC-Cys	drug_n	_	false	formulation of fluorescence labelled drugn and druga in unconjugated drugn -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugb # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s9.p5	NaCMC	drug_n	_	CMC-Cys	drug_n	_	false	formulation of fluorescence labelled drugn and drugn in unconjugated druga -lcb- 1 % m/v -rcb- did not significantly improve the permeation , however in the presence of 1 % -lcb- m/v -rcb- drugb # a significantly improved permeation was observed -lcb- r = # -rcb- .
DDI-MedLine.d76.s10.p0	NaCMC	drug_n	_	cysteine	drug	_	false	conjugation at druga with drugb moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs drugn and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p1	NaCMC	drug_n	_	NaFlu	drug	_	false	conjugation at druga with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule drugb and the model peptide drugs drugn and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p2	NaCMC	drug_n	_	bacitracin	drug	_	false	conjugation at druga with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs drugb and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p3	NaCMC	drug_n	_	insulin	drug	_	false	conjugation at druga with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs drugn and drugb in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p4	cysteine	drug	_	NaFlu	drug	_	false	conjugation at drugn with druga moieties significantly improves the intestinal permeation of the hydrophilic molecule drugb and the model peptide drugs drugn and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p5	cysteine	drug	_	bacitracin	drug	_	false	conjugation at drugn with druga moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs drugb and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p6	cysteine	drug	_	insulin	drug	_	false	conjugation at drugn with druga moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs drugn and drugb in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p7	NaFlu	drug	_	bacitracin	drug	_	false	conjugation at drugn with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule druga and the model peptide drugs drugb and drugn in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p8	NaFlu	drug	_	insulin	drug	_	false	conjugation at drugn with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule druga and the model peptide drugs drugn and drugb in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d76.s10.p9	bacitracin	drug	_	insulin	drug	_	false	conjugation at drugn with drugn moieties significantly improves the intestinal permeation of the hydrophilic molecule drugn and the model peptide drugs druga and drugb in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .
DDI-MedLine.d3.s1.p0	amprenavir	drug	_	rifabutin	drug	_	false	the objective of this study was to determine if there is a pharmacokinetic interaction when druga is given with drugb or drugn and to determine the effects of these drugs on the erythromycin breath test -lcb- ermbt -rcb- .
DDI-MedLine.d3.s1.p1	amprenavir	drug	_	rifampin	drug	_	false	the objective of this study was to determine if there is a pharmacokinetic interaction when druga is given with drugn or drugb and to determine the effects of these drugs on the erythromycin breath test -lcb- ermbt -rcb- .
DDI-MedLine.d3.s1.p2	rifabutin	drug	_	rifampin	drug	_	false	the objective of this study was to determine if there is a pharmacokinetic interaction when drugn is given with druga or drugb and to determine the effects of these drugs on the erythromycin breath test -lcb- ermbt -rcb- .
DDI-MedLine.d3.s3.p0	amprenavir	drug	_	rifabutin	drug	_	false	all subjects received druga -lcb- 1,200 mg twice a day -rcb- for # days , followed by a 7-day washout period , followed by either drugb -lcb- 300 mg once a day -lsb- qd -rsb- -rcb- -lcb- cohort 1 -rcb- or drugn -lcb- 600 mg qd -rcb- -lcb- cohort 2 -rcb- for # days .
DDI-MedLine.d3.s3.p1	amprenavir	drug	_	rifampin	drug	_	false	all subjects received druga -lcb- 1,200 mg twice a day -rcb- for # days , followed by a 7-day washout period , followed by either drugn -lcb- 300 mg once a day -lsb- qd -rsb- -rcb- -lcb- cohort 1 -rcb- or drugb -lcb- 600 mg qd -rcb- -lcb- cohort 2 -rcb- for # days .
DDI-MedLine.d3.s3.p2	rifabutin	drug	_	rifampin	drug	_	false	all subjects received drugn -lcb- 1,200 mg twice a day -rcb- for # days , followed by a 7-day washout period , followed by either druga -lcb- 300 mg once a day -lsb- qd -rsb- -rcb- -lcb- cohort 1 -rcb- or drugb -lcb- 600 mg qd -rcb- -lcb- cohort 2 -rcb- for # days .
DDI-MedLine.d3.s4.p0	amprenavir	drug	_	rifabutin	drug	_	false	cohort # then received druga plus drugb for # days , and cohort # received drugn plus drugn for # days .
DDI-MedLine.d3.s4.p2	amprenavir	drug	_	rifampin	drug	_	false	cohort # then received druga plus drugn for # days , and cohort # received drugn plus drugb for # days .
DDI-MedLine.d3.s4.p3	rifabutin	drug	_	amprenavir	drug	_	false	cohort # then received drugn plus druga for # days , and cohort # received drugb plus drugn for # days .
DDI-MedLine.d3.s4.p4	rifabutin	drug	_	rifampin	drug	_	false	cohort # then received drugn plus druga for # days , and cohort # received drugn plus drugb for # days .
DDI-MedLine.d3.s4.p5	amprenavir	drug	_	rifampin	drug	_	false	cohort # then received drugn plus drugn for # days , and cohort # received druga plus drugb for # days .
DDI-MedLine.d3.s6.p0	Rifabutin	drug	_	amprenavir	drug	_	false	druga did not significantly affect drugb 's pharmacokinetics .
DDI-MedLine.d3.s7.p0	Amprenavir	drug	_	rifabutin	drug	_	mechanism	druga significantly increased the area under the curve at steady state -lcb- auc -lcb- ss -rcb- -rcb- of drugb by # - fold and the auc -lcb- ss -rcb- of drugn by # - fold .
DDI-MedLine.d3.s7.p1	Amprenavir	drug	_	25-O-desacetylrifabutin	drug_n	_	mechanism	druga significantly increased the area under the curve at steady state -lcb- auc -lcb- ss -rcb- -rcb- of drugn by # - fold and the auc -lcb- ss -rcb- of drugb by # - fold .
DDI-MedLine.d3.s8.p0	Rifampin	drug	_	amprenavir	drug	_	mechanism	druga significantly decreased the auc -lcb- ss -rcb- of drugb by 82 % , but drugn had no effect on drugn pharmacokinetics .
DDI-MedLine.d3.s8.p1	Rifampin	drug	_	amprenavir	drug	_	false	druga significantly decreased the auc -lcb- ss -rcb- of drugn by 82 % , but drugb had no effect on drugn pharmacokinetics .
DDI-MedLine.d3.s8.p4	amprenavir	drug	_	rifampin	drug	_	false	drugn significantly decreased the auc -lcb- ss -rcb- of druga by 82 % , but drugn had no effect on drugb pharmacokinetics .
DDI-MedLine.d3.s8.p5	amprenavir	drug	_	rifampin	drug	_	false	drugn significantly decreased the auc -lcb- ss -rcb- of drugn by 82 % , but druga had no effect on drugb pharmacokinetics .
DDI-MedLine.d3.s10.p0	rifabutin	drug	_	rifampin	drug	_	false	the results of the ermbt after # weeks of druga and drugb therapy were increased # and 156 % , respectively .
DDI-MedLine.d3.s11.p0	Amprenavir	drug	_	rifampin	drug	_	false	druga plus drugb was well tolerated .
DDI-MedLine.d3.s12.p0	Amprenavir	drug	_	rifabutin	drug	_	effect	druga plus drugb was poorly tolerated , and # of # subjects discontinued therapy .
DDI-MedLine.d3.s13.p0	Rifampin	drug	_	amprenavir	drug	_	mechanism	druga markedly increases the metabolic clearance of drugb , and coadministration is contraindicated .
DDI-MedLine.d3.s14.p0	Amprenavir	drug	_	rifabutin	drug	_	mechanism	druga significantly decreases clearance of drugb and drugn , and the combination is poorly tolerated .
DDI-MedLine.d3.s14.p1	Amprenavir	drug	_	25-O-desacetylrifabutin	drug_n	_	mechanism	druga significantly decreases clearance of drugn and drugb , and the combination is poorly tolerated .
DDI-MedLine.d3.s15.p0	Amprenavir	drug	_	rifampin	drug	_	false	druga inhibits the ermbt , and drugb and drugn are equipotent inducers of the ermbt .
DDI-MedLine.d3.s15.p1	Amprenavir	drug	_	rifabutin	drug	_	false	druga inhibits the ermbt , and drugn and drugb are equipotent inducers of the ermbt .
DDI-MedLine.d3.s15.p2	rifampin	drug	_	rifabutin	drug	_	false	drugn inhibits the ermbt , and druga and drugb are equipotent inducers of the ermbt .
DDI-MedLine.d28.s7.p2	thiazolidinediones	group	_	antidiabetic agents	group	_	false	the druga -lcb- drugn and drugn -rcb- , a new class of oral drugb , are `` insulin sensitizers ''
DDI-MedLine.d28.s7.p4	rosiglitazone	drug	_	antidiabetic agents	group	_	false	the drugn -lcb- druga and drugn -rcb- , a new class of oral drugb , are `` insulin sensitizers ''
DDI-MedLine.d28.s7.p5	pioglitazone	drug	_	antidiabetic agents	group	_	false	the drugn -lcb- drugn and druga -rcb- , a new class of oral drugb , are `` insulin sensitizers ''
DDI-MedLine.d74.s4.p0	Glucose	drug	_	theophylline	drug	_	false	druga , alone and in the presence of drugb , caused subnormal irdn release and less suppression of glucagon release in the diabectics than in the normals .
DDI-MedLine.d74.s5.p0	Arginine	drug	_	glucose	drug	_	false	druga , in the presence of drugb and drugn , caused excessive gcg release but nearly normal insulin release in the diabetics .
DDI-MedLine.d74.s5.p1	Arginine	drug	_	theophylline	drug	_	false	druga , in the presence of drugn and drugb , caused excessive gcg release but nearly normal insulin release in the diabetics .
DDI-MedLine.d74.s5.p2	glucose	drug	_	theophylline	drug	_	false	drugn , in the presence of druga and drugb , caused excessive gcg release but nearly normal insulin release in the diabetics .
DDI-MedLine.d74.s6.p0	Arginine	drug	_	glucose	drug	_	false	druga , in the absence of drugb or drugn , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .
DDI-MedLine.d74.s6.p1	Arginine	drug	_	theophylline	drug	_	false	druga , in the absence of drugn or drugb , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .
DDI-MedLine.d74.s6.p2	glucose	drug	_	theophylline	drug	_	false	drugn , in the absence of druga or drugb , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .
DDI-MedLine.d74.s11.p0	theophylline	drug	_	glucose	drug	_	false	further , these results confirm that the diabetic chinese hamster 's alpha and beta cells respond normally to druga , but are relatively insensitive to drugb .
DDI-MedLine.d44.s6.p0	Etofibrate	drug	_	heparin	drug	_	effect	druga elicited 62 % enhancement of post - drugb lipolytic activity and 100 % increase of 3h-triglyceride fractional clearance rate compared with placebo treatment .
DDI-MedLine.d125.s0.p0	gliftor	drug_n	_	1,3-difluoroacetone	drug_n	_	false	the mode of toxic action of the pesticide druga : the metabolism of drugb to drugn .
DDI-MedLine.d125.s0.p1	gliftor	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	the mode of toxic action of the pesticide druga : the metabolism of drugn to drugb .
DDI-MedLine.d125.s0.p2	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	the mode of toxic action of the pesticide drugn : the metabolism of druga to drugb .
DDI-MedLine.d125.s1.p0	1,3-difluoroacetone	drug_n	_	Gliftor	drug_n	_	false	the biochemical toxicology of druga , a known metabolite of the major ingredient of the pesticide drugb -lcb- drugn -rcb- , was investigated in vivo and in vitro .
DDI-MedLine.d125.s1.p1	1,3-difluoroacetone	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	the biochemical toxicology of druga , a known metabolite of the major ingredient of the pesticide drugn -lcb- drugb -rcb- , was investigated in vivo and in vitro .
DDI-MedLine.d125.s2.p0	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	rat kidney homogenates supplemented with coenzyme a , atp , oxaloacetate , and mg2 + converted druga to drugb in vitro .
DDI-MedLine.d125.s3.p0	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	administration of druga -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to rats in vivo resulted in drugb synthesis in the kidney , which was preceded by an elevation in fluoride levels and followed by citrate accumulation .
DDI-MedLine.d125.s4.p0	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	animals dosed with druga did not display the 2-3 hour lag phase in either drugb synthesis or in citrate and fluoride accumulation characteristic of animals dosed with drugn .
DDI-MedLine.d125.s4.p1	1,3-difluoroacetone	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	animals dosed with druga did not display the 2-3 hour lag phase in either drugn synthesis or in citrate and fluoride accumulation characteristic of animals dosed with drugb .
DDI-MedLine.d125.s4.p2	(-)-erythro-fluorocitrate	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	animals dosed with drugn did not display the 2-3 hour lag phase in either druga synthesis or in citrate and fluoride accumulation characteristic of animals dosed with drugb .
DDI-MedLine.d125.s5.p0	1,3-difluoro-2-propanol	drug_n	_	1,3-difluoroacetone	drug_n	_	false	we demonstrate that the conversion of druga to drugb by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , drugn from drugn .
DDI-MedLine.d125.s5.p1	1,3-difluoro-2-propanol	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	we demonstrate that the conversion of druga to drugn by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , drugb from drugn .
DDI-MedLine.d125.s5.p3	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	we demonstrate that the conversion of drugn to druga by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , drugb from drugn .
DDI-MedLine.d125.s5.p4	1,3-difluoroacetone	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	we demonstrate that the conversion of drugn to druga by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , drugn from drugb .
DDI-MedLine.d125.s5.p5	(-)-erythro-fluorocitrate	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	we demonstrate that the conversion of drugn to drugn by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , druga from drugb .
DDI-MedLine.d125.s6.p0	4-methylpyrazole	drug	_	1,3-difluoro-2-propanol	drug_n	_	effect	prior administration of druga -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- was shown to prevent the conversion of drugb -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to drugn in vivo and to eliminate the fluoride and citrate elevations seen in drugn - intoxicated animals .
DDI-MedLine.d125.s6.p1	4-methylpyrazole	drug	_	(-)-erythro-fluorocitrate	drug_n	_	false	prior administration of druga -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- was shown to prevent the conversion of drugn -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to drugb in vivo and to eliminate the fluoride and citrate elevations seen in drugn - intoxicated animals .
DDI-MedLine.d125.s6.p2	4-methylpyrazole	drug	_	1,3-difluoro-2-propanol	drug_n	_	false	prior administration of druga -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- was shown to prevent the conversion of drugn -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to drugn in vivo and to eliminate the fluoride and citrate elevations seen in drugb - intoxicated animals .
DDI-MedLine.d125.s6.p3	1,3-difluoro-2-propanol	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	prior administration of drugn -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- was shown to prevent the conversion of druga -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to drugb in vivo and to eliminate the fluoride and citrate elevations seen in drugn - intoxicated animals .
DDI-MedLine.d125.s6.p5	(-)-erythro-fluorocitrate	drug_n	_	1,3-difluoro-2-propanol	drug_n	_	false	prior administration of drugn -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- was shown to prevent the conversion of drugn -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- to druga in vivo and to eliminate the fluoride and citrate elevations seen in drugb - intoxicated animals .
DDI-MedLine.d125.s7.p0	4-methylpyrazole	drug	_	1,3-difluoroacetone	drug_n	_	false	however , administration of druga -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- to rats # hours prior to drugb -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- was ineffective in preventing drugn synthesis and did not diminish fluoride or citrate accumulation in vivo .
DDI-MedLine.d125.s7.p1	4-methylpyrazole	drug	_	(-)-erythro-fluorocitrate	drug_n	_	false	however , administration of druga -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- to rats # hours prior to drugn -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- was ineffective in preventing drugb synthesis and did not diminish fluoride or citrate accumulation in vivo .
DDI-MedLine.d125.s7.p2	1,3-difluoroacetone	drug_n	_	(-)-erythro-fluorocitrate	drug_n	_	false	however , administration of drugn -lcb- 90 mg kg -lcb- -1 -rcb- body weight -rcb- to rats # hours prior to druga -lcb- 100 mg kg -lcb- -1 -rcb- body weight -rcb- was ineffective in preventing drugb synthesis and did not diminish fluoride or citrate accumulation in vivo .
DDI-MedLine.d125.s8.p0	4-methylpyrazole	drug	_	1,3-difluoro-2-propanol	drug_n	_	effect	we conclude that the prophylactic and antidotal properties of druga seen in animals treated with drugb derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting drugn to drugn in the committed step of the toxic pathway .
DDI-MedLine.d125.s8.p1	4-methylpyrazole	drug	_	1,3-difluoro-2-propanol	drug_n	_	false	we conclude that the prophylactic and antidotal properties of druga seen in animals treated with drugn derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting drugb to drugn in the committed step of the toxic pathway .
DDI-MedLine.d125.s8.p2	4-methylpyrazole	drug	_	1,3-difluoroacetone	drug_n	_	false	we conclude that the prophylactic and antidotal properties of druga seen in animals treated with drugn derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting drugn to drugb in the committed step of the toxic pathway .
DDI-MedLine.d125.s8.p4	1,3-difluoro-2-propanol	drug_n	_	1,3-difluoroacetone	drug_n	_	false	we conclude that the prophylactic and antidotal properties of drugn seen in animals treated with druga derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting drugn to drugb in the committed step of the toxic pathway .
DDI-MedLine.d125.s8.p5	1,3-difluoro-2-propanol	drug_n	_	1,3-difluoroacetone	drug_n	_	false	we conclude that the prophylactic and antidotal properties of drugn seen in animals treated with drugn derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting druga to drugb in the committed step of the toxic pathway .
DDI-MedLine.d129.s0.p0	Green tea polyphenols	drug	_	enhancers	drug	_	false	druga as potent drugb of glucocorticoid-induced mouse mammary tumor virus gene expression .
DDI-MedLine.d129.s3.p0	n-dodecyl gallate	drug	_	tannic acid	drug	_	false	druga showed the most potent inhibition -lcb- 66 % inhibition at # microm -rcb- , which was far more potent than that of crude drugb .
DDI-MedLine.d86.s0.p0	diltiazem	drug	_	sirolimus	drug	_	mechanism	pharmacokinetic interaction between single oral doses of druga and drugb in healthy volunteers .
DDI-MedLine.d86.s1.p0	sirolimus	drug	_	macrolide immunosuppressant	group	_	false	aim and background : the pharmacokinetic interaction between druga , a drugb metabolized by cyp3a4 , and the drugn drugn was studied in # healthy subjects .
DDI-MedLine.d86.s1.p1	sirolimus	drug	_	calcium channel blocker	group	_	false	aim and background : the pharmacokinetic interaction between druga , a drugn metabolized by cyp3a4 , and the drugb drugn was studied in # healthy subjects .
DDI-MedLine.d86.s1.p2	sirolimus	drug	_	diltiazem	drug	_	false	aim and background : the pharmacokinetic interaction between druga , a drugn metabolized by cyp3a4 , and the drugn drugb was studied in # healthy subjects .
DDI-MedLine.d86.s1.p3	macrolide immunosuppressant	group	_	calcium channel blocker	group	_	false	aim and background : the pharmacokinetic interaction between drugn , a druga metabolized by cyp3a4 , and the drugb drugn was studied in # healthy subjects .
DDI-MedLine.d86.s1.p4	macrolide immunosuppressant	group	_	diltiazem	drug	_	false	aim and background : the pharmacokinetic interaction between drugn , a druga metabolized by cyp3a4 , and the drugn drugb was studied in # healthy subjects .
DDI-MedLine.d86.s1.p5	calcium channel blocker	group	_	diltiazem	drug	_	false	aim and background : the pharmacokinetic interaction between drugn , a drugn metabolized by cyp3a4 , and the druga drugb was studied in # healthy subjects .
DDI-MedLine.d86.s2.p0	immunosuppressive drugs	group	_	calcium antagonists	group	_	false	several clinically important interactions have previously been reported for other druga that are metabolized by the same enzyme and for drugb .
DDI-MedLine.d86.s3.p0	sirolimus	drug	_	diltiazem	drug	_	false	methods : healthy subjects who were # to # years old participated in an open , three-period , randomized , crossover study of the pharmacokinetics of a single 10-mg oral dose of druga , a single oral 120-mg dose of drugb , and the two drugs given together .
DDI-MedLine.d86.s5.p0	sirolimus	drug	_	diltiazem	drug	_	mechanism	results : the geometric mean -lcb- 90 % confidence interval -rcb- whole blood druga area under the plasma concentration time-curve increased 60 % -lcb- 35 % -90 % -rcb- , from # to # ng x h/ml , and maximum concentration increased 43 % -lcb- 14 % -81 % -rcb- , from # to # ng/ml , with drugb coadministration , whereas the mean elimination half-life of drugn decreased slightly , from # to # hours .
DDI-MedLine.d86.s5.p2	diltiazem	drug	_	sirolimus	drug	_	false	results : the geometric mean -lcb- 90 % confidence interval -rcb- whole blood drugn area under the plasma concentration time-curve increased 60 % -lcb- 35 % -90 % -rcb- , from # to # ng x h/ml , and maximum concentration increased 43 % -lcb- 14 % -81 % -rcb- , from # to # ng/ml , with druga coadministration , whereas the mean elimination half-life of drugb decreased slightly , from # to # hours .
DDI-MedLine.d86.s6.p1	sirolimus	drug	_	diltiazem	drug	_	false	apparent oral clearance and volume of distribution of druga decreased with 38 % and 45 % , respectively , when drugn was given with drugb .
DDI-MedLine.d86.s6.p2	sirolimus	drug	_	diltiazem	drug	_	mechanism	apparent oral clearance and volume of distribution of drugn decreased with 38 % and 45 % , respectively , when druga was given with drugb .
DDI-MedLine.d86.s7.p2	diltiazem	drug	_	sirolimus	drug	_	false	the plasma maximum concentration and area under the plasma concentration-time curve of druga , drugn , and drugn were unchanged after coadministration of drugb , and no potentiation of the effects of drugn on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
DDI-MedLine.d86.s7.p5	desacetyldiltiazem	drug_n	_	sirolimus	drug	_	false	the plasma maximum concentration and area under the plasma concentration-time curve of drugn , druga , and drugn were unchanged after coadministration of drugb , and no potentiation of the effects of drugn on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
DDI-MedLine.d86.s7.p7	desmethyldiltiazem	drug_n	_	sirolimus	drug	_	false	the plasma maximum concentration and area under the plasma concentration-time curve of drugn , drugn , and druga were unchanged after coadministration of drugb , and no potentiation of the effects of drugn on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
DDI-MedLine.d86.s7.p9	sirolimus	drug	_	diltiazem	drug	_	false	the plasma maximum concentration and area under the plasma concentration-time curve of drugn , drugn , and drugn were unchanged after coadministration of druga , and no potentiation of the effects of drugb on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .
DDI-MedLine.d86.s8.p0	diltiazem	drug	_	sirolimus	drug	_	mechanism	conclusions : single-dose druga coadministration leads to higher drugb exposure , presumably by inhibition of the first-pass metabolism of drugn .
DDI-MedLine.d86.s8.p1	diltiazem	drug	_	sirolimus	drug	_	false	conclusions : single-dose druga coadministration leads to higher drugn exposure , presumably by inhibition of the first-pass metabolism of drugb .
DDI-MedLine.d86.s9.p0	sirolimus	drug	_	diltiazem	drug	_	advise	because of the pronounced intersubject variability in the extent of the druga - drugb interaction , whole blood drugn concentrations should be monitored closely in patients treated with the two drugs .
DDI-MedLine.d86.s9.p2	diltiazem	drug	_	sirolimus	drug	_	false	because of the pronounced intersubject variability in the extent of the drugn - druga interaction , whole blood drugb concentrations should be monitored closely in patients treated with the two drugs .
DDI-MedLine.d99.s0.p0	Fluvoxamine	drug	_	tolbutamide	drug	_	mechanism	druga inhibits the cyp2c9 catalyzed biotransformation of drugb .
DDI-MedLine.d99.s1.p0	fluvoxamine	drug	_	tolbutamide	drug	_	false	objective : our objective was to examine the interaction between druga and drugb to confirm that drugn inhibits cyp2c9 .
DDI-MedLine.d99.s1.p2	tolbutamide	drug	_	fluvoxamine	drug	_	false	objective : our objective was to examine the interaction between drugn and druga to confirm that drugb inhibits cyp2c9 .
DDI-MedLine.d99.s8.p5	4-hydroxytolbutamide	drug_n	_	carboxytolbutamide	drug_n	_	false	plasma was analyzed for drugn , and urine was analyzed for drugn and its two metabolites , druga and drugb by means of hplc .
DDI-MedLine.d99.s9.p0	fluvoxamine	drug	_	tolbutamide	drug	_	mechanism	results : during treatment with druga , there was a statistically significant decrease in the median of the total clearance of drugb , from # ml/h to # ml/h , among the volunteers who received # mg/d .
DDI-MedLine.d99.s11.p0	4-hydroxytolbutamide	drug_n	_	carboxytolbutamide	drug_n	_	false	the clearance by means of druga and drugb was significantly reduced in both groups -lcb- ie , from # ml/h to # ml/h in the group that received # mg of drugn per day and from # ml/h to # ml/h in the group that received # mg of drugn per day -rcb- .
DDI-MedLine.d140.s0.p0	everolimus	drug	_	cyclosporine	drug	_	false	longitudinal assessment of druga in de novo renal transplant recipients over the first post-transplant year : pharmacokinetics , exposure-response relationships , and influence on drugb .
DDI-MedLine.d140.s1.p0	everolimus	drug	_	cyclosporine	drug	_	false	objective : our objective was to characterize the steady-state pharmacokinetics of druga and drugb -lcb- inn , drugn -rcb- when coadministered in de novo kidney allograft recipients during the first year after transplantation .
DDI-MedLine.d140.s1.p1	everolimus	drug	_	ciclosporin	drug	_	false	objective : our objective was to characterize the steady-state pharmacokinetics of druga and drugn -lcb- inn , drugb -rcb- when coadministered in de novo kidney allograft recipients during the first year after transplantation .
DDI-MedLine.d140.s2.p0	everolimus	drug	_	cyclosporine	drug	_	false	method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive druga tablets at doses of # mg , # mg , or # mg twice daily with drugb and drugn .
DDI-MedLine.d140.s2.p1	everolimus	drug	_	prednisone	drug	_	false	method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive druga tablets at doses of # mg , # mg , or # mg twice daily with drugn and drugb .
DDI-MedLine.d140.s2.p2	cyclosporine	drug	_	prednisone	drug	_	false	method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive drugn tablets at doses of # mg , # mg , or # mg twice daily with druga and drugb .
DDI-MedLine.d140.s3.p0	everolimus	drug	_	cyclosporine	drug	_	false	blood sampling for the pharmacokinetics of druga and drugb was performed on day 1 , on weeks 1 , 2 , 3 , and 4 , and on months 2 , 3 , 6 , 9 , and 12 .
DDI-MedLine.d140.s6.p0	cyclosporine	drug	_	everolimus	drug	_	false	potential differences in druga dosing and pharmacokinetics at different levels of drugb exposure were assessed in the context of anova .
DDI-MedLine.d140.s13.p0	Cyclosporine	drug	_	everolimus	drug	_	false	druga doses , trough concentrations , and auc exhibited similar temporal patterns during the course of the study regardless of the co-administered drugb dose level -lcb- p = # , # , and # , respectively -rcb- .
DDI-MedLine.d140.s15.p0	everolimus	drug	_	cyclosporine	drug	_	false	for a 4-fold range of druga doses there were no differential effects on drugb dosing or pharmacokinetics .
DDI-MedLine.d87.s0.p0	ADL 8-2698	drug	_	morphine	drug	_	effect	druga , a trans-3 ,4 - dimethyl-4 - -lcb- 3-hydroxyphenyl -rcb- piperidine , prevents gastrointestinal effects of intravenous drugb without affecting analgesia .
DDI-MedLine.d87.s1.p0	ADL-8-2698	drug	_	peripherally restricted opioid antagonist	group	_	false	druga is a novel drugb that may selectively prevent drugn - induced gastrointestinal effects without reversing analgesia .
DDI-MedLine.d87.s1.p1	ADL-8-2698	drug	_	opioid	group	_	effect	druga is a novel drugn that may selectively prevent drugb - induced gastrointestinal effects without reversing analgesia .
DDI-MedLine.d87.s2.p0	morphine	drug	_	ADL 8-2698	drug	_	false	gastrointestinal transit time -lcb- lactulose hydrogen breath test -rcb- was measured in # volunteers with oral and intravenous placebo , oral placebo and intravenous druga -lcb- # mg x kg -lcb- -1 -rcb- -rcb- , and oral drugb -lcb- 4 mg -rcb- and intravenous drugn -lcb- # mg x kg -lcb- -1 -rcb- -rcb- in a double blind , cross-over study .
DDI-MedLine.d87.s2.p2	ADL 8-2698	drug	_	morphine	drug	_	false	gastrointestinal transit time -lcb- lactulose hydrogen breath test -rcb- was measured in # volunteers with oral and intravenous placebo , oral placebo and intravenous drugn -lcb- # mg x kg -lcb- -1 -rcb- -rcb- , and oral druga -lcb- 4 mg -rcb- and intravenous drugb -lcb- # mg x kg -lcb- -1 -rcb- -rcb- in a double blind , cross-over study .
DDI-MedLine.d87.s4.p0	Morphine	drug	_	ADL 8-2698	drug	_	effect	druga prolonged gastrointestinal transit time from # to # minutes -lcb- p = # -rcb- ; this was prevented by drugb -lcb- p = # -rcb- .
DDI-MedLine.d87.s7.p0	Morphine	drug	_	ADL 8-2698	drug	_	false	druga analgesia and pupil constriction were unaffected by drugb and differed from placebo -lcb- p < # -rcb- .
DDI-MedLine.d87.s8.p0	ADL 8-2698	drug	_	morphine	drug	_	effect	we conclude that druga prevents drugb - induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia .
DDI-MedLine.d25.s0.p0	simvastatin	drug	_	clarithromycin	drug	_	effect	rhabdomyolysis secondary to a drug interaction between druga and drugb .
DDI-MedLine.d25.s1.p0	clarithromycin	drug	_	simvastatin	drug	_	false	objective : to report a case of rhabdomyolysis resulting from concomitant use of druga and drugb .
DDI-MedLine.d25.s9.p0	Clarithromycin	drug	_	simvastatin	drug	_	mechanism	discussion : druga is a potent inhibitor of cyp3a4 , the major enzyme responsible for drugb metabolism .
DDI-MedLine.d25.s10.p0	macrolide antibiotics	group	_	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	group	_	effect	the concomitant administration of druga and other drugb have resulted in previous reports of rhabdomyolysis .
DDI-MedLine.d25.s12.p0	Macrolide antibiotics	group	_	HMG-CoA reductase inhibitors	group	_	false	conclusions : druga inhibit the metabolism of drugb that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugn , drugn , drugn -rcb- .
DDI-MedLine.d25.s12.p1	Macrolide antibiotics	group	_	atorvastatin	drug	_	mechanism	conclusions : druga inhibit the metabolism of drugn that are metabolized by cyp3a4 -lcb- i , e , , drugb , drugn , drugn , drugn -rcb- .
DDI-MedLine.d25.s12.p2	Macrolide antibiotics	group	_	cerivastatin	drug	_	mechanism	conclusions : druga inhibit the metabolism of drugn that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugb , drugn , drugn -rcb- .
DDI-MedLine.d25.s12.p3	Macrolide antibiotics	group	_	lovastatin	drug	_	mechanism	conclusions : druga inhibit the metabolism of drugn that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugn , drugb , drugn -rcb- .
DDI-MedLine.d25.s12.p4	Macrolide antibiotics	group	_	simvastatin	drug	_	mechanism	conclusions : druga inhibit the metabolism of drugn that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugn , drugn , drugb -rcb- .
DDI-MedLine.d25.s12.p5	HMG-CoA reductase inhibitors	group	_	atorvastatin	drug	_	false	conclusions : drugn inhibit the metabolism of druga that are metabolized by cyp3a4 -lcb- i , e , , drugb , drugn , drugn , drugn -rcb- .
DDI-MedLine.d25.s12.p6	HMG-CoA reductase inhibitors	group	_	cerivastatin	drug	_	false	conclusions : drugn inhibit the metabolism of druga that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugb , drugn , drugn -rcb- .
DDI-MedLine.d25.s12.p7	HMG-CoA reductase inhibitors	group	_	lovastatin	drug	_	false	conclusions : drugn inhibit the metabolism of druga that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugn , drugb , drugn -rcb- .
DDI-MedLine.d25.s12.p8	HMG-CoA reductase inhibitors	group	_	simvastatin	drug	_	false	conclusions : drugn inhibit the metabolism of druga that are metabolized by cyp3a4 -lcb- i , e , , drugn , drugn , drugn , drugb -rcb- .
DDI-MedLine.d0.s0.p0	phenytoin	drug	_	quetiapine	drug	_	false	the effects of concomitant druga administration on the steady-state pharmacokinetics of drugb .
DDI-MedLine.d0.s1.p1	Quetiapine fumarate	drug	_	atypical antipsychotic	group	_	false	druga -lcb- ' drugn ' -rcb- is a newly introduced drugb with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .
DDI-MedLine.d0.s1.p2	Seroquel	brand	_	atypical antipsychotic	group	_	false	drugn -lcb- ' druga ' -rcb- is a newly introduced drugb with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .
DDI-MedLine.d0.s4.p0	phenytoin	drug	_	quetiapine	drug	_	mechanism	this study demonstrated that the potent cytochrome p450 enzyme-inducer druga did indeed have a marked effect on the metabolism of drugb , resulting in a 5-fold increase in clearance when administered concomitantly to patients with dsm-iv-diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder .
DDI-MedLine.d111.s5.p0	acetaminophen	drug	_	theophylline	drug	_	false	druga / drugb , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p1	acetaminophen	drug	_	lidocaine	drug	_	false	druga / drugn , drugb / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p2	acetaminophen	drug	_	quinidine	drug	_	false	druga / drugn , drugn / drugb , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p3	acetaminophen	drug	_	phenobarbital	drug	_	false	druga / drugn , drugn / drugn , drugb / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p5	acetaminophen	drug	_	phenobarbital	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugb / drugn , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p6	acetaminophen	drug	_	valproic acid	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugb , drugn / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p7	acetaminophen	drug	_	quinidine	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugb / drugn , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p8	acetaminophen	drug	_	lidocaine	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugb , drugn / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p9	acetaminophen	drug	_	theophylline	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugb / drugn , and drugn / drugn .
DDI-MedLine.d111.s5.p11	acetaminophen	drug	_	valproic acid	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugb / drugn .
DDI-MedLine.d111.s5.p12	acetaminophen	drug	_	phenobarbital	drug	_	false	druga / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , drugn / drugn , and drugn / drugb .
DDI-MedLine.d111.s7.p2	phenobarbital	drug	_	ethanol	drug	_	false	similarly dialyzed were druga , drugn , and drugn , both alone at therapeutic concentrations in serum and with drugb at three different concentrations in serum .
DDI-MedLine.d111.s7.p4	quinidine	drug	_	ethanol	drug	_	false	similarly dialyzed were drugn , druga , and drugn , both alone at therapeutic concentrations in serum and with drugb at three different concentrations in serum .
DDI-MedLine.d111.s7.p5	theophylline	drug	_	ethanol	drug	_	false	similarly dialyzed were drugn , drugn , and druga , both alone at therapeutic concentrations in serum and with drugb at three different concentrations in serum .
DDI-MedLine.d111.s9.p0	Acetaminophen	drug	_	theophylline	drug	_	mechanism	druga diminished the binding of drugb to human serum by a net change of # % -lcb- percentage increase in free drug fraction -lsb- fdf -rsb- , # % -rcb- at # micromol/l and by a net change of # % -lcb- percentage increase in fdf , # % -rcb- at # micromol/l .
DDI-MedLine.d111.s10.p0	Theophylline	drug	_	acetaminophen	drug	_	mechanism	druga decreased the binding of drugb by a net change of # % -lcb- percentage increase in fdf , # % -rcb- at # micromol/l ;
DDI-MedLine.d111.s12.p0	Valproic acid	drug	_	phenobarbital	drug	_	mechanism	druga diminished binding of drugb by a net change of # % -lcb- percentage increase in fdf , # % -rcb- at # micromol/l .
DDI-MedLine.d111.s14.p0	acetaminophen	drug	_	theophylline	drug	_	effect	coingestion of druga with drugb , drugn with drugn , and drugn with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p1	acetaminophen	drug	_	phenobarbital	drug	_	false	coingestion of druga with drugn , drugb with drugn , and drugn with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p3	acetaminophen	drug	_	valproic acid	drug	_	false	coingestion of druga with drugn , drugn with drugn , and drugb with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p4	acetaminophen	drug	_	phenobarbital	drug	_	false	coingestion of druga with drugn , drugn with drugn , and drugn with drugb at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p5	theophylline	drug	_	phenobarbital	drug	_	false	coingestion of drugn with druga , drugb with drugn , and drugn with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p6	theophylline	drug	_	acetaminophen	drug	_	false	coingestion of drugn with druga , drugn with drugb , and drugn with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p7	theophylline	drug	_	valproic acid	drug	_	false	coingestion of drugn with druga , drugn with drugn , and drugb with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p8	theophylline	drug	_	phenobarbital	drug	_	false	coingestion of drugn with druga , drugn with drugn , and drugn with drugb at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p9	phenobarbital	drug	_	acetaminophen	drug	_	effect	coingestion of drugn with drugn , druga with drugb , and drugn with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p10	phenobarbital	drug	_	valproic acid	drug	_	false	coingestion of drugn with drugn , druga with drugn , and drugb with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p12	acetaminophen	drug	_	valproic acid	drug	_	false	coingestion of drugn with drugn , drugn with druga , and drugb with drugn at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p13	acetaminophen	drug	_	phenobarbital	drug	_	false	coingestion of drugn with drugn , drugn with druga , and drugn with drugb at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d111.s14.p14	valproic acid	drug	_	phenobarbital	drug	_	effect	coingestion of drugn with drugn , drugn with drugn , and druga with drugb at high to toxic concentrations decreases the binding of the target drug .
DDI-MedLine.d60.s2.p0	phenytoin	drug	_	fluvoxamine	drug	_	false	the serum concentration of druga increased dramatically from # to # microg/ml when drugb was coadministered , although the daily dosage of drugn and other drugn had not changed .
DDI-MedLine.d60.s2.p2	phenytoin	drug	_	drugs	drug	_	false	the serum concentration of druga increased dramatically from # to # microg/ml when drugn was coadministered , although the daily dosage of drugn and other drugb had not changed .
DDI-MedLine.d60.s2.p3	fluvoxamine	drug	_	phenytoin	drug	_	false	the serum concentration of drugn increased dramatically from # to # microg/ml when druga was coadministered , although the daily dosage of drugb and other drugn had not changed .
DDI-MedLine.d60.s2.p4	fluvoxamine	drug	_	drugs	drug	_	false	the serum concentration of drugn increased dramatically from # to # microg/ml when druga was coadministered , although the daily dosage of drugn and other drugb had not changed .
DDI-MedLine.d60.s2.p5	phenytoin	drug	_	drugs	drug	_	false	the serum concentration of drugn increased dramatically from # to # microg/ml when drugn was coadministered , although the daily dosage of druga and other drugb had not changed .
DDI-MedLine.d60.s5.p0	CYP2C9	drug	_	fluvoxamine	drug	_	false	the interaction may be a result of inhibition of both druga and 2c19 by drugb .
DDI-MedLine.d123.s2.p0	galangin	drug	_	vancomycin	drug	_	false	here we show that a combination of druga or 3_7_dihydroxyflavone with drugb may be used to sensitize resistant strains of enterococcus faecalis and enterococcus faecium to the level of vancomycin-sensitive strains .
DDI-MedLine.d137.s0.p0	Glucose	drug	_	insulin	drug	_	false	druga and drugb exert additive ocular and renal vasodilator effects on healthy humans .
DDI-MedLine.d137.s1.p0	insulin	drug	_	glucose	drug	_	false	aims/hypothesis : there is evidence that druga and drugb cause renal and ocular vasodilation .
DDI-MedLine.d137.s9.p0	glucose	drug	_	insulin	drug	_	false	haemodynamic effects of druga and drugb were additive when drugn was co-administered but not under basal conditions .
DDI-MedLine.d137.s9.p1	glucose	drug	_	somatostatin	drug	_	false	haemodynamic effects of druga and drugn were additive when drugb was co-administered but not under basal conditions .
DDI-MedLine.d137.s9.p2	insulin	drug	_	somatostatin	drug	_	false	haemodynamic effects of drugn and druga were additive when drugb was co-administered but not under basal conditions .
DDI-MedLine.d137.s10.p0	Glucose	drug	_	insulin	drug	_	false	conclusions/interpretation : druga and drugb can exert additive vasodilator properties on renal and ocular circulation .
DDI-MedLine.d124.s0.p0	levofloxacin	drug	_	oxycodone	drug	_	false	lack of interaction between druga and drugb : pharmacokinetics and drug disposition .
DDI-MedLine.d124.s1.p0	trovafloxacin	drug	_	ciprofloxacin	drug	_	false	previous studies have demonstrated a significant reduction in the oral bioavailability of druga and drugb when administered concomitantly with an intravenous drugn such as drugn .
DDI-MedLine.d124.s1.p1	trovafloxacin	drug	_	opiate	group	_	mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of druga and drugn when administered concomitantly with an intravenous drugb such as drugn .
DDI-MedLine.d124.s1.p2	trovafloxacin	drug	_	morphine	drug	_	mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of druga and drugn when administered concomitantly with an intravenous drugn such as drugb .
DDI-MedLine.d124.s1.p3	ciprofloxacin	drug	_	opiate	group	_	mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of drugn and druga when administered concomitantly with an intravenous drugb such as drugn .
DDI-MedLine.d124.s1.p4	ciprofloxacin	drug	_	morphine	drug	_	mechanism	previous studies have demonstrated a significant reduction in the oral bioavailability of drugn and druga when administered concomitantly with an intravenous drugn such as drugb .
DDI-MedLine.d124.s1.p5	opiate	group	_	morphine	drug	_	false	previous studies have demonstrated a significant reduction in the oral bioavailability of drugn and drugn when administered concomitantly with an intravenous druga such as drugb .
DDI-MedLine.d124.s2.p0	trovafloxacin	drug	_	ciprofloxacin	drug	_	false	this decrease in absorption results in a 36 % and 50 % lower auc for druga and drugb , respectively , which could cause clinical failures .
DDI-MedLine.d124.s3.p0	oxycodone	drug	_	levofloxacin	drug	_	false	the authors investigated the possibility of a similar interaction between druga and drugb .
DDI-MedLine.d124.s6.p0	oxycodone	drug	_	levofloxacin	drug	_	false	1 hour after starting the druga or drugb # mg p , o.
DDI-MedLine.d124.s9.p1	levofloxacin	drug	_	oxycodone	drug	_	false	there was not a significant difference -lcb- p > # -rcb- in auc -lcb- # + / - # vs , # + / - # -rcb- , cmax -lcb- # + / - # vs , # + / - # -rcb- , and tmax -lcb- # + / - # vs , # + / - # -rcb- for druga versus drugn / drugb regimens .
DDI-MedLine.d124.s10.p0	oxycodone	drug	_	levofloxacin	drug	_	false	it was concluded that oral druga and drugb can be administered concomitantly without a significant decrease in auc , cmax , or tmax .
DDI-MedLine.d105.s0.p0	azithromycin	drug	_	zidovudine	drug	_	false	lack of an effect of druga on the disposition of drugb and drugn in hiv-infected patients .
DDI-MedLine.d105.s0.p1	azithromycin	drug	_	dideoxyinosine	drug	_	false	lack of an effect of druga on the disposition of drugn and drugb in hiv-infected patients .
DDI-MedLine.d105.s0.p2	zidovudine	drug	_	dideoxyinosine	drug	_	false	lack of an effect of drugn on the disposition of druga and drugb in hiv-infected patients .
DDI-MedLine.d105.s1.p0	azithromycin	drug	_	zidovudine	drug	_	false	two studies were conducted in hiv-infected subjects to assess the potential for druga to interact with drugb and drugn .
DDI-MedLine.d105.s1.p1	azithromycin	drug	_	dideoxyinosine	drug	_	false	two studies were conducted in hiv-infected subjects to assess the potential for druga to interact with drugn and drugb .
DDI-MedLine.d105.s1.p2	zidovudine	drug	_	dideoxyinosine	drug	_	false	two studies were conducted in hiv-infected subjects to assess the potential for drugn to interact with druga and drugb .
DDI-MedLine.d105.s3.p0	zidovudine	drug	_	azithromycin	drug	_	false	the druga study dosed subjects with # mg/day of drugb -lcb- n = 7 -rcb- -lcb- later changed to # mg/day -lsb- n = 5 -rsb- -rcb- for days # to # of a 21-day course of # mg , five times/day of drugn .
DDI-MedLine.d105.s3.p2	azithromycin	drug	_	zidovudine	drug	_	false	the drugn study dosed subjects with # mg/day of druga -lcb- n = 7 -rcb- -lcb- later changed to # mg/day -lsb- n = 5 -rsb- -rcb- for days # to # of a 21-day course of # mg , five times/day of drugb .
DDI-MedLine.d105.s4.p0	dideoxyinosine	drug	_	azithromycin	drug	_	false	subjects treated with # mg of druga twice daily for # days received # mg of drugb or an equivalent amount of placebo/day for days # to 21 .
DDI-MedLine.d105.s7.p0	Azithromycin	drug	_	zidovudine	drug	_	false	druga had no significant impact on the cmax and auc of drugb , although it significantly decreased the drugn tmax by 44 % and increased the intracellular exposure to phosphorylated drugn by 110 % .
DDI-MedLine.d105.s7.p1	Azithromycin	drug	_	zidovudine	drug	_	mechanism	druga had no significant impact on the cmax and auc of drugn , although it significantly decreased the drugb tmax by 44 % and increased the intracellular exposure to phosphorylated drugn by 110 % .
DDI-MedLine.d105.s7.p2	Azithromycin	drug	_	zidovudine	drug	_	mechanism	druga had no significant impact on the cmax and auc of drugn , although it significantly decreased the drugn tmax by 44 % and increased the intracellular exposure to phosphorylated drugb by 110 % .
DDI-MedLine.d105.s8.p0	Azithromycin	drug	_	dideoxyinosine	drug	_	false	druga had no significant effect on drugb pharmacokinetics .
DDI-MedLine.d105.s9.p0	azithromycin	drug	_	zidovudine	drug	_	false	based on the results of these studies , it is concluded that druga may be safely coadministered with both drugb and drugn .
DDI-MedLine.d105.s9.p1	azithromycin	drug	_	dideoxyinosine	drug	_	false	based on the results of these studies , it is concluded that druga may be safely coadministered with both drugn and drugb .
DDI-MedLine.d105.s9.p2	zidovudine	drug	_	dideoxyinosine	drug	_	false	based on the results of these studies , it is concluded that drugn may be safely coadministered with both druga and drugb .
DDI-MedLine.d67.s0.p0	diazepam	drug	_	midazolam	drug	_	false	effect of druga and drugb on the antinociceptive effect of drugn , drugn and drugn in mice .
DDI-MedLine.d67.s0.p1	diazepam	drug	_	morphine	drug	_	false	effect of druga and drugn on the antinociceptive effect of drugb , drugn and drugn in mice .
DDI-MedLine.d67.s0.p2	diazepam	drug	_	metamizol	drug	_	false	effect of druga and drugn on the antinociceptive effect of drugn , drugb and drugn in mice .
DDI-MedLine.d67.s0.p3	diazepam	drug	_	indomethacin	drug	_	false	effect of druga and drugn on the antinociceptive effect of drugn , drugn and drugb in mice .
DDI-MedLine.d67.s0.p4	midazolam	drug	_	morphine	drug	_	false	effect of drugn and druga on the antinociceptive effect of drugb , drugn and drugn in mice .
DDI-MedLine.d67.s0.p5	midazolam	drug	_	metamizol	drug	_	false	effect of drugn and druga on the antinociceptive effect of drugn , drugb and drugn in mice .
DDI-MedLine.d67.s0.p6	midazolam	drug	_	indomethacin	drug	_	false	effect of drugn and druga on the antinociceptive effect of drugn , drugn and drugb in mice .
DDI-MedLine.d67.s1.p0	midazolam	drug	_	diazepam	drug	_	false	the influence of druga and drugb on antinociceptive effect of drugn -lcb- 10 mg/kg -rcb- , drugn -lcb- 500 mg/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p1	midazolam	drug	_	morphine	drug	_	false	the influence of druga and drugn on antinociceptive effect of drugb -lcb- 10 mg/kg -rcb- , drugn -lcb- 500 mg/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p2	midazolam	drug	_	metamizol	drug	_	false	the influence of druga and drugn on antinociceptive effect of drugn -lcb- 10 mg/kg -rcb- , drugb -lcb- 500 mg/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p3	midazolam	drug	_	indomethacin	drug	_	false	the influence of druga and drugn on antinociceptive effect of drugn -lcb- 10 mg/kg -rcb- , drugn -lcb- 500 mg/kg -rcb- and drugb -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p4	diazepam	drug	_	morphine	drug	_	false	the influence of drugn and druga on antinociceptive effect of drugb -lcb- 10 mg/kg -rcb- , drugn -lcb- 500 mg/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p5	diazepam	drug	_	metamizol	drug	_	false	the influence of drugn and druga on antinociceptive effect of drugn -lcb- 10 mg/kg -rcb- , drugb -lcb- 500 mg/kg -rcb- and drugn -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s1.p6	diazepam	drug	_	indomethacin	drug	_	false	the influence of drugn and druga on antinociceptive effect of drugn -lcb- 10 mg/kg -rcb- , drugn -lcb- 500 mg/kg -rcb- and drugb -lcb- 10 mg/kg -rcb- was investigated in a mouse model using the tail-flick and hot-plate tests .
DDI-MedLine.d67.s3.p0	Benzodiazepines	group	_	analgesic drugs	group	_	false	druga were administered to mice # min before applying the drugb .
DDI-MedLine.d67.s5.p0	Diazepam	drug	_	morphine	drug	_	effect	druga at doses of # mg/kg and # mg/kg injected with drugb was found to decrease the antinociceptive effect of drugn .
DDI-MedLine.d67.s5.p1	Diazepam	drug	_	morphine	drug	_	false	druga at doses of # mg/kg and # mg/kg injected with drugn was found to decrease the antinociceptive effect of drugb .
DDI-MedLine.d67.s6.p0	diazepam	drug	_	metamizol	drug	_	effect	similarly , druga decreased the antinociceptive effect of drugb -lcb- only in the tail-flick test -rcb- and drugn .
DDI-MedLine.d67.s6.p1	diazepam	drug	_	indomethacin	drug	_	effect	similarly , druga decreased the antinociceptive effect of drugn -lcb- only in the tail-flick test -rcb- and drugb .
DDI-MedLine.d67.s6.p2	metamizol	drug	_	indomethacin	drug	_	false	similarly , drugn decreased the antinociceptive effect of druga -lcb- only in the tail-flick test -rcb- and drugb .
DDI-MedLine.d67.s7.p0	Midazolam	drug	_	morphine	drug	_	effect	druga used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of drugb , drugn -lcb- only in the tail-flick test -rcb- and drugn .
DDI-MedLine.d67.s7.p1	Midazolam	drug	_	metamizol	drug	_	effect	druga used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of drugn , drugb -lcb- only in the tail-flick test -rcb- and drugn .
DDI-MedLine.d67.s7.p2	Midazolam	drug	_	indomethacin	drug	_	effect	druga used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of drugn , drugn -lcb- only in the tail-flick test -rcb- and drugb .
DDI-MedLine.d102.s0.p0	estradiol	drug	_	progesterone	drug	_	false	influence of druga and drugb on the sensitivity of rat thoracic aorta to drugn .
DDI-MedLine.d102.s0.p1	estradiol	drug	_	noradrenaline	drug	_	false	influence of druga and drugn on the sensitivity of rat thoracic aorta to drugb .
DDI-MedLine.d102.s0.p2	progesterone	drug	_	noradrenaline	drug	_	false	influence of drugn and druga on the sensitivity of rat thoracic aorta to drugb .
DDI-MedLine.d102.s1.p0	estradiol	drug	_	progesterone	drug	_	false	the aim of this study was to investigate the effects of low and high doses of druga , and of drugb on the response to drugn in rat thoracic aorta .
DDI-MedLine.d102.s1.p1	estradiol	drug	_	noradrenaline	drug	_	false	the aim of this study was to investigate the effects of low and high doses of druga , and of drugn on the response to drugb in rat thoracic aorta .
DDI-MedLine.d102.s1.p2	progesterone	drug	_	noradrenaline	drug	_	false	the aim of this study was to investigate the effects of low and high doses of drugn , and of druga on the response to drugb in rat thoracic aorta .
DDI-MedLine.d102.s3.p0	estradiol	drug	_	progesterone	drug	_	false	injection of vehicle -lcb- corn oil , # ml/day -rcb- , druga -lcb- 10 microg/kg/day or # mg/kg/day -rcb- and/or drugb -lcb- 20 mg/kg/day -rcb- , for eight days .
DDI-MedLine.d102.s5.p0	estradiol	drug	_	noradrenaline	drug	_	effect	aortic rings with intact endothelium from the high-dose -lcb- 4 mg/kg/day -rcb- druga group were supersensitive to drugb compared to the vehicle or low-dose -lcb- 10 microg/kg/day -rcb- estradiol groups -lcb- pd2 values = # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p0	estradiol	drug	_	noradrenaline	drug	_	effect	endothelium-intact aortic rings from high - druga rats were supersensitive to drugb when compared to vehicle - , drugn - and drugn + high - drugn - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p1	estradiol	drug	_	progesterone	drug	_	false	endothelium-intact aortic rings from high - druga rats were supersensitive to drugn when compared to vehicle - , drugb - and drugn + high - drugn - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p2	estradiol	drug	_	progesterone	drug	_	false	endothelium-intact aortic rings from high - druga rats were supersensitive to drugn when compared to vehicle - , drugn - and drugb + high - drugn - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p4	noradrenaline	drug	_	progesterone	drug	_	false	endothelium-intact aortic rings from high - drugn rats were supersensitive to druga when compared to vehicle - , drugb - and drugn + high - drugn - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p5	noradrenaline	drug	_	progesterone	drug	_	false	endothelium-intact aortic rings from high - drugn rats were supersensitive to druga when compared to vehicle - , drugn - and drugb + high - drugn - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p6	noradrenaline	drug	_	estradiol	drug	_	false	endothelium-intact aortic rings from high - drugn rats were supersensitive to druga when compared to vehicle - , drugn - and drugn + high - drugb - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p8	progesterone	drug	_	estradiol	drug	_	false	endothelium-intact aortic rings from high - drugn rats were supersensitive to drugn when compared to vehicle - , druga - and drugn + high - drugb - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d102.s6.p9	progesterone	drug	_	estradiol	drug	_	false	endothelium-intact aortic rings from high - drugn rats were supersensitive to drugn when compared to vehicle - , drugn - and druga + high - drugb - treated rats -lcb- pd2 values = # + / # , # + / # , # + / # and # + / # , respectively -rcb- .
DDI-MedLine.d1.s5.p0	Sildenafil	drug	_	long-acting nitrates	group	_	advise	druga is contraindicated in patients using drugb or who may need to use drugn , because the combination may cause a sharp fall of the blood pressure .
DDI-MedLine.d1.s5.p1	Sildenafil	drug	_	short-acting nitrates	group	_	advise	druga is contraindicated in patients using drugn or who may need to use drugb , because the combination may cause a sharp fall of the blood pressure .
DDI-MedLine.d1.s5.p2	long-acting nitrates	group	_	short-acting nitrates	group	_	false	drugn is contraindicated in patients using druga or who may need to use drugb , because the combination may cause a sharp fall of the blood pressure .
DDI-MedLine.d1.s6.p2	beta-receptor blockers	group	_	loop diuretics	group	_	false	no interactions have been observed with druga , drugn , drugn and drugb and drugn .
DDI-MedLine.d1.s6.p3	beta-receptor blockers	group	_	ACE inhibitors	group	_	false	no interactions have been observed with druga , drugn , drugn and drugn and drugb .
DDI-MedLine.d1.s6.p5	calcium antagonists	group	_	loop diuretics	group	_	false	no interactions have been observed with drugn , druga , drugn and drugb and drugn .
DDI-MedLine.d1.s6.p6	calcium antagonists	group	_	ACE inhibitors	group	_	false	no interactions have been observed with drugn , druga , drugn and drugn and drugb .
DDI-MedLine.d1.s6.p7	thiazide diuretics	group	_	loop diuretics	group	_	false	no interactions have been observed with drugn , drugn , druga and drugb and drugn .
DDI-MedLine.d1.s6.p8	thiazide diuretics	group	_	ACE inhibitors	group	_	false	no interactions have been observed with drugn , drugn , druga and drugn and drugb .
DDI-MedLine.d1.s6.p9	loop diuretics	group	_	ACE inhibitors	group	_	false	no interactions have been observed with drugn , drugn , drugn and druga and drugb .
DDI-MedLine.d46.s0.p0	fluoxetine	drug	_	cisapride	drug	_	false	influence of coadministration of druga on drugb pharmacokinetics and qtc intervals in healthy volunteers .
DDI-MedLine.d46.s1.p0	fluoxetine	drug	_	cisapride	drug	_	false	study objective : to evaluate the effect of druga on the pharmacokinetics and cardiovascular safety of drugb at steady state in healthy men .
DDI-MedLine.d46.s9.p0	cisapride	drug	_	fluoxetine	drug	_	false	and phase # -lcb- days 45-52 -rcb- : druga # mg # times/day -lcb- days 45-51 -rcb- plus drugb # mg/day -lcb- days 45-52 -rcb- .
DDI-MedLine.d46.s13.p0	fluoxetine	drug	_	cisapride	drug	_	mechanism	coadministration of druga significantly decreased drugb plasma concentrations .
DDI-MedLine.d46.s14.p0	cisapride	drug	_	fluoxetine	drug	_	false	there were no clinically significant changes in corrected qt intervals during administration of druga alone or with drugb .
DDI-MedLine.d46.s15.p0	Cisapride	drug	_	fluoxetine	drug	_	false	druga was well tolerated when administered alone or with drugb .
DDI-MedLine.d46.s16.p0	Cisapride	drug	_	fluoxetine	drug	_	false	conclusion : druga can be administered safely to patients receiving low therapeutic dosages of drugb .
DDI-MedLine.d83.s1.p0	Olanzapine	drug	_	thienobenzodiazepine derivative	group	_	false	druga , a drugb , is a drugn which has proven efficacy against the positive and negative symptoms of schizophrenia .
DDI-MedLine.d83.s1.p1	Olanzapine	drug	_	second generation (atypical) antipsychotic agent	group	_	false	druga , a drugn , is a drugb which has proven efficacy against the positive and negative symptoms of schizophrenia .
DDI-MedLine.d83.s1.p2	thienobenzodiazepine derivative	group	_	second generation (atypical) antipsychotic agent	group	_	false	drugn , a druga , is a drugb which has proven efficacy against the positive and negative symptoms of schizophrenia .
DDI-MedLine.d83.s3.p0	olanzapine	drug	_	haloperidol	drug	_	false	in large , well controlled trials in patients with schizophrenia or related psychoses , druga # to # mg/day was significantly superior to drugb # to # mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms , and was comparable in effects on positive psychotic symptoms .
DDI-MedLine.d83.s4.p0	olanzapine	drug	_	haloperidol	drug	_	false	the 1-year risk of relapse -lcb- rehospitalisation -rcb- was significantly lower with druga than with drugb treatment .
DDI-MedLine.d83.s5.p0	olanzapine	drug	_	risperidone	drug	_	false	in the first double-blind comparative study -lcb- 28-week -rcb- of druga and drugb , drugn # to # mg/day proved to be significantly more effective than drugn # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
DDI-MedLine.d83.s5.p2	olanzapine	drug	_	risperidone	drug	_	false	in the first double-blind comparative study -lcb- 28-week -rcb- of druga and drugn , drugn # to # mg/day proved to be significantly more effective than drugb # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
DDI-MedLine.d83.s5.p3	risperidone	drug	_	olanzapine	drug	_	false	in the first double-blind comparative study -lcb- 28-week -rcb- of drugn and druga , drugb # to # mg/day proved to be significantly more effective than drugn # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
DDI-MedLine.d83.s5.p5	olanzapine	drug	_	risperidone	drug	_	false	in the first double-blind comparative study -lcb- 28-week -rcb- of drugn and drugn , druga # to # mg/day proved to be significantly more effective than drugb # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .
DDI-MedLine.d83.s6.p0	risperidone	drug	_	olanzapine	drug	_	false	in contrast , preliminary results from an 8-week controlled study suggested druga # to # mg/day was superior to drugb # to # mg/day against positive and anxiety/depressive symptoms -lcb- p < # -rcb- , although consistent with the first study , both agents demonstrated similar efficacy on measures of overall psychopathology .
DDI-MedLine.d83.s7.p0	olanzapine	drug	_	risperidone	drug	_	false	improvements in general cognitive function seen with druga treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either drugb or drugn .
DDI-MedLine.d83.s7.p1	olanzapine	drug	_	haloperidol	drug	_	false	improvements in general cognitive function seen with druga treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either drugn or drugb .
DDI-MedLine.d83.s7.p2	risperidone	drug	_	haloperidol	drug	_	false	improvements in general cognitive function seen with drugn treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either druga or drugb .
DDI-MedLine.d83.s8.p0	olanzapine	drug	_	risperidone	drug	_	false	however , preliminary results from an 8-week trial showed comparable cognitive enhancing effects of druga and drugb treatment in patients with schizophrenia or schizoaffective disorder .
DDI-MedLine.d83.s10.p0	Olanzapine	drug	_	haloperidol	drug	_	false	druga is associated with significantly fewer extrapyramidal symptoms than drugb and drugn .
DDI-MedLine.d83.s10.p1	Olanzapine	drug	_	risperidone	drug	_	false	druga is associated with significantly fewer extrapyramidal symptoms than drugn and drugb .
DDI-MedLine.d83.s10.p2	haloperidol	drug	_	risperidone	drug	_	false	drugn is associated with significantly fewer extrapyramidal symptoms than druga and drugb .
DDI-MedLine.d83.s11.p0	olanzapine	drug	_	clozapine	drug	_	false	in addition , druga is not associated with a risk of agranulocytosis as seen with drugb or clinically significant hyperprolactinemia as seen with drugn or prolongation of the qt interval .
DDI-MedLine.d83.s11.p1	olanzapine	drug	_	risperidone	drug	_	false	in addition , druga is not associated with a risk of agranulocytosis as seen with drugn or clinically significant hyperprolactinemia as seen with drugb or prolongation of the qt interval .
DDI-MedLine.d83.s11.p2	clozapine	drug	_	risperidone	drug	_	false	in addition , drugn is not associated with a risk of agranulocytosis as seen with druga or clinically significant hyperprolactinemia as seen with drugb or prolongation of the qt interval .
DDI-MedLine.d83.s13.p0	haloperidol	drug	_	olanzapine	drug	_	false	in comparison with druga , the adverse events reported significantly more frequently with drugb in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with drugn , only bodyweight gain occurred significantly more frequently with drugn .
DDI-MedLine.d83.s13.p1	haloperidol	drug	_	risperidone	drug	_	false	in comparison with druga , the adverse events reported significantly more frequently with drugn in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with drugb , only bodyweight gain occurred significantly more frequently with drugn .
DDI-MedLine.d83.s13.p2	haloperidol	drug	_	olanzapine	drug	_	false	in comparison with druga , the adverse events reported significantly more frequently with drugn in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with drugn , only bodyweight gain occurred significantly more frequently with drugb .
DDI-MedLine.d83.s13.p3	olanzapine	drug	_	risperidone	drug	_	false	in comparison with drugn , the adverse events reported significantly more frequently with druga in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with drugb , only bodyweight gain occurred significantly more frequently with drugn .
DDI-MedLine.d83.s13.p5	risperidone	drug	_	olanzapine	drug	_	false	in comparison with drugn , the adverse events reported significantly more frequently with drugn in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with druga , only bodyweight gain occurred significantly more frequently with drugb .
DDI-MedLine.d83.s15.p0	olanzapine	drug	_	haloperidol	drug	_	false	pharmacoeconomic analyses indicate that druga does not significantly increase , and may even decrease , the overall direct treatment costs of schizophrenia , compared with drugb .
DDI-MedLine.d83.s16.p0	risperidone	drug	_	olanzapine	drug	_	false	compared with druga , drugb has also been reported to decrease overall treatment costs , despite the several-fold higher daily acquisition cost of the drug .
DDI-MedLine.d83.s17.p0	Olanzapine	drug	_	haloperidol	drug	_	false	druga treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than drugb , and to broadly the same extent as drugn .
DDI-MedLine.d83.s17.p1	Olanzapine	drug	_	risperidone	drug	_	false	druga treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than drugn , and to broadly the same extent as drugb .
DDI-MedLine.d83.s17.p2	haloperidol	drug	_	risperidone	drug	_	false	drugn treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than druga , and to broadly the same extent as drugb .
DDI-MedLine.d83.s18.p0	Olanzapine	drug	_	haloperidol	drug	_	false	conclusions : druga demonstrated superior antipsychotic efficacy compared with drugb in the treatment of acute phase schizophrenia , and in the treatment of some patients with first-episode or treatment-resistant schizophrenia .
DDI-MedLine.d83.s19.p0	haloperidol	drug	_	risperidone	drug	_	false	the reduced risk of adverse events and therapeutic superiority compared with druga and drugb in the treatment of negative and depressive symptoms support the choice of drugn as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
DDI-MedLine.d83.s19.p1	haloperidol	drug	_	olanzapine	drug	_	false	the reduced risk of adverse events and therapeutic superiority compared with druga and drugn in the treatment of negative and depressive symptoms support the choice of drugb as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
DDI-MedLine.d83.s19.p2	risperidone	drug	_	olanzapine	drug	_	false	the reduced risk of adverse events and therapeutic superiority compared with drugn and druga in the treatment of negative and depressive symptoms support the choice of drugb as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .
DDI-MedLine.d132.s0.p0	non-nucleoside reverse transcriptase inhibitors	group	_	antiretroviral	group	_	false	the emerging roles of druga in drugb therapy .
DDI-MedLine.d132.s1.p1	non-nucleoside reverse transcriptase inhibitor	group	_	antiretroviral	group	_	false	the availability of potent druga -lcb- drugn -rcb- - based regimens for drugb therapy and concerns regarding drugn -lcb- drugn -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p2	non-nucleoside reverse transcriptase inhibitor	group	_	protease inhibitor	group	_	false	the availability of potent druga -lcb- drugn -rcb- - based regimens for drugn therapy and concerns regarding drugb -lcb- drugn -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p3	non-nucleoside reverse transcriptase inhibitor	group	_	PI	group	_	false	the availability of potent druga -lcb- drugn -rcb- - based regimens for drugn therapy and concerns regarding drugn -lcb- drugb -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p4	NNRTI	group	_	antiretroviral	group	_	false	the availability of potent drugn -lcb- druga -rcb- - based regimens for drugb therapy and concerns regarding drugn -lcb- drugn -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p5	NNRTI	group	_	protease inhibitor	group	_	false	the availability of potent drugn -lcb- druga -rcb- - based regimens for drugn therapy and concerns regarding drugb -lcb- drugn -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p6	NNRTI	group	_	PI	group	_	false	the availability of potent drugn -lcb- druga -rcb- - based regimens for drugn therapy and concerns regarding drugn -lcb- drugb -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p7	antiretroviral	group	_	protease inhibitor	group	_	false	the availability of potent drugn -lcb- drugn -rcb- - based regimens for druga therapy and concerns regarding drugb -lcb- drugn -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s1.p8	antiretroviral	group	_	PI	group	_	false	the availability of potent drugn -lcb- drugn -rcb- - based regimens for druga therapy and concerns regarding drugn -lcb- drugb -rcb- - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .
DDI-MedLine.d132.s2.p0	NNRTI	group	_	PI	group	_	false	druga - based regimens may have several advantages over drugb - based therapy for initial or prolonged therapy , including more convenient administration regimens , lower tablet volume , fewer drug interactions , and central nervous system penetration .
DDI-MedLine.d132.s4.p0	efavirenz	drug	_	nevirapine	drug	_	false	both druga and drugb have been compared to triple therapy with the drugn drugn over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p1	efavirenz	drug	_	PI	group	_	false	both druga and drugn have been compared to triple therapy with the drugb drugn over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p2	efavirenz	drug	_	indinavir	drug	_	false	both druga and drugn have been compared to triple therapy with the drugn drugb over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p3	efavirenz	drug	_	nevirapine	drug	_	false	both druga and drugn have been compared to triple therapy with the drugn drugn over # weeks as initial therapy , with similar responses being observed with drugb regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p6	nevirapine	drug	_	indinavir	drug	_	false	both drugn and druga have been compared to triple therapy with the drugn drugb over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p8	nevirapine	drug	_	efavirenz	drug	_	false	both drugn and druga have been compared to triple therapy with the drugn drugn over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugb .
DDI-MedLine.d132.s4.p9	PI	group	_	indinavir	drug	_	false	both drugn and drugn have been compared to triple therapy with the druga drugb over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p11	PI	group	_	efavirenz	drug	_	false	both drugn and drugn have been compared to triple therapy with the druga drugn over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugb .
DDI-MedLine.d132.s4.p12	indinavir	drug	_	nevirapine	drug	_	false	both drugn and drugn have been compared to triple therapy with the drugn druga over # weeks as initial therapy , with similar responses being observed with drugb regimens and superiority observed with drugn .
DDI-MedLine.d132.s4.p13	indinavir	drug	_	efavirenz	drug	_	false	both drugn and drugn have been compared to triple therapy with the drugn druga over # weeks as initial therapy , with similar responses being observed with drugn regimens and superiority observed with drugb .
DDI-MedLine.d132.s4.p14	nevirapine	drug	_	efavirenz	drug	_	false	both drugn and drugn have been compared to triple therapy with the drugn drugn over # weeks as initial therapy , with similar responses being observed with druga regimens and superiority observed with drugb .
DDI-MedLine.d132.s5.p1	nevirapine	drug	_	nelfinavir	drug	_	false	a smaller 24-week study has suggested druga may be superior to the drugn drugb .
DDI-MedLine.d132.s5.p2	PI	group	_	nelfinavir	drug	_	false	a smaller 24-week study has suggested drugn may be superior to the druga drugb .
DDI-MedLine.d132.s6.p0	nevirapine	drug	_	delavirdine	drug	_	false	limited comparative data in patients with high viral loads treated with druga - or drugb - based regimens currently exist .
DDI-MedLine.d132.s8.p0	efavirenz	drug	_	indinavir	drug	_	false	the superiority of druga over drugb - based regimens has been observed in comparative data in a subset of patients with high viral loads .
DDI-MedLine.d132.s10.p0	Efavirenz	drug	_	nelfinavir	drug	_	false	druga has demonstrated superiority over drugb in nucleoside-experienced patients , although combining these # agents may represent the best approach in these circumstances .
DDI-MedLine.d42.s4.p1	sildenafil	drug	_	Viagra	brand	_	false	methods : clinical studies , case reports , and commentaries and editorials concerning druga published in the international literature between january # and august # were identified through searches of medline , premedline , and international pharmaceutical abstracts , using the terms drugn , drugb , and erectile dysfunction .
DDI-MedLine.d42.s4.p2	sildenafil	drug	_	Viagra	brand	_	false	methods : clinical studies , case reports , and commentaries and editorials concerning drugn published in the international literature between january # and august # were identified through searches of medline , premedline , and international pharmaceutical abstracts , using the terms druga , drugb , and erectile dysfunction .
DDI-MedLine.d42.s5.p0	Sildenafil	drug	_	selective serotonin reuptake inhibitors	group	_	false	results : druga has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy -lcb- eg , drugb -lsb- drugn -rsb- -rcb- .
DDI-MedLine.d42.s5.p1	Sildenafil	drug	_	SSRIs	group	_	false	results : druga has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy -lcb- eg , drugn -lsb- drugb -rsb- -rcb- .
DDI-MedLine.d42.s9.p0	nitrate	group	_	sildenafil	drug	_	effect	however , patients with moderate to severe cardiovascular disease or those taking druga therapy are at increased risk for potentially serious cardiovascular adverse effects with drugb therapy .
DDI-MedLine.d38.s0.p0	hydrocortisone	drug	_	d-amphetamine	drug	_	false	acute druga administration does not affect subjective responses to drugb in humans .
DDI-MedLine.d38.s2.p0	glucocorticoids	group	_	psychostimulants	group	_	false	however , the effects of stress and druga on the subjective and behavioral effects of drugb have not been well studied in humans .
DDI-MedLine.d38.s3.p0	hydrocortisone	drug	_	d-amphetamine	drug	_	false	objectives : to examine the effects of acute druga pretreatment on the subjective and behavioral effects of drugb .
DDI-MedLine.d38.s4.p0	Hydrocortisone	drug	_	d-amphetamine	drug	_	false	methods : druga -lcb- 100 mg -rcb- and drugb -lcb- 20 mg -rcb- were administered orally to # healthy male and female volunteers in a four-session , placebo-controlled , within-subject , crossover design .
DDI-MedLine.d38.s8.p0	hydrocortisone	drug	_	d-amphetamine	drug	_	false	however , druga pretreatment did not affect any of the physiological , behavioral , or subjective effects of drugb .
DDI-MedLine.d38.s9.p0	glucocorticoids	group	_	d-amphetamine	drug	_	false	conclusions : in contrast to the effects of druga in rodent studies , these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of drugb in humans .
DDI-MedLine.d23.s0.p0	ketamine	drug	_	Innovar	brand	_	false	the effects of druga and of drugb anesthesia on drugn tolerance in dogs .
DDI-MedLine.d23.s0.p1	ketamine	drug	_	digitalis	group	_	false	the effects of druga and of drugn anesthesia on drugb tolerance in dogs .
DDI-MedLine.d23.s0.p2	Innovar	brand	_	digitalis	group	_	false	the effects of drugn and of druga anesthesia on drugb tolerance in dogs .
DDI-MedLine.d23.s1.p0	digitalis	group	_	ketamine	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugb , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p1	digitalis	group	_	Innovar Vet	brand	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugb , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p2	digitalis	group	_	pentobarbital	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugb , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p3	digitalis	group	_	ouabain	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugb needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p4	digitalis	group	_	ouabain	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugb , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p5	digitalis	group	_	ketamine	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugb or drugn than with drugn .
DDI-MedLine.d23.s1.p6	digitalis	group	_	Innovar	brand	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugb than with drugn .
DDI-MedLine.d23.s1.p7	digitalis	group	_	pentobarbital	drug	_	false	in a comparison of druga tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugb .
DDI-MedLine.d23.s1.p9	ketamine	drug	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with druga , drugn , or drugb , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p10	ketamine	drug	_	ouabain	drug	_	effect	in a comparison of drugn tolerance in dogs anesthetized with druga , drugn , or drugn , the dosage of drugb needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p11	ketamine	drug	_	ouabain	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with druga , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugb , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p13	ketamine	drug	_	Innovar	brand	_	false	in a comparison of drugn tolerance in dogs anesthetized with druga , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugb than with drugn .
DDI-MedLine.d23.s1.p14	ketamine	drug	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with druga , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugb .
DDI-MedLine.d23.s1.p16	Innovar Vet	brand	_	ouabain	drug	_	effect	in a comparison of drugn tolerance in dogs anesthetized with drugn , druga , or drugn , the dosage of drugb needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p17	Innovar Vet	brand	_	ouabain	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , druga , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugb , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p18	Innovar Vet	brand	_	ketamine	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , druga , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugb or drugn than with drugn .
DDI-MedLine.d23.s1.p20	Innovar Vet	brand	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , druga , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugb .
DDI-MedLine.d23.s1.p21	pentobarbital	drug	_	ouabain	drug	_	effect	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or druga , the dosage of drugb needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p22	pentobarbital	drug	_	ouabain	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or druga , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugb , with drugn or drugn than with drugn .
DDI-MedLine.d23.s1.p23	pentobarbital	drug	_	ketamine	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or druga , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugb or drugn than with drugn .
DDI-MedLine.d23.s1.p24	pentobarbital	drug	_	Innovar	brand	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or druga , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugb than with drugn .
DDI-MedLine.d23.s1.p27	ouabain	drug	_	ketamine	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of druga needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugb or drugn than with drugn .
DDI-MedLine.d23.s1.p28	ouabain	drug	_	Innovar	brand	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of druga needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugb than with drugn .
DDI-MedLine.d23.s1.p29	ouabain	drug	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of druga needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or drugn than with drugb .
DDI-MedLine.d23.s1.p30	ouabain	drug	_	ketamine	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of druga , with drugb or drugn than with drugn .
DDI-MedLine.d23.s1.p31	ouabain	drug	_	Innovar	brand	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of druga , with drugn or drugb than with drugn .
DDI-MedLine.d23.s1.p32	ouabain	drug	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of druga , with drugn or drugn than with drugb .
DDI-MedLine.d23.s1.p33	ketamine	drug	_	Innovar	brand	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with druga or drugb than with drugn .
DDI-MedLine.d23.s1.p34	ketamine	drug	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with druga or drugn than with drugb .
DDI-MedLine.d23.s1.p35	Innovar	brand	_	pentobarbital	drug	_	false	in a comparison of drugn tolerance in dogs anesthetized with drugn , drugn , or drugn , the dosage of drugn needed to cause ventricular tachycardia was significantly higher , as was the ld50 of drugn , with drugn or druga than with drugb .
DDI-MedLine.d23.s2.p0	ouabain	drug	_	Innovar	brand	_	effect	ventricular tachycardia induced by druga was generally converted to sinus rhythm following administration of drugb , drugn , or drugn but not after administration of drugn alone or after drugn .
DDI-MedLine.d23.s2.p1	ouabain	drug	_	ketamine	drug	_	effect	ventricular tachycardia induced by druga was generally converted to sinus rhythm following administration of drugn , drugb , or drugn but not after administration of drugn alone or after drugn .
DDI-MedLine.d23.s2.p2	ouabain	drug	_	droperidol	drug	_	effect	ventricular tachycardia induced by druga was generally converted to sinus rhythm following administration of drugn , drugn , or drugb but not after administration of drugn alone or after drugn .
DDI-MedLine.d23.s2.p3	ouabain	drug	_	fentayl	drug	_	false	ventricular tachycardia induced by druga was generally converted to sinus rhythm following administration of drugn , drugn , or drugn but not after administration of drugb alone or after drugn .
DDI-MedLine.d23.s2.p4	ouabain	drug	_	pentobarbital	drug	_	false	ventricular tachycardia induced by druga was generally converted to sinus rhythm following administration of drugn , drugn , or drugn but not after administration of drugn alone or after drugb .
DDI-MedLine.d23.s2.p7	Innovar	brand	_	fentayl	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of druga , drugn , or drugn but not after administration of drugb alone or after drugn .
DDI-MedLine.d23.s2.p8	Innovar	brand	_	pentobarbital	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of druga , drugn , or drugn but not after administration of drugn alone or after drugb .
DDI-MedLine.d23.s2.p10	ketamine	drug	_	fentayl	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of drugn , druga , or drugn but not after administration of drugb alone or after drugn .
DDI-MedLine.d23.s2.p11	ketamine	drug	_	pentobarbital	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of drugn , druga , or drugn but not after administration of drugn alone or after drugb .
DDI-MedLine.d23.s2.p12	droperidol	drug	_	fentayl	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of drugn , drugn , or druga but not after administration of drugb alone or after drugn .
DDI-MedLine.d23.s2.p13	droperidol	drug	_	pentobarbital	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of drugn , drugn , or druga but not after administration of drugn alone or after drugb .
DDI-MedLine.d23.s2.p14	fentayl	drug	_	pentobarbital	drug	_	false	ventricular tachycardia induced by drugn was generally converted to sinus rhythm following administration of drugn , drugn , or drugn but not after administration of druga alone or after drugb .
DDI-MedLine.d49.s0.p0	clindamycin	drug	_	gentamicin	drug	_	int	interaction of druga and drugb in vitro .
DDI-MedLine.d49.s1.p0	clindamycin	drug	_	gentamicin	drug	_	false	the minimal inhibitory concentrations of druga and drugb alone and in combinations were determined by a microdilution method for # aerobic , facultative , and anaerobic clinical isolates .
DDI-MedLine.d49.s3.p0	Gentamicin	drug	_	clindamycin	drug	_	false	druga did not interfere with the activity of drugb within the range of concentrations tested -lcb- # to # mug/ml -rcb- ;
DDI-MedLine.d49.s6.p0	clindamycin	drug	_	gentamicin	drug	_	effect	combinations of druga and drugb were indifferent for # strains and synergistic for # strains .
DDI-MedLine.d49.s7.p0	clindamycin	drug	_	gentamicin	drug	_	false	all # strains of enterococcus , three strains of clostridium , three strains of escherichia coli , and one strain of proteus rettgeri were resistant to both druga -lcb- minimal inhibitory concentration greater than # mug/ml -rcb- and drugb -lcb- minimal inhibitory concentration greater than # mug/ml -rcb- .
DDI-MedLine.d49.s8.p0	clindamycin	drug	_	gentamicin	drug	_	effect	combinations of druga and drugb were indifferent for # and synergistic for # of the resistant strains .
DDI-MedLine.d120.s0.p0	amphotericin B	drug	_	filipin	drug_n	_	false	molecular basis for the selective toxicity of druga for yeast and drugb for animal cells .
DDI-MedLine.d120.s1.p0	polyene antibiotics	group	_	filipin	drug_n	_	false	among the druga , many , like drugb , can not be used clinically because they are toxic ;
DDI-MedLine.d120.s3.p0	filipin	drug_n	_	amphotericin B	drug	_	false	both the toxicity of druga and the therapeutic value of drugb can be rationalized at the cellular and molecular level by the following observations : -lcb- i -rcb- these drugn showed differential effects on cells ;
DDI-MedLine.d120.s3.p1	filipin	drug_n	_	polyene antibiotics	group	_	false	both the toxicity of druga and the therapeutic value of drugn can be rationalized at the cellular and molecular level by the following observations : -lcb- i -rcb- these drugb showed differential effects on cells ;
DDI-MedLine.d120.s3.p2	amphotericin B	drug	_	polyene antibiotics	group	_	false	both the toxicity of drugn and the therapeutic value of druga can be rationalized at the cellular and molecular level by the following observations : -lcb- i -rcb- these drugb showed differential effects on cells ;
DDI-MedLine.d120.s4.p0	filipin	drug_n	_	amphotericin B	drug	_	false	druga was more potent in lysing human red blood cells , whereas drugb was more potent in inhibiting yeast cell growth ;
DDI-MedLine.d120.s5.p0	filipin	drug_n	_	amphotericin B	drug	_	false	and -lcb- ii -rcb- the effects of druga were more efficiently inhibited by added cholesterol , the major membrane sterol in human cells , whereas the effects of drugb were more efficiently inhibited by ergosterol , the major membrane sterol in yeast .
DDI-MedLine.d40.s1.p0	antifungal drug	group	_	miconazole nitrate	drug	_	false	the druga , drugb , inhibits the growth of several species of candida .
DDI-MedLine.d29.s0.p0	probenecid	drug	_	cloxacillin	drug	_	false	effect of druga on the apparent volume of distribution and elimination of drugb .
DDI-MedLine.d29.s2.p0	penicillins	group	_	cephaloridine	drug	_	false	-lcb- 1968 , 1970 -rcb- , the higher serum concentrations of druga and drugb reached after administration of drugn are due not only to slower renal elimination but also to an altered distribution in the body .
DDI-MedLine.d29.s2.p1	penicillins	group	_	probenecid	drug	_	mechanism	-lcb- 1968 , 1970 -rcb- , the higher serum concentrations of druga and drugn reached after administration of drugb are due not only to slower renal elimination but also to an altered distribution in the body .
DDI-MedLine.d29.s2.p2	cephaloridine	drug	_	probenecid	drug	_	mechanism	-lcb- 1968 , 1970 -rcb- , the higher serum concentrations of drugn and druga reached after administration of drugb are due not only to slower renal elimination but also to an altered distribution in the body .
DDI-MedLine.d29.s3.p0	probenecid	drug	_	cloxacillin	drug	_	false	to determine whether druga has a direct effect on the distribution of drugb , the elimination and distribution of drugn was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of drugn .
DDI-MedLine.d29.s3.p1	probenecid	drug	_	cloxacillin	drug	_	false	to determine whether druga has a direct effect on the distribution of drugn , the elimination and distribution of drugb was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of drugn .
DDI-MedLine.d29.s3.p4	cloxacillin	drug	_	probenecid	drug	_	false	to determine whether drugn has a direct effect on the distribution of druga , the elimination and distribution of drugn was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of drugb .
DDI-MedLine.d29.s3.p5	cloxacillin	drug	_	probenecid	drug	_	false	to determine whether drugn has a direct effect on the distribution of drugn , the elimination and distribution of druga was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of drugb .
DDI-MedLine.d29.s4.p0	cloxacillin	drug	_	probenecid	drug	_	false	no significant difference was found between the mean values of the volume of distribution of druga with and without drugb -lcb- # and # liters , respectively -rcb- .
DDI-MedLine.d29.s8.p0	probenecid	drug	_	cloxacillin	drug	_	mechanism	this might be explained by a blockade by druga of the elimination of drugb by the liver .
DDI-MedLine.d122.s1.p0	alcohol	drug	_	nicotine	drug	_	false	many people use both druga and drugb -lcb- i , e , , cigarettes and other tobacco products -rcb- .
DDI-MedLine.d122.s3.p0	alcohol	drug	_	nicotine	drug	_	false	the initiation of druga or drugb use may be precipitated by similar personality characteristics in the user , such as impulsivity and sensation seeking .
DDI-MedLine.d122.s4.p0	alcohol	drug	_	nicotine	drug	_	false	moreover , the mechanisms underlying the development of dependence may be similar for druga and drugb .
DDI-MedLine.d134.s0.p0	radiopertechnetate	drug	_	sodium perchlorate	drug_n	_	false	-lsb- dose-time effects of competitive displacement of druga by drugb following oral and intravenous administration -rsb- the effect of various doses of drugn in several dose fractions on the extent and the time scale of displacement of drugn , in dependence on application mode , was studied .
DDI-MedLine.d134.s0.p5	sodium perchlorate	drug_n	_	radiopertechnetate	drug	_	false	-lsb- dose-time effects of competitive displacement of drugn by drugn following oral and intravenous administration -rsb- the effect of various doses of druga in several dose fractions on the extent and the time scale of displacement of drugb , in dependence on application mode , was studied .
DDI-MedLine.d134.s1.p0	perchlorate	drug_n	_	pertechnetate	drug	_	false	an intravenous dose of # mg druga was in respect of competitive suppression of organs actively concentrating drugb as effective as intravenous # mg clo-4 - simultaneously or # mg orally # min before the injection of drugn .
DDI-MedLine.d134.s1.p1	perchlorate	drug_n	_	radiopertechnetate	drug	_	false	an intravenous dose of # mg druga was in respect of competitive suppression of organs actively concentrating drugn as effective as intravenous # mg clo-4 - simultaneously or # mg orally # min before the injection of drugb .
DDI-MedLine.d134.s2.p0	perchlorate	drug_n	_	pertechnetate	drug	_	mechanism	an intravenous injection of druga given later also produces a complete and immediately beginning depletion of drugb already accumulated in the thyroid , within a period of # min after 99m-tco-4-injection with a corresponding increase in blood levels .
DDI-MedLine.d118.s0.p0	Sirolimus	drug	_	rapamycin	drug	_	false	druga : mammalian target of drugb inhibitor to prevent kidney rejection .
DDI-MedLine.d118.s2.p0	Sirolimus	drug	_	immunosuppressants	group	_	false	druga works differently from the drugb currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with drugn or drugn .
DDI-MedLine.d118.s2.p2	Sirolimus	drug	_	cyclosporine	drug	_	false	druga works differently from the drugn currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with drugb or drugn .
DDI-MedLine.d118.s2.p3	Sirolimus	drug	_	tacrolimus	drug	_	false	druga works differently from the drugn currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with drugn or drugb .
DDI-MedLine.d118.s2.p4	immunosuppressants	group	_	sirolimus	drug	_	false	drugn works differently from the druga currently available , and except for increased lipid levels , the adverse reaction profile of drugb does not appear to overlap to any great extent with that associated with drugn or drugn .
DDI-MedLine.d118.s2.p5	immunosuppressants	group	_	cyclosporine	drug	_	false	drugn works differently from the druga currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with drugb or drugn .
DDI-MedLine.d118.s2.p6	immunosuppressants	group	_	tacrolimus	drug	_	false	drugn works differently from the druga currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with drugn or drugb .
DDI-MedLine.d118.s2.p7	sirolimus	drug	_	cyclosporine	drug	_	false	drugn works differently from the drugn currently available , and except for increased lipid levels , the adverse reaction profile of druga does not appear to overlap to any great extent with that associated with drugb or drugn .
DDI-MedLine.d118.s2.p8	sirolimus	drug	_	tacrolimus	drug	_	false	drugn works differently from the drugn currently available , and except for increased lipid levels , the adverse reaction profile of druga does not appear to overlap to any great extent with that associated with drugn or drugb .
DDI-MedLine.d118.s2.p9	cyclosporine	drug	_	tacrolimus	drug	_	false	drugn works differently from the drugn currently available , and except for increased lipid levels , the adverse reaction profile of drugn does not appear to overlap to any great extent with that associated with druga or drugb .
DDI-MedLine.d118.s3.p0	sirolimus	drug	_	cyclosporine	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that druga , in combination with drugb or drugn , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugn or drugn dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p1	sirolimus	drug	_	tacrolimus	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that druga , in combination with drugn or drugb , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugn or drugn dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p2	sirolimus	drug	_	cyclosporine	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that druga , in combination with drugn or drugn , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugb or drugn dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p3	sirolimus	drug	_	tacrolimus	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that druga , in combination with drugn or drugn , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugn or drugb dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p4	cyclosporine	drug	_	tacrolimus	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that drugn , in combination with druga or drugb , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugn or drugn dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p6	cyclosporine	drug	_	tacrolimus	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that drugn , in combination with druga or drugn , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugn or drugb dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p7	tacrolimus	drug	_	cyclosporine	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that drugn , in combination with drugn or druga , might have the potential to reduce the frequency of rejection episodes , permit reductions in drugb or drugn dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d118.s3.p9	cyclosporine	drug	_	tacrolimus	drug	_	false	while additional research is needed , the initial clinical data in kidney recipients suggest that drugn , in combination with drugn or drugn , might have the potential to reduce the frequency of rejection episodes , permit reductions in druga or drugb dosage , and permit steroid withdrawal -lcb- kelly , 1999 -rcb- .
DDI-MedLine.d88.s4.p0	cocaine	drug	_	amphetamine	drug	_	false	the concomitant administration of either druga or drugb , compounds which inhibit neuronal reuptake of norepinephrine , disrupts the behavioral response of the genetically nervous e-strain subjects to a far greater extent than the stable a-strain subjects .
DDI-MedLine.d119.s1.p0	Fluvastatin	drug	_	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	group	_	false	druga is the first drugb to be approved for clinical use , and has been studied extensively in humans since 1986 .
DDI-MedLine.d119.s15.p0	Cholestyramine	drug	_	fluvastatin	drug	_	mechanism	druga , an anionic-binding resin , has a considerable effect in lowering the rate and extent of drugb bioavailability .
DDI-MedLine.d119.s16.p0	cholestyramine	drug	_	fluvastatin	drug	_	effect	although this effect was noted even when druga was given # hours prior to drugb , this regimen did not result in diminished efficacy .
DDI-MedLine.d119.s17.p1	warfarin	drug	_	fluvastatin	drug	_	false	further , no effects on either druga levels or prothrombin times were observed in a study involving concomitant administration of drugn and drugb .
DDI-MedLine.d119.s17.p2	warfarin	drug	_	fluvastatin	drug	_	false	further , no effects on either drugn levels or prothrombin times were observed in a study involving concomitant administration of druga and drugb .
DDI-MedLine.d119.s18.p0	niacin	drug	_	propranolol	drug	_	false	moreover , additional interaction studies with druga and drugb have not demonstrated any effect on drugn plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p1	niacin	drug	_	fluvastatin	drug	_	false	moreover , additional interaction studies with druga and drugn have not demonstrated any effect on drugb plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p2	niacin	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with druga and drugn have not demonstrated any effect on drugn plasma levels , and administration to a patient population chronically receiving drugb resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p3	niacin	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with druga and drugn have not demonstrated any effect on drugn plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugb relative to control data .
DDI-MedLine.d119.s18.p4	propranolol	drug	_	fluvastatin	drug	_	false	moreover , additional interaction studies with drugn and druga have not demonstrated any effect on drugb plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p5	propranolol	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with drugn and druga have not demonstrated any effect on drugn plasma levels , and administration to a patient population chronically receiving drugb resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p6	propranolol	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with drugn and druga have not demonstrated any effect on drugn plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugb relative to control data .
DDI-MedLine.d119.s18.p7	fluvastatin	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with drugn and drugn have not demonstrated any effect on druga plasma levels , and administration to a patient population chronically receiving drugb resulted in no difference in the extent of bioavailability of drugn relative to control data .
DDI-MedLine.d119.s18.p8	fluvastatin	drug	_	digoxin	drug	_	false	moreover , additional interaction studies with drugn and drugn have not demonstrated any effect on druga plasma levels , and administration to a patient population chronically receiving drugn resulted in no difference in the extent of bioavailability of drugb relative to control data .
DDI-MedLine.d57.s1.p0	antihistaminics	group	_	analgesic agents	group	_	false	the literature provides considerable evidence indicating that several , but not all druga , are indeed drugb and some are drugn as well .
DDI-MedLine.d57.s1.p1	antihistaminics	group	_	analgesic adjuvants	group	_	false	the literature provides considerable evidence indicating that several , but not all druga , are indeed drugn and some are drugb as well .
DDI-MedLine.d57.s1.p2	analgesic agents	group	_	analgesic adjuvants	group	_	false	the literature provides considerable evidence indicating that several , but not all drugn , are indeed druga and some are drugb as well .
DDI-MedLine.d27.s0.p0	picrotoxin	drug_n	_	diazepam	drug	_	effect	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that druga -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugb , drugn , drugn and drugn and reduces the action of drugn .
DDI-MedLine.d27.s0.p1	picrotoxin	drug_n	_	phenazepam	drug_n	_	effect	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that druga -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugb , drugn and drugn and reduces the action of drugn .
DDI-MedLine.d27.s0.p2	picrotoxin	drug_n	_	phenibut	drug_n	_	effect	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that druga -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugn , drugb and drugn and reduces the action of drugn .
DDI-MedLine.d27.s0.p3	picrotoxin	drug_n	_	amizyl	drug_n	_	effect	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that druga -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugn , drugn and drugb and reduces the action of drugn .
DDI-MedLine.d27.s0.p4	picrotoxin	drug_n	_	phentolamine	drug	_	effect	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that druga -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugn , drugn and drugn and reduces the action of drugb .
DDI-MedLine.d27.s0.p8	diazepam	drug	_	phentolamine	drug	_	false	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that drugn -lcb- 1 mg/kg -rcb- removes the antiedematous action of druga , drugn , drugn and drugn and reduces the action of drugb .
DDI-MedLine.d27.s0.p11	phenazepam	drug_n	_	phentolamine	drug	_	false	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that drugn -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , druga , drugn and drugn and reduces the action of drugb .
DDI-MedLine.d27.s0.p13	phenibut	drug_n	_	phentolamine	drug	_	false	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that drugn -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugn , druga and drugn and reduces the action of drugb .
DDI-MedLine.d27.s0.p14	amizyl	drug_n	_	phentolamine	drug	_	false	-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that drugn -lcb- 1 mg/kg -rcb- removes the antiedematous action of drugn , drugn , drugn and druga and reduces the action of drugb .
DDI-MedLine.d15.s0.p0	cerulein	drug_n	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by druga -- an analog of the octapeptide cholecystokinin -- of drugb binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p1	cerulein	drug_n	_	neuroleptics	group	_	false	-lsb- stimulation by druga -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugb -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p8	3H-spiroperidol	drug_n	_	neuroleptics	group	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of druga binding after the long-term administration of drugb -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p21	haloperidol	drug	_	pyreneperone	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of druga -lcb- # mg/kg -rcb- and drugb -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p22	haloperidol	drug	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of druga -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugb and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p23	haloperidol	drug	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of druga -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugb in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p24	haloperidol	drug	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of druga -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugb binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p25	haloperidol	drug	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of druga -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugb increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p26	pyreneperone	drug_n	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and druga -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugb and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p27	pyreneperone	drug_n	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and druga -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugb in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p28	pyreneperone	drug_n	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and druga -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugb binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p29	pyreneperone	drug_n	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and druga -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugb increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p30	3H-spiroperidol	drug_n	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between druga and low affinity binding sites for drugb in subcortical structures , whereas drugn binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p32	3H-spiroperidol	drug_n	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between druga and low affinity binding sites for drugn in subcortical structures , whereas drugn binding with high affinity binding sites for drugb increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p33	apomorphine	drug	_	3H-spiroperidol	drug_n	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for druga in subcortical structures , whereas drugb binding with high affinity binding sites for drugn increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s0.p35	3H-spiroperidol	drug_n	_	apomorphine	drug	_	false	-lsb- stimulation by drugn -- an analog of the octapeptide cholecystokinin -- of drugn binding after the long-term administration of drugn -rsb- it has been established in experiments on white male rats that prolonged administration -lcb- twice a day for # days -rcb- of drugn -lcb- # mg/kg -rcb- and drugn -lcb- # mg/kg -rcb- resulted in the reduced interaction between drugn and low affinity binding sites for drugn in subcortical structures , whereas druga binding with high affinity binding sites for drugb increased both in the frontal cortex and subcortical structures of the forebrain .
DDI-MedLine.d15.s1.p0	neuroleptics	group	_	cerulein	drug_n	_	false	after prolonged administration of druga the displacing effect of drugb , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on drugn binding .
DDI-MedLine.d15.s1.p1	neuroleptics	group	_	3H-spiroperidol	drug_n	_	false	after prolonged administration of druga the displacing effect of drugn , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on drugb binding .
DDI-MedLine.d15.s1.p2	cerulein	drug_n	_	3H-spiroperidol	drug_n	_	false	after prolonged administration of drugn the displacing effect of druga , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on drugb binding .
DDI-MedLine.d15.s2.p0	3H-spiroperidol	drug_n	_	apomorphine	drug	_	false	it is assumed that increased interaction between druga and high affinity binding sites for drugb on dopamine2 - and serotonin2-receptors underlies the antipsychotic action of drugn after their prolonged administration .
DDI-MedLine.d15.s2.p1	3H-spiroperidol	drug_n	_	neuroleptics	group	_	false	it is assumed that increased interaction between druga and high affinity binding sites for drugn on dopamine2 - and serotonin2-receptors underlies the antipsychotic action of drugb after their prolonged administration .
DDI-MedLine.d15.s2.p2	apomorphine	drug	_	neuroleptics	group	_	false	it is assumed that increased interaction between drugn and high affinity binding sites for druga on dopamine2 - and serotonin2-receptors underlies the antipsychotic action of drugb after their prolonged administration .
DDI-MedLine.d56.s0.p0	ouabain	drug	_	palytoxin	drug_n	_	false	dual effect of druga on the drugb - induced contraction and norepinephrine release in the guinea-pig vas deferens .
DDI-MedLine.d56.s2.p0	ouabain	drug	_	PTX	drug_n	_	effect	in the presence of druga -lcb- 10 -lcb- -5 -rcb- m -rcb- , drugb -lcb- 10 -lcb- -8 -rcb- m -rcb- failed to cause the first contraction ;
DDI-MedLine.d56.s5.p0	ouabain	drug	_	phentolamine	drug	_	effect	when druga was applied to the muscle in the presence of drugb , both first and second contractile responses to drugn were abolished .
DDI-MedLine.d56.s5.p1	ouabain	drug	_	PTX	drug_n	_	false	when druga was applied to the muscle in the presence of drugn , both first and second contractile responses to drugb were abolished .
DDI-MedLine.d56.s5.p2	phentolamine	drug	_	PTX	drug_n	_	false	when drugn was applied to the muscle in the presence of druga , both first and second contractile responses to drugb were abolished .
DDI-MedLine.d56.s8.p0	ouabain	drug	_	PTX	drug_n	_	effect	exposure of the muscle to druga -lcb- 10 -lcb- -5 -rcb- m -rcb- markedly increased the drugb - induced release .
DDI-MedLine.d82.s2.p0	arsenate	drug_n	_	As(V)	drug_n	_	false	by this procedure , it was observed that druga is rapidly and essentially completely absorbed -lcb- 80-95 % -rcb- from the lumen at drugb concentrations up to # mm , declining to about 50 % absorption at # mm .
DDI-MedLine.d82.s7.p0	arsenate	drug_n	_	phosphate	drug	_	false	furthermore , druga and drugb do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level .
DDI-MedLine.d82.s8.p0	Vitamin D3	drug	_	arsenate	drug_n	_	mechanism	druga administration to rachitic chicks was effective in significantly elevating duodenal drugb absorption , acting primarily to enhance serosal transport .
DDI-MedLine.d22.s2.p0	spermidine	drug_n	_	putrescine	drug_n	_	false	by contrast , druga -lcb- 1 mm -rcb- and drugb -lcb- 1 mm -rcb- had no significant effect on the translocation when added alone .
DDI-MedLine.d22.s3.p0	Spermine	drug	_	spermidine	drug_n	_	false	druga , and to a lesser extent , drugb , enhanced the translocating action of oleic_acid and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction .
DDI-MedLine.d100.s5.p0	Slow-channel calcium blockers	group	_	verapamil	drug	_	false	druga , such as drugb , drugn and drugn , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
DDI-MedLine.d100.s5.p1	Slow-channel calcium blockers	group	_	diltiazem	drug	_	false	druga , such as drugn , drugb and drugn , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
DDI-MedLine.d100.s5.p2	Slow-channel calcium blockers	group	_	nifedipine	drug	_	false	druga , such as drugn , drugn and drugb , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .
DDI-MedLine.d63.s0.p0	naloxone	drug	_	beta-endorphin	drug_n	_	false	differential actions of intrathecal druga on blocking the tail-flick inhibition induced by intraventricular drugb and drugn in rats .
DDI-MedLine.d63.s0.p1	naloxone	drug	_	morphine	drug	_	false	differential actions of intrathecal druga on blocking the tail-flick inhibition induced by intraventricular drugn and drugb in rats .
DDI-MedLine.d63.s0.p2	beta-endorphin	drug_n	_	morphine	drug	_	false	differential actions of intrathecal drugn on blocking the tail-flick inhibition induced by intraventricular druga and drugb in rats .
DDI-MedLine.d63.s2.p0	naloxone	drug	_	beta-endorphin	drug_n	_	false	the blockade of the spinal endorphinergic system by intrathecal druga on the production of tail-flick inhibition induced by intraventricular drugb and drugn was then studied .
DDI-MedLine.d63.s2.p1	naloxone	drug	_	morphine	drug	_	false	the blockade of the spinal endorphinergic system by intrathecal druga on the production of tail-flick inhibition induced by intraventricular drugn and drugb was then studied .
DDI-MedLine.d63.s2.p2	beta-endorphin	drug_n	_	morphine	drug	_	false	the blockade of the spinal endorphinergic system by intrathecal drugn on the production of tail-flick inhibition induced by intraventricular druga and drugb was then studied .
DDI-MedLine.d63.s3.p0	beta-endorphin	drug_n	_	morphine	drug	_	false	intraventricular injection of druga and drugb produced an inhibition of the tail-flick response to the heat stimulus in rats .
DDI-MedLine.d63.s4.p0	naloxone	drug	_	beta-endorphin	drug_n	_	effect	intrathecal injection of druga at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drugb , and a high dose of drugn -lcb- 40 micrograms -rcb- completely blocked the tail-flick inhibition induced by intraventricular drugn -lcb- 16 micrograms -rcb- .
DDI-MedLine.d63.s4.p2	naloxone	drug	_	beta-endorphin	drug_n	_	false	intrathecal injection of druga at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drugn , and a high dose of drugn -lcb- 40 micrograms -rcb- completely blocked the tail-flick inhibition induced by intraventricular drugb -lcb- 16 micrograms -rcb- .
DDI-MedLine.d63.s4.p3	beta-endorphin	drug_n	_	naloxone	drug	_	false	intrathecal injection of drugn at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of druga , and a high dose of drugb -lcb- 40 micrograms -rcb- completely blocked the tail-flick inhibition induced by intraventricular drugn -lcb- 16 micrograms -rcb- .
DDI-MedLine.d63.s4.p5	naloxone	drug	_	beta-endorphin	drug_n	_	effect	intrathecal injection of drugn at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drugn , and a high dose of druga -lcb- 40 micrograms -rcb- completely blocked the tail-flick inhibition induced by intraventricular drugb -lcb- 16 micrograms -rcb- .
DDI-MedLine.d63.s5.p0	naloxone	drug	_	morphine	drug	_	effect	on the other hand , intrathecal druga -lcb- 12-120 micrograms -rcb- had only a very weak effect on the tail-flick inhibition induced by intraventricular drugb -lcb- 40 micrograms -rcb- .
DDI-MedLine.d63.s6.p0	naloxone	drug	_	beta-endorphin	drug_n	_	effect	intraventricular injection of druga at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drugb and drugn .
DDI-MedLine.d63.s6.p1	naloxone	drug	_	morphine	drug	_	effect	intraventricular injection of druga at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drugn and drugb .
DDI-MedLine.d63.s6.p2	beta-endorphin	drug_n	_	morphine	drug	_	false	intraventricular injection of drugn at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular druga and drugb .
DDI-MedLine.d63.s7.p0	naloxone	drug	_	beta-endorphin	drug_n	_	false	the results indicate that a spinal druga - sensitive endorphinergic system is involved in the production of drugb but not drugn - induced tail-flick inhibition , and suggest that intraventricular drugn and drugn elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p1	naloxone	drug	_	morphine	drug	_	false	the results indicate that a spinal druga - sensitive endorphinergic system is involved in the production of drugn but not drugb - induced tail-flick inhibition , and suggest that intraventricular drugn and drugn elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p2	naloxone	drug	_	beta-endorphin	drug_n	_	false	the results indicate that a spinal druga - sensitive endorphinergic system is involved in the production of drugn but not drugn - induced tail-flick inhibition , and suggest that intraventricular drugb and drugn elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p3	naloxone	drug	_	morphine	drug	_	false	the results indicate that a spinal druga - sensitive endorphinergic system is involved in the production of drugn but not drugn - induced tail-flick inhibition , and suggest that intraventricular drugn and drugb elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p4	beta-endorphin	drug_n	_	morphine	drug	_	false	the results indicate that a spinal drugn - sensitive endorphinergic system is involved in the production of druga but not drugb - induced tail-flick inhibition , and suggest that intraventricular drugn and drugn elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p6	beta-endorphin	drug_n	_	morphine	drug	_	false	the results indicate that a spinal drugn - sensitive endorphinergic system is involved in the production of druga but not drugn - induced tail-flick inhibition , and suggest that intraventricular drugn and drugb elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p7	morphine	drug	_	beta-endorphin	drug_n	_	false	the results indicate that a spinal drugn - sensitive endorphinergic system is involved in the production of drugn but not druga - induced tail-flick inhibition , and suggest that intraventricular drugb and drugn elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s7.p9	beta-endorphin	drug_n	_	morphine	drug	_	false	the results indicate that a spinal drugn - sensitive endorphinergic system is involved in the production of drugn but not drugn - induced tail-flick inhibition , and suggest that intraventricular druga and drugb elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
DDI-MedLine.d63.s8.p0	beta-endorphin	drug_n	_	morphine	drug	_	false	descending epsilon and mu systems for druga and drugb , respectively , are proposed .
DDI-MedLine.d73.s0.p1	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	drug_n	_	methamphetamine	drug	_	false	neurochemical and functional consequences following druga -lcb- drugn -rcb- and drugb .
DDI-MedLine.d73.s0.p2	MPTP	drug_n	_	methamphetamine	drug	_	false	neurochemical and functional consequences following drugn -lcb- druga -rcb- and drugb .
DDI-MedLine.d73.s1.p0	MPTP	drug_n	_	methamphetamine	drug	_	false	the neurochemical and functional consequences following druga administration to the rat were evaluated and compared to similar effects following drugb administration .
DDI-MedLine.d73.s2.p0	MPTP	drug_n	_	pargyline	drug	_	effect	it was observed that druga induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by drugb pretreatment .
DDI-MedLine.d73.s3.p0	MPTP	drug	_	amphetamine	drug	_	effect	the druga - induced neuronal damage produced a tolerance to the disruptive effects of drugb and a supersensitivity to the disruptive effects of drugn in rats responding in a schedule controlled paradigm .
DDI-MedLine.d73.s3.p1	MPTP	drug	_	apomorphine	drug	_	effect	the druga - induced neuronal damage produced a tolerance to the disruptive effects of drugn and a supersensitivity to the disruptive effects of drugb in rats responding in a schedule controlled paradigm .
DDI-MedLine.d73.s3.p2	amphetamine	drug	_	apomorphine	drug	_	false	the drugn - induced neuronal damage produced a tolerance to the disruptive effects of druga and a supersensitivity to the disruptive effects of drugb in rats responding in a schedule controlled paradigm .
DDI-MedLine.d73.s4.p0	Methamphetamine	drug	_	MPTP	drug_n	_	false	druga , like drugb , produced depletions of striatal dopamine but these actions were potentiated by drugn pretreatment .
DDI-MedLine.d73.s4.p1	Methamphetamine	drug	_	pargyline	drug	_	effect	druga , like drugn , produced depletions of striatal dopamine but these actions were potentiated by drugb pretreatment .
DDI-MedLine.d73.s4.p2	MPTP	drug_n	_	pargyline	drug	_	false	drugn , like druga , produced depletions of striatal dopamine but these actions were potentiated by drugb pretreatment .
DDI-MedLine.d12.s0.p0	Dexamethasone	drug	_	retinyl acetate	drug	_	false	druga and drugb similarly inhibit and stimulate drugn - or drugn - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s0.p1	Dexamethasone	drug	_	EGF	drug_n	_	effect	druga and drugn similarly inhibit and stimulate drugb - or drugn - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s0.p2	Dexamethasone	drug	_	insulin	drug	_	effect	druga and drugn similarly inhibit and stimulate drugn - or drugb - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s0.p3	retinyl acetate	drug	_	EGF	drug_n	_	effect	drugn and druga similarly inhibit and stimulate drugb - or drugn - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s0.p4	retinyl acetate	drug	_	insulin	drug	_	effect	drugn and druga similarly inhibit and stimulate drugn - or drugb - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s0.p5	EGF	drug_n	_	insulin	drug	_	false	drugn and drugn similarly inhibit and stimulate druga - or drugb - induced proliferation of prostatic epithelium .
DDI-MedLine.d12.s2.p0	dexamethasone	drug	_	retinyl acetate	drug	_	false	although neither druga nor drugb affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of drugn and drugn .
DDI-MedLine.d12.s2.p1	dexamethasone	drug	_	transferrin	drug_n	_	false	although neither druga nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing drugb alone , they modify the mitogenic effect of drugn and drugn .
DDI-MedLine.d12.s2.p2	dexamethasone	drug	_	EGF	drug_n	_	effect	although neither druga nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of drugb and drugn .
DDI-MedLine.d12.s2.p3	dexamethasone	drug	_	insulin	drug	_	effect	although neither druga nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of drugn and drugb .
DDI-MedLine.d12.s2.p4	retinyl acetate	drug	_	transferrin	drug_n	_	false	although neither drugn nor druga affected the proliferation of prostatic epithelium in rpmi1640 containing drugb alone , they modify the mitogenic effect of drugn and drugn .
DDI-MedLine.d12.s2.p5	retinyl acetate	drug	_	EGF	drug_n	_	effect	although neither drugn nor druga affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of drugb and drugn .
DDI-MedLine.d12.s2.p6	retinyl acetate	drug	_	insulin	drug	_	effect	although neither drugn nor druga affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of drugn and drugb .
DDI-MedLine.d12.s2.p7	transferrin	drug_n	_	EGF	drug_n	_	false	although neither drugn nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing druga alone , they modify the mitogenic effect of drugb and drugn .
DDI-MedLine.d12.s2.p8	transferrin	drug_n	_	insulin	drug	_	false	although neither drugn nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing druga alone , they modify the mitogenic effect of drugn and drugb .
DDI-MedLine.d12.s2.p9	EGF	drug_n	_	insulin	drug	_	false	although neither drugn nor drugn affected the proliferation of prostatic epithelium in rpmi1640 containing drugn alone , they modify the mitogenic effect of druga and drugb .
DDI-MedLine.d12.s3.p0	Dexamethasone	drug	_	retinyl acetate	drug	_	false	druga at 10 -lcb- -10 -rcb- m or drugb at about # x 10 -lcb- -9 -rcb- m inhibits proliferation stimulated by drugn .
DDI-MedLine.d12.s3.p1	Dexamethasone	drug	_	EGF	drug_n	_	effect	druga at 10 -lcb- -10 -rcb- m or drugn at about # x 10 -lcb- -9 -rcb- m inhibits proliferation stimulated by drugb .
DDI-MedLine.d12.s3.p2	retinyl acetate	drug	_	EGF	drug_n	_	effect	drugn at 10 -lcb- -10 -rcb- m or druga at about # x 10 -lcb- -9 -rcb- m inhibits proliferation stimulated by drugb .
DDI-MedLine.d12.s4.p0	dexamethasone	drug	_	retinyl acetate	drug	_	false	higher concentrations of druga -lcb- 10 -lcb- -8 -rcb- - 10 -lcb- -6 -rcb- m -rcb- or drugb -lcb- 3 x 10 -lcb- -8 -rcb- - 10 -lcb- -7 -rcb- m -rcb- enhance the mitogenic activity of drugn .
DDI-MedLine.d12.s4.p1	dexamethasone	drug	_	EGF	drug_n	_	effect	higher concentrations of druga -lcb- 10 -lcb- -8 -rcb- - 10 -lcb- -6 -rcb- m -rcb- or drugn -lcb- 3 x 10 -lcb- -8 -rcb- - 10 -lcb- -7 -rcb- m -rcb- enhance the mitogenic activity of drugb .
DDI-MedLine.d12.s4.p2	retinyl acetate	drug	_	EGF	drug_n	_	effect	higher concentrations of drugn -lcb- 10 -lcb- -8 -rcb- - 10 -lcb- -6 -rcb- m -rcb- or druga -lcb- 3 x 10 -lcb- -8 -rcb- - 10 -lcb- -7 -rcb- m -rcb- enhance the mitogenic activity of drugb .
DDI-MedLine.d12.s5.p0	Dexamethasone	drug	_	insulin	drug	_	false	druga had a similar effect in the presence of drugb .
DDI-MedLine.d12.s6.p0	retinyl acetate	drug	_	insulin	drug	_	effect	however , druga stimulated , but did not significantly inhibit , proliferation in the presence of drugb .
DDI-MedLine.d12.s7.p0	dexamethasone	drug	_	retinyl acetate	drug	_	false	these results suggest that both druga and drugb , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p1	dexamethasone	drug	_	glucocorticoids	group	_	false	these results suggest that both druga and drugn , and possibly other drugb and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p2	dexamethasone	drug	_	retinoids	group	_	false	these results suggest that both druga and drugn , and possibly other drugn and drugb , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p3	dexamethasone	drug	_	insulin	drug	_	effect	these results suggest that both druga and drugn , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugb and drugn .
DDI-MedLine.d12.s7.p4	dexamethasone	drug	_	EGF	drug_n	_	effect	these results suggest that both druga and drugn , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugb .
DDI-MedLine.d12.s7.p5	retinyl acetate	drug	_	glucocorticoids	group	_	false	these results suggest that both drugn and druga , and possibly other drugb and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p6	retinyl acetate	drug	_	retinoids	group	_	false	these results suggest that both drugn and druga , and possibly other drugn and drugb , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p7	retinyl acetate	drug	_	insulin	drug	_	effect	these results suggest that both drugn and druga , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugb and drugn .
DDI-MedLine.d12.s7.p8	retinyl acetate	drug	_	EGF	drug_n	_	effect	these results suggest that both drugn and druga , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugb .
DDI-MedLine.d12.s7.p9	glucocorticoids	group	_	retinoids	group	_	false	these results suggest that both drugn and drugn , and possibly other druga and drugb , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugn .
DDI-MedLine.d12.s7.p10	glucocorticoids	group	_	insulin	drug	_	effect	these results suggest that both drugn and drugn , and possibly other druga and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugb and drugn .
DDI-MedLine.d12.s7.p11	glucocorticoids	group	_	EGF	drug_n	_	effect	these results suggest that both drugn and drugn , and possibly other druga and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugb .
DDI-MedLine.d12.s7.p12	retinoids	group	_	insulin	drug	_	effect	these results suggest that both drugn and drugn , and possibly other drugn and druga , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugb and drugn .
DDI-MedLine.d12.s7.p13	retinoids	group	_	EGF	drug_n	_	effect	these results suggest that both drugn and drugn , and possibly other drugn and druga , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drugn and drugb .
DDI-MedLine.d12.s7.p14	insulin	drug	_	EGF	drug_n	_	false	these results suggest that both drugn and drugn , and possibly other drugn and drugn , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of druga and drugb .
DDI-MedLine.d9.s3.p0	calcium-entry blocking agents	group	_	verapamil	drug	_	false	for the druga now available in the united states -lcb- drugb , drugn and drugn -rcb- , these data appeared well after clinical patterns of use evolved .
DDI-MedLine.d9.s3.p1	calcium-entry blocking agents	group	_	nifedipine	drug	_	false	for the druga now available in the united states -lcb- drugn , drugb and drugn -rcb- , these data appeared well after clinical patterns of use evolved .
DDI-MedLine.d9.s3.p2	calcium-entry blocking agents	group	_	diltiazem	drug	_	false	for the druga now available in the united states -lcb- drugn , drugn and drugb -rcb- , these data appeared well after clinical patterns of use evolved .
DDI-MedLine.d9.s5.p0	verapamil	drug	_	diltiazem	drug	_	false	by the nonlinear kinetic characteristics for druga and drugb -lcb- and probably for drugn , as well -rcb- and the derivative implications for decreased dosing frequency requirements ;
DDI-MedLine.d9.s5.p1	verapamil	drug	_	nifedipine	drug	_	false	by the nonlinear kinetic characteristics for druga and drugn -lcb- and probably for drugb , as well -rcb- and the derivative implications for decreased dosing frequency requirements ;
DDI-MedLine.d45.s0.p0	pentazocine	drug	_	tripelennamine	drug	_	false	selective survival in druga and drugb of pseudomonas aeruginosa serotype igkv2_40 from drug addicts .
DDI-MedLine.d45.s1.p0	pentazocine	drug	_	tripelennamine	drug	_	false	the growth of pseudomonas aeruginosa , particularly serotype o11 , in druga and drugb
DDI-MedLine.d45.s5.p0	heroin	drug_n	_	pentazocine	drug	_	false	twelve strains of staphylococcus aureus -lcb- a frequent cause of infection in druga , but not in drugb and drugn , addicts -rcb- were completely inhibited by the drug combination .
DDI-MedLine.d45.s5.p1	heroin	drug_n	_	tripelennamine	drug	_	false	twelve strains of staphylococcus aureus -lcb- a frequent cause of infection in druga , but not in drugn and drugb , addicts -rcb- were completely inhibited by the drug combination .
DDI-MedLine.d45.s5.p2	pentazocine	drug	_	tripelennamine	drug	_	effect	twelve strains of staphylococcus aureus -lcb- a frequent cause of infection in drugn , but not in druga and drugb , addicts -rcb- were completely inhibited by the drug combination .
DDI-MedLine.d45.s6.p0	tripelennamine	drug	_	pentazocine	drug	_	effect	dose-response curves -lcb- derived from the results of using the tablets as well as pure powders -rcb- showed that druga was responsible for the inhibitory activity , which was partially antagonized by drugb .
DDI-MedLine.d45.s9.p0	pentazocine	drug	_	tripelennamine	drug	_	false	aureus , to survive in druga and drugb may explain in part a shift from s.
DDI-MedLine.d61.s0.p0	digoxin	drug	_	amiodarone	drug	_	false	pharmacokinetic evaluation of the druga - drugb interaction .
DDI-MedLine.d61.s1.p0	Amiodarone	drug	_	digoxin	drug	_	mechanism	druga is known to raise serum drugb levels .
DDI-MedLine.d61.s3.p1	digoxin	drug	_	amiodarone	drug	_	false	the pharmacokinetic variables for druga were determined after a # mg intravenous dose of drugn in each subject , before and after oral drugb , # mg daily for # weeks .
DDI-MedLine.d61.s3.p2	digoxin	drug	_	amiodarone	drug	_	false	the pharmacokinetic variables for drugn were determined after a # mg intravenous dose of druga in each subject , before and after oral drugb , # mg daily for # weeks .
DDI-MedLine.d61.s4.p0	amiodarone	drug	_	digoxin	drug	_	mechanism	during druga administration , systemic clearance of drugb was reduced from # + / - # ml/min -lcb- mean + / - standard deviation -rcb- to # + / - # ml/min -lcb- p less than # -rcb- .
DDI-MedLine.d61.s8.p0	Amiodarone	drug	_	digoxin	drug	_	false	druga caused a three - to fivefold increase in serum reverse_triiodothyronine levels , but changes in thyroid function were not quantitatively related to the changes in drugb pharmacokinetics .
DDI-MedLine.d61.s9.p0	digoxin	drug	_	amiodarone	drug	_	mechanism	these alterations in druga pharmacokinetics produced by drugb explain the increase in serum drugn level that has been observed when this drug combination has been used clinically .
DDI-MedLine.d61.s9.p2	amiodarone	drug	_	digoxin	drug	_	false	these alterations in drugn pharmacokinetics produced by druga explain the increase in serum drugb level that has been observed when this drug combination has been used clinically .
DDI-MedLine.d85.s0.p0	Misonidazole	drug_n	_	CCNU	drug	_	effect	druga protects mouse tumour and normal tissues from the toxicity of oral drugb .
DDI-MedLine.d85.s1.p0	nitrosourea	group	_	CCNU	drug	_	false	because the druga drugb is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral drugn , either alone or in combination with the chemosensitizer drugn .
DDI-MedLine.d85.s1.p1	nitrosourea	group	_	CCNU	drug	_	false	because the druga drugn is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral drugb , either alone or in combination with the chemosensitizer drugn .
DDI-MedLine.d85.s1.p2	nitrosourea	group	_	misonidazole	drug_n	_	false	because the druga drugn is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral drugn , either alone or in combination with the chemosensitizer drugb .
DDI-MedLine.d85.s1.p4	CCNU	drug	_	misonidazole	drug_n	_	false	because the drugn druga is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral drugn , either alone or in combination with the chemosensitizer drugb .
DDI-MedLine.d85.s1.p5	CCNU	drug	_	misonidazole	drug_n	_	false	because the drugn drugn is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral druga , either alone or in combination with the chemosensitizer drugb .
DDI-MedLine.d85.s7.p0	Misonidazole	drug_n	_	CCNU	drug	_	effect	druga reduced the antitumour activity of oral drugb by dose modifying factors -lcb- dmf -rcb- of ## .
DDI-MedLine.d85.s9.p0	Misonidazole	drug_n	_	CCNU	drug	_	mechanism	druga has a complex effect on oral drugb pharmacokinetics .
DDI-MedLine.d85.s14.p0	CCNU	drug	_	misonidazole	drug_n	_	mechanism	we propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral druga cytotoxicity by drugb .
DDI-MedLine.d7.s0.p0	theophylline	drug	_	phenytoin	drug	_	mechanism	enhanced druga clearance secondary to drugb therapy .
DDI-MedLine.d7.s1.p0	theophylline	drug	_	phenytoin	drug	_	mechanism	this report describes two cases in which druga clearance accelerated markedly with concomitant drugb administration .
DDI-MedLine.d7.s4.p0	phenytoin	drug	_	theophylline	drug	_	effect	with combined use , clinicians should be aware , when druga is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum drugb concentrations .
DDI-MedLine.d30.s1.p1	N-allylnormetazocine	drug_n	_	phencyclidine	drug_n	_	false	the behavioral effects of the stereoisomers of druga -lcb- drugn -rcb- were compared with those of drugb -lcb- drugn -rcb- in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio -lcb- fi fr -rcb- schedule of food presentation .
DDI-MedLine.d30.s1.p2	N-allylnormetazocine	drug_n	_	PCP	drug_n	_	false	the behavioral effects of the stereoisomers of druga -lcb- drugn -rcb- were compared with those of drugn -lcb- drugb -rcb- in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio -lcb- fi fr -rcb- schedule of food presentation .
DDI-MedLine.d30.s1.p3	NANM	drug_n	_	phencyclidine	drug_n	_	false	the behavioral effects of the stereoisomers of drugn -lcb- druga -rcb- were compared with those of drugb -lcb- drugn -rcb- in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio -lcb- fi fr -rcb- schedule of food presentation .
DDI-MedLine.d30.s1.p4	NANM	drug_n	_	PCP	drug_n	_	false	the behavioral effects of the stereoisomers of drugn -lcb- druga -rcb- were compared with those of drugn -lcb- drugb -rcb- in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio -lcb- fi fr -rcb- schedule of food presentation .
DDI-MedLine.d30.s2.p0	(+)-NANM	drug_n	_	PCP	drug_n	_	false	intermediate doses of druga or drugb produced transient increases in fi responding in monkeys and sustained increases in fi responding in pigeons ;
DDI-MedLine.d30.s6.p0	(-)-NANM	drug_n	_	(+)-NANM	drug_n	_	false	in monkeys , druga was about # times more potent than drugb in decreasing responding , whereas in pigeons drugn was about equipotent with drugn .
DDI-MedLine.d30.s6.p2	(-)-NANM	drug_n	_	(+)-NANM	drug_n	_	false	in monkeys , druga was about # times more potent than drugn in decreasing responding , whereas in pigeons drugn was about equipotent with drugb .
DDI-MedLine.d30.s6.p3	(+)-NANM	drug_n	_	(-)-NANM	drug_n	_	false	in monkeys , drugn was about # times more potent than druga in decreasing responding , whereas in pigeons drugb was about equipotent with drugn .
DDI-MedLine.d30.s6.p5	(-)-NANM	drug_n	_	(+)-NANM	drug_n	_	false	in monkeys , drugn was about # times more potent than drugn in decreasing responding , whereas in pigeons druga was about equipotent with drugb .
DDI-MedLine.d30.s7.p0	(-)-NANM	drug_n	_	(+)-NANM	drug_n	_	false	in both species , druga , but not drugb , antagonized the rate-decreasing effects of drugn on fi and fr responding .
DDI-MedLine.d30.s7.p1	(-)-NANM	drug_n	_	morphine	drug	_	effect	in both species , druga , but not drugn , antagonized the rate-decreasing effects of drugb on fi and fr responding .
DDI-MedLine.d30.s7.p2	(+)-NANM	drug_n	_	morphine	drug	_	false	in both species , drugn , but not druga , antagonized the rate-decreasing effects of drugb on fi and fr responding .
DDI-MedLine.d30.s8.p0	(-)-NANM	drug_n	_	(+)-NANM	drug_n	_	false	in monkeys , the effects of druga , but not drugb or drugn , were antagonized by drugn ;
DDI-MedLine.d30.s8.p1	(-)-NANM	drug_n	_	PCP	drug_n	_	false	in monkeys , the effects of druga , but not drugn or drugb , were antagonized by drugn ;
DDI-MedLine.d30.s8.p2	(-)-NANM	drug_n	_	naloxone	drug	_	effect	in monkeys , the effects of druga , but not drugn or drugn , were antagonized by drugb ;
DDI-MedLine.d30.s8.p3	(+)-NANM	drug_n	_	PCP	drug_n	_	false	in monkeys , the effects of drugn , but not druga or drugb , were antagonized by drugn ;
DDI-MedLine.d30.s8.p4	(+)-NANM	drug_n	_	naloxone	drug	_	false	in monkeys , the effects of drugn , but not druga or drugn , were antagonized by drugb ;
DDI-MedLine.d30.s8.p5	PCP	drug_n	_	naloxone	drug	_	false	in monkeys , the effects of drugn , but not drugn or druga , were antagonized by drugb ;
DDI-MedLine.d30.s9.p0	naloxone	drug	_	(-)-NANM	drug_n	_	effect	the doses of druga required to antagonize the effects of drugb were more than # times higher than those required to antagonize the effects of drugn .
DDI-MedLine.d30.s9.p1	naloxone	drug	_	morphine	drug	_	effect	the doses of druga required to antagonize the effects of drugn were more than # times higher than those required to antagonize the effects of drugb .
DDI-MedLine.d30.s9.p2	(-)-NANM	drug_n	_	morphine	drug	_	false	the doses of drugn required to antagonize the effects of druga were more than # times higher than those required to antagonize the effects of drugb .
DDI-MedLine.d30.s10.p0	naloxone	drug	_	(-)-NANM	drug_n	_	false	in pigeons , druga did not systematically alter the effects of drugb , drugn or drugn .
DDI-MedLine.d30.s10.p1	naloxone	drug	_	(+)-NANM	drug_n	_	false	in pigeons , druga did not systematically alter the effects of drugn , drugb or drugn .
DDI-MedLine.d30.s10.p2	naloxone	drug	_	PCP	drug_n	_	false	in pigeons , druga did not systematically alter the effects of drugn , drugn or drugb .
DDI-MedLine.d30.s11.p0	Haloperidol	drug	_	(+)-NANM	drug_n	_	effect	druga reduced or eliminated the increases in fi responding produced by intermediate doses of either drugb or drugn in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of drugn .
DDI-MedLine.d30.s11.p1	Haloperidol	drug	_	PCP	drug_n	_	effect	druga reduced or eliminated the increases in fi responding produced by intermediate doses of either drugn or drugb in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of drugn .
DDI-MedLine.d30.s11.p2	Haloperidol	drug	_	NANM	drug_n	_	false	druga reduced or eliminated the increases in fi responding produced by intermediate doses of either drugn or drugn in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of drugb .
DDI-MedLine.d30.s11.p3	(+)-NANM	drug_n	_	PCP	drug_n	_	false	drugn reduced or eliminated the increases in fi responding produced by intermediate doses of either druga or drugb in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of drugn .
DDI-MedLine.d30.s11.p5	PCP	drug_n	_	NANM	drug_n	_	false	drugn reduced or eliminated the increases in fi responding produced by intermediate doses of either drugn or druga in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of drugb .
DDI-MedLine.d55.s0.p0	acetaminophen	drug	_	caffeine	drug	_	effect	increased hepatotoxicity of druga by concomitant administration of drugb in the rat .
DDI-MedLine.d55.s1.p0	caffeine	drug	_	acetaminophen	drug	_	false	since druga is frequently co-administered with drugb , it is of clinical interest to study the effect of drugn on the hepatotoxicity of drugn .
DDI-MedLine.d55.s1.p2	caffeine	drug	_	acetaminophen	drug	_	false	since druga is frequently co-administered with drugn , it is of clinical interest to study the effect of drugn on the hepatotoxicity of drugb .
DDI-MedLine.d55.s1.p3	acetaminophen	drug	_	caffeine	drug	_	false	since drugn is frequently co-administered with druga , it is of clinical interest to study the effect of drugb on the hepatotoxicity of drugn .
DDI-MedLine.d55.s1.p5	caffeine	drug	_	acetaminophen	drug	_	false	since drugn is frequently co-administered with drugn , it is of clinical interest to study the effect of druga on the hepatotoxicity of drugb .
DDI-MedLine.d55.s4.p0	acetaminophen	drug	_	caffeine	drug	_	effect	careful observations on hepatotoxicity are suggested when druga is prescribed with drugb .
DDI-MedLine.d130.s0.p0	cisplatin	drug	_	sodium thiosulfate	drug	_	effect	high-dose druga with drugb protection .
DDI-MedLine.d130.s2.p0	Sodium thiosulfate	drug	_	cisplatin	drug	_	effect	druga is a neutralizing agent for drugb that protects against renal damage .
DDI-MedLine.d130.s3.p0	thiosulfate	drug	_	cisplatin	drug	_	false	to determine whether injection of druga would permit larger doses of drugb to be administered , a fixed # - g/m2 dose of drugn was given intravenously over three hours concurrently with escalating doses of drugn .
DDI-MedLine.d130.s3.p2	thiosulfate	drug	_	cisplatin	drug	_	false	to determine whether injection of druga would permit larger doses of drugn to be administered , a fixed # - g/m2 dose of drugn was given intravenously over three hours concurrently with escalating doses of drugb .
DDI-MedLine.d130.s3.p3	cisplatin	drug	_	thiosulfate	drug	_	false	to determine whether injection of drugn would permit larger doses of druga to be administered , a fixed # - g/m2 dose of drugb was given intravenously over three hours concurrently with escalating doses of drugn .
DDI-MedLine.d130.s3.p5	thiosulfate	drug	_	cisplatin	drug	_	false	to determine whether injection of drugn would permit larger doses of drugn to be administered , a fixed # - g/m2 dose of druga was given intravenously over three hours concurrently with escalating doses of drugb .
DDI-MedLine.d130.s4.p0	Cisplatin	drug	_	thiosulfate	drug	_	false	druga was administered over the last two hours of the drugb infusion .
DDI-MedLine.d130.s6.p0	cisplatin	drug	_	thiosulfate	drug	_	false	comparison of druga pharmacokinetics in patients treated with # mg/m2 plus drugb to those in patients treated with # mg/m2 without drugn indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of drugn .
DDI-MedLine.d130.s6.p1	cisplatin	drug	_	thiosulfate	drug	_	false	comparison of druga pharmacokinetics in patients treated with # mg/m2 plus drugn to those in patients treated with # mg/m2 without drugb indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of drugn .
DDI-MedLine.d130.s6.p4	thiosulfate	drug	_	cisplatin	drug	_	false	comparison of drugn pharmacokinetics in patients treated with # mg/m2 plus druga to those in patients treated with # mg/m2 without drugn indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of drugb .
DDI-MedLine.d130.s6.p5	thiosulfate	drug	_	cisplatin	drug	_	false	comparison of drugn pharmacokinetics in patients treated with # mg/m2 plus drugn to those in patients treated with # mg/m2 without druga indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of drugb .
DDI-MedLine.d130.s8.p0	thiosulfate	drug	_	cisplatin	drug	_	mechanism	this study demonstrates that concurrent administration of druga permits at least a twofold increase in dose and total exposure to drugb .
DDI-MedLine.d5.s0.p1	coumaphos	drug_n	_	bishydroxycoumarin	drug	_	false	repeated oral administration of druga in sheep : interactions of drugn with drugb , drugn , and drugn .
DDI-MedLine.d5.s0.p2	coumaphos	drug_n	_	trichlorfon	drug_n	_	false	repeated oral administration of druga in sheep : interactions of drugn with drugn , drugb , and drugn .
DDI-MedLine.d5.s0.p3	coumaphos	drug_n	_	phenobarbital sodium	drug	_	false	repeated oral administration of druga in sheep : interactions of drugn with drugn , drugn , and drugb .
DDI-MedLine.d5.s0.p4	coumaphos	drug_n	_	bishydroxycoumarin	drug	_	false	repeated oral administration of drugn in sheep : interactions of druga with drugb , drugn , and drugn .
DDI-MedLine.d5.s0.p5	coumaphos	drug_n	_	trichlorfon	drug_n	_	false	repeated oral administration of drugn in sheep : interactions of druga with drugn , drugb , and drugn .
DDI-MedLine.d5.s0.p6	coumaphos	drug_n	_	phenobarbital sodium	drug	_	false	repeated oral administration of drugn in sheep : interactions of druga with drugn , drugn , and drugb .
DDI-MedLine.d5.s2.p0	coumaphos	drug_n	_	bishydroxy-coumarin	drug	_	false	a daily dose of # mg of druga / kg of body weight for # days did not affect the plasma enzymes or the antiprothrombinemic effect of drugb in wethers .
DDI-MedLine.d5.s3.p0	trichlorfon	drug_n	_	coumaphos	drug_n	_	effect	the treatment of ewes with an intravenous -lcb- iv -rcb- injection of druga , insufficient to produce significant inhibition of erythrocyte aces_human -lcb- ache -rcb- activity , appeared to produce additive effects with those produced by subsequent treatment with # mg of drugb / kg/day .
DDI-MedLine.d5.s4.p0	phenobarbital sodium	drug	_	coumaphos	drug_n	_	effect	in ewes given # mg of druga / kg for # days intraperitoneally -lcb- ip -rcb- , the anticholinesterase effect of # mg of drugb / kg was significantly reduced and signs of toxicity were not present .
DDI-MedLine.d2.s0.p0	neomycin	drug	_	ACTH	group	_	false	failure of druga to modify drugb induced hypertension in sheep .
DDI-MedLine.d2.s1.p0	neomycin	drug	_	adrenocortical steroid	group	_	false	studies in rats have shown that druga administration attenuates certain types of drugb dependent hypertension , including drugn hypertension .
DDI-MedLine.d2.s1.p1	neomycin	drug	_	ACTH	drug	_	effect	studies in rats have shown that druga administration attenuates certain types of drugn dependent hypertension , including drugb hypertension .
DDI-MedLine.d2.s1.p2	adrenocortical steroid	group	_	ACTH	drug	_	false	studies in rats have shown that drugn administration attenuates certain types of druga dependent hypertension , including drugb hypertension .
DDI-MedLine.d2.s2.p0	neomycin	drug	_	ACTH	group	_	false	the effects of oral druga on drugb induced hypertension were examined in conscious sheep .
DDI-MedLine.d2.s3.p0	Neomycin	drug	_	ACTH	group	_	false	druga has no effect on the blood pressure or metabolic responses to drugb in sheep .
DDI-MedLine.d66.s1.p0	ethynyl estradiol	drug	_	levonorgestrel	drug	_	false	the present work involved the administration of both druga and drugb to groups of rats , followed by determination of the homocysteine excretion rate in urine .
DDI-MedLine.d66.s2.p0	levonorgestrel	drug	_	ethynyl estradiol	drug	_	false	the results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and druga - treated rats and the levels shown by rats treated with drugb .
DDI-MedLine.d93.s6.p0	alcohol	drug	_	ethanol	drug	_	false	the 20 % v/v solution of druga was prepared in water from a stock solution of 95 % drugb .
DDI-MedLine.d93.s9.p0	lead	drug_n	_	alcohol	drug	_	effect	these results suggest that exposure to environmental druga may alter the biological and behavioral responsiveness of an animal to drugb .
DDI-MedLine.d54.s8.p0	Physostigmine	drug	_	alcohol	drug	_	effect	druga pretreatment augmented the depressant effect of drugb on the early components p1 and n1 , while attenuating drugn 's influence on components p2 and p3 .
DDI-MedLine.d54.s8.p1	Physostigmine	drug	_	alcohol	drug	_	effect	druga pretreatment augmented the depressant effect of drugn on the early components p1 and n1 , while attenuating drugb 's influence on components p2 and p3 .
DDI-MedLine.d54.s10.p0	Atropine	drug	_	alcohol	drug	_	false	druga , either alone or in combination with drugb , produced approximately the same degree of enhancement of component p2 .
DDI-MedLine.d81.s0.p0	disulfiram	drug	_	ethanol	drug	_	false	hypothermia as an index of the druga - drugb reaction in the rat .
DDI-MedLine.d81.s1.p0	disulfiram	drug	_	ethanol	drug	_	false	decreased core temperature in female rats was investigated as one possible index of the druga - drugb reaction -lcb- der -rcb- .
DDI-MedLine.d81.s2.p0	ethanol	drug	_	disulfiram	drug	_	effect	core temperature was decreased in rats in a dose-dependent manner when druga was administered to rats treated with drugb # hours before the drugn challenge .
DDI-MedLine.d81.s2.p2	disulfiram	drug	_	ethanol	drug	_	false	core temperature was decreased in rats in a dose-dependent manner when drugn was administered to rats treated with druga # hours before the drugb challenge .
DDI-MedLine.d131.s1.p0	neurotensin	drug_n	_	enkephalins	drug_n	_	false	the aim of this paper was to study the interaction between druga and both drugb or its synthetic analogue drugn , or drugn , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s1.p1	neurotensin	drug_n	_	D-Ala2-metenkephalinamide	drug_n	_	false	the aim of this paper was to study the interaction between druga and both drugn or its synthetic analogue drugb , or drugn , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s1.p2	neurotensin	drug_n	_	tuftsin	drug_n	_	false	the aim of this paper was to study the interaction between druga and both drugn or its synthetic analogue drugn , or drugb , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s1.p3	enkephalins	drug_n	_	D-Ala2-metenkephalinamide	drug_n	_	false	the aim of this paper was to study the interaction between drugn and both druga or its synthetic analogue drugb , or drugn , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s1.p4	enkephalins	drug_n	_	tuftsin	drug_n	_	false	the aim of this paper was to study the interaction between drugn and both druga or its synthetic analogue drugn , or drugb , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s1.p5	D-Ala2-metenkephalinamide	drug_n	_	tuftsin	drug_n	_	false	the aim of this paper was to study the interaction between drugn and both drugn or its synthetic analogue druga , or drugb , on the antinonciceptive effect of these peptides in mice after intracisternal injection .
DDI-MedLine.d131.s3.p0	neurotensin	drug_n	_	enkephalins	drug_n	_	effect	it was shown that druga antagonized evidently the antinociceptive effect of drugb and their analogue .
DDI-MedLine.d131.s4.p0	neurotensin	drug_n	_	tuftsin	drug_n	_	effect	on the contrary , druga and drugb were agonists in induction of analgesia .
DDI-MedLine.d131.s5.p0	neurotensin	drug_n	_	tuftsin	drug_n	_	effect	it is concluded that druga modulates in an opposite way the function of the enkephalinergic neurons and the central action of drugb .
DDI-MedLine.d97.s8.p0	thiabendazole	drug	_	melarsoprol	drug	_	effect	among the risk factors studied , two appear to increase the risk of are : the prescription of druga to treat strongyloidiasis during the drugb cure and the bad general clinical conditions of patients .
DDI-MedLine.d97.s10.p0	anti-helminthic	group	_	melarsoprol	drug	_	false	recommendations were to avoid administration of diffusible druga treatment during the cure , and to improve the general conditions of patients before the cure of drugb .
DDI-MedLine.d34.s0.p0	cobalt	drug	_	iron	drug	_	mechanism	interactions of druga and drugb in absorption and retention .
DDI-MedLine.d34.s1.p0	cobalt	drug	_	iron	drug	_	false	the effects of supplementary oral druga and drugb , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of drugn and # or # mg/kg of drugn over a period of # days in a total of # rats .
DDI-MedLine.d34.s1.p2	cobalt	drug	_	Fe	drug	_	false	the effects of supplementary oral druga and drugn , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of drugn and # or # mg/kg of drugb over a period of # days in a total of # rats .
DDI-MedLine.d34.s1.p3	iron	drug	_	Co	drug	_	false	the effects of supplementary oral drugn and druga , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of drugb and # or # mg/kg of drugn over a period of # days in a total of # rats .
DDI-MedLine.d34.s1.p4	iron	drug	_	Fe	drug	_	false	the effects of supplementary oral drugn and druga , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of drugn and # or # mg/kg of drugb over a period of # days in a total of # rats .
DDI-MedLine.d34.s1.p5	Co	drug	_	Fe	drug	_	false	the effects of supplementary oral drugn and drugn , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of druga and # or # mg/kg of drugb over a period of # days in a total of # rats .
DDI-MedLine.d34.s7.p0	iron	drug	_	cobalt	drug	_	mechanism	additional druga significantly inhibited the absorption of drugb in both dietary drugn treatments .
DDI-MedLine.d34.s7.p1	iron	drug	_	cobalt	drug	_	mechanism	additional druga significantly inhibited the absorption of drugn in both dietary drugb treatments .
DDI-MedLine.d34.s8.p1	Fe	drug	_	cobalt	drug	_	mechanism	the lower rate of absorption in the groups receiving # mg druga instead of # mg of drugn per kg diet resulted in a decreased renal excretion of drugb .
DDI-MedLine.d34.s8.p2	Fe	drug	_	cobalt	drug	_	false	the lower rate of absorption in the groups receiving # mg drugn instead of # mg of druga per kg diet resulted in a decreased renal excretion of drugb .
DDI-MedLine.d34.s9.p0	iron	drug	_	cobalt	drug	_	mechanism	consequently , the effect of druga on the retention of drugb was lower than on absorption .
DDI-MedLine.d34.s11.p0	cobalt	drug	_	iron	drug	_	false	because of the low dietary druga concentration as compared to the drugb contents of the diets , no effect of drugn on drugn absorption and excretion occurred .
DDI-MedLine.d34.s11.p2	cobalt	drug	_	iron	drug	_	false	because of the low dietary druga concentration as compared to the drugn contents of the diets , no effect of drugn on drugb absorption and excretion occurred .
DDI-MedLine.d34.s11.p3	iron	drug	_	cobalt	drug	_	false	because of the low dietary drugn concentration as compared to the druga contents of the diets , no effect of drugb on drugn absorption and excretion occurred .
DDI-MedLine.d34.s11.p5	cobalt	drug	_	iron	drug	_	false	because of the low dietary drugn concentration as compared to the drugn contents of the diets , no effect of druga on drugb absorption and excretion occurred .
DDI-MedLine.d34.s12.p0	iron	drug	_	Fe	drug	_	false	differences in druga balance were only observed between both dietary concentrations , showing a higher absolute but a lower relative absorption as well as retention in the groups fed further drugb , -lcb- abstract truncated at # words -rcb-
DDI-MedLine.d39.s0.p0	estradiol	drug	_	endotoxin	drug_n	_	false	effect of druga on drugb - induced changes in steroid hormone levels and lethality in male rats .
DDI-MedLine.d39.s1.p0	estradiol	drug	_	endotoxin	drug_n	_	false	we examined the effect of exogenous druga on the changes in serum steroid hormone levels induced by a nonlethal dose of escherichia coli drugb in male rats and the deaths due to nonlethal and lethal doses of drugn .
DDI-MedLine.d39.s1.p1	estradiol	drug	_	endotoxin	drug_n	_	false	we examined the effect of exogenous druga on the changes in serum steroid hormone levels induced by a nonlethal dose of escherichia coli drugn in male rats and the deaths due to nonlethal and lethal doses of drugb .
DDI-MedLine.d39.s2.p0	estradiol	drug	_	endotoxin	drug_n	_	effect	injection of druga # min before a nonlethal dose of drugb changed the serum sex steroid hormone response of male rats to drugn .
DDI-MedLine.d39.s2.p1	estradiol	drug	_	endotoxin	drug_n	_	false	injection of druga # min before a nonlethal dose of drugn changed the serum sex steroid hormone response of male rats to drugb .
DDI-MedLine.d39.s3.p0	estradiol	drug	_	endotoxin	drug_n	_	mechanism	the serum estrogen concentrations of druga + drugb - treated rats decreased by 50 % , while those of the drugn - treated rats increased -lcb- 2 - to 5-fold -rcb- .
DDI-MedLine.d39.s3.p1	estradiol	drug	_	endotoxin	drug_n	_	false	the serum estrogen concentrations of druga + drugn - treated rats decreased by 50 % , while those of the drugb - treated rats increased -lcb- 2 - to 5-fold -rcb- .
DDI-MedLine.d39.s4.p0	estradiol	drug	_	endotoxin	drug_n	_	false	the serum androgen concentrations of druga + drugb - treated rats did not change significantly , while those of drugn - treated rats dropped to 30-40 %
DDI-MedLine.d39.s4.p1	estradiol	drug	_	endotoxin	drug_n	_	false	the serum androgen concentrations of druga + drugn - treated rats did not change significantly , while those of drugb - treated rats dropped to 30-40 %
DDI-MedLine.d39.s6.p0	estradiol	drug	_	endotoxin	drug_n	_	effect	exogenous druga also appeared to influence the percentage of drugb - induced deaths in a dose-dependent manner .
DDI-MedLine.d128.s12.p0	Loperamide	drug	_	morphine	drug	_	false	druga and drugb -lcb- # and # mg/kg , s , c.
DDI-MedLine.d128.s13.p0	Loperamide	drug	_	morphine	drug	_	false	druga and drugb -lcb- # and # mg/kg , s , c , -rcb- inhibited the drugn -lcb- # mg/kg , p , o , -rcb- - induced diarrhea in cecectomized rats .
DDI-MedLine.d128.s13.p1	Loperamide	drug	_	dmPGE2	drug_n	_	effect	druga and drugn -lcb- # and # mg/kg , s , c , -rcb- inhibited the drugb -lcb- # mg/kg , p , o , -rcb- - induced diarrhea in cecectomized rats .
DDI-MedLine.d128.s13.p2	morphine	drug	_	dmPGE2	drug_n	_	effect	drugn and druga -lcb- # and # mg/kg , s , c , -rcb- inhibited the drugb -lcb- # mg/kg , p , o , -rcb- - induced diarrhea in cecectomized rats .
DDI-MedLine.d128.s15.p0	N-methyllevallorphan	drug_n	_	loperamide	drug	_	effect	druga -lcb- 5 mg/kg , s , c , -rcb- completely antagonized the inhibitory effect of drugb and partly antagonized the effect of drugn .
DDI-MedLine.d128.s15.p1	N-methyllevallorphan	drug_n	_	morphine	drug	_	effect	druga -lcb- 5 mg/kg , s , c , -rcb- completely antagonized the inhibitory effect of drugn and partly antagonized the effect of drugb .
DDI-MedLine.d128.s15.p2	loperamide	drug	_	morphine	drug	_	false	drugn -lcb- 5 mg/kg , s , c , -rcb- completely antagonized the inhibitory effect of druga and partly antagonized the effect of drugb .
DDI-MedLine.d89.s0.p0	99mTc-methylene diphosphonate	drug	_	gentamicin	drug	_	effect	therapeutic drug monitoring can avoid iatrogenic alterations caused by druga -lcb- mdp -rcb- - drugb interaction .
DDI-MedLine.d89.s1.p0	Gentamicin	drug	_	aminoglycoside antibiotic	group	_	false	druga is an drugb used to treat a wide variety of infections caused by gram-negative organisms , but it is potentially toxic to the kidneys .
DDI-MedLine.d89.s2.p0	gentamicin	drug	_	99mTc-MDP	drug	_	mechanism	due to its nephrotoxicity , druga may cause abnormal renal uptake to be seen on drugb bone scintigraphy .
DDI-MedLine.d89.s7.p0	gentamicin	drug	_	99mTc-MDP	drug	_	false	therapeutic drug monitoring -lcb- tdm -rcb- of druga therapy , and bone scintigraphy employing drugb as the drugn was carried out in # patients .
DDI-MedLine.d89.s7.p1	gentamicin	drug	_	radiopharmaceutical	group	_	false	therapeutic drug monitoring -lcb- tdm -rcb- of druga therapy , and bone scintigraphy employing drugn as the drugb was carried out in # patients .
DDI-MedLine.d89.s7.p2	99mTc-MDP	drug	_	radiopharmaceutical	group	_	false	therapeutic drug monitoring -lcb- tdm -rcb- of drugn therapy , and bone scintigraphy employing druga as the drugb was carried out in # patients .
DDI-MedLine.d11.s4.p0	immunosuppressive drugs	group	_	corticosteroids	group	_	false	this article looks at five commonly used druga in turn -lcb- drugb , drugn , drugn , drugn , drugn -rcb- , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
DDI-MedLine.d11.s4.p1	immunosuppressive drugs	group	_	cyclosporin	drug	_	false	this article looks at five commonly used druga in turn -lcb- drugn , drugb , drugn , drugn , drugn -rcb- , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
DDI-MedLine.d11.s4.p2	immunosuppressive drugs	group	_	azathioprine	drug	_	false	this article looks at five commonly used druga in turn -lcb- drugn , drugn , drugb , drugn , drugn -rcb- , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
DDI-MedLine.d11.s4.p3	immunosuppressive drugs	group	_	methotrexate	drug	_	false	this article looks at five commonly used druga in turn -lcb- drugn , drugn , drugn , drugb , drugn -rcb- , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
DDI-MedLine.d11.s4.p4	immunosuppressive drugs	group	_	cyclophosphamide	drug	_	false	this article looks at five commonly used druga in turn -lcb- drugn , drugn , drugn , drugn , drugb -rcb- , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .
DDI-MedLine.d107.s1.p0	ethanol	drug	_	acetaldehyde	drug_n	_	false	little has been studied of the adverse effects of the exposure of the liver to the interaction of druga with its congeners and drugb , coexisting in the contents of alcoholic beverages .
DDI-MedLine.d107.s9.p0	ethanol	drug	_	acetaldehyde	drug_n	_	effect	these results suggest that the hepatoxicity of druga in alcoholic beverages is enhanced by interaction with its congeners and drugb ;
DDI-MedLine.d53.s0.p0	vitamin D	group	_	antiestrogens	group	_	false	induction of apoptosis in breast cancer cells in response to druga and drugb .
DDI-MedLine.d53.s1.p1	25-Dihydroxycholecalciferol D3	drug	_	vitamin D	group	_	false	1 , druga -lcb- drugn -rcb- , the active metabolite of drugb , is a potent inhibitor of breast_cancer cell growth both in vivo and in vitro .
DDI-MedLine.d53.s1.p2	1,25(OH)2D3	drug	_	vitamin D	group	_	false	1 , drugn -lcb- druga -rcb- , the active metabolite of drugb , is a potent inhibitor of breast_cancer cell growth both in vivo and in vitro .
DDI-MedLine.d53.s3.p0	1,25(OH)2D3	drug	_	antiestrogen	group	_	false	in the experiments reported here , we examined the interactions between druga and the drugb drugn -lcb- drugn -rcb- , which also induces apoptosis in mcf-7 cells .
DDI-MedLine.d53.s3.p1	1,25(OH)2D3	drug	_	4-hydroxytamoxifen	drug_n	_	false	in the experiments reported here , we examined the interactions between druga and the drugn drugb -lcb- drugn -rcb- , which also induces apoptosis in mcf-7 cells .
DDI-MedLine.d53.s3.p2	1,25(OH)2D3	drug	_	TAM	drug_n	_	false	in the experiments reported here , we examined the interactions between druga and the drugn drugn -lcb- drugb -rcb- , which also induces apoptosis in mcf-7 cells .
DDI-MedLine.d53.s3.p3	antiestrogen	group	_	4-hydroxytamoxifen	drug_n	_	false	in the experiments reported here , we examined the interactions between drugn and the druga drugb -lcb- drugn -rcb- , which also induces apoptosis in mcf-7 cells .
DDI-MedLine.d53.s3.p4	antiestrogen	group	_	TAM	drug_n	_	false	in the experiments reported here , we examined the interactions between drugn and the druga drugn -lcb- drugb -rcb- , which also induces apoptosis in mcf-7 cells .
DDI-MedLine.d53.s4.p0	TAM	drug_n	_	1,25(OH)2D3	drug	_	effect	our data suggest that druga significantly potentiates the reduction in cell number induced by drugb alone .
DDI-MedLine.d53.s5.p0	1,25(OH)2D3	drug	_	TAM	drug_n	_	effect	combined treatment with druga and drugb enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation .
DDI-MedLine.d53.s9.p0	vitamin-D	group	_	estrogen	group	_	false	these data emphasize that apoptosis can be induced in mcf-7 cells either by activation of druga - mediated signalling or disruption of drugb - dependent signalling .
DDI-MedLine.d51.s3.p0	theophylline	drug	_	CGS 21680	drug_n	_	effect	the anxiogenic effects of druga were reduced by pretreatment with drugb , an a2-selective agonist , but not by drugn -lcb- drugn -rcb- , an a1-selective agonist .
DDI-MedLine.d51.s3.p1	theophylline	drug	_	N6-cyclopentyladenosine	drug_n	_	false	the anxiogenic effects of druga were reduced by pretreatment with drugn , an a2-selective agonist , but not by drugb -lcb- drugn -rcb- , an a1-selective agonist .
DDI-MedLine.d51.s3.p2	theophylline	drug	_	CPA	drug_n	_	false	the anxiogenic effects of druga were reduced by pretreatment with drugn , an a2-selective agonist , but not by drugn -lcb- drugb -rcb- , an a1-selective agonist .
DDI-MedLine.d51.s3.p3	CGS 21680	drug_n	_	N6-cyclopentyladenosine	drug_n	_	false	the anxiogenic effects of drugn were reduced by pretreatment with druga , an a2-selective agonist , but not by drugb -lcb- drugn -rcb- , an a1-selective agonist .
DDI-MedLine.d51.s3.p4	CGS 21680	drug_n	_	CPA	drug_n	_	false	the anxiogenic effects of drugn were reduced by pretreatment with druga , an a2-selective agonist , but not by drugn -lcb- drugb -rcb- , an a1-selective agonist .
DDI-MedLine.d51.s4.p0	theophylline	drug	_	CGS21680	drug_n	_	effect	however , the antagonism of the druga - induced anxiogenic effects by drugb was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by drugn nor by drugn .
DDI-MedLine.d51.s4.p1	theophylline	drug	_	DPCPX	drug_n	_	false	however , the antagonism of the druga - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and drugb - induced anxiogenic effects were neither reversed by drugn nor by drugn .
DDI-MedLine.d51.s4.p2	theophylline	drug	_	CGS 21680	drug	_	false	however , the antagonism of the druga - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by drugb nor by drugn .
DDI-MedLine.d51.s4.p3	theophylline	drug	_	CPA	drug_n	_	false	however , the antagonism of the druga - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by drugn nor by drugb .
DDI-MedLine.d51.s4.p4	CGS21680	drug_n	_	DPCPX	drug_n	_	false	however , the antagonism of the drugn - induced anxiogenic effects by druga was only observed in the time spent in the light zone , and drugb - induced anxiogenic effects were neither reversed by drugn nor by drugn .
DDI-MedLine.d51.s4.p5	CGS21680	drug_n	_	CGS 21680	drug	_	false	however , the antagonism of the drugn - induced anxiogenic effects by druga was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by drugb nor by drugn .
DDI-MedLine.d51.s4.p6	CGS21680	drug_n	_	CPA	drug_n	_	false	however , the antagonism of the drugn - induced anxiogenic effects by druga was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by drugn nor by drugb .
DDI-MedLine.d51.s4.p7	DPCPX	drug_n	_	CGS 21680	drug	_	false	however , the antagonism of the drugn - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and druga - induced anxiogenic effects were neither reversed by drugb nor by drugn .
DDI-MedLine.d51.s4.p8	DPCPX	drug_n	_	CPA	drug_n	_	false	however , the antagonism of the drugn - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and druga - induced anxiogenic effects were neither reversed by drugn nor by drugb .
DDI-MedLine.d51.s4.p9	CGS 21680	drug	_	CPA	drug_n	_	false	however , the antagonism of the drugn - induced anxiogenic effects by drugn was only observed in the time spent in the light zone , and drugn - induced anxiogenic effects were neither reversed by druga nor by drugb .
DDI-MedLine.d4.s0.p2	immunodepressant	group	_	sandimmune	brand	_	false	-lsb- the effect of drugn on the activity of mixed-function mono-oxidases in the liver microsomes -rsb- the effects of the druga -- the drug drugb -- on hepatic cyp4b1 activities were studied .
DDI-MedLine.d68.s0.p0	cimetidine	drug	_	verografin	drug	_	false	-lsb- the effect of druga on the renal excretion of drugb and drugn in dogs -rsb- the intravenous injection of drugn in a dose of # mg/kg enhanced drugn and drugn excretion in chronic canine experiments .
DDI-MedLine.d68.s0.p1	cimetidine	drug	_	iodamide	drug	_	false	-lsb- the effect of druga on the renal excretion of drugn and drugb in dogs -rsb- the intravenous injection of drugn in a dose of # mg/kg enhanced drugn and drugn excretion in chronic canine experiments .
DDI-MedLine.d68.s0.p5	verografin	drug	_	iodamide	drug	_	false	-lsb- the effect of drugn on the renal excretion of druga and drugb in dogs -rsb- the intravenous injection of drugn in a dose of # mg/kg enhanced drugn and drugn excretion in chronic canine experiments .
DDI-MedLine.d68.s0.p12	cimetidine	drug	_	verografine	drug	_	mechanism	-lsb- the effect of drugn on the renal excretion of drugn and drugn in dogs -rsb- the intravenous injection of druga in a dose of # mg/kg enhanced drugb and drugn excretion in chronic canine experiments .
DDI-MedLine.d68.s0.p13	cimetidine	drug	_	iodamide	drug	_	mechanism	-lsb- the effect of drugn on the renal excretion of drugn and drugn in dogs -rsb- the intravenous injection of druga in a dose of # mg/kg enhanced drugn and drugb excretion in chronic canine experiments .
DDI-MedLine.d68.s0.p14	verografine	drug	_	iodamide	drug	_	false	-lsb- the effect of drugn on the renal excretion of drugn and drugn in dogs -rsb- the intravenous injection of drugn in a dose of # mg/kg enhanced druga and drugb excretion in chronic canine experiments .
DDI-MedLine.d68.s1.p0	verografine	drug	_	iodamide	drug	_	false	the higher druga and drugb excretion was due to their increased renal tubular secretion .
DDI-MedLine.d68.s2.p0	cimetidine	drug	_	cardiotrast	drug	_	false	in dogs , druga unchanged the secretion of drugb , a test agent for anionic transport .
DDI-MedLine.d68.s3.p0	cimetidine	drug	_	verografine	drug	_	false	possible extrarenal mechanisms of action of druga on drugb and drugn transport were also examined .
DDI-MedLine.d68.s3.p1	cimetidine	drug	_	iodamide	drug	_	false	possible extrarenal mechanisms of action of druga on drugn and drugb transport were also examined .
DDI-MedLine.d68.s3.p2	verografine	drug	_	iodamide	drug	_	false	possible extrarenal mechanisms of action of drugn on druga and drugb transport were also examined .
DDI-MedLine.d103.s6.p1	magnesium	drug	_	vitamin B6	drug	_	false	specific and aspecific treatments of druga depletion are tricky using for example drugn , pharmacological doses of drugb , physiological doses of drugn and of drugn .
DDI-MedLine.d103.s6.p2	magnesium	drug	_	vitamin D	group	_	false	specific and aspecific treatments of druga depletion are tricky using for example drugn , pharmacological doses of drugn , physiological doses of drugb and of drugn .
DDI-MedLine.d103.s6.p3	magnesium	drug	_	selenium	drug	_	false	specific and aspecific treatments of druga depletion are tricky using for example drugn , pharmacological doses of drugn , physiological doses of drugn and of drugb .
DDI-MedLine.d103.s6.p4	magnesium sparing diuretics	group	_	vitamin B6	drug	_	false	specific and aspecific treatments of drugn depletion are tricky using for example druga , pharmacological doses of drugb , physiological doses of drugn and of drugn .
DDI-MedLine.d103.s6.p5	magnesium sparing diuretics	group	_	vitamin D	group	_	false	specific and aspecific treatments of drugn depletion are tricky using for example druga , pharmacological doses of drugn , physiological doses of drugb and of drugn .
DDI-MedLine.d103.s6.p6	magnesium sparing diuretics	group	_	selenium	drug	_	false	specific and aspecific treatments of drugn depletion are tricky using for example druga , pharmacological doses of drugn , physiological doses of drugn and of drugb .
DDI-MedLine.d103.s6.p7	vitamin B6	drug	_	vitamin D	group	_	false	specific and aspecific treatments of drugn depletion are tricky using for example drugn , pharmacological doses of druga , physiological doses of drugb and of drugn .
DDI-MedLine.d103.s6.p8	vitamin B6	drug	_	selenium	drug	_	false	specific and aspecific treatments of drugn depletion are tricky using for example drugn , pharmacological doses of druga , physiological doses of drugn and of drugb .
DDI-MedLine.d103.s6.p9	vitamin D	group	_	selenium	drug	_	false	specific and aspecific treatments of drugn depletion are tricky using for example drugn , pharmacological doses of drugn , physiological doses of druga and of drugb .
DDI-MedLine.d103.s15.p0	magnesium	drug	_	cardioplegic solutions	drug	_	false	lastly local use of the mucocutaneous and cytoprotective properties of druga is still valid , in drugb and for preservation of transplants particularly .
DDI-MedLine.d20.s0.p0	glycine	drug	_	glutamate	drug	_	effect	interaction between druga and drugb in the development of spontaneous motility in chick embryos .
DDI-MedLine.d20.s4.p0	glycine	drug	_	glutamate	drug	_	effect	the successive application of druga -lcb- 5 or # mg/kg egg weight -lcb- e , w , -rcb- and drugb -lcb- 15 mg/kg e , w , -rcb- in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drugn alone .
DDI-MedLine.d20.s4.p1	glycine	drug	_	glutamate	drug	_	false	the successive application of druga -lcb- 5 or # mg/kg egg weight -lcb- e , w , -rcb- and drugn -lcb- 15 mg/kg e , w , -rcb- in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drugb alone .
DDI-MedLine.d94.s11.p0	isoproterenol	drug	_	norepinephrine	drug	_	false	the ec50 values for druga , which is not a substrate for drugb uptake-1 , were reduced in myocardium in functional classes ii to iii and iv compared with those in nonfailing myocardium .
DDI-MedLine.d94.s12.p0	cocaine	drug	_	desipramine	drug	_	false	the uptake inhibitors druga and drugb -lcb- 3 mumol/liter -rcb- potentiated the positive inotropic effects of drugn in nonfailing myocardium -lcb- p < # -rcb- but not in functional class iv myocardium .
DDI-MedLine.d94.s12.p1	cocaine	drug	_	norepinephrine	drug	_	effect	the uptake inhibitors druga and drugn -lcb- 3 mumol/liter -rcb- potentiated the positive inotropic effects of drugb in nonfailing myocardium -lcb- p < # -rcb- but not in functional class iv myocardium .
DDI-MedLine.d94.s12.p2	desipramine	drug	_	norepinephrine	drug	_	effect	the uptake inhibitors drugn and druga -lcb- 3 mumol/liter -rcb- potentiated the positive inotropic effects of drugb in nonfailing myocardium -lcb- p < # -rcb- but not in functional class iv myocardium .
DDI-MedLine.d94.s13.p0	mazindol	drug	_	norepinephrine	drug	_	false	radioligand binding experiments using the uptake inhibitor hydrogen-3 druga revealed a significant decrease by approximately 30 % in drugb uptake-1 carrier density in functional classes ii to iii and iv myocardium versus nonfailing myocardium -lcb- p < # -rcb- .
DDI-MedLine.d94.s16.p0	cocaine	drug	_	desipramine	drug	_	false	this defect in the failing heart can be mimicked by the effects of uptake blocking agents , such as druga and drugb , in the nonfailing heart only .
DDI-MedLine.d94.s17.p0	norepinephrine	drug	_	cocaine	drug	_	false	compromised druga uptake-1 in functional class iv can not be further increased by drugb and drugn .
DDI-MedLine.d94.s17.p1	norepinephrine	drug	_	desipramine	drug	_	false	compromised druga uptake-1 in functional class iv can not be further increased by drugn and drugb .
DDI-MedLine.d94.s17.p2	cocaine	drug	_	desipramine	drug	_	false	compromised drugn uptake-1 in functional class iv can not be further increased by druga and drugb .
DDI-MedLine.d14.s0.p4	angiotensin 1	drug_n	_	angiotensin 2	drug_n	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of druga and drugb on drugn - and drugn - induced gastric acid secretion .
DDI-MedLine.d14.s0.p5	angiotensin 1	drug_n	_	pentagastrin	drug	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of druga and drugn on drugb - and drugn - induced gastric acid secretion .
DDI-MedLine.d14.s0.p6	angiotensin 1	drug_n	_	histamine	drug	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of druga and drugn on drugn - and drugb - induced gastric acid secretion .
DDI-MedLine.d14.s0.p7	angiotensin 2	drug_n	_	pentagastrin	drug	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of drugn and druga on drugb - and drugn - induced gastric acid secretion .
DDI-MedLine.d14.s0.p8	angiotensin 2	drug_n	_	histamine	drug	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of drugn and druga on drugn - and drugb - induced gastric acid secretion .
DDI-MedLine.d14.s0.p9	pentagastrin	drug	_	histamine	drug	_	false	-lsb- a pharmacological analysis of the effect of drugn on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of drugn and drugn on druga - and drugb - induced gastric acid secretion .
DDI-MedLine.d14.s1.p0	pentagastrin	drug	_	histamine	drug	_	false	it was established that both angiotensins inhibited gastric acid secretion stimulated by druga but not by drugb .
DDI-MedLine.d90.s0.p0	gentamycin	drug	_	atracurium	drug	_	int	interaction of druga and drugb in anaesthetised horses .
DDI-MedLine.d90.s1.p0	atracurium	drug	_	halothane	drug	_	false	evoked hind limb digital extensor tension -lcb- hoof twitch -rcb- was maintained at 40 % of baseline for # h by druga infusion in # horses anaesthetised with drugb .
DDI-MedLine.d90.s3.p0	Atracurium	drug	_	gentamycin	drug	_	false	druga was again given by infusion to maintain 40 % twitch for a second hour , then # mg drugb / kg bwt were given i , v.
DDI-MedLine.d90.s7.p1	atracurium	drug	_	gentamycin	drug	_	false	recovery of hoof twitch from 50 % to 75 % took # + / - # min for druga alone and # + / - # min for drugn plus drugb -lcb- p = # -rcb- .
DDI-MedLine.d90.s7.p2	atracurium	drug	_	gentamycin	drug	_	effect	recovery of hoof twitch from 50 % to 75 % took # + / - # min for drugn alone and # + / - # min for druga plus drugb -lcb- p = # -rcb- .
DDI-MedLine.d90.s8.p1	atracurium	drug	_	gentamycin	drug	_	false	recovery from 50 % twitch to 75 % fade recovery took # + / - # min for druga alone and # + / - # min for drugn plus drugb .
DDI-MedLine.d90.s8.p2	atracurium	drug	_	gentamycin	drug	_	effect	recovery from 50 % twitch to 75 % fade recovery took # + / - # min for drugn alone and # + / - # min for druga plus drugb .
DDI-MedLine.d90.s9.p1	atracurium	drug	_	gentamycin	drug	_	false	at 75 % recovery of fade , hoof twitch was # + / - 3 % for druga alone and # + / - 4 % for drugn plus drugb .
DDI-MedLine.d90.s9.p2	atracurium	drug	_	gentamycin	drug	_	effect	at 75 % recovery of fade , hoof twitch was # + / - 3 % for drugn alone and # + / - 4 % for druga plus drugb .
DDI-MedLine.d90.s11.p0	gentamycin	drug	_	atracurium	drug	_	effect	it was concluded that , although druga did augment the neuromuscular blockade of drugb , the effect was minimal .
DDI-MedLine.d113.s0.p0	temazepam	drug	_	ethanol	drug	_	mechanism	acid-catalyzed ethanolysis of druga in anhydrous and aqueous drugb solutions .
DDI-MedLine.d113.s1.p0	benzodiazepines	group	_	anxiolytic	group	_	false	the druga are a family of drugb and drugn .
DDI-MedLine.d113.s1.p1	benzodiazepines	group	_	hypnotic drugs	group	_	false	the druga are a family of drugn and drugb .
DDI-MedLine.d113.s1.p2	anxiolytic	group	_	hypnotic drugs	group	_	false	the drugn are a family of druga and drugb .
DDI-MedLine.d113.s3.p1	temazepam	drug	_	ethanol	drug	_	mechanism	in addition to this pharmacological interaction , this report describes a novel chemical reaction between druga -lcb- a drugn -rcb- and drugb under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .
DDI-MedLine.d113.s3.p2	benzodiazepine	group	_	ethanol	drug	_	false	in addition to this pharmacological interaction , this report describes a novel chemical reaction between drugn -lcb- a druga -rcb- and drugb under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .
DDI-MedLine.d113.s5.p0	alcohol	drug	_	3-hydroxy-1,4-benzodiazepine	group	_	mechanism	the results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume druga and drugb on a regular basis .
DDI-DrugBank.d519.s3.p0	Plenaxis	brand	_	testosterone	drug	_	false	laboratory tests response to druga should be monitored by measuring serum total drugb concentrations just prior to administration on day # and every # weeks thereafter .
DDI-DrugBank.d297.s1.p3	MTX	drug	_	abatacept	drug	_	false	population pharmacokinetic analyses revealed that druga , drugn , drugn , and drugn did not influence drugb clearance .
DDI-DrugBank.d297.s1.p6	NSAIDs	group	_	abatacept	drug	_	false	population pharmacokinetic analyses revealed that drugn , druga , drugn , and drugn did not influence drugb clearance .
DDI-DrugBank.d297.s1.p8	corticosteroids	group	_	abatacept	drug	_	false	population pharmacokinetic analyses revealed that drugn , drugn , druga , and drugn did not influence drugb clearance .
DDI-DrugBank.d297.s1.p9	TNF blocking agents	group	_	abatacept	drug	_	false	population pharmacokinetic analyses revealed that drugn , drugn , drugn , and druga did not influence drugb clearance .
DDI-DrugBank.d297.s2.p0	ORENCIA	brand	_	MTX	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p1	ORENCIA	brand	_	NSAIDs	group	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p2	ORENCIA	brand	_	corticosteroids	group	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p3	ORENCIA	brand	_	TNF blocking agents	group	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p4	ORENCIA	brand	_	azathioprine	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p5	ORENCIA	brand	_	chloroquine	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p6	ORENCIA	brand	_	gold	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p7	ORENCIA	brand	_	hydroxychloroquine	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d297.s2.p8	ORENCIA	brand	_	leflunomide	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d297.s2.p9	ORENCIA	brand	_	sulfasalazine	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d297.s2.p10	ORENCIA	brand	_	anakinra	drug	_	false	the majority of patients in ra clinical studies received one or more of the following concomitant medications with druga : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d297.s3.p0	TNF antagonist	group	_	ORENCIA	brand	_	effect	concurrent administration of a druga with drugb has been associated with an increased risk of serious infections and no significant additional efficacy over use of the drugn alone .
DDI-DrugBank.d297.s3.p2	ORENCIA	brand	_	TNF antagonists	group	_	false	concurrent administration of a drugn with druga has been associated with an increased risk of serious infections and no significant additional efficacy over use of the drugb alone .
DDI-DrugBank.d297.s4.p0	ORENCIA	brand	_	TNF antagonists	group	_	advise	concurrent therapy with druga and drugb is not recommended .
DDI-DrugBank.d297.s5.p0	ORENCIA	brand	_	anakinra	drug	_	advise	there is insufficient experience to assess the safety and efficacy of druga administered concurrently with drugb , and therefore such use is not recommended .
DDI-DrugBank.d532.s2.p4	heparin	drug	_	nitrates	group	_	false	these medications have included druga , drugn , drugn , drugn , drugn , intravenous and oral drugb , drugn , and drugn .
DDI-DrugBank.d532.s2.p5	heparin	drug	_	ticlopidine	drug	_	false	these medications have included druga , drugn , drugn , drugn , drugn , intravenous and oral drugn , drugb , and drugn .
DDI-DrugBank.d532.s2.p6	heparin	drug	_	aspirin	brand	_	false	these medications have included druga , drugn , drugn , drugn , drugn , intravenous and oral drugn , drugn , and drugb .
DDI-DrugBank.d532.s2.p10	warfarin	drug	_	nitrates	group	_	false	these medications have included drugn , druga , drugn , drugn , drugn , intravenous and oral drugb , drugn , and drugn .
DDI-DrugBank.d532.s2.p11	warfarin	drug	_	ticlopidine	drug	_	false	these medications have included drugn , druga , drugn , drugn , drugn , intravenous and oral drugn , drugb , and drugn .
DDI-DrugBank.d532.s2.p12	warfarin	drug	_	aspirin	brand	_	false	these medications have included drugn , druga , drugn , drugn , drugn , intravenous and oral drugn , drugn , and drugb .
DDI-DrugBank.d532.s2.p15	beta-adrenergic receptor blockers	group	_	nitrates	group	_	false	these medications have included drugn , drugn , druga , drugn , drugn , intravenous and oral drugb , drugn , and drugn .
DDI-DrugBank.d532.s2.p16	beta-adrenergic receptor blockers	group	_	ticlopidine	drug	_	false	these medications have included drugn , drugn , druga , drugn , drugn , intravenous and oral drugn , drugb , and drugn .
DDI-DrugBank.d532.s2.p17	beta-adrenergic receptor blockers	group	_	aspirin	brand	_	false	these medications have included drugn , drugn , druga , drugn , drugn , intravenous and oral drugn , drugn , and drugb .
DDI-DrugBank.d532.s2.p19	calcium channel antagonists	group	_	nitrates	group	_	false	these medications have included drugn , drugn , drugn , druga , drugn , intravenous and oral drugb , drugn , and drugn .
DDI-DrugBank.d532.s2.p20	calcium channel antagonists	group	_	ticlopidine	drug	_	false	these medications have included drugn , drugn , drugn , druga , drugn , intravenous and oral drugn , drugb , and drugn .
DDI-DrugBank.d532.s2.p21	calcium channel antagonists	group	_	aspirin	brand	_	false	these medications have included drugn , drugn , drugn , druga , drugn , intravenous and oral drugn , drugn , and drugb .
DDI-DrugBank.d532.s2.p22	angiotensin converting enzyme inhibitors	group	_	nitrates	group	_	false	these medications have included drugn , drugn , drugn , drugn , druga , intravenous and oral drugb , drugn , and drugn .
DDI-DrugBank.d532.s2.p23	angiotensin converting enzyme inhibitors	group	_	ticlopidine	drug	_	false	these medications have included drugn , drugn , drugn , drugn , druga , intravenous and oral drugn , drugb , and drugn .
DDI-DrugBank.d532.s2.p24	angiotensin converting enzyme inhibitors	group	_	aspirin	brand	_	false	these medications have included drugn , drugn , drugn , drugn , druga , intravenous and oral drugn , drugn , and drugb .
DDI-DrugBank.d532.s4.p0	diagnostic monoclonal antibodies	group	_	therapeutic monoclonal antibodies	group	_	false	patients with haca titers may have allergic or hypersensitivity reactions when treated with other druga or drugb .
DDI-DrugBank.d0.s0.p0	alcohol	drug	_	Acamprosate	drug	_	false	the concomitant intake of druga and drugb does not affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d0.s0.p2	alcohol	drug	_	acamprosate	drug	_	false	the concomitant intake of druga and drugn does not affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d0.s0.p3	Acamprosate	drug	_	alcohol	drug	_	false	the concomitant intake of drugn and druga does not affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d0.s0.p5	alcohol	drug	_	acamprosate	drug	_	false	the concomitant intake of drugn and drugn does not affect the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d0.s1.p0	disulfiram	drug	_	diazepam	drug	_	false	pharmacokinetic studies indicate that administration of druga or drugb does not affect the pharmacokinetics of drugn .
DDI-DrugBank.d0.s1.p1	disulfiram	drug	_	acamprosate	drug	_	false	pharmacokinetic studies indicate that administration of druga or drugn does not affect the pharmacokinetics of drugb .
DDI-DrugBank.d0.s1.p2	diazepam	drug	_	acamprosate	drug	_	false	pharmacokinetic studies indicate that administration of drugn or druga does not affect the pharmacokinetics of drugb .
DDI-DrugBank.d0.s2.p0	naltrexone	drug	_	Acamprosate	drug	_	mechanism	co-administration of druga with drugb produced a 25 % increase in auc and a 33 % increase in the cmax of drugn .
DDI-DrugBank.d0.s2.p1	naltrexone	drug	_	acamprosate	drug	_	false	co-administration of druga with drugn produced a 25 % increase in auc and a 33 % increase in the cmax of drugb .
DDI-DrugBank.d0.s4.p0	naltrexone	drug	_	6-beta-naltrexol	drug_n	_	false	the pharmacokinetics of druga and its major metabolite drugb were unaffected following co-administration with drugn .
DDI-DrugBank.d0.s4.p1	naltrexone	drug	_	Acamprosate	drug	_	false	the pharmacokinetics of druga and its major metabolite drugn were unaffected following co-administration with drugb .
DDI-DrugBank.d0.s4.p2	6-beta-naltrexol	drug_n	_	Acamprosate	drug	_	false	the pharmacokinetics of drugn and its major metabolite druga were unaffected following co-administration with drugb .
DDI-DrugBank.d0.s5.p0	Acamprosate	drug	_	anxiolytics	group	_	false	other concomitant therapies : in clinical trials , the safety profile in subjects treated with druga concomitantly with drugb , drugn and drugn -lcb- including drugn -rcb- , or drugn was similar to that of subjects taking placebo with these concomitant medications .
DDI-DrugBank.d0.s5.p1	Acamprosate	drug	_	hypnotics	group	_	false	other concomitant therapies : in clinical trials , the safety profile in subjects treated with druga concomitantly with drugn , drugb and drugn -lcb- including drugn -rcb- , or drugn was similar to that of subjects taking placebo with these concomitant medications .
DDI-DrugBank.d0.s5.p2	Acamprosate	drug	_	sedatives	group	_	false	other concomitant therapies : in clinical trials , the safety profile in subjects treated with druga concomitantly with drugn , drugn and drugb -lcb- including drugn -rcb- , or drugn was similar to that of subjects taking placebo with these concomitant medications .
DDI-DrugBank.d0.s5.p3	Acamprosate	drug	_	benzodiazepines	group	_	false	other concomitant therapies : in clinical trials , the safety profile in subjects treated with druga concomitantly with drugn , drugn and drugn -lcb- including drugb -rcb- , or drugn was similar to that of subjects taking placebo with these concomitant medications .
DDI-DrugBank.d0.s5.p4	Acamprosate	drug	_	non-opioid analgesics	group	_	false	other concomitant therapies : in clinical trials , the safety profile in subjects treated with druga concomitantly with drugn , drugn and drugn -lcb- including drugn -rcb- , or drugb was similar to that of subjects taking placebo with these concomitant medications .
DDI-DrugBank.d0.s6.p0	Acamprosate	drug	_	antidepressants	group	_	effect	patients taking druga concomitantly with drugb more commonly reported both weight gain and weight loss , compared with patients taking either medication alone .
DDI-DrugBank.d536.s1.p0	thiazides	group	_	diuretics	group	_	false	these drugs include the druga and other drugb , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s1.p1	thiazides	group	_	corticosteroids	group	_	false	these drugs include the druga and other drugn , drugb , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s1.p11	diuretics	group	_	corticosteroids	group	_	false	these drugs include the drugn and other druga , drugb , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s1.p12	diuretics	group	_	phenothiazines	group	_	false	these drugs include the drugn and other druga , drugn , drugb , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s1.p23	corticosteroids	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , druga , drugn , drugn , drugb , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s1.p38	thyroid products	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , drugn , drugn , druga , drugb , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d536.s3.p0	Acarbose	drug	_	sulfonylureas	group	_	false	when such drugs are withdrawn from patients receiving druga in combination with drugb or drugn , patients should be observed closely for any evidence of hypoglycemia .
DDI-DrugBank.d536.s3.p1	Acarbose	drug	_	insulin	drug	_	false	when such drugs are withdrawn from patients receiving druga in combination with drugn or drugb , patients should be observed closely for any evidence of hypoglycemia .
DDI-DrugBank.d536.s3.p2	sulfonylureas	group	_	insulin	drug	_	false	when such drugs are withdrawn from patients receiving drugn in combination with druga or drugb , patients should be observed closely for any evidence of hypoglycemia .
DDI-DrugBank.d536.s4.p1	Intestinal adsorbents	group	_	digestive enzyme preparations	group	_	false	druga -lcb- e , g , , drugn -rcb- and drugb containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugn -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p2	Intestinal adsorbents	group	_	amylase	drug	_	false	druga -lcb- e , g , , drugn -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugb , drugn -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p3	Intestinal adsorbents	group	_	pancreatin	drug	_	false	druga -lcb- e , g , , drugn -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugb -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p4	Intestinal adsorbents	group	_	Acarbose	drug	_	mechanism	druga -lcb- e , g , , drugn -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugn -rcb- may reduce the effect of drugb and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p5	charcoal	drug	_	digestive enzyme preparations	group	_	false	drugn -lcb- e , g , , druga -rcb- and drugb containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugn -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p6	charcoal	drug	_	amylase	drug	_	false	drugn -lcb- e , g , , druga -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugb , drugn -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p7	charcoal	drug	_	pancreatin	drug	_	false	drugn -lcb- e , g , , druga -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugb -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p8	charcoal	drug	_	Acarbose	drug	_	mechanism	drugn -lcb- e , g , , druga -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugn -rcb- may reduce the effect of drugb and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p9	digestive enzyme preparations	group	_	amylase	drug	_	false	drugn -lcb- e , g , , drugn -rcb- and druga containing carbohydrate-splitting enzymes -lcb- e , g , , drugb , drugn -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p10	digestive enzyme preparations	group	_	pancreatin	drug	_	false	drugn -lcb- e , g , , drugn -rcb- and druga containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugb -rcb- may reduce the effect of drugn and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p11	digestive enzyme preparations	group	_	Acarbose	drug	_	false	drugn -lcb- e , g , , drugn -rcb- and druga containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , drugn -rcb- may reduce the effect of drugb and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p13	amylase	drug	_	Acarbose	drug	_	mechanism	drugn -lcb- e , g , , drugn -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , druga , drugn -rcb- may reduce the effect of drugb and should not be taken concomitantly .
DDI-DrugBank.d536.s4.p14	pancreatin	drug	_	Acarbose	drug	_	mechanism	drugn -lcb- e , g , , drugn -rcb- and drugn containing carbohydrate-splitting enzymes -lcb- e , g , , drugn , druga -rcb- may reduce the effect of drugb and should not be taken concomitantly .
DDI-DrugBank.d536.s5.p0	Acarbose	drug	_	digoxin	drug	_	mechanism	druga has been shown to change the bioavailabillty drugb when they are co-administered , which may require drugn dose adjustment .
DDI-DrugBank.d536.s5.p1	Acarbose	drug	_	digoxin	drug	_	false	druga has been shown to change the bioavailabillty drugn when they are co-administered , which may require drugb dose adjustment .
DDI-DrugBank.d536.s6.p0	Acarbose	drug	_	digoxin	drug	_	false	studies in healthy volunteers have shown that druga has no effect on either the pharmacokinetics or pharmacodynamics of drugb , drugn , drugn , or drugn .
DDI-DrugBank.d536.s6.p1	Acarbose	drug	_	nifedipine	drug	_	false	studies in healthy volunteers have shown that druga has no effect on either the pharmacokinetics or pharmacodynamics of drugn , drugb , drugn , or drugn .
DDI-DrugBank.d536.s6.p2	Acarbose	drug	_	propranolol	drug	_	false	studies in healthy volunteers have shown that druga has no effect on either the pharmacokinetics or pharmacodynamics of drugn , drugn , drugb , or drugn .
DDI-DrugBank.d536.s6.p3	Acarbose	drug	_	ranitidine	drug	_	false	studies in healthy volunteers have shown that druga has no effect on either the pharmacokinetics or pharmacodynamics of drugn , drugn , drugn , or drugb .
DDI-DrugBank.d536.s7.p0	Acarbose	drug	_	sulfonylurea	drug	_	false	druga did not interfere with the absorption or disposition of the drugb drugn in diabetic patients .
DDI-DrugBank.d536.s7.p1	Acarbose	drug	_	glyburide	drug	_	false	druga did not interfere with the absorption or disposition of the drugn drugb in diabetic patients .
DDI-DrugBank.d536.s7.p2	sulfonylurea	drug	_	glyburide	drug	_	false	drugn did not interfere with the absorption or disposition of the druga drugb in diabetic patients .
DDI-DrugBank.d536.s8.p0	Acarbose	drug	_	digoxin	drug	_	false	druga may affect drugb bioavailabillty and may require dose adjustment of drugn by 16 % -lcb- 90 % confidence interval : 8-23 % -rcb- , decrease mean c max drugn by 26 % -lcb- 90 % confidence interval : 16-34 % -rcb- and decrease mean trough concentrations of drugn by 9 % -lcb- 90 % confidence limit : 19 % decrease to 2 % increase -rcb- .
DDI-DrugBank.d536.s8.p1	Acarbose	drug	_	digoxin	drug	_	false	druga may affect drugn bioavailabillty and may require dose adjustment of drugb by 16 % -lcb- 90 % confidence interval : 8-23 % -rcb- , decrease mean c max drugn by 26 % -lcb- 90 % confidence interval : 16-34 % -rcb- and decrease mean trough concentrations of drugn by 9 % -lcb- 90 % confidence limit : 19 % decrease to 2 % increase -rcb- .
DDI-DrugBank.d536.s8.p2	Acarbose	drug	_	digoxin	drug	_	false	druga may affect drugn bioavailabillty and may require dose adjustment of drugn by 16 % -lcb- 90 % confidence interval : 8-23 % -rcb- , decrease mean c max drugb by 26 % -lcb- 90 % confidence interval : 16-34 % -rcb- and decrease mean trough concentrations of drugn by 9 % -lcb- 90 % confidence limit : 19 % decrease to 2 % increase -rcb- .
DDI-DrugBank.d536.s8.p3	Acarbose	drug	_	digoxin	drug	_	false	druga may affect drugn bioavailabillty and may require dose adjustment of drugn by 16 % -lcb- 90 % confidence interval : 8-23 % -rcb- , decrease mean c max drugn by 26 % -lcb- 90 % confidence interval : 16-34 % -rcb- and decrease mean trough concentrations of drugb by 9 % -lcb- 90 % confidence limit : 19 % decrease to 2 % increase -rcb- .
DDI-DrugBank.d536.s9.p0	metformin	drug	_	Acarbose	drug	_	false	the amount of druga absorbed while taking drugb was bioequivalent to the amount absorbed when taking placebo , as indicated by the plasma auc values .
DDI-DrugBank.d536.s10.p0	metformin	drug	_	Acarbose	drug	_	mechanism	however , the peak plasma level of druga was reduced by approximately 20 % when taking drugb due to a slight delay in the absorption of drugn .
DDI-DrugBank.d536.s10.p2	Acarbose	drug	_	metformin	drug	_	mechanism	however , the peak plasma level of drugn was reduced by approximately 20 % when taking druga due to a slight delay in the absorption of drugb .
DDI-DrugBank.d536.s11.p0	Acarbose	drug	_	metformin	drug	_	false	there is little if any clinically significant interaction between druga and drugb .
DDI-DrugBank.d388.s0.p0	Catecholamine-depleting drugs	group	_	reserpine	drug	_	false	druga , such as drugb , may have an additive effect when given with drugn .
DDI-DrugBank.d388.s0.p1	Catecholamine-depleting drugs	group	_	beta-blocking agents	group	_	effect	druga , such as drugn , may have an additive effect when given with drugb .
DDI-DrugBank.d388.s0.p2	reserpine	drug	_	beta-blocking agents	group	_	effect	drugn , such as druga , may have an additive effect when given with drugb .
DDI-DrugBank.d388.s1.p0	acebutolol	drug	_	catecholamine depletors	group	_	advise	patients treated with druga plus drugb should , therefore , be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo , syncope/presyncope , or orthostatic changes in blood pressure without compensatory tachycardia .
DDI-DrugBank.d388.s2.p0	beta-adrenergic antagonists	group	_	alpha-adrenergic stimulants	group	_	effect	exaggerated hypertensive responses have been reported from the combined use of druga and drugb , including those contained in proprietary cold remedies and vasoconstrictive nasal drops .
DDI-DrugBank.d388.s4.p0	beta-adrenoceptor blocking agents	group	_	nonsteroidal anti-inflammatory drugs	group	_	effect	blunting of the antihypertensive effect of druga by drugb has been reported .
DDI-DrugBank.d368.s0.p0	DIAMOX	brand	_	phenytoin	drug	_	mechanism	druga modifies drugb metabolism with increased serum levels of drugn .
DDI-DrugBank.d368.s0.p1	DIAMOX	brand	_	phenytoin	drug	_	mechanism	druga modifies drugn metabolism with increased serum levels of drugb .
DDI-DrugBank.d368.s3.p0	primidone	drug	_	DIAMOX	brand	_	false	by decreasing the gastrointestinal absorption of druga , drugb may decrease serum concentrations of drugn and its metabolites , with a consequent possible decrease in anticonvulsant effect .
DDI-DrugBank.d368.s3.p2	DIAMOX	brand	_	primidone	drug	_	mechanism	by decreasing the gastrointestinal absorption of drugn , druga may decrease serum concentrations of drugb and its metabolites , with a consequent possible decrease in anticonvulsant effect .
DDI-DrugBank.d368.s4.p0	DIAMOX	brand	_	primidone	drug	_	advise	caution is advised when beginning , discontinuing , or changing the dose of druga in patients receiving drugb .
DDI-DrugBank.d368.s6.p0	Acetazolamide	drug	_	folic acid antagonists	group	_	effect	druga may increase the effects of other drugb .
DDI-DrugBank.d368.s9.p0	Acetazolamide	drug	_	amphetamine	drug	_	mechanism	druga decreases urinary excretion of drugb and may enhance the magnitude and duration of their effect .
DDI-DrugBank.d368.s10.p0	Acetazolamide	drug	_	quinidine	drug	_	mechanism	druga reduces urinary excretion of drugb and may enhance its effect .
DDI-DrugBank.d368.s11.p0	Acetazolamide	drug	_	methenamine	drug	_	effect	druga may prevent the urinary antiseptic effect of drugb .
DDI-DrugBank.d368.s12.p0	Acetazolamide	drug	_	lithium	drug	_	mechanism	druga increases drugb excretion and the drugn may be decreased .
DDI-DrugBank.d368.s12.p1	Acetazolamide	drug	_	lithium	drug	_	false	druga increases drugn excretion and the drugb may be decreased .
DDI-DrugBank.d368.s13.p0	Acetazolamide	drug	_	sodium bicarbonate	drug	_	effect	druga and drugb used concurrently increases the risk of renal calculus formation .
DDI-DrugBank.d368.s14.p0	Acetazolamide	drug	_	cyclosporine	drug	_	mechanism	druga may elevate drugb levels .
DDI-DrugBank.d200.s0.p0	probenecid	drug	_	acyclovir	drug	_	mechanism	co-administration of druga with drugb has been shown to increase the mean half-life and the area under the concentration-time curve .
DDI-DrugBank.d353.s0.p0	Ethanol	drug	_	etretinate	drug	_	false	druga : clinical evidence has shown that drugb can be formed with concurrent ingestion of drugn and drugn .
DDI-DrugBank.d353.s0.p1	Ethanol	drug	_	acitretin	drug	_	false	druga : clinical evidence has shown that drugn can be formed with concurrent ingestion of drugb and drugn .
DDI-DrugBank.d353.s0.p3	etretinate	drug	_	acitretin	drug	_	false	drugn : clinical evidence has shown that druga can be formed with concurrent ingestion of drugb and drugn .
DDI-DrugBank.d353.s0.p4	etretinate	drug	_	ethanol	drug	_	false	drugn : clinical evidence has shown that druga can be formed with concurrent ingestion of drugn and drugb .
DDI-DrugBank.d353.s0.p5	acitretin	drug	_	ethanol	drug	_	mechanism	drugn : clinical evidence has shown that drugn can be formed with concurrent ingestion of druga and drugb .
DDI-DrugBank.d353.s1.p4	acitretin	drug	_	glibenclamide	drug	_	effect	drugn : in a study of # healthy male volunteers , druga treatment potentiated the blood glucose lowering effect of drugb -lcb- a drugn similar to drugn -rcb- in # of the # subjects .
DDI-DrugBank.d353.s1.p5	acitretin	drug	_	sulfonylurea	group	_	false	drugn : in a study of # healthy male volunteers , druga treatment potentiated the blood glucose lowering effect of drugn -lcb- a drugb similar to drugn -rcb- in # of the # subjects .
DDI-DrugBank.d353.s1.p6	acitretin	drug	_	chlorpropamide	drug	_	false	drugn : in a study of # healthy male volunteers , druga treatment potentiated the blood glucose lowering effect of drugn -lcb- a drugn similar to drugb -rcb- in # of the # subjects .
DDI-DrugBank.d353.s1.p7	glibenclamide	drug	_	sulfonylurea	group	_	false	drugn : in a study of # healthy male volunteers , drugn treatment potentiated the blood glucose lowering effect of druga -lcb- a drugb similar to drugn -rcb- in # of the # subjects .
DDI-DrugBank.d353.s1.p8	glibenclamide	drug	_	chlorpropamide	drug	_	false	drugn : in a study of # healthy male volunteers , drugn treatment potentiated the blood glucose lowering effect of druga -lcb- a drugn similar to drugb -rcb- in # of the # subjects .
DDI-DrugBank.d353.s1.p9	sulfonylurea	group	_	chlorpropamide	drug	_	false	drugn : in a study of # healthy male volunteers , drugn treatment potentiated the blood glucose lowering effect of drugn -lcb- a druga similar to drugb -rcb- in # of the # subjects .
DDI-DrugBank.d353.s2.p0	glibenclamide	drug	_	acitretin	drug	_	false	repeating the study with # healthy male volunteers in the absence of druga did not detect an effect of drugb on glucose tolerance .
DDI-DrugBank.d353.s4.p2	acitretin	drug	_	combined oral contraceptives	group	_	false	drugn : it has not been established if there is a pharmacokinetic interaction between druga and drugb .
DDI-DrugBank.d353.s5.p0	acitretin	drug	_	progestin	drug	_	effect	however , it has been established that druga interferes with the contraceptive effect of microdosed drugb minipill preparations .
DDI-DrugBank.d353.s6.p0	progestin	drug	_	Soriatane	drug	_	advise	microdosed minipill druga preparations are not recommended for use with drugb .
DDI-DrugBank.d353.s7.p0	progestational contraceptives	group	_	acitretin	drug	_	false	it is not known whether other druga , such as implants and injectables , are adequate methods of contraception during drugb therapy .
DDI-DrugBank.d353.s8.p2	methotrexate	drug	_	etretinate	drug	_	effect	drugn : an increased risk of hepatitis has been reported to result from combined use of druga and drugb .
DDI-DrugBank.d353.s9.p0	methotrexate	drug	_	acitretin	drug	_	advise	consequently , the combination of druga with drugb is also contraindicated .
DDI-DrugBank.d353.s10.p3	acitretin	drug	_	phenytoin	drug	_	mechanism	drugn : if druga is given concurrently with drugb , the protein binding of drugn may be reduced .
DDI-DrugBank.d353.s10.p4	acitretin	drug	_	phenytoin	drug	_	false	drugn : if druga is given concurrently with drugn , the protein binding of drugb may be reduced .
DDI-DrugBank.d353.s11.p2	acitretin	drug	_	tetracyclines	group	_	effect	drugn : since both druga and drugb can cause increased intracranial pressure , their combined use is contraindicated .
DDI-DrugBank.d353.s12.p0	Vitamin A	group	_	retinoids	group	_	false	druga and oral drugb : concomitant administration of drugn and/or other oral drugn with drugn must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p2	Vitamin A	group	_	retinoids	group	_	false	druga and oral drugn : concomitant administration of drugn and/or other oral drugb with drugn must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p3	Vitamin A	group	_	acitretin	drug	_	false	druga and oral drugn : concomitant administration of drugn and/or other oral drugn with drugb must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p4	retinoids	group	_	vitamin A	group	_	false	drugn and oral druga : concomitant administration of drugb and/or other oral drugn with drugn must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p6	retinoids	group	_	acitretin	drug	_	false	drugn and oral druga : concomitant administration of drugn and/or other oral drugn with drugb must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p7	vitamin A	group	_	retinoids	group	_	false	drugn and oral drugn : concomitant administration of druga and/or other oral drugb with drugn must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p8	vitamin A	group	_	acitretin	drug	_	advise	drugn and oral drugn : concomitant administration of druga and/or other oral drugn with drugb must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s12.p9	retinoids	group	_	acitretin	drug	_	advise	drugn and oral drugn : concomitant administration of drugn and/or other oral druga with drugb must be avoided because of the risk of hypervitaminosis a.
DDI-DrugBank.d353.s14.p0	acitretin	drug	_	anticoagulants of the coumarin type	group	_	false	investigations into the effect of druga on the protein binding of drugb -lcb- drugn -rcb- revealed no interaction .
DDI-DrugBank.d353.s14.p1	acitretin	drug	_	warfarin	drug	_	false	investigations into the effect of druga on the protein binding of drugn -lcb- drugb -rcb- revealed no interaction .
DDI-DrugBank.d493.s0.p2	HUMIRA	brand	_	MTX	drug	_	false	drugn : druga has been studied in rheumatoid_arthritis patients taking concomitant drugb .
DDI-DrugBank.d493.s1.p0	HUMIRA	brand	_	MTX	drug	_	false	the data do not suggest the need for dose adjustment of either druga or drugb .
DDI-DrugBank.d493.s2.p1	Anakinra	drug	_	interleukin-1 antagonist	group	_	false	druga : concurrent administration of drugn -lcb- an drugb -rcb- and another drugn has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d493.s2.p2	Anakinra	drug	_	TNF-blocking agent	group	_	false	druga : concurrent administration of drugn -lcb- an drugn -rcb- and another drugb has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d493.s2.p4	anakinra	drug	_	TNF-blocking agent	group	_	effect	drugn : concurrent administration of druga -lcb- an drugn -rcb- and another drugb has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d493.s2.p5	interleukin-1 antagonist	group	_	TNF-blocking agent	group	_	effect	drugn : concurrent administration of drugn -lcb- an druga -rcb- and another drugb has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d493.s3.p0	anakinra	drug	_	HUMIRA	brand	_	false	the safety and efficacy of druga used in combination with drugb has not been studied .
DDI-DrugBank.d493.s4.p0	anakinra	drug	_	TNF-blocking agents	group	_	effect	therefore the , combination of druga with other drugb , including drugn , may also result i n similar toxicities .
DDI-DrugBank.d493.s4.p1	anakinra	drug	_	HUMIRA	brand	_	effect	therefore the , combination of druga with other drugn , including drugb , may also result i n similar toxicities .
DDI-DrugBank.d493.s4.p2	TNF-blocking agents	group	_	HUMIRA	brand	_	false	therefore the , combination of drugn with other druga , including drugb , may also result i n similar toxicities .
DDI-DrugBank.d370.s1.p2	sulfur	drug	_	DIFFERIN	brand	_	false	particular caution should be exercised in using preparations containing druga , drugn , or drugn in combination with drugb gel .
DDI-DrugBank.d370.s1.p4	resorcinol	drug	_	DIFFERIN	brand	_	false	particular caution should be exercised in using preparations containing drugn , druga , or drugn in combination with drugb gel .
DDI-DrugBank.d370.s1.p5	salicylic acid	drug	_	DIFFERIN	brand	_	false	particular caution should be exercised in using preparations containing drugn , drugn , or druga in combination with drugb gel .
DDI-DrugBank.d244.s0.p21	amphotericin B	drug	_	cyclosporine	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , druga , drugb , drugn drugs -lcb- e , g , , drugn -rcb- , drugn , drugn .
DDI-DrugBank.d244.s0.p24	amphotericin B	drug	_	tacrolimus	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , druga , drugn , drugn drugs -lcb- e , g , , drugn -rcb- , drugb , drugn .
DDI-DrugBank.d244.s0.p25	amphotericin B	drug	_	vancomycin	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , druga , drugn , drugn drugs -lcb- e , g , , drugn -rcb- , drugn , drugb .
DDI-DrugBank.d244.s0.p28	cyclosporine	drug	_	tacrolimus	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , drugn , druga , drugn drugs -lcb- e , g , , drugn -rcb- , drugb , drugn .
DDI-DrugBank.d244.s0.p29	cyclosporine	drug	_	vancomycin	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , drugn , druga , drugn drugs -lcb- e , g , , drugn -rcb- , drugn , drugb .
DDI-DrugBank.d244.s0.p35	tacrolimus	drug	_	vancomycin	drug	_	false	before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : drugn -lcb- e , g , , drugn , drugn -rcb- , drugn , drugn , drugn drugs -lcb- e , g , , drugn -rcb- , druga , drugb .
DDI-DrugBank.d226.s0.p1	Adenocard	brand	_	quinidine	drug	_	false	intravenous druga -lcb- drugn -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugb , drugn , drugn , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p2	Adenocard	brand	_	beta-adrenergic blocking agents	group	_	false	intravenous druga -lcb- drugn -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugb , drugn , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p3	Adenocard	brand	_	calcium channel blocking agents	group	_	false	intravenous druga -lcb- drugn -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugn , drugb , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p4	Adenocard	brand	_	angiotensin converting enzyme inhibitors	group	_	false	intravenous druga -lcb- drugn -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugn , drugn , and drugb , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p5	adenosine	drug	_	quinidine	drug	_	false	intravenous drugn -lcb- druga -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugb , drugn , drugn , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p6	adenosine	drug	_	beta-adrenergic blocking agents	group	_	false	intravenous drugn -lcb- druga -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugb , drugn , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p7	adenosine	drug	_	calcium channel blocking agents	group	_	false	intravenous drugn -lcb- druga -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugn , drugb , and drugn , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s0.p8	adenosine	drug	_	angiotensin converting enzyme inhibitors	group	_	false	intravenous drugn -lcb- druga -rcb- has been effectively administered in the presence of other cardioactive drugs , such as drugn , drugn , drugn , and drugb , without any change in the adverse reaction profile .
DDI-DrugBank.d226.s1.p0	Digoxin	drug	_	verapamil	drug	_	false	druga and drugb use may be rarely associated with ventricular fibrillation when combined with drugn .
DDI-DrugBank.d226.s1.p1	Digoxin	drug	_	Adenocard	brand	_	effect	druga and drugn use may be rarely associated with ventricular fibrillation when combined with drugb .
DDI-DrugBank.d226.s1.p2	verapamil	drug	_	Adenocard	brand	_	effect	drugn and druga use may be rarely associated with ventricular fibrillation when combined with drugb .
DDI-DrugBank.d226.s3.p0	Adenocard	brand	_	digitalis	group	_	effect	the use of druga in patients receiving drugb may be rarely associated with ventricular fibrillation .
DDI-DrugBank.d226.s4.p0	adenosine	drug	_	methylxanthines	group	_	effect	the effects of druga are antagonized by drugb such as drugn and drugn .
DDI-DrugBank.d226.s4.p1	adenosine	drug	_	caffeine	drug	_	effect	the effects of druga are antagonized by drugn such as drugb and drugn .
DDI-DrugBank.d226.s4.p2	adenosine	drug	_	theophylline	drug	_	effect	the effects of druga are antagonized by drugn such as drugn and drugb .
DDI-DrugBank.d226.s4.p3	methylxanthines	group	_	caffeine	drug	_	false	the effects of drugn are antagonized by druga such as drugb and drugn .
DDI-DrugBank.d226.s4.p4	methylxanthines	group	_	theophylline	drug	_	false	the effects of drugn are antagonized by druga such as drugn and drugb .
DDI-DrugBank.d226.s4.p5	caffeine	drug	_	theophylline	drug	_	false	the effects of drugn are antagonized by drugn such as druga and drugb .
DDI-DrugBank.d226.s5.p0	methylxanthines	group	_	adenosine	drug	_	advise	in the presence of these druga , larger doses of drugb may be required or drugn may not be effective .
DDI-DrugBank.d226.s5.p1	methylxanthines	group	_	adenosine	drug	_	advise	in the presence of these druga , larger doses of drugn may be required or drugb may not be effective .
DDI-DrugBank.d226.s6.p0	Adenosine	drug	_	dipyridamole	drug	_	effect	druga effects are potentiated by drugb .
DDI-DrugBank.d226.s7.p0	adenosine	drug	_	dipyridamole	drug	_	effect	thus , smaller doses of druga may be effective in the presence of drugb .
DDI-DrugBank.d226.s9.p0	adenosine	drug	_	carbamazepine	drug	_	effect	as the primary effect of druga is to decrease conduction through the a-v node , higher degrees of heart block may be produced in the presence of drugb .
DDI-DrugBank.d449.s0.p0	antifungal agents	group	_	ketoconazole	drug	_	false	co-administration with druga such as drugb or drugn is not recommended .
DDI-DrugBank.d449.s0.p1	antifungal agents	group	_	itraconazole	drug	_	false	co-administration with druga such as drugn or drugb is not recommended .
DDI-DrugBank.d449.s0.p2	ketoconazole	drug	_	itraconazole	drug	_	false	co-administration with drugn such as druga or drugb is not recommended .
DDI-DrugBank.d449.s1.p0	Nafazodone	drug	_	fluvoxamine	drug	_	false	druga , drugb , drugn -lcb- consider drugn dose reduction -rcb- .
DDI-DrugBank.d449.s1.p1	Nafazodone	drug	_	cimetidine	drug	_	false	druga , drugn , drugb -lcb- consider drugn dose reduction -rcb- .
DDI-DrugBank.d449.s1.p2	Nafazodone	drug	_	Xanax	brand	_	advise	druga , drugn , drugn -lcb- consider drugb dose reduction -rcb- .
DDI-DrugBank.d449.s1.p3	fluvoxamine	drug	_	cimetidine	drug	_	false	drugn , druga , drugb -lcb- consider drugn dose reduction -rcb- .
DDI-DrugBank.d449.s1.p4	fluvoxamine	drug	_	Xanax	brand	_	advise	drugn , druga , drugn -lcb- consider drugb dose reduction -rcb- .
DDI-DrugBank.d449.s1.p5	cimetidine	drug	_	Xanax	brand	_	advise	drugn , drugn , druga -lcb- consider drugb dose reduction -rcb- .
DDI-DrugBank.d321.s0.p3	albendazole sulfoxide	drug	_	dexamethasone	drug	_	false	drugn : steady-state trough concentrations of druga were about 56 % higher when # mg drugb was coadministered with each dose of drugn -lcb- 15 mg/kg/day -rcb- in eight neurocysticercosis patients .
DDI-DrugBank.d321.s0.p5	dexamethasone	drug	_	albendazole	drug	_	mechanism	drugn : steady-state trough concentrations of drugn were about 56 % higher when # mg druga was coadministered with each dose of drugb -lcb- 15 mg/kg/day -rcb- in eight neurocysticercosis patients .
DDI-DrugBank.d321.s1.p1	Praziquantel	drug	_	albendazole sulfoxide	drug	_	false	druga : in the fed state , drugn -lcb- 40 mg/kg -rcb- increased mean maximum plasma concentration and area under the curve of drugb by about 50 % in healthy subjects -lcb- n = 10 -rcb- compared with a separate group of subjects -lcb- n = 6 -rcb- given drugn alone .
DDI-DrugBank.d321.s1.p2	Praziquantel	drug	_	albendazole	drug	_	false	druga : in the fed state , drugn -lcb- 40 mg/kg -rcb- increased mean maximum plasma concentration and area under the curve of drugn by about 50 % in healthy subjects -lcb- n = 10 -rcb- compared with a separate group of subjects -lcb- n = 6 -rcb- given drugb alone .
DDI-DrugBank.d321.s1.p3	praziquantel	drug	_	albendazole sulfoxide	drug	_	mechanism	drugn : in the fed state , druga -lcb- 40 mg/kg -rcb- increased mean maximum plasma concentration and area under the curve of drugb by about 50 % in healthy subjects -lcb- n = 10 -rcb- compared with a separate group of subjects -lcb- n = 6 -rcb- given drugn alone .
DDI-DrugBank.d321.s1.p4	praziquantel	drug	_	albendazole	drug	_	false	drugn : in the fed state , druga -lcb- 40 mg/kg -rcb- increased mean maximum plasma concentration and area under the curve of drugn by about 50 % in healthy subjects -lcb- n = 10 -rcb- compared with a separate group of subjects -lcb- n = 6 -rcb- given drugb alone .
DDI-DrugBank.d321.s3.p0	praziquantel	drug	_	albendazole	drug	_	false	the pharmacokinetics of druga were unchanged following coadministration with drugb -lcb- 400 mg -rcb- .
DDI-DrugBank.d321.s4.p3	Albendazole sulfoxide	drug	_	cimetidine	drug	_	mechanism	drugn : druga concentrations in bile and cystic fluid were increased -lcb- about 2-fold -rcb- in hydatid cyst patients treated with drugb -lcb- 10 mg/kg/day -rcb- -lcb- n = 7 -rcb- compared with drugn -lcb- 20 mg/kg/day -rcb- alone -lcb- n = 12 -rcb- .
DDI-DrugBank.d321.s4.p5	cimetidine	drug	_	albendazole	drug	_	false	drugn : drugn concentrations in bile and cystic fluid were increased -lcb- about 2-fold -rcb- in hydatid cyst patients treated with druga -lcb- 10 mg/kg/day -rcb- -lcb- n = 7 -rcb- compared with drugb -lcb- 20 mg/kg/day -rcb- alone -lcb- n = 12 -rcb- .
DDI-DrugBank.d321.s6.p1	Theophylline	drug	_	aminophylline	drug	_	false	druga : the pharmacokinetics of drugn -lcb- drugb # mg/kg infused over # minutes -rcb- were unchanged following a single oral dose of drugn -lcb- 400 mg -rcb- in # healthy subjects .
DDI-DrugBank.d321.s6.p3	theophylline	drug	_	aminophylline	drug	_	false	drugn : the pharmacokinetics of druga -lcb- drugb # mg/kg infused over # minutes -rcb- were unchanged following a single oral dose of drugn -lcb- 400 mg -rcb- in # healthy subjects .
DDI-DrugBank.d321.s6.p4	theophylline	drug	_	albendazole	drug	_	false	drugn : the pharmacokinetics of druga -lcb- drugn # mg/kg infused over # minutes -rcb- were unchanged following a single oral dose of drugb -lcb- 400 mg -rcb- in # healthy subjects .
DDI-DrugBank.d321.s6.p5	aminophylline	drug	_	albendazole	drug	_	false	drugn : the pharmacokinetics of drugn -lcb- druga # mg/kg infused over # minutes -rcb- were unchanged following a single oral dose of drugb -lcb- 400 mg -rcb- in # healthy subjects .
DDI-DrugBank.d114.s2.p5	aminoglycosides	group	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , druga , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , drugn -rcb- or hepatotoxic -lcb- e , g , , drugn , drugn -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p10	indomethacin	drug	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , druga -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , drugn -rcb- or hepatotoxic -lcb- e , g , , drugn , drugn -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p14	cytotoxic	group	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , druga chemotherapy -rcb- , cardiotoxic -lcb- e , g , , drugn -rcb- or hepatotoxic -lcb- e , g , , drugn , drugn -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p15	doxorubicin	drug	_	methotrexate	drug	_	false	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , druga -rcb- or hepatotoxic -lcb- e , g , , drugb , drugn -rcb- effects with drugn may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p16	doxorubicin	drug	_	asparaginase	drug	_	false	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , druga -rcb- or hepatotoxic -lcb- e , g , , drugn , drugb -rcb- effects with drugn may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p17	doxorubicin	drug	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , druga -rcb- or hepatotoxic -lcb- e , g , , drugn , drugn -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p19	methotrexate	drug	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , drugn -rcb- or hepatotoxic -lcb- e , g , , druga , drugn -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s2.p20	asparaginase	drug	_	PROLEUKIN	brand	_	effect	concurrent administration of drugs possessing nephrotoxic -lcb- e , g , , drugn , drugn -rcb- , myelotoxic -lcb- e , g , , drugn chemotherapy -rcb- , cardiotoxic -lcb- e , g , , drugn -rcb- or hepatotoxic -lcb- e , g , , drugn , druga -rcb- effects with drugb may increase toxicity in these organ systems .
DDI-DrugBank.d114.s3.p0	PROLEUKIN	brand	_	antineoplastic agents	group	_	false	the safety and efficacy of druga in combination with any drugb have not been established .
DDI-DrugBank.d114.s5.p0	PROLEUKIN	brand	_	antineoplastic agents	group	_	effect	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose druga and drugb , specifically , drugn , drugn , drugn and drugn .
DDI-DrugBank.d114.s5.p1	PROLEUKIN	brand	_	dacarbazine	drug	_	effect	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose druga and drugn , specifically , drugb , drugn , drugn and drugn .
DDI-DrugBank.d114.s5.p2	PROLEUKIN	brand	_	cis-platinum	drug	_	effect	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose druga and drugn , specifically , drugn , drugb , drugn and drugn .
DDI-DrugBank.d114.s5.p3	PROLEUKIN	brand	_	tamoxifen	drug	_	effect	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose druga and drugn , specifically , drugn , drugn , drugb and drugn .
DDI-DrugBank.d114.s5.p4	PROLEUKIN	brand	_	interferon-alfa	drug	_	effect	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose druga and drugn , specifically , drugn , drugn , drugn and drugb .
DDI-DrugBank.d114.s5.p5	antineoplastic agents	group	_	dacarbazine	drug	_	false	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drugn and druga , specifically , drugb , drugn , drugn and drugn .
DDI-DrugBank.d114.s5.p6	antineoplastic agents	group	_	cis-platinum	drug	_	false	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drugn and druga , specifically , drugn , drugb , drugn and drugn .
DDI-DrugBank.d114.s5.p7	antineoplastic agents	group	_	tamoxifen	drug	_	false	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drugn and druga , specifically , drugn , drugn , drugb and drugn .
DDI-DrugBank.d114.s5.p8	antineoplastic agents	group	_	interferon-alfa	drug	_	false	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drugn and druga , specifically , drugn , drugn , drugn and drugb .
DDI-DrugBank.d114.s8.p0	PROLEUKIN	brand	_	interferon-alfa	drug	_	effect	myocardial injury , including myocardial infarction , myocarditis , ventricular hypokinesia , and severe rhabdomyolysis appear to be increased in patients receiving druga and drugb concurrently .
DDI-DrugBank.d114.s9.p0	interferon-alfa	drug	_	PROLEUKIN	brand	_	effect	exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of druga and drugb , including crescentic iga glomerulonephritis , oculo-bulbar myasthenia gravis , inflammatory arthritis , thyroiditis , bullous pemphigoid , and stevens-johnson syndrome .
DDI-DrugBank.d114.s10.p0	glucocorticoids	group	_	PROLEUKIN	brand	_	effect	although druga have been shown to reduce drugb - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p1	glucocorticoids	group	_	PROLEUKIN	brand	_	false	although druga have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugb may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p2	glucocorticoids	group	_	PROLEUKIN	brand	_	false	although druga have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugb and thus should be avoided , # drugn and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p3	glucocorticoids	group	_	Beta-blockers	group	_	false	although druga have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugb and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p4	glucocorticoids	group	_	antihypertensives	group	_	false	although druga have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugb may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p5	glucocorticoids	group	_	PROLEUKIN	brand	_	false	although druga have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugn may potentiate the hypotension seen with drugb .
DDI-DrugBank.d114.s10.p8	PROLEUKIN	brand	_	Beta-blockers	group	_	false	although drugn have been shown to reduce druga - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugb and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p9	PROLEUKIN	brand	_	antihypertensives	group	_	false	although drugn have been shown to reduce druga - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugb may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p12	PROLEUKIN	brand	_	Beta-blockers	group	_	false	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with druga may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugb and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p13	PROLEUKIN	brand	_	antihypertensives	group	_	false	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with druga may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other drugb may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p15	PROLEUKIN	brand	_	Beta-blockers	group	_	false	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of druga and thus should be avoided , # drugb and other drugn may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p16	PROLEUKIN	brand	_	antihypertensives	group	_	false	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of druga and thus should be avoided , # drugn and other drugb may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p18	Beta-blockers	group	_	antihypertensives	group	_	false	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # druga and other drugb may potentiate the hypotension seen with drugn .
DDI-DrugBank.d114.s10.p19	Beta-blockers	group	_	PROLEUKIN	brand	_	effect	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # druga and other drugn may potentiate the hypotension seen with drugb .
DDI-DrugBank.d114.s10.p20	antihypertensives	group	_	PROLEUKIN	brand	_	effect	although drugn have been shown to reduce drugn - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drugn may reduce the antitumor effectiveness of drugn and thus should be avoided , # drugn and other druga may potentiate the hypotension seen with drugb .
DDI-DrugBank.d114.s11.p2	interleukin-2	drug	_	radiographic iodinated contrast media	group	_	effect	delayed adverse reactions to drugn : a review of the literature revealed that # % -lcb- range 11-28 % -rcb- of # patients treated with various druga containing regimens who were subsequently administered drugb experienced acute , atypical adverse reactions .
DDI-DrugBank.d491.s1.p0	AMEVIVE	brand	_	immunosuppressive	group	_	false	the duration of the period following treatment with druga before one should consider starting other drugb therapy has not been evaluated .
DDI-DrugBank.d407.s1.p0	Campath	brand	_	antibodies	group	_	false	an immune response to druga may interfere with subsequent diagnostic serum tests that utilize drugb
DDI-DrugBank.d430.s0.p0	ranitidine	drug	_	alendronate	drug	_	mechanism	intravenous druga was shown to double the bioavailability of oral drugb .
DDI-DrugBank.d430.s3.p0	calcium	drug	_	multivalent cations	drug	_	false	products containing druga and other drugb likely will interfere with absorption of drugn .
DDI-DrugBank.d430.s3.p1	calcium	drug	_	alendronate	drug	_	mechanism	products containing druga and other drugn likely will interfere with absorption of drugb .
DDI-DrugBank.d430.s3.p2	multivalent cations	drug	_	alendronate	drug	_	mechanism	products containing drugn and other druga likely will interfere with absorption of drugb .
DDI-DrugBank.d8.s0.p0	ALFENTA	brand	_	CNS depressants	group	_	effect	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when druga is administered in combination with other drugb such as drugn , drugn , drugn , or inhalation general drugn .
DDI-DrugBank.d8.s0.p1	ALFENTA	brand	_	barbiturates	group	_	effect	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when druga is administered in combination with other drugn such as drugb , drugn , drugn , or inhalation general drugn .
DDI-DrugBank.d8.s0.p2	ALFENTA	brand	_	tranquilizers	group	_	effect	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when druga is administered in combination with other drugn such as drugn , drugb , drugn , or inhalation general drugn .
DDI-DrugBank.d8.s0.p3	ALFENTA	brand	_	opioids	group	_	effect	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when druga is administered in combination with other drugn such as drugn , drugn , drugb , or inhalation general drugn .
DDI-DrugBank.d8.s0.p4	ALFENTA	brand	_	anesthetics	group	_	effect	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when druga is administered in combination with other drugn such as drugn , drugn , drugn , or inhalation general drugb .
DDI-DrugBank.d8.s0.p5	CNS depressants	group	_	barbiturates	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other druga such as drugb , drugn , drugn , or inhalation general drugn .
DDI-DrugBank.d8.s0.p6	CNS depressants	group	_	tranquilizers	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other druga such as drugn , drugb , drugn , or inhalation general drugn .
DDI-DrugBank.d8.s0.p7	CNS depressants	group	_	opioids	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other druga such as drugn , drugn , drugb , or inhalation general drugn .
DDI-DrugBank.d8.s0.p8	CNS depressants	group	_	anesthetics	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other druga such as drugn , drugn , drugn , or inhalation general drugb .
DDI-DrugBank.d8.s0.p11	barbiturates	group	_	anesthetics	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other drugn such as druga , drugn , drugn , or inhalation general drugb .
DDI-DrugBank.d8.s0.p13	tranquilizers	group	_	anesthetics	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other drugn such as drugn , druga , drugn , or inhalation general drugb .
DDI-DrugBank.d8.s0.p14	opioids	group	_	anesthetics	group	_	false	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drugn is administered in combination with other drugn such as drugn , drugn , druga , or inhalation general drugb .
DDI-DrugBank.d8.s3.p0	volatile inhalation anesthetics	group	_	ALFENTA	brand	_	mechanism	limited clinical experience indicates that requirements for druga are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugb induction the concomitant use of drugn with drugn can significantly inhibit drugn clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p1	volatile inhalation anesthetics	group	_	erythromycin	drug	_	false	limited clinical experience indicates that requirements for druga are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugn induction the concomitant use of drugb with drugn can significantly inhibit drugn clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p2	volatile inhalation anesthetics	group	_	ALFENTA	brand	_	false	limited clinical experience indicates that requirements for druga are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugn induction the concomitant use of drugn with drugb can significantly inhibit drugn clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p3	volatile inhalation anesthetics	group	_	ALFENTA	brand	_	false	limited clinical experience indicates that requirements for druga are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugn induction the concomitant use of drugn with drugn can significantly inhibit drugb clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p4	ALFENTA	brand	_	erythromycin	drug	_	false	limited clinical experience indicates that requirements for drugn are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following druga induction the concomitant use of drugb with drugn can significantly inhibit drugn clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p7	erythromycin	drug	_	ALFENTA	brand	_	mechanism	limited clinical experience indicates that requirements for drugn are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugn induction the concomitant use of druga with drugb can significantly inhibit drugn clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s3.p8	erythromycin	drug	_	ALFENTA	brand	_	false	limited clinical experience indicates that requirements for drugn are reduced by # to 50 % for the first sixty -lcb- 60 -rcb- minutes following drugn induction the concomitant use of druga with drugn can significantly inhibit drugb clearance and may increase the risk of prolonged or delayed respiratory depression .
DDI-DrugBank.d8.s4.p0	Cimetidine	drug	_	ALFENTA	brand	_	mechanism	druga reduces the clearance of drugb .
DDI-DrugBank.d273.s0.p0	UROXATRAL	brand	_	alpha-blockers	group	_	false	drug-drug interactions : the pharmacokinetic and pharmacodynamic interactions between druga and other drugb have not been determined .
DDI-DrugBank.d273.s1.p0	UROXATRAL	brand	_	alpha-blockers	group	_	advise	however , interactions may be expected , and druga should not be used in combination with other drugb .
DDI-DrugBank.d533.s1.p10	lovastatin	drug	_	aliskiren	drug	_	false	co-administration of druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p20	atenolol	drug	_	aliskiren	drug	_	false	co-administration of drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p29	warfarin	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p37	furosemide	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p44	digoxin	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p50	celecoxib	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p55	hydrochlorothiazide	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p59	ramipril	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p62	valsartan	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p64	metformin	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga and drugn did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s1.p65	amlodipine	drug	_	aliskiren	drug	_	false	co-administration of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn and druga did not result in clinically significant increases in drugb exposure .
DDI-DrugBank.d533.s2.p0	irbesartan	drug	_	aliskiren	drug	_	mechanism	co-administration of druga reduced drugb cmax up to 50 % after multiple dosing .
DDI-DrugBank.d533.s3.p0	atorvastatin	drug	_	aliskiren	drug	_	mechanism	co-administration of druga resulted in about a 50 % increase in drugb cmax and auc after multiple dosing .
DDI-DrugBank.d533.s4.p1	Ketoconazole	drug	_	aliskiren	drug	_	false	druga : co-administration of # mg twice-daily drugn with drugb resulted in an approximate 80 % increase in plasma levels of drugn .
DDI-DrugBank.d533.s4.p2	Ketoconazole	drug	_	aliskiren	drug	_	false	druga : co-administration of # mg twice-daily drugn with drugn resulted in an approximate 80 % increase in plasma levels of drugb .
DDI-DrugBank.d533.s4.p3	ketoconazole	drug	_	aliskiren	drug	_	mechanism	drugn : co-administration of # mg twice-daily druga with drugb resulted in an approximate 80 % increase in plasma levels of drugn .
DDI-DrugBank.d533.s4.p4	ketoconazole	drug	_	aliskiren	drug	_	false	drugn : co-administration of # mg twice-daily druga with drugn resulted in an approximate 80 % increase in plasma levels of drugb .
DDI-DrugBank.d533.s7.p0	aliskiren	drug	_	lovastatin	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p1	aliskiren	drug	_	digoxin	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p2	aliskiren	drug	_	valsartan	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p3	aliskiren	drug	_	amlodipine	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p4	aliskiren	drug	_	metformin	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p5	aliskiren	drug	_	celecoxib	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p6	aliskiren	drug	_	atenolol	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d533.s7.p7	aliskiren	drug	_	atorvastatin	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d533.s7.p8	aliskiren	drug	_	ramipril	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d533.s7.p9	aliskiren	drug	_	hydrochlorothiazide	drug	_	false	co-administration of druga did not significantly affect the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d533.s8.p2	aliskiren	drug	_	warfarin	drug	_	false	drugn : the effects of druga on drugb pharmacokinetics have not been evaluated in a well-controlled clinical trial .
DDI-DrugBank.d533.s9.p3	aliskiren	drug	_	furosemide	drug	_	mechanism	drugn : when druga was co-administered with drugb , the auc and cmax of drugn were reduced by about 30 % and 50 % , respectively .
DDI-DrugBank.d533.s9.p4	aliskiren	drug	_	furosemide	drug	_	false	drugn : when druga was co-administered with drugn , the auc and cmax of drugb were reduced by about 30 % and 50 % , respectively .
DDI-DrugBank.d392.s0.p0	Panretin	brand	_	DEET	drug	_	advise	patients who are applying druga gel should not concurrently use products that contain drugb -lcb- n , drugn -rcb- , a common component of insect repellent products .
DDI-DrugBank.d392.s0.p1	Panretin	brand	_	N-diethyl-m-toluamide	drug	_	advise	patients who are applying druga gel should not concurrently use products that contain drugn -lcb- n , drugb -rcb- , a common component of insect repellent products .
DDI-DrugBank.d392.s2.p0	antiretroviral agents	group	_	protease inhibitors	group	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic druga , including drugb , drugn , and drugn , the effect of drugn gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p1	antiretroviral agents	group	_	macrolide antibiotics	group	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic druga , including drugn , drugb , and drugn , the effect of drugn gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p2	antiretroviral agents	group	_	azole antifungals	group	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic druga , including drugn , drugn , and drugb , the effect of drugn gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p3	antiretroviral agents	group	_	Panretin	brand	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic druga , including drugn , drugn , and drugn , the effect of drugb gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p6	protease inhibitors	group	_	Panretin	brand	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic drugn , including druga , drugn , and drugn , the effect of drugb gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p7	macrolide antibiotics	group	_	azole antifungals	group	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic drugn , including drugn , druga , and drugb , the effect of drugn gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p8	macrolide antibiotics	group	_	Panretin	brand	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic drugn , including drugn , druga , and drugn , the effect of drugb gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d392.s2.p9	azole antifungals	group	_	Panretin	brand	_	false	although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic drugn , including drugn , drugn , and druga , the effect of drugb gel on the steady-state concentrations of these drugs is not known .
DDI-DrugBank.d413.s2.p0	Mercaptopurine	drug	_	Azathioprine	drug	_	false	druga / drugb : drugn inhibits the enzymatic oxidation of drugn and drugn to drugn .
DDI-DrugBank.d413.s2.p9	Allopurinol	drug	_	mercaptopurine	drug	_	mechanism	drugn / drugn : druga inhibits the enzymatic oxidation of drugb and drugn to drugn .
DDI-DrugBank.d413.s2.p10	Allopurinol	drug	_	azathioprine	drug	_	mechanism	drugn / drugn : druga inhibits the enzymatic oxidation of drugn and drugb to drugn .
DDI-DrugBank.d413.s2.p11	Allopurinol	drug	_	6-thiouric acid	drug	_	false	drugn / drugn : druga inhibits the enzymatic oxidation of drugn and drugn to drugb .
DDI-DrugBank.d413.s2.p12	mercaptopurine	drug	_	azathioprine	drug	_	false	drugn / drugn : drugn inhibits the enzymatic oxidation of druga and drugb to drugn .
DDI-DrugBank.d413.s2.p13	mercaptopurine	drug	_	6-thiouric acid	drug	_	false	drugn / drugn : drugn inhibits the enzymatic oxidation of druga and drugn to drugb .
DDI-DrugBank.d413.s2.p14	azathioprine	drug	_	6-thiouric acid	drug	_	false	drugn / drugn : drugn inhibits the enzymatic oxidation of drugn and druga to drugb .
DDI-DrugBank.d413.s4.p1	mercaptopurine	drug	_	azathioprine	drug	_	false	in patients receiving druga -lcb- drugn -rcb- or drugb -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p2	mercaptopurine	drug	_	Imuran	brand	_	false	in patients receiving druga -lcb- drugn -rcb- or drugn -lcb- drugb -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p3	mercaptopurine	drug	_	allopurinol	drug	_	false	in patients receiving druga -lcb- drugn -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugb per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p5	mercaptopurine	drug	_	azathioprine	drug	_	false	in patients receiving druga -lcb- drugn -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugb .
DDI-DrugBank.d413.s4.p6	Purinethol	brand	_	azathioprine	drug	_	false	in patients receiving drugn -lcb- druga -rcb- or drugb -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p7	Purinethol	brand	_	Imuran	brand	_	false	in patients receiving drugn -lcb- druga -rcb- or drugn -lcb- drugb -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p8	Purinethol	brand	_	allopurinol	drug	_	false	in patients receiving drugn -lcb- druga -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugb per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p9	Purinethol	brand	_	mercaptopurine	drug	_	false	in patients receiving drugn -lcb- druga -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugb or drugn .
DDI-DrugBank.d413.s4.p10	Purinethol	brand	_	azathioprine	drug	_	false	in patients receiving drugn -lcb- druga -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugb .
DDI-DrugBank.d413.s4.p12	azathioprine	drug	_	allopurinol	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or druga -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugb per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p13	azathioprine	drug	_	mercaptopurine	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or druga -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugb or drugn .
DDI-DrugBank.d413.s4.p15	Imuran	brand	_	allopurinol	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- druga -rcb- , the concomitant administration of 300-600 mg of drugb per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugn .
DDI-DrugBank.d413.s4.p16	Imuran	brand	_	mercaptopurine	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- druga -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugb or drugn .
DDI-DrugBank.d413.s4.p17	Imuran	brand	_	azathioprine	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- druga -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugb .
DDI-DrugBank.d413.s4.p18	allopurinol	drug	_	mercaptopurine	drug	_	advise	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of druga per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugb or drugn .
DDI-DrugBank.d413.s4.p19	allopurinol	drug	_	azathioprine	drug	_	advise	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of druga per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drugn or drugb .
DDI-DrugBank.d413.s4.p20	mercaptopurine	drug	_	azathioprine	drug	_	false	in patients receiving drugn -lcb- drugn -rcb- or drugn -lcb- drugn -rcb- , the concomitant administration of 300-600 mg of drugn per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of druga or drugb .
DDI-DrugBank.d413.s5.p0	mercaptopurine	drug	_	azathioprine	drug	_	false	subsequent adjustment of doses of druga or drugb should be made on the basis of therapeutic response and the appearance of toxic effects .
DDI-DrugBank.d413.s6.p3	allopurinol	drug	_	anticoagulant	group	_	false	drugn : it has been reported that druga prolongs the half-life of the drugb , drugn .
DDI-DrugBank.d413.s6.p4	allopurinol	drug	_	dicumarol	drug	_	mechanism	drugn : it has been reported that druga prolongs the half-life of the drugn , drugb .
DDI-DrugBank.d413.s6.p5	anticoagulant	group	_	dicumarol	drug	_	false	drugn : it has been reported that drugn prolongs the half-life of the druga , drugb .
DDI-DrugBank.d413.s7.p0	allopurinol	drug	_	dicumarol	drug	_	false	the clinical basis of this drug interaction has not been established but should be noted when druga is given to patients already on drugb therapy .
DDI-DrugBank.d413.s9.p3	oxipurinol	drug	_	uricosuric agents	group	_	false	drugn : since the excretion of druga is similar to that of urate , drugb , which increase the excretion of urate , are also likely to increase the excretion of drugn and thus lower the degree of inhibition of xanthine oxidase .
DDI-DrugBank.d413.s9.p5	uricosuric agents	group	_	oxipurinol	drug	_	mechanism	drugn : since the excretion of drugn is similar to that of urate , druga , which increase the excretion of urate , are also likely to increase the excretion of drugb and thus lower the degree of inhibition of xanthine oxidase .
DDI-DrugBank.d413.s10.p0	uricosuric agents	group	_	allopurinol	drug	_	mechanism	the concomitant administration of druga and drugb has been associated with a decrease in the excretion of oxypurines -lcb- hypoxanthine and xanthine -rcb- and an increase in urinary uric_acid excretion compared with that observed with drugn alone .
DDI-DrugBank.d413.s10.p1	uricosuric agents	group	_	allopurinol	drug	_	false	the concomitant administration of druga and drugn has been associated with a decrease in the excretion of oxypurines -lcb- hypoxanthine and xanthine -rcb- and an increase in urinary uric_acid excretion compared with that observed with drugb alone .
DDI-DrugBank.d413.s11.p0	allopurinol	drug	_	uricosuric agents	group	_	false	although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on druga alone or in combination with drugb , the possibility should be kept in mind .
DDI-DrugBank.d413.s12.p3	allopurinol	drug	_	thiazide diuretics	group	_	effect	drugn : the reports that the concomitant use of druga and drugb may contribute to the enhancement of drugn toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation .
DDI-DrugBank.d413.s12.p5	thiazide diuretics	group	_	allopurinol	drug	_	false	drugn : the reports that the concomitant use of drugn and druga may contribute to the enhancement of drugb toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation .
DDI-DrugBank.d413.s15.p0	thiazide diuretics	group	_	allopurinol	drug	_	advise	although a causal mechanism and a cause-and-effect relationship have not been established , current evidence suggests that renal function should be monitored in patients on druga and drugb even in the absence of renal failure , and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected , .
DDI-DrugBank.d413.s16.p0	Ampicillin	drug	_	Amoxicillin	drug	_	false	druga / drugb : an increase in the frequency of skin rash has been reported among patients receiving drugn or drugn concurrently with drugn compared to patients who are not receiving both drugs .
DDI-DrugBank.d413.s16.p7	ampicillin	drug	_	amoxicillin	drug	_	false	drugn / drugn : an increase in the frequency of skin rash has been reported among patients receiving druga or drugb concurrently with drugn compared to patients who are not receiving both drugs .
DDI-DrugBank.d413.s16.p8	ampicillin	drug	_	allopurinol	drug	_	effect	drugn / drugn : an increase in the frequency of skin rash has been reported among patients receiving druga or drugn concurrently with drugb compared to patients who are not receiving both drugs .
DDI-DrugBank.d413.s16.p9	amoxicillin	drug	_	allopurinol	drug	_	effect	drugn / drugn : an increase in the frequency of skin rash has been reported among patients receiving drugn or druga concurrently with drugb compared to patients who are not receiving both drugs .
DDI-DrugBank.d413.s18.p0	Cytotoxic Agents	group	_	cyclophosphamide	drug	_	false	druga : enhanced bone marrow suppression by drugb and other drugn has been reported among patients with neoplastic disease , except leukemia , in the presence of drugn .
DDI-DrugBank.d413.s18.p2	Cytotoxic Agents	group	_	allopurinol	drug	_	false	druga : enhanced bone marrow suppression by drugn and other drugn has been reported among patients with neoplastic disease , except leukemia , in the presence of drugb .
DDI-DrugBank.d413.s18.p3	cyclophosphamide	drug	_	cytotoxic agents	group	_	false	drugn : enhanced bone marrow suppression by druga and other drugb has been reported among patients with neoplastic disease , except leukemia , in the presence of drugn .
DDI-DrugBank.d413.s18.p4	cyclophosphamide	drug	_	allopurinol	drug	_	effect	drugn : enhanced bone marrow suppression by druga and other drugn has been reported among patients with neoplastic disease , except leukemia , in the presence of drugb .
DDI-DrugBank.d413.s18.p5	cytotoxic agents	group	_	allopurinol	drug	_	effect	drugn : enhanced bone marrow suppression by drugn and other druga has been reported among patients with neoplastic disease , except leukemia , in the presence of drugb .
DDI-DrugBank.d413.s19.p0	allopurinol	drug	_	cyclophosphamide	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , druga did not increase the marrow toxicity of patients treated with drugb , drugn , drugn , drugn and/or drugn .
DDI-DrugBank.d413.s19.p1	allopurinol	drug	_	doxorubicin	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , druga did not increase the marrow toxicity of patients treated with drugn , drugb , drugn , drugn and/or drugn .
DDI-DrugBank.d413.s19.p2	allopurinol	drug	_	bleomycin	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , druga did not increase the marrow toxicity of patients treated with drugn , drugn , drugb , drugn and/or drugn .
DDI-DrugBank.d413.s19.p3	allopurinol	drug	_	procarbazine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , druga did not increase the marrow toxicity of patients treated with drugn , drugn , drugn , drugb and/or drugn .
DDI-DrugBank.d413.s19.p4	allopurinol	drug	_	mechlorethamine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , druga did not increase the marrow toxicity of patients treated with drugn , drugn , drugn , drugn and/or drugb .
DDI-DrugBank.d413.s19.p8	cyclophosphamide	drug	_	mechlorethamine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , drugn did not increase the marrow toxicity of patients treated with druga , drugn , drugn , drugn and/or drugb .
DDI-DrugBank.d413.s19.p11	doxorubicin	drug	_	mechlorethamine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , drugn did not increase the marrow toxicity of patients treated with drugn , druga , drugn , drugn and/or drugb .
DDI-DrugBank.d413.s19.p13	bleomycin	drug	_	mechlorethamine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , drugn did not increase the marrow toxicity of patients treated with drugn , drugn , druga , drugn and/or drugb .
DDI-DrugBank.d413.s19.p14	procarbazine	drug	_	mechlorethamine	drug	_	false	however , in a well-controlled study of patients with lymphoma on combination therapy , drugn did not increase the marrow toxicity of patients treated with drugn , drugn , drugn , druga and/or drugb .
DDI-DrugBank.d413.s20.p4	Chlorpropamide	drug	_	allopurinol	drug	_	mechanism	drugn : druga s plasma half-life may be prolonged by drugb , since drugn and drugn may compete for excretion in the renal tubule .
DDI-DrugBank.d413.s20.p5	Chlorpropamide	drug	_	allopurinol	drug	_	false	drugn : druga s plasma half-life may be prolonged by drugn , since drugb and drugn may compete for excretion in the renal tubule .
DDI-DrugBank.d413.s20.p8	allopurinol	drug	_	chlorpropamide	drug	_	false	drugn : drugn s plasma half-life may be prolonged by druga , since drugn and drugb may compete for excretion in the renal tubule .
DDI-DrugBank.d413.s20.p9	allopurinol	drug	_	chlorpropamide	drug	_	mechanism	drugn : drugn s plasma half-life may be prolonged by drugn , since druga and drugb may compete for excretion in the renal tubule .
DDI-DrugBank.d413.s21.p0	allopurinol	drug	_	chlorpropamide	drug	_	effect	the risk of hypoglycemia secondary to this mechanism may be increased if druga and drugb are given concomitantly in the presence of renal insufficiency .
DDI-DrugBank.d413.s22.p2	cyclosporine	drug	_	allopurinol sodium	drug	_	mechanism	drugn : reports indicate that druga levels may be increased during concomitant treatment with drugb for injection .
DDI-DrugBank.d299.s1.p0	ergotamine	drug	_	ergot-type medications	group	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugb -lcb- like drugn or drugn -rcb- and drugn within # hours of each other should be avoided .
DDI-DrugBank.d299.s1.p2	ergotamine	drug	_	methysergide	drug	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugb -rcb- and drugn within # hours of each other should be avoided .
DDI-DrugBank.d299.s1.p3	ergotamine	drug	_	AXERT	brand	_	advise	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d299.s1.p6	ergot-type medications	group	_	AXERT	brand	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or druga -lcb- like drugn or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d299.s1.p8	dihydroergotamine	drug	_	AXERT	brand	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like druga or drugn -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d299.s1.p9	methysergide	drug	_	AXERT	brand	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like drugn or druga -rcb- and drugb within # hours of each other should be avoided .
DDI-DrugBank.d299.s2.p0	Monoamine Oxidase Inhibitors	group	_	moclobemide	drug	_	false	druga : coadministration of drugb resulted in a 27 % decrease in drugn clearance and an increase in cmax of approximately 6 % .
DDI-DrugBank.d299.s2.p1	Monoamine Oxidase Inhibitors	group	_	almotriptan	drug	_	false	druga : coadministration of drugn resulted in a 27 % decrease in drugb clearance and an increase in cmax of approximately 6 % .
DDI-DrugBank.d299.s2.p2	moclobemide	drug	_	almotriptan	drug	_	mechanism	drugn : coadministration of druga resulted in a 27 % decrease in drugb clearance and an increase in cmax of approximately 6 % .
DDI-DrugBank.d299.s4.p1	5-HT1B/1D Agonists	group	_	AXERT	brand	_	false	other druga concomitant use of other drugn within # hours of treatment with drugb is contraindicated .
DDI-DrugBank.d299.s4.p2	5-HT1B/1D agonists	group	_	AXERT	brand	_	advise	other drugn concomitant use of other druga within # hours of treatment with drugb is contraindicated .
DDI-DrugBank.d299.s5.p2	almotriptan	drug	_	propranolol	drug	_	false	drugn : the pharmacokinetics of druga were not affected by coadministration of drugb .
DDI-DrugBank.d299.s6.p2	Selective Serotonin Reuptake Inhibitors	group	_	fluoxetine	drug	_	false	druga -lcb- drugn -rcb- : drugn -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p3	Selective Serotonin Reuptake Inhibitors	group	_	fluvoxamine	drug	_	false	druga -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p4	Selective Serotonin Reuptake Inhibitors	group	_	paroxetine	drug	_	false	druga -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p5	Selective Serotonin Reuptake Inhibitors	group	_	sertraline	drug	_	false	druga -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p8	SSRIs	group	_	fluoxetine	drug	_	false	drugn -lcb- druga -rcb- : drugn -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p9	SSRIs	group	_	fluvoxamine	drug	_	false	drugn -lcb- druga -rcb- : drugn -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p10	SSRIs	group	_	paroxetine	drug	_	false	drugn -lcb- druga -rcb- : drugn -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p11	SSRIs	group	_	sertraline	drug	_	false	drugn -lcb- druga -rcb- : drugn -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
DDI-DrugBank.d299.s6.p17	SSRIs	group	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- : druga -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d299.s6.p21	fluoxetine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- : drugn -lcb- e , g , , druga , drugn , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d299.s6.p24	fluvoxamine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , druga , drugn , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d299.s6.p26	paroxetine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , drugn , druga , drugn -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d299.s6.p27	sertraline	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- : drugn -lcb- e , g , , drugn , drugn , drugn , druga -rcb- have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d299.s7.p0	AXERT	brand	_	SSRI	group	_	advise	if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d299.s8.p0	Verapamil	drug	_	almotriptan	drug	_	false	druga : coadministration of drugb and drugn resulted in a 24 % increase in plasma concentrations of drugn .
DDI-DrugBank.d299.s8.p2	Verapamil	drug	_	almotriptan	drug	_	false	druga : coadministration of drugn and drugn resulted in a 24 % increase in plasma concentrations of drugb .
DDI-DrugBank.d299.s8.p3	almotriptan	drug	_	verapamil	drug	_	mechanism	drugn : coadministration of druga and drugb resulted in a 24 % increase in plasma concentrations of drugn .
DDI-DrugBank.d299.s8.p5	verapamil	drug	_	almotriptan	drug	_	false	drugn : coadministration of drugn and druga resulted in a 24 % increase in plasma concentrations of drugb .
DDI-DrugBank.d299.s10.p0	almotriptan	drug	_	ketoconazole	drug	_	mechanism	coadministration of druga and the potent cyp3a4 inhibitor drugb -lcb- 400 mg q , d , for # days -rcb- resulted in an approximately 60 % increase in the area under the plasma concentration-time curve and maximal plasma concentrations of drugn .
DDI-DrugBank.d299.s10.p2	ketoconazole	drug	_	almotriptan	drug	_	false	coadministration of drugn and the potent cyp3a4 inhibitor druga -lcb- 400 mg q , d , for # days -rcb- resulted in an approximately 60 % increase in the area under the plasma concentration-time curve and maximal plasma concentrations of drugb .
DDI-DrugBank.d299.s11.p0	almotriptan	drug	_	itraconazole	drug	_	false	although the interaction between druga and other potent cyp3a4 inhibitors -lcb- e , g , , drugb , drugn , and drugn -rcb- has not been studied , increased exposures to drugn may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p1	almotriptan	drug	_	ritonavir	drug	_	false	although the interaction between druga and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugb , and drugn -rcb- has not been studied , increased exposures to drugn may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p2	almotriptan	drug	_	erythromycin	drug	_	false	although the interaction between druga and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , and drugb -rcb- has not been studied , increased exposures to drugn may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p7	itraconazole	drug	_	almotriptan	drug	_	false	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , druga , drugn , and drugn -rcb- has not been studied , increased exposures to drugb may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p8	itraconazole	drug	_	almotriptan	drug	_	advise	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , druga , drugn , and drugn -rcb- has not been studied , increased exposures to drugn may be expected when drugb is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p10	ritonavir	drug	_	almotriptan	drug	_	false	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , druga , and drugn -rcb- has not been studied , increased exposures to drugb may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p11	ritonavir	drug	_	almotriptan	drug	_	advise	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , druga , and drugn -rcb- has not been studied , increased exposures to drugn may be expected when drugb is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p12	erythromycin	drug	_	almotriptan	drug	_	false	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , and druga -rcb- has not been studied , increased exposures to drugb may be expected when drugn is used concomitantly with these medications .
DDI-DrugBank.d299.s11.p13	erythromycin	drug	_	almotriptan	drug	_	advise	although the interaction between drugn and other potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , and druga -rcb- has not been studied , increased exposures to drugn may be expected when drugb is used concomitantly with these medications .
DDI-DrugBank.d364.s2.p0	fluvoxamine	drug	_	alosetron	drug	_	false	in a pharmacokinetic study , # healthy female subjects received druga in escalating doses from # to # mg per day for # days , with coadministration of drugb # mg on the last day .
DDI-DrugBank.d364.s3.p0	Fluvoxamine	drug	_	alosetron	drug	_	mechanism	druga increased mean drugb plasma concentrations -lcb- auc -rcb- approximately 6-fold and prolonged the half-life by approximately 3-fold .
DDI-DrugBank.d364.s4.p0	alosetron	drug	_	fluvoxamine	drug	_	advise	concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d364.s5.p0	alosetron	drug	_	quinolone antibiotics	group	_	advise	concomitant administration of druga and moderate cyp1a2 inhibitors , including drugb and drugn , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .
DDI-DrugBank.d364.s5.p1	alosetron	drug	_	cimetidine	drug	_	advise	concomitant administration of druga and moderate cyp1a2 inhibitors , including drugn and drugb , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .
DDI-DrugBank.d364.s5.p2	quinolone antibiotics	group	_	cimetidine	drug	_	false	concomitant administration of drugn and moderate cyp1a2 inhibitors , including druga and drugb , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .
DDI-DrugBank.d364.s7.p0	ketoconazole	drug	_	alosetron	drug	_	false	in a pharmacokinetic study , # healthy female subjects received druga # mg twice daily for # days , with coadministration of drugb # mg on the last day .
DDI-DrugBank.d364.s8.p0	Ketoconazole	drug	_	alosetron	drug	_	mechanism	druga increased mean drugb plasma concentrations -lcb- auc -rcb- by 29 % .
DDI-DrugBank.d364.s9.p0	alosetron	drug	_	ketoconazole	drug	_	advise	caution should be used when druga and drugb are administered concomitantly .
DDI-DrugBank.d364.s10.p0	alosetron	drug	_	clarithromycin	drug	_	advise	coadministration of druga and strong cyp3a4 inhibitors , such as drugb , drugn , drugn , drugn , and drugn has not been evaluated but should be undertaken with caution because of similar potential drug interactions .
DDI-DrugBank.d364.s10.p1	alosetron	drug	_	telithromycin	drug	_	advise	coadministration of druga and strong cyp3a4 inhibitors , such as drugn , drugb , drugn , drugn , and drugn has not been evaluated but should be undertaken with caution because of similar potential drug interactions .
DDI-DrugBank.d364.s10.p2	alosetron	drug	_	protease inhibitors	group	_	advise	coadministration of druga and strong cyp3a4 inhibitors , such as drugn , drugn , drugb , drugn , and drugn has not been evaluated but should be undertaken with caution because of similar potential drug interactions .
DDI-DrugBank.d364.s10.p3	alosetron	drug	_	voriconazole	drug	_	advise	coadministration of druga and strong cyp3a4 inhibitors , such as drugn , drugn , drugn , drugb , and drugn has not been evaluated but should be undertaken with caution because of similar potential drug interactions .
DDI-DrugBank.d364.s10.p4	alosetron	drug	_	itraconazole	drug	_	advise	coadministration of druga and strong cyp3a4 inhibitors , such as drugn , drugn , drugn , drugn , and drugb has not been evaluated but should be undertaken with caution because of similar potential drug interactions .
DDI-DrugBank.d364.s15.p0	alosetron	drug	_	isoniazid	drug	_	effect	although not studied with druga , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as drugb , drugn , and drugn .
DDI-DrugBank.d364.s15.p1	alosetron	drug	_	procainamide	drug	_	effect	although not studied with druga , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as drugn , drugb , and drugn .
DDI-DrugBank.d364.s15.p2	alosetron	drug	_	hydralazine	drug	_	effect	although not studied with druga , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as drugn , drugn , and drugb .
DDI-DrugBank.d364.s17.p0	alosetron	drug	_	contraceptive agents	group	_	false	another study showed that druga had no clinically significant effect on plasma concentrations of the oral drugb drugn and drugn -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s17.p1	alosetron	drug	_	ethinyl estradiol	drug	_	false	another study showed that druga had no clinically significant effect on plasma concentrations of the oral drugn drugb and drugn -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s17.p2	alosetron	drug	_	levonorgestrel	drug	_	false	another study showed that druga had no clinically significant effect on plasma concentrations of the oral drugn drugn and drugb -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s17.p3	contraceptive agents	group	_	ethinyl estradiol	drug	_	false	another study showed that drugn had no clinically significant effect on plasma concentrations of the oral druga drugb and drugn -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s17.p4	contraceptive agents	group	_	levonorgestrel	drug	_	false	another study showed that drugn had no clinically significant effect on plasma concentrations of the oral druga drugn and drugb -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s17.p5	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	another study showed that drugn had no clinically significant effect on plasma concentrations of the oral drugn druga and drugb -lcb- cyp3a4 substrates -rcb- .
DDI-DrugBank.d364.s18.p0	alosetron	drug	_	cisapride	drug	_	false	a clinical interaction study was also conducted with druga and the cyp3a4 substrate drugb .
DDI-DrugBank.d131.s0.p0	benzodiazepines	group	_	alprazolam	drug	_	false	the druga , including drugb , produce additive cns depressant effects when co-administered with other drugn , drugn , drugn , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p1	benzodiazepines	group	_	psychotropic medications	group	_	effect	the druga , including drugn , produce additive cns depressant effects when co-administered with other drugb , drugn , drugn , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p2	benzodiazepines	group	_	anticonvulsants	group	_	effect	the druga , including drugn , produce additive cns depressant effects when co-administered with other drugn , drugb , drugn , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p3	benzodiazepines	group	_	antihistaminics	group	_	effect	the druga , including drugn , produce additive cns depressant effects when co-administered with other drugn , drugn , drugb , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p4	benzodiazepines	group	_	ethanol	drug	_	effect	the druga , including drugn , produce additive cns depressant effects when co-administered with other drugn , drugn , drugn , drugb , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p5	alprazolam	drug	_	psychotropic medications	group	_	effect	the drugn , including druga , produce additive cns depressant effects when co-administered with other drugb , drugn , drugn , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p6	alprazolam	drug	_	anticonvulsants	group	_	effect	the drugn , including druga , produce additive cns depressant effects when co-administered with other drugn , drugb , drugn , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p7	alprazolam	drug	_	antihistaminics	group	_	effect	the drugn , including druga , produce additive cns depressant effects when co-administered with other drugn , drugn , drugb , drugn , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s0.p8	alprazolam	drug	_	ethanol	drug	_	effect	the drugn , including druga , produce additive cns depressant effects when co-administered with other drugn , drugn , drugn , drugb , and other drugs which themselves produce cns depression .
DDI-DrugBank.d131.s1.p0	imipramine	drug	_	desipramine	drug	_	false	the steady state plasma concentrations of druga and drugb have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of drugn tablets in doses up to # mg/day .
DDI-DrugBank.d131.s1.p1	imipramine	drug	_	alprazolam	drug	_	mechanism	the steady state plasma concentrations of druga and drugn have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of drugb tablets in doses up to # mg/day .
DDI-DrugBank.d131.s1.p2	desipramine	drug	_	alprazolam	drug	_	mechanism	the steady state plasma concentrations of drugn and druga have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of drugb tablets in doses up to # mg/day .
DDI-DrugBank.d131.s5.p1	Alprazolam	drug	_	fluoxetine	drug	_	false	drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving druga -lcb- caution is recommended during coadministration with drugn -rcb- : coadministration of drugb with drugn increased the maximum plasma concentration of drugn by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .
DDI-DrugBank.d131.s5.p4	alprazolam	drug	_	fluoxetine	drug	_	false	drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving drugn -lcb- caution is recommended during coadministration with druga -rcb- : coadministration of drugb with drugn increased the maximum plasma concentration of drugn by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .
DDI-DrugBank.d131.s5.p7	fluoxetine	drug	_	alprazolam	drug	_	mechanism	drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving drugn -lcb- caution is recommended during coadministration with drugn -rcb- : coadministration of druga with drugb increased the maximum plasma concentration of drugn by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .
DDI-DrugBank.d131.s5.p8	fluoxetine	drug	_	alprazolam	drug	_	false	drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving drugn -lcb- caution is recommended during coadministration with drugn -rcb- : coadministration of druga with drugn increased the maximum plasma concentration of drugb by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .
DDI-DrugBank.d131.s6.p0	propoxyphene	drug	_	alprazolam	drug	_	mechanism	coadministration of druga decreased the maximum plasma concentration of drugb by 6 % , decreased clearance by 38 % , and increased half-life by 58 % .
DDI-DrugBank.d131.s7.p0	contraceptives	group	_	alprazolam	drug	_	mechanism	coadministration of oral druga increased the maximum plasma concentration of drugb by 18 % , decreased clearance by 22 % , and increased half-life by 29 % .
DDI-DrugBank.d131.s8.p0	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving druga metabolized similarly to drugb or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p1	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving druga metabolized similarly to drugn or on the basis of in vitro studies with drugb or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p3	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving druga metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugb -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p13	alprazolam	drug	_	benzodiazepines	group	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to druga or on the basis of in vitro studies with drugn or other drugb -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p23	alprazolam	drug	_	benzodiazepines	group	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with druga or other drugb -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p33	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other druga -lcb- caution is recommended during coadministration with drugb -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p50	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugb suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p51	benzodiazepines	group	_	alprazolam	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugb for the following : drugn , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p52	benzodiazepines	group	_	diltiazem	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugn for the following : drugb , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p53	benzodiazepines	group	_	isoniazid	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugb , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p54	benzodiazepines	group	_	macrolide antibiotics	group	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugb such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p55	benzodiazepines	group	_	erythromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugb and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p56	benzodiazepines	group	_	clarithromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of druga other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugb , and grapefruit juice .
DDI-DrugBank.d131.s8.p58	alprazolam	drug	_	diltiazem	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than druga suggest a possible drug interaction with drugn for the following : drugb , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p59	alprazolam	drug	_	isoniazid	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than druga suggest a possible drug interaction with drugn for the following : drugn , drugb , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p60	alprazolam	drug	_	macrolide antibiotics	group	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than druga suggest a possible drug interaction with drugn for the following : drugn , drugn , drugb such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p61	alprazolam	drug	_	erythromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than druga suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugb and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p62	alprazolam	drug	_	clarithromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than druga suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as drugn and drugb , and grapefruit juice .
DDI-DrugBank.d131.s8.p63	alprazolam	drug	_	diltiazem	drug	_	int	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with druga for the following : drugb , drugn , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p64	alprazolam	drug	_	isoniazid	drug	_	int	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with druga for the following : drugn , drugb , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p65	alprazolam	drug	_	macrolide antibiotics	group	_	int	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with druga for the following : drugn , drugn , drugb such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p66	alprazolam	drug	_	erythromycin	drug	_	int	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with druga for the following : drugn , drugn , drugn such as drugb and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p67	alprazolam	drug	_	clarithromycin	drug	_	int	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with druga for the following : drugn , drugn , drugn such as drugn and drugb , and grapefruit juice .
DDI-DrugBank.d131.s8.p68	diltiazem	drug	_	isoniazid	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : druga , drugb , drugn such as drugn and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p70	diltiazem	drug	_	erythromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : druga , drugn , drugn such as drugb and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p71	diltiazem	drug	_	clarithromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : druga , drugn , drugn such as drugn and drugb , and grapefruit juice .
DDI-DrugBank.d131.s8.p73	isoniazid	drug	_	erythromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , druga , drugn such as drugb and drugn , and grapefruit juice .
DDI-DrugBank.d131.s8.p74	isoniazid	drug	_	clarithromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , druga , drugn such as drugn and drugb , and grapefruit juice .
DDI-DrugBank.d131.s8.p77	erythromycin	drug	_	clarithromycin	drug	_	false	drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving drugn metabolized similarly to drugn or on the basis of in vitro studies with drugn or other drugn -lcb- caution is recommended during coadministration with drugn -rcb- : available data from clinical studies of drugn other than drugn suggest a possible drug interaction with drugn for the following : drugn , drugn , drugn such as druga and drugb , and grapefruit juice .
DDI-DrugBank.d131.s9.p1	alprazolam	drug	_	sertraline	drug	_	false	data from in vitro studies of druga suggest a possible drug interaction with drugn for the following : drugb and drugn .
DDI-DrugBank.d131.s9.p2	alprazolam	drug	_	paroxetine	drug	_	false	data from in vitro studies of druga suggest a possible drug interaction with drugn for the following : drugn and drugb .
DDI-DrugBank.d131.s9.p3	alprazolam	drug	_	sertraline	drug	_	int	data from in vitro studies of drugn suggest a possible drug interaction with druga for the following : drugb and drugn .
DDI-DrugBank.d131.s9.p4	alprazolam	drug	_	paroxetine	drug	_	int	data from in vitro studies of drugn suggest a possible drug interaction with druga for the following : drugn and drugb .
DDI-DrugBank.d131.s9.p5	sertraline	drug	_	paroxetine	drug	_	false	data from in vitro studies of drugn suggest a possible drug interaction with drugn for the following : druga and drugb .
DDI-DrugBank.d131.s10.p0	benzodiazepines	group	_	alprazolam	drug	_	false	data from in vitro studies of druga other than drugb suggest a possible drug interaction for the following : drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d131.s10.p1	benzodiazepines	group	_	ergotamine	drug	_	int	data from in vitro studies of druga other than drugn suggest a possible drug interaction for the following : drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d131.s10.p2	benzodiazepines	group	_	cyclosporine	drug	_	int	data from in vitro studies of druga other than drugn suggest a possible drug interaction for the following : drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d131.s10.p3	benzodiazepines	group	_	amiodarone	drug	_	int	data from in vitro studies of druga other than drugn suggest a possible drug interaction for the following : drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d131.s10.p4	benzodiazepines	group	_	nicardipine	drug	_	int	data from in vitro studies of druga other than drugn suggest a possible drug interaction for the following : drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d131.s10.p5	benzodiazepines	group	_	nifedipine	drug	_	int	data from in vitro studies of druga other than drugn suggest a possible drug interaction for the following : drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d131.s10.p6	alprazolam	drug	_	ergotamine	drug	_	int	data from in vitro studies of drugn other than druga suggest a possible drug interaction for the following : drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d131.s10.p7	alprazolam	drug	_	cyclosporine	drug	_	int	data from in vitro studies of drugn other than druga suggest a possible drug interaction for the following : drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d131.s10.p8	alprazolam	drug	_	amiodarone	drug	_	int	data from in vitro studies of drugn other than druga suggest a possible drug interaction for the following : drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d131.s10.p9	alprazolam	drug	_	nicardipine	drug	_	int	data from in vitro studies of drugn other than druga suggest a possible drug interaction for the following : drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d131.s10.p10	alprazolam	drug	_	nifedipine	drug	_	int	data from in vitro studies of drugn other than druga suggest a possible drug interaction for the following : drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d290.s1.p0	antibiotics	group	_	penicillin	drug	_	false	standard therapy includes druga , such as drugb and drugn ;
DDI-DrugBank.d290.s1.p1	antibiotics	group	_	gentamicin	drug	_	false	standard therapy includes druga , such as drugn and drugb ;
DDI-DrugBank.d290.s1.p2	penicillin	drug	_	gentamicin	drug	_	false	standard therapy includes drugn , such as druga and drugb ;
DDI-DrugBank.d290.s2.p0	vasopressors	group	_	dopamine	drug	_	false	druga , such as drugb and drugn ;
DDI-DrugBank.d290.s2.p1	vasopressors	group	_	isoproterenol	drug	_	false	druga , such as drugn and drugb ;
DDI-DrugBank.d290.s2.p2	dopamine	drug	_	isoproterenol	drug	_	false	drugn , such as druga and drugb ;
DDI-DrugBank.d290.s4.p0	diuretics	group	_	furosemide	drug	_	false	and druga , such as drugb .
DDI-DrugBank.d508.s1.p0	heparin	drug	_	vitamin K antagonists	group	_	false	in addition to bleeding associated with druga and drugb , drugs that alter platelet function -lcb- such as drugn , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p1	heparin	drug	_	acetylsalicylic acid	drug	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugb , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p2	heparin	drug	_	dipyridamole	drug	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugb and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p3	heparin	drug	_	Abciximab	drug	_	false	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugn and drugb -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p4	heparin	drug	_	Activase	brand	_	effect	in addition to bleeding associated with druga and drugn , drugs that alter platelet function -lcb- such as drugn , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d508.s1.p5	vitamin K antagonists	group	_	acetylsalicylic acid	drug	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugb , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p6	vitamin K antagonists	group	_	dipyridamole	drug	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugb and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p7	vitamin K antagonists	group	_	Abciximab	drug	_	false	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugn and drugb -rcb- may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
DDI-DrugBank.d508.s1.p8	vitamin K antagonists	group	_	Activase	brand	_	effect	in addition to bleeding associated with drugn and druga , drugs that alter platelet function -lcb- such as drugn , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d508.s1.p11	acetylsalicylic acid	drug	_	Activase	brand	_	int	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as druga , drugn and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d508.s1.p13	dipyridamole	drug	_	Activase	brand	_	effect	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as drugn , druga and drugn -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d508.s1.p14	Abciximab	drug	_	Activase	brand	_	effect	in addition to bleeding associated with drugn and drugn , drugs that alter platelet function -lcb- such as drugn , drugn and druga -rcb- may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
DDI-DrugBank.d508.s2.p0	Antithrombotics	group	_	Aspirin	brand	_	false	use of druga drugb and drugn have been administered concomitantly with and following infusions of drugn in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s2.p1	Antithrombotics	group	_	heparin	drug	_	false	use of druga drugn and drugb have been administered concomitantly with and following infusions of drugn in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s2.p2	Antithrombotics	group	_	Activase	brand	_	false	use of druga drugn and drugn have been administered concomitantly with and following infusions of drugb in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s2.p3	Aspirin	brand	_	heparin	drug	_	false	use of drugn druga and drugb have been administered concomitantly with and following infusions of drugn in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s2.p4	Aspirin	brand	_	Activase	brand	_	false	use of drugn druga and drugn have been administered concomitantly with and following infusions of drugb in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s2.p5	heparin	drug	_	Activase	brand	_	false	use of drugn drugn and druga have been administered concomitantly with and following infusions of drugb in the management of acute myocardial infarction or pulmonary embolism .
DDI-DrugBank.d508.s4.p0	heparin	drug	_	aspirin	brand	_	false	the concomitant use of druga or drugb during the first # hours following symptom onset were prohibited in the ninds plat stroke trial .
DDI-DrugBank.d188.s0.p0	HEXALEN	brand	_	antidepressants of the MAO inhibitor class	group	_	effect	concurrent administration of druga and drugb may cause severe orthostatic hypotension , drugn , an inhibitor of microsomal drug metabolism , increased drugn s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s0.p1	HEXALEN	brand	_	Cimetidine	drug	_	false	concurrent administration of druga and drugn may cause severe orthostatic hypotension , drugb , an inhibitor of microsomal drug metabolism , increased drugn s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s0.p2	HEXALEN	brand	_	altretamine	drug	_	false	concurrent administration of druga and drugn may cause severe orthostatic hypotension , drugn , an inhibitor of microsomal drug metabolism , increased drugb s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s0.p3	antidepressants of the MAO inhibitor class	group	_	Cimetidine	drug	_	false	concurrent administration of drugn and druga may cause severe orthostatic hypotension , drugb , an inhibitor of microsomal drug metabolism , increased drugn s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s0.p4	antidepressants of the MAO inhibitor class	group	_	altretamine	drug	_	false	concurrent administration of drugn and druga may cause severe orthostatic hypotension , drugn , an inhibitor of microsomal drug metabolism , increased drugb s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s0.p5	Cimetidine	drug	_	altretamine	drug	_	mechanism	concurrent administration of drugn and drugn may cause severe orthostatic hypotension , druga , an inhibitor of microsomal drug metabolism , increased drugb s half-life and toxicity in a rat model .
DDI-DrugBank.d188.s1.p0	HEXALEN	brand	_	cisplatin	drug	_	effect	data from a randomized trial of druga and drugb plus or minus drugn in ovarian_cancer indicated that drugn significantly reduced neurotoxicity ;
DDI-DrugBank.d188.s1.p1	HEXALEN	brand	_	pyridoxine	drug	_	false	data from a randomized trial of druga and drugn plus or minus drugb in ovarian_cancer indicated that drugn significantly reduced neurotoxicity ;
DDI-DrugBank.d188.s1.p2	HEXALEN	brand	_	pyridoxine	drug	_	false	data from a randomized trial of druga and drugn plus or minus drugn in ovarian_cancer indicated that drugb significantly reduced neurotoxicity ;
DDI-DrugBank.d188.s1.p3	cisplatin	drug	_	pyridoxine	drug	_	false	data from a randomized trial of drugn and druga plus or minus drugb in ovarian_cancer indicated that drugn significantly reduced neurotoxicity ;
DDI-DrugBank.d188.s1.p4	cisplatin	drug	_	pyridoxine	drug	_	false	data from a randomized trial of drugn and druga plus or minus drugn in ovarian_cancer indicated that drugb significantly reduced neurotoxicity ;
DDI-DrugBank.d188.s2.p0	pyridoxine	drug	_	HEXALEN	brand	_	advise	however , it adversely affected response duration suggesting that druga should not be administered with drugb and/or drugn #
DDI-DrugBank.d188.s2.p1	pyridoxine	drug	_	cisplatin	drug	_	advise	however , it adversely affected response duration suggesting that druga should not be administered with drugn and/or drugb #
DDI-DrugBank.d188.s2.p2	HEXALEN	brand	_	cisplatin	drug	_	false	however , it adversely affected response duration suggesting that drugn should not be administered with druga and/or drugb #
DDI-DrugBank.d116.s0.p0	amantadine	drug	_	central nervous system stimulants	group	_	advise	careful observation is required when druga is administered concurrently with drugb .
DDI-DrugBank.d563.s0.p0	ETHYOL	brand	_	antihypertensive medications	group	_	advise	special consideration should be given to the administration of druga in patients receiving drugb or other drugs that could cause or potentiate hypotension .
DDI-DrugBank.d356.s0.p0	amiloride	drug	_	angiotensin-converting enzyme inhibitor	group	_	effect	when druga hydrochloride is administered concomitantly with an drugb , the risk of hyperkalemia may be increased .
DDI-DrugBank.d356.s2.p0	Lithium	drug	_	diuretics	group	_	advise	druga generally should not be given with drugb because they reduce its renal clearance and add a high risk of lithium toxicity .
DDI-DrugBank.d356.s4.p0	non-steroidal anti-inflammatory agent	group	_	loop diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d356.s4.p1	non-steroidal anti-inflammatory agent	group	_	potassium-sparing diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d356.s4.p2	non-steroidal anti-inflammatory agent	group	_	thiazide diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d356.s4.p4	loop diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of druga , drugn and drugb .
DDI-DrugBank.d356.s4.p5	potassium-sparing diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , druga and drugb .
DDI-DrugBank.d356.s5.p0	MIDAMOR	brand	_	non-steroidal anti-inflammatory agents	group	_	advise	therefore , when druga and drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained .
DDI-DrugBank.d356.s5.p1	MIDAMOR	brand	_	diuretic	group	_	false	therefore , when druga and drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d356.s5.p2	non-steroidal anti-inflammatory agents	group	_	diuretic	group	_	false	therefore , when drugn and druga are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d356.s6.p0	indomethacin	drug	_	potassium-sparing diuretics	group	_	effect	since druga and drugb , including drugn , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .
DDI-DrugBank.d356.s6.p1	indomethacin	drug	_	MIDAMOR	brand	_	effect	since druga and drugn , including drugb , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .
DDI-DrugBank.d356.s6.p2	potassium-sparing diuretics	group	_	MIDAMOR	brand	_	false	since drugn and druga , including drugb , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .
DDI-DrugBank.d372.s0.p0	Cytadren	brand	_	dexamethasone	drug	_	mechanism	druga accelerates the metabolism of drugb ;
DDI-DrugBank.d372.s1.p0	glucocorticoid	group	_	hydrocortisone	drug	_	false	therefore , if druga replacement is needed , drugb should be prescribed .
DDI-DrugBank.d372.s2.p0	Aminoglutethimide	drug	_	coumarin	group	_	effect	druga diminishes the effect of drugb and drugn .
DDI-DrugBank.d372.s2.p1	Aminoglutethimide	drug	_	warfarin	drug	_	effect	druga diminishes the effect of drugn and drugb .
DDI-DrugBank.d372.s2.p2	coumarin	group	_	warfarin	drug	_	false	drugn diminishes the effect of druga and drugb .
DDI-DrugBank.d416.s0.p0	PAH	drug	_	sulfonamides	group	_	effect	renal clearance measurements of druga can not be made with any significant accuracy in patients receiving drugb , drugn , or drugn .
DDI-DrugBank.d416.s0.p1	PAH	drug	_	procaine	drug	_	effect	renal clearance measurements of druga can not be made with any significant accuracy in patients receiving drugn , drugb , or drugn .
DDI-DrugBank.d416.s0.p2	PAH	drug	_	thiazolesulfone	drug	_	effect	renal clearance measurements of druga can not be made with any significant accuracy in patients receiving drugn , drugn , or drugb .
DDI-DrugBank.d416.s2.p0	Probenecid	drug	_	PAH	drug	_	mechanism	druga depresses tubular secretion of certain weak acids such as drugb .
DDI-DrugBank.d416.s3.p0	probenecid	drug	_	PAH	drug	_	effect	therefore , patients receiving druga will have erroneously low erpf and tm drugb values .
DDI-DrugBank.d379.s1.p0	photosensitizing agents	group	_	griseofulvin	drug	_	false	it is , however , possible that concomitant use of other known druga such as drugb , drugn , drugn , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p1	photosensitizing agents	group	_	thiazide diuretics	group	_	false	it is , however , possible that concomitant use of other known druga such as drugn , drugb , drugn , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p2	photosensitizing agents	group	_	sulfonylureas	group	_	false	it is , however , possible that concomitant use of other known druga such as drugn , drugn , drugb , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p3	photosensitizing agents	group	_	phenothiazines	group	_	false	it is , however , possible that concomitant use of other known druga such as drugn , drugn , drugn , drugb , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p4	photosensitizing agents	group	_	sulfonamides	group	_	false	it is , however , possible that concomitant use of other known druga such as drugn , drugn , drugn , drugn , drugb and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p5	photosensitizing agents	group	_	tetracyclines	group	_	false	it is , however , possible that concomitant use of other known druga such as drugn , drugn , drugn , drugn , drugn and drugb might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p6	photosensitizing agents	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known druga such as drugn , drugn , drugn , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p12	griseofulvin	drug	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as druga , drugn , drugn , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p17	thiazide diuretics	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as drugn , druga , drugn , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p21	sulfonylureas	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as drugn , drugn , druga , drugn , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p24	phenothiazines	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as drugn , drugn , drugn , druga , drugn and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p25	sulfonamides	group	_	tetracyclines	group	_	false	it is , however , possible that concomitant use of other known drugn such as drugn , drugn , drugn , drugn , druga and drugb might increase the photosensitivity reaction of actinic_keratosis treated with the drugn for topical solution .
DDI-DrugBank.d379.s1.p26	sulfonamides	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as drugn , drugn , drugn , drugn , druga and drugn might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d379.s1.p27	tetracyclines	group	_	LEVULAN KERASTICK	brand	_	effect	it is , however , possible that concomitant use of other known drugn such as drugn , drugn , drugn , drugn , drugn and druga might increase the photosensitivity reaction of actinic_keratosis treated with the drugb for topical solution .
DDI-DrugBank.d22.s0.p0	Aminosalicylic acid	drug	_	digoxin	drug	_	mechanism	druga may decrease the amount of drugb -lcb- drugn , drugn -rcb- that gets absorbed into your body .
DDI-DrugBank.d22.s0.p1	Aminosalicylic acid	drug	_	Lanoxin	brand	_	mechanism	druga may decrease the amount of drugn -lcb- drugb , drugn -rcb- that gets absorbed into your body .
DDI-DrugBank.d22.s0.p2	Aminosalicylic acid	drug	_	Lanoxicaps	drug	_	false	druga may decrease the amount of drugn -lcb- drugn , drugb -rcb- that gets absorbed into your body .
DDI-DrugBank.d22.s1.p0	digoxin	drug	_	aminosalicylic acid	drug	_	advise	in the case that you are taking druga while taking drugb , higher doses of drugn may be needed .
DDI-DrugBank.d22.s1.p2	aminosalicylic acid	drug	_	digoxin	drug	_	false	in the case that you are taking drugn while taking druga , higher doses of drugb may be needed .
DDI-DrugBank.d22.s2.p0	Aminosalicylic acid	drug	_	vitamin B12	drug	_	mechanism	druga may also decrease the absorption of drugb , which can lead to a deficiency .
DDI-DrugBank.d22.s3.p0	vitamin B12	drug	_	aminosalicylic acid	drug	_	advise	therefore you may need to take a druga supplement while taking drugb .
DDI-DrugBank.d143.s10.p0	amiodarone	drug	_	indinavir	drug	_	mechanism	a case report of one patient taking druga # mg and drugb # mg three times a day resulted in increases in drugn concentrations from # mg/l to # mg/l .
DDI-DrugBank.d143.s10.p2	indinavir	drug	_	amiodarone	drug	_	false	a case report of one patient taking drugn # mg and druga # mg three times a day resulted in increases in drugb concentrations from # mg/l to # mg/l .
DDI-DrugBank.d143.s13.p1	amiodarone	drug	_	protease inhibitor	group	_	false	monitoring for druga toxicity and serial measurement of drugn serum concentration during concomitant drugb therapy should be considered .
DDI-DrugBank.d143.s13.p2	amiodarone	drug	_	protease inhibitor	group	_	advise	monitoring for drugn toxicity and serial measurement of druga serum concentration during concomitant drugb therapy should be considered .
DDI-DrugBank.d143.s14.p2	Cimetidine	drug	_	amiodarone	drug	_	false	drugn : druga inhibits cyp3a4 and can increase serum drugb levels .
DDI-DrugBank.d143.s18.p0	Amiodarone	drug	_	CYP1A2	drug	_	false	druga may suppress certain cyp450 enzymes , including drugb , drugn , drugn , and drugn .
DDI-DrugBank.d143.s18.p1	Amiodarone	drug	_	CYP2C9	drug	_	false	druga may suppress certain cyp450 enzymes , including drugn , drugb , drugn , and drugn .
DDI-DrugBank.d143.s18.p2	Amiodarone	drug	_	CYP2D6	drug	_	false	druga may suppress certain cyp450 enzymes , including drugn , drugn , drugb , and drugn .
DDI-DrugBank.d143.s18.p3	Amiodarone	drug	_	CYP3A4	drug	_	false	druga may suppress certain cyp450 enzymes , including drugn , drugn , drugn , and drugb .
DDI-DrugBank.d143.s20.p6	Cyclosporine	drug	_	amiodarone	drug	_	false	reported examples of this interaction include the following : drugn s : druga -lcb- drugn substrate -rcb- administered in combination with oral drugb has been reported to produce persistently elevated plasma concentrations of drugn resulting in elevated creatinine , despite reduction in dose of drugn .
DDI-DrugBank.d143.s20.p9	CYP3A4	drug	_	amiodarone	drug	_	false	reported examples of this interaction include the following : drugn s : drugn -lcb- druga substrate -rcb- administered in combination with oral drugb has been reported to produce persistently elevated plasma concentrations of drugn resulting in elevated creatinine , despite reduction in dose of drugn .
DDI-DrugBank.d143.s20.p10	CYP3A4	drug	_	cyclosporine	drug	_	false	reported examples of this interaction include the following : drugn s : drugn -lcb- druga substrate -rcb- administered in combination with oral drugn has been reported to produce persistently elevated plasma concentrations of drugb resulting in elevated creatinine , despite reduction in dose of drugn .
DDI-DrugBank.d143.s20.p11	CYP3A4	drug	_	cyclosporine	drug	_	false	reported examples of this interaction include the following : drugn s : drugn -lcb- druga substrate -rcb- administered in combination with oral drugn has been reported to produce persistently elevated plasma concentrations of drugn resulting in elevated creatinine , despite reduction in dose of drugb .
DDI-DrugBank.d143.s20.p12	amiodarone	drug	_	cyclosporine	drug	_	false	reported examples of this interaction include the following : drugn s : drugn -lcb- drugn substrate -rcb- administered in combination with oral druga has been reported to produce persistently elevated plasma concentrations of drugb resulting in elevated creatinine , despite reduction in dose of drugn .
DDI-DrugBank.d143.s20.p13	amiodarone	drug	_	cyclosporine	drug	_	false	reported examples of this interaction include the following : drugn s : drugn -lcb- drugn substrate -rcb- administered in combination with oral druga has been reported to produce persistently elevated plasma concentrations of drugn resulting in elevated creatinine , despite reduction in dose of drugb .
DDI-DrugBank.d143.s21.p4	Simvastatin	drug	_	amiodarone	drug	_	false	drugn : druga -lcb- drugn substrate -rcb- in combination with drugb has been associated with reports of myopathy/rhabdomyolysis .
DDI-DrugBank.d143.s21.p5	CYP3A4	drug	_	amiodarone	drug	_	false	drugn : drugn -lcb- druga substrate -rcb- in combination with drugb has been associated with reports of myopathy/rhabdomyolysis .
DDI-DrugBank.d143.s22.p3	digoxin	drug	_	amiodarone	drug	_	false	cardiovasculars : drugn : in patients receiving druga therapy , administration of oral drugb regularly results in an increase in serum drugn concentration that may reach toxic levels with resultant clinical toxicity .
DDI-DrugBank.d143.s22.p5	amiodarone	drug	_	digoxin	drug	_	false	cardiovasculars : drugn : in patients receiving drugn therapy , administration of oral druga regularly results in an increase in serum drugb concentration that may reach toxic levels with resultant clinical toxicity .
DDI-DrugBank.d143.s23.p0	Amiodarone	drug	_	digoxin	drug	_	false	druga taken concomitantly with drugb increases the serum drugn concentration by 70 % after one day .
DDI-DrugBank.d143.s23.p1	Amiodarone	drug	_	digoxin	drug	_	false	druga taken concomitantly with drugn increases the serum drugb concentration by 70 % after one day .
DDI-DrugBank.d143.s24.p0	amiodarone	drug	_	digitalis	group	_	advise	on administration of oral druga , the need for drugb therapy should be reviewed and the dose reduced by approximately 50 % or discontinued .
DDI-DrugBank.d143.s27.p1	Antiarrhythmics	drug	_	quinidine	drug	_	false	druga : other drugn drugs , such as drugb , drugn , drugn , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p2	Antiarrhythmics	drug	_	procainamide	drug	_	false	druga : other drugn drugs , such as drugn , drugb , drugn , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p3	Antiarrhythmics	drug	_	disopyramide	drug	_	false	druga : other drugn drugs , such as drugn , drugn , drugb , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p4	Antiarrhythmics	drug	_	phenytoin	drug	_	false	druga : other drugn drugs , such as drugn , drugn , drugn , and drugb , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p5	Antiarrhythmics	drug	_	amiodarone	drug	_	false	druga : other drugn drugs , such as drugn , drugn , drugn , and drugn , have been used concurrently with drugb .
DDI-DrugBank.d143.s27.p6	antiarrhythmic	drug	_	quinidine	drug	_	false	drugn : other druga drugs , such as drugb , drugn , drugn , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p7	antiarrhythmic	drug	_	procainamide	drug	_	false	drugn : other druga drugs , such as drugn , drugb , drugn , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p8	antiarrhythmic	drug	_	disopyramide	drug	_	false	drugn : other druga drugs , such as drugn , drugn , drugb , and drugn , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p9	antiarrhythmic	drug	_	phenytoin	drug	_	false	drugn : other druga drugs , such as drugn , drugn , drugn , and drugb , have been used concurrently with drugn .
DDI-DrugBank.d143.s27.p10	antiarrhythmic	drug	_	amiodarone	drug	_	false	drugn : other druga drugs , such as drugn , drugn , drugn , and drugn , have been used concurrently with drugb .
DDI-DrugBank.d143.s27.p14	quinidine	drug	_	amiodarone	drug	_	false	drugn : other drugn drugs , such as druga , drugn , drugn , and drugn , have been used concurrently with drugb .
DDI-DrugBank.d143.s27.p17	procainamide	drug	_	amiodarone	drug	_	false	drugn : other drugn drugs , such as drugn , druga , drugn , and drugn , have been used concurrently with drugb .
DDI-DrugBank.d143.s27.p19	disopyramide	drug	_	amiodarone	drug	_	false	drugn : other drugn drugs , such as drugn , drugn , druga , and drugn , have been used concurrently with drugb .
DDI-DrugBank.d143.s27.p20	phenytoin	drug	_	amiodarone	drug	_	false	drugn : other drugn drugs , such as drugn , drugn , drugn , and druga , have been used concurrently with drugb .
DDI-DrugBank.d143.s28.p2	quinidine	drug	_	amiodarone	drug	_	false	there have been case reports of increased steady-state levels of druga , drugn , and drugn during concomitant therapy with drugb .
DDI-DrugBank.d143.s28.p4	procainamide	drug	_	amiodarone	drug	_	false	there have been case reports of increased steady-state levels of drugn , druga , and drugn during concomitant therapy with drugb .
DDI-DrugBank.d143.s28.p5	phenytoin	drug	_	amiodarone	drug	_	false	there have been case reports of increased steady-state levels of drugn , drugn , and druga during concomitant therapy with drugb .
DDI-DrugBank.d143.s30.p0	Amiodarone	drug	_	quinidine	drug	_	false	druga taken concomitantly with drugb increases drugn serum concentration by 33 % after two days .
DDI-DrugBank.d143.s30.p1	Amiodarone	drug	_	quinidine	drug	_	false	druga taken concomitantly with drugn increases drugb serum concentration by 33 % after two days .
DDI-DrugBank.d143.s31.p0	Amiodarone	drug	_	procainamide	drug	_	false	druga taken concomitantly with drugb for less than seven days increases plasma concentrations of drugn and n_acetyl drugn by 55 % and 33 % , respectively .
DDI-DrugBank.d143.s31.p1	Amiodarone	drug	_	procainamide	drug	_	false	druga taken concomitantly with drugn for less than seven days increases plasma concentrations of drugb and n_acetyl drugn by 55 % and 33 % , respectively .
DDI-DrugBank.d143.s31.p2	Amiodarone	drug	_	procainamide	drug	_	false	druga taken concomitantly with drugn for less than seven days increases plasma concentrations of drugn and n_acetyl drugb by 55 % and 33 % , respectively .
DDI-DrugBank.d143.s32.p0	Quinidine	drug	_	amiodarone	drug	_	false	druga and procainamide doses should be reduced by one-third when either is administered with drugb .
DDI-DrugBank.d143.s33.p0	flecainide	drug	_	amiodarone	drug	_	false	plasma levels of druga have been reported to increase in the presence of oral drugb ;
DDI-DrugBank.d143.s34.p0	flecainide	drug	_	drugs	drug	_	false	because of this , the dosage of druga should be adjusted when these drugb are administered concomitantly .
DDI-DrugBank.d143.s36.p0	amiodarone	drug	_	antiarrhythmic	drug	_	false	combination of druga with other drugb therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to drugn .
DDI-DrugBank.d143.s36.p2	antiarrhythmic	drug	_	amiodarone	drug	_	false	combination of drugn with other druga therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to drugb .
DDI-DrugBank.d143.s38.p0	antiarrhythmic	drug	_	amiodarone	drug	_	false	the continued need for the other druga agent should be reviewed after the effects of drugb have been established , and discontinuation ordinarily should be attempted .
DDI-DrugBank.d143.s40.p0	amiodarone	drug	_	antiarrhythmic	drug	_	false	in druga - treated patients who require additional drugb therapy , the initial dose of such agents should be approximately half of the usual recommended dose .
DDI-DrugBank.d143.s41.p9	Amiodarone	drug	_	receptor	drug	_	false	drugn : druga should be used with caution in patients receiving - drugb blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p10	Amiodarone	drug	_	propranolol	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugb , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p11	Amiodarone	drug	_	CYP3A4	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugb inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p12	Amiodarone	drug	_	calcium channel	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugb antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p13	Amiodarone	drug	_	verapamil	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugb , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p14	Amiodarone	drug	_	CYP3A4	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugb substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p15	Amiodarone	drug	_	diltiazem	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugb , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p16	Amiodarone	drug	_	CYP3A4	drug	_	false	drugn : druga should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugb inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p17	receptor	drug	_	propranolol	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugb , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p18	receptor	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugb inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p19	receptor	drug	_	calcium channel	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugb antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p20	receptor	drug	_	verapamil	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugb , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p21	receptor	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugb substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p22	receptor	drug	_	diltiazem	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugb , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p23	receptor	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - druga blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugb inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p25	propranolol	drug	_	calcium channel	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , druga , a drugn inhibitor -rcb- or drugb antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p26	propranolol	drug	_	verapamil	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , druga , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugb , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p27	propranolol	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , druga , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugb substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p28	propranolol	drug	_	diltiazem	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , druga , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugb , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p29	propranolol	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , druga , a drugn inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugb inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p30	CYP3A4	drug	_	calcium channel	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a druga inhibitor -rcb- or drugb antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p31	CYP3A4	drug	_	verapamil	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a druga inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugb , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p33	CYP3A4	drug	_	diltiazem	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a druga inhibitor -rcb- or drugn antagonists -lcb- e , g , , drugn , a drugn substrate , and drugb , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p35	calcium channel	drug	_	verapamil	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or druga antagonists -lcb- e , g , , drugb , a drugn substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p36	calcium channel	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or druga antagonists -lcb- e , g , , drugn , a drugb substrate , and drugn , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p37	calcium channel	drug	_	diltiazem	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or druga antagonists -lcb- e , g , , drugn , a drugn substrate , and drugb , a drugn inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s41.p38	calcium channel	drug	_	CYP3A4	drug	_	false	drugn : drugn should be used with caution in patients receiving - drugn blocking agents -lcb- e , g , , drugn , a drugn inhibitor -rcb- or druga antagonists -lcb- e , g , , drugn , a drugn substrate , and drugn , a drugb inhibitor -rcb- because of the possible potentiation of bradycardia , sinus arrest , and av block ;
DDI-DrugBank.d143.s43.p5	warfarin	drug	_	CYP2C9	drug	_	false	drugn : potentiation of druga - type -lcb- drugb and drugn substrate -rcb- drugn response is almost always seen in patients receiving drugn and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p6	warfarin	drug	_	CYP3A4	drug	_	false	drugn : potentiation of druga - type -lcb- drugn and drugb substrate -rcb- drugn response is almost always seen in patients receiving drugn and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p7	warfarin	drug	_	anticoagulant	drug	_	false	drugn : potentiation of druga - type -lcb- drugn and drugn substrate -rcb- drugb response is almost always seen in patients receiving drugn and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p8	warfarin	drug	_	amiodarone	drug	_	false	drugn : potentiation of druga - type -lcb- drugn and drugn substrate -rcb- drugn response is almost always seen in patients receiving drugb and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p10	CYP2C9	drug	_	anticoagulant	drug	_	false	drugn : potentiation of drugn - type -lcb- druga and drugn substrate -rcb- drugb response is almost always seen in patients receiving drugn and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p11	CYP2C9	drug	_	amiodarone	drug	_	false	drugn : potentiation of drugn - type -lcb- druga and drugn substrate -rcb- drugn response is almost always seen in patients receiving drugb and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p12	CYP3A4	drug	_	anticoagulant	drug	_	false	drugn : potentiation of drugn - type -lcb- drugn and druga substrate -rcb- drugb response is almost always seen in patients receiving drugn and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p13	CYP3A4	drug	_	amiodarone	drug	_	false	drugn : potentiation of drugn - type -lcb- drugn and druga substrate -rcb- drugn response is almost always seen in patients receiving drugb and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s43.p14	anticoagulant	drug	_	amiodarone	drug	_	false	drugn : potentiation of drugn - type -lcb- drugn and drugn substrate -rcb- druga response is almost always seen in patients receiving drugb and can result in serious or fatal bleeding .
DDI-DrugBank.d143.s44.p0	warfarin	drug	_	amiodarone	drug	_	false	since the concomitant administration of druga with drugb increases the prothrombin time by 100 % after # to # days , the dose of the drugn should be reduced by one-third to one-half , and prothrombin times should be monitored closely .
DDI-DrugBank.d143.s44.p1	warfarin	drug	_	anticoagulant	drug	_	false	since the concomitant administration of druga with drugn increases the prothrombin time by 100 % after # to # days , the dose of the drugb should be reduced by one-third to one-half , and prothrombin times should be monitored closely .
DDI-DrugBank.d143.s44.p2	amiodarone	drug	_	anticoagulant	drug	_	false	since the concomitant administration of drugn with druga increases the prothrombin time by 100 % after # to # days , the dose of the drugb should be reduced by one-third to one-half , and prothrombin times should be monitored closely .
DDI-DrugBank.d143.s45.p0	drugs	drug	_	amiodarone	drug	_	false	some druga / substances are known to accelerate the metabolism of drugb by stimulating the synthesis of drugn -lcb- enzyme induction -rcb- .
DDI-DrugBank.d143.s45.p1	drugs	drug	_	CYP3A4	drug	_	false	some druga / substances are known to accelerate the metabolism of drugn by stimulating the synthesis of drugb -lcb- enzyme induction -rcb- .
DDI-DrugBank.d143.s45.p2	amiodarone	drug	_	CYP3A4	drug	_	false	some drugn / substances are known to accelerate the metabolism of druga by stimulating the synthesis of drugb -lcb- enzyme induction -rcb- .
DDI-DrugBank.d143.s47.p2	Rifampin	drug	_	CYP3A4	drug	_	false	reported examples of this interaction include the following : drugn : druga is a potent inducer of drugb .
DDI-DrugBank.d143.s48.p0	rifampin	drug	_	amiodarone	drug	_	false	administration of druga concomitantly with oral drugb has been shown to result in decreases in serum concentrations of drugn and drugn .
DDI-DrugBank.d143.s48.p1	rifampin	drug	_	amiodarone	drug	_	false	administration of druga concomitantly with oral drugn has been shown to result in decreases in serum concentrations of drugb and drugn .
DDI-DrugBank.d143.s48.p2	rifampin	drug	_	desethylamiodarone	drug	_	false	administration of druga concomitantly with oral drugn has been shown to result in decreases in serum concentrations of drugn and drugb .
DDI-DrugBank.d143.s50.p0	amiodarone	drug	_	CYP3A4	drug	_	false	since druga is a substrate for drugb , there is the potential that the use of st , john s wort in patients receiving drugn could result in reduced drugn levels .
DDI-DrugBank.d143.s51.p4	Fentanyl	drug	_	amiodarone	drug	_	false	other reported interactions with drugn : druga -lcb- drugn substrate -rcb- in combination with drugb may cause hypotension , bradycardia , and decreased cardiac output .
DDI-DrugBank.d143.s51.p5	CYP3A4	drug	_	amiodarone	drug	_	false	other reported interactions with drugn : drugn -lcb- druga substrate -rcb- in combination with drugb may cause hypotension , bradycardia , and decreased cardiac output .
DDI-DrugBank.d143.s52.p0	amiodarone	drug	_	lidocaine	drug	_	false	sinus bradycardia has been reported with oral druga in combination with drugb -lcb- drugn substrate -rcb- given for local drugn .
DDI-DrugBank.d143.s52.p1	amiodarone	drug	_	CYP3A4	drug	_	false	sinus bradycardia has been reported with oral druga in combination with drugn -lcb- drugb substrate -rcb- given for local drugn .
DDI-DrugBank.d143.s52.p2	amiodarone	drug	_	anesthesia	drug	_	false	sinus bradycardia has been reported with oral druga in combination with drugn -lcb- drugn substrate -rcb- given for local drugb .
DDI-DrugBank.d143.s52.p4	lidocaine	drug	_	anesthesia	drug	_	false	sinus bradycardia has been reported with oral drugn in combination with druga -lcb- drugn substrate -rcb- given for local drugb .
DDI-DrugBank.d143.s52.p5	CYP3A4	drug	_	anesthesia	drug	_	false	sinus bradycardia has been reported with oral drugn in combination with drugn -lcb- druga substrate -rcb- given for local drugb .
DDI-DrugBank.d143.s53.p0	lidocaine	drug	_	amiodarone	drug	_	false	seizure , associated with increased druga concentrations , has been reported with concomitant administration of intravenous drugb .
DDI-DrugBank.d143.s54.p0	Dextromethorphan	drug	_	CYP2D6	drug	_	false	druga is a substrate for both drugb and drugn .
DDI-DrugBank.d143.s54.p1	Dextromethorphan	drug	_	CYP3A4	drug	_	false	druga is a substrate for both drugn and drugb .
DDI-DrugBank.d143.s54.p2	CYP2D6	drug	_	CYP3A4	drug	_	false	drugn is a substrate for both druga and drugb .
DDI-DrugBank.d143.s55.p0	Amiodarone	drug	_	CYP2D6	drug	_	false	druga inhibits drugb .
DDI-DrugBank.d143.s56.p0	Cholestyramine	drug	_	amiodarone	drug	_	false	druga increases enterohepatic elimination of drugb and may reduce its serum levels and drugn / 2 .
DDI-DrugBank.d143.s56.p1	Cholestyramine	drug	_	t1	drug	_	false	druga increases enterohepatic elimination of drugn and may reduce its serum levels and drugb / 2 .
DDI-DrugBank.d143.s56.p2	amiodarone	drug	_	t1	drug	_	false	drugn increases enterohepatic elimination of druga and may reduce its serum levels and drugb / 2 .
DDI-DrugBank.d143.s59.p0	amiodarone	drug	_	fluoroquinolones	drug	_	false	there have been reports of qtc prolongation , with or without tdp , in patients taking druga when drugb , drugn , or azoles were administered concomitantly .
DDI-DrugBank.d143.s59.p1	amiodarone	drug	_	macrolide antibiotics	drug	_	false	there have been reports of qtc prolongation , with or without tdp , in patients taking druga when drugn , drugb , or azoles were administered concomitantly .
DDI-DrugBank.d143.s62.p0	Cordarone	drug	_	phenytoin	drug	_	false	in addition to the interactions noted above , chronic -lcb- # weeks -rcb- oral druga administration impairs metabolism of drugb , drugn , and drugn .
DDI-DrugBank.d143.s62.p1	Cordarone	drug	_	dextromethorphan	drug	_	false	in addition to the interactions noted above , chronic -lcb- # weeks -rcb- oral druga administration impairs metabolism of drugn , drugb , and drugn .
DDI-DrugBank.d143.s62.p2	Cordarone	drug	_	methotrexate	drug	_	false	in addition to the interactions noted above , chronic -lcb- # weeks -rcb- oral druga administration impairs metabolism of drugn , drugn , and drugb .
DDI-DrugBank.d99.s7.p0	cimetidine	drug	_	antidepressants	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugb , drugn , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d99.s7.p1	cimetidine	drug	_	phenothiazines	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugb , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d99.s7.p2	cimetidine	drug	_	Type 1C antiarrhythmics	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugb drugn and drugn -rcb- .
DDI-DrugBank.d99.s7.p3	cimetidine	drug	_	propafenone	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugb and drugn -rcb- .
DDI-DrugBank.d99.s7.p4	cimetidine	drug	_	flecainide	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugn and drugb -rcb- .
DDI-DrugBank.d99.s8.p1	serotonin reuptake inhibitors	group	_	fluoxetine	drug	_	false	while all the selective druga -lcb- drugn -rcb- , e , g , , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s8.p2	serotonin reuptake inhibitors	group	_	sertraline	drug	_	false	while all the selective druga -lcb- drugn -rcb- , e , g , , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s8.p3	serotonin reuptake inhibitors	group	_	paroxetine	drug	_	false	while all the selective druga -lcb- drugn -rcb- , e , g , , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s8.p4	SSRIs	group	_	fluoxetine	drug	_	false	while all the selective drugn -lcb- druga -rcb- , e , g , , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s8.p5	SSRIs	group	_	sertraline	drug	_	false	while all the selective drugn -lcb- druga -rcb- , e , g , , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s8.p6	SSRIs	group	_	paroxetine	drug	_	false	while all the selective drugn -lcb- druga -rcb- , e , g , , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d99.s9.p0	SSRI	group	_	TCA	group	_	effect	the extent to which druga - drugb interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugn involved .
DDI-DrugBank.d99.s9.p2	TCA	group	_	SSRI	group	_	false	the extent to which drugn - druga interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugb involved .
DDI-DrugBank.d99.s10.p0	TCAs	group	_	SSRIs	group	_	advise	nevertheless , caution is indicated in the coadministration of druga with any of the drugb and also in switching from one class to the other .
DDI-DrugBank.d99.s18.p0	disulfiram	drug	_	amitriptyline HCl	drug	_	false	and druga when drugb is given with drugn agents or drugn drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p1	disulfiram	drug	_	anticholinergic	drug	_	false	and druga when drugn is given with drugb agents or drugn drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p2	disulfiram	drug	_	sympathomimetic	drug	_	false	and druga when drugn is given with drugn agents or drugb drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p3	disulfiram	drug	_	epinephrine	drug	_	false	and druga when drugn is given with drugn agents or drugn drugs , including drugb combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p4	disulfiram	drug	_	anesthetics	drug	_	false	and druga when drugn is given with drugn agents or drugn drugs , including drugn combined with local drugb , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p5	amitriptyline HCl	drug	_	anticholinergic	drug	_	false	and drugn when druga is given with drugb agents or drugn drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p6	amitriptyline HCl	drug	_	sympathomimetic	drug	_	false	and drugn when druga is given with drugn agents or drugb drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p7	amitriptyline HCl	drug	_	epinephrine	drug	_	false	and drugn when druga is given with drugn agents or drugn drugs , including drugb combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p8	amitriptyline HCl	drug	_	anesthetics	drug	_	false	and drugn when druga is given with drugn agents or drugn drugs , including drugn combined with local drugb , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p9	anticholinergic	drug	_	sympathomimetic	drug	_	false	and drugn when drugn is given with druga agents or drugb drugs , including drugn combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p10	anticholinergic	drug	_	epinephrine	drug	_	false	and drugn when drugn is given with druga agents or drugn drugs , including drugb combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p11	anticholinergic	drug	_	anesthetics	drug	_	false	and drugn when drugn is given with druga agents or drugn drugs , including drugn combined with local drugb , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p12	sympathomimetic	drug	_	epinephrine	drug	_	false	and drugn when drugn is given with drugn agents or druga drugs , including drugb combined with local drugn , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p13	sympathomimetic	drug	_	anesthetics	drug	_	false	and drugn when drugn is given with drugn agents or druga drugs , including drugn combined with local drugb , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s18.p14	epinephrine	drug	_	anesthetics	drug	_	false	and drugn when drugn is given with drugn agents or drugn drugs , including druga combined with local drugb , close supervision and careful adjustment of dosages are required .
DDI-DrugBank.d99.s19.p0	amitriptyline HCl	drug	_	anticholinergic	drug	_	effect	hyperpyrexia has been reported when druga is administered with drugb agents or with drugn drugs , particularly during hot weather .
DDI-DrugBank.d99.s19.p1	amitriptyline HCl	drug	_	neuroleptic	drug	_	false	hyperpyrexia has been reported when druga is administered with drugn agents or with drugb drugs , particularly during hot weather .
DDI-DrugBank.d99.s19.p2	anticholinergic	drug	_	neuroleptic	drug	_	false	hyperpyrexia has been reported when drugn is administered with druga agents or with drugb drugs , particularly during hot weather .
DDI-DrugBank.d99.s20.p0	tricyclic antidepressants	drug	_	anticholinergic	drug	_	effect	paralytic ileus may occur in patients taking druga in combination with drugb - type drugs .
DDI-DrugBank.d99.s21.p0	Cimetidine	drug	_	tricyclic antidepressants	drug	_	mechanism	druga is reported to reduce hepatic metabolism of certain drugb , thereby delaying elimination and increasing steady-state concentrations of these drugn .
DDI-DrugBank.d99.s21.p1	Cimetidine	drug	_	drugs	drug	_	false	druga is reported to reduce hepatic metabolism of certain drugn , thereby delaying elimination and increasing steady-state concentrations of these drugb .
DDI-DrugBank.d99.s21.p2	tricyclic antidepressants	drug	_	drugs	drug	_	false	drugn is reported to reduce hepatic metabolism of certain druga , thereby delaying elimination and increasing steady-state concentrations of these drugb .
DDI-DrugBank.d99.s22.p0	tricyclic antidepressants	drug	_	cimetidine	drug	_	effect	clinically significant effects have been reported with the druga when used concomitantly with drugb .
DDI-DrugBank.d99.s23.p0	tricyclic antidepressants	drug	_	anticholinergic	drug	_	false	increases in plasma levels of druga , and in the frequency and severity of side effects , particularly drugb , have been reported when drugn was added to the drugn regimen .
DDI-DrugBank.d99.s23.p1	tricyclic antidepressants	drug	_	cimetidine	drug	_	mechanism	increases in plasma levels of druga , and in the frequency and severity of side effects , particularly drugn , have been reported when drugb was added to the drugn regimen .
DDI-DrugBank.d99.s23.p2	tricyclic antidepressants	drug	_	drug	drug	_	false	increases in plasma levels of druga , and in the frequency and severity of side effects , particularly drugn , have been reported when drugn was added to the drugb regimen .
DDI-DrugBank.d99.s23.p3	anticholinergic	drug	_	cimetidine	drug	_	false	increases in plasma levels of drugn , and in the frequency and severity of side effects , particularly druga , have been reported when drugb was added to the drugn regimen .
DDI-DrugBank.d99.s23.p4	anticholinergic	drug	_	drug	drug	_	false	increases in plasma levels of drugn , and in the frequency and severity of side effects , particularly druga , have been reported when drugn was added to the drugb regimen .
DDI-DrugBank.d99.s23.p5	cimetidine	drug	_	drug	drug	_	false	increases in plasma levels of drugn , and in the frequency and severity of side effects , particularly drugn , have been reported when druga was added to the drugb regimen .
DDI-DrugBank.d99.s24.p0	cimetidine	drug	_	tricyclic antidepressants	drug	_	false	discontinuation of druga in well-controlled patients receiving drugb and drugn may decrease the plasma levels and efficacy of the drugn .
DDI-DrugBank.d99.s24.p2	cimetidine	drug	_	antidepressants	drug	_	false	discontinuation of druga in well-controlled patients receiving drugn and drugn may decrease the plasma levels and efficacy of the drugb .
DDI-DrugBank.d99.s24.p3	tricyclic antidepressants	drug	_	cimetidine	drug	_	mechanism	discontinuation of drugn in well-controlled patients receiving druga and drugb may decrease the plasma levels and efficacy of the drugn .
DDI-DrugBank.d99.s24.p5	cimetidine	drug	_	antidepressants	drug	_	false	discontinuation of drugn in well-controlled patients receiving drugn and druga may decrease the plasma levels and efficacy of the drugb .
DDI-DrugBank.d99.s26.p0	ethchlorvynol	drug	_	amitriptyline HCl	drug	_	effect	transient delirium has been reported in patients who were treated with one gram of druga and # - # mg of drugb .
DDI-DrugBank.d318.s0.p0	amphotericin B	drug	_	Antineoplastic agents	group	_	effect	when administered concurrently , the following drugs may interact with druga : drugb : may enhance the potential for renal toxicity , bronchospasm and hypotension .
DDI-DrugBank.d318.s2.p0	Corticosteroids	group	_	Corticotropin	drug	_	false	druga and drugb -lcb- drugn -rcb- : may potentiate drugn - induced hypokalemia which may predispose the patient to cardiac dysfunction .
DDI-DrugBank.d318.s2.p1	Corticosteroids	group	_	ACTH	group	_	false	druga and drugn -lcb- drugb -rcb- : may potentiate drugn - induced hypokalemia which may predispose the patient to cardiac dysfunction .
DDI-DrugBank.d318.s2.p2	Corticosteroids	group	_	amphotericin B	drug	_	effect	druga and drugn -lcb- drugn -rcb- : may potentiate drugb - induced hypokalemia which may predispose the patient to cardiac dysfunction .
DDI-DrugBank.d318.s2.p4	Corticotropin	drug	_	amphotericin B	drug	_	effect	drugn and druga -lcb- drugn -rcb- : may potentiate drugb - induced hypokalemia which may predispose the patient to cardiac dysfunction .
DDI-DrugBank.d318.s2.p5	ACTH	group	_	amphotericin B	drug	_	effect	drugn and drugn -lcb- druga -rcb- : may potentiate drugb - induced hypokalemia which may predispose the patient to cardiac dysfunction .
DDI-DrugBank.d318.s5.p0	Digitalis glycosides	group	_	amphotericin B	drug	_	false	druga : drugb - induced hypokalemia may potentiate drugn toxicity .
DDI-DrugBank.d318.s5.p2	amphotericin B	drug	_	digitalis	group	_	effect	drugn : druga - induced hypokalemia may potentiate drugb toxicity .
DDI-DrugBank.d318.s7.p0	Flucytosine	drug	_	amphotericin B	drug	_	false	druga : while a synergistic relationship with drugb has been reported , concomitant use may increase the toxicity of drugn by possibly increasing its cellular uptake and/or impairing its renal excretion .
DDI-DrugBank.d318.s7.p2	amphotericin B	drug	_	flucytosine	drug	_	effect	drugn : while a synergistic relationship with druga has been reported , concomitant use may increase the toxicity of drugb by possibly increasing its cellular uptake and/or impairing its renal excretion .
DDI-DrugBank.d318.s8.p4	Imidazoles	group	_	amphotericin B	drug	_	false	druga -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugb and drugn suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p7	Imidazoles	group	_	amphotericin B	drug	_	false	druga -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p11	ketoconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , druga , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugb and drugn suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p12	ketoconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , druga , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugb suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p13	ketoconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , druga , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugb may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p14	ketoconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , druga , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p17	miconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , druga , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugb and drugn suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p18	miconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , druga , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugb suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p19	miconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , druga , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugb may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p20	miconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , druga , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p22	clotrimazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , drugn , druga , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugb and drugn suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p23	clotrimazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , druga , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugb suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p24	clotrimazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , druga , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugb may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p25	clotrimazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , drugn , druga , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p26	fluconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , druga , etc , -rcb- : in vitro and animal studies with the combination of drugb and drugn suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p27	fluconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , druga , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugb suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p28	fluconazole	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , druga , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugb may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p29	fluconazole	drug	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , druga , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p30	amphotericin B	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of druga and drugb suggest that drugn may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p31	amphotericin B	drug	_	imidazoles	group	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of druga and drugn suggest that drugb may induce fungal resistance to drugn .
DDI-DrugBank.d318.s8.p34	imidazoles	group	_	amphotericin B	drug	_	false	drugn -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and druga suggest that drugn may induce fungal resistance to drugb .
DDI-DrugBank.d318.s8.p35	imidazoles	group	_	amphotericin B	drug	_	effect	drugn -lcb- e , g , , drugn , drugn , drugn , drugn , etc , -rcb- : in vitro and animal studies with the combination of drugn and drugn suggest that druga may induce fungal resistance to drugb .
DDI-DrugBank.d318.s12.p0	Skeletal muscle relaxants	group	_	amphotericin B	drug	_	false	druga : drugb - induced hypokalemia may enhance the curariform effect of drugn -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d318.s12.p2	Skeletal muscle relaxants	group	_	tubocurarine	drug	_	false	druga : drugn - induced hypokalemia may enhance the curariform effect of drugn -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d318.s12.p3	amphotericin B	drug	_	skeletal muscle relaxants	group	_	effect	drugn : druga - induced hypokalemia may enhance the curariform effect of drugb -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d318.s12.p4	amphotericin B	drug	_	tubocurarine	drug	_	effect	drugn : druga - induced hypokalemia may enhance the curariform effect of drugn -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d318.s14.p0	Leukocyte transfusions	drug_n	_	amphotericin B	drug	_	false	druga : acute pulmonary toxicity has been reported in patients receiving intravenous drugb and drugn .
DDI-DrugBank.d318.s14.p2	amphotericin B	drug	_	leukocyte transfusions	drug_n	_	effect	drugn : acute pulmonary toxicity has been reported in patients receiving intravenous druga and drugb .
DDI-DrugBank.d211.s2.p0	Bacteriostatic Antibiotics	group	_	Chloramphenicol	drug	_	false	druga : drugb , drugn , drugn , or drugn may interfere with the bactericidal effect of drugn .
DDI-DrugBank.d211.s2.p1	Bacteriostatic Antibiotics	group	_	erythromycins	drug	_	false	druga : drugn , drugb , drugn , or drugn may interfere with the bactericidal effect of drugn .
DDI-DrugBank.d211.s2.p2	Bacteriostatic Antibiotics	group	_	sulfonamides	group	_	false	druga : drugn , drugn , drugb , or drugn may interfere with the bactericidal effect of drugn .
DDI-DrugBank.d211.s2.p3	Bacteriostatic Antibiotics	group	_	tetracyclines	group	_	false	druga : drugn , drugn , drugn , or drugb may interfere with the bactericidal effect of drugn .
DDI-DrugBank.d211.s2.p4	Bacteriostatic Antibiotics	group	_	penicillins	group	_	false	druga : drugn , drugn , drugn , or drugn may interfere with the bactericidal effect of drugb .
DDI-DrugBank.d211.s2.p8	Chloramphenicol	drug	_	penicillins	group	_	effect	drugn : druga , drugn , drugn , or drugn may interfere with the bactericidal effect of drugb .
DDI-DrugBank.d211.s2.p11	erythromycins	drug	_	penicillins	group	_	effect	drugn : drugn , druga , drugn , or drugn may interfere with the bactericidal effect of drugb .
DDI-DrugBank.d211.s2.p13	sulfonamides	group	_	penicillins	group	_	effect	drugn : drugn , drugn , druga , or drugn may interfere with the bactericidal effect of drugb .
DDI-DrugBank.d211.s2.p14	tetracyclines	group	_	penicillins	group	_	effect	drugn : drugn , drugn , drugn , or druga may interfere with the bactericidal effect of drugb .
DDI-DrugBank.d211.s5.p0	Probenecid	drug	_	ampicillin	drug	_	mechanism	druga : may decrease renal tubular secretion of drugb resulting in increased blood levels and/or drugn toxicity .
DDI-DrugBank.d211.s5.p1	Probenecid	drug	_	ampicillin	drug	_	false	druga : may decrease renal tubular secretion of drugn resulting in increased blood levels and/or drugb toxicity .
DDI-DrugBank.d211.s6.p0	ampicillin	drug	_	copper sulfate	drug_n	_	false	drug/laboratory test interaction after treatment with druga , a false-positive reaction for glucose in the urine may occur with drugb tests -lcb- benedicts solution , fehlings solution , or clinitest tablets -rcb- but not with enzyme based tests such as clinistix and glucose enzymatic test strip usp .
DDI-DrugBank.d437.s4.p2	amprenavir	drug	_	HIV protease inhibitors	group	_	false	drugn : the effect of druga on total drug concentrations of other drugb in subjects receiving both agents was evaluated using comparisons to historical data .
DDI-DrugBank.d437.s5.p0	Indinavir	drug	_	amprenavir	drug	_	mechanism	druga steady-state cmax , a , c , and cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant drugb .
DDI-DrugBank.d437.s7.p0	Saquinavir	drug	_	amprenavir	drug	_	mechanism	druga steady-state cmax , a , c , and cmin were increased 21 % , decreased 19 % , and decreased 48 % , respectively , by concomitant drugb .
DDI-DrugBank.d437.s8.p0	Nelfinavir	drug	_	amprenavir	drug	_	mechanism	druga steady-state cmax , a , c , and cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant drugb .
DDI-DrugBank.d437.s9.p0	Methadone	drug	_	amprenavir	drug	_	false	druga : coadministration of drugb and drugn can decrease plasma levels of drugn .
DDI-DrugBank.d437.s9.p3	amprenavir	drug	_	methadone	drug	_	effect	drugn : coadministration of druga and drugb can decrease plasma levels of drugn .
DDI-DrugBank.d437.s9.p4	amprenavir	drug	_	methadone	drug	_	false	drugn : coadministration of druga and drugn can decrease plasma levels of drugb .
DDI-DrugBank.d437.s10.p0	amprenavir	drug	_	methadone	drug	_	mechanism	coadministration of druga and drugb as compared to a non-matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum drugn auc , cmax , andcmin , respectively .
DDI-DrugBank.d437.s10.p2	methadone	drug	_	amprenavir	drug	_	false	coadministration of drugn and druga as compared to a non-matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum drugb auc , cmax , andcmin , respectively .
DDI-DrugBank.d437.s13.p0	Amprenavir	drug	_	ritonavir	drug	_	effect	laboratory tests : the combination of druga and low-dose drugb has been associated with elevations of cholesterol and triglycerides , sgot -lcb- ast -rcb- , and sgpt -lcb- alt -rcb- in some patients .
DDI-DrugBank.d437.s14.p0	Amprenavir	drug	_	ritonavir	drug	_	advise	appropriate laboratory testing should be considered prior to initiating combination therapy with druga and drugb and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy .
DDI-DrugBank.d437.s15.p0	ritonavir	drug	_	NORVIR	brand	_	false	for comprehensive information concerning laboratory test alterations associated with druga , physicians should refer to the complete prescribing information for drugb -lcb- drugn -rcb- .
DDI-DrugBank.d56.s0.p0	amyl nitrite	drug	_	alcohol	drug	_	effect	taking druga after drinking drugb may worsen side effects and may cause severe hypotension and cardiovascular collapse .
DDI-DrugBank.d75.s1.p0	digoxin	drug	_	warfarin	drug	_	false	in vivo interaction studies in humans have demonstrated that druga and drugb do not affect the pk properties of drugn , nor does drugn affect the pk properties of drugn or drugn .
DDI-DrugBank.d75.s1.p1	digoxin	drug	_	anagrelide	drug	_	false	in vivo interaction studies in humans have demonstrated that druga and drugn do not affect the pk properties of drugb , nor does drugn affect the pk properties of drugn or drugn .
DDI-DrugBank.d75.s1.p2	digoxin	drug	_	anagrelide	drug	_	false	in vivo interaction studies in humans have demonstrated that druga and drugn do not affect the pk properties of drugn , nor does drugb affect the pk properties of drugn or drugn .
DDI-DrugBank.d75.s1.p4	digoxin	drug	_	warfarin	drug	_	false	in vivo interaction studies in humans have demonstrated that druga and drugn do not affect the pk properties of drugn , nor does drugn affect the pk properties of drugn or drugb .
DDI-DrugBank.d75.s1.p5	warfarin	drug	_	anagrelide	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and druga do not affect the pk properties of drugb , nor does drugn affect the pk properties of drugn or drugn .
DDI-DrugBank.d75.s1.p6	warfarin	drug	_	anagrelide	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and druga do not affect the pk properties of drugn , nor does drugb affect the pk properties of drugn or drugn .
DDI-DrugBank.d75.s1.p7	warfarin	drug	_	digoxin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and druga do not affect the pk properties of drugn , nor does drugn affect the pk properties of drugb or drugn .
DDI-DrugBank.d75.s1.p10	anagrelide	drug	_	digoxin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and drugn do not affect the pk properties of druga , nor does drugn affect the pk properties of drugb or drugn .
DDI-DrugBank.d75.s1.p11	anagrelide	drug	_	warfarin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and drugn do not affect the pk properties of druga , nor does drugn affect the pk properties of drugn or drugb .
DDI-DrugBank.d75.s1.p12	anagrelide	drug	_	digoxin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and drugn do not affect the pk properties of drugn , nor does druga affect the pk properties of drugb or drugn .
DDI-DrugBank.d75.s1.p13	anagrelide	drug	_	warfarin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and drugn do not affect the pk properties of drugn , nor does druga affect the pk properties of drugn or drugb .
DDI-DrugBank.d75.s1.p14	digoxin	drug	_	warfarin	drug	_	false	in vivo interaction studies in humans have demonstrated that drugn and drugn do not affect the pk properties of drugn , nor does drugn affect the pk properties of druga or drugb .
DDI-DrugBank.d75.s2.p0	anagrelide	drug	_	aspirin	brand	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d75.s2.p1	anagrelide	drug	_	acetaminophen	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d75.s2.p2	anagrelide	drug	_	furosemide	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d75.s2.p3	anagrelide	drug	_	iron	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d75.s2.p4	anagrelide	drug	_	ranitidine	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d75.s2.p5	anagrelide	drug	_	hydroxyurea	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d75.s2.p6	anagrelide	drug	_	allopurinol	drug	_	false	although additional drug interaction studies have not been conducted , the most common medications used concomitantly with druga in clinical trials were drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d75.s4.p0	anagrelide	drug	_	aspirin	brand	_	false	an in vivo interaction study in humans demonstrated that a single 1mg dose of druga administered concomitantly with a single # mg dose of drugb was generally well tolerated .
DDI-DrugBank.d75.s6.p0	anagrelide	drug	_	acetylsalicylic acid	drug	_	false	no clinically relevant pharmacokinetic interactions between druga and drugb were observed .
DDI-DrugBank.d75.s8.p0	Anagrelide	drug	_	aspirin	brand	_	effect	druga alone had no effect on platelet aggregation , but did slightly enhance the inhibition of platelet aggregation by drugb .
DDI-DrugBank.d75.s10.p0	fluvoxamine	drug	_	anagrelide	drug	_	mechanism	it is known that cyp1a2 is inhibited by several medicinal products , including druga , and such medicinal products could theoretically adversely influence the clearance of drugb .
DDI-DrugBank.d75.s12.p0	Anagrelide	drug	_	theophylline	drug	_	mechanism	druga demonstrates some limited inhibitory activity towards cyp1a2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e , g , drugb .
DDI-DrugBank.d75.s14.p4	milrinone	drug	_	anagrelide	drug	_	effect	the effects of medicinal products with similar properties such as inotropes druga , drugn , drugn , drugn and drugn may be exacerbated by drugb .
DDI-DrugBank.d75.s14.p8	enoximone	drug	_	anagrelide	drug	_	effect	the effects of medicinal products with similar properties such as inotropes drugn , druga , drugn , drugn and drugn may be exacerbated by drugb .
DDI-DrugBank.d75.s14.p11	amrinone	drug	_	anagrelide	drug	_	effect	the effects of medicinal products with similar properties such as inotropes drugn , drugn , druga , drugn and drugn may be exacerbated by drugb .
DDI-DrugBank.d75.s14.p13	olprinone	drug_n	_	anagrelide	drug	_	effect	the effects of medicinal products with similar properties such as inotropes drugn , drugn , drugn , druga and drugn may be exacerbated by drugb .
DDI-DrugBank.d75.s14.p14	cilostazol	drug	_	anagrelide	drug	_	effect	the effects of medicinal products with similar properties such as inotropes drugn , drugn , drugn , drugn and druga may be exacerbated by drugb .
DDI-DrugBank.d75.s15.p0	sucralfate	drug	_	anagrelide	drug	_	mechanism	there is a single case report , which suggests that druga may interfere with drugb absorption .
DDI-DrugBank.d275.s1.p0	methotrexate	drug	_	Kineret	brand	_	false	toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either druga or drugb when the two agents were administered together .
DDI-DrugBank.d275.s2.p0	Kineret	brand	_	etanercept	drug	_	effect	in a study in which patients with active ra were treated for up to # weeks with concurrent druga and drugb therapy , a 7 % rate of serious infections was observed , which was higher than that observed with drugn alone -lcb- 0 % -rcb- .
DDI-DrugBank.d275.s2.p1	Kineret	brand	_	etanercept	drug	_	false	in a study in which patients with active ra were treated for up to # weeks with concurrent druga and drugn therapy , a 7 % rate of serious infections was observed , which was higher than that observed with drugb alone -lcb- 0 % -rcb- .
DDI-DrugBank.d275.s3.p0	Kineret	brand	_	etanercept	drug	_	effect	two percent of patients treated concurrently with druga and drugb developed neutropenia -lcb- anc # x 109/l -rcb- .
DDI-DrugBank.d195.s2.p0	Anastrozole	drug	_	antipyrine	drug	_	false	druga did not alter the pharmacokinetics of drugb .
DDI-DrugBank.d195.s3.p0	antipyrine	drug	_	ARIMIDEX	brand	_	false	although there have been no formal interaction studies other than with druga , based on these in vivo and in vitro studies , it is unlikely that co-administration of a # mg dose of drugb with other drugs will result in clinically significant drug inhibition of cytochrome p450-mediated metabolism of the other drugs .
DDI-DrugBank.d195.s4.p0	warfarin	drug	_	anastrozole	drug	_	false	an interaction study with druga showed no clinically significant effect of drugb on drugn pharmacokinetics or anticoagulant activity .
DDI-DrugBank.d195.s4.p2	anastrozole	drug	_	warfarin	drug	_	false	an interaction study with drugn showed no clinically significant effect of druga on drugb pharmacokinetics or anticoagulant activity .
DDI-DrugBank.d195.s5.p0	ARIMIDEX	brand	_	tamoxifen	drug	_	false	at a median follow-up of # months , the combination of druga and drugb did not demonstrate any efficacy benefit when compared with drugn in all patients as well as in the hormone receptor-positive subpopulation .
DDI-DrugBank.d195.s5.p1	ARIMIDEX	brand	_	tamoxifen	drug	_	false	at a median follow-up of # months , the combination of druga and drugn did not demonstrate any efficacy benefit when compared with drugb in all patients as well as in the hormone receptor-positive subpopulation .
DDI-DrugBank.d195.s7.p0	tamoxifen	drug	_	anastrozole	drug	_	advise	based on clinical and pharmacokinetic results from the atac trial , druga should not be administered with drugb -lcb- see clinical pharmacology drug interactions and clinical pharmacology - clinical studies - adjuvant treatment of breast_cancer in postmenopausal women subsections -rcb- .
DDI-DrugBank.d195.s8.p0	anastrozole	drug	_	tamoxifen	drug	_	mechanism	co-administration of druga and drugb resulted in a reduction of drugn plasma levels by 27 % compared with those achieved with drugn alone .
DDI-DrugBank.d195.s8.p3	tamoxifen	drug	_	anastrozole	drug	_	false	co-administration of drugn and druga resulted in a reduction of drugb plasma levels by 27 % compared with those achieved with drugn alone .
DDI-DrugBank.d195.s8.p4	tamoxifen	drug	_	anastrozole	drug	_	false	co-administration of drugn and druga resulted in a reduction of drugn plasma levels by 27 % compared with those achieved with drugb alone .
DDI-DrugBank.d195.s9.p0	Estrogen	group	_	ARIMIDEX	brand	_	advise	druga - containing therapies should not be used with drugb as they may diminish its pharmacologic action .
DDI-DrugBank.d215.s0.p0	anileridine	drug	_	opioids	group	_	advise	caution should be observed when druga is coadministered with other drugb , drugn , drugn , or drugn , as these agents may increase respiratory and circulatory depression .
DDI-DrugBank.d215.s0.p1	anileridine	drug	_	sedatives	group	_	advise	caution should be observed when druga is coadministered with other drugn , drugb , drugn , or drugn , as these agents may increase respiratory and circulatory depression .
DDI-DrugBank.d215.s0.p2	anileridine	drug	_	phenothiazines	group	_	advise	caution should be observed when druga is coadministered with other drugn , drugn , drugb , or drugn , as these agents may increase respiratory and circulatory depression .
DDI-DrugBank.d215.s0.p3	anileridine	drug	_	anesthetics	group	_	advise	caution should be observed when druga is coadministered with other drugn , drugn , drugn , or drugb , as these agents may increase respiratory and circulatory depression .
DDI-DrugBank.d64.s3.p0	cholestyramine	drug	_	anticoagulants	group	_	mechanism	for example , since druga may reduce the gastrointestinal absorption of both the oral drugb and drugn , the net effects are unpredictable .
DDI-DrugBank.d64.s3.p1	cholestyramine	drug	_	vitamin K	group	_	mechanism	for example , since druga may reduce the gastrointestinal absorption of both the oral drugn and drugb , the net effects are unpredictable .
DDI-DrugBank.d64.s3.p2	anticoagulants	group	_	vitamin K	group	_	false	for example , since drugn may reduce the gastrointestinal absorption of both the oral druga and drugb , the net effects are unpredictable .
DDI-DrugBank.d64.s4.p0	Chloral hydrate	drug	_	anticoagulant	group	_	mechanism	druga may cause an increased prothrombin response by displacing the drugb from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction , thus leading to inter-patient variation in ultimate prothrombin effect .
DDI-DrugBank.d64.s6.p0	anticoagulant	group	_	adrenocortical steroids	group	_	effect	drugs that have been reported to diminish oral druga response , ie , decreased prothrom-bin time response , in man significantly include : drugb ;
DDI-DrugBank.d64.s30.p0	anticoagulant	group	_	alcohol	drug	_	effect	drugs that reportedly may increase oral druga response , ie , increased prothrombin response , in man include : drugb * ;
DDI-DrugBank.d64.s79.p0	salicylates	group	_	sulfinpyrazone	drug	_	false	druga ; drugb ;
DDI-DrugBank.d64.s85.p0	trimethoprim	drug	_	sulfamethoxazole	drug	_	false	druga / drugb ;
DDI-DrugBank.d64.s88.p0	anticoagulants	group	_	hypoglycemic agents	group	_	mechanism	oral druga may potentiate the hypoglycemic action of drugb , eg , drugn and drugn , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s88.p1	anticoagulants	group	_	tolbutamide	drug	_	mechanism	oral druga may potentiate the hypoglycemic action of drugn , eg , drugb and drugn , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s88.p2	anticoagulants	group	_	chlorpropamide	drug	_	mechanism	oral druga may potentiate the hypoglycemic action of drugn , eg , drugn and drugb , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s88.p3	hypoglycemic agents	group	_	tolbutamide	drug	_	false	oral drugn may potentiate the hypoglycemic action of druga , eg , drugb and drugn , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s88.p4	hypoglycemic agents	group	_	chlorpropamide	drug	_	false	oral drugn may potentiate the hypoglycemic action of druga , eg , drugn and drugb , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s88.p5	tolbutamide	drug	_	chlorpropamide	drug	_	false	oral drugn may potentiate the hypoglycemic action of drugn , eg , druga and drugb , by inhibiting their metabolism in the liver .
DDI-DrugBank.d64.s89.p0	anticoagulants	group	_	phenytoin	drug	_	mechanism	because oral druga may interfere with the hepatic metabolism of drugb , toxic levels of the drugn may occur when an oral drugn and drugn are administered concurrently .
DDI-DrugBank.d64.s89.p1	anticoagulants	group	_	anticonvulsant	group	_	false	because oral druga may interfere with the hepatic metabolism of drugn , toxic levels of the drugb may occur when an oral drugn and drugn are administered concurrently .
DDI-DrugBank.d64.s89.p3	anticoagulants	group	_	phenytoin	drug	_	false	because oral druga may interfere with the hepatic metabolism of drugn , toxic levels of the drugn may occur when an oral drugn and drugb are administered concurrently .
DDI-DrugBank.d64.s89.p4	phenytoin	drug	_	anticonvulsant	group	_	false	because oral drugn may interfere with the hepatic metabolism of druga , toxic levels of the drugb may occur when an oral drugn and drugn are administered concurrently .
DDI-DrugBank.d64.s89.p5	phenytoin	drug	_	anticoagulant	group	_	false	because oral drugn may interfere with the hepatic metabolism of druga , toxic levels of the drugn may occur when an oral drugb and drugn are administered concurrently .
DDI-DrugBank.d64.s89.p7	anticonvulsant	group	_	anticoagulant	group	_	false	because oral drugn may interfere with the hepatic metabolism of drugn , toxic levels of the druga may occur when an oral drugb and drugn are administered concurrently .
DDI-DrugBank.d64.s89.p8	anticonvulsant	group	_	phenytoin	drug	_	false	because oral drugn may interfere with the hepatic metabolism of drugn , toxic levels of the druga may occur when an oral drugn and drugb are administered concurrently .
DDI-DrugBank.d64.s89.p9	anticoagulant	group	_	phenytoin	drug	_	mechanism	because oral drugn may interfere with the hepatic metabolism of drugn , toxic levels of the drugn may occur when an oral druga and drugb are administered concurrently .
DDI-DrugBank.d64.s90.p0	antineoplastic agents	group	_	aspirin	brand	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugb and other drugn , drugn , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p1	antineoplastic agents	group	_	non-steroidal anti-inflammatory drugs	group	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugb , drugn , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p2	antineoplastic agents	group	_	dipyridamole	drug	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugb , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p3	antineoplastic agents	group	_	hydrochloroquine	drug	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugb , drugn , drugn -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p4	antineoplastic agents	group	_	clofibrate	drug	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugn , drugb , drugn -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p5	antineoplastic agents	group	_	dextran	drug	_	false	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugn , drugn , drugb -rcb- may increase the bleeding tendency produced by drugn without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p6	antineoplastic agents	group	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as druga -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p12	aspirin	brand	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , druga and other drugn , drugn , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p17	non-steroidal anti-inflammatory drugs	group	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other druga , drugn , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p21	dipyridamole	drug	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , druga , drugn , drugn , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p24	hydrochloroquine	drug	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , druga , drugn , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p26	clofibrate	drug	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugn , druga , drugn -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s90.p27	dextran	drug	_	anticoagulants	group	_	effect	drugs that reduce the number of blood platelets by causing bone marrow depression -lcb- such as drugn -rcb- or drugs which inhibit platelet function -lcb- eg , drugn and other drugn , drugn , drugn , drugn , druga -rcb- may increase the bleeding tendency produced by drugb without altering prothrombin time determinations .
DDI-DrugBank.d64.s91.p0	antiplatelet medication	group	_	anticoagulant medication	group	_	advise	the beneficial effects on arterial thrombus formation from combined therapy with druga and drugb must be weighed against an increased risk of inducing hemorrhage .
DDI-DrugBank.d64.s93.p0	Dicumarol	drug	_	indanedione anticoagulants	group	_	false	drug/laboratory test interferences : druga and drugb , including drugn , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .
DDI-DrugBank.d64.s93.p1	Dicumarol	drug	_	anisindione	drug	_	false	drug/laboratory test interferences : druga and drugn , including drugb , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .
DDI-DrugBank.d64.s93.p2	indanedione anticoagulants	group	_	anisindione	drug	_	false	drug/laboratory test interferences : drugn and druga , including drugb , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .
DDI-DrugBank.d357.s0.p9	apomorphine	drug	_	ondansetron	drug	_	effect	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugb , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p11	apomorphine	drug	_	5HT3 antagonist class	group	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugb -lcb- including , for example , drugn , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p12	apomorphine	drug	_	ondansetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugb , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p13	apomorphine	drug	_	granisetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugb , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p14	apomorphine	drug	_	dolasetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugb , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p15	apomorphine	drug	_	palonosetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugb , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p16	apomorphine	drug	_	alosetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when druga was administered with drugn , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugn , and drugb -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p17	ondansetron	drug	_	apomorphine	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugb with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p18	ondansetron	drug	_	5HT3 antagonist class	group	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugn with drugs of the drugb -lcb- including , for example , drugn , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p20	ondansetron	drug	_	granisetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugb , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p21	ondansetron	drug	_	dolasetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugb , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p22	ondansetron	drug	_	palonosetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugb , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p23	ondansetron	drug	_	alosetron	drug	_	false	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with druga , the concomitant use of drugn with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugn , and drugb -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p24	apomorphine	drug	_	5HT3 antagonist class	group	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugb -lcb- including , for example , drugn , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p25	apomorphine	drug	_	ondansetron	drug	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugn -lcb- including , for example , drugb , drugn , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p26	apomorphine	drug	_	granisetron	drug	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugn -lcb- including , for example , drugn , drugb , drugn , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p27	apomorphine	drug	_	dolasetron	drug	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugn -lcb- including , for example , drugn , drugn , drugb , drugn , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p28	apomorphine	drug	_	palonosetron	drug	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugb , and drugn -rcb- is contraindicated .
DDI-DrugBank.d357.s0.p29	apomorphine	drug	_	alosetron	drug	_	advise	drugn : based on reports of profound hypotension and loss of consciousness when drugn was administered with drugn , the concomitant use of druga with drugs of the drugn -lcb- including , for example , drugn , drugn , drugn , drugn , and drugb -rcb- is contraindicated .
DDI-DrugBank.d357.s1.p0	Antihypertensive Medication	group	_	Vasodilators	group	_	false	druga s and drugb : the following adverse events were experienced more commonly in patients receiving concomitant drugn or drugn -lcb- n = 94 -rcb- compared to patients not receiving these concomitant drugs -lcb- n = 456 -rcb- : hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonias 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .
DDI-DrugBank.d357.s1.p5	antihypertensive medications	group	_	vasodilators	group	_	effect	drugn s and drugn : the following adverse events were experienced more commonly in patients receiving concomitant druga or drugb -lcb- n = 94 -rcb- compared to patients not receiving these concomitant drugs -lcb- n = 456 -rcb- : hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonias 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .
DDI-DrugBank.d357.s3.p9	apomorphine	drug	_	dopamine agonist	group	_	false	drugn : since druga is a drugb , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p10	apomorphine	drug	_	dopamine antagonists	group	_	false	drugn : since druga is a drugn , it is possible that drugb , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p11	apomorphine	drug	_	neuroleptics	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p12	apomorphine	drug	_	phenothiazines	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p13	apomorphine	drug	_	butyrophenones	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p14	apomorphine	drug	_	thioxanthenes	group	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p15	apomorphine	drug	_	metoclopramide	drug	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p16	apomorphine	drug	_	APOKYN	brand	_	false	drugn : since druga is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p17	dopamine agonist	group	_	dopamine antagonists	group	_	false	drugn : since drugn is a druga , it is possible that drugb , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p18	dopamine agonist	group	_	neuroleptics	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p19	dopamine agonist	group	_	phenothiazines	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p20	dopamine agonist	group	_	butyrophenones	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p21	dopamine agonist	group	_	thioxanthenes	group	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p22	dopamine agonist	group	_	metoclopramide	drug	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p23	dopamine agonist	group	_	APOKYN	brand	_	false	drugn : since drugn is a druga , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p24	dopamine antagonists	group	_	neuroleptics	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugb -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p25	dopamine antagonists	group	_	phenothiazines	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugb , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p26	dopamine antagonists	group	_	butyrophenones	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugb , drugn -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p27	dopamine antagonists	group	_	thioxanthenes	group	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugb -rcb- or drugn , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p28	dopamine antagonists	group	_	metoclopramide	drug	_	effect	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p29	dopamine antagonists	group	_	APOKYN	brand	_	false	drugn : since drugn is a drugn , it is possible that druga , such as the drugn -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p33	neuroleptics	group	_	metoclopramide	drug	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p34	neuroleptics	group	_	APOKYN	brand	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the druga -lcb- drugn , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p37	phenothiazines	group	_	metoclopramide	drug	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p38	phenothiazines	group	_	APOKYN	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- druga , drugn , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p40	butyrophenones	group	_	metoclopramide	drug	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p41	butyrophenones	group	_	APOKYN	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , druga , drugn -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p42	thioxanthenes	group	_	metoclopramide	drug	_	false	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugb , may diminish the effectiveness of drugn .
DDI-DrugBank.d357.s3.p43	thioxanthenes	group	_	APOKYN	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , druga -rcb- or drugn , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s3.p44	metoclopramide	drug	_	APOKYN	brand	_	effect	drugn : since drugn is a drugn , it is possible that drugn , such as the drugn -lcb- drugn , drugn , drugn -rcb- or druga , may diminish the effectiveness of drugb .
DDI-DrugBank.d357.s4.p0	neuroleptics	group	_	dopamine agonists	group	_	advise	patients with major psychotic disorders , treated with druga , should be treated with drugb only if the potential benefits outweigh the risks .
DDI-DrugBank.d224.s0.p0	Apraclonidine	drug	_	MAO inhibitors	group	_	advise	druga should not be used in patients receiving drugb , .
DDI-DrugBank.d224.s1.p0	IOPIDINE	brand	_	CNS depressants	group	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugb -lcb- drugn , drugn , drugn , drugn , drugn -rcb- should be considered .
DDI-DrugBank.d224.s1.p1	IOPIDINE	brand	_	alcohol	drug	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugn -lcb- drugb , drugn , drugn , drugn , drugn -rcb- should be considered .
DDI-DrugBank.d224.s1.p2	IOPIDINE	brand	_	barbiturates	group	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugb , drugn , drugn , drugn -rcb- should be considered .
DDI-DrugBank.d224.s1.p3	IOPIDINE	brand	_	opiates	group	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugb , drugn , drugn -rcb- should be considered .
DDI-DrugBank.d224.s1.p4	IOPIDINE	brand	_	sedatives	group	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugn , drugb , drugn -rcb- should be considered .
DDI-DrugBank.d224.s1.p5	IOPIDINE	brand	_	anesthetics	group	_	advise	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of druga # % ophthalmic solution , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugn , drugn , drugb -rcb- should be considered .
DDI-DrugBank.d224.s2.p0	Tricyclic antidepressants	group	_	clonidine	drug	_	effect	druga have been reported to blunt the hypotensive effect of systemic drugb .
DDI-DrugBank.d224.s6.p0	clonidine	drug	_	neuroleptic	group	_	effect	an additive hypotensive effect has been reported with the combination of systemic druga and drugb therapy .
DDI-DrugBank.d224.s8.p0	apraclonidine	drug	_	beta-blockers	group	_	advise	since druga may reduce pulse and blood pressure , caution in using drugs such as drugb -lcb- ophthalmic and systemic -rcb- , drugn , and drugn is advised .
DDI-DrugBank.d224.s8.p1	apraclonidine	drug	_	antihypertensives	group	_	advise	since druga may reduce pulse and blood pressure , caution in using drugs such as drugn -lcb- ophthalmic and systemic -rcb- , drugb , and drugn is advised .
DDI-DrugBank.d224.s8.p2	apraclonidine	drug	_	cardiac glycosides	group	_	advise	since druga may reduce pulse and blood pressure , caution in using drugs such as drugn -lcb- ophthalmic and systemic -rcb- , drugn , and drugb is advised .
DDI-DrugBank.d382.s4.p0	Aprepitant	drug	_	S(-) warfarin	drug	_	mechanism	druga has been shown to induce the metabolism of drugb and drugn , which are metabolized through cyp2c9 .
DDI-DrugBank.d382.s4.p1	Aprepitant	drug	_	tolbutamide	drug	_	mechanism	druga has been shown to induce the metabolism of drugn and drugb , which are metabolized through cyp2c9 .
DDI-DrugBank.d382.s4.p2	S(-) warfarin	drug	_	tolbutamide	drug	_	false	drugn has been shown to induce the metabolism of druga and drugb , which are metabolized through cyp2c9 .
DDI-DrugBank.d382.s5.p0	Aprepitant	drug	_	phenytoin	drug	_	mechanism	coadministration of druga with these drugs or other drugs that are known to be metabolized by cyp2c9 , such as drugb , may result in lower plasma concentrations of these drugs .
DDI-DrugBank.d382.s6.p1	Aprepitant	drug	_	digoxin	drug	_	false	druga is unlikely to interact with drugs that are substrates for the p_glycoprotein transporter , as demonstrated by the lack of interaction of drugn with drugb in a clinical drug interaction study .
DDI-DrugBank.d382.s6.p2	Aprepitant	drug	_	digoxin	drug	_	false	drugn is unlikely to interact with drugs that are substrates for the p_glycoprotein transporter , as demonstrated by the lack of interaction of druga with drugb in a clinical drug interaction study .
DDI-DrugBank.d382.s7.p3	aprepitant	drug	_	ondansetron	drug	_	false	drugn : in clinical drug interaction studies , druga did not have clinically important effects on the pharmacokinetics of drugb or drugn .
DDI-DrugBank.d382.s7.p4	aprepitant	drug	_	granisetron	drug	_	false	drugn : in clinical drug interaction studies , druga did not have clinically important effects on the pharmacokinetics of drugn or drugb .
DDI-DrugBank.d382.s7.p5	ondansetron	drug	_	granisetron	drug	_	false	drugn : in clinical drug interaction studies , drugn did not have clinically important effects on the pharmacokinetics of druga or drugb .
DDI-DrugBank.d382.s9.p0	Corticosteroids	group	_	Dexamethasone	drug	_	false	druga : drugb : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p1	Corticosteroids	group	_	Aprepitant	drug	_	false	druga : drugn : drugb , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p2	Corticosteroids	group	_	dexamethasone	drug	_	false	druga : drugn : drugn , when given as a regimen of 125mg with drugb coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p3	Corticosteroids	group	_	Aprepitant	drug	_	false	druga : drugn : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugb when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p4	Corticosteroids	group	_	dexamethasone	drug	_	false	druga : drugn : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugb coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p5	Corticosteroids	group	_	dexamethasone	drug	_	false	druga : drugn : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugb , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p6	Dexamethasone	drug	_	Aprepitant	drug	_	false	drugn : druga : drugb , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p8	Dexamethasone	drug	_	Aprepitant	drug	_	false	drugn : druga : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugb when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p11	Aprepitant	drug	_	dexamethasone	drug	_	mechanism	drugn : drugn : druga , when given as a regimen of 125mg with drugb coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p13	Aprepitant	drug	_	dexamethasone	drug	_	false	drugn : drugn : druga , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugb coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p14	Aprepitant	drug	_	dexamethasone	drug	_	false	drugn : drugn : druga , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and drugn when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugb , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p15	dexamethasone	drug	_	Aprepitant	drug	_	false	drugn : drugn : drugn , when given as a regimen of 125mg with druga coadministered orally as # mg on day 1 , and drugb when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p18	Aprepitant	drug	_	dexamethasone	drug	_	mechanism	drugn : drugn : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and druga when given as # mg/day with drugb coadministered orally as # mg on days # through 5 , increased the auc of drugn , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s9.p19	Aprepitant	drug	_	dexamethasone	drug	_	false	drugn : drugn : drugn , when given as a regimen of 125mg with drugn coadministered orally as # mg on day 1 , and druga when given as # mg/day with drugn coadministered orally as # mg on days # through 5 , increased the auc of drugb , a cyp3a4 substrate by # - fold , on days # and 5 .
DDI-DrugBank.d382.s10.p0	dexamethasone	drug	_	Aprepitant	drug	_	advise	the oral druga doses should be reduced by approximately 50 % when coadministered with drugb , to achieve exposures of drugn similar to those obtained when it is given without drugn .
DDI-DrugBank.d382.s10.p2	dexamethasone	drug	_	Aprepitant	drug	_	false	the oral druga doses should be reduced by approximately 50 % when coadministered with drugn , to achieve exposures of drugn similar to those obtained when it is given without drugb .
DDI-DrugBank.d382.s10.p3	Aprepitant	drug	_	dexamethasone	drug	_	false	the oral drugn doses should be reduced by approximately 50 % when coadministered with druga , to achieve exposures of drugb similar to those obtained when it is given without drugn .
DDI-DrugBank.d382.s10.p5	dexamethasone	drug	_	Aprepitant	drug	_	false	the oral drugn doses should be reduced by approximately 50 % when coadministered with drugn , to achieve exposures of druga similar to those obtained when it is given without drugb .
DDI-DrugBank.d382.s11.p0	dexamethasone	drug	_	Aprepitant	drug	_	mechanism	the daily dose of druga administered in clinical studies with drugb reflects an approximate 50 % reduction of the dose of drugn .
DDI-DrugBank.d382.s11.p2	Aprepitant	drug	_	dexamethasone	drug	_	false	the daily dose of drugn administered in clinical studies with druga reflects an approximate 50 % reduction of the dose of drugb .
DDI-DrugBank.d382.s13.p0	Aprepitant	drug	_	methylprednisolone	drug	_	mechanism	druga , when given as a regimen of # mg on day # and # mg/day on days # and 3 , increased the auc of drugb , a cyp3a4 substrate , by # - fold on day # and by # - fold on day 3 , when drugn was coadministered intravenously as # mg on day # and orally as # mg on days # and 3 .
DDI-DrugBank.d382.s13.p1	Aprepitant	drug	_	methylprednisolone	drug	_	false	druga , when given as a regimen of # mg on day # and # mg/day on days # and 3 , increased the auc of drugn , a cyp3a4 substrate , by # - fold on day # and by # - fold on day 3 , when drugb was coadministered intravenously as # mg on day # and orally as # mg on days # and 3 .
DDI-DrugBank.d382.s14.p1	methylprednisolone	drug	_	Aprepitant	drug	_	advise	the iv druga dose should be reduced by approximately 25 % , and the oral drugn dose should be reduced by approximately 50 % when coadministered with drugb to achieve exposures of drugn similar to those obtained when it is given without drugn .
DDI-DrugBank.d382.s14.p3	methylprednisolone	drug	_	Aprepitant	drug	_	false	the iv druga dose should be reduced by approximately 25 % , and the oral drugn dose should be reduced by approximately 50 % when coadministered with drugn to achieve exposures of drugn similar to those obtained when it is given without drugb .
DDI-DrugBank.d382.s14.p4	methylprednisolone	drug	_	Aprepitant	drug	_	advise	the iv drugn dose should be reduced by approximately 25 % , and the oral druga dose should be reduced by approximately 50 % when coadministered with drugb to achieve exposures of drugn similar to those obtained when it is given without drugn .
DDI-DrugBank.d382.s14.p6	methylprednisolone	drug	_	Aprepitant	drug	_	false	the iv drugn dose should be reduced by approximately 25 % , and the oral druga dose should be reduced by approximately 50 % when coadministered with drugn to achieve exposures of drugn similar to those obtained when it is given without drugb .
DDI-DrugBank.d382.s14.p7	Aprepitant	drug	_	methylprednisolone	drug	_	false	the iv drugn dose should be reduced by approximately 25 % , and the oral drugn dose should be reduced by approximately 50 % when coadministered with druga to achieve exposures of drugb similar to those obtained when it is given without drugn .
DDI-DrugBank.d382.s14.p9	methylprednisolone	drug	_	Aprepitant	drug	_	false	the iv drugn dose should be reduced by approximately 25 % , and the oral drugn dose should be reduced by approximately 50 % when coadministered with drugn to achieve exposures of druga similar to those obtained when it is given without drugb .
DDI-DrugBank.d382.s15.p2	Aprepitant	drug	_	warfarin	drug	_	false	drugn : a single 125-mg dose of druga was administered on day # and # mg/day on days # and # to healthy subjects who were stabilized on chronic drugb therapy .
DDI-DrugBank.d382.s16.p0	Aprepitant	drug	_	R(+) warfarin	drug	_	false	although there was no effect of druga on the plasma auc of drugb or drugn determined on day 3 , there was a 34 % decrease in drugn -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p1	Aprepitant	drug	_	S(-) warfarin	drug	_	false	although there was no effect of druga on the plasma auc of drugn or drugb determined on day 3 , there was a 34 % decrease in drugn -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p2	Aprepitant	drug	_	S(-)warfarin	drug	_	false	although there was no effect of druga on the plasma auc of drugn or drugn determined on day 3 , there was a 34 % decrease in drugb -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p4	R(+) warfarin	drug	_	S(-) warfarin	drug	_	false	although there was no effect of drugn on the plasma auc of druga or drugb determined on day 3 , there was a 34 % decrease in drugn -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p5	R(+) warfarin	drug	_	S(-)warfarin	drug	_	false	although there was no effect of drugn on the plasma auc of druga or drugn determined on day 3 , there was a 34 % decrease in drugb -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p6	R(+) warfarin	drug	_	Aprepitant	drug	_	false	although there was no effect of drugn on the plasma auc of druga or drugn determined on day 3 , there was a 34 % decrease in drugn -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugb .
DDI-DrugBank.d382.s16.p7	S(-) warfarin	drug	_	S(-)warfarin	drug	_	false	although there was no effect of drugn on the plasma auc of drugn or druga determined on day 3 , there was a 34 % decrease in drugb -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugn .
DDI-DrugBank.d382.s16.p8	S(-) warfarin	drug	_	Aprepitant	drug	_	false	although there was no effect of drugn on the plasma auc of drugn or druga determined on day 3 , there was a 34 % decrease in drugn -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugb .
DDI-DrugBank.d382.s16.p9	S(-)warfarin	drug	_	Aprepitant	drug	_	mechanism	although there was no effect of drugn on the plasma auc of drugn or drugn determined on day 3 , there was a 34 % decrease in druga -lcb- a cyp2c9 substrate -rcb- trough concentration accompanied by a 14 % decrease in the prothrombin time -lcb- reported as international normalized ratio or inr -rcb- # days after completion of dosing with drugb .
DDI-DrugBank.d382.s17.p0	warfarin	drug	_	Aprepitant	drug	_	advise	in patients on chronic druga therapy , the prothrombin time -lcb- inr -rcb- should be closely monitored in the 2-week period , particularly at # to # days , following initiation of the 3-day regimen of drugb with each chemotherapy cycle .
DDI-DrugBank.d382.s18.p0	Tolbutamide	drug	_	Aprepitant	drug	_	false	druga : drugb , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of drugn -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of drugn # mg was admini , stered orally prior to the administration of the 3-day regimen of drugn and on days 4,8 , and 15 .
DDI-DrugBank.d382.s18.p3	Tolbutamide	drug	_	Aprepitant	drug	_	false	druga : drugn , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of drugn -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of drugn # mg was admini , stered orally prior to the administration of the 3-day regimen of drugb and on days 4,8 , and 15 .
DDI-DrugBank.d382.s18.p4	Aprepitant	drug	_	tolbutamide	drug	_	false	drugn : druga , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of drugb -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of drugn # mg was admini , stered orally prior to the administration of the 3-day regimen of drugn and on days 4,8 , and 15 .
DDI-DrugBank.d382.s18.p5	Aprepitant	drug	_	tolbutamide	drug	_	false	drugn : druga , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of drugn -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of drugb # mg was admini , stered orally prior to the administration of the 3-day regimen of drugn and on days 4,8 , and 15 .
DDI-DrugBank.d382.s18.p8	tolbutamide	drug	_	Aprepitant	drug	_	false	drugn : drugn , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of druga -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of drugn # mg was admini , stered orally prior to the administration of the 3-day regimen of drugb and on days 4,8 , and 15 .
DDI-DrugBank.d382.s18.p9	tolbutamide	drug	_	Aprepitant	drug	_	mechanism	drugn : drugn , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of drugn -lcb- a cyp2c9 substrate -rcb- by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of druga # mg was admini , stered orally prior to the administration of the 3-day regimen of drugb and on days 4,8 , and 15 .
DDI-DrugBank.d382.s19.p0	contraceptives	group	_	Aprepitant	drug	_	false	oral druga : drugb , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p2	contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugb and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p3	contraceptives	group	_	norethindrone	drug	_	false	oral druga : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugb , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p4	contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of drugb by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p5	contraceptives	group	_	norethindrone	drug	_	false	oral druga : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugb by 8 % ;
DDI-DrugBank.d382.s19.p6	Aprepitant	drug	_	contraceptive	group	_	false	oral drugn : druga , when given once daily for # days as a 100-mg capsule with an oral drugb containing # mcg of drugn and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p7	Aprepitant	drug	_	ethinyl estradiol	drug	_	mechanism	oral drugn : druga , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugb and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p8	Aprepitant	drug	_	norethindrone	drug	_	mechanism	oral drugn : druga , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugb , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p9	Aprepitant	drug	_	ethinyl estradiol	drug	_	false	oral drugn : druga , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of drugb by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p10	Aprepitant	drug	_	norethindrone	drug	_	false	oral drugn : druga , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugb by 8 % ;
DDI-DrugBank.d382.s19.p11	contraceptive	group	_	ethinyl estradiol	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral druga containing # mcg of drugb and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p12	contraceptive	group	_	norethindrone	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral druga containing # mcg of drugn and # mg of drugb , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p13	contraceptive	group	_	ethinyl estradiol	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral druga containing # mcg of drugn and # mg of drugn , decreased the auc of drugb by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p14	contraceptive	group	_	norethindrone	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral druga containing # mcg of drugn and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugb by 8 % ;
DDI-DrugBank.d382.s19.p15	ethinyl estradiol	drug	_	norethindrone	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of druga and # mg of drugb , decreased the auc of drugn by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p17	ethinyl estradiol	drug	_	norethindrone	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of druga and # mg of drugn , decreased the auc of drugn by 43 % , and decreased the auc of drugb by 8 % ;
DDI-DrugBank.d382.s19.p18	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of druga , decreased the auc of drugb by 43 % , and decreased the auc of drugn by 8 % ;
DDI-DrugBank.d382.s19.p20	ethinyl estradiol	drug	_	norethindrone	drug	_	false	oral drugn : drugn , when given once daily for # days as a 100-mg capsule with an oral drugn containing # mcg of drugn and # mg of drugn , decreased the auc of druga by 43 % , and decreased the auc of drugb by 8 % ;
DDI-DrugBank.d382.s20.p0	contraceptives	group	_	Aprepitant	drug	_	effect	therefore , the efficacy of oral druga during administration of drugb may be reduced .
DDI-DrugBank.d382.s21.p0	Aprepitant	drug	_	contraceptives	group	_	advise	although a 3-day regimen of druga given concomitantly with oral drugb has not been studied , alternative or back-up methods of contraception should be used .
DDI-DrugBank.d382.s22.p4	Aprepitant	drug	_	midazolam	drug	_	mechanism	drugn : druga increased the auc of drugb , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of drugn # mg was coadministered on day # and day # of a regimen of drugn # mg on day # and # mg/day on days # through 5 .
DDI-DrugBank.d382.s22.p5	Aprepitant	drug	_	midazolam	drug	_	false	drugn : druga increased the auc of drugn , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of drugb # mg was coadministered on day # and day # of a regimen of drugn # mg on day # and # mg/day on days # through 5 .
DDI-DrugBank.d382.s22.p8	midazolam	drug	_	Aprepitant	drug	_	false	drugn : drugn increased the auc of druga , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of drugn # mg was coadministered on day # and day # of a regimen of drugb # mg on day # and # mg/day on days # through 5 .
DDI-DrugBank.d382.s22.p9	midazolam	drug	_	Aprepitant	drug	_	false	drugn : drugn increased the auc of drugn , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of druga # mg was coadministered on day # and day # of a regimen of drugb # mg on day # and # mg/day on days # through 5 .
DDI-DrugBank.d382.s23.p0	midazolam	drug	_	benzodiazepines	group	_	false	the potential effects of increased plasma concentrations of druga or other drugb metabolized via cyp3a4 -lcb- drugn , drugn -rcb- should be considered when coadministering these agents with drugn .
DDI-DrugBank.d382.s23.p1	midazolam	drug	_	alprazolam	drug	_	false	the potential effects of increased plasma concentrations of druga or other drugn metabolized via cyp3a4 -lcb- drugb , drugn -rcb- should be considered when coadministering these agents with drugn .
DDI-DrugBank.d382.s23.p2	midazolam	drug	_	triazolam	drug	_	false	the potential effects of increased plasma concentrations of druga or other drugn metabolized via cyp3a4 -lcb- drugn , drugb -rcb- should be considered when coadministering these agents with drugn .
DDI-DrugBank.d382.s23.p3	midazolam	drug	_	Aprepitant	drug	_	advise	the potential effects of increased plasma concentrations of druga or other drugn metabolized via cyp3a4 -lcb- drugn , drugn -rcb- should be considered when coadministering these agents with drugb .
DDI-DrugBank.d382.s23.p4	benzodiazepines	group	_	alprazolam	drug	_	false	the potential effects of increased plasma concentrations of drugn or other druga metabolized via cyp3a4 -lcb- drugb , drugn -rcb- should be considered when coadministering these agents with drugn .
DDI-DrugBank.d382.s23.p5	benzodiazepines	group	_	triazolam	drug	_	false	the potential effects of increased plasma concentrations of drugn or other druga metabolized via cyp3a4 -lcb- drugn , drugb -rcb- should be considered when coadministering these agents with drugn .
DDI-DrugBank.d382.s23.p6	benzodiazepines	group	_	Aprepitant	drug	_	advise	the potential effects of increased plasma concentrations of drugn or other druga metabolized via cyp3a4 -lcb- drugn , drugn -rcb- should be considered when coadministering these agents with drugb .
DDI-DrugBank.d382.s23.p8	alprazolam	drug	_	Aprepitant	drug	_	advise	the potential effects of increased plasma concentrations of drugn or other drugn metabolized via cyp3a4 -lcb- druga , drugn -rcb- should be considered when coadministering these agents with drugb .
DDI-DrugBank.d382.s23.p9	triazolam	drug	_	Aprepitant	drug	_	advise	the potential effects of increased plasma concentrations of drugn or other drugn metabolized via cyp3a4 -lcb- drugn , druga -rcb- should be considered when coadministering these agents with drugb .
DDI-DrugBank.d382.s24.p0	midazolam	drug	_	Aprepitant	drug	_	false	in another study with intravenous administration of druga , drugb was given as # mg on day # and # mg/day on days # and 3 , and drugn # mg iv was given prior to the administration of the 3-day regimen of drugn and on days 4 , 8 , and 15 .
DDI-DrugBank.d382.s24.p2	midazolam	drug	_	Aprepitant	drug	_	false	in another study with intravenous administration of druga , drugn was given as # mg on day # and # mg/day on days # and 3 , and drugn # mg iv was given prior to the administration of the 3-day regimen of drugb and on days 4 , 8 , and 15 .
DDI-DrugBank.d382.s24.p3	Aprepitant	drug	_	midazolam	drug	_	false	in another study with intravenous administration of drugn , druga was given as # mg on day # and # mg/day on days # and 3 , and drugb # mg iv was given prior to the administration of the 3-day regimen of drugn and on days 4 , 8 , and 15 .
DDI-DrugBank.d382.s24.p5	midazolam	drug	_	Aprepitant	drug	_	false	in another study with intravenous administration of drugn , drugn was given as # mg on day # and # mg/day on days # and 3 , and druga # mg iv was given prior to the administration of the 3-day regimen of drugb and on days 4 , 8 , and 15 .
DDI-DrugBank.d382.s25.p0	Aprepitant	drug	_	midazolam	drug	_	mechanism	druga increased the auc of drugb by 25 % on day # and decreased the auc of drugn by 19 % on day # relative to the dosing of drugn on days # through 3 .
DDI-DrugBank.d382.s25.p1	Aprepitant	drug	_	midazolam	drug	_	mechanism	druga increased the auc of drugn by 25 % on day # and decreased the auc of drugb by 19 % on day # relative to the dosing of drugn on days # through 3 .
DDI-DrugBank.d382.s25.p4	midazolam	drug	_	Aprepitant	drug	_	false	drugn increased the auc of druga by 25 % on day # and decreased the auc of drugn by 19 % on day # relative to the dosing of drugb on days # through 3 .
DDI-DrugBank.d382.s25.p5	midazolam	drug	_	Aprepitant	drug	_	false	drugn increased the auc of drugn by 25 % on day # and decreased the auc of druga by 19 % on day # relative to the dosing of drugb on days # through 3 .
DDI-DrugBank.d382.s31.p0	Aprepitant	drug	_	ketoconazole	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p1	Aprepitant	drug	_	itraconazole	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p2	Aprepitant	drug	_	nefazodone	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p3	Aprepitant	drug	_	troleandomycin	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p4	Aprepitant	drug	_	clarithromycin	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p5	Aprepitant	drug	_	ritonavir	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- should be approached with caution .
DDI-DrugBank.d382.s31.p6	Aprepitant	drug	_	nelfinavir	drug	_	advise	consequently , concomitant administration of druga with strong cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- should be approached with caution .
DDI-DrugBank.d382.s32.p0	diltiazem	drug	_	aprepitant	drug	_	advise	because moderate cyp3a4 inhibitors -lcb- e , g , , druga -rcb- result in 2-fold increase in plasma concentrations of drugb , concomitant administration should also be approached with caution .
DDI-DrugBank.d382.s34.p0	Aprepitant	drug	_	rifampin	drug	_	mechanism	therefore , coadministration of druga with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugb , drugn , drugn -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p1	Aprepitant	drug	_	carbamazepine	drug	_	false	therefore , coadministration of druga with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , drugb , drugn -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p2	Aprepitant	drug	_	phenytoin	drug	_	mechanism	therefore , coadministration of druga with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , drugn , drugb -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p7	rifampin	drug	_	aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , druga , drugn , drugn -rcb- may result in reduced plasma concentrations of drugb that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p8	rifampin	drug	_	Aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , druga , drugn , drugn -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugb .
DDI-DrugBank.d382.s34.p10	carbamazepine	drug	_	aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , druga , drugn -rcb- may result in reduced plasma concentrations of drugb that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p11	carbamazepine	drug	_	Aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , druga , drugn -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugb .
DDI-DrugBank.d382.s34.p12	phenytoin	drug	_	aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , drugn , druga -rcb- may result in reduced plasma concentrations of drugb that may result in decreased efficacy of drugn .
DDI-DrugBank.d382.s34.p13	phenytoin	drug	_	Aprepitant	drug	_	false	therefore , coadministration of drugn with drugs that strongly induce cyp3a4 activity -lcb- e , g , , drugn , drugn , druga -rcb- may result in reduced plasma concentrations of drugn that may result in decreased efficacy of drugb .
DDI-DrugBank.d382.s36.p4	Aprepitant	drug	_	ketoconazole	drug	_	mechanism	drugn : when a single 125-mg dose of druga was administered on day5 of a 10-day regimen of # mg/day of drugb , a strong cyp3a4 inhibitor , the auc of drugn increased approximately 5-fold and the mean terminal half-life of drugn increased approximately 3-fold .
DDI-DrugBank.d382.s36.p7	ketoconazole	drug	_	aprepitant	drug	_	false	drugn : when a single 125-mg dose of drugn was administered on day5 of a 10-day regimen of # mg/day of druga , a strong cyp3a4 inhibitor , the auc of drugb increased approximately 5-fold and the mean terminal half-life of drugn increased approximately 3-fold .
DDI-DrugBank.d382.s36.p8	ketoconazole	drug	_	aprepitant	drug	_	false	drugn : when a single 125-mg dose of drugn was administered on day5 of a 10-day regimen of # mg/day of druga , a strong cyp3a4 inhibitor , the auc of drugn increased approximately 5-fold and the mean terminal half-life of drugb increased approximately 3-fold .
DDI-DrugBank.d382.s38.p3	Aprepitant	drug	_	rifampin	drug	_	mechanism	drugn : when a single 375-mg dose of druga was administered on day9 of a 14-day regimen of # mg/day of drugb , a strong cyp3a4 inducer , the auc of drugn decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold .
DDI-DrugBank.d382.s38.p5	rifampin	drug	_	aprepitant	drug	_	false	drugn : when a single 375-mg dose of drugn was administered on day9 of a 14-day regimen of # mg/day of druga , a strong cyp3a4 inducer , the auc of drugb decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold .
DDI-DrugBank.d382.s41.p4	aprepitant	drug	_	diltiazem	drug	_	mechanism	drugn : in patients with mild to moderate hypertension , administration of druga once daily , as a tablet formulation comparable to # mg of the capsule formulation , with drugb # mg # times daily for # days , resulted in a 2-fold increase of drugn auc and a simultaneous # - fold increase of drugn auc .
DDI-DrugBank.d382.s41.p6	aprepitant	drug	_	diltiazem	drug	_	false	drugn : in patients with mild to moderate hypertension , administration of druga once daily , as a tablet formulation comparable to # mg of the capsule formulation , with drugn # mg # times daily for # days , resulted in a 2-fold increase of drugn auc and a simultaneous # - fold increase of drugb auc .
DDI-DrugBank.d382.s41.p7	diltiazem	drug	_	aprepitant	drug	_	false	drugn : in patients with mild to moderate hypertension , administration of drugn once daily , as a tablet formulation comparable to # mg of the capsule formulation , with druga # mg # times daily for # days , resulted in a 2-fold increase of drugb auc and a simultaneous # - fold increase of drugn auc .
DDI-DrugBank.d382.s41.p9	aprepitant	drug	_	diltiazem	drug	_	false	drugn : in patients with mild to moderate hypertension , administration of drugn once daily , as a tablet formulation comparable to # mg of the capsule formulation , with drugn # mg # times daily for # days , resulted in a 2-fold increase of druga auc and a simultaneous # - fold increase of drugb auc .
DDI-DrugBank.d382.s43.p0	Paroxetine	drug	_	aprepitant	drug	_	false	druga : coadministration of once daily doses of drugb , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with drugn # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both drugn and drugn .
DDI-DrugBank.d382.s43.p2	Paroxetine	drug	_	aprepitant	drug	_	false	druga : coadministration of once daily doses of drugn , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with drugn # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both drugb and drugn .
DDI-DrugBank.d382.s43.p4	aprepitant	drug	_	paroxetine	drug	_	mechanism	drugn : coadministration of once daily doses of druga , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with drugb # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both drugn and drugn .
DDI-DrugBank.d382.s43.p6	aprepitant	drug	_	paroxetine	drug	_	false	drugn : coadministration of once daily doses of druga , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with drugn # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both drugn and drugb .
DDI-DrugBank.d382.s43.p7	paroxetine	drug	_	aprepitant	drug	_	false	drugn : coadministration of once daily doses of drugn , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with druga # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both drugb and drugn .
DDI-DrugBank.d382.s43.p9	aprepitant	drug	_	paroxetine	drug	_	false	drugn : coadministration of once daily doses of drugn , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with drugn # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both druga and drugb .
DDI-DrugBank.d253.s0.p0	Beta-adrenergic blocking agents	group	_	arbutamine	drug	_	false	druga : concurrent use may blunt the response to drugb .
DDI-DrugBank.d253.s1.p0	Beta-adrenergic blocking agents	group	_	arbutamine	drug	_	advise	druga should be withdrawn at least # hours before conducting an drugb - mediated stress test .
DDI-DrugBank.d253.s2.p3	Antiarrhythmic agents, class I	drug	_	arbutamine	drug	_	false	druga -lcb- such as drugn , drugn , or drugn -rcb- : concurrent use with drugb may have a proarrhythmic effect .
DDI-DrugBank.d253.s2.p6	flecainide	drug	_	arbutamine	drug	_	false	drugn -lcb- such as druga , drugn , or drugn -rcb- : concurrent use with drugb may have a proarrhythmic effect .
DDI-DrugBank.d253.s2.p8	lidocaine	drug	_	arbutamine	drug	_	false	drugn -lcb- such as drugn , druga , or drugn -rcb- : concurrent use with drugb may have a proarrhythmic effect .
DDI-DrugBank.d253.s2.p9	quinidine	drug	_	arbutamine	drug	_	false	drugn -lcb- such as drugn , drugn , or druga -rcb- : concurrent use with drugb may have a proarrhythmic effect .
DDI-DrugBank.d253.s3.p4	Antidepressants	group	_	arbutamine	drug	_	false	druga -lcb- drugn -rcb- , drugn or other drugn , or drugn : concurrent use with drugb may produce additive inotropic and/or chronotropic effects .
DDI-DrugBank.d253.s3.p8	tricyclic	group	_	arbutamine	drug	_	false	drugn -lcb- druga -rcb- , drugn or other drugn , or drugn : concurrent use with drugb may produce additive inotropic and/or chronotropic effects .
DDI-DrugBank.d253.s3.p11	atropine	drug	_	arbutamine	drug	_	false	drugn -lcb- drugn -rcb- , druga or other drugn , or drugn : concurrent use with drugb may produce additive inotropic and/or chronotropic effects .
DDI-DrugBank.d253.s3.p13	anticholinergic agents	group	_	arbutamine	drug	_	false	drugn -lcb- drugn -rcb- , drugn or other druga , or drugn : concurrent use with drugb may produce additive inotropic and/or chronotropic effects .
DDI-DrugBank.d253.s3.p14	digitalis glycosides	group	_	arbutamine	drug	_	false	drugn -lcb- drugn -rcb- , drugn or other drugn , or druga : concurrent use with drugb may produce additive inotropic and/or chronotropic effects .
DDI-DrugBank.d105.s0.p0	Anticoagulants	group	_	platelet aggregation inhibitors	group	_	false	druga including coumarin derivatives , indandione derivatives , and drugb such as drugn -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p1	Anticoagulants	group	_	nonsteroidal anti-inflammatory drugs	group	_	false	druga including coumarin derivatives , indandione derivatives , and drugn such as drugb -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p2	Anticoagulants	group	_	NSAIDs	group	_	false	druga including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- drugb -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p3	Anticoagulants	group	_	aspirin	brand	_	false	druga including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- drugn -rcb- , and drugb may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p4	Anticoagulants	group	_	ardeparin	drug	_	effect	druga including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugb .
DDI-DrugBank.d105.s0.p5	platelet aggregation inhibitors	group	_	nonsteroidal anti-inflammatory drugs	group	_	false	drugn including coumarin derivatives , indandione derivatives , and druga such as drugb -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p6	platelet aggregation inhibitors	group	_	NSAIDs	group	_	false	drugn including coumarin derivatives , indandione derivatives , and druga such as drugn -lcb- drugb -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p7	platelet aggregation inhibitors	group	_	aspirin	brand	_	false	drugn including coumarin derivatives , indandione derivatives , and druga such as drugn -lcb- drugn -rcb- , and drugb may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p8	platelet aggregation inhibitors	group	_	ardeparin	drug	_	effect	drugn including coumarin derivatives , indandione derivatives , and druga such as drugn -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugb .
DDI-DrugBank.d105.s0.p10	nonsteroidal anti-inflammatory drugs	group	_	aspirin	brand	_	false	drugn including coumarin derivatives , indandione derivatives , and drugn such as druga -lcb- drugn -rcb- , and drugb may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p11	nonsteroidal anti-inflammatory drugs	group	_	ardeparin	drug	_	effect	drugn including coumarin derivatives , indandione derivatives , and drugn such as druga -lcb- drugn -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugb .
DDI-DrugBank.d105.s0.p12	NSAIDs	group	_	aspirin	brand	_	false	drugn including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- druga -rcb- , and drugb may increase the risk of bleeding when administered concomitantly with drugn .
DDI-DrugBank.d105.s0.p13	NSAIDs	group	_	ardeparin	drug	_	effect	drugn including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- druga -rcb- , and drugn may increase the risk of bleeding when administered concomitantly with drugb .
DDI-DrugBank.d105.s0.p14	aspirin	brand	_	ardeparin	drug	_	effect	drugn including coumarin derivatives , indandione derivatives , and drugn such as drugn -lcb- drugn -rcb- , and druga may increase the risk of bleeding when administered concomitantly with drugb .
DDI-DrugBank.d284.s0.p0	adrenergic drugs	group	_	BROVANA	brand	_	advise	if additional druga are to be administered by any route , they should be used with caution because the pharmacologically predictable sympathetic effects of drugb may be potentiated .
DDI-DrugBank.d284.s1.p0	paroxetine	drug	_	BROVANA	brand	_	false	when druga , a potent inhibitor of cyp2d6 , was co-administered with drugb at steady-state , exposure to either drug was not altered .
DDI-DrugBank.d284.s3.p4	methylxanthines	group	_	adrenergic agonists	group	_	effect	concomitant treatment with druga -lcb- drugn , drugn -rcb- , drugn , or drugn may potentiate any hypokalemic effect of drugb .
DDI-DrugBank.d284.s3.p8	aminophylline	drug	_	adrenergic agonists	group	_	effect	concomitant treatment with drugn -lcb- druga , drugn -rcb- , drugn , or drugn may potentiate any hypokalemic effect of drugb .
DDI-DrugBank.d284.s3.p11	theophylline	drug	_	adrenergic agonists	group	_	effect	concomitant treatment with drugn -lcb- drugn , druga -rcb- , drugn , or drugn may potentiate any hypokalemic effect of drugb .
DDI-DrugBank.d284.s3.p13	steroids	group	_	adrenergic agonists	group	_	effect	concomitant treatment with drugn -lcb- drugn , drugn -rcb- , druga , or drugn may potentiate any hypokalemic effect of drugb .
DDI-DrugBank.d284.s3.p14	diuretics	group	_	adrenergic agonists	group	_	effect	concomitant treatment with drugn -lcb- drugn , drugn -rcb- , drugn , or druga may potentiate any hypokalemic effect of drugb .
DDI-DrugBank.d284.s4.p2	non-potassium sparing diuretics	group	_	beta-agonists	group	_	effect	the ecg changes and/or hypokalemia that may result from the administration of druga -lcb- such as drugn or drugn -rcb- can be acutely worsened by drugb , especially when the recommended dose of the drugn is exceeded .
DDI-DrugBank.d284.s4.p3	non-potassium sparing diuretics	group	_	beta-agonist	group	_	false	the ecg changes and/or hypokalemia that may result from the administration of druga -lcb- such as drugn or drugn -rcb- can be acutely worsened by drugn , especially when the recommended dose of the drugb is exceeded .
DDI-DrugBank.d284.s4.p5	loop diuretics	group	_	beta-agonists	group	_	effect	the ecg changes and/or hypokalemia that may result from the administration of drugn -lcb- such as druga or drugn -rcb- can be acutely worsened by drugb , especially when the recommended dose of the drugn is exceeded .
DDI-DrugBank.d284.s4.p6	loop diuretics	group	_	beta-agonist	group	_	false	the ecg changes and/or hypokalemia that may result from the administration of drugn -lcb- such as druga or drugn -rcb- can be acutely worsened by drugn , especially when the recommended dose of the drugb is exceeded .
DDI-DrugBank.d284.s4.p7	thiazide diuretics	group	_	beta-agonists	group	_	effect	the ecg changes and/or hypokalemia that may result from the administration of drugn -lcb- such as drugn or druga -rcb- can be acutely worsened by drugb , especially when the recommended dose of the drugn is exceeded .
DDI-DrugBank.d284.s4.p8	thiazide diuretics	group	_	beta-agonist	group	_	false	the ecg changes and/or hypokalemia that may result from the administration of drugn -lcb- such as drugn or druga -rcb- can be acutely worsened by drugn , especially when the recommended dose of the drugb is exceeded .
DDI-DrugBank.d284.s5.p0	beta-agonists	group	_	non-potassium sparing diuretics	group	_	advise	although the clinical significance of these effects is not known , caution is advised in the co-administration of druga with drugb .
DDI-DrugBank.d284.s6.p0	BROVANA	brand	_	beta2-agonists	group	_	false	druga , as with other drugb , should be administered with extreme caution to patients being treated with drugn , drugn , or drugs known to prolong the qtc interval because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p1	BROVANA	brand	_	monoamine oxidase inhibitors	group	_	advise	druga , as with other drugn , should be administered with extreme caution to patients being treated with drugb , drugn , or drugs known to prolong the qtc interval because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p2	BROVANA	brand	_	tricyclic antidepressants	group	_	advise	druga , as with other drugn , should be administered with extreme caution to patients being treated with drugn , drugb , or drugs known to prolong the qtc interval because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p3	BROVANA	brand	_	adrenergic agonists	group	_	false	druga , as with other drugn , should be administered with extreme caution to patients being treated with drugn , drugn , or drugs known to prolong the qtc interval because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p4	beta2-agonists	group	_	monoamine oxidase inhibitors	group	_	advise	drugn , as with other druga , should be administered with extreme caution to patients being treated with drugb , drugn , or drugs known to prolong the qtc interval because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p5	beta2-agonists	group	_	tricyclic antidepressants	group	_	advise	drugn , as with other druga , should be administered with extreme caution to patients being treated with drugn , drugb , or drugs known to prolong the qtc interval because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p6	beta2-agonists	group	_	adrenergic agonists	group	_	false	drugn , as with other druga , should be administered with extreme caution to patients being treated with drugn , drugn , or drugs known to prolong the qtc interval because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p8	monoamine oxidase inhibitors	group	_	adrenergic agonists	group	_	effect	drugn , as with other drugn , should be administered with extreme caution to patients being treated with druga , drugn , or drugs known to prolong the qtc interval because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s6.p9	tricyclic antidepressants	group	_	adrenergic agonists	group	_	effect	drugn , as with other drugn , should be administered with extreme caution to patients being treated with drugn , druga , or drugs known to prolong the qtc interval because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d284.s8.p2	methylxanthines	group	_	BROVANA	brand	_	false	the concurrent use of intravenously or orally administered druga -lcb- e , g , , drugn , drugn -rcb- by patients receiving drugb has not been completely evaluated .
DDI-DrugBank.d284.s8.p4	aminophylline	drug	_	BROVANA	brand	_	false	the concurrent use of intravenously or orally administered drugn -lcb- e , g , , druga , drugn -rcb- by patients receiving drugb has not been completely evaluated .
DDI-DrugBank.d284.s8.p5	theophylline	drug	_	BROVANA	brand	_	false	the concurrent use of intravenously or orally administered drugn -lcb- e , g , , drugn , druga -rcb- by patients receiving drugb has not been completely evaluated .
DDI-DrugBank.d284.s9.p1	BROVANA	brand	_	theophylline	drug	_	false	in two combined 12-week placebo controlled trials that included druga doses of # mcg twice daily , # mcg twice daily , and # mcg once daily , # of # drugn - treated subjects received concomitant drugb at study entry .
DDI-DrugBank.d284.s9.p2	BROVANA	brand	_	theophylline	drug	_	false	in two combined 12-week placebo controlled trials that included drugn doses of # mcg twice daily , # mcg twice daily , and # mcg once daily , # of # druga - treated subjects received concomitant drugb at study entry .
DDI-DrugBank.d284.s10.p1	BROVANA	brand	_	theophylline	drug	_	false	in a 12-month controlled trial that included a # mcg once daily druga dose , # of the # drugn - treated subjects received concomitant drugb at study entry .
DDI-DrugBank.d284.s10.p2	BROVANA	brand	_	theophylline	drug	_	false	in a 12-month controlled trial that included a # mcg once daily drugn dose , # of the # druga - treated subjects received concomitant drugb at study entry .
DDI-DrugBank.d284.s12.p1	Beta-adrenergic receptor antagonists	group	_	BROVANA	brand	_	effect	druga -lcb- drugn -rcb- and drugb may interfere with the effect of each other when administered concurrently .
DDI-DrugBank.d284.s12.p2	beta-blockers	group	_	BROVANA	brand	_	effect	drugn -lcb- druga -rcb- and drugb may interfere with the effect of each other when administered concurrently .
DDI-DrugBank.d284.s13.p0	Beta-blockers	group	_	beta-agonists	group	_	effect	druga not only block the therapeutic effects of drugb , but may produce severe bronchospasm in copd patients .
DDI-DrugBank.d148.s0.p5	heparin	drug	_	Argatroban	drug	_	false	drugn : since druga is contraindicated in patients with drugn - induced thrombocytopenia , the co-administration of drugb and drugn is unlikely for this indication .
DDI-DrugBank.d148.s0.p7	heparin	drug	_	Argatroban	drug	_	false	drugn : since drugn is contraindicated in patients with druga - induced thrombocytopenia , the co-administration of drugb and drugn is unlikely for this indication .
DDI-DrugBank.d148.s0.p9	Argatroban	drug	_	heparin	drug	_	false	drugn : since drugn is contraindicated in patients with drugn - induced thrombocytopenia , the co-administration of druga and drugb is unlikely for this indication .
DDI-DrugBank.d148.s1.p0	Argatroban	drug	_	heparin	drug	_	false	however , if druga is to be initiated after cessation of drugb therapy , allow sufficient time for heparin effect on the aptt to decrease prior to initiation of drugn therapy .
DDI-DrugBank.d148.s1.p2	heparin	drug	_	Argatroban	drug	_	false	however , if drugn is to be initiated after cessation of druga therapy , allow sufficient time for heparin effect on the aptt to decrease prior to initiation of drugb therapy .
DDI-DrugBank.d148.s2.p0	Aspirin	brand	_	Acetaminophen	drug	_	false	druga / drugb : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered drugn -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or drugn -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p11	Argatroban	drug	_	aspirin	brand	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between druga and concomitantly administered drugb -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or drugn -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p13	Argatroban	drug	_	acetaminophen	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between druga and concomitantly administered drugn -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or drugb -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p15	aspirin	brand	_	Argatroban	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered druga -lcb- # mg orally given # and # hours prior to initiation of drugb # g/kg/min , over # hours -rcb- or drugn -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p16	aspirin	brand	_	acetaminophen	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered druga -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or drugb -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p17	aspirin	brand	_	Argatroban	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered druga -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or drugn -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugb # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p18	Argatroban	drug	_	acetaminophen	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered drugn -lcb- # mg orally given # and # hours prior to initiation of druga # g/kg/min , over # hours -rcb- or drugb -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugn # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s2.p20	acetaminophen	drug	_	Argatroban	drug	_	false	drugn / drugn : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drugn and concomitantly administered drugn -lcb- # mg orally given # and # hours prior to initiation of drugn # g/kg/min , over # hours -rcb- or druga -lcb- 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of drugb # g/kg/min , over # hours -rcb- .
DDI-DrugBank.d148.s3.p2	Argatroban	drug	_	warfarin	drug	_	false	oral drugn : pharmacokinetic drug-drug interactions between druga and drugb -lcb- # mg single oral dose -rcb- have not been demonstrated .
DDI-DrugBank.d148.s4.p0	Argatroban	drug	_	warfarin	drug	_	effect	however , the concomitant use of druga and drugb -lcb- 5 # mg initial oral dose followed by # -6 mg/day orally for 6-10 days -rcb- results in prolongation of the prothrombin time -lcb- pt -rcb- and international normalized ratio -lcb- inr -rcb- .
DDI-DrugBank.d148.s5.p2	Argatroban	drug	_	thrombolytic agents	group	_	false	drugn : the safety and effectiveness of druga with drugb have not been established .
DDI-DrugBank.d148.s6.p0	Argatroban	drug	_	antiplatelet agents	group	_	effect	co-administration : concomitant use of druga with drugb , drugn , and other drugn may increase the risk of bleeding .
DDI-DrugBank.d148.s6.p1	Argatroban	drug	_	thrombolytics	group	_	effect	co-administration : concomitant use of druga with drugn , drugb , and other drugn may increase the risk of bleeding .
DDI-DrugBank.d148.s6.p2	Argatroban	drug	_	anticoagulants	group	_	effect	co-administration : concomitant use of druga with drugn , drugn , and other drugb may increase the risk of bleeding .
DDI-DrugBank.d148.s6.p3	antiplatelet agents	group	_	thrombolytics	group	_	false	co-administration : concomitant use of drugn with druga , drugb , and other drugn may increase the risk of bleeding .
DDI-DrugBank.d148.s6.p4	antiplatelet agents	group	_	anticoagulants	group	_	false	co-administration : concomitant use of drugn with druga , drugn , and other drugb may increase the risk of bleeding .
DDI-DrugBank.d148.s6.p5	thrombolytics	group	_	anticoagulants	group	_	false	co-administration : concomitant use of drugn with drugn , druga , and other drugb may increase the risk of bleeding .
DDI-DrugBank.d509.s0.p0	aripiprazole	drug	_	ABILIFY	brand	_	false	drug-drug interactions given the primary cns effects of druga , caution should be used when drugb is taken in combination with other drugn and drugn .
DDI-DrugBank.d509.s0.p1	aripiprazole	drug	_	centrally acting drugs	group	_	false	drug-drug interactions given the primary cns effects of druga , caution should be used when drugn is taken in combination with other drugb and drugn .
DDI-DrugBank.d509.s0.p2	aripiprazole	drug	_	alcohol	drug	_	false	drug-drug interactions given the primary cns effects of druga , caution should be used when drugn is taken in combination with other drugn and drugb .
DDI-DrugBank.d509.s0.p3	ABILIFY	brand	_	centrally acting drugs	group	_	advise	drug-drug interactions given the primary cns effects of drugn , caution should be used when druga is taken in combination with other drugb and drugn .
DDI-DrugBank.d509.s0.p4	ABILIFY	brand	_	alcohol	drug	_	advise	drug-drug interactions given the primary cns effects of drugn , caution should be used when druga is taken in combination with other drugn and drugb .
DDI-DrugBank.d509.s0.p5	centrally acting drugs	group	_	alcohol	drug	_	false	drug-drug interactions given the primary cns effects of drugn , caution should be used when drugn is taken in combination with other druga and drugb .
DDI-DrugBank.d509.s2.p0	aripiprazole	drug	_	antihypertensive agents	group	_	effect	1 - adrenergic receptor antagonism , druga has the potential to enhance the effect of certain drugb .
DDI-DrugBank.d509.s3.p0	ABILIFY	brand	_	Aripiprazole	brand	_	false	potential for other drugs to affect druga drugb is not a substrate of cyp1a1 , cyp1a2 , cyp2a6 , cyp2b6 , cyp2c8 , cyp2c9 , cyp2c19 , or cyp2e1 enzymes .
DDI-DrugBank.d509.s7.p0	carbamazepine	drug	_	aripiprazole	drug	_	mechanism	agents that induce cyp3a4 -lcb- eg , druga -rcb- could cause an increase in drugb clearance and lower blood levels .
DDI-DrugBank.d509.s8.p0	ketoconazole	drug	_	quinidine	drug	_	false	inhibitors of cyp3a4 -lcb- eg , druga -rcb- or cyp2d6 -lcb- eg , drugb , drugn , or drugn -rcb- can inhibit drugn elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p1	ketoconazole	drug	_	fluoxetine	drug	_	false	inhibitors of cyp3a4 -lcb- eg , druga -rcb- or cyp2d6 -lcb- eg , drugn , drugb , or drugn -rcb- can inhibit drugn elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p2	ketoconazole	drug	_	paroxetine	drug	_	false	inhibitors of cyp3a4 -lcb- eg , druga -rcb- or cyp2d6 -lcb- eg , drugn , drugn , or drugb -rcb- can inhibit drugn elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p3	ketoconazole	drug	_	aripiprazole	drug	_	mechanism	inhibitors of cyp3a4 -lcb- eg , druga -rcb- or cyp2d6 -lcb- eg , drugn , drugn , or drugn -rcb- can inhibit drugb elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p6	quinidine	drug	_	aripiprazole	drug	_	mechanism	inhibitors of cyp3a4 -lcb- eg , drugn -rcb- or cyp2d6 -lcb- eg , druga , drugn , or drugn -rcb- can inhibit drugb elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p8	fluoxetine	drug	_	aripiprazole	drug	_	mechanism	inhibitors of cyp3a4 -lcb- eg , drugn -rcb- or cyp2d6 -lcb- eg , drugn , druga , or drugn -rcb- can inhibit drugb elimination and cause increased blood levels .
DDI-DrugBank.d509.s8.p9	paroxetine	drug	_	aripiprazole	drug	_	mechanism	inhibitors of cyp3a4 -lcb- eg , drugn -rcb- or cyp2d6 -lcb- eg , drugn , drugn , or druga -rcb- can inhibit drugb elimination and cause increased blood levels .
DDI-DrugBank.d509.s9.p1	Ketoconazole	drug	_	aripiprazole	drug	_	false	druga : coadministration of drugn -lcb- 200 mg/day for # days -rcb- with a 15-mg single dose of drugb increased the auc of drugn and its active metabolite by 63 % and 77 % , respectively .
DDI-DrugBank.d509.s9.p2	Ketoconazole	drug	_	aripiprazole	drug	_	false	druga : coadministration of drugn -lcb- 200 mg/day for # days -rcb- with a 15-mg single dose of drugn increased the auc of drugb and its active metabolite by 63 % and 77 % , respectively .
DDI-DrugBank.d509.s9.p3	ketoconazole	drug	_	aripiprazole	drug	_	mechanism	drugn : coadministration of druga -lcb- 200 mg/day for # days -rcb- with a 15-mg single dose of drugb increased the auc of drugn and its active metabolite by 63 % and 77 % , respectively .
DDI-DrugBank.d509.s9.p4	ketoconazole	drug	_	aripiprazole	drug	_	false	drugn : coadministration of druga -lcb- 200 mg/day for # days -rcb- with a 15-mg single dose of drugn increased the auc of drugb and its active metabolite by 63 % and 77 % , respectively .
DDI-DrugBank.d509.s11.p0	ketoconazole	drug	_	aripiprazole	drug	_	advise	when concomitant administration of druga with drugb occurs , drugn dose should be reduced to one-half of its normal dose .
DDI-DrugBank.d509.s11.p1	ketoconazole	drug	_	aripiprazole	drug	_	false	when concomitant administration of druga with drugn occurs , drugb dose should be reduced to one-half of its normal dose .
DDI-DrugBank.d509.s15.p0	Quinidine	drug	_	aripiprazole	drug	_	false	druga : coadministration of a 10-mg single dose of drugb with drugn -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugn by 112 % but decreased the auc of its active metabolite , drugn , by 35 % .
DDI-DrugBank.d509.s15.p2	Quinidine	drug	_	aripiprazole	drug	_	false	druga : coadministration of a 10-mg single dose of drugn with drugn -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugb by 112 % but decreased the auc of its active metabolite , drugn , by 35 % .
DDI-DrugBank.d509.s15.p3	Quinidine	drug	_	dehydroaripiprazole	drug_n	_	false	druga : coadministration of a 10-mg single dose of drugn with drugn -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugn by 112 % but decreased the auc of its active metabolite , drugb , by 35 % .
DDI-DrugBank.d509.s15.p4	aripiprazole	drug	_	quinidine	drug	_	mechanism	drugn : coadministration of a 10-mg single dose of druga with drugb -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugn by 112 % but decreased the auc of its active metabolite , drugn , by 35 % .
DDI-DrugBank.d509.s15.p7	quinidine	drug	_	aripiprazole	drug	_	false	drugn : coadministration of a 10-mg single dose of drugn with druga -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugb by 112 % but decreased the auc of its active metabolite , drugn , by 35 % .
DDI-DrugBank.d509.s15.p8	quinidine	drug	_	dehydroaripiprazole	drug_n	_	false	drugn : coadministration of a 10-mg single dose of drugn with druga -lcb- 166 mg/day for # days -rcb- , a potent inhibitor of cyp2d6 , increased the auc of drugn by 112 % but decreased the auc of its active metabolite , drugb , by 35 % .
DDI-DrugBank.d509.s16.p0	Aripiprazole	drug	_	quinidine	drug	_	false	druga dose should be reduced to one-half of its normal dose when concomitant administration of drugb with drugn occurs .
DDI-DrugBank.d509.s16.p2	quinidine	drug	_	aripiprazole	drug	_	advise	drugn dose should be reduced to one-half of its normal dose when concomitant administration of druga with drugb occurs .
DDI-DrugBank.d509.s17.p0	fluoxetine	drug	_	paroxetine	drug	_	false	other significant inhibitors of cyp2d6 , such as druga or drugb , would be expected to have similar effects and , therefore , should be accompanied by similar dose reductions .
DDI-DrugBank.d509.s19.p1	Carbamazepine	drug	_	aripiprazole	drug	_	false	druga : coadministration of drugn -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugb -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugn and its active metabolite , drugn .
DDI-DrugBank.d509.s19.p2	Carbamazepine	drug	_	aripiprazole	drug	_	false	druga : coadministration of drugn -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugn -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugb and its active metabolite , drugn .
DDI-DrugBank.d509.s19.p3	Carbamazepine	drug	_	dehydro-aripiprazole	drug_n	_	false	druga : coadministration of drugn -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugn -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugn and its active metabolite , drugb .
DDI-DrugBank.d509.s19.p4	carbamazepine	drug	_	aripiprazole	drug	_	mechanism	drugn : coadministration of druga -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugb -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugn and its active metabolite , drugn .
DDI-DrugBank.d509.s19.p5	carbamazepine	drug	_	aripiprazole	drug	_	false	drugn : coadministration of druga -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugn -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugb and its active metabolite , drugn .
DDI-DrugBank.d509.s19.p6	carbamazepine	drug	_	dehydro-aripiprazole	drug_n	_	false	drugn : coadministration of druga -lcb- 200 mg bid -rcb- , a potent cyp3a4 inducer , with drugn -lcb- 30 mg qd -rcb- resulted in an approximate 70 % decrease in cmax and auc values of both drugn and its active metabolite , drugb .
DDI-DrugBank.d509.s20.p0	carbamazepine	drug	_	aripiprazole	drug	_	advise	when druga is added to drugb therapy , drugn dose should be doubled .
DDI-DrugBank.d509.s20.p1	carbamazepine	drug	_	aripiprazole	drug	_	false	when druga is added to drugn therapy , drugb dose should be doubled .
DDI-DrugBank.d509.s22.p0	carbamazepine	drug	_	aripiprazole	drug	_	advise	when druga is withdrawn from the combination therapy , drugb dose should then be reduced .
DDI-DrugBank.d509.s23.p2	famotidine	drug	_	aripiprazole	drug	_	false	no clinically significant effect of druga , drugn , or drugn was seen on the pharmacokinetics of drugb -lcb- see clinical pharmacology : drug - drug interactions -rcb- .
DDI-DrugBank.d509.s23.p4	valproate	drug	_	aripiprazole	drug	_	false	no clinically significant effect of drugn , druga , or drugn was seen on the pharmacokinetics of drugb -lcb- see clinical pharmacology : drug - drug interactions -rcb- .
DDI-DrugBank.d509.s23.p5	lithium	drug	_	aripiprazole	drug	_	false	no clinically significant effect of drugn , drugn , or druga was seen on the pharmacokinetics of drugb -lcb- see clinical pharmacology : drug - drug interactions -rcb- .
DDI-DrugBank.d509.s24.p0	ABILIFY	brand	_	Aripiprazole	drug	_	false	potential for druga to affect other drugs drugb is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome cyp2b6 enzymes .
DDI-DrugBank.d509.s25.p0	aripiprazole	drug	_	dextromethorphan	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of druga had no significant effect on metabolism by cyp2d6 -lcb- drugb -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- drugn , drugn -rcb- , and cyp3a4 -lcb- drugn -rcb- substrates .
DDI-DrugBank.d509.s25.p1	aripiprazole	drug	_	warfarin	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of druga had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugb -rcb- , cyp2c19 -lcb- drugn , drugn -rcb- , and cyp3a4 -lcb- drugn -rcb- substrates .
DDI-DrugBank.d509.s25.p2	aripiprazole	drug	_	omeprazole	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of druga had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- drugb , drugn -rcb- , and cyp3a4 -lcb- drugn -rcb- substrates .
DDI-DrugBank.d509.s25.p3	aripiprazole	drug	_	warfarin	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of druga had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- drugn , drugb -rcb- , and cyp3a4 -lcb- drugn -rcb- substrates .
DDI-DrugBank.d509.s25.p4	aripiprazole	drug	_	dextromethorphan	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of druga had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- drugn , drugn -rcb- , and cyp3a4 -lcb- drugb -rcb- substrates .
DDI-DrugBank.d509.s25.p11	warfarin	drug	_	dextromethorphan	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of drugn had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- druga -rcb- , cyp2c19 -lcb- drugn , drugn -rcb- , and cyp3a4 -lcb- drugb -rcb- substrates .
DDI-DrugBank.d509.s25.p13	omeprazole	drug	_	dextromethorphan	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of drugn had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- druga , drugn -rcb- , and cyp3a4 -lcb- drugb -rcb- substrates .
DDI-DrugBank.d509.s25.p14	warfarin	drug	_	dextromethorphan	drug	_	false	in in vivo studies , 10 - to 30-mg/day doses of drugn had no significant effect on metabolism by cyp2d6 -lcb- drugn -rcb- , cyp2c9 -lcb- drugn -rcb- , cyp2c19 -lcb- drugn , druga -rcb- , and cyp3a4 -lcb- drugb -rcb- substrates .
DDI-DrugBank.d509.s27.p3	aripiprazole	drug	_	ethanol	drug	_	false	drugn : there was no significant difference between druga coadministered with drugb and placebo coadministered with drugn on performance of gross motor skills or stimulus response in healthy subjects .
DDI-DrugBank.d509.s27.p4	aripiprazole	drug	_	ethanol	drug	_	false	drugn : there was no significant difference between druga coadministered with drugn and placebo coadministered with drugb on performance of gross motor skills or stimulus response in healthy subjects .
DDI-DrugBank.d509.s28.p0	alcohol	drug	_	ABILIFY	brand	_	advise	as with most psychoactive medications , patients should be advised to avoid druga while taking drugb
DDI-DrugBank.d470.s1.p0	TRISENOX	brand	_	antiarrhythmics	group	_	advise	caution is advised when druga is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugb or drugn -rcb- or lead to electrolyte abnormalities -lcb- such as drugn or drugn -rcb- .
DDI-DrugBank.d470.s1.p1	TRISENOX	brand	_	thioridazine	drug	_	advise	caution is advised when druga is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugn or drugb -rcb- or lead to electrolyte abnormalities -lcb- such as drugn or drugn -rcb- .
DDI-DrugBank.d470.s1.p2	TRISENOX	brand	_	diuretics	group	_	advise	caution is advised when druga is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugn or drugn -rcb- or lead to electrolyte abnormalities -lcb- such as drugb or drugn -rcb- .
DDI-DrugBank.d470.s1.p3	TRISENOX	brand	_	amphotericin B	drug	_	advise	caution is advised when druga is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugn or drugn -rcb- or lead to electrolyte abnormalities -lcb- such as drugn or drugb -rcb- .
DDI-DrugBank.d470.s1.p5	antiarrhythmics	group	_	diuretics	group	_	false	caution is advised when drugn is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain druga or drugn -rcb- or lead to electrolyte abnormalities -lcb- such as drugb or drugn -rcb- .
DDI-DrugBank.d470.s1.p6	antiarrhythmics	group	_	amphotericin B	drug	_	false	caution is advised when drugn is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain druga or drugn -rcb- or lead to electrolyte abnormalities -lcb- such as drugn or drugb -rcb- .
DDI-DrugBank.d470.s1.p7	thioridazine	drug	_	diuretics	group	_	false	caution is advised when drugn is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugn or druga -rcb- or lead to electrolyte abnormalities -lcb- such as drugb or drugn -rcb- .
DDI-DrugBank.d470.s1.p8	thioridazine	drug	_	amphotericin B	drug	_	false	caution is advised when drugn is coadministered with other medications that can prolong the qt interval -lcb- e , g , certain drugn or druga -rcb- or lead to electrolyte abnormalities -lcb- such as drugn or drugb -rcb- .
DDI-DrugBank.d21.s0.p0	ELSPAR	brand	_	methotrexate	drug	_	effect	tissue culture and animal studies indicate that druga can diminish or abolish the effect of drugb on malignant cells # this effect on drugn activity persists as long as plasma asparagine levels are suppressed .
DDI-DrugBank.d21.s0.p1	ELSPAR	brand	_	methotrexate	drug	_	false	tissue culture and animal studies indicate that druga can diminish or abolish the effect of drugn on malignant cells # this effect on drugb activity persists as long as plasma asparagine levels are suppressed .
DDI-DrugBank.d21.s1.p0	methotrexate	drug	_	ELSPAR	brand	_	advise	these results would seem to dictate against the clinical use of druga with drugb , or during the period following drugn therapy when plasma asparagine levels are below normal .
DDI-DrugBank.d21.s1.p1	methotrexate	drug	_	ELSPAR	brand	_	false	these results would seem to dictate against the clinical use of druga with drugn , or during the period following drugb therapy when plasma asparagine levels are below normal .
DDI-DrugBank.d443.s0.p4	Aspirin	brand	_	probenecid	drug	_	effect	drugn : druga may decrease the effects of drugb , drugn , and drugn .
DDI-DrugBank.d443.s0.p5	Aspirin	brand	_	sulfinpyrazone	drug	_	effect	drugn : druga may decrease the effects of drugn , drugb , and drugn .
DDI-DrugBank.d443.s0.p6	Aspirin	brand	_	phenylbutazone	drug	_	effect	drugn : druga may decrease the effects of drugn , drugn , and drugb .
DDI-DrugBank.d443.s2.p0	Corticosteroids	group	_	aspirin	brand	_	effect	druga : concomitant administration with drugb may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels .
DDI-DrugBank.d443.s3.p3	Pyrazolone Derivatives	group	_	aspirin	drug	_	effect	druga -lcb- drugn , drugn , and possibly drugn -rcb- : concomitant administration with drugb may increase the risk of gastrointestinal ulceration .
DDI-DrugBank.d443.s3.p6	phenylbutazone	drug	_	aspirin	drug	_	effect	drugn -lcb- druga , drugn , and possibly drugn -rcb- : concomitant administration with drugb may increase the risk of gastrointestinal ulceration .
DDI-DrugBank.d443.s3.p8	oxyphenbutazone	drug	_	aspirin	drug	_	effect	drugn -lcb- drugn , druga , and possibly drugn -rcb- : concomitant administration with drugb may increase the risk of gastrointestinal ulceration .
DDI-DrugBank.d443.s3.p9	dipyrone	drug	_	aspirin	drug	_	effect	drugn -lcb- drugn , drugn , and possibly druga -rcb- : concomitant administration with drugb may increase the risk of gastrointestinal ulceration .
DDI-DrugBank.d443.s4.p2	Aspirin	drug	_	nonsteroidal anti-inflammatory	drug	_	advise	drugn agents : druga is contraindicated in patients who are hypersensitive to drugb agents .
DDI-DrugBank.d443.s5.p0	aspirin	brand	_	salicylate	group	_	false	urinary alkalinizers : decrease druga effectiveness by increasing the rate of drugb renal excretion .
DDI-DrugBank.d443.s6.p0	Phenobarbital	drug	_	aspirin	brand	_	mechanism	druga : decreases drugb effectiveness by enzyme induction .
DDI-DrugBank.d443.s7.p2	phenytoin	drug	_	aspirin	brand	_	effect	drugn : serum druga levels may be increased by drugb .
DDI-DrugBank.d443.s8.p0	Propranolol	drug	_	aspirins	brand	_	effect	druga : may decrease drugb anti-inflammatory action by competing for the same receptors .
DDI-DrugBank.d443.s9.p2	Aspirin	brand	_	antacids	group	_	advise	drugn : enteric coated druga should not be given concurrently with drugb , since an increase in the ph of the stomach may effect the enteric coating of the tablets .
DDI-DrugBank.d109.s0.p0	Ketoconazole	drug	_	Itraconazole	drug	_	false	druga / drugb , drugn , including drugn
DDI-DrugBank.d109.s0.p1	Ketoconazole	drug	_	Macrolides	group	_	false	druga / drugn , drugb , including drugn
DDI-DrugBank.d109.s0.p2	Ketoconazole	drug	_	Erythromycin	drug	_	false	druga / drugn , drugn , including drugb
DDI-DrugBank.d109.s0.p3	Itraconazole	drug	_	Macrolides	group	_	false	drugn / druga , drugb , including drugn
DDI-DrugBank.d109.s0.p4	Itraconazole	drug	_	Erythromycin	drug	_	false	drugn / druga , drugn , including drugb
DDI-DrugBank.d109.s0.p5	Macrolides	group	_	Erythromycin	drug	_	false	drugn / drugn , druga , including drugb
DDI-DrugBank.d73.s0.p0	reserpine	drug	_	beta-blocking agent	group	_	effect	catecholamine-depleting drugs -lcb- eg , druga -rcb- may have an additive effect when given with drugb s.
DDI-DrugBank.d73.s2.p0	Calcium channel blockers	group	_	TENORMIN	brand	_	effect	druga may also have an additive effect when given with drugb .
DDI-DrugBank.d73.s3.p0	Beta blockers	group	_	clonidine	drug	_	effect	druga may exacerbate the rebound hypertension which can follow the withdrawal of drugb .
DDI-DrugBank.d73.s4.p0	beta blocker	group	_	clonidine	drug	_	advise	if the two drugs are coadministered , the druga should be withdrawn several days before the gradual withdrawal of drugb .
DDI-DrugBank.d73.s5.p0	clonidine	drug	_	beta-blocker	group	_	false	if replacing druga by drugb therapy , the introduction of drugn should be delayed for several days after drugn administration has stopped .
DDI-DrugBank.d73.s5.p1	clonidine	drug	_	beta blockers	group	_	false	if replacing druga by drugn therapy , the introduction of drugb should be delayed for several days after drugn administration has stopped .
DDI-DrugBank.d73.s5.p3	beta-blocker	group	_	beta blockers	group	_	false	if replacing drugn by druga therapy , the introduction of drugb should be delayed for several days after drugn administration has stopped .
DDI-DrugBank.d73.s5.p4	beta-blocker	group	_	clonidine	drug	_	false	if replacing drugn by druga therapy , the introduction of drugn should be delayed for several days after drugb administration has stopped .
DDI-DrugBank.d73.s5.p5	beta blockers	group	_	clonidine	drug	_	advise	if replacing drugn by drugn therapy , the introduction of druga should be delayed for several days after drugb administration has stopped .
DDI-DrugBank.d73.s6.p0	indomethacin	drug	_	beta blockers	group	_	effect	concomitant use of prostaglandin synthase inhibiting drugs , eg , druga , may decrease the hypotensive effects of drugb .
DDI-DrugBank.d73.s7.p0	atenolol	drug	_	aspirin	brand	_	false	information on concurrent usage of druga and drugb is limited .
DDI-DrugBank.d73.s8.p0	aspirin	brand	_	beta blockers	group	_	false	data from several studies , ie , timi-ii , isis-2 , currently do not suggest any clinical interaction between druga and drugb in the acute myocardial infarction setting .
DDI-DrugBank.d11.s0.p0	Albuterol	drug	_	STRATTERA	brand	_	false	drug-drug interactions druga - drugb should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugn -lcb- or other drugn -rcb- because the action of drugn on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s0.p2	Albuterol	drug	_	beta2 agonists	group	_	false	drug-drug interactions druga - drugn should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugn -lcb- or other drugb -rcb- because the action of drugn on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s0.p4	STRATTERA	brand	_	albuterol	drug	_	advise	drug-drug interactions drugn - druga should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugb -lcb- or other drugn -rcb- because the action of drugn on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s0.p5	STRATTERA	brand	_	beta2 agonists	group	_	false	drug-drug interactions drugn - druga should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugn -lcb- or other drugb -rcb- because the action of drugn on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s0.p6	STRATTERA	brand	_	albuterol	drug	_	false	drug-drug interactions drugn - druga should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugn -lcb- or other drugn -rcb- because the action of drugb on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s0.p9	beta2 agonists	group	_	albuterol	drug	_	false	drug-drug interactions drugn - drugn should be administered with caution to patients being treated with systemically-administered -lcb- oral or intravenous -rcb- drugn -lcb- or other druga -rcb- because the action of drugb on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .
DDI-DrugBank.d11.s3.p0	STRATTERA	brand	_	paroxetine	drug	_	advise	dosage adjustment of druga may be necessary when coadministered with cyp2d6 inhibitors , e , g , , drugb , drugn , and drugn .
DDI-DrugBank.d11.s3.p1	STRATTERA	brand	_	fluoxetine	drug	_	advise	dosage adjustment of druga may be necessary when coadministered with cyp2d6 inhibitors , e , g , , drugn , drugb , and drugn .
DDI-DrugBank.d11.s3.p2	STRATTERA	brand	_	quinidine	drug	_	advise	dosage adjustment of druga may be necessary when coadministered with cyp2d6 inhibitors , e , g , , drugn , drugn , and drugb .
DDI-DrugBank.d11.s4.p0	paroxetine	drug	_	fluoxetine	drug	_	false	in em individuals treated with druga or drugb , the auc of drugn is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than drugn alone .
DDI-DrugBank.d11.s4.p1	paroxetine	drug	_	atomoxetine	drug	_	mechanism	in em individuals treated with druga or drugn , the auc of drugb is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than drugn alone .
DDI-DrugBank.d11.s4.p2	paroxetine	drug	_	atomoxetine	drug	_	false	in em individuals treated with druga or drugn , the auc of drugn is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than drugb alone .
DDI-DrugBank.d11.s4.p3	fluoxetine	drug	_	atomoxetine	drug	_	mechanism	in em individuals treated with drugn or druga , the auc of drugb is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than drugn alone .
DDI-DrugBank.d11.s4.p4	fluoxetine	drug	_	atomoxetine	drug	_	false	in em individuals treated with drugn or druga , the auc of drugn is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than drugb alone .
DDI-DrugBank.d140.s1.p3	atorvastatin	drug	_	Maalox TC	brand	_	mechanism	drugn : when druga and drugb suspension were coadministered , plasma concentrations of drugn decreased approximately 35 % .
DDI-DrugBank.d140.s1.p5	Maalox TC	brand	_	atorvastatin	drug	_	false	drugn : when drugn and druga suspension were coadministered , plasma concentrations of drugb decreased approximately 35 % .
DDI-DrugBank.d140.s3.p3	atorvastatin	drug	_	antipyrine	drug	_	false	drugn : because druga does not affect the pharmacokinetics of drugb , interactions with other drugn metabolized via the same cytochrome isozymes are not expected .
DDI-DrugBank.d140.s3.p4	atorvastatin	drug	_	drugs	drug	_	false	drugn : because druga does not affect the pharmacokinetics of drugn , interactions with other drugb metabolized via the same cytochrome isozymes are not expected .
DDI-DrugBank.d140.s3.p5	antipyrine	drug	_	drugs	drug	_	false	drugn : because drugn does not affect the pharmacokinetics of druga , interactions with other drugb metabolized via the same cytochrome isozymes are not expected .
DDI-DrugBank.d140.s4.p3	atorvastatin	drug	_	colestipol	drug	_	false	drugn : plasma concentrations of druga decreased approximately 25 % when drugb and drugn were coadministered .
DDI-DrugBank.d140.s4.p5	colestipol	drug	_	atorvastatin	drug	_	mechanism	drugn : plasma concentrations of drugn decreased approximately 25 % when druga and drugb were coadministered .
DDI-DrugBank.d140.s5.p0	atorvastatin	drug	_	colestipol	drug	_	effect	however , ldl-c reduction was greater when druga and drugb were coadministered than when either drug was given alone .
DDI-DrugBank.d140.s6.p2	Atorvastatin	drug	_	cimetidine	drug	_	false	drugn : druga plasma concentrations and ldl-c reduction were not altered by coadministration of drugb .
DDI-DrugBank.d140.s7.p3	atorvastatin	drug	_	digoxin	drug	_	mechanism	drugn : when multiple doses of druga and drugb were coadministered , steady-state plasma drugn concentrations increased by approximately 20 % .
DDI-DrugBank.d140.s7.p4	atorvastatin	drug	_	digoxin	drug	_	false	drugn : when multiple doses of druga and drugn were coadministered , steady-state plasma drugb concentrations increased by approximately 20 % .
DDI-DrugBank.d140.s9.p0	Erythromycin	drug	_	atorvastatin	drug	_	false	druga : in healthy individuals , plasma concentrations of drugb increased approximately 40 % with coadministration of drugn and drugn , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d140.s9.p1	Erythromycin	drug	_	atorvastatin	drug	_	false	druga : in healthy individuals , plasma concentrations of drugn increased approximately 40 % with coadministration of drugb and drugn , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d140.s9.p4	atorvastatin	drug	_	erythromycin	drug	_	false	drugn : in healthy individuals , plasma concentrations of druga increased approximately 40 % with coadministration of drugn and drugb , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d140.s9.p5	atorvastatin	drug	_	erythromycin	drug	_	mechanism	drugn : in healthy individuals , plasma concentrations of drugn increased approximately 40 % with coadministration of druga and drugb , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d140.s10.p0	Contraceptives	group	_	atorvastatin	drug	_	false	oral druga : coadministration of drugb and an oral drugn increased auc values for drugn and drugn by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p2	Contraceptives	group	_	norethindrone	drug	_	false	oral druga : coadministration of drugn and an oral drugn increased auc values for drugb and drugn by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p3	Contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga : coadministration of drugn and an oral drugn increased auc values for drugn and drugb by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p4	atorvastatin	drug	_	contraceptive	group	_	mechanism	oral drugn : coadministration of druga and an oral drugb increased auc values for drugn and drugn by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p5	atorvastatin	drug	_	norethindrone	drug	_	mechanism	oral drugn : coadministration of druga and an oral drugn increased auc values for drugb and drugn by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p6	atorvastatin	drug	_	ethinyl estradiol	drug	_	mechanism	oral drugn : coadministration of druga and an oral drugn increased auc values for drugn and drugb by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p7	contraceptive	group	_	norethindrone	drug	_	false	oral drugn : coadministration of drugn and an oral druga increased auc values for drugb and drugn by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p8	contraceptive	group	_	ethinyl estradiol	drug	_	false	oral drugn : coadministration of drugn and an oral druga increased auc values for drugn and drugb by approximately 30 % and 20 % .
DDI-DrugBank.d140.s10.p9	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : coadministration of drugn and an oral drugn increased auc values for druga and drugb by approximately 30 % and 20 % .
DDI-DrugBank.d140.s11.p0	contraceptive	group	_	atorvastatin	drug	_	advise	these increases should be considered when selecting an oral druga for a woman taking drugb .
DDI-DrugBank.d140.s12.p2	Atorvastatin	drug	_	warfarin	drug	_	false	drugn : druga had no clinically significant effect on prothrombin time when administered to patients receiving chronic drugb treatment .
DDI-DrugBank.d140.s17.p0	HMG-CoA reductase inhibitor	group	_	ketoconazole	drug	_	advise	caution should be exercised if an druga is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drugb , drugn , and drugn .
DDI-DrugBank.d140.s17.p1	HMG-CoA reductase inhibitor	group	_	spironolactone	drug	_	advise	caution should be exercised if an druga is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drugn , drugb , and drugn .
DDI-DrugBank.d140.s17.p2	HMG-CoA reductase inhibitor	group	_	cimetidine	drug	_	advise	caution should be exercised if an druga is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drugn , drugn , and drugb .
DDI-DrugBank.d424.s2.p0	atovaquone	drug	_	phenytoin	drug	_	false	the extent of plasma protein binding of druga in human plasma is not affected by the presence of therapeutic concentrations of drugb -lcb- 15 mcg / ml -rcb- , nor is the binding of drugn affected by the presence of drugn .
DDI-DrugBank.d424.s2.p1	atovaquone	drug	_	phenytoin	drug	_	false	the extent of plasma protein binding of druga in human plasma is not affected by the presence of therapeutic concentrations of drugn -lcb- 15 mcg / ml -rcb- , nor is the binding of drugb affected by the presence of drugn .
DDI-DrugBank.d424.s2.p4	phenytoin	drug	_	atovaquone	drug	_	false	the extent of plasma protein binding of drugn in human plasma is not affected by the presence of therapeutic concentrations of druga -lcb- 15 mcg / ml -rcb- , nor is the binding of drugn affected by the presence of drugb .
DDI-DrugBank.d424.s2.p5	phenytoin	drug	_	atovaquone	drug	_	false	the extent of plasma protein binding of drugn in human plasma is not affected by the presence of therapeutic concentrations of drugn -lcb- 15 mcg / ml -rcb- , nor is the binding of druga affected by the presence of drugb .
DDI-DrugBank.d424.s3.p1	Rifampin	drug	_	MEPRON	brand	_	false	druga : coadministration of drugn and drugb suspension results in a significant decrease in average steady - state plasma drugn concentrations .
DDI-DrugBank.d424.s3.p2	Rifampin	drug	_	atovaquone	drug	_	false	druga : coadministration of drugn and drugn suspension results in a significant decrease in average steady - state plasma drugb concentrations .
DDI-DrugBank.d424.s3.p3	rifampin	drug	_	MEPRON	brand	_	mechanism	drugn : coadministration of druga and drugb suspension results in a significant decrease in average steady - state plasma drugn concentrations .
DDI-DrugBank.d424.s3.p4	rifampin	drug	_	atovaquone	drug	_	false	drugn : coadministration of druga and drugn suspension results in a significant decrease in average steady - state plasma drugb concentrations .
DDI-DrugBank.d424.s3.p5	MEPRON	brand	_	atovaquone	drug	_	false	drugn : coadministration of drugn and druga suspension results in a significant decrease in average steady - state plasma drugb concentrations .
DDI-DrugBank.d424.s4.p0	rifampin	drug	_	MEPRON	brand	_	advise	alternatives to druga should be considered during the course of pgpep1 treatment with drugb .
DDI-DrugBank.d424.s5.p0	Rifabutin	drug	_	rifamycin	drug	_	false	druga , another drugb , is structurally similar to drugn and may possibly have some of the same drug interactions as drugn .
DDI-DrugBank.d424.s5.p1	Rifabutin	drug	_	rifampin	drug	_	false	druga , another drugn , is structurally similar to drugb and may possibly have some of the same drug interactions as drugn .
DDI-DrugBank.d424.s5.p2	Rifabutin	drug	_	rifampin	drug	_	false	druga , another drugn , is structurally similar to drugn and may possibly have some of the same drug interactions as drugb .
DDI-DrugBank.d424.s5.p3	rifamycin	drug	_	rifampin	drug	_	false	drugn , another druga , is structurally similar to drugb and may possibly have some of the same drug interactions as drugn .
DDI-DrugBank.d424.s5.p4	rifamycin	drug	_	rifampin	drug	_	false	drugn , another druga , is structurally similar to drugn and may possibly have some of the same drug interactions as drugb .
DDI-DrugBank.d424.s6.p0	MEPRON	brand	_	rifabutin	drug	_	false	no interaction trials have been conducted with druga and drugb .
DDI-DrugBank.d469.s0.p0	TRACRIUM	brand	_	enflurane	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugb ;
DDI-DrugBank.d469.s3.p0	antibiotics	group	_	aminoglycosides	group	_	false	certain druga , especially the drugb and drugn ;
DDI-DrugBank.d469.s3.p1	antibiotics	group	_	polymyxins	group	_	false	certain druga , especially the drugn and drugb ;
DDI-DrugBank.d469.s3.p2	aminoglycosides	group	_	polymyxins	group	_	false	certain drugn , especially the druga and drugb ;
DDI-DrugBank.d469.s7.p0	TRACRIUM	brand	_	enflurane	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugb ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p1	TRACRIUM	brand	_	isoflurane	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugb ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p2	TRACRIUM	brand	_	halothane	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugb ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p3	TRACRIUM	brand	_	antibiotics	group	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugb , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p4	TRACRIUM	brand	_	aminoglycosides	group	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugb and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p5	TRACRIUM	brand	_	polymyxins	group	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p6	TRACRIUM	brand	_	lithium	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p7	TRACRIUM	brand	_	magnesium	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p8	TRACRIUM	brand	_	procainamide	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p9	TRACRIUM	brand	_	quinidine	drug	_	effect	drugs which may enhance the neuromuscular blocking action of druga include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p10	enflurane	drug	_	isoflurane	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugb ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p11	enflurane	drug	_	halothane	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugb ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p12	enflurane	drug	_	antibiotics	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugb , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p13	enflurane	drug	_	aminoglycosides	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugb and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p14	enflurane	drug	_	polymyxins	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugn and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p15	enflurane	drug	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p16	enflurane	drug	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p17	enflurane	drug	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p18	enflurane	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : druga ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p19	isoflurane	drug	_	halothane	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugb ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p20	isoflurane	drug	_	antibiotics	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugb , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p21	isoflurane	drug	_	aminoglycosides	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugb and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p22	isoflurane	drug	_	polymyxins	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugn and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p23	isoflurane	drug	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugn and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p24	isoflurane	drug	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p25	isoflurane	drug	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p26	isoflurane	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; druga ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p27	halothane	drug	_	antibiotics	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugb , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p28	halothane	drug	_	aminoglycosides	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugb and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p29	halothane	drug	_	polymyxins	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugn and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p30	halothane	drug	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugn and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p31	halothane	drug	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugn and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p32	halothane	drug	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p33	halothane	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; druga ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p34	antibiotics	group	_	aminoglycosides	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugb and drugn ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p35	antibiotics	group	_	polymyxins	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugn and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p36	antibiotics	group	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugn and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p37	antibiotics	group	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugn and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p38	antibiotics	group	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugn and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p39	antibiotics	group	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain druga , especially the drugn and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p40	aminoglycosides	group	_	polymyxins	group	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the druga and drugb ; drugn ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p41	aminoglycosides	group	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the druga and drugn ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p42	aminoglycosides	group	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the druga and drugn ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p43	aminoglycosides	group	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the druga and drugn ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p44	aminoglycosides	group	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the druga and drugn ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p45	polymyxins	group	_	lithium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and druga ; drugb ; drugn salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p46	polymyxins	group	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and druga ; drugn ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p47	polymyxins	group	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and druga ; drugn ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p48	polymyxins	group	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and druga ; drugn ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p49	lithium	drug	_	magnesium	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; druga ; drugb salts ; drugn ; and drugn .
DDI-DrugBank.d469.s7.p50	lithium	drug	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; druga ; drugn salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p51	lithium	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; druga ; drugn salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p52	magnesium	drug	_	procainamide	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; druga salts ; drugb ; and drugn .
DDI-DrugBank.d469.s7.p53	magnesium	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; druga salts ; drugn ; and drugb .
DDI-DrugBank.d469.s7.p54	procainamide	drug	_	quinidine	drug	_	false	drugs which may enhance the neuromuscular blocking action of drugn include : drugn ; drugn ; drugn ; certain drugn , especially the drugn and drugn ; drugn ; drugn salts ; druga ; and drugb .
DDI-DrugBank.d469.s9.p0	succinylcholine	drug	_	TRACRIUM	brand	_	effect	the prior administration of druga does not enhance the duration , but quickens the onset and may increase the depth , of neuromuscular block induced by drugb .
DDI-DrugBank.d469.s10.p0	TRACRIUM	brand	_	succinylcholine	drug	_	advise	druga should not be administered until a patient has recovered from drugb - induced neuromuscular block .
DDI-DrugBank.d222.s0.p0	atropine	drug	_	pralidoxime	drug	_	effect	when druga and drugb are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when drugn is used alone because drugn may potentiate the effect of drugn .
DDI-DrugBank.d222.s0.p2	atropine	drug	_	pralidoxime	drug	_	false	when druga and drugn are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when drugn is used alone because drugb may potentiate the effect of drugn .
DDI-DrugBank.d222.s0.p4	pralidoxime	drug	_	atropine	drug	_	false	when drugn and druga are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when drugb is used alone because drugn may potentiate the effect of drugn .
DDI-DrugBank.d222.s0.p6	pralidoxime	drug	_	atropine	drug	_	false	when drugn and druga are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when drugn is used alone because drugn may potentiate the effect of drugb .
DDI-DrugBank.d222.s0.p7	atropine	drug	_	pralidoxime	drug	_	false	when drugn and drugn are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when druga is used alone because drugb may potentiate the effect of drugn .
DDI-DrugBank.d222.s0.p9	pralidoxime	drug	_	atropine	drug	_	effect	when drugn and drugn are used together , the signs of atropinization -lcb- flushing , mydriasis , tachycardia , dryness of the mouth and nose -rcb- may occur earlier than might be expected than when drugn is used alone because druga may potentiate the effect of drugb .
DDI-DrugBank.d222.s1.p0	atropine	drug	_	pralidoxime	drug	_	advise	the following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of druga and drugb .
DDI-DrugBank.d222.s2.p0	barbiturates	group	_	anticholinesterases	group	_	advise	since druga are potentiated by the drugb , they should be used cautiously in the treatment of convulsions .
DDI-DrugBank.d374.s0.p0	Auranofin	drug	_	gold medication	group	_	advise	druga should be avoided by patients with a history of serious reaction to any drugb , including drugn and drugn .
DDI-DrugBank.d374.s0.p1	Auranofin	drug	_	Solganal	brand	_	advise	druga should be avoided by patients with a history of serious reaction to any drugn , including drugb and drugn .
DDI-DrugBank.d374.s0.p2	Auranofin	drug	_	Myochrysine	brand	_	advise	druga should be avoided by patients with a history of serious reaction to any drugn , including drugn and drugb .
DDI-DrugBank.d374.s0.p3	gold medication	group	_	Solganal	brand	_	false	drugn should be avoided by patients with a history of serious reaction to any druga , including drugb and drugn .
DDI-DrugBank.d374.s0.p4	gold medication	group	_	Myochrysine	brand	_	false	drugn should be avoided by patients with a history of serious reaction to any druga , including drugn and drugb .
DDI-DrugBank.d374.s0.p5	Solganal	brand	_	Myochrysine	brand	_	false	drugn should be avoided by patients with a history of serious reaction to any drugn , including druga and drugb .
DDI-DrugBank.d374.s1.p0	Auranofin	drug	_	penicillamine	drug	_	advise	druga should not be used together with drugb -lcb- drugn , drugn -rcb- , another arthritis medication .
DDI-DrugBank.d374.s1.p1	Auranofin	drug	_	Depen	brand	_	advise	druga should not be used together with drugn -lcb- drugb , drugn -rcb- , another arthritis medication .
DDI-DrugBank.d374.s1.p2	Auranofin	drug	_	Cuprimine	brand	_	advise	druga should not be used together with drugn -lcb- drugn , drugb -rcb- , another arthritis medication .
DDI-DrugBank.d448.s0.p0	MAO inhibitors	group	_	antihistamines	group	_	effect	druga prolong and intensify the effects of drugb .
DDI-DrugBank.d448.s1.p0	antihistamines	group	_	alcohol	drug	_	effect	concomitant use of druga with drugb , drugn , drugn , or other drugn may have an additive effect .
DDI-DrugBank.d448.s1.p1	antihistamines	group	_	tricyclic antidepressants	group	_	effect	concomitant use of druga with drugn , drugb , drugn , or other drugn may have an additive effect .
DDI-DrugBank.d448.s1.p2	antihistamines	group	_	barbiturates	group	_	effect	concomitant use of druga with drugn , drugn , drugb , or other drugn may have an additive effect .
DDI-DrugBank.d448.s1.p3	antihistamines	group	_	central nervous system depressants	group	_	effect	concomitant use of druga with drugn , drugn , drugn , or other drugb may have an additive effect .
DDI-DrugBank.d448.s1.p6	alcohol	drug	_	central nervous system depressants	group	_	false	concomitant use of drugn with druga , drugn , drugn , or other drugb may have an additive effect .
DDI-DrugBank.d448.s1.p8	tricyclic antidepressants	group	_	central nervous system depressants	group	_	false	concomitant use of drugn with drugn , druga , drugn , or other drugb may have an additive effect .
DDI-DrugBank.d448.s1.p9	barbiturates	group	_	central nervous system depressants	group	_	false	concomitant use of drugn with drugn , drugn , druga , or other drugb may have an additive effect .
DDI-DrugBank.d448.s2.p0	sympathomimetic drugs	group	_	monoamine oxidase inhibitors	group	_	effect	when druga are given to patients receiving drugb , hypertensive reactions , including hypertensive crises , may occur .
DDI-DrugBank.d448.s3.p3	methyldopa	drug	_	sympathomimetics	group	_	effect	the antihypertensive effects of druga , drugn , drugn , and drugn may be reduced by drugb .
DDI-DrugBank.d448.s3.p6	mecamylamine	drug	_	sympathomimetics	group	_	effect	the antihypertensive effects of drugn , druga , drugn , and drugn may be reduced by drugb .
DDI-DrugBank.d448.s3.p8	reserpine	drug	_	sympathomimetics	group	_	effect	the antihypertensive effects of drugn , drugn , druga , and drugn may be reduced by drugb .
DDI-DrugBank.d448.s3.p9	veratrum alkaloids	drug	_	sympathomimetics	group	_	effect	the antihypertensive effects of drugn , drugn , drugn , and druga may be reduced by drugb .
DDI-DrugBank.d448.s4.p0	Beta-adrenergic blocking agents	group	_	sympathomimetics	group	_	int	druga may also interact with drugb .
DDI-DrugBank.d448.s5.p0	pseudoephedrine	drug	_	digitalis	group	_	effect	increased ectopic pacemaker activity can occur when druga is used concomitantly with drugb .
DDI-DrugBank.d448.s6.p0	Antacids	group	_	pseudoephedrine	drug	_	mechanism	druga increase the rate of absorption of drugb , while drugn decreases it .
DDI-DrugBank.d448.s6.p1	Antacids	group	_	kaolin	drug	_	false	druga increase the rate of absorption of drugn , while drugb decreases it .
DDI-DrugBank.d448.s6.p2	pseudoephedrine	drug	_	kaolin	drug	_	mechanism	drugn increase the rate of absorption of druga , while drugb decreases it .
DDI-DrugBank.d233.s0.p2	azathioprine	drug	_	allopurinol	drug	_	mechanism	use with drugn : the principal pathway for detoxification of druga is inhibited by drugb .
DDI-DrugBank.d233.s1.p0	azathioprine	drug	_	allopurinol	drug	_	advise	patients receiving druga and drugb concomitantly should have a dose reduction of drugn , to approximately 1/3 to 1/4 the usual dose .
DDI-DrugBank.d233.s1.p2	allopurinol	drug	_	azathioprine	drug	_	false	patients receiving drugn and druga concomitantly should have a dose reduction of drugb , to approximately 1/3 to 1/4 the usual dose .
DDI-DrugBank.d233.s3.p2	angiotensin converting enzyme inhibitors	group	_	azathioprine	drug	_	effect	use with drugn : the use of druga to control hypertension in patients on drugb has been reported to induce severe leukopenia .
DDI-DrugBank.d53.s0.p0	nelfinavir	drug	_	azithromycin	drug	_	false	co-administration of druga at steady-state with a single dose of drugb .
DDI-DrugBank.d53.s1.p0	nelfinavir	drug	_	azithromycin	drug	_	effect	co-administration of druga at steady-state with a single dose of drugb -lcb- 2 x # mg tablets -rcb- results in increased drugn serum concentrations .
DDI-DrugBank.d53.s1.p1	nelfinavir	drug	_	azithromycin	drug	_	false	co-administration of druga at steady-state with a single dose of drugn -lcb- 2 x # mg tablets -rcb- results in increased drugb serum concentrations .
DDI-DrugBank.d53.s2.p0	azithromycin	drug	_	nelfinavir	drug	_	advise	although a dose adjustment of druga is not recommended when administered in combination with drugb , close monitoring for known side effects of drugn , such as liver enzyme abnormalities and hearing impairment , is warranted .
DDI-DrugBank.d53.s2.p2	nelfinavir	drug	_	azithromycin	drug	_	false	although a dose adjustment of drugn is not recommended when administered in combination with druga , close monitoring for known side effects of drugb , such as liver enzyme abnormalities and hearing impairment , is warranted .
DDI-DrugBank.d53.s3.p0	Azithromycin	drug	_	warfarin	drug	_	false	druga did not affect the prothrombin time response to a single dose of drugb .
DDI-DrugBank.d53.s4.p0	azithromycin	drug	_	warfarin	drug	_	advise	however , prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with druga and drugb concomitantly .
DDI-DrugBank.d53.s5.p0	macrolides	group	_	warfarin	drug	_	effect	concurrent use of druga and drugb in clinical practice has been associated with increased anticoagulant effects .
DDI-DrugBank.d53.s7.p0	azithromycin	drug	_	atorvastatin	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p1	azithromycin	drug	_	carbamazepine	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p2	azithromycin	drug	_	cetirizine	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p3	azithromycin	drug	_	didanosine	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p4	azithromycin	drug	_	efavirenz	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p5	azithromycin	drug	_	fluconazole	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p6	azithromycin	drug	_	indinavir	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p7	azithromycin	drug	_	midazolam	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p8	azithromycin	drug	_	rifabutin	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p9	azithromycin	drug	_	sildenafil	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p10	azithromycin	drug	_	theophylline	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p11	azithromycin	drug	_	triazolam	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugb , drugn / drugn or drugn .
DDI-DrugBank.d53.s7.p12	azithromycin	drug	_	trimethoprim	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugb / drugn or drugn .
DDI-DrugBank.d53.s7.p13	azithromycin	drug	_	sulfamethoxazole	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugb or drugn .
DDI-DrugBank.d53.s7.p14	azithromycin	drug	_	zidovudine	drug	_	mechanism	when used in therapeutic doses , druga had a modest effect on the pharmacokinetics of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- intravenous and oral -rcb- , drugn , drugn / drugn or drugb .
DDI-DrugBank.d53.s8.p0	efavirenz	drug	_	fluconazole	drug	_	false	co-administration with druga or drugb had a modest effect on the pharmacokinetics of drugn .
DDI-DrugBank.d53.s8.p1	efavirenz	drug	_	azithromycin	drug	_	mechanism	co-administration with druga or drugn had a modest effect on the pharmacokinetics of drugb .
DDI-DrugBank.d53.s8.p2	fluconazole	drug	_	azithromycin	drug	_	mechanism	co-administration with drugn or druga had a modest effect on the pharmacokinetics of drugb .
DDI-DrugBank.d53.s13.p0	azithromycin	drug	_	Digoxin	drug	_	false	until further data are developed regarding drug interactions when druga and these drugs are used concomitantly , careful monitoring of patients is advised : drugb elevated drugn concentrations .
DDI-DrugBank.d53.s13.p1	azithromycin	drug	_	digoxin	drug	_	false	until further data are developed regarding drug interactions when druga and these drugs are used concomitantly , careful monitoring of patients is advised : drugn elevated drugb concentrations .
DDI-DrugBank.d9.s0.p0	Azlocillin	drug	_	amikacin	drug	_	advise	druga should not be administered concomitantly with drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d9.s0.p1	Azlocillin	drug	_	ciprofloxacin	drug	_	advise	druga should not be administered concomitantly with drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d9.s0.p2	Azlocillin	drug	_	gentamicin	drug	_	advise	druga should not be administered concomitantly with drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d9.s0.p3	Azlocillin	drug	_	netilmicin	drug	_	advise	druga should not be administered concomitantly with drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d9.s0.p4	Azlocillin	drug	_	tobramycin	drug	_	advise	druga should not be administered concomitantly with drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d523.s1.p0	baclofen	drug	_	morphine	drug	_	effect	interactions attributed to the combined use of druga injection and epidural drugb include hypotension and dyspnea .
DDI-DrugBank.d523.s2.p0	KEMSTRO	brand	_	baclofen	drug	_	false	side effects -lcb- druga -rcb- the most common adverse reaction during treatment with drugb is transient drowsiness -lcb- 10-63 % -rcb- .
DDI-DrugBank.d523.s16.p0	KEMSTROTM	brand	_	baclofen	drug	_	false	the adverse experience profile seen with druga was similar to that seen with drugb tablets .
DDI-DrugBank.d486.s0.p0	COLAZAL	brand	_	antibiotics	group	_	false	no drug interaction studies have been conducted for druga , however the use of orally administered drugb could , theoretically , interfere with the release of drugn in the colon .
DDI-DrugBank.d486.s0.p1	COLAZAL	brand	_	mesalamine	drug	_	false	no drug interaction studies have been conducted for druga , however the use of orally administered drugn could , theoretically , interfere with the release of drugb in the colon .
DDI-DrugBank.d486.s0.p2	antibiotics	group	_	mesalamine	drug	_	false	no drug interaction studies have been conducted for drugn , however the use of orally administered druga could , theoretically , interfere with the release of drugb in the colon .
DDI-DrugBank.d544.s0.p0	Simulect	brand	_	cyclosporine	drug	_	false	no dose adjustment is necessary when druga is added to triple-immunosuppression regimens including drugb , drugn , and either drugn or drugn .
DDI-DrugBank.d544.s0.p1	Simulect	brand	_	corticosteroids	group	_	false	no dose adjustment is necessary when druga is added to triple-immunosuppression regimens including drugn , drugb , and either drugn or drugn .
DDI-DrugBank.d544.s0.p2	Simulect	brand	_	azathioprine	drug	_	false	no dose adjustment is necessary when druga is added to triple-immunosuppression regimens including drugn , drugn , and either drugb or drugn .
DDI-DrugBank.d544.s0.p3	Simulect	brand	_	mycophenolate mofetil	drug	_	false	no dose adjustment is necessary when druga is added to triple-immunosuppression regimens including drugn , drugn , and either drugn or drugb .
DDI-DrugBank.d544.s0.p4	cyclosporine	drug	_	corticosteroids	group	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including druga , drugb , and either drugn or drugn .
DDI-DrugBank.d544.s0.p5	cyclosporine	drug	_	azathioprine	drug	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including druga , drugn , and either drugb or drugn .
DDI-DrugBank.d544.s0.p6	cyclosporine	drug	_	mycophenolate mofetil	drug	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including druga , drugn , and either drugn or drugb .
DDI-DrugBank.d544.s0.p7	corticosteroids	group	_	azathioprine	drug	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including drugn , druga , and either drugb or drugn .
DDI-DrugBank.d544.s0.p8	corticosteroids	group	_	mycophenolate mofetil	drug	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including drugn , druga , and either drugn or drugb .
DDI-DrugBank.d544.s0.p9	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	no dose adjustment is necessary when drugn is added to triple-immunosuppression regimens including drugn , drugn , and either druga or drugb .
DDI-DrugBank.d544.s3.p0	Simulect	brand	_	azathioprine	drug	_	mechanism	total body clearance of druga was reduced by an average 22 % and 51 % when drugb and drugn , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p1	Simulect	brand	_	mycophenolate mofetil	drug	_	mechanism	total body clearance of druga was reduced by an average 22 % and 51 % when drugn and drugb , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p2	Simulect	brand	_	cyclosporine	drug	_	false	total body clearance of druga was reduced by an average 22 % and 51 % when drugn and drugn , respectively , were added to a regimen consisting of drugb , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p3	Simulect	brand	_	corticosteroids	group	_	false	total body clearance of druga was reduced by an average 22 % and 51 % when drugn and drugn , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugb .
DDI-DrugBank.d544.s3.p4	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	total body clearance of drugn was reduced by an average 22 % and 51 % when druga and drugb , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p5	azathioprine	drug	_	cyclosporine	drug	_	false	total body clearance of drugn was reduced by an average 22 % and 51 % when druga and drugn , respectively , were added to a regimen consisting of drugb , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p6	azathioprine	drug	_	corticosteroids	group	_	false	total body clearance of drugn was reduced by an average 22 % and 51 % when druga and drugn , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugb .
DDI-DrugBank.d544.s3.p7	mycophenolate mofetil	drug	_	cyclosporine	drug	_	false	total body clearance of drugn was reduced by an average 22 % and 51 % when drugn and druga , respectively , were added to a regimen consisting of drugb , usp -lcb- modified -rcb- and drugn .
DDI-DrugBank.d544.s3.p8	mycophenolate mofetil	drug	_	corticosteroids	group	_	false	total body clearance of drugn was reduced by an average 22 % and 51 % when drugn and druga , respectively , were added to a regimen consisting of drugn , usp -lcb- modified -rcb- and drugb .
DDI-DrugBank.d544.s4.p0	Simulect	brand	_	azathioprine	drug	_	false	nonetheless , the range of individual druga clearance values in the presence of drugb -lcb- 12-57 ml/h -rcb- or drugn -lcb- 7-54 ml/h -rcb- did not extend outside the range observed with dual therapy -lcb- 10-78 ml/h -rcb- .
DDI-DrugBank.d544.s4.p1	Simulect	brand	_	mycophenolate mofetil	drug	_	false	nonetheless , the range of individual druga clearance values in the presence of drugn -lcb- 12-57 ml/h -rcb- or drugb -lcb- 7-54 ml/h -rcb- did not extend outside the range observed with dual therapy -lcb- 10-78 ml/h -rcb- .
DDI-DrugBank.d544.s4.p2	azathioprine	drug	_	mycophenolate mofetil	drug	_	false	nonetheless , the range of individual drugn clearance values in the presence of druga -lcb- 12-57 ml/h -rcb- or drugb -lcb- 7-54 ml/h -rcb- did not extend outside the range observed with dual therapy -lcb- 10-78 ml/h -rcb- .
DDI-DrugBank.d544.s5.p0	Simulect	brand	_	azathioprine	drug	_	false	the following medications have been administered in clinical trials with druga with no increase in adverse reactions : atg/alg , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d544.s5.p1	Simulect	brand	_	corticosteroids	group	_	false	the following medications have been administered in clinical trials with druga with no increase in adverse reactions : atg/alg , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d544.s5.p2	Simulect	brand	_	cyclosporine	drug	_	false	the following medications have been administered in clinical trials with druga with no increase in adverse reactions : atg/alg , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d544.s5.p3	Simulect	brand	_	mycophenolate mofetil	drug	_	false	the following medications have been administered in clinical trials with druga with no increase in adverse reactions : atg/alg , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d544.s5.p4	Simulect	brand	_	muromonab-CD3	drug	_	false	the following medications have been administered in clinical trials with druga with no increase in adverse reactions : atg/alg , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d524.s0.p1	Albuterol	drug	_	antidiabetic drugs	group	_	false	druga , drugn , drugb , drugn , drugn .
DDI-DrugBank.d524.s0.p3	Albuterol	drug	_	digitalis	group	_	false	druga , drugn , drugn , drugn , drugb .
DDI-DrugBank.d524.s0.p6	Antihistamines	group	_	digitalis	group	_	false	drugn , druga , drugn , drugn , drugb .
DDI-DrugBank.d524.s0.p8	antidiabetic drugs	group	_	digitalis	group	_	false	drugn , drugn , druga , drugn , drugb .
DDI-DrugBank.d561.s0.p1	Diuretics	group	_	Lotensin	brand	_	false	druga : patients on drugn , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb .
DDI-DrugBank.d561.s0.p2	diuretics	group	_	Lotensin	brand	_	effect	drugn : patients on druga , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb .
DDI-DrugBank.d561.s1.p0	Lotensin	brand	_	diuretic	group	_	false	the possibility of hypotensive effects with druga can be minimized by either discontinuing the drugb or increasing the salt intake prior to initiation of treatment with drugn .
DDI-DrugBank.d561.s1.p2	diuretic	group	_	Lotensin	brand	_	advise	the possibility of hypotensive effects with drugn can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb .
DDI-DrugBank.d561.s3.p1	Potassium	drug	_	thiazide diuretics	group	_	false	druga supplements and drugn benazepril can attenuate potassium loss caused by drugb .
DDI-DrugBank.d561.s3.p2	Potassium-Sparing Diuretics	group	_	thiazide diuretics	group	_	effect	drugn supplements and druga benazepril can attenuate potassium loss caused by drugb .
DDI-DrugBank.d561.s4.p6	spironolactone	drug	_	potassium	drug	_	false	drugn -lcb- druga , drugn , drugn , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d561.s4.p8	amiloride	drug	_	potassium	drug	_	false	drugn -lcb- drugn , druga , drugn , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d561.s4.p9	triamterene	drug	_	potassium	drug	_	false	drugn -lcb- drugn , drugn , druga , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d561.s6.p0	Anticoagulants	group	_	warfarin	drug	_	false	oral druga interaction studies with drugb and drugn failed to identify any clinically important effects on the serum concentrations or clinical effects of these drugn .
DDI-DrugBank.d561.s6.p1	Anticoagulants	group	_	acenocoumarol	drug	_	false	oral druga interaction studies with drugn and drugb failed to identify any clinically important effects on the serum concentrations or clinical effects of these drugn .
DDI-DrugBank.d561.s6.p3	warfarin	drug	_	acenocoumarol	drug	_	false	oral drugn interaction studies with druga and drugb failed to identify any clinically important effects on the serum concentrations or clinical effects of these drugn .
DDI-DrugBank.d561.s6.p4	warfarin	drug	_	anticoagulants	group	_	false	oral drugn interaction studies with druga and drugn failed to identify any clinically important effects on the serum concentrations or clinical effects of these drugb .
DDI-DrugBank.d561.s6.p5	acenocoumarol	drug	_	anticoagulants	group	_	false	oral drugn interaction studies with drugn and druga failed to identify any clinically important effects on the serum concentrations or clinical effects of these drugb .
DDI-DrugBank.d561.s7.p2	Lithium	drug	_	ACE inhibitors	group	_	false	druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d561.s7.p5	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d561.s7.p7	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d561.s7.p9	ACE inhibitors	group	_	lithium	drug	_	mechanism	drugn : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving druga during therapy with drugb .
DDI-DrugBank.d561.s9.p0	diuretic	group	_	lithium	drug	_	effect	if a druga is also used , the risk of drugb toxicity may be increased .
DDI-DrugBank.d561.s10.p0	Lotensin	brand	_	hydrochlorothiazide	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d561.s10.p1	Lotensin	brand	_	chlorthalidone	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d561.s10.p2	Lotensin	brand	_	furosemide	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d561.s10.p3	Lotensin	brand	_	digoxin	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d561.s10.p4	Lotensin	brand	_	propranolol	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d561.s10.p5	Lotensin	brand	_	atenolol	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d561.s10.p6	Lotensin	brand	_	naproxen	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d561.s10.p7	Lotensin	brand	_	cimetidine	drug	_	false	other no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d561.s11.p0	Lotensin	brand	_	beta-adrenergic-blocking agents	group	_	false	druga has been used concomitantly with drugb , drugn , drugn , drugn , and drugn , without evidence of clinically important adverse interactions .
DDI-DrugBank.d561.s11.p1	Lotensin	brand	_	calcium-channel-blocking agents	group	_	false	druga has been used concomitantly with drugn , drugb , drugn , drugn , and drugn , without evidence of clinically important adverse interactions .
DDI-DrugBank.d561.s11.p2	Lotensin	brand	_	diuretics	group	_	false	druga has been used concomitantly with drugn , drugn , drugb , drugn , and drugn , without evidence of clinically important adverse interactions .
DDI-DrugBank.d561.s11.p3	Lotensin	brand	_	digoxin	drug	_	false	druga has been used concomitantly with drugn , drugn , drugn , drugb , and drugn , without evidence of clinically important adverse interactions .
DDI-DrugBank.d561.s11.p4	Lotensin	brand	_	hydralazine	drug	_	false	druga has been used concomitantly with drugn , drugn , drugn , drugn , and drugb , without evidence of clinically important adverse interactions .
DDI-DrugBank.d561.s12.p0	Benazepril	drug	_	ACE inhibitors	group	_	false	druga , like other drugb , has had less than additive effects with drugn , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d561.s12.p1	Benazepril	drug	_	beta-adrenergic blockers	group	_	effect	druga , like other drugn , has had less than additive effects with drugb , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d561.s12.p2	ACE inhibitors	group	_	beta-adrenergic blockers	group	_	effect	drugn , like other druga , has had less than additive effects with drugb , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
DDI-DrugBank.d304.s0.p0	cholestyramine	drug	_	colestipol	drug	_	false	may interact with the following : druga , drugb -lcb- use with drugn may prevent the drugn from working properly ;
DDI-DrugBank.d304.s0.p1	cholestyramine	drug	_	thiazide diuretics	group	_	effect	may interact with the following : druga , drugn -lcb- use with drugb may prevent the drugn from working properly ;
DDI-DrugBank.d304.s0.p2	cholestyramine	drug	_	diuretic	group	_	false	may interact with the following : druga , drugn -lcb- use with drugn may prevent the drugb from working properly ;
DDI-DrugBank.d304.s0.p3	colestipol	drug	_	thiazide diuretics	group	_	effect	may interact with the following : drugn , druga -lcb- use with drugb may prevent the drugn from working properly ;
DDI-DrugBank.d304.s0.p4	colestipol	drug	_	diuretic	group	_	false	may interact with the following : drugn , druga -lcb- use with drugn may prevent the drugb from working properly ;
DDI-DrugBank.d537.s0.p0	Bentiromide	drug	_	acetaminophen	drug	_	int	druga may interact with drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p1	Bentiromide	drug	_	Tylenol	brand	_	int	druga may interact with drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p2	Bentiromide	drug	_	chloramphenicol	drug	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p3	Bentiromide	drug	_	Chloromycetin	brand	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p4	Bentiromide	drug	_	anesthetics	group	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugb -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p5	Bentiromide	drug	_	benzocaine	drug	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugb and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p6	Bentiromide	drug	_	lidocaine	drug	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugb -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p7	Bentiromide	drug	_	para-aminobenzoic acid	drug_n	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p8	Bentiromide	drug	_	PABA	drug_n	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p9	Bentiromide	drug	_	multivitamins	group	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p10	Bentiromide	drug	_	procainamide	drug	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p11	Bentiromide	drug	_	Pronestyl	brand	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p12	Bentiromide	drug	_	sulfonamides	group	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p13	Bentiromide	drug	_	thiazide diuretics	group	_	int	druga may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p20	acetaminophen	drug	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p21	acetaminophen	drug	_	PABA	drug_n	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p22	acetaminophen	drug	_	multivitamins	group	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p23	acetaminophen	drug	_	procainamide	drug	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p24	acetaminophen	drug	_	Pronestyl	brand	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p25	acetaminophen	drug	_	sulfonamides	group	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p26	acetaminophen	drug	_	thiazide diuretics	group	_	false	drugn may interact with druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p32	Tylenol	brand	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p33	Tylenol	brand	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p34	Tylenol	brand	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p35	Tylenol	brand	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p36	Tylenol	brand	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p37	Tylenol	brand	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p38	Tylenol	brand	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p43	chloramphenicol	drug	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p44	chloramphenicol	drug	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p45	chloramphenicol	drug	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p46	chloramphenicol	drug	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p47	chloramphenicol	drug	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p48	chloramphenicol	drug	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p49	chloramphenicol	drug	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p53	Chloromycetin	brand	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p54	Chloromycetin	brand	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p55	Chloromycetin	brand	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p56	Chloromycetin	brand	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p57	Chloromycetin	brand	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p58	Chloromycetin	brand	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p59	Chloromycetin	brand	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p62	anesthetics	group	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p63	anesthetics	group	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p64	anesthetics	group	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p65	anesthetics	group	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p66	anesthetics	group	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p67	anesthetics	group	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p68	anesthetics	group	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local druga -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p70	benzocaine	drug	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p71	benzocaine	drug	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p72	benzocaine	drug	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p73	benzocaine	drug	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p74	benzocaine	drug	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p75	benzocaine	drug	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p76	benzocaine	drug	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , druga and drugn -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p77	lidocaine	drug	_	para-aminobenzoic acid	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugb -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p78	lidocaine	drug	_	PABA	drug_n	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugb -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p79	lidocaine	drug	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p80	lidocaine	drug	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p81	lidocaine	drug	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p82	lidocaine	drug	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p83	lidocaine	drug	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and druga -rcb- , drugn -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p85	para-aminobenzoic acid	drug_n	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , druga -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p86	para-aminobenzoic acid	drug_n	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , druga -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p87	para-aminobenzoic acid	drug_n	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , druga -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p88	para-aminobenzoic acid	drug_n	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , druga -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p89	para-aminobenzoic acid	drug_n	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , druga -lcb- drugn -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p90	PABA	drug_n	_	multivitamins	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- druga -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p91	PABA	drug_n	_	procainamide	drug	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- druga -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p92	PABA	drug_n	_	Pronestyl	brand	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- druga -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p93	PABA	drug_n	_	sulfonamides	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- druga -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- sulfa medicines -rcb- , drugn -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d537.s0.p94	PABA	drug_n	_	thiazide diuretics	group	_	false	drugn may interact with drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , local drugn -lcb- e , g , , drugn and drugn -rcb- , drugn -lcb- druga -rcb- - containing preparations -lcb- e , g , , sunscreens and some drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- sulfa medicines -rcb- , drugb -lcb- use of these medicines during the test period will affect the test results -rcb- , and pancreatic supplements -lcb- use of pancreatic supplements may give false test results -rcb- .
DDI-DrugBank.d477.s0.p0	sympathomimetic amines	group	_	monoamine oxidase inhibitors	group	_	effect	hypertensive crises have resulted when druga have been used concomitantly within14 days following use of drugb .
DDI-DrugBank.d477.s1.p0	DIDREX	brand	_	CNS stimulants	group	_	advise	druga should not be used concomitantly with other drugb .
DDI-DrugBank.d477.s2.p0	Amphetamines	group	_	antihypertensives	group	_	effect	druga may decrease the hypotensive effect of drugb .
DDI-DrugBank.d477.s3.p0	Amphetamines	group	_	tricyclic antidepressants	group	_	effect	druga may enhance the effects of drugb .
DDI-DrugBank.d477.s5.p0	Urinary acidifying	drug	_	amphetamines	group	_	mechanism	druga agents decrease blood levels and increase excretion of drugb .
DDI-DrugBank.d208.s0.p0	Benzthiazide	drug	_	alcohol	drug	_	int	druga may interact with drugb , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p1	Benzthiazide	drug	_	blood thinner	group	_	int	druga may interact with drugn , drugb s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p2	Benzthiazide	drug	_	decongestant drugs	group	_	int	druga may interact with drugn , drugn s , drugb -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p3	Benzthiazide	drug	_	lithium	drug	_	int	druga may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugb , drugn , drugn like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p4	Benzthiazide	drug	_	norepinephrine	drug	_	int	druga may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugb , drugn like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p5	Benzthiazide	drug	_	NSAIDs	group	_	int	druga may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugb like drugn or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p6	Benzthiazide	drug	_	Aleve	brand	_	int	druga may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p7	Benzthiazide	drug	_	Ibuprofen	drug	_	int	druga may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p13	alcohol	drug	_	Aleve	brand	_	false	drugn may interact with druga , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p14	alcohol	drug	_	Ibuprofen	drug	_	false	drugn may interact with druga , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p19	blood thinner	group	_	Aleve	brand	_	false	drugn may interact with drugn , druga s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p20	blood thinner	group	_	Ibuprofen	drug	_	false	drugn may interact with drugn , druga s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p24	decongestant drugs	group	_	Aleve	brand	_	false	drugn may interact with drugn , drugn s , druga -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p25	decongestant drugs	group	_	Ibuprofen	drug	_	false	drugn may interact with drugn , drugn s , druga -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p28	lithium	drug	_	Aleve	brand	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , druga , drugn , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p29	lithium	drug	_	Ibuprofen	drug	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , druga , drugn , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p31	norepinephrine	drug	_	Aleve	brand	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , druga , drugn like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p32	norepinephrine	drug	_	Ibuprofen	drug	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , druga , drugn like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p33	NSAIDs	group	_	Aleve	brand	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , druga like drugb or drugn , and high blood pressure medications .
DDI-DrugBank.d208.s0.p34	NSAIDs	group	_	Ibuprofen	drug	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , druga like drugn or drugb , and high blood pressure medications .
DDI-DrugBank.d208.s0.p35	Aleve	brand	_	Ibuprofen	drug	_	false	drugn may interact with drugn , drugn s , drugn -lcb- allergy , cold , and sinus medicines -rcb- , diabetic drugs , drugn , drugn , drugn like druga or drugb , and high blood pressure medications .
DDI-DrugBank.d390.s0.p0	Antipsychotic drugs	group	_	phenothiazines	group	_	false	druga such as drugb or drugn ;
DDI-DrugBank.d390.s0.p1	Antipsychotic drugs	group	_	haloperidol	drug	_	false	druga such as drugn or drugb ;
DDI-DrugBank.d390.s0.p2	phenothiazines	group	_	haloperidol	drug	_	false	drugn such as druga or drugb ;
DDI-DrugBank.d137.s0.p2	Bepridil	drug	_	nitrates	group	_	false	drugn : the concomitant use of druga with long - and short-acting drugb has been safely tolerated in patients with stable angina pectoris .
DDI-DrugBank.d137.s1.p0	nitroglycerin	drug	_	Bepridil	drug	_	false	sublingual druga may be taken if necessary for the control of acute angina attacks during drugb therapy .
DDI-DrugBank.d137.s2.p2	Bepridil	drug	_	beta-blocking agents	group	_	false	drugn : the concomitant use of druga and drugb has been well tolerated in patients with stable angina .
DDI-DrugBank.d137.s4.p2	bepridil hydrochloride	drug	_	digoxin	drug	_	mechanism	drugn : in controlled studies in healthy volunteers , druga either had no effect -lcb- one study -rcb- or was associated with modest increases , about 30 % -lcb- two studies -rcb- in steady-state serum drugb concentrations .
DDI-DrugBank.d137.s5.p0	bepridil hydrochloride	drug	_	digoxin	drug	_	false	limited clinical data in angina patients receiving concomitant druga and drugb therapy indicate no discernible changes in serum digoxin levels .
DDI-DrugBank.d137.s7.p3	Bepridil	drug	_	insulin	drug	_	false	oral drugn : druga has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for drugb or oral drugn .
DDI-DrugBank.d137.s7.p4	Bepridil	drug	_	hypoglycemic agents	group	_	false	oral drugn : druga has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for drugn or oral drugb .
DDI-DrugBank.d137.s7.p5	insulin	drug	_	hypoglycemic agents	group	_	false	oral drugn : drugn has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for druga or oral drugb .
DDI-DrugBank.d137.s9.p0	bepridil hydrochloride	drug	_	anti-arrhythmic agents	group	_	false	in general , these are drugs that have one or more pharmacologic activities similar to druga , including drugb such as drugn and drugn , drugn and drugn .
DDI-DrugBank.d137.s9.p1	bepridil hydrochloride	drug	_	quinidine	drug	_	false	in general , these are drugs that have one or more pharmacologic activities similar to druga , including drugn such as drugb and drugn , drugn and drugn .
DDI-DrugBank.d137.s9.p2	bepridil hydrochloride	drug	_	procainamide	drug	_	false	in general , these are drugs that have one or more pharmacologic activities similar to druga , including drugn such as drugn and drugb , drugn and drugn .
DDI-DrugBank.d137.s9.p3	bepridil hydrochloride	drug	_	cardiac glycosides	group	_	false	in general , these are drugs that have one or more pharmacologic activities similar to druga , including drugn such as drugn and drugn , drugb and drugn .
DDI-DrugBank.d137.s9.p4	bepridil hydrochloride	drug	_	tricyclic anti-depressants	group	_	false	in general , these are drugs that have one or more pharmacologic activities similar to druga , including drugn such as drugn and drugn , drugn and drugb .
DDI-DrugBank.d137.s9.p5	anti-arrhythmic agents	group	_	quinidine	drug	_	false	in general , these are drugs that have one or more pharmacologic activities similar to drugn , including druga such as drugb and drugn , drugn and drugn .
DDI-DrugBank.d137.s9.p6	anti-arrhythmic agents	group	_	procainamide	drug	_	false	in general , these are drugs that have one or more pharmacologic activities similar to drugn , including druga such as drugn and drugb , drugn and drugn .
DDI-DrugBank.d137.s9.p7	anti-arrhythmic agents	group	_	cardiac glycosides	group	_	false	in general , these are drugs that have one or more pharmacologic activities similar to drugn , including druga such as drugn and drugn , drugb and drugn .
DDI-DrugBank.d137.s9.p8	anti-arrhythmic agents	group	_	tricyclic anti-depressants	group	_	false	in general , these are drugs that have one or more pharmacologic activities similar to drugn , including druga such as drugn and drugn , drugn and drugb .
DDI-DrugBank.d137.s10.p0	Anti-arrhythmics	group	_	tricyclic anti-depressants	group	_	false	druga and drugb could exaggerate the prolongation of the qt interval observed with drugn .
DDI-DrugBank.d137.s10.p1	Anti-arrhythmics	group	_	bepridil hydrochloride	drug	_	effect	druga and drugn could exaggerate the prolongation of the qt interval observed with drugb .
DDI-DrugBank.d137.s10.p2	tricyclic anti-depressants	group	_	bepridil hydrochloride	drug	_	effect	drugn and druga could exaggerate the prolongation of the qt interval observed with drugb .
DDI-DrugBank.d137.s11.p0	Cardiac glycosides	group	_	bepridil hydrochloride	drug	_	effect	druga could exaggerate the depression of av nodal conduction observed with drugb .
DDI-DrugBank.d489.s0.p0	Kerlone	brand	_	cimetidine	drug	_	false	the following drugs have been coadministered with druga and have not altered its pharmacokinetics : drugb , drugn , drugn , and drugn .
DDI-DrugBank.d489.s0.p1	Kerlone	brand	_	nifedipine	drug	_	false	the following drugs have been coadministered with druga and have not altered its pharmacokinetics : drugn , drugb , drugn , and drugn .
DDI-DrugBank.d489.s0.p2	Kerlone	brand	_	chlorthalidone	drug	_	false	the following drugs have been coadministered with druga and have not altered its pharmacokinetics : drugn , drugn , drugb , and drugn .
DDI-DrugBank.d489.s0.p3	Kerlone	brand	_	hydrochlorothiazide	drug	_	false	the following drugs have been coadministered with druga and have not altered its pharmacokinetics : drugn , drugn , drugn , and drugb .
DDI-DrugBank.d489.s1.p0	Kerlone	brand	_	anticoagulant	group	_	false	concomitant administration of druga with the oral drugb drugn has been shown not to potentiate the anticoagulant effect of drugn .
DDI-DrugBank.d489.s1.p1	Kerlone	brand	_	warfarin	drug	_	false	concomitant administration of druga with the oral drugn drugb has been shown not to potentiate the anticoagulant effect of drugn .
DDI-DrugBank.d489.s1.p2	Kerlone	brand	_	warfarin	drug	_	false	concomitant administration of druga with the oral drugn drugn has been shown not to potentiate the anticoagulant effect of drugb .
DDI-DrugBank.d489.s1.p3	anticoagulant	group	_	warfarin	drug	_	false	concomitant administration of drugn with the oral druga drugb has been shown not to potentiate the anticoagulant effect of drugn .
DDI-DrugBank.d489.s1.p4	anticoagulant	group	_	warfarin	drug	_	false	concomitant administration of drugn with the oral druga drugn has been shown not to potentiate the anticoagulant effect of drugb .
DDI-DrugBank.d489.s2.p0	reserpine	drug	_	beta-blocking	drug	_	effect	catecholamine-depleting drugs -lcb- e , g , , druga -rcb- may have an additive effect when given with drugb agents .
DDI-DrugBank.d489.s4.p0	beta-blockers	group	_	clonidine	drug	_	advise	should it be decided to discontinue therapy in patients receiving druga and drugb concurrently , the drugn should be discontinued slowly over several days before the gradual withdrawal of drugn .
DDI-DrugBank.d489.s4.p2	beta-blockers	group	_	clonidine	drug	_	false	should it be decided to discontinue therapy in patients receiving druga and drugn concurrently , the drugn should be discontinued slowly over several days before the gradual withdrawal of drugb .
DDI-DrugBank.d489.s4.p3	clonidine	drug	_	beta-blocker	group	_	false	should it be decided to discontinue therapy in patients receiving drugn and druga concurrently , the drugb should be discontinued slowly over several days before the gradual withdrawal of drugn .
DDI-DrugBank.d489.s4.p5	beta-blocker	group	_	clonidine	drug	_	advise	should it be decided to discontinue therapy in patients receiving drugn and drugn concurrently , the druga should be discontinued slowly over several days before the gradual withdrawal of drugb .
DDI-DrugBank.d489.s5.p0	calcium antagonists	group	_	beta-adrenergic blocking agents	group	_	advise	literature reports suggest that oral druga may be used in combination with drugb when heart function is normal , but should be avoided in patients with impaired cardiac function .
DDI-DrugBank.d489.s6.p0	beta-adrenergic blocking agents	group	_	calcium antagonist	group	_	effect	hypotension , av conduction disturbances , and left ventricular failure have been reported in some patients receiving druga when an oral drugb was added to the treatment regimen .
DDI-DrugBank.d489.s7.p0	calcium antagonist	group	_	dihydropyridine derivative	group	_	false	hypotension was more likely to occur if the druga were a drugb , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugn .
DDI-DrugBank.d489.s7.p1	calcium antagonist	group	_	nifedipine	drug	_	false	hypotension was more likely to occur if the druga were a drugn , e , g , , drugb , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugn .
DDI-DrugBank.d489.s7.p2	calcium antagonist	group	_	verapamil	drug	_	false	hypotension was more likely to occur if the druga were a drugn , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugb or drugn .
DDI-DrugBank.d489.s7.p3	calcium antagonist	group	_	diltiazem	drug	_	false	hypotension was more likely to occur if the druga were a drugn , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugb .
DDI-DrugBank.d489.s7.p4	dihydropyridine derivative	group	_	nifedipine	drug	_	false	hypotension was more likely to occur if the drugn were a druga , e , g , , drugb , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugn .
DDI-DrugBank.d489.s7.p5	dihydropyridine derivative	group	_	verapamil	drug	_	false	hypotension was more likely to occur if the drugn were a druga , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugb or drugn .
DDI-DrugBank.d489.s7.p6	dihydropyridine derivative	group	_	diltiazem	drug	_	false	hypotension was more likely to occur if the drugn were a druga , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugb .
DDI-DrugBank.d489.s7.p7	nifedipine	drug	_	verapamil	drug	_	false	hypotension was more likely to occur if the drugn were a drugn , e , g , , druga , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugb or drugn .
DDI-DrugBank.d489.s7.p8	nifedipine	drug	_	diltiazem	drug	_	false	hypotension was more likely to occur if the drugn were a drugn , e , g , , druga , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either drugn or drugb .
DDI-DrugBank.d489.s7.p9	verapamil	drug	_	diltiazem	drug	_	false	hypotension was more likely to occur if the drugn were a drugn , e , g , , drugn , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either druga or drugb .
DDI-DrugBank.d489.s8.p0	beta-blockers	group	_	epinephrine	drug	_	effect	risk of anaphylactic reaction : although it is known that patients on druga may be refractory to drugb in the treatment of anaphylactic shock , drugn can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks .
DDI-DrugBank.d489.s8.p2	epinephrine	drug	_	beta-blockers	group	_	false	risk of anaphylactic reaction : although it is known that patients on drugn may be refractory to druga in the treatment of anaphylactic shock , drugb can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks .
DDI-DrugBank.d312.s1.p2	irinotecan	drug	_	AVASTIN	brand	_	false	in study 1 , patients with colorectal cancer were given druga / drugn / drugn -lcb- bolus-ifl -rcb- with or without drugb .
DDI-DrugBank.d312.s1.p4	5-FU	drug	_	AVASTIN	brand	_	false	in study 1 , patients with colorectal cancer were given drugn / druga / drugn -lcb- bolus-ifl -rcb- with or without drugb .
DDI-DrugBank.d312.s1.p5	leucovorin	drug	_	AVASTIN	brand	_	false	in study 1 , patients with colorectal cancer were given drugn / drugn / druga -lcb- bolus-ifl -rcb- with or without drugb .
DDI-DrugBank.d312.s2.p0	Irinotecan	drug	_	AVASTIN	brand	_	false	druga concentrations were similar in patients receiving bolus-ifl alone and in combination with drugb .
DDI-DrugBank.d312.s3.p0	SN38	drug_n	_	irinotecan	drug	_	false	the concentrations of druga , the active metabolite of drugb , were on average 33 % higher in patients receiving bolus-ifl in combination with drugn when compared with bolus-ifl alone .
DDI-DrugBank.d312.s3.p1	SN38	drug_n	_	AVASTIN	brand	_	false	the concentrations of druga , the active metabolite of drugn , were on average 33 % higher in patients receiving bolus-ifl in combination with drugb when compared with bolus-ifl alone .
DDI-DrugBank.d312.s3.p2	irinotecan	drug	_	AVASTIN	brand	_	false	the concentrations of drugn , the active metabolite of druga , were on average 33 % higher in patients receiving bolus-ifl in combination with drugb when compared with bolus-ifl alone .
DDI-DrugBank.d312.s5.p0	SN38	drug_n	_	irinotecan	drug	_	false	due to high inter-patient variability and limited sampling , the extent of the increase in druga levels in patients receiving concurrent drugb and drugn is uncertain .
DDI-DrugBank.d312.s5.p1	SN38	drug_n	_	AVASTIN	brand	_	false	due to high inter-patient variability and limited sampling , the extent of the increase in druga levels in patients receiving concurrent drugn and drugb is uncertain .
DDI-DrugBank.d312.s5.p2	irinotecan	drug	_	AVASTIN	brand	_	false	due to high inter-patient variability and limited sampling , the extent of the increase in drugn levels in patients receiving concurrent druga and drugb is uncertain .
DDI-DrugBank.d467.s2.p0	bexarotene	drug	_	ketoconazole	drug	_	false	on the basis of the metabolism of druga by cytochrome p450 3a4 , drugb , drugn , drugn , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugn concentrations .
DDI-DrugBank.d467.s2.p1	bexarotene	drug	_	itraconazole	drug	_	false	on the basis of the metabolism of druga by cytochrome p450 3a4 , drugn , drugb , drugn , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugn concentrations .
DDI-DrugBank.d467.s2.p2	bexarotene	drug	_	erythromycin	drug	_	false	on the basis of the metabolism of druga by cytochrome p450 3a4 , drugn , drugn , drugb , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugn concentrations .
DDI-DrugBank.d467.s2.p3	bexarotene	drug	_	gemfibrozil	drug	_	false	on the basis of the metabolism of druga by cytochrome p450 3a4 , drugn , drugn , drugn , drugb , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugn concentrations .
DDI-DrugBank.d467.s2.p8	ketoconazole	drug	_	bexarotene	drug	_	mechanism	on the basis of the metabolism of drugn by cytochrome p450 3a4 , druga , drugn , drugn , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugb concentrations .
DDI-DrugBank.d467.s2.p11	itraconazole	drug	_	bexarotene	drug	_	mechanism	on the basis of the metabolism of drugn by cytochrome p450 3a4 , drugn , druga , drugn , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugb concentrations .
DDI-DrugBank.d467.s2.p13	erythromycin	drug	_	bexarotene	drug	_	mechanism	on the basis of the metabolism of drugn by cytochrome p450 3a4 , drugn , drugn , druga , drugn , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugb concentrations .
DDI-DrugBank.d467.s2.p14	gemfibrozil	drug	_	bexarotene	drug	_	mechanism	on the basis of the metabolism of drugn by cytochrome p450 3a4 , drugn , drugn , drugn , druga , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma drugb concentrations .
DDI-DrugBank.d467.s3.p2	rifampin	drug	_	bexarotene	drug	_	mechanism	furthermore , druga , drugn , drugn , and other inducers of cyp3a4 may cause a reduction in plasma drugb concentrations .
DDI-DrugBank.d467.s3.p4	phenytoin	drug	_	bexarotene	drug	_	mechanism	furthermore , drugn , druga , drugn , and other inducers of cyp3a4 may cause a reduction in plasma drugb concentrations .
DDI-DrugBank.d467.s3.p5	phenobarbital	drug	_	bexarotene	drug	_	mechanism	furthermore , drugn , drugn , druga , and other inducers of cyp3a4 may cause a reduction in plasma drugb concentrations .
DDI-DrugBank.d467.s4.p0	Targretin	brand	_	gemfibrozil	drug	_	mechanism	concomitant administration of druga capsules and drugb resulted in substantial increases in plasma concentrations of drugn , probably at least partially related to cyp3a4 inhibition by drugn .
DDI-DrugBank.d467.s4.p1	Targretin	brand	_	bexarotene	drug	_	false	concomitant administration of druga capsules and drugn resulted in substantial increases in plasma concentrations of drugb , probably at least partially related to cyp3a4 inhibition by drugn .
DDI-DrugBank.d467.s4.p2	Targretin	brand	_	gemfibrozil	drug	_	false	concomitant administration of druga capsules and drugn resulted in substantial increases in plasma concentrations of drugn , probably at least partially related to cyp3a4 inhibition by drugb .
DDI-DrugBank.d467.s4.p3	gemfibrozil	drug	_	bexarotene	drug	_	false	concomitant administration of drugn capsules and druga resulted in substantial increases in plasma concentrations of drugb , probably at least partially related to cyp3a4 inhibition by drugn .
DDI-DrugBank.d467.s4.p5	bexarotene	drug	_	gemfibrozil	drug	_	false	concomitant administration of drugn capsules and drugn resulted in substantial increases in plasma concentrations of druga , probably at least partially related to cyp3a4 inhibition by drugb .
DDI-DrugBank.d467.s5.p0	bexarotene	drug	_	atorvastatin	drug	_	false	under similar conditions , druga concentrations were not affected by concomitant drugb administration .
DDI-DrugBank.d467.s6.p0	gemfibrozil	drug	_	Targretin	brand	_	advise	concomitant administration of druga with drugb capsules is not recommended .
DDI-DrugBank.d291.s0.p3	Bezalip	brand	_	anticoagulants of the coumarin type	group	_	false	when druga or drugn is used at the same time as other medicines or substances the following interactions must be taken into account : - drugn and drugn may enhance the action of drugb .
DDI-DrugBank.d291.s0.p6	Bezalip retard	brand	_	anticoagulants of the coumarin type	group	_	false	when drugn or druga is used at the same time as other medicines or substances the following interactions must be taken into account : - drugn and drugn may enhance the action of drugb .
DDI-DrugBank.d291.s0.p8	Bezalip	brand	_	anticoagulants of the coumarin type	group	_	effect	when drugn or drugn is used at the same time as other medicines or substances the following interactions must be taken into account : - druga and drugn may enhance the action of drugb .
DDI-DrugBank.d291.s0.p9	Bezalip retard	brand	_	anticoagulants of the coumarin type	group	_	effect	when drugn or drugn is used at the same time as other medicines or substances the following interactions must be taken into account : - drugn and druga may enhance the action of drugb .
DDI-DrugBank.d291.s1.p0	anticoagulant	drug	_	Bezalip	brand	_	advise	for this reason , the dose of the druga should be reduced by # - 50 % at the start of treatment with drugb or drugn retard and then titrated according to the blood clotting parameters
DDI-DrugBank.d291.s1.p1	anticoagulant	drug	_	Bezalip	brand	_	advise	for this reason , the dose of the druga should be reduced by # - 50 % at the start of treatment with drugn or drugb retard and then titrated according to the blood clotting parameters
DDI-DrugBank.d291.s3.p0	sulphonylureas	group	_	insulin	drug	_	false	- the action of druga and drugb may be enhanced by drugn or drugn .
DDI-DrugBank.d291.s3.p1	sulphonylureas	group	_	Bezalip	brand	_	effect	- the action of druga and drugn may be enhanced by drugb or drugn .
DDI-DrugBank.d291.s3.p2	sulphonylureas	group	_	Bezalip retard	brand	_	effect	- the action of druga and drugn may be enhanced by drugn or drugb .
DDI-DrugBank.d291.s3.p3	insulin	drug	_	Bezalip	brand	_	effect	- the action of drugn and druga may be enhanced by drugb or drugn .
DDI-DrugBank.d291.s3.p4	insulin	drug	_	Bezalip retard	brand	_	effect	- the action of drugn and druga may be enhanced by drugn or drugb .
DDI-DrugBank.d291.s6.p0	immuno-suppressant	group	_	bezafibrate	drug	_	effect	- in isolated cases , a pronounced though reversible , impairment of renal function -lcb- accompanied by a corresponding increase in the serum creatinine level -rcb- has been reported in organ transplant patients receiving druga therapy and concomitant drugb .
DDI-DrugBank.d291.s9.p1	Bezalip	brand	_	anion-exchange resins	group	_	advise	- when druga or drugn is used concurrently with drugb -lcb- e , g , drugn -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugn is impaired
DDI-DrugBank.d291.s9.p2	Bezalip	brand	_	cholestryramine	drug	_	advise	- when druga or drugn is used concurrently with drugn -lcb- e , g , drugb -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugn is impaired
DDI-DrugBank.d291.s9.p5	Bezalip retard	brand	_	anion-exchange resins	group	_	advise	- when drugn or druga is used concurrently with drugb -lcb- e , g , drugn -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugn is impaired
DDI-DrugBank.d291.s9.p6	Bezalip retard	brand	_	cholestryramine	drug	_	advise	- when drugn or druga is used concurrently with drugn -lcb- e , g , drugb -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugn is impaired
DDI-DrugBank.d291.s9.p10	anion-exchange resins	group	_	Bezalip	brand	_	false	- when drugn or drugn is used concurrently with druga -lcb- e , g , drugn -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugb or drugn is impaired
DDI-DrugBank.d291.s9.p11	anion-exchange resins	group	_	Bezalip retard	brand	_	false	- when drugn or drugn is used concurrently with druga -lcb- e , g , drugn -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugb is impaired
DDI-DrugBank.d291.s9.p12	cholestryramine	drug	_	Bezalip	brand	_	false	- when drugn or drugn is used concurrently with drugn -lcb- e , g , druga -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugb or drugn is impaired
DDI-DrugBank.d291.s9.p13	cholestryramine	drug	_	Bezalip retard	brand	_	false	- when drugn or drugn is used concurrently with drugn -lcb- e , g , druga -rcb- , an interval of at least # hours should be maintained between the two medicines , since the absorption of drugn or drugb is impaired
DDI-DrugBank.d291.s11.p0	Perhexiline hydrogen maleate	drug	_	MAO-inhibitors	group	_	false	- druga or drugb -lcb- with hepatotoxic potential -rcb- must not be administered together with drugn or drugn .
DDI-DrugBank.d291.s11.p1	Perhexiline hydrogen maleate	drug	_	Bezalip	brand	_	advise	- druga or drugn -lcb- with hepatotoxic potential -rcb- must not be administered together with drugb or drugn .
DDI-DrugBank.d291.s11.p2	Perhexiline hydrogen maleate	drug	_	Bezalip retard	brand	_	advise	- druga or drugn -lcb- with hepatotoxic potential -rcb- must not be administered together with drugn or drugb .
DDI-DrugBank.d291.s11.p3	MAO-inhibitors	group	_	Bezalip	brand	_	advise	- drugn or druga -lcb- with hepatotoxic potential -rcb- must not be administered together with drugb or drugn .
DDI-DrugBank.d291.s11.p4	MAO-inhibitors	group	_	Bezalip retard	brand	_	advise	- drugn or druga -lcb- with hepatotoxic potential -rcb- must not be administered together with drugn or drugb .
DDI-DrugBank.d266.s0.p0	CASODEX	brand	_	coumarin anticoagulant	group	_	mechanism	in vitro studies have shown druga can displace drugb s , such as drugn , from their protein-binding sites .
DDI-DrugBank.d266.s0.p1	CASODEX	brand	_	warfarin	drug	_	mechanism	in vitro studies have shown druga can displace drugn s , such as drugb , from their protein-binding sites .
DDI-DrugBank.d266.s0.p2	coumarin anticoagulant	group	_	warfarin	drug	_	false	in vitro studies have shown drugn can displace druga s , such as drugb , from their protein-binding sites .
DDI-DrugBank.d266.s1.p0	CASODEX	brand	_	coumarin anticoagulants	group	_	advise	it is recommended that if druga is started in patients already receiving drugb , prothrombin times should be closely monitored and adjustment of the drugn dose may be necessary .
DDI-DrugBank.d266.s1.p1	CASODEX	brand	_	anticoagulant	group	_	advise	it is recommended that if druga is started in patients already receiving drugn , prothrombin times should be closely monitored and adjustment of the drugb dose may be necessary .
DDI-DrugBank.d401.s0.p0	anticholinergic	group	_	AKINETON	brand	_	false	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugb are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p1	anticholinergic	group	_	narcotic analgesics	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugb such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p2	anticholinergic	group	_	meperidine	drug	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugb , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p3	anticholinergic	group	_	phenothiazines	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugb and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p4	anticholinergic	group	_	antipsychotics	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugb , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p5	anticholinergic	group	_	tricyclic antidepressants	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p6	anticholinergic	group	_	antiarrhythmics	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p7	anticholinergic	group	_	quinidine	drug	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p8	anticholinergic	group	_	antihistamines	group	_	effect	drug interactions : the central druga syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p9	AKINETON	brand	_	narcotic analgesics	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugb such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p10	AKINETON	brand	_	meperidine	drug	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugb , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p11	AKINETON	brand	_	phenothiazines	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugb and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p12	AKINETON	brand	_	antipsychotics	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugb , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p13	AKINETON	brand	_	tricyclic antidepressants	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p14	AKINETON	brand	_	antiarrhythmics	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p15	AKINETON	brand	_	quinidine	drug	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p16	AKINETON	brand	_	antihistamines	group	_	effect	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as druga are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p17	narcotic analgesics	group	_	meperidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugb , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p18	narcotic analgesics	group	_	phenothiazines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugb and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p19	narcotic analgesics	group	_	antipsychotics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugn and other drugb , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p20	narcotic analgesics	group	_	tricyclic antidepressants	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugn and other drugn , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p21	narcotic analgesics	group	_	antiarrhythmics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugn and other drugn , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p22	narcotic analgesics	group	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p23	narcotic analgesics	group	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain druga such as drugn , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p24	meperidine	drug	_	phenothiazines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugb and other drugn , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p25	meperidine	drug	_	antipsychotics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugn and other drugb , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p26	meperidine	drug	_	tricyclic antidepressants	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugn and other drugn , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p27	meperidine	drug	_	antiarrhythmics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugn and other drugn , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p28	meperidine	drug	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugn and other drugn , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p29	meperidine	drug	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as druga , the drugn and other drugn , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p30	phenothiazines	group	_	antipsychotics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the druga and other drugb , drugn , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p31	phenothiazines	group	_	tricyclic antidepressants	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the druga and other drugn , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p32	phenothiazines	group	_	antiarrhythmics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the druga and other drugn , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p33	phenothiazines	group	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the druga and other drugn , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p34	phenothiazines	group	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the druga and other drugn , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p35	antipsychotics	group	_	tricyclic antidepressants	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other druga , drugb , certain drugn such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p36	antipsychotics	group	_	antiarrhythmics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other druga , drugn , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p37	antipsychotics	group	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other druga , drugn , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p38	antipsychotics	group	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other druga , drugn , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p39	tricyclic antidepressants	group	_	antiarrhythmics	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , druga , certain drugb such as the drugn salts , and drugn .
DDI-DrugBank.d401.s0.p40	tricyclic antidepressants	group	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , druga , certain drugn such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p41	tricyclic antidepressants	group	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , druga , certain drugn such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p42	antiarrhythmics	group	_	quinidine	drug	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain druga such as the drugb salts , and drugn .
DDI-DrugBank.d401.s0.p43	antiarrhythmics	group	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain druga such as the drugn salts , and drugb .
DDI-DrugBank.d401.s0.p44	quinidine	drug	_	antihistamines	group	_	false	drug interactions : the central drugn syndrome can occur when anticholinergic agents such as drugn are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain drugn such as drugn , the drugn and other drugn , drugn , certain drugn such as the druga salts , and drugb .
DDI-DrugBank.d476.s0.p0	ZEBETA	brand	_	beta-blocking agents	group	_	advise	druga should not be combined with other drugb .
DDI-DrugBank.d476.s1.p0	reserpine	drug	_	guanethidine	drug	_	false	patients receiving catecholamine-depleting drugs , such as druga or drugb , should be closely monitored , because the added beta-adrenergic blocking action of drugn may produce excessive reduction of sympathetic activity .
DDI-DrugBank.d476.s1.p1	reserpine	drug	_	ZEBETA	brand	_	effect	patients receiving catecholamine-depleting drugs , such as druga or drugn , should be closely monitored , because the added beta-adrenergic blocking action of drugb may produce excessive reduction of sympathetic activity .
DDI-DrugBank.d476.s1.p2	guanethidine	drug	_	ZEBETA	brand	_	effect	patients receiving catecholamine-depleting drugs , such as drugn or druga , should be closely monitored , because the added beta-adrenergic blocking action of drugb may produce excessive reduction of sympathetic activity .
DDI-DrugBank.d476.s2.p0	clonidine	drug	_	ZEBETA	brand	_	false	in patients receiving concurrent therapy with druga , if therapy is to be discontinued , it is suggested that drugb be discontinued for several days before the withdrawal of drugn .
DDI-DrugBank.d476.s2.p2	ZEBETA	brand	_	clonidine	drug	_	advise	in patients receiving concurrent therapy with drugn , if therapy is to be discontinued , it is suggested that druga be discontinued for several days before the withdrawal of drugb .
DDI-DrugBank.d476.s3.p0	ZEBETA	brand	_	myocardial depressants	group	_	advise	druga should be used with care when drugb or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p1	ZEBETA	brand	_	calcium antagonists	group	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugb -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p2	ZEBETA	brand	_	phenylalkylamine	group	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugb -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p3	ZEBETA	brand	_	verapamil	drug	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugb -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p4	ZEBETA	brand	_	benzothiazepine	group	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugb -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p5	ZEBETA	brand	_	diltiazem	drug	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p6	ZEBETA	brand	_	antiarrhythmic agents	group	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p7	ZEBETA	brand	_	disopyramide	drug	_	advise	druga should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p8	myocardial depressants	group	_	calcium antagonists	group	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugb -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p9	myocardial depressants	group	_	phenylalkylamine	group	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugb -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p10	myocardial depressants	group	_	verapamil	drug	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugb -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p11	myocardial depressants	group	_	benzothiazepine	group	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugb -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p12	myocardial depressants	group	_	diltiazem	drug	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p13	myocardial depressants	group	_	antiarrhythmic agents	group	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p14	myocardial depressants	group	_	disopyramide	drug	_	false	drugn should be used with care when druga or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p15	calcium antagonists	group	_	phenylalkylamine	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugb -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p16	calcium antagonists	group	_	verapamil	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugn -lsb- drugb -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p17	calcium antagonists	group	_	benzothiazepine	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugn -lsb- drugn -rsb- and drugb -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p18	calcium antagonists	group	_	diltiazem	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p19	calcium antagonists	group	_	antiarrhythmic agents	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p20	calcium antagonists	group	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain druga -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p21	phenylalkylamine	group	_	verapamil	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the druga -lsb- drugb -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p22	phenylalkylamine	group	_	benzothiazepine	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the druga -lsb- drugn -rsb- and drugb -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p23	phenylalkylamine	group	_	diltiazem	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the druga -lsb- drugn -rsb- and drugn -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p24	phenylalkylamine	group	_	antiarrhythmic agents	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the druga -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p25	phenylalkylamine	group	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the druga -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p26	verapamil	drug	_	benzothiazepine	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- druga -rsb- and drugb -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p27	verapamil	drug	_	diltiazem	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- druga -rsb- and drugn -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p28	verapamil	drug	_	antiarrhythmic agents	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- druga -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p29	verapamil	drug	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- druga -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p30	benzothiazepine	group	_	diltiazem	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and druga -lsb- drugb -rsb- classes -rcb- , or drugn , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p31	benzothiazepine	group	_	antiarrhythmic agents	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and druga -lsb- drugn -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p32	benzothiazepine	group	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and druga -lsb- drugn -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p33	diltiazem	drug	_	antiarrhythmic agents	group	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- druga -rsb- classes -rcb- , or drugb , such as drugn , are used concurrently .
DDI-DrugBank.d476.s3.p34	diltiazem	drug	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- druga -rsb- classes -rcb- , or drugn , such as drugb , are used concurrently .
DDI-DrugBank.d476.s3.p35	antiarrhythmic agents	group	_	disopyramide	drug	_	false	drugn should be used with care when drugn or inhibitors of av conduction , such as certain drugn -lcb- particularly of the drugn -lsb- drugn -rsb- and drugn -lsb- drugn -rsb- classes -rcb- , or druga , such as drugb , are used concurrently .
DDI-DrugBank.d476.s4.p0	rifampin	drug	_	ZEBETA	brand	_	mechanism	concurrent use of druga increases the metabolic clearance of drugb , resulting in a shortened elimination half-life of drugn .
DDI-DrugBank.d476.s4.p1	rifampin	drug	_	ZEBETA	brand	_	false	concurrent use of druga increases the metabolic clearance of drugn , resulting in a shortened elimination half-life of drugb .
DDI-DrugBank.d476.s7.p0	ZEBETA	brand	_	warfarin	drug	_	false	there was no effect of druga on prothrombin time in patients on stable doses of drugb .
DDI-DrugBank.d560.s1.p0	steroid	group	_	bitolterol	drug	_	advise	if you are also using a druga inhaler , take drugb first and then wait about # minutes before using the drugn inhaler .
DDI-DrugBank.d560.s1.p2	bitolterol	drug	_	steroid	group	_	advise	if you are also using a drugn inhaler , take druga first and then wait about # minutes before using the drugb inhaler .
DDI-DrugBank.d560.s2.p0	bitolterol	drug	_	steroid	group	_	effect	this allows druga to open air passages , increasing the effectiveness of the drugb .
DDI-DrugBank.d569.s1.p0	Angiomax	brand	_	heparin	drug	_	effect	in clinical trials in patients undergoing ptca/pci , co-administration of druga with drugb , drugn , drugn or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .
DDI-DrugBank.d569.s1.p1	Angiomax	brand	_	warfarin	drug	_	effect	in clinical trials in patients undergoing ptca/pci , co-administration of druga with drugn , drugb , drugn or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .
DDI-DrugBank.d569.s1.p2	Angiomax	brand	_	thrombolytics	group	_	effect	in clinical trials in patients undergoing ptca/pci , co-administration of druga with drugn , drugn , drugb or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .
DDI-DrugBank.d569.s2.p0	Angiomax	brand	_	dextran	drug	_	false	there is no experience with co-administration of druga and plasma expanders such as drugb .
DDI-DrugBank.d569.s5.p0	Angiomax	brand	_	bivalirudin	drug	_	false	among # subjects who received druga in clinical trials and were tested for antibodies , # subjects had treatment-emergent positive drugb antibody tests .
DDI-DrugBank.d571.s4.p0	antidiabetic agents	group	_	VELCADE	brand	_	advise	patients on oral druga receiving drugb treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drugn .
DDI-DrugBank.d571.s4.p1	antidiabetic agents	group	_	antidiabetic medication	group	_	false	patients on oral druga receiving drugn treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drugb .
DDI-DrugBank.d571.s4.p2	VELCADE	brand	_	antidiabetic medication	group	_	false	patients on oral drugn receiving druga treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drugb .
DDI-DrugBank.d289.s6.p11	bosentan	drug	_	hormonal contraceptive	group	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of druga and the oral drugb drugn produced average decreases of drugn and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p12	bosentan	drug	_	Ortho-Novum	brand	_	mechanism	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of druga and the oral drugn drugb produced average decreases of drugn and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p13	bosentan	drug	_	norethindrone	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of druga and the oral drugn drugn produced average decreases of drugb and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p14	bosentan	drug	_	ethinyl estradiol	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of druga and the oral drugn drugn produced average decreases of drugn and drugb levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p15	hormonal contraceptive	group	_	Ortho-Novum	brand	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral druga drugb produced average decreases of drugn and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p16	hormonal contraceptive	group	_	norethindrone	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral druga drugn produced average decreases of drugb and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p17	hormonal contraceptive	group	_	ethinyl estradiol	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral druga drugn produced average decreases of drugn and drugb levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p18	Ortho-Novum	brand	_	norethindrone	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral drugn druga produced average decreases of drugb and drugn levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p19	Ortho-Novum	brand	_	ethinyl estradiol	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral drugn druga produced average decreases of drugn and drugb levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s6.p20	norethindrone	drug	_	ethinyl estradiol	drug	_	false	drugn , including oral , injectable , transdermal , and implantable drugn : an interaction study demonstrated that co-administration of drugn and the oral drugn drugn produced average decreases of druga and drugb levels of 14 % and 31 % , respectively .
DDI-DrugBank.d289.s8.p0	hormonal contraceptives	group	_	TRACLEER	brand	_	effect	therefore , druga , including oral , injectable , transdermal , and implantable forms , may not be reliable when drugb is co-administered .
DDI-DrugBank.d289.s11.p0	bosentan	drug	_	cyclosporine A	drug	_	mechanism	steady-state druga plasma concentrations were 3 - to 4-fold higher than in the absence of drugb .
DDI-DrugBank.d289.s12.p0	bosentan	drug	_	cyclosporine A	drug	_	advise	the concomitant administration of druga and drugb is contraindicated .
DDI-DrugBank.d289.s13.p0	bosentan	drug	_	cyclosporine A	drug	_	mechanism	co-administration of druga decreased the plasma concentrations of drugb -lcb- a cyp3a4 substrate -rcb- by approximately 50 % .
DDI-DrugBank.d289.s14.p1	Tacrolimus	drug	_	bosentan	drug	_	false	druga : co-administration of drugn and drugb has not been studied in man .
DDI-DrugBank.d289.s14.p2	tacrolimus	drug	_	bosentan	drug	_	false	drugn : co-administration of druga and drugb has not been studied in man .
DDI-DrugBank.d289.s15.p0	tacrolimus	drug	_	bosentan	drug	_	mechanism	co-administration of druga and drugb resulted in markedly increased plasma concentrations of drugn in animals .
DDI-DrugBank.d289.s15.p1	tacrolimus	drug	_	bosentan	drug	_	false	co-administration of druga and drugn resulted in markedly increased plasma concentrations of drugb in animals .
DDI-DrugBank.d289.s16.p0	tacrolimus	drug	_	bosentan	drug	_	advise	caution should be exercised if druga and drugb are used together .
DDI-DrugBank.d289.s18.p0	TRACLEER	brand	_	glyburide	drug	_	advise	therefore , the concomitant administration of druga and drugb is contraindicated , and alternative drugn should be considered .
DDI-DrugBank.d289.s18.p1	TRACLEER	brand	_	hypoglycemic agents	group	_	false	therefore , the concomitant administration of druga and drugn is contraindicated , and alternative drugb should be considered .
DDI-DrugBank.d289.s18.p2	glyburide	drug	_	hypoglycemic agents	group	_	false	therefore , the concomitant administration of drugn and druga is contraindicated , and alternative drugb should be considered .
DDI-DrugBank.d289.s19.p0	bosentan	drug	_	glyburide	drug	_	mechanism	co-administration of druga decreased the plasma concentrations of drugb by approximately 40 % .
DDI-DrugBank.d289.s21.p0	Bosentan	drug	_	hypoglycemic agents	group	_	mechanism	druga is also expected to reduce plasma concentrations of other oral drugb that are predominantly metabolized by cyp2c9 or cyp3a4 .
DDI-DrugBank.d289.s23.p0	Ketoconazole	drug	_	bosentan	drug	_	false	druga : co-administration of drugb # mg b , i , d , and drugn , a potent cyp3a4 inhibitor , increased the plasma concentrations of drugn by approximately 2-fold .
DDI-DrugBank.d289.s23.p2	Ketoconazole	drug	_	bosentan	drug	_	false	druga : co-administration of drugn # mg b , i , d , and drugn , a potent cyp3a4 inhibitor , increased the plasma concentrations of drugb by approximately 2-fold .
DDI-DrugBank.d289.s23.p3	bosentan	drug	_	ketoconazole	drug	_	mechanism	drugn : co-administration of druga # mg b , i , d , and drugb , a potent cyp3a4 inhibitor , increased the plasma concentrations of drugn by approximately 2-fold .
DDI-DrugBank.d289.s23.p5	ketoconazole	drug	_	bosentan	drug	_	false	drugn : co-administration of drugn # mg b , i , d , and druga , a potent cyp3a4 inhibitor , increased the plasma concentrations of drugb by approximately 2-fold .
DDI-DrugBank.d289.s25.p0	Simvastatin	drug	_	Statins	group	_	false	druga and other drugb : co-administration of drugn decreased the plasma concentrations of drugn -lcb- a cyp3a4 substrate -rcb- , and its active - hydroxy acid metabolite , by approximately 50 % .
DDI-DrugBank.d289.s25.p1	Simvastatin	drug	_	bosentan	drug	_	false	druga and other drugn : co-administration of drugb decreased the plasma concentrations of drugn -lcb- a cyp3a4 substrate -rcb- , and its active - hydroxy acid metabolite , by approximately 50 % .
DDI-DrugBank.d289.s25.p3	Statins	group	_	bosentan	drug	_	false	drugn and other druga : co-administration of drugb decreased the plasma concentrations of drugn -lcb- a cyp3a4 substrate -rcb- , and its active - hydroxy acid metabolite , by approximately 50 % .
DDI-DrugBank.d289.s25.p4	Statins	group	_	simvastatin	drug	_	false	drugn and other druga : co-administration of drugn decreased the plasma concentrations of drugb -lcb- a cyp3a4 substrate -rcb- , and its active - hydroxy acid metabolite , by approximately 50 % .
DDI-DrugBank.d289.s25.p5	bosentan	drug	_	simvastatin	drug	_	mechanism	drugn and other drugn : co-administration of druga decreased the plasma concentrations of drugb -lcb- a cyp3a4 substrate -rcb- , and its active - hydroxy acid metabolite , by approximately 50 % .
DDI-DrugBank.d289.s27.p0	Bosentan	drug	_	statins	group	_	mechanism	druga is also expected to reduce plasma concentrations of other drugb that have significant metabolism by cyp3a4 , such as drugn and drugn .
DDI-DrugBank.d289.s27.p1	Bosentan	drug	_	lovastatin	drug	_	mechanism	druga is also expected to reduce plasma concentrations of other drugn that have significant metabolism by cyp3a4 , such as drugb and drugn .
DDI-DrugBank.d289.s27.p2	Bosentan	drug	_	atorvastatin	drug	_	mechanism	druga is also expected to reduce plasma concentrations of other drugn that have significant metabolism by cyp3a4 , such as drugn and drugb .
DDI-DrugBank.d289.s27.p3	statins	group	_	lovastatin	drug	_	false	drugn is also expected to reduce plasma concentrations of other druga that have significant metabolism by cyp3a4 , such as drugb and drugn .
DDI-DrugBank.d289.s27.p4	statins	group	_	atorvastatin	drug	_	false	drugn is also expected to reduce plasma concentrations of other druga that have significant metabolism by cyp3a4 , such as drugn and drugb .
DDI-DrugBank.d289.s27.p5	lovastatin	drug	_	atorvastatin	drug	_	false	drugn is also expected to reduce plasma concentrations of other drugn that have significant metabolism by cyp3a4 , such as druga and drugb .
DDI-DrugBank.d289.s29.p0	statins	group	_	TRACLEER	brand	_	advise	patients using cyp3a4 metabolized druga should have cholesterol levels monitored after drugb is initiated to see whether the drugn dose needs adjustment .
DDI-DrugBank.d289.s29.p2	TRACLEER	brand	_	statin	group	_	false	patients using cyp3a4 metabolized drugn should have cholesterol levels monitored after druga is initiated to see whether the drugb dose needs adjustment .
DDI-DrugBank.d289.s30.p0	Warfarin	drug	_	bosentan	drug	_	false	druga : co-administration of drugb # mg b , i , d , for # days decreased the plasma concentrations of both drugn -lcb- a cyp2c9 substrate -rcb- and drugn -lcb- a cyp3a4 substrate -rcb- by # and 38 % , respectively .
DDI-DrugBank.d289.s30.p3	bosentan	drug	_	S-warfarin	drug	_	mechanism	drugn : co-administration of druga # mg b , i , d , for # days decreased the plasma concentrations of both drugb -lcb- a cyp2c9 substrate -rcb- and drugn -lcb- a cyp3a4 substrate -rcb- by # and 38 % , respectively .
DDI-DrugBank.d289.s30.p4	bosentan	drug	_	R-warfarin	drug	_	mechanism	drugn : co-administration of druga # mg b , i , d , for # days decreased the plasma concentrations of both drugn -lcb- a cyp2c9 substrate -rcb- and drugb -lcb- a cyp3a4 substrate -rcb- by # and 38 % , respectively .
DDI-DrugBank.d289.s30.p5	S-warfarin	drug	_	R-warfarin	drug	_	false	drugn : co-administration of drugn # mg b , i , d , for # days decreased the plasma concentrations of both druga -lcb- a cyp2c9 substrate -rcb- and drugb -lcb- a cyp3a4 substrate -rcb- by # and 38 % , respectively .
DDI-DrugBank.d289.s31.p0	bosentan	drug	_	warfarin	drug	_	false	clinical experience with concomitant administration of druga and drugb in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or drugn dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the drugn dose during the trials due to changes in inr or due to adverse events was similar among drugn - and placebo-treated patients .
DDI-DrugBank.d289.s31.p1	bosentan	drug	_	warfarin	drug	_	false	clinical experience with concomitant administration of druga and drugn in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or drugb dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the drugn dose during the trials due to changes in inr or due to adverse events was similar among drugn - and placebo-treated patients .
DDI-DrugBank.d289.s31.p2	bosentan	drug	_	warfarin	drug	_	false	clinical experience with concomitant administration of druga and drugn in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or drugn dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the drugb dose during the trials due to changes in inr or due to adverse events was similar among drugn - and placebo-treated patients .
DDI-DrugBank.d289.s31.p6	warfarin	drug	_	bosentan	drug	_	false	clinical experience with concomitant administration of drugn and druga in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or drugn dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the drugn dose during the trials due to changes in inr or due to adverse events was similar among drugb - and placebo-treated patients .
DDI-DrugBank.d289.s31.p8	warfarin	drug	_	bosentan	drug	_	false	clinical experience with concomitant administration of drugn and drugn in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or druga dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the drugn dose during the trials due to changes in inr or due to adverse events was similar among drugb - and placebo-treated patients .
DDI-DrugBank.d289.s31.p9	warfarin	drug	_	bosentan	drug	_	false	clinical experience with concomitant administration of drugn and drugn in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or drugn dose -lcb- baseline vs , end of the clinical studies -rcb- , and the need to change the druga dose during the trials due to changes in inr or due to adverse events was similar among drugb - and placebo-treated patients .
DDI-DrugBank.d289.s32.p18	Bosentan	drug	_	digoxin	drug	_	false	drugn , drugn and drugn : druga has no significant pharmacokinetic interactions with drugb and drugn , and drugn has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p19	Bosentan	drug	_	nimodipine	drug	_	false	drugn , drugn and drugn : druga has no significant pharmacokinetic interactions with drugn and drugb , and drugn has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p20	Bosentan	drug	_	losartan	drug	_	false	drugn , drugn and drugn : druga has no significant pharmacokinetic interactions with drugn and drugn , and drugb has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p22	digoxin	drug	_	nimodipine	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with druga and drugb , and drugn has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p23	digoxin	drug	_	losartan	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with druga and drugn , and drugb has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p24	digoxin	drug	_	bosentan	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with druga and drugn , and drugn has no significant effect on plasma levels of drugb .
DDI-DrugBank.d289.s32.p25	nimodipine	drug	_	losartan	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with drugn and druga , and drugb has no significant effect on plasma levels of drugn .
DDI-DrugBank.d289.s32.p26	nimodipine	drug	_	bosentan	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with drugn and druga , and drugn has no significant effect on plasma levels of drugb .
DDI-DrugBank.d289.s32.p27	losartan	drug	_	bosentan	drug	_	false	drugn , drugn and drugn : drugn has no significant pharmacokinetic interactions with drugn and drugn , and druga has no significant effect on plasma levels of drugb .
DDI-DrugBank.d133.s0.p1	BOTOX	brand	_	curare-like compounds	group	_	advise	co-administration of druga and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , drugb -rcb- should only be performed with caution as the effect of the drugn may be potentiated .
DDI-DrugBank.d133.s0.p2	BOTOX	brand	_	toxin	drug	_	false	co-administration of druga and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , drugn -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d133.s0.p3	aminoglycosides	group	_	curare-like compounds	group	_	false	co-administration of drugn and druga or other agents interfering with neuromuscular transmission -lcb- e , g , , drugb -rcb- should only be performed with caution as the effect of the drugn may be potentiated .
DDI-DrugBank.d133.s0.p4	aminoglycosides	group	_	toxin	drug	_	false	co-administration of drugn and druga or other agents interfering with neuromuscular transmission -lcb- e , g , , drugn -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d133.s0.p5	curare-like compounds	group	_	toxin	drug	_	false	co-administration of drugn and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , druga -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d323.s0.p1	MYOBLOC	brand	_	curare-like compounds	group	_	advise	co-administration of druga and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , drugb -rcb- should only be performed with caution as the effect of the drugn may be potentiated .
DDI-DrugBank.d323.s0.p2	MYOBLOC	brand	_	toxin	drug	_	false	co-administration of druga and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , drugn -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d323.s0.p3	aminoglycosides	group	_	curare-like compounds	group	_	false	co-administration of drugn and druga or other agents interfering with neuromuscular transmission -lcb- e , g , , drugb -rcb- should only be performed with caution as the effect of the drugn may be potentiated .
DDI-DrugBank.d323.s0.p4	aminoglycosides	group	_	toxin	drug	_	false	co-administration of drugn and druga or other agents interfering with neuromuscular transmission -lcb- e , g , , drugn -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d323.s0.p5	curare-like compounds	group	_	toxin	drug	_	false	co-administration of drugn and drugn or other agents interfering with neuromuscular transmission -lcb- e , g , , druga -rcb- should only be performed with caution as the effect of the drugb may be potentiated .
DDI-DrugBank.d180.s0.p0	Digitalis	group	_	Bretylium Tosylate	drug	_	effect	druga toxicity may be aggravated by the initial release of norepinephrine caused by drugb injection .
DDI-DrugBank.d180.s1.p0	catecholamines	group	_	dopamine	drug	_	false	the pressor effects of druga such as drugb or drugn are enhanced by drugn .
DDI-DrugBank.d180.s1.p1	catecholamines	group	_	norepinephrine	drug	_	false	the pressor effects of druga such as drugn or drugb are enhanced by drugn .
DDI-DrugBank.d180.s1.p2	catecholamines	group	_	Bretylium Tosylate	drug	_	effect	the pressor effects of druga such as drugn or drugn are enhanced by drugb .
DDI-DrugBank.d180.s1.p3	dopamine	drug	_	norepinephrine	drug	_	false	the pressor effects of drugn such as druga or drugb are enhanced by drugn .
DDI-DrugBank.d180.s1.p4	dopamine	drug	_	Bretylium Tosylate	drug	_	effect	the pressor effects of drugn such as druga or drugn are enhanced by drugb .
DDI-DrugBank.d180.s1.p5	norepinephrine	drug	_	Bretylium Tosylate	drug	_	effect	the pressor effects of drugn such as drugn or druga are enhanced by drugb .
DDI-DrugBank.d180.s3.p0	lidocaine	drug	_	Bretylium Tosylate	drug	_	false	although there is little published information on concomitant administration of druga and drugb , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy .
DDI-DrugBank.d138.s0.p0	ALPHAGAN P	brand	_	CNS depressants	group	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugb -lcb- drugn , drugn , drugn , drugn , or drugn -rcb- should be considered .
DDI-DrugBank.d138.s0.p1	ALPHAGAN P	brand	_	alcohol	drug	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugn -lcb- drugb , drugn , drugn , drugn , or drugn -rcb- should be considered .
DDI-DrugBank.d138.s0.p2	ALPHAGAN P	brand	_	barbiturates	group	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugb , drugn , drugn , or drugn -rcb- should be considered .
DDI-DrugBank.d138.s0.p3	ALPHAGAN P	brand	_	opiates	group	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugb , drugn , or drugn -rcb- should be considered .
DDI-DrugBank.d138.s0.p4	ALPHAGAN P	brand	_	sedatives	group	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugn , drugb , or drugn -rcb- should be considered .
DDI-DrugBank.d138.s0.p5	ALPHAGAN P	brand	_	anesthetics	group	_	advise	although specific drug interaction studies have not been conducted with druga , the possibility of an additive or potentiating effect with drugn -lcb- drugn , drugn , drugn , drugn , or drugb -rcb- should be considered .
DDI-DrugBank.d138.s2.p0	beta-blockers	group	_	anti-hypertensives	group	_	false	caution in using concomitant drugs such as druga -lcb- ophthalmic and systemic -rcb- , drugb and/or drugn is advised .
DDI-DrugBank.d138.s2.p1	beta-blockers	group	_	cardiac glycosides	group	_	false	caution in using concomitant drugs such as druga -lcb- ophthalmic and systemic -rcb- , drugn and/or drugb is advised .
DDI-DrugBank.d138.s2.p2	anti-hypertensives	group	_	cardiac glycosides	group	_	false	caution in using concomitant drugs such as drugn -lcb- ophthalmic and systemic -rcb- , druga and/or drugb is advised .
DDI-DrugBank.d138.s3.p0	Tricyclic antidepressants	group	_	clonidine	drug	_	effect	druga have been reported to blunt the hypotensive effect of systemic drugb , it is not known whether the concurrent use of these agents with drugn in humans can lead to resulting interference with the iop lowering effect .
DDI-DrugBank.d138.s3.p1	Tricyclic antidepressants	group	_	ALPHAGAN P	brand	_	false	druga have been reported to blunt the hypotensive effect of systemic drugn , it is not known whether the concurrent use of these agents with drugb in humans can lead to resulting interference with the iop lowering effect .
DDI-DrugBank.d138.s3.p2	clonidine	drug	_	ALPHAGAN P	brand	_	false	drugn have been reported to blunt the hypotensive effect of systemic druga , it is not known whether the concurrent use of these agents with drugb in humans can lead to resulting interference with the iop lowering effect .
DDI-DrugBank.d497.s0.p1	AZOPT	brand	_	carbonic anhydrase inhibitor	group	_	false	druga -lcb- drugn ophthalmic suspension -rcb- 1 % contains a drugb .
DDI-DrugBank.d497.s0.p2	brinzolamide	drug	_	carbonic anhydrase inhibitor	group	_	false	drugn -lcb- druga ophthalmic suspension -rcb- 1 % contains a drugb .
DDI-DrugBank.d497.s2.p0	carbonic anhydrase inhibitors	group	_	salicylate	drug	_	int	however , in patients treated with oral druga , rare instances of drug interactions have occurred with high-dose drugb therapy .
DDI-DrugBank.d272.s0.p0	bromocriptine mesylate	drug	_	alcohol	drug	_	false	the risk of using druga in combination with other drugs has not been systematically evaluated , but drugb may potentiate the side effects of drugn .
DDI-DrugBank.d272.s0.p2	alcohol	drug	_	bromocriptine mesylate	drug	_	effect	the risk of using drugn in combination with other drugs has not been systematically evaluated , but druga may potentiate the side effects of drugb .
DDI-DrugBank.d272.s1.p0	Bromocriptine mesylate	drug	_	dopamine antagonists	group	_	int	druga may interact with drugb , drugn , and certain other agents .
DDI-DrugBank.d272.s1.p1	Bromocriptine mesylate	drug	_	butyrophenones	group	_	int	druga may interact with drugn , drugb , and certain other agents .
DDI-DrugBank.d272.s1.p2	dopamine antagonists	group	_	butyrophenones	group	_	false	drugn may interact with druga , drugb , and certain other agents .
DDI-DrugBank.d272.s2.p0	bromocriptine mesylate	drug	_	phenothiazines	group	_	effect	compounds in these categories result in a decreased efficacy of druga : drugb , drugn , drugn , drugn .
DDI-DrugBank.d272.s2.p1	bromocriptine mesylate	drug	_	haloperidol	drug	_	effect	compounds in these categories result in a decreased efficacy of druga : drugn , drugb , drugn , drugn .
DDI-DrugBank.d272.s2.p2	bromocriptine mesylate	drug	_	metoclopramide	drug	_	effect	compounds in these categories result in a decreased efficacy of druga : drugn , drugn , drugb , drugn .
DDI-DrugBank.d272.s2.p3	bromocriptine mesylate	drug	_	pimozide	drug	_	effect	compounds in these categories result in a decreased efficacy of druga : drugn , drugn , drugn , drugb .
DDI-DrugBank.d272.s2.p7	haloperidol	drug	_	metoclopramide	drug	_	false	compounds in these categories result in a decreased efficacy of drugn : drugn , druga , drugb , drugn .
DDI-DrugBank.d272.s2.p8	haloperidol	drug	_	pimozide	drug	_	false	compounds in these categories result in a decreased efficacy of drugn : drugn , druga , drugn , drugb .
DDI-DrugBank.d272.s2.p9	metoclopramide	drug	_	pimozide	drug	_	false	compounds in these categories result in a decreased efficacy of drugn : drugn , drugn , druga , drugb .
DDI-DrugBank.d272.s3.p0	bromocriptine mesylate	drug	_	ergot alkaloids	group	_	advise	concomitant use of druga with other drugb is not recommended .
DDI-DrugBank.d192.s0.p0	Dexbrompheniramine	drug	_	alcohol	drug	_	effect	druga can interact with drugb or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p1	Dexbrompheniramine	drug	_	CNS depressants	group	_	effect	druga can interact with drugn or other drugb -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p2	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p3	Dexbrompheniramine	drug	_	anticholinergics	group	_	effect	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p4	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p5	Dexbrompheniramine	drug	_	monoamine oxidase (MAO) inhibitors	group	_	effect	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p6	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p7	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d192.s0.p9	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p11	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p12	alcohol	drug	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p13	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p14	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d192.s0.p15	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p17	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p18	CNS depressants	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p19	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p20	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d192.s0.p21	antihistamines	group	_	anticholinergics	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p23	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p26	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p27	anticholinergics	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p28	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p29	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d192.s0.p30	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with druga -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p33	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d192.s0.p34	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d342.s0.p1	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p3	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p4	alcohol	drug	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p5	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p6	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d342.s0.p7	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p9	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p10	CNS depressants	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p11	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p12	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d342.s0.p13	antihistamines	group	_	anticholinergics	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p15	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p18	anticholinergics	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p19	anticholinergics	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p20	anticholinergics	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p21	anticholinergics	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d342.s0.p22	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with druga -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p25	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d342.s0.p26	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d144.s0.p0	ketoconazole	drug	_	budesonide	drug	_	mechanism	concomitant oral administration of druga -lcb- a known inhibitor of cyp3a4 activity in the liver and in the intestinal mucosa -rcb- caused an eight-fold increase of the systemic exposure to oral drugb .
DDI-DrugBank.d144.s1.p5	ketoconazole	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as druga , drugn , drugn , drugn , drugn , drugn , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d144.s1.p10	intraconazole	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as drugn , druga , drugn , drugn , drugn , drugn , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d144.s1.p14	ritonavir	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as drugn , drugn , druga , drugn , drugn , drugn , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d144.s1.p17	indinavir	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as drugn , drugn , drugn , druga , drugn , drugn , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d144.s1.p19	saquinavir	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as drugn , drugn , drugn , drugn , druga , drugn , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d144.s1.p20	erythromycin	drug	_	budesonide	drug	_	advise	if treatment with inhibitors of cyp3a4 activity -lcb- such as drugn , drugn , drugn , drugn , drugn , druga , etc , -rcb- is indicated , reduction of the drugb dose should be considered .
DDI-DrugBank.d331.s0.p0	bumetanide	drug	_	aminoglycoside antibiotics	group	_	advise	- drugs with ototoxic potential : especially in the presence of impaired renal function , the use of parenterally administered druga in patients to whom drugb are also being given should be avoided , except in life-threatening conditions .
DDI-DrugBank.d331.s3.p4	Lithium	drug	_	diuretics	group	_	advise	- drugn : druga should generally not be given with drugb -lcb- such as drugn -rcb- because they reduce its renal clearance and add a high risk of drugn toxicity .
DDI-DrugBank.d331.s3.p5	Lithium	drug	_	bumetanide	drug	_	advise	- drugn : druga should generally not be given with drugn -lcb- such as drugb -rcb- because they reduce its renal clearance and add a high risk of drugn toxicity .
DDI-DrugBank.d331.s3.p8	diuretics	group	_	lithium	drug	_	false	- drugn : drugn should generally not be given with druga -lcb- such as drugn -rcb- because they reduce its renal clearance and add a high risk of drugb toxicity .
DDI-DrugBank.d331.s3.p9	bumetanide	drug	_	lithium	drug	_	false	- drugn : drugn should generally not be given with drugn -lcb- such as druga -rcb- because they reduce its renal clearance and add a high risk of drugb toxicity .
DDI-DrugBank.d331.s4.p2	probenecid	drug	_	bumetanide	drug	_	effect	- drugn : pretreatment with druga reduces both the natriuresis and hyperreninemia produced by drugb .
DDI-DrugBank.d331.s5.p0	probenecid	drug	_	bumetanide	drug	_	mechanism	this antagonistic effect of druga on drugb natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drugn .
DDI-DrugBank.d331.s5.p1	probenecid	drug	_	bumetanide	drug	_	false	this antagonistic effect of druga on drugn natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drugb .
DDI-DrugBank.d331.s6.p0	probenecid	drug	_	bumetanide	drug	_	advise	thus , druga should not be administered concurrently with drugb .
DDI-DrugBank.d331.s7.p3	Indomethacin	drug	_	bumetanide	drug	_	mechanism	- drugn : druga blunts the increases in urine volume and sodium excretion seen during drugb treatment and inhibits the drugn - induced increase in plasma renin activity .
DDI-DrugBank.d331.s7.p4	Indomethacin	drug	_	bumetanide	drug	_	effect	- drugn : druga blunts the increases in urine volume and sodium excretion seen during drugn treatment and inhibits the drugb - induced increase in plasma renin activity .
DDI-DrugBank.d331.s9.p2	Bumetanide	drug	_	antihypertensive drugs	group	_	effect	- drugn : druga may potentiate the effect of various drugb , necessitating a reduction in the dosage of these drugs .
DDI-DrugBank.d331.s11.p0	Anticoagulants	group	_	bumetanide	drug	_	false	- druga : interaction studies in humans have shown drugb to have no effect on drugn metabolism or on plasma prothrombin activity .
DDI-DrugBank.d331.s11.p1	Anticoagulants	group	_	warfarin	drug	_	false	- druga : interaction studies in humans have shown drugn to have no effect on drugb metabolism or on plasma prothrombin activity .
DDI-DrugBank.d331.s11.p2	bumetanide	drug	_	warfarin	drug	_	false	- drugn : interaction studies in humans have shown druga to have no effect on drugb metabolism or on plasma prothrombin activity .
DDI-DrugBank.d153.s0.p0	anesthetic solutions	group	_	epinephrine	drug	_	false	the administration of local druga containing drugb or drugn to patients receiving drugn or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p1	anesthetic solutions	group	_	norepinephrine	drug	_	false	the administration of local druga containing drugn or drugb to patients receiving drugn or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p2	anesthetic solutions	group	_	monoamine oxidase inhibitors	group	_	false	the administration of local druga containing drugn or drugn to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p3	anesthetic solutions	group	_	tricyclic antidepressants	group	_	false	the administration of local druga containing drugn or drugn to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p5	epinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p6	epinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p7	norepinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p8	norepinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s0.p9	monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	the administration of local drugn containing drugn or drugn to patients receiving druga or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d153.s3.p0	vasopressor drugs	group	_	ergot-type oxytocic drugs	group	_	false	concurrent administration of druga and of drugb may cause severe , persistent hypertension or cerebrovascular accidents .
DDI-DrugBank.d153.s4.p0	Phenothiazines	group	_	butyrophenones	group	_	false	druga and drugb may reduce or reverse the pressor effect of drugn .
DDI-DrugBank.d153.s4.p1	Phenothiazines	group	_	epinephrine	drug	_	effect	druga and drugn may reduce or reverse the pressor effect of drugb .
DDI-DrugBank.d153.s4.p2	butyrophenones	group	_	epinephrine	drug	_	effect	drugn and druga may reduce or reverse the pressor effect of drugb .
DDI-DrugBank.d380.s1.p0	buprenorphine	drug	_	azole antifungals	group	_	false	because cyp 3a4 inhibitors may increase plasma concentrations of druga , patients already on ppig 3a4 inhibitors such as drugb -lcb- e , g.
DDI-DrugBank.d380.s2.p6	ketoconazole	drug	_	SUBUTEX	brand	_	false	druga -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p7	ketoconazole	drug	_	SUBOXONE	brand	_	false	druga -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p13	macrolide antibiotics	group	_	SUBUTEX	brand	_	false	drugn -rcb- , druga -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p14	macrolide antibiotics	group	_	SUBOXONE	brand	_	false	drugn -rcb- , druga -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p19	erythromycin	drug	_	SUBUTEX	brand	_	false	drugn -rcb- , drugn -lcb- e , g , druga -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p20	erythromycin	drug	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , druga -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p24	HIV protease inhibitors	group	_	SUBUTEX	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and druga -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p25	HIV protease inhibitors	group	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and druga -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p28	ritonavir	drug	_	SUBUTEX	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , druga , drugn and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p29	ritonavir	drug	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , druga , drugn and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p31	indinavir	drug	_	SUBUTEX	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , druga and drugn -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p32	indinavir	drug	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , druga and drugn -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p33	saquinavir	drug	_	SUBUTEX	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and druga -rcb- should have their dose of drugb or drugn adjusted .
DDI-DrugBank.d380.s2.p34	saquinavir	drug	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and druga -rcb- should have their dose of drugn or drugb adjusted .
DDI-DrugBank.d380.s2.p35	SUBUTEX	brand	_	SUBOXONE	brand	_	false	drugn -rcb- , drugn -lcb- e , g , drugn -rcb- , and drugn -lcb- e , g , drugn , drugn and drugn -rcb- should have their dose of druga or drugb adjusted .
DDI-DrugBank.d380.s3.p0	buprenorphine	drug	_	benzodiazepines	group	_	int	based on anecdotal reports , there may be an interaction between druga and drugb .
DDI-DrugBank.d380.s4.p0	buprenorphine	drug	_	benzodiazepines	drug	_	effect	there have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of druga and drugb by addicts .
DDI-DrugBank.d380.s5.p0	buprenorphine	drug	_	SUBUTEX	brand	_	false	in many of these cases , druga was misused by self-injection of crushed drugb tablets .
DDI-DrugBank.d380.s6.p0	SUBUTEX	brand	_	SUBOXONE	brand	_	false	druga and drugb should be prescribed with caution to patients on drugn or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .
DDI-DrugBank.d380.s6.p1	SUBUTEX	brand	_	benzodiazepines	group	_	advise	druga and drugn should be prescribed with caution to patients on drugb or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .
DDI-DrugBank.d380.s6.p2	SUBOXONE	brand	_	benzodiazepines	group	_	advise	drugn and druga should be prescribed with caution to patients on drugb or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .
DDI-DrugBank.d380.s7.p0	benzodiazepines	group	_	SUBOXONE	brand	_	advise	patients should be warned of the potential danger of the intravenous self-administration of druga while under treatment with drugb or drugn .
DDI-DrugBank.d380.s7.p1	benzodiazepines	group	_	SUBUTEX	brand	_	advise	patients should be warned of the potential danger of the intravenous self-administration of druga while under treatment with drugn or drugb .
DDI-DrugBank.d380.s7.p2	SUBOXONE	brand	_	SUBUTEX	brand	_	false	patients should be warned of the potential danger of the intravenous self-administration of drugn while under treatment with druga or drugb .
DDI-DrugBank.d5.s3.p0	WELLBUTRIN	brand	_	orphenadrine	drug	_	int	therefore , the potential exists for a drug interaction between druga and drugs that affect the cyp2b6 isoenzyme -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d5.s3.p1	WELLBUTRIN	brand	_	cyclophosphamide	drug	_	int	therefore , the potential exists for a drug interaction between druga and drugs that affect the cyp2b6 isoenzyme -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d5.s5.p0	cimetidine	drug	_	bupropion	drug	_	false	the effects of concomitant administration of druga on the pharmacokinetics of drugb and its active metabolites were studied in # healthy young male volunteers .
DDI-DrugBank.d5.s6.p0	cimetidine	drug	_	bupropion	drug	_	false	following oral administration of two 150-mg sustained-release tablets with and without # mg of druga , the pharmacokinetics of drugb and drugn were unaffected .
DDI-DrugBank.d5.s6.p1	cimetidine	drug	_	hydroxybupropion	drug_n	_	false	following oral administration of two 150-mg sustained-release tablets with and without # mg of druga , the pharmacokinetics of drugn and drugb were unaffected .
DDI-DrugBank.d5.s7.p0	threohydrobupropion	drug_n	_	erythrohydrobupropion	drug_n	_	false	however , there were 16 % and 32 % increases in the auc and cmax , respectively , of the combined moieties of druga and drugb .
DDI-DrugBank.d5.s12.p7	beta-blockers	group	_	antiarrhythmics	drug	_	false	drugs metabolized by cytochrome p450iid6 -lcb- cyp2d6 -rcb- : many drugs , including most drugn -lcb- ssris , many drugn -rcb- , druga , drugb , and drugn are metabolized by the cyp2d6 isoenzyme .
DDI-DrugBank.d5.s14.p0	bupropion	drug	_	desipramine	drug	_	mechanism	in a study of # male subjects -lcb- ages # to # years -rcb- who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of druga given as # mg twice daily followed by a single dose of # mg drugb increased the cmax , auc , and t1/2 of drugn by an average of approximately 2 - , 5 - and 2-fold , respectively .
DDI-DrugBank.d5.s14.p1	bupropion	drug	_	desipramine	drug	_	false	in a study of # male subjects -lcb- ages # to # years -rcb- who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of druga given as # mg twice daily followed by a single dose of # mg drugn increased the cmax , auc , and t1/2 of drugb by an average of approximately 2 - , 5 - and 2-fold , respectively .
DDI-DrugBank.d5.s17.p0	bupropion	drug	_	antidepressants	group	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p1	bupropion	drug	_	nortriptyline	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p2	bupropion	drug	_	imipramine	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p3	bupropion	drug	_	desipramine	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p4	bupropion	drug	_	paroxetine	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p5	bupropion	drug	_	fluoxetine	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p6	bupropion	drug	_	sertraline	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p7	bupropion	drug	_	antipsychotics	group	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p8	bupropion	drug	_	haloperidol	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugb , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p9	bupropion	drug	_	risperidone	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugb , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p10	bupropion	drug	_	thioridazine	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p11	bupropion	drug	_	beta-blockers	group	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p12	bupropion	drug	_	metoprolol	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p13	bupropion	drug	_	Type 1C antiarrhythmics	group	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p14	bupropion	drug	_	propafenone	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p15	bupropion	drug	_	flecainide	drug	_	advise	therefore , co-administration of druga with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p103	antipsychotics	group	_	beta-blockers	group	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p104	antipsychotics	group	_	metoprolol	drug	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p110	haloperidol	drug	_	beta-blockers	group	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p111	haloperidol	drug	_	metoprolol	drug	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p116	risperidone	drug	_	beta-blockers	group	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p117	risperidone	drug	_	metoprolol	drug	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p121	thioridazine	drug	_	beta-blockers	group	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s17.p122	thioridazine	drug	_	metoprolol	drug	_	false	therefore , co-administration of drugn with drugs that are metabolized by cyp2d6 isoenzyme including certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
DDI-DrugBank.d5.s19.p3	bupropion	drug	_	MAO inhibitor	group	_	false	drugn : studies in animals demonstrate that the acute toxicity of druga is enhanced by the drugb drugn .
DDI-DrugBank.d5.s19.p4	bupropion	drug	_	phenelzine	drug	_	effect	drugn : studies in animals demonstrate that the acute toxicity of druga is enhanced by the drugn drugb .
DDI-DrugBank.d5.s19.p5	MAO inhibitor	group	_	phenelzine	drug	_	false	drugn : studies in animals demonstrate that the acute toxicity of drugn is enhanced by the druga drugb .
DDI-DrugBank.d5.s20.p0	Levodopa	drug	_	Amantadine	drug	_	false	druga and drugb : limited clinical data suggest a higher incidence of adverse experiences in patients receiving drugn concurrently with either drugn or drugn .
DDI-DrugBank.d5.s20.p7	bupropion	drug	_	levodopa	drug	_	effect	drugn and drugn : limited clinical data suggest a higher incidence of adverse experiences in patients receiving druga concurrently with either drugb or drugn .
DDI-DrugBank.d5.s20.p8	bupropion	drug	_	amantadine	drug	_	effect	drugn and drugn : limited clinical data suggest a higher incidence of adverse experiences in patients receiving druga concurrently with either drugn or drugb .
DDI-DrugBank.d5.s20.p9	levodopa	drug	_	amantadine	drug	_	false	drugn and drugn : limited clinical data suggest a higher incidence of adverse experiences in patients receiving drugn concurrently with either druga or drugb .
DDI-DrugBank.d5.s21.p0	WELLBUTRIN	brand	_	levodopa	drug	_	advise	administration of druga tablets to patients receiving either drugb or drugn concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .
DDI-DrugBank.d5.s21.p1	WELLBUTRIN	brand	_	amantadine	drug	_	advise	administration of druga tablets to patients receiving either drugn or drugb concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .
DDI-DrugBank.d5.s21.p2	levodopa	drug	_	amantadine	drug	_	false	administration of drugn tablets to patients receiving either druga or drugb concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .
DDI-DrugBank.d5.s22.p0	WELLBUTRIN	brand	_	antipsychotics	group	_	advise	drugs that lower seizure threshold : concurrent administration of druga and agents -lcb- e , g , , drugb , other drugn , drugn , systemic drugn , etc , -rcb- that lower seizure threshold should be undertaken only with extreme caution .
DDI-DrugBank.d5.s22.p1	WELLBUTRIN	brand	_	antidepressants	group	_	advise	drugs that lower seizure threshold : concurrent administration of druga and agents -lcb- e , g , , drugn , other drugb , drugn , systemic drugn , etc , -rcb- that lower seizure threshold should be undertaken only with extreme caution .
DDI-DrugBank.d5.s22.p2	WELLBUTRIN	brand	_	theophylline	drug	_	advise	drugs that lower seizure threshold : concurrent administration of druga and agents -lcb- e , g , , drugn , other drugn , drugb , systemic drugn , etc , -rcb- that lower seizure threshold should be undertaken only with extreme caution .
DDI-DrugBank.d5.s22.p3	WELLBUTRIN	brand	_	steroids	group	_	advise	drugs that lower seizure threshold : concurrent administration of druga and agents -lcb- e , g , , drugn , other drugn , drugn , systemic drugb , etc , -rcb- that lower seizure threshold should be undertaken only with extreme caution .
DDI-DrugBank.d5.s25.p2	Alcohol	drug	_	WELLBUTRIN	brand	_	false	druga : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced drugn tolerance in patients who were drinking drugn during treatment with drugb .
DDI-DrugBank.d5.s25.p4	alcohol	drug	_	WELLBUTRIN	brand	_	false	drugn : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced druga tolerance in patients who were drinking drugn during treatment with drugb .
DDI-DrugBank.d5.s25.p5	alcohol	drug	_	WELLBUTRIN	brand	_	effect	drugn : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced drugn tolerance in patients who were drinking druga during treatment with drugb .
DDI-DrugBank.d5.s26.p0	alcohol	drug	_	WELLBUTRIN	brand	_	advise	the consumption of druga during treatment with drugb should be minimized or avoided -lcb- also see a href = bupropz_od , htm #ci contraindications -rcb-
DDI-DrugBank.d463.s0.p0	buspirone hydrochloride	drug	_	MAO inhibitors	group	_	advise	it is recommended that druga not be used concomitantly with drugb because the effects of concomitant administration of drugn with most other drugn have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p1	buspirone hydrochloride	drug	_	buspirone HCl	drug	_	false	it is recommended that druga not be used concomitantly with drugn because the effects of concomitant administration of drugb with most other drugn have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p2	buspirone hydrochloride	drug	_	psychotropic drugs	group	_	false	it is recommended that druga not be used concomitantly with drugn because the effects of concomitant administration of drugn with most other drugb have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p3	buspirone hydrochloride	drug	_	buspirone HCl	drug	_	false	it is recommended that druga not be used concomitantly with drugn because the effects of concomitant administration of drugn with most other drugn have not been studied , the concomitant use of drugb with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p4	MAO inhibitors	group	_	buspirone HCl	drug	_	false	it is recommended that drugn not be used concomitantly with druga because the effects of concomitant administration of drugb with most other drugn have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p5	MAO inhibitors	group	_	psychotropic drugs	group	_	false	it is recommended that drugn not be used concomitantly with druga because the effects of concomitant administration of drugn with most other drugb have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p6	MAO inhibitors	group	_	buspirone HCl	drug	_	false	it is recommended that drugn not be used concomitantly with druga because the effects of concomitant administration of drugn with most other drugn have not been studied , the concomitant use of drugb with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p7	buspirone HCl	drug	_	psychotropic drugs	group	_	false	it is recommended that drugn not be used concomitantly with drugn because the effects of concomitant administration of druga with most other drugb have not been studied , the concomitant use of drugn with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s0.p9	psychotropic drugs	group	_	buspirone HCl	drug	_	false	it is recommended that drugn not be used concomitantly with drugn because the effects of concomitant administration of drugn with most other druga have not been studied , the concomitant use of drugb with other cns-active drugs should be approached with caution .
DDI-DrugBank.d463.s1.p1	trazodone hydrochloride	drug	_	buspirone HCl	drug	_	effect	there is one report suggesting that the concomitant use of druga -lcb- drugn -rcb- and drugb may have caused 3 - to 6-fold elevations on sgpt -lcb- alt -rcb- in a few patients .
DDI-DrugBank.d463.s1.p2	Desyrel	brand	_	buspirone HCl	drug	_	effect	there is one report suggesting that the concomitant use of drugn -lcb- druga -rcb- and drugb may have caused 3 - to 6-fold elevations on sgpt -lcb- alt -rcb- in a few patients .
DDI-DrugBank.d463.s3.p0	buspirone HCl	drug	_	haloperidol	drug	_	mechanism	in a study in normal volunteers , concomitant administration of druga and drugb resulted in increased serum drugn concentrations .
DDI-DrugBank.d463.s3.p1	buspirone HCl	drug	_	haloperidol	drug	_	false	in a study in normal volunteers , concomitant administration of druga and drugn resulted in increased serum drugb concentrations .
DDI-DrugBank.d463.s5.p0	buspirone	drug	_	phenytoin	drug	_	false	in vitro , druga does not displace tightly bound drugs like drugb , drugn , and drugn from serum proteins .
DDI-DrugBank.d463.s5.p1	buspirone	drug	_	propranolol	drug	_	false	in vitro , druga does not displace tightly bound drugs like drugn , drugb , and drugn from serum proteins .
DDI-DrugBank.d463.s5.p2	buspirone	drug	_	warfarin	drug	_	false	in vitro , druga does not displace tightly bound drugs like drugn , drugn , and drugb from serum proteins .
DDI-DrugBank.d463.s6.p0	buspirone	drug	_	warfarin	drug	_	effect	however , there has been one report of prolonged prothrombin time when druga was added to the regimen of a patient treated with drugb .
DDI-DrugBank.d463.s8.p0	buspirone	drug	_	digoxin	drug	_	mechanism	in vitro , druga may displace less firmly bound drugs like drugb .
DDI-DrugBank.d72.s0.p0	Itraconazole	drug	_	busulfan	drug	_	mechanism	druga decreases drugb clearance by up to 25 % , and may produce aucs # m min in some patients .
DDI-DrugBank.d72.s1.p0	Fluconazole	drug	_	5-HT3 antiemetics	group	_	false	druga , and the drugb drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p1	Fluconazole	drug	_	ondansetron	drug	_	false	druga , and the drugn drugb -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p2	Fluconazole	drug	_	Zofran	brand	_	false	druga , and the drugn drugn -lcb- drugb -rcb- and drugn -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p3	Fluconazole	drug	_	granisetron	drug	_	false	druga , and the drugn drugn -lcb- drugn -rcb- and drugb -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p4	Fluconazole	drug	_	Kytril	brand	_	false	druga , and the drugn drugn -lcb- drugn -rcb- and drugn -lcb- drugb -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p5	Fluconazole	drug	_	BUSULFEX	brand	_	false	druga , and the drugn drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugb .
DDI-DrugBank.d72.s1.p6	5-HT3 antiemetics	group	_	ondansetron	drug	_	false	drugn , and the druga drugb -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p7	5-HT3 antiemetics	group	_	Zofran	brand	_	false	drugn , and the druga drugn -lcb- drugb -rcb- and drugn -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p8	5-HT3 antiemetics	group	_	granisetron	drug	_	false	drugn , and the druga drugn -lcb- drugn -rcb- and drugb -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p9	5-HT3 antiemetics	group	_	Kytril	brand	_	false	drugn , and the druga drugn -lcb- drugn -rcb- and drugn -lcb- drugb -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p10	5-HT3 antiemetics	group	_	BUSULFEX	brand	_	false	drugn , and the druga drugn -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugb .
DDI-DrugBank.d72.s1.p12	ondansetron	drug	_	granisetron	drug	_	false	drugn , and the drugn druga -lcb- drugn -rcb- and drugb -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p13	ondansetron	drug	_	Kytril	brand	_	false	drugn , and the drugn druga -lcb- drugn -rcb- and drugn -lcb- drugb -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p14	ondansetron	drug	_	BUSULFEX	brand	_	false	drugn , and the drugn druga -lcb- drugn -rcb- and drugn -lcb- drugn -rcb- have all been used with drugb .
DDI-DrugBank.d72.s1.p15	Zofran	brand	_	granisetron	drug	_	false	drugn , and the drugn drugn -lcb- druga -rcb- and drugb -lcb- drugn -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p16	Zofran	brand	_	Kytril	brand	_	false	drugn , and the drugn drugn -lcb- druga -rcb- and drugn -lcb- drugb -rcb- have all been used with drugn .
DDI-DrugBank.d72.s1.p17	Zofran	brand	_	BUSULFEX	brand	_	false	drugn , and the drugn drugn -lcb- druga -rcb- and drugn -lcb- drugn -rcb- have all been used with drugb .
DDI-DrugBank.d72.s1.p19	granisetron	drug	_	BUSULFEX	brand	_	false	drugn , and the drugn drugn -lcb- drugn -rcb- and druga -lcb- drugn -rcb- have all been used with drugb .
DDI-DrugBank.d72.s1.p20	Kytril	brand	_	BUSULFEX	brand	_	false	drugn , and the drugn drugn -lcb- drugn -rcb- and drugn -lcb- druga -rcb- have all been used with drugb .
DDI-DrugBank.d72.s2.p0	Phenytoin	drug	_	busulfan	drug	_	mechanism	druga increases the clearance of drugb by 15 % or more , possibly due to the induction of glutathione-s-transferase .
DDI-DrugBank.d72.s3.p0	BUSULFEX	brand	_	phenytoin	drug	_	mechanism	since the pharmacokinetics of druga were studied in patients treated with drugb , the clearance of drugn at the recommended dose may be lower and exposure -lcb- auc -rcb- higher in patients not treated with drugn .
DDI-DrugBank.d72.s3.p2	BUSULFEX	brand	_	phenytoin	drug	_	false	since the pharmacokinetics of druga were studied in patients treated with drugn , the clearance of drugn at the recommended dose may be lower and exposure -lcb- auc -rcb- higher in patients not treated with drugb .
DDI-DrugBank.d72.s3.p3	phenytoin	drug	_	BUSULFEX	brand	_	false	since the pharmacokinetics of drugn were studied in patients treated with druga , the clearance of drugb at the recommended dose may be lower and exposure -lcb- auc -rcb- higher in patients not treated with drugn .
DDI-DrugBank.d72.s3.p5	BUSULFEX	brand	_	phenytoin	drug	_	false	since the pharmacokinetics of drugn were studied in patients treated with drugn , the clearance of druga at the recommended dose may be lower and exposure -lcb- auc -rcb- higher in patients not treated with drugb .
DDI-DrugBank.d72.s4.p0	busulfan	drug	_	acetaminophen	drug	_	false	because druga is eliminated from the body via conjugation with glutathione , use of drugb prior to -lcb- # hours -rcb- or concurrent with drugn may result in reduced drugn clearance based upon the known property of drugn to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p1	busulfan	drug	_	BUSULFEX	brand	_	false	because druga is eliminated from the body via conjugation with glutathione , use of drugn prior to -lcb- # hours -rcb- or concurrent with drugb may result in reduced drugn clearance based upon the known property of drugn to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p3	busulfan	drug	_	acetaminophen	drug	_	false	because druga is eliminated from the body via conjugation with glutathione , use of drugn prior to -lcb- # hours -rcb- or concurrent with drugn may result in reduced drugn clearance based upon the known property of drugb to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p4	acetaminophen	drug	_	BUSULFEX	brand	_	mechanism	because drugn is eliminated from the body via conjugation with glutathione , use of druga prior to -lcb- # hours -rcb- or concurrent with drugb may result in reduced drugn clearance based upon the known property of drugn to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p5	acetaminophen	drug	_	busulfan	drug	_	false	because drugn is eliminated from the body via conjugation with glutathione , use of druga prior to -lcb- # hours -rcb- or concurrent with drugn may result in reduced drugb clearance based upon the known property of drugn to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p7	BUSULFEX	brand	_	busulfan	drug	_	false	because drugn is eliminated from the body via conjugation with glutathione , use of drugn prior to -lcb- # hours -rcb- or concurrent with druga may result in reduced drugb clearance based upon the known property of drugn to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p8	BUSULFEX	brand	_	acetaminophen	drug	_	false	because drugn is eliminated from the body via conjugation with glutathione , use of drugn prior to -lcb- # hours -rcb- or concurrent with druga may result in reduced drugn clearance based upon the known property of drugb to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d72.s4.p9	busulfan	drug	_	acetaminophen	drug	_	false	because drugn is eliminated from the body via conjugation with glutathione , use of drugn prior to -lcb- # hours -rcb- or concurrent with drugn may result in reduced druga clearance based upon the known property of drugb to decrease glutathione levels in the blood and tissues .
DDI-DrugBank.d184.s0.p3	anticoagulants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugb may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p5	anticoagulants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugb may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p8	anticoagulants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p9	anticoagulants	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p10	anticoagulants	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p11	anticoagulants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p12	anticoagulants	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , druga -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p15	blood thinner	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugb may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p17	blood thinner	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugb may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p20	blood thinner	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p21	blood thinner	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p22	blood thinner	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p23	blood thinner	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p24	blood thinner	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- druga s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p26	carbamazepine	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugb may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p28	carbamazepine	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugb may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p31	carbamazepine	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p32	carbamazepine	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p33	carbamazepine	drug	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p34	carbamazepine	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p35	carbamazepine	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , druga , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p36	corticotropin	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugb may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p38	corticotropin	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugb may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p41	corticotropin	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p42	corticotropin	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p43	corticotropin	drug	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p44	corticotropin	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p45	corticotropin	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , druga -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p46	barbiturates	group	_	central nervous system (CNS) depressants	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugb -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p48	barbiturates	group	_	divalproex sodium	drug	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugb , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p49	barbiturates	group	_	valproic acid	drug	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugb -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p51	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p52	barbiturates	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p54	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- druga may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p55	central nervous system (CNS) depressants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugb may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p58	central nervous system (CNS) depressants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p59	central nervous system (CNS) depressants	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p60	central nervous system (CNS) depressants	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p61	central nervous system (CNS) depressants	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p62	central nervous system (CNS) depressants	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , druga -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p63	barbiturates	group	_	divalproex sodium	drug	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with druga may result in increased cns depressant effects -rcb- , drugb , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p64	barbiturates	group	_	valproic acid	drug	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with druga may result in increased cns depressant effects -rcb- , drugn , drugb -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p66	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with druga may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p67	barbiturates	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with druga may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p69	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with druga may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p71	divalproex sodium	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , druga , drugn -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p72	divalproex sodium	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , druga , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p73	divalproex sodium	drug	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , druga , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p74	divalproex sodium	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , druga , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p75	divalproex sodium	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , druga , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p76	valproic acid	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , druga -lcb- using these medicines with drugb may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p77	valproic acid	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , druga -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p78	valproic acid	drug	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , druga -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p79	valproic acid	drug	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , druga -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p80	valproic acid	drug	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , druga -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p81	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with druga may change the amount of either medicine that you need to take -rcb- , and oral drugb containing drugn -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p82	barbiturates	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with druga may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p84	barbiturates	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with druga may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p85	contraceptives	group	_	estrogens	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral druga containing drugb -lcb- drugn may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p86	contraceptives	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral druga containing drugn -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p88	estrogens	group	_	barbiturates	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing druga -lcb- drugb may decrease the effectiveness of these oral drugn , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p89	estrogens	group	_	contraceptives	group	_	false	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing druga -lcb- drugn may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d184.s0.p90	barbiturates	group	_	contraceptives	group	_	effect	interactions may occur with the following : adrenocorticoids -lcb- cortisone-like medicine -rcb- , drugn -lcb- drugn s -rcb- , drugn , drugn -lcb- drugn may decrease the effects of these medicines -rcb- , drugn -lcb- using these medicines with drugn may result in increased cns depressant effects -rcb- , drugn , drugn -lcb- using these medicines with drugn may change the amount of either medicine that you need to take -rcb- , and oral drugn containing drugn -lcb- druga may decrease the effectiveness of these oral drugb , and you may need to change to a different type of birth control -rcb- .
DDI-DrugBank.d559.s0.p0	butalbital	drug	_	monoamine oxidase (MAO) inhibitors	group	_	effect	the cns effects of druga may be enhanced by drugb .
DDI-DrugBank.d559.s1.p2	Butalbital	drug	_	narcotic analgesic	group	_	effect	druga , drugn and drugn may enhance the effects of : other drugb s , drugn , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p3	Butalbital	drug	_	alcohol	drug	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugb , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p4	Butalbital	drug	_	anesthetics	group	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugb , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p5	Butalbital	drug	_	tranquilizers	group	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p6	Butalbital	drug	_	chlordiazepoxide	drug	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p7	Butalbital	drug	_	sedative-hypnotics	group	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p8	Butalbital	drug	_	CNS depressants	group	_	effect	druga , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p9	acetaminophen	drug	_	caffeine	drug	_	false	drugn , druga and drugb may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p10	acetaminophen	drug	_	narcotic analgesic	group	_	effect	drugn , druga and drugn may enhance the effects of : other drugb s , drugn , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p11	acetaminophen	drug	_	alcohol	drug	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugb , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p12	acetaminophen	drug	_	anesthetics	group	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugn , general drugb , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p13	acetaminophen	drug	_	tranquilizers	group	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p14	acetaminophen	drug	_	chlordiazepoxide	drug	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p15	acetaminophen	drug	_	sedative-hypnotics	group	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p16	acetaminophen	drug	_	CNS depressants	group	_	effect	drugn , druga and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p17	caffeine	drug	_	narcotic analgesic	group	_	effect	drugn , drugn and druga may enhance the effects of : other drugb s , drugn , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p18	caffeine	drug	_	alcohol	drug	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugb , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p19	caffeine	drug	_	anesthetics	group	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugn , general drugb , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p20	caffeine	drug	_	tranquilizers	group	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugn , general drugn , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p21	caffeine	drug	_	chlordiazepoxide	drug	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p22	caffeine	drug	_	sedative-hypnotics	group	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p23	caffeine	drug	_	CNS depressants	group	_	effect	drugn , drugn and druga may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p24	narcotic analgesic	group	_	alcohol	drug	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugb , general drugn , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p25	narcotic analgesic	group	_	anesthetics	group	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugn , general drugb , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p26	narcotic analgesic	group	_	tranquilizers	group	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugn , general drugn , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p27	narcotic analgesic	group	_	chlordiazepoxide	drug	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugn , general drugn , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p28	narcotic analgesic	group	_	sedative-hypnotics	group	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugn , general drugn , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p29	narcotic analgesic	group	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other druga s , drugn , general drugn , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p30	alcohol	drug	_	anesthetics	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , druga , general drugb , drugn such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p31	alcohol	drug	_	tranquilizers	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , druga , general drugn , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p32	alcohol	drug	_	chlordiazepoxide	drug	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , druga , general drugn , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p33	alcohol	drug	_	sedative-hypnotics	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , druga , general drugn , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p34	alcohol	drug	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , druga , general drugn , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p35	anesthetics	group	_	tranquilizers	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general druga , drugb such as drugn , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p36	anesthetics	group	_	chlordiazepoxide	drug	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general druga , drugn such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p37	anesthetics	group	_	sedative-hypnotics	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general druga , drugn such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p38	anesthetics	group	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general druga , drugn such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p39	tranquilizers	group	_	chlordiazepoxide	drug	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , druga such as drugb , drugn , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p40	tranquilizers	group	_	sedative-hypnotics	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , druga such as drugn , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p41	tranquilizers	group	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , druga such as drugn , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p42	chlordiazepoxide	drug	_	sedative-hypnotics	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as druga , drugb , or other drugn , causing increased cns depression .
DDI-DrugBank.d559.s1.p43	chlordiazepoxide	drug	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as druga , drugn , or other drugb , causing increased cns depression .
DDI-DrugBank.d559.s1.p44	sedative-hypnotics	group	_	CNS depressants	group	_	false	drugn , drugn and drugn may enhance the effects of : other drugn s , drugn , general drugn , drugn such as drugn , druga , or other drugb , causing increased cns depression .
DDI-DrugBank.d246.s0.p0	butorphanol	drug	_	central nervous system depressants	group	_	effect	concurrent use of druga with drugb -lcb- e , g , , drugn , drugn , drugn , and drugn -rcb- may result in increased drugn effects .
DDI-DrugBank.d246.s0.p1	butorphanol	drug	_	alcohol	drug	_	effect	concurrent use of druga with drugn -lcb- e , g , , drugb , drugn , drugn , and drugn -rcb- may result in increased drugn effects .
DDI-DrugBank.d246.s0.p2	butorphanol	drug	_	barbiturates	group	_	effect	concurrent use of druga with drugn -lcb- e , g , , drugn , drugb , drugn , and drugn -rcb- may result in increased drugn effects .
DDI-DrugBank.d246.s0.p3	butorphanol	drug	_	tranquilizers	group	_	effect	concurrent use of druga with drugn -lcb- e , g , , drugn , drugn , drugb , and drugn -rcb- may result in increased drugn effects .
DDI-DrugBank.d246.s0.p4	butorphanol	drug	_	antihistamines	group	_	effect	concurrent use of druga with drugn -lcb- e , g , , drugn , drugn , drugn , and drugb -rcb- may result in increased drugn effects .
DDI-DrugBank.d246.s0.p5	butorphanol	drug	_	central nervous system depressant	group	_	false	concurrent use of druga with drugn -lcb- e , g , , drugn , drugn , drugn , and drugn -rcb- may result in increased drugb effects .
DDI-DrugBank.d246.s0.p14	alcohol	drug	_	central nervous system depressant	group	_	false	concurrent use of drugn with drugn -lcb- e , g , , druga , drugn , drugn , and drugn -rcb- may result in increased drugb effects .
DDI-DrugBank.d246.s0.p17	barbiturates	group	_	central nervous system depressant	group	_	false	concurrent use of drugn with drugn -lcb- e , g , , drugn , druga , drugn , and drugn -rcb- may result in increased drugb effects .
DDI-DrugBank.d246.s0.p19	tranquilizers	group	_	central nervous system depressant	group	_	false	concurrent use of drugn with drugn -lcb- e , g , , drugn , drugn , druga , and drugn -rcb- may result in increased drugb effects .
DDI-DrugBank.d246.s0.p20	antihistamines	group	_	central nervous system depressant	group	_	false	concurrent use of drugn with drugn -lcb- e , g , , drugn , drugn , drugn , and druga -rcb- may result in increased drugb effects .
DDI-DrugBank.d246.s1.p0	butorphanol	drug	_	opioids	group	_	false	when used concurrently with such drugs , the dose of druga should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of drugb .
DDI-DrugBank.d246.s2.p0	butorphanol	drug	_	STADOL NS	brand	_	false	in healthy volunteers , the pharmacokinetics of a 1-mg dose of druga administered as drugb were not affected by the coadministration of a single 6-mg subcutaneous dose of drugn .
DDI-DrugBank.d246.s2.p1	butorphanol	drug	_	sumatriptan	drug	_	false	in healthy volunteers , the pharmacokinetics of a 1-mg dose of druga administered as drugn were not affected by the coadministration of a single 6-mg subcutaneous dose of drugb .
DDI-DrugBank.d246.s2.p2	STADOL NS	brand	_	sumatriptan	drug	_	false	in healthy volunteers , the pharmacokinetics of a 1-mg dose of drugn administered as druga were not affected by the coadministration of a single 6-mg subcutaneous dose of drugb .
DDI-DrugBank.d246.s3.p0	butorphanol	drug	_	STADOL NS	brand	_	false	however , in another study in healthy volunteers , the pharmacokinetics of druga were significantly altered -lcb- 29 % decrease in auc and 38 % decrease in cmax -rcb- when a 1-mg dose of drugb was administered # minute after a 20-mg dose of drugn nasal spray .
DDI-DrugBank.d246.s3.p1	butorphanol	drug	_	sumatriptan	drug	_	false	however , in another study in healthy volunteers , the pharmacokinetics of druga were significantly altered -lcb- 29 % decrease in auc and 38 % decrease in cmax -rcb- when a 1-mg dose of drugn was administered # minute after a 20-mg dose of drugb nasal spray .
DDI-DrugBank.d246.s3.p2	STADOL NS	brand	_	sumatriptan	drug	_	mechanism	however , in another study in healthy volunteers , the pharmacokinetics of drugn were significantly altered -lcb- 29 % decrease in auc and 38 % decrease in cmax -rcb- when a 1-mg dose of druga was administered # minute after a 20-mg dose of drugb nasal spray .
DDI-DrugBank.d246.s5.p0	STADOL NS	brand	_	sumatriptan	drug	_	mechanism	when the druga was administered # minutes after the drugb nasal spray , the auc of drugn increased 11 % and cmax decreased 18 % .
DDI-DrugBank.d246.s5.p1	STADOL NS	brand	_	butorphanol	drug	_	false	when the druga was administered # minutes after the drugn nasal spray , the auc of drugb increased 11 % and cmax decreased 18 % .
DDI-DrugBank.d246.s5.p2	sumatriptan	drug	_	butorphanol	drug	_	false	when the drugn was administered # minutes after the druga nasal spray , the auc of drugb increased 11 % and cmax decreased 18 % .
DDI-DrugBank.d246.s6.p0	sumatriptan	drug	_	STADOL NS	brand	_	false	in neither case were the pharmacokinetics of druga affected by coadministration with drugb .
DDI-DrugBank.d246.s7.p0	STADOL NS	brand	_	sumatriptan	drug	_	effect	these results suggest that the analgesic effect of druga may be diminished when it is administered shortly after drugb nasal spray , but by # minutes any such reduction in effect should be minimal .
DDI-DrugBank.d246.s8.p0	STADOL NS	brand	_	IMITREX	brand	_	false	the safety of using druga and drugb -lcb- drugn -rcb- nasal spray during the same episode of migraine has not been established .
DDI-DrugBank.d246.s8.p1	STADOL NS	brand	_	sumatriptan	drug	_	false	the safety of using druga and drugn -lcb- drugb -rcb- nasal spray during the same episode of migraine has not been established .
DDI-DrugBank.d246.s10.p0	butorphanol	drug	_	STADOL NS	brand	_	false	the pharmacokinetics of a 1-mg dose of druga administered as drugb were not affected by the coadministration of drugn -lcb- 300 mg qid -rcb- .
DDI-DrugBank.d246.s10.p1	butorphanol	drug	_	cimetidine	drug	_	false	the pharmacokinetics of a 1-mg dose of druga administered as drugn were not affected by the coadministration of drugb -lcb- 300 mg qid -rcb- .
DDI-DrugBank.d246.s10.p2	STADOL NS	brand	_	cimetidine	drug	_	false	the pharmacokinetics of a 1-mg dose of drugn administered as druga were not affected by the coadministration of drugb -lcb- 300 mg qid -rcb- .
DDI-DrugBank.d246.s11.p1	STADOL NS	brand	_	cimetidine	drug	_	false	conversely , the administration of druga -lcb- 1 mg drugn qid -rcb- did not alter the pharmacokinetics of a 300-mg dose of drugb .
DDI-DrugBank.d246.s11.p2	butorphanol	drug	_	cimetidine	drug	_	false	conversely , the administration of drugn -lcb- 1 mg druga qid -rcb- did not alter the pharmacokinetics of a 300-mg dose of drugb .
DDI-DrugBank.d246.s12.p0	butorphanol	drug	_	erythromycin	drug	_	advise	it is not known if the effects of druga are altered by concomitant medications that affect hepatic metabolism of drugs -lcb- drugb , etc , -rcb- , but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed .
DDI-DrugBank.d246.s13.p0	STADOL NS	brand	_	nasal vasoconstrictor	group	_	false	the fraction of druga absorbed is unaffected by the concomitant administration of a drugb -lcb- drugn -rcb- , but the rate of absorption is decreased .
DDI-DrugBank.d246.s13.p1	STADOL NS	brand	_	oxymetazoline	drug	_	false	the fraction of druga absorbed is unaffected by the concomitant administration of a drugn -lcb- drugb -rcb- , but the rate of absorption is decreased .
DDI-DrugBank.d246.s14.p0	STADOL NS	brand	_	nasal vasoconstrictor	group	_	effect	therefore , a slower onset can be anticipated if druga is administered concomitantly with , or immediately following , a drugb .
DDI-DrugBank.d246.s15.p0	butorphanol	drug	_	MAO inhibitors	group	_	false	no information is available about the use of druga concurrently with drugb .
DDI-DrugBank.d282.s0.p0	DOSTINEX	brand	_	phenothiazines	group	_	advise	druga should not be administered concurrently with d2-antagonists , such as drugb , drugn , drugn , or drugn .
DDI-DrugBank.d282.s0.p1	DOSTINEX	brand	_	butyrophenones	group	_	advise	druga should not be administered concurrently with d2-antagonists , such as drugn , drugb , drugn , or drugn .
DDI-DrugBank.d282.s0.p2	DOSTINEX	brand	_	thioxanthines	group	_	advise	druga should not be administered concurrently with d2-antagonists , such as drugn , drugn , drugb , or drugn .
DDI-DrugBank.d282.s0.p3	DOSTINEX	brand	_	metoclopramide	drug	_	advise	druga should not be administered concurrently with d2-antagonists , such as drugn , drugn , drugn , or drugb .
DDI-DrugBank.d89.s3.p1	caffeine	drug	_	cimetidine	drug	_	advise	based on adult data , lower doses of druga may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugb and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p2	caffeine	drug	_	ketoconazole	drug	_	advise	based on adult data , lower doses of druga may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugb -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p5	caffeine	drug	_	phenobarbital	drug	_	false	based on adult data , lower doses of druga may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p6	caffeine	drug	_	phenytoin	drug	_	false	based on adult data , lower doses of druga may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s3.p7	caffeine	drug	_	cimetidine	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease druga elimination -lcb- e , g , , drugb and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p8	caffeine	drug	_	ketoconazole	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease druga elimination -lcb- e , g , , drugn and drugb -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p11	caffeine	drug	_	phenobarbital	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease druga elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p12	caffeine	drug	_	phenytoin	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease druga elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s3.p14	cimetidine	drug	_	caffeine	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , druga and drugn -rcb- and higher drugb doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p15	cimetidine	drug	_	caffeine	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , druga and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugb elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p16	cimetidine	drug	_	phenobarbital	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , druga and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p17	cimetidine	drug	_	phenytoin	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , druga and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s3.p18	ketoconazole	drug	_	caffeine	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and druga -rcb- and higher drugb doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p19	ketoconazole	drug	_	caffeine	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and druga -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugb elimination -lcb- e , g , , drugn and drugn -rcb- .
DDI-DrugBank.d89.s3.p20	ketoconazole	drug	_	phenobarbital	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and druga -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p21	ketoconazole	drug	_	phenytoin	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and druga -rcb- and higher drugn doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s3.p23	caffeine	drug	_	phenobarbital	drug	_	advise	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher druga doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p24	caffeine	drug	_	phenytoin	drug	_	advise	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher druga doses may be needed following coadministration of drugs that increase drugn elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s3.p25	caffeine	drug	_	phenobarbital	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase druga elimination -lcb- e , g , , drugb and drugn -rcb- .
DDI-DrugBank.d89.s3.p26	caffeine	drug	_	phenytoin	drug	_	false	based on adult data , lower doses of drugn may be needed following coadministration of drugs which are reported to decrease drugn elimination -lcb- e , g , , drugn and drugn -rcb- and higher drugn doses may be needed following coadministration of drugs that increase druga elimination -lcb- e , g , , drugn and drugb -rcb- .
DDI-DrugBank.d89.s4.p0	Caffeine	drug	_	ketoprofen	drug	_	effect	druga administered concurrently with drugb reduced the urine volume in # healthy volunteers .
DDI-DrugBank.d89.s6.p0	caffeine	drug	_	theophylline	drug	_	false	interconversion between druga and drugb has been reported in preterm neonates .
DDI-DrugBank.d98.s0.p4	vitamin D analogues	group	_	Cholestyramine	drug	_	false	interactions for druga -lcb- drugn , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d98.s0.p10	Vitamin D2	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- druga , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d98.s0.p15	Vitamin D3	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , druga , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d98.s0.p19	Calcitriol	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , drugn , druga , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d98.s0.p22	Calcidiol	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , drugn , drugn , and druga -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d98.s0.p27	Cholestyramine	drug	_	fat soluble vitamins	group	_	mechanism	interactions for drugn -lcb- drugn , drugn , drugn , and drugn -rcb- : drugn : druga has been reported to reduce intestinal absorption of drugb ;
DDI-DrugBank.d98.s2.p0	Phenytoin	drug	_	Phenobarbital	drug	_	false	druga / drugb : the coadministration of drugn or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p9	phenytoin	drug	_	phenobarbital	drug	_	false	drugn / drugn : the coadministration of druga or drugb will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p10	phenytoin	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p11	phenytoin	drug	_	calcitriol	drug	_	mechanism	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p12	phenobarbital	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p13	phenobarbital	drug	_	calcitriol	drug	_	mechanism	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s2.p14	vitamin D	group	_	calcitriol	drug	_	false	drugn / drugn : the coadministration of drugn or drugn will not affect plasma concentrations of druga , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d98.s3.p0	calcitriol	drug	_	Rocaltrol	brand	_	false	since blood level of druga / ergocalcitriol will be reduced , higher doses of drugb may be necessary if these drugs are administered simultaneously .
DDI-DrugBank.d98.s5.p0	thiazides	group	_	vitamin D	group	_	effect	some reports have shown that the concomitant administration of druga with drugb causes hypercalcemia .
DDI-DrugBank.d98.s7.p2	Vitamin D	group	_	digitalis	group	_	advise	drugn : druga dosage must be determined with care in patients undergoing treatment with drugb , as hypercalcemia in such patients may precipitate cardiac arrhythmias .
DDI-DrugBank.d98.s8.p2	Ketoconazole	drug	_	vitamin D	group	_	mechanism	drugn : druga may inhibit both synthetic and catabolic enzymes of drugb .
DDI-DrugBank.d98.s10.p0	ketoconazole	drug	_	vitamin D	group	_	false	however , in vivo drug interaction studies of druga with drugb have not been investigated .
DDI-DrugBank.d98.s11.p2	vitamin D analogues	group	_	corticosteroids	group	_	mechanism	drugn : a relationship of functional antagonism exists between druga , which promote calcium absorption , and drugb , which inhibit calcium absorption .
DDI-DrugBank.d98.s15.p3	Magnesium	drug	_	antacids	group	_	false	drugn : druga - containing preparations -lcb- eg , drugb -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugn by patients on chronic renal dialysis .
DDI-DrugBank.d98.s15.p4	Magnesium	drug	_	vitamin D	group	_	advise	drugn : druga - containing preparations -lcb- eg , drugn -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d98.s15.p5	antacids	group	_	vitamin D	group	_	advise	drugn : drugn - containing preparations -lcb- eg , druga -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d384.s0.p4	vitamin D analogues	group	_	Cholestyramine	drug	_	false	interactions for druga -lcb- drugn , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d384.s0.p10	Vitamin D2	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- druga , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d384.s0.p15	Vitamin D3	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , druga , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d384.s0.p19	Calcitriol	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , drugn , druga , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d384.s0.p22	Calcidiol	drug	_	Cholestyramine	drug	_	false	interactions for drugn -lcb- drugn , drugn , drugn , and druga -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d384.s0.p27	Cholestyramine	drug	_	fat soluble vitamins	group	_	mechanism	interactions for drugn -lcb- drugn , drugn , drugn , and drugn -rcb- : drugn : druga has been reported to reduce intestinal absorption of drugb ;
DDI-DrugBank.d384.s2.p0	Phenytoin	drug	_	Phenobarbital	drug	_	false	druga / drugb : the coadministration of drugn or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p9	phenytoin	drug	_	phenobarbital	drug	_	false	drugn / drugn : the coadministration of druga or drugb will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p10	phenytoin	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p11	phenytoin	drug	_	calcitriol	drug	_	mechanism	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p12	phenobarbital	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p13	phenobarbital	drug	_	calcitriol	drug	_	mechanism	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s2.p14	vitamin D	group	_	calcitriol	drug	_	false	drugn / drugn : the coadministration of drugn or drugn will not affect plasma concentrations of druga , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d384.s3.p0	calcitriol	drug	_	Rocaltrol	brand	_	false	since blood level of druga / ergocalcitriol will be reduced , higher doses of drugb may be necessary if these drugs are administered simultaneously .
DDI-DrugBank.d384.s4.p2	Thiazides	group	_	calcium	drug	_	false	drugn : druga are known to induce hypercalcemia by the reduction of drugb excretion in urine .
DDI-DrugBank.d384.s5.p0	thiazides	group	_	vitamin D	group	_	effect	some reports have shown that the concomitant administration of druga with drugb causes hypercalcemia .
DDI-DrugBank.d384.s7.p2	Vitamin D	group	_	digitalis	group	_	advise	drugn : druga dosage must be determined with care in patients undergoing treatment with drugb , as hypercalcemia in such patients may precipitate cardiac arrhythmias .
DDI-DrugBank.d384.s8.p2	Ketoconazole	drug	_	vitamin D	group	_	mechanism	drugn : druga may inhibit both synthetic and catabolic enzymes of drugb .
DDI-DrugBank.d384.s10.p0	ketoconazole	drug	_	vitamin D	group	_	false	however , in vivo drug interaction studies of druga with drugb have not been investigated .
DDI-DrugBank.d384.s11.p2	vitamin D analogues	group	_	corticosteroids	group	_	mechanism	drugn : a relationship of functional antagonism exists between druga , which promote calcium absorption , and drugb , which inhibit calcium absorption .
DDI-DrugBank.d384.s15.p3	Magnesium	drug	_	antacids	group	_	false	drugn : druga - containing preparations -lcb- eg , drugb -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugn by patients on chronic renal dialysis .
DDI-DrugBank.d384.s15.p4	Magnesium	drug	_	vitamin D	group	_	advise	drugn : druga - containing preparations -lcb- eg , drugn -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d384.s15.p5	antacids	group	_	vitamin D	group	_	advise	drugn : drugn - containing preparations -lcb- eg , druga -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d494.s0.p0	calcium	drug	_	antacids	group	_	false	concomitant use with other druga - containing medicines -lcb- including drugb -rcb- may cause too much drugn in the blood or urine , which may increase the chance of side effects .
DDI-DrugBank.d494.s0.p2	antacids	group	_	calcium	drug	_	false	concomitant use with other drugn - containing medicines -lcb- including druga -rcb- may cause too much drugb in the blood or urine , which may increase the chance of side effects .
DDI-DrugBank.d494.s1.p0	calcium acetate	drug	_	digitalis glycosides	group	_	effect	using druga with drugb -lcb- heart medicine -rcb- may cause hypercalcemia -lcb- too much drugn in the blood -rcb- , which could increase the chance of developing an irregular heartbeat .
DDI-DrugBank.d494.s1.p2	digitalis glycosides	group	_	calcium	drug	_	false	using drugn with druga -lcb- heart medicine -rcb- may cause hypercalcemia -lcb- too much drugb in the blood -rcb- , which could increase the chance of developing an irregular heartbeat .
DDI-DrugBank.d547.s0.p0	candesartan cilexetil	drug	_	glyburide	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugb , drugn , drugn , drugn , drugn , and oral drugn in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p1	candesartan cilexetil	drug	_	nifedipine	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugb , drugn , drugn , drugn , and oral drugn in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p2	candesartan cilexetil	drug	_	digoxin	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugn , drugb , drugn , drugn , and oral drugn in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p3	candesartan cilexetil	drug	_	warfarin	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugn , drugn , drugb , drugn , and oral drugn in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p4	candesartan cilexetil	drug	_	hydrochlorothiazide	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugn , drugn , drugn , drugb , and oral drugn in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p5	candesartan cilexetil	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugn , drugn , drugn , drugn , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p6	candesartan cilexetil	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of druga given with other drugs such as drugn , drugn , drugn , drugn , drugn , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p11	glyburide	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as druga , drugn , drugn , drugn , drugn , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p12	glyburide	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as druga , drugn , drugn , drugn , drugn , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p16	nifedipine	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , druga , drugn , drugn , drugn , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p17	nifedipine	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , druga , drugn , drugn , drugn , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p20	digoxin	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , druga , drugn , drugn , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p21	digoxin	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , druga , drugn , drugn , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p23	warfarin	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , drugn , druga , drugn , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p24	warfarin	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , drugn , druga , drugn , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p25	hydrochlorothiazide	drug	_	contraceptives	group	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , drugn , drugn , druga , and oral drugb in healthy volunteers , or given with drugn to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p26	hydrochlorothiazide	drug	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , drugn , drugn , druga , and oral drugn in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s0.p27	contraceptives	group	_	enalapril	drug	_	false	no significant drug interactions have been reported in studies of drugn given with other drugs such as drugn , drugn , drugn , drugn , drugn , and oral druga in healthy volunteers , or given with drugb to patients with heart failure -lcb- nyha class ii and iii -rcb- .
DDI-DrugBank.d547.s2.p2	Lithium	drug	_	ACE inhibitors	group	_	false	druga reversible increases in serum drugn concentrations and toxicity have been reported during concomitant administration of drugn with drugb , and with some drugn .
DDI-DrugBank.d547.s2.p3	Lithium	drug	_	angiotensin II receptor antagonists	group	_	false	druga reversible increases in serum drugn concentrations and toxicity have been reported during concomitant administration of drugn with drugn , and with some drugb .
DDI-DrugBank.d547.s2.p5	lithium	drug	_	ACE inhibitors	group	_	false	drugn reversible increases in serum druga concentrations and toxicity have been reported during concomitant administration of drugn with drugb , and with some drugn .
DDI-DrugBank.d547.s2.p6	lithium	drug	_	angiotensin II receptor antagonists	group	_	false	drugn reversible increases in serum druga concentrations and toxicity have been reported during concomitant administration of drugn with drugn , and with some drugb .
DDI-DrugBank.d547.s2.p7	lithium	drug	_	ACE inhibitors	group	_	mechanism	drugn reversible increases in serum drugn concentrations and toxicity have been reported during concomitant administration of druga with drugb , and with some drugn .
DDI-DrugBank.d547.s2.p8	lithium	drug	_	angiotensin II receptor antagonists	group	_	mechanism	drugn reversible increases in serum drugn concentrations and toxicity have been reported during concomitant administration of druga with drugn , and with some drugb .
DDI-DrugBank.d547.s2.p9	ACE inhibitors	group	_	angiotensin II receptor antagonists	group	_	false	drugn reversible increases in serum drugn concentrations and toxicity have been reported during concomitant administration of drugn with druga , and with some drugb .
DDI-DrugBank.d547.s3.p1	lithium	drug	_	ATACAND	brand	_	false	an increase in serum druga concentration has been reported during concomitant administration of drugn with drugb , so careful monitoring of serum drugn levels is recommended during concomitant use .
DDI-DrugBank.d547.s3.p3	lithium	drug	_	ATACAND	brand	_	mechanism	an increase in serum drugn concentration has been reported during concomitant administration of druga with drugb , so careful monitoring of serum drugn levels is recommended during concomitant use .
DDI-DrugBank.d547.s3.p5	ATACAND	brand	_	lithium	drug	_	false	an increase in serum drugn concentration has been reported during concomitant administration of drugn with druga , so careful monitoring of serum drugb levels is recommended during concomitant use .
DDI-DrugBank.d88.s0.p5	aluminum hydroxide	drug	_	magnesium hydroxide	drug	_	false	drugn : the effect of an druga - and drugb - containing drugn -lcb- drugn -rcb- * on the pharmacokinetics of drugn was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p6	aluminum hydroxide	drug	_	antacid	group	_	false	drugn : the effect of an druga - and drugn - containing drugb -lcb- drugn -rcb- * on the pharmacokinetics of drugn was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p7	aluminum hydroxide	drug	_	Maalox	brand	_	false	drugn : the effect of an druga - and drugn - containing drugn -lcb- drugb -rcb- * on the pharmacokinetics of drugn was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p8	aluminum hydroxide	drug	_	capecitabine	drug	_	false	drugn : the effect of an druga - and drugn - containing drugn -lcb- drugn -rcb- * on the pharmacokinetics of drugb was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p9	magnesium hydroxide	drug	_	antacid	group	_	false	drugn : the effect of an drugn - and druga - containing drugb -lcb- drugn -rcb- * on the pharmacokinetics of drugn was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p10	magnesium hydroxide	drug	_	Maalox	brand	_	false	drugn : the effect of an drugn - and druga - containing drugn -lcb- drugb -rcb- * on the pharmacokinetics of drugn was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p11	magnesium hydroxide	drug	_	capecitabine	drug	_	false	drugn : the effect of an drugn - and druga - containing drugn -lcb- drugn -rcb- * on the pharmacokinetics of drugb was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p13	antacid	group	_	capecitabine	drug	_	false	drugn : the effect of an drugn - and drugn - containing druga -lcb- drugn -rcb- * on the pharmacokinetics of drugb was investigated in # cancer patients .
DDI-DrugBank.d88.s0.p14	Maalox	brand	_	capecitabine	drug	_	false	drugn : the effect of an drugn - and drugn - containing drugn -lcb- druga -rcb- * on the pharmacokinetics of drugb was investigated in # cancer patients .
DDI-DrugBank.d88.s1.p0	capecitabine	drug	_	5-DFCR	drug_n	_	false	there was a small increase in plasma concentrations of druga and one metabolite -lcb- drugb -rcb- ;
DDI-DrugBank.d88.s3.p0	Coumarin Anticoagulants	group	_	capecitabine	drug	_	false	druga altered coagulation parameters and/or bleeding have been reported in patients taking drugb concomitantly with drugn such as drugn and drugn .
DDI-DrugBank.d88.s3.p1	Coumarin Anticoagulants	group	_	coumarin-derivative anticoagulants	group	_	false	druga altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with drugb such as drugn and drugn .
DDI-DrugBank.d88.s3.p2	Coumarin Anticoagulants	group	_	warfarin	drug	_	false	druga altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with drugn such as drugb and drugn .
DDI-DrugBank.d88.s3.p3	Coumarin Anticoagulants	group	_	phenprocoumon	drug	_	false	druga altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with drugn such as drugn and drugb .
DDI-DrugBank.d88.s3.p4	capecitabine	drug	_	coumarin-derivative anticoagulants	group	_	effect	drugn altered coagulation parameters and/or bleeding have been reported in patients taking druga concomitantly with drugb such as drugn and drugn .
DDI-DrugBank.d88.s3.p5	capecitabine	drug	_	warfarin	drug	_	false	drugn altered coagulation parameters and/or bleeding have been reported in patients taking druga concomitantly with drugn such as drugb and drugn .
DDI-DrugBank.d88.s3.p6	capecitabine	drug	_	phenprocoumon	drug	_	effect	drugn altered coagulation parameters and/or bleeding have been reported in patients taking druga concomitantly with drugn such as drugn and drugb .
DDI-DrugBank.d88.s3.p7	coumarin-derivative anticoagulants	group	_	warfarin	drug	_	false	drugn altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with druga such as drugb and drugn .
DDI-DrugBank.d88.s3.p8	coumarin-derivative anticoagulants	group	_	phenprocoumon	drug	_	false	drugn altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with druga such as drugn and drugb .
DDI-DrugBank.d88.s3.p9	warfarin	drug	_	phenprocoumon	drug	_	false	drugn altered coagulation parameters and/or bleeding have been reported in patients taking drugn concomitantly with drugn such as druga and drugb .
DDI-DrugBank.d88.s4.p0	coumarin-derivative anticoagulants	group	_	capecitabine	drug	_	advise	patients taking druga concomitantly with drugb should be monitored regularly for alterations in their coagulation parameters -lcb- pt or inr -rcb- .
DDI-DrugBank.d88.s5.p2	5-fluorouracil	drug	_	leucovorin	drug	_	mechanism	drugn : the concentration of druga is increased and its toxicity may be enhanced by drugb .
DDI-DrugBank.d88.s6.p0	leucovorin	drug	_	fluorouracil	drug	_	effect	deaths from severe enterocolitis , diarrhea , and dehydration have been reported in elderly patients receiving weekly druga and drugb .
DDI-DrugBank.d175.s0.p4	diuretics	group	_	captopril	drug	_	effect	hypotension patients on drugn therapy : patients on druga and especially those in whom drugn therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of drugb .
DDI-DrugBank.d175.s0.p5	diuretic	group	_	captopril	drug	_	false	hypotension patients on drugn therapy : patients on drugn and especially those in whom druga therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of drugb .
DDI-DrugBank.d175.s1.p0	captopril	drug	_	diuretic	group	_	effect	the possibility of hypotensive effects with druga can be minimized by either discontinuing the drugb or increasing the salt intake approximately one week prior to initiation of treatment with drugn -lcb- drugn tablets , usp -rcb- or initiating therapy with small doses -lcb- # or # mg -rcb- .
DDI-DrugBank.d175.s1.p3	diuretic	group	_	captopril	drug	_	false	the possibility of hypotensive effects with drugn can be minimized by either discontinuing the druga or increasing the salt intake approximately one week prior to initiation of treatment with drugb -lcb- drugn tablets , usp -rcb- or initiating therapy with small doses -lcb- # or # mg -rcb- .
DDI-DrugBank.d175.s1.p4	diuretic	group	_	captopril	drug	_	false	the possibility of hypotensive effects with drugn can be minimized by either discontinuing the druga or increasing the salt intake approximately one week prior to initiation of treatment with drugn -lcb- drugb tablets , usp -rcb- or initiating therapy with small doses -lcb- # or # mg -rcb- .
DDI-DrugBank.d175.s5.p0	vasodilators	group	_	captopril	drug	_	false	agents having vasodilator activity : data on the effect of concomitant use of other druga in patients receiving drugb for heart failure are not available ;
DDI-DrugBank.d175.s6.p1	nitroglycerin	drug	_	captopril	drug	_	advise	therefore , druga or other drugn -lcb- as used for management of angina -rcb- or other drugs having vasodilator activity should , if possible , be discontinued before starting drugb .
DDI-DrugBank.d175.s6.p2	nitrates	group	_	captopril	drug	_	advise	therefore , drugn or other druga -lcb- as used for management of angina -rcb- or other drugs having vasodilator activity should , if possible , be discontinued before starting drugb .
DDI-DrugBank.d175.s8.p0	Captopril	drug	_	antihypertensive agents	group	_	effect	agents causing renin release druga 's effect will be augmented by drugb that cause renin release .
DDI-DrugBank.d175.s10.p0	captopril	drug	_	diuretics	group	_	false	agents affecting sympathetic activity the sympathetic nervous system may be especially important in supporting blood pressure in patients receiving druga alone or with drugb .
DDI-DrugBank.d175.s12.p0	Beta-adrenergic blocking drugs	group	_	captopril	drug	_	effect	druga add some further antihypertensive effect to drugb , but the overall response is less than additive .
DDI-DrugBank.d175.s14.p0	Potassium-sparing diuretics	group	_	spironolactone	drug	_	false	druga such as drugb , drugn , or drugn , or drugn supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s14.p1	Potassium-sparing diuretics	group	_	triamterene	drug	_	false	druga such as drugn , drugb , or drugn , or drugn supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s14.p2	Potassium-sparing diuretics	group	_	amiloride	drug	_	false	druga such as drugn , drugn , or drugb , or drugn supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s14.p6	spironolactone	drug	_	potassium	drug	_	false	drugn such as druga , drugn , or drugn , or drugb supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s14.p8	triamterene	drug	_	potassium	drug	_	false	drugn such as drugn , druga , or drugn , or drugb supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s14.p9	amiloride	drug	_	potassium	drug	_	false	drugn such as drugn , drugn , or druga , or drugb supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .
DDI-DrugBank.d175.s16.p0	indomethacin	drug	_	captopril	drug	_	effect	inhibitors of endogenous prostaglandin synthesis it has been reported that druga may reduce the antihypertensive effect of drugb , especially in cases of low renin hypertension .
DDI-DrugBank.d175.s18.p3	Lithium	drug	_	ACE inhibitor	group	_	false	druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving concomitant drugn and drugb therapy .
DDI-DrugBank.d175.s18.p6	lithium	drug	_	ACE inhibitor	group	_	false	drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving concomitant drugn and drugb therapy .
DDI-DrugBank.d175.s18.p8	lithium	drug	_	ACE inhibitor	group	_	false	drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving concomitant drugn and drugb therapy .
DDI-DrugBank.d175.s18.p9	lithium	drug	_	ACE inhibitor	group	_	effect	drugn : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving concomitant druga and drugb therapy .
DDI-DrugBank.d175.s20.p0	diuretic	group	_	lithium	drug	_	effect	if a druga is also used , it may increase the risk of drugb toxicity .
DDI-DrugBank.d175.s21.p2	captopril	drug	_	digoxin	drug	_	false	drugn : in a study of young healthy male subjects no evidence of a direct pharmacokinetic druga - drugb interaction could be found .
DDI-DrugBank.d175.s22.p3	Furosemide	drug	_	captopril	drug	_	false	drugn : druga administered concurrently with drugb does not alter the pharmacokinetics of drugn in renally impaired hypertensive patients .
DDI-DrugBank.d175.s22.p4	Furosemide	drug	_	captopril	drug	_	false	drugn : druga administered concurrently with drugn does not alter the pharmacokinetics of drugb in renally impaired hypertensive patients .
DDI-DrugBank.d175.s23.p2	captopril	drug	_	allopurinol	drug	_	false	drugn : in a study of healthy male volunteers no significant pharmacokinetic interaction occurred when druga and drugb were administered concomitantly for # days .
DDI-DrugBank.d94.s4.p0	EQUETROTM	brand	_	Acetazolamide	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugb , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p1	EQUETROTM	brand	_	azole antifungals	group	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugb , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p2	EQUETROTM	brand	_	cimetidine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugb , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p3	EQUETROTM	brand	_	clarithromycin	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugb -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p4	EQUETROTM	brand	_	dalfopristin	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugb , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p5	EQUETROTM	brand	_	danazol	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugb , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p6	EQUETROTM	brand	_	delavirdine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugb , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p7	EQUETROTM	brand	_	diltiazem	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugb , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p8	EQUETROTM	brand	_	erythromycin	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugb -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p9	EQUETROTM	brand	_	fluoxetine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugb , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p10	EQUETROTM	brand	_	fluvoxamine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugb , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p11	EQUETROTM	brand	_	isoniazid	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p12	EQUETROTM	brand	_	itraconazole	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p13	EQUETROTM	brand	_	ketoconazole	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p14	EQUETROTM	brand	_	loratadine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p15	EQUETROTM	brand	_	nefazodone	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p16	EQUETROTM	brand	_	niacinamide	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p17	EQUETROTM	brand	_	nicotinamide	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p18	EQUETROTM	brand	_	protease inhibitors	group	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p19	EQUETROTM	brand	_	propoxyphene	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p20	EQUETROTM	brand	_	quinine	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p21	EQUETROTM	brand	_	quinupristin	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p22	EQUETROTM	brand	_	troleandomycin	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p23	EQUETROTM	brand	_	valproate	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- 1 -rcb- , drugn , drugn .
DDI-DrugBank.d94.s4.p24	EQUETROTM	brand	_	verapamil	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugb , drugn .
DDI-DrugBank.d94.s4.p25	EQUETROTM	brand	_	zileuton	drug	_	mechanism	agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of druga are the following : drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- 1 -rcb- , drugn , drugb .
DDI-DrugBank.d94.s8.p0	EQUETROTM	brand	_	Cisplatin	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugb , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p1	EQUETROTM	brand	_	doxorubicin HCL	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugb , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p2	EQUETROTM	brand	_	felbamate	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugb , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p3	EQUETROTM	brand	_	rifampin	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugb , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p4	EQUETROTM	brand	_	phenobarbital	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugn , drugb , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p5	EQUETROTM	brand	_	Phenytoin	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugn , drugn , drugb -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p6	EQUETROTM	brand	_	primidone	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugb , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p7	EQUETROTM	brand	_	methsuximide	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugb , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p8	EQUETROTM	brand	_	theophylline	drug	_	mechanism	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of druga are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugb thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p19	Cisplatin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p20	Cisplatin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : druga , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p28	doxorubicin HCL	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p29	doxorubicin HCL	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , druga , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p36	felbamate	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p37	felbamate	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , druga , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p43	rifampin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p44	rifampin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , druga , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p49	phenobarbital	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p50	phenobarbital	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , druga , drugn -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p54	Phenytoin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p55	Phenytoin	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , druga -lcb- 2 -rcb- , drugn , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p58	primidone	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , druga , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p59	primidone	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , druga , drugn , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p61	methsuximide	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , druga , and drugn thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p62	methsuximide	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , druga , and drugn thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s8.p63	theophylline	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and druga thus , if a patient has been titrated to a stable dosage on drugb , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugn may be necessary .
DDI-DrugBank.d94.s8.p64	theophylline	drug	_	EQUETROTM	brand	_	false	agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of drugn are the following : drugn , drugn , drugn , drugn , drugn , drugn -lcb- 2 -rcb- , drugn , drugn , and druga thus , if a patient has been titrated to a stable dosage on drugn , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for drugb may be necessary .
DDI-DrugBank.d94.s13.p5	EQUETROTM	brand	_	Clomipramine HCl	drug	_	mechanism	agents with increased levels in the presence of drugn : druga increases the plasma levels of the following agents : drugb , drugn -lcb- 6 -rcb- , and drugn thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugn , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s13.p6	EQUETROTM	brand	_	Phenytoin	drug	_	mechanism	agents with increased levels in the presence of drugn : druga increases the plasma levels of the following agents : drugn , drugb -lcb- 6 -rcb- , and drugn thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugn , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s13.p7	EQUETROTM	brand	_	primidone	drug	_	mechanism	agents with increased levels in the presence of drugn : druga increases the plasma levels of the following agents : drugn , drugn -lcb- 6 -rcb- , and drugb thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugn , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s13.p11	Clomipramine HCl	drug	_	EQUETROTM	brand	_	false	agents with increased levels in the presence of drugn : drugn increases the plasma levels of the following agents : druga , drugn -lcb- 6 -rcb- , and drugn thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugb , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s13.p13	Phenytoin	drug	_	EQUETROTM	brand	_	false	agents with increased levels in the presence of drugn : drugn increases the plasma levels of the following agents : drugn , druga -lcb- 6 -rcb- , and drugn thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugb , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s13.p14	primidone	drug	_	EQUETROTM	brand	_	false	agents with increased levels in the presence of drugn : drugn increases the plasma levels of the following agents : drugn , drugn -lcb- 6 -rcb- , and druga thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drugb , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .
DDI-DrugBank.d94.s14.p1	Carbamazepine	drug	_	lithium	drug	_	false	pharmacological/pharmacodynamic interactions with druga concomitant administration of drugn and drugb may increase the risk of neurotoxic side effects .
DDI-DrugBank.d94.s14.p2	carbamazepine	drug	_	lithium	drug	_	effect	pharmacological/pharmacodynamic interactions with drugn concomitant administration of druga and drugb may increase the risk of neurotoxic side effects .
DDI-DrugBank.d94.s15.p0	carbamazepine	drug	_	EQUETROTM	brand	_	false	given the anticonvulsant properties of druga , drugb may reduce the thyroid function as has been reported with other drugn .
DDI-DrugBank.d94.s15.p1	carbamazepine	drug	_	anticonvulsants	group	_	false	given the anticonvulsant properties of druga , drugn may reduce the thyroid function as has been reported with other drugb .
DDI-DrugBank.d94.s15.p2	EQUETROTM	brand	_	anticonvulsants	group	_	false	given the anticonvulsant properties of drugn , druga may reduce the thyroid function as has been reported with other drugb .
DDI-DrugBank.d94.s16.p0	anti-malarial drugs	group	_	chloroquine	drug	_	false	additionally , druga , such as drugb and drugn , may antagonize the activity of drugn .
DDI-DrugBank.d94.s16.p1	anti-malarial drugs	group	_	mefloquine	drug	_	false	additionally , druga , such as drugn and drugb , may antagonize the activity of drugn .
DDI-DrugBank.d94.s16.p2	anti-malarial drugs	group	_	carbamazepine	drug	_	effect	additionally , druga , such as drugn and drugn , may antagonize the activity of drugb .
DDI-DrugBank.d94.s16.p3	chloroquine	drug	_	mefloquine	drug	_	false	additionally , drugn , such as druga and drugb , may antagonize the activity of drugn .
DDI-DrugBank.d94.s16.p4	chloroquine	drug	_	carbamazepine	drug	_	effect	additionally , drugn , such as druga and drugn , may antagonize the activity of drugb .
DDI-DrugBank.d94.s16.p5	mefloquine	drug	_	carbamazepine	drug	_	effect	additionally , drugn , such as drugn and druga , may antagonize the activity of drugb .
DDI-DrugBank.d94.s18.p0	EQUETROTM	brand	_	centrally acting drugs	group	_	advise	because of its primary cns effect , caution should be used when druga is taken with other drugb and drugn .
DDI-DrugBank.d94.s18.p1	EQUETROTM	brand	_	alcohol	drug	_	advise	because of its primary cns effect , caution should be used when druga is taken with other drugn and drugb .
DDI-DrugBank.d94.s18.p2	centrally acting drugs	group	_	alcohol	drug	_	false	because of its primary cns effect , caution should be used when drugn is taken with other druga and drugb .
DDI-DrugBank.d545.s0.p1	Geocillin	brand	_	probenecid	drug	_	mechanism	druga -lcb- drugn -rcb- blood levels may be increased and prolonged by concurrent administration of drugb .
DDI-DrugBank.d545.s0.p2	carbenicillin indanyl sodium	drug	_	probenecid	drug	_	mechanism	drugn -lcb- druga -rcb- blood levels may be increased and prolonged by concurrent administration of drugb .
DDI-DrugBank.d47.s0.p1	LODOSYN	brand	_	levodopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with druga -lcb- drugn -rcb- given with drugb or drugn - drugn combination products .
DDI-DrugBank.d47.s0.p2	LODOSYN	brand	_	carbidopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with druga -lcb- drugn -rcb- given with drugn or drugb - drugn combination products .
DDI-DrugBank.d47.s0.p3	LODOSYN	brand	_	levodopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with druga -lcb- drugn -rcb- given with drugn or drugn - drugb combination products .
DDI-DrugBank.d47.s0.p4	Carbidopa	drug	_	levodopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with drugn -lcb- druga -rcb- given with drugb or drugn - drugn combination products .
DDI-DrugBank.d47.s0.p6	Carbidopa	drug	_	levodopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with drugn -lcb- druga -rcb- given with drugn or drugn - drugb combination products .
DDI-DrugBank.d47.s0.p7	levodopa	drug	_	carbidopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with drugn -lcb- drugn -rcb- given with druga or drugb - drugn combination products .
DDI-DrugBank.d47.s0.p9	carbidopa	drug	_	levodopa	drug	_	false	caution should be exercised when the following drugs are administered concomitantly with drugn -lcb- drugn -rcb- given with drugn or druga - drugb combination products .
DDI-DrugBank.d47.s2.p3	Dopamine D2 receptor antagonists	group	_	isoniazid	drug	_	false	druga -lcb- e , g , , drugn , drugn , drugn -rcb- and drugb may reduce the therapeutic effects of drugn .
DDI-DrugBank.d47.s2.p4	Dopamine D2 receptor antagonists	group	_	levodopa	drug	_	effect	druga -lcb- e , g , , drugn , drugn , drugn -rcb- and drugn may reduce the therapeutic effects of drugb .
DDI-DrugBank.d47.s2.p7	phenothiazines	group	_	isoniazid	drug	_	false	drugn -lcb- e , g , , druga , drugn , drugn -rcb- and drugb may reduce the therapeutic effects of drugn .
DDI-DrugBank.d47.s2.p8	phenothiazines	group	_	levodopa	drug	_	effect	drugn -lcb- e , g , , druga , drugn , drugn -rcb- and drugn may reduce the therapeutic effects of drugb .
DDI-DrugBank.d47.s2.p10	butyrophenones	group	_	isoniazid	drug	_	false	drugn -lcb- e , g , , drugn , druga , drugn -rcb- and drugb may reduce the therapeutic effects of drugn .
DDI-DrugBank.d47.s2.p11	butyrophenones	group	_	levodopa	drug	_	effect	drugn -lcb- e , g , , drugn , druga , drugn -rcb- and drugn may reduce the therapeutic effects of drugb .
DDI-DrugBank.d47.s2.p12	risperidone	drug	_	isoniazid	drug	_	false	drugn -lcb- e , g , , drugn , drugn , druga -rcb- and drugb may reduce the therapeutic effects of drugn .
DDI-DrugBank.d47.s2.p13	risperidone	drug	_	levodopa	drug	_	effect	drugn -lcb- e , g , , drugn , drugn , druga -rcb- and drugn may reduce the therapeutic effects of drugb .
DDI-DrugBank.d47.s2.p14	isoniazid	drug	_	levodopa	drug	_	effect	drugn -lcb- e , g , , drugn , drugn , drugn -rcb- and druga may reduce the therapeutic effects of drugb .
DDI-DrugBank.d47.s3.p0	levodopa	drug	_	phenytoin	drug	_	effect	in addition , the beneficial effects of druga in parkinsons disease have been reported to be reversed by drugb and drugn .
DDI-DrugBank.d47.s3.p1	levodopa	drug	_	papaverine	drug	_	effect	in addition , the beneficial effects of druga in parkinsons disease have been reported to be reversed by drugn and drugb .
DDI-DrugBank.d47.s3.p2	phenytoin	drug	_	papaverine	drug	_	false	in addition , the beneficial effects of drugn in parkinsons disease have been reported to be reversed by druga and drugb .
DDI-DrugBank.d47.s4.p0	LODOSYN	brand	_	levodopa	drug	_	false	patients taking these drugs with druga and drugb or drugn - drugn combination products should be carefully observed for loss of therapeutic response .
DDI-DrugBank.d47.s4.p1	LODOSYN	brand	_	carbidopa	drug	_	false	patients taking these drugs with druga and drugn or drugb - drugn combination products should be carefully observed for loss of therapeutic response .
DDI-DrugBank.d47.s4.p2	LODOSYN	brand	_	levodopa	drug	_	false	patients taking these drugs with druga and drugn or drugn - drugb combination products should be carefully observed for loss of therapeutic response .
DDI-DrugBank.d47.s4.p3	levodopa	drug	_	carbidopa	drug	_	false	patients taking these drugs with drugn and druga or drugb - drugn combination products should be carefully observed for loss of therapeutic response .
DDI-DrugBank.d47.s4.p5	carbidopa	drug	_	levodopa	drug	_	false	patients taking these drugs with drugn and drugn or druga - drugb combination products should be carefully observed for loss of therapeutic response .
DDI-DrugBank.d47.s5.p0	Iron	drug	_	carbidopa	drug	_	mechanism	druga salts may reduce the bioavailability of drugb and drugn .
DDI-DrugBank.d47.s5.p1	Iron	drug	_	levodopa	drug	_	mechanism	druga salts may reduce the bioavailability of drugn and drugb .
DDI-DrugBank.d47.s5.p2	carbidopa	drug	_	levodopa	drug	_	false	drugn salts may reduce the bioavailability of druga and drugb .
DDI-DrugBank.d47.s7.p0	metoclopramide	drug	_	levodopa	drug	_	mechanism	although druga may increase the bioavailability of drugb by increasing gastric emptying , drugn may also adversely affect disease control by its dopamine receptor antagonistic properties .
DDI-DrugBank.d47.s7.p2	levodopa	drug	_	metoclopramide	drug	_	false	although drugn may increase the bioavailability of druga by increasing gastric emptying , drugb may also adversely affect disease control by its dopamine receptor antagonistic properties .
DDI-DrugBank.d213.s0.p1	Iodine	drug	_	Carbimazole	drug	_	effect	druga or drugn excess may decrease the effect of drugb , and an drugn deficiency can increase the effect of drugn .
DDI-DrugBank.d213.s0.p3	Iodine	drug	_	Carbimazole	drug	_	false	druga or drugn excess may decrease the effect of drugn , and an drugn deficiency can increase the effect of drugb .
DDI-DrugBank.d213.s0.p4	iodine	drug	_	Carbimazole	drug	_	false	drugn or druga excess may decrease the effect of drugb , and an drugn deficiency can increase the effect of drugn .
DDI-DrugBank.d213.s0.p6	iodine	drug	_	Carbimazole	drug	_	false	drugn or druga excess may decrease the effect of drugn , and an drugn deficiency can increase the effect of drugb .
DDI-DrugBank.d213.s0.p7	Carbimazole	drug	_	iodine	drug	_	false	drugn or drugn excess may decrease the effect of druga , and an drugb deficiency can increase the effect of drugn .
DDI-DrugBank.d213.s0.p9	iodine	drug	_	Carbimazole	drug	_	effect	drugn or drugn excess may decrease the effect of drugn , and an druga deficiency can increase the effect of drugb .
DDI-DrugBank.d213.s1.p0	digoxin	drug	_	digitoxin	drug	_	false	serum concentration of druga and drugb may increase when patients take drugn .
DDI-DrugBank.d213.s1.p1	digoxin	drug	_	antithyroid agents	group	_	mechanism	serum concentration of druga and drugn may increase when patients take drugb .
DDI-DrugBank.d213.s1.p2	digitoxin	drug	_	antithyroid agents	group	_	mechanism	serum concentration of drugn and druga may increase when patients take drugb .
DDI-DrugBank.d213.s3.p0	Antithyroid agents	group	_	sodium iodide I131	drug	_	effect	druga may decrease thyroidal uptake of drugb , a rebound in uptake may occur up to # days after sudden withdrawal of drugn .
DDI-DrugBank.d213.s3.p1	Antithyroid agents	group	_	Carbimazole	drug	_	false	druga may decrease thyroidal uptake of drugn , a rebound in uptake may occur up to # days after sudden withdrawal of drugb .
DDI-DrugBank.d213.s3.p2	sodium iodide I131	drug	_	Carbimazole	drug	_	false	drugn may decrease thyroidal uptake of druga , a rebound in uptake may occur up to # days after sudden withdrawal of drugb .
DDI-DrugBank.d389.s0.p0	Antihistamines	group	_	tricyclic antidepressants	group	_	effect	druga may enhance the effects of drugb , drugn , drugn , and other drugn .
DDI-DrugBank.d389.s0.p1	Antihistamines	group	_	barbiturates	group	_	effect	druga may enhance the effects of drugn , drugb , drugn , and other drugn .
DDI-DrugBank.d389.s0.p2	Antihistamines	group	_	alcohol	drug	_	effect	druga may enhance the effects of drugn , drugn , drugb , and other drugn .
DDI-DrugBank.d389.s0.p3	Antihistamines	group	_	CNS depressants	group	_	effect	druga may enhance the effects of drugn , drugn , drugn , and other drugb .
DDI-DrugBank.d389.s0.p6	tricyclic antidepressants	group	_	CNS depressants	group	_	false	drugn may enhance the effects of druga , drugn , drugn , and other drugb .
DDI-DrugBank.d389.s0.p8	barbiturates	group	_	CNS depressants	group	_	false	drugn may enhance the effects of drugn , druga , drugn , and other drugb .
DDI-DrugBank.d389.s0.p9	alcohol	drug	_	CNS depressants	group	_	false	drugn may enhance the effects of drugn , drugn , druga , and other drugb .
DDI-DrugBank.d389.s1.p0	MAO inhibitors	group	_	antihistamines	group	_	effect	druga prolong and intensify the anticholinergic effects of drugb .
DDI-DrugBank.d389.s2.p0	Sympathomimetic amines	group	_	reserpine	drug	_	effect	druga may reduce the antihypertensive effects of drugb , drugn , drugn and drugn .
DDI-DrugBank.d389.s2.p1	Sympathomimetic amines	group	_	veratrum alkaloids	group	_	effect	druga may reduce the antihypertensive effects of drugn , drugb , drugn and drugn .
DDI-DrugBank.d389.s2.p2	Sympathomimetic amines	group	_	methyldopa	drug	_	effect	druga may reduce the antihypertensive effects of drugn , drugn , drugb and drugn .
DDI-DrugBank.d389.s2.p3	Sympathomimetic amines	group	_	mecamylamine	drug	_	effect	druga may reduce the antihypertensive effects of drugn , drugn , drugn and drugb .
DDI-DrugBank.d389.s3.p0	sympathomimetics	group	_	MAO inhibitors	group	_	effect	effects of druga are increased with drugb and drugn .
DDI-DrugBank.d389.s3.p1	sympathomimetics	group	_	beta adrenergic blockers	group	_	effect	effects of druga are increased with drugn and drugb .
DDI-DrugBank.d389.s3.p2	MAO inhibitors	group	_	beta adrenergic blockers	group	_	false	effects of drugn are increased with druga and drugb .
DDI-DrugBank.d23.s0.p0	HEMABATE	brand	_	oxytocic agents	group	_	effect	druga may augment the activity of other drugb .
DDI-DrugBank.d502.s0.p0	Ocupress	brand	_	beta-adrenergic blocking agent	group	_	advise	druga should be used with caution in patients who are receiving a drugb orally because of the potential for additive effects on systemic beta-blockade .
DDI-DrugBank.d502.s1.p0	beta-blocker	group	_	reserpine	drug	_	advise	close observation of the patient is recommended when a druga is administered to patients receiving catecholamine-depleting drugs such as drugb , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope , or postural hypotension .
DDI-DrugBank.d269.s1.p0	debrisoquin	drug	_	carvedilol	drug	_	false	poor metabolizers of druga : interactions of drugb with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p1	debrisoquin	drug	_	quinidine	drug	_	false	poor metabolizers of druga : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugb , drugn , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p2	debrisoquin	drug	_	fluoxetine	drug	_	false	poor metabolizers of druga : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugb , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p3	debrisoquin	drug	_	paroxetine	drug	_	false	poor metabolizers of druga : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugb , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p4	debrisoquin	drug	_	propafenone	drug	_	false	poor metabolizers of druga : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugn , and drugb -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p5	debrisoquin	drug	_	carvedilol	drug	_	false	poor metabolizers of druga : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugb .
DDI-DrugBank.d269.s1.p6	carvedilol	drug	_	quinidine	drug	_	false	poor metabolizers of drugn : interactions of druga with strong inhibitors of cyp2d6 -lcb- such as drugb , drugn , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p7	carvedilol	drug	_	fluoxetine	drug	_	false	poor metabolizers of drugn : interactions of druga with strong inhibitors of cyp2d6 -lcb- such as drugn , drugb , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p8	carvedilol	drug	_	paroxetine	drug	_	false	poor metabolizers of drugn : interactions of druga with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugb , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p9	carvedilol	drug	_	propafenone	drug	_	false	poor metabolizers of drugn : interactions of druga with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugn , and drugb -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugn .
DDI-DrugBank.d269.s1.p14	quinidine	drug	_	carvedilol	drug	_	effect	poor metabolizers of drugn : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as druga , drugn , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugb .
DDI-DrugBank.d269.s1.p17	fluoxetine	drug	_	carvedilol	drug	_	effect	poor metabolizers of drugn : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , druga , drugn , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugb .
DDI-DrugBank.d269.s1.p19	paroxetine	drug	_	carvedilol	drug	_	effect	poor metabolizers of drugn : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , druga , and drugn -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugb .
DDI-DrugBank.d269.s1.p20	propafenone	drug	_	carvedilol	drug	_	effect	poor metabolizers of drugn : interactions of drugn with strong inhibitors of cyp2d6 -lcb- such as drugn , drugn , drugn , and druga -rcb- have not been studied , but these drugs would be expected to increase blood levels of the r -lcb- + -rcb- enantiomer of drugb .
DDI-DrugBank.d269.s3.p0	agents with b-blocking properties	group	_	reserpine	drug	_	effect	catecholamine-depleting agents : patients taking both druga and a drug that can deplete catecholamines -lcb- e , g , , drugb and drugn -rcb- should be observed closely for signs of hypotension and/or severe bradycardia .
DDI-DrugBank.d269.s3.p1	agents with b-blocking properties	group	_	monoamine oxidase inhibitors	group	_	effect	catecholamine-depleting agents : patients taking both druga and a drug that can deplete catecholamines -lcb- e , g , , drugn and drugb -rcb- should be observed closely for signs of hypotension and/or severe bradycardia .
DDI-DrugBank.d269.s4.p1	Clonidine	drug	_	agents with b-blocking properties	group	_	false	druga : concomitant administration of drugn with drugb may potentiate blood-pressure - and heart-rate-lowering effects .
DDI-DrugBank.d269.s4.p2	clonidine	drug	_	agents with b-blocking properties	group	_	effect	drugn : concomitant administration of druga with drugb may potentiate blood-pressure - and heart-rate-lowering effects .
DDI-DrugBank.d269.s5.p0	agents with b-blocking properties	group	_	clonidine	drug	_	advise	when concomitant treatment with druga and drugb is to be terminated , the drugn should be discontinued first .
DDI-DrugBank.d269.s5.p1	agents with b-blocking properties	group	_	b-blocking agent	group	_	false	when concomitant treatment with druga and drugn is to be terminated , the drugb should be discontinued first .
DDI-DrugBank.d269.s5.p2	clonidine	drug	_	b-blocking agent	group	_	false	when concomitant treatment with drugn and druga is to be terminated , the drugb should be discontinued first .
DDI-DrugBank.d269.s7.p2	cyclosporine	drug	_	carvedilol	drug	_	mechanism	drugn : modest increases in mean trough druga concentrations were observed following initiation of drugb treatment in # renal transplant patients suffering from chronic vascular rejection .
DDI-DrugBank.d269.s10.p0	cyclosporine	drug	_	carvedilol	drug	_	advise	due to wide interindividual variability in the dose adjustment required , it is recommended that druga concentrations be monitored closely after initiation of drugb therapy and that the dose of drugn be adjusted as appropriate .
DDI-DrugBank.d269.s10.p2	carvedilol	drug	_	cyclosporine	drug	_	advise	due to wide interindividual variability in the dose adjustment required , it is recommended that drugn concentrations be monitored closely after initiation of druga therapy and that the dose of drugb be adjusted as appropriate .
DDI-DrugBank.d269.s11.p4	Digoxin	drug	_	carvedilol	drug	_	false	drugn : druga concentrations are increased by about 15 % when drugn and drugb are administered concomitantly .
DDI-DrugBank.d269.s11.p5	digoxin	drug	_	carvedilol	drug	_	mechanism	drugn : drugn concentrations are increased by about 15 % when druga and drugb are administered concomitantly .
DDI-DrugBank.d269.s12.p0	digoxin	drug	_	COREG	brand	_	effect	both druga and drugb slow av conduction .
DDI-DrugBank.d269.s13.p0	digoxin	drug	_	COREG	brand	_	advise	therefore , increased monitoring of druga is recommended when initiating , adjusting , or discontinuing drugb .
DDI-DrugBank.d269.s14.p0	Rifampin	drug	_	carvedilol	drug	_	mechanism	inducers and inhibitors of hepatic metabolism : druga reduced plasma concentrations of drugb by about 70 % .
DDI-DrugBank.d269.s16.p2	COREG	brand	_	diltiazem	drug	_	effect	drugn : isolated cases of conduction disturbance -lcb- rarely with hemodynamic compromise -rcb- have been observed when druga is co-administered with drugb .
DDI-DrugBank.d269.s17.p0	agents with b-blocking properties	group	_	COREG	brand	_	false	as with other druga , if drugb is to be administered orally with drugn of the drugn or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p1	agents with b-blocking properties	group	_	calcium channel blockers	group	_	false	as with other druga , if drugn is to be administered orally with drugb of the drugn or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p2	agents with b-blocking properties	group	_	verapamil	drug	_	false	as with other druga , if drugn is to be administered orally with drugn of the drugb or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p3	agents with b-blocking properties	group	_	diltiazem	drug	_	false	as with other druga , if drugn is to be administered orally with drugn of the drugn or drugb type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p4	COREG	brand	_	calcium channel blockers	group	_	false	as with other drugn , if druga is to be administered orally with drugb of the drugn or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p5	COREG	brand	_	verapamil	drug	_	advise	as with other drugn , if druga is to be administered orally with drugn of the drugb or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p6	COREG	brand	_	diltiazem	drug	_	advise	as with other drugn , if druga is to be administered orally with drugn of the drugn or drugb type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p7	calcium channel blockers	group	_	verapamil	drug	_	false	as with other drugn , if drugn is to be administered orally with druga of the drugb or drugn type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p8	calcium channel blockers	group	_	diltiazem	drug	_	false	as with other drugn , if drugn is to be administered orally with druga of the drugn or drugb type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s17.p9	verapamil	drug	_	diltiazem	drug	_	false	as with other drugn , if drugn is to be administered orally with drugn of the druga or drugb type , it is recommended that ecg and blood pressure be monitored .
DDI-DrugBank.d269.s18.p0	Insulin	drug	_	Hypoglycemics	group	_	false	druga or oral drugb : drugn may enhance the blood-sugar-reducing effect of drugn and oral drugn .
DDI-DrugBank.d269.s18.p7	Agents with b-blocking properties	group	_	insulin	drug	_	effect	drugn or oral drugn : druga may enhance the blood-sugar-reducing effect of drugb and oral drugn .
DDI-DrugBank.d269.s18.p8	Agents with b-blocking properties	group	_	hypoglycemics	group	_	effect	drugn or oral drugn : druga may enhance the blood-sugar-reducing effect of drugn and oral drugb .
DDI-DrugBank.d269.s18.p9	insulin	drug	_	hypoglycemics	group	_	false	drugn or oral drugn : drugn may enhance the blood-sugar-reducing effect of druga and oral drugb .
DDI-DrugBank.d269.s19.p0	insulin	drug	_	hypoglycemics	group	_	false	therefore , in patients taking druga or oral drugb , regular monitoring of blood glucose is recommended .
DDI-DrugBank.d350.s3.p0	CANCIDAS	brand	_	itraconazole	drug	_	false	clinical studies in healthy volunteers show that the pharmacokinetics of druga are not altered by drugb , drugn , drugn , drugn , or drugn .
DDI-DrugBank.d350.s3.p1	CANCIDAS	brand	_	amphotericin B	drug	_	false	clinical studies in healthy volunteers show that the pharmacokinetics of druga are not altered by drugn , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d350.s3.p2	CANCIDAS	brand	_	mycophenolate	drug	_	false	clinical studies in healthy volunteers show that the pharmacokinetics of druga are not altered by drugn , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d350.s3.p3	CANCIDAS	brand	_	nelfinavir	drug	_	false	clinical studies in healthy volunteers show that the pharmacokinetics of druga are not altered by drugn , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d350.s3.p4	CANCIDAS	brand	_	tacrolimus	drug	_	false	clinical studies in healthy volunteers show that the pharmacokinetics of druga are not altered by drugn , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d350.s4.p0	CANCIDAS	brand	_	itraconazole	drug	_	false	druga has no effect on the pharmacokinetics of drugb , drugn , or the active metabolite of mycophenolate .
DDI-DrugBank.d350.s4.p1	CANCIDAS	brand	_	amphotericin B	drug	_	false	druga has no effect on the pharmacokinetics of drugn , drugb , or the active metabolite of mycophenolate .
DDI-DrugBank.d350.s4.p2	itraconazole	drug	_	amphotericin B	drug	_	false	drugn has no effect on the pharmacokinetics of druga , drugb , or the active metabolite of mycophenolate .
DDI-DrugBank.d350.s5.p0	CANCIDAS	brand	_	tacrolimus	drug	_	mechanism	druga reduced the blood auc0-12 of drugb by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when drugn -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of drugn # mg daily , as compared to results from a control period in which drugn was administered alone .
DDI-DrugBank.d350.s5.p1	CANCIDAS	brand	_	tacrolimus	drug	_	false	druga reduced the blood auc0-12 of drugn by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when drugb -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of drugn # mg daily , as compared to results from a control period in which drugn was administered alone .
DDI-DrugBank.d350.s5.p3	CANCIDAS	brand	_	tacrolimus	drug	_	false	druga reduced the blood auc0-12 of drugn by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when drugn -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of drugn # mg daily , as compared to results from a control period in which drugb was administered alone .
DDI-DrugBank.d350.s5.p5	tacrolimus	drug	_	CANCIDAS	brand	_	false	drugn reduced the blood auc0-12 of druga by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when drugn -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of drugb # mg daily , as compared to results from a control period in which drugn was administered alone .
DDI-DrugBank.d350.s5.p7	tacrolimus	drug	_	CANCIDAS	brand	_	false	drugn reduced the blood auc0-12 of drugn by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when druga -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of drugb # mg daily , as compared to results from a control period in which drugn was administered alone .
DDI-DrugBank.d350.s5.p9	CANCIDAS	brand	_	tacrolimus	drug	_	false	drugn reduced the blood auc0-12 of drugn by approximately 20 % , peak blood concentration -lcb- cmax -rcb- by 16 % , and 12-hour blood concentration -lcb- c12hr -rcb- by 26 % in healthy subjects when drugn -lcb- 2 doses of # mg/kg # hours apart -rcb- was administered on the 10th day of druga # mg daily , as compared to results from a control period in which drugb was administered alone .
DDI-DrugBank.d350.s7.p0	cyclosporine	drug	_	caspofungin	drug	_	mechanism	in two clinical studies , druga -lcb- one # mg/kg dose or two # mg/kg doses -rcb- increased the auc of drugb by approximately 35 % .
DDI-DrugBank.d350.s8.p0	CANCIDAS	brand	_	cyclosporine	drug	_	false	druga did not increase the plasma levels of drugb .
DDI-DrugBank.d350.s9.p0	CANCIDAS	brand	_	cyclosporine	drug	_	effect	there were transient increases in liver alt and ast when druga and drugb were co-administered .
DDI-DrugBank.d350.s10.p0	rifampin	drug	_	caspofungin	drug	_	mechanism	a drug-drug interaction study with druga in healthy volunteers has shown a 30 % decrease in drugb trough concentrations .
DDI-DrugBank.d350.s11.p0	rifampin	drug	_	CANCIDAS	brand	_	advise	patients on druga should receive # mg of drugb daily .
DDI-DrugBank.d350.s12.p4	efavirenz	drug	_	CANCIDAS	brand	_	mechanism	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- druga , drugn , drugn , drugn , or drugn -rcb- with drugb may result in clinically meaningful reductions in drugn concentrations .
DDI-DrugBank.d350.s12.p5	efavirenz	drug	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- druga , drugn , drugn , drugn , or drugn -rcb- with drugn may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s12.p9	nevirapine	drug	_	CANCIDAS	brand	_	mechanism	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , druga , drugn , drugn , or drugn -rcb- with drugb may result in clinically meaningful reductions in drugn concentrations .
DDI-DrugBank.d350.s12.p10	nevirapine	drug	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , druga , drugn , drugn , or drugn -rcb- with drugn may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s12.p13	phenytoin	drug	_	CANCIDAS	brand	_	mechanism	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , druga , drugn , or drugn -rcb- with drugb may result in clinically meaningful reductions in drugn concentrations .
DDI-DrugBank.d350.s12.p14	phenytoin	drug	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , druga , drugn , or drugn -rcb- with drugn may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s12.p16	dexamethasone	drug	_	CANCIDAS	brand	_	mechanism	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , drugn , druga , or drugn -rcb- with drugb may result in clinically meaningful reductions in drugn concentrations .
DDI-DrugBank.d350.s12.p17	dexamethasone	drug	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , drugn , druga , or drugn -rcb- with drugn may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s12.p18	carbamazepine	drug	_	CANCIDAS	brand	_	mechanism	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , drugn , drugn , or druga -rcb- with drugb may result in clinically meaningful reductions in drugn concentrations .
DDI-DrugBank.d350.s12.p19	carbamazepine	drug	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , drugn , drugn , or druga -rcb- with drugn may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s12.p20	CANCIDAS	brand	_	caspofungin	drug	_	false	in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance -lcb- drugn , drugn , drugn , drugn , or drugn -rcb- with druga may result in clinically meaningful reductions in drugb concentrations .
DDI-DrugBank.d350.s14.p0	CANCIDAS	brand	_	efavirenz	drug	_	advise	when druga is co-administered with inducers of drug clearance , such as drugb , drugn , drugn , drugn , or drugn , use of a daily dose of # mg of drugn should be considered
DDI-DrugBank.d350.s14.p1	CANCIDAS	brand	_	nevirapine	drug	_	advise	when druga is co-administered with inducers of drug clearance , such as drugn , drugb , drugn , drugn , or drugn , use of a daily dose of # mg of drugn should be considered
DDI-DrugBank.d350.s14.p2	CANCIDAS	brand	_	phenytoin	drug	_	advise	when druga is co-administered with inducers of drug clearance , such as drugn , drugn , drugb , drugn , or drugn , use of a daily dose of # mg of drugn should be considered
DDI-DrugBank.d350.s14.p3	CANCIDAS	brand	_	dexamethasone	drug	_	advise	when druga is co-administered with inducers of drug clearance , such as drugn , drugn , drugn , drugb , or drugn , use of a daily dose of # mg of drugn should be considered
DDI-DrugBank.d350.s14.p4	CANCIDAS	brand	_	carbamazepine	drug	_	advise	when druga is co-administered with inducers of drug clearance , such as drugn , drugn , drugn , drugn , or drugb , use of a daily dose of # mg of drugn should be considered
DDI-DrugBank.d350.s14.p10	efavirenz	drug	_	CANCIDAS	brand	_	false	when drugn is co-administered with inducers of drug clearance , such as druga , drugn , drugn , drugn , or drugn , use of a daily dose of # mg of drugb should be considered
DDI-DrugBank.d350.s14.p14	nevirapine	drug	_	CANCIDAS	brand	_	false	when drugn is co-administered with inducers of drug clearance , such as drugn , druga , drugn , drugn , or drugn , use of a daily dose of # mg of drugb should be considered
DDI-DrugBank.d350.s14.p17	phenytoin	drug	_	CANCIDAS	brand	_	false	when drugn is co-administered with inducers of drug clearance , such as drugn , drugn , druga , drugn , or drugn , use of a daily dose of # mg of drugb should be considered
DDI-DrugBank.d350.s14.p19	dexamethasone	drug	_	CANCIDAS	brand	_	false	when drugn is co-administered with inducers of drug clearance , such as drugn , drugn , drugn , druga , or drugn , use of a daily dose of # mg of drugb should be considered
DDI-DrugBank.d350.s14.p20	carbamazepine	drug	_	CANCIDAS	brand	_	false	when drugn is co-administered with inducers of drug clearance , such as drugn , drugn , drugn , drugn , or druga , use of a daily dose of # mg of drugb should be considered
DDI-DrugBank.d281.s0.p0	Probenecid	drug	_	cephalosporins	group	_	mechanism	druga may decrease renal tubular secretion of drugb when used concurrently , resulting in increased and more prolonged drugn blood levels .
DDI-DrugBank.d281.s0.p1	Probenecid	drug	_	cephalosporin	group	_	false	druga may decrease renal tubular secretion of drugn when used concurrently , resulting in increased and more prolonged drugb blood levels .
DDI-DrugBank.d420.s0.p2	Antacids	group	_	cefdinir	drug	_	false	druga -lcb- drugn - or drugn - containing -rcb- : concomitant administration of 300-mg drugb capsules with # ml drugn suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p3	Antacids	group	_	Maalox TC	brand	_	false	druga -lcb- drugn - or drugn - containing -rcb- : concomitant administration of 300-mg drugn capsules with # ml drugb suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p5	aluminum	drug	_	cefdinir	drug	_	false	drugn -lcb- druga - or drugn - containing -rcb- : concomitant administration of 300-mg drugb capsules with # ml drugn suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p6	aluminum	drug	_	Maalox TC	brand	_	false	drugn -lcb- druga - or drugn - containing -rcb- : concomitant administration of 300-mg drugn capsules with # ml drugb suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p7	magnesium	drug	_	cefdinir	drug	_	false	drugn -lcb- drugn - or druga - containing -rcb- : concomitant administration of 300-mg drugb capsules with # ml drugn suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p8	magnesium	drug	_	Maalox TC	brand	_	false	drugn -lcb- drugn - or druga - containing -rcb- : concomitant administration of 300-mg drugn capsules with # ml drugb suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s0.p9	cefdinir	drug	_	Maalox TC	brand	_	mechanism	drugn -lcb- drugn - or drugn - containing -rcb- : concomitant administration of 300-mg druga capsules with # ml drugb suspension reduces the rate -lcb- cmax -rcb- and extent -lcb- auc -rcb- of absorption by approximately 40 % .
DDI-DrugBank.d420.s2.p0	cefdinir	drug	_	antacid	group	_	false	there are no significant effects on druga pharmacokinetics if the drugb is administered # hours before or # hours after drugn .
DDI-DrugBank.d420.s2.p2	antacid	group	_	cefdinir	drug	_	false	there are no significant effects on drugn pharmacokinetics if the druga is administered # hours before or # hours after drugb .
DDI-DrugBank.d420.s3.p0	antacids	group	_	OMNICEF	brand	_	false	if druga are required during drugb therapy , drugn should be taken at least # hours before or after the drugn .
DDI-DrugBank.d420.s3.p1	antacids	group	_	OMNICEF	brand	_	false	if druga are required during drugn therapy , drugb should be taken at least # hours before or after the drugn .
DDI-DrugBank.d420.s3.p4	OMNICEF	brand	_	antacid	group	_	false	if drugn are required during druga therapy , drugn should be taken at least # hours before or after the drugb .
DDI-DrugBank.d420.s3.p5	OMNICEF	brand	_	antacid	group	_	advise	if drugn are required during drugn therapy , druga should be taken at least # hours before or after the drugb .
DDI-DrugBank.d420.s4.p0	Probenecid	drug	_	b-lactam antibiotics	group	_	false	druga : as with other drugb , drugn inhibits the renal excretion of drugn , resulting in an approximate doubling in a , c , a 54 % increase in peak drugn plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p2	Probenecid	drug	_	cefdinir	drug	_	false	druga : as with other drugn , drugn inhibits the renal excretion of drugb , resulting in an approximate doubling in a , c , a 54 % increase in peak drugn plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p3	Probenecid	drug	_	cefdinir	drug	_	false	druga : as with other drugn , drugn inhibits the renal excretion of drugn , resulting in an approximate doubling in a , c , a 54 % increase in peak drugb plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p4	b-lactam antibiotics	group	_	probenecid	drug	_	false	drugn : as with other druga , drugb inhibits the renal excretion of drugn , resulting in an approximate doubling in a , c , a 54 % increase in peak drugn plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p5	b-lactam antibiotics	group	_	cefdinir	drug	_	mechanism	drugn : as with other druga , drugn inhibits the renal excretion of drugb , resulting in an approximate doubling in a , c , a 54 % increase in peak drugn plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p6	b-lactam antibiotics	group	_	cefdinir	drug	_	false	drugn : as with other druga , drugn inhibits the renal excretion of drugn , resulting in an approximate doubling in a , c , a 54 % increase in peak drugb plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p7	probenecid	drug	_	cefdinir	drug	_	mechanism	drugn : as with other drugn , druga inhibits the renal excretion of drugb , resulting in an approximate doubling in a , c , a 54 % increase in peak drugn plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s4.p8	probenecid	drug	_	cefdinir	drug	_	false	drugn : as with other drugn , druga inhibits the renal excretion of drugn , resulting in an approximate doubling in a , c , a 54 % increase in peak drugb plasma levels , and a 50 % prolongation in the apparent elimination half-life .
DDI-DrugBank.d420.s5.p1	Iron Supplements	group	_	cefdinir	drug	_	false	druga and foods fortified with drugn concomitant administration of drugb with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugn supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p4	Iron Supplements	group	_	vitamins	group	_	false	druga and foods fortified with drugn concomitant administration of drugn with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugb supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p6	Iron	drug	_	cefdinir	drug	_	false	drugn and foods fortified with druga concomitant administration of drugb with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugn supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p9	Iron	drug	_	vitamins	group	_	false	drugn and foods fortified with druga concomitant administration of drugn with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugb supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p11	cefdinir	drug	_	iron supplement	group	_	false	drugn and foods fortified with drugn concomitant administration of druga with a therapeutic drugb containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugn supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p12	cefdinir	drug	_	iron	drug	_	mechanism	drugn and foods fortified with drugn concomitant administration of druga with a therapeutic drugn containing # mg of elemental drugb -lcb- as feso4 -rcb- or drugn supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p13	cefdinir	drug	_	vitamins	group	_	false	drugn and foods fortified with drugn concomitant administration of druga with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugb supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p14	cefdinir	drug	_	iron	drug	_	mechanism	drugn and foods fortified with drugn concomitant administration of druga with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugn supplemented with # mg of elemental drugb reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p16	iron supplement	group	_	vitamins	group	_	false	drugn and foods fortified with drugn concomitant administration of drugn with a therapeutic druga containing # mg of elemental drugn -lcb- as feso4 -rcb- or drugb supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p18	iron	drug	_	vitamins	group	_	false	drugn and foods fortified with drugn concomitant administration of drugn with a therapeutic drugn containing # mg of elemental druga -lcb- as feso4 -rcb- or drugb supplemented with # mg of elemental drugn reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s5.p20	vitamins	group	_	iron	drug	_	false	drugn and foods fortified with drugn concomitant administration of drugn with a therapeutic drugn containing # mg of elemental drugn -lcb- as feso4 -rcb- or druga supplemented with # mg of elemental drugb reduced extent of absorption by 80 % and 31 % , respectively .
DDI-DrugBank.d420.s6.p0	iron supplements	group	_	OMNICEF	brand	_	false	if druga are required during drugb therapy , drugn should be taken at least # hours before or after the supplement .
DDI-DrugBank.d420.s6.p1	iron supplements	group	_	OMNICEF	brand	_	advise	if druga are required during drugn therapy , drugb should be taken at least # hours before or after the supplement .
DDI-DrugBank.d420.s7.p1	iron	drug_n	_	cefdinir	drug	_	false	the effect of foods highly fortified with elemental druga -lcb- primarily drugn - fortified breakfast cereals -rcb- on drugb absorption has not been studied .
DDI-DrugBank.d420.s7.p2	iron	drug_n	_	cefdinir	drug	_	false	the effect of foods highly fortified with elemental drugn -lcb- primarily druga - fortified breakfast cereals -rcb- on drugb absorption has not been studied .
DDI-DrugBank.d420.s8.p1	iron	drug_n	_	cefdinir	drug	_	false	concomitantly administered druga - fortified infant formula -lcb- # mg elemental drugn / 6 oz -rcb- has no significant effect on drugb pharmacokinetics .
DDI-DrugBank.d420.s8.p2	iron	drug_n	_	cefdinir	drug	_	false	concomitantly administered drugn - fortified infant formula -lcb- # mg elemental druga / 6 oz -rcb- has no significant effect on drugb pharmacokinetics .
DDI-DrugBank.d420.s9.p0	OMNICEF	brand	_	iron	drug_n	_	false	therefore , druga for oral suspension can be administered with drugb - fortified infant formula .
DDI-DrugBank.d420.s11.p0	cefdinir	drug	_	iron	drug	_	mechanism	the reddish color is due to the formation of a nonabsorbable complex between druga or its breakdown products and drugb in the gastrointestinal tract .
DDI-DrugBank.d420.s12.p0	nitroprusside	drug	_	nitroferricyanide	drug	_	false	drug/laboratory test interactions a false-positive reaction for ketones in the urine may occur with tests using druga , but not with those using drugb .
DDI-DrugBank.d550.s0.p0	Contraceptives	group	_	cefditoren pivoxil	drug	_	false	oral druga multiple doses of drugb had no effect on the pharmacokinetics of drugn , the estrogenic component in most oral drugn .
DDI-DrugBank.d550.s0.p1	Contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga multiple doses of drugn had no effect on the pharmacokinetics of drugb , the estrogenic component in most oral drugn .
DDI-DrugBank.d550.s0.p3	cefditoren pivoxil	drug	_	ethinyl estradiol	drug	_	false	oral drugn multiple doses of druga had no effect on the pharmacokinetics of drugb , the estrogenic component in most oral drugn .
DDI-DrugBank.d550.s0.p4	cefditoren pivoxil	drug	_	contraceptives	group	_	false	oral drugn multiple doses of druga had no effect on the pharmacokinetics of drugn , the estrogenic component in most oral drugb .
DDI-DrugBank.d550.s0.p5	ethinyl estradiol	drug	_	contraceptives	group	_	false	oral drugn multiple doses of drugn had no effect on the pharmacokinetics of druga , the estrogenic component in most oral drugb .
DDI-DrugBank.d550.s1.p0	cefditoren pivoxil	drug	_	antacids	group	_	advise	although the clinical significance is not known , it is not recommended that druga be taken concomitantly with drugb .
DDI-DrugBank.d550.s2.p0	H2-Receptor Antagonists	group	_	famotidine	drug	_	false	druga : co-administration of a single dose of intravenously administered drugb -lcb- 20 mg -rcb- reduced the oral absorption of a single # mg dose of drugn administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .
DDI-DrugBank.d550.s2.p1	H2-Receptor Antagonists	group	_	cefditoren pivoxil	drug	_	false	druga : co-administration of a single dose of intravenously administered drugn -lcb- 20 mg -rcb- reduced the oral absorption of a single # mg dose of drugb administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .
DDI-DrugBank.d550.s2.p2	famotidine	drug	_	cefditoren pivoxil	drug	_	mechanism	drugn : co-administration of a single dose of intravenously administered druga -lcb- 20 mg -rcb- reduced the oral absorption of a single # mg dose of drugb administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .
DDI-DrugBank.d550.s3.p0	cefditoren pivoxil	drug	_	H2 receptor antagonists	group	_	false	although the clinical significance is not known , it is not recommended that druga be taken concomitantly with drugb .
DDI-DrugBank.d550.s4.p0	Probenecid	drug	_	b-lactam antibiotics	group	_	false	druga : as with other drugb , co-administration of drugn with drugn resulted in an increase in the plasma exposure of drugn , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p2	Probenecid	drug	_	cefditoren pivoxil	drug	_	false	druga : as with other drugn , co-administration of drugn with drugb resulted in an increase in the plasma exposure of drugn , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p3	Probenecid	drug	_	cefditoren	drug	_	false	druga : as with other drugn , co-administration of drugn with drugn resulted in an increase in the plasma exposure of drugb , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p4	b-lactam antibiotics	group	_	probenecid	drug	_	false	drugn : as with other druga , co-administration of drugb with drugn resulted in an increase in the plasma exposure of drugn , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p5	b-lactam antibiotics	group	_	cefditoren pivoxil	drug	_	mechanism	drugn : as with other druga , co-administration of drugn with drugb resulted in an increase in the plasma exposure of drugn , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p6	b-lactam antibiotics	group	_	cefditoren	drug	_	false	drugn : as with other druga , co-administration of drugn with drugn resulted in an increase in the plasma exposure of drugb , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p7	probenecid	drug	_	cefditoren pivoxil	drug	_	mechanism	drugn : as with other drugn , co-administration of druga with drugb resulted in an increase in the plasma exposure of drugn , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d550.s4.p8	probenecid	drug	_	cefditoren	drug	_	false	drugn : as with other drugn , co-administration of druga with drugn resulted in an increase in the plasma exposure of drugb , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .
DDI-DrugBank.d378.s0.p0	aminoglycosides	group	_	MAXIPIME	brand	_	advise	renal function should be monitored carefully if high doses of druga are to be administered with drugb because of the increased potential of nephrotoxicity and ototoxicity of drugn .
DDI-DrugBank.d378.s0.p1	aminoglycosides	group	_	aminoglycoside antibiotics	group	_	false	renal function should be monitored carefully if high doses of druga are to be administered with drugn because of the increased potential of nephrotoxicity and ototoxicity of drugb .
DDI-DrugBank.d378.s0.p2	MAXIPIME	brand	_	aminoglycoside antibiotics	group	_	false	renal function should be monitored carefully if high doses of drugn are to be administered with druga because of the increased potential of nephrotoxicity and ototoxicity of drugb .
DDI-DrugBank.d378.s1.p0	cephalosporins	group	_	diuretics	group	_	effect	nephrotoxicity has been reported following concomitant administration of other druga with potent drugb such as drugn .
DDI-DrugBank.d378.s1.p1	cephalosporins	group	_	furosemide	drug	_	effect	nephrotoxicity has been reported following concomitant administration of other druga with potent drugn such as drugb .
DDI-DrugBank.d378.s1.p2	diuretics	group	_	furosemide	drug	_	false	nephrotoxicity has been reported following concomitant administration of other drugn with potent druga such as drugb .
DDI-DrugBank.d339.s0.p1	Carbamazepine	drug	_	SUPRAX	brand	_	false	druga : elevated drugn levels have been reported in postmarketing experience when drugb is administered concomitantly .
DDI-DrugBank.d339.s0.p2	carbamazepine	drug	_	SUPRAX	brand	_	mechanism	drugn : elevated druga levels have been reported in postmarketing experience when drugb is administered concomitantly .
DDI-DrugBank.d339.s2.p0	Warfarin	drug	_	Anticoagulants	group	_	false	druga and drugb : increased prothrombin time , with or without clinical bleeding , has been reported when drugn is administered concomitantly .
DDI-DrugBank.d339.s2.p1	Warfarin	drug	_	cefixime	drug	_	effect	druga and drugn : increased prothrombin time , with or without clinical bleeding , has been reported when drugb is administered concomitantly .
DDI-DrugBank.d339.s2.p2	Anticoagulants	group	_	cefixime	drug	_	effect	drugn and druga : increased prothrombin time , with or without clinical bleeding , has been reported when drugb is administered concomitantly .
DDI-DrugBank.d339.s3.p0	nitroprusside	drug	_	nitroferricyanide	drug	_	false	drug/laboratory test interactions a false-positive reaction for ketones in the urine may occur with tests using druga but not with those using drugb .
DDI-DrugBank.d100.s0.p0	cephalosporins	group	_	aminoglycoside antibiotics	group	_	effect	increased nephrotoxicity has been reported following concomitant administration of druga and drugb .
DDI-DrugBank.d100.s1.p0	Cephalosporins	group	_	cefotaxime sodium	drug	_	false	drug/laboratory test interactions druga , including drugb , are known to occasionally induce a positive direct coombs test .
DDI-DrugBank.d483.s1.p0	CEFOTAN	brand	_	aminoglycoside	group	_	effect	if druga and an drugb are used concomitantly , renal function should be carefully monitored , because nephrotoxicity may be potentiated .
DDI-DrugBank.d483.s4.p0	cephalosporins	group	_	cefotetan	drug	_	false	as with other druga , high concentrations of drugb may interfere with measurement of serum and urine creatinine levels by jaffe reaction and produce false increases in the levels of creatinine reported .
DDI-DrugBank.d556.s0.p0	cephalosporins	group	_	aminoglycoside antibiotics	group	_	effect	increased nephrotoxicity has been reported following concomitant administration of druga and drugb .
DDI-DrugBank.d556.s1.p0	cephalothin	drug	_	cefoxitin	drug	_	false	drug/laboratory test interactions as with druga , high concentrations of drugb -lcb- # micrograms/ml -rcb- may interfere with measurement of serum and urine creatinine levels by the jaff reaction , and produce false increases of modest degree in the levels of creatinine reported .
DDI-DrugBank.d121.s0.p0	aminoglycoside antibiotics	group	_	cephalosporin antibiotics	group	_	effect	nephrotoxicity has been reported following concomitant administration of druga and drugb .
DDI-DrugBank.d121.s1.p0	probenecid	drug	_	cefprozil	drug	_	mechanism	concomitant administration of druga doubled the auc for drugb .
DDI-DrugBank.d121.s2.p0	cefprozil	drug	_	antacid	group	_	false	the bioavailability of the capsule formulation of druga was not affected when administered # minutes following an drugb .
DDI-DrugBank.d122.s0.p0	cephalosporins	group	_	aminoglycoside antibiotics	group	_	effect	nephrotoxicity has been reported following concomitant administration of druga with drugb or potent drugn such as drugn .
DDI-DrugBank.d122.s0.p1	cephalosporins	group	_	diuretics	group	_	effect	nephrotoxicity has been reported following concomitant administration of druga with drugn or potent drugb such as drugn .
DDI-DrugBank.d122.s0.p2	cephalosporins	group	_	furosemide	drug	_	effect	nephrotoxicity has been reported following concomitant administration of druga with drugn or potent drugn such as drugb .
DDI-DrugBank.d122.s0.p3	aminoglycoside antibiotics	group	_	diuretics	group	_	false	nephrotoxicity has been reported following concomitant administration of drugn with druga or potent drugb such as drugn .
DDI-DrugBank.d122.s0.p4	aminoglycoside antibiotics	group	_	furosemide	drug	_	false	nephrotoxicity has been reported following concomitant administration of drugn with druga or potent drugn such as drugb .
DDI-DrugBank.d122.s0.p5	diuretics	group	_	furosemide	drug	_	false	nephrotoxicity has been reported following concomitant administration of drugn with drugn or potent druga such as drugb .
DDI-DrugBank.d122.s1.p0	aminoglycosides	group	_	aminoglycosidic antibiotics	group	_	false	renal function should be carefully monitored , especially if higher dosages of the druga are to be administered or if therapy is prolonged , because of the potential nephrotoxicity and ototoxicity of drugb .
DDI-DrugBank.d122.s3.p0	Chloramphenicol	drug	_	beta-lactam antibiotics	group	_	effect	druga has been shown to be antagonistic to drugb , including drugn , based on in vitro studies and time kill curves with enteric gram-negative bacilli .
DDI-DrugBank.d122.s3.p1	Chloramphenicol	drug	_	ceftazidime	drug	_	effect	druga has been shown to be antagonistic to drugn , including drugb , based on in vitro studies and time kill curves with enteric gram-negative bacilli .
DDI-DrugBank.d122.s3.p2	beta-lactam antibiotics	group	_	ceftazidime	drug	_	false	drugn has been shown to be antagonistic to druga , including drugb , based on in vitro studies and time kill curves with enteric gram-negative bacilli .
DDI-DrugBank.d32.s1.p0	ceftibuten	drug	_	theophylline	drug	_	false	with the morning dose of druga on day 6 , each volunteer received a single intravenous infusion of drugb -lcb- 4 mg/kg -rcb- .
DDI-DrugBank.d32.s3.p0	ceftibuten	drug	_	theophylline	drug	_	false	the effect of druga on the pharmacokinetics of drugb administered orally has not been investigated .
DDI-DrugBank.d32.s4.p0	Antacids	group	_	H 2 -receptor antagonists	group	_	false	druga or drugb : the effect of increased gastric ph on the bioavailability of drugn was evaluated in # healthy adult volunteers .
DDI-DrugBank.d32.s6.p0	antacid	group	_	ceftibuten	drug	_	false	a single dose of liquid druga did not affect the c max or auc of drugb ;
DDI-DrugBank.d32.s7.p0	ranitidine	drug	_	ceftibuten	drug	_	mechanism	however , # mg of druga q12h for # days increased the drugb c max by 23 % and drugn auc by 16 % .
DDI-DrugBank.d32.s7.p1	ranitidine	drug	_	ceftibuten	drug	_	mechanism	however , # mg of druga q12h for # days increased the drugn c max by 23 % and drugb auc by 16 % .
DDI-DrugBank.d33.s0.p0	Cefizox	brand	_	cephalosporins	group	_	false	although the occurrence has not been reported with druga , nephrotoxicity has been reported following concomitant administration of other drugb and drugn .
DDI-DrugBank.d33.s0.p1	Cefizox	brand	_	aminoglycosides	group	_	false	although the occurrence has not been reported with druga , nephrotoxicity has been reported following concomitant administration of other drugn and drugb .
DDI-DrugBank.d33.s0.p2	cephalosporins	group	_	aminoglycosides	group	_	effect	although the occurrence has not been reported with drugn , nephrotoxicity has been reported following concomitant administration of other druga and drugb .
DDI-DrugBank.d172.s6.p0	celecoxib	drug	_	fluconazole	drug	_	int	clinical studies with druga have identified potentially significant interactions with drugb and drugn .
DDI-DrugBank.d172.s6.p1	celecoxib	drug	_	lithium	drug	_	int	clinical studies with druga have identified potentially significant interactions with drugn and drugb .
DDI-DrugBank.d172.s6.p2	fluconazole	drug	_	lithium	drug	_	false	clinical studies with drugn have identified potentially significant interactions with druga and drugb .
DDI-DrugBank.d172.s7.p1	nonsteroidal anti-inflammatory drugs	group	_	furosemide	drug	_	int	experience with druga -lcb- drugn -rcb- suggests the potential for interactions with drugb and drugn .
DDI-DrugBank.d172.s7.p2	nonsteroidal anti-inflammatory drugs	group	_	ACE inhibitors	group	_	int	experience with druga -lcb- drugn -rcb- suggests the potential for interactions with drugn and drugb .
DDI-DrugBank.d172.s7.p3	NSAIDs	group	_	furosemide	drug	_	int	experience with drugn -lcb- druga -rcb- suggests the potential for interactions with drugb and drugn .
DDI-DrugBank.d172.s7.p4	NSAIDs	group	_	ACE inhibitors	group	_	int	experience with drugn -lcb- druga -rcb- suggests the potential for interactions with drugn and drugb .
DDI-DrugBank.d172.s7.p5	furosemide	drug	_	ACE inhibitors	group	_	false	experience with drugn -lcb- drugn -rcb- suggests the potential for interactions with druga and drugb .
DDI-DrugBank.d172.s8.p0	celecoxib	drug	_	glyburide	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugb , drugn , drugn , drugn , drugn , and drugn have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p1	celecoxib	drug	_	ketoconazole	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugn , drugb , drugn , drugn , drugn , and drugn have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p2	celecoxib	drug	_	methotrexate	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugb , drugn , drugn , and drugn have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p3	celecoxib	drug	_	phenytoin	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugn , drugb , drugn , and drugn have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p4	celecoxib	drug	_	tolbutamide	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugn , drugn , drugb , and drugn have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p5	celecoxib	drug	_	warfarin	drug	_	false	the effects druga on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugn , drugn , drugn , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p10	glyburide	drug	_	warfarin	drug	_	false	the effects drugn on the pharmacokinetics and/or pharmacodynamics of druga , drugn , drugn , drugn , drugn , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p14	ketoconazole	drug	_	warfarin	drug	_	false	the effects drugn on the pharmacokinetics and/or pharmacodynamics of drugn , druga , drugn , drugn , drugn , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p17	methotrexate	drug	_	warfarin	drug	_	false	the effects drugn on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , druga , drugn , drugn , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p19	phenytoin	drug	_	warfarin	drug	_	false	the effects drugn on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugn , druga , drugn , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s8.p20	tolbutamide	drug	_	warfarin	drug	_	false	the effects drugn on the pharmacokinetics and/or pharmacodynamics of drugn , drugn , drugn , drugn , druga , and drugb have been studied in vivo and clinically important interactions have not been found .
DDI-DrugBank.d172.s9.p2	NSAIDs	group	_	Angiotensin Converting Enzyme (ACE) inhibitors	group	_	effect	drugn : reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d172.s10.p0	CELEBREX	brand	_	ACE-inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d172.s11.p0	Furosemide	drug	_	NSAIDs	group	_	false	druga : clinical studies , as well as post marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d172.s11.p2	Furosemide	drug	_	thiazides	group	_	false	druga : clinical studies , as well as post marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d172.s11.p3	NSAIDs	group	_	furosemide	drug	_	effect	drugn : clinical studies , as well as post marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d172.s11.p4	NSAIDs	group	_	thiazides	group	_	effect	drugn : clinical studies , as well as post marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d172.s11.p5	furosemide	drug	_	thiazides	group	_	false	drugn : clinical studies , as well as post marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d172.s13.p2	CELEBREX	brand	_	aspirin	brand	_	advise	drugn : druga can be used with low dose drugb .
DDI-DrugBank.d172.s14.p0	aspirin	brand	_	CELEBREX	brand	_	effect	however , concomitant administration of druga with drugb may result in an increased rate of gi ulceration or other complications , compared to use of drugn alone .
DDI-DrugBank.d172.s14.p1	aspirin	brand	_	CELEBREX	brand	_	false	however , concomitant administration of druga with drugn may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d172.s15.p0	CELEBREX	brand	_	aspirin	brand	_	false	because of its lack of platelet effects , druga is not a substitute for drugb for cardiovascular prophylaxis .
DDI-DrugBank.d172.s16.p1	Fluconazole	drug	_	celecoxib	drug	_	false	druga : concomitant administration of drugn at # mg qd resulted in a two-fold increase in drugb plasma concentration .
DDI-DrugBank.d172.s16.p2	fluconazole	drug	_	celecoxib	drug	_	mechanism	drugn : concomitant administration of druga at # mg qd resulted in a two-fold increase in drugb plasma concentration .
DDI-DrugBank.d172.s17.p0	celecoxib	drug	_	fluconazole	drug	_	mechanism	this increase is due to the inhibition of druga metabolism via cyp2b6 2c9 by drugb -lcb- see clinical pharmacology - pharmacokinetics : metabolism -rcb- .
DDI-DrugBank.d172.s18.p0	CELEBREX	brand	_	fluconazole	drug	_	advise	druga should be introduced at the lowest recommended dose in patients receiving drugb .
DDI-DrugBank.d172.s19.p5	lithium	drug	_	CELEBREX	brand	_	false	drugn : in a study conducted in healthy subjects , mean steady-state druga plasma levels increased approximately 17 % in subjects receiving drugn # mg bid with drugb # mg bid as compared to subjects receiving drugn alone .
DDI-DrugBank.d172.s19.p7	lithium	drug	_	CELEBREX	brand	_	mechanism	drugn : in a study conducted in healthy subjects , mean steady-state drugn plasma levels increased approximately 17 % in subjects receiving druga # mg bid with drugb # mg bid as compared to subjects receiving drugn alone .
DDI-DrugBank.d172.s19.p9	CELEBREX	brand	_	lithium	drug	_	false	drugn : in a study conducted in healthy subjects , mean steady-state drugn plasma levels increased approximately 17 % in subjects receiving drugn # mg bid with druga # mg bid as compared to subjects receiving drugb alone .
DDI-DrugBank.d172.s20.p0	lithium	drug	_	CELEBREX	brand	_	advise	patients on druga treatment should be closely monitored when drugb is introduced or withdrawn .
DDI-DrugBank.d172.s21.p3	methotrexate	drug	_	CELEBREX	brand	_	false	drugn : in an interaction study of rheumatoid_arthritis patients taking druga , drugb did not have a significant effect on the pharmacokinetics of drugn .
DDI-DrugBank.d172.s21.p5	CELEBREX	brand	_	methotrexate	drug	_	false	drugn : in an interaction study of rheumatoid_arthritis patients taking drugn , druga did not have a significant effect on the pharmacokinetics of drugb .
DDI-DrugBank.d172.s22.p3	celecoxib	drug	_	warfarin	drug	_	false	drugn : the effect of druga on the anti-coagulant effect of drugb was studied in a group of healthy subjects receiving daily doses of 2-5 mg of drugn .
DDI-DrugBank.d172.s22.p4	celecoxib	drug	_	warfarin	drug	_	false	drugn : the effect of druga on the anti-coagulant effect of drugn was studied in a group of healthy subjects receiving daily doses of 2-5 mg of drugb .
DDI-DrugBank.d172.s23.p0	celecoxib	drug	_	warfarin	drug	_	false	in these subjects , druga did not alter the anticoagulant effect of drugb as determined by prothrombin time .
DDI-DrugBank.d172.s24.p0	CELEBREX	brand	_	warfarin	drug	_	advise	however , caution should be used when administering druga with drugb since these patients are at increased risk of bleeding complications .
DDI-DrugBank.d303.s0.p4	cephalexin	drug	_	metformin	drug	_	mechanism	drugn : in healthy subjects given single # mg doses of druga and drugb , plasma drugn mean cmax and auc increased by an average of 34 % and 24 % , respectively , and drugn mean renal clearance decreased by 14 % .
DDI-DrugBank.d303.s0.p5	cephalexin	drug	_	metformin	drug	_	false	drugn : in healthy subjects given single # mg doses of druga and drugn , plasma drugb mean cmax and auc increased by an average of 34 % and 24 % , respectively , and drugn mean renal clearance decreased by 14 % .
DDI-DrugBank.d303.s0.p6	cephalexin	drug	_	metformin	drug	_	false	drugn : in healthy subjects given single # mg doses of druga and drugn , plasma drugn mean cmax and auc increased by an average of 34 % and 24 % , respectively , and drugb mean renal clearance decreased by 14 % .
DDI-DrugBank.d303.s1.p0	cephalexin	drug	_	metformin	drug	_	false	no information is available about the interaction of druga and drugb following multiple doses of either drug .
DDI-DrugBank.d303.s2.p0	cephalexin	drug	_	metformin	drug	_	mechanism	although not observed in this study , adverse effects could potentially arise from co-administration of druga and drugb by inhibition of tubular secretion via organic cationic transporter systems .
DDI-DrugBank.d303.s3.p0	metformin	drug	_	cephalexin	drug	_	false	accordingly , careful patient monitoring and dose adjustment of druga is recommended in patients concomitantly taking drugb and drugn .
DDI-DrugBank.d303.s3.p2	cephalexin	drug	_	metformin	drug	_	advise	accordingly , careful patient monitoring and dose adjustment of drugn is recommended in patients concomitantly taking druga and drugb .
DDI-DrugBank.d303.s4.p0	Probenecid	drug	_	b-lactams	group	_	false	druga : as with other drugb , the renal excretion of drugn is inhibited by drugn .
DDI-DrugBank.d303.s4.p1	Probenecid	drug	_	cephalexin	drug	_	false	druga : as with other drugn , the renal excretion of drugb is inhibited by drugn .
DDI-DrugBank.d303.s4.p3	b-lactams	group	_	cephalexin	drug	_	false	drugn : as with other druga , the renal excretion of drugb is inhibited by drugn .
DDI-DrugBank.d303.s4.p4	b-lactams	group	_	probenecid	drug	_	false	drugn : as with other druga , the renal excretion of drugn is inhibited by drugb .
DDI-DrugBank.d303.s4.p5	cephalexin	drug	_	probenecid	drug	_	mechanism	drugn : as with other drugn , the renal excretion of druga is inhibited by drugb .
DDI-DrugBank.d141.s0.p1	Immunosuppressive Drugs	group	_	Niacin	drug	_	false	druga , drugn , drugb -lcb- drugn , drugn , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p2	Immunosuppressive Drugs	group	_	Nicotinic Acid	drug	_	false	druga , drugn , drugn -lcb- drugb , drugn , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p3	Immunosuppressive Drugs	group	_	Erythromycin	drug	_	false	druga , drugn , drugn -lcb- drugn , drugb , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p4	Immunosuppressive Drugs	group	_	Azole Antifungals	group	_	false	druga , drugn , drugn -lcb- drugn , drugn , drugb : skeletal muscle .
DDI-DrugBank.d141.s0.p5	Fibric Acid Derivatives	group	_	Niacin	drug	_	false	drugn , druga , drugb -lcb- drugn , drugn , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p6	Fibric Acid Derivatives	group	_	Nicotinic Acid	drug	_	false	drugn , druga , drugn -lcb- drugb , drugn , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p7	Fibric Acid Derivatives	group	_	Erythromycin	drug	_	false	drugn , druga , drugn -lcb- drugn , drugb , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p8	Fibric Acid Derivatives	group	_	Azole Antifungals	group	_	false	drugn , druga , drugn -lcb- drugn , drugn , drugb : skeletal muscle .
DDI-DrugBank.d141.s0.p9	Niacin	drug	_	Nicotinic Acid	drug	_	false	drugn , drugn , druga -lcb- drugb , drugn , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p10	Niacin	drug	_	Erythromycin	drug	_	false	drugn , drugn , druga -lcb- drugn , drugb , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p11	Niacin	drug	_	Azole Antifungals	group	_	false	drugn , drugn , druga -lcb- drugn , drugn , drugb : skeletal muscle .
DDI-DrugBank.d141.s0.p12	Nicotinic Acid	drug	_	Erythromycin	drug	_	false	drugn , drugn , drugn -lcb- druga , drugb , drugn : skeletal muscle .
DDI-DrugBank.d141.s0.p13	Nicotinic Acid	drug	_	Azole Antifungals	group	_	false	drugn , drugn , drugn -lcb- druga , drugn , drugb : skeletal muscle .
DDI-DrugBank.d141.s0.p14	Erythromycin	drug	_	Azole Antifungals	group	_	false	drugn , drugn , drugn -lcb- drugn , druga , drugb : skeletal muscle .
DDI-DrugBank.d141.s1.p5	Cerivastatin	drug	_	antacid	group	_	false	drugn -lcb- drugn -rcb- : druga plasma concentrations were not affected by co-administration of drugb .
DDI-DrugBank.d141.s2.p2	Cerivastatin	drug	_	cimetidine	drug	_	false	drugn : druga plasma concentrations were not affected by co-administration of drugb .
DDI-DrugBank.d141.s3.p2	cholestyramine	drug	_	cerivastatin sodium	drug	_	false	drugn : the influence of the bile-acidsequestering agent druga on the pharmacokinetits of drugb was evaluated in # healthy males in # separate randomized crossover studies .
DDI-DrugBank.d141.s4.p0	cerivastatin sodium	drug	_	cholestyramine	drug	_	mechanism	in the first study , concomitant administration of # mg druga and # g drugb resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing drugn alone .
DDI-DrugBank.d141.s4.p2	cholestyramine	drug	_	cerivastatin sodium	drug	_	false	in the first study , concomitant administration of # mg drugn and # g druga resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing drugb alone .
DDI-DrugBank.d141.s5.p0	cholestyramine	drug	_	cerivastatin sodium	drug	_	mechanism	however , in the second study , administration of # g druga # hour before the evening meal and # mg drugb approximately # hours after the same evening meal resulted in a decrease in the drugn auc of less than 8 % , and a decrease in cmax of about 30 % when compared to dosing drugn alone .
DDI-DrugBank.d141.s5.p1	cholestyramine	drug	_	cerivastatin	drug	_	false	however , in the second study , administration of # g druga # hour before the evening meal and # mg drugn approximately # hours after the same evening meal resulted in a decrease in the drugb auc of less than 8 % , and a decrease in cmax of about 30 % when compared to dosing drugn alone .
DDI-DrugBank.d141.s5.p2	cholestyramine	drug	_	cerivastatin sodium	drug	_	false	however , in the second study , administration of # g druga # hour before the evening meal and # mg drugn approximately # hours after the same evening meal resulted in a decrease in the drugn auc of less than 8 % , and a decrease in cmax of about 30 % when compared to dosing drugb alone .
DDI-DrugBank.d141.s6.p0	cerivastatin sodium	drug	_	cholestyramine	drug	_	false	therefore , it would be expected that a dosing schedule of druga given at bedtime and drugb given before the evening meal would not result in a significant decrease in the clinical effect of drugn .
DDI-DrugBank.d141.s6.p2	cholestyramine	drug	_	cerivastatin sodium	drug	_	false	therefore , it would be expected that a dosing schedule of drugn given at bedtime and druga given before the evening meal would not result in a significant decrease in the clinical effect of drugb .
DDI-DrugBank.d141.s7.p4	digoxin	drug	_	cerivastatin sodium	drug	_	false	drugn : plasma druga levels and drugn clearance at steady-state were not affected by co-administration of # mg drugb .
DDI-DrugBank.d141.s7.p5	digoxin	drug	_	cerivastatin sodium	drug	_	false	drugn : plasma drugn levels and druga clearance at steady-state were not affected by co-administration of # mg drugb .
DDI-DrugBank.d141.s8.p0	Cerivastatin	drug	_	digoxin	drug	_	false	druga plasma concentrations were also not affected by co-administration of drugb .
DDI-DrugBank.d141.s9.p3	warfarin	drug	_	cerivastatin	drug	_	false	drugn : co - administration of druga and drugb to healthy volunteers did not result in any changes in prothrombin time or clotting factor vii when compared to co-administration of drugn and placebo .
DDI-DrugBank.d141.s9.p5	cerivastatin	drug	_	warfarin	drug	_	false	drugn : co - administration of drugn and druga to healthy volunteers did not result in any changes in prothrombin time or clotting factor vii when compared to co-administration of drugb and placebo .
DDI-DrugBank.d141.s10.p0	warfarin	drug	_	cerivastatin sodium	drug	_	false	the auc and cmax of both the -lcb- r -rcb- and -lcb- s -rcb- isomers of druga were unaffected by concurrent dosing of # mg drugb .
DDI-DrugBank.d141.s11.p0	warfarin	drug	_	cerivastatin	drug	_	false	co-administration of druga and drugb did not alter the pharmacokinetics of drugn .
DDI-DrugBank.d141.s11.p1	warfarin	drug	_	cerivastatin sodium	drug	_	false	co-administration of druga and drugn did not alter the pharmacokinetics of drugb .
DDI-DrugBank.d141.s12.p0	ERYTHROMYCIN	drug	_	cerivastatin	drug	_	false	druga : in hypercholesterolemic patients , steady-state drugb auc and cmax increased approximately 50 % and 24 % respectively after # days with co-administration of drugn , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d141.s12.p2	cerivastatin	drug	_	erythromycin	drug	_	mechanism	drugn : in hypercholesterolemic patients , steady-state druga auc and cmax increased approximately 50 % and 24 % respectively after # days with co-administration of drugb , a known inhibitor of cytochrome p450 3a4 .
DDI-DrugBank.d141.s13.p0	cerivastatin sodium	drug	_	angiotensin- converting enzyme (ACE) inhibitors	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugb , drugn , drugn , drugn , and drugn -lcb- drugn -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d141.s13.p1	cerivastatin sodium	drug	_	betablockers	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugn , drugb , drugn , drugn , and drugn -lcb- drugn -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d141.s13.p2	cerivastatin sodium	drug	_	calcium-channel blockers	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugn , drugn , drugb , drugn , and drugn -lcb- drugn -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d141.s13.p3	cerivastatin sodium	drug	_	diuretics	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugn , drugn , drugn , drugb , and drugn -lcb- drugn -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d141.s13.p4	cerivastatin sodium	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugn , drugn , drugn , drugn , and drugb -lcb- drugn -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d141.s13.p5	cerivastatin sodium	drug	_	NSAIDs	group	_	false	other concomitant therapy : although specific interaction studies were not performed , in clinical studies , druga was used concomitantly with drugn , drugn , drugn , drugn , and drugn -lcb- drugb -rcb- without evidence of clinically significant adverse interactions .
DDI-DrugBank.d393.s0.p0	cetirizine	drug	_	pseudoephedrine	drug	_	false	pharmacokinetic interaction studies with druga in adults were conducted with drugb , drugn , drugn , drugn and drugn .
DDI-DrugBank.d393.s0.p1	cetirizine	drug	_	antipyrine	drug	_	false	pharmacokinetic interaction studies with druga in adults were conducted with drugn , drugb , drugn , drugn and drugn .
DDI-DrugBank.d393.s0.p2	cetirizine	drug	_	ketoconazole	drug	_	false	pharmacokinetic interaction studies with druga in adults were conducted with drugn , drugn , drugb , drugn and drugn .
DDI-DrugBank.d393.s0.p3	cetirizine	drug	_	erythromycin	drug	_	false	pharmacokinetic interaction studies with druga in adults were conducted with drugn , drugn , drugn , drugb and drugn .
DDI-DrugBank.d393.s0.p4	cetirizine	drug	_	azithromycin	drug	_	false	pharmacokinetic interaction studies with druga in adults were conducted with drugn , drugn , drugn , drugn and drugb .
DDI-DrugBank.d393.s2.p0	theophylline	drug	_	cetirizine	drug	_	mechanism	in a multiple dose study of druga -lcb- 400 mg once daily for # days -rcb- and drugb -lcb- 20 mg once daily for # days -rcb- , a 16 % decrease in the clearance of drugn was observed .
DDI-DrugBank.d393.s2.p1	theophylline	drug	_	cetirizine	drug	_	false	in a multiple dose study of druga -lcb- 400 mg once daily for # days -rcb- and drugn -lcb- 20 mg once daily for # days -rcb- , a 16 % decrease in the clearance of drugb was observed .
DDI-DrugBank.d393.s3.p0	theophylline	drug	_	cetirizine	drug	_	false	the disposition of druga was not altered by concomitant drugb administration .
DDI-DrugBank.d393.s4.p0	theophylline	drug	_	azithromycin	drug	_	false	drug-drug interactions : no clinically significant drug interactions have been found with druga at a low dose , drugb , drugn , drugn , or drugn .
DDI-DrugBank.d393.s4.p1	theophylline	drug	_	pseudoephedrine	drug	_	false	drug-drug interactions : no clinically significant drug interactions have been found with druga at a low dose , drugn , drugb , drugn , or drugn .
DDI-DrugBank.d393.s4.p2	theophylline	drug	_	ketoconazole	drug	_	false	drug-drug interactions : no clinically significant drug interactions have been found with druga at a low dose , drugn , drugn , drugb , or drugn .
DDI-DrugBank.d393.s4.p3	theophylline	drug	_	erythromycin	drug	_	false	drug-drug interactions : no clinically significant drug interactions have been found with druga at a low dose , drugn , drugn , drugn , or drugb .
DDI-DrugBank.d393.s5.p0	cetirizine	drug	_	theophylline	drug	_	mechanism	there was a small decrease in the clearance of druga caused by a 400-mg dose of drugb ;
DDI-DrugBank.d193.s0.p0	ERBITUX	brand	_	irinotecan	drug	_	false	a drug interaction study was performed in which druga was administered in combination with drugb .
DDI-DrugBank.d193.s1.p0	ERBITUX	brand	_	irinotecan	drug	_	false	there was no evidence of any pharmacokinetic interactions between druga and drugb .
DDI-DrugBank.d287.s0.p0	Cevimeline	drug	_	beta adrenergic antagonists	group	_	advise	druga should be administered with caution to patients taking drugb , because of the possibility of conduction disturbances .
DDI-DrugBank.d336.s0.p0	anticoagulants	group	_	chlordiazepoxide	drug	_	effect	although clinical studies have not established a cause and effect relationship , physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral druga and drugb .
DDI-DrugBank.d336.s1.p0	alcohol	drug	_	central nervous system depressants	group	_	false	the concomitant use of druga or other drugb may have an additive effect .
DDI-DrugBank.d110.s0.p0	anesthetic solutions	group	_	epinephrine	drug	_	false	the administration of local druga containing drugb or drugn to patients receiving drugn , drugn or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p1	anesthetic solutions	group	_	norepinephrine	drug	_	false	the administration of local druga containing drugn or drugb to patients receiving drugn , drugn or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p2	anesthetic solutions	group	_	monoamine oxidase inhibitors	group	_	false	the administration of local druga containing drugn or drugn to patients receiving drugb , drugn or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p3	anesthetic solutions	group	_	tricyclic antidepressants	group	_	effect	the administration of local druga containing drugn or drugn to patients receiving drugn , drugb or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p4	anesthetic solutions	group	_	phenothiazines	group	_	effect	the administration of local druga containing drugn or drugn to patients receiving drugn , drugn or drugb may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p6	epinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugb , drugn or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p7	epinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugn , drugb or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p8	epinephrine	drug	_	phenothiazines	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugn , drugn or drugb may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p9	norepinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugb , drugn or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p10	norepinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugn , drugb or drugn may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p11	norepinephrine	drug	_	phenothiazines	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugn , drugn or drugb may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s0.p14	tricyclic antidepressants	group	_	phenothiazines	group	_	false	the administration of local drugn containing drugn or drugn to patients receiving drugn , druga or drugb may produce severe , prolonged hypotension or hypertension .
DDI-DrugBank.d110.s3.p0	vasopressor drugs	group	_	ergot-type oxytocic drugs	group	_	effect	concurrent administration of druga -lcb- for the treatment of hypotension related to obstetric blocks -rcb- and drugb may cause severe , persistent hypertension or cerebrovascular accidents .
DDI-DrugBank.d110.s5.p0	chloroprocaine	drug	_	sulfonamide drug	group	_	advise	therefore , druga should not be used in any condition in which a drugb is being employed .
DDI-DrugBank.d429.s0.p0	Antacids	group	_	kaolin	drug	_	false	druga and drugb : drugn and drugn can reduce absorption of drugn ;
DDI-DrugBank.d429.s0.p7	Antacids	group	_	kaolin	drug	_	false	drugn and drugn : druga and drugb can reduce absorption of drugn ;
DDI-DrugBank.d429.s0.p8	Antacids	group	_	chloroquine	drug	_	mechanism	drugn and drugn : druga and drugn can reduce absorption of drugb ;
DDI-DrugBank.d429.s0.p9	kaolin	drug	_	chloroquine	drug	_	mechanism	drugn and drugn : drugn and druga can reduce absorption of drugb ;
DDI-DrugBank.d429.s2.p2	Cimetidine	drug	_	chloroquine	drug	_	mechanism	drugn : druga can inhibit the metabolism of drugb , increasing its plasma level .
DDI-DrugBank.d429.s4.p2	chloroquine	drug	_	ampicillin	drug	_	mechanism	drugn : in a study of healthy volunteers , druga significantly reduced the bioavailability of drugb .
DDI-DrugBank.d429.s6.p0	Cyclosporin	drug	_	chloroquine	drug	_	false	druga : after introduction of drugb -lcb- oral form -rcb- , a sudden increase in serum drugn level has been reported .
DDI-DrugBank.d429.s6.p2	chloroquine	drug	_	cyclosporin	drug	_	mechanism	drugn : after introduction of druga -lcb- oral form -rcb- , a sudden increase in serum drugb level has been reported .
DDI-DrugBank.d429.s7.p0	cyclosporin	drug	_	chloroquine	drug	_	false	therefore , close monitoring of serum druga level is recommended and , if necessary , drugb should be discontinued .
DDI-DrugBank.d46.s3.p0	Antidiabetic drugs	group	_	insulin	drug	_	false	- druga : -lcb- oral agents and drugb -rcb- dosage adjustment of the drugn may be required
DDI-DrugBank.d46.s3.p2	insulin	drug	_	antidiabetic drug	group	_	false	- drugn : -lcb- oral agents and druga -rcb- dosage adjustment of the drugb may be required
DDI-DrugBank.d46.s7.p0	Cholestyramine	drug	_	colestipol	drug	_	false	- druga and drugb drugn : drugn and drugn drugn have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p1	Cholestyramine	drug	_	resins	group	_	false	- druga and drugn drugb : drugn and drugn drugn have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p7	colestipol	drug	_	resins	group	_	false	- drugn and druga drugb : drugn and drugn drugn have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p18	Cholestytamine	drug	_	colestipol	drug	_	false	- drugn and drugn drugn : druga and drugb drugn have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p19	Cholestytamine	drug	_	resins	group	_	false	- drugn and drugn drugn : druga and drugn drugb have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p20	Cholestytamine	drug	_	thiazide diuretics	group	_	mechanism	- drugn and drugn drugn : druga and drugn drugn have the potential of binding drugb and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p21	Cholestytamine	drug	_	diuretic	group	_	false	- drugn and drugn drugn : druga and drugn drugn have the potential of binding drugn and reducing drugb absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p22	colestipol	drug	_	resins	group	_	false	- drugn and drugn drugn : drugn and druga drugb have the potential of binding drugn and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p23	colestipol	drug	_	thiazide diuretics	group	_	mechanism	- drugn and drugn drugn : drugn and druga drugn have the potential of binding drugb and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p24	colestipol	drug	_	diuretic	group	_	false	- drugn and drugn drugn : drugn and druga drugn have the potential of binding drugn and reducing drugb absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p25	resins	group	_	thiazide diuretics	group	_	false	- drugn and drugn drugn : drugn and drugn druga have the potential of binding drugb and reducing drugn absorption from the gastrointestinal tract
DDI-DrugBank.d46.s7.p26	resins	group	_	diuretic	group	_	false	- drugn and drugn drugn : drugn and drugn druga have the potential of binding drugn and reducing drugb absorption from the gastrointestinal tract
DDI-DrugBank.d46.s9.p0	Corticosteroids	group	_	ACTH	drug	_	false	- druga , drugb : intensified electrolyte depletion , particularly hypokalemia
DDI-DrugBank.d46.s13.p0	Skeletal muscle relaxants	group	_	tubocurarine	drug	_	false	- druga , nondepolarizing -lcb- e , g , , drugb -rcb- : possible increased responsiveness to the drugn
DDI-DrugBank.d46.s16.p0	Diuretic agents	group	_	lithium	drug	_	mechanism	druga reduce the renal clearance of drugb and add a high risk of drugn toxicity .
DDI-DrugBank.d46.s16.p1	Diuretic agents	group	_	lithium	drug	_	mechanism	druga reduce the renal clearance of drugn and add a high risk of drugb toxicity .
DDI-DrugBank.d46.s17.p0	lithium	drug	_	chlorothiazide	drug	_	advise	refer to the package insert for druga preparations before use of such preparations with drugb
DDI-DrugBank.d46.s19.p0	Non-steroidal Anti-inflammatory Drugs	group	_	non-steroidal anti-inflammatory agent	group	_	false	- druga : in some patients , the administration of a drugb can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugn .
DDI-DrugBank.d46.s19.p1	Non-steroidal Anti-inflammatory Drugs	group	_	loop diuretics	group	_	false	- druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d46.s19.p2	Non-steroidal Anti-inflammatory Drugs	group	_	potassium-sparing diuretics	group	_	false	- druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d46.s19.p3	Non-steroidal Anti-inflammatory Drugs	group	_	thiazide diuretics	drug	_	false	- druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d46.s19.p4	non-steroidal anti-inflammatory agent	group	_	loop diuretics	group	_	effect	- drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d46.s19.p5	non-steroidal anti-inflammatory agent	group	_	potassium-sparing diuretics	group	_	effect	- drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d46.s19.p6	non-steroidal anti-inflammatory agent	group	_	thiazide diuretics	drug	_	effect	- drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d46.s20.p0	chlorothiazide	drug	_	non-steroidal anti-inflammatory agents	group	_	advise	therefore , when druga and drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained
DDI-DrugBank.d46.s20.p1	chlorothiazide	drug	_	diuretic	group	_	false	therefore , when druga and drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained
DDI-DrugBank.d46.s20.p2	non-steroidal anti-inflammatory agents	group	_	diuretic	group	_	false	therefore , when drugn and druga are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained
DDI-DrugBank.d446.s0.p0	Chlorotrianisene	drug	_	antidepressants	group	_	int	druga may interact with drugb , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p1	Chlorotrianisene	drug	_	aspirin	brand	_	int	druga may interact with drugn , drugb , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p2	Chlorotrianisene	drug	_	barbiturates	group	_	int	druga may interact with drugn , drugn , drugb , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p3	Chlorotrianisene	drug	_	bromocriptine	drug	_	int	druga may interact with drugn , drugn , drugn , drugb , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p4	Chlorotrianisene	drug	_	calcium	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugb supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p5	Chlorotrianisene	drug	_	corticosteroids	group	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p6	Chlorotrianisene	drug	_	corticotropin	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p7	Chlorotrianisene	drug	_	cyclosporine	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p8	Chlorotrianisene	drug	_	dantrolene	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p9	Chlorotrianisene	drug	_	nicotine	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d446.s0.p10	Chlorotrianisene	drug	_	somatropin	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d446.s0.p11	Chlorotrianisene	drug	_	tamoxifen	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d446.s0.p12	Chlorotrianisene	drug	_	warfarin	drug	_	int	druga may interact with drugn , drugn , drugn , drugn , drugn supplements , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d235.s2.p0	CNS depressants	group	_	MAO inhibitors	group	_	false	increased toxicity -lcb- cns depression -rcb- : druga , drugb , drugn , drugn .
DDI-DrugBank.d235.s2.p2	CNS depressants	group	_	phenothiazines	group	_	false	increased toxicity -lcb- cns depression -rcb- : druga , drugn , drugn , drugb .
DDI-DrugBank.d235.s2.p4	MAO inhibitors	group	_	phenothiazines	group	_	false	increased toxicity -lcb- cns depression -rcb- : drugn , druga , drugn , drugb .
DDI-DrugBank.d235.s2.p5	tricyclic antidepressants	group	_	phenothiazines	group	_	false	increased toxicity -lcb- cns depression -rcb- : drugn , drugn , druga , drugb .
DDI-DrugBank.d86.s0.p1	antipsychotic drug	group	_	antiparkinsonian drug	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an druga -lcb- eg , drugn -rcb- , an drugb -lcb- eg , drugn -rcb- , and/or a drugn -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p2	antipsychotic drug	group	_	trihexyphenidyl	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an druga -lcb- eg , drugn -rcb- , an drugn -lcb- eg , drugb -rcb- , and/or a drugn -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p3	antipsychotic drug	group	_	tricyclic antidepressant	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an druga -lcb- eg , drugn -rcb- , an drugn -lcb- eg , drugn -rcb- , and/or a drugb -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p4	antipsychotic drug	group	_	amitriptyline	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an druga -lcb- eg , drugn -rcb- , an drugn -lcb- eg , drugn -rcb- , and/or a drugn -lcb- eg , drugb -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p5	chlorpromazine	drug	_	antiparkinsonian drug	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , druga -rcb- , an drugb -lcb- eg , drugn -rcb- , and/or a drugn -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p6	chlorpromazine	drug	_	trihexyphenidyl	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , druga -rcb- , an drugn -lcb- eg , drugb -rcb- , and/or a drugn -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p7	chlorpromazine	drug	_	tricyclic antidepressant	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , druga -rcb- , an drugn -lcb- eg , drugn -rcb- , and/or a drugb -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p8	chlorpromazine	drug	_	amitriptyline	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , druga -rcb- , an drugn -lcb- eg , drugn -rcb- , and/or a drugn -lcb- eg , drugb -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p10	antiparkinsonian drug	group	_	tricyclic antidepressant	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , drugn -rcb- , an druga -lcb- eg , drugn -rcb- , and/or a drugb -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p11	antiparkinsonian drug	group	_	amitriptyline	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , drugn -rcb- , an druga -lcb- eg , drugn -rcb- , and/or a drugn -lcb- eg , drugb -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p12	trihexyphenidyl	drug	_	tricyclic antidepressant	group	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , drugn -rcb- , an drugn -lcb- eg , druga -rcb- , and/or a drugb -lcb- eg , drugn -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s0.p13	trihexyphenidyl	drug	_	amitriptyline	drug	_	effect	the concurrent use of two or more drugs with anticholinergic activity -- such as an drugn -lcb- eg , drugn -rcb- , an drugn -lcb- eg , druga -rcb- , and/or a drugn -lcb- eg , drugb -rcb- -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .
DDI-DrugBank.d86.s1.p1	anti-depressants	group	_	beta-blockers	group	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugb -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p2	anti-depressants	group	_	propranolol	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p3	anti-depressants	group	_	sparfloxacin	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p4	anti-depressants	group	_	grepafloxacin	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p5	anti-depressants	group	_	guanethidine	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p6	anti-depressants	group	_	guanadrel	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p7	anti-depressants	group	_	metrizamide	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p8	anti-depressants	group	_	cabergoline	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p9	anti-depressants	group	_	lithium	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p10	anti-depressants	group	_	narcotic	group	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p11	anti-depressants	group	_	codeine	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p12	anti-depressants	group	_	antihistamines	group	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p13	anti-depressants	group	_	diphenhydramine	drug	_	false	interactions may also occur with the following : druga / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p14	anti-anxiety drugs	group	_	beta-blockers	group	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugb -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p15	anti-anxiety drugs	group	_	propranolol	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p16	anti-anxiety drugs	group	_	sparfloxacin	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p17	anti-anxiety drugs	group	_	grepafloxacin	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p18	anti-anxiety drugs	group	_	guanethidine	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p19	anti-anxiety drugs	group	_	guanadrel	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p20	anti-anxiety drugs	group	_	metrizamide	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p21	anti-anxiety drugs	group	_	cabergoline	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p22	anti-anxiety drugs	group	_	lithium	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p23	anti-anxiety drugs	group	_	narcotic	group	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p24	anti-anxiety drugs	group	_	codeine	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p25	anti-anxiety drugs	group	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p26	anti-anxiety drugs	group	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / druga , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p35	beta-blockers	group	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , druga -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p36	beta-blockers	group	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , druga -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p37	beta-blockers	group	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , druga -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p38	beta-blockers	group	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , druga -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p46	propranolol	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p47	propranolol	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p48	propranolol	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p49	propranolol	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p56	sparfloxacin	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p57	sparfloxacin	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p58	sparfloxacin	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p59	sparfloxacin	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p65	grepafloxacin	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p66	grepafloxacin	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p67	grepafloxacin	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p68	grepafloxacin	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p73	guanethidine	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p74	guanethidine	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p75	guanethidine	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p76	guanethidine	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p80	guanadrel	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p81	guanadrel	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p82	guanadrel	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p83	guanadrel	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p86	metrizamide	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p87	metrizamide	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p88	metrizamide	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p89	metrizamide	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p91	cabergoline	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p92	cabergoline	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p93	cabergoline	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p94	cabergoline	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p95	lithium	drug	_	narcotic	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p96	lithium	drug	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p97	lithium	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p98	lithium	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p99	narcotic	group	_	codeine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga pain medication -lcb- e , g , , drugb -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p100	narcotic	group	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p101	narcotic	group	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga pain medication -lcb- e , g , , drugn -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p102	codeine	drug	_	antihistamines	group	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , druga -rcb- , drugs used to aid sleep , drowsiness-causing drugb -lcb- e , g , , drugn -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d86.s1.p103	codeine	drug	_	diphenhydramine	drug	_	false	interactions may also occur with the following : drugn / drugn , drugs used to treat an overactive thyroid , drugn -lcb- e , g , , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn pain medication -lcb- e , g , , druga -rcb- , drugs used to aid sleep , drowsiness-causing drugn -lcb- e , g , , drugb -rcb- , any other drugs that may make you drowsy .
DDI-DrugBank.d245.s0.p0	sulfonylurea	group	_	nonsteroidal anti-inflammatory agents	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugb and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p1	sulfonylurea	group	_	salicylates	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p2	sulfonylurea	group	_	sulfonamides	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p3	sulfonylurea	group	_	chloramphenicol	drug	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p4	sulfonylurea	group	_	probenecid	drug	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p5	sulfonylurea	group	_	coumarins	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d245.s0.p6	sulfonylurea	group	_	monoamine oxidase inhibitors	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d245.s0.p7	sulfonylurea	group	_	beta adrenergic blocking agents	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d245.s0.p8	nonsteroidal anti-inflammatory agents	group	_	salicylates	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p9	nonsteroidal anti-inflammatory agents	group	_	sulfonamides	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p10	nonsteroidal anti-inflammatory agents	group	_	chloramphenicol	drug	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p11	nonsteroidal anti-inflammatory agents	group	_	probenecid	drug	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d245.s0.p12	nonsteroidal anti-inflammatory agents	group	_	coumarins	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d245.s0.p13	nonsteroidal anti-inflammatory agents	group	_	monoamine oxidase inhibitors	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d245.s0.p14	nonsteroidal anti-inflammatory agents	group	_	beta adrenergic blocking agents	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d245.s4.p0	thiazides	group	_	diuretics	group	_	false	these drugs include the druga and other drugb , drugn , drugn , thyroid products , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s4.p11	diuretics	group	_	phenothiazines	group	_	false	these drugs include the drugn and other druga , drugn , drugb , thyroid products , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s4.p19	corticosteroids	group	_	phenothiazines	group	_	false	these drugs include the drugn and other drugn , druga , drugb , thyroid products , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d245.s7.p0	barbiturates	group	_	chlorpropamide	drug	_	effect	since animal studies suggest that the action of druga may be prolonged by therapy with drugb , drugn should be employed with caution .
DDI-DrugBank.d245.s7.p2	chlorpropamide	drug	_	barbiturates	group	_	false	since animal studies suggest that the action of drugn may be prolonged by therapy with druga , drugb should be employed with caution .
DDI-DrugBank.d245.s8.p0	disulfiram	drug	_	alcohol	drug	_	false	in some patients , a druga - like reaction may be produced by the ingestion of drugb .
DDI-DrugBank.d245.s9.p0	miconazole	drug	_	hypoglycemic agents	group	_	effect	a potential interaction between oral druga and oral drugb leading to severe hypoglycemia has been reported .
DDI-DrugBank.d503.s0.p0	Chlorprothixene	drug	_	lithium	drug	_	mechanism	druga may increase the plasma-level of concomitantly given drugb .
DDI-DrugBank.d503.s2.p0	chlorprothixene	drug	_	opioids	group	_	advise	if druga is given concomitantly with drugb , the drugn dose should be reduced -lcb- by approx , 50 % -rcb- , because drugn amplifies the therapeutic actions and side-effects of drugn massively .
DDI-DrugBank.d503.s2.p1	chlorprothixene	drug	_	opioid	group	_	false	if druga is given concomitantly with drugn , the drugb dose should be reduced -lcb- by approx , 50 % -rcb- , because drugn amplifies the therapeutic actions and side-effects of drugn massively .
DDI-DrugBank.d503.s2.p3	chlorprothixene	drug	_	opioids	group	_	false	if druga is given concomitantly with drugn , the drugn dose should be reduced -lcb- by approx , 50 % -rcb- , because drugn amplifies the therapeutic actions and side-effects of drugb massively .
DDI-DrugBank.d503.s2.p5	opioids	group	_	chlorprothixene	drug	_	false	if drugn is given concomitantly with druga , the drugn dose should be reduced -lcb- by approx , 50 % -rcb- , because drugb amplifies the therapeutic actions and side-effects of drugn massively .
DDI-DrugBank.d503.s2.p7	opioid	group	_	chlorprothixene	drug	_	false	if drugn is given concomitantly with drugn , the druga dose should be reduced -lcb- by approx , 50 % -rcb- , because drugb amplifies the therapeutic actions and side-effects of drugn massively .
DDI-DrugBank.d503.s2.p9	chlorprothixene	drug	_	opioids	group	_	effect	if drugn is given concomitantly with drugn , the drugn dose should be reduced -lcb- by approx , 50 % -rcb- , because druga amplifies the therapeutic actions and side-effects of drugb massively .
DDI-DrugBank.d503.s3.p0	chlorprothixene	drug	_	tramadol	drug	_	advise	avoid the concomitant use of druga and drugb -lcb- drugn -rcb- .
DDI-DrugBank.d503.s3.p1	chlorprothixene	drug	_	Ultram	brand	_	advise	avoid the concomitant use of druga and drugn -lcb- drugb -rcb- .
DDI-DrugBank.d503.s5.p0	chlorprothixene	drug	_	benzodiazepines	group	_	effect	consider additive sedative effects and confusional states to emerge , if druga is given with drugb or drugn .
DDI-DrugBank.d503.s5.p1	chlorprothixene	drug	_	barbituates	group	_	effect	consider additive sedative effects and confusional states to emerge , if druga is given with drugn or drugb .
DDI-DrugBank.d503.s5.p2	benzodiazepines	group	_	barbituates	group	_	false	consider additive sedative effects and confusional states to emerge , if drugn is given with druga or drugb .
DDI-DrugBank.d503.s7.p0	chlorprothixene	drug	_	anticholinergic drugs	group	_	advise	exert particular caution in combining druga with other drugb -lcb- drugn and drugn -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d503.s7.p1	chlorprothixene	drug	_	tricyclic antidepressants	group	_	advise	exert particular caution in combining druga with other drugn -lcb- drugb and drugn -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d503.s7.p2	chlorprothixene	drug	_	antiparkinsonian agents	group	_	advise	exert particular caution in combining druga with other drugn -lcb- drugn and drugb -rcb- : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d265.s0.p0	Chlorthalidone	drug	_	antihypertensive drugs	group	_	effect	druga may add to or potentiate the action of other drugb .
DDI-DrugBank.d265.s7.p0	Chlorthalidone	drug	_	tubocurarine	drug	_	effect	druga and related drugs may increase the responsiveness to drugb .
DDI-DrugBank.d265.s8.p0	Chlorthalidone	drug	_	norepinephrine	drug	_	effect	druga and related drugs may decrease arterial responsiveness to drugb .
DDI-DrugBank.d262.s0.p0	alcohol	drug	_	central nervous system depressants	group	_	false	the concomitant use of druga or other drugb may have an additive effect .
DDI-DrugBank.d404.s0.p2	vitamin D	group	_	Calcitriol	drug	_	false	interactions for druga analogues -lcb- drugn , drugn , drugb , and drugn -rcb- : drugn : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p3	vitamin D	group	_	Calcidiol	drug	_	false	interactions for druga analogues -lcb- drugn , drugn , drugn , and drugb -rcb- : drugn : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p4	vitamin D	group	_	Cholestyramine	drug	_	false	interactions for druga analogues -lcb- drugn , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p10	Vitamin D2	drug	_	Cholestyramine	drug	_	false	interactions for drugn analogues -lcb- druga , drugn , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p15	Vitamin D3	drug	_	Cholestyramine	drug	_	false	interactions for drugn analogues -lcb- drugn , druga , drugn , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p19	Calcitriol	drug	_	Cholestyramine	drug	_	false	interactions for drugn analogues -lcb- drugn , drugn , druga , and drugn -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p22	Calcidiol	drug	_	Cholestyramine	drug	_	false	interactions for drugn analogues -lcb- drugn , drugn , drugn , and druga -rcb- : drugb : drugn has been reported to reduce intestinal absorption of drugn ;
DDI-DrugBank.d404.s0.p27	Cholestyramine	drug	_	fat soluble vitamins	group	_	mechanism	interactions for drugn analogues -lcb- drugn , drugn , drugn , and drugn -rcb- : drugn : druga has been reported to reduce intestinal absorption of drugb ;
DDI-DrugBank.d404.s2.p0	Phenytoin	drug	_	Phenobarbital	drug	_	false	druga / drugb : the coadministration of drugn or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p9	phenytoin	drug	_	phenobarbital	drug	_	false	drugn / drugn : the coadministration of druga or drugb will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p10	phenytoin	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p11	phenytoin	drug	_	calcitriol	drug	_	false	drugn / drugn : the coadministration of druga or drugn will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p12	phenobarbital	drug	_	vitamin D	group	_	false	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugb , but may reduce endogenous plasma levels of drugn / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p13	phenobarbital	drug	_	calcitriol	drug	_	false	drugn / drugn : the coadministration of drugn or druga will not affect plasma concentrations of drugn , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s2.p14	vitamin D	group	_	calcitriol	drug	_	false	drugn / drugn : the coadministration of drugn or drugn will not affect plasma concentrations of druga , but may reduce endogenous plasma levels of drugb / ergocalcitriol by accelerating metabolism .
DDI-DrugBank.d404.s3.p0	calcitriol	drug	_	Rocaltrol	brand	_	false	since blood level of druga / ergocalcitriol will be reduced , higher doses of drugb may be necessary if these drugs are administered simultaneously .
DDI-DrugBank.d404.s5.p0	thiazides	group	_	vitamin D	group	_	effect	some reports have shown that the concomitant administration of druga with drugb causes hypercalcemia .
DDI-DrugBank.d404.s7.p2	Vitamin D	group	_	digitalis	group	_	advise	drugn : druga dosage must be determined with care in patients undergoing treatment with drugb , as hypercalcemia in such patients may precipitate cardiac arrhythmias .
DDI-DrugBank.d404.s8.p2	Ketoconazole	drug	_	vitamin D	group	_	mechanism	drugn : druga may inhibit both synthetic and catabolic enzymes of drugb .
DDI-DrugBank.d404.s10.p0	ketoconazole	drug	_	vitamin D	group	_	false	however , in vivo drug interaction studies of druga with drugb have not been investigated .
DDI-DrugBank.d404.s11.p2	vitamin D	group	_	corticosteroids	group	_	effect	drugn : a relationship of functional antagonism exists between druga analogues , which promote calcium absorption , and drugb , which inhibit calcium absorption .
DDI-DrugBank.d404.s15.p3	Magnesium	drug	_	antacids	group	_	false	drugn : druga - containing preparations -lcb- eg , drugb -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugn by patients on chronic renal dialysis .
DDI-DrugBank.d404.s15.p4	Magnesium	drug	_	vitamin D	group	_	effect	drugn : druga - containing preparations -lcb- eg , drugn -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d404.s15.p5	antacids	group	_	vitamin D	group	_	effect	drugn : drugn - containing preparations -lcb- eg , druga -rcb- may cause hypermagnesemia and should therefore not be taken during therapy with drugb by patients on chronic renal dialysis .
DDI-DrugBank.d566.s0.p0	Cholestyramine	drug	_	resin	group	_	false	druga drugb may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p1	Cholestyramine	drug	_	phenylbutazone	group	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugb , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p2	Cholestyramine	drug	_	warfarin	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugb , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p3	Cholestyramine	drug	_	thiazide diuretics	group	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugb -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p4	Cholestyramine	drug	_	propranolol	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugb -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p5	Cholestyramine	drug	_	tetracycline	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugb drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p6	Cholestyramine	drug	_	penicillin G	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugb , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p7	Cholestyramine	drug	_	phenobarbital	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugb , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p8	Cholestyramine	drug	_	thyroxine	drug	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugb preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p9	Cholestyramine	drug	_	estrogens	group	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugb and drugn , and drugn .
DDI-DrugBank.d566.s0.p10	Cholestyramine	drug	_	progestins	group	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugb , and drugn .
DDI-DrugBank.d566.s0.p11	Cholestyramine	drug	_	digitalis	group	_	mechanism	druga drugn may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugb .
DDI-DrugBank.d566.s0.p12	resin	group	_	phenylbutazone	group	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugb , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p13	resin	group	_	warfarin	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugb , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p14	resin	group	_	thiazide diuretics	group	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugb -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p15	resin	group	_	propranolol	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugb -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p16	resin	group	_	tetracycline	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugb drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p17	resin	group	_	penicillin G	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugb , drugn , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p18	resin	group	_	phenobarbital	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugb , thyroid and drugn preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p19	resin	group	_	thyroxine	drug	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugb preparations , drugn and drugn , and drugn .
DDI-DrugBank.d566.s0.p20	resin	group	_	estrogens	group	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugb and drugn , and drugn .
DDI-DrugBank.d566.s0.p21	resin	group	_	progestins	group	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugb , and drugn .
DDI-DrugBank.d566.s0.p22	resin	group	_	digitalis	group	_	false	drugn druga may delay or reduce the absorption of concomitant oral medication such as drugn , drugn , drugn -lcb- acidic -rcb- or drugn -lcb- basic -rcb- , as well as drugn drugn , drugn , thyroid and drugn preparations , drugn and drugn , and drugb .
DDI-DrugBank.d566.s2.p0	Cholestyramine	drug	_	resin	group	_	false	druga drugb may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p2	Cholestyramine	drug	_	resin	group	_	false	druga drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugb could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p3	Cholestyramine	drug	_	digitalis	group	_	false	druga drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugb has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p5	Cholestyramine	drug	_	resin	group	_	false	druga drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugb .
DDI-DrugBank.d566.s2.p6	resin	group	_	cholestyramine	drug	_	false	drugn druga may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugb drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p8	resin	group	_	digitalis	group	_	false	drugn druga may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugb has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p9	resin	group	_	cholestyramine	drug	_	false	drugn druga may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugb drugn .
DDI-DrugBank.d566.s2.p11	cholestyramine	drug	_	resin	group	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of druga drugb could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p12	cholestyramine	drug	_	digitalis	group	_	mechanism	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of druga drugn could pose a hazard to health if a potentially toxic drug such as drugb has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p14	cholestyramine	drug	_	resin	group	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of druga drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugn drugb .
DDI-DrugBank.d566.s2.p15	resin	group	_	digitalis	group	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn druga could pose a hazard to health if a potentially toxic drug such as drugb has been filtrated to a maintenance level while the patient was taking drugn drugn .
DDI-DrugBank.d566.s2.p16	resin	group	_	cholestyramine	drug	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn druga could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking drugb drugn .
DDI-DrugBank.d566.s2.p18	digitalis	group	_	cholestyramine	drug	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as druga has been filtrated to a maintenance level while the patient was taking drugb drugn .
DDI-DrugBank.d566.s2.p19	digitalis	group	_	resin	group	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as druga has been filtrated to a maintenance level while the patient was taking drugn drugb .
DDI-DrugBank.d566.s2.p20	cholestyramine	drug	_	resin	group	_	false	drugn drugn may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of drugn drugn could pose a hazard to health if a potentially toxic drug such as drugn has been filtrated to a maintenance level while the patient was taking druga drugb .
DDI-DrugBank.d566.s3.p1	cholestyramine	drug	_	resin	group	_	false	because druga binds bile acids , drugn drugb may interfere with normal fat digestion and absorption and thus may prevent absorption of drugn such as a , d , e , and k.
DDI-DrugBank.d566.s3.p2	cholestyramine	drug	_	fat soluble vitamins	group	_	false	because druga binds bile acids , drugn drugn may interfere with normal fat digestion and absorption and thus may prevent absorption of drugb such as a , d , e , and k.
DDI-DrugBank.d566.s3.p3	cholestyramine	drug	_	resin	group	_	false	because drugn binds bile acids , druga drugb may interfere with normal fat digestion and absorption and thus may prevent absorption of drugn such as a , d , e , and k.
DDI-DrugBank.d566.s3.p4	cholestyramine	drug	_	fat soluble vitamins	group	_	false	because drugn binds bile acids , druga drugn may interfere with normal fat digestion and absorption and thus may prevent absorption of drugb such as a , d , e , and k.
DDI-DrugBank.d566.s3.p5	resin	group	_	fat soluble vitamins	group	_	false	because drugn binds bile acids , drugn druga may interfere with normal fat digestion and absorption and thus may prevent absorption of drugb such as a , d , e , and k.
DDI-DrugBank.d566.s4.p0	cholestyramine	drug	_	resin	group	_	false	when druga drugb is given for long periods of time , concomitant supplementation with water-miscible -lcb- or parenteral -rcb- forms of drugn should be considered .
DDI-DrugBank.d566.s4.p1	cholestyramine	drug	_	fat-soluble vitamins	group	_	false	when druga drugn is given for long periods of time , concomitant supplementation with water-miscible -lcb- or parenteral -rcb- forms of drugb should be considered .
DDI-DrugBank.d566.s4.p2	resin	group	_	fat-soluble vitamins	group	_	false	when drugn druga is given for long periods of time , concomitant supplementation with water-miscible -lcb- or parenteral -rcb- forms of drugb should be considered .
DDI-DrugBank.d566.s5.p0	CHOLESTYRAMINE	drug	_	RESIN	group	_	false	since druga drugb may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after drugn drugn -lcb- or at as rxfp2 an interval as possible -rcb- to avoid impeding their absorption .
DDI-DrugBank.d566.s5.p2	CHOLESTYRAMINE	drug	_	RESIN	group	_	false	since druga drugn may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after drugn drugb -lcb- or at as rxfp2 an interval as possible -rcb- to avoid impeding their absorption .
DDI-DrugBank.d566.s5.p3	RESIN	group	_	CHOLESTYRAMINE	drug	_	false	since drugn druga may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after drugb drugn -lcb- or at as rxfp2 an interval as possible -rcb- to avoid impeding their absorption .
DDI-DrugBank.d566.s5.p5	CHOLESTYRAMINE	drug	_	RESIN	group	_	false	since drugn drugn may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after druga drugb -lcb- or at as rxfp2 an interval as possible -rcb- to avoid impeding their absorption .
DDI-DrugBank.d362.s2.p0	des-ciclesonide	drug	_	warfarin	drug	_	false	in vitro studies demonstrated that the plasma protein binding of druga was not affected by drugb or drugn , indicating no potential for protein binding-based drug interactions .
DDI-DrugBank.d362.s2.p1	des-ciclesonide	drug	_	salicylic acid	drug	_	false	in vitro studies demonstrated that the plasma protein binding of druga was not affected by drugn or drugb , indicating no potential for protein binding-based drug interactions .
DDI-DrugBank.d362.s2.p2	warfarin	drug	_	salicylic acid	drug	_	false	in vitro studies demonstrated that the plasma protein binding of drugn was not affected by druga or drugb , indicating no potential for protein binding-based drug interactions .
DDI-DrugBank.d362.s3.p0	ciclesonide	drug	_	erythromycin	drug	_	false	in a drug interaction study , co-administration of orally inhaled druga and oral drugb , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d362.s3.p2	ciclesonide	drug	_	erythromycin	drug	_	false	in a drug interaction study , co-administration of orally inhaled druga and oral drugn , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d362.s3.p3	erythromycin	drug	_	des-ciclesonide	drug	_	false	in a drug interaction study , co-administration of orally inhaled drugn and oral druga , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d362.s3.p5	des-ciclesonide	drug	_	erythromycin	drug	_	false	in a drug interaction study , co-administration of orally inhaled drugn and oral drugn , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d362.s4.p0	ciclesonide	drug	_	ketoconazole	drug	_	mechanism	in another drug interaction study , co-administration of orally inhaled druga and oral drugb , a potent inhibitor of cytochrome p450 3a4 , increased the exposure -lcb- auc -rcb- of drugn by approximately # - fold at steady state , while levels of drugn remained unchanged .
DDI-DrugBank.d362.s4.p3	ketoconazole	drug	_	des-ciclesonide	drug	_	false	in another drug interaction study , co-administration of orally inhaled drugn and oral druga , a potent inhibitor of cytochrome p450 3a4 , increased the exposure -lcb- auc -rcb- of drugb by approximately # - fold at steady state , while levels of drugn remained unchanged .
DDI-DrugBank.d362.s4.p4	ketoconazole	drug	_	ciclesonide	drug	_	false	in another drug interaction study , co-administration of orally inhaled drugn and oral druga , a potent inhibitor of cytochrome p450 3a4 , increased the exposure -lcb- auc -rcb- of drugn by approximately # - fold at steady state , while levels of drugb remained unchanged .
DDI-DrugBank.d362.s5.p0	ketoconazole	drug	_	ciclesonide	drug	_	advise	therefore , druga should be administered with caution with intranasal drugb .
DDI-DrugBank.d260.s0.p15	Probenecid	drug	_	acetaminophen	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p16	Probenecid	drug	_	acyclovir	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p17	Probenecid	drug	_	angiotensin-converting enzyme inhibitors	group	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p18	Probenecid	drug	_	aminosalicylic acid	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p19	Probenecid	drug	_	barbiturates	group	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p20	Probenecid	drug	_	benzodiazepines	group	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p21	Probenecid	drug	_	bumetanide	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p22	Probenecid	drug	_	clofibrate	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p23	Probenecid	drug	_	methotrexate	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p24	Probenecid	drug	_	famotidine	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p25	Probenecid	drug	_	furosemide	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p26	Probenecid	drug	_	nonsteroidal anti-inflammatory	group	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb agents , drugn , and drugn -rcb- .
DDI-DrugBank.d260.s0.p27	Probenecid	drug	_	theophylline	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugb , and drugn -rcb- .
DDI-DrugBank.d260.s0.p28	Probenecid	drug	_	zidovudine	drug	_	mechanism	drugn : druga is known to interact with the metabolism or renal tubular excretion of many drugs -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn agents , drugn , and drugb -rcb- .
DDI-DrugBank.d260.s2.p0	Zidovudine	drug	_	probenecid	drug	_	advise	druga should either be temporarily discontinued or decreased by 50 % when coadministered with drugb on the day of drugn infusion .
DDI-DrugBank.d260.s2.p1	Zidovudine	drug	_	VISTIDE	brand	_	false	druga should either be temporarily discontinued or decreased by 50 % when coadministered with drugn on the day of drugb infusion .
DDI-DrugBank.d260.s2.p2	probenecid	drug	_	VISTIDE	brand	_	false	drugn should either be temporarily discontinued or decreased by 50 % when coadministered with druga on the day of drugb infusion .
DDI-DrugBank.d260.s3.p0	VISTIDE	brand	_	aminoglycosides	group	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugb -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugn , drugn , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p1	VISTIDE	brand	_	tobramycin	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugb , drugn , and drugn -rcb- , drugn , drugn , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p2	VISTIDE	brand	_	gentamicin	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugb , and drugn -rcb- , drugn , drugn , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p3	VISTIDE	brand	_	amikacin	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugb -rcb- , drugn , drugn , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p4	VISTIDE	brand	_	amphotericin B	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugb , drugn , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p5	VISTIDE	brand	_	foscarnet	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugn , drugb , intravenous drugn , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p6	VISTIDE	brand	_	pentamidine	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugn , drugn , intravenous drugb , drugn , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p7	VISTIDE	brand	_	vancomycin	drug	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugn , drugn , intravenous drugn , drugb , and drugn -rsb- is contraindicated .
DDI-DrugBank.d260.s3.p8	VISTIDE	brand	_	non-steroidal anti-inflammatory agents	group	_	advise	nephrotoxic agents : concomitant administration of druga and agents with nephrotoxic potential -lsb- e , g , , intravenous drugn -lcb- e , g , , drugn , drugn , and drugn -rcb- , drugn , drugn , intravenous drugn , drugn , and drugb -rsb- is contraindicated .
DDI-DrugBank.d358.s0.p1	PLETAL	brand	_	ketoconazole	drug	_	false	since druga is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as drugb and drugn or inhibitors of cyp2c19 such as drugn .
DDI-DrugBank.d358.s0.p2	PLETAL	brand	_	erythromycin	drug	_	false	since druga is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as drugn and drugb or inhibitors of cyp2c19 such as drugn .
DDI-DrugBank.d358.s0.p3	PLETAL	brand	_	omeprazole	drug	_	false	since druga is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as drugn and drugn or inhibitors of cyp2c19 such as drugb .
DDI-DrugBank.d358.s0.p4	PLETAL	brand	_	ketoconazole	drug	_	advise	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when druga is coadministered with inhibitors of c , p , a , such as drugb and drugn or inhibitors of cyp2c19 such as drugn .
DDI-DrugBank.d358.s0.p5	PLETAL	brand	_	erythromycin	drug	_	advise	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when druga is coadministered with inhibitors of c , p , a , such as drugn and drugb or inhibitors of cyp2c19 such as drugn .
DDI-DrugBank.d358.s0.p6	PLETAL	brand	_	omeprazole	drug	_	advise	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when druga is coadministered with inhibitors of c , p , a , such as drugn and drugn or inhibitors of cyp2c19 such as drugb .
DDI-DrugBank.d358.s0.p7	ketoconazole	drug	_	erythromycin	drug	_	false	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as druga and drugb or inhibitors of cyp2c19 such as drugn .
DDI-DrugBank.d358.s0.p8	ketoconazole	drug	_	omeprazole	drug	_	false	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as druga and drugn or inhibitors of cyp2c19 such as drugb .
DDI-DrugBank.d358.s0.p9	erythromycin	drug	_	omeprazole	drug	_	false	since drugn is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when drugn is coadministered with inhibitors of c , p , a , such as drugn and druga or inhibitors of cyp2c19 such as drugb .
DDI-DrugBank.d358.s1.p0	omeprazole	drug	_	erythromycin	drug	_	false	pharmacokinetic studies have demonstrated that druga and drugb significantly increased the systemic exposure of drugn and/or its major metabolites .
DDI-DrugBank.d358.s1.p1	omeprazole	drug	_	cilostazol	drug	_	mechanism	pharmacokinetic studies have demonstrated that druga and drugn significantly increased the systemic exposure of drugb and/or its major metabolites .
DDI-DrugBank.d358.s1.p2	erythromycin	drug	_	cilostazol	drug	_	mechanism	pharmacokinetic studies have demonstrated that drugn and druga significantly increased the systemic exposure of drugb and/or its major metabolites .
DDI-DrugBank.d358.s2.p0	cilostazol	drug	_	diltiazem	drug	_	mechanism	population pharmacokinetic studies showed higher concentrations of druga among patients concurrently treated with drugb , an inhibitor of c , p , a , .
DDI-DrugBank.d358.s3.p0	Pletal	brand	_	lovastatin	drug	_	false	druga does not , however , appear to cause increased blood levels of drugs metabolized by cyp3a4 , as it had no effect on drugb , a drug with metabolism very sensitive to c , p , a , inhibition .
DDI-DrugBank.d171.s0.p0	Tagamet	brand	_	warfarin-type anticoagulants	group	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugb , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p1	Tagamet	brand	_	phenytoin	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugb , drugn , drugn , drugn , drugn , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p2	Tagamet	brand	_	propranolol	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugb , drugn , drugn , drugn , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p3	Tagamet	brand	_	nifedipine	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugb , drugn , drugn , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p4	Tagamet	brand	_	chlordiazepoxide	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugb , drugn , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p5	Tagamet	brand	_	diazepam	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugb , certain drugn , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p6	Tagamet	brand	_	tricyclic antidepressants	group	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugb , drugn , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p7	Tagamet	brand	_	lidocaine	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , drugb , drugn and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p8	Tagamet	brand	_	theophylline	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p9	Tagamet	brand	_	metronidazole	drug	_	mechanism	druga , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p17	warfarin-type anticoagulants	group	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of druga , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p18	warfarin-type anticoagulants	group	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of druga , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p25	phenytoin	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , druga , drugn , drugn , drugn , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p26	phenytoin	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , druga , drugn , drugn , drugn , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p32	propranolol	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , druga , drugn , drugn , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p33	propranolol	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , druga , drugn , drugn , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p38	nifedipine	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , druga , drugn , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p39	nifedipine	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , druga , drugn , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p43	chlordiazepoxide	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , druga , drugn , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p44	chlordiazepoxide	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , druga , drugn , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p47	diazepam	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , druga , certain drugn , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p48	diazepam	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , druga , certain drugn , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p50	tricyclic antidepressants	group	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain druga , drugn , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p51	tricyclic antidepressants	group	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain druga , drugn , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p52	lidocaine	drug	_	theophylline	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , druga , drugb and drugn , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p53	lidocaine	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , druga , drugn and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s0.p54	theophylline	drug	_	metronidazole	drug	_	false	drugn , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drugn , drugn , drugn , drugn , drugn , drugn , certain drugn , drugn , druga and drugb , thereby delaying elimination and increasing blood levels of these drugs .
DDI-DrugBank.d171.s2.p0	anticoagulant	group	_	Tagamet	brand	_	advise	therefore , close monitoring of prothrombin time is recommended , and adjustment of the druga dose may be necessary when drugb is administered concomitantly .
DDI-DrugBank.d171.s4.p0	Tagamet	brand	_	theophylline	drug	_	mechanism	however , a crossover study in healthy subjects receiving either druga # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of drugb -lcb- drugn , key pharmaceuticals , inc , -rcb- demonstrated less alteration in steady-state drugn peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .
DDI-DrugBank.d171.s4.p1	Tagamet	brand	_	Theo-Dur	brand	_	mechanism	however , a crossover study in healthy subjects receiving either druga # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of drugn -lcb- drugb , key pharmaceuticals , inc , -rcb- demonstrated less alteration in steady-state drugn peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .
DDI-DrugBank.d171.s4.p2	Tagamet	brand	_	theophylline	drug	_	false	however , a crossover study in healthy subjects receiving either druga # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of drugn -lcb- drugn , key pharmaceuticals , inc , -rcb- demonstrated less alteration in steady-state drugb peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .
DDI-DrugBank.d171.s4.p5	Theo-Dur	brand	_	theophylline	drug	_	false	however , a crossover study in healthy subjects receiving either drugn # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of drugn -lcb- druga , key pharmaceuticals , inc , -rcb- demonstrated less alteration in steady-state drugb peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .
DDI-DrugBank.d512.s3.p0	Amitriptyline	drug	_	cinacalcet	drug	_	false	druga : concurrent administration of # mg or # mg drugb with # mg drugn increased drugn exposure and drugn -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p3	Amitriptyline	drug	_	nortriptyline	drug_n	_	false	druga : concurrent administration of # mg or # mg drugn with # mg drugn increased drugn exposure and drugb -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p4	cinacalcet	drug	_	amitriptyline	drug	_	mechanism	drugn : concurrent administration of # mg or # mg druga with # mg drugb increased drugn exposure and drugn -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p5	cinacalcet	drug	_	amitriptyline	drug	_	false	drugn : concurrent administration of # mg or # mg druga with # mg drugn increased drugb exposure and drugn -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p6	cinacalcet	drug	_	nortriptyline	drug_n	_	false	drugn : concurrent administration of # mg or # mg druga with # mg drugn increased drugn exposure and drugb -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p8	amitriptyline	drug	_	nortriptyline	drug_n	_	false	drugn : concurrent administration of # mg or # mg drugn with # mg druga increased drugn exposure and drugb -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s3.p9	amitriptyline	drug	_	nortriptyline	drug_n	_	false	drugn : concurrent administration of # mg or # mg drugn with # mg drugn increased druga exposure and drugb -lcb- active metabolite -rcb- exposure by approximately 20 % in cyp2d6 extensive metabolizers .
DDI-DrugBank.d512.s6.p0	ketoconazole	drug	_	cinacalcet	drug	_	mechanism	co-administration of druga , a strong inhibitor of cyp3a4 , increased drugb exposure following a single # mg dose of drugn by # fold .
DDI-DrugBank.d512.s6.p1	ketoconazole	drug	_	Sensipar	brand	_	false	co-administration of druga , a strong inhibitor of cyp3a4 , increased drugn exposure following a single # mg dose of drugb by # fold .
DDI-DrugBank.d512.s6.p2	cinacalcet	drug	_	Sensipar	brand	_	false	co-administration of drugn , a strong inhibitor of cyp3a4 , increased druga exposure following a single # mg dose of drugb by # fold .
DDI-DrugBank.d512.s7.p0	Sensipar	brand	_	ketoconazole	drug	_	advise	dose adjustment of druga may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , drugb , drugn , drugn ;
DDI-DrugBank.d512.s7.p1	Sensipar	brand	_	erythromycin	drug	_	advise	dose adjustment of druga may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , drugn , drugb , drugn ;
DDI-DrugBank.d512.s7.p2	Sensipar	brand	_	itraconazole	drug	_	advise	dose adjustment of druga may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , drugn , drugn , drugb ;
DDI-DrugBank.d512.s7.p3	ketoconazole	drug	_	erythromycin	drug	_	false	dose adjustment of drugn may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , druga , drugb , drugn ;
DDI-DrugBank.d512.s7.p4	ketoconazole	drug	_	itraconazole	drug	_	false	dose adjustment of drugn may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , druga , drugn , drugb ;
DDI-DrugBank.d512.s7.p5	erythromycin	drug	_	itraconazole	drug	_	false	dose adjustment of drugn may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor -lcb- e , g , , drugn , druga , drugb ;
DDI-DrugBank.d562.s0.p0	theophylline	drug	_	quinolones	group	_	mechanism	elevated plasma levels of druga have been reported with concomitant use of some drugb .
DDI-DrugBank.d562.s1.p1	theophylline	drug	_	quinolone	group	_	false	there have been reports of druga - related side-effects in patients on concomitant drugn - drugb therapy .
DDI-DrugBank.d562.s1.p2	theophylline	drug	_	quinolone	group	_	effect	there have been reports of drugn - related side-effects in patients on concomitant druga - drugb therapy .
DDI-DrugBank.d562.s3.p0	Quinolones	group	_	caffeine	drug	_	mechanism	druga have also been shown to interfere with the metabolism of drugb .
DDI-DrugBank.d562.s5.p1	cinoxacin	drug	_	caffeine	drug	_	false	although this interaction has not been reported with druga , caution should be exercised when drugn is given concomitantly with drugb - containing products .
DDI-DrugBank.d562.s5.p2	cinoxacin	drug	_	caffeine	drug	_	advise	although this interaction has not been reported with drugn , caution should be exercised when druga is given concomitantly with drugb - containing products .
DDI-DrugBank.d562.s6.p0	Antacids	group	_	sucralfate	drug	_	false	druga or drugb substantially interfere with the absorption of some drugn , resulting in low urine levels .
DDI-DrugBank.d562.s6.p1	Antacids	group	_	quinolones	group	_	mechanism	druga or drugn substantially interfere with the absorption of some drugb , resulting in low urine levels .
DDI-DrugBank.d562.s6.p2	sucralfate	drug	_	quinolones	group	_	mechanism	drugn or druga substantially interfere with the absorption of some drugb , resulting in low urine levels .
DDI-DrugBank.d562.s7.p0	quinolones	group	_	iron	drug	_	mechanism	also , concomitant administration of druga with products containing drugb , drugn containing drugn , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p1	quinolones	group	_	multivitamins	group	_	false	also , concomitant administration of druga with products containing drugn , drugb containing drugn , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p2	quinolones	group	_	zinc	drug	_	mechanism	also , concomitant administration of druga with products containing drugn , drugn containing drugb , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p3	quinolones	group	_	Videx	brand	_	mechanism	also , concomitant administration of druga with products containing drugn , drugn containing drugn , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p4	quinolones	group	_	didanosine	drug	_	mechanism	also , concomitant administration of druga with products containing drugn , drugn containing drugn , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p5	iron	drug	_	multivitamins	group	_	false	also , concomitant administration of drugn with products containing druga , drugb containing drugn , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p6	iron	drug	_	zinc	drug	_	false	also , concomitant administration of drugn with products containing druga , drugn containing drugb , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p7	iron	drug	_	Videx	brand	_	false	also , concomitant administration of drugn with products containing druga , drugn containing drugn , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p8	iron	drug	_	didanosine	drug	_	false	also , concomitant administration of drugn with products containing druga , drugn containing drugn , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p9	multivitamins	group	_	zinc	drug	_	false	also , concomitant administration of drugn with products containing drugn , druga containing drugb , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p10	multivitamins	group	_	Videx	brand	_	false	also , concomitant administration of drugn with products containing drugn , druga containing drugn , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p11	multivitamins	group	_	didanosine	drug	_	false	also , concomitant administration of drugn with products containing drugn , druga containing drugn , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p12	zinc	drug	_	Videx	brand	_	false	also , concomitant administration of drugn with products containing drugn , drugn containing druga , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s7.p13	zinc	drug	_	didanosine	drug	_	false	also , concomitant administration of drugn with products containing drugn , drugn containing druga , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .
DDI-DrugBank.d562.s8.p0	Quinolones	group	_	cinoxacin	drug	_	false	druga , including drugb , may enhance the effects of oral drugn , such as drugn or its derivatives .
DDI-DrugBank.d562.s8.p1	Quinolones	group	_	anticoagulants	group	_	effect	druga , including drugn , may enhance the effects of oral drugb , such as drugn or its derivatives .
DDI-DrugBank.d562.s8.p2	Quinolones	group	_	warfarin	drug	_	effect	druga , including drugn , may enhance the effects of oral drugn , such as drugb or its derivatives .
DDI-DrugBank.d562.s8.p3	cinoxacin	drug	_	anticoagulants	group	_	effect	drugn , including druga , may enhance the effects of oral drugb , such as drugn or its derivatives .
DDI-DrugBank.d562.s8.p4	cinoxacin	drug	_	warfarin	drug	_	effect	drugn , including druga , may enhance the effects of oral drugn , such as drugb or its derivatives .
DDI-DrugBank.d562.s8.p5	anticoagulants	group	_	warfarin	drug	_	false	drugn , including drugn , may enhance the effects of oral druga , such as drugb or its derivatives .
DDI-DrugBank.d562.s10.p0	quinolone class antimicrobial	group	_	nonsteroidal anti-inflammatory drug	group	_	effect	seizures have been reported in patients taking another druga and the drugb drugn concurrently .
DDI-DrugBank.d562.s10.p1	quinolone class antimicrobial	group	_	fenbufen	drug	_	effect	seizures have been reported in patients taking another druga and the drugn drugb concurrently .
DDI-DrugBank.d562.s10.p2	nonsteroidal anti-inflammatory drug	group	_	fenbufen	drug	_	false	seizures have been reported in patients taking another drugn and the druga drugb concurrently .
DDI-DrugBank.d562.s13.p0	cinoxacin	drug	_	nonsteroidal anti-inflammatory agents	group	_	advise	physicians are provided this information to increase awareness of the potential for serious interactions when druga and certain drugb are administered concomitantly .
DDI-DrugBank.d562.s14.p0	cyclosporine	drug	_	quinolones	group	_	false	elevated druga serum levels have been reported with the concomitant use of drugb and drugn .
DDI-DrugBank.d562.s14.p2	quinolones	group	_	cyclosporine	drug	_	mechanism	elevated drugn serum levels have been reported with the concomitant use of druga and drugb .
DDI-DrugBank.d123.s0.p0	quinolones	group	_	ciprofloxacin	drug	_	false	some druga , including drugb , have also been shown to interfere with the metabolism of drugn .
DDI-DrugBank.d123.s0.p1	quinolones	group	_	caffeine	drug	_	mechanism	some druga , including drugn , have also been shown to interfere with the metabolism of drugb .
DDI-DrugBank.d123.s0.p2	ciprofloxacin	drug	_	caffeine	drug	_	mechanism	some drugn , including druga , have also been shown to interfere with the metabolism of drugb .
DDI-DrugBank.d123.s2.p0	quinolones	group	_	ciprofloxacin	drug	_	false	some druga , including drugb , have been associated with transient elevations in serum creatinine in patients receiving drugn concomitantly .
DDI-DrugBank.d123.s2.p1	quinolones	group	_	cyclosporine	drug	_	effect	some druga , including drugn , have been associated with transient elevations in serum creatinine in patients receiving drugb concomitantly .
DDI-DrugBank.d123.s2.p2	ciprofloxacin	drug	_	cyclosporine	drug	_	effect	some drugn , including druga , have been associated with transient elevations in serum creatinine in patients receiving drugb concomitantly .
DDI-DrugBank.d123.s3.p3	ciprofloxacin	drug	_	sulfonylurea	group	_	effect	drugn : the concomitant administration of druga with the drugb drugn has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d123.s3.p4	ciprofloxacin	drug	_	glyburide	drug	_	effect	drugn : the concomitant administration of druga with the drugn drugb has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d123.s3.p5	sulfonylurea	group	_	glyburide	drug	_	false	drugn : the concomitant administration of drugn with the druga drugb has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d123.s4.p2	Histamine H2-receptor antagonists	group	_	ciprofloxacin	drug	_	false	drugn : druga appear to have no significant effect on the bioavailability of drugb .
DDI-DrugBank.d123.s5.p1	Methotrexate	drug	_	ciprofloxacin	drug	_	false	druga renal tubular transport of drugn may be inhibited by concomitant administration of drugb , potentially leading to increased plasma levels of drugn .
DDI-DrugBank.d123.s5.p3	methotrexate	drug	_	ciprofloxacin	drug	_	mechanism	drugn renal tubular transport of druga may be inhibited by concomitant administration of drugb , potentially leading to increased plasma levels of drugn .
DDI-DrugBank.d123.s5.p5	ciprofloxacin	drug	_	methotrexate	drug	_	false	drugn renal tubular transport of drugn may be inhibited by concomitant administration of druga , potentially leading to increased plasma levels of drugb .
DDI-DrugBank.d123.s7.p0	methotrexate	drug	_	ciprofloxacin	drug	_	advise	therefore , patients under druga therapy should be carefully monitored when concomitant drugb therapy is indicated .
DDI-DrugBank.d123.s8.p0	quinolone	group	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a druga , including drugb , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p1	quinolone	group	_	magnesium	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugb or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p2	quinolone	group	_	aluminum	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugb drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p3	quinolone	group	_	antacids	group	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugb , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p4	quinolone	group	_	sucralfate	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugb , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p5	quinolone	group	_	VIDEX	brand	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugb chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p6	quinolone	group	_	calcium	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p7	quinolone	group	_	iron	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p8	quinolone	group	_	zinc	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p9	quinolone	group	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a druga , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p10	ciprofloxacin	drug	_	magnesium	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugb or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p11	ciprofloxacin	drug	_	aluminum	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugb drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p12	ciprofloxacin	drug	_	antacids	group	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugb , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p13	ciprofloxacin	drug	_	sucralfate	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugn , drugb , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p14	ciprofloxacin	drug	_	VIDEX	brand	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugb chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p15	ciprofloxacin	drug	_	calcium	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p16	ciprofloxacin	drug	_	iron	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p17	ciprofloxacin	drug	_	zinc	drug	_	mechanism	multivalent cation-containing products : concurrent administration of a drugn , including druga , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p22	magnesium	drug	_	VIDEX	brand	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as druga or drugn drugn , drugn , drugb chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p23	magnesium	drug	_	calcium	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as druga or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p24	magnesium	drug	_	iron	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as druga or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p25	magnesium	drug	_	zinc	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as druga or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p26	magnesium	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as druga or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p29	aluminum	drug	_	VIDEX	brand	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or druga drugn , drugn , drugb chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p30	aluminum	drug	_	calcium	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or druga drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p31	aluminum	drug	_	iron	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or druga drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p32	aluminum	drug	_	zinc	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or druga drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p33	aluminum	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or druga drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p36	antacids	group	_	calcium	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn druga , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p37	antacids	group	_	iron	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn druga , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p38	antacids	group	_	zinc	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn druga , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p39	antacids	group	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn druga , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p41	sucralfate	drug	_	calcium	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , druga , drugn chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p42	sucralfate	drug	_	iron	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , druga , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p43	sucralfate	drug	_	zinc	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , druga , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p44	sucralfate	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , druga , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p45	VIDEX	brand	_	calcium	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , druga chewable/buffered tablets or pediatric powder , or products containing drugb , drugn , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p46	VIDEX	brand	_	iron	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , druga chewable/buffered tablets or pediatric powder , or products containing drugn , drugb , or drugn may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p47	VIDEX	brand	_	zinc	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , druga chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugb may substantially decrease the absorption of drugn , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p48	VIDEX	brand	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , druga chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p51	calcium	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing druga , drugn , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p53	iron	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , druga , or drugn may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s8.p54	zinc	drug	_	ciprofloxacin	drug	_	false	multivalent cation-containing products : concurrent administration of a drugn , including drugn , with multivalent cation-containing products such as drugn or drugn drugn , drugn , drugn chewable/buffered tablets or pediatric powder , or products containing drugn , drugn , or druga may substantially decrease the absorption of drugb , resulting in serum and urine levels considerably lower than desired .
DDI-DrugBank.d123.s10.p0	ciprofloxacin	drug	_	antacids	group	_	advise	this time window is different than for other oral formulations of druga , which are usually administered # hours before or # hours after drugb .
DDI-DrugBank.d123.s12.p4	ciprofloxacin	drug	_	Proquin XR	brand	_	false	drugn : the rate and extent of absorption of druga was bioequivalent when drugb was given alone or when drugn was given # hours after drugn at the dose that maximally suppresses gastric acid secretion .
DDI-DrugBank.d123.s12.p5	ciprofloxacin	drug	_	Proquin XR	brand	_	false	drugn : the rate and extent of absorption of druga was bioequivalent when drugn was given alone or when drugb was given # hours after drugn at the dose that maximally suppresses gastric acid secretion .
DDI-DrugBank.d123.s12.p6	ciprofloxacin	drug	_	omeprazole	drug	_	false	drugn : the rate and extent of absorption of druga was bioequivalent when drugn was given alone or when drugn was given # hours after drugb at the dose that maximally suppresses gastric acid secretion .
DDI-DrugBank.d123.s12.p8	Proquin XR	brand	_	omeprazole	drug	_	false	drugn : the rate and extent of absorption of drugn was bioequivalent when druga was given alone or when drugn was given # hours after drugb at the dose that maximally suppresses gastric acid secretion .
DDI-DrugBank.d123.s12.p9	Proquin XR	brand	_	omeprazole	drug	_	false	drugn : the rate and extent of absorption of drugn was bioequivalent when drugn was given alone or when druga was given # hours after drugb at the dose that maximally suppresses gastric acid secretion .
DDI-DrugBank.d123.s13.p0	Omeprazole	drug	_	Proquin XR	brand	_	false	druga should be taken as directed and drugb should be taken with a main meal of the day , preferably the evening meal , .
DDI-DrugBank.d123.s14.p1	Phenytoin	drug	_	ciprofloxacin	drug	_	false	druga : altered serum levels of drugn -lcb- increased and decreased -rcb- have been reported in patients receiving concomitant drugb .
DDI-DrugBank.d123.s14.p2	phenytoin	drug	_	ciprofloxacin	drug	_	mechanism	drugn : altered serum levels of druga -lcb- increased and decreased -rcb- have been reported in patients receiving concomitant drugb .
DDI-DrugBank.d123.s15.p3	Probenecid	drug	_	ciprofloxacin	drug	_	mechanism	drugn : druga interferes with renal tubular secretion of drugb and produces an increase in the level of drugn in serum .
DDI-DrugBank.d123.s15.p4	Probenecid	drug	_	ciprofloxacin	drug	_	mechanism	drugn : druga interferes with renal tubular secretion of drugn and produces an increase in the level of drugb in serum .
DDI-DrugBank.d123.s16.p4	quinolones	group	_	ciprofloxacin	drug	_	false	drugn : as with some other druga , concurrent administration of drugb with drugn may lead to elevated serum concentrations of drugn and prolongation of its elimination half-life .
DDI-DrugBank.d123.s16.p5	quinolones	group	_	theophylline	drug	_	mechanism	drugn : as with some other druga , concurrent administration of drugn with drugb may lead to elevated serum concentrations of drugn and prolongation of its elimination half-life .
DDI-DrugBank.d123.s16.p6	quinolones	group	_	theophylline	drug	_	false	drugn : as with some other druga , concurrent administration of drugn with drugn may lead to elevated serum concentrations of drugb and prolongation of its elimination half-life .
DDI-DrugBank.d123.s16.p7	ciprofloxacin	drug	_	theophylline	drug	_	mechanism	drugn : as with some other drugn , concurrent administration of druga with drugb may lead to elevated serum concentrations of drugn and prolongation of its elimination half-life .
DDI-DrugBank.d123.s16.p8	ciprofloxacin	drug	_	theophylline	drug	_	false	drugn : as with some other drugn , concurrent administration of druga with drugn may lead to elevated serum concentrations of drugb and prolongation of its elimination half-life .
DDI-DrugBank.d123.s19.p3	Quinolones	group	_	anticoagulant	group	_	false	drugn : druga have been reported to enhance the effects of the oral drugb drugn or its derivatives .
DDI-DrugBank.d123.s19.p4	Quinolones	group	_	warfarin	drug	_	effect	drugn : druga have been reported to enhance the effects of the oral drugn drugb or its derivatives .
DDI-DrugBank.d123.s19.p5	anticoagulant	group	_	warfarin	drug	_	false	drugn : drugn have been reported to enhance the effects of the oral druga drugb or its derivatives .
DDI-DrugBank.d237.s2.p7	clarithromycin	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data show that druga , drugn , and drugn markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s2.p8	clarithromycin	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data show that druga , drugn , and drugn markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s2.p10	erythromycin	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data show that drugn , druga , and drugn markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s2.p11	erythromycin	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data show that drugn , druga , and drugn markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s2.p12	troleandomycin	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data show that drugn , drugn , and druga markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s2.p13	troleandomycin	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data show that drugn , drugn , and druga markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s3.p0	Anticholinergics	group	_	anticholinergic compounds	group	_	false	druga : concurrent administration of certain drugb , such as drugn and drugn , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p1	Anticholinergics	group	_	belladonna alkaloids	group	_	false	druga : concurrent administration of certain drugn , such as drugb and drugn , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p2	Anticholinergics	group	_	dicyclomine	drug	_	false	druga : concurrent administration of certain drugn , such as drugn and drugb , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p3	Anticholinergics	group	_	cisapride	drug	_	false	druga : concurrent administration of certain drugn , such as drugn and drugn , would be expected to compromise the beneficial effects of drugb .
DDI-DrugBank.d237.s3.p4	anticholinergic compounds	group	_	belladonna alkaloids	group	_	false	drugn : concurrent administration of certain druga , such as drugb and drugn , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p5	anticholinergic compounds	group	_	dicyclomine	drug	_	false	drugn : concurrent administration of certain druga , such as drugn and drugb , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p6	anticholinergic compounds	group	_	cisapride	drug	_	effect	drugn : concurrent administration of certain druga , such as drugn and drugn , would be expected to compromise the beneficial effects of drugb .
DDI-DrugBank.d237.s3.p7	belladonna alkaloids	group	_	dicyclomine	drug	_	false	drugn : concurrent administration of certain drugn , such as druga and drugb , would be expected to compromise the beneficial effects of drugn .
DDI-DrugBank.d237.s3.p8	belladonna alkaloids	group	_	cisapride	drug	_	effect	drugn : concurrent administration of certain drugn , such as druga and drugn , would be expected to compromise the beneficial effects of drugb .
DDI-DrugBank.d237.s3.p9	dicyclomine	drug	_	cisapride	drug	_	effect	drugn : concurrent administration of certain drugn , such as drugn and druga , would be expected to compromise the beneficial effects of drugb .
DDI-DrugBank.d237.s5.p0	cisapride	drug	_	anticoagulant	group	_	advise	it is advisable to check coagulation time within the first few days after the start and discontinuation of druga therapy , with an appropriate adjustment of the drugb dose , if necessary .
DDI-DrugBank.d237.s6.p3	nefazodone	drug	_	cisapride	drug	_	mechanism	drugn : in vitro data indicate that druga inhibits the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s6.p4	nefazodone	drug	_	cisapride	drug	_	false	drugn : in vitro data indicate that druga inhibits the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p5	fluconazole	drug	_	itraconazole	drug	_	false	drugn : in vitro and/or in vivo data indicate that druga , drugb , and oral drugn markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p6	fluconazole	drug	_	ketoconazole	drug	_	false	drugn : in vitro and/or in vivo data indicate that druga , drugn , and oral drugb markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p7	fluconazole	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data indicate that druga , drugn , and oral drugn markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p8	fluconazole	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data indicate that druga , drugn , and oral drugn markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p9	itraconazole	drug	_	ketoconazole	drug	_	false	drugn : in vitro and/or in vivo data indicate that drugn , druga , and oral drugb markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p10	itraconazole	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data indicate that drugn , druga , and oral drugn markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p11	itraconazole	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data indicate that drugn , druga , and oral drugn markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p12	ketoconazole	drug	_	cisapride	drug	_	mechanism	drugn : in vitro and/or in vivo data indicate that drugn , drugn , and oral druga markedly inhibit the metabolism of drugb , which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s7.p13	ketoconazole	drug	_	cisapride	drug	_	false	drugn : in vitro and/or in vivo data indicate that drugn , drugn , and oral druga markedly inhibit the metabolism of drugn , which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s8.p0	ketoconazole	drug	_	cisapride	drug	_	mechanism	human pharmacokinetic data indicate that oral druga markedly inhibits the metabolism of drugb , resulting in a mean eight-fold increase in auc of drugn .
DDI-DrugBank.d237.s8.p1	ketoconazole	drug	_	cisapride	drug	_	false	human pharmacokinetic data indicate that oral druga markedly inhibits the metabolism of drugn , resulting in a mean eight-fold increase in auc of drugb .
DDI-DrugBank.d237.s9.p0	cisapride	drug	_	ketoconazole	drug	_	effect	a study in # normal male and female volunteers suggests that coadministration of druga and drugb can result in prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s10.p4	Cimetidine	drug	_	cisapride	drug	_	mechanism	drugn : druga coadministration leads to an increased peak plasma concentration and auc of drugb , there is no effect on drugn absorption when it is coadministered with drugn .
DDI-DrugBank.d237.s10.p5	Cimetidine	drug	_	cisapride	drug	_	false	drugn : druga coadministration leads to an increased peak plasma concentration and auc of drugn , there is no effect on drugb absorption when it is coadministered with drugn .
DDI-DrugBank.d237.s10.p6	Cimetidine	drug	_	ranitidine	drug	_	false	drugn : druga coadministration leads to an increased peak plasma concentration and auc of drugn , there is no effect on drugn absorption when it is coadministered with drugb .
DDI-DrugBank.d237.s10.p8	cisapride	drug	_	ranitidine	drug	_	false	drugn : drugn coadministration leads to an increased peak plasma concentration and auc of druga , there is no effect on drugn absorption when it is coadministered with drugb .
DDI-DrugBank.d237.s10.p9	cisapride	drug	_	ranitidine	drug	_	false	drugn : drugn coadministration leads to an increased peak plasma concentration and auc of drugn , there is no effect on druga absorption when it is coadministered with drugb .
DDI-DrugBank.d237.s11.p0	cimetidine	drug	_	ranitidine	drug	_	false	the gastrointestinal absorption of druga and drugb is accelerated when they are coadministered with drugn .
DDI-DrugBank.d237.s11.p1	cimetidine	drug	_	cisapride	drug	_	mechanism	the gastrointestinal absorption of druga and drugn is accelerated when they are coadministered with drugb .
DDI-DrugBank.d237.s11.p2	ranitidine	drug	_	cisapride	drug	_	mechanism	the gastrointestinal absorption of drugn and druga is accelerated when they are coadministered with drugb .
DDI-DrugBank.d237.s12.p4	indinavir	drug	_	ritonavir	drug	_	false	drugn : in vitro data indicate that druga and drugb markedly inhibit the metabolism of drugn which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s12.p5	indinavir	drug	_	cisapride	drug	_	mechanism	drugn : in vitro data indicate that druga and drugn markedly inhibit the metabolism of drugb which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s12.p6	indinavir	drug	_	cisapride	drug	_	false	drugn : in vitro data indicate that druga and drugn markedly inhibit the metabolism of drugn which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s12.p7	ritonavir	drug	_	cisapride	drug	_	mechanism	drugn : in vitro data indicate that drugn and druga markedly inhibit the metabolism of drugb which can result in an increase in plasma drugn levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s12.p8	ritonavir	drug	_	cisapride	drug	_	false	drugn : in vitro data indicate that drugn and druga markedly inhibit the metabolism of drugn which can result in an increase in plasma drugb levels and prolongation of the qt interval on the ecg .
DDI-DrugBank.d237.s14.p0	Cisapride	drug	_	antiarrhythmics	group	_	advise	druga should not be used concomitantly with other drugs known to prolong the qt interval : certain drugb , including those of class ia -lcb- such as drugn and drugn -rcb- and class iii -lcb- such as drugn -rcb- ;
DDI-DrugBank.d237.s14.p1	Cisapride	drug	_	quinidine	drug	_	advise	druga should not be used concomitantly with other drugs known to prolong the qt interval : certain drugn , including those of class ia -lcb- such as drugb and drugn -rcb- and class iii -lcb- such as drugn -rcb- ;
DDI-DrugBank.d237.s14.p2	Cisapride	drug	_	procainamide	drug	_	advise	druga should not be used concomitantly with other drugs known to prolong the qt interval : certain drugn , including those of class ia -lcb- such as drugn and drugb -rcb- and class iii -lcb- such as drugn -rcb- ;
DDI-DrugBank.d237.s14.p3	Cisapride	drug	_	sotalol	drug	_	advise	druga should not be used concomitantly with other drugs known to prolong the qt interval : certain drugn , including those of class ia -lcb- such as drugn and drugn -rcb- and class iii -lcb- such as drugb -rcb- ;
DDI-DrugBank.d237.s14.p4	antiarrhythmics	group	_	quinidine	drug	_	false	drugn should not be used concomitantly with other drugs known to prolong the qt interval : certain druga , including those of class ia -lcb- such as drugb and drugn -rcb- and class iii -lcb- such as drugn -rcb- ;
DDI-DrugBank.d237.s14.p5	antiarrhythmics	group	_	procainamide	drug	_	false	drugn should not be used concomitantly with other drugs known to prolong the qt interval : certain druga , including those of class ia -lcb- such as drugn and drugb -rcb- and class iii -lcb- such as drugn -rcb- ;
DDI-DrugBank.d237.s14.p6	antiarrhythmics	group	_	sotalol	drug	_	false	drugn should not be used concomitantly with other drugs known to prolong the qt interval : certain druga , including those of class ia -lcb- such as drugn and drugn -rcb- and class iii -lcb- such as drugb -rcb- ;
DDI-DrugBank.d237.s14.p8	quinidine	drug	_	sotalol	drug	_	false	drugn should not be used concomitantly with other drugs known to prolong the qt interval : certain drugn , including those of class ia -lcb- such as druga and drugn -rcb- and class iii -lcb- such as drugb -rcb- ;
DDI-DrugBank.d237.s14.p9	procainamide	drug	_	sotalol	drug	_	false	drugn should not be used concomitantly with other drugs known to prolong the qt interval : certain drugn , including those of class ia -lcb- such as drugn and druga -rcb- and class iii -lcb- such as drugb -rcb- ;
DDI-DrugBank.d60.s0.p0	NIMBEX	brand	_	succinylcholine	drug	_	effect	administration of # - mg/kg -lcb- 2 x ed95 -rcb- druga at 10 % or 95 % recovery following an intubating dose of drugb -lcb- 1 mg/kg -rcb- produced 95 % neuromuscular block .
DDI-DrugBank.d60.s1.p0	NIMBEX	brand	_	succinylcholine	drug	_	effect	the time to onset of maximum block following druga is approximately # minutes faster with prior administration of drugb .
DDI-DrugBank.d60.s2.p0	succinylcholine	drug	_	NIMBEX	brand	_	false	prior administration of druga had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of drugb .
DDI-DrugBank.d60.s3.p0	NIMBEX	brand	_	succinylcholine	drug	_	false	infusion requirements of druga in patients administered drugb prior to infusions of drugn were comparable to or slightly greater than when drugn was not administered .
DDI-DrugBank.d60.s3.p2	NIMBEX	brand	_	succinylcholine	drug	_	false	infusion requirements of druga in patients administered drugn prior to infusions of drugn were comparable to or slightly greater than when drugb was not administered .
DDI-DrugBank.d60.s3.p3	succinylcholine	drug	_	NIMBEX	brand	_	effect	infusion requirements of drugn in patients administered druga prior to infusions of drugb were comparable to or slightly greater than when drugn was not administered .
DDI-DrugBank.d60.s3.p5	NIMBEX	brand	_	succinylcholine	drug	_	false	infusion requirements of drugn in patients administered drugn prior to infusions of druga were comparable to or slightly greater than when drugb was not administered .
DDI-DrugBank.d60.s4.p0	NIMBEX	brand	_	succinylcholine	drug	_	false	the use of druga before drugb to attenuate some of the side effects of drugn has not been studied .
DDI-DrugBank.d60.s4.p1	NIMBEX	brand	_	succinylcholine	drug	_	false	the use of druga before drugn to attenuate some of the side effects of drugb has not been studied .
DDI-DrugBank.d60.s5.p2	vecuronium	drug	_	NIMBEX	brand	_	false	although not studied systematically in clinical trials , no drug interactions were observed when druga , drugn , or drugn were administered following varying degrees of recovery from single doses or infusions of drugb .
DDI-DrugBank.d60.s5.p4	pancuronium	drug	_	NIMBEX	brand	_	false	although not studied systematically in clinical trials , no drug interactions were observed when drugn , druga , or drugn were administered following varying degrees of recovery from single doses or infusions of drugb .
DDI-DrugBank.d60.s5.p5	atracurium	drug	_	NIMBEX	brand	_	false	although not studied systematically in clinical trials , no drug interactions were observed when drugn , drugn , or druga were administered following varying degrees of recovery from single doses or infusions of drugb .
DDI-DrugBank.d60.s6.p0	Isoflurane	drug	_	enflurane	drug	_	false	druga or drugb administered with drugn / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p1	Isoflurane	drug	_	nitrous oxide	drug	_	false	druga or drugn administered with drugb / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p2	Isoflurane	drug	_	oxygen	drug	_	false	druga or drugn administered with drugn / drugb to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p3	Isoflurane	drug	_	NIMBEX	brand	_	effect	druga or drugn administered with drugn / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugb and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p4	Isoflurane	drug	_	NIMBEX	brand	_	effect	druga or drugn administered with drugn / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugb .
DDI-DrugBank.d60.s6.p5	enflurane	drug	_	nitrous oxide	drug	_	false	drugn or druga administered with drugb / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p6	enflurane	drug	_	oxygen	drug	_	false	drugn or druga administered with drugn / drugb to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p7	enflurane	drug	_	NIMBEX	brand	_	effect	drugn or druga administered with drugn / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugb and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p8	enflurane	drug	_	NIMBEX	brand	_	effect	drugn or druga administered with drugn / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugb .
DDI-DrugBank.d60.s6.p10	nitrous oxide	drug	_	NIMBEX	brand	_	effect	drugn or drugn administered with druga / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugb and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p11	nitrous oxide	drug	_	NIMBEX	brand	_	effect	drugn or drugn administered with druga / drugn to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugb .
DDI-DrugBank.d60.s6.p12	oxygen	drug	_	NIMBEX	brand	_	false	drugn or drugn administered with drugn / druga to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugb and decrease the required infusion rate of drugn .
DDI-DrugBank.d60.s6.p13	oxygen	drug	_	NIMBEX	brand	_	false	drugn or drugn administered with drugn / druga to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of drugn and decrease the required infusion rate of drugb .
DDI-DrugBank.d60.s8.p0	isoflurane	drug	_	enflurane	drug	_	false	fifteen to # minutes of exposure to # mac druga or drugb had minimal effects on the duration of action of initial doses of drugn and therefore , no adjustment to the initial dose should be necessary when drugn is administered shortly after initiation of volatile agents .
DDI-DrugBank.d60.s8.p1	isoflurane	drug	_	NIMBEX	brand	_	false	fifteen to # minutes of exposure to # mac druga or drugn had minimal effects on the duration of action of initial doses of drugb and therefore , no adjustment to the initial dose should be necessary when drugn is administered shortly after initiation of volatile agents .
DDI-DrugBank.d60.s8.p2	isoflurane	drug	_	NIMBEX	brand	_	false	fifteen to # minutes of exposure to # mac druga or drugn had minimal effects on the duration of action of initial doses of drugn and therefore , no adjustment to the initial dose should be necessary when drugb is administered shortly after initiation of volatile agents .
DDI-DrugBank.d60.s8.p3	enflurane	drug	_	NIMBEX	brand	_	false	fifteen to # minutes of exposure to # mac drugn or druga had minimal effects on the duration of action of initial doses of drugb and therefore , no adjustment to the initial dose should be necessary when drugn is administered shortly after initiation of volatile agents .
DDI-DrugBank.d60.s8.p4	enflurane	drug	_	NIMBEX	brand	_	false	fifteen to # minutes of exposure to # mac drugn or druga had minimal effects on the duration of action of initial doses of drugn and therefore , no adjustment to the initial dose should be necessary when drugb is administered shortly after initiation of volatile agents .
DDI-DrugBank.d60.s9.p0	enflurane	drug	_	isoflurane	drug	_	false	in long surgical procedures during druga or drugb anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of drugn may be necessary .
DDI-DrugBank.d60.s9.p1	enflurane	drug	_	NIMBEX	brand	_	advise	in long surgical procedures during druga or drugn anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of drugb may be necessary .
DDI-DrugBank.d60.s9.p2	isoflurane	drug	_	NIMBEX	brand	_	advise	in long surgical procedures during drugn or druga anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of drugb may be necessary .
DDI-DrugBank.d60.s11.p0	propofol	drug	_	NIMBEX	brand	_	false	in clinical studies druga had no effect on the duration of action or dosing requirements for drugb .
DDI-DrugBank.d60.s12.p0	nondepolarizing agents	group	_	NIMBEX	brand	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugb include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p1	nondepolarizing agents	group	_	antibiotics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p2	nondepolarizing agents	group	_	aminoglycosides	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p3	nondepolarizing agents	group	_	tetracyclines	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p4	nondepolarizing agents	group	_	bacitracin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p5	nondepolarizing agents	group	_	polymyxins	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p6	nondepolarizing agents	group	_	lincomycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p7	nondepolarizing agents	group	_	clindamycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p8	nondepolarizing agents	group	_	colistin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p9	nondepolarizing agents	group	_	sodium colistemethate	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p10	nondepolarizing agents	group	_	magnesium	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugb salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p11	nondepolarizing agents	group	_	lithium	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p12	nondepolarizing agents	group	_	anesthetics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d60.s12.p13	nondepolarizing agents	group	_	procainamide	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d60.s12.p14	nondepolarizing agents	group	_	quinidine	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d60.s12.p15	NIMBEX	brand	_	antibiotics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p16	NIMBEX	brand	_	aminoglycosides	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p17	NIMBEX	brand	_	tetracyclines	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p18	NIMBEX	brand	_	bacitracin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p19	NIMBEX	brand	_	polymyxins	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p20	NIMBEX	brand	_	lincomycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p21	NIMBEX	brand	_	clindamycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p22	NIMBEX	brand	_	colistin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p23	NIMBEX	brand	_	sodium colistemethate	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p24	NIMBEX	brand	_	magnesium	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugb salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p25	NIMBEX	brand	_	lithium	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p26	NIMBEX	brand	_	anesthetics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d60.s12.p27	NIMBEX	brand	_	procainamide	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d60.s12.p28	NIMBEX	brand	_	quinidine	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d60.s12.p110	magnesium	group	_	lithium	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d60.s12.p111	magnesium	group	_	anesthetics	group	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d60.s12.p112	magnesium	group	_	procainamide	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d60.s12.p113	magnesium	group	_	quinidine	drug	_	false	other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d60.s13.p0	nondepolarizing neuromuscular blocking agents	group	_	phenytoin	drug	_	effect	resistance to the neuromuscular blocking action of druga has been demonstrated in patients chronically administered drugb or drugn .
DDI-DrugBank.d60.s13.p1	nondepolarizing neuromuscular blocking agents	group	_	carbamazepine	drug	_	effect	resistance to the neuromuscular blocking action of druga has been demonstrated in patients chronically administered drugn or drugb .
DDI-DrugBank.d60.s13.p2	phenytoin	drug	_	carbamazepine	drug	_	false	resistance to the neuromuscular blocking action of drugn has been demonstrated in patients chronically administered druga or drugb .
DDI-DrugBank.d60.s14.p0	phenytoin	drug	_	carbamazepine	drug	_	false	while the effects of chronic druga or drugb therapy on the action of drugn are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d60.s14.p1	phenytoin	drug	_	NIMBEX	brand	_	effect	while the effects of chronic druga or drugn therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d60.s14.p2	carbamazepine	drug	_	NIMBEX	brand	_	effect	while the effects of chronic drugn or druga therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d145.s0.p0	anticonvulsant agents	group	_	cisplatin	drug	_	mechanism	plasma levels of druga may become subtherapeutic during drugb therapy .
DDI-DrugBank.d472.s0.p0	Central nervous system depressant	group	_	alcohol	drug	_	false	druga -lcb- cns -rcb- drugs including drugb , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p1	Central nervous system depressant	group	_	antidepressants	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugb , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p2	Central nervous system depressant	group	_	antihistamines	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugb , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p3	Central nervous system depressant	group	_	antipsychotics	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugb , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p4	Central nervous system depressant	group	_	reserpine	drug	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugb , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p5	Central nervous system depressant	group	_	methyldopa	drug	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugb , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p6	Central nervous system depressant	group	_	beta-blockers	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugb -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p7	Central nervous system depressant	group	_	muscle relaxants	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p8	Central nervous system depressant	group	_	narcotics	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p9	Central nervous system depressant	group	_	sedatives	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p10	Central nervous system depressant	group	_	tranquilizers	group	_	false	druga -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p14	alcohol	drug	_	reserpine	drug	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugb , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p15	alcohol	drug	_	methyldopa	drug	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugb , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p16	alcohol	drug	_	beta-blockers	group	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugb -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p17	alcohol	drug	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p18	alcohol	drug	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p19	alcohol	drug	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p20	alcohol	drug	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including druga , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p23	antidepressants	group	_	reserpine	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugb , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p24	antidepressants	group	_	methyldopa	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugb , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p25	antidepressants	group	_	beta-blockers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugb -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p26	antidepressants	group	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p27	antidepressants	group	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p28	antidepressants	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p29	antidepressants	group	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , druga , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p31	antihistamines	group	_	reserpine	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugb , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p32	antihistamines	group	_	methyldopa	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugb , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p33	antihistamines	group	_	beta-blockers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugn , drugb -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p34	antihistamines	group	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p35	antihistamines	group	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p36	antihistamines	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p37	antihistamines	group	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , druga , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p38	antipsychotics	group	_	reserpine	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugb , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p39	antipsychotics	group	_	methyldopa	drug	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugb , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p40	antipsychotics	group	_	beta-blockers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugn , drugb -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p41	antipsychotics	group	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p42	antipsychotics	group	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p43	antipsychotics	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p44	antipsychotics	group	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , druga , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p47	reserpine	drug	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- druga , drugn , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p48	reserpine	drug	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- druga , drugn , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p49	reserpine	drug	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- druga , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p50	reserpine	drug	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- druga , drugn , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p52	methyldopa	drug	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , druga , drugn -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p53	methyldopa	drug	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , druga , drugn -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p54	methyldopa	drug	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , druga , drugn -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p55	methyldopa	drug	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , druga , drugn -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p56	beta-blockers	group	_	muscle relaxants	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , druga -rcb- , motion sickness medications , drugb , drugn , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p57	beta-blockers	group	_	narcotics	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , druga -rcb- , motion sickness medications , drugn , drugb , drugn , sleeping pills and drugn
DDI-DrugBank.d472.s0.p58	beta-blockers	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , druga -rcb- , motion sickness medications , drugn , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p59	beta-blockers	group	_	tranquilizers	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , druga -rcb- , motion sickness medications , drugn , drugn , drugn , sleeping pills and drugb
DDI-DrugBank.d472.s0.p61	muscle relaxants	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , druga , drugn , drugb , sleeping pills and drugn
DDI-DrugBank.d472.s0.p63	narcotics	group	_	sedatives	group	_	false	drugn -lcb- cns -rcb- drugs including drugn , drugn , drugn , drugn , blood pressure medications -lcb- drugn , drugn , drugn -rcb- , motion sickness medications , drugn , druga , drugb , sleeping pills and drugn
DDI-DrugBank.d419.s0.p0	allopurinol	drug	_	ampicillin	drug	_	effect	the concurrent administration of druga and drugb increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving drugn alone .
DDI-DrugBank.d419.s0.p1	allopurinol	drug	_	ampicillin	drug	_	false	the concurrent administration of druga and drugn increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving drugb alone .
DDI-DrugBank.d419.s1.p0	ampicillin	drug	_	allopurinol	drug	_	effect	it is not known whether this potentiation of druga rashes is due to drugb or the hyperuricemia present in these patients .
DDI-DrugBank.d419.s2.p0	AUGMENTIN XR	brand	_	allopurinol	drug	_	false	in controlled clinical trials of druga , # patients received concomitant drugb and drugn .
DDI-DrugBank.d419.s2.p2	allopurinol	drug	_	AUGMENTIN XR	brand	_	false	in controlled clinical trials of drugn , # patients received concomitant druga and drugb .
DDI-DrugBank.d419.s4.p0	AUGMENTIN XR	brand	_	allopurinol	drug	_	false	however , this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant druga and drugb use .
DDI-DrugBank.d419.s5.p0	broad-spectrum antibiotics	group	_	AUGMENTIN XR	brand	_	false	in common with other druga , drugb may reduce the efficacy of oral drugn
DDI-DrugBank.d419.s5.p1	broad-spectrum antibiotics	group	_	contraceptives	group	_	effect	in common with other druga , drugn may reduce the efficacy of oral drugb
DDI-DrugBank.d419.s5.p2	AUGMENTIN XR	brand	_	contraceptives	group	_	effect	in common with other drugn , druga may reduce the efficacy of oral drugb
DDI-DrugBank.d309.s0.p0	antihistamines	group	_	CNS depressants	group	_	effect	additive cns depression may occur when druga are administered concomitantly with other drugb including drugn , drugn , and drugn .
DDI-DrugBank.d309.s0.p1	antihistamines	group	_	barbiturates	group	_	effect	additive cns depression may occur when druga are administered concomitantly with other drugn including drugb , drugn , and drugn .
DDI-DrugBank.d309.s0.p2	antihistamines	group	_	tranquilizers	group	_	effect	additive cns depression may occur when druga are administered concomitantly with other drugn including drugn , drugb , and drugn .
DDI-DrugBank.d309.s0.p3	antihistamines	group	_	alcohol	drug	_	effect	additive cns depression may occur when druga are administered concomitantly with other drugn including drugn , drugn , and drugb .
DDI-DrugBank.d309.s0.p4	CNS depressants	group	_	barbiturates	group	_	false	additive cns depression may occur when drugn are administered concomitantly with other druga including drugb , drugn , and drugn .
DDI-DrugBank.d309.s0.p5	CNS depressants	group	_	tranquilizers	group	_	false	additive cns depression may occur when drugn are administered concomitantly with other druga including drugn , drugb , and drugn .
DDI-DrugBank.d309.s0.p6	CNS depressants	group	_	alcohol	drug	_	false	additive cns depression may occur when drugn are administered concomitantly with other druga including drugn , drugn , and drugb .
DDI-DrugBank.d309.s1.p0	antihistamines	group	_	CNS depressant drugs	group	_	advise	patients receiving druga should be advised against the concurrent use of other drugb .
DDI-DrugBank.d309.s2.p0	Monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	effect	druga prolong and intensify the anticholinergic effects of drugb .
DDI-DrugBank.d322.s0.p2	Amantadine	drug	_	clidinium	drug	_	effect	druga , drugn , and drugn may increase anticholinergic effect of drugb .
DDI-DrugBank.d322.s0.p4	tricyclic antidepressants	group	_	clidinium	drug	_	effect	drugn , druga , and drugn may increase anticholinergic effect of drugb .
DDI-DrugBank.d322.s0.p5	MAOIs	group	_	clidinium	drug	_	effect	drugn , drugn , and druga may increase anticholinergic effect of drugb .
DDI-DrugBank.d322.s1.p0	Clidinium	drug	_	phenothiazines	group	_	effect	druga may decrease the effect of drugb , drugn , and drugn .
DDI-DrugBank.d322.s1.p1	Clidinium	drug	_	levodopa	drug	_	effect	druga may decrease the effect of drugn , drugb , and drugn .
DDI-DrugBank.d322.s1.p2	Clidinium	drug	_	ketoconazole	drug	_	effect	druga may decrease the effect of drugn , drugn , and drugb .
DDI-DrugBank.d256.s0.p0	Clindamycin	drug	_	neuromuscular blocking agents	group	_	effect	druga has been shown to have neuromuscular blocking properties that may enhance the action of other drugb .
DDI-DrugBank.d256.s2.p0	clindamycin	drug	_	erythromycin	drug	_	effect	antagonism has been demonstrated between druga and drugb in vitro .
DDI-DrugBank.d399.s0.p0	dapsone	drug	_	Lamprene	brand	_	effect	preliminary data which suggest that druga may inhibit the anti-inflammatory activity of drugb have not been confirmed .
DDI-DrugBank.d399.s1.p0	dapsone	drug	_	clofazimine	drug	_	advise	if leprosy-associated inflammatory reactions develop in patients being treated with druga and drugb , it is still advisable to continue treatment with both drugs .
DDI-DrugBank.d12.s0.p0	anticoagulants	group	_	Atromid-S	brand	_	advise	caution should be exercised when druga are given in conjunction with drugb .
DDI-DrugBank.d12.s3.p0	Atromid-S	brand	_	phenytoin	drug	_	mechanism	druga may displace acidic drugs such as drugb or drugn from their binding sites .
DDI-DrugBank.d12.s3.p1	Atromid-S	brand	_	tolbutamide	drug	_	mechanism	druga may displace acidic drugs such as drugn or drugb from their binding sites .
DDI-DrugBank.d12.s3.p2	phenytoin	drug	_	tolbutamide	drug	_	false	drugn may displace acidic drugs such as druga or drugb from their binding sites .
DDI-DrugBank.d12.s5.p0	tolbutamide	drug	_	Atromid-S	brand	_	effect	the hypoglycemic effect of druga has been reported to increase when drugb is given concurrently .
DDI-DrugBank.d12.s6.p0	fibrate	group	_	lovastatin	drug	_	effect	fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another druga and drugb but may be seen after several months .
DDI-DrugBank.d12.s7.p0	lovastatin	drug	_	fibrate	group	_	effect	for these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with druga and a drugb do not outweigh the risks of severe myopathy , rhabdomyolysis , and acute renal failure .
DDI-DrugBank.d12.s8.p0	fibrates	group	_	gemfibrozil	drug	_	false	while it is not known whether this interaction occurs with druga other than drugb , myopathy and rhabdomyolysis have occasionally been associated with the use of drugn alone , including drugn .
DDI-DrugBank.d12.s8.p2	fibrates	group	_	clofibrate	drug	_	false	while it is not known whether this interaction occurs with druga other than drugn , myopathy and rhabdomyolysis have occasionally been associated with the use of drugn alone , including drugb .
DDI-DrugBank.d12.s8.p3	gemfibrozil	drug	_	fibrates	group	_	false	while it is not known whether this interaction occurs with drugn other than druga , myopathy and rhabdomyolysis have occasionally been associated with the use of drugb alone , including drugn .
DDI-DrugBank.d12.s8.p4	gemfibrozil	drug	_	clofibrate	drug	_	false	while it is not known whether this interaction occurs with drugn other than druga , myopathy and rhabdomyolysis have occasionally been associated with the use of drugn alone , including drugb .
DDI-DrugBank.d12.s8.p5	fibrates	group	_	clofibrate	drug	_	false	while it is not known whether this interaction occurs with drugn other than drugn , myopathy and rhabdomyolysis have occasionally been associated with the use of druga alone , including drugb .
DDI-DrugBank.d12.s9.p0	lovastatin	drug	_	fibrates	group	_	advise	therefore , the combined use of druga with drugb should generally be avoided .
DDI-DrugBank.d238.s2.p0	Anafranil	brand	_	MAO inhibitors	group	_	advise	druga should not be used with drugb .
DDI-DrugBank.d238.s3.p0	Anafranil	brand	_	anticholinergic	group	_	advise	close supervision and careful adjustment of dosage are required when druga is administered with drugb or drugn .
DDI-DrugBank.d238.s3.p1	Anafranil	brand	_	sympathomimetic drugs	group	_	advise	close supervision and careful adjustment of dosage are required when druga is administered with drugn or drugb .
DDI-DrugBank.d238.s3.p2	anticholinergic	group	_	sympathomimetic drugs	group	_	false	close supervision and careful adjustment of dosage are required when drugn is administered with druga or drugb .
DDI-DrugBank.d238.s4.p0	tricyclic antidepressants	group	_	guanethidine	drug	_	effect	several druga have been reported to block the pharmacologic effects of drugb , drugn , or similar agents , and such an effect may be anticipated with drugn because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p1	tricyclic antidepressants	group	_	clonidine	drug	_	effect	several druga have been reported to block the pharmacologic effects of drugn , drugb , or similar agents , and such an effect may be anticipated with drugn because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p2	tricyclic antidepressants	group	_	CMI	drug	_	effect	several druga have been reported to block the pharmacologic effects of drugn , drugn , or similar agents , and such an effect may be anticipated with drugb because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p4	guanethidine	drug	_	clonidine	drug	_	false	several drugn have been reported to block the pharmacologic effects of druga , drugb , or similar agents , and such an effect may be anticipated with drugn because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p5	guanethidine	drug	_	CMI	drug	_	false	several drugn have been reported to block the pharmacologic effects of druga , drugn , or similar agents , and such an effect may be anticipated with drugb because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p6	guanethidine	drug	_	tricyclic antidepressants	group	_	false	several drugn have been reported to block the pharmacologic effects of druga , drugn , or similar agents , and such an effect may be anticipated with drugn because of its structural similarity to other drugb .
DDI-DrugBank.d238.s4.p7	clonidine	drug	_	CMI	drug	_	false	several drugn have been reported to block the pharmacologic effects of drugn , druga , or similar agents , and such an effect may be anticipated with drugb because of its structural similarity to other drugn .
DDI-DrugBank.d238.s4.p8	clonidine	drug	_	tricyclic antidepressants	group	_	false	several drugn have been reported to block the pharmacologic effects of drugn , druga , or similar agents , and such an effect may be anticipated with drugn because of its structural similarity to other drugb .
DDI-DrugBank.d238.s4.p9	CMI	drug	_	tricyclic antidepressants	group	_	false	several drugn have been reported to block the pharmacologic effects of drugn , drugn , or similar agents , and such an effect may be anticipated with druga because of its structural similarity to other drugb .
DDI-DrugBank.d238.s5.p0	CMI	drug	_	haloperidol	drug	_	mechanism	the plasma concentration of druga has been reported to be increased by the concomitant administration of drugb ;
DDI-DrugBank.d238.s6.p0	tricyclic antidepressants	group	_	methylphenidate	drug	_	mechanism	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugb or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p1	tricyclic antidepressants	group	_	cimetidine	drug	_	mechanism	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugb , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p2	tricyclic antidepressants	group	_	fluoxetine	drug	_	mechanism	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugb -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p3	tricyclic antidepressants	group	_	barbiturates	group	_	mechanism	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p4	tricyclic antidepressants	group	_	phenytoin	drug	_	mechanism	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p5	tricyclic antidepressants	group	_	CMI	drug	_	false	plasma levels of several closely related druga have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s6.p6	methylphenidate	drug	_	cimetidine	drug	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of druga or hepatic enzyme inhibitors -lcb- e , g , , drugb , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p7	methylphenidate	drug	_	fluoxetine	drug	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of druga or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugb -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p8	methylphenidate	drug	_	barbiturates	group	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of druga or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p9	methylphenidate	drug	_	phenytoin	drug	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of druga or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p10	methylphenidate	drug	_	CMI	drug	_	mechanism	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of druga or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s6.p12	cimetidine	drug	_	barbiturates	group	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p13	cimetidine	drug	_	phenytoin	drug	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p14	cimetidine	drug	_	CMI	drug	_	mechanism	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s6.p15	fluoxetine	drug	_	barbiturates	group	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p16	fluoxetine	drug	_	phenytoin	drug	_	false	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and such an effect may be anticipated with drugn as well .
DDI-DrugBank.d238.s6.p17	fluoxetine	drug	_	CMI	drug	_	mechanism	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s6.p19	barbiturates	group	_	CMI	drug	_	mechanism	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , druga , drugn -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s6.p20	phenytoin	drug	_	CMI	drug	_	mechanism	plasma levels of several closely related drugn have been reported to be increased by the concomitant administration of drugn or hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decreased by the concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , druga -rcb- , and such an effect may be anticipated with drugb as well .
DDI-DrugBank.d238.s7.p0	CMI	drug	_	phenobarbital	drug	_	mechanism	administration of druga has been reported to increase the plasma levels of drugb , if given concomitantly .
DDI-DrugBank.d238.s15.p0	cimetidine	drug	_	antidepressants	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugb , drugn , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d238.s15.p1	cimetidine	drug	_	phenothiazines	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugb , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d238.s15.p2	cimetidine	drug	_	Type 1C antiarrhythmics	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugb drugn and drugn -rcb- .
DDI-DrugBank.d238.s15.p3	cimetidine	drug	_	propafenone	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugb and drugn -rcb- .
DDI-DrugBank.d238.s15.p4	cimetidine	drug	_	flecainide	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugn and drugb -rcb- .
DDI-DrugBank.d238.s16.p1	selective serotonin reuptake inhibitors	group	_	fluoxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugb , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p2	selective serotonin reuptake inhibitors	group	_	sertraline	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p3	selective serotonin reuptake inhibitors	group	_	paroxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p4	selective serotonin reuptake inhibitors	group	_	fluvoxamine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p5	SSRIs	group	_	fluoxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugb , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p6	SSRIs	group	_	sertraline	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p7	SSRIs	group	_	paroxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s16.p8	SSRIs	group	_	fluvoxamine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d238.s17.p0	Fluvoxamine	drug	_	TCA	group	_	mechanism	druga has also been shown to inhibit cyp2b6 1a2 , an isoform also involved in drugb metabolism .
DDI-DrugBank.d238.s18.p0	SSRI	group	_	TCA	group	_	int	the extent to which druga - drugb interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugn involved .
DDI-DrugBank.d238.s18.p2	TCA	group	_	SSRI	group	_	false	the extent to which drugn - druga interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugb involved .
DDI-DrugBank.d238.s19.p0	TCAs	group	_	SSRIs	group	_	advise	nevertheless , caution is indicated in the co-administration of druga with any of the drugb and also in switching from one class to the other .
DDI-DrugBank.d238.s20.p0	TCA	group	_	fluoxetine	drug	_	advise	of particular importance , sufficient time must elapse before initiating druga treatment in a patient being withdrawn from drugb , given the long half-life of the parent and active metabolite -lcb- at least # weeks may be necessary -rcb- .
DDI-DrugBank.d238.s21.p1	tricyclic antidepressant class	group	_	tricyclic antidepressant agent	group	_	false	concomitant use of agents in the druga -lcb- which includes drugn -rcb- with drugs that can inhibit cyp2d6 may require lower doses than usually prescribed for either the drugb or the other drug .
DDI-DrugBank.d238.s21.p2	Anafranil	brand	_	tricyclic antidepressant agent	group	_	false	concomitant use of agents in the drugn -lcb- which includes druga -rcb- with drugs that can inhibit cyp2d6 may require lower doses than usually prescribed for either the drugb or the other drug .
DDI-DrugBank.d238.s23.p0	TCA	group	_	tricyclic antidepressant class	group	_	false	it is desirable to monitor druga plasma levels whenever an agent of the drugb including drugn is going to be co-administered with another drug known to be an inhibitor of cyp2b6 2d6 -lcb- and/or p450 1a2 -rcb- .
DDI-DrugBank.d238.s23.p1	TCA	group	_	Anafranil	brand	_	false	it is desirable to monitor druga plasma levels whenever an agent of the drugn including drugb is going to be co-administered with another drug known to be an inhibitor of cyp2b6 2d6 -lcb- and/or p450 1a2 -rcb- .
DDI-DrugBank.d238.s23.p2	tricyclic antidepressant class	group	_	Anafranil	brand	_	false	it is desirable to monitor drugn plasma levels whenever an agent of the druga including drugb is going to be co-administered with another drug known to be an inhibitor of cyp2b6 2d6 -lcb- and/or p450 1a2 -rcb- .
DDI-DrugBank.d238.s24.p1	Anafranil	brand	_	warfarin	drug	_	false	because druga is highly bound to serum protein , the administration of drugn to patients taking other drugs that are highly bound to protein -lcb- e , g , , drugb , drugn -rcb- may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .
DDI-DrugBank.d238.s24.p2	Anafranil	brand	_	digoxin	drug	_	false	because druga is highly bound to serum protein , the administration of drugn to patients taking other drugs that are highly bound to protein -lcb- e , g , , drugn , drugb -rcb- may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .
DDI-DrugBank.d238.s24.p3	Anafranil	brand	_	warfarin	drug	_	mechanism	because drugn is highly bound to serum protein , the administration of druga to patients taking other drugs that are highly bound to protein -lcb- e , g , , drugb , drugn -rcb- may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .
DDI-DrugBank.d238.s24.p4	Anafranil	brand	_	digoxin	drug	_	mechanism	because drugn is highly bound to serum protein , the administration of druga to patients taking other drugs that are highly bound to protein -lcb- e , g , , drugn , drugb -rcb- may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .
DDI-DrugBank.d333.s0.p4	Clonazepam	drug	_	phenytoin	drug	_	false	effect of drugn on the pharmacokinetics of other drugs : druga does not appear to alter the pharmacokinetics of drugb , drugn , or drugn .
DDI-DrugBank.d333.s0.p5	Clonazepam	drug	_	carbamazepine	drug	_	false	effect of drugn on the pharmacokinetics of other drugs : druga does not appear to alter the pharmacokinetics of drugn , drugb , or drugn .
DDI-DrugBank.d333.s0.p6	Clonazepam	drug	_	phenobarbital	drug	_	false	effect of drugn on the pharmacokinetics of other drugs : druga does not appear to alter the pharmacokinetics of drugn , drugn , or drugb .
DDI-DrugBank.d333.s2.p2	ranitidine	drug	_	clonazepam	drug	_	false	effect of other drugs on the pharmacokinetics of drugn : literature reports suggest that druga , an agent that decreases stomach acidity , does not greatly alter drugb pharmacokinetics .
DDI-DrugBank.d333.s3.p0	clonazepam	drug	_	propantheline	drug	_	mechanism	in a study in which the # mg druga orally disintegrating tablet was administered with and without drugb -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p1	clonazepam	drug	_	anticholinergic agent	group	_	false	in a study in which the # mg druga orally disintegrating tablet was administered with and without drugn -lcb- an drugb with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p4	clonazepam	drug	_	propantheline	drug	_	false	in a study in which the # mg druga orally disintegrating tablet was administered with and without drugn -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugb compared to when it was given alone .
DDI-DrugBank.d333.s3.p5	propantheline	drug	_	anticholinergic agent	group	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without druga -lcb- an drugb with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p6	propantheline	drug	_	clonazepam	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without druga -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugb was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p7	propantheline	drug	_	clonazepam	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without druga -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugb was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p9	anticholinergic agent	group	_	clonazepam	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without drugn -lcb- an druga with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugb was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p10	anticholinergic agent	group	_	clonazepam	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without drugn -lcb- an druga with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugb was 20 % lower when the orally disintegrating tablet was given with drugn compared to when it was given alone .
DDI-DrugBank.d333.s3.p11	anticholinergic agent	group	_	propantheline	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without drugn -lcb- an druga with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugb compared to when it was given alone .
DDI-DrugBank.d333.s3.p13	clonazepam	drug	_	propantheline	drug	_	false	in a study in which the # mg drugn orally disintegrating tablet was administered with and without drugn -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of druga was 10 % lower and the cmax of drugn was 20 % lower when the orally disintegrating tablet was given with drugb compared to when it was given alone .
DDI-DrugBank.d333.s3.p14	clonazepam	drug	_	propantheline	drug	_	mechanism	in a study in which the # mg drugn orally disintegrating tablet was administered with and without drugn -lcb- an drugn with multiple effects on the gi tract -rcb- to healthy volunteers , the auc of drugn was 10 % lower and the cmax of druga was 20 % lower when the orally disintegrating tablet was given with drugb compared to when it was given alone .
DDI-DrugBank.d333.s4.p0	Fluoxetine	drug	_	clonazepam	drug	_	false	druga does not affect the pharmacokinetics of drugb .
DDI-DrugBank.d333.s5.p2	phenytoin	drug	_	clonazepam	drug	_	mechanism	cytochrome p-450 inducers , such as druga , drugn and drugn , induce drugb metabolism , causing an approximately 30 % decrease in plasma drugn levels .
DDI-DrugBank.d333.s5.p3	phenytoin	drug	_	clonazepam	drug	_	false	cytochrome p-450 inducers , such as druga , drugn and drugn , induce drugn metabolism , causing an approximately 30 % decrease in plasma drugb levels .
DDI-DrugBank.d333.s5.p5	carbamazepine	drug	_	clonazepam	drug	_	mechanism	cytochrome p-450 inducers , such as drugn , druga and drugn , induce drugb metabolism , causing an approximately 30 % decrease in plasma drugn levels .
DDI-DrugBank.d333.s5.p6	carbamazepine	drug	_	clonazepam	drug	_	false	cytochrome p-450 inducers , such as drugn , druga and drugn , induce drugn metabolism , causing an approximately 30 % decrease in plasma drugb levels .
DDI-DrugBank.d333.s5.p7	phenobarbital	drug	_	clonazepam	drug	_	mechanism	cytochrome p-450 inducers , such as drugn , drugn and druga , induce drugb metabolism , causing an approximately 30 % decrease in plasma drugn levels .
DDI-DrugBank.d333.s5.p8	phenobarbital	drug	_	clonazepam	drug	_	false	cytochrome p-450 inducers , such as drugn , drugn and druga , induce drugn metabolism , causing an approximately 30 % decrease in plasma drugb levels .
DDI-DrugBank.d333.s6.p0	clonazepam	drug	_	antifungal agents	group	_	false	although clinical studies have not been performed , based on the involvement of the cytochrome p-450 3a family in druga metabolism , inhibitors of this enzyme system , notably oral drugb , should be used cautiously in patients receiving drugn .
DDI-DrugBank.d333.s6.p2	antifungal agents	group	_	clonazepam	drug	_	advise	although clinical studies have not been performed , based on the involvement of the cytochrome p-450 3a family in drugn metabolism , inhibitors of this enzyme system , notably oral druga , should be used cautiously in patients receiving drugb .
DDI-DrugBank.d333.s7.p0	benzodiazepine class	group	_	alcohol	drug	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugb , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p1	benzodiazepine class	group	_	narcotics	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugb , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p2	benzodiazepine class	group	_	barbiturates	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugb , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p3	benzodiazepine class	group	_	nonbarbiturate hypnotics	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugb , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p4	benzodiazepine class	group	_	antianxiety agents	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugb , the drugn , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p5	benzodiazepine class	group	_	phenothiazines classes of antipsychotic agents	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugb , drugn and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p6	benzodiazepine class	group	_	thioxanthene classes of antipsychotic agents	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p7	benzodiazepine class	group	_	butyrophenone classes of antipsychotic agents	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p8	benzodiazepine class	group	_	monoamine oxidase inhibitors	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p9	benzodiazepine class	group	_	tricyclic antidepressants	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugb , and by other drugn .
DDI-DrugBank.d333.s7.p10	benzodiazepine class	group	_	anticonvulsant drugs	group	_	effect	pharmacodynamic interactions : the cns-depressant action of the druga of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p16	alcohol	drug	_	thioxanthene classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by druga , drugn , drugn , drugn , drugn , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p17	alcohol	drug	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by druga , drugn , drugn , drugn , drugn , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p18	alcohol	drug	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by druga , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p20	alcohol	drug	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by druga , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p25	narcotics	group	_	thioxanthene classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , druga , drugn , drugn , drugn , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p26	narcotics	group	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , druga , drugn , drugn , drugn , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p27	narcotics	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , druga , drugn , drugn , drugn , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p29	narcotics	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , druga , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p33	barbiturates	group	_	thioxanthene classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , druga , drugn , drugn , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p34	barbiturates	group	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , druga , drugn , drugn , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p35	barbiturates	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , druga , drugn , drugn , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p37	barbiturates	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , druga , drugn , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p40	nonbarbiturate hypnotics	group	_	thioxanthene classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , druga , drugn , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p41	nonbarbiturate hypnotics	group	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , druga , drugn , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p42	nonbarbiturate hypnotics	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , druga , drugn , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p44	nonbarbiturate hypnotics	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , druga , drugn , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p46	antianxiety agents	group	_	thioxanthene classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , druga , the drugn , drugb and drugn , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p47	antianxiety agents	group	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , druga , the drugn , drugn and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p48	antianxiety agents	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , druga , the drugn , drugn and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p50	antianxiety agents	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , druga , the drugn , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p55	phenothiazines classes of antipsychotic agents	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the druga , drugn and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p56	thioxanthene classes of antipsychotic agents	group	_	butyrophenone classes of antipsychotic agents	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , druga and drugb , drugn and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p57	thioxanthene classes of antipsychotic agents	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , druga and drugn , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p58	thioxanthene classes of antipsychotic agents	group	_	tricyclic antidepressants	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , druga and drugn , drugn and the drugb , and by other drugn .
DDI-DrugBank.d333.s7.p59	thioxanthene classes of antipsychotic agents	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , druga and drugn , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p60	butyrophenone classes of antipsychotic agents	group	_	monoamine oxidase inhibitors	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and druga , drugb and the drugn , and by other drugn .
DDI-DrugBank.d333.s7.p61	butyrophenone classes of antipsychotic agents	group	_	tricyclic antidepressants	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and druga , drugn and the drugb , and by other drugn .
DDI-DrugBank.d333.s7.p62	butyrophenone classes of antipsychotic agents	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and druga , drugn and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p63	monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , druga and the drugb , and by other drugn .
DDI-DrugBank.d333.s7.p64	monoamine oxidase inhibitors	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , druga and the drugn , and by other drugb .
DDI-DrugBank.d333.s7.p65	tricyclic antidepressants	group	_	anticonvulsant drugs	group	_	false	pharmacodynamic interactions : the cns-depressant action of the drugn of drugs may be potentiated by drugn , drugn , drugn , drugn , drugn , the drugn , drugn and drugn , drugn and the druga , and by other drugb .
DDI-DrugBank.d495.s0.p0	clonidine hydrochloride	drug	_	tricyclic antidepressants	group	_	effect	tablet if a patient receiving druga is also taking drugb , the effect of drugn may be reduced , thus necessitating an increase in dosage .
DDI-DrugBank.d495.s0.p2	tricyclic antidepressants	group	_	clonidine	drug	_	false	tablet if a patient receiving drugn is also taking druga , the effect of drugb may be reduced , thus necessitating an increase in dosage .
DDI-DrugBank.d495.s1.p0	Clonidine hydrochloride	drug	_	alcohol	drug	_	effect	druga may enhance the cns-depressive effects of drugb , drugn or other drugn .
DDI-DrugBank.d495.s1.p1	Clonidine hydrochloride	drug	_	barbiturates	group	_	effect	druga may enhance the cns-depressive effects of drugn , drugb or other drugn .
DDI-DrugBank.d495.s1.p2	Clonidine hydrochloride	drug	_	sedatives	group	_	effect	druga may enhance the cns-depressive effects of drugn , drugn or other drugb .
DDI-DrugBank.d495.s2.p0	Amitriptyline	drug	_	clonidine	drug	_	effect	druga in combination with drugb enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugn , drugn or other drugn .
DDI-DrugBank.d495.s2.p1	Amitriptyline	drug	_	Clonidine	drug	_	false	druga in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection drugb may potentiate the cns-depressive effect of drugn , drugn or other drugn .
DDI-DrugBank.d495.s2.p2	Amitriptyline	drug	_	alcohol	drug	_	false	druga in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugb , drugn or other drugn .
DDI-DrugBank.d495.s2.p3	Amitriptyline	drug	_	barbiturates	group	_	false	druga in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugn , drugb or other drugn .
DDI-DrugBank.d495.s2.p4	Amitriptyline	drug	_	sedating drugs	group	_	false	druga in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugn , drugn or other drugb .
DDI-DrugBank.d495.s2.p6	clonidine	drug	_	alcohol	drug	_	false	drugn in combination with druga enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugb , drugn or other drugn .
DDI-DrugBank.d495.s2.p7	clonidine	drug	_	barbiturates	group	_	false	drugn in combination with druga enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugn , drugb or other drugn .
DDI-DrugBank.d495.s2.p8	clonidine	drug	_	sedating drugs	group	_	false	drugn in combination with druga enhances the manifestation of corneal lesions in rats epidural injection drugn may potentiate the cns-depressive effect of drugn , drugn or other drugb .
DDI-DrugBank.d495.s2.p9	Clonidine	drug	_	alcohol	drug	_	effect	drugn in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection druga may potentiate the cns-depressive effect of drugb , drugn or other drugn .
DDI-DrugBank.d495.s2.p10	Clonidine	drug	_	barbiturates	group	_	effect	drugn in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection druga may potentiate the cns-depressive effect of drugn , drugb or other drugn .
DDI-DrugBank.d495.s2.p11	Clonidine	drug	_	sedating drugs	group	_	effect	drugn in combination with drugn enhances the manifestation of corneal lesions in rats epidural injection druga may potentiate the cns-depressive effect of drugn , drugn or other drugb .
DDI-DrugBank.d495.s3.p0	Narcotic analgesics	group	_	clonidine	drug	_	effect	druga may potentiate the hypotensive effects of drugb .
DDI-DrugBank.d495.s4.p0	Tricyclic antidepressants	group	_	clonidine	drug	_	effect	druga may antagonize the hypotensive effects of drugb .
DDI-DrugBank.d495.s5.p0	tricyclic antidepressants	group	_	clonidine	drug	_	false	the effects of druga on drugb s analgesic actions are not known .
DDI-DrugBank.d495.s6.p0	Beta blockers	group	_	clonidine	drug	_	effect	druga may exacerbate the hypertensive response seen with drugb withdrawl .
DDI-DrugBank.d495.s7.p0	clonidine	drug	_	digitalis	group	_	advise	also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving druga with agents known to affect sinus node function or av nodal conduction -lcb- e , g , , drugb , drugn , and drugn .
DDI-DrugBank.d495.s7.p1	clonidine	drug	_	calcium channel blockers	group	_	advise	also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving druga with agents known to affect sinus node function or av nodal conduction -lcb- e , g , , drugn , drugb , and drugn .
DDI-DrugBank.d495.s7.p2	clonidine	drug	_	beta-blockers	group	_	advise	also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving druga with agents known to affect sinus node function or av nodal conduction -lcb- e , g , , drugn , drugn , and drugb .
DDI-DrugBank.d495.s8.p0	fluphenazine	drug	_	clonidine	drug	_	effect	there is one reported case of a patient with acute delirium associated with the simultaneous use of druga and oral drugb .
DDI-DrugBank.d495.s10.p0	clonidine	drug	_	anesthetics	group	_	effect	epidural druga may prolong the duration of pharmacologic effects of epidural local drugb , including both sensory and motor blockade .
DDI-DrugBank.d335.s1.p0	clorazepate dipotassium	drug	_	hexobarbital	drug	_	effect	animal experience indicates that druga prolongs the sleeping time after drugb or after drugn , increases the inhibitory effects of drugn , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s1.p1	clorazepate dipotassium	drug	_	ethyl alcohol	drug	_	effect	animal experience indicates that druga prolongs the sleeping time after drugn or after drugb , increases the inhibitory effects of drugn , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s1.p2	clorazepate dipotassium	drug	_	chlorpromazine	drug	_	effect	animal experience indicates that druga prolongs the sleeping time after drugn or after drugn , increases the inhibitory effects of drugb , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s1.p3	hexobarbital	drug	_	ethyl alcohol	drug	_	false	animal experience indicates that drugn prolongs the sleeping time after druga or after drugb , increases the inhibitory effects of drugn , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s1.p4	hexobarbital	drug	_	chlorpromazine	drug	_	false	animal experience indicates that drugn prolongs the sleeping time after druga or after drugn , increases the inhibitory effects of drugb , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s1.p5	ethyl alcohol	drug	_	chlorpromazine	drug	_	false	animal experience indicates that drugn prolongs the sleeping time after drugn or after druga , increases the inhibitory effects of drugb , but does not exhibit maoa inhibition .
DDI-DrugBank.d335.s3.p0	benzodiazepines	group	_	barbiturates	group	_	effect	the actions of the druga may be potentiated by drugb , drugn , drugn , drugn or other drugn .
DDI-DrugBank.d335.s3.p1	benzodiazepines	group	_	narcotics	group	_	effect	the actions of the druga may be potentiated by drugn , drugb , drugn , drugn or other drugn .
DDI-DrugBank.d335.s3.p2	benzodiazepines	group	_	phenothiazines	group	_	effect	the actions of the druga may be potentiated by drugn , drugn , drugb , drugn or other drugn .
DDI-DrugBank.d335.s3.p3	benzodiazepines	group	_	monoamine oxidase inhibitors	group	_	effect	the actions of the druga may be potentiated by drugn , drugn , drugn , drugb or other drugn .
DDI-DrugBank.d335.s3.p4	benzodiazepines	group	_	antidepressants	group	_	effect	the actions of the druga may be potentiated by drugn , drugn , drugn , drugn or other drugb .
DDI-DrugBank.d335.s5.p0	antacids	group	_	TRANXENE	brand	_	false	in bioavailability studies with normal subjects , the concurrent administration of druga at therapeutic levels did not significantly influence the bioavailability of drugb tablets .
DDI-DrugBank.d480.s4.p0	Clozapine	drug	_	alcohol	drug	_	effect	given the primary cns effects of druga , caution is advised in using it concomitantly with other cns-active drugs or drugb .
DDI-DrugBank.d480.s7.p0	psychotropic drugs	group	_	Clozapine	drug	_	false	similar events have been reported in patients taking other druga or even drugb by itself .
DDI-DrugBank.d480.s8.p3	Clozapine	drug	_	benzodiazepine	group	_	false	although it has not been established that there is an interaction between druga and drugn or other drugn , caution is advised when drugn is initiated in patients taking a drugb or any other drugn .
DDI-DrugBank.d480.s8.p4	Clozapine	drug	_	psychotropic drug	group	_	false	although it has not been established that there is an interaction between druga and drugn or other drugn , caution is advised when drugn is initiated in patients taking a drugn or any other drugb .
DDI-DrugBank.d480.s8.p6	benzodiazepines	group	_	clozapine	drug	_	false	although it has not been established that there is an interaction between drugn and druga or other drugn , caution is advised when drugb is initiated in patients taking a drugn or any other drugn .
DDI-DrugBank.d480.s8.p8	benzodiazepines	group	_	psychotropic drug	group	_	false	although it has not been established that there is an interaction between drugn and druga or other drugn , caution is advised when drugn is initiated in patients taking a drugn or any other drugb .
DDI-DrugBank.d480.s8.p9	psychotropics	group	_	clozapine	drug	_	false	although it has not been established that there is an interaction between drugn and drugn or other druga , caution is advised when drugb is initiated in patients taking a drugn or any other drugn .
DDI-DrugBank.d480.s8.p10	psychotropics	group	_	benzodiazepine	group	_	false	although it has not been established that there is an interaction between drugn and drugn or other druga , caution is advised when drugn is initiated in patients taking a drugb or any other drugn .
DDI-DrugBank.d480.s8.p11	psychotropics	group	_	psychotropic drug	group	_	false	although it has not been established that there is an interaction between drugn and drugn or other druga , caution is advised when drugn is initiated in patients taking a drugn or any other drugb .
DDI-DrugBank.d480.s8.p12	clozapine	drug	_	benzodiazepine	group	_	advise	although it has not been established that there is an interaction between drugn and drugn or other drugn , caution is advised when druga is initiated in patients taking a drugb or any other drugn .
DDI-DrugBank.d480.s8.p13	clozapine	drug	_	psychotropic drug	group	_	advise	although it has not been established that there is an interaction between drugn and drugn or other drugn , caution is advised when druga is initiated in patients taking a drugn or any other drugb .
DDI-DrugBank.d480.s8.p14	benzodiazepine	group	_	psychotropic drug	group	_	false	although it has not been established that there is an interaction between drugn and drugn or other drugn , caution is advised when drugn is initiated in patients taking a druga or any other drugb .
DDI-DrugBank.d480.s9.p0	Clozapine	drug	_	antihypertensive drugs	group	_	effect	druga may potentiate the hypotensive effects of drugb and the anticholinergic effects of drugn - type drugs .
DDI-DrugBank.d480.s9.p1	Clozapine	drug	_	atropine	drug	_	effect	druga may potentiate the hypotensive effects of drugn and the anticholinergic effects of drugb - type drugs .
DDI-DrugBank.d480.s9.p2	antihypertensive drugs	group	_	atropine	drug	_	false	drugn may potentiate the hypotensive effects of druga and the anticholinergic effects of drugb - type drugs .
DDI-DrugBank.d480.s15.p2	Phenytoin	drug	_	Clozapine	drug	_	mechanism	druga , drugn , and drugn may decrease drugb plasma levels , resulting in a decrease in effectiveness of a previously effective drugn dose .
DDI-DrugBank.d480.s15.p3	Phenytoin	drug	_	Clozapine	drug	_	false	druga , drugn , and drugn may decrease drugn plasma levels , resulting in a decrease in effectiveness of a previously effective drugb dose .
DDI-DrugBank.d480.s15.p5	nicotine	drug	_	Clozapine	drug	_	mechanism	drugn , druga , and drugn may decrease drugb plasma levels , resulting in a decrease in effectiveness of a previously effective drugn dose .
DDI-DrugBank.d480.s15.p6	nicotine	drug	_	Clozapine	drug	_	false	drugn , druga , and drugn may decrease drugn plasma levels , resulting in a decrease in effectiveness of a previously effective drugb dose .
DDI-DrugBank.d480.s15.p7	rifampin	drug	_	Clozapine	drug	_	mechanism	drugn , drugn , and druga may decrease drugb plasma levels , resulting in a decrease in effectiveness of a previously effective drugn dose .
DDI-DrugBank.d480.s15.p8	rifampin	drug	_	Clozapine	drug	_	false	drugn , drugn , and druga may decrease drugn plasma levels , resulting in a decrease in effectiveness of a previously effective drugb dose .
DDI-DrugBank.d480.s17.p2	Cimetidine	drug	_	Clozapine	drug	_	mechanism	druga , drugn , and drugn may increase plasma levels of drugb , potentially resulting in adverse effects .
DDI-DrugBank.d480.s17.p4	caffeine	drug	_	Clozapine	drug	_	mechanism	drugn , druga , and drugn may increase plasma levels of drugb , potentially resulting in adverse effects .
DDI-DrugBank.d480.s17.p5	erythromycin	drug	_	Clozapine	drug	_	mechanism	drugn , drugn , and druga may increase plasma levels of drugb , potentially resulting in adverse effects .
DDI-DrugBank.d480.s18.p0	Clozapine	drug	_	carbamazepine	drug	_	advise	although concomitant use of druga and drugb is not recommended , it should be noted that discontinuation of concomitant drugn administration may result in an increase in drugn plasma levels .
DDI-DrugBank.d480.s18.p1	Clozapine	drug	_	carbamazepine	drug	_	false	although concomitant use of druga and drugn is not recommended , it should be noted that discontinuation of concomitant drugb administration may result in an increase in drugn plasma levels .
DDI-DrugBank.d480.s18.p4	carbamazepine	drug	_	Clozapine	drug	_	false	although concomitant use of drugn and druga is not recommended , it should be noted that discontinuation of concomitant drugn administration may result in an increase in drugb plasma levels .
DDI-DrugBank.d480.s18.p5	carbamazepine	drug	_	Clozapine	drug	_	mechanism	although concomitant use of drugn and drugn is not recommended , it should be noted that discontinuation of concomitant druga administration may result in an increase in drugb plasma levels .
DDI-DrugBank.d480.s19.p0	clozapine	drug	_	fluvoxamine	drug	_	false	in a study of schizophrenic patients who received druga under steady state conditions , drugb or drugn was added in # and # patients , respectively .
DDI-DrugBank.d480.s19.p1	clozapine	drug	_	paroxetine	drug	_	false	in a study of schizophrenic patients who received druga under steady state conditions , drugn or drugb was added in # and # patients , respectively .
DDI-DrugBank.d480.s19.p2	fluvoxamine	drug	_	paroxetine	drug	_	false	in a study of schizophrenic patients who received drugn under steady state conditions , druga or drugb was added in # and # patients , respectively .
DDI-DrugBank.d480.s20.p2	clozapine	drug	_	fluvoxamine	drug	_	false	after # days of co-administration , mean trough concentrations of druga and its metabolites , drugn and drugn , were elevated with drugb by about three-fold compared to baseline concentrations .
DDI-DrugBank.d480.s20.p3	N-desmethylclozapine	drug_n	_	clozapine N-oxide	drug_n	_	false	after # days of co-administration , mean trough concentrations of drugn and its metabolites , druga and drugb , were elevated with drugn by about three-fold compared to baseline concentrations .
DDI-DrugBank.d480.s20.p4	N-desmethylclozapine	drug_n	_	fluvoxamine	drug	_	false	after # days of co-administration , mean trough concentrations of drugn and its metabolites , druga and drugn , were elevated with drugb by about three-fold compared to baseline concentrations .
DDI-DrugBank.d480.s20.p5	clozapine N-oxide	drug_n	_	fluvoxamine	drug	_	false	after # days of co-administration , mean trough concentrations of drugn and its metabolites , drugn and druga , were elevated with drugb by about three-fold compared to baseline concentrations .
DDI-DrugBank.d480.s21.p0	Paroxetine	drug	_	clozapine	drug	_	mechanism	druga produced only minor changes in the levels of drugb and its metabolites .
DDI-DrugBank.d480.s22.p1	clozapine	drug	_	paroxetine	drug	_	false	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of druga and metabolite concentrations when drugn was taken with drugb , drugn , and drugn .
DDI-DrugBank.d480.s22.p2	clozapine	drug	_	fluoxetine	drug	_	false	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of druga and metabolite concentrations when drugn was taken with drugn , drugb , and drugn .
DDI-DrugBank.d480.s22.p3	clozapine	drug	_	sertraline	drug	_	false	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of druga and metabolite concentrations when drugn was taken with drugn , drugn , and drugb .
DDI-DrugBank.d480.s22.p4	clozapine	drug	_	paroxetine	drug	_	mechanism	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of drugn and metabolite concentrations when druga was taken with drugb , drugn , and drugn .
DDI-DrugBank.d480.s22.p5	clozapine	drug	_	fluoxetine	drug	_	mechanism	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of drugn and metabolite concentrations when druga was taken with drugn , drugb , and drugn .
DDI-DrugBank.d480.s22.p6	clozapine	drug	_	sertraline	drug	_	mechanism	however , other published reports describe modest elevations -lcb- less than two-fold -rcb- of drugn and metabolite concentrations when druga was taken with drugn , drugn , and drugb .
DDI-DrugBank.d480.s23.p0	Clozapine	drug	_	fluvoxamine	drug	_	advise	therefore , such combined treatment should be approached with caution and patients should be monitored closely when druga is combined with these drugs , particularly with drugb .
DDI-DrugBank.d480.s26.p0	debrisoquin	drug	_	dextromethorphan	drug	_	false	such individuals are referred to as poor metabolizers of drugs such as druga , drugb , the drugn , and drugn .
DDI-DrugBank.d480.s26.p1	debrisoquin	drug	_	tricyclic antidepressants	group	_	false	such individuals are referred to as poor metabolizers of drugs such as druga , drugn , the drugb , and drugn .
DDI-DrugBank.d480.s26.p2	debrisoquin	drug	_	clozapine	drug	_	false	such individuals are referred to as poor metabolizers of drugs such as druga , drugn , the drugn , and drugb .
DDI-DrugBank.d480.s26.p3	dextromethorphan	drug	_	tricyclic antidepressants	group	_	false	such individuals are referred to as poor metabolizers of drugs such as drugn , druga , the drugb , and drugn .
DDI-DrugBank.d480.s26.p4	dextromethorphan	drug	_	clozapine	drug	_	false	such individuals are referred to as poor metabolizers of drugs such as drugn , druga , the drugn , and drugb .
DDI-DrugBank.d480.s26.p5	tricyclic antidepressants	group	_	clozapine	drug	_	false	such individuals are referred to as poor metabolizers of drugs such as drugn , drugn , the druga , and drugb .
DDI-DrugBank.d480.s30.p0	clozapine	drug	_	antidepressants	group	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugb , drugn , drugn , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p1	clozapine	drug	_	phenothiazines	group	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugb , drugn , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p2	clozapine	drug	_	carbamazepine	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugb , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p3	clozapine	drug	_	Type 1C antiarrhythmics	group	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugb -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p4	clozapine	drug	_	propafenone	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugb , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p5	clozapine	drug	_	flecainide	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugn , drugb and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p6	clozapine	drug	_	encainide	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugn , drugn and drugb -rcb- , or that inhibit this enzyme -lcb- e , g , , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p7	clozapine	drug	_	quinidine	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p14	antidepressants	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including druga , drugn , drugn , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p20	phenothiazines	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , druga , drugn , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p25	carbamazepine	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , drugn , druga , and drugn -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p29	Type 1C antiarrhythmics	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and druga -lcb- e , g , , drugn , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p32	propafenone	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , druga , drugn and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p34	flecainide	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugn , druga and drugn -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d480.s30.p35	encainide	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isozyme , including drugn , drugn , drugn , and drugn -lcb- e , g , , drugn , drugn and druga -rcb- , or that inhibit this enzyme -lcb- e , g , , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d221.s0.p0	NovoSeven	brand	_	coagulation factor	group	_	false	the risk of a potential interaction between druga and drugb concentrates has not been adequately evaluated in preclinical or clinical studies .
DDI-DrugBank.d221.s2.p1	tranexamic acid	drug	_	NovoSeven	brand	_	false	although the specific drug interaction was not studied in a clinical trial , there have been more than # episodes of concomitant use of antifibrinolytic therapies -lcb- i , e , , druga , drugn -rcb- and drugb .
DDI-DrugBank.d221.s2.p2	aminocaproic acid	drug	_	NovoSeven	brand	_	false	although the specific drug interaction was not studied in a clinical trial , there have been more than # episodes of concomitant use of antifibrinolytic therapies -lcb- i , e , , drugn , druga -rcb- and drugb .
DDI-DrugBank.d464.s0.p0	Codeine	drug	_	narcotic analgesics	group	_	effect	druga in combination with other drugb , general drugn , drugn , drugn , drugn , or other drugn -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p1	Codeine	drug	_	anesthetics	group	_	effect	druga in combination with other drugn , general drugb , drugn , drugn , drugn , or other drugn -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p2	Codeine	drug	_	phenothiazines	group	_	effect	druga in combination with other drugn , general drugn , drugb , drugn , drugn , or other drugn -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p3	Codeine	drug	_	tranquilizers	group	_	effect	druga in combination with other drugn , general drugn , drugn , drugb , drugn , or other drugn -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p4	Codeine	drug	_	sedative-hypnotics	group	_	effect	druga in combination with other drugn , general drugn , drugn , drugn , drugb , or other drugn -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p5	Codeine	drug	_	CNS depressants	group	_	effect	druga in combination with other drugn , general drugn , drugn , drugn , drugn , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p6	Codeine	drug	_	alcohol	drug	_	effect	druga in combination with other drugn , general drugn , drugn , drugn , drugn , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p11	narcotic analgesics	group	_	CNS depressants	group	_	false	drugn in combination with other druga , general drugn , drugn , drugn , drugn , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p12	narcotic analgesics	group	_	alcohol	drug	_	false	drugn in combination with other druga , general drugn , drugn , drugn , drugn , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p16	anesthetics	group	_	CNS depressants	group	_	false	drugn in combination with other drugn , general druga , drugn , drugn , drugn , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p17	anesthetics	group	_	alcohol	drug	_	false	drugn in combination with other drugn , general druga , drugn , drugn , drugn , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p20	phenothiazines	group	_	CNS depressants	group	_	false	drugn in combination with other drugn , general drugn , druga , drugn , drugn , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p21	phenothiazines	group	_	alcohol	drug	_	false	drugn in combination with other drugn , general drugn , druga , drugn , drugn , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p23	tranquilizers	group	_	CNS depressants	group	_	false	drugn in combination with other drugn , general drugn , drugn , druga , drugn , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p24	tranquilizers	group	_	alcohol	drug	_	false	drugn in combination with other drugn , general drugn , drugn , druga , drugn , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p25	sedative-hypnotics	group	_	CNS depressants	group	_	false	drugn in combination with other drugn , general drugn , drugn , drugn , druga , or other drugb -lcb- including drugn -rcb- has additive depressant effects .
DDI-DrugBank.d464.s0.p26	sedative-hypnotics	group	_	alcohol	drug	_	false	drugn in combination with other drugn , general drugn , drugn , drugn , druga , or other drugn -lcb- including drugb -rcb- has additive depressant effects .
DDI-DrugBank.d146.s0.p0	Colchicine	drug	_	acidifying agents	group	_	mechanism	druga is inhibited by drugb .
DDI-DrugBank.d146.s1.p0	colchicine	drug	_	alkalinizing agents	group	_	mechanism	the action of druga is potentiated by drugb .
DDI-DrugBank.d146.s2.p0	Colchicine	drug	_	CNS depressants	group	_	effect	druga may increase sensitivity to the drugb .
DDI-DrugBank.d146.s3.p0	sympathomimetic agents	group	_	colchicine	drug	_	effect	response to druga may be enhanced by drugb .
DDI-DrugBank.d551.s1.p0	WelChol	brand	_	digoxin	drug	_	false	druga was found to have no significant effect on the bioavailability of drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d551.s1.p1	WelChol	brand	_	lovastatin	drug	_	false	druga was found to have no significant effect on the bioavailability of drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d551.s1.p2	WelChol	brand	_	metoprolol	drug	_	false	druga was found to have no significant effect on the bioavailability of drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d551.s1.p3	WelChol	brand	_	quinidine	drug	_	false	druga was found to have no significant effect on the bioavailability of drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d551.s1.p4	WelChol	brand	_	valproic acid	drug	_	false	druga was found to have no significant effect on the bioavailability of drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d551.s1.p5	WelChol	brand	_	warfarin	drug	_	false	druga was found to have no significant effect on the bioavailability of drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d551.s2.p0	WelChol	brand	_	verapamil	drug	_	mechanism	druga decreased the cmax and auc of sustained-release drugb -lcb- drugn -rcb- by approximately 31 % and 11 % , respectively .
DDI-DrugBank.d551.s2.p1	WelChol	brand	_	Calan SR	brand	_	mechanism	druga decreased the cmax and auc of sustained-release drugn -lcb- drugb -rcb- by approximately 31 % and 11 % , respectively .
DDI-DrugBank.d551.s4.p0	WelChol	brand	_	atorvastatin	drug	_	false	in clinical studies , coadministration of druga with drugb , drugn , or drugn did not interfere with the lipid-lowering activity of the drugn .
DDI-DrugBank.d551.s4.p1	WelChol	brand	_	lovastatin	drug	_	false	in clinical studies , coadministration of druga with drugn , drugb , or drugn did not interfere with the lipid-lowering activity of the drugn .
DDI-DrugBank.d551.s4.p2	WelChol	brand	_	simvastatin	drug	_	false	in clinical studies , coadministration of druga with drugn , drugn , or drugb did not interfere with the lipid-lowering activity of the drugn .
DDI-DrugBank.d551.s4.p3	WelChol	brand	_	HMG-CoA reductase inhibitor	group	_	false	in clinical studies , coadministration of druga with drugn , drugn , or drugn did not interfere with the lipid-lowering activity of the drugb .
DDI-DrugBank.d551.s4.p6	atorvastatin	drug	_	HMG-CoA reductase inhibitor	group	_	false	in clinical studies , coadministration of drugn with druga , drugn , or drugn did not interfere with the lipid-lowering activity of the drugb .
DDI-DrugBank.d551.s4.p8	lovastatin	drug	_	HMG-CoA reductase inhibitor	group	_	false	in clinical studies , coadministration of drugn with drugn , druga , or drugn did not interfere with the lipid-lowering activity of the drugb .
DDI-DrugBank.d551.s4.p9	simvastatin	drug	_	HMG-CoA reductase inhibitor	group	_	false	in clinical studies , coadministration of drugn with drugn , drugn , or druga did not interfere with the lipid-lowering activity of the drugb .
DDI-DrugBank.d345.s0.p0	colestipol hydrochloride	drug	_	anion exchange resin	group	_	false	since druga is an drugb , it may have a strong affinity for anions other than the bile acids .
DDI-DrugBank.d345.s5.p0	colestipol hydrochloride	drug	_	propranolol	drug	_	mechanism	repeated doses of druga given prior to a single dose of drugb in human trials have been reported to decrease drugn absorption .
DDI-DrugBank.d345.s5.p1	colestipol hydrochloride	drug	_	propranolol	drug	_	false	repeated doses of druga given prior to a single dose of drugn in human trials have been reported to decrease drugb absorption .
DDI-DrugBank.d345.s6.p1	colestipol hydrochloride	drug	_	propranolol	drug	_	false	however , in a follow-up study in normal subjects , single-dose administration of druga and drugn and twice-a-day administration for # days of both agents did not affect the extent of drugb absorption , but had a small yet statistically significant effect on its rate of absorption ;
DDI-DrugBank.d345.s9.p0	propranolol	drug	_	COLESTID	brand	_	advise	therefore , patients on druga should be observed when drugb tablets are either added or deleted from a therapeutic regimen .
DDI-DrugBank.d345.s10.p0	chlorothiazide	drug	_	colestipol hydrochloride	drug	_	mechanism	studies in humans show that the absorption of druga as reflected in urinary excretion is markedly decreased even when administered one hour before drugb .
DDI-DrugBank.d345.s11.p4	tetracycline	drug	_	colestipol hydrochloride	drug	_	mechanism	the absorption of druga , drugn , drugn , drugn , and drugn was significantly decreased when given simultaneously with drugb ;
DDI-DrugBank.d345.s11.p8	furosemide	drug	_	colestipol hydrochloride	drug	_	mechanism	the absorption of drugn , druga , drugn , drugn , and drugn was significantly decreased when given simultaneously with drugb ;
DDI-DrugBank.d345.s11.p11	penicillin G	drug	_	colestipol hydrochloride	drug	_	mechanism	the absorption of drugn , drugn , druga , drugn , and drugn was significantly decreased when given simultaneously with drugb ;
DDI-DrugBank.d345.s11.p13	hydrochlorothiazide	drug	_	colestipol hydrochloride	drug	_	mechanism	the absorption of drugn , drugn , drugn , druga , and drugn was significantly decreased when given simultaneously with drugb ;
DDI-DrugBank.d345.s11.p14	gemfibrozil	drug	_	colestipol hydrochloride	drug	_	mechanism	the absorption of drugn , drugn , drugn , drugn , and druga was significantly decreased when given simultaneously with drugb ;
DDI-DrugBank.d345.s13.p0	colestipol hydrochloride	drug	_	aspirin	brand	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugb , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p1	colestipol hydrochloride	drug	_	clindamycin	brand	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugb , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p2	colestipol hydrochloride	drug	_	clofibrate	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugb , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p3	colestipol hydrochloride	drug	_	methyldopa	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugb , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p4	colestipol hydrochloride	drug	_	nicotinic acid	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugb -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p5	colestipol hydrochloride	drug	_	niacin	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugb -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p6	colestipol hydrochloride	drug	_	tolbutamide	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugb , drugn or drugn .
DDI-DrugBank.d345.s13.p7	colestipol hydrochloride	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p8	colestipol hydrochloride	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when druga was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p9	aspirin	brand	_	clindamycin	brand	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugb , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p10	aspirin	brand	_	clofibrate	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugb , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p11	aspirin	brand	_	methyldopa	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugb , drugn -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p12	aspirin	brand	_	nicotinic acid	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugn , drugb -lcb- drugn -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p13	aspirin	brand	_	niacin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugn , drugn -lcb- drugb -rcb- , drugn , drugn or drugn .
DDI-DrugBank.d345.s13.p14	aspirin	brand	_	tolbutamide	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugb , drugn or drugn .
DDI-DrugBank.d345.s13.p15	aspirin	brand	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p16	aspirin	brand	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : druga , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p22	clindamycin	brand	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , druga , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p23	clindamycin	brand	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , druga , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p28	clofibrate	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , druga , drugn , drugn -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p29	clofibrate	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , druga , drugn , drugn -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p33	methyldopa	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , druga , drugn -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p34	methyldopa	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , druga , drugn -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p37	nicotinic acid	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , druga -lcb- drugn -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p38	nicotinic acid	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , druga -lcb- drugn -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p40	niacin	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- druga -rcb- , drugn , drugb or drugn .
DDI-DrugBank.d345.s13.p41	niacin	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- druga -rcb- , drugn , drugn or drugb .
DDI-DrugBank.d345.s13.p42	tolbutamide	drug	_	phenytoin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , druga , drugb or drugn .
DDI-DrugBank.d345.s13.p43	tolbutamide	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , druga , drugn or drugb .
DDI-DrugBank.d345.s13.p44	phenytoin	drug	_	warfarin	drug	_	false	no depressant effect on blood levels in humans was noted when drugn was administered with any of the following drugs : drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , drugn , druga or drugb .
DDI-DrugBank.d345.s14.p0	digitalis preparations	group	_	colestipol hydrochloride	drug	_	effect	particular caution should be observed with druga since there are conflicting results for the effect of drugb on the availability of drugn and drugn .
DDI-DrugBank.d345.s14.p1	digitalis preparations	group	_	digoxin	drug	_	false	particular caution should be observed with druga since there are conflicting results for the effect of drugn on the availability of drugb and drugn .
DDI-DrugBank.d345.s14.p2	digitalis preparations	group	_	digitoxin	drug	_	false	particular caution should be observed with druga since there are conflicting results for the effect of drugn on the availability of drugn and drugb .
DDI-DrugBank.d345.s14.p3	colestipol hydrochloride	drug	_	digoxin	drug	_	mechanism	particular caution should be observed with drugn since there are conflicting results for the effect of druga on the availability of drugb and drugn .
DDI-DrugBank.d345.s14.p4	colestipol hydrochloride	drug	_	digitoxin	drug	_	mechanism	particular caution should be observed with drugn since there are conflicting results for the effect of druga on the availability of drugn and drugb .
DDI-DrugBank.d345.s14.p5	digoxin	drug	_	digitoxin	drug	_	false	particular caution should be observed with drugn since there are conflicting results for the effect of drugn on the availability of druga and drugb .
DDI-DrugBank.d345.s16.p0	colestipol hydrochloride	drug	_	resin	group	_	false	discontinuing druga could pose a hazard to health if a potentially toxic drug that is significantly bound to the drugb has been titrated to a maintenance level while the patient was taking drugn .
DDI-DrugBank.d345.s16.p2	resin	group	_	colestipol hydrochloride	drug	_	false	discontinuing drugn could pose a hazard to health if a potentially toxic drug that is significantly bound to the druga has been titrated to a maintenance level while the patient was taking drugb .
DDI-DrugBank.d345.s17.p0	Bile acid binding resins	group	_	phosphate	drug	_	mechanism	druga may also interfere with the absorption of oral drugb supplements and drugn .
DDI-DrugBank.d345.s17.p1	Bile acid binding resins	group	_	hydrocortisone	drug	_	mechanism	druga may also interfere with the absorption of oral drugn supplements and drugb .
DDI-DrugBank.d345.s17.p2	phosphate	drug	_	hydrocortisone	drug	_	false	drugn may also interfere with the absorption of oral druga supplements and drugb .
DDI-DrugBank.d250.s2.p1	Curariform muscle relaxants	brand	_	succinylcholine	drug	_	false	druga -lcb- eg , drugn -rcb- and other drugs , including ether , drugb , drugn , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p2	Curariform muscle relaxants	brand	_	gallamine	drug	_	false	druga -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugb , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p3	Curariform muscle relaxants	brand	_	decamethonium	drug	_	false	druga -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugn , drugb and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p4	Curariform muscle relaxants	brand	_	sodium citrate	drug	_	false	druga -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugn , drugn and drugb , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p5	Curariform muscle relaxants	brand	_	Coly-Mycin M	brand	_	effect	druga -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugn , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s2.p6	tubocurarine	drug	_	succinylcholine	drug	_	false	drugn -lcb- eg , druga -rcb- and other drugs , including ether , drugb , drugn , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p7	tubocurarine	drug	_	gallamine	drug	_	false	drugn -lcb- eg , druga -rcb- and other drugs , including ether , drugn , drugb , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p8	tubocurarine	drug	_	decamethonium	drug	_	false	drugn -lcb- eg , druga -rcb- and other drugs , including ether , drugn , drugn , drugb and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p9	tubocurarine	drug	_	sodium citrate	drug	_	false	drugn -lcb- eg , druga -rcb- and other drugs , including ether , drugn , drugn , drugn and drugb , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugn parenteral .
DDI-DrugBank.d250.s2.p10	tubocurarine	drug	_	Coly-Mycin M	brand	_	effect	drugn -lcb- eg , druga -rcb- and other drugs , including ether , drugn , drugn , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s2.p14	succinylcholine	drug	_	Coly-Mycin M	brand	_	effect	drugn -lcb- eg , drugn -rcb- and other drugs , including ether , druga , drugn , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s2.p17	gallamine	drug	_	Coly-Mycin M	brand	_	effect	drugn -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , druga , drugn and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s2.p19	decamethonium	drug	_	Coly-Mycin M	brand	_	effect	drugn -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugn , druga and drugn , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s2.p20	sodium citrate	drug	_	Coly-Mycin M	brand	_	effect	drugn -lcb- eg , drugn -rcb- and other drugs , including ether , drugn , drugn , drugn and druga , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drugb parenteral .
DDI-DrugBank.d250.s3.p0	Sodium cephalothin	drug	_	Coly-Mycin M	brand	_	effect	druga may enhance the nephrotoxicity of drugb parenteral .
DDI-DrugBank.d250.s4.p0	sodium cephalothin	drug	_	Coly-Mycin M	brand	_	advise	the concomitant use of druga and drugb parenteral should be avoided .
DDI-DrugBank.d315.s0.p1	Digoxin	drug	_	conivaptan	drug	_	false	druga : coadministration of drugn , a p_glycoprotein substrate , with oral drugb resulted in a reduction in clearance and an increase in drugn cmax and auc values .
DDI-DrugBank.d315.s0.p3	digoxin	drug	_	conivaptan	drug	_	mechanism	drugn : coadministration of druga , a p_glycoprotein substrate , with oral drugb resulted in a reduction in clearance and an increase in drugn cmax and auc values .
DDI-DrugBank.d315.s0.p5	conivaptan	drug	_	digoxin	drug	_	false	drugn : coadministration of drugn , a p_glycoprotein substrate , with oral druga resulted in a reduction in clearance and an increase in drugb cmax and auc values .
DDI-DrugBank.d315.s1.p0	digoxin	drug	_	VAPRISOL	brand	_	mechanism	therefore , if druga is administered with drugb , the clinician should be alert to the possibility of increases in drugn levels .
DDI-DrugBank.d315.s1.p2	VAPRISOL	brand	_	digoxin	drug	_	false	therefore , if drugn is administered with druga , the clinician should be alert to the possibility of increases in drugb levels .
DDI-DrugBank.d317.s13.p0	corticosteroids	group	_	sex steroids	group	_	false	other binding proteins may be elevated in serum , -lcb- i , e , , corticosteroid binding globulin -lcb- cbg -rcb- , sex hormone binding globulin -lcb- shbg -rcb- -rcb- leading to increased total circulating druga and drugb , respectively .
DDI-DrugBank.d25.s0.p0	Corticotropin	drug	_	diuretic	drug	_	effect	druga may accentuate the electrolyte loss associated with drugb therapy .
DDI-DrugBank.d487.s1.p2	phenobarbital	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d487.s1.p3	phenobarbital	drug	_	corticosteroid	group	_	advise	drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d487.s1.p5	phenytoin	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d487.s1.p6	phenytoin	drug	_	corticosteroid	group	_	advise	drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d487.s1.p7	rifampin	drug	_	corticosteroids	group	_	mechanism	drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
DDI-DrugBank.d487.s1.p8	rifampin	drug	_	corticosteroid	group	_	advise	drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
DDI-DrugBank.d487.s2.p0	troleandomycin	drug	_	ketoconazole	drug	_	false	drugs such as druga and drugb may inhibit the metabolism of drugn and thus decrease their clearance .
DDI-DrugBank.d487.s2.p1	troleandomycin	drug	_	corticosteroids	group	_	mechanism	drugs such as druga and drugn may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d487.s2.p2	ketoconazole	drug	_	corticosteroids	group	_	mechanism	drugs such as drugn and druga may inhibit the metabolism of drugb and thus decrease their clearance .
DDI-DrugBank.d487.s4.p0	Corticosteroids	group	_	aspirin	brand	_	effect	druga may increase the clearance of chronic high dose drugb .
DDI-DrugBank.d487.s5.p1	salicylate	group	_	corticosteroid	drug	_	false	this could lead to decreased druga serum levels or increase the risk of drugn toxicity when drugb is withdrawn .
DDI-DrugBank.d487.s5.p2	salicylate	group	_	corticosteroid	drug	_	effect	this could lead to decreased drugn serum levels or increase the risk of druga toxicity when drugb is withdrawn .
DDI-DrugBank.d487.s6.p0	Aspirin	brand	_	cortico-steroids	group	_	advise	druga should be used cautiously in conjunction with drugb in patients suffering from hypopro-thrombinemia .
DDI-DrugBank.d487.s7.p0	corticosteroids	group	_	anticoagulants	group	_	effect	the effect of druga on oral drugb is variable .
DDI-DrugBank.d487.s8.p0	anticoagulants	group	_	corticosteroids	group	_	effect	there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
DDI-DrugBank.d439.s0.p0	Corticotropin	drug	_	diuretic	group	_	effect	druga may accentuate the electrolyte loss associated with drugb therapy .
DDI-DrugBank.d229.s0.p0	Cromolyn sodium	drug	_	isoproterenol	drug	_	false	drug interaction during pregnancy : druga and drugb were studied following subcutaneous injections in pregnant mice .
DDI-DrugBank.d229.s3.p0	cromolyn sodium	drug	_	isoproterenol	drug	_	effect	the addition of # mg/kg/day of druga -lcb- approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis -rcb- to # mg/kg/day of drugb -lcb- approximately # times the maximum recommended daily inhalation dose in adults on a mg/m2 basis -rcb- appears to have increased the incidence of both resorptions and malformations .
DDI-DrugBank.d39.s0.p2	antibiotics	group	_	folic acid	drug	_	false	persons taking most druga , drugn and drugn invalidate drugb and drugn diagnostic blood assays .
DDI-DrugBank.d39.s0.p3	antibiotics	group	_	vitamin B12	drug	_	false	persons taking most druga , drugn and drugn invalidate drugn and drugb diagnostic blood assays .
DDI-DrugBank.d39.s0.p4	methotrexate	drug	_	pyrimethamine	drug	_	false	persons taking most drugn , druga and drugb invalidate drugn and drugn diagnostic blood assays .
DDI-DrugBank.d39.s0.p5	methotrexate	drug	_	folic acid	drug	_	false	persons taking most drugn , druga and drugn invalidate drugb and drugn diagnostic blood assays .
DDI-DrugBank.d39.s0.p6	methotrexate	drug	_	vitamin B12	drug	_	false	persons taking most drugn , druga and drugn invalidate drugn and drugb diagnostic blood assays .
DDI-DrugBank.d39.s0.p7	pyrimethamine	drug	_	folic acid	drug	_	false	persons taking most drugn , drugn and druga invalidate drugb and drugn diagnostic blood assays .
DDI-DrugBank.d39.s0.p8	pyrimethamine	drug	_	vitamin B12	drug	_	false	persons taking most drugn , drugn and druga invalidate drugn and drugb diagnostic blood assays .
DDI-DrugBank.d39.s0.p9	folic acid	drug	_	vitamin B12	drug	_	false	persons taking most drugn , drugn and drugn invalidate druga and drugb diagnostic blood assays .
DDI-DrugBank.d39.s1.p0	Colchicine	drug	_	para-aminosalicylic acid	drug	_	false	druga drugb and heavy drugn intake for longer than # weeks may produce malabsorption of drugn .
DDI-DrugBank.d39.s1.p1	Colchicine	drug	_	alcohol	drug	_	false	druga drugn and heavy drugb intake for longer than # weeks may produce malabsorption of drugn .
DDI-DrugBank.d39.s1.p2	Colchicine	drug	_	vitamin B12	drug	_	mechanism	druga drugn and heavy drugn intake for longer than # weeks may produce malabsorption of drugb .
DDI-DrugBank.d39.s1.p3	para-aminosalicylic acid	drug	_	alcohol	drug	_	false	drugn druga and heavy drugb intake for longer than # weeks may produce malabsorption of drugn .
DDI-DrugBank.d39.s1.p4	para-aminosalicylic acid	drug	_	vitamin B12	drug	_	mechanism	drugn druga and heavy drugn intake for longer than # weeks may produce malabsorption of drugb .
DDI-DrugBank.d39.s1.p5	alcohol	drug	_	vitamin B12	drug	_	mechanism	drugn drugn and heavy druga intake for longer than # weeks may produce malabsorption of drugb .
DDI-DrugBank.d150.s0.p0	FLEXERIL	brand	_	MAO inhibitors	group	_	int	druga may have life-threatening interactions with drugb .
DDI-DrugBank.d150.s1.p0	FLEXERIL	brand	_	alcohol	drug	_	effect	druga may enhance the effects of drugb , drugn , and other drugn .
DDI-DrugBank.d150.s1.p1	FLEXERIL	brand	_	barbiturates	group	_	effect	druga may enhance the effects of drugn , drugb , and other drugn .
DDI-DrugBank.d150.s1.p2	FLEXERIL	brand	_	CNS depressants	group	_	effect	druga may enhance the effects of drugn , drugn , and other drugb .
DDI-DrugBank.d150.s1.p3	alcohol	drug	_	barbiturates	group	_	false	drugn may enhance the effects of druga , drugb , and other drugn .
DDI-DrugBank.d150.s1.p4	alcohol	drug	_	CNS depressants	group	_	false	drugn may enhance the effects of druga , drugn , and other drugb .
DDI-DrugBank.d150.s1.p5	barbiturates	group	_	CNS depressants	group	_	false	drugn may enhance the effects of drugn , druga , and other drugb .
DDI-DrugBank.d150.s2.p0	Tricyclic antidepressants	group	_	guanethidine	drug	_	effect	druga may block the antihypertensive action of drugb and similarly acting compounds .
DDI-DrugBank.d150.s3.p0	Tricyclic antidepressants	group	_	tramadol	drug	_	effect	druga may enhance the seizure risk in patients taking drugb
DDI-DrugBank.d298.s0.p0	Cyclopentolate	drug	_	carbachol	drug	_	effect	druga may interfere with the anti-glaucoma action of drugb or drugn ;
DDI-DrugBank.d298.s0.p1	Cyclopentolate	drug	_	pilocarpine	drug	_	effect	druga may interfere with the anti-glaucoma action of drugn or drugb ;
DDI-DrugBank.d298.s0.p2	carbachol	drug	_	pilocarpine	drug	_	false	drugn may interfere with the anti-glaucoma action of druga or drugb ;
DDI-DrugBank.d7.s0.p0	cyclophosphamide	drug	_	phenobarbital	drug	_	mechanism	the rate of metabolism and the leukopenic activity of druga reportedly are increased by chronic administration of high doses of drugb .
DDI-DrugBank.d7.s2.p0	Cyclophosphamide	drug	_	succinylcholine chloride	drug	_	effect	druga treatment , which causes a marked and persistent inhibition of bche activity , potentiates the effect of drugb .
DDI-DrugBank.d128.s0.p0	Trecator-SC	brand	_	isoniazid	drug	_	false	may interact with wthionamide -lcb- druga -rcb- and drugb -lcb- drugn -rcb- .
DDI-DrugBank.d128.s0.p1	Trecator-SC	brand	_	Nydrazid	brand	_	false	may interact with wthionamide -lcb- druga -rcb- and drugn -lcb- drugb -rcb- .
DDI-DrugBank.d492.s0.p0	MAO inhibitors	group	_	antihistamines	group	_	effect	druga prolong and intensify the anticholinergic effects of drugb .
DDI-DrugBank.d492.s1.p0	Antihistamines	group	_	alcohol	drug	_	effect	druga may have additive effects with drugb and other drugn , e , g , , drugn , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p1	Antihistamines	group	_	CNS depressants	group	_	effect	druga may have additive effects with drugn and other drugb , e , g , , drugn , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p2	Antihistamines	group	_	hypnotics	group	_	effect	druga may have additive effects with drugn and other drugn , e , g , , drugb , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p3	Antihistamines	group	_	sedatives	group	_	effect	druga may have additive effects with drugn and other drugn , e , g , , drugn , drugb , drugn , drugn .
DDI-DrugBank.d492.s1.p4	Antihistamines	group	_	tranquilizers	group	_	effect	druga may have additive effects with drugn and other drugn , e , g , , drugn , drugn , drugb , drugn .
DDI-DrugBank.d492.s1.p5	Antihistamines	group	_	antianxiety agents	group	_	effect	druga may have additive effects with drugn and other drugn , e , g , , drugn , drugn , drugn , drugb .
DDI-DrugBank.d492.s1.p6	alcohol	drug	_	CNS depressants	group	_	false	drugn may have additive effects with druga and other drugb , e , g , , drugn , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p7	alcohol	drug	_	hypnotics	group	_	false	drugn may have additive effects with druga and other drugn , e , g , , drugb , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p8	alcohol	drug	_	sedatives	group	_	false	drugn may have additive effects with druga and other drugn , e , g , , drugn , drugb , drugn , drugn .
DDI-DrugBank.d492.s1.p9	alcohol	drug	_	tranquilizers	group	_	false	drugn may have additive effects with druga and other drugn , e , g , , drugn , drugn , drugb , drugn .
DDI-DrugBank.d492.s1.p10	alcohol	drug	_	antianxiety agents	group	_	false	drugn may have additive effects with druga and other drugn , e , g , , drugn , drugn , drugn , drugb .
DDI-DrugBank.d492.s1.p11	CNS depressants	group	_	hypnotics	group	_	false	drugn may have additive effects with drugn and other druga , e , g , , drugb , drugn , drugn , drugn .
DDI-DrugBank.d492.s1.p12	CNS depressants	group	_	sedatives	group	_	false	drugn may have additive effects with drugn and other druga , e , g , , drugn , drugb , drugn , drugn .
DDI-DrugBank.d492.s1.p13	CNS depressants	group	_	tranquilizers	group	_	false	drugn may have additive effects with drugn and other druga , e , g , , drugn , drugn , drugb , drugn .
DDI-DrugBank.d492.s1.p14	CNS depressants	group	_	antianxiety agents	group	_	false	drugn may have additive effects with drugn and other druga , e , g , , drugn , drugn , drugn , drugb .
DDI-DrugBank.d492.s1.p17	hypnotics	group	_	antianxiety agents	group	_	false	drugn may have additive effects with drugn and other drugn , e , g , , druga , drugn , drugn , drugb .
DDI-DrugBank.d492.s1.p19	sedatives	group	_	antianxiety agents	group	_	false	drugn may have additive effects with drugn and other drugn , e , g , , drugn , druga , drugn , drugb .
DDI-DrugBank.d294.s0.p0	Dactinomycin	drug	_	antibacterial drug	group	_	false	drug/laboratorytest interactions druga may interfere with bioassay procedures for the determination of drugb levels .
DDI-DrugBank.d305.s1.p0	phenobarbital	drug	_	diazepam	drug	_	false	however , neither druga nor drugb appears to affect drugn metabolism .
DDI-DrugBank.d305.s1.p1	phenobarbital	drug	_	Dantrium	brand	_	false	however , neither druga nor drugn appears to affect drugb metabolism .
DDI-DrugBank.d305.s1.p2	diazepam	drug	_	Dantrium	brand	_	false	however , neither drugn nor druga appears to affect drugb metabolism .
DDI-DrugBank.d305.s3.p0	warfarin	drug	_	tolbutamide	drug	_	false	binding to plasma proteins is reduced by druga and clotibrate and increased by drugb .
DDI-DrugBank.d305.s5.p0	dantrolene sodium	drug	_	verapamil	drug	_	false	the combination of therapeutic doses of intravenous druga and drugb in drugn a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .
DDI-DrugBank.d305.s5.p1	dantrolene sodium	drug	_	halothane	drug	_	false	the combination of therapeutic doses of intravenous druga and drugn in drugb a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .
DDI-DrugBank.d305.s5.p2	verapamil	drug	_	halothane	drug	_	false	the combination of therapeutic doses of intravenous drugn and druga in drugb a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .
DDI-DrugBank.d305.s6.p0	dantrolene sodium	drug	_	calcium channel blockers	group	_	advise	it is recommended that the combination of intravenous druga and drugb , such as drugn , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .
DDI-DrugBank.d305.s6.p1	dantrolene sodium	drug	_	verapamil	drug	_	advise	it is recommended that the combination of intravenous druga and drugn , such as drugb , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .
DDI-DrugBank.d305.s6.p2	calcium channel blockers	group	_	verapamil	drug	_	false	it is recommended that the combination of intravenous drugn and druga , such as drugb , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .
DDI-DrugBank.d305.s7.p0	dantrolene	drug	_	vecuronium	drug	_	effect	administration of druga may potentiate drugb - induced neuromuscular block .
DDI-DrugBank.d185.s0.p0	ACZONE	brand	_	trimethoprim	drug	_	false	a drug-drug interaction study evaluated the effect of the use of druga gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- drugb / drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d185.s0.p1	ACZONE	brand	_	sulfamethoxazole	drug	_	false	a drug-drug interaction study evaluated the effect of the use of druga gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- drugn / drugb -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d185.s0.p2	ACZONE	brand	_	TMP	drug	_	false	a drug-drug interaction study evaluated the effect of the use of druga gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- drugn / drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d185.s0.p3	ACZONE	brand	_	SMX	drug	_	false	a drug-drug interaction study evaluated the effect of the use of druga gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- drugn / drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d185.s0.p5	trimethoprim	drug	_	TMP	drug	_	false	a drug-drug interaction study evaluated the effect of the use of drugn gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- druga / drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d185.s0.p6	trimethoprim	drug	_	SMX	drug	_	false	a drug-drug interaction study evaluated the effect of the use of drugn gel , 5 % , in combination with double_strength -lcb- 160 mg/800 mg -rcb- druga / drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d185.s1.p0	TMP	drug	_	SMX	drug	_	false	during co-administration , systemic levels of druga and drugb were essentially unchanged .
DDI-DrugBank.d185.s2.p1	dapsone hydroxylamine	drug_n	_	TMP	drug	_	false	notably , systemic exposure -lcb- auc0-12 -rcb- of druga -lcb- drugn -rcb- was more than doubled in the presence of drugb / drugn .
DDI-DrugBank.d185.s2.p2	dapsone hydroxylamine	drug_n	_	SMX	drug	_	false	notably , systemic exposure -lcb- auc0-12 -rcb- of druga -lcb- drugn -rcb- was more than doubled in the presence of drugn / drugb .
DDI-DrugBank.d185.s2.p3	DHA	drug_n	_	TMP	drug	_	false	notably , systemic exposure -lcb- auc0-12 -rcb- of drugn -lcb- druga -rcb- was more than doubled in the presence of drugb / drugn .
DDI-DrugBank.d185.s2.p4	DHA	drug_n	_	SMX	drug	_	false	notably , systemic exposure -lcb- auc0-12 -rcb- of drugn -lcb- druga -rcb- was more than doubled in the presence of drugn / drugb .
DDI-DrugBank.d185.s4.p0	rifampin	drug	_	anticonvulsants	group	_	false	certain concomitant medications -lcb- such as druga , drugb , st.
DDI-DrugBank.d185.s6.p0	dapsone	drug	_	folic acid antagonists	group	_	effect	with oral druga treatment , drugb such as drugn have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d185.s6.p1	dapsone	drug	_	pyrimethamine	drug	_	effect	with oral druga treatment , drugn such as drugb have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d185.s6.p2	folic acid antagonists	group	_	pyrimethamine	drug	_	false	with oral drugn treatment , druga such as drugb have been noted to possibly increase the likelihood of hematologic reactions
DDI-DrugBank.d337.s0.p0	Warfarin	drug	_	daptomycin	drug	_	false	druga : concomitant administration of drugb -lcb- 6 mg/kg once every # hours for # days -rcb- and drugn -lcb- 25 mg single oral dose -rcb- had no significant effect on the pharmacokinetics of either drug , and the inr was not significantly altered .
DDI-DrugBank.d337.s0.p2	daptomycin	drug	_	warfarin	drug	_	false	drugn : concomitant administration of druga -lcb- 6 mg/kg once every # hours for # days -rcb- and drugb -lcb- 25 mg single oral dose -rcb- had no significant effect on the pharmacokinetics of either drug , and the inr was not significantly altered .
DDI-DrugBank.d337.s1.p0	HMG-CoA Reductase Inhibitors	group	_	Inhibitors of HMG-CoA reductase	group	_	false	druga : drugb may cause myopathy , which is manifested as muscle_pain or weakness associated with elevated levels of cpk .
DDI-DrugBank.d337.s2.p0	simvastatin	drug	_	daptomycin	drug	_	false	there were no reports of skeletal myopathy in a placebo-controlled phase i trial in which # healthy subjects on stable druga therapy were treated concurrently with drugb -lcb- 4 mg/kg once every # hours -rcb- for # days .
DDI-DrugBank.d337.s3.p0	HMG-CoA reductase inhibitors	group	_	Fentanyl	drug	_	false	experience with co-administration of druga and drugb in patients is limited , therefore , consideration should be given to temporarily suspending use of drugn in patients receiving drugn .
DDI-DrugBank.d337.s3.p2	HMG-CoA reductase inhibitors	group	_	Fentanyl	drug	_	false	experience with co-administration of druga and drugn in patients is limited , therefore , consideration should be given to temporarily suspending use of drugn in patients receiving drugb .
DDI-DrugBank.d337.s3.p3	Fentanyl	drug	_	HMG-CoA reductase inhibitors	group	_	false	experience with co-administration of drugn and druga in patients is limited , therefore , consideration should be given to temporarily suspending use of drugb in patients receiving drugn .
DDI-DrugBank.d337.s3.p5	HMG-CoA reductase inhibitors	group	_	Fentanyl	drug	_	advise	experience with co-administration of drugn and drugn in patients is limited , therefore , consideration should be given to temporarily suspending use of druga in patients receiving drugb .
DDI-DrugBank.d459.s0.p0	ENABLEX	brand	_	ketoconazole	drug	_	advise	the daily dose of druga should not exceed # mg when coadministered with potent cyp3a4 inhibitors -lcb- e , g , , drugb , drugn , drugn , drugn , drugn and nefazadone -rcb- .
DDI-DrugBank.d459.s0.p1	ENABLEX	brand	_	itraconazole	drug	_	advise	the daily dose of druga should not exceed # mg when coadministered with potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugb , drugn , drugn , drugn and nefazadone -rcb- .
DDI-DrugBank.d459.s0.p2	ENABLEX	brand	_	ritonavir	drug	_	advise	the daily dose of druga should not exceed # mg when coadministered with potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugb , drugn , drugn and nefazadone -rcb- .
DDI-DrugBank.d459.s0.p3	ENABLEX	brand	_	nelfinavir	drug	_	advise	the daily dose of druga should not exceed # mg when coadministered with potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugb , drugn and nefazadone -rcb- .
DDI-DrugBank.d459.s0.p4	ENABLEX	brand	_	clarithromycin	drug	_	advise	the daily dose of druga should not exceed # mg when coadministered with potent cyp3a4 inhibitors -lcb- e , g , , drugn , drugn , drugn , drugn , drugb and nefazadone -rcb- .
DDI-DrugBank.d459.s1.p0	ENABLEX	brand	_	flecainide	drug	_	advise	caution should be taken when druga is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as drugb , drugn and drugn -lcb- see clinical pharmacology -rcb- .
DDI-DrugBank.d459.s1.p1	ENABLEX	brand	_	thioridazine	drug	_	advise	caution should be taken when druga is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as drugn , drugb and drugn -lcb- see clinical pharmacology -rcb- .
DDI-DrugBank.d459.s1.p2	ENABLEX	brand	_	tricyclic antidepressants	group	_	advise	caution should be taken when druga is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as drugn , drugn and drugb -lcb- see clinical pharmacology -rcb- .
DDI-DrugBank.d459.s2.p0	ENABLEX	brand	_	anticholinergic agents	group	_	effect	the concomitant use of druga with other drugb may increase the frequency and/or severity of dry mouth , constipation , blurred vision and other anticholinergic pharmacological effects .
DDI-DrugBank.d48.s1.p0	SPRYCEL	brand	_	ketoconazole	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p1	SPRYCEL	brand	_	itraconazole	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p2	SPRYCEL	brand	_	erythromycin	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p3	SPRYCEL	brand	_	clarithromycin	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p4	SPRYCEL	brand	_	ritonavir	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p5	SPRYCEL	brand	_	atazanavir	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p6	SPRYCEL	brand	_	indinavir	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p7	SPRYCEL	brand	_	nefazodone	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p8	SPRYCEL	brand	_	nelfinavir	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p9	SPRYCEL	brand	_	saquinavir	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p10	SPRYCEL	brand	_	telithromycin	drug	_	mechanism	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- may increase exposure to drugn and should be avoided .
DDI-DrugBank.d48.s1.p11	SPRYCEL	brand	_	dasatinib	drug	_	false	concomitant use of druga and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p22	ketoconazole	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p32	itraconazole	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p41	erythromycin	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p49	clarithromycin	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p56	ritonavir	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p62	atazanavir	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p67	indinavir	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p71	nefazodone	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p74	nelfinavir	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p76	saquinavir	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s1.p77	telithromycin	drug	_	dasatinib	drug	_	false	concomitant use of drugn and drugs that inhibit cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- may increase exposure to drugb and should be avoided .
DDI-DrugBank.d48.s9.p0	SPRYCEL	brand	_	antacids	group	_	advise	simultaneous administration of druga with drugb should be avoided .
DDI-DrugBank.d48.s10.p0	antacid	group	_	SPRYCEL	brand	_	advise	if druga therapy is needed , the antacid dose should be administered at least # hours prior to or # hours after the dose of drugb .
DDI-DrugBank.d48.s11.p0	H2 Blockers	group	_	Proton Pump Inhibitors	group	_	false	druga / drugb : long-term suppression of gastric acid secretion by drugn or drugn -lcb- eg , drugn and drugn -rcb- is likely to reduce drugn exposure .
DDI-DrugBank.d48.s11.p11	H2 blockers	group	_	proton pump inhibitors	group	_	false	drugn / drugn : long-term suppression of gastric acid secretion by druga or drugb -lcb- eg , drugn and drugn -rcb- is likely to reduce drugn exposure .
DDI-DrugBank.d48.s11.p12	H2 blockers	group	_	famotidine	drug	_	false	drugn / drugn : long-term suppression of gastric acid secretion by druga or drugn -lcb- eg , drugb and drugn -rcb- is likely to reduce drugn exposure .
DDI-DrugBank.d48.s11.p13	H2 blockers	group	_	omeprazole	drug	_	false	drugn / drugn : long-term suppression of gastric acid secretion by druga or drugn -lcb- eg , drugn and drugb -rcb- is likely to reduce drugn exposure .
DDI-DrugBank.d48.s11.p14	H2 blockers	group	_	dasatinib	drug	_	effect	drugn / drugn : long-term suppression of gastric acid secretion by druga or drugn -lcb- eg , drugn and drugn -rcb- is likely to reduce drugb exposure .
DDI-DrugBank.d48.s11.p17	proton pump inhibitors	group	_	dasatinib	drug	_	effect	drugn / drugn : long-term suppression of gastric acid secretion by drugn or druga -lcb- eg , drugn and drugn -rcb- is likely to reduce drugb exposure .
DDI-DrugBank.d48.s11.p19	famotidine	drug	_	dasatinib	drug	_	effect	drugn / drugn : long-term suppression of gastric acid secretion by drugn or drugn -lcb- eg , druga and drugn -rcb- is likely to reduce drugb exposure .
DDI-DrugBank.d48.s11.p20	omeprazole	drug	_	dasatinib	drug	_	effect	drugn / drugn : long-term suppression of gastric acid secretion by drugn or drugn -lcb- eg , drugn and druga -rcb- is likely to reduce drugb exposure .
DDI-DrugBank.d48.s12.p0	H2 blockers	group	_	proton pump inhibitors	group	_	false	the concomitant use of druga or drugb with drugn is not recommended .
DDI-DrugBank.d48.s12.p1	H2 blockers	group	_	SPRYCEL	brand	_	advise	the concomitant use of druga or drugn with drugb is not recommended .
DDI-DrugBank.d48.s12.p2	proton pump inhibitors	group	_	SPRYCEL	brand	_	advise	the concomitant use of drugn or druga with drugb is not recommended .
DDI-DrugBank.d48.s13.p0	antacids	group	_	H2 blockers	group	_	false	the use of druga should be considered in place of drugb or drugn in patients receiving drugn therapy .
DDI-DrugBank.d48.s13.p1	antacids	group	_	proton pump inhibitors	group	_	false	the use of druga should be considered in place of drugn or drugb in patients receiving drugn therapy .
DDI-DrugBank.d48.s13.p2	antacids	group	_	SPRYCEL	brand	_	false	the use of druga should be considered in place of drugn or drugn in patients receiving drugb therapy .
DDI-DrugBank.d48.s13.p3	H2 blockers	group	_	proton pump inhibitors	group	_	false	the use of drugn should be considered in place of druga or drugb in patients receiving drugn therapy .
DDI-DrugBank.d48.s13.p4	H2 blockers	group	_	SPRYCEL	brand	_	advise	the use of drugn should be considered in place of druga or drugn in patients receiving drugb therapy .
DDI-DrugBank.d48.s13.p5	proton pump inhibitors	group	_	SPRYCEL	brand	_	advise	the use of drugn should be considered in place of drugn or druga in patients receiving drugb therapy .
DDI-DrugBank.d48.s15.p12	alfentanil	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p24	astemizole	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p35	terfenadine	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p45	cisapride	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p54	cyclosporine	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p62	fentanyl	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p69	pimozide	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p75	quinidine	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p80	sirolimus	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p84	tacrolimus	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , or drugn -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p87	ergot alkaloids	group	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or druga -lcb- drugn , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p89	ergotamine	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- druga , drugn -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d48.s15.p90	dihydroergotamine	drug	_	SPRYCEL	brand	_	advise	therefore , cyp3a4 substrates known to have a narrow therapeutic index such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn -lcb- drugn , druga -rcb- should be administered with caution in patients receiving drugb .
DDI-DrugBank.d69.s0.p0	Cerubidine	brand	_	doxorubicin	drug	_	effect	use of druga in a patient who has previously received drugb increases the risk of cardiotoxicity .
DDI-DrugBank.d69.s1.p0	Cerubidine	brand	_	doxorubicin	drug	_	advise	druga should not be used in patients who have previously received the recommended maximum cumulative doses of drugb or drugn .
DDI-DrugBank.d69.s1.p2	doxorubicin	drug	_	Cerubidine	brand	_	false	drugn should not be used in patients who have previously received the recommended maximum cumulative doses of druga or drugb .
DDI-DrugBank.d69.s2.p0	Cyclophosphamide	drug	_	Cerubidine	brand	_	effect	druga used concurrently with drugb may also result in increased cardiotoxicity .
DDI-DrugBank.d167.s2.p1	anesthetics	group	_	lidocaine	drug	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p2	anesthetics	group	_	procaine	drug	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p3	anesthetics	group	_	beta-blockers	group	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p4	anesthetics	group	_	metaclopramide	drug	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d167.s2.p5	anesthetics	group	_	lithium carbonate	drug	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d167.s2.p6	anesthetics	group	_	terbutaline	drug	_	false	in addition , neuromuscular blocking action is enhanced by general druga , local drugn like drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d167.s2.p7	anesthetics	group	_	lidocaine	drug	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p8	anesthetics	group	_	procaine	drug	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p9	anesthetics	group	_	beta-blockers	group	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d167.s2.p10	anesthetics	group	_	metaclopramide	drug	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d167.s2.p11	anesthetics	group	_	lithium carbonate	drug	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d167.s2.p12	anesthetics	group	_	terbutaline	drug	_	false	in addition , neuromuscular blocking action is enhanced by general drugn , local druga like drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d84.s0.p0	Exjade	brand	_	aluminum	drug	_	false	the concomitant administration of druga and drugb - containing drugn has not been formally studied .
DDI-DrugBank.d84.s0.p1	Exjade	brand	_	antacid preparations	group	_	false	the concomitant administration of druga and drugn - containing drugb has not been formally studied .
DDI-DrugBank.d84.s0.p2	aluminum	drug	_	antacid preparations	group	_	false	the concomitant administration of drugn and druga - containing drugb has not been formally studied .
DDI-DrugBank.d84.s1.p0	deferasirox	drug	_	aluminum	drug	_	false	although druga has a lower affinity for drugb than for drugn , drugn should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p1	deferasirox	drug	_	iron	drug	_	false	although druga has a lower affinity for drugn than for drugb , drugn should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p2	deferasirox	drug	_	Exjade	brand	_	false	although druga has a lower affinity for drugn than for drugn , drugb should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p3	deferasirox	drug	_	aluminum	drug	_	false	although druga has a lower affinity for drugn than for drugn , drugn should not be taken with drugb - containing drugn .
DDI-DrugBank.d84.s1.p4	deferasirox	drug	_	antacid preparations	group	_	false	although druga has a lower affinity for drugn than for drugn , drugn should not be taken with drugn - containing drugb .
DDI-DrugBank.d84.s1.p5	aluminum	drug	_	iron	drug	_	false	although drugn has a lower affinity for druga than for drugb , drugn should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p6	aluminum	drug	_	Exjade	brand	_	false	although drugn has a lower affinity for druga than for drugn , drugb should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p8	aluminum	drug	_	antacid preparations	group	_	false	although drugn has a lower affinity for druga than for drugn , drugn should not be taken with drugn - containing drugb .
DDI-DrugBank.d84.s1.p9	iron	drug	_	Exjade	brand	_	false	although drugn has a lower affinity for drugn than for druga , drugb should not be taken with drugn - containing drugn .
DDI-DrugBank.d84.s1.p10	iron	drug	_	aluminum	drug	_	false	although drugn has a lower affinity for drugn than for druga , drugn should not be taken with drugb - containing drugn .
DDI-DrugBank.d84.s1.p11	iron	drug	_	antacid preparations	group	_	false	although drugn has a lower affinity for drugn than for druga , drugn should not be taken with drugn - containing drugb .
DDI-DrugBank.d84.s1.p12	Exjade	brand	_	aluminum	drug	_	advise	although drugn has a lower affinity for drugn than for drugn , druga should not be taken with drugb - containing drugn .
DDI-DrugBank.d84.s1.p13	Exjade	brand	_	antacid preparations	group	_	false	although drugn has a lower affinity for drugn than for drugn , druga should not be taken with drugn - containing drugb .
DDI-DrugBank.d84.s1.p14	aluminum	drug	_	antacid preparations	group	_	false	although drugn has a lower affinity for drugn than for drugn , drugn should not be taken with druga - containing drugb .
DDI-DrugBank.d84.s2.p0	Exjade	brand	_	digoxin	drug	_	false	in healthy volunteers , druga had no effect on the pharmacokinetics of drugb .
DDI-DrugBank.d84.s3.p0	digoxin	drug	_	Exjade	brand	_	false	the effect of druga on drugb pharmacokinetics has not been studied .
DDI-DrugBank.d84.s4.p0	Exjade	brand	_	vitamin C	drug	_	false	the concomitant administration of druga and drugb has not been formally studied .
DDI-DrugBank.d84.s6.p0	Exjade	brand	_	hydroxyurea	drug	_	false	the interaction of druga with drugb has not been formally studied .
DDI-DrugBank.d84.s7.p0	deferasirox	drug	_	hydroxyurea	drug	_	false	no inhibition of druga metabolism by drugb is expected based on the results of an in vitro study .
DDI-DrugBank.d251.s0.p6	clarithromycin	drug	_	Rifabutin	drug	_	false	antiacid , druga , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p7	clarithromycin	drug	_	Rifampin	drug	_	false	antiacid , druga , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p8	clarithromycin	drug	_	Saquinavir	drug	_	false	antiacid , druga , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p14	Didanosine	drug	_	Rifabutin	drug	_	false	antiacid , drugn , druga , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p15	Didanosine	drug	_	Rifampin	drug	_	false	antiacid , drugn , druga , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p16	Didanosine	drug	_	Saquinavir	drug	_	false	antiacid , drugn , druga , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p21	Fluconazole	drug	_	Rifabutin	drug	_	false	antiacid , drugn , drugn , druga , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p22	Fluconazole	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , druga , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p23	Fluconazole	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , druga , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p27	Fluoxetine	drug	_	Rifabutin	drug	_	false	antiacid , drugn , drugn , drugn , druga , indanavir , drugn , drugn , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p28	Fluoxetine	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , drugn , druga , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p29	Fluoxetine	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , drugn , druga , indanavir , drugn , drugn , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p32	Ketoconazole	drug	_	Rifabutin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , druga , drugn , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p33	Ketoconazole	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , druga , drugn , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p34	Ketoconazole	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , druga , drugn , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p36	Phenytoin	drug	_	Rifabutin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , druga , phenobarbitol , drugn , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p37	Phenytoin	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , druga , phenobarbitol , drugn , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p38	Phenytoin	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , druga , phenobarbitol , drugn , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p39	carbamazepine	drug	_	Rifabutin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , druga , drugb , drugn , ritanovir , drugn .
DDI-DrugBank.d251.s0.p40	carbamazepine	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , druga , drugn , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p41	carbamazepine	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , druga , drugn , drugn , ritanovir , drugb .
DDI-DrugBank.d251.s0.p42	Rifabutin	drug	_	Rifampin	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , druga , drugb , ritanovir , drugn .
DDI-DrugBank.d251.s0.p43	Rifabutin	drug	_	Saquinavir	drug	_	false	antiacid , drugn , drugn , drugn , drugn , indanavir , drugn , drugn , phenobarbitol , drugn , druga , drugn , ritanovir , drugb .
DDI-DrugBank.d149.s0.p0	HUMORSOL	brand	_	succinylcholine	drug	_	int	possible drug interactions of druga with drugb or with other drugn .
DDI-DrugBank.d149.s0.p1	HUMORSOL	brand	_	anticholinesterase agents	group	_	int	possible drug interactions of druga with drugn or with other drugb .
DDI-DrugBank.d149.s0.p2	succinylcholine	drug	_	anticholinesterase agents	group	_	false	possible drug interactions of drugn with druga or with other drugb .
DDI-DrugBank.d409.s0.p0	tetracyclines	group	_	anticoagulant	group	_	advise	because the druga have been shown to depress plasma prothrombin activity , patients who are on drugb therapy may require downward adjustment of their drugn dosage .
DDI-DrugBank.d409.s0.p1	tetracyclines	group	_	anticoagulant	group	_	false	because the druga have been shown to depress plasma prothrombin activity , patients who are on drugn therapy may require downward adjustment of their drugb dosage .
DDI-DrugBank.d409.s1.p0	tetracycline class	group	_	antibiotics	group	_	false	since bacteriostatic drugs , such as the druga of drugb , may interfere with the bactericidal action of drugn , it is not advisable to administer these drugs concomitantly .
DDI-DrugBank.d409.s1.p1	tetracycline class	group	_	penicillins	group	_	effect	since bacteriostatic drugs , such as the druga of drugn , may interfere with the bactericidal action of drugb , it is not advisable to administer these drugs concomitantly .
DDI-DrugBank.d409.s1.p2	antibiotics	group	_	penicillins	group	_	false	since bacteriostatic drugs , such as the drugn of druga , may interfere with the bactericidal action of drugb , it is not advisable to administer these drugs concomitantly .
DDI-DrugBank.d409.s2.p0	tetracyclines	group	_	contraceptives	group	_	effect	concurrent use of druga with oral drugb may render oral drugn less effective .
DDI-DrugBank.d409.s2.p1	tetracyclines	group	_	contraceptives	group	_	false	concurrent use of druga with oral drugn may render oral drugb less effective .
DDI-DrugBank.d311.s0.p0	rauwolfia alkaloid	group	_	MAO inhibitors	group	_	effect	taking a druga while you are taking or within # weeks of taking drugb may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction .
DDI-DrugBank.d363.s2.p0	isoflurane	drug	_	desflurane	drug	_	false	like druga , drugb does not predispose to premature ventricular arrhythmias in the presence of exogenously infused drugn in swine .
DDI-DrugBank.d363.s2.p1	isoflurane	drug	_	epinephrine	drug	_	false	like druga , drugn does not predispose to premature ventricular arrhythmias in the presence of exogenously infused drugb in swine .
DDI-DrugBank.d363.s2.p2	desflurane	drug	_	epinephrine	drug	_	false	like drugn , druga does not predispose to premature ventricular arrhythmias in the presence of exogenously infused drugb in swine .
DDI-DrugBank.d386.s9.p0	cimetidine	drug	_	antidepressants	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugb , drugn , and the type 1c antiarrhythrnics propatenone and drugn -rcb- .
DDI-DrugBank.d386.s9.p1	cimetidine	drug	_	phenothiazines	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugb , and the type 1c antiarrhythrnics propatenone and drugn -rcb- .
DDI-DrugBank.d386.s9.p2	cimetidine	drug	_	flecainide	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the type 1c antiarrhythrnics propatenone and drugb -rcb- .
DDI-DrugBank.d386.s10.p1	selective serotonin reuptake inhibitors	group	_	fluoxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugb , seriraline , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d386.s10.p2	selective serotonin reuptake inhibitors	group	_	paroxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , seriraline , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d386.s10.p3	SSRIs	group	_	fluoxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugb , seriraline , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d386.s10.p4	SSRIs	group	_	paroxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , seriraline , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d386.s11.p0	SSRI	group	_	TCA	group	_	int	the extent to which druga - drugb interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugn involved .
DDI-DrugBank.d386.s11.p2	TCA	group	_	SSRI	group	_	false	the extent to which drugn - druga interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugb involved .
DDI-DrugBank.d386.s12.p0	T.A.	group	_	SSRIs	group	_	advise	nevertheless , caution is indicated in the co-administration of druga with any of the drugb and also in switching from one class to the other .
DDI-DrugBank.d386.s18.p0	anticholinergic	group	_	sympathomimetic drugs	group	_	false	close supervision and careful adjustment of dosage are required when this drug is given concomitantly with druga or drugb .
DDI-DrugBank.d386.s23.p0	desipramine hydrochloride	drug	_	psychotropic agents	group	_	effect	if druga is to be combined with other drugb such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p1	desipramine hydrochloride	drug	_	tranquilizers	group	_	effect	if druga is to be combined with other drugn such as drugb or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p2	desipramine hydrochloride	drug	_	sedative	group	_	effect	if druga is to be combined with other drugn such as drugn or drugb / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p3	desipramine hydrochloride	drug	_	hypnotics	group	_	effect	if druga is to be combined with other drugn such as drugn or drugn / drugb , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p5	desipramine hydrochloride	drug	_	benzodiazepines	group	_	false	if druga is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p6	desipramine hydrochloride	drug	_	chlordiazepoxide	drug	_	false	if druga is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p7	desipramine hydrochloride	drug	_	diazepam	drug	_	false	if druga is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s23.p8	psychotropic agents	group	_	tranquilizers	group	_	false	if drugn is to be combined with other druga such as drugb or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p9	psychotropic agents	group	_	sedative	group	_	false	if drugn is to be combined with other druga such as drugn or drugb / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p10	psychotropic agents	group	_	hypnotics	group	_	false	if drugn is to be combined with other druga such as drugn or drugn / drugb , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p11	psychotropic agents	group	_	desipramine	drug	_	false	if drugn is to be combined with other druga such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugb and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p12	psychotropic agents	group	_	benzodiazepines	group	_	false	if drugn is to be combined with other druga such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p13	psychotropic agents	group	_	chlordiazepoxide	drug	_	false	if drugn is to be combined with other druga such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p14	psychotropic agents	group	_	diazepam	drug	_	false	if drugn is to be combined with other druga such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s23.p15	tranquilizers	group	_	sedative	group	_	false	if drugn is to be combined with other drugn such as druga or drugb / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p16	tranquilizers	group	_	hypnotics	group	_	false	if drugn is to be combined with other drugn such as druga or drugn / drugb , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p17	tranquilizers	group	_	desipramine	drug	_	false	if drugn is to be combined with other drugn such as druga or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugb and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p18	tranquilizers	group	_	benzodiazepines	group	_	false	if drugn is to be combined with other drugn such as druga or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p19	tranquilizers	group	_	chlordiazepoxide	drug	_	false	if drugn is to be combined with other drugn such as druga or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p20	tranquilizers	group	_	diazepam	drug	_	false	if drugn is to be combined with other drugn such as druga or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s23.p22	sedative	group	_	desipramine	drug	_	false	if drugn is to be combined with other drugn such as drugn or druga / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugb and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p23	sedative	group	_	benzodiazepines	group	_	false	if drugn is to be combined with other drugn such as drugn or druga / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p24	sedative	group	_	chlordiazepoxide	drug	_	false	if drugn is to be combined with other drugn such as drugn or druga / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p25	sedative	group	_	diazepam	drug	_	false	if drugn is to be combined with other drugn such as drugn or druga / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s23.p26	hypnotics	group	_	desipramine	drug	_	false	if drugn is to be combined with other drugn such as drugn or drugn / druga , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugb and drugn -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p27	hypnotics	group	_	benzodiazepines	group	_	false	if drugn is to be combined with other drugn such as drugn or drugn / druga , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p28	hypnotics	group	_	chlordiazepoxide	drug	_	false	if drugn is to be combined with other drugn such as drugn or drugn / druga , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p29	hypnotics	group	_	diazepam	drug	_	false	if drugn is to be combined with other drugn such as drugn or drugn / druga , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drugn and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s23.p30	desipramine	drug	_	benzodiazepines	group	_	effect	if drugn is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of druga and drugb -lcb- e , g , , drugn or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p31	desipramine	drug	_	chlordiazepoxide	drug	_	effect	if drugn is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of druga and drugn -lcb- e , g , , drugb or drugn -rcb- are additive .
DDI-DrugBank.d386.s23.p32	desipramine	drug	_	diazepam	drug	_	effect	if drugn is to be combined with other drugn such as drugn or drugn / drugn , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of druga and drugn -lcb- e , g , , drugn or drugb -rcb- are additive .
DDI-DrugBank.d386.s24.p0	major tranquilizers	group	_	desipramine	drug	_	effect	both the sedative and anticholinergic effects of the druga are also additive to those of drugb .
DDI-DrugBank.d386.s26.p0	cimetidine	drug	_	tricyclic antidepressants	group	_	mechanism	concurrent administration of druga and drugb can produce clinically significant increases in the plasma levels of the drugn .
DDI-DrugBank.d386.s26.p1	cimetidine	drug	_	tricyclic antidepressants	group	_	false	concurrent administration of druga and drugn can produce clinically significant increases in the plasma levels of the drugb .
DDI-DrugBank.d386.s27.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	mechanism	conversely , decreases in plasma levels of the druga have been reported upon discontinuation of drugb which may result in the loss of the therapeutic efficacy of the drugn 6 .
DDI-DrugBank.d386.s27.p2	cimetidine	drug	_	tricyclic antidepressant	group	_	false	conversely , decreases in plasma levels of the drugn have been reported upon discontinuation of druga which may result in the loss of the therapeutic efficacy of the drugb 6 .
DDI-DrugBank.d386.s28.p0	tricyclic antidepressants	group	_	fluoxetine	drug	_	mechanism	there have been greater than two-fold increases of previously stable plasma levels of druga when drugb has been administered in combination with these agents .
DDI-DrugBank.d67.s0.p0	desloratadine	drug	_	erythromycin	drug	_	false	in two controlled crossover clinical pharmacology studies in healthy male -lcb- n = 12 in each study -rcb- a nd female -lcb- n = 12 in each study -rcb- volunteers , druga # mg -lcb- # times the daily dose -rcb- once daily was coadministered with drugb # mg every # hours or drugn # mg every # hours for # days .
DDI-DrugBank.d67.s0.p1	desloratadine	drug	_	ketoconazole	drug	_	false	in two controlled crossover clinical pharmacology studies in healthy male -lcb- n = 12 in each study -rcb- a nd female -lcb- n = 12 in each study -rcb- volunteers , druga # mg -lcb- # times the daily dose -rcb- once daily was coadministered with drugn # mg every # hours or drugb # mg every # hours for # days .
DDI-DrugBank.d67.s0.p2	erythromycin	drug	_	ketoconazole	drug	_	false	in two controlled crossover clinical pharmacology studies in healthy male -lcb- n = 12 in each study -rcb- a nd female -lcb- n = 12 in each study -rcb- volunteers , drugn # mg -lcb- # times the daily dose -rcb- once daily was coadministered with druga # mg every # hours or drugb # mg every # hours for # days .
DDI-DrugBank.d67.s1.p0	desloratadine	drug	_	azithromycin	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , druga at the clinical dose of # mg has been coadministered with drugb # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugn # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p1	desloratadine	drug	_	fluoxetine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , druga at the clinical dose of # mg has been coadministered with drugn # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugb # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugn # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p2	desloratadine	drug	_	fluoxetine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , druga at the clinical dose of # mg has been coadministered with drugn # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with drugb -lcb- n = 18 -rcb- or with drugn # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p3	desloratadine	drug	_	cimetidine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , druga at the clinical dose of # mg has been coadministered with drugn # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugb # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p4	azithromycin	drug	_	fluoxetine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , drugn at the clinical dose of # mg has been coadministered with druga # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugb # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugn # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p5	azithromycin	drug	_	fluoxetine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , drugn at the clinical dose of # mg has been coadministered with druga # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with drugb -lcb- n = 18 -rcb- or with drugn # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p6	azithromycin	drug	_	cimetidine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , drugn at the clinical dose of # mg has been coadministered with druga # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugb # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p8	fluoxetine	drug	_	cimetidine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , drugn at the clinical dose of # mg has been coadministered with drugn # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with druga # mg once daily for # days after a # day pretreatment period with drugn -lcb- n = 18 -rcb- or with drugb # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d67.s1.p9	fluoxetine	drug	_	cimetidine	drug	_	false	in three separate controlled , parallel group clinical pharmacology studies , drugn at the clinical dose of # mg has been coadministered with drugn # mg followed by # mg once daily for # days -lcb- n = 18 -rcb- or with drugn # mg once daily for # days after a # day pretreatment period with druga -lcb- n = 18 -rcb- or with drugb # mg every # hours for # days -lcb- n = 18 -rcb- under steady state conditions to normal healthy male and female volunteers .
DDI-DrugBank.d285.s1.p2	barbiturates	group	_	griseofulvin	drug	_	false	a similar association , though less marked , has been suggested with druga , phenyl-butazone , drugn , drugn and possibly with drugb , drugn , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p3	barbiturates	group	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with druga , phenyl-butazone , drugn , drugn and possibly with drugn , drugb , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p4	barbiturates	group	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with druga , phenyl-butazone , drugn , drugn and possibly with drugn , drugn , and drugb -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p6	phenytoin sodium	drug	_	griseofulvin	drug	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , druga , drugn and possibly with drugb , drugn , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p7	phenytoin sodium	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , druga , drugn and possibly with drugn , drugb , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p8	phenytoin sodium	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , druga , drugn and possibly with drugn , drugn , and drugb -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p9	carbamazepine	drug	_	griseofulvin	drug	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , drugn , druga and possibly with drugb , drugn , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p10	carbamazepine	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , drugn , druga and possibly with drugn , drugb , and drugn -lcb- 72 -rcb-
DDI-DrugBank.d285.s1.p11	carbamazepine	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , phenyl-butazone , drugn , druga and possibly with drugn , drugn , and drugb -lcb- 72 -rcb-
DDI-DrugBank.d314.s0.p2	Aminoglutethimide	drug	_	corticosteroids	group	_	effect	drugn : druga may diminish adrenal suppression by drugb .
DDI-DrugBank.d314.s1.p3	corticosteroids	group	_	amphotericin B	drug	_	advise	drugn injection and potassium-depleting agents : when druga are administered concomitantly with potassium-depleting agents -lcb- e , g , , drugb , drugn -rcb- , patients should be observed closely for development of hypokalemia .
DDI-DrugBank.d314.s1.p4	corticosteroids	group	_	diuretics	group	_	advise	drugn injection and potassium-depleting agents : when druga are administered concomitantly with potassium-depleting agents -lcb- e , g , , drugn , drugb -rcb- , patients should be observed closely for development of hypokalemia .
DDI-DrugBank.d314.s2.p0	amphotericin B	drug	_	hydrocortisone	drug	_	effect	in addition , there have been cases reported in which concomitant use of druga and drugb was followed by cardiac enlargement and congestive heart failure .
DDI-DrugBank.d314.s3.p2	Macrolide antibiotics	group	_	corticosteroid	group	_	mechanism	drugn : druga have been reported to cause a significant decrease in drugb clearance .
DDI-DrugBank.d314.s4.p0	Anticholinesterases	group	_	anticholinesterase agents	group	_	false	druga : concomitant use of drugb and drugn may produce severe weakness in patients with myasthenia gravis .
DDI-DrugBank.d314.s4.p1	Anticholinesterases	group	_	corticosteroids	group	_	false	druga : concomitant use of drugn and drugb may produce severe weakness in patients with myasthenia gravis .
DDI-DrugBank.d314.s4.p2	anticholinesterase agents	group	_	corticosteroids	group	_	effect	drugn : concomitant use of druga and drugb may produce severe weakness in patients with myasthenia gravis .
DDI-DrugBank.d314.s5.p0	anticholinesterase agents	group	_	corticosteroid	group	_	advise	if possible , druga should be withdrawn at least # hours before initiating drugb therapy .
DDI-DrugBank.d314.s6.p0	Anticoagulants	group	_	corticosteroids	group	_	false	druga , oral : co-administration of drugb and drugn usually results in inhibition of response to drugn , although there have been some conflicting reports .
DDI-DrugBank.d314.s6.p1	Anticoagulants	group	_	warfarin	drug	_	false	druga , oral : co-administration of drugn and drugb usually results in inhibition of response to drugn , although there have been some conflicting reports .
DDI-DrugBank.d314.s6.p2	Anticoagulants	group	_	warfarin	drug	_	false	druga , oral : co-administration of drugn and drugn usually results in inhibition of response to drugb , although there have been some conflicting reports .
DDI-DrugBank.d314.s6.p3	corticosteroids	group	_	warfarin	drug	_	effect	drugn , oral : co-administration of druga and drugb usually results in inhibition of response to drugn , although there have been some conflicting reports .
DDI-DrugBank.d314.s6.p4	corticosteroids	group	_	warfarin	drug	_	false	drugn , oral : co-administration of druga and drugn usually results in inhibition of response to drugb , although there have been some conflicting reports .
DDI-DrugBank.d314.s8.p2	corticosteroids	group	_	antidiabetic agents	group	_	effect	drugn : because druga may increase blood glucose concentrations , dosage adjustments of drugb may be required .
DDI-DrugBank.d314.s10.p2	Cholestyramine	drug	_	corticosteroids	group	_	mechanism	drugn : druga may increase the clearance of drugb .
DDI-DrugBank.d314.s11.p1	Cyclosporine	drug	_	corticosteroids	group	_	false	druga : increased activity of both drugn and drugb may occur when the two are used concurrently .
DDI-DrugBank.d314.s11.p2	cyclosporine	drug	_	corticosteroids	group	_	effect	drugn : increased activity of both druga and drugb may occur when the two are used concurrently .
DDI-DrugBank.d314.s16.p3	Ephedrine	drug	_	corticosteroids	group	_	mechanism	drugn : druga may enhance the metabolic clearance of drugb , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in drugn dosage .
DDI-DrugBank.d314.s16.p4	Ephedrine	drug	_	corticosteroid	group	_	false	drugn : druga may enhance the metabolic clearance of drugn , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in drugb dosage .
DDI-DrugBank.d314.s17.p0	Estrogens	group	_	contraceptives	group	_	false	druga , including oral drugb : drugn may decrease the hepatic metabolism of certain drugn , thereby increasing their effect .
DDI-DrugBank.d314.s17.p5	Estrogens	group	_	corticosteroids	group	_	mechanism	drugn , including oral drugn : druga may decrease the hepatic metabolism of certain drugb , thereby increasing their effect .
DDI-DrugBank.d314.s18.p3	barbiturates	group	_	corticosteroids	group	_	mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , druga , drugn , drugn , drugn -rcb- may enhance the metabolism of drugb and require that the dosage of the drugn be increased .
DDI-DrugBank.d314.s18.p4	barbiturates	group	_	corticosteroid	group	_	false	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , druga , drugn , drugn , drugn -rcb- may enhance the metabolism of drugn and require that the dosage of the drugb be increased .
DDI-DrugBank.d314.s18.p7	phenytoin	drug	_	corticosteroids	group	_	mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , druga , drugn , drugn -rcb- may enhance the metabolism of drugb and require that the dosage of the drugn be increased .
DDI-DrugBank.d314.s18.p8	phenytoin	drug	_	corticosteroid	group	_	false	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , druga , drugn , drugn -rcb- may enhance the metabolism of drugn and require that the dosage of the drugb be increased .
DDI-DrugBank.d314.s18.p10	carbamazepine	drug	_	corticosteroids	group	_	mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , drugn , druga , drugn -rcb- may enhance the metabolism of drugb and require that the dosage of the drugn be increased .
DDI-DrugBank.d314.s18.p11	carbamazepine	drug	_	corticosteroid	group	_	false	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , drugn , druga , drugn -rcb- may enhance the metabolism of drugn and require that the dosage of the drugb be increased .
DDI-DrugBank.d314.s18.p12	rifampin	drug	_	corticosteroids	group	_	mechanism	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , drugn , drugn , druga -rcb- may enhance the metabolism of drugb and require that the dosage of the drugn be increased .
DDI-DrugBank.d314.s18.p13	rifampin	drug	_	corticosteroid	group	_	false	hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 -lcb- cyp 3a4 -rcb- enzyme activity -lcb- e , g , , drugn , drugn , drugn , druga -rcb- may enhance the metabolism of drugn and require that the dosage of the drugb be increased .
DDI-DrugBank.d314.s19.p0	ketoconazole	drug	_	macrolide antibiotics	group	_	false	drugs which inhibit cyp 3a4 -lcb- e , g , , druga , drugb such as drugn -rcb- have the potential to result in increased plasma concentrations of drugn .
DDI-DrugBank.d314.s19.p1	ketoconazole	drug	_	erythromycin	drug	_	false	drugs which inhibit cyp 3a4 -lcb- e , g , , druga , drugn such as drugb -rcb- have the potential to result in increased plasma concentrations of drugn .
DDI-DrugBank.d314.s19.p2	ketoconazole	drug	_	corticosteroids	group	_	mechanism	drugs which inhibit cyp 3a4 -lcb- e , g , , druga , drugn such as drugn -rcb- have the potential to result in increased plasma concentrations of drugb .
DDI-DrugBank.d314.s19.p3	macrolide antibiotics	group	_	erythromycin	drug	_	false	drugs which inhibit cyp 3a4 -lcb- e , g , , drugn , druga such as drugb -rcb- have the potential to result in increased plasma concentrations of drugn .
DDI-DrugBank.d314.s19.p4	macrolide antibiotics	group	_	corticosteroids	group	_	mechanism	drugs which inhibit cyp 3a4 -lcb- e , g , , drugn , druga such as drugn -rcb- have the potential to result in increased plasma concentrations of drugb .
DDI-DrugBank.d314.s19.p5	erythromycin	drug	_	corticosteroids	group	_	mechanism	drugs which inhibit cyp 3a4 -lcb- e , g , , drugn , drugn such as druga -rcb- have the potential to result in increased plasma concentrations of drugb .
DDI-DrugBank.d314.s22.p3	Ketoconazole	drug	_	corticosteroids	group	_	mechanism	drugn : druga has been reported to decrease the metabolism of certain drugb by up to 60 % , leading to increased risk of drugn side effects .
DDI-DrugBank.d314.s22.p4	Ketoconazole	drug	_	corticosteroid	group	_	false	drugn : druga has been reported to decrease the metabolism of certain drugn by up to 60 % , leading to increased risk of drugb side effects .
DDI-DrugBank.d314.s23.p0	ketoconazole	drug	_	corticosteroid	drug	_	effect	in addition , druga alone can inhibit adrenal drugb synthesis and may cause adrenal_insufficiency during corticosteroid withdrawal .
DDI-DrugBank.d314.s24.p1	Nonsteroidal anti-inflammatory agents	group	_	aspirin	brand	_	false	druga -lcb- drugn -rcb- : concomitant use of drugb -lcb- or other drugn -rcb- and drugn increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p2	Nonsteroidal anti-inflammatory agents	group	_	nonsteroidal antiinflammatory agents	group	_	false	druga -lcb- drugn -rcb- : concomitant use of drugn -lcb- or other drugb -rcb- and drugn increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p3	Nonsteroidal anti-inflammatory agents	group	_	corticosteroids	group	_	false	druga -lcb- drugn -rcb- : concomitant use of drugn -lcb- or other drugn -rcb- and drugb increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p4	NSAIDS	group	_	aspirin	brand	_	false	drugn -lcb- druga -rcb- : concomitant use of drugb -lcb- or other drugn -rcb- and drugn increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p5	NSAIDS	group	_	nonsteroidal antiinflammatory agents	group	_	false	drugn -lcb- druga -rcb- : concomitant use of drugn -lcb- or other drugb -rcb- and drugn increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p6	NSAIDS	group	_	corticosteroids	group	_	false	drugn -lcb- druga -rcb- : concomitant use of drugn -lcb- or other drugn -rcb- and drugb increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p8	aspirin	brand	_	corticosteroids	group	_	effect	drugn -lcb- drugn -rcb- : concomitant use of druga -lcb- or other drugn -rcb- and drugb increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s24.p9	nonsteroidal antiinflammatory agents	group	_	corticosteroids	group	_	effect	drugn -lcb- drugn -rcb- : concomitant use of drugn -lcb- or other druga -rcb- and drugb increases the risk of gastrointestinal side effects .
DDI-DrugBank.d314.s25.p0	Aspirin	brand	_	corticosteroids	group	_	advise	druga should be used cautiously in conjunction with drugb in hypoprothrombinemia .
DDI-DrugBank.d314.s26.p0	salicylates	group	_	corticosteroids	group	_	mechanism	the clearance of druga may be increased with concurrent use of drugb .
DDI-DrugBank.d314.s27.p1	Phenytoin	drug	_	dexamethasone	drug	_	false	druga : in post-marketing experience , there have been reports of both increases and decreases in drugn levels with drugb co-administration , leading to alterations in seizure control .
DDI-DrugBank.d314.s27.p2	phenytoin	drug	_	dexamethasone	drug	_	mechanism	drugn : in post-marketing experience , there have been reports of both increases and decreases in druga levels with drugb co-administration , leading to alterations in seizure control .
DDI-DrugBank.d314.s30.p3	corticosteroid	group	_	live vaccines	group	_	effect	drugn : patients on druga therapy may exhibit a diminished response to toxoids and drugb or drugn due to inhibition of antibody response .
DDI-DrugBank.d314.s30.p4	corticosteroid	group	_	inactivated vaccines	group	_	effect	drugn : patients on druga therapy may exhibit a diminished response to toxoids and drugn or drugb due to inhibition of antibody response .
DDI-DrugBank.d314.s30.p5	live vaccines	group	_	inactivated vaccines	group	_	false	drugn : patients on drugn therapy may exhibit a diminished response to toxoids and druga or drugb due to inhibition of antibody response .
DDI-DrugBank.d314.s31.p0	Corticosteroids	group	_	live attenuated vaccines	group	_	effect	druga may also potentiate the replication of some organisms contained in drugb .
DDI-DrugBank.d314.s32.p0	vaccines	group	_	corticosteroid	group	_	advise	routine administration of druga or toxoids should be deferred until drugb therapy is discontinued if possible .
DDI-DrugBank.d62.s0.p0	Dexbrompheniramine	drug	_	alcohol	drug	_	int	druga can interact with drugb or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p1	Dexbrompheniramine	drug	_	CNS depressants	group	_	int	druga can interact with drugn or other drugb -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p2	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p3	Dexbrompheniramine	drug	_	anticholinergics	group	_	int	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p4	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p5	Dexbrompheniramine	drug	_	monoamine oxidase (MAO) inhibitors	group	_	int	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p6	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p7	Dexbrompheniramine	drug	_	antihistamines	group	_	false	druga can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d62.s0.p9	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p11	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p12	alcohol	drug	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p13	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p14	alcohol	drug	_	antihistamines	group	_	false	drugn can interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d62.s0.p15	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p17	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p18	CNS depressants	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p19	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p20	CNS depressants	group	_	antihistamines	group	_	false	drugn can interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d62.s0.p21	antihistamines	group	_	anticholinergics	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p23	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p26	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p27	anticholinergics	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p28	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p29	anticholinergics	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d62.s0.p30	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with druga -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p33	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d62.s0.p34	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	group	_	false	drugn can interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d423.s0.p2	monoamine oxidase inhibitors	group	_	serotoninergic agents	group	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p3	monoamine oxidase inhibitors	group	_	fluoxetine	drug	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p4	monoamine oxidase inhibitors	group	_	fluvoxamine	drug	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p5	monoamine oxidase inhibitors	group	_	paroxetine	drug	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p6	monoamine oxidase inhibitors	group	_	sertraline	drug	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p7	monoamine oxidase inhibitors	group	_	venlafaxine	drug	_	effect	in patients receiving nonselective druga -lcb- drugn -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p9	MAOIs	group	_	serotoninergic agents	group	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p10	MAOIs	group	_	fluoxetine	drug	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p11	MAOIs	group	_	fluvoxamine	drug	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p12	MAOIs	group	_	paroxetine	drug	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p13	MAOIs	group	_	sertraline	drug	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p14	MAOIs	group	_	venlafaxine	drug	_	effect	in patients receiving nonselective drugn -lcb- druga -rcb- -lcb- e , g , , drugn -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p15	selegiline hydrochloride	drug	_	serotoninergic agents	group	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p16	selegiline hydrochloride	drug	_	fluoxetine	drug	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p17	selegiline hydrochloride	drug	_	fluvoxamine	drug	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p18	selegiline hydrochloride	drug	_	paroxetine	drug	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p19	selegiline hydrochloride	drug	_	sertraline	drug	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s0.p20	selegiline hydrochloride	drug	_	venlafaxine	drug	_	effect	in patients receiving nonselective drugn -lcb- drugn -rcb- -lcb- e , g , , druga -rcb- in combination with drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb -rcb- , there have been reports of serious , sometimes fatal , reactions .
DDI-DrugBank.d423.s1.p1	dexfenfluramine	drug	_	MAO inhibitor	group	_	false	because druga is a serotonin releaser and reuptake inhibitor , drugn should not be used concomitantly with a drugb .
DDI-DrugBank.d423.s1.p2	dexfenfluramine	drug	_	MAO inhibitor	group	_	advise	because drugn is a serotonin releaser and reuptake inhibitor , druga should not be used concomitantly with a drugb .
DDI-DrugBank.d423.s2.p0	MAO inhibitor	group	_	dexfenfluramine	drug	_	advise	at least # days should elapse between discontinuation of a druga and initiation of treatment with drugb .
DDI-DrugBank.d423.s3.p0	dexfenfluramine	drug	_	MAO inhibitor	group	_	advise	at least # weeks should elapse between discontinuation of druga and initiation of treatment with a drugb .
DDI-DrugBank.d423.s4.p1	selective serotonin reuptake inhibitors	group	_	Imitrex	brand	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of druga -lcb- drugn -rcb- and agents for migraine therapy , such as drugb -lcb- drugn -rcb- and drugn .
DDI-DrugBank.d423.s4.p2	selective serotonin reuptake inhibitors	group	_	sumatriptan succinate	drug	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of druga -lcb- drugn -rcb- and agents for migraine therapy , such as drugn -lcb- drugb -rcb- and drugn .
DDI-DrugBank.d423.s4.p3	selective serotonin reuptake inhibitors	group	_	dihydroergotamine	drug	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of druga -lcb- drugn -rcb- and agents for migraine therapy , such as drugn -lcb- drugn -rcb- and drugb .
DDI-DrugBank.d423.s4.p4	SSRIs	group	_	Imitrex	brand	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drugn -lcb- druga -rcb- and agents for migraine therapy , such as drugb -lcb- drugn -rcb- and drugn .
DDI-DrugBank.d423.s4.p5	SSRIs	group	_	sumatriptan succinate	drug	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drugn -lcb- druga -rcb- and agents for migraine therapy , such as drugn -lcb- drugb -rcb- and drugn .
DDI-DrugBank.d423.s4.p6	SSRIs	group	_	dihydroergotamine	drug	_	effect	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drugn -lcb- druga -rcb- and agents for migraine therapy , such as drugn -lcb- drugn -rcb- and drugb .
DDI-DrugBank.d423.s4.p8	Imitrex	brand	_	dihydroergotamine	drug	_	false	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drugn -lcb- drugn -rcb- and agents for migraine therapy , such as druga -lcb- drugn -rcb- and drugb .
DDI-DrugBank.d423.s4.p9	sumatriptan succinate	drug	_	dihydroergotamine	drug	_	false	a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drugn -lcb- drugn -rcb- and agents for migraine therapy , such as drugn -lcb- druga -rcb- and drugb .
DDI-DrugBank.d423.s6.p0	Dexfenfluramine	drug	_	serotoninergic agents	group	_	advise	druga should not be administered with other drugb .
DDI-DrugBank.d197.s1.p0	Anesthetics	group	_	Sedatives	group	_	false	druga / drugb / drugn / drugn : co-administration of drugn with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p1	Anesthetics	group	_	Hypnotics	group	_	false	druga / drugn / drugb / drugn : co-administration of drugn with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p2	Anesthetics	group	_	Opioids	group	_	false	druga / drugn / drugn / drugb : co-administration of drugn with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p3	Anesthetics	group	_	PRECEDEX	brand	_	false	druga / drugn / drugn / drugn : co-administration of drugb with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p5	Anesthetics	group	_	sedatives	group	_	false	druga / drugn / drugn / drugn : co-administration of drugn with drugn , drugb , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p6	Anesthetics	group	_	hypnotics	group	_	false	druga / drugn / drugn / drugn : co-administration of drugn with drugn , drugn , drugb , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p7	Anesthetics	group	_	opioids	group	_	false	druga / drugn / drugn / drugn : co-administration of drugn with drugn , drugn , drugn , and drugb is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p10	Sedatives	group	_	PRECEDEX	brand	_	false	drugn / druga / drugn / drugn : co-administration of drugb with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p11	Sedatives	group	_	anesthetics	group	_	false	drugn / druga / drugn / drugn : co-administration of drugn with drugb , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p13	Sedatives	group	_	hypnotics	group	_	false	drugn / druga / drugn / drugn : co-administration of drugn with drugn , drugn , drugb , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p14	Sedatives	group	_	opioids	group	_	false	drugn / druga / drugn / drugn : co-administration of drugn with drugn , drugn , drugn , and drugb is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p16	Hypnotics	group	_	PRECEDEX	brand	_	false	drugn / drugn / druga / drugn : co-administration of drugb with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p17	Hypnotics	group	_	anesthetics	group	_	false	drugn / drugn / druga / drugn : co-administration of drugn with drugb , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p18	Hypnotics	group	_	sedatives	group	_	false	drugn / drugn / druga / drugn : co-administration of drugn with drugn , drugb , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p20	Hypnotics	group	_	opioids	group	_	false	drugn / drugn / druga / drugn : co-administration of drugn with drugn , drugn , drugn , and drugb is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p21	Opioids	group	_	PRECEDEX	brand	_	false	drugn / drugn / drugn / druga : co-administration of drugb with drugn , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p22	Opioids	group	_	anesthetics	group	_	false	drugn / drugn / drugn / druga : co-administration of drugn with drugb , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p23	Opioids	group	_	sedatives	group	_	false	drugn / drugn / drugn / druga : co-administration of drugn with drugn , drugb , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p24	Opioids	group	_	hypnotics	group	_	false	drugn / drugn / drugn / druga : co-administration of drugn with drugn , drugn , drugb , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p26	PRECEDEX	brand	_	anesthetics	group	_	effect	drugn / drugn / drugn / drugn : co-administration of druga with drugb , drugn , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p27	PRECEDEX	brand	_	sedatives	group	_	effect	drugn / drugn / drugn / drugn : co-administration of druga with drugn , drugb , drugn , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p28	PRECEDEX	brand	_	hypnotics	group	_	effect	drugn / drugn / drugn / drugn : co-administration of druga with drugn , drugn , drugb , and drugn is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s1.p29	PRECEDEX	brand	_	opioids	group	_	effect	drugn / drugn / drugn / drugn : co-administration of druga with drugn , drugn , drugn , and drugb is likely to lead to an enhancement of effects .
DDI-DrugBank.d197.s4.p1	PRECEDEX	brand	_	anesthetic	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with druga , a reduction in dosage of drugn on the concomitant drugb , drugn , drugn or drugn may be required .
DDI-DrugBank.d197.s4.p2	PRECEDEX	brand	_	sedative	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with druga , a reduction in dosage of drugn on the concomitant drugn , drugb , drugn or drugn may be required .
DDI-DrugBank.d197.s4.p3	PRECEDEX	brand	_	hypnotic	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with druga , a reduction in dosage of drugn on the concomitant drugn , drugn , drugb or drugn may be required .
DDI-DrugBank.d197.s4.p4	PRECEDEX	brand	_	opioid	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with druga , a reduction in dosage of drugn on the concomitant drugn , drugn , drugn or drugb may be required .
DDI-DrugBank.d197.s4.p5	PRECEDEX	brand	_	anesthetic	group	_	advise	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of druga on the concomitant drugb , drugn , drugn or drugn may be required .
DDI-DrugBank.d197.s4.p6	PRECEDEX	brand	_	sedative	group	_	advise	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of druga on the concomitant drugn , drugb , drugn or drugn may be required .
DDI-DrugBank.d197.s4.p7	PRECEDEX	brand	_	hypnotic	group	_	advise	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of druga on the concomitant drugn , drugn , drugb or drugn may be required .
DDI-DrugBank.d197.s4.p8	PRECEDEX	brand	_	opioid	group	_	advise	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of druga on the concomitant drugn , drugn , drugn or drugb may be required .
DDI-DrugBank.d197.s4.p9	anesthetic	group	_	sedative	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of drugn on the concomitant druga , drugb , drugn or drugn may be required .
DDI-DrugBank.d197.s4.p10	anesthetic	group	_	hypnotic	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of drugn on the concomitant druga , drugn , drugb or drugn may be required .
DDI-DrugBank.d197.s4.p11	anesthetic	group	_	opioid	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of drugn on the concomitant druga , drugn , drugn or drugb may be required .
DDI-DrugBank.d197.s4.p13	sedative	group	_	opioid	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of drugn on the concomitant drugn , druga , drugn or drugb may be required .
DDI-DrugBank.d197.s4.p14	hypnotic	group	_	opioid	group	_	false	however , due to possible pharmacodynamic interactions , when co-administered with drugn , a reduction in dosage of drugn on the concomitant drugn , drugn , druga or drugb may be required .
DDI-DrugBank.d197.s5.p2	PRECEDEX	brand	_	rocuronium	drug	_	false	drugn : in one study of # healthy volunteers , administration of druga for # minutes at a plasma concentration of # -lcb- one -rcb- ng/ml resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with drugb administration .
DDI-DrugBank.d38.s0.p0	ZINECARD	brand	_	doxorubicin	drug	_	false	druga does not influence the pharmacokinetics of drugb .
DDI-DrugBank.d236.s0.p1	Acidifying agents	group	_	guanethidine	drug	_	false	druga : drugn -lcb- drugb , drugn , drugn , drugn , fruit juices , etc , -rcb- lower absorption of drugn .
DDI-DrugBank.d236.s0.p2	Acidifying agents	group	_	reserpine	drug	_	false	druga : drugn -lcb- drugn , drugb , drugn , drugn , fruit juices , etc , -rcb- lower absorption of drugn .
DDI-DrugBank.d236.s0.p3	Acidifying agents	group	_	glutamic acid HCl	drug	_	false	druga : drugn -lcb- drugn , drugn , drugb , drugn , fruit juices , etc , -rcb- lower absorption of drugn .
DDI-DrugBank.d236.s0.p4	Acidifying agents	group	_	ascorbic acid	drug	_	false	druga : drugn -lcb- drugn , drugn , drugn , drugb , fruit juices , etc , -rcb- lower absorption of drugn .
DDI-DrugBank.d236.s0.p10	Gastrointestinal acidifying agents	group	_	amphetamines	group	_	mechanism	drugn : druga -lcb- drugn , drugn , drugn , drugn , fruit juices , etc , -rcb- lower absorption of drugb .
DDI-DrugBank.d236.s0.p14	guanethidine	drug	_	amphetamines	group	_	mechanism	drugn : drugn -lcb- druga , drugn , drugn , drugn , fruit juices , etc , -rcb- lower absorption of drugb .
DDI-DrugBank.d236.s0.p17	reserpine	drug	_	amphetamines	group	_	mechanism	drugn : drugn -lcb- drugn , druga , drugn , drugn , fruit juices , etc , -rcb- lower absorption of drugb .
DDI-DrugBank.d236.s0.p19	glutamic acid HCl	drug	_	amphetamines	group	_	mechanism	drugn : drugn -lcb- drugn , drugn , druga , drugn , fruit juices , etc , -rcb- lower absorption of drugb .
DDI-DrugBank.d236.s0.p20	ascorbic acid	drug	_	amphetamines	group	_	mechanism	drugn : drugn -lcb- drugn , drugn , drugn , druga , fruit juices , etc , -rcb- lower absorption of drugb .
DDI-DrugBank.d236.s1.p2	Urinary acidifying agents	group	_	amphetamine	drug	_	mechanism	druga -lcb- drugn , drugn , etc , -rcb- increase the concentration of the ionized species of the drugb molecule , thereby increasing urinary excretion .
DDI-DrugBank.d236.s1.p4	ammonium chloride	drug	_	amphetamine	drug	_	mechanism	drugn -lcb- druga , drugn , etc , -rcb- increase the concentration of the ionized species of the drugb molecule , thereby increasing urinary excretion .
DDI-DrugBank.d236.s1.p5	sodium acid phosphate	drug	_	amphetamine	drug	_	mechanism	drugn -lcb- drugn , druga , etc , -rcb- increase the concentration of the ionized species of the drugb molecule , thereby increasing urinary excretion .
DDI-DrugBank.d236.s3.p2	Adrenergic blockers	group	_	amphetamines	group	_	effect	drugn : druga are inhibited by drugb .
DDI-DrugBank.d236.s4.p0	sodium bicarbonate	drug	_	amphetamines	drug	_	mechanism	alkalinizing agents : gastrointestinal alkalinizing agents -lcb- druga , etc , -rcb- increase absorption of drugb .
DDI-DrugBank.d236.s5.p1	acetazolamide	drug	_	amphetamine	drug	_	mechanism	urinary alkalinizing agents -lcb- druga , some drugn -rcb- increase the concentration of the non-ionized species of the drugb molecule , thereby decreasing urinary excretion .
DDI-DrugBank.d236.s5.p2	thiazides	group	_	amphetamine	drug	_	mechanism	urinary alkalinizing agents -lcb- drugn , some druga -rcb- increase the concentration of the non-ionized species of the drugb molecule , thereby decreasing urinary excretion .
DDI-DrugBank.d236.s7.p0	Antidepressants	group	_	tricyclic	group	_	false	druga , drugb : drugn may enhance the activity of drugn or drugn ;
DDI-DrugBank.d236.s7.p7	Amphetamines	group	_	tricyclic	group	_	effect	drugn , drugn : druga may enhance the activity of drugb or drugn ;
DDI-DrugBank.d236.s7.p8	Amphetamines	group	_	sympathomimetic agents	group	_	effect	drugn , drugn : druga may enhance the activity of drugn or drugb ;
DDI-DrugBank.d236.s7.p9	tricyclic	group	_	sympathomimetic agents	group	_	false	drugn , drugn : drugn may enhance the activity of druga or drugb ;
DDI-DrugBank.d236.s8.p0	d-amphetamine	drug	_	desipramine	drug	_	mechanism	druga with drugb or drugn and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p1	d-amphetamine	drug	_	protriptyline	drug	_	mechanism	druga with drugn or drugb and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p2	d-amphetamine	drug	_	tricyclics	group	_	mechanism	druga with drugn or drugn and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p4	desipramine	drug	_	protriptyline	drug	_	false	drugn with druga or drugb and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p5	desipramine	drug	_	tricyclics	group	_	false	drugn with druga or drugn and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p6	desipramine	drug	_	d-amphetamine	drug	_	false	drugn with druga or drugn and possibly other drugn cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d236.s8.p7	protriptyline	drug	_	tricyclics	group	_	false	drugn with drugn or druga and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d236.s8.p8	protriptyline	drug	_	d-amphetamine	drug	_	false	drugn with drugn or druga and possibly other drugn cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d236.s8.p9	tricyclics	group	_	d-amphetamine	drug	_	false	drugn with drugn or drugn and possibly other druga cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d236.s10.p0	MAO inhibitors	group	_	MAOI antidepressants	group	_	false	druga : drugb , as well as a metabolite of drugn , slow drugn metabolism .
DDI-DrugBank.d236.s10.p1	MAO inhibitors	group	_	furazolidone	drug	_	false	druga : drugn , as well as a metabolite of drugb , slow drugn metabolism .
DDI-DrugBank.d236.s10.p2	MAO inhibitors	group	_	amphetamine	group	_	false	druga : drugn , as well as a metabolite of drugn , slow drugb metabolism .
DDI-DrugBank.d236.s10.p3	MAOI antidepressants	group	_	furazolidone	drug	_	false	drugn : druga , as well as a metabolite of drugb , slow drugn metabolism .
DDI-DrugBank.d236.s10.p4	MAOI antidepressants	group	_	amphetamine	group	_	mechanism	drugn : druga , as well as a metabolite of drugn , slow drugb metabolism .
DDI-DrugBank.d236.s10.p5	furazolidone	drug	_	amphetamine	group	_	mechanism	drugn : drugn , as well as a metabolite of druga , slow drugb metabolism .
DDI-DrugBank.d236.s14.p2	Amphetamines	group	_	antihistamines	group	_	effect	drugn : druga may counteract the sedative effect of drugb .
DDI-DrugBank.d236.s15.p2	Amphetamines	group	_	antihypertensives	group	_	effect	drugn : druga may antagonize the hypotensive effects of drugb .
DDI-DrugBank.d236.s16.p3	Chlorpromazine	drug	_	amphetamines	group	_	effect	drugn : druga blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of drugb , and can be used to treat drugn poisoning .
DDI-DrugBank.d236.s16.p4	Chlorpromazine	drug	_	amphetamine	group	_	false	drugn : druga blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of drugn , and can be used to treat drugb poisoning .
DDI-DrugBank.d236.s17.p2	Amphetamines	group	_	ethosuximide	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb .
DDI-DrugBank.d236.s18.p2	Haloperidol	drug	_	amphetamines	group	_	effect	drugn : druga blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of drugb .
DDI-DrugBank.d236.s19.p2	amphetamines	group	_	lithium carbonate	drug	_	effect	drugn : the stimulatory effects of druga may be inhibited by drugb .
DDI-DrugBank.d236.s20.p2	Amphetamines	group	_	meperidine	drug	_	effect	drugn : druga potentiate the analgesic effect of drugb .
DDI-DrugBank.d236.s21.p3	amphetamines	group	_	acidifying agents	group	_	mechanism	drugn therapy : urinary excretion of druga is increased , and efficacy is reduced , by drugb used in drugn therapy .
DDI-DrugBank.d236.s21.p4	amphetamines	group	_	methenamine	drug	_	false	drugn therapy : urinary excretion of druga is increased , and efficacy is reduced , by drugn used in drugb therapy .
DDI-DrugBank.d236.s21.p5	acidifying agents	group	_	methenamine	drug	_	false	drugn therapy : urinary excretion of drugn is increased , and efficacy is reduced , by druga used in drugb therapy .
DDI-DrugBank.d236.s22.p2	Amphetamines	group	_	norepinephrine	drug	_	effect	drugn : druga enhance the adrenergic effect of drugb .
DDI-DrugBank.d236.s23.p2	Amphetamines	group	_	phenobarbital	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb ;
DDI-DrugBank.d236.s25.p2	Amphetamines	group	_	phenytoin	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb ;
DDI-DrugBank.d236.s27.p2	propoxyphene	drug	_	amphetamine	group	_	effect	drugn : in cases of druga overdosage , drugb cns stimulation is potentiated and fatal convulsions can occur .
DDI-DrugBank.d236.s28.p2	Amphetamines	group	_	veratrum alkaloids	group	_	effect	drugn : druga inhibit the hypotensive effect of drugb .
DDI-DrugBank.d461.s0.p4	anesthetics	group	_	opiate analgesics	group	_	false	additive depressant effect when used with general druga , drugn , drugn , drugn , drugn , and other drugb .
DDI-DrugBank.d461.s0.p8	sedatives	group	_	opiate analgesics	group	_	false	additive depressant effect when used with general drugn , druga , drugn , drugn , drugn , and other drugb .
DDI-DrugBank.d461.s0.p11	antianxiety drugs	group	_	opiate analgesics	group	_	false	additive depressant effect when used with general drugn , drugn , druga , drugn , drugn , and other drugb .
DDI-DrugBank.d461.s0.p13	hypnotics	group	_	opiate analgesics	group	_	false	additive depressant effect when used with general drugn , drugn , drugn , druga , drugn , and other drugb .
DDI-DrugBank.d461.s0.p14	alcohol	drug	_	opiate analgesics	group	_	false	additive depressant effect when used with general drugn , drugn , drugn , drugn , druga , and other drugb .
DDI-DrugBank.d293.s0.p0	levothyroxine	drug	_	iodine	drug	_	false	may interact with thyroid medication -lcb- e , g , , druga -rcb- , drugb - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p5	levothyroxine	drug	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , druga -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p6	levothyroxine	drug	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , druga -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p7	levothyroxine	drug	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , druga -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d293.s0.p8	iodine	drug	_	antacids	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugb , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p9	iodine	drug	_	H2-antagonists	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugb -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p10	iodine	drug	_	famotidine	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugn -lcb- e , g , , drugb , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p11	iodine	drug	_	ranitidine	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugn -lcb- e , g , , drugn , drugb -rcb- , and drugn -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p12	iodine	drug	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p13	iodine	drug	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p14	iodine	drug	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , druga - containing products , drugn , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d293.s0.p18	antacids	group	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , druga , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p19	antacids	group	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , druga , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p20	antacids	group	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , druga , drugn -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d293.s0.p23	H2-antagonists	group	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , druga -lcb- e , g , , drugn , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p24	H2-antagonists	group	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , druga -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p25	H2-antagonists	group	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , druga -lcb- e , g , , drugn , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d293.s0.p27	famotidine	drug	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , druga , drugn -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p28	famotidine	drug	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , druga , drugn -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p29	famotidine	drug	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , druga , drugn -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d293.s0.p30	ranitidine	drug	_	proton pump inhibitors	group	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , druga -rcb- , and drugb -lcb- e , g , , drugn , drugn -rcb- .
DDI-DrugBank.d293.s0.p31	ranitidine	drug	_	lansoprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , druga -rcb- , and drugn -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d293.s0.p32	ranitidine	drug	_	omeprazole	drug	_	false	may interact with thyroid medication -lcb- e , g , , drugn -rcb- , drugn - containing products , drugn , drugn -lcb- e , g , , drugn , druga -rcb- , and drugn -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d36.s0.p0	aspirin	brand	_	carbonic anhydrase inhibitors	group	_	advise	caution is advised in patients receiving concomitant high-dose druga and drugb , as anorexia , tachypnea , lethargy and coma have been rarely reported due to a possible drug interaction .
DDI-DrugBank.d249.s0.p0	Aspirin	brand	_	diclofenac	drug	_	false	druga : concomitant administration of drugb and drugn is not recommended because drugn is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s0.p2	Aspirin	brand	_	diclofenac	drug	_	false	druga : concomitant administration of drugn and drugn is not recommended because drugb is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s0.p4	diclofenac	drug	_	aspirin	brand	_	advise	drugn : concomitant administration of druga and drugb is not recommended because drugn is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s0.p6	diclofenac	drug	_	aspirin	brand	_	false	drugn : concomitant administration of druga and drugn is not recommended because drugn is displaced from its binding sites during the concomitant administration of drugb , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s0.p7	aspirin	brand	_	diclofenac	drug	_	false	drugn : concomitant administration of drugn and druga is not recommended because drugb is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s0.p9	diclofenac	drug	_	aspirin	brand	_	mechanism	drugn : concomitant administration of drugn and drugn is not recommended because druga is displaced from its binding sites during the concomitant administration of drugb , resulting in lower plasma concentrations , peak plasma levels , and auc values .
DDI-DrugBank.d249.s1.p3	diclofenac	drug	_	anticoagulants of the warfarin type	group	_	false	drugn : while studies have not shown druga to interact with drugb , caution should be exercised , nonetheless , since interactions have been seen with other drugn .
DDI-DrugBank.d249.s1.p4	diclofenac	drug	_	NSAIDs	group	_	advise	drugn : while studies have not shown druga to interact with drugn , caution should be exercised , nonetheless , since interactions have been seen with other drugb .
DDI-DrugBank.d249.s1.p5	anticoagulants of the warfarin type	group	_	NSAIDs	group	_	false	drugn : while studies have not shown drugn to interact with druga , caution should be exercised , nonetheless , since interactions have been seen with other drugb .
DDI-DrugBank.d249.s2.p1	NSAIDs	group	_	diclofenac	drug	_	false	because prostaglandins play an important role in hemostasis , and druga affect platelet function as well , concurrent therapy with all drugn , including drugb , and drugn requires close monitoring of patients to be certain that no change in their drugn dosage is required .
DDI-DrugBank.d249.s2.p2	NSAIDs	group	_	warfarin	drug	_	false	because prostaglandins play an important role in hemostasis , and druga affect platelet function as well , concurrent therapy with all drugn , including drugn , and drugb requires close monitoring of patients to be certain that no change in their drugn dosage is required .
DDI-DrugBank.d249.s2.p3	NSAIDs	group	_	anticoagulant	group	_	false	because prostaglandins play an important role in hemostasis , and druga affect platelet function as well , concurrent therapy with all drugn , including drugn , and drugn requires close monitoring of patients to be certain that no change in their drugb dosage is required .
DDI-DrugBank.d249.s2.p4	NSAIDs	group	_	diclofenac	drug	_	false	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all druga , including drugb , and drugn requires close monitoring of patients to be certain that no change in their drugn dosage is required .
DDI-DrugBank.d249.s2.p5	NSAIDs	group	_	warfarin	drug	_	advise	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all druga , including drugn , and drugb requires close monitoring of patients to be certain that no change in their drugn dosage is required .
DDI-DrugBank.d249.s2.p6	NSAIDs	group	_	anticoagulant	group	_	false	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all druga , including drugn , and drugn requires close monitoring of patients to be certain that no change in their drugb dosage is required .
DDI-DrugBank.d249.s2.p7	diclofenac	drug	_	warfarin	drug	_	advise	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all drugn , including druga , and drugb requires close monitoring of patients to be certain that no change in their drugn dosage is required .
DDI-DrugBank.d249.s2.p8	diclofenac	drug	_	anticoagulant	group	_	false	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all drugn , including druga , and drugn requires close monitoring of patients to be certain that no change in their drugb dosage is required .
DDI-DrugBank.d249.s2.p9	warfarin	drug	_	anticoagulant	group	_	false	because prostaglandins play an important role in hemostasis , and drugn affect platelet function as well , concurrent therapy with all drugn , including drugn , and druga requires close monitoring of patients to be certain that no change in their drugb dosage is required .
DDI-DrugBank.d249.s3.p0	Digoxin	drug	_	Methotrexate	drug	_	false	druga , drugb , drugn : drugn , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p1	Digoxin	drug	_	Cyclosporine	drug	_	false	druga , drugn , drugb : drugn , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p2	Digoxin	drug	_	Diclofenac	drug	_	false	druga , drugn , drugn : drugb , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p3	Digoxin	drug	_	NSAIDs	group	_	false	druga , drugn , drugn : drugn , like other drugb , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p4	Methotrexate	drug	_	Cyclosporine	drug	_	false	drugn , druga , drugb : drugn , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p5	Methotrexate	drug	_	Diclofenac	drug	_	false	drugn , druga , drugn : drugb , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p6	Methotrexate	drug	_	NSAIDs	group	_	false	drugn , druga , drugn : drugn , like other drugb , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p7	Cyclosporine	drug	_	Diclofenac	drug	_	false	drugn , drugn , druga : drugb , like other drugn , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p8	Cyclosporine	drug	_	NSAIDs	group	_	false	drugn , drugn , druga : drugn , like other drugb , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s3.p9	Diclofenac	drug	_	NSAIDs	group	_	false	drugn , drugn , drugn : druga , like other drugb , may affect renal prostaglandins and increase the toxicity of certain drugs .
DDI-DrugBank.d249.s4.p0	diclofenac	drug	_	digoxin	drug	_	mechanism	ingestion of druga may increase serum concentrations of drugb and drugn and increase drugn s nephrotoxicity .
DDI-DrugBank.d249.s4.p1	diclofenac	drug	_	methotrexate	drug	_	mechanism	ingestion of druga may increase serum concentrations of drugn and drugb and increase drugn s nephrotoxicity .
DDI-DrugBank.d249.s4.p2	diclofenac	drug	_	cyclosporine	drug	_	effect	ingestion of druga may increase serum concentrations of drugn and drugn and increase drugb s nephrotoxicity .
DDI-DrugBank.d249.s4.p3	digoxin	drug	_	methotrexate	drug	_	false	ingestion of drugn may increase serum concentrations of druga and drugb and increase drugn s nephrotoxicity .
DDI-DrugBank.d249.s4.p4	digoxin	drug	_	cyclosporine	drug	_	false	ingestion of drugn may increase serum concentrations of druga and drugn and increase drugb s nephrotoxicity .
DDI-DrugBank.d249.s4.p5	methotrexate	drug	_	cyclosporine	drug	_	false	ingestion of drugn may increase serum concentrations of drugn and druga and increase drugb s nephrotoxicity .
DDI-DrugBank.d249.s5.p1	diclofenac	drug	_	NSAID	group	_	false	patients who begin taking druga or who increase their drugn dose or any other drugb while taking drugn , drugn , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p2	diclofenac	drug	_	digoxin	drug	_	effect	patients who begin taking druga or who increase their drugn dose or any other drugn while taking drugb , drugn , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p3	diclofenac	drug	_	methotrexate	drug	_	effect	patients who begin taking druga or who increase their drugn dose or any other drugn while taking drugn , drugb , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p4	diclofenac	drug	_	cyclosporine	drug	_	effect	patients who begin taking druga or who increase their drugn dose or any other drugn while taking drugn , drugn , or drugb may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p5	diclofenac	drug	_	NSAID	group	_	false	patients who begin taking drugn or who increase their druga dose or any other drugb while taking drugn , drugn , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p6	diclofenac	drug	_	digoxin	drug	_	false	patients who begin taking drugn or who increase their druga dose or any other drugn while taking drugb , drugn , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p7	diclofenac	drug	_	methotrexate	drug	_	false	patients who begin taking drugn or who increase their druga dose or any other drugn while taking drugn , drugb , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p8	diclofenac	drug	_	cyclosporine	drug	_	false	patients who begin taking drugn or who increase their druga dose or any other drugn while taking drugn , drugn , or drugb may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p9	NSAID	group	_	digoxin	drug	_	effect	patients who begin taking drugn or who increase their drugn dose or any other druga while taking drugb , drugn , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p10	NSAID	group	_	methotrexate	drug	_	effect	patients who begin taking drugn or who increase their drugn dose or any other druga while taking drugn , drugb , or drugn may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s5.p11	NSAID	group	_	cyclosporine	drug	_	effect	patients who begin taking drugn or who increase their drugn dose or any other druga while taking drugn , drugn , or drugb may develop toxicity characteristics for these drugs .
DDI-DrugBank.d249.s8.p3	Diclofenac	drug	_	lithium	drug	_	mechanism	drugn : druga decreases drugb renal clearance and increases drugn plasma levels .
DDI-DrugBank.d249.s8.p4	Diclofenac	drug	_	lithium	drug	_	mechanism	drugn : druga decreases drugn renal clearance and increases drugb plasma levels .
DDI-DrugBank.d249.s9.p0	diclofenac	drug	_	lithium	drug	_	effect	in patients taking druga and drugb concomitantly , drugn toxicity may develop .
DDI-DrugBank.d249.s9.p1	diclofenac	drug	_	lithium	drug	_	false	in patients taking druga and drugn concomitantly , drugb toxicity may develop .
DDI-DrugBank.d249.s10.p2	Diclofenac	drug	_	hypoglycemic agents	group	_	false	oral drugn : druga does not alter glucose metabolism in normal subjects nor does it alter the effects of oral drugb .
DDI-DrugBank.d249.s11.p0	insulin	drug	_	hypoglycemic agents	group	_	false	there are rare reports , however , from marketing experiences , of changes in effects of druga or oral drugb in the presence of drugn that necessitated changes in the doses of such agents .
DDI-DrugBank.d249.s11.p1	insulin	drug	_	diclofenac	drug	_	effect	there are rare reports , however , from marketing experiences , of changes in effects of druga or oral drugn in the presence of drugb that necessitated changes in the doses of such agents .
DDI-DrugBank.d249.s11.p2	hypoglycemic agents	group	_	diclofenac	drug	_	effect	there are rare reports , however , from marketing experiences , of changes in effects of drugn or oral druga in the presence of drugb that necessitated changes in the doses of such agents .
DDI-DrugBank.d249.s13.p0	diclofenac	drug	_	insulin	drug	_	effect	a direct causal relationship has not been established , but physicians should consider the possibility that druga may alter a diabetic patient s response to drugb or oral drugn .
DDI-DrugBank.d249.s13.p1	diclofenac	drug	_	hypoglycemic agents	group	_	effect	a direct causal relationship has not been established , but physicians should consider the possibility that druga may alter a diabetic patient s response to drugn or oral drugb .
DDI-DrugBank.d249.s13.p2	insulin	drug	_	hypoglycemic agents	group	_	false	a direct causal relationship has not been established , but physicians should consider the possibility that drugn may alter a diabetic patient s response to druga or oral drugb .
DDI-DrugBank.d249.s14.p3	Diclofenac	drug	_	NSAIDs	group	_	false	drugn : druga and other drugb can inhibit the activity of drugn .
DDI-DrugBank.d249.s14.p4	Diclofenac	drug	_	diuretics	group	_	effect	drugn : druga and other drugn can inhibit the activity of drugb .
DDI-DrugBank.d249.s14.p5	NSAIDs	group	_	diuretics	group	_	effect	drugn : drugn and other druga can inhibit the activity of drugb .
DDI-DrugBank.d249.s16.p6	azathioprine	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of druga , drugn , drugn , drugn , drugn , drugn , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p12	gold	group	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , druga , drugn , drugn , drugn , drugn , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p17	chloroquine	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , drugn , druga , drugn , drugn , drugn , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p21	D-penicillamine	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , drugn , drugn , druga , drugn , drugn , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p24	prednisolone	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , drugn , drugn , drugn , druga , drugn , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p26	doxycycline	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , drugn , drugn , drugn , drugn , druga , or drugn did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s16.p27	digitoxin	drug	_	diclofenac	drug	_	false	other drugs : in small groups of patients -lcb- 7-10 / interaction study -rcb- , the concomitant administration of drugn , drugn , drugn , drugn , drugn , drugn , or druga did not significantly affect the peak levels and auc values of drugb .
DDI-DrugBank.d249.s17.p1	Phenobarbital	drug	_	diclofenac	drug	_	false	druga toxicity has been reported to have occurred in a patient on chronic drugn treatment following the initiation of drugb therapy .
DDI-DrugBank.d249.s17.p2	phenobarbital	drug	_	diclofenac	drug	_	effect	drugn toxicity has been reported to have occurred in a patient on chronic druga treatment following the initiation of drugb therapy .
DDI-DrugBank.d249.s18.p0	diclofenac	drug	_	salicylic acid	drug	_	mechanism	protein binding in vitro , druga interferes minimally or not at all with the protein binding of drugb -lcb- 20 % decrease in binding -rcb- , drugn , drugn -lcb- 10 % decrease in binding -rcb- , or drugn .
DDI-DrugBank.d249.s18.p1	diclofenac	drug	_	tolbutamide	drug	_	mechanism	protein binding in vitro , druga interferes minimally or not at all with the protein binding of drugn -lcb- 20 % decrease in binding -rcb- , drugb , drugn -lcb- 10 % decrease in binding -rcb- , or drugn .
DDI-DrugBank.d249.s18.p2	diclofenac	drug	_	prednisolone	drug	_	mechanism	protein binding in vitro , druga interferes minimally or not at all with the protein binding of drugn -lcb- 20 % decrease in binding -rcb- , drugn , drugb -lcb- 10 % decrease in binding -rcb- , or drugn .
DDI-DrugBank.d249.s18.p3	diclofenac	drug	_	warfarin	drug	_	mechanism	protein binding in vitro , druga interferes minimally or not at all with the protein binding of drugn -lcb- 20 % decrease in binding -rcb- , drugn , drugn -lcb- 10 % decrease in binding -rcb- , or drugb .
DDI-DrugBank.d249.s19.p7	Benzylpenicillin	drug	_	diclofenac	drug	_	false	druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p14	ampicillin	drug	_	diclofenac	drug	_	false	drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p20	oxacillin	drug	_	diclofenac	drug	_	false	drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p25	chlortetracycline	drug	_	diclofenac	drug	_	false	drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p29	doxycycline	drug	_	diclofenac	drug	_	false	drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p32	cephalothin	drug	_	diclofenac	drug	_	false	drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p34	erythromycin	drug	_	diclofenac	drug	_	false	drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d249.s19.p35	sulfamethoxazole	drug	_	diclofenac	drug	_	false	drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga have no influence in vitro on the protein binding of drugb in human serum .
DDI-DrugBank.d517.s0.p0	Tetracycline	drug	_	bacteriostatic antibiotic	group	_	false	druga , a drugb , may antagonize the bactercidal effect of drugn and concurrent use of these drugs should be avoided .
DDI-DrugBank.d517.s0.p1	Tetracycline	drug	_	penicillin	drug	_	effect	druga , a drugn , may antagonize the bactercidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d517.s0.p2	bacteriostatic antibiotic	group	_	penicillin	drug	_	false	drugn , a druga , may antagonize the bactercidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d543.s0.p0	anticholinergic drugs	group	_	amantadine	drug	_	false	the following agents may increase certain actions or side effects of druga , drugb drugn of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p1	anticholinergic drugs	group	_	antiarrhythmic agents	group	_	false	the following agents may increase certain actions or side effects of druga , drugn drugb of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p2	anticholinergic drugs	group	_	quinidine	drug	_	false	the following agents may increase certain actions or side effects of druga , drugn drugn of class -lcb- e , g , drugb -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p3	anticholinergic drugs	group	_	antihistamines	group	_	false	the following agents may increase certain actions or side effects of druga , drugn drugn of class -lcb- e , g , drugn -rcb- , drugb drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p4	anticholinergic drugs	group	_	antipsychotic agents	group	_	false	the following agents may increase certain actions or side effects of druga , drugn drugn of class -lcb- e , g , drugn -rcb- , drugn drugb -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p5	anticholinergic drugs	group	_	phenothiazines	group	_	false	the following agents may increase certain actions or side effects of druga , drugn drugn of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugb -rcb- , drugn .
DDI-DrugBank.d543.s0.p6	anticholinergic drugs	group	_	benzodiazepines	group	_	false	the following agents may increase certain actions or side effects of druga , drugn drugn of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugb .
DDI-DrugBank.d543.s0.p7	amantadine	drug	_	antiarrhythmic agents	group	_	false	the following agents may increase certain actions or side effects of drugn , druga drugb of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p8	amantadine	drug	_	quinidine	drug	_	false	the following agents may increase certain actions or side effects of drugn , druga drugn of class -lcb- e , g , drugb -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p9	amantadine	drug	_	antihistamines	group	_	false	the following agents may increase certain actions or side effects of drugn , druga drugn of class -lcb- e , g , drugn -rcb- , drugb drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p10	amantadine	drug	_	antipsychotic agents	group	_	false	the following agents may increase certain actions or side effects of drugn , druga drugn of class -lcb- e , g , drugn -rcb- , drugn drugb -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p11	amantadine	drug	_	phenothiazines	group	_	false	the following agents may increase certain actions or side effects of drugn , druga drugn of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugb -rcb- , drugn .
DDI-DrugBank.d543.s0.p12	amantadine	drug	_	benzodiazepines	group	_	false	the following agents may increase certain actions or side effects of drugn , druga drugn of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugb .
DDI-DrugBank.d543.s0.p13	antiarrhythmic agents	group	_	quinidine	drug	_	false	the following agents may increase certain actions or side effects of drugn , drugn druga of class -lcb- e , g , drugb -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p14	antiarrhythmic agents	group	_	antihistamines	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn druga of class -lcb- e , g , drugn -rcb- , drugb drugn -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p15	antiarrhythmic agents	group	_	antipsychotic agents	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn druga of class -lcb- e , g , drugn -rcb- , drugn drugb -lcb- e , g , drugn -rcb- , drugn .
DDI-DrugBank.d543.s0.p16	antiarrhythmic agents	group	_	phenothiazines	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn druga of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugb -rcb- , drugn .
DDI-DrugBank.d543.s0.p17	antiarrhythmic agents	group	_	benzodiazepines	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn druga of class -lcb- e , g , drugn -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugb .
DDI-DrugBank.d543.s0.p21	quinidine	drug	_	benzodiazepines	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn drugn of class -lcb- e , g , druga -rcb- , drugn drugn -lcb- e , g , drugn -rcb- , drugb .
DDI-DrugBank.d543.s0.p24	antihistamines	group	_	benzodiazepines	group	_	false	the following agents may increase certain actions or side effects of drugn , drugn drugn of class -lcb- e , g , drugn -rcb- , druga drugn -lcb- e , g , drugn -rcb- , drugb .
DDI-DrugBank.d543.s2.p0	Anticholinergics	group	_	antiglaucoma agents	group	_	false	druga antagonize the effects of drugb .
DDI-DrugBank.d543.s4.p0	Anticholinergic agents	group	_	digoxin	drug	_	mechanism	druga may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of drugb ;
DDI-DrugBank.d543.s6.p0	Anticholinergic drugs	group	_	metoclopramide	drug	_	mechanism	druga may antagonize the effects of the drugs that alter gastrointestinal motility , such as drugb .
DDI-DrugBank.d543.s7.p0	antacids	group	_	anticholinergic agents	group	_	mechanism	because druga may interfere with the absorption of drugb , simultaneous use of these drugs should be avoided .
DDI-DrugBank.d43.s1.p0	stavudine	drug	_	VIDEX	brand	_	false	neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy , including druga , and these patients may be at increased risk of neuropathy during drugb therapy -lcb- see adverse reactions -rcb- .
DDI-DrugBank.d43.s2.p3	didanosine	drug	_	allopurinol	drug	_	false	drugn : the auc of druga was increased about 4-fold when drugb at # mg/day was coadministered with a single 200-mg dose of drugn to two patients with renal impairment -lcb- clcr = 15 and # ml/min -rcb- .
DDI-DrugBank.d43.s2.p4	didanosine	drug	_	VIDEX	brand	_	false	drugn : the auc of druga was increased about 4-fold when drugn at # mg/day was coadministered with a single 200-mg dose of drugb to two patients with renal impairment -lcb- clcr = 15 and # ml/min -rcb- .
DDI-DrugBank.d43.s2.p5	allopurinol	drug	_	VIDEX	brand	_	mechanism	drugn : the auc of drugn was increased about 4-fold when druga at # mg/day was coadministered with a single 200-mg dose of drugb to two patients with renal impairment -lcb- clcr = 15 and # ml/min -rcb- .
DDI-DrugBank.d43.s3.p0	allopurinol	drug	_	didanosine	drug	_	false	the effects of druga on drugb pharmacokinetics in subjects with normal renal function are not known .
DDI-DrugBank.d43.s4.p1	Antacids	group	_	magnesium	drug	_	false	druga : concomitant administration of drugn containing drugb or drugn with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p2	Antacids	group	_	aluminum	drug	_	false	druga : concomitant administration of drugn containing drugn or drugb with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p3	Antacids	group	_	VIDEX	brand	_	false	druga : concomitant administration of drugn containing drugn or drugn with drugb chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p5	antacids	group	_	magnesium	drug	_	false	drugn : concomitant administration of druga containing drugb or drugn with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p6	antacids	group	_	aluminum	drug	_	false	drugn : concomitant administration of druga containing drugn or drugb with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p7	antacids	group	_	VIDEX	brand	_	effect	drugn : concomitant administration of druga containing drugn or drugn with drugb chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p9	magnesium	drug	_	aluminum	drug	_	false	drugn : concomitant administration of drugn containing druga or drugb with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p10	magnesium	drug	_	VIDEX	brand	_	effect	drugn : concomitant administration of drugn containing druga or drugn with drugb chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p11	magnesium	drug	_	antacid	group	_	false	drugn : concomitant administration of drugn containing druga or drugn with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugb components .
DDI-DrugBank.d43.s4.p12	aluminum	drug	_	VIDEX	brand	_	effect	drugn : concomitant administration of drugn containing drugn or druga with drugb chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugn components .
DDI-DrugBank.d43.s4.p13	aluminum	drug	_	antacid	group	_	false	drugn : concomitant administration of drugn containing drugn or druga with drugn chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugb components .
DDI-DrugBank.d43.s4.p14	VIDEX	brand	_	antacid	group	_	false	drugn : concomitant administration of drugn containing drugn or drugn with druga chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the drugb components .
DDI-DrugBank.d43.s5.p0	ketoconazole	drug	_	itraconazole	drug	_	false	drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as druga and drugb should be administered at least # hours prior to dosing with drugn .
DDI-DrugBank.d43.s5.p1	ketoconazole	drug	_	VIDEX	brand	_	advise	drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as druga and drugn should be administered at least # hours prior to dosing with drugb .
DDI-DrugBank.d43.s5.p2	itraconazole	drug	_	VIDEX	brand	_	advise	drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as drugn and druga should be administered at least # hours prior to dosing with drugb .
DDI-DrugBank.d43.s6.p0	Ganciclovir	drug	_	VIDEX	brand	_	false	druga : administration of drugb # hours prior to or concurrent with oral drugn was associated with a # -lcb- 114 -rcb- % increase in the steady-state auc of drugn -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s6.p2	Ganciclovir	drug	_	didanosine	drug	_	false	druga : administration of drugn # hours prior to or concurrent with oral drugn was associated with a # -lcb- 114 -rcb- % increase in the steady-state auc of drugb -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s6.p3	VIDEX	brand	_	ganciclovir	drug	_	mechanism	drugn : administration of druga # hours prior to or concurrent with oral drugb was associated with a # -lcb- 114 -rcb- % increase in the steady-state auc of drugn -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s6.p4	VIDEX	brand	_	didanosine	drug	_	false	drugn : administration of druga # hours prior to or concurrent with oral drugn was associated with a # -lcb- 114 -rcb- % increase in the steady-state auc of drugb -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s6.p5	ganciclovir	drug	_	didanosine	drug	_	false	drugn : administration of drugn # hours prior to or concurrent with oral druga was associated with a # -lcb- 114 -rcb- % increase in the steady-state auc of drugb -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s7.p0	ganciclovir	drug	_	VIDEX	brand	_	false	a # -lcb- 17 -rcb- % decrease in the steady-state auc of druga was observed when drugb was administered # hours prior to drugn , but not when the two drugs were administered simultaneously -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s7.p2	VIDEX	brand	_	ganciclovir	drug	_	mechanism	a # -lcb- 17 -rcb- % decrease in the steady-state auc of drugn was observed when druga was administered # hours prior to drugb , but not when the two drugs were administered simultaneously -lcb- n = 12 -rcb- .
DDI-DrugBank.d43.s8.p7	VIDEX	brand	_	ciprofloxacin	drug	_	advise	drugn s : druga should be administered at least # hours after or # hours before dosing with drugb because plasma concentrations of drugn are decreased when administered with drugn containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s8.p8	VIDEX	brand	_	ciprofloxacin	drug	_	false	drugn s : druga should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugb are decreased when administered with drugn containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s8.p9	VIDEX	brand	_	antacids	group	_	false	drugn s : druga should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with drugb containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s8.p10	VIDEX	brand	_	magnesium	drug	_	false	drugn s : druga should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with drugn containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s8.p11	VIDEX	brand	_	calcium	drug	_	false	drugn s : druga should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with drugn containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s8.p12	VIDEX	brand	_	aluminum	drug	_	false	drugn s : druga should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with drugn containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s8.p14	ciprofloxacin	drug	_	antacids	group	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with druga because plasma concentrations of drugn are decreased when administered with drugb containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s8.p15	ciprofloxacin	drug	_	magnesium	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with druga because plasma concentrations of drugn are decreased when administered with drugn containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s8.p16	ciprofloxacin	drug	_	calcium	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with druga because plasma concentrations of drugn are decreased when administered with drugn containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s8.p17	ciprofloxacin	drug	_	aluminum	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with druga because plasma concentrations of drugn are decreased when administered with drugn containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s8.p18	ciprofloxacin	drug	_	antacids	group	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of druga are decreased when administered with drugb containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s8.p19	ciprofloxacin	drug	_	magnesium	drug	_	mechanism	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of druga are decreased when administered with drugn containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s8.p20	ciprofloxacin	drug	_	calcium	drug	_	mechanism	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of druga are decreased when administered with drugn containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s8.p21	ciprofloxacin	drug	_	aluminum	drug	_	mechanism	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of druga are decreased when administered with drugn containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s8.p22	antacids	group	_	magnesium	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with druga containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s8.p23	antacids	group	_	calcium	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with druga containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s8.p24	antacids	group	_	aluminum	drug	_	false	drugn s : drugn should be administered at least # hours after or # hours before dosing with drugn because plasma concentrations of drugn are decreased when administered with druga containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s9.p1	ciprofloxacin	drug	_	VIDEX	brand	_	false	in eight hiv-infected patients , the steady-state auc of druga was decreased an average of 26 % -lcb- 95 % ci = 14 % , 37 % -rcb- when drugn was administered # hours prior to a marketed chewable/dispersible tablet formulation of drugb .
DDI-DrugBank.d43.s9.p2	ciprofloxacin	drug	_	VIDEX	brand	_	mechanism	in eight hiv-infected patients , the steady-state auc of drugn was decreased an average of 26 % -lcb- 95 % ci = 14 % , 37 % -rcb- when druga was administered # hours prior to a marketed chewable/dispersible tablet formulation of drugb .
DDI-DrugBank.d43.s10.p1	ciprofloxacin	drug	_	didanosine	drug	_	false	the auc of druga was decreased an average of 15-fold in # healthy subjects given drugn and drugb - placebo tablets concurrently .
DDI-DrugBank.d43.s10.p2	ciprofloxacin	drug	_	didanosine	drug	_	mechanism	the auc of drugn was decreased an average of 15-fold in # healthy subjects given druga and drugb - placebo tablets concurrently .
DDI-DrugBank.d43.s11.p0	ciprofloxacin	drug	_	didanosine	drug	_	mechanism	in a single subject given one dose of druga # hours after a dose of drugb - placebo tablets , a greater than 50 % reduction in the auc of drugn was observed .
DDI-DrugBank.d43.s11.p2	didanosine	drug	_	ciprofloxacin	drug	_	false	in a single subject given one dose of drugn # hours after a dose of druga - placebo tablets , a greater than 50 % reduction in the auc of drugb was observed .
DDI-DrugBank.d43.s12.p0	quinolone antibiotics	group	_	antacids	group	_	false	plasma concentrations of druga are decreased when administered with drugb containing drugn , drugn , or drugn .
DDI-DrugBank.d43.s12.p1	quinolone antibiotics	group	_	magnesium	drug	_	mechanism	plasma concentrations of druga are decreased when administered with drugn containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s12.p2	quinolone antibiotics	group	_	calcium	drug	_	mechanism	plasma concentrations of druga are decreased when administered with drugn containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s12.p3	quinolone antibiotics	group	_	aluminum	drug	_	mechanism	plasma concentrations of druga are decreased when administered with drugn containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s12.p4	antacids	group	_	magnesium	drug	_	false	plasma concentrations of drugn are decreased when administered with druga containing drugb , drugn , or drugn .
DDI-DrugBank.d43.s12.p5	antacids	group	_	calcium	drug	_	false	plasma concentrations of drugn are decreased when administered with druga containing drugn , drugb , or drugn .
DDI-DrugBank.d43.s12.p6	antacids	group	_	aluminum	drug	_	false	plasma concentrations of drugn are decreased when administered with druga containing drugn , drugn , or drugb .
DDI-DrugBank.d43.s13.p0	VIDEX	brand	_	quinolone	group	_	false	the optimal dosing interval for coadministration with druga should be determined by consulting the appropriate drugb package insert .
DDI-DrugBank.d43.s14.p3	delavirdine	drug	_	indinavir	drug	_	false	interactions with other drugn : significant decreases in the auc of druga -lcb- 20 % -rcb- and drugb -lcb- 84 % -rcb- occurred following simultaneous administration of these agents with drugn .
DDI-DrugBank.d43.s14.p4	delavirdine	drug	_	VIDEX	brand	_	mechanism	interactions with other drugn : significant decreases in the auc of druga -lcb- 20 % -rcb- and drugn -lcb- 84 % -rcb- occurred following simultaneous administration of these agents with drugb .
DDI-DrugBank.d43.s14.p5	indinavir	drug	_	VIDEX	brand	_	mechanism	interactions with other drugn : significant decreases in the auc of drugn -lcb- 20 % -rcb- and druga -lcb- 84 % -rcb- occurred following simultaneous administration of these agents with drugb .
DDI-DrugBank.d43.s15.p0	delavirdine	drug	_	indinavir	drug	_	false	to avoid this interaction , druga or drugb should be given # hour prior to dosing with drugn .
DDI-DrugBank.d43.s15.p1	delavirdine	drug	_	VIDEX	brand	_	advise	to avoid this interaction , druga or drugn should be given # hour prior to dosing with drugb .
DDI-DrugBank.d43.s15.p2	indinavir	drug	_	VIDEX	brand	_	advise	to avoid this interaction , drugn or druga should be given # hour prior to dosing with drugb .
DDI-DrugBank.d43.s16.p0	nelfinavir	drug	_	VIDEX	brand	_	false	the pharmacokinetics of druga are not altered to a clinically significant degree when it is administered with a light meal # hour after drugb .
DDI-DrugBank.d570.s0.p0	estrogen	group	_	contraceptives	group	_	false	drug / laboratory test interactions certain endocrine and liver function tests may be affected by druga - containing oral drugb .
DDI-DrugBank.d352.s0.p0	Antidiabetic drug	group	_	insulin	drug	_	false	druga requirements -lcb- i , e , , drugb -rcb- may be altered .
DDI-DrugBank.d352.s3.p0	diethylpropion	drug	_	antihypertensive drugs	group	_	int	conversely , druga may interfere with drugb -lcb- i , e , , drugn , drugn -rcb- .
DDI-DrugBank.d352.s3.p1	diethylpropion	drug	_	guanethidine	drug	_	int	conversely , druga may interfere with drugn -lcb- i , e , , drugb , drugn -rcb- .
DDI-DrugBank.d352.s3.p2	diethylpropion	drug	_	a-methyldopa	drug	_	int	conversely , druga may interfere with drugn -lcb- i , e , , drugn , drugb -rcb- .
DDI-DrugBank.d352.s4.p0	phenothiazines	group	_	diethylpropion	drug	_	effect	concurrent use of druga may antagonize the anorectic effect of drugb .
DDI-DrugBank.d248.s0.p2	anticoagulants	group	_	diethylstilbestrol	drug	_	false	may interact druga -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugb -rcb- , drugn -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p3	anticoagulants	group	_	corticosteroids	group	_	false	may interact druga -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugb -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p4	anticoagulants	group	_	corticosteroids	group	_	false	may interact druga -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugn -lcb- increased effect of drugb -rcb- .
DDI-DrugBank.d248.s0.p6	barbiturates	group	_	diethylstilbestrol	drug	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , druga , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugb -rcb- , drugn -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p7	barbiturates	group	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , druga , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugb -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p8	barbiturates	group	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , druga , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugn -lcb- increased effect of drugb -rcb- .
DDI-DrugBank.d248.s0.p9	rifampin	drug	_	diethylstilbestrol	drug	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , druga and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugb -rcb- , drugn -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p10	rifampin	drug	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , druga and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugb -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p11	rifampin	drug	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , druga and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of drugn -rcb- , drugn -lcb- increased effect of drugb -rcb- .
DDI-DrugBank.d248.s0.p12	diethylstilbestrol	drug	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of druga -rcb- , drugb -lcb- increased effect of drugn -rcb- .
DDI-DrugBank.d248.s0.p13	diethylstilbestrol	drug	_	corticosteroids	group	_	false	may interact drugn -lcb- altered hypo-prothrombinemic effect -rcb- , drugn , drugn and other inducers of hepatic microsomal enzyme oxidation system -lcb- decreased effect of druga -rcb- , drugn -lcb- increased effect of drugb -rcb- .
DDI-DrugBank.d132.s0.p0	Anticoagulants	group	_	diflunisal	drug	_	false	oral druga : in some normal volunteers , the concomitant administration of drugb and drugn , drugn , or drugn resulted in prolongation of prothrombin time .
DDI-DrugBank.d132.s0.p1	Anticoagulants	group	_	warfarin	drug	_	false	oral druga : in some normal volunteers , the concomitant administration of drugn and drugb , drugn , or drugn resulted in prolongation of prothrombin time .
DDI-DrugBank.d132.s0.p2	Anticoagulants	group	_	acenocoumarol	drug	_	false	oral druga : in some normal volunteers , the concomitant administration of drugn and drugn , drugb , or drugn resulted in prolongation of prothrombin time .
DDI-DrugBank.d132.s0.p3	Anticoagulants	group	_	phenprocoumon	drug	_	false	oral druga : in some normal volunteers , the concomitant administration of drugn and drugn , drugn , or drugb resulted in prolongation of prothrombin time .
DDI-DrugBank.d132.s1.p0	diflunisal	drug	_	coumarins	group	_	mechanism	this may occur because druga competitively displaces drugb from protein binding sites .
DDI-DrugBank.d132.s2.p0	diflunisal	drug	_	anticoagulants	group	_	advise	accordingly , when druga is administered with oral drugb , the prothrombin time should be closely monitored during and for several days after concomitant drug administration .
DDI-DrugBank.d132.s4.p3	diflunisal	drug	_	tolbutamide	drug	_	false	drugn : in diabetic patients receiving druga and drugb , no significant effects were seen on drugn plasma levels or fasting blood glucose .
DDI-DrugBank.d132.s4.p4	diflunisal	drug	_	tolbutamide	drug	_	false	drugn : in diabetic patients receiving druga and drugn , no significant effects were seen on drugb plasma levels or fasting blood glucose .
DDI-DrugBank.d132.s5.p0	Hydrochlorothiazide	drug	_	diflunisal	drug	_	false	druga : in normal volunteers , concomitant administration of drugb and drugn resulted in significantly increased plasma levels of drugn .
DDI-DrugBank.d132.s5.p3	diflunisal	drug	_	hydrochlorothiazide	drug	_	mechanism	drugn : in normal volunteers , concomitant administration of druga and drugb resulted in significantly increased plasma levels of drugn .
DDI-DrugBank.d132.s5.p4	diflunisal	drug	_	hydrochlorothiazide	drug	_	false	drugn : in normal volunteers , concomitant administration of druga and drugn resulted in significantly increased plasma levels of drugb .
DDI-DrugBank.d132.s6.p0	Diflunisal	drug	_	hydrochlorothiazide	drug	_	effect	druga decreased the hyperuricemic effect of drugb .
DDI-DrugBank.d132.s7.p0	Furosemide	drug	_	diflunisal	drug	_	false	druga : in normal volunteers , the concomitant administration of drugb and drugn had no effect on the diuretic activity of drugn .
DDI-DrugBank.d132.s7.p3	diflunisal	drug	_	furosemide	drug	_	false	drugn : in normal volunteers , the concomitant administration of druga and drugb had no effect on the diuretic activity of drugn .
DDI-DrugBank.d132.s7.p4	diflunisal	drug	_	furosemide	drug	_	false	drugn : in normal volunteers , the concomitant administration of druga and drugn had no effect on the diuretic activity of drugb .
DDI-DrugBank.d132.s8.p0	Diflunisal	drug	_	furosemide	drug	_	effect	druga decreased the hyperuricemic effect of drugb .
DDI-DrugBank.d132.s9.p1	Antacids	group	_	diflunisal	drug	_	false	druga : concomitant administration of drugn may reduce plasma levels of drugb .
DDI-DrugBank.d132.s9.p2	antacids	group	_	diflunisal	drug	_	mechanism	drugn : concomitant administration of druga may reduce plasma levels of drugb .
DDI-DrugBank.d132.s11.p0	Acetaminophen	drug	_	diflunisal	drug	_	false	druga : in normal volunteers , concomitant administration of drugb and drugn resulted in an approximate 50 % increase in plasma levels of drugn .
DDI-DrugBank.d132.s11.p3	diflunisal	drug	_	acetaminophen	drug	_	mechanism	drugn : in normal volunteers , concomitant administration of druga and drugb resulted in an approximate 50 % increase in plasma levels of drugn .
DDI-DrugBank.d132.s11.p4	diflunisal	drug	_	acetaminophen	drug	_	false	drugn : in normal volunteers , concomitant administration of druga and drugn resulted in an approximate 50 % increase in plasma levels of drugb .
DDI-DrugBank.d132.s12.p0	Acetaminophen	drug	_	diflunisal	drug	_	false	druga had no effect on plasma levels of drugb .
DDI-DrugBank.d132.s13.p0	acetaminophen	drug	_	diflunisal	drug	_	false	since druga in high doses has been associated with hepatotoxicity , concomitant administration of drugb and drugn should be used cautiously , with careful monitoring of patients .
DDI-DrugBank.d132.s13.p2	diflunisal	drug	_	acetaminophen	drug	_	advise	since drugn in high doses has been associated with hepatotoxicity , concomitant administration of druga and drugb should be used cautiously , with careful monitoring of patients .
DDI-DrugBank.d132.s14.p0	diflunisal	drug	_	acetaminophen	drug	_	effect	concomitant administration of druga and drugb in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each -lcb- 40 to # mg/kg/day of drugn / drugn -rcb- resulted in greater gastrointestinal toxicity than when either drug was administered alone .
DDI-DrugBank.d132.s14.p2	diflunisal	drug	_	acetaminophen	drug	_	false	concomitant administration of druga and drugn in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each -lcb- 40 to # mg/kg/day of drugn / drugb -rcb- resulted in greater gastrointestinal toxicity than when either drug was administered alone .
DDI-DrugBank.d132.s14.p3	acetaminophen	drug	_	diflunisal	drug	_	false	concomitant administration of drugn and druga in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each -lcb- 40 to # mg/kg/day of drugb / drugn -rcb- resulted in greater gastrointestinal toxicity than when either drug was administered alone .
DDI-DrugBank.d132.s16.p0	Methotrexate	drug	_	diflunisal	drug	_	false	druga : caution should be used if drugb is administered concomitantly with drugn .
DDI-DrugBank.d132.s16.p2	diflunisal	drug	_	methotrexate	drug	_	advise	drugn : caution should be used if druga is administered concomitantly with drugb .
DDI-DrugBank.d132.s17.p0	Nonsteroidal anti-inflammatory drugs	group	_	methotrexate	drug	_	mechanism	druga have been reported to decrease the tubular secretion of drugb and to potentiate its toxicity .
DDI-DrugBank.d132.s18.p0	Cyclosporine	drug	_	nonsteroial anti-inflammatory drugs	group	_	false	druga : administration of drugb concomitantly with drugn has been associated with an increase in drugn - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .
DDI-DrugBank.d132.s18.p3	nonsteroial anti-inflammatory drugs	group	_	cyclosporine	drug	_	mechanism	drugn : administration of druga concomitantly with drugb has been associated with an increase in drugn - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .
DDI-DrugBank.d132.s18.p4	nonsteroial anti-inflammatory drugs	group	_	cyclosporine	drug	_	false	drugn : administration of druga concomitantly with drugn has been associated with an increase in drugb - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .
DDI-DrugBank.d132.s19.p0	NSAIDs	group	_	cyclosporine	drug	_	advise	druga should be used with caution in patients taking drugb , and renal function should be carefully monitored .
DDI-DrugBank.d132.s20.p3	diflunisal	drug	_	indomethacin	drug	_	mechanism	drugn : the administration of druga to normal volunteers receiving drugb decreased the renal clearance and significantly increased the plasma levels of drugn .
DDI-DrugBank.d132.s20.p4	diflunisal	drug	_	indomethacin	drug	_	false	drugn : the administration of druga to normal volunteers receiving drugn decreased the renal clearance and significantly increased the plasma levels of drugb .
DDI-DrugBank.d132.s21.p0	indomethacin	drug	_	diflunisal	drug	_	effect	in some patients the combined use of druga and drugb has been associated with fatal gastrointestinal hemorrhage .
DDI-DrugBank.d132.s22.p0	indomethacin	drug	_	diflunisal	drug	_	advise	therefore , druga and drugb should not be used concomitantly .
DDI-DrugBank.d132.s23.p0	diflunisal	drug	_	NSAIDs	group	_	effect	the concomitant use of druga tablets and other drugb is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .
DDI-DrugBank.d132.s25.p0	Aspirin	brand	_	diflunisal	drug	_	false	druga : in normal volunteers , a small decrease in drugb levels was observed when multiple doses of drugn and drugn were administered concomitantly .
DDI-DrugBank.d132.s25.p1	Aspirin	brand	_	diflunisal	drug	_	false	druga : in normal volunteers , a small decrease in drugn levels was observed when multiple doses of drugb and drugn were administered concomitantly .
DDI-DrugBank.d132.s25.p4	diflunisal	drug	_	aspirin	brand	_	false	drugn : in normal volunteers , a small decrease in druga levels was observed when multiple doses of drugn and drugb were administered concomitantly .
DDI-DrugBank.d132.s25.p5	diflunisal	drug	_	aspirin	brand	_	mechanism	drugn : in normal volunteers , a small decrease in drugn levels was observed when multiple doses of druga and drugb were administered concomitantly .
DDI-DrugBank.d132.s26.p2	diflunisal	drug	_	sulindac	drug	_	mechanism	drugn : the concomitant administration of druga and drugb in normal volunteers resulted in lowering of the plasma levels of the active sulindac_sulfide metabolite by approximately one-third .
DDI-DrugBank.d132.s27.p4	diflunisal	drug	_	naproxen	drug	_	mechanism	drugn : the concomitant administration of druga and drugb in normal volunteers had no effect on the plasma levels of drugn , but significantly decreased the urinary excretion of drugn and its glucuronide metabolite .
DDI-DrugBank.d132.s27.p5	diflunisal	drug	_	naproxen	drug	_	false	drugn : the concomitant administration of druga and drugn in normal volunteers had no effect on the plasma levels of drugb , but significantly decreased the urinary excretion of drugn and its glucuronide metabolite .
DDI-DrugBank.d132.s27.p6	diflunisal	drug	_	naproxen	drug	_	false	drugn : the concomitant administration of druga and drugn in normal volunteers had no effect on the plasma levels of drugn , but significantly decreased the urinary excretion of drugb and its glucuronide metabolite .
DDI-DrugBank.d132.s28.p0	Naproxen	drug	_	diflunisal	drug	_	false	druga had no effect on plasma levels of drugb .
DDI-DrugBank.d450.s0.p0	Potassium-depleting diuretics	group	_	digitalis	group	_	effect	druga are a major contributing factor to drugb toxicity .
DDI-DrugBank.d450.s2.p7	Quinidine	drug	_	digoxin	drug	_	mechanism	druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p8	Quinidine	drug	_	digitalis	group	_	false	druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p15	verapamil	drug	_	digoxin	drug	_	mechanism	drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p16	verapamil	drug	_	digitalis	group	_	false	drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p22	amiodarone	drug	_	digoxin	drug	_	mechanism	drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p23	amiodarone	drug	_	digitalis	group	_	false	drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p28	propafenone	drug	_	digoxin	drug	_	mechanism	drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p29	propafenone	drug	_	digitalis	group	_	false	drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p33	indomethacin	drug	_	digoxin	drug	_	mechanism	drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p34	indomethacin	drug	_	digitalis	group	_	false	drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p37	itraconazole	drug	_	digoxin	drug	_	mechanism	drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p38	itraconazole	drug	_	digitalis	group	_	false	drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p40	alprazolam	drug	_	digoxin	drug	_	mechanism	drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p41	alprazolam	drug	_	digitalis	group	_	false	drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p42	spironolactone	drug	_	digoxin	drug	_	mechanism	drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga raise the serum drugb concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugn intoxication may result .
DDI-DrugBank.d450.s2.p43	spironolactone	drug	_	digitalis	group	_	false	drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga raise the serum drugn concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s2.p44	digoxin	drug	_	digitalis	group	_	false	drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn raise the serum druga concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drugb intoxication may result .
DDI-DrugBank.d450.s3.p3	Erythromycin	drug	_	digoxin	drug	_	mechanism	druga and drugn -lcb- and possibly other drugn -rcb- and drugn may increase drugb absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p4	Erythromycin	drug	_	digoxin	drug	_	false	druga and drugn -lcb- and possibly other drugn -rcb- and drugn may increase drugn absorption in patients who inactivate drugb by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p5	Erythromycin	drug	_	digitalis	group	_	false	druga and drugn -lcb- and possibly other drugn -rcb- and drugn may increase drugn absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s3.p8	clarithromycin	drug	_	digoxin	drug	_	mechanism	drugn and druga -lcb- and possibly other drugn -rcb- and drugn may increase drugb absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p9	clarithromycin	drug	_	digoxin	drug	_	false	drugn and druga -lcb- and possibly other drugn -rcb- and drugn may increase drugn absorption in patients who inactivate drugb by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p10	clarithromycin	drug	_	digitalis	group	_	false	drugn and druga -lcb- and possibly other drugn -rcb- and drugn may increase drugn absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s3.p12	macrolide antibiotics	group	_	digoxin	drug	_	mechanism	drugn and drugn -lcb- and possibly other druga -rcb- and drugn may increase drugb absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p13	macrolide antibiotics	group	_	digoxin	drug	_	false	drugn and drugn -lcb- and possibly other druga -rcb- and drugn may increase drugn absorption in patients who inactivate drugb by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p14	macrolide antibiotics	group	_	digitalis	group	_	false	drugn and drugn -lcb- and possibly other druga -rcb- and drugn may increase drugn absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s3.p15	tetracycline	drug	_	digoxin	drug	_	mechanism	drugn and drugn -lcb- and possibly other drugn -rcb- and druga may increase drugb absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p16	tetracycline	drug	_	digoxin	drug	_	false	drugn and drugn -lcb- and possibly other drugn -rcb- and druga may increase drugn absorption in patients who inactivate drugb by bacterial metabolism in the lower intestine , so that drugn intoxication may result .
DDI-DrugBank.d450.s3.p17	tetracycline	drug	_	digitalis	group	_	false	drugn and drugn -lcb- and possibly other drugn -rcb- and druga may increase drugn absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s3.p19	digoxin	drug	_	digitalis	group	_	false	drugn and drugn -lcb- and possibly other drugn -rcb- and drugn may increase druga absorption in patients who inactivate drugn by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s3.p20	digoxin	drug	_	digitalis	group	_	false	drugn and drugn -lcb- and possibly other drugn -rcb- and drugn may increase drugn absorption in patients who inactivate druga by bacterial metabolism in the lower intestine , so that drugb intoxication may result .
DDI-DrugBank.d450.s5.p0	Propantheline	drug	_	diphenoxylate	drug	_	false	druga and drugb , by decreasing gut motility , may increase drugn absorption .
DDI-DrugBank.d450.s5.p1	Propantheline	drug	_	digoxin	drug	_	mechanism	druga and drugn , by decreasing gut motility , may increase drugb absorption .
DDI-DrugBank.d450.s5.p2	diphenoxylate	drug	_	digoxin	drug	_	mechanism	drugn and druga , by decreasing gut motility , may increase drugb absorption .
DDI-DrugBank.d450.s6.p0	Antacids	group	_	kaolin	drug	_	false	druga , drugb - pectin , drugn , drugn , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p4	Antacids	group	_	metoclopramide	drug	_	false	druga , drugn - pectin , drugn , drugn , drugn , certain anticancer drugs , and drugb may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p5	Antacids	group	_	digoxin	drug	_	mechanism	druga , drugn - pectin , drugn , drugn , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p6	kaolin	drug	_	sulfasalazine	drug	_	false	drugn , druga - pectin , drugb , drugn , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p7	kaolin	drug	_	neomycin	drug	_	false	drugn , druga - pectin , drugn , drugb , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p8	kaolin	drug	_	cholestyramine	drug	_	false	drugn , druga - pectin , drugn , drugn , drugb , certain anticancer drugs , and drugn may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p9	kaolin	drug	_	metoclopramide	drug	_	false	drugn , druga - pectin , drugn , drugn , drugn , certain anticancer drugs , and drugb may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p10	kaolin	drug	_	digoxin	drug	_	mechanism	drugn , druga - pectin , drugn , drugn , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p13	sulfasalazine	drug	_	metoclopramide	drug	_	false	drugn , drugn - pectin , druga , drugn , drugn , certain anticancer drugs , and drugb may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p14	sulfasalazine	drug	_	digoxin	drug	_	mechanism	drugn , drugn - pectin , druga , drugn , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p16	neomycin	drug	_	metoclopramide	drug	_	false	drugn , drugn - pectin , drugn , druga , drugn , certain anticancer drugs , and drugb may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p17	neomycin	drug	_	digoxin	drug	_	mechanism	drugn , drugn - pectin , drugn , druga , drugn , certain anticancer drugs , and drugn may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p18	cholestyramine	drug	_	metoclopramide	drug	_	false	drugn , drugn - pectin , drugn , drugn , druga , certain anticancer drugs , and drugb may interfere with intestinal drugn absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p19	cholestyramine	drug	_	digoxin	drug	_	mechanism	drugn , drugn - pectin , drugn , drugn , druga , certain anticancer drugs , and drugn may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s6.p20	metoclopramide	drug	_	digoxin	drug	_	mechanism	drugn , drugn - pectin , drugn , drugn , drugn , certain anticancer drugs , and druga may interfere with intestinal drugb absorption , resulting in unexpectedly low serum concentrations .
DDI-DrugBank.d450.s7.p0	Rifampin	drug	_	digoxin	drug	_	mechanism	druga may decrease serum drugb concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of drugn .
DDI-DrugBank.d450.s7.p1	Rifampin	drug	_	digoxin	drug	_	false	druga may decrease serum drugn concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of drugb .
DDI-DrugBank.d450.s8.p1	quinine	drug	_	digoxin	drug	_	false	there have been inconsistent reports regarding the effects of other drugs -lcb- e , g , , druga , drugn -rcb- on serum drugb concentration .
DDI-DrugBank.d450.s8.p2	penicillamine	drug	_	digoxin	drug	_	false	there have been inconsistent reports regarding the effects of other drugs -lcb- e , g , , drugn , druga -rcb- on serum drugb concentration .
DDI-DrugBank.d450.s9.p0	Thyroid	group	_	digoxin	drug	_	advise	druga administration to a digitalized , hypothyroid patient may increase the dose requirement of drugb .
DDI-DrugBank.d450.s10.p0	digoxin	drug	_	sympathomimetics	group	_	effect	concomitant use of druga and drugb increases the risk of cardiac arrhythmias .
DDI-DrugBank.d410.s0.p0	Vasoconstrictors	group	_	D.H.E. 45	brand	_	false	druga : drugb -lcb- drugn -rcb- injection , usp should not be used with drugn because the combination may cause synergistic elevation of blood pressure .
DDI-DrugBank.d410.s0.p1	Vasoconstrictors	group	_	dihydroergotamine mesylate	drug	_	false	druga : drugn -lcb- drugb -rcb- injection , usp should not be used with drugn because the combination may cause synergistic elevation of blood pressure .
DDI-DrugBank.d410.s0.p4	D.H.E. 45	brand	_	peripheral vasoconstrictors	group	_	effect	drugn : druga -lcb- drugn -rcb- injection , usp should not be used with drugb because the combination may cause synergistic elevation of blood pressure .
DDI-DrugBank.d410.s0.p5	dihydroergotamine mesylate	drug	_	peripheral vasoconstrictors	group	_	effect	drugn : drugn -lcb- druga -rcb- injection , usp should not be used with drugb because the combination may cause synergistic elevation of blood pressure .
DDI-DrugBank.d410.s1.p3	Sumatriptan	drug	_	D.H.E. 45	brand	_	effect	drugn : druga has been reported to cause coronary artery vasospasm , and its effect could be additive with drugb -lcb- drugn -rcb- injection , usp .
DDI-DrugBank.d410.s1.p4	Sumatriptan	drug	_	dihydroergotamine mesylate	drug	_	effect	drugn : druga has been reported to cause coronary artery vasospasm , and its effect could be additive with drugn -lcb- drugb -rcb- injection , usp .
DDI-DrugBank.d410.s2.p0	Sumatriptan	drug	_	D.H.E. 45	brand	_	advise	druga and drugb -lcb- drugn -rcb- injection , usp should not be taken within # hours of each other , .
DDI-DrugBank.d410.s2.p1	Sumatriptan	drug	_	dihydroergotamine mesylate	drug	_	advise	druga and drugn -lcb- drugb -rcb- injection , usp should not be taken within # hours of each other , .
DDI-DrugBank.d410.s3.p6	D.H.E. 45	brand	_	propranolol	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of druga -lcb- drugn -rcb- injection , usp to subjects already receiving drugb , there have been reports that drugn may potentiate the vasoconstrictive action of drugn by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p7	D.H.E. 45	brand	_	propranolol	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of druga -lcb- drugn -rcb- injection , usp to subjects already receiving drugn , there have been reports that drugb may potentiate the vasoconstrictive action of drugn by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p8	D.H.E. 45	brand	_	ergotamine	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of druga -lcb- drugn -rcb- injection , usp to subjects already receiving drugn , there have been reports that drugn may potentiate the vasoconstrictive action of drugb by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p9	dihydroergotamine mesylate	drug	_	propranolol	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of drugn -lcb- druga -rcb- injection , usp to subjects already receiving drugb , there have been reports that drugn may potentiate the vasoconstrictive action of drugn by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p10	dihydroergotamine mesylate	drug	_	propranolol	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of drugn -lcb- druga -rcb- injection , usp to subjects already receiving drugn , there have been reports that drugb may potentiate the vasoconstrictive action of drugn by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p13	propranolol	drug	_	ergotamine	drug	_	false	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of drugn -lcb- drugn -rcb- injection , usp to subjects already receiving druga , there have been reports that drugn may potentiate the vasoconstrictive action of drugb by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s3.p14	propranolol	drug	_	ergotamine	drug	_	effect	drugn : although the results of a clinical study did not indicate a safe problem associated with the administration of drugn -lcb- drugn -rcb- injection , usp to subjects already receiving drugn , there have been reports that druga may potentiate the vasoconstrictive action of drugb by blocking the vasodilating property of epinephrine .
DDI-DrugBank.d410.s4.p2	Nicotine	drug	_	ergot	drug	_	effect	drugn : druga may provoke vasoconstriction in some patients , predisposing to a greater ischemic response to drugb therapy .
DDI-DrugBank.d410.s5.p0	Macrolide Antibiotics	group	_	erythromycin	drug	_	false	druga -lcb- e , g , drugb and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p1	Macrolide Antibiotics	group	_	troleandomycin	drug	_	false	druga -lcb- e , g , drugn and drugb -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p2	Macrolide Antibiotics	group	_	ergot alkaloid class	group	_	false	druga -lcb- e , g , drugn and drugn -rcb- : agents of the drugb , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p3	Macrolide Antibiotics	group	_	D.H.E. 45	brand	_	false	druga -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugb -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p4	Macrolide Antibiotics	group	_	dihydroergotamine mesylate	drug	_	false	druga -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugb -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p6	Macrolide Antibiotics	group	_	macrolide class	group	_	false	druga -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p7	erythromycin	drug	_	troleandomycin	drug	_	false	drugn -lcb- e , g , druga and drugb -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p8	erythromycin	drug	_	ergot alkaloid class	group	_	false	drugn -lcb- e , g , druga and drugn -rcb- : agents of the drugb , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p9	erythromycin	drug	_	D.H.E. 45	brand	_	false	drugn -lcb- e , g , druga and drugn -rcb- : agents of the drugn , of which drugb -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p10	erythromycin	drug	_	dihydroergotamine mesylate	drug	_	false	drugn -lcb- e , g , druga and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugb -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p11	erythromycin	drug	_	antibiotics	group	_	false	drugn -lcb- e , g , druga and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugb of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p12	erythromycin	drug	_	macrolide class	group	_	false	drugn -lcb- e , g , druga and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p13	troleandomycin	drug	_	ergot alkaloid class	group	_	false	drugn -lcb- e , g , drugn and druga -rcb- : agents of the drugb , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p14	troleandomycin	drug	_	D.H.E. 45	brand	_	false	drugn -lcb- e , g , drugn and druga -rcb- : agents of the drugn , of which drugb -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p15	troleandomycin	drug	_	dihydroergotamine mesylate	drug	_	false	drugn -lcb- e , g , drugn and druga -rcb- : agents of the drugn , of which drugn -lcb- drugb -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p16	troleandomycin	drug	_	antibiotics	group	_	false	drugn -lcb- e , g , drugn and druga -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugb of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p17	troleandomycin	drug	_	macrolide class	group	_	false	drugn -lcb- e , g , drugn and druga -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p18	ergot alkaloid class	group	_	D.H.E. 45	brand	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the druga , of which drugb -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p19	ergot alkaloid class	group	_	dihydroergotamine mesylate	drug	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the druga , of which drugn -lcb- drugb -rcb- injection , usp is a member , have been shown to interact with drugn of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p20	ergot alkaloid class	group	_	antibiotics	group	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the druga , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugb of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p21	ergot alkaloid class	group	_	macrolide class	group	_	mechanism	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the druga , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p23	D.H.E. 45	brand	_	antibiotics	group	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which druga -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugb of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p24	D.H.E. 45	brand	_	macrolide class	group	_	mechanism	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which druga -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p25	dihydroergotamine mesylate	drug	_	antibiotics	group	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugn -lcb- druga -rcb- injection , usp is a member , have been shown to interact with drugb of the drugn , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p26	dihydroergotamine mesylate	drug	_	macrolide class	group	_	mechanism	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugn -lcb- druga -rcb- injection , usp is a member , have been shown to interact with drugn of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s5.p27	antibiotics	group	_	macrolide class	group	_	false	drugn -lcb- e , g , drugn and drugn -rcb- : agents of the drugn , of which drugn -lcb- drugn -rcb- injection , usp is a member , have been shown to interact with druga of the drugb , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .
DDI-DrugBank.d410.s6.p0	ergotamine	drug	_	antibiotics	group	_	effect	vasospastic reactions have been reported with therapeutic doses of druga - containing drugs when co-administered with these drugb .
DDI-DrugBank.d410.s7.p0	SSRIs	group	_	5-HT1 agonists	group	_	false	druga : weakness hyperreflexia , and incoordination have been reported rarely when drugb have been co-administered with drugn -lcb- e , g.
DDI-DrugBank.d410.s7.p2	5-HT1 agonists	group	_	SSRIs	group	_	effect	drugn : weakness hyperreflexia , and incoordination have been reported rarely when druga have been co-administered with drugb -lcb- e , g.
DDI-DrugBank.d410.s8.p2	fluoxetine	drug	_	sertraline	drug	_	false	druga , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d410.s8.p4	fluvoxamine	drug	_	sertraline	drug	_	false	drugn , druga , drugn , drugb -rcb- .
DDI-DrugBank.d410.s8.p5	paroxetine	drug	_	sertraline	drug	_	false	drugn , drugn , druga , drugb -rcb- .
DDI-DrugBank.d410.s9.p0	SSRIs	group	_	D.H.E. 45	brand	_	false	there have been no reported cases from spontaneous reports of drug interaction between druga and drugb -lcb- drugn -rcb- injection , usp .
DDI-DrugBank.d410.s9.p1	SSRIs	group	_	dihydroergotamine mesylate	drug	_	false	there have been no reported cases from spontaneous reports of drug interaction between druga and drugn -lcb- drugb -rcb- injection , usp .
DDI-DrugBank.d410.s10.p3	contraceptives	group	_	D.H.E. 45	brand	_	false	oral drugn : the effect of oral druga on the pharmacokinetics of drugb -lcb- drugn -rcb- injection , usp has not been studied .
DDI-DrugBank.d410.s10.p4	contraceptives	group	_	dihydroergotamine mesylate	drug	_	false	oral drugn : the effect of oral druga on the pharmacokinetics of drugn -lcb- drugb -rcb- injection , usp has not been studied .
DDI-DrugBank.d452.s0.p0	thiazide diuretics	group	_	dihydrotachysterol	drug	_	effect	administration of druga to hypoparathyroid patients who are concurrently being treated with drugb may cause hypercalcemia .
DDI-DrugBank.d565.s1.p0	beta-blockers	group	_	digitalis	group	_	false	pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using druga or drugb concomitantly with drugn .
DDI-DrugBank.d565.s1.p1	beta-blockers	group	_	Tiazac	brand	_	effect	pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using druga or drugn concomitantly with drugb .
DDI-DrugBank.d565.s1.p2	digitalis	group	_	Tiazac	brand	_	effect	pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using drugn or druga concomitantly with drugb .
DDI-DrugBank.d565.s7.p0	diltiazem hydrochloride	drug	_	beta-blockers	group	_	false	controlled and uncontrolled domestic studies suggest that concomitant use of druga and drugb is usually well tolerated , but available data are not sufficient to predict the effects of concomitant treatment in patients with left_ventricular_dysfunctions or cardiac conduction abnormalities .
DDI-DrugBank.d565.s8.p0	diltiazem hydrochloride	drug	_	propranolol	drug	_	mechanism	administration of druga concomitantly with drugb in five normal volunteers resulted in increased drugn levels in all subjects and bioavailability of drugn was increased approximately 50 % .
DDI-DrugBank.d565.s8.p1	diltiazem hydrochloride	drug	_	propranolol	drug	_	false	administration of druga concomitantly with drugn in five normal volunteers resulted in increased drugb levels in all subjects and bioavailability of drugn was increased approximately 50 % .
DDI-DrugBank.d565.s8.p2	diltiazem hydrochloride	drug	_	propranolol	drug	_	false	administration of druga concomitantly with drugn in five normal volunteers resulted in increased drugn levels in all subjects and bioavailability of drugb was increased approximately 50 % .
DDI-DrugBank.d565.s9.p0	propranolol	drug	_	diltiazem	drug	_	mechanism	in vitro , druga appears to be displaced from its binding sites by drugb .
DDI-DrugBank.d565.s12.p0	diltiazem	drug	_	cimetidine	drug	_	false	a study in six healthy volunteers has shown a significant increase in peak druga plasma levels -lcb- 58 % -rcb- and auc -lcb- 53 % -rcb- after a 1-week course of drugb # mg/day and a single dose of drugn 60mg .
DDI-DrugBank.d565.s12.p2	cimetidine	drug	_	diltiazem	drug	_	mechanism	a study in six healthy volunteers has shown a significant increase in peak drugn plasma levels -lcb- 58 % -rcb- and auc -lcb- 53 % -rcb- after a 1-week course of druga # mg/day and a single dose of drugb 60mg .
DDI-DrugBank.d565.s14.p0	cimetidine	drug	_	diltiazem	drug	_	mechanism	the effect may be mediated by druga s known inhibition of hepatic cytochrome p-450 , the enzyme system responsible for the first-pass metabolism of drugb .
DDI-DrugBank.d565.s15.p0	diltiazem	drug	_	cimetidine	drug	_	advise	patients currently receiving druga therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with drugb .
DDI-DrugBank.d565.s18.p0	diltiazem hydrochloride	drug	_	digoxin	drug	_	mechanism	administration of druga with drugb in # healthy male subjects increased plasma drugn concentrations approximately 20 % .
DDI-DrugBank.d565.s18.p1	diltiazem hydrochloride	drug	_	digoxin	drug	_	false	administration of druga with drugn in # healthy male subjects increased plasma drugb concentrations approximately 20 % .
DDI-DrugBank.d565.s20.p1	digoxin	drug	_	diltiazem hydrochloride	drug	_	false	since there have been conflicting results regarding the effect of druga levels , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugb therapy to avoid possible over - or under-digitalization .
DDI-DrugBank.d565.s20.p2	digoxin	drug	_	diltiazem hydrochloride	drug	_	advise	since there have been conflicting results regarding the effect of drugn levels , it is recommended that druga levels be monitored when initiating , adjusting , and discontinuing drugb therapy to avoid possible over - or under-digitalization .
DDI-DrugBank.d565.s22.p0	anesthetics	group	_	calcium channel blockers	group	_	effect	the depression of cardiac contractility , conductivity , and automaticity as well as the vascular dilation associated with druga may be potentiated by drugb .
DDI-DrugBank.d565.s23.p0	anesthetics	group	_	calcium channel blockers	group	_	advise	when used concomitantly , druga and drugb should be titrated carefully .
DDI-DrugBank.d565.s25.p0	diltiazem	drug	_	cyclosporine	drug	_	int	a pharmacokinetic interaction between druga and drugb has been observed during studies involving renal and cardiac transplant patients .
DDI-DrugBank.d565.s26.p1	cyclosporine	drug	_	diltiazem	drug	_	mechanism	in renal and cardiac transplant recipients , a reduction of druga dose ranging from 15 % to 48 % was necessary to maintain drugn trough concentrations similar to those seen prior to the addition of drugb .
DDI-DrugBank.d565.s26.p2	cyclosporine	drug	_	diltiazem	drug	_	false	in renal and cardiac transplant recipients , a reduction of drugn dose ranging from 15 % to 48 % was necessary to maintain druga trough concentrations similar to those seen prior to the addition of drugb .
DDI-DrugBank.d565.s27.p0	cyclosporine	drug	_	diltiazem	drug	_	advise	if these agents are to be administered concurrently , druga concentrations should be monitored , especially when drugb therapy is initiated , adjusted , or discontinued .
DDI-DrugBank.d565.s28.p0	cyclosporine	drug	_	diltiazem	drug	_	false	the effect of druga on drugb plasma concentrations has not been evaluated .
DDI-DrugBank.d565.s30.p0	diltiazem	drug	_	carbamazepine	drug	_	mechanism	concomitant administration of druga with drugb has been reported to result in elevated serum levels of drugn -lcb- 40 % to 72 % increase -rcb- , resulting in toxicity in some cases .
DDI-DrugBank.d565.s30.p1	diltiazem	drug	_	carbamazepine	drug	_	false	concomitant administration of druga with drugn has been reported to result in elevated serum levels of drugb -lcb- 40 % to 72 % increase -rcb- , resulting in toxicity in some cases .
DDI-DrugBank.d565.s33.p0	diltiazem	drug	_	midazolam	drug	_	mechanism	studies showed that druga increased the auc of drugb and drugn by 3-4 fold and the cmax by 2-fold , compared to placebo .
DDI-DrugBank.d565.s33.p1	diltiazem	drug	_	triazolam	drug	_	mechanism	studies showed that druga increased the auc of drugn and drugb by 3-4 fold and the cmax by 2-fold , compared to placebo .
DDI-DrugBank.d565.s33.p2	midazolam	drug	_	triazolam	drug	_	false	studies showed that drugn increased the auc of druga and drugb by 3-4 fold and the cmax by 2-fold , compared to placebo .
DDI-DrugBank.d565.s34.p0	midazolam	drug	_	triazolam	drug	_	false	the elimination half life of druga and drugb also increased -lcb- ## fold -rcb- during coadministration with drugn .
DDI-DrugBank.d565.s34.p1	midazolam	drug	_	diltiazem	drug	_	mechanism	the elimination half life of druga and drugn also increased -lcb- ## fold -rcb- during coadministration with drugb .
DDI-DrugBank.d565.s34.p2	triazolam	drug	_	diltiazem	drug	_	mechanism	the elimination half life of drugn and druga also increased -lcb- ## fold -rcb- during coadministration with drugb .
DDI-DrugBank.d565.s35.p0	diltiazem	drug	_	midazolam	drug	_	effect	these pharmacokinetic effects seen during druga coadministration can result in increased clinical effects -lcb- e , g , , prolonged sodation -rcb- of both drugb and drugn .
DDI-DrugBank.d565.s35.p1	diltiazem	drug	_	triazolam	drug	_	effect	these pharmacokinetic effects seen during druga coadministration can result in increased clinical effects -lcb- e , g , , prolonged sodation -rcb- of both drugn and drugb .
DDI-DrugBank.d565.s35.p2	midazolam	drug	_	triazolam	drug	_	false	these pharmacokinetic effects seen during drugn coadministration can result in increased clinical effects -lcb- e , g , , prolonged sodation -rcb- of both druga and drugb .
DDI-DrugBank.d565.s37.p0	diltiazem	drug	_	lovastatin	drug	_	mechanism	in a ten-subject study , coadministration of druga -lcb- 120 mg bid -rcb- with drugb resulted in a 3-4 times increase in mean drugn auc and cmax vs , drugn alone ;
DDI-DrugBank.d565.s37.p1	diltiazem	drug	_	lovastatin	drug	_	false	in a ten-subject study , coadministration of druga -lcb- 120 mg bid -rcb- with drugn resulted in a 3-4 times increase in mean drugb auc and cmax vs , drugn alone ;
DDI-DrugBank.d565.s37.p2	diltiazem	drug	_	lovastatin	drug	_	false	in a ten-subject study , coadministration of druga -lcb- 120 mg bid -rcb- with drugn resulted in a 3-4 times increase in mean drugn auc and cmax vs , drugb alone ;
DDI-DrugBank.d565.s38.p0	pravastatin	drug	_	diltiazem	drug	_	false	no change in druga auc and cmax was observed during drugb coadministration .
DDI-DrugBank.d565.s39.p0	Diltiazem	drug	_	lovastatin	drug	_	false	druga plasma levels were not significantly affected by drugb or drugn .
DDI-DrugBank.d565.s39.p1	Diltiazem	drug	_	pravastatin	drug	_	false	druga plasma levels were not significantly affected by drugn or drugb .
DDI-DrugBank.d565.s39.p2	lovastatin	drug	_	pravastatin	drug	_	false	drugn plasma levels were not significantly affected by druga or drugb .
DDI-DrugBank.d565.s41.p0	rifampin	drug	_	diltiazem	drug	_	mechanism	coadministration of druga with drugb lowered the drugn plasma concentrations to undetectable levels .
DDI-DrugBank.d565.s41.p1	rifampin	drug	_	diltiazem	drug	_	false	coadministration of druga with drugn lowered the drugb plasma concentrations to undetectable levels .
DDI-DrugBank.d565.s42.p0	diltiazem	drug	_	rifampin	drug	_	advise	coadministration of druga with drugb or any known cyp3a4 inducer should be avoided when possible , and alternative therapy considered .
DDI-DrugBank.d96.s0.p0	Dimenhydrinate	drug	_	emetic	group	_	false	druga may decrease drugb response to drugn .
DDI-DrugBank.d96.s0.p1	Dimenhydrinate	drug	_	apomorphine	drug	_	effect	druga may decrease drugn response to drugb .
DDI-DrugBank.d96.s0.p2	emetic	group	_	apomorphine	drug	_	false	drugn may decrease druga response to drugb .
DDI-DrugBank.d181.s0.p0	Oxytocin	drug	_	oxytocics	group	_	false	druga or other drugb -lcb- concurrent use with drugn may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;
DDI-DrugBank.d181.s0.p1	Oxytocin	drug	_	dinoprost	drug	_	effect	druga or other drugn -lcb- concurrent use with drugb may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;
DDI-DrugBank.d181.s0.p2	oxytocics	group	_	dinoprost	drug	_	effect	drugn or other druga -lcb- concurrent use with drugb may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;
DDI-DrugBank.d2.s0.p0	PROSTIN E2	brand	_	oxytocic drugs	group	_	effect	druga may augment the activity of other drugb .
DDI-DrugBank.d296.s0.p0	Diphenhydramine hydrochloride	drug	_	alcohol	drug	_	effect	druga has additive effects with drugb and other drugn -lcb- drugn , drugn , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p1	Diphenhydramine hydrochloride	drug	_	CNS depressants	group	_	effect	druga has additive effects with drugn and other drugb -lcb- drugn , drugn , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p2	Diphenhydramine hydrochloride	drug	_	hypnotics	group	_	effect	druga has additive effects with drugn and other drugn -lcb- drugb , drugn , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p3	Diphenhydramine hydrochloride	drug	_	sedatives	group	_	effect	druga has additive effects with drugn and other drugn -lcb- drugn , drugb , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p4	Diphenhydramine hydrochloride	drug	_	tranquilizers	group	_	effect	druga has additive effects with drugn and other drugn -lcb- drugn , drugn , drugb , etc -rcb- .
DDI-DrugBank.d296.s0.p5	alcohol	drug	_	CNS depressants	group	_	false	drugn has additive effects with druga and other drugb -lcb- drugn , drugn , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p6	alcohol	drug	_	hypnotics	group	_	false	drugn has additive effects with druga and other drugn -lcb- drugb , drugn , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p7	alcohol	drug	_	sedatives	group	_	false	drugn has additive effects with druga and other drugn -lcb- drugn , drugb , drugn , etc -rcb- .
DDI-DrugBank.d296.s0.p8	alcohol	drug	_	tranquilizers	group	_	false	drugn has additive effects with druga and other drugn -lcb- drugn , drugn , drugb , etc -rcb- .
DDI-DrugBank.d296.s1.p0	MAO inhibitors	group	_	antihistamines	group	_	effect	druga prolong and intensify the anticholinergic -lcb- drying -rcb- effects of drugb .
DDI-DrugBank.d120.s1.p0	anticholinergics	group	_	diphenidol	drug	_	false	druga or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with drugb ;
DDI-DrugBank.d120.s2.p0	apomorphine	drug	_	diphenidol	drug	_	false	druga - prior ingestion of drugb may decrease the drugn response to drugn in the treatment of poisoning .
DDI-DrugBank.d120.s2.p1	apomorphine	drug	_	emetic	group	_	false	druga - prior ingestion of drugn may decrease the drugb response to drugn in the treatment of poisoning .
DDI-DrugBank.d120.s2.p3	diphenidol	drug	_	emetic	group	_	false	drugn - prior ingestion of druga may decrease the drugb response to drugn in the treatment of poisoning .
DDI-DrugBank.d120.s2.p4	diphenidol	drug	_	apomorphine	drug	_	effect	drugn - prior ingestion of druga may decrease the drugn response to drugb in the treatment of poisoning .
DDI-DrugBank.d120.s2.p5	emetic	group	_	apomorphine	drug	_	false	drugn - prior ingestion of drugn may decrease the druga response to drugb in the treatment of poisoning .
DDI-DrugBank.d538.s1.p0	Diphenoxylate HCl	drug	_	atropine sulfate	drug	_	false	druga and drugb may interact with drugn in studies with male rats , drugn was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d538.s1.p1	Diphenoxylate HCl	drug	_	MAO inhibitors	group	_	int	druga and drugn may interact with drugb in studies with male rats , drugn was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d538.s1.p2	Diphenoxylate HCl	drug	_	diphenoxylate hydrochloride	drug	_	false	druga and drugn may interact with drugn in studies with male rats , drugb was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d538.s1.p3	atropine sulfate	drug	_	MAO inhibitors	group	_	int	drugn and druga may interact with drugb in studies with male rats , drugn was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d538.s1.p4	atropine sulfate	drug	_	diphenoxylate hydrochloride	drug	_	false	drugn and druga may interact with drugn in studies with male rats , drugb was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d538.s1.p5	MAO inhibitors	group	_	diphenoxylate hydrochloride	drug	_	false	drugn and drugn may interact with druga in studies with male rats , drugb was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .
DDI-DrugBank.d168.s0.p1	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p3	alcohol	drug	_	antihistamines	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p4	alcohol	drug	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p5	alcohol	drug	_	antihistamines	drug	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p6	alcohol	drug	_	antihistamines	drug	_	false	this drug may interact with druga or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d168.s0.p7	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugb -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p9	CNS depressants	group	_	antihistamines	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p10	CNS depressants	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p11	CNS depressants	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p12	CNS depressants	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other druga -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d168.s0.p13	antihistamines	group	_	anticholinergics	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugb or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p15	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or druga -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p18	anticholinergics	group	_	antihistamines	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugb -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p19	anticholinergics	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p20	anticholinergics	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p21	anticholinergics	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , druga or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and drugn -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d168.s0.p22	antihistamines	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with druga -rcb- , and drugb -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p25	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugb may prolong and intensify the anticholinergic and cns depressant effects of drugn -rcb- .
DDI-DrugBank.d168.s0.p26	monoamine oxidase (MAO) inhibitors	group	_	antihistamines	drug	_	false	this drug may interact with drugn or other drugn -lcb- may potentiate the cns depressant effects of either these medications or drugn -rcb- , drugn or other medications with anticholinergic activity -lcb- anticholinergic effects may be potentiated when these medications are used concurrently with drugn -rcb- , and druga -lcb- concurrent use with drugn may prolong and intensify the anticholinergic and cns depressant effects of drugb -rcb- .
DDI-DrugBank.d505.s2.p2	Dipyridamole	drug	_	adenosine	drug	_	mechanism	drugn : druga has been reported to increase the plasma levels and cardiovascular effects of drugb .
DDI-DrugBank.d505.s4.p2	Dipyridamole	drug	_	cholinesterase inhibitors	group	_	effect	drugn : druga may counteract the anticholinesterase effect of drugb , thereby potentially aggravating myasthenia gravis .
DDI-DrugBank.d522.s0.p2	dirithromycin	drug	_	terfenadine	drug	_	false	drugn : in a prospective study involving six-healthy-male volunteers , druga did not affect the metabolism of drugb .
DDI-DrugBank.d522.s1.p1	terfenadine	drug	_	dirithromycin	drug	_	false	these six volunteers received druga alone -lcb- 60 mg twice daily -rcb- for # days , followed by drugn in combination with drugb -lcb- 500 mg once daily -rcb- for # days .
DDI-DrugBank.d522.s1.p2	terfenadine	drug	_	dirithromycin	drug	_	false	these six volunteers received drugn alone -lcb- 60 mg twice daily -rcb- for # days , followed by druga in combination with drugb -lcb- 500 mg once daily -rcb- for # days .
DDI-DrugBank.d522.s3.p2	terfenadine	drug	_	dirithromycin	drug	_	false	the pharmacokinetics of druga and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with drugn alone , and with drugn plus drugb .
DDI-DrugBank.d522.s3.p4	terfenadine	drug	_	dirithromycin	drug	_	false	the pharmacokinetics of drugn and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with druga alone , and with drugn plus drugb .
DDI-DrugBank.d522.s3.p5	terfenadine	drug	_	dirithromycin	drug	_	false	the pharmacokinetics of drugn and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with drugn alone , and with druga plus drugb .
DDI-DrugBank.d522.s5.p2	terfenadine	drug	_	dirithromycin	drug	_	false	in one man , the c max of druga was # ng/ml with drugn alone and # ng/ml with drugn plus drugb .
DDI-DrugBank.d522.s5.p4	terfenadine	drug	_	dirithromycin	drug	_	false	in one man , the c max of drugn was # ng/ml with druga alone and # ng/ml with drugn plus drugb .
DDI-DrugBank.d522.s5.p5	terfenadine	drug	_	dirithromycin	drug	_	mechanism	in one man , the c max of drugn was # ng/ml with drugn alone and # ng/ml with druga plus drugb .
DDI-DrugBank.d522.s7.p1	terfenadine	drug	_	dirithromycin	drug	_	false	the mean qt c interval -lcb- msec -rcb- was # with druga alone and # with drugn plus drugb .
DDI-DrugBank.d522.s7.p2	terfenadine	drug	_	dirithromycin	drug	_	effect	the mean qt c interval -lcb- msec -rcb- was # with drugn alone and # with druga plus drugb .
DDI-DrugBank.d522.s8.p0	dirithromycin	drug	_	terfenadine	drug	_	false	also , in vitro experiments demonstrated a lack of interaction between druga and drugb .
DDI-DrugBank.d522.s9.p0	erythromycin	drug	_	terfenadine	drug	_	int	thus , the interaction observed between druga and drugb is not expected for drugn .
DDI-DrugBank.d522.s9.p1	erythromycin	drug	_	dirithromycin	drug	_	false	thus , the interaction observed between druga and drugn is not expected for drugb .
DDI-DrugBank.d522.s9.p2	terfenadine	drug	_	dirithromycin	drug	_	false	thus , the interaction observed between drugn and druga is not expected for drugb .
DDI-DrugBank.d522.s10.p0	terfenadine	drug	_	macrolide antibiotics	group	_	effect	serious cardiac dysrhythmias , some resulting in death , have occurred in patients receiving druga concomitantly with other drugb .
DDI-DrugBank.d522.s11.p0	macrolides	group	_	terfenadine	drug	_	advise	in addition , most druga are contraindicated in patients receiving drugb therapy who have pre-existing cardiac abnormalities -lcb- arrhythmia , bradycardia , qt c interval prolongation , ischemic heart disease , congestive heart failure , etc , -rcb- or electrolyte disturbances .
DDI-DrugBank.d522.s12.p3	dirithromycin	drug	_	theophylline	drug	_	false	drugn : following co-administration of two 250-mg druga tablets administered once daily with 200-mg drugb tablets administered twice daily for # days to # healthy subjects , the steady-state plasma concentration of drugn was not significantly altered .
DDI-DrugBank.d522.s12.p4	dirithromycin	drug	_	theophylline	drug	_	false	drugn : following co-administration of two 250-mg druga tablets administered once daily with 200-mg drugn tablets administered twice daily for # days to # healthy subjects , the steady-state plasma concentration of drugb was not significantly altered .
DDI-DrugBank.d522.s13.p0	dirithromycin	drug	_	theophylline	drug	_	false	in general , most patients treated with druga who are receiving concomitant drugb therapy may not require empiric adjustment of drugn dosage or monitoring of drugn plasma concentrations .
DDI-DrugBank.d522.s13.p1	dirithromycin	drug	_	theophylline	drug	_	false	in general , most patients treated with druga who are receiving concomitant drugn therapy may not require empiric adjustment of drugb dosage or monitoring of drugn plasma concentrations .
DDI-DrugBank.d522.s13.p2	dirithromycin	drug	_	theophylline	drug	_	false	in general , most patients treated with druga who are receiving concomitant drugn therapy may not require empiric adjustment of drugn dosage or monitoring of drugb plasma concentrations .
DDI-DrugBank.d522.s15.p0	Antacids	group	_	H 2 receptor antagonists	group	_	false	druga or drugb : when drugn is administered immediately following drugn or drugn , the absorption of drugn is slightly enhanced .
DDI-DrugBank.d522.s15.p9	dirithromycin	drug	_	antacids	group	_	mechanism	drugn or drugn : when druga is administered immediately following drugb or drugn , the absorption of drugn is slightly enhanced .
DDI-DrugBank.d522.s15.p10	dirithromycin	drug	_	H 2 -receptor antagonists	group	_	mechanism	drugn or drugn : when druga is administered immediately following drugn or drugb , the absorption of drugn is slightly enhanced .
DDI-DrugBank.d522.s15.p12	antacids	group	_	H 2 -receptor antagonists	group	_	false	drugn or drugn : when drugn is administered immediately following druga or drugb , the absorption of drugn is slightly enhanced .
DDI-DrugBank.d522.s15.p13	antacids	group	_	dirithromycin	drug	_	false	drugn or drugn : when drugn is administered immediately following druga or drugn , the absorption of drugb is slightly enhanced .
DDI-DrugBank.d522.s15.p14	H 2 -receptor antagonists	group	_	dirithromycin	drug	_	false	drugn or drugn : when drugn is administered immediately following drugn or druga , the absorption of drugb is slightly enhanced .
DDI-DrugBank.d522.s19.p3	Erythromycin	drug	_	triazolam	drug	_	mechanism	drugn : druga has been reported to decrease the clearance of drugb and , thus , may increase the pharmacologic effect of drugn .
DDI-DrugBank.d522.s19.p4	Erythromycin	drug	_	triazolam	drug	_	effect	drugn : druga has been reported to decrease the clearance of drugn and , thus , may increase the pharmacologic effect of drugb .
DDI-DrugBank.d522.s20.p0	Digoxin	drug	_	erythromycin	drug	_	false	druga : concomitant administration of drugb and drugn has been reported to result in elevated drugn serum levels .
DDI-DrugBank.d522.s20.p3	erythromycin	drug	_	digoxin	drug	_	mechanism	drugn : concomitant administration of druga and drugb has been reported to result in elevated drugn serum levels .
DDI-DrugBank.d522.s20.p4	erythromycin	drug	_	digoxin	drug	_	false	drugn : concomitant administration of druga and drugn has been reported to result in elevated drugb serum levels .
DDI-DrugBank.d522.s21.p2	erythromycin	drug	_	anticoagulants	group	_	effect	drugn : there have been reports of increased anticoagulant effects when druga and oral drugb were used concomitantly .
DDI-DrugBank.d522.s23.p0	Ergotamine	drug	_	erythromycin	drug	_	false	druga : concurrent use of drugb and drugn or drugn has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia .
DDI-DrugBank.d522.s24.p0	erythromycin	drug	_	cyclosporine	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p1	erythromycin	drug	_	hexobarbital	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p2	erythromycin	drug	_	carbamazepine	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p3	erythromycin	drug	_	alfentanil	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p4	erythromycin	drug	_	disopyramide	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p5	erythromycin	drug	_	phenytoin	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p6	erythromycin	drug	_	bromocriptine	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d522.s24.p7	erythromycin	drug	_	valproate	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d522.s24.p8	erythromycin	drug	_	astemizole	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d522.s24.p9	erythromycin	drug	_	lovastatin	drug	_	int	other drugs drug interactions have been reported with concomitant administration of druga and other medications , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d506.s0.p0	phenytoin	drug	_	Norpace	brand	_	mechanism	if druga or other hepatic enzyme inducers are taken concurrently with drugb or drugn , lower plasma levels of drugn may occur .
DDI-DrugBank.d506.s0.p1	phenytoin	drug	_	Norpace CR	brand	_	mechanism	if druga or other hepatic enzyme inducers are taken concurrently with drugn or drugb , lower plasma levels of drugn may occur .
DDI-DrugBank.d506.s0.p2	phenytoin	drug	_	disopyramide	drug	_	false	if druga or other hepatic enzyme inducers are taken concurrently with drugn or drugn , lower plasma levels of drugb may occur .
DDI-DrugBank.d506.s0.p4	Norpace	brand	_	disopyramide	drug	_	false	if drugn or other hepatic enzyme inducers are taken concurrently with druga or drugn , lower plasma levels of drugb may occur .
DDI-DrugBank.d506.s0.p5	Norpace CR	brand	_	disopyramide	drug	_	false	if drugn or other hepatic enzyme inducers are taken concurrently with drugn or druga , lower plasma levels of drugb may occur .
DDI-DrugBank.d506.s2.p4	antiarrhythmic drugs	group	_	Norpace	brand	_	false	other druga -lcb- eg , drugn , drugn , drugn , drugn -rcb- have occasionally been used concurrently with drugb .
DDI-DrugBank.d506.s2.p8	quinidine	drug	_	Norpace	brand	_	false	other drugn -lcb- eg , druga , drugn , drugn , drugn -rcb- have occasionally been used concurrently with drugb .
DDI-DrugBank.d506.s2.p11	procainamide	drug	_	Norpace	brand	_	false	other drugn -lcb- eg , drugn , druga , drugn , drugn -rcb- have occasionally been used concurrently with drugb .
DDI-DrugBank.d506.s2.p13	lidocaine	drug	_	Norpace	brand	_	false	other drugn -lcb- eg , drugn , drugn , druga , drugn -rcb- have occasionally been used concurrently with drugb .
DDI-DrugBank.d506.s2.p14	propranolol	drug	_	Norpace	brand	_	false	other drugn -lcb- eg , drugn , drugn , drugn , druga -rcb- have occasionally been used concurrently with drugb .
DDI-DrugBank.d506.s4.p0	Norpace	brand	_	propranolol	drug	_	false	in healthy subjects , no significant drug-drug interaction was observed when druga was coadministered with either drugb or drugn .
DDI-DrugBank.d506.s4.p1	Norpace	brand	_	diazepam	drug	_	false	in healthy subjects , no significant drug-drug interaction was observed when druga was coadministered with either drugn or drugb .
DDI-DrugBank.d506.s4.p2	propranolol	drug	_	diazepam	drug	_	false	in healthy subjects , no significant drug-drug interaction was observed when drugn was coadministered with either druga or drugb .
DDI-DrugBank.d506.s5.p0	Norpace	brand	_	quinidine	drug	_	mechanism	concomitant administration of druga and drugb resulted in slight increases in plasma drugn levels and slight decreases in plasma drugn levels .
DDI-DrugBank.d506.s5.p1	Norpace	brand	_	disopyramide	drug	_	false	concomitant administration of druga and drugn resulted in slight increases in plasma drugb levels and slight decreases in plasma drugn levels .
DDI-DrugBank.d506.s5.p2	Norpace	brand	_	quinidine	drug	_	false	concomitant administration of druga and drugn resulted in slight increases in plasma drugn levels and slight decreases in plasma drugb levels .
DDI-DrugBank.d506.s5.p3	quinidine	drug	_	disopyramide	drug	_	false	concomitant administration of drugn and druga resulted in slight increases in plasma drugb levels and slight decreases in plasma drugn levels .
DDI-DrugBank.d506.s5.p5	disopyramide	drug	_	quinidine	drug	_	false	concomitant administration of drugn and drugn resulted in slight increases in plasma druga levels and slight decreases in plasma drugb levels .
DDI-DrugBank.d506.s6.p0	Norpace	brand	_	digoxin	drug	_	false	druga does not increase serum drugb levels .
DDI-DrugBank.d506.s7.p0	disopyramide phosphate	drug	_	erythromycin	drug	_	mechanism	patients taking druga and drugb concomitantly may develop increased serum concentrations of drugn resulting in excessive widening of the qrs complex and/or prolongation of the q-t interval .
DDI-DrugBank.d506.s7.p2	erythromycin	drug	_	disopyramide	drug	_	false	patients taking drugn and druga concomitantly may develop increased serum concentrations of drugb resulting in excessive widening of the qrs complex and/or prolongation of the q-t interval .
DDI-DrugBank.d506.s9.p0	verapamil	drug	_	disopyramide phosphate	drug	_	false	until data on possible interactions between druga and drugb are obtained , drugn should not be administered within # hours before or # hours after drugn administration .
DDI-DrugBank.d506.s9.p1	verapamil	drug	_	disopyramide	drug	_	false	until data on possible interactions between druga and drugn are obtained , drugb should not be administered within # hours before or # hours after drugn administration .
DDI-DrugBank.d506.s9.p4	disopyramide phosphate	drug	_	verapamil	drug	_	false	until data on possible interactions between drugn and druga are obtained , drugn should not be administered within # hours before or # hours after drugb administration .
DDI-DrugBank.d506.s9.p5	disopyramide	drug	_	verapamil	drug	_	advise	until data on possible interactions between drugn and drugn are obtained , druga should not be administered within # hours before or # hours after drugb administration .
DDI-DrugBank.d19.s1.p0	DISULFIRAM	drug	_	PHENYTOIN	drug	_	advise	druga should be used with caution in those patients reveiving drugb and its congeners .
DDI-DrugBank.d19.s2.p0	PHENYTOIN	drug	_	DISULFIRAM	drug	_	false	since the concomitant administration of these two drugs can lead to druga intoxication , prior to administering drugb to a patient on drugn therapy , a baseline drugn serum level should be obtained .
DDI-DrugBank.d19.s2.p3	DISULFIRAM	drug	_	PHENYTOIN	drug	_	effect	since the concomitant administration of these two drugs can lead to drugn intoxication , prior to administering druga to a patient on drugb therapy , a baseline drugn serum level should be obtained .
DDI-DrugBank.d19.s2.p4	DISULFIRAM	drug	_	PHENYTOIN	drug	_	false	since the concomitant administration of these two drugs can lead to drugn intoxication , prior to administering druga to a patient on drugn therapy , a baseline drugb serum level should be obtained .
DDI-DrugBank.d19.s6.p0	anticoagulants	group	_	disulfiram	drug	_	advise	it may be necessary to adjust the dosage of oral druga upon beginning or stopping drugb , since drugn may prolong prothrombin time .
DDI-DrugBank.d19.s6.p1	anticoagulants	group	_	disulfiram	drug	_	false	it may be necessary to adjust the dosage of oral druga upon beginning or stopping drugn , since drugb may prolong prothrombin time .
DDI-DrugBank.d19.s7.p0	isoniazid	drug	_	disulfiram	drug	_	advise	patients taking druga when drugb is given should be observed for the appearance of unsteady gait or marked changes in mental status ;
DDI-DrugBank.d19.s9.p0	disulfiram	drug	_	nitrite	drug	_	effect	in rats , simultaneous ingestion of druga and drugb in the diet for # weeks has been reported to cause tumors , and it has been suggested that drugn may react with drugn in the rat stomach to form a nitrosamine , which is tumorigenic .
DDI-DrugBank.d19.s9.p2	disulfiram	drug	_	nitrites	group	_	false	in rats , simultaneous ingestion of druga and drugn in the diet for # weeks has been reported to cause tumors , and it has been suggested that drugn may react with drugb in the rat stomach to form a nitrosamine , which is tumorigenic .
DDI-DrugBank.d19.s9.p3	nitrite	drug	_	disulfiram	drug	_	false	in rats , simultaneous ingestion of drugn and druga in the diet for # weeks has been reported to cause tumors , and it has been suggested that drugb may react with drugn in the rat stomach to form a nitrosamine , which is tumorigenic .
DDI-DrugBank.d19.s9.p5	disulfiram	drug	_	nitrites	group	_	effect	in rats , simultaneous ingestion of drugn and drugn in the diet for # weeks has been reported to cause tumors , and it has been suggested that druga may react with drugb in the rat stomach to form a nitrosamine , which is tumorigenic .
DDI-DrugBank.d274.s0.p0	dobutamine	drug	_	b-blocking drug	group	_	effect	animal studies indicate that druga may be ineffective if the patient has recently received a drugb .
DDI-DrugBank.d274.s2.p0	dobutamine	drug	_	nitroprusside	drug	_	effect	preliminary studies indicate that the concomitant use of druga and drugb results in a higher cardiac output and , usually , a lower pulmonary wedge pressure than when either drug is used alone .
DDI-DrugBank.d274.s3.p0	dobutamine	drug	_	digitalis preparations	group	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p1	dobutamine	drug	_	furosemide	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p2	dobutamine	drug	_	spironolactone	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p3	dobutamine	drug	_	lidocaine	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p4	dobutamine	drug	_	glyceryl trinitrate	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p5	dobutamine	drug	_	isosorbide dinitrate	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p6	dobutamine	drug	_	morphine	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p7	dobutamine	drug	_	atropine	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p8	dobutamine	drug	_	heparin	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p9	dobutamine	drug	_	protamine	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d274.s3.p10	dobutamine	drug	_	potassium chloride	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d274.s3.p11	dobutamine	drug	_	folic acid	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d274.s3.p12	dobutamine	drug	_	acetaminophen	drug	_	false	there was no evidence of drug interactions in clinical studies in which druga was administered concurrently with other drugs , including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d371.s1.p0	docetaxel	drug	_	cyclosporine	drug	_	mechanism	in vitro studies have shown that the metabolism of druga may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d371.s1.p1	docetaxel	drug	_	terfenadine	drug	_	mechanism	in vitro studies have shown that the metabolism of druga may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d371.s1.p2	docetaxel	drug	_	ketoconazole	drug	_	mechanism	in vitro studies have shown that the metabolism of druga may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d371.s1.p3	docetaxel	drug	_	erythromycin	drug	_	mechanism	in vitro studies have shown that the metabolism of druga may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d371.s1.p4	docetaxel	drug	_	troleandomycin	drug	_	mechanism	in vitro studies have shown that the metabolism of druga may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d558.s2.p0	Cimetidine	drug	_	TIKOSYN	brand	_	mechanism	druga at # mg bid -lcb- the usual prescription dose -rcb- co-administered with drugb -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugn plasma levels by 58 % .
DDI-DrugBank.d558.s2.p1	Cimetidine	drug	_	dofetilide	drug	_	false	druga at # mg bid -lcb- the usual prescription dose -rcb- co-administered with drugn -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugb plasma levels by 58 % .
DDI-DrugBank.d558.s2.p2	TIKOSYN	brand	_	dofetilide	drug	_	false	drugn at # mg bid -lcb- the usual prescription dose -rcb- co-administered with druga -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugb plasma levels by 58 % .
DDI-DrugBank.d558.s3.p0	Cimetidine	drug	_	dofetilide	drug	_	mechanism	druga at doses of # mg bid -lcb- otc dose -rcb- resulted in a 13 % increase in drugb plasma levels -lcb- 500 mcg single dose -rcb- .
DDI-DrugBank.d558.s5.p0	TIKOSYN	brand	_	anti-ulcer	group	_	false	if a patient requires druga and drugb therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p1	TIKOSYN	brand	_	omeprazole	drug	_	false	if a patient requires druga and drugn therapy , it is suggested that drugb , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p2	TIKOSYN	brand	_	ranitidine	drug	_	false	if a patient requires druga and drugn therapy , it is suggested that drugn , drugb , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p3	TIKOSYN	brand	_	antacids	group	_	false	if a patient requires druga and drugn therapy , it is suggested that drugn , drugn , or drugb -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p4	TIKOSYN	brand	_	aluminum hydroxide	drug	_	false	if a patient requires druga and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugb and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p5	TIKOSYN	brand	_	magnesium hydroxide	drug	_	false	if a patient requires druga and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugb -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p6	TIKOSYN	brand	_	cimetidine	drug	_	advise	if a patient requires druga and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p8	anti-ulcer	group	_	omeprazole	drug	_	false	if a patient requires drugn and druga therapy , it is suggested that drugb , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p9	anti-ulcer	group	_	ranitidine	drug	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugb , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p10	anti-ulcer	group	_	antacids	group	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugn , or drugb -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p11	anti-ulcer	group	_	aluminum hydroxide	drug	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugn , or drugn -lcb- drugb and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p12	anti-ulcer	group	_	magnesium hydroxide	drug	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugb -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p13	anti-ulcer	group	_	cimetidine	drug	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p14	anti-ulcer	group	_	TIKOSYN	brand	_	false	if a patient requires drugn and druga therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p19	omeprazole	drug	_	cimetidine	drug	_	false	if a patient requires drugn and drugn therapy , it is suggested that druga , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p20	omeprazole	drug	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that druga , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p24	ranitidine	drug	_	cimetidine	drug	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , druga , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p25	ranitidine	drug	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , druga , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p28	antacids	group	_	cimetidine	drug	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or druga -lcb- drugn and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p29	antacids	group	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or druga -lcb- drugn and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p31	aluminum hydroxide	drug	_	cimetidine	drug	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- druga and drugn -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p32	aluminum hydroxide	drug	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- druga and drugn -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p33	magnesium hydroxide	drug	_	cimetidine	drug	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and druga -rcb- be used as alternatives to drugb , as these agents have no effect on the pharmacokinetic profile of drugn .
DDI-DrugBank.d558.s5.p34	magnesium hydroxide	drug	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and druga -rcb- be used as alternatives to drugn , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s5.p35	cimetidine	drug	_	TIKOSYN	brand	_	false	if a patient requires drugn and drugn therapy , it is suggested that drugn , drugn , or drugn -lcb- drugn and drugn -rcb- be used as alternatives to druga , as these agents have no effect on the pharmacokinetic profile of drugb .
DDI-DrugBank.d558.s7.p0	TIKOSYN	brand	_	verapamil	drug	_	mechanism	co-administration of druga with drugb resulted in increases in drugn peak plasma levels of 42 % , although overall exposure to drugn was not significantly increased .
DDI-DrugBank.d558.s7.p1	TIKOSYN	brand	_	dofetilide	drug	_	false	co-administration of druga with drugn resulted in increases in drugb peak plasma levels of 42 % , although overall exposure to drugn was not significantly increased .
DDI-DrugBank.d558.s7.p2	TIKOSYN	brand	_	dofetilide	drug	_	false	co-administration of druga with drugn resulted in increases in drugn peak plasma levels of 42 % , although overall exposure to drugb was not significantly increased .
DDI-DrugBank.d558.s7.p3	verapamil	drug	_	dofetilide	drug	_	false	co-administration of drugn with druga resulted in increases in drugb peak plasma levels of 42 % , although overall exposure to drugn was not significantly increased .
DDI-DrugBank.d558.s7.p4	verapamil	drug	_	dofetilide	drug	_	false	co-administration of drugn with druga resulted in increases in drugn peak plasma levels of 42 % , although overall exposure to drugb was not significantly increased .
DDI-DrugBank.d558.s8.p0	verapamil	drug	_	dofetilide	drug	_	effect	in an analysis of the supraventricular arrhythmia and diamond patient populations , the concomitant administration of druga with drugb was associated with a higher occurrence of torsade de pointes .
DDI-DrugBank.d558.s10.p0	Ketoconazole	drug	_	TIKOSYN	brand	_	mechanism	druga at # mg daily -lcb- the maximum approved prescription dose -rcb- co-administered with drugb -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugn cmax by 53 % in males and 97 % in females , and auc by 41 % in males and 69 % in females .
DDI-DrugBank.d558.s10.p1	Ketoconazole	drug	_	dofetilide	drug	_	false	druga at # mg daily -lcb- the maximum approved prescription dose -rcb- co-administered with drugn -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugb cmax by 53 % in males and 97 % in females , and auc by 41 % in males and 69 % in females .
DDI-DrugBank.d558.s10.p2	TIKOSYN	brand	_	dofetilide	drug	_	false	drugn at # mg daily -lcb- the maximum approved prescription dose -rcb- co-administered with druga -lcb- 500 mcg bid -rcb- for # days has been shown to increase drugb cmax by 53 % in males and 97 % in females , and auc by 41 % in males and 69 % in females .
DDI-DrugBank.d558.s11.p0	Trimethoprim	drug	_	Sulfamethoxazole	drug	_	false	druga alone or in combination with drugb : concomitant use of drugn alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s11.p2	Trimethoprim	drug	_	sulfamethoxazole	drug	_	false	druga alone or in combination with drugn : concomitant use of drugn alone or in combination with drugb is contraindicated .
DDI-DrugBank.d558.s11.p3	Sulfamethoxazole	drug	_	trimethoprim	drug	_	false	drugn alone or in combination with druga : concomitant use of drugb alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s11.p5	trimethoprim	drug	_	sulfamethoxazole	drug	_	false	drugn alone or in combination with drugn : concomitant use of druga alone or in combination with drugb is contraindicated .
DDI-DrugBank.d558.s12.p1	Hydrochlorothiazide	drug	_	Triamterene	drug	_	false	druga -lcb- drugn -rcb- alone or in combination with drugb : concomitant use of drugn alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s12.p2	Hydrochlorothiazide	drug	_	HCTZ	drug	_	false	druga -lcb- drugn -rcb- alone or in combination with drugn : concomitant use of drugb alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s12.p3	Hydrochlorothiazide	drug	_	triamterene	drug	_	false	druga -lcb- drugn -rcb- alone or in combination with drugn : concomitant use of drugn alone or in combination with drugb is contraindicated .
DDI-DrugBank.d558.s12.p4	HCTZ	drug	_	Triamterene	drug	_	false	drugn -lcb- druga -rcb- alone or in combination with drugb : concomitant use of drugn alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s12.p6	HCTZ	drug	_	triamterene	drug	_	false	drugn -lcb- druga -rcb- alone or in combination with drugn : concomitant use of drugn alone or in combination with drugb is contraindicated .
DDI-DrugBank.d558.s12.p7	Triamterene	drug	_	HCTZ	drug	_	false	drugn -lcb- drugn -rcb- alone or in combination with druga : concomitant use of drugb alone or in combination with drugn is contraindicated .
DDI-DrugBank.d558.s12.p9	HCTZ	drug	_	triamterene	drug	_	false	drugn -lcb- drugn -rcb- alone or in combination with drugn : concomitant use of druga alone or in combination with drugb is contraindicated .
DDI-DrugBank.d558.s13.p1	HCTZ	drug	_	triamterene	drug	_	false	druga # mg qd or drugn / drugb 50/100 mg qd was co-administered with drugn -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugn use at half dose -rcb- .
DDI-DrugBank.d558.s13.p2	HCTZ	drug	_	TIKOSYN	brand	_	false	druga # mg qd or drugn / drugn 50/100 mg qd was co-administered with drugb -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugn use at half dose -rcb- .
DDI-DrugBank.d558.s13.p3	HCTZ	drug	_	diuretic	group	_	false	druga # mg qd or drugn / drugn 50/100 mg qd was co-administered with drugn -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugb use at half dose -rcb- .
DDI-DrugBank.d558.s13.p5	HCTZ	drug	_	TIKOSYN	brand	_	false	drugn # mg qd or druga / drugn 50/100 mg qd was co-administered with drugb -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugn use at half dose -rcb- .
DDI-DrugBank.d558.s13.p6	HCTZ	drug	_	diuretic	group	_	false	drugn # mg qd or druga / drugn 50/100 mg qd was co-administered with drugn -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugb use at half dose -rcb- .
DDI-DrugBank.d558.s13.p7	triamterene	drug	_	TIKOSYN	brand	_	false	drugn # mg qd or drugn / druga 50/100 mg qd was co-administered with drugb -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugn use at half dose -rcb- .
DDI-DrugBank.d558.s13.p8	triamterene	drug	_	diuretic	group	_	false	drugn # mg qd or drugn / druga 50/100 mg qd was co-administered with drugn -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugb use at half dose -rcb- .
DDI-DrugBank.d558.s13.p9	TIKOSYN	brand	_	diuretic	group	_	false	drugn # mg qd or drugn / drugn 50/100 mg qd was co-administered with druga -lcb- 500 mcg bid -rcb- for # days -lcb- following # days of drugb use at half dose -rcb- .
DDI-DrugBank.d558.s14.p0	HCTZ	drug	_	dofetilide	drug	_	mechanism	in patients receiving druga alone , drugb auc increased by 27 % and cmax by 21 % .
DDI-DrugBank.d558.s18.p0	TIKOSYN	brand	_	diuretics	group	_	false	in the diamond trials , # patients were treated with druga and drugb concomitantly of whom # died compared to # deaths among the # patients receiving placebo and drugn .
DDI-DrugBank.d558.s18.p1	TIKOSYN	brand	_	diuretics	group	_	false	in the diamond trials , # patients were treated with druga and drugn concomitantly of whom # died compared to # deaths among the # patients receiving placebo and drugb .
DDI-DrugBank.d558.s19.p0	potassium depleting diuretics	group	_	TIKOSYN	brand	_	false	of the # patients who had druga added to their concomitant medications in the diamond trials , the patients on drugb had a non-significantly reduced relative risk for death of # -lcb- 95 % ci # , # -rcb- .
DDI-DrugBank.d558.s22.p2	triamterene	drug	_	dofetilide	drug	_	advise	in addition , drugs that are actively secreted via this route -lcb- e , g , , druga , drugn and drugn -rcb- should be co-administered with care as they might increase drugb levels .
DDI-DrugBank.d558.s22.p4	metformin	drug	_	dofetilide	drug	_	advise	in addition , drugs that are actively secreted via this route -lcb- e , g , , drugn , druga and drugn -rcb- should be co-administered with care as they might increase drugb levels .
DDI-DrugBank.d558.s22.p5	amiloride	drug	_	dofetilide	drug	_	advise	in addition , drugs that are actively secreted via this route -lcb- e , g , , drugn , drugn and druga -rcb- should be co-administered with care as they might increase drugb levels .
DDI-DrugBank.d558.s25.p10	macrolide antibiotics	group	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p11	macrolide antibiotics	group	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , druga , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p21	azole antifungal agents	group	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p22	azole antifungal agents	group	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , druga , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p31	protease inhibitors	group	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p32	protease inhibitors	group	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , druga , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p40	serotonin reuptake inhibitors	group	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p41	serotonin reuptake inhibitors	group	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , druga , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p48	amiodarone	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p49	amiodarone	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , druga , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p55	cannabinoids	group	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p56	cannabinoids	group	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , druga , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p61	diltiazem	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , druga , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p62	diltiazem	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , druga , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p66	nefazadone	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , druga , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p67	nefazadone	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , druga , drugn , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p70	norfloxacin	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , druga , drugn , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p71	norfloxacin	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , druga , drugn , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p73	quinine	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , druga , drugn -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p74	quinine	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , druga , drugn -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p75	zafirlukast	drug	_	TIKOSYN	brand	_	advise	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , druga -rcb- should be cautiously coadministered with drugb as they can potentially increase drugn levels .
DDI-DrugBank.d558.s25.p76	zafirlukast	drug	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , druga -rcb- should be cautiously coadministered with drugn as they can potentially increase drugb levels .
DDI-DrugBank.d558.s25.p77	TIKOSYN	brand	_	dofetilide	drug	_	false	inhibitors of this isoenzyme -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , grapefruit juice , drugn , drugn , drugn , drugn -rcb- should be cautiously coadministered with druga as they can potentially increase drugb levels .
DDI-DrugBank.d558.s27.p2	TIKOSYN	brand	_	digoxin	drug	_	false	other drug interaction information drugn : studies in healthy volunteers have shown that druga does not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s28.p0	digoxin	drug	_	dofetilide	drug	_	effect	in patients , the concomitant administration of druga with drugb was associated with a higher occurrence of torsade de pointes .
DDI-DrugBank.d558.s29.p0	TIKOSYN	brand	_	digoxin	drug	_	false	it is not clear whether this represents an interaction with druga or the presence of more severe structural heart disease in patients on drugb ;
DDI-DrugBank.d558.s32.p4	amlodipine	drug	_	estrogens	group	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugb and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p5	amlodipine	drug	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p6	amlodipine	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p7	amlodipine	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p8	amlodipine	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p9	amlodipine	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p10	amlodipine	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , druga , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p14	phenytoin	drug	_	estrogens	group	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugb and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p15	phenytoin	drug	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p16	phenytoin	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p17	phenytoin	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p18	phenytoin	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p19	phenytoin	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p20	phenytoin	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , druga , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p23	glyburide	drug	_	estrogens	group	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugb and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p24	glyburide	drug	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p25	glyburide	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p26	glyburide	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p27	glyburide	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p28	glyburide	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p29	glyburide	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , druga , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p31	ranitidine	drug	_	estrogens	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugb and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p32	ranitidine	drug	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p33	ranitidine	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p34	ranitidine	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p35	ranitidine	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p36	ranitidine	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p37	ranitidine	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , druga , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p38	omeprazole	drug	_	estrogens	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugb and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p39	omeprazole	drug	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p40	omeprazole	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p41	omeprazole	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p42	omeprazole	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p43	omeprazole	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p44	omeprazole	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , druga , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p45	estrogens	group	_	medroxyprogesterone	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugb -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p46	estrogens	group	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugn -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p47	estrogens	group	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugn -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p48	estrogens	group	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugn -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p49	estrogens	group	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p50	estrogens	group	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated druga and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p51	medroxyprogesterone	drug	_	antacid	group	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and druga -rcb- , drugb -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p52	medroxyprogesterone	drug	_	aluminum hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and druga -rcb- , drugn -lcb- drugb and drugn -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p53	medroxyprogesterone	drug	_	magnesium hydroxide	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and druga -rcb- , drugn -lcb- drugn and drugb -rcb- and drugn did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p54	medroxyprogesterone	drug	_	theophylline	drug	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and druga -rcb- , drugn -lcb- drugn and drugn -rcb- and drugb did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d558.s32.p55	medroxyprogesterone	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and druga -rcb- , drugn -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p59	antacid	group	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , druga -lcb- drugn and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p62	aluminum hydroxide	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- druga and drugn -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p64	magnesium hydroxide	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and druga -rcb- and drugn did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s32.p65	theophylline	drug	_	TIKOSYN	brand	_	false	other drugs : in healthy volunteers , drugn , drugn , drugn , drugn , drugn , hormone replacement therapy -lcb- a combination of conjugated drugn and drugn -rcb- , drugn -lcb- drugn and drugn -rcb- and druga did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d558.s33.p0	TIKOSYN	brand	_	warfarin	drug	_	false	in addition , studies in healthy volunteers have shown that druga does not affect the pharmacokinetics or pharmacodynamics of drugb , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugn .
DDI-DrugBank.d558.s33.p1	TIKOSYN	brand	_	propranolol	drug	_	false	in addition , studies in healthy volunteers have shown that druga does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugb -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugn .
DDI-DrugBank.d558.s33.p2	TIKOSYN	brand	_	phenytoin	drug	_	false	in addition , studies in healthy volunteers have shown that druga does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugb , drugn , or oral drugn .
DDI-DrugBank.d558.s33.p3	TIKOSYN	brand	_	theophylline	drug	_	false	in addition , studies in healthy volunteers have shown that druga does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , drugb , or oral drugn .
DDI-DrugBank.d558.s33.p4	TIKOSYN	brand	_	contraceptives	group	_	false	in addition , studies in healthy volunteers have shown that druga does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugb .
DDI-DrugBank.d558.s33.p5	warfarin	drug	_	propranolol	drug	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of druga , or the pharmacokinetics of drugb -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugn .
DDI-DrugBank.d558.s33.p6	warfarin	drug	_	phenytoin	drug	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of druga , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugb , drugn , or oral drugn .
DDI-DrugBank.d558.s33.p7	warfarin	drug	_	theophylline	drug	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of druga , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , drugb , or oral drugn .
DDI-DrugBank.d558.s33.p8	warfarin	drug	_	contraceptives	group	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of druga , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugb .
DDI-DrugBank.d558.s33.p11	propranolol	drug	_	contraceptives	group	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of druga -lcb- 40 mg twice daily -rcb- , drugn , drugn , or oral drugb .
DDI-DrugBank.d558.s33.p13	phenytoin	drug	_	contraceptives	group	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , druga , drugn , or oral drugb .
DDI-DrugBank.d558.s33.p14	theophylline	drug	_	contraceptives	group	_	false	in addition , studies in healthy volunteers have shown that drugn does not affect the pharmacokinetics or pharmacodynamics of drugn , or the pharmacokinetics of drugn -lcb- 40 mg twice daily -rcb- , drugn , druga , or oral drugb .
DDI-DrugBank.d558.s35.p30	cardiac glycosides	group	_	nitrates	group	_	false	concomitant medications were grouped as drugn , oral drugn , drugn , drugn , druga , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , drugb , drugn , drugn , drugn , drugn , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .
DDI-DrugBank.d558.s35.p31	cardiac glycosides	group	_	sulphonylureas	group	_	false	concomitant medications were grouped as drugn , oral drugn , drugn , drugn , druga , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , drugn , drugb , drugn , drugn , drugn , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .
DDI-DrugBank.d558.s35.p32	cardiac glycosides	group	_	loop diuretics	group	_	false	concomitant medications were grouped as drugn , oral drugn , drugn , drugn , druga , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , drugn , drugn , drugb , drugn , drugn , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .
DDI-DrugBank.d558.s35.p33	cardiac glycosides	group	_	potassium sparing diuretics	group	_	false	concomitant medications were grouped as drugn , oral drugn , drugn , drugn , druga , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , drugn , drugn , drugn , drugb , drugn , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .
DDI-DrugBank.d558.s37.p0	dofetilide	drug	_	thiazide diuretics	group	_	mechanism	the mean clearances of druga were 16 % and 15 % lower in patients on drugb and inhibitors of tubular organic cation transport , respectively .
DDI-DrugBank.d42.s1.p1	hydrodolasetron	drug_n	_	cimetidine	drug	_	false	blood levels of druga increased 24 % when drugn was coadministered with drugb -lcb- nonselective inhibitor of cytochrome p-450 -rcb- for # days , and decreased 28 % with coadministration of drugn -lcb- potent inducer of cytochrome p-450 -rcb- for # days .
DDI-DrugBank.d42.s1.p2	hydrodolasetron	drug_n	_	rifampin	drug	_	false	blood levels of druga increased 24 % when drugn was coadministered with drugn -lcb- nonselective inhibitor of cytochrome p-450 -rcb- for # days , and decreased 28 % with coadministration of drugb -lcb- potent inducer of cytochrome p-450 -rcb- for # days .
DDI-DrugBank.d42.s1.p3	dolasetron	drug	_	cimetidine	drug	_	mechanism	blood levels of drugn increased 24 % when druga was coadministered with drugb -lcb- nonselective inhibitor of cytochrome p-450 -rcb- for # days , and decreased 28 % with coadministration of drugn -lcb- potent inducer of cytochrome p-450 -rcb- for # days .
DDI-DrugBank.d42.s1.p4	dolasetron	drug	_	rifampin	drug	_	mechanism	blood levels of drugn increased 24 % when druga was coadministered with drugn -lcb- nonselective inhibitor of cytochrome p-450 -rcb- for # days , and decreased 28 % with coadministration of drugb -lcb- potent inducer of cytochrome p-450 -rcb- for # days .
DDI-DrugBank.d42.s1.p5	cimetidine	drug	_	rifampin	drug	_	false	blood levels of drugn increased 24 % when drugn was coadministered with druga -lcb- nonselective inhibitor of cytochrome p-450 -rcb- for # days , and decreased 28 % with coadministration of drugb -lcb- potent inducer of cytochrome p-450 -rcb- for # days .
DDI-DrugBank.d42.s4.p6	furosemide	drug	_	hydrodolasetron	drug_n	_	false	in patients taking druga , drugn , drugn , drugn , drugn , drugn , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p12	nifedipine	drug	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , druga , drugn , drugn , drugn , drugn , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p17	diltiazem	drug	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , drugn , druga , drugn , drugn , drugn , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p21	ACE inhibitors	group	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , drugn , drugn , druga , drugn , drugn , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p24	verapamil	drug	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , drugn , drugn , drugn , druga , drugn , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p26	glyburide	drug	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , drugn , drugn , drugn , drugn , druga , drugn , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s4.p27	propranolol	drug	_	hydrodolasetron	drug_n	_	false	in patients taking drugn , drugn , drugn , drugn , drugn , drugn , druga , and various chemotherapy agents , no effect was shown on the clearance of drugb .
DDI-DrugBank.d42.s5.p0	hydrodolasetron	drug_n	_	dolasetron mesylate	drug	_	false	clearance of druga decreased by about 27 % when drugb was administered intravenously concomitantly with drugn .
DDI-DrugBank.d42.s5.p1	hydrodolasetron	drug_n	_	atenolol	drug	_	false	clearance of druga decreased by about 27 % when drugn was administered intravenously concomitantly with drugb .
DDI-DrugBank.d42.s5.p2	dolasetron mesylate	drug	_	atenolol	drug	_	mechanism	clearance of drugn decreased by about 27 % when druga was administered intravenously concomitantly with drugb .
DDI-DrugBank.d42.s7.p0	Dolasetron mesylate	drug	_	chemotherapeutic agents	group	_	false	druga did not inhibit the antitumor activity of four drugb -lcb- drugn , drugn , drugn , drugn -rcb- in four murine models .
DDI-DrugBank.d42.s7.p1	Dolasetron mesylate	drug	_	cisplatin	drug	_	false	druga did not inhibit the antitumor activity of four drugn -lcb- drugb , drugn , drugn , drugn -rcb- in four murine models .
DDI-DrugBank.d42.s7.p2	Dolasetron mesylate	drug	_	5-fluorouracil	drug	_	false	druga did not inhibit the antitumor activity of four drugn -lcb- drugn , drugb , drugn , drugn -rcb- in four murine models .
DDI-DrugBank.d42.s7.p3	Dolasetron mesylate	drug	_	doxorubicin	drug	_	false	druga did not inhibit the antitumor activity of four drugn -lcb- drugn , drugn , drugb , drugn -rcb- in four murine models .
DDI-DrugBank.d42.s7.p4	Dolasetron mesylate	drug	_	cyclophosphamide	drug	_	false	druga did not inhibit the antitumor activity of four drugn -lcb- drugn , drugn , drugn , drugb -rcb- in four murine models .
DDI-DrugBank.d325.s1.p0	MAO inhibitors	group	_	dopamine HCl	drug	_	advise	patients who have been treated with druga within two to three weeks prior to the administration of drugb should receive initial doses of drugn no greater than one-tenth -lcb- 1/10 -rcb- of the usual dose .
DDI-DrugBank.d325.s1.p1	MAO inhibitors	group	_	dopamine HCl	drug	_	false	patients who have been treated with druga within two to three weeks prior to the administration of drugn should receive initial doses of drugb no greater than one-tenth -lcb- 1/10 -rcb- of the usual dose .
DDI-DrugBank.d325.s2.p0	dopamine HCl	drug	_	diuretic agents	group	_	effect	concurrent administration of low-dose druga and drugb may produce an additive or potentiating effect on urine flow .
DDI-DrugBank.d325.s4.p0	dopamine	drug	_	beta-adrenergic blocking agents	group	_	effect	cardiac effects of druga are antagonized by drugb , such as drugn and drugn .
DDI-DrugBank.d325.s4.p1	dopamine	drug	_	propranolol	drug	_	effect	cardiac effects of druga are antagonized by drugn , such as drugb and drugn .
DDI-DrugBank.d325.s4.p2	dopamine	drug	_	metoprolol	drug	_	effect	cardiac effects of druga are antagonized by drugn , such as drugn and drugb .
DDI-DrugBank.d325.s4.p3	beta-adrenergic blocking agents	group	_	propranolol	drug	_	false	cardiac effects of drugn are antagonized by druga , such as drugb and drugn .
DDI-DrugBank.d325.s4.p4	beta-adrenergic blocking agents	group	_	metoprolol	drug	_	false	cardiac effects of drugn are antagonized by druga , such as drugn and drugb .
DDI-DrugBank.d325.s4.p5	propranolol	drug	_	metoprolol	drug	_	false	cardiac effects of drugn are antagonized by drugn , such as druga and drugb .
DDI-DrugBank.d325.s5.p0	dopamine HCl	drug	_	alpha-adrenergic blocking agents	group	_	effect	the peripheral vasoconstriction caused by high doses of druga is antagonized by drugb .
DDI-DrugBank.d325.s6.p0	Dopamine	drug	_	alpha-adrenergic blocking agents	group	_	false	druga - induced renal and mesenteric vasodilation is not antagonized by either drugb or drugn .
DDI-DrugBank.d325.s6.p1	Dopamine	drug	_	beta-adrenergic blocking agents	drug	_	false	druga - induced renal and mesenteric vasodilation is not antagonized by either drugn or drugb .
DDI-DrugBank.d325.s6.p2	alpha-adrenergic blocking agents	group	_	beta-adrenergic blocking agents	drug	_	false	drugn - induced renal and mesenteric vasodilation is not antagonized by either druga or drugb .
DDI-DrugBank.d325.s7.p1	Butyrophenones	group	_	phenothiazines	group	_	false	druga -lcb- such as drugn -rcb- and drugb can suppress the drugn rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .
DDI-DrugBank.d325.s7.p2	Butyrophenones	group	_	dopamine	drug	_	effect	druga -lcb- such as drugn -rcb- and drugn can suppress the drugb rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .
DDI-DrugBank.d325.s7.p3	haloperidol	drug	_	phenothiazines	group	_	false	drugn -lcb- such as druga -rcb- and drugb can suppress the drugn rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .
DDI-DrugBank.d325.s7.p4	haloperidol	drug	_	dopamine	drug	_	effect	drugn -lcb- such as druga -rcb- and drugn can suppress the drugb rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .
DDI-DrugBank.d325.s7.p5	phenothiazines	group	_	dopamine	drug	_	effect	drugn -lcb- such as drugn -rcb- and druga can suppress the drugb rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .
DDI-DrugBank.d325.s8.p0	Cyclopropane	drug	_	halogenated hydrocarbon anesthetics	group	_	false	druga or drugb increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drugn , such as drugn .
DDI-DrugBank.d325.s8.p1	Cyclopropane	drug	_	catecholamines	group	_	effect	druga or drugn increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drugb , such as drugn .
DDI-DrugBank.d325.s8.p2	Cyclopropane	drug	_	dopamine	drug	_	effect	druga or drugn increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drugn , such as drugb .
DDI-DrugBank.d325.s8.p3	halogenated hydrocarbon anesthetics	group	_	catecholamines	group	_	effect	drugn or druga increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drugb , such as drugn .
DDI-DrugBank.d325.s8.p4	halogenated hydrocarbon anesthetics	group	_	dopamine	drug	_	effect	drugn or druga increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drugn , such as drugb .
DDI-DrugBank.d325.s8.p5	catecholamines	group	_	dopamine	drug	_	false	drugn or drugn increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered druga , such as drugb .
DDI-DrugBank.d325.s10.p0	dopamine HCl	drug	_	cyclopropane	drug	_	advise	therefore , extreme caution should be exercised when administering druga to patients receiving drugb or drugn .
DDI-DrugBank.d325.s10.p1	dopamine HCl	drug	_	halogenated hydrocarbon anesthetics	group	_	advise	therefore , extreme caution should be exercised when administering druga to patients receiving drugn or drugb .
DDI-DrugBank.d325.s10.p2	cyclopropane	drug	_	halogenated hydrocarbon anesthetics	group	_	false	therefore , extreme caution should be exercised when administering drugn to patients receiving druga or drugb .
DDI-DrugBank.d325.s11.p0	dopamine	drug	_	propranolol	drug	_	effect	it has been reported that results of studies in animals indicate that druga - induced ventricular arrhythmias during anesthesia can be reversed by drugb .
DDI-DrugBank.d325.s12.p0	vasopressor	group	_	ergonovine	drug	_	false	the concomitant use of druga s , vasoconstricting agents -lcb- such as drugb -rcb- and some drugn may result in severe hypertension .
DDI-DrugBank.d325.s12.p2	ergonovine	drug	_	oxytocic drugs	group	_	effect	the concomitant use of drugn s , vasoconstricting agents -lcb- such as druga -rcb- and some drugb may result in severe hypertension .
DDI-DrugBank.d325.s13.p0	phenytoin	drug	_	dopamine HCl	drug	_	effect	administration of druga to patients receiving drugb has been reported to lead to hypotension and bradycardia .
DDI-DrugBank.d325.s14.p0	dopamine HCl	drug	_	phenytoin	drug	_	advise	it is suggested that in patients receiving druga , alternatives to drugb should be used if drugn therapy is needed .
DDI-DrugBank.d325.s14.p1	dopamine HCl	drug	_	anticonvulsant	group	_	false	it is suggested that in patients receiving druga , alternatives to drugn should be used if drugb therapy is needed .
DDI-DrugBank.d325.s14.p2	phenytoin	drug	_	anticonvulsant	group	_	false	it is suggested that in patients receiving drugn , alternatives to druga should be used if drugb therapy is needed .
DDI-DrugBank.d93.s0.p0	Pulmozyme	brand	_	antibiotics	group	_	false	clinical trials have indicated that druga can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugb , drugn , enzyme supplements , drugn , oral or inhaled drugn , and drugn .
DDI-DrugBank.d93.s0.p1	Pulmozyme	brand	_	bronchodilators	group	_	false	clinical trials have indicated that druga can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugb , enzyme supplements , drugn , oral or inhaled drugn , and drugn .
DDI-DrugBank.d93.s0.p2	Pulmozyme	brand	_	vitamins	group	_	false	clinical trials have indicated that druga can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugn , enzyme supplements , drugb , oral or inhaled drugn , and drugn .
DDI-DrugBank.d93.s0.p3	Pulmozyme	brand	_	corticosteroids	group	_	false	clinical trials have indicated that druga can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugn , enzyme supplements , drugn , oral or inhaled drugb , and drugn .
DDI-DrugBank.d93.s0.p4	Pulmozyme	brand	_	analgesics	group	_	false	clinical trials have indicated that druga can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugn , enzyme supplements , drugn , oral or inhaled drugn , and drugb .
DDI-DrugBank.d93.s0.p7	antibiotics	group	_	corticosteroids	group	_	false	clinical trials have indicated that drugn can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral druga , drugn , enzyme supplements , drugn , oral or inhaled drugb , and drugn .
DDI-DrugBank.d93.s0.p10	bronchodilators	group	_	corticosteroids	group	_	false	clinical trials have indicated that drugn can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , druga , enzyme supplements , drugn , oral or inhaled drugb , and drugn .
DDI-DrugBank.d93.s0.p12	vitamins	group	_	corticosteroids	group	_	false	clinical trials have indicated that drugn can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugn , enzyme supplements , druga , oral or inhaled drugb , and drugn .
DDI-DrugBank.d93.s0.p14	corticosteroids	group	_	analgesics	group	_	false	clinical trials have indicated that drugn can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral drugn , drugn , enzyme supplements , drugn , oral or inhaled druga , and drugb .
DDI-DrugBank.d34.s0.p0	dorzolamide	drug	_	carbonic anhydrase inhibitors	group	_	effect	although acid-base and electrolyte disturbances were not reported in the clinical trials with druga , these disturbances have been reported with oral drugb and have , in some instances , resulted in drug interactions -lcb- e , g , , toxicity associated with high-dose drugn therapy -rcb- .
DDI-DrugBank.d34.s0.p1	dorzolamide	drug	_	salicylate	group	_	false	although acid-base and electrolyte disturbances were not reported in the clinical trials with druga , these disturbances have been reported with oral drugn and have , in some instances , resulted in drug interactions -lcb- e , g , , toxicity associated with high-dose drugb therapy -rcb- .
DDI-DrugBank.d34.s0.p2	carbonic anhydrase inhibitors	group	_	salicylate	group	_	false	although acid-base and electrolyte disturbances were not reported in the clinical trials with drugn , these disturbances have been reported with oral druga and have , in some instances , resulted in drug interactions -lcb- e , g , , toxicity associated with high-dose drugb therapy -rcb- .
DDI-DrugBank.d267.s0.p0	succinylcholine	drug	_	NUROMAX	brand	_	false	prior administration of druga has no clinically important effect on the neuromuscular blocking action of drugb .
DDI-DrugBank.d267.s1.p0	NUROMAX	brand	_	succinylcholine	drug	_	false	the use of druga before drugb to attenuate some of the side effects of drugn has not been studied .
DDI-DrugBank.d267.s1.p1	NUROMAX	brand	_	succinylcholine	drug	_	false	the use of druga before drugn to attenuate some of the side effects of drugb has not been studied .
DDI-DrugBank.d267.s2.p0	NUROMAX	brand	_	neuromuscular blocking agents	group	_	false	there are no clinical data on concomitant use of druga and other nondepolarizing drugb .
DDI-DrugBank.d267.s3.p2	Isoflurane	drug	_	NUROMAX	brand	_	mechanism	druga , drugn , and drugn decrease the ed50 of drugb by 30 % to 45 % .
DDI-DrugBank.d267.s3.p4	enflurane	drug	_	NUROMAX	brand	_	mechanism	drugn , druga , and drugn decrease the ed50 of drugb by 30 % to 45 % .
DDI-DrugBank.d267.s3.p5	halothane	drug	_	NUROMAX	brand	_	mechanism	drugn , drugn , and druga decrease the ed50 of drugb by 30 % to 45 % .
DDI-DrugBank.d267.s5.p0	NUROMAX	brand	_	antibiotics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p1	NUROMAX	brand	_	aminoglycosides	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p2	NUROMAX	brand	_	tetracyclines	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p3	NUROMAX	brand	_	bacitracin	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p4	NUROMAX	brand	_	polymyxins	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p5	NUROMAX	brand	_	lincomycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p6	NUROMAX	brand	_	clindamycin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p7	NUROMAX	brand	_	colistin	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p8	NUROMAX	brand	_	sodium colistimethate	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb -rcb- , drugn salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p9	NUROMAX	brand	_	magnesium	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugb salts , drugn , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p10	NUROMAX	brand	_	lithium	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p11	NUROMAX	brand	_	anesthetics	group	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d267.s5.p12	NUROMAX	brand	_	procainamide	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d267.s5.p13	NUROMAX	brand	_	quinidine	drug	_	effect	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as druga include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , drugn salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d267.s5.p95	magnesium	drug	_	lithium	drug	_	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugb , local drugn , drugn , and drugn .
DDI-DrugBank.d267.s5.p96	magnesium	drug	_	anesthetics	group	_	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugb , drugn , and drugn .
DDI-DrugBank.d267.s5.p97	magnesium	drug	_	procainamide	drug	_	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugb , and drugn .
DDI-DrugBank.d267.s5.p98	magnesium	drug	_	quinidine	drug	_	false	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drugn include certain drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- , druga salts , drugn , local drugn , drugn , and drugb .
DDI-DrugBank.d267.s6.p0	nondepolarizing neuromuscular blocking agents	group	_	NUROMAX	brand	_	false	as with some other druga , the time of onset of neuromuscular block induced by drugb is lengthened and the duration of block is shortened in patients receiving drugn or drugn .
DDI-DrugBank.d267.s6.p1	nondepolarizing neuromuscular blocking agents	group	_	phenytoin	drug	_	effect	as with some other druga , the time of onset of neuromuscular block induced by drugn is lengthened and the duration of block is shortened in patients receiving drugb or drugn .
DDI-DrugBank.d267.s6.p2	nondepolarizing neuromuscular blocking agents	group	_	carbamazepine	drug	_	effect	as with some other druga , the time of onset of neuromuscular block induced by drugn is lengthened and the duration of block is shortened in patients receiving drugn or drugb .
DDI-DrugBank.d267.s6.p3	NUROMAX	brand	_	phenytoin	drug	_	effect	as with some other drugn , the time of onset of neuromuscular block induced by druga is lengthened and the duration of block is shortened in patients receiving drugb or drugn .
DDI-DrugBank.d267.s6.p4	NUROMAX	brand	_	carbamazepine	drug	_	effect	as with some other drugn , the time of onset of neuromuscular block induced by druga is lengthened and the duration of block is shortened in patients receiving drugn or drugb .
DDI-DrugBank.d267.s6.p5	phenytoin	drug	_	carbamazepine	drug	_	false	as with some other drugn , the time of onset of neuromuscular block induced by drugn is lengthened and the duration of block is shortened in patients receiving druga or drugb .
DDI-DrugBank.d332.s0.p0	doxapram	drug	_	sympathomimetic	group	_	effect	administration of druga to patients who are receiving drugb or drugn may result in an additive pressor effect .
DDI-DrugBank.d332.s0.p1	doxapram	drug	_	monoamine oxidase inhibiting drugs	group	_	effect	administration of druga to patients who are receiving drugn or drugb may result in an additive pressor effect .
DDI-DrugBank.d332.s0.p2	sympathomimetic	group	_	monoamine oxidase inhibiting drugs	group	_	false	administration of drugn to patients who are receiving druga or drugb may result in an additive pressor effect .
DDI-DrugBank.d332.s1.p0	muscle relaxants	group	_	doxapram	drug	_	false	in patients who have received druga , drugb may temporarily mask the residual effects of drugn .
DDI-DrugBank.d332.s1.p1	muscle relaxants	group	_	muscle relaxant drugs	group	_	false	in patients who have received druga , drugn may temporarily mask the residual effects of drugb .
DDI-DrugBank.d332.s1.p2	doxapram	drug	_	muscle relaxant drugs	group	_	effect	in patients who have received drugn , druga may temporarily mask the residual effects of drugb .
DDI-DrugBank.d367.s1.p0	doxazosin mesylate	drug	_	digoxin	drug	_	false	in vitro data in human plasma indicate that druga has no effect on protein binding of drugb , drugn , drugn or drugn .
DDI-DrugBank.d367.s1.p1	doxazosin mesylate	drug	_	warfarin	drug	_	false	in vitro data in human plasma indicate that druga has no effect on protein binding of drugn , drugb , drugn or drugn .
DDI-DrugBank.d367.s1.p2	doxazosin mesylate	drug	_	phenytoin	drug	_	false	in vitro data in human plasma indicate that druga has no effect on protein binding of drugn , drugn , drugb or drugn .
DDI-DrugBank.d367.s1.p3	doxazosin mesylate	drug	_	indomethacin	drug	_	false	in vitro data in human plasma indicate that druga has no effect on protein binding of drugn , drugn , drugn or drugb .
DDI-DrugBank.d367.s3.p0	Doxazosin mesylate	drug	_	thiazide diuretics	group	_	false	druga has been administered without any evidence of an adverse drug interaction to patients receiving drugb , drugn s , and drugn .
DDI-DrugBank.d367.s3.p1	Doxazosin mesylate	drug	_	beta-blocking agent	group	_	false	druga has been administered without any evidence of an adverse drug interaction to patients receiving drugn , drugb s , and drugn .
DDI-DrugBank.d367.s3.p2	Doxazosin mesylate	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	druga has been administered without any evidence of an adverse drug interaction to patients receiving drugn , drugn s , and drugb .
DDI-DrugBank.d367.s4.p0	doxazosin	drug	_	cimetidine	drug	_	mechanism	in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of druga on day # of a four-day regimen of oral drugb -lcb- 400 mg twice daily -rcb- resulted in a 10 % increase in mean auc of drugn -lcb- p = # -rcb- , and a slight but not statistically significant increase in mean cmax and mean half-life of drugn .
DDI-DrugBank.d367.s4.p3	cimetidine	drug	_	doxazosin	drug	_	false	in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of drugn on day # of a four-day regimen of oral druga -lcb- 400 mg twice daily -rcb- resulted in a 10 % increase in mean auc of drugb -lcb- p = # -rcb- , and a slight but not statistically significant increase in mean cmax and mean half-life of drugn .
DDI-DrugBank.d367.s4.p4	cimetidine	drug	_	doxazosin	drug	_	false	in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of drugn on day # of a four-day regimen of oral druga -lcb- 400 mg twice daily -rcb- resulted in a 10 % increase in mean auc of drugn -lcb- p = # -rcb- , and a slight but not statistically significant increase in mean cmax and mean half-life of drugb .
DDI-DrugBank.d367.s9.p0	Analgesic	group	_	anti-inflammatory	group	_	false	druga / drugb -lcb- e , g , , drugn , drugn , drugn and drugn combinations , drugn , drugn -rcb- .
DDI-DrugBank.d367.s9.p1	Analgesic	group	_	acetaminophen	drug	_	false	druga / drugn -lcb- e , g , , drugb , drugn , drugn and drugn combinations , drugn , drugn -rcb- .
DDI-DrugBank.d367.s9.p2	Analgesic	group	_	aspirin	brand	_	false	druga / drugn -lcb- e , g , , drugn , drugb , drugn and drugn combinations , drugn , drugn -rcb- .
DDI-DrugBank.d367.s9.p3	Analgesic	group	_	codeine	drug	_	false	druga / drugn -lcb- e , g , , drugn , drugn , drugb and drugn combinations , drugn , drugn -rcb- .
DDI-DrugBank.d367.s9.p4	Analgesic	group	_	codeine	drug	_	false	druga / drugn -lcb- e , g , , drugn , drugn , drugn and drugb combinations , drugn , drugn -rcb- .
DDI-DrugBank.d367.s9.p5	Analgesic	group	_	ibuprofen	drug	_	false	druga / drugn -lcb- e , g , , drugn , drugn , drugn and drugn combinations , drugb , drugn -rcb- .
DDI-DrugBank.d367.s9.p6	Analgesic	group	_	indomethacin	drug	_	false	druga / drugn -lcb- e , g , , drugn , drugn , drugn and drugn combinations , drugn , drugb -rcb- .
DDI-DrugBank.d367.s23.p0	Sedatives	group	_	tranquilizers	group	_	false	druga and drugb -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d367.s23.p1	Sedatives	group	_	diazepam	drug	_	false	druga and drugn -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d223.s7.p0	cimetidine	drug	_	antidepressants	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugb , drugn , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d223.s7.p1	cimetidine	drug	_	phenothiazines	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugb , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d223.s7.p2	cimetidine	drug	_	Type 1C antiarrhythmics	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugb drugn and drugn -rcb- .
DDI-DrugBank.d223.s7.p3	cimetidine	drug	_	propafenone	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugb and drugn -rcb- .
DDI-DrugBank.d223.s7.p4	cimetidine	drug	_	flecainide	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugn and drugb -rcb- .
DDI-DrugBank.d223.s8.p1	selective serotonin reuptake inhibitors	group	_	citalopram	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugb , drugn , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p2	selective serotonin reuptake inhibitors	group	_	escitalopram	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugb , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p3	selective serotonin reuptake inhibitors	group	_	fluoxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p4	selective serotonin reuptake inhibitors	group	_	sertraline	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p5	selective serotonin reuptake inhibitors	group	_	paroxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p6	SSRIs	group	_	citalopram	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugb , drugn , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p7	SSRIs	group	_	escitalopram	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugb , drugn , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p8	SSRIs	group	_	fluoxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p9	SSRIs	group	_	sertraline	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s8.p10	SSRIs	group	_	paroxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d223.s9.p0	SSRI	group	_	TCA	group	_	int	the extent to which druga - drugb interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugn involved .
DDI-DrugBank.d223.s9.p2	TCA	group	_	SSRI	group	_	false	the extent to which drugn - druga interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drugb involved .
DDI-DrugBank.d223.s10.p0	TCAs	group	_	SSRIs	group	_	advise	nevertheless , caution is indicated in the co-administration of druga with any of the drugb and also in switching from one class to the other .
DDI-DrugBank.d223.s16.p1	quinidine	drug	_	SSRIs	group	_	false	inhibitors or substrates of cyp2d6 -lcb- i , e , , druga , drugn -lsb- drugb -rsb- -rcb- may increase the plasma concentration of drugn when administered concomitantly .
DDI-DrugBank.d223.s16.p2	quinidine	drug	_	doxepin	drug	_	mechanism	inhibitors or substrates of cyp2d6 -lcb- i , e , , druga , drugn -lsb- drugn -rsb- -rcb- may increase the plasma concentration of drugb when administered concomitantly .
DDI-DrugBank.d223.s16.p3	selective serotonin reuptake inhibitors	group	_	SSRIs	group	_	false	inhibitors or substrates of cyp2d6 -lcb- i , e , , drugn , druga -lsb- drugb -rsb- -rcb- may increase the plasma concentration of drugn when administered concomitantly .
DDI-DrugBank.d223.s16.p4	selective serotonin reuptake inhibitors	group	_	doxepin	drug	_	mechanism	inhibitors or substrates of cyp2d6 -lcb- i , e , , drugn , druga -lsb- drugn -rsb- -rcb- may increase the plasma concentration of drugb when administered concomitantly .
DDI-DrugBank.d223.s16.p5	SSRIs	group	_	doxepin	drug	_	mechanism	inhibitors or substrates of cyp2d6 -lcb- i , e , , drugn , drugn -lsb- druga -rsb- -rcb- may increase the plasma concentration of drugb when administered concomitantly .
DDI-DrugBank.d223.s20.p0	MAO inhibitors	group	_	SINEQUAN	brand	_	advise	therefore , druga should be discontinued at least two weeks prior to the cautious initiation of therapy with drugb .
DDI-DrugBank.d223.s22.p2	Cimetidine	drug	_	tricyclic antidepressants	group	_	mechanism	drugn : druga has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various drugb .
DDI-DrugBank.d223.s23.p0	tricyclic antidepressant	group	_	cimetidine	drug	_	effect	serious anticholinergic symptoms -lcb- i , e , , severe dry mouth , urinary retention and blurred vision -rcb- have been associated with elevations in the serum levels of druga when drugb therapy is initiated .
DDI-DrugBank.d223.s24.p0	tricyclic antidepressant	group	_	cimetidine	drug	_	mechanism	additionally , higher than expected druga levels have been observed when they are begun in patients already taking drugb .
DDI-DrugBank.d223.s25.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	false	in patients who have been reported to be well controlled on druga receiving concurrent drugb therapy , discontinuation of drugn has been reported to decrease established steady-state serum drugn levels and compromise their therapeutic effects .
DDI-DrugBank.d223.s25.p1	tricyclic antidepressants	group	_	cimetidine	drug	_	false	in patients who have been reported to be well controlled on druga receiving concurrent drugn therapy , discontinuation of drugb has been reported to decrease established steady-state serum drugn levels and compromise their therapeutic effects .
DDI-DrugBank.d223.s25.p4	cimetidine	drug	_	tricyclic antidepressant	group	_	false	in patients who have been reported to be well controlled on drugn receiving concurrent druga therapy , discontinuation of drugn has been reported to decrease established steady-state serum drugb levels and compromise their therapeutic effects .
DDI-DrugBank.d223.s25.p5	cimetidine	drug	_	tricyclic antidepressant	group	_	mechanism	in patients who have been reported to be well controlled on drugn receiving concurrent drugn therapy , discontinuation of druga has been reported to decrease established steady-state serum drugb levels and compromise their therapeutic effects .
DDI-DrugBank.d223.s26.p2	alcohol	drug	_	SINEQUAN	brand	_	mechanism	drugn : it should be borne in mind that druga ingestion may increase the danger inherent in any intentional or unintentional drugb overdosage .
DDI-DrugBank.d223.s28.p2	tolazamide	drug	_	doxepin	drug	_	effect	drugn : a case of severe hypoglycemia has been reported in a type ii diabetic patient maintained on druga -lcb- 1 gm/day -rcb- # days after the addition of drugb -lcb- 75 mg/day -rcb- .
DDI-DrugBank.d127.s2.p0	DOXIL	brand	_	doxorubicin HCl	drug	_	false	druga may interact with drugs known to interact with the conventional formulation of drugb .
DDI-DrugBank.d500.s0.p0	tetracyclines	group	_	anticoagulant	group	_	advise	because druga have been shown to depress plasma prothrombin activity , patients who are on drugb therapy may require downward adjustment of their drugn dosage .
DDI-DrugBank.d500.s0.p1	tetracyclines	group	_	anticoagulant	group	_	false	because druga have been shown to depress plasma prothrombin activity , patients who are on drugn therapy may require downward adjustment of their drugb dosage .
DDI-DrugBank.d500.s1.p0	penicillin	drug	_	tetracyclines	group	_	false	since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving drugb in conjunction with drugn .
DDI-DrugBank.d500.s1.p2	tetracyclines	group	_	penicillin	group	_	advise	since bacteriostatic drugs may interfere with the bactericidal action of drugn , it is advisable to avoid giving druga in conjunction with drugb .
DDI-DrugBank.d500.s2.p0	tetracyclines	group	_	antacids	group	_	false	absorption of druga is impaired by drugb containing drugn , drugn , or drugn , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p1	tetracyclines	group	_	aluminum	drug	_	mechanism	absorption of druga is impaired by drugn containing drugb , drugn , or drugn , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p2	tetracyclines	group	_	calcium	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugb , or drugn , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p3	tetracyclines	group	_	magnesium	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugn , or drugb , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p4	tetracyclines	group	_	iron	drug	_	mechanism	absorption of druga is impaired by drugn containing drugn , drugn , or drugn , and drugb - containing preparations .
DDI-DrugBank.d500.s2.p5	antacids	group	_	aluminum	drug	_	false	absorption of drugn is impaired by druga containing drugb , drugn , or drugn , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p6	antacids	group	_	calcium	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugb , or drugn , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p7	antacids	group	_	magnesium	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugn , or drugb , and drugn - containing preparations .
DDI-DrugBank.d500.s2.p8	antacids	group	_	iron	drug	_	false	absorption of drugn is impaired by druga containing drugn , drugn , or drugn , and drugb - containing preparations .
DDI-DrugBank.d500.s2.p11	aluminum	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing druga , drugn , or drugn , and drugb - containing preparations .
DDI-DrugBank.d500.s2.p13	calcium	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing drugn , druga , or drugn , and drugb - containing preparations .
DDI-DrugBank.d500.s2.p14	magnesium	drug	_	iron	drug	_	false	absorption of drugn is impaired by drugn containing drugn , drugn , or druga , and drugb - containing preparations .
DDI-DrugBank.d500.s3.p0	tetracycline	drug	_	bismuth subsalicylate	drug	_	mechanism	absorption of druga is impaired by drugb .
DDI-DrugBank.d500.s4.p2	Barbiturates	group	_	doxycycline	drug	_	mechanism	druga , drugn , and drugn decrease the half-life of drugb .
DDI-DrugBank.d500.s4.p4	carbamazepine	drug	_	doxycycline	drug	_	mechanism	drugn , druga , and drugn decrease the half-life of drugb .
DDI-DrugBank.d500.s4.p5	phenytoin	drug	_	doxycycline	drug	_	mechanism	drugn , drugn , and druga decrease the half-life of drugb .
DDI-DrugBank.d500.s5.p0	tetracycline	drug	_	Penthrane	brand	_	effect	the concurrent use of druga and drugb -lcb- drugn -rcb- has been reported to result in fatal renal toxicity .
DDI-DrugBank.d500.s5.p1	tetracycline	drug	_	methoxyflurane	drug	_	effect	the concurrent use of druga and drugn -lcb- drugb -rcb- has been reported to result in fatal renal toxicity .
DDI-DrugBank.d500.s6.p0	tetracycline	drug	_	contraceptives	group	_	effect	concurrent use of druga may render oral drugb less effective .
DDI-DrugBank.d387.s0.p1	doxylamine	drug	_	CNS depressant drugs	group	_	false	potential drug interactions for druga include , increased sedation if drugn is combined with other drugb .
DDI-DrugBank.d387.s0.p2	doxylamine	drug	_	CNS depressant drugs	group	_	effect	potential drug interactions for drugn include , increased sedation if druga is combined with other drugb .
DDI-DrugBank.d387.s1.p0	Antihistamines	group	_	heparin	drug	_	effect	druga may partially counteract the anticoagulation effects of drugb or drugn .
DDI-DrugBank.d387.s1.p1	Antihistamines	group	_	warfarin	drug	_	effect	druga may partially counteract the anticoagulation effects of drugn or drugb .
DDI-DrugBank.d387.s1.p2	heparin	drug	_	warfarin	drug	_	false	drugn may partially counteract the anticoagulation effects of druga or drugb .
DDI-DrugBank.d387.s2.p0	Doxylamine	drug	_	epinephrine	drug	_	effect	druga may enhance the effects of drugb .
DDI-DrugBank.d129.s2.p0	oxyphenbutazone	drug	_	androgens	group	_	mechanism	concurrent administration of druga and drugb may result in elevated serum levels of drugn .
DDI-DrugBank.d129.s2.p2	androgens	group	_	oxyphenbutazone	drug	_	false	concurrent administration of drugn and druga may result in elevated serum levels of drugb .
DDI-DrugBank.d129.s3.p0	androgens	group	_	insulin	drug	_	effect	in diabetic patients , the metabolic effects of druga may decrease blood glucose and therefore , drugb requirements .
DDI-DrugBank.d254.s0.p4	CNS depressant drugs	group	_	INAPSINE	brand	_	effect	other druga -lcb- e , g , drugn , drugn , drugn and general drugn -rcb- have additive or potentiating effects with drugb .
DDI-DrugBank.d254.s0.p8	barbiturates	group	_	INAPSINE	brand	_	effect	other drugn -lcb- e , g , druga , drugn , drugn and general drugn -rcb- have additive or potentiating effects with drugb .
DDI-DrugBank.d254.s0.p11	tranquilizers	group	_	INAPSINE	brand	_	effect	other drugn -lcb- e , g , drugn , druga , drugn and general drugn -rcb- have additive or potentiating effects with drugb .
DDI-DrugBank.d254.s0.p13	opioids	group	_	INAPSINE	brand	_	effect	other drugn -lcb- e , g , drugn , drugn , druga and general drugn -rcb- have additive or potentiating effects with drugb .
DDI-DrugBank.d254.s0.p14	anesthetics	group	_	INAPSINE	brand	_	effect	other drugn -lcb- e , g , drugn , drugn , drugn and general druga -rcb- have additive or potentiating effects with drugb .
DDI-DrugBank.d254.s2.p0	INAPSINE	brand	_	CNS depressant drugs	group	_	advise	following the administration of druga , the dose of other drugb should be reduced .
DDI-DrugBank.d190.s2.p2	unfractionated heparin	drug	_	low molecular weight heparins	group	_	false	approximately 2/3 of the patients in the phase # study received either prophylactic low dose drugn -lcb- druga up to 15,000 units/day -rcb- or prophylactic doses of drugb as indicated in the prescribing information for the specific products .
DDI-DrugBank.d190.s3.p0	heparin	drug	_	Xigris	brand	_	false	concomitant use of prophylactic low dose druga did not appear to affect safety , however , its effects on the efficacy of drugb have not been evaluated in an adequate and well-controlled clinical trial .
DDI-DrugBank.d548.s1.p0	duloxetine	drug	_	fluvoxamine	drug	_	mechanism	inhibitors of cyp1a2 : concomitant use of druga with drugb , an inhibitor of cyp1a2 , results in approximately a 6-fold increase in auc and about a # - fold increase in cmax of drugn .
DDI-DrugBank.d548.s1.p2	fluvoxamine	drug	_	duloxetine	drug	_	false	inhibitors of cyp1a2 : concomitant use of drugn with druga , an inhibitor of cyp1a2 , results in approximately a 6-fold increase in auc and about a # - fold increase in cmax of drugb .
DDI-DrugBank.d548.s4.p0	Paroxetine	drug	_	duloxetine	drug	_	mechanism	druga -lcb- 20 mg qd -rcb- increased the concentration of drugb -lcb- 40 mg qd -rcb- by about 60 % , and greater degrees of inhibition are expected with higher doses of drugn .
DDI-DrugBank.d548.s4.p2	duloxetine	drug	_	paroxetine	drug	_	false	drugn -lcb- 20 mg qd -rcb- increased the concentration of druga -lcb- 40 mg qd -rcb- by about 60 % , and greater degrees of inhibition are expected with higher doses of drugb .
DDI-DrugBank.d548.s8.p0	duloxetine	drug	_	desipramine	drug	_	mechanism	when druga was administered -lcb- at a dose of # mg bid -rcb- in conjunction with a single 50-mg dose of drugb , a cyp2d6 substrate , the auc of drugn increased 3-fold .
DDI-DrugBank.d548.s8.p1	duloxetine	drug	_	desipramine	drug	_	false	when druga was administered -lcb- at a dose of # mg bid -rcb- in conjunction with a single 50-mg dose of drugn , a cyp2d6 substrate , the auc of drugb increased 3-fold .
DDI-DrugBank.d548.s9.p0	Duloxetine	drug	_	antidepressants	group	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugb -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p1	Duloxetine	drug	_	tricyclic antidepressants	group	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugb -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p2	Duloxetine	drug	_	TCAs	group	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugb -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p3	Duloxetine	drug	_	nortriptyline	drug	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugb , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p4	Duloxetine	drug	_	amitriptyline	drug	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugb , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p5	Duloxetine	drug	_	imipramine	drug	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugb -rcb- , drugn and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p6	Duloxetine	drug	_	phenothiazines	group	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugb and drugn -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p7	Duloxetine	drug	_	Type 1C antiarrhythmics	group	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugb -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p8	Duloxetine	drug	_	propafenone	drug	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugb , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p9	Duloxetine	drug	_	flecainide	drug	_	advise	therefore , co-administration of druga with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , drugn and drugn -lcb- e , g , , drugn , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p49	phenothiazines	group	_	Type 1C antiarrhythmics	group	_	false	therefore , co-administration of drugn with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , druga and drugb -lcb- e , g , , drugn , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p50	phenothiazines	group	_	propafenone	drug	_	false	therefore , co-administration of drugn with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , druga and drugn -lcb- e , g , , drugb , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d548.s9.p51	phenothiazines	group	_	flecainide	drug	_	false	therefore , co-administration of drugn with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drugn -lcb- drugn -lsb- drugn -rsb- , such as drugn , drugn , and drugn -rcb- , druga and drugn -lcb- e , g , , drugn , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d548.s10.p2	TCA	group	_	Duloxetine	drug	_	false	plasma druga concentrations may need to be monitored and the dose of the drugn may need to be reduced if a drugn is co-administered with drugb .
DDI-DrugBank.d548.s10.p4	TCA	group	_	Duloxetine	drug	_	false	plasma drugn concentrations may need to be monitored and the dose of the druga may need to be reduced if a drugn is co-administered with drugb .
DDI-DrugBank.d548.s10.p5	TCA	group	_	Duloxetine	drug	_	advise	plasma drugn concentrations may need to be monitored and the dose of the drugn may need to be reduced if a druga is co-administered with drugb .
DDI-DrugBank.d548.s11.p0	thioridazine	drug	_	Duloxetine	drug	_	false	because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of druga , drugb and drugn should not be co-administered .
DDI-DrugBank.d548.s11.p2	Duloxetine	drug	_	thioridazine	drug	_	advise	because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of drugn , druga and drugb should not be co-administered .
DDI-DrugBank.d548.s13.p0	Duloxetine	drug	_	Alcohol	drug	_	false	druga may have a clinically important interaction with the following other drugs : drugb : when drugn and drugn were administered several hours apart so that peak concentrations of each would coincide , drugn did not increase the impairment of mental and motor skills caused by drugn .
DDI-DrugBank.d548.s13.p9	Duloxetine	drug	_	ethanol	drug	_	false	drugn may have a clinically important interaction with the following other drugs : drugn : when druga and drugb were administered several hours apart so that peak concentrations of each would coincide , drugn did not increase the impairment of mental and motor skills caused by drugn .
DDI-DrugBank.d548.s13.p11	Duloxetine	drug	_	alcohol	drug	_	false	drugn may have a clinically important interaction with the following other drugs : drugn : when druga and drugn were administered several hours apart so that peak concentrations of each would coincide , drugn did not increase the impairment of mental and motor skills caused by drugb .
DDI-DrugBank.d548.s13.p12	ethanol	drug	_	Duloxetine	drug	_	false	drugn may have a clinically important interaction with the following other drugs : drugn : when drugn and druga were administered several hours apart so that peak concentrations of each would coincide , drugb did not increase the impairment of mental and motor skills caused by drugn .
DDI-DrugBank.d548.s13.p13	ethanol	drug	_	alcohol	drug	_	false	drugn may have a clinically important interaction with the following other drugs : drugn : when drugn and druga were administered several hours apart so that peak concentrations of each would coincide , drugn did not increase the impairment of mental and motor skills caused by drugb .
DDI-DrugBank.d548.s13.p14	Duloxetine	drug	_	alcohol	drug	_	false	drugn may have a clinically important interaction with the following other drugs : drugn : when drugn and drugn were administered several hours apart so that peak concentrations of each would coincide , druga did not increase the impairment of mental and motor skills caused by drugb .
DDI-DrugBank.d548.s21.p0	Duloxetine	drug	_	aluminum	drug	_	false	however , co-administration of druga with drugb - and drugn - containing drugn -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p1	Duloxetine	drug	_	magnesium	drug	_	false	however , co-administration of druga with drugn - and drugb - containing drugn -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p2	Duloxetine	drug	_	antacids	group	_	false	however , co-administration of druga with drugn - and drugn - containing drugb -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p4	Duloxetine	drug	_	famotidine	drug	_	false	however , co-administration of druga with drugn - and drugn - containing drugn -lcb- 51 meq -rcb- or drugn with drugb , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p6	aluminum	drug	_	magnesium	drug	_	false	however , co-administration of drugn with druga - and drugb - containing drugn -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p7	aluminum	drug	_	antacids	group	_	false	however , co-administration of drugn with druga - and drugn - containing drugb -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p8	aluminum	drug	_	Duloxetine	drug	_	false	however , co-administration of drugn with druga - and drugn - containing drugn -lcb- 51 meq -rcb- or drugb with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p9	aluminum	drug	_	famotidine	drug	_	false	however , co-administration of drugn with druga - and drugn - containing drugn -lcb- 51 meq -rcb- or drugn with drugb , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p10	aluminum	drug	_	duloxetine	drug	_	false	however , co-administration of drugn with druga - and drugn - containing drugn -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugb absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p11	magnesium	drug	_	antacids	group	_	false	however , co-administration of drugn with drugn - and druga - containing drugb -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p12	magnesium	drug	_	Duloxetine	drug	_	false	however , co-administration of drugn with drugn - and druga - containing drugn -lcb- 51 meq -rcb- or drugb with drugn , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p13	magnesium	drug	_	famotidine	drug	_	false	however , co-administration of drugn with drugn - and druga - containing drugn -lcb- 51 meq -rcb- or drugn with drugb , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p14	magnesium	drug	_	duloxetine	drug	_	false	however , co-administration of drugn with drugn - and druga - containing drugn -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugb absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p16	antacids	group	_	famotidine	drug	_	false	however , co-administration of drugn with drugn - and drugn - containing druga -lcb- 51 meq -rcb- or drugn with drugb , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p17	antacids	group	_	duloxetine	drug	_	false	however , co-administration of drugn with drugn - and drugn - containing druga -lcb- 51 meq -rcb- or drugn with drugn , had no significant effect on the rate or extent of drugb absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p18	Duloxetine	drug	_	famotidine	drug	_	false	however , co-administration of drugn with drugn - and drugn - containing drugn -lcb- 51 meq -rcb- or druga with drugb , had no significant effect on the rate or extent of drugn absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s21.p20	famotidine	drug	_	duloxetine	drug	_	false	however , co-administration of drugn with drugn - and drugn - containing drugn -lcb- 51 meq -rcb- or drugn with druga , had no significant effect on the rate or extent of drugb absorption after administration of a 40-mg oral dose .
DDI-DrugBank.d548.s22.p0	proton pump inhibitors	group	_	duloxetine	drug	_	false	it is unknown whether the concomitant administration of druga affects drugb absorption .
DDI-DrugBank.d4.s0.p1	xanthine bronchodilators	group	_	ephedrine	drug	_	false	synergism between druga -lcb- e , g , , drugn -rcb- , drugb , and other drugn has been reported .
DDI-DrugBank.d4.s0.p2	xanthine bronchodilators	group	_	sympathomimetic bronchodilators	group	_	effect	synergism between druga -lcb- e , g , , drugn -rcb- , drugn , and other drugb has been reported .
DDI-DrugBank.d4.s0.p3	theophylline	drug	_	ephedrine	drug	_	false	synergism between drugn -lcb- e , g , , druga -rcb- , drugb , and other drugn has been reported .
DDI-DrugBank.d4.s0.p4	theophylline	drug	_	sympathomimetic bronchodilators	group	_	effect	synergism between drugn -lcb- e , g , , druga -rcb- , drugn , and other drugb has been reported .
DDI-DrugBank.d4.s0.p5	ephedrine	drug	_	sympathomimetic bronchodilators	group	_	effect	synergism between drugn -lcb- e , g , , drugn -rcb- , druga , and other drugb has been reported .
DDI-DrugBank.d4.s2.p0	dyphylline	drug	_	probenecid	drug	_	mechanism	concurrent administration of druga and drugb , which competes for tubular secretion , has been shown to increase the plasma half-life of drugn .
DDI-DrugBank.d4.s2.p2	probenecid	drug	_	dyphylline	drug	_	false	concurrent administration of drugn and druga , which competes for tubular secretion , has been shown to increase the plasma half-life of drugb .
DDI-DrugBank.d377.s0.p0	Phospholine Iodide	drug	_	cholinesterase inhibitors	group	_	effect	druga potentiates other drugb such as drugn or drugn and drugn .
DDI-DrugBank.d377.s0.p1	Phospholine Iodide	drug	_	succinylcholine	drug	_	effect	druga potentiates other drugn such as drugb or drugn and drugn .
DDI-DrugBank.d377.s0.p2	Phospholine Iodide	drug	_	organophosphate insecticide	drug_n	_	effect	druga potentiates other drugn such as drugn or drugb and drugn .
DDI-DrugBank.d377.s0.p3	Phospholine Iodide	drug	_	carbamate insecticide	drug_n	_	effect	druga potentiates other drugn such as drugn or drugn and drugb .
DDI-DrugBank.d377.s0.p4	cholinesterase inhibitors	group	_	succinylcholine	drug	_	false	drugn potentiates other druga such as drugb or drugn and drugn .
DDI-DrugBank.d377.s0.p5	cholinesterase inhibitors	group	_	organophosphate insecticide	drug_n	_	false	drugn potentiates other druga such as drugn or drugb and drugn .
DDI-DrugBank.d377.s0.p6	cholinesterase inhibitors	group	_	carbamate insecticide	drug_n	_	false	drugn potentiates other druga such as drugn or drugn and drugb .
DDI-DrugBank.d377.s0.p7	succinylcholine	drug	_	organophosphate insecticide	drug_n	_	false	drugn potentiates other drugn such as druga or drugb and drugn .
DDI-DrugBank.d377.s0.p9	organophosphate insecticide	drug_n	_	carbamate insecticide	drug_n	_	false	drugn potentiates other drugn such as drugn or druga and drugb .
DDI-DrugBank.d191.s1.p0	Steroids	group	_	edetate calcium disodium	drug	_	effect	druga enhance the renal toxicity of drugb in animals , # drugn interferes with the action of drugn preparations by chelating the drugn , 7
DDI-DrugBank.d191.s1.p1	Steroids	group	_	Edetate calcium disodium	drug	_	false	druga enhance the renal toxicity of drugn in animals , # drugb interferes with the action of drugn preparations by chelating the drugn , 7
DDI-DrugBank.d191.s1.p2	Steroids	group	_	zinc insulin	drug	_	false	druga enhance the renal toxicity of drugn in animals , # drugn interferes with the action of drugb preparations by chelating the drugn , 7
DDI-DrugBank.d191.s1.p3	Steroids	group	_	zinc	drug	_	false	druga enhance the renal toxicity of drugn in animals , # drugn interferes with the action of drugn preparations by chelating the drugb , 7
DDI-DrugBank.d191.s1.p5	edetate calcium disodium	drug	_	zinc insulin	drug	_	false	drugn enhance the renal toxicity of druga in animals , # drugn interferes with the action of drugb preparations by chelating the drugn , 7
DDI-DrugBank.d191.s1.p6	edetate calcium disodium	drug	_	zinc	drug	_	false	drugn enhance the renal toxicity of druga in animals , # drugn interferes with the action of drugn preparations by chelating the drugb , 7
DDI-DrugBank.d191.s1.p7	Edetate calcium disodium	drug	_	zinc insulin	drug	_	mechanism	drugn enhance the renal toxicity of drugn in animals , # druga interferes with the action of drugb preparations by chelating the drugn , 7
DDI-DrugBank.d191.s1.p8	Edetate calcium disodium	drug	_	zinc	drug	_	false	drugn enhance the renal toxicity of drugn in animals , # druga interferes with the action of drugn preparations by chelating the drugb , 7
DDI-DrugBank.d44.s1.p0	RAPTIVA	brand	_	immunosuppressive drugs	group	_	advise	druga should not be used with other drugb .
DDI-DrugBank.d44.s2.p1	Acellular vaccines	group	_	live-attenuated vaccines	group	_	false	druga , drugn and drugb should not be administered during drugn treatment .
DDI-DrugBank.d44.s2.p2	Acellular vaccines	group	_	RAPTIVA	brand	_	advise	druga , drugn and drugn should not be administered during drugb treatment .
DDI-DrugBank.d44.s2.p4	live vaccines	group	_	RAPTIVA	brand	_	advise	drugn , druga and drugn should not be administered during drugb treatment .
DDI-DrugBank.d44.s2.p5	live-attenuated vaccines	group	_	RAPTIVA	brand	_	advise	drugn , drugn and druga should not be administered during drugb treatment .
DDI-DrugBank.d531.s5.p2	phenobarbital	drug	_	efavirenz	drug	_	mechanism	drugs which induce cyp3a4 activity -lcb- eg , druga , drugn , drugn -rcb- would be expected to increase the clearance of drugb resulting in lowered plasma concentrations .
DDI-DrugBank.d531.s5.p4	rifampin	drug	_	efavirenz	drug	_	mechanism	drugs which induce cyp3a4 activity -lcb- eg , drugn , druga , drugn -rcb- would be expected to increase the clearance of drugb resulting in lowered plasma concentrations .
DDI-DrugBank.d531.s5.p5	rifabutin	drug	_	efavirenz	drug	_	mechanism	drugs which induce cyp3a4 activity -lcb- eg , drugn , drugn , druga -rcb- would be expected to increase the clearance of drugb resulting in lowered plasma concentrations .
DDI-DrugBank.d531.s10.p3	Benzodiazepines	group	_	Anti-Migraine	group	_	false	drugn : druga gi motility agents drugb drugn
DDI-DrugBank.d531.s10.p4	Benzodiazepines	group	_	Antifungal	group	_	false	drugn : druga gi motility agents drugn drugb
DDI-DrugBank.d531.s10.p5	Anti-Migraine	group	_	Antifungal	group	_	false	drugn : drugn gi motility agents druga drugb
DDI-DrugBank.d531.s11.p0	astemizole	drug	_	midazolam	drug	_	false	druga drugb , drugn drugn ergot derivatives drugn
DDI-DrugBank.d531.s11.p1	astemizole	drug	_	triazolam	drug	_	false	druga drugn , drugb drugn ergot derivatives drugn
DDI-DrugBank.d531.s11.p2	astemizole	drug	_	cisapride	drug	_	false	druga drugn , drugn drugb ergot derivatives drugn
DDI-DrugBank.d531.s11.p3	astemizole	drug	_	voriconazole	drug	_	false	druga drugn , drugn drugn ergot derivatives drugb
DDI-DrugBank.d531.s11.p4	midazolam	drug	_	triazolam	drug	_	false	drugn druga , drugb drugn ergot derivatives drugn
DDI-DrugBank.d531.s11.p5	midazolam	drug	_	cisapride	drug	_	false	drugn druga , drugn drugb ergot derivatives drugn
DDI-DrugBank.d531.s11.p6	midazolam	drug	_	voriconazole	drug	_	false	drugn druga , drugn drugn ergot derivatives drugb
DDI-DrugBank.d531.s11.p7	triazolam	drug	_	cisapride	drug	_	false	drugn drugn , druga drugb ergot derivatives drugn
DDI-DrugBank.d531.s11.p8	triazolam	drug	_	voriconazole	drug	_	false	drugn drugn , druga drugn ergot derivatives drugb
DDI-DrugBank.d531.s11.p9	cisapride	drug	_	voriconazole	drug	_	false	drugn drugn , drugn druga ergot derivatives drugb
DDI-DrugBank.d531.s19.p0	SUSTIVA	brand	_	atazanavir	drug	_	false	when coadministered with druga in treatment-naive patients , the recommended dose of drugb is # mg with drugn # mg and drugn # mg -lcb- all once daily -rcb- .
DDI-DrugBank.d531.s19.p1	SUSTIVA	brand	_	ritonavir	drug	_	false	when coadministered with druga in treatment-naive patients , the recommended dose of drugn is # mg with drugb # mg and drugn # mg -lcb- all once daily -rcb- .
DDI-DrugBank.d531.s19.p3	atazanavir	drug	_	ritonavir	drug	_	false	when coadministered with drugn in treatment-naive patients , the recommended dose of druga is # mg with drugb # mg and drugn # mg -lcb- all once daily -rcb- .
DDI-DrugBank.d531.s19.p4	atazanavir	drug	_	SUSTIVA	brand	_	false	when coadministered with drugn in treatment-naive patients , the recommended dose of druga is # mg with drugn # mg and drugb # mg -lcb- all once daily -rcb- .
DDI-DrugBank.d531.s19.p5	ritonavir	drug	_	SUSTIVA	brand	_	false	when coadministered with drugn in treatment-naive patients , the recommended dose of drugn is # mg with druga # mg and drugb # mg -lcb- all once daily -rcb- .
DDI-DrugBank.d531.s20.p0	SUSTIVA	brand	_	atazanavir	drug	_	false	dosing recommendations for druga and drugb in treatment-experienced patients have not been established .
DDI-DrugBank.d531.s29.p0	SUSTIVA	brand	_	clarithromycin	drug	_	effect	in uninfected volunteers , 46 % developed rash while receiving druga and drugb .
DDI-DrugBank.d531.s30.p0	SUSTIVA	brand	_	clarithromycin	drug	_	false	no dose adjustment of druga is recommended when given with drugb .
DDI-DrugBank.d531.s31.p0	clarithromycin	drug	_	azithromycin	drug	_	false	alternatives to druga , such as drugb , should be considered .
DDI-DrugBank.d531.s32.p0	macrolide antibiotics	group	_	erythromycin	drug	_	false	other druga , such as drugb , have not been studied in combination with drugn .
DDI-DrugBank.d531.s32.p1	macrolide antibiotics	group	_	SUSTIVA	brand	_	false	other druga , such as drugn , have not been studied in combination with drugb .
DDI-DrugBank.d531.s32.p2	erythromycin	drug	_	SUSTIVA	brand	_	false	other drugn , such as druga , have not been studied in combination with drugb .
DDI-DrugBank.d531.s37.p0	indinavir	drug	_	SUSTIVA	brand	_	false	the optimal dose of druga , when given in combination with drugb , is not known .
DDI-DrugBank.d531.s38.p1	indinavir	drug	_	SUSTIVA	brand	_	false	increasing the druga dose to # mg every # hours does not compensate for the increased drugn metabolism due to drugb .
DDI-DrugBank.d531.s38.p2	indinavir	drug	_	SUSTIVA	brand	_	mechanism	increasing the drugn dose to # mg every # hours does not compensate for the increased druga metabolism due to drugb .
DDI-DrugBank.d531.s39.p0	indinavir	drug	_	SUSTIVA	brand	_	mechanism	when druga at an increased dose -lcb- 1000 mg every # hours -rcb- was given with drugb -lcb- 600 mg once daily -rcb- , the drugn auc and cmin were decreased on average by 33-46 % and 39-57 % , respectively , compared to when drugn -lcb- 800 mg every # hours -rcb- was given alone .
DDI-DrugBank.d531.s39.p3	SUSTIVA	brand	_	indinavir	drug	_	false	when drugn at an increased dose -lcb- 1000 mg every # hours -rcb- was given with druga -lcb- 600 mg once daily -rcb- , the drugb auc and cmin were decreased on average by 33-46 % and 39-57 % , respectively , compared to when drugn -lcb- 800 mg every # hours -rcb- was given alone .
DDI-DrugBank.d531.s39.p4	SUSTIVA	brand	_	indinavir	drug	_	false	when drugn at an increased dose -lcb- 1000 mg every # hours -rcb- was given with druga -lcb- 600 mg once daily -rcb- , the drugn auc and cmin were decreased on average by 33-46 % and 39-57 % , respectively , compared to when drugb -lcb- 800 mg every # hours -rcb- was given alone .
DDI-DrugBank.d531.s40.p0	Lopinavir	drug	_	ritonavir	drug	_	false	druga / drugb
DDI-DrugBank.d531.s42.p1	lopinavir	drug	_	SUSTIVA	brand	_	advise	a dose increase of druga / drugn to 533/133 mg -lcb- 4 capsules or # ml -rcb- twice daily taken with food is recommended when used in combination with drugb .
DDI-DrugBank.d531.s42.p2	ritonavir	drug	_	SUSTIVA	brand	_	advise	a dose increase of drugn / druga to 533/133 mg -lcb- 4 capsules or # ml -rcb- twice daily taken with food is recommended when used in combination with drugb .
DDI-DrugBank.d531.s45.p0	methadone	drug	_	opiate	group	_	false	coadministration in hiv-infected individuals with a history of injection drug use resulted in decreased plasma levels of druga and signs of drugb withdrawal .
DDI-DrugBank.d531.s52.p0	efavirenz	drug	_	contraceptives	group	_	advise	because the potential interaction of druga with oral drugb has not been fully characterized , a reliable method of barrier contraception should be used in addition to oral drugn .
DDI-DrugBank.d531.s52.p1	efavirenz	drug	_	contraceptives	group	_	false	because the potential interaction of druga with oral drugn has not been fully characterized , a reliable method of barrier contraception should be used in addition to oral drugb .
DDI-DrugBank.d531.s63.p0	SUSTIVA	brand	_	ritonavir	drug	_	advise	monitoring of liver enzymes is recommended when druga is used in combination with drugb .
DDI-DrugBank.d531.s67.p0	protease inhibitor	group	_	SUSTIVA	brand	_	false	should not be used as sole druga in combination with drugb .
DDI-DrugBank.d531.s72.p0	Anticoagulants	group	_	Warfarin	drug	_	false	druga : drugb
DDI-DrugBank.d531.s74.p0	Anticonvulsants	group	_	Phenytoin	drug	_	false	druga : drugb drugn drugn
DDI-DrugBank.d531.s74.p1	Anticonvulsants	group	_	Phenobarbital	drug	_	false	druga : drugn drugb drugn
DDI-DrugBank.d531.s74.p2	Anticonvulsants	group	_	Carbamazepine	drug	_	false	druga : drugn drugn drugb
DDI-DrugBank.d531.s74.p3	Phenytoin	drug	_	Phenobarbital	drug	_	false	drugn : druga drugb drugn
DDI-DrugBank.d531.s74.p4	Phenytoin	drug	_	Carbamazepine	drug	_	false	drugn : druga drugn drugb
DDI-DrugBank.d531.s74.p5	Phenobarbital	drug	_	Carbamazepine	drug	_	false	drugn : drugn druga drugb
DDI-DrugBank.d531.s75.p0	anticonvulsant	group	_	efavirenz	drug	_	mechanism	potential for reduction in druga and/or drugb plasma levels ;
DDI-DrugBank.d531.s77.p0	Antifungals	group	_	Itraconazole	drug	_	false	druga : drugb drugn
DDI-DrugBank.d531.s77.p1	Antifungals	group	_	Ketoconazole	drug	_	false	druga : drugn drugb
DDI-DrugBank.d531.s77.p2	Itraconazole	drug	_	Ketoconazole	drug	_	false	drugn : druga drugb
DDI-DrugBank.d531.s78.p0	SUSTIVA	brand	_	imidazole antifungals	group	_	false	drug interaction studies with druga and these drugb and drugn have not been conducted .
DDI-DrugBank.d531.s79.p0	SUSTIVA	brand	_	itraconazole	drug	_	mechanism	druga has the potential to decrease plasma concentrations of drugb and drugn .
DDI-DrugBank.d531.s79.p1	SUSTIVA	brand	_	ketoconazole	drug	_	mechanism	druga has the potential to decrease plasma concentrations of drugn and drugb .
DDI-DrugBank.d531.s79.p2	itraconazole	drug	_	ketoconazole	drug	_	false	drugn has the potential to decrease plasma concentrations of druga and drugb .
DDI-DrugBank.d531.s80.p0	Anti-HIV protease inhibitors	group	_	Saquinavir	drug	_	false	druga : drugb / drugn combination
DDI-DrugBank.d531.s80.p1	Anti-HIV protease inhibitors	group	_	ritonavir	drug	_	false	druga : drugn / drugb combination
DDI-DrugBank.d531.s87.p0	efavirenz	drug	_	SUSTIVA	brand	_	false	expected to substantially decrease plasma levels of druga ; has not been studied in combination with drugb .
DDI-DrugBank.d531.s90.p1	SUSTIVA	brand	_	aluminum/magnesium hydroxide antacids	group	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p2	SUSTIVA	brand	_	azithromycin	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p3	SUSTIVA	brand	_	cetirizine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p4	SUSTIVA	brand	_	famotidine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p5	SUSTIVA	brand	_	fluconazole	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p6	SUSTIVA	brand	_	lamivudine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p7	SUSTIVA	brand	_	lorazepam	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p8	SUSTIVA	brand	_	nelfinavir	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d531.s90.p9	SUSTIVA	brand	_	paroxetine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d531.s90.p10	SUSTIVA	brand	_	zidovudine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when druga -lcb- drugn -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d531.s90.p11	efavirenz	drug	_	aluminum/magnesium hydroxide antacids	group	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p12	efavirenz	drug	_	azithromycin	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p13	efavirenz	drug	_	cetirizine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p14	efavirenz	drug	_	famotidine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p15	efavirenz	drug	_	fluconazole	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p16	efavirenz	drug	_	lamivudine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p17	efavirenz	drug	_	lorazepam	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d531.s90.p18	efavirenz	drug	_	nelfinavir	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d531.s90.p19	efavirenz	drug	_	paroxetine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d531.s90.p20	efavirenz	drug	_	zidovudine	drug	_	false	other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when drugn -lcb- druga -rcb- is given with the following : drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d531.s91.p0	SUSTIVA	brand	_	NRTIs	group	_	false	specific drug interaction studies have not been performed with druga and drugb other than drugn and drugn .
DDI-DrugBank.d531.s91.p1	SUSTIVA	brand	_	lamivudine	drug	_	false	specific drug interaction studies have not been performed with druga and drugn other than drugb and drugn .
DDI-DrugBank.d531.s91.p2	SUSTIVA	brand	_	zidovudine	drug	_	false	specific drug interaction studies have not been performed with druga and drugn other than drugn and drugb .
DDI-DrugBank.d531.s91.p3	NRTIs	group	_	lamivudine	drug	_	false	specific drug interaction studies have not been performed with drugn and druga other than drugb and drugn .
DDI-DrugBank.d531.s91.p4	NRTIs	group	_	zidovudine	drug	_	false	specific drug interaction studies have not been performed with drugn and druga other than drugn and drugb .
DDI-DrugBank.d531.s91.p5	lamivudine	drug	_	zidovudine	drug	_	false	specific drug interaction studies have not been performed with drugn and drugn other than druga and drugb .
DDI-DrugBank.d531.s92.p0	NRTIs	group	_	efavirenz	drug	_	false	clinically significant interactions would not be expected since the druga are metabolized via a different route than drugb and would be unlikely to compete for the same metabolic enzymes and elimination pathways .
DDI-DrugBank.d375.s0.p0	EMTRIVA	brand	_	indinavir	drug	_	false	the potential for drug interactions with druga has been studied in combination with drugb , drugn , drugn , and drugn .
DDI-DrugBank.d375.s0.p1	EMTRIVA	brand	_	stavudine	drug	_	false	the potential for drug interactions with druga has been studied in combination with drugn , drugb , drugn , and drugn .
DDI-DrugBank.d375.s0.p2	EMTRIVA	brand	_	famciclovir	drug	_	false	the potential for drug interactions with druga has been studied in combination with drugn , drugn , drugb , and drugn .
DDI-DrugBank.d375.s0.p3	EMTRIVA	brand	_	tenofovir disoproxil fumarate	drug	_	false	the potential for drug interactions with druga has been studied in combination with drugn , drugn , drugn , and drugb .
DDI-DrugBank.d107.s0.p0	diuretics	drug	_	enalapril	drug	_	effect	hypotension : patients on diuretic therapy : patients on druga and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb or drugn .
DDI-DrugBank.d107.s0.p1	diuretics	drug	_	enalaprilat	drug	_	effect	hypotension : patients on diuretic therapy : patients on druga and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugn or drugb .
DDI-DrugBank.d107.s1.p1	enalapril	drug	_	diuretic	drug	_	effect	the possibility of hypotensive effects with druga or drugn can be minimized by either discontinuing the drugb or increasing the salt intake prior to initiation of treatment with drugn or drugn .
DDI-DrugBank.d107.s1.p4	enalaprilat	drug	_	diuretic	drug	_	effect	the possibility of hypotensive effects with drugn or druga can be minimized by either discontinuing the drugb or increasing the salt intake prior to initiation of treatment with drugn or drugn .
DDI-DrugBank.d107.s1.p7	diuretic	drug	_	enalapril	drug	_	false	the possibility of hypotensive effects with drugn or drugn can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb or drugn .
DDI-DrugBank.d107.s1.p8	diuretic	drug	_	enalaprilat	drug	_	false	the possibility of hypotensive effects with drugn or drugn can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugn or drugb .
DDI-DrugBank.d107.s3.p1	enalapril	drug	_	antihypertensive agents	group	_	effect	agents causing renin release : the antihypertensive effect of druga and drugn iv is augmented by drugb that cause renin release -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d107.s3.p2	enalapril	drug	_	diuretics	group	_	effect	agents causing renin release : the antihypertensive effect of druga and drugn iv is augmented by drugn that cause renin release -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d107.s3.p3	enalapril	drug	_	antihypertensive agents	group	_	effect	agents causing renin release : the antihypertensive effect of drugn and druga iv is augmented by drugb that cause renin release -lcb- e , g , , drugn -rcb- .
DDI-DrugBank.d107.s3.p4	enalapril	drug	_	diuretics	group	_	effect	agents causing renin release : the antihypertensive effect of drugn and druga iv is augmented by drugn that cause renin release -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d107.s3.p5	antihypertensive agents	group	_	diuretics	group	_	false	agents causing renin release : the antihypertensive effect of drugn and drugn iv is augmented by druga that cause renin release -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d107.s4.p2	nonsteroidal anti-inflammatory drugs	group	_	enalapril	drug	_	effect	drugn : in some patients with compromised renal function who are being treated with druga , the co-administration of drugb may result in a further deterioration of renal function .
DDI-DrugBank.d107.s6.p0	indomethacin	drug	_	sulindac	drug	_	false	in a clinical pharmacology study , druga or drugb was administered to hypertensive patients receiving drugn .
DDI-DrugBank.d107.s6.p1	indomethacin	drug	_	VASOTEC	brand	_	false	in a clinical pharmacology study , druga or drugn was administered to hypertensive patients receiving drugb .
DDI-DrugBank.d107.s6.p2	sulindac	drug	_	VASOTEC	brand	_	false	in a clinical pharmacology study , drugn or druga was administered to hypertensive patients receiving drugb .
DDI-DrugBank.d107.s8.p0	NSAIDs	group	_	ACE inhibitors	group	_	effect	however , reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d107.s9.p0	NSAIDs	group	_	ACE inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d107.s10.p1	Enalapril	drug	_	beta adrenergic-blocking agents	group	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugb , drugn , drugn , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p2	Enalapril	drug	_	methyldopa	drug	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugb , drugn , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p3	Enalapril	drug	_	nitrates	group	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugn , drugb , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p4	Enalapril	drug	_	calcium-blocking agents	group	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugn , drugn , drugb , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p5	Enalapril	drug	_	hydralazine	drug	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , drugb , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p6	Enalapril	drug	_	prazosin	drug	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , drugn , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p7	Enalapril	drug	_	digoxin	drug	_	false	other cardiovascular agents : druga and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , drugn , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p8	enalapril	drug	_	beta adrenergic-blocking agents	group	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugb , drugn , drugn , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p9	enalapril	drug	_	methyldopa	drug	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugb , drugn , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p10	enalapril	drug	_	nitrates	group	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugn , drugb , drugn , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p11	enalapril	drug	_	calcium-blocking agents	group	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugn , drugn , drugb , drugn , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p12	enalapril	drug	_	hydralazine	drug	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugn , drugn , drugn , drugb , drugn and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p13	enalapril	drug	_	prazosin	drug	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugn , drugn , drugn , drugn , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p14	enalapril	drug	_	digoxin	drug	_	false	other cardiovascular agents : drugn and druga iv have been used concomitantly with drugn , drugn , drugn , drugn , drugn , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p24	methyldopa	drug	_	prazosin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , druga , drugn , drugn , drugn , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p25	methyldopa	drug	_	digoxin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , druga , drugn , drugn , drugn , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p28	nitrates	group	_	prazosin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , druga , drugn , drugn , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p29	nitrates	group	_	digoxin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , druga , drugn , drugn , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p31	calcium-blocking agents	group	_	prazosin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , drugn , druga , drugn , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p32	calcium-blocking agents	group	_	digoxin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , drugn , druga , drugn , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p33	hydralazine	drug	_	prazosin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , druga , drugb and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p34	hydralazine	drug	_	digoxin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , druga , drugn and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s10.p35	prazosin	drug	_	digoxin	drug	_	false	other cardiovascular agents : drugn and drugn iv have been used concomitantly with drugn , drugn , drugn , drugn , drugn , druga and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d107.s11.p0	Enalapril	drug	_	digitalis	group	_	false	druga iv has been used concomitantly with drugb without evidence of clinically significant adverse reactions .
DDI-DrugBank.d107.s12.p1	Enalapril	drug	_	thiazide-type diuretics	group	_	effect	agents increasing serum potassium : druga and drugn iv attenuate potassium loss caused by drugb .
DDI-DrugBank.d107.s12.p2	enalapril	drug	_	thiazide-type diuretics	group	_	effect	agents increasing serum potassium : drugn and druga iv attenuate potassium loss caused by drugb .
DDI-DrugBank.d107.s13.p7	spironolactone	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , druga , drugn , or drugn -rcb- , drugb supplements , or drugn - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s13.p8	spironolactone	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , druga , drugn , or drugn -rcb- , drugn supplements , or drugb - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s13.p10	triamterene	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , drugn , druga , or drugn -rcb- , drugb supplements , or drugn - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s13.p11	triamterene	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , drugn , druga , or drugn -rcb- , drugn supplements , or drugb - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s13.p12	amiloride	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , drugn , drugn , or druga -rcb- , drugb supplements , or drugn - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s13.p13	amiloride	drug	_	potassium	drug	_	false	drugn -lcb- e , g , , drugn , drugn , or druga -rcb- , drugn supplements , or drugb - containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d107.s16.p4	Lithium	drug	_	ACE inhibitors	group	_	false	drugn : druga toxicity has been reported in patients receiving drugn concomitantly with drugs which cause elimination of sodium , including drugb .
DDI-DrugBank.d107.s16.p5	lithium	drug	_	ACE inhibitors	group	_	effect	drugn : drugn toxicity has been reported in patients receiving druga concomitantly with drugs which cause elimination of sodium , including drugb .
DDI-DrugBank.d107.s17.p0	lithium	drug	_	enalapril	drug	_	false	it is recommended that serum druga levels be monitored frequently if drugb is administered concomitantly with drugn .
DDI-DrugBank.d107.s17.p2	enalapril	drug	_	lithium	drug	_	advise	it is recommended that serum drugn levels be monitored frequently if druga is administered concomitantly with drugb .
DDI-DrugBank.d6.s2.p0	Enflurane	drug	_	halothane	drug	_	false	if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of druga than when drugb or drugn with a balanced technique are used .
DDI-DrugBank.d6.s2.p1	Enflurane	drug	_	nitrous oxide	drug	_	false	if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of druga than when drugn or drugb with a balanced technique are used .
DDI-DrugBank.d6.s2.p2	halothane	drug	_	nitrous oxide	drug	_	false	if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of drugn than when druga or drugb with a balanced technique are used .
DDI-DrugBank.d535.s1.p3	antiretroviral medications	group	_	enfuvirtide	drug	_	false	drugn : no drug interactions with other druga have been identified that would warrant alteration of either the drugb dose or the dose of the other drugn .
DDI-DrugBank.d535.s1.p5	enfuvirtide	drug	_	antiretroviral medication	group	_	false	drugn : no drug interactions with other drugn have been identified that would warrant alteration of either the druga dose or the dose of the other drugb .
DDI-DrugBank.d395.s0.p1	Bismuth	drug	_	enoxacin	drug	_	false	druga : drugn , given concomitantly with drugb or # minutes following drugn administration , decreased drugn bioavailability by approximately 25 % .
DDI-DrugBank.d395.s0.p2	Bismuth	drug	_	enoxacin	drug	_	false	druga : drugn , given concomitantly with drugn or # minutes following drugb administration , decreased drugn bioavailability by approximately 25 % .
DDI-DrugBank.d395.s0.p3	Bismuth	drug	_	enoxacin	drug	_	false	druga : drugn , given concomitantly with drugn or # minutes following drugn administration , decreased drugb bioavailability by approximately 25 % .
DDI-DrugBank.d395.s0.p4	Bismuth subsalicylate	drug	_	enoxacin	drug	_	mechanism	drugn : druga , given concomitantly with drugb or # minutes following drugn administration , decreased drugn bioavailability by approximately 25 % .
DDI-DrugBank.d395.s0.p5	Bismuth subsalicylate	drug	_	enoxacin	drug	_	false	drugn : druga , given concomitantly with drugn or # minutes following drugb administration , decreased drugn bioavailability by approximately 25 % .
DDI-DrugBank.d395.s0.p6	Bismuth subsalicylate	drug	_	enoxacin	drug	_	false	drugn : druga , given concomitantly with drugn or # minutes following drugn administration , decreased drugb bioavailability by approximately 25 % .
DDI-DrugBank.d395.s1.p0	enoxacin	drug	_	bismuth subsalicylate	drug	_	advise	thus , concomitant administration of druga and drugb should be avoided .
DDI-DrugBank.d395.s2.p2	Enoxacin	drug	_	methylxanthines	group	_	mechanism	drugn : druga is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of drugb .
DDI-DrugBank.d395.s3.p0	enoxacin	drug	_	caffeine	drug	_	mechanism	in a multiple-dose study , druga caused a dose-related increase in the mean elimination half-life of drugb , thereby decreasing the clearance of drugn by up to 80 % and leading to a five-fold increase in the auc and the half-life of drugn .
DDI-DrugBank.d395.s3.p1	enoxacin	drug	_	caffeine	drug	_	false	in a multiple-dose study , druga caused a dose-related increase in the mean elimination half-life of drugn , thereby decreasing the clearance of drugb by up to 80 % and leading to a five-fold increase in the auc and the half-life of drugn .
DDI-DrugBank.d395.s3.p2	enoxacin	drug	_	caffeine	drug	_	false	in a multiple-dose study , druga caused a dose-related increase in the mean elimination half-life of drugn , thereby decreasing the clearance of drugn by up to 80 % and leading to a five-fold increase in the auc and the half-life of drugb .
DDI-DrugBank.d395.s4.p0	enoxacin	drug	_	caffeine	drug	_	false	trough plasma druga levels were also 20 % higher when drugb and drugn were administered concomitantly .
DDI-DrugBank.d395.s4.p2	caffeine	drug	_	enoxacin	drug	_	mechanism	trough plasma drugn levels were also 20 % higher when druga and drugb were administered concomitantly .
DDI-DrugBank.d395.s5.p1	Caffeine	drug	_	enoxacin	drug	_	false	druga - related adverse effects have occurred in patients consuming drugn while on therapy with drugb .
DDI-DrugBank.d395.s5.p2	caffeine	drug	_	enoxacin	drug	_	effect	drugn - related adverse effects have occurred in patients consuming druga while on therapy with drugb .
DDI-DrugBank.d395.s6.p2	Cyclosporine	drug	_	quinolone class	group	_	false	druga : elevated serum levels of drugn have been reported with concomitant use of drugn with other members of the drugb .
DDI-DrugBank.d395.s6.p4	cyclosporine	drug	_	quinolone class	group	_	false	drugn : elevated serum levels of druga have been reported with concomitant use of drugn with other members of the drugb .
DDI-DrugBank.d395.s6.p5	cyclosporine	drug	_	quinolone class	group	_	mechanism	drugn : elevated serum levels of drugn have been reported with concomitant use of druga with other members of the drugb .
DDI-DrugBank.d395.s7.p2	Enoxacin	drug	_	digoxin	drug	_	mechanism	drugn : druga may raise serum drugb levels in some individuals .
DDI-DrugBank.d395.s8.p0	digoxin	drug	_	enoxacin	drug	_	false	if signs and symptoms suggestive of druga toxicity occur when drugb and drugn are given concomitantly , physicians are advised to obtain serum drugn levels and adjust drugn doses appropriately .
DDI-DrugBank.d395.s8.p4	enoxacin	drug	_	digoxin	drug	_	effect	if signs and symptoms suggestive of drugn toxicity occur when druga and drugb are given concomitantly , physicians are advised to obtain serum drugn levels and adjust drugn doses appropriately .
DDI-DrugBank.d395.s8.p5	enoxacin	drug	_	digoxin	drug	_	false	if signs and symptoms suggestive of drugn toxicity occur when druga and drugn are given concomitantly , physicians are advised to obtain serum drugb levels and adjust drugn doses appropriately .
DDI-DrugBank.d395.s8.p6	enoxacin	drug	_	digoxin	drug	_	false	if signs and symptoms suggestive of drugn toxicity occur when druga and drugn are given concomitantly , physicians are advised to obtain serum drugn levels and adjust drugb doses appropriately .
DDI-DrugBank.d395.s9.p3	enoxacin	drug	_	nonsteroidal anti-inflammatory drug	group	_	false	drugn : seizures have been reported in patients taking druga concomitantly with the drugb drugn .
DDI-DrugBank.d395.s9.p4	enoxacin	drug	_	fenbufen	drug	_	effect	drugn : seizures have been reported in patients taking druga concomitantly with the drugn drugb .
DDI-DrugBank.d395.s9.p5	nonsteroidal anti-inflammatory drug	group	_	fenbufen	drug	_	false	drugn : seizures have been reported in patients taking drugn concomitantly with the druga drugb .
DDI-DrugBank.d395.s12.p0	Sucralfate	drug	_	antacids	group	_	false	druga and drugb : drugn form chelates with metal cations .
DDI-DrugBank.d395.s13.p0	quinolones	group	_	antacids	group	_	false	therefore , administration of druga with drugb containing drugn , drugn , or drugn ;
DDI-DrugBank.d395.s13.p1	quinolones	group	_	calcium	drug	_	false	therefore , administration of druga with drugn containing drugb , drugn , or drugn ;
DDI-DrugBank.d395.s13.p2	quinolones	group	_	magnesium	drug	_	false	therefore , administration of druga with drugn containing drugn , drugb , or drugn ;
DDI-DrugBank.d395.s13.p3	quinolones	group	_	aluminum	drug	_	false	therefore , administration of druga with drugn containing drugn , drugn , or drugb ;
DDI-DrugBank.d395.s13.p4	antacids	group	_	calcium	drug	_	false	therefore , administration of drugn with druga containing drugb , drugn , or drugn ;
DDI-DrugBank.d395.s13.p5	antacids	group	_	magnesium	drug	_	false	therefore , administration of drugn with druga containing drugn , drugb , or drugn ;
DDI-DrugBank.d395.s13.p6	antacids	group	_	aluminum	drug	_	false	therefore , administration of drugn with druga containing drugn , drugn , or drugb ;
DDI-DrugBank.d395.s16.p0	multivitamins	group	_	zinc	drug	_	false	or with druga containing drugb may substantially interfere with drug absorption and result in insufficient plasma and tissue drugn concentrations .
DDI-DrugBank.d395.s16.p1	multivitamins	group	_	quinolone	group	_	false	or with druga containing drugn may substantially interfere with drug absorption and result in insufficient plasma and tissue drugb concentrations .
DDI-DrugBank.d395.s16.p2	zinc	drug	_	quinolone	group	_	mechanism	or with drugn containing druga may substantially interfere with drug absorption and result in insufficient plasma and tissue drugb concentrations .
DDI-DrugBank.d395.s17.p0	Antacids	group	_	aluminum hydroxide	drug	_	false	druga containing drugb and drugn reduce the oral absorption of drugn by 75 % .
DDI-DrugBank.d395.s17.p1	Antacids	group	_	magnesium hydroxide	drug	_	false	druga containing drugn and drugb reduce the oral absorption of drugn by 75 % .
DDI-DrugBank.d395.s17.p2	Antacids	group	_	enoxacin	drug	_	false	druga containing drugn and drugn reduce the oral absorption of drugb by 75 % .
DDI-DrugBank.d395.s17.p3	aluminum hydroxide	drug	_	magnesium hydroxide	drug	_	false	drugn containing druga and drugb reduce the oral absorption of drugn by 75 % .
DDI-DrugBank.d395.s17.p4	aluminum hydroxide	drug	_	enoxacin	drug	_	mechanism	drugn containing druga and drugn reduce the oral absorption of drugb by 75 % .
DDI-DrugBank.d395.s17.p5	magnesium hydroxide	drug	_	enoxacin	drug	_	mechanism	drugn containing drugn and druga reduce the oral absorption of drugb by 75 % .
DDI-DrugBank.d395.s18.p0	enoxacin	drug	_	ranitidine	drug	_	mechanism	the oral bioavailability of druga is reduced by 60 % with coadministration of drugb .
DDI-DrugBank.d395.s20.p2	Enoxacin	drug	_	methylxanthines	group	_	mechanism	drugn : druga is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of drugb .
DDI-DrugBank.d395.s21.p0	Enoxacin	drug	_	theophylline	drug	_	mechanism	druga interferes with the metabolism of drugb resulting in a 42 % to 74 % dose-related decrease in drugn clearance and a subsequent 260 % to 350 % increase in serum theophylline levels .
DDI-DrugBank.d395.s21.p1	Enoxacin	drug	_	theophylline	drug	_	false	druga interferes with the metabolism of drugn resulting in a 42 % to 74 % dose-related decrease in drugb clearance and a subsequent 260 % to 350 % increase in serum theophylline levels .
DDI-DrugBank.d395.s22.p1	Theophylline	drug	_	enoxacin	drug	_	false	druga - related adverse effects have occurred in patients when drugn and drugb were coadministered .
DDI-DrugBank.d395.s22.p2	theophylline	drug	_	enoxacin	drug	_	effect	drugn - related adverse effects have occurred in patients when druga and drugb were coadministered .
DDI-DrugBank.d395.s23.p0	Warfarin	drug	_	Quinolones	group	_	false	druga : drugb , including drugn , decrease the clearance of drugn , the less active isomer of racemic drugn .
DDI-DrugBank.d395.s23.p1	Warfarin	drug	_	enoxacin	drug	_	false	druga : drugn , including drugb , decrease the clearance of drugn , the less active isomer of racemic drugn .
DDI-DrugBank.d395.s23.p4	Quinolones	group	_	enoxacin	drug	_	false	drugn : druga , including drugb , decrease the clearance of drugn , the less active isomer of racemic drugn .
DDI-DrugBank.d395.s23.p5	Quinolones	group	_	R-warfarin	drug	_	mechanism	drugn : druga , including drugn , decrease the clearance of drugb , the less active isomer of racemic drugn .
DDI-DrugBank.d395.s23.p6	Quinolones	group	_	warfarin	drug	_	false	drugn : druga , including drugn , decrease the clearance of drugn , the less active isomer of racemic drugb .
DDI-DrugBank.d395.s23.p7	enoxacin	drug	_	R-warfarin	drug	_	mechanism	drugn : drugn , including druga , decrease the clearance of drugb , the less active isomer of racemic drugn .
DDI-DrugBank.d395.s23.p8	enoxacin	drug	_	warfarin	drug	_	false	drugn : drugn , including druga , decrease the clearance of drugn , the less active isomer of racemic drugb .
DDI-DrugBank.d395.s24.p1	Enoxacin	drug	_	warfarin	drug	_	false	druga does not affect the clearance of the active s-isomer , and changes in clotting time have not been observed when drugn and drugb were coadministered .
DDI-DrugBank.d395.s24.p2	enoxacin	drug	_	warfarin	drug	_	false	drugn does not affect the clearance of the active s-isomer , and changes in clotting time have not been observed when druga and drugb were coadministered .
DDI-DrugBank.d474.s1.p0	anticoagulants	group	_	platelet inhibitors	group	_	false	these agents include medications such as : druga , drugb including drugn , sali-cylates , drugn -lcb- including drugn -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p1	anticoagulants	group	_	acetylsalicylic acid	drug	_	false	these agents include medications such as : druga , drugn including drugb , sali-cylates , drugn -lcb- including drugn -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p2	anticoagulants	group	_	NSAIDs	group	_	false	these agents include medications such as : druga , drugn including drugn , sali-cylates , drugb -lcb- including drugn -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p3	anticoagulants	group	_	ketorolac tromethamine	drug	_	false	these agents include medications such as : druga , drugn including drugn , sali-cylates , drugn -lcb- including drugb -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p4	anticoagulants	group	_	dipyridamole	drug	_	false	these agents include medications such as : druga , drugn including drugn , sali-cylates , drugn -lcb- including drugn -rcb- , drugb , or drugn .
DDI-DrugBank.d474.s1.p5	anticoagulants	group	_	sulfinpyrazone	drug	_	false	these agents include medications such as : druga , drugn including drugn , sali-cylates , drugn -lcb- including drugn -rcb- , drugn , or drugb .
DDI-DrugBank.d474.s1.p6	platelet inhibitors	group	_	acetylsalicylic acid	drug	_	false	these agents include medications such as : drugn , druga including drugb , sali-cylates , drugn -lcb- including drugn -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p7	platelet inhibitors	group	_	NSAIDs	group	_	false	these agents include medications such as : drugn , druga including drugn , sali-cylates , drugb -lcb- including drugn -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p8	platelet inhibitors	group	_	ketorolac tromethamine	drug	_	false	these agents include medications such as : drugn , druga including drugn , sali-cylates , drugn -lcb- including drugb -rcb- , drugn , or drugn .
DDI-DrugBank.d474.s1.p9	platelet inhibitors	group	_	dipyridamole	drug	_	false	these agents include medications such as : drugn , druga including drugn , sali-cylates , drugn -lcb- including drugn -rcb- , drugb , or drugn .
DDI-DrugBank.d474.s1.p10	platelet inhibitors	group	_	sulfinpyrazone	drug	_	false	these agents include medications such as : drugn , druga including drugn , sali-cylates , drugn -lcb- including drugn -rcb- , drugn , or drugb .
DDI-DrugBank.d455.s4.p0	entacapone	drug	_	warfarin	drug	_	false	in vitro studies have shown no binding displacement between druga and other highly bound drugs , such as drugb , drugn , drugn , and drugn .
DDI-DrugBank.d455.s4.p1	entacapone	drug	_	salicylic acid	drug	_	false	in vitro studies have shown no binding displacement between druga and other highly bound drugs , such as drugn , drugb , drugn , and drugn .
DDI-DrugBank.d455.s4.p2	entacapone	drug	_	phenylbutazone	drug	_	false	in vitro studies have shown no binding displacement between druga and other highly bound drugs , such as drugn , drugn , drugb , and drugn .
DDI-DrugBank.d455.s4.p3	entacapone	drug	_	diazepam	drug	_	false	in vitro studies have shown no binding displacement between druga and other highly bound drugs , such as drugn , drugn , drugn , and drugb .
DDI-DrugBank.d455.s6.p0	entacapone	drug	_	levodopa	drug	_	false	treatment with druga coadministered with drugb / drugn does not change these effects .
DDI-DrugBank.d455.s6.p1	entacapone	drug	_	dopa decarboxylase inhibitor	group	_	false	treatment with druga coadministered with drugn / drugb does not change these effects .
DDI-DrugBank.d455.s7.p0	MAO-B inhibitor	group	_	selegiline	drug	_	false	no interaction was noted with the druga drugb in two multiple-dose interaction studies when drugn was coadministered with a drugn / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p1	MAO-B inhibitor	group	_	entacapone	drug	_	false	no interaction was noted with the druga drugn in two multiple-dose interaction studies when drugb was coadministered with a drugn / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p2	MAO-B inhibitor	group	_	levodopa	drug	_	false	no interaction was noted with the druga drugn in two multiple-dose interaction studies when drugn was coadministered with a drugb / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p3	MAO-B inhibitor	group	_	dopa decarboxylase inhibitor	group	_	false	no interaction was noted with the druga drugn in two multiple-dose interaction studies when drugn was coadministered with a drugn / drugb -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p4	selegiline	drug	_	entacapone	drug	_	false	no interaction was noted with the drugn druga in two multiple-dose interaction studies when drugb was coadministered with a drugn / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p5	selegiline	drug	_	levodopa	drug	_	false	no interaction was noted with the drugn druga in two multiple-dose interaction studies when drugn was coadministered with a drugb / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p6	selegiline	drug	_	dopa decarboxylase inhibitor	group	_	false	no interaction was noted with the drugn druga in two multiple-dose interaction studies when drugn was coadministered with a drugn / drugb -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p7	entacapone	drug	_	levodopa	drug	_	false	no interaction was noted with the drugn drugn in two multiple-dose interaction studies when druga was coadministered with a drugb / drugn -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s7.p8	entacapone	drug	_	dopa decarboxylase inhibitor	group	_	false	no interaction was noted with the drugn drugn in two multiple-dose interaction studies when druga was coadministered with a drugn / drugb -lcb- n = 29 -rcb- .
DDI-DrugBank.d455.s8.p0	selegiline	drug	_	entacapone	drug	_	false	more than # parkinsons disease patients in clinical trials have used druga in combination with drugb and drugn / drugn .
DDI-DrugBank.d455.s8.p1	selegiline	drug	_	levodopa	drug	_	false	more than # parkinsons disease patients in clinical trials have used druga in combination with drugn and drugb / drugn .
DDI-DrugBank.d455.s8.p2	selegiline	drug	_	dopa decarboxylase inhibitor	group	_	false	more than # parkinsons disease patients in clinical trials have used druga in combination with drugn and drugn / drugb .
DDI-DrugBank.d455.s8.p3	entacapone	drug	_	levodopa	drug	_	false	more than # parkinsons disease patients in clinical trials have used drugn in combination with druga and drugb / drugn .
DDI-DrugBank.d455.s8.p4	entacapone	drug	_	dopa decarboxylase inhibitor	group	_	false	more than # parkinsons disease patients in clinical trials have used drugn in combination with druga and drugn / drugb .
DDI-DrugBank.d455.s10.p0	probenecid	drug	_	cholestyramine	drug	_	false	these include druga , drugb , and some drugn -lcb- e , g , drugn , rifamipicin , drugn and drugn -rcb- .
DDI-DrugBank.d455.s10.p1	probenecid	drug	_	antibiotics	group	_	false	these include druga , drugn , and some drugb -lcb- e , g , drugn , rifamipicin , drugn and drugn -rcb- .
DDI-DrugBank.d455.s10.p2	probenecid	drug	_	erythromycin	drug	_	false	these include druga , drugn , and some drugn -lcb- e , g , drugb , rifamipicin , drugn and drugn -rcb- .
DDI-DrugBank.d455.s10.p3	probenecid	drug	_	ampicillin	drug	_	false	these include druga , drugn , and some drugn -lcb- e , g , drugn , rifamipicin , drugb and drugn -rcb- .
DDI-DrugBank.d455.s10.p4	probenecid	drug	_	chloramphenicol	drug	_	false	these include druga , drugn , and some drugn -lcb- e , g , drugn , rifamipicin , drugn and drugb -rcb- .
DDI-DrugBank.d455.s10.p5	cholestyramine	drug	_	antibiotics	group	_	false	these include drugn , druga , and some drugb -lcb- e , g , drugn , rifamipicin , drugn and drugn -rcb- .
DDI-DrugBank.d455.s10.p6	cholestyramine	drug	_	erythromycin	drug	_	false	these include drugn , druga , and some drugn -lcb- e , g , drugb , rifamipicin , drugn and drugn -rcb- .
DDI-DrugBank.d455.s10.p7	cholestyramine	drug	_	ampicillin	drug	_	false	these include drugn , druga , and some drugn -lcb- e , g , drugn , rifamipicin , drugb and drugn -rcb- .
DDI-DrugBank.d455.s10.p8	cholestyramine	drug	_	chloramphenicol	drug	_	false	these include drugn , druga , and some drugn -lcb- e , g , drugn , rifamipicin , drugn and drugb -rcb- .
DDI-DrugBank.d455.s11.p0	tricyclic antidepressant	group	_	imipramine	drug	_	false	no interaction with the druga drugb was shown in a single-dose study with drugn without coadministered drugn / drugn .
DDI-DrugBank.d455.s11.p1	tricyclic antidepressant	group	_	entacapone	drug	_	false	no interaction with the druga drugn was shown in a single-dose study with drugb without coadministered drugn / drugn .
DDI-DrugBank.d455.s11.p2	tricyclic antidepressant	group	_	levodopa	drug	_	false	no interaction with the druga drugn was shown in a single-dose study with drugn without coadministered drugb / drugn .
DDI-DrugBank.d455.s11.p3	tricyclic antidepressant	group	_	dopa-decarboxylase inhibitor	group	_	false	no interaction with the druga drugn was shown in a single-dose study with drugn without coadministered drugn / drugb .
DDI-DrugBank.d455.s11.p4	imipramine	drug	_	entacapone	drug	_	false	no interaction with the drugn druga was shown in a single-dose study with drugb without coadministered drugn / drugn .
DDI-DrugBank.d455.s11.p5	imipramine	drug	_	levodopa	drug	_	false	no interaction with the drugn druga was shown in a single-dose study with drugn without coadministered drugb / drugn .
DDI-DrugBank.d455.s11.p6	imipramine	drug	_	dopa-decarboxylase inhibitor	group	_	false	no interaction with the drugn druga was shown in a single-dose study with drugn without coadministered drugn / drugb .
DDI-DrugBank.d455.s11.p7	entacapone	drug	_	levodopa	drug	_	false	no interaction with the drugn drugn was shown in a single-dose study with druga without coadministered drugb / drugn .
DDI-DrugBank.d455.s11.p8	entacapone	drug	_	dopa-decarboxylase inhibitor	group	_	false	no interaction with the drugn drugn was shown in a single-dose study with druga without coadministered drugn / drugb .
DDI-DrugBank.d295.s0.p0	entecavir	drug	_	BARACLUDE	brand	_	false	since druga is primarily eliminated by the kidneys , coadministration of drugb with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either drugn or the coadministered drug .
DDI-DrugBank.d295.s0.p2	BARACLUDE	brand	_	entecavir	drug	_	false	since drugn is primarily eliminated by the kidneys , coadministration of druga with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either drugb or the coadministered drug .
DDI-DrugBank.d295.s1.p0	entecavir	drug	_	lamivudine	drug	_	false	coadministration of druga with drugb , drugn , or drugn did not result in significant drug interactions .
DDI-DrugBank.d295.s1.p1	entecavir	drug	_	adefovir dipivoxil	drug	_	false	coadministration of druga with drugn , drugb , or drugn did not result in significant drug interactions .
DDI-DrugBank.d295.s1.p2	entecavir	drug	_	tenofovir disoproxil fumarate	drug	_	false	coadministration of druga with drugn , drugn , or drugb did not result in significant drug interactions .
DDI-DrugBank.d247.s1.p0	vasopressors	group	_	monoamine oxidase (MAO) inhibitors	group	_	advise	all druga should be used cautiously in patients taking drugb .
DDI-DrugBank.d247.s2.p0	Epinephrine	drug	_	sympathomimetic drugs	group	_	advise	druga should not be administered concomitantly with other drugb -lcb- such as drugn -rcb- because of possible additive effects and increased toxicity .
DDI-DrugBank.d247.s2.p1	Epinephrine	drug	_	isoproterenol	drug	_	advise	druga should not be administered concomitantly with other drugn -lcb- such as drugb -rcb- because of possible additive effects and increased toxicity .
DDI-DrugBank.d247.s5.p0	epinephrine	drug	_	cyclopropane	drug	_	effect	administration of druga to patients receiving drugb or drugn such as drugn which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s5.p1	epinephrine	drug	_	halogenated hydrocarbon general anesthetics	group	_	effect	administration of druga to patients receiving drugn or drugb such as drugn which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s5.p2	epinephrine	drug	_	halothane	drug	_	effect	administration of druga to patients receiving drugn or drugn such as drugb which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s5.p3	cyclopropane	drug	_	halogenated hydrocarbon general anesthetics	group	_	false	administration of drugn to patients receiving druga or drugb such as drugn which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s5.p4	cyclopropane	drug	_	halothane	drug	_	false	administration of drugn to patients receiving druga or drugn such as drugb which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s5.p5	halogenated hydrocarbon general anesthetics	group	_	halothane	drug	_	false	administration of drugn to patients receiving drugn or druga such as drugb which sensitize the myocardium , may induce cardiac arrhythmia , .
DDI-DrugBank.d247.s7.p0	Epinephrine	drug	_	digitalis	group	_	advise	druga also should be used cautiously with other drugs -lcb- e , g , , drugb , drugn -rcb- that sensitize the myocardium to the actions of drugn .
DDI-DrugBank.d247.s7.p1	Epinephrine	drug	_	glycosides	group	_	advise	druga also should be used cautiously with other drugs -lcb- e , g , , drugn , drugb -rcb- that sensitize the myocardium to the actions of drugn .
DDI-DrugBank.d247.s7.p2	Epinephrine	drug	_	sympathomimetic drugs	group	_	false	druga also should be used cautiously with other drugs -lcb- e , g , , drugn , drugn -rcb- that sensitize the myocardium to the actions of drugb .
DDI-DrugBank.d247.s7.p4	digitalis	group	_	sympathomimetic drugs	group	_	false	drugn also should be used cautiously with other drugs -lcb- e , g , , druga , drugn -rcb- that sensitize the myocardium to the actions of drugb .
DDI-DrugBank.d247.s7.p5	glycosides	group	_	sympathomimetic drugs	group	_	false	drugn also should be used cautiously with other drugs -lcb- e , g , , drugn , druga -rcb- that sensitize the myocardium to the actions of drugb .
DDI-DrugBank.d247.s8.p0	Diuretic agents	group	_	epinephrine	drug	_	effect	druga may decrease vascular response to pressor drugs such as drugb .
DDI-DrugBank.d247.s9.p0	Epinephrine	drug	_	guanethidine	drug	_	effect	druga may antagonize the neuron blockade produced by drugb resulting in decreased antihypertensive effect and requiring increased dosage of the latter .
DDI-DrugBank.d428.s1.p0	ELLENCE	brand	_	calcium channel blockers	group	_	advise	concomitant use of druga with other cardioactive compounds that could cause heart failure -lcb- e , g , , drugb -rcb- , requires close monitoring of cardiac function throughout treatment .
DDI-DrugBank.d428.s10.p0	Cimetidine	drug	_	epirubicin	drug	_	mechanism	druga increased the auc of drugb by 50 % .
DDI-DrugBank.d428.s11.p0	Cimetidine	drug	_	ELLENCE	brand	_	advise	druga treatment should be stopped during treatment with drugb .
DDI-DrugBank.d20.s1.p0	INSPRA	brand	_	ketoconazole	drug	_	mechanism	a pharmacokinetic study evaluating the administration of a single dose of druga # mg with drugb # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of drugn and a # - fold increase in auc of drugn .
DDI-DrugBank.d20.s1.p1	INSPRA	brand	_	eplerenone	drug	_	false	a pharmacokinetic study evaluating the administration of a single dose of druga # mg with drugn # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of drugb and a # - fold increase in auc of drugn .
DDI-DrugBank.d20.s1.p2	INSPRA	brand	_	eplerenone	drug	_	false	a pharmacokinetic study evaluating the administration of a single dose of druga # mg with drugn # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of drugn and a # - fold increase in auc of drugb .
DDI-DrugBank.d20.s1.p3	ketoconazole	drug	_	eplerenone	drug	_	false	a pharmacokinetic study evaluating the administration of a single dose of drugn # mg with druga # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of drugb and a # - fold increase in auc of drugn .
DDI-DrugBank.d20.s1.p4	ketoconazole	drug	_	eplerenone	drug	_	false	a pharmacokinetic study evaluating the administration of a single dose of drugn # mg with druga # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of drugn and a # - fold increase in auc of drugb .
DDI-DrugBank.d20.s3.p0	eplerenone	drug	_	erythromycin	drug	_	mechanism	administration of druga with other cyp3a4 inhibitors -lcb- e , g , , drugb # mg bid , drugn # mg qd , drugn # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p1	eplerenone	drug	_	verapamil	drug	_	mechanism	administration of druga with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugb # mg qd , drugn # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p2	eplerenone	drug	_	saquinavir	drug	_	mechanism	administration of druga with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugn # mg qd , drugb # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p3	eplerenone	drug	_	fluconazole	drug	_	mechanism	administration of druga with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugn # mg qd , drugn # mg tid , drugb # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p5	erythromycin	drug	_	verapamil	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , druga # mg bid , drugb # mg qd , drugn # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p6	erythromycin	drug	_	saquinavir	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , druga # mg bid , drugn # mg qd , drugb # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p7	erythromycin	drug	_	fluconazole	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , druga # mg bid , drugn # mg qd , drugn # mg tid , drugb # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p8	erythromycin	drug	_	eplerenone	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , druga # mg bid , drugn # mg qd , drugn # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugb ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p9	verapamil	drug	_	saquinavir	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , druga # mg qd , drugb # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p10	verapamil	drug	_	fluconazole	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , druga # mg qd , drugn # mg tid , drugb # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p11	verapamil	drug	_	eplerenone	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , druga # mg qd , drugn # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugb ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p12	saquinavir	drug	_	fluconazole	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugn # mg qd , druga # mg tid , drugb # mg qd -rcb- resulted in increases in cmax of drugn ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p13	saquinavir	drug	_	eplerenone	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugn # mg qd , druga # mg tid , drugn # mg qd -rcb- resulted in increases in cmax of drugb ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s3.p14	fluconazole	drug	_	eplerenone	drug	_	false	administration of drugn with other cyp3a4 inhibitors -lcb- e , g , , drugn # mg bid , drugn # mg qd , drugn # mg tid , druga # mg qd -rcb- resulted in increases in cmax of drugb ranging from # - to # - fold and auc from # - to # - fold .
DDI-DrugBank.d20.s4.p0	ACE Inhibitors	group	_	Angiotensin II Receptor Antagonists	group	_	false	druga and drugb -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p1	ACE Inhibitors	group	_	INSPRA	brand	_	false	druga and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugb # to # mg also received drugn or drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p3	ACE Inhibitors	group	_	angiotensin II receptor antagonists	group	_	false	druga and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugb -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p4	ACE Inhibitors	group	_	ACEI	group	_	false	druga and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d20.s4.p5	ACE Inhibitors	group	_	ARB	group	_	false	druga and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d20.s4.p6	Angiotensin II Receptor Antagonists	group	_	INSPRA	brand	_	false	drugn and druga -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugb # to # mg also received drugn or drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p7	Angiotensin II Receptor Antagonists	group	_	ACE inhibitors	group	_	false	drugn and druga -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugb or drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p9	Angiotensin II Receptor Antagonists	group	_	ACEI	group	_	false	drugn and druga -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d20.s4.p10	Angiotensin II Receptor Antagonists	group	_	ARB	group	_	false	drugn and druga -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received drugn or drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d20.s4.p11	INSPRA	brand	_	ACE inhibitors	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving druga # to # mg also received drugb or drugn -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p12	INSPRA	brand	_	angiotensin II receptor antagonists	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving druga # to # mg also received drugn or drugb -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p13	INSPRA	brand	_	ACEI	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving druga # to # mg also received drugn or drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d20.s4.p14	INSPRA	brand	_	ARB	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving druga # to # mg also received drugn or drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d20.s4.p15	ACE inhibitors	group	_	angiotensin II receptor antagonists	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received druga or drugb -lcb- drugn / drugn -rcb- .
DDI-DrugBank.d20.s4.p16	ACE inhibitors	group	_	ACEI	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received druga or drugn -lcb- drugb / drugn -rcb- .
DDI-DrugBank.d20.s4.p17	ACE inhibitors	group	_	ARB	group	_	false	drugn and drugn -lcb- congestive heart failure post-myocardial infarction -rcb- - in ephesus , # -lcb- 91 % -rcb- patients receiving drugn # to # mg also received druga or drugn -lcb- drugn / drugb -rcb- .
DDI-DrugBank.d20.s6.p0	ACE Inhibitors	group	_	Angiotensin II Receptor Antagonists	group	_	false	druga and drugb -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugn # to # mg to drugn and drugn increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p1	ACE Inhibitors	group	_	INSPRA	brand	_	false	druga and drugn -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugb # to # mg to drugn and drugn increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p3	ACE Inhibitors	group	_	angiotensin II receptor antagonists	group	_	false	druga and drugn -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugn # to # mg to drugn and drugb increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p4	Angiotensin II Receptor Antagonists	group	_	INSPRA	brand	_	false	drugn and druga -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugb # to # mg to drugn and drugn increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p5	Angiotensin II Receptor Antagonists	group	_	ACE inhibitors	group	_	false	drugn and druga -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugn # to # mg to drugb and drugn increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p7	INSPRA	brand	_	ACE inhibitors	group	_	effect	drugn and drugn -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of druga # to # mg to drugb and drugn increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p8	INSPRA	brand	_	angiotensin II receptor antagonists	group	_	effect	drugn and drugn -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of druga # to # mg to drugn and drugb increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s6.p9	ACE inhibitors	group	_	angiotensin II receptor antagonists	group	_	false	drugn and drugn -lcb- hypertension -rcb- - in clinical studies of patients with hypertension , the addition of drugn # to # mg to druga and drugb increased mean serum potassium slightly -lcb- about ## meq/l -rcb- .
DDI-DrugBank.d20.s7.p0	INSPRA	brand	_	ACE inhibitor	group	_	false	in a study in diabetics with microalbuminuria druga # mg combined with the drugb drugn # mg increased the frequency of hyperkalemia -lcb- serum potassium # meq/l -rcb- from 17 % on drugn alone to 38 % .
DDI-DrugBank.d20.s7.p1	INSPRA	brand	_	enalapril	drug	_	effect	in a study in diabetics with microalbuminuria druga # mg combined with the drugn drugb # mg increased the frequency of hyperkalemia -lcb- serum potassium # meq/l -rcb- from 17 % on drugn alone to 38 % .
DDI-DrugBank.d20.s7.p2	INSPRA	brand	_	enalapril	drug	_	false	in a study in diabetics with microalbuminuria druga # mg combined with the drugn drugn # mg increased the frequency of hyperkalemia -lcb- serum potassium # meq/l -rcb- from 17 % on drugb alone to 38 % .
DDI-DrugBank.d20.s7.p3	ACE inhibitor	group	_	enalapril	drug	_	false	in a study in diabetics with microalbuminuria drugn # mg combined with the druga drugb # mg increased the frequency of hyperkalemia -lcb- serum potassium # meq/l -rcb- from 17 % on drugn alone to 38 % .
DDI-DrugBank.d20.s7.p4	ACE inhibitor	group	_	enalapril	drug	_	false	in a study in diabetics with microalbuminuria drugn # mg combined with the druga drugn # mg increased the frequency of hyperkalemia -lcb- serum potassium # meq/l -rcb- from 17 % on drugb alone to 38 % .
DDI-DrugBank.d20.s8.p0	Lithium	drug	_	eplerenone	drug	_	false	druga - a drug interaction study of drugb with drugn has not been conducted .
DDI-DrugBank.d20.s8.p2	eplerenone	drug	_	lithium	drug	_	false	drugn - a drug interaction study of druga with drugb has not been conducted .
DDI-DrugBank.d20.s9.p0	lithium	drug	_	INSPRA	brand	_	false	serum druga levels should be monitored frequently if drugb is administered concomitantly with drugn .
DDI-DrugBank.d20.s9.p2	INSPRA	brand	_	lithium	drug	_	advise	serum drugn levels should be monitored frequently if druga is administered concomitantly with drugb .
DDI-DrugBank.d20.s10.p1	Nonsteroidal Anti-Inflammatory Drugs	group	_	eplerenone	drug	_	false	druga -lcb- drugn -rcb- - a drug interaction study of drugb with an drugn has not been conducted .
DDI-DrugBank.d20.s10.p2	Nonsteroidal Anti-Inflammatory Drugs	group	_	NSAID	group	_	false	druga -lcb- drugn -rcb- - a drug interaction study of drugn with an drugb has not been conducted .
DDI-DrugBank.d20.s10.p3	NSAIDs	group	_	eplerenone	drug	_	false	drugn -lcb- druga -rcb- - a drug interaction study of drugb with an drugn has not been conducted .
DDI-DrugBank.d20.s10.p5	eplerenone	drug	_	NSAID	group	_	false	drugn -lcb- drugn -rcb- - a drug interaction study of druga with an drugb has not been conducted .
DDI-DrugBank.d20.s11.p0	potassium-sparing antihypertensives	group	_	NSAIDs	group	_	effect	the administration of other druga with drugb has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function .
DDI-DrugBank.d20.s12.p0	INSPRA	brand	_	NSAIDs	group	_	advise	therefore , when druga and drugb are used concomitantly , patients should be observed to determine whether the desired effect on blood pressure is obtained .
DDI-DrugBank.d241.s0.p0	FLOLAN	brand	_	diuretics	group	_	effect	additional reductions in blood pressure may occur when druga is administered with drugb , drugn , or other drugn .
DDI-DrugBank.d241.s0.p1	FLOLAN	brand	_	antihypertensive agents	group	_	effect	additional reductions in blood pressure may occur when druga is administered with drugn , drugb , or other drugn .
DDI-DrugBank.d241.s0.p2	FLOLAN	brand	_	vasodilators	group	_	effect	additional reductions in blood pressure may occur when druga is administered with drugn , drugn , or other drugb .
DDI-DrugBank.d241.s0.p3	diuretics	group	_	antihypertensive agents	group	_	false	additional reductions in blood pressure may occur when drugn is administered with druga , drugb , or other drugn .
DDI-DrugBank.d241.s0.p4	diuretics	group	_	vasodilators	group	_	false	additional reductions in blood pressure may occur when drugn is administered with druga , drugn , or other drugb .
DDI-DrugBank.d241.s0.p5	antihypertensive agents	group	_	vasodilators	group	_	false	additional reductions in blood pressure may occur when drugn is administered with drugn , druga , or other drugb .
DDI-DrugBank.d241.s1.p0	antiplatelet agents	group	_	anticoagulants	group	_	false	when other druga or drugb are used concomitantly , there is the potential for drugn to increase the risk of bleeding .
DDI-DrugBank.d241.s1.p1	antiplatelet agents	group	_	FLOLAN	brand	_	effect	when other druga or drugn are used concomitantly , there is the potential for drugb to increase the risk of bleeding .
DDI-DrugBank.d241.s1.p2	anticoagulants	group	_	FLOLAN	brand	_	effect	when other drugn or druga are used concomitantly , there is the potential for drugb to increase the risk of bleeding .
DDI-DrugBank.d241.s2.p0	FLOLAN	brand	_	anticoagulants	group	_	false	however , patients receiving infusions of druga in clinical trials were maintained on drugb without evidence of increased bleeding .
DDI-DrugBank.d241.s3.p0	FLOLAN	brand	_	digoxin	drug	_	false	in clinical trials , druga was used with drugb , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p1	FLOLAN	brand	_	diuretics	group	_	false	in clinical trials , druga was used with drugn , drugb , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p2	FLOLAN	brand	_	anticoagulants	group	_	false	in clinical trials , druga was used with drugn , drugn , drugb , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p3	FLOLAN	brand	_	vasodilators	group	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugb , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p4	FLOLAN	brand	_	oxygen	drug	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugn , and supplemental drugb , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p5	FLOLAN	brand	_	furosemide	drug	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p6	FLOLAN	brand	_	digoxin	drug	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p8	FLOLAN	brand	_	furosemide	drug	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p9	FLOLAN	brand	_	digoxin	drug	_	false	in clinical trials , druga was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p13	digoxin	drug	_	oxygen	drug	_	false	in clinical trials , drugn was used with druga , drugn , drugn , oral drugn , and supplemental drugb , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p14	digoxin	drug	_	furosemide	drug	_	false	in clinical trials , drugn was used with druga , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p16	digoxin	drug	_	FLOLAN	brand	_	false	in clinical trials , drugn was used with druga , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p17	digoxin	drug	_	furosemide	drug	_	false	in clinical trials , drugn was used with druga , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p21	diuretics	group	_	oxygen	drug	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugb , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p22	diuretics	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p23	diuretics	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p24	diuretics	group	_	FLOLAN	brand	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p25	diuretics	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p26	diuretics	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , druga , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p28	anticoagulants	group	_	oxygen	drug	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugb , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p29	anticoagulants	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p30	anticoagulants	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p31	anticoagulants	group	_	FLOLAN	brand	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p32	anticoagulants	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p33	anticoagulants	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , druga , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p34	vasodilators	group	_	oxygen	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugb , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p35	vasodilators	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p36	vasodilators	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p37	vasodilators	group	_	FLOLAN	brand	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p38	vasodilators	group	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p39	vasodilators	group	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral druga , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p40	oxygen	drug	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental druga , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugb or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p41	oxygen	drug	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental druga , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p42	oxygen	drug	_	FLOLAN	brand	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental druga , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p43	oxygen	drug	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental druga , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p44	oxygen	drug	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental druga , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p45	furosemide	drug	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving druga or drugb in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p46	furosemide	drug	_	FLOLAN	brand	_	mechanism	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving druga or drugn in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p48	furosemide	drug	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving druga or drugn in whom therapy with drugn was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p49	digoxin	drug	_	FLOLAN	brand	_	mechanism	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or druga in whom therapy with drugb was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p50	digoxin	drug	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or druga in whom therapy with drugn was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p52	FLOLAN	brand	_	furosemide	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with druga was initiated , apparent oral clearance values for drugb -lcb- n = 23 -rcb- and drugn -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p53	FLOLAN	brand	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with druga was initiated , apparent oral clearance values for drugn -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s3.p54	furosemide	drug	_	digoxin	drug	_	false	in clinical trials , drugn was used with drugn , drugn , drugn , oral drugn , and supplemental drugn , in a pharmacokinetic substudy in patients with congestive heart failure receiving drugn or drugn in whom therapy with drugn was initiated , apparent oral clearance values for druga -lcb- n = 23 -rcb- and drugb -lcb- n = 30 -rcb- were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .
DDI-DrugBank.d241.s5.p1	digoxin	drug	_	FLOLAN	brand	_	mechanism	however , patients on druga may show elevations of drugn concentrations after initiation of therapy with drugb , which may be clinically significant in patients prone to drugn toxicity .
DDI-DrugBank.d241.s5.p3	digoxin	drug	_	FLOLAN	brand	_	false	however , patients on drugn may show elevations of druga concentrations after initiation of therapy with drugb , which may be clinically significant in patients prone to drugn toxicity .
DDI-DrugBank.d241.s5.p5	FLOLAN	brand	_	digoxin	drug	_	false	however , patients on drugn may show elevations of drugn concentrations after initiation of therapy with druga , which may be clinically significant in patients prone to drugb toxicity .
DDI-DrugBank.d525.s0.p0	Eprosartan	drug	_	digoxin	drug	_	false	druga has been shown to have no effect on the pharmacokinetics of drugb and the pharmacodynamics of drugn and drugn .
DDI-DrugBank.d525.s0.p1	Eprosartan	drug	_	warfarin	drug	_	false	druga has been shown to have no effect on the pharmacokinetics of drugn and the pharmacodynamics of drugb and drugn .
DDI-DrugBank.d525.s0.p2	Eprosartan	drug	_	glyburide	drug	_	false	druga has been shown to have no effect on the pharmacokinetics of drugn and the pharmacodynamics of drugn and drugb .
DDI-DrugBank.d525.s0.p3	digoxin	drug	_	warfarin	drug	_	false	drugn has been shown to have no effect on the pharmacokinetics of druga and the pharmacodynamics of drugb and drugn .
DDI-DrugBank.d525.s0.p4	digoxin	drug	_	glyburide	drug	_	false	drugn has been shown to have no effect on the pharmacokinetics of druga and the pharmacodynamics of drugn and drugb .
DDI-DrugBank.d525.s0.p5	warfarin	drug	_	glyburide	drug	_	false	drugn has been shown to have no effect on the pharmacokinetics of drugn and the pharmacodynamics of druga and drugb .
DDI-DrugBank.d525.s2.p0	eprosartan	drug	_	ketoconazole	drug	_	false	because druga is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and drugb and drugn , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on drugn pharmacokinetics .
DDI-DrugBank.d525.s2.p1	eprosartan	drug	_	fluconazole	drug	_	false	because druga is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and drugn and drugb , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on drugn pharmacokinetics .
DDI-DrugBank.d525.s2.p3	ketoconazole	drug	_	fluconazole	drug	_	false	because drugn is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and druga and drugb , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on drugn pharmacokinetics .
DDI-DrugBank.d525.s2.p4	ketoconazole	drug	_	eprosartan	drug	_	false	because drugn is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and druga and drugn , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on drugb pharmacokinetics .
DDI-DrugBank.d525.s2.p5	fluconazole	drug	_	eprosartan	drug	_	false	because drugn is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and drugn and druga , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on drugb pharmacokinetics .
DDI-DrugBank.d525.s3.p0	Ranitidine	drug	_	eprosartan	drug	_	false	druga also has no effect on drugb pharmacokinetics .
DDI-DrugBank.d525.s4.p0	Eprosartan	drug	_	thiazide diuretic	group	_	false	druga -lcb- up to # mg b , i , d , or # mg q , d , -rcb- doses have been safely used concomitantly with a drugb -lcb- drugn -rcb- .
DDI-DrugBank.d525.s4.p1	Eprosartan	drug	_	hydrochlorothiazide	drug	_	false	druga -lcb- up to # mg b , i , d , or # mg q , d , -rcb- doses have been safely used concomitantly with a drugn -lcb- drugb -rcb- .
DDI-DrugBank.d525.s5.p0	Eprosartan	drug	_	calcium channel blockers	group	_	false	druga doses of up to # mg b , i , d , have been safely used concomitantly with sustained-release drugb -lcb- sustained-release drugn -rcb- with no clinically significant adverse interactions .
DDI-DrugBank.d525.s5.p1	Eprosartan	drug	_	nifedipine	drug	_	false	druga doses of up to # mg b , i , d , have been safely used concomitantly with sustained-release drugn -lcb- sustained-release drugb -rcb- with no clinically significant adverse interactions .
DDI-DrugBank.d278.s0.p0	Enoxaparin	drug	_	eptifibatide	drug	_	false	druga dosed as a # mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of drugb or the level of platelet aggregation in healthy adults .
DDI-DrugBank.d471.s0.p0	Mineral oil	drug	_	fat-soluble vitamins	group	_	mechanism	druga interferes with the absorption of drugb , including drugn .
DDI-DrugBank.d471.s0.p1	Mineral oil	drug	_	vitamin D preparations	group	_	mechanism	druga interferes with the absorption of drugn , including drugb .
DDI-DrugBank.d471.s0.p2	fat-soluble vitamins	group	_	vitamin D preparations	group	_	false	drugn interferes with the absorption of druga , including drugb .
DDI-DrugBank.d471.s1.p0	thiazide diuretics	group	_	ergocalciferol	drug	_	effect	administration of druga to hypoparathyroid patients who are concurrently being treated with drugb may cause hypercalcemia .
DDI-DrugBank.d59.s0.p0	ERGOMAR	brand	_	triacetyloleandomycin	drug	_	mechanism	the effects of druga may be potentiated by drugb which inhibits the metabolism of drugn .
DDI-DrugBank.d59.s0.p1	ERGOMAR	brand	_	ergotamine	drug	_	false	the effects of druga may be potentiated by drugn which inhibits the metabolism of drugb .
DDI-DrugBank.d59.s0.p2	triacetyloleandomycin	drug	_	ergotamine	drug	_	mechanism	the effects of drugn may be potentiated by druga which inhibits the metabolism of drugb .
DDI-DrugBank.d59.s1.p0	ERGOMAR	brand	_	vasoconstrictor drugs	group	_	effect	the pressor effects of druga and other drugb can combine to cause dangerous hypertension .
DDI-DrugBank.d456.s0.p0	ketoconazole	drug	_	erlotinib	drug	_	mechanism	co-treatment with the potent cyp3a4 inhibitor druga increases drugb auc by 2/3 .
DDI-DrugBank.d456.s1.p0	TARCEVA	brand	_	ketoconazole	drug	_	advise	caution should be used when administering or taking druga with drugb and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p1	TARCEVA	brand	_	atazanavir	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p2	TARCEVA	brand	_	clarithromycin	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p3	TARCEVA	brand	_	indinavir	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p4	TARCEVA	brand	_	itraconazole	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p5	TARCEVA	brand	_	nefazodone	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p6	TARCEVA	brand	_	nelfinavir	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p7	TARCEVA	brand	_	ritonavir	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p8	TARCEVA	brand	_	saquinavir	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p9	TARCEVA	brand	_	telithromycin	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p10	TARCEVA	brand	_	troleandomycin	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p11	TARCEVA	brand	_	TAO	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d456.s1.p12	TARCEVA	brand	_	voriconazole	drug	_	advise	caution should be used when administering or taking druga with drugn and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d456.s1.p13	ketoconazole	drug	_	atazanavir	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p14	ketoconazole	drug	_	clarithromycin	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p15	ketoconazole	drug	_	indinavir	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p16	ketoconazole	drug	_	itraconazole	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p17	ketoconazole	drug	_	nefazodone	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p18	ketoconazole	drug	_	nelfinavir	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p19	ketoconazole	drug	_	ritonavir	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p20	ketoconazole	drug	_	saquinavir	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p21	ketoconazole	drug	_	telithromycin	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p22	ketoconazole	drug	_	troleandomycin	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d456.s1.p23	ketoconazole	drug	_	TAO	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d456.s1.p24	ketoconazole	drug	_	voriconazole	drug	_	false	caution should be used when administering or taking drugn with druga and other strong cyp3a4 inhibitors such as , but not limited to , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d456.s2.p0	rifampicin	drug	_	erlotinib	drug	_	mechanism	pre-treatment with the cyp3a4 inducer druga decreased drugb auc by about 2/3 .
DDI-DrugBank.d456.s5.p0	TARCEVA	brand	_	rifampicin	drug	_	advise	if the druga dose is adjusted upward , the dose will need to be reduced upon discontinuation of drugb or other inducers .
DDI-DrugBank.d456.s13.p0	warfarin	drug	_	coumarin-derivative anticoagulants	group	_	false	patients taking druga or other drugb should be monitored regularly for changes in prothrombin time or inr
DDI-DrugBank.d329.s0.p0	ertapenem	drug	_	probenecid	drug	_	false	when druga is co-administered with drugb -lcb- 500 mg p , o , every # hours -rcb- , drugn competes for active tubular secretion and reduces the renal clearance of drugn .
DDI-DrugBank.d329.s0.p1	ertapenem	drug	_	probenecid	drug	_	false	when druga is co-administered with drugn -lcb- 500 mg p , o , every # hours -rcb- , drugb competes for active tubular secretion and reduces the renal clearance of drugn .
DDI-DrugBank.d329.s0.p4	probenecid	drug	_	ertapenem	drug	_	false	when drugn is co-administered with druga -lcb- 500 mg p , o , every # hours -rcb- , drugn competes for active tubular secretion and reduces the renal clearance of drugb .
DDI-DrugBank.d329.s0.p5	probenecid	drug	_	ertapenem	drug	_	mechanism	when drugn is co-administered with drugn -lcb- 500 mg p , o , every # hours -rcb- , druga competes for active tubular secretion and reduces the renal clearance of drugb .
DDI-DrugBank.d329.s1.p0	ertapenem	drug	_	probenecid	drug	_	mechanism	based on total druga concentrations , drugb increased the auc by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively .
DDI-DrugBank.d329.s3.p0	probenecid	drug	_	ertapenem	drug	_	advise	because of the small effect on half-life , the coadministration with druga to extend the half-life of drugb is not recommended .
DDI-DrugBank.d329.s4.p0	ertapenem	drug	_	digoxin	drug	_	false	in vitro studies indicate that druga does not inhibit p-glycoprotein-mediated transport of drugb or drugn and that drugn is not a substrate for p-glycoprotein-mediated transport .
DDI-DrugBank.d329.s4.p1	ertapenem	drug	_	vinblastine	drug	_	false	in vitro studies indicate that druga does not inhibit p-glycoprotein-mediated transport of drugn or drugb and that drugn is not a substrate for p-glycoprotein-mediated transport .
DDI-DrugBank.d329.s4.p3	digoxin	drug	_	vinblastine	drug	_	false	in vitro studies indicate that drugn does not inhibit p-glycoprotein-mediated transport of druga or drugb and that drugn is not a substrate for p-glycoprotein-mediated transport .
DDI-DrugBank.d329.s4.p4	digoxin	drug	_	ertapenem	drug	_	false	in vitro studies indicate that drugn does not inhibit p-glycoprotein-mediated transport of druga or drugn and that drugb is not a substrate for p-glycoprotein-mediated transport .
DDI-DrugBank.d329.s4.p5	vinblastine	drug	_	ertapenem	drug	_	false	in vitro studies indicate that drugn does not inhibit p-glycoprotein-mediated transport of drugn or druga and that drugb is not a substrate for p-glycoprotein-mediated transport .
DDI-DrugBank.d397.s0.p0	Erythromycin	drug	_	theophylline	drug	_	effect	druga use in patients who are receiving high doses of drugb may be associated with an increase in serum drugn levels and potential drugn toxicity .
DDI-DrugBank.d397.s0.p1	Erythromycin	drug	_	theophylline	drug	_	false	druga use in patients who are receiving high doses of drugn may be associated with an increase in serum drugb levels and potential drugn toxicity .
DDI-DrugBank.d397.s0.p2	Erythromycin	drug	_	theophylline	drug	_	false	druga use in patients who are receiving high doses of drugn may be associated with an increase in serum drugn levels and potential drugb toxicity .
DDI-DrugBank.d397.s1.p2	theophylline	drug	_	erythromycin	drug	_	false	in case of druga toxicity and/or elevated serum drugn levels , the dose of drugn should be reduced while the patient is receiving concomitant drugb therapy .
DDI-DrugBank.d397.s1.p4	theophylline	drug	_	erythromycin	drug	_	false	in case of drugn toxicity and/or elevated serum druga levels , the dose of drugn should be reduced while the patient is receiving concomitant drugb therapy .
DDI-DrugBank.d397.s1.p5	theophylline	drug	_	erythromycin	drug	_	advise	in case of drugn toxicity and/or elevated serum drugn levels , the dose of druga should be reduced while the patient is receiving concomitant drugb therapy .
DDI-DrugBank.d397.s2.p0	erythromycin	drug	_	digoxin	drug	_	mechanism	concomitant administration of druga and drugb has been reported to result in elevated drugn serum levels .
DDI-DrugBank.d397.s2.p1	erythromycin	drug	_	digoxin	drug	_	false	concomitant administration of druga and drugn has been reported to result in elevated drugb serum levels .
DDI-DrugBank.d397.s3.p0	erythromycin	drug	_	anticoagulants	group	_	effect	there have been reports of increased anticoagulant effects when druga and oral drugb were used concomitantly .
DDI-DrugBank.d397.s6.p0	Erythromycin	drug	_	triazolam	drug	_	mechanism	druga has been reported to decrease the clearance of drugb and drugn and thus may increase the pharmacologic effect of these drugn .
DDI-DrugBank.d397.s6.p1	Erythromycin	drug	_	midazolam	drug	_	mechanism	druga has been reported to decrease the clearance of drugn and drugb and thus may increase the pharmacologic effect of these drugn .
DDI-DrugBank.d397.s6.p2	Erythromycin	drug	_	benzodiazepines	group	_	effect	druga has been reported to decrease the clearance of drugn and drugn and thus may increase the pharmacologic effect of these drugb .
DDI-DrugBank.d397.s6.p3	triazolam	drug	_	midazolam	drug	_	false	drugn has been reported to decrease the clearance of druga and drugb and thus may increase the pharmacologic effect of these drugn .
DDI-DrugBank.d397.s6.p4	triazolam	drug	_	benzodiazepines	group	_	false	drugn has been reported to decrease the clearance of druga and drugn and thus may increase the pharmacologic effect of these drugb .
DDI-DrugBank.d397.s6.p5	midazolam	drug	_	benzodiazepines	group	_	false	drugn has been reported to decrease the clearance of drugn and druga and thus may increase the pharmacologic effect of these drugb .
DDI-DrugBank.d397.s8.p0	erythromycin	drug	_	carbamazepine	drug	_	int	there have been reports of interactions of druga with drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p1	erythromycin	drug	_	cyclosporine	drug	_	int	there have been reports of interactions of druga with drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p2	erythromycin	drug	_	tacrolimus	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p3	erythromycin	drug	_	hexobarbital	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p4	erythromycin	drug	_	phenytoin	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p5	erythromycin	drug	_	alfentanil	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p6	erythromycin	drug	_	cisapride	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p7	erythromycin	drug	_	disopyramide	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p8	erythromycin	drug	_	lovastatin	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p9	erythromycin	drug	_	bromocriptine	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d397.s8.p10	erythromycin	drug	_	valproate	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d397.s8.p11	erythromycin	drug	_	terfenadine	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d397.s8.p12	erythromycin	drug	_	astemizole	drug	_	int	there have been reports of interactions of druga with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d397.s10.p0	Erythromycin	drug	_	antihistamines	group	_	false	druga has been reported to significantly alter the metabolism of nonsedating drugb drugn and drugn when taken concomitantly .
DDI-DrugBank.d397.s10.p1	Erythromycin	drug	_	terfenadine	drug	_	mechanism	druga has been reported to significantly alter the metabolism of nonsedating drugn drugb and drugn when taken concomitantly .
DDI-DrugBank.d397.s10.p2	Erythromycin	drug	_	astemizole	drug	_	mechanism	druga has been reported to significantly alter the metabolism of nonsedating drugn drugn and drugb when taken concomitantly .
DDI-DrugBank.d397.s10.p3	antihistamines	group	_	terfenadine	drug	_	false	drugn has been reported to significantly alter the metabolism of nonsedating druga drugb and drugn when taken concomitantly .
DDI-DrugBank.d397.s10.p4	antihistamines	group	_	astemizole	drug	_	false	drugn has been reported to significantly alter the metabolism of nonsedating druga drugn and drugb when taken concomitantly .
DDI-DrugBank.d397.s10.p5	terfenadine	drug	_	astemizole	drug	_	false	drugn has been reported to significantly alter the metabolism of nonsedating drugn druga and drugb when taken concomitantly .
DDI-DrugBank.d397.s12.p0	terfenadine	drug	_	erythromycin	drug	_	effect	in addition , deaths have been reported rarely with concomitant administration of druga and drugb .
DDI-DrugBank.d397.s13.p0	erythromycin	drug	_	cisapride	drug	_	effect	there have been postmarketing reports of drug interactions when druga is coadministered with drugb , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of drugn by drugn .
DDI-DrugBank.d397.s13.p1	erythromycin	drug	_	cisapride	drug	_	false	there have been postmarketing reports of drug interactions when druga is coadministered with drugn , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of drugb by drugn .
DDI-DrugBank.d397.s13.p4	cisapride	drug	_	erythromycin	drug	_	false	there have been postmarketing reports of drug interactions when drugn is coadministered with druga , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of drugn by drugb .
DDI-DrugBank.d397.s13.p5	cisapride	drug	_	erythromycin	drug	_	mechanism	there have been postmarketing reports of drug interactions when drugn is coadministered with drugn , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of druga by drugb .
DDI-DrugBank.d397.s15.p0	lovastatin	drug	_	erythromycin	drug	_	advise	patients receiving concomitant druga and drugb should be carefully monitored ;
DDI-DrugBank.d568.s1.p0	Alcohol	drug	_	LEXAPRO	brand	_	false	druga - although drugb did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugn , the use of drugn by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p2	Alcohol	drug	_	psychotropic medications	group	_	false	druga - although drugn did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugb , the use of drugn by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p4	Alcohol	drug	_	LEXAPRO	brand	_	false	druga - although drugn did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugn , the use of drugn by patients taking drugb is not recommended .
DDI-DrugBank.d568.s1.p5	LEXAPRO	brand	_	alcohol	drug	_	false	drugn - although druga did not potentiate the cognitive and motor effects of drugb in a clinical trial , as with other drugn , the use of drugn by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p6	LEXAPRO	brand	_	psychotropic medications	group	_	false	drugn - although druga did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugb , the use of drugn by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p7	LEXAPRO	brand	_	alcohol	drug	_	false	drugn - although druga did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugn , the use of drugb by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p9	alcohol	drug	_	psychotropic medications	group	_	false	drugn - although drugn did not potentiate the cognitive and motor effects of druga in a clinical trial , as with other drugb , the use of drugn by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p11	alcohol	drug	_	LEXAPRO	brand	_	false	drugn - although drugn did not potentiate the cognitive and motor effects of druga in a clinical trial , as with other drugn , the use of drugn by patients taking drugb is not recommended .
DDI-DrugBank.d568.s1.p12	psychotropic medications	group	_	alcohol	drug	_	false	drugn - although drugn did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other druga , the use of drugb by patients taking drugn is not recommended .
DDI-DrugBank.d568.s1.p13	psychotropic medications	group	_	LEXAPRO	brand	_	advise	drugn - although drugn did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other druga , the use of drugn by patients taking drugb is not recommended .
DDI-DrugBank.d568.s1.p14	alcohol	drug	_	LEXAPRO	brand	_	advise	drugn - although drugn did not potentiate the cognitive and motor effects of drugn in a clinical trial , as with other drugn , the use of druga by patients taking drugb is not recommended .
DDI-DrugBank.d568.s5.p0	psychotropic drugs	group	_	NSAID	group	_	effect	epidemiological studies of the case-control and cohort design that have demonstrated an association between use of druga that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drugb or drugn potentiated the risk of bleeding .
DDI-DrugBank.d568.s5.p1	psychotropic drugs	group	_	aspirin	brand	_	effect	epidemiological studies of the case-control and cohort design that have demonstrated an association between use of druga that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drugn or drugb potentiated the risk of bleeding .
DDI-DrugBank.d568.s5.p2	NSAID	group	_	aspirin	brand	_	false	epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drugn that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an druga or drugb potentiated the risk of bleeding .
DDI-DrugBank.d568.s7.p0	Cimetidine	drug	_	citalopram	drug	_	false	druga - in subjects who had received # days of # mg/day racemic drugb , combined administration of # mg/day drugn for # days resulted in an increase in drugn auc and cmax of 43 % and 39 % , respectively .
DDI-DrugBank.d568.s7.p2	Cimetidine	drug	_	citalopram	drug	_	false	druga - in subjects who had received # days of # mg/day racemic drugn , combined administration of # mg/day drugn for # days resulted in an increase in drugb auc and cmax of 43 % and 39 % , respectively .
DDI-DrugBank.d568.s7.p3	citalopram	drug	_	cimetidine	drug	_	mechanism	drugn - in subjects who had received # days of # mg/day racemic druga , combined administration of # mg/day drugb for # days resulted in an increase in drugn auc and cmax of 43 % and 39 % , respectively .
DDI-DrugBank.d568.s7.p5	cimetidine	drug	_	citalopram	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic drugn , combined administration of # mg/day druga for # days resulted in an increase in drugb auc and cmax of 43 % and 39 % , respectively .
DDI-DrugBank.d568.s9.p0	Digoxin	drug	_	citalopram	drug	_	false	druga - in subjects who had received # days of # mg/day racemic drugb , combined administration of drugn and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s9.p1	Digoxin	drug	_	citalopram	drug	_	false	druga - in subjects who had received # days of # mg/day racemic drugn , combined administration of drugb and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s9.p3	Digoxin	drug	_	citalopram	drug	_	false	druga - in subjects who had received # days of # mg/day racemic drugn , combined administration of drugn and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d568.s9.p6	citalopram	drug	_	digoxin	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic druga , combined administration of drugn and drugb -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s9.p8	citalopram	drug	_	digoxin	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic druga , combined administration of drugn and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d568.s9.p9	citalopram	drug	_	digoxin	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic drugn , combined administration of druga and drugb -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s9.p11	citalopram	drug	_	digoxin	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic drugn , combined administration of druga and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d568.s9.p12	digoxin	drug	_	citalopram	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic drugn , combined administration of drugn and druga -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d568.s9.p14	citalopram	drug	_	digoxin	drug	_	false	drugn - in subjects who had received # days of # mg/day racemic drugn , combined administration of drugn and drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d568.s10.p0	Lithium	drug	_	citalopram	drug	_	false	druga - coadministration of racemic drugb -lcb- 40 mg/day for # days -rcb- and drugn -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of drugn or drugn .
DDI-DrugBank.d568.s10.p2	Lithium	drug	_	citalopram	drug	_	false	druga - coadministration of racemic drugn -lcb- 40 mg/day for # days -rcb- and drugn -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of drugb or drugn .
DDI-DrugBank.d568.s10.p4	citalopram	drug	_	lithium	drug	_	false	drugn - coadministration of racemic druga -lcb- 40 mg/day for # days -rcb- and drugb -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of drugn or drugn .
DDI-DrugBank.d568.s10.p6	citalopram	drug	_	lithium	drug	_	false	drugn - coadministration of racemic druga -lcb- 40 mg/day for # days -rcb- and drugn -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of drugn or drugb .
DDI-DrugBank.d568.s10.p7	lithium	drug	_	citalopram	drug	_	false	drugn - coadministration of racemic drugn -lcb- 40 mg/day for # days -rcb- and druga -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of drugb or drugn .
DDI-DrugBank.d568.s10.p9	citalopram	drug	_	lithium	drug	_	false	drugn - coadministration of racemic drugn -lcb- 40 mg/day for # days -rcb- and drugn -lcb- 30 mmol/day for # days -rcb- had no significant effect on the pharmacokinetics of druga or drugb .
DDI-DrugBank.d568.s12.p0	lithium	drug	_	escitalopram	drug	_	effect	because druga may enhance the serotonergic effects of drugb , caution should be exercised when drugn and drugn are coadministered .
DDI-DrugBank.d568.s12.p1	lithium	drug	_	LEXAPRO	brand	_	false	because druga may enhance the serotonergic effects of drugn , caution should be exercised when drugb and drugn are coadministered .
DDI-DrugBank.d568.s12.p3	escitalopram	drug	_	LEXAPRO	brand	_	false	because drugn may enhance the serotonergic effects of druga , caution should be exercised when drugb and drugn are coadministered .
DDI-DrugBank.d568.s12.p4	escitalopram	drug	_	lithium	drug	_	false	because drugn may enhance the serotonergic effects of druga , caution should be exercised when drugn and drugb are coadministered .
DDI-DrugBank.d568.s12.p5	LEXAPRO	brand	_	lithium	drug	_	advise	because drugn may enhance the serotonergic effects of drugn , caution should be exercised when druga and drugb are coadministered .
DDI-DrugBank.d568.s13.p0	Pimozide	drug	_	Celexa	brand	_	false	druga and drugb - in a controlled study , a single dose of drugn # mg co-administered with racemic drugn # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugn given alone .
DDI-DrugBank.d568.s13.p2	Pimozide	drug	_	citalopram	drug	_	false	druga and drugn - in a controlled study , a single dose of drugn # mg co-administered with racemic drugb # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugn given alone .
DDI-DrugBank.d568.s13.p4	Celexa	brand	_	pimozide	drug	_	false	drugn and druga - in a controlled study , a single dose of drugb # mg co-administered with racemic drugn # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugn given alone .
DDI-DrugBank.d568.s13.p5	Celexa	brand	_	citalopram	drug	_	false	drugn and druga - in a controlled study , a single dose of drugn # mg co-administered with racemic drugb # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugn given alone .
DDI-DrugBank.d568.s13.p6	Celexa	brand	_	pimozide	drug	_	false	drugn and druga - in a controlled study , a single dose of drugn # mg co-administered with racemic drugn # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugb given alone .
DDI-DrugBank.d568.s13.p7	pimozide	drug	_	citalopram	drug	_	effect	drugn and drugn - in a controlled study , a single dose of druga # mg co-administered with racemic drugb # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugn given alone .
DDI-DrugBank.d568.s13.p9	citalopram	drug	_	pimozide	drug	_	false	drugn and drugn - in a controlled study , a single dose of drugn # mg co-administered with racemic druga # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to drugb given alone .
DDI-DrugBank.d568.s14.p0	citalopram	drug	_	pimozide	drug	_	false	racemic druga did not alter the mean auc or cmax of drugb .
DDI-DrugBank.d568.s16.p0	Sumatriptan	drug	_	selective serotonin reuptake inhibitor	group	_	false	druga - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a drugb -lcb- drugn -rcb- and drugn .
DDI-DrugBank.d568.s16.p1	Sumatriptan	drug	_	SSRI	group	_	false	druga - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a drugn -lcb- drugb -rcb- and drugn .
DDI-DrugBank.d568.s16.p4	selective serotonin reuptake inhibitor	group	_	sumatriptan	drug	_	effect	drugn - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a druga -lcb- drugn -rcb- and drugb .
DDI-DrugBank.d568.s16.p5	SSRI	group	_	sumatriptan	drug	_	effect	drugn - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a drugn -lcb- druga -rcb- and drugb .
DDI-DrugBank.d568.s17.p0	sumatriptan	drug	_	SSRI	group	_	advise	if concomitant treatment with druga and an drugb -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p1	sumatriptan	drug	_	fluoxetine	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugb , drugn , drugn , drugn , drugn , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p2	sumatriptan	drug	_	fluvoxamine	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugn , drugb , drugn , drugn , drugn , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p3	sumatriptan	drug	_	paroxetine	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugn , drugn , drugb , drugn , drugn , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p4	sumatriptan	drug	_	sertraline	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugn , drugn , drugn , drugb , drugn , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p5	sumatriptan	drug	_	citalopram	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugb , drugn -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s17.p6	sumatriptan	drug	_	escitalopram	drug	_	advise	if concomitant treatment with druga and an drugn -lcb- e , g , , drugn , drugn , drugn , drugn , drugn , drugb -rcb- is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d568.s18.p0	Theophylline	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugb -lcb- 40 mg/day for # days -rcb- and the cyp1a2 substrate drugn -lcb- single dose of # mg -rcb- did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s18.p3	citalopram	drug	_	theophylline	drug	_	false	drugn - combined administration of racemic druga -lcb- 40 mg/day for # days -rcb- and the cyp1a2 substrate drugb -lcb- single dose of # mg -rcb- did not affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s18.p4	citalopram	drug	_	theophylline	drug	_	false	drugn - combined administration of racemic druga -lcb- 40 mg/day for # days -rcb- and the cyp1a2 substrate drugn -lcb- single dose of # mg -rcb- did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d568.s19.p0	theophylline	drug	_	citalopram	drug	_	false	the effect of druga on the pharmacokinetics of drugb was not evaluated .
DDI-DrugBank.d568.s20.p0	Warfarin	drug	_	citalopram	drug	_	false	druga - administration of # mg/day racemic drugb for # days did not affect the pharmacokinetics of drugn , a cyp3a4 substrate .
DDI-DrugBank.d568.s20.p2	citalopram	drug	_	warfarin	drug	_	false	drugn - administration of # mg/day racemic druga for # days did not affect the pharmacokinetics of drugb , a cyp3a4 substrate .
DDI-DrugBank.d568.s22.p0	Carbamazepine	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugb -lcb- 40 mg/day for # days -rcb- and drugn -lcb- titrated to # mg/day for # days -rcb- did not significantly affect the pharmacokinetics of drugn , a cyp3a4 substrate .
DDI-DrugBank.d568.s22.p3	citalopram	drug	_	carbamazepine	drug	_	false	drugn - combined administration of racemic druga -lcb- 40 mg/day for # days -rcb- and drugb -lcb- titrated to # mg/day for # days -rcb- did not significantly affect the pharmacokinetics of drugn , a cyp3a4 substrate .
DDI-DrugBank.d568.s22.p4	citalopram	drug	_	carbamazepine	drug	_	false	drugn - combined administration of racemic druga -lcb- 40 mg/day for # days -rcb- and drugn -lcb- titrated to # mg/day for # days -rcb- did not significantly affect the pharmacokinetics of drugb , a cyp3a4 substrate .
DDI-DrugBank.d568.s23.p0	citalopram	drug	_	carbamazepine	drug	_	false	although trough druga plasma levels were unaffected , given the enzyme-inducing properties of drugb , the possibility that drugn might increase the clearance of drugn should be considered if the two drugs are coadministered .
DDI-DrugBank.d568.s23.p1	citalopram	drug	_	carbamazepine	drug	_	false	although trough druga plasma levels were unaffected , given the enzyme-inducing properties of drugn , the possibility that drugb might increase the clearance of drugn should be considered if the two drugs are coadministered .
DDI-DrugBank.d568.s23.p4	carbamazepine	drug	_	escitalopram	drug	_	false	although trough drugn plasma levels were unaffected , given the enzyme-inducing properties of druga , the possibility that drugn might increase the clearance of drugb should be considered if the two drugs are coadministered .
DDI-DrugBank.d568.s23.p5	carbamazepine	drug	_	escitalopram	drug	_	mechanism	although trough drugn plasma levels were unaffected , given the enzyme-inducing properties of drugn , the possibility that druga might increase the clearance of drugb should be considered if the two drugs are coadministered .
DDI-DrugBank.d568.s24.p0	Triazolam	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugb -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s24.p2	Triazolam	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugn -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d568.s24.p4	citalopram	drug	_	triazolam	drug	_	false	drugn - combined administration of racemic druga -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate drugb -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s24.p6	citalopram	drug	_	triazolam	drug	_	false	drugn - combined administration of racemic druga -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d568.s24.p7	triazolam	drug	_	citalopram	drug	_	false	drugn - combined administration of racemic drugn -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate druga -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d568.s24.p9	citalopram	drug	_	triazolam	drug	_	false	drugn - combined administration of racemic drugn -lcb- titrated to # mg/day for # days -rcb- and the cyp3a4 substrate drugn -lcb- single dose of # mg -rcb- did not significantly affect the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d568.s25.p0	Ketoconazole	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugb -lcb- 40 mg -rcb- and drugn -lcb- 200 mg -rcb- decreased the cmax and auc of drugn by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s25.p3	Ketoconazole	drug	_	citalopram	drug	_	false	druga - combined administration of racemic drugn -lcb- 40 mg -rcb- and drugn -lcb- 200 mg -rcb- decreased the cmax and auc of drugn by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugb .
DDI-DrugBank.d568.s25.p4	citalopram	drug	_	ketoconazole	drug	_	mechanism	drugn - combined administration of racemic druga -lcb- 40 mg -rcb- and drugb -lcb- 200 mg -rcb- decreased the cmax and auc of drugn by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s25.p5	citalopram	drug	_	ketoconazole	drug	_	false	drugn - combined administration of racemic druga -lcb- 40 mg -rcb- and drugn -lcb- 200 mg -rcb- decreased the cmax and auc of drugb by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s25.p8	ketoconazole	drug	_	citalopram	drug	_	false	drugn - combined administration of racemic drugn -lcb- 40 mg -rcb- and druga -lcb- 200 mg -rcb- decreased the cmax and auc of drugn by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugb .
DDI-DrugBank.d568.s25.p9	ketoconazole	drug	_	citalopram	drug	_	false	drugn - combined administration of racemic drugn -lcb- 40 mg -rcb- and drugn -lcb- 200 mg -rcb- decreased the cmax and auc of druga by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drugb .
DDI-DrugBank.d568.s26.p1	Ritonavir	drug	_	escitalopram	drug	_	false	druga - combined administration of a single dose of drugn -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and drugb -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s26.p3	Ritonavir	drug	_	escitalopram	drug	_	false	druga - combined administration of a single dose of drugn -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and drugn -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d568.s26.p4	ritonavir	drug	_	escitalopram	drug	_	false	drugn - combined administration of a single dose of druga -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and drugb -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d568.s26.p6	ritonavir	drug	_	escitalopram	drug	_	false	drugn - combined administration of a single dose of druga -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and drugn -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d568.s26.p7	escitalopram	drug	_	ritonavir	drug	_	false	drugn - combined administration of a single dose of drugn -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and druga -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d568.s26.p9	ritonavir	drug	_	escitalopram	drug	_	false	drugn - combined administration of a single dose of drugn -lcb- 600 mg -rcb- , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and drugn -lcb- 20 mg -rcb- did not affect the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d568.s28.p0	escitalopram	drug	_	ritonavir	drug	_	false	however , coadministration of druga -lcb- 20 mg -rcb- and drugb -lcb- 600 mg -rcb- , a potent inhibitor of cyp3a4 , did not significantly affect the pharmacokinetics of drugn .
DDI-DrugBank.d568.s28.p2	ritonavir	drug	_	escitalopram	drug	_	false	however , coadministration of drugn -lcb- 20 mg -rcb- and druga -lcb- 600 mg -rcb- , a potent inhibitor of cyp3a4 , did not significantly affect the pharmacokinetics of drugb .
DDI-DrugBank.d568.s32.p1	escitalopram	drug	_	tricyclic antidepressant	group	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for druga , i , e , , coadministration of drugn -lcb- 20 mg/day for # days -rcb- with the drugb drugn -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugn .
DDI-DrugBank.d568.s32.p2	escitalopram	drug	_	desipramine	drug	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for druga , i , e , , coadministration of drugn -lcb- 20 mg/day for # days -rcb- with the drugn drugb -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugn .
DDI-DrugBank.d568.s32.p3	escitalopram	drug	_	desipramine	drug	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for druga , i , e , , coadministration of drugn -lcb- 20 mg/day for # days -rcb- with the drugn drugn -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugb .
DDI-DrugBank.d568.s32.p4	escitalopram	drug	_	tricyclic antidepressant	group	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for drugn , i , e , , coadministration of druga -lcb- 20 mg/day for # days -rcb- with the drugb drugn -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugn .
DDI-DrugBank.d568.s32.p5	escitalopram	drug	_	desipramine	drug	_	mechanism	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for drugn , i , e , , coadministration of druga -lcb- 20 mg/day for # days -rcb- with the drugn drugb -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugn .
DDI-DrugBank.d568.s32.p6	escitalopram	drug	_	desipramine	drug	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for drugn , i , e , , coadministration of druga -lcb- 20 mg/day for # days -rcb- with the drugn drugn -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugb .
DDI-DrugBank.d568.s32.p7	tricyclic antidepressant	group	_	desipramine	drug	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for drugn , i , e , , coadministration of drugn -lcb- 20 mg/day for # days -rcb- with the druga drugb -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugn .
DDI-DrugBank.d568.s32.p8	tricyclic antidepressant	group	_	desipramine	drug	_	false	however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for drugn , i , e , , coadministration of drugn -lcb- 20 mg/day for # days -rcb- with the druga drugn -lcb- single dose of # mg -rcb- , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of drugb .
DDI-DrugBank.d568.s35.p0	Metoprolol	drug	_	LEXAPRO	brand	_	false	druga - administration of # mg/day drugb for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the drugn drugn -lcb- given in a single dose of # mg -rcb- .
DDI-DrugBank.d568.s35.p1	Metoprolol	drug	_	beta-adrenergic blocker	group	_	false	druga - administration of # mg/day drugn for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the drugb drugn -lcb- given in a single dose of # mg -rcb- .
DDI-DrugBank.d568.s35.p3	LEXAPRO	brand	_	beta-adrenergic blocker	group	_	false	drugn - administration of # mg/day druga for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the drugb drugn -lcb- given in a single dose of # mg -rcb- .
DDI-DrugBank.d568.s35.p4	LEXAPRO	brand	_	metoprolol	drug	_	mechanism	drugn - administration of # mg/day druga for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the drugn drugb -lcb- given in a single dose of # mg -rcb- .
DDI-DrugBank.d568.s35.p5	beta-adrenergic blocker	group	_	metoprolol	drug	_	false	drugn - administration of # mg/day drugn for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the druga drugb -lcb- given in a single dose of # mg -rcb- .
DDI-DrugBank.d568.s37.p0	LEXAPRO	brand	_	metoprolol	drug	_	false	coadministration of druga and drugb had no clinically significant effects on blood pressure or heart rate .
DDI-DrugBank.d568.s39.p3	Citalopram	drug	_	Celexa	brand	_	false	concomitant administration with racemic druga drugn - since drugn is the active isomer of racemic drugn -lcb- drugb -rcb- , the two agents should not be coadministered .
DDI-DrugBank.d568.s39.p6	Citalopram	drug	_	Celexa	brand	_	false	concomitant administration with racemic drugn druga - since drugn is the active isomer of racemic drugn -lcb- drugb -rcb- , the two agents should not be coadministered .
DDI-DrugBank.d568.s39.p8	escitalopram	drug	_	Celexa	brand	_	advise	concomitant administration with racemic drugn drugn - since druga is the active isomer of racemic drugn -lcb- drugb -rcb- , the two agents should not be coadministered .
DDI-DrugBank.d422.s0.p0	reserpine	drug	_	beta blocking agents	group	_	effect	catecholamine-depleting drugs , e , g , , druga , may have an additive effect when given with drugb .
DDI-DrugBank.d422.s2.p0	BREVIBLOC	brand	_	warfarin	drug	_	false	a study of interaction between druga and drugb showed that concomitant administration of drugn and drugn does not alter drugn plasma levels .
DDI-DrugBank.d422.s2.p2	BREVIBLOC	brand	_	warfarin	drug	_	false	a study of interaction between druga and drugn showed that concomitant administration of drugn and drugb does not alter drugn plasma levels .
DDI-DrugBank.d422.s2.p3	BREVIBLOC	brand	_	warfarin	drug	_	false	a study of interaction between druga and drugn showed that concomitant administration of drugn and drugn does not alter drugb plasma levels .
DDI-DrugBank.d422.s2.p4	warfarin	drug	_	BREVIBLOC	brand	_	false	a study of interaction between drugn and druga showed that concomitant administration of drugb and drugn does not alter drugn plasma levels .
DDI-DrugBank.d422.s2.p7	BREVIBLOC	brand	_	warfarin	drug	_	false	a study of interaction between drugn and drugn showed that concomitant administration of druga and drugb does not alter drugn plasma levels .
DDI-DrugBank.d422.s2.p8	BREVIBLOC	brand	_	warfarin	drug	_	false	a study of interaction between drugn and drugn showed that concomitant administration of druga and drugn does not alter drugb plasma levels .
DDI-DrugBank.d422.s3.p0	BREVIBLOC	brand	_	warfarin	drug	_	mechanism	druga concentrations were equivocally higher when given with drugb , but this is not likely to be clinically important .
DDI-DrugBank.d422.s4.p0	digoxin	drug	_	BREVIBLOC	brand	_	mechanism	when druga and drugb were concomitantly administered intravenously to normal volunteers , there was a 10-20 % increase in drugn blood levels at some time points .
DDI-DrugBank.d422.s4.p2	BREVIBLOC	brand	_	digoxin	drug	_	false	when drugn and druga were concomitantly administered intravenously to normal volunteers , there was a 10-20 % increase in drugb blood levels at some time points .
DDI-DrugBank.d422.s5.p0	Digoxin	drug	_	BREVIBLOC	brand	_	false	druga did not affect drugb pharmacokinetics .
DDI-DrugBank.d422.s6.p0	morphine	drug	_	BREVIBLOC	brand	_	false	when intravenous druga and drugb were concomitantly administered in normal subjects , no effect on drugn blood levels was seen , but drugn steady-state blood levels were increased by 46 % in the presence of drugn .
DDI-DrugBank.d422.s6.p2	morphine	drug	_	BREVIBLOC	brand	_	false	when intravenous druga and drugn were concomitantly administered in normal subjects , no effect on drugn blood levels was seen , but drugb steady-state blood levels were increased by 46 % in the presence of drugn .
DDI-DrugBank.d422.s6.p4	BREVIBLOC	brand	_	morphine	drug	_	false	when intravenous drugn and druga were concomitantly administered in normal subjects , no effect on drugb blood levels was seen , but drugn steady-state blood levels were increased by 46 % in the presence of drugn .
DDI-DrugBank.d422.s6.p6	BREVIBLOC	brand	_	morphine	drug	_	false	when intravenous drugn and druga were concomitantly administered in normal subjects , no effect on drugn blood levels was seen , but drugn steady-state blood levels were increased by 46 % in the presence of drugb .
DDI-DrugBank.d422.s6.p7	morphine	drug	_	BREVIBLOC	brand	_	false	when intravenous drugn and drugn were concomitantly administered in normal subjects , no effect on druga blood levels was seen , but drugb steady-state blood levels were increased by 46 % in the presence of drugn .
DDI-DrugBank.d422.s6.p9	BREVIBLOC	brand	_	morphine	drug	_	mechanism	when intravenous drugn and drugn were concomitantly administered in normal subjects , no effect on drugn blood levels was seen , but druga steady-state blood levels were increased by 46 % in the presence of drugb .
DDI-DrugBank.d422.s8.p0	BREVIBLOC	drug	_	succinylcholine	drug	_	false	the effect of druga on the duration of drugb - induced neuromuscular blockade was studied in patients undergoing surgery .
DDI-DrugBank.d422.s9.p0	succinylcholine	drug	_	BREVIBLOC	brand	_	effect	the onset of neuromuscular blockade by druga was unaffected by drugb , but the duration of neuromuscular blockade was prolonged from # minutes to # minutes .
DDI-DrugBank.d422.s10.p0	BREVIBLOC	brand	_	digoxin	drug	_	advise	although the interactions observed in these studies do not appear to be of major clinical importance , druga should be titrated with caution in patients being treated concurrently with drugb , drugn , drugn or drugn .
DDI-DrugBank.d422.s10.p1	BREVIBLOC	brand	_	morphine	drug	_	advise	although the interactions observed in these studies do not appear to be of major clinical importance , druga should be titrated with caution in patients being treated concurrently with drugn , drugb , drugn or drugn .
DDI-DrugBank.d422.s10.p2	BREVIBLOC	brand	_	succinylcholine	drug	_	advise	although the interactions observed in these studies do not appear to be of major clinical importance , druga should be titrated with caution in patients being treated concurrently with drugn , drugn , drugb or drugn .
DDI-DrugBank.d422.s10.p3	BREVIBLOC	brand	_	warfarin	drug	_	advise	although the interactions observed in these studies do not appear to be of major clinical importance , druga should be titrated with caution in patients being treated concurrently with drugn , drugn , drugn or drugb .
DDI-DrugBank.d422.s13.p0	BREVIBLOC	brand	_	verapamil	drug	_	advise	caution should be exercised when considering the use of druga and drugb in patients with depressed myocardial function .
DDI-DrugBank.d422.s15.p0	BREVIBLOC	brand	_	dopamine	drug	_	advise	additionally , druga should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drugb , drugn , and drugn because of the danger of blocking cardiac contractility when systemic vascular resistance is high .
DDI-DrugBank.d422.s15.p1	BREVIBLOC	brand	_	epinephrine	drug	_	advise	additionally , druga should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drugn , drugb , and drugn because of the danger of blocking cardiac contractility when systemic vascular resistance is high .
DDI-DrugBank.d422.s15.p2	BREVIBLOC	brand	_	norepinephrine	drug	_	advise	additionally , druga should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drugn , drugn , and drugb because of the danger of blocking cardiac contractility when systemic vascular resistance is high .
DDI-DrugBank.d29.s3.p0	esomeprazole	drug	_	phenytoin	drug	_	false	drug interaction studies have shown that druga does not have any clinically significant interactions with drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d29.s3.p1	esomeprazole	drug	_	warfarin	drug	_	false	drug interaction studies have shown that druga does not have any clinically significant interactions with drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d29.s3.p2	esomeprazole	drug	_	quinidine	drug	_	false	drug interaction studies have shown that druga does not have any clinically significant interactions with drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d29.s3.p3	esomeprazole	drug	_	clarithromycin	drug	_	false	drug interaction studies have shown that druga does not have any clinically significant interactions with drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d29.s3.p4	esomeprazole	drug	_	amoxicillin	drug	_	false	drug interaction studies have shown that druga does not have any clinically significant interactions with drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d29.s4.p0	warfarin	drug	_	esomeprazole	drug	_	false	post-marketing reports of changes in prothrombin measures have been received among patients on concomitant druga and drugb therapy .
DDI-DrugBank.d29.s6.p0	proton pump inhibitors	group	_	warfarin	drug	_	effect	patients treated with druga and drugb concomitantly may need to be monitored for increases in inr and prothrombin time .
DDI-DrugBank.d29.s8.p0	esomeprazole	drug	_	diazepam	drug	_	mechanism	coadministration of druga # mg and drugb , a cyp2c19 substrate , resulted in a 45 % decrease in clearance of drugn .
DDI-DrugBank.d29.s8.p1	esomeprazole	drug	_	diazepam	drug	_	false	coadministration of druga # mg and drugn , a cyp2c19 substrate , resulted in a 45 % decrease in clearance of drugb .
DDI-DrugBank.d29.s12.p0	esomeprazole	drug	_	ketoconazole	drug	_	mechanism	therefore , druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- eg , drugb , drugn salts and drugn -rcb- .
DDI-DrugBank.d29.s12.p1	esomeprazole	drug	_	iron	drug	_	mechanism	therefore , druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- eg , drugn , drugb salts and drugn -rcb- .
DDI-DrugBank.d29.s12.p2	esomeprazole	drug	_	digoxin	drug	_	mechanism	therefore , druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- eg , drugn , drugn salts and drugb -rcb- .
DDI-DrugBank.d29.s13.p3	contraceptives	group	_	esomeprazole	drug	_	false	coadministration of oral druga , drugn , drugn , or drugn did not seem to change the pharmacokinetic profile of drugb .
DDI-DrugBank.d29.s13.p6	diazepam	drug	_	esomeprazole	drug	_	false	coadministration of oral drugn , druga , drugn , or drugn did not seem to change the pharmacokinetic profile of drugb .
DDI-DrugBank.d29.s13.p8	phenytoin	drug	_	esomeprazole	drug	_	false	coadministration of oral drugn , drugn , druga , or drugn did not seem to change the pharmacokinetic profile of drugb .
DDI-DrugBank.d29.s13.p9	quinidine	drug	_	esomeprazole	drug	_	false	coadministration of oral drugn , drugn , drugn , or druga did not seem to change the pharmacokinetic profile of drugb .
DDI-DrugBank.d29.s14.p0	clarithromycin	drug	_	pimozide	drug	_	advise	concomitant administration of druga with drugb is contraindicated .
DDI-DrugBank.d338.s1.p0	benzodiazepines	group	_	anticonvulsants	group	_	effect	the action of the druga may be potentiated by drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p1	benzodiazepines	group	_	antihistamines	group	_	effect	the action of the druga may be potentiated by drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p2	benzodiazepines	group	_	alcohol	drug	_	effect	the action of the druga may be potentiated by drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p3	benzodiazepines	group	_	barbiturates	group	_	effect	the action of the druga may be potentiated by drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p4	benzodiazepines	group	_	monoamine oxidase inhibitors	group	_	effect	the action of the druga may be potentiated by drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p5	benzodiazepines	group	_	narcotics	group	_	effect	the action of the druga may be potentiated by drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p6	benzodiazepines	group	_	phenothiazines	group	_	effect	the action of the druga may be potentiated by drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or other drugs that produce cns depression .
DDI-DrugBank.d338.s1.p7	benzodiazepines	group	_	psychotropic medications	group	_	effect	the action of the druga may be potentiated by drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or other drugs that produce cns depression .
DDI-DrugBank.d338.s4.p0	estazolam	drug	_	carbamazepine	drug	_	mechanism	while no in vivo drug-drug interaction studies were conducted between druga and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugb , drugn , drugn , and drugn -rcb- would be expected to decrease drugn concentrations .
DDI-DrugBank.d338.s4.p1	estazolam	drug	_	phenytoin	drug	_	mechanism	while no in vivo drug-drug interaction studies were conducted between druga and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , drugb , drugn , and drugn -rcb- would be expected to decrease drugn concentrations .
DDI-DrugBank.d338.s4.p2	estazolam	drug	_	rifampin	drug	_	mechanism	while no in vivo drug-drug interaction studies were conducted between druga and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , drugn , drugb , and drugn -rcb- would be expected to decrease drugn concentrations .
DDI-DrugBank.d338.s4.p3	estazolam	drug	_	barbiturates	group	_	mechanism	while no in vivo drug-drug interaction studies were conducted between druga and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , drugn , drugn , and drugb -rcb- would be expected to decrease drugn concentrations .
DDI-DrugBank.d338.s4.p8	carbamazepine	drug	_	estazolam	drug	_	false	while no in vivo drug-drug interaction studies were conducted between drugn and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as druga , drugn , drugn , and drugn -rcb- would be expected to decrease drugb concentrations .
DDI-DrugBank.d338.s4.p11	phenytoin	drug	_	estazolam	drug	_	false	while no in vivo drug-drug interaction studies were conducted between drugn and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , druga , drugn , and drugn -rcb- would be expected to decrease drugb concentrations .
DDI-DrugBank.d338.s4.p13	rifampin	drug	_	estazolam	drug	_	false	while no in vivo drug-drug interaction studies were conducted between drugn and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , drugn , druga , and drugn -rcb- would be expected to decrease drugb concentrations .
DDI-DrugBank.d338.s4.p14	barbiturates	group	_	estazolam	drug	_	false	while no in vivo drug-drug interaction studies were conducted between drugn and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers -lcb- such as drugn , drugn , drugn , and druga -rcb- would be expected to decrease drugb concentrations .
DDI-DrugBank.d338.s5.p4	estazolam	drug	_	triazolobenzodiazepines	group	_	false	drugn : interaction with drugs that inhibit metabolism via cytochrome cyp2b6 3a -lcb- cyp3a -rcb- : the metabolism of druga to the major circulating metabolite drugn and the metabolism of other drugb is catalyzed by cyp3a .
DDI-DrugBank.d338.s5.p5	4-hydroxy-estazolam	drug_n	_	triazolobenzodiazepines	group	_	false	drugn : interaction with drugs that inhibit metabolism via cytochrome cyp2b6 3a -lcb- cyp3a -rcb- : the metabolism of drugn to the major circulating metabolite druga and the metabolism of other drugb is catalyzed by cyp3a .
DDI-DrugBank.d338.s6.p0	estazolam	drug	_	ketoconazole	drug	_	advise	consequently , druga should be avoided in patients receiving drugb and drugn , which are very potent inhibitors of cyp3a .
DDI-DrugBank.d338.s6.p1	estazolam	drug	_	itraconazole	drug	_	advise	consequently , druga should be avoided in patients receiving drugn and drugb , which are very potent inhibitors of cyp3a .
DDI-DrugBank.d338.s6.p2	ketoconazole	drug	_	itraconazole	drug	_	false	consequently , drugn should be avoided in patients receiving druga and drugb , which are very potent inhibitors of cyp3a .
DDI-DrugBank.d338.s8.p0	benzodiazepines	group	_	nefazodone	drug	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugb , drugn , drugn , drugn , drugn , and some drugn .
DDI-DrugBank.d338.s8.p1	benzodiazepines	group	_	fluvoxamine	drug	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugn , drugb , drugn , drugn , drugn , and some drugn .
DDI-DrugBank.d338.s8.p2	benzodiazepines	group	_	cimetidine	drug	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugn , drugn , drugb , drugn , drugn , and some drugn .
DDI-DrugBank.d338.s8.p3	benzodiazepines	group	_	diltiazem	drug	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugn , drugn , drugn , drugb , drugn , and some drugn .
DDI-DrugBank.d338.s8.p4	benzodiazepines	group	_	isoniazide	drug	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugn , drugn , drugn , drugn , drugb , and some drugn .
DDI-DrugBank.d338.s8.p5	benzodiazepines	group	_	macrolide antibiotics	group	_	mechanism	the following are examples of drugs known to inhibit the metabolism of other related druga , presumably through inhibition of cyp3a : drugn , drugn , drugn , drugn , drugn , and some drugb .
DDI-DrugBank.d338.s8.p10	nefazodone	drug	_	macrolide antibiotics	group	_	false	the following are examples of drugs known to inhibit the metabolism of other related drugn , presumably through inhibition of cyp3a : druga , drugn , drugn , drugn , drugn , and some drugb .
DDI-DrugBank.d338.s8.p14	fluvoxamine	drug	_	macrolide antibiotics	group	_	false	the following are examples of drugs known to inhibit the metabolism of other related drugn , presumably through inhibition of cyp3a : drugn , druga , drugn , drugn , drugn , and some drugb .
DDI-DrugBank.d338.s8.p17	cimetidine	drug	_	macrolide antibiotics	group	_	false	the following are examples of drugs known to inhibit the metabolism of other related drugn , presumably through inhibition of cyp3a : drugn , drugn , druga , drugn , drugn , and some drugb .
DDI-DrugBank.d338.s8.p19	diltiazem	drug	_	macrolide antibiotics	group	_	false	the following are examples of drugs known to inhibit the metabolism of other related drugn , presumably through inhibition of cyp3a : drugn , drugn , drugn , druga , drugn , and some drugb .
DDI-DrugBank.d338.s8.p20	isoniazide	drug	_	macrolide antibiotics	group	_	false	the following are examples of drugs known to inhibit the metabolism of other related drugn , presumably through inhibition of cyp3a : drugn , drugn , drugn , drugn , druga , and some drugb .
DDI-DrugBank.d338.s9.p2	fluoxetine	drug	_	estazolam	drug	_	false	drug interaction with drugn : a multiple-dose study was conducted to assess the effect of druga # mg bid on the pharmacokinetics of drugb # mg qhs after seven days .
DDI-DrugBank.d338.s10.p0	estazolam	drug	_	fluoxetine	drug	_	false	the pharmacokinetics of druga -lcb- cmax and auc -rcb- were not affected during multiple-dose drugb , suggesting no clinically significant pharmacokinetic interaction .
DDI-DrugBank.d301.s14.p0	corticosteroids	group	_	sex steroids	group	_	false	other binding proteins may be elevated in serum , i , e , , corticosteroid binding globulin -lcb- cbg -rcb- , sex hormone-binding globulin -lcb- shbg -rcb- , leading to increased total circulating druga and drugb , respectively .
DDI-DrugBank.d481.s0.p0	calcium	drug	_	EMCYT	brand	_	mechanism	milk , milk products , and druga - rich foods or drugs may impair the absorption of drugb .
DDI-DrugBank.d216.s0.p0	Ethanol	drug	_	eszopiclone	drug	_	false	cns-active drugs druga an additive effect on psychomotor performance was seen with coadministration of drugb and drugn # g/kg for up to # hours after drugn administration .
DDI-DrugBank.d216.s0.p3	eszopiclone	drug	_	ethanol	drug	_	effect	cns-active drugs drugn an additive effect on psychomotor performance was seen with coadministration of druga and drugb # g/kg for up to # hours after drugn administration .
DDI-DrugBank.d216.s0.p4	eszopiclone	drug	_	ethanol	drug	_	false	cns-active drugs drugn an additive effect on psychomotor performance was seen with coadministration of druga and drugn # g/kg for up to # hours after drugb administration .
DDI-DrugBank.d216.s1.p0	Paroxetine	drug	_	eszopiclone	drug	_	false	druga : coadministration of single doses of drugb # mg and drugn # mg daily for # days produced no pharmacokinetic or pharmacodynamic interaction .
DDI-DrugBank.d216.s1.p2	eszopiclone	drug	_	paroxetine	drug	_	false	drugn : coadministration of single doses of druga # mg and drugb # mg daily for # days produced no pharmacokinetic or pharmacodynamic interaction .
DDI-DrugBank.d216.s2.p0	Lorazepam	drug	_	eszopiclone	drug	_	false	druga : coadministration of single doses of drugb # mg and drugn # mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .
DDI-DrugBank.d216.s2.p2	eszopiclone	drug	_	lorazepam	drug	_	false	drugn : coadministration of single doses of druga # mg and drugb # mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .
DDI-DrugBank.d216.s3.p0	Olanzapine	drug	_	eszopiclone	drug	_	false	druga : coadministration of drugb # mg and drugn # mg produced a decrease in dsst scores .
DDI-DrugBank.d216.s3.p2	eszopiclone	drug	_	olanzapine	drug	_	effect	drugn : coadministration of druga # mg and drugb # mg produced a decrease in dsst scores .
DDI-DrugBank.d216.s6.p0	Ketoconazole	drug	_	eszopiclone	drug	_	false	drugs that inhibit cyp3a4 -lcb- druga -rcb- cyp3a4 is a major metabolic pathway for elimination of drugb .
DDI-DrugBank.d216.s7.p0	eszopiclone	drug	_	ketoconazole	drug	_	mechanism	the auc of druga was increased # - fold by coadministration of drugb , a potent inhibitor of cyp3a4 , # mg daily for # days .
DDI-DrugBank.d216.s10.p0	Rifampicin	drug	_	zopiclone	drug	_	false	drugs that induce cyp3a4 -lcb- druga -rcb- racemic drugb exposure was decreased 80 % by concomitant useof drugn , a potent inducer of cyp3a4 .
DDI-DrugBank.d216.s10.p2	zopiclone	drug	_	rifampicin	drug	_	mechanism	drugs that induce cyp3a4 -lcb- drugn -rcb- racemic druga exposure was decreased 80 % by concomitant useof drugb , a potent inducer of cyp3a4 .
DDI-DrugBank.d216.s15.p0	Digoxin	drug	_	eszopiclone	drug	_	false	drugs with a narrow therapeutic index druga a single dose of drugb # mg did not affect the pharmacokinetics of drugn measured at steady state following dosing of # mg twice daily for one day and # mg daily for the next # days .
DDI-DrugBank.d216.s15.p2	eszopiclone	drug	_	digoxin	drug	_	false	drugs with a narrow therapeutic index drugn a single dose of druga # mg did not affect the pharmacokinetics of drugb measured at steady state following dosing of # mg twice daily for one day and # mg daily for the next # days .
DDI-DrugBank.d216.s16.p4	Eszopiclone	drug	_	(R)-warfarin	drug	_	false	drugn : druga # mg administered daily for # days did not affect the pharmacokinetics of drugb or drugn nor were there any changes in the pharmacodynamic profile -lcb- prothrombin time -rcb- following a single # mg oral dose of drugn
DDI-DrugBank.d216.s16.p5	Eszopiclone	drug	_	(S)-warfarin	drug	_	false	drugn : druga # mg administered daily for # days did not affect the pharmacokinetics of drugn or drugb nor were there any changes in the pharmacodynamic profile -lcb- prothrombin time -rcb- following a single # mg oral dose of drugn
DDI-DrugBank.d216.s16.p6	Eszopiclone	drug	_	warfarin	drug	_	false	drugn : druga # mg administered daily for # days did not affect the pharmacokinetics of drugn or drugn nor were there any changes in the pharmacodynamic profile -lcb- prothrombin time -rcb- following a single # mg oral dose of drugb
DDI-DrugBank.d216.s16.p7	(R)-warfarin	drug	_	(S)-warfarin	drug	_	false	drugn : drugn # mg administered daily for # days did not affect the pharmacokinetics of druga or drugb nor were there any changes in the pharmacodynamic profile -lcb- prothrombin time -rcb- following a single # mg oral dose of drugn
DDI-DrugBank.d216.s16.p8	(R)-warfarin	drug	_	warfarin	drug	_	false	drugn : drugn # mg administered daily for # days did not affect the pharmacokinetics of druga or drugn nor were there any changes in the pharmacodynamic profile -lcb- prothrombin time -rcb- following a single # mg oral dose of drugb
DDI-DrugBank.d341.s1.p0	ENBREL	brand	_	methotrexate	drug	_	false	however , it was observed that the pharmacokinetics of druga was unaltered by concomitant drugb in rheumatoid_arthritis patients .
DDI-DrugBank.d341.s2.p0	ENBREL	brand	_	anakinra	drug	_	effect	in a study in which patients with active ra were treated for up to # weeks with concurrent druga and drugb therapy , a 7 % rate of serious infections was observed , which was higher than that observed with drugn alone -lcb- 0 % -rcb- .
DDI-DrugBank.d341.s2.p2	anakinra	drug	_	ENBREL	brand	_	false	in a study in which patients with active ra were treated for up to # weeks with concurrent drugn and druga therapy , a 7 % rate of serious infections was observed , which was higher than that observed with drugb alone -lcb- 0 % -rcb- .
DDI-DrugBank.d341.s3.p0	ENBREL	brand	_	anakinra	drug	_	effect	two percent of patients treated concurrently with druga and drugb developed neutropenia -lcb- anc # x 109/l -rcb- .
DDI-DrugBank.d341.s4.p0	sulfasalazine	drug	_	ENBREL	brand	_	effect	patients in a clinical study who were on established therapy with druga , to which drugb was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drugn ci or drugn alone .
DDI-DrugBank.d341.s4.p1	sulfasalazine	drug	_	ENBREL	brand	_	false	patients in a clinical study who were on established therapy with druga , to which drugn was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drugb ci or drugn alone .
DDI-DrugBank.d341.s4.p4	ENBREL	brand	_	sulfasalazine	drug	_	false	patients in a clinical study who were on established therapy with drugn , to which druga was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drugn ci or drugb alone .
DDI-DrugBank.d341.s4.p5	ENBREL	brand	_	sulfasalazine	drug	_	false	patients in a clinical study who were on established therapy with drugn , to which drugn was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either druga ci or drugb alone .
DDI-DrugBank.d414.s0.p0	Lithium	drug	_	diuretics	group	_	mechanism	druga generally should not be given with drugb because they reduce its renal clearance and add a high risk of drugn toxicity .
DDI-DrugBank.d414.s0.p2	diuretics	group	_	lithium	drug	_	false	drugn generally should not be given with druga because they reduce its renal clearance and add a high risk of drugb toxicity .
DDI-DrugBank.d414.s2.p0	EDECRIN	brand	_	aminoglycoside	group	_	effect	druga may increase the ototoxic potential of other drugs such as drugb and some drugn .
DDI-DrugBank.d414.s2.p1	EDECRIN	brand	_	cephalosporin antibiotics	group	_	effect	druga may increase the ototoxic potential of other drugs such as drugn and some drugb .
DDI-DrugBank.d414.s2.p2	aminoglycoside	group	_	cephalosporin antibiotics	group	_	false	drugn may increase the ototoxic potential of other drugs such as druga and some drugb .
DDI-DrugBank.d414.s4.p0	ethacrynic acid	drug	_	warfarin	drug	_	mechanism	a number of drugs , including druga , have been shown to displace drugb from plasma protein ;
DDI-DrugBank.d414.s6.p0	non- steroidal antiinflammatory agent	group	_	loop diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d414.s6.p1	non- steroidal antiinflammatory agent	group	_	potassium- sparing diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d414.s6.p2	non- steroidal antiinflammatory agent	group	_	thiazide diuretics	group	_	effect	in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d414.s6.p4	loop diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of druga , drugn and drugb .
DDI-DrugBank.d414.s6.p5	potassium- sparing diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , druga and drugb .
DDI-DrugBank.d414.s7.p0	EDECRIN	brand	_	non- steroidal anti- inflammatory agents	group	_	effect	therefore , when druga and drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained .
DDI-DrugBank.d414.s7.p1	EDECRIN	brand	_	diuretic	group	_	false	therefore , when druga and drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d414.s7.p2	non- steroidal anti- inflammatory agents	group	_	diuretic	group	_	false	therefore , when drugn and druga are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d160.s0.p0	ethambutol	drug	_	aluminum hydroxide	drug	_	mechanism	the results of a study of coadministration of druga -lcb- 50 mg/kg -rcb- with an drugb containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugn .
DDI-DrugBank.d160.s0.p1	ethambutol	drug	_	antacid	group	_	false	the results of a study of coadministration of druga -lcb- 50 mg/kg -rcb- with an drugn containing drugb to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugn .
DDI-DrugBank.d160.s0.p4	ethambutol	drug	_	antacid products	group	_	false	the results of a study of coadministration of druga -lcb- 50 mg/kg -rcb- with an drugn containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugb .
DDI-DrugBank.d160.s0.p5	aluminum hydroxide	drug	_	antacid	group	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an druga containing drugb to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugn .
DDI-DrugBank.d160.s0.p6	aluminum hydroxide	drug	_	ethambutol	drug	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an druga containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugb of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugn .
DDI-DrugBank.d160.s0.p7	aluminum hydroxide	drug	_	ethambutol	drug	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an druga containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugb may be reduced by these drugn .
DDI-DrugBank.d160.s0.p8	aluminum hydroxide	drug	_	antacid products	group	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an druga containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugb .
DDI-DrugBank.d160.s0.p9	antacid	group	_	ethambutol	drug	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an drugn containing druga to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugb of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugn .
DDI-DrugBank.d160.s0.p10	antacid	group	_	ethambutol	drug	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an drugn containing druga to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugb may be reduced by these drugn .
DDI-DrugBank.d160.s0.p13	ethambutol	drug	_	antacid products	group	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an drugn containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of druga of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drugn may be reduced by these drugb .
DDI-DrugBank.d160.s0.p14	ethambutol	drug	_	antacid products	group	_	false	the results of a study of coadministration of drugn -lcb- 50 mg/kg -rcb- with an drugn containing drugn to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drugn of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of druga may be reduced by these drugb .
DDI-DrugBank.d160.s1.p0	ethambutol	drug	_	aluminum hydroxide	drug	_	advise	it is recommended to avoid concurrent administration of druga with drugb containing drugn for at least # hours following drugn administration .
DDI-DrugBank.d160.s1.p1	ethambutol	drug	_	antacids	group	_	false	it is recommended to avoid concurrent administration of druga with drugn containing drugb for at least # hours following drugn administration .
DDI-DrugBank.d160.s1.p3	aluminum hydroxide	drug	_	antacids	group	_	false	it is recommended to avoid concurrent administration of drugn with druga containing drugb for at least # hours following drugn administration .
DDI-DrugBank.d160.s1.p4	aluminum hydroxide	drug	_	ethambutol	drug	_	false	it is recommended to avoid concurrent administration of drugn with druga containing drugn for at least # hours following drugb administration .
DDI-DrugBank.d160.s1.p5	antacids	group	_	ethambutol	drug	_	false	it is recommended to avoid concurrent administration of drugn with drugn containing druga for at least # hours following drugb administration .
DDI-DrugBank.d405.s0.p0	Dicumarol	drug	_	warfarin	drug	_	false	druga and drugb may decrease hypoprothrombinemic effect .
DDI-DrugBank.d405.s1.p2	alcohol	drug	_	ethchlorvynol	drug	_	effect	other depressasnts such as druga , drugn , and drugn may enhance cns depression when administered with drugb .
DDI-DrugBank.d405.s1.p4	barbiturates	group	_	ethchlorvynol	drug	_	effect	other depressasnts such as drugn , druga , and drugn may enhance cns depression when administered with drugb .
DDI-DrugBank.d405.s1.p5	MAOIs	group	_	ethchlorvynol	drug	_	effect	other depressasnts such as drugn , drugn , and druga may enhance cns depression when administered with drugb .
DDI-DrugBank.d376.s0.p0	central nervous system (CNS) depressants	group	_	alcohol	drug	_	false	may interact with addictive medications , especially druga with habituating potential -lcb- prolonged concurrent use may increase the risk of habituation -rcb- , drugb or cns depression producing medications -lcb- concurrent use may increase the cns depressant effects of either these medications or drugn -rcb- .
DDI-DrugBank.d376.s0.p1	central nervous system (CNS) depressants	group	_	ethinamate	drug	_	false	may interact with addictive medications , especially druga with habituating potential -lcb- prolonged concurrent use may increase the risk of habituation -rcb- , drugn or cns depression producing medications -lcb- concurrent use may increase the cns depressant effects of either these medications or drugb -rcb- .
DDI-DrugBank.d376.s0.p2	alcohol	drug	_	ethinamate	drug	_	false	may interact with addictive medications , especially drugn with habituating potential -lcb- prolonged concurrent use may increase the risk of habituation -rcb- , druga or cns depression producing medications -lcb- concurrent use may increase the cns depressant effects of either these medications or drugb -rcb- .
DDI-DrugBank.d152.s0.p0	estrogen	group	_	contraceptives	group	_	false	certain endocrine and liver function tests may be affected by druga - containing oral drugb .
DDI-DrugBank.d166.s0.p0	Trecator	brand	_	isoniazid	drug	_	mechanism	druga has been found to temporarily raise serum concentrations of drugb .
DDI-DrugBank.d166.s1.p0	Trecator	brand	_	antituberculous drugs	group	_	effect	druga may potentiate the adverse effects of other drugb administered concomitantly .
DDI-DrugBank.d166.s2.p0	ethionamide	drug	_	cycloserine	drug	_	effect	in particular , convulsions have been reported when druga is administered with drugb and special care should be taken when the treatment regimen includes both of these drugs .
DDI-DrugBank.d240.s0.p0	Ethopropazine	drug	_	alcohol	drug	_	effect	druga may interact with drugb or other drugn , causing increased sedative effects .
DDI-DrugBank.d240.s0.p1	Ethopropazine	drug	_	CNS depressants	group	_	effect	druga may interact with drugn or other drugb , causing increased sedative effects .
DDI-DrugBank.d240.s0.p2	alcohol	drug	_	CNS depressants	group	_	false	drugn may interact with druga or other drugb , causing increased sedative effects .
DDI-DrugBank.d240.s2.p0	Ethopropazine	drug	_	chlorpromazine	drug	_	mechanism	druga can interact with drugb , increasing the metabolism of drugn .
DDI-DrugBank.d240.s2.p1	Ethopropazine	drug	_	chlorpromazine	drug	_	false	druga can interact with drugn , increasing the metabolism of drugb .
DDI-DrugBank.d205.s0.p1	Zarontin	brand	_	antiepileptic drugs	group	_	int	since druga -lcb- drugn -rcb- may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p2	Zarontin	brand	_	ethosuximide	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugb may elevate drugn serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p3	Zarontin	brand	_	phenytoin	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugb serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p4	Zarontin	brand	_	valproic acid	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugb has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p5	Zarontin	brand	_	ethosuximide	drug	_	false	since druga -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugn has been reported to both increase and decrease drugb levels -rcb- .
DDI-DrugBank.d205.s0.p6	ethosuximide	drug	_	antiepileptic drugs	group	_	int	since drugn -lcb- druga -rcb- may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p8	ethosuximide	drug	_	phenytoin	drug	_	false	since drugn -lcb- druga -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugb serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p9	ethosuximide	drug	_	valproic acid	drug	_	false	since drugn -lcb- druga -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugb has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p11	antiepileptic drugs	group	_	ethosuximide	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugb may elevate drugn serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p12	antiepileptic drugs	group	_	phenytoin	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugb serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p13	antiepileptic drugs	group	_	valproic acid	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugb has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p14	antiepileptic drugs	group	_	ethosuximide	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and drugn has been reported to both increase and decrease drugb levels -rcb- .
DDI-DrugBank.d205.s0.p15	ethosuximide	drug	_	phenytoin	drug	_	mechanism	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , druga may elevate drugb serum levels and drugn has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p16	ethosuximide	drug	_	valproic acid	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , druga may elevate drugn serum levels and drugb has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p18	phenytoin	drug	_	valproic acid	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate druga serum levels and drugb has been reported to both increase and decrease drugn levels -rcb- .
DDI-DrugBank.d205.s0.p19	phenytoin	drug	_	ethosuximide	drug	_	false	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate druga serum levels and drugn has been reported to both increase and decrease drugb levels -rcb- .
DDI-DrugBank.d205.s0.p20	valproic acid	drug	_	ethosuximide	drug	_	mechanism	since drugn -lcb- drugn -rcb- may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary -lcb- eg , drugn may elevate drugn serum levels and druga has been reported to both increase and decrease drugb levels -rcb- .
DDI-DrugBank.d359.s1.p0	PEGANONE	brand	_	Phenurone	brand	_	advise	considerable caution should be exercised if druga is administered concurrently with drugb -lcb- drugn -rcb- since paranoid symptoms have been reported during therapy with this combination .
DDI-DrugBank.d359.s1.p1	PEGANONE	brand	_	phenacemide	drug	_	advise	considerable caution should be exercised if druga is administered concurrently with drugn -lcb- drugb -rcb- since paranoid symptoms have been reported during therapy with this combination .
DDI-DrugBank.d359.s2.p0	hydantoin antiepileptic	group	_	phenytoin	drug	_	int	a two-way interaction between the druga , drugb , and the drugn s has been suggested .
DDI-DrugBank.d359.s2.p1	hydantoin antiepileptic	group	_	coumarin anticoagulant	group	_	int	a two-way interaction between the druga , drugn , and the drugb s has been suggested .
DDI-DrugBank.d359.s2.p2	phenytoin	drug	_	coumarin anticoagulant	group	_	false	a two-way interaction between the drugn , druga , and the drugb s has been suggested .
DDI-DrugBank.d359.s3.p0	phenytoin	drug	_	coumarin	group	_	mechanism	presumably , druga acts as a stimulator of drugb metabolism and has been reported to cause decreased serum levels of the drugn and increased prothrombin-proconvertin concentrations .
DDI-DrugBank.d359.s3.p1	phenytoin	drug	_	coumarin anticoagulants	group	_	mechanism	presumably , druga acts as a stimulator of drugn metabolism and has been reported to cause decreased serum levels of the drugb and increased prothrombin-proconvertin concentrations .
DDI-DrugBank.d359.s4.p0	coumarin anticoagulants	group	_	phenytoin	drug	_	mechanism	conversely , the druga have been reported to increase the serum levels and prolong the serum half-life of drugb by inhibiting its metabolism .
DDI-DrugBank.d359.s5.p0	ethotoin	drug	_	coumarin anticoagulants	group	_	false	although there is no documentation of such , a similar interaction between druga and the drugb may occur .
DDI-DrugBank.d359.s6.p0	PEGANONE	brand	_	coumarin anticoagulants	group	_	advise	caution is therefore advised when administering druga to patients receiving drugb .
DDI-DrugBank.d286.s0.p0	Ethoxzolamide	drug	_	tricyclics	group	_	effect	druga may increase the action of drugb , drugn , drugn , and drugn .
DDI-DrugBank.d286.s0.p1	Ethoxzolamide	drug	_	amphetamines	group	_	effect	druga may increase the action of drugn , drugb , drugn , and drugn .
DDI-DrugBank.d286.s0.p2	Ethoxzolamide	drug	_	procainamide	drug	_	effect	druga may increase the action of drugn , drugn , drugb , and drugn .
DDI-DrugBank.d286.s0.p3	Ethoxzolamide	drug	_	quinidine	drug	_	effect	druga may increase the action of drugn , drugn , drugn , and drugb .
DDI-DrugBank.d286.s1.p2	barbiturates	group	_	salicylates	group	_	false	it may increase excretion of druga , drugn , and drugn and may also increase the toxicity of drugb .
DDI-DrugBank.d286.s1.p3	lithium	drug	_	ASA	drug	_	false	it may increase excretion of drugn , druga , and drugb and may also increase the toxicity of drugn .
DDI-DrugBank.d286.s1.p4	lithium	drug	_	salicylates	group	_	false	it may increase excretion of drugn , druga , and drugn and may also increase the toxicity of drugb .
DDI-DrugBank.d286.s1.p5	ASA	drug	_	salicylates	group	_	false	it may increase excretion of drugn , drugn , and druga and may also increase the toxicity of drugb .
DDI-DrugBank.d286.s2.p0	ethoxzolamide	drug	_	diuretics	group	_	effect	coadministration of druga with other drugb , drugn , and drugn may cause hypokalemia .
DDI-DrugBank.d286.s2.p1	ethoxzolamide	drug	_	amphotericin B	drug	_	effect	coadministration of druga with other drugn , drugb , and drugn may cause hypokalemia .
DDI-DrugBank.d286.s2.p2	ethoxzolamide	drug	_	corticosteroids	group	_	effect	coadministration of druga with other drugn , drugn , and drugb may cause hypokalemia .
DDI-DrugBank.d485.s2.p0	Acetaminophen	drug	_	synthetic estrogens	group	_	mechanism	druga : may increase plasma concentration of drugb , possibly by inhibiting conjugation .
DDI-DrugBank.d485.s3.p0	hormonal contraceptives	group	_	acetaminophen	drug	_	mechanism	combination druga may also decrease the plasma concentration of drugb .
DDI-DrugBank.d485.s4.p0	Acitretin	drug	_	progestin	group	_	effect	druga : interferes with the contraceptive effect of microdosed drugb - containing minipill preparations .
DDI-DrugBank.d485.s6.p0	Aminoglutethimide	drug	_	progestins	group	_	mechanism	druga : may increase ppig metabolism of drugb leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s8.p9	antibiotics	group	_	synthetic steroids	group	_	false	drugn -lcb- drugn , drugn -rcb- : pregnancy has been reported following concomitant use , however , pharmacokinetic studies have not shown consistent effects with these druga on plasma concentrations of drugb .
DDI-DrugBank.d485.s10.p0	Anticoagulants	group	_	hormonal contraceptives	group	_	false	druga : combination drugb may increase or decrease the effects of drugn .
DDI-DrugBank.d485.s10.p1	Anticoagulants	group	_	coumarin derivatives	group	_	false	druga : combination drugn may increase or decrease the effects of drugb .
DDI-DrugBank.d485.s10.p2	hormonal contraceptives	group	_	coumarin derivatives	group	_	effect	drugn : combination druga may increase or decrease the effects of drugb .
DDI-DrugBank.d485.s12.p5	Anticonvulsants	group	_	ethinyl estradiol	drug	_	mechanism	druga -lcb- drugn , drugn , drugn , drugn , drugn -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p6	Anticonvulsants	group	_	progestins	group	_	mechanism	druga -lcb- drugn , drugn , drugn , drugn , drugn -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p11	carbamazepine	drug	_	ethinyl estradiol	drug	_	mechanism	drugn -lcb- druga , drugn , drugn , drugn , drugn -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p12	carbamazepine	drug	_	progestins	group	_	mechanism	drugn -lcb- druga , drugn , drugn , drugn , drugn -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p16	felbamate	drug	_	ethinyl estradiol	drug	_	mechanism	drugn -lcb- drugn , druga , drugn , drugn , drugn -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p17	felbamate	drug	_	progestins	group	_	mechanism	drugn -lcb- drugn , druga , drugn , drugn , drugn -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p20	phenobarbital	drug	_	ethinyl estradiol	drug	_	mechanism	drugn -lcb- drugn , drugn , druga , drugn , drugn -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p21	phenobarbital	drug	_	progestins	group	_	mechanism	drugn -lcb- drugn , drugn , druga , drugn , drugn -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p23	phenytoin	drug	_	ethinyl estradiol	drug	_	mechanism	drugn -lcb- drugn , drugn , drugn , druga , drugn -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p24	phenytoin	drug	_	progestins	group	_	mechanism	drugn -lcb- drugn , drugn , drugn , druga , drugn -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p25	topiramate	drug	_	ethinyl estradiol	drug	_	mechanism	drugn -lcb- drugn , drugn , drugn , drugn , druga -rcb- : increase the metabolism of drugb and/or some drugn , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p26	topiramate	drug	_	progestins	group	_	mechanism	drugn -lcb- drugn , drugn , drugn , drugn , druga -rcb- : increase the metabolism of drugn and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s12.p27	ethinyl estradiol	drug	_	progestins	group	_	false	drugn -lcb- drugn , drugn , drugn , drugn , drugn -rcb- : increase the metabolism of druga and/or some drugb , leading to possible decrease in contraceptive effectiveness .
DDI-DrugBank.d485.s14.p4	ascorbic acid	drug	_	synthetic estrogens	group	_	mechanism	drugn : doses of druga -lcb- drugn -rcb- # g/day have been reported to increase plasma concentration of drugb by ~ 47 % , possibly by inhibiting conjugation ;
DDI-DrugBank.d485.s14.p5	vitamin C	drug	_	synthetic estrogens	group	_	mechanism	drugn : doses of drugn -lcb- druga -rcb- # g/day have been reported to increase plasma concentration of drugb by ~ 47 % , possibly by inhibiting conjugation ;
DDI-DrugBank.d485.s16.p3	Atorvastatin	drug	_	norethindrone	drug	_	mechanism	drugn : druga increases the auc for drugb and drugn .
DDI-DrugBank.d485.s16.p4	Atorvastatin	drug	_	ethinyl estradiol	drug	_	mechanism	drugn : druga increases the auc for drugn and drugb .
DDI-DrugBank.d485.s16.p5	norethindrone	drug	_	ethinyl estradiol	drug	_	false	drugn : drugn increases the auc for druga and drugb .
DDI-DrugBank.d485.s17.p0	Benzodiazepines	group	_	hormonal contraceptives	group	_	false	druga : combination drugb may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p2	Benzodiazepines	group	_	alprazolam	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugb , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p3	Benzodiazepines	group	_	chlordiazepoxide	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugb , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p4	Benzodiazepines	group	_	diazepam	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , drugb -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p5	Benzodiazepines	group	_	lorazepam	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p6	Benzodiazepines	group	_	oxazepam	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p7	Benzodiazepines	group	_	temazepam	drug	_	false	druga : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s17.p8	hormonal contraceptives	group	_	benzodiazepines	group	_	mechanism	drugn : combination druga may decrease the clearance of some drugb -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p9	hormonal contraceptives	group	_	alprazolam	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugb , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p10	hormonal contraceptives	group	_	chlordiazepoxide	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugn , drugb , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p11	hormonal contraceptives	group	_	diazepam	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugn , drugn , drugb -rcb- and increase the clearance of others -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p12	hormonal contraceptives	group	_	lorazepam	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p13	hormonal contraceptives	group	_	oxazepam	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p14	hormonal contraceptives	group	_	temazepam	drug	_	mechanism	drugn : combination druga may decrease the clearance of some drugn -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s17.p18	benzodiazepines	group	_	lorazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some druga -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p19	benzodiazepines	group	_	oxazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some druga -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p20	benzodiazepines	group	_	temazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some druga -lcb- drugn , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s17.p23	alprazolam	drug	_	lorazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- druga , drugn , drugn -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p24	alprazolam	drug	_	oxazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- druga , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p25	alprazolam	drug	_	temazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- druga , drugn , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s17.p27	chlordiazepoxide	drug	_	lorazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , druga , drugn -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p28	chlordiazepoxide	drug	_	oxazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , druga , drugn -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p29	chlordiazepoxide	drug	_	temazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , druga , drugn -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s17.p30	diazepam	drug	_	lorazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , druga -rcb- and increase the clearance of others -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d485.s17.p31	diazepam	drug	_	oxazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , druga -rcb- and increase the clearance of others -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d485.s17.p32	diazepam	drug	_	temazepam	drug	_	false	drugn : combination drugn may decrease the clearance of some drugn -lcb- drugn , drugn , druga -rcb- and increase the clearance of others -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d485.s18.p0	Clofibric acid	drug_n	_	hormonal contraceptives	group	_	false	druga : combination drugb may increase the clearance of drugn .
DDI-DrugBank.d485.s18.p2	hormonal contraceptives	group	_	clofibric acid	drug_n	_	mechanism	drugn : combination druga may increase the clearance of drugb .
DDI-DrugBank.d485.s19.p0	Cyclosporine	drug	_	hormonal contraceptives	group	_	false	druga : combination drugb may inhibit the metabolism of drugn , leading to increased plasma concentrations ;
DDI-DrugBank.d485.s19.p2	hormonal contraceptives	group	_	cyclosporine	drug	_	mechanism	drugn : combination druga may inhibit the metabolism of drugb , leading to increased plasma concentrations ;
DDI-DrugBank.d485.s23.p2	Griseofulvin	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn : druga may induce the metabolism of drugb causing menstrual changes ;
DDI-DrugBank.d485.s26.p0	Morphine	drug	_	hormonal contraceptives	group	_	false	druga : combination drugb may increase the clearance of drugn .
DDI-DrugBank.d485.s26.p2	hormonal contraceptives	group	_	morphine	drug	_	mechanism	drugn : combination druga may increase the clearance of drugb .
DDI-DrugBank.d485.s27.p5	Nevirapine	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn -lcb- drugn -rcb- : druga may decrease plasma levels of drugb ;
DDI-DrugBank.d485.s31.p2	Ethinyl estradiol	drug	_	prednisolone	drug	_	mechanism	drugn : druga may inhibit the metabolism of drugb , leading to increased plasma concentrations .
DDI-DrugBank.d485.s32.p0	Protease inhibitors	group	_	Amprenavir	drug	_	false	druga : drugb , drugn , drugn , and drugn have been shown to decrease plasma levels of drugn ;
DDI-DrugBank.d485.s32.p1	Protease inhibitors	group	_	lopinavir	drug	_	false	druga : drugn , drugb , drugn , and drugn have been shown to decrease plasma levels of drugn ;
DDI-DrugBank.d485.s32.p2	Protease inhibitors	group	_	nelfinavir	drug	_	false	druga : drugn , drugn , drugb , and drugn have been shown to decrease plasma levels of drugn ;
DDI-DrugBank.d485.s32.p3	Protease inhibitors	group	_	ritonavir	drug	_	false	druga : drugn , drugn , drugn , and drugb have been shown to decrease plasma levels of drugn ;
DDI-DrugBank.d485.s32.p4	Protease inhibitors	group	_	combination hormonal contraceptives	group	_	false	druga : drugn , drugn , drugn , and drugn have been shown to decrease plasma levels of drugb ;
DDI-DrugBank.d485.s32.p8	Amprenavir	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn : druga , drugn , drugn , and drugn have been shown to decrease plasma levels of drugb ;
DDI-DrugBank.d485.s32.p11	lopinavir	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn : drugn , druga , drugn , and drugn have been shown to decrease plasma levels of drugb ;
DDI-DrugBank.d485.s32.p13	nelfinavir	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn : drugn , drugn , druga , and drugn have been shown to decrease plasma levels of drugb ;
DDI-DrugBank.d485.s32.p14	ritonavir	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn : drugn , drugn , drugn , and druga have been shown to decrease plasma levels of drugb ;
DDI-DrugBank.d485.s34.p0	Indinavir	drug	_	combination hormonal contraceptives	group	_	mechanism	druga has been shown to increase plasma levels of drugb .
DDI-DrugBank.d485.s36.p4	Rifampin	drug	_	ethinyl estradiol	drug	_	mechanism	drugn : druga increases the metabolism of drugb and some drugn -lcb- drugn -rcb- resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
DDI-DrugBank.d485.s36.p5	Rifampin	drug	_	progestins	group	_	mechanism	drugn : druga increases the metabolism of drugn and some drugb -lcb- drugn -rcb- resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
DDI-DrugBank.d485.s36.p6	Rifampin	drug	_	norethindrone	drug	_	mechanism	drugn : druga increases the metabolism of drugn and some drugn -lcb- drugb -rcb- resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
DDI-DrugBank.d485.s36.p7	ethinyl estradiol	drug	_	progestins	group	_	false	drugn : drugn increases the metabolism of druga and some drugb -lcb- drugn -rcb- resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
DDI-DrugBank.d485.s36.p8	ethinyl estradiol	drug	_	norethindrone	drug	_	false	drugn : drugn increases the metabolism of druga and some drugn -lcb- drugb -rcb- resulting in decreased contraceptive effectiveness and increased menstrual irregularities .
DDI-DrugBank.d485.s38.p0	Salicylic acid	drug	_	hormonal contraceptives	group	_	false	druga : combination drugb may increase the clearance of drugn .
DDI-DrugBank.d485.s38.p2	hormonal contraceptives	group	_	salicylic acid	drug	_	mechanism	drugn : combination druga may increase the clearance of drugb .
DDI-DrugBank.d485.s39.p2	Combination hormonal contraceptives	group	_	selegiline	drug	_	mechanism	drugn : druga may increase the serum concentration of drugb .
DDI-DrugBank.d485.s40.p2	Ethinyl estradiol	drug	_	theophylline	drug	_	mechanism	drugn : druga may inhibit the metabolism of drugb , leading to increased plasma concentrations .
DDI-DrugBank.d485.s41.p3	Tricyclic antidepressants	group	_	combination hormonal contraceptives	group	_	mechanism	druga -lcb- drugn , drugn , drugn -rcb- : metabolism may be inhibited by drugb , increasing plasma levels of drugn ;
DDI-DrugBank.d485.s41.p7	amitriptyline	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn -lcb- druga , drugn , drugn -rcb- : metabolism may be inhibited by drugb , increasing plasma levels of drugn ;
DDI-DrugBank.d485.s41.p8	amitriptyline	drug	_	antidepressant	group	_	false	drugn -lcb- druga , drugn , drugn -rcb- : metabolism may be inhibited by drugn , increasing plasma levels of drugb ;
DDI-DrugBank.d485.s41.p10	imipramine	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn -lcb- drugn , druga , drugn -rcb- : metabolism may be inhibited by drugb , increasing plasma levels of drugn ;
DDI-DrugBank.d485.s41.p11	imipramine	drug	_	antidepressant	group	_	false	drugn -lcb- drugn , druga , drugn -rcb- : metabolism may be inhibited by drugn , increasing plasma levels of drugb ;
DDI-DrugBank.d485.s41.p12	nortriptyline	drug	_	combination hormonal contraceptives	group	_	mechanism	drugn -lcb- drugn , drugn , druga -rcb- : metabolism may be inhibited by drugb , increasing plasma levels of drugn ;
DDI-DrugBank.d485.s41.p13	nortriptyline	drug	_	antidepressant	group	_	false	drugn -lcb- drugn , drugn , druga -rcb- : metabolism may be inhibited by drugn , increasing plasma levels of drugb ;
DDI-DrugBank.d485.s41.p14	combination hormonal contraceptives	group	_	antidepressant	group	_	false	drugn -lcb- drugn , drugn , drugn -rcb- : metabolism may be inhibited by druga , increasing plasma levels of drugb ;
DDI-DrugBank.d485.s43.p3	caffeine	drug	_	combination hormonal contraceptives	group	_	false	drugn / nutrition / herb interactions : food : cns effects of druga may be enhanced if drugb are used concurrently with drugn .
DDI-DrugBank.d485.s43.p5	combination hormonal contraceptives	group	_	caffeine	drug	_	effect	drugn / nutrition / herb interactions : food : cns effects of drugn may be enhanced if druga are used concurrently with drugb .
DDI-DrugBank.d485.s44.p0	ethinyl estradiol	drug	_	progesterone	drug	_	false	grapefruit juice increases druga concentrations and would be expected to increase drugb serum levels as well ;
DDI-DrugBank.d327.s0.p0	etidronate	drug	_	warfarin	drug	_	effect	there have been isolated reports of patients experiencing increases in their prothrombin times when druga was added to drugb therapy .
DDI-DrugBank.d219.s0.p0	ACE-inhibitors	group	_	NSAIDs	group	_	false	druga reports suggest that drugb may diminish the antihypertensive effect of drugn .
DDI-DrugBank.d219.s0.p2	NSAIDs	group	_	ACE-inhibitors	group	_	effect	drugn reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d219.s1.p0	NSAIDs	group	_	ACE-inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d219.s2.p2	antacids	group	_	Lodine	brand	_	false	drugn : the concomitant administration of druga has no apparent effect on the extent of absorption of drugb .
DDI-DrugBank.d219.s4.p3	Lodine	brand	_	aspirin	brand	_	mechanism	drugn : when druga is administered with drugb , its protein binding is reduced , although the clearance of free drugn is not altered .
DDI-DrugBank.d219.s4.p4	Lodine	brand	_	etodolac	drug	_	false	drugn : when druga is administered with drugn , its protein binding is reduced , although the clearance of free drugb is not altered .
DDI-DrugBank.d219.s4.p5	aspirin	brand	_	etodolac	drug	_	false	drugn : when drugn is administered with druga , its protein binding is reduced , although the clearance of free drugb is not altered .
DDI-DrugBank.d219.s6.p0	NSAIDs	group	_	Lodine	brand	_	false	however , as with other druga , concomitant administration of drugb and drugn is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d219.s6.p1	NSAIDs	group	_	aspirin	brand	_	false	however , as with other druga , concomitant administration of drugn and drugb is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d219.s6.p2	Lodine	brand	_	aspirin	brand	_	advise	however , as with other drugn , concomitant administration of druga and drugb is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d219.s7.p0	Lodine	brand	_	NSAIDs	group	_	false	cyclosporine , digoxin , methotrexate druga , like other drugb , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugn , drugn , drugn , and increased toxicity .
DDI-DrugBank.d219.s7.p1	Lodine	brand	_	cyclosporine	drug	_	mechanism	cyclosporine , digoxin , methotrexate druga , like other drugn , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugb , drugn , drugn , and increased toxicity .
DDI-DrugBank.d219.s7.p2	Lodine	brand	_	digoxin	drug	_	mechanism	cyclosporine , digoxin , methotrexate druga , like other drugn , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugn , drugb , drugn , and increased toxicity .
DDI-DrugBank.d219.s7.p3	Lodine	brand	_	methotrexate	drug	_	mechanism	cyclosporine , digoxin , methotrexate druga , like other drugn , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugn , drugn , drugb , and increased toxicity .
DDI-DrugBank.d219.s7.p4	NSAIDs	group	_	cyclosporine	drug	_	mechanism	cyclosporine , digoxin , methotrexate drugn , like other druga , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugb , drugn , drugn , and increased toxicity .
DDI-DrugBank.d219.s7.p5	NSAIDs	group	_	digoxin	drug	_	mechanism	cyclosporine , digoxin , methotrexate drugn , like other druga , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugn , drugb , drugn , and increased toxicity .
DDI-DrugBank.d219.s7.p6	NSAIDs	group	_	methotrexate	drug	_	mechanism	cyclosporine , digoxin , methotrexate drugn , like other druga , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drugn , drugn , drugb , and increased toxicity .
DDI-DrugBank.d219.s9.p0	Lodine	brand	_	NSAID	group	_	false	patients receiving these drugs who are given druga , or any other drugb , and particularly those patients with altered renal function , should be observed for the development of the specific toxicities of these drugs .
DDI-DrugBank.d219.s10.p2	furosemide	drug	_	hydrochlorothiazide	drug	_	false	drugn : etodolac has no apparent pharmacokinetic interaction when administered with druga or drugb .
DDI-DrugBank.d219.s11.p0	Lodine	brand	_	furosemide	drug	_	effect	nevertheless , clinical studies , as well as postmarketing observations have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d219.s11.p1	Lodine	brand	_	thiazides	group	_	effect	nevertheless , clinical studies , as well as postmarketing observations have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d219.s11.p2	furosemide	drug	_	thiazides	group	_	false	nevertheless , clinical studies , as well as postmarketing observations have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d219.s14.p2	Etodolac	drug	_	glyburide	drug	_	false	drugn : druga has no apparent pharmacokinetic interaction when administered with drugb .
DDI-DrugBank.d219.s15.p3	NSAIDs	group	_	lithium	drug	_	mechanism	drugn : druga have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
DDI-DrugBank.d219.s15.p4	NSAIDs	group	_	lithium	drug	_	false	drugn : druga have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
DDI-DrugBank.d219.s18.p0	NSAIDs	group	_	lithium	drug	_	effect	thus , when druga and drugb are administered concurrently , subjects should be observed carefully for signs of drugn toxicity .
DDI-DrugBank.d219.s18.p1	NSAIDs	group	_	lithium	drug	_	false	thus , when druga and drugn are administered concurrently , subjects should be observed carefully for signs of drugb toxicity .
DDI-DrugBank.d219.s19.p2	Phenylbutazone	drug	_	etodolac	drug	_	mechanism	drugn : druga causes increase -lcb- by about 80 % -rcb- in the free fraction of drugb .
DDI-DrugBank.d219.s20.p0	etodolac	drug	_	phenylbutazone	drug	_	advise	although in vivo studies have not been done to see if druga clearance is changed by coadministration of drugb , it is not recommended that they be coadministered .
DDI-DrugBank.d219.s21.p2	Etodolac	drug	_	phenytoin	drug	_	false	drugn : druga has no apparent pharmacokinetic interaction when administered with drugb .
DDI-DrugBank.d219.s22.p2	warfarin	drug	_	NSAIDs	group	_	effect	drugn : the effects of druga and drugb on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than that of users of either drug alone .
DDI-DrugBank.d219.s23.p0	warfarin	drug	_	Lodine	brand	_	mechanism	short-term pharmacokinetic studies have demonstrated that concomitant administration of druga and drugb -lcb- drugn capsules and tablets -rcb- results in reduced protein binding of drugn , but there was no change in the clearance of free drugn .
DDI-DrugBank.d219.s23.p1	warfarin	drug	_	etodolac	drug	_	mechanism	short-term pharmacokinetic studies have demonstrated that concomitant administration of druga and drugn -lcb- drugb capsules and tablets -rcb- results in reduced protein binding of drugn , but there was no change in the clearance of free drugn .
DDI-DrugBank.d219.s23.p5	Lodine	brand	_	warfarin	drug	_	false	short-term pharmacokinetic studies have demonstrated that concomitant administration of drugn and druga -lcb- drugn capsules and tablets -rcb- results in reduced protein binding of drugb , but there was no change in the clearance of free drugn .
DDI-DrugBank.d219.s23.p6	Lodine	brand	_	warfarin	drug	_	false	short-term pharmacokinetic studies have demonstrated that concomitant administration of drugn and druga -lcb- drugn capsules and tablets -rcb- results in reduced protein binding of drugn , but there was no change in the clearance of free drugb .
DDI-DrugBank.d219.s23.p7	etodolac	drug	_	warfarin	drug	_	false	short-term pharmacokinetic studies have demonstrated that concomitant administration of drugn and drugn -lcb- druga capsules and tablets -rcb- results in reduced protein binding of drugb , but there was no change in the clearance of free drugn .
DDI-DrugBank.d219.s23.p8	etodolac	drug	_	warfarin	drug	_	false	short-term pharmacokinetic studies have demonstrated that concomitant administration of drugn and drugn -lcb- druga capsules and tablets -rcb- results in reduced protein binding of drugn , but there was no change in the clearance of free drugb .
DDI-DrugBank.d219.s24.p1	warfarin	drug	_	Lodine	brand	_	false	there was no significant difference in the pharmacodynamic effect of druga administered alone and drugn administered with drugb as measured by prothrombin time .
DDI-DrugBank.d219.s24.p2	warfarin	drug	_	Lodine	brand	_	false	there was no significant difference in the pharmacodynamic effect of drugn administered alone and druga administered with drugb as measured by prothrombin time .
DDI-DrugBank.d219.s25.p0	warfarin	drug	_	Lodine	brand	_	false	thus , concomitant therapy with druga and drugb should not require dosage adjustment of either drug .
DDI-DrugBank.d219.s26.p0	etodolac	drug	_	warfarin	drug	_	effect	however , caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times , with or without bleeding , in druga - treated patients receiving concomitant drugb therapy .
DDI-DrugBank.d219.s27.p0	Lodine	brand	_	etodolac	drug	_	false	drug/laboratory test interactions the urine of patients who take druga can give a false-positive reaction for urinary bilirubin -lcb- urobilin -rcb- due to the presence of phenolic metabolites of drugb .
DDI-DrugBank.d119.s2.p0	Probenecid	drug	_	etomidate	drug	_	false	druga prolonged action of drugb
DDI-DrugBank.d119.s4.p0	Zimelidine	drug_n	_	etomidate	drug	_	false	druga drugb antagonism
DDI-DrugBank.d119.s6.p0	Aminophylline	drug	_	Etomidate	drug	_	false	druga drugb antagonism
DDI-DrugBank.d484.s0.p0	Etonogestrel	drug	_	acetaminophen	drug	_	int	druga may interact with the following medications : drugb -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p1	Etonogestrel	drug	_	Tylenol	brand	_	int	druga may interact with the following medications : drugn -lcb- drugb -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p2	Etonogestrel	drug	_	antibiotics	group	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugb such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p3	Etonogestrel	drug	_	ampicillin	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugb and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p4	Etonogestrel	drug	_	tetracycline	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugb , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p5	Etonogestrel	drug	_	anticonvulsants	group	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p6	Etonogestrel	drug	_	Dilantin	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p7	Etonogestrel	drug	_	Phenobarbital	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p8	Etonogestrel	drug	_	Tegretol	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p9	Etonogestrel	drug	_	Trileptal	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p10	Etonogestrel	drug	_	Topamax	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p11	Etonogestrel	drug	_	Felbatol	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p12	Etonogestrel	drug	_	antifungals	group	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p13	Etonogestrel	drug	_	Gris-PEG	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p14	Etonogestrel	drug	_	Nizoral	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p15	Etonogestrel	drug	_	Sporanox	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p16	Etonogestrel	drug	_	atorvastatin	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p17	Etonogestrel	drug	_	Lipitor	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p18	Etonogestrel	drug	_	clofibrate	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p19	Etonogestrel	drug	_	Atromid-S	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p20	Etonogestrel	drug	_	cyclosporine	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p21	Etonogestrel	drug	_	Neoral	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p22	Etonogestrel	drug	_	Sandimmune	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p23	Etonogestrel	drug	_	protease inhibitors	group	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p24	Etonogestrel	drug	_	Agenerase	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p25	Etonogestrel	drug	_	Crixivan	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p26	Etonogestrel	drug	_	Fortovase	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p27	Etonogestrel	drug	_	Invirase	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p28	Etonogestrel	drug	_	Kaletra	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p29	Etonogestrel	drug	_	Norvir	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p30	Etonogestrel	drug	_	Viracept	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p31	Etonogestrel	drug	_	morphine	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p32	Etonogestrel	drug	_	Astramorph	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p33	Etonogestrel	drug	_	Kadian	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p34	Etonogestrel	drug	_	MS Contin	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p35	Etonogestrel	drug	_	phenylbutazone	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p36	Etonogestrel	drug	_	prednisolone	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p37	Etonogestrel	drug	_	Prelone	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p38	Etonogestrel	drug	_	rifadin	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p39	Etonogestrel	drug	_	rifampin	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p40	Etonogestrel	drug	_	temazepam	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p41	Etonogestrel	drug	_	theophylline	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p42	Etonogestrel	drug	_	Theo-Dur	brand	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p43	Etonogestrel	drug	_	vitamin C	drug	_	int	druga may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p45	acetaminophen	drug	_	antibiotics	group	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugb such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p46	acetaminophen	drug	_	ampicillin	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugb and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p47	acetaminophen	drug	_	tetracycline	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugb , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p48	acetaminophen	drug	_	anticonvulsants	group	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p49	acetaminophen	drug	_	Dilantin	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p50	acetaminophen	drug	_	Phenobarbital	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p51	acetaminophen	drug	_	Tegretol	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p52	acetaminophen	drug	_	Trileptal	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p53	acetaminophen	drug	_	Topamax	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p54	acetaminophen	drug	_	Felbatol	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p55	acetaminophen	drug	_	antifungals	group	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p56	acetaminophen	drug	_	Gris-PEG	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p57	acetaminophen	drug	_	Nizoral	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p58	acetaminophen	drug	_	Sporanox	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p59	acetaminophen	drug	_	atorvastatin	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p60	acetaminophen	drug	_	Lipitor	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p61	acetaminophen	drug	_	clofibrate	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p62	acetaminophen	drug	_	Atromid-S	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p63	acetaminophen	drug	_	cyclosporine	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p64	acetaminophen	drug	_	Neoral	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p65	acetaminophen	drug	_	Sandimmune	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p66	acetaminophen	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p67	acetaminophen	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p68	acetaminophen	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p69	acetaminophen	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p70	acetaminophen	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p71	acetaminophen	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p72	acetaminophen	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p73	acetaminophen	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p74	acetaminophen	drug	_	morphine	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p75	acetaminophen	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p76	acetaminophen	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p77	acetaminophen	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p78	acetaminophen	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p79	acetaminophen	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p80	acetaminophen	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p81	acetaminophen	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p82	acetaminophen	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p83	acetaminophen	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p84	acetaminophen	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p85	acetaminophen	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p86	acetaminophen	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : druga -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p87	Tylenol	brand	_	antibiotics	group	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugb such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p88	Tylenol	brand	_	ampicillin	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugb and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p89	Tylenol	brand	_	tetracycline	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugb , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p90	Tylenol	brand	_	anticonvulsants	group	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p91	Tylenol	brand	_	Dilantin	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p92	Tylenol	brand	_	Phenobarbital	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p93	Tylenol	brand	_	Tegretol	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p94	Tylenol	brand	_	Trileptal	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p95	Tylenol	brand	_	Topamax	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p96	Tylenol	brand	_	Felbatol	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p97	Tylenol	brand	_	antifungals	group	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p98	Tylenol	brand	_	Gris-PEG	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p99	Tylenol	brand	_	Nizoral	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p100	Tylenol	brand	_	Sporanox	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p101	Tylenol	brand	_	atorvastatin	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p102	Tylenol	brand	_	Lipitor	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p103	Tylenol	brand	_	clofibrate	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p104	Tylenol	brand	_	Atromid-S	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p105	Tylenol	brand	_	cyclosporine	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p106	Tylenol	brand	_	Neoral	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p107	Tylenol	brand	_	Sandimmune	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p108	Tylenol	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p109	Tylenol	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p110	Tylenol	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p111	Tylenol	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p112	Tylenol	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p113	Tylenol	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p114	Tylenol	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p115	Tylenol	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p116	Tylenol	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p117	Tylenol	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p118	Tylenol	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p119	Tylenol	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p120	Tylenol	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p121	Tylenol	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p122	Tylenol	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p123	Tylenol	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p124	Tylenol	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p125	Tylenol	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p126	Tylenol	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p127	Tylenol	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p128	Tylenol	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- druga -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p129	antibiotics	group	_	ampicillin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugb and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p130	antibiotics	group	_	tetracycline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugb , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p131	antibiotics	group	_	anticonvulsants	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p132	antibiotics	group	_	Dilantin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p133	antibiotics	group	_	Phenobarbital	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p134	antibiotics	group	_	Tegretol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p135	antibiotics	group	_	Trileptal	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p136	antibiotics	group	_	Topamax	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p137	antibiotics	group	_	Felbatol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p138	antibiotics	group	_	antifungals	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p139	antibiotics	group	_	Gris-PEG	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p140	antibiotics	group	_	Nizoral	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p141	antibiotics	group	_	Sporanox	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p142	antibiotics	group	_	atorvastatin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p143	antibiotics	group	_	Lipitor	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p144	antibiotics	group	_	clofibrate	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p145	antibiotics	group	_	Atromid-S	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p146	antibiotics	group	_	cyclosporine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p147	antibiotics	group	_	Neoral	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p148	antibiotics	group	_	Sandimmune	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p149	antibiotics	group	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p150	antibiotics	group	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p151	antibiotics	group	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p152	antibiotics	group	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p153	antibiotics	group	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p154	antibiotics	group	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p155	antibiotics	group	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p156	antibiotics	group	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p157	antibiotics	group	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p158	antibiotics	group	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p159	antibiotics	group	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p160	antibiotics	group	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p161	antibiotics	group	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p162	antibiotics	group	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p163	antibiotics	group	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p164	antibiotics	group	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p165	antibiotics	group	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p166	antibiotics	group	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p167	antibiotics	group	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p168	antibiotics	group	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p169	antibiotics	group	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , druga such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p171	ampicillin	drug	_	anticonvulsants	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p172	ampicillin	drug	_	Dilantin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p173	ampicillin	drug	_	Phenobarbital	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p174	ampicillin	drug	_	Tegretol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p175	ampicillin	drug	_	Trileptal	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p176	ampicillin	drug	_	Topamax	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p177	ampicillin	drug	_	Felbatol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p189	ampicillin	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p190	ampicillin	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p191	ampicillin	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p192	ampicillin	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p193	ampicillin	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p194	ampicillin	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p195	ampicillin	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p196	ampicillin	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p197	ampicillin	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p198	ampicillin	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p199	ampicillin	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p200	ampicillin	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p201	ampicillin	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p202	ampicillin	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p203	ampicillin	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p204	ampicillin	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p205	ampicillin	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p206	ampicillin	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p207	ampicillin	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p208	ampicillin	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p209	ampicillin	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as druga and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p210	tetracycline	drug	_	anticonvulsants	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p211	tetracycline	drug	_	Dilantin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p212	tetracycline	drug	_	Phenobarbital	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p213	tetracycline	drug	_	Tegretol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p214	tetracycline	drug	_	Trileptal	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p215	tetracycline	drug	_	Topamax	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p216	tetracycline	drug	_	Felbatol	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p228	tetracycline	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p229	tetracycline	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p230	tetracycline	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p231	tetracycline	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p232	tetracycline	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p233	tetracycline	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p234	tetracycline	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p235	tetracycline	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p236	tetracycline	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p237	tetracycline	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p238	tetracycline	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p239	tetracycline	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p240	tetracycline	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p241	tetracycline	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p242	tetracycline	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p243	tetracycline	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p244	tetracycline	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p245	tetracycline	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p246	tetracycline	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p247	tetracycline	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p248	tetracycline	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and druga , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p274	anticonvulsants	group	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p275	anticonvulsants	group	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p276	anticonvulsants	group	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p277	anticonvulsants	group	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p278	anticonvulsants	group	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p279	anticonvulsants	group	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p280	anticonvulsants	group	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p281	anticonvulsants	group	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p282	anticonvulsants	group	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p283	anticonvulsants	group	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p284	anticonvulsants	group	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p285	anticonvulsants	group	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p286	anticonvulsants	group	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p311	Dilantin	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p312	Dilantin	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p313	Dilantin	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p314	Dilantin	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p315	Dilantin	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p316	Dilantin	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p317	Dilantin	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p318	Dilantin	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p319	Dilantin	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p320	Dilantin	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p321	Dilantin	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p322	Dilantin	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p323	Dilantin	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p347	Phenobarbital	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p348	Phenobarbital	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p349	Phenobarbital	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p350	Phenobarbital	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p351	Phenobarbital	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p352	Phenobarbital	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p353	Phenobarbital	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p354	Phenobarbital	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p355	Phenobarbital	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p356	Phenobarbital	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p357	Phenobarbital	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p358	Phenobarbital	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p359	Phenobarbital	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p382	Tegretol	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p383	Tegretol	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p384	Tegretol	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p385	Tegretol	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p386	Tegretol	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p387	Tegretol	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p388	Tegretol	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p389	Tegretol	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p390	Tegretol	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p391	Tegretol	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p392	Tegretol	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p393	Tegretol	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p394	Tegretol	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p416	Trileptal	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p417	Trileptal	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p418	Trileptal	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p419	Trileptal	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p420	Trileptal	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p421	Trileptal	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p422	Trileptal	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p423	Trileptal	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p424	Trileptal	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p425	Trileptal	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p426	Trileptal	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p427	Trileptal	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p428	Trileptal	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p449	Topamax	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p450	Topamax	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p451	Topamax	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p452	Topamax	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p453	Topamax	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p454	Topamax	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p455	Topamax	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p456	Topamax	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p457	Topamax	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p458	Topamax	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p459	Topamax	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p460	Topamax	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p461	Topamax	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p481	Felbatol	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p482	Felbatol	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p483	Felbatol	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p484	Felbatol	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p485	Felbatol	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p486	Felbatol	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p487	Felbatol	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p488	Felbatol	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p489	Felbatol	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p490	Felbatol	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p491	Felbatol	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p492	Felbatol	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p493	Felbatol	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p504	antifungals	group	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p505	antifungals	group	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p506	antifungals	group	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p507	antifungals	group	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p508	antifungals	group	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p509	antifungals	group	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p510	antifungals	group	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p511	antifungals	group	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p512	antifungals	group	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p513	antifungals	group	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p514	antifungals	group	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p515	antifungals	group	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p516	antifungals	group	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p517	antifungals	group	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p518	antifungals	group	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p519	antifungals	group	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p520	antifungals	group	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p521	antifungals	group	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p522	antifungals	group	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p523	antifungals	group	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p524	antifungals	group	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p534	Gris-PEG	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p535	Gris-PEG	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p536	Gris-PEG	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p537	Gris-PEG	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p538	Gris-PEG	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p539	Gris-PEG	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p540	Gris-PEG	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p541	Gris-PEG	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p542	Gris-PEG	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p543	Gris-PEG	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p544	Gris-PEG	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p545	Gris-PEG	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p546	Gris-PEG	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p547	Gris-PEG	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p548	Gris-PEG	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p549	Gris-PEG	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p550	Gris-PEG	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p551	Gris-PEG	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p552	Gris-PEG	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p553	Gris-PEG	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p554	Gris-PEG	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p563	Nizoral	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p564	Nizoral	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p565	Nizoral	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p566	Nizoral	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p567	Nizoral	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p568	Nizoral	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p569	Nizoral	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p570	Nizoral	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p571	Nizoral	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p572	Nizoral	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p573	Nizoral	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p574	Nizoral	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p575	Nizoral	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p576	Nizoral	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p577	Nizoral	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p578	Nizoral	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p579	Nizoral	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p580	Nizoral	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p581	Nizoral	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p582	Nizoral	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p583	Nizoral	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p591	Sporanox	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p592	Sporanox	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p593	Sporanox	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p594	Sporanox	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p595	Sporanox	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p596	Sporanox	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p597	Sporanox	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p598	Sporanox	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p599	Sporanox	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p600	Sporanox	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p601	Sporanox	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p602	Sporanox	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p603	Sporanox	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p604	Sporanox	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p605	Sporanox	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p606	Sporanox	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p607	Sporanox	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p608	Sporanox	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p609	Sporanox	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p610	Sporanox	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p611	Sporanox	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p618	atorvastatin	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p619	atorvastatin	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p620	atorvastatin	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p621	atorvastatin	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p622	atorvastatin	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p623	atorvastatin	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p624	atorvastatin	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p625	atorvastatin	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p626	atorvastatin	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p627	atorvastatin	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p628	atorvastatin	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p629	atorvastatin	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p630	atorvastatin	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p631	atorvastatin	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p632	atorvastatin	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p633	atorvastatin	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p634	atorvastatin	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p635	atorvastatin	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p636	atorvastatin	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p637	atorvastatin	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p638	atorvastatin	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p644	Lipitor	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p645	Lipitor	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p646	Lipitor	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p647	Lipitor	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p648	Lipitor	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p649	Lipitor	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p650	Lipitor	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p651	Lipitor	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p652	Lipitor	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p653	Lipitor	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p654	Lipitor	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p655	Lipitor	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p656	Lipitor	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p657	Lipitor	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p658	Lipitor	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p659	Lipitor	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p660	Lipitor	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p661	Lipitor	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p662	Lipitor	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p663	Lipitor	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p664	Lipitor	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p669	clofibrate	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p670	clofibrate	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p671	clofibrate	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p672	clofibrate	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p673	clofibrate	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p674	clofibrate	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p675	clofibrate	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p676	clofibrate	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p677	clofibrate	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p678	clofibrate	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p679	clofibrate	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p680	clofibrate	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p681	clofibrate	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p682	clofibrate	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p683	clofibrate	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p684	clofibrate	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p685	clofibrate	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p686	clofibrate	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p687	clofibrate	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p688	clofibrate	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p689	clofibrate	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p693	Atromid-S	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p694	Atromid-S	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p695	Atromid-S	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p696	Atromid-S	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p697	Atromid-S	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p698	Atromid-S	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p699	Atromid-S	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p700	Atromid-S	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p701	Atromid-S	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p702	Atromid-S	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p703	Atromid-S	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p704	Atromid-S	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p705	Atromid-S	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p706	Atromid-S	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p707	Atromid-S	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p708	Atromid-S	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p709	Atromid-S	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p710	Atromid-S	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p711	Atromid-S	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p712	Atromid-S	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p713	Atromid-S	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p716	cyclosporine	drug	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p717	cyclosporine	drug	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p718	cyclosporine	drug	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p719	cyclosporine	drug	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p720	cyclosporine	drug	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p721	cyclosporine	drug	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p722	cyclosporine	drug	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p723	cyclosporine	drug	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p724	cyclosporine	drug	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p725	cyclosporine	drug	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p726	cyclosporine	drug	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p727	cyclosporine	drug	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p728	cyclosporine	drug	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p729	cyclosporine	drug	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p730	cyclosporine	drug	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p731	cyclosporine	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p732	cyclosporine	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p733	cyclosporine	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p734	cyclosporine	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p735	cyclosporine	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p736	cyclosporine	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p738	Neoral	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p739	Neoral	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p740	Neoral	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p741	Neoral	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p742	Neoral	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p743	Neoral	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p744	Neoral	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p745	Neoral	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p746	Neoral	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p747	Neoral	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p748	Neoral	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p749	Neoral	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p750	Neoral	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p751	Neoral	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p752	Neoral	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p753	Neoral	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p754	Neoral	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p755	Neoral	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p756	Neoral	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p757	Neoral	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p758	Neoral	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p759	Sandimmune	brand	_	protease inhibitors	group	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p760	Sandimmune	brand	_	Agenerase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p761	Sandimmune	brand	_	Crixivan	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p762	Sandimmune	brand	_	Fortovase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p763	Sandimmune	brand	_	Invirase	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p764	Sandimmune	brand	_	Kaletra	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p765	Sandimmune	brand	_	Norvir	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p766	Sandimmune	brand	_	Viracept	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p767	Sandimmune	brand	_	morphine	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p768	Sandimmune	brand	_	Astramorph	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p769	Sandimmune	brand	_	Kadian	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p770	Sandimmune	brand	_	MS Contin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p771	Sandimmune	brand	_	phenylbutazone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p772	Sandimmune	brand	_	prednisolone	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p773	Sandimmune	brand	_	Prelone	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p774	Sandimmune	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p775	Sandimmune	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p776	Sandimmune	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p777	Sandimmune	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p778	Sandimmune	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p779	Sandimmune	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , druga -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p796	protease inhibitors	group	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p797	protease inhibitors	group	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p798	protease inhibitors	group	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p799	protease inhibitors	group	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p815	Agenerase	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p816	Agenerase	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p817	Agenerase	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p818	Agenerase	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p833	Crixivan	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p834	Crixivan	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p835	Crixivan	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p836	Crixivan	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p850	Fortovase	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p851	Fortovase	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p852	Fortovase	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p853	Fortovase	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p866	Invirase	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p867	Invirase	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p868	Invirase	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p869	Invirase	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p881	Kaletra	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p882	Kaletra	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p883	Kaletra	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p884	Kaletra	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p895	Norvir	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p896	Norvir	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p897	Norvir	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p898	Norvir	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p908	Viracept	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p909	Viracept	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p910	Viracept	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p911	Viracept	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , druga -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p918	morphine	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p919	morphine	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p920	morphine	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p921	morphine	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p922	morphine	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p923	morphine	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , druga -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p929	Astramorph	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p930	Astramorph	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p931	Astramorph	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p932	Astramorph	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p933	Astramorph	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p934	Astramorph	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- druga , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p939	Kadian	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p940	Kadian	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p941	Kadian	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p942	Kadian	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p943	Kadian	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p944	Kadian	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , druga , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p948	MS Contin	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p949	MS Contin	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p950	MS Contin	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p951	MS Contin	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p952	MS Contin	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p953	MS Contin	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , druga -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p956	phenylbutazone	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p957	phenylbutazone	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p958	phenylbutazone	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p959	phenylbutazone	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p960	phenylbutazone	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p961	phenylbutazone	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , druga , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p963	prednisolone	drug	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p964	prednisolone	drug	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p965	prednisolone	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p966	prednisolone	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p967	prednisolone	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p968	prednisolone	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p969	Prelone	brand	_	rifadin	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugb -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p970	Prelone	brand	_	rifampin	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugn -lcb- drugb -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p971	Prelone	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p972	Prelone	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p973	Prelone	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p974	Prelone	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p976	rifadin	brand	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p977	rifadin	brand	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p978	rifadin	brand	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p979	rifadin	brand	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d484.s0.p980	rifampin	drug	_	temazepam	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , st , johns wort , drugb , drugn -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p981	rifampin	drug	_	theophylline	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , st , johns wort , drugn , drugb -lcb- drugn -rcb- , and drugn .
DDI-DrugBank.d484.s0.p982	rifampin	drug	_	Theo-Dur	brand	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , st , johns wort , drugn , drugn -lcb- drugb -rcb- , and drugn .
DDI-DrugBank.d484.s0.p983	rifampin	drug	_	vitamin C	drug	_	false	drugn may interact with the following medications : drugn -lcb- drugn -rcb- , drugn such as drugn and drugn , drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , hiv drugs classified as drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , st , johns wort , drugn , drugn -lcb- drugn -rcb- , and drugb .
DDI-DrugBank.d194.s0.p0	ETOPOPHOS	brand	_	levamisole hydrochloride	drug	_	advise	caution should be exercised when administering druga with drugs that are known to inhibit phosphatase activities -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d194.s1.p0	cyclosporin A	drug	_	etoposide	drug	_	mechanism	high-dose druga resulting in concentrations above # ng/ml administered with oral drugb has led to an 80 % increase in drugn exposure with a 38 % decrease in total body clearance of drugn compared to drugn alone .
DDI-DrugBank.d194.s1.p1	cyclosporin A	drug	_	etoposide	drug	_	false	high-dose druga resulting in concentrations above # ng/ml administered with oral drugn has led to an 80 % increase in drugb exposure with a 38 % decrease in total body clearance of drugn compared to drugn alone .
DDI-DrugBank.d194.s1.p2	cyclosporin A	drug	_	etoposide	drug	_	false	high-dose druga resulting in concentrations above # ng/ml administered with oral drugn has led to an 80 % increase in drugn exposure with a 38 % decrease in total body clearance of drugb compared to drugn alone .
DDI-DrugBank.d194.s1.p3	cyclosporin A	drug	_	etoposide	drug	_	false	high-dose druga resulting in concentrations above # ng/ml administered with oral drugn has led to an 80 % increase in drugn exposure with a 38 % decrease in total body clearance of drugn compared to drugb alone .
DDI-DrugBank.d435.s0.p0	Exemestane	drug	_	ketoconazole	drug	_	false	druga is extensively metabolized by ppig 3a4 , but coadministration of drugb , a potent inhibitor of ppig 3a4 , has no significant effect on drugn pharmacokinetics .
DDI-DrugBank.d435.s0.p2	ketoconazole	drug	_	exemestane	drug	_	false	drugn is extensively metabolized by ppig 3a4 , but coadministration of druga , a potent inhibitor of ppig 3a4 , has no significant effect on drugb pharmacokinetics .
DDI-DrugBank.d435.s2.p3	rifampicin	drug	_	exemestane	drug	_	mechanism	co-medications that induce cyp 3a4 -lcb- e , g , , druga , drugn , drugn , drugn , or st , john s wort -rcb- may significantly decrease exposure to drugb .
DDI-DrugBank.d435.s2.p6	phenytoin	drug	_	exemestane	drug	_	mechanism	co-medications that induce cyp 3a4 -lcb- e , g , , drugn , druga , drugn , drugn , or st , john s wort -rcb- may significantly decrease exposure to drugb .
DDI-DrugBank.d435.s2.p8	carbamazepine	drug	_	exemestane	drug	_	mechanism	co-medications that induce cyp 3a4 -lcb- e , g , , drugn , drugn , druga , drugn , or st , john s wort -rcb- may significantly decrease exposure to drugb .
DDI-DrugBank.d435.s2.p9	phenobarbital	drug	_	exemestane	drug	_	mechanism	co-medications that induce cyp 3a4 -lcb- e , g , , drugn , drugn , drugn , druga , or st , john s wort -rcb- may significantly decrease exposure to drugb .
DDI-DrugBank.d112.s0.p0	probenecid	drug	_	penciclovir	drug	_	mechanism	concurrent use with druga or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of drugb .
DDI-DrugBank.d434.s1.p0	Antiepileptic Drugs	group	_	Felbatol	brand	_	false	use in conjunction with other druga : the addition of drugb to drugn -lcb- drugn -rcb- affects the steady-state plasma concentrations of drugn .
DDI-DrugBank.d434.s1.p4	Felbatol	brand	_	antiepileptic drugs	group	_	mechanism	use in conjunction with other drugn : the addition of druga to drugb -lcb- drugn -rcb- affects the steady-state plasma concentrations of drugn .
DDI-DrugBank.d434.s1.p5	Felbatol	brand	_	AEDs	group	_	mechanism	use in conjunction with other drugn : the addition of druga to drugn -lcb- drugb -rcb- affects the steady-state plasma concentrations of drugn .
DDI-DrugBank.d434.s1.p6	Felbatol	brand	_	AEDs	group	_	false	use in conjunction with other drugn : the addition of druga to drugn -lcb- drugn -rcb- affects the steady-state plasma concentrations of drugb .
DDI-DrugBank.d434.s1.p8	antiepileptic drugs	group	_	AEDs	group	_	false	use in conjunction with other drugn : the addition of drugn to druga -lcb- drugn -rcb- affects the steady-state plasma concentrations of drugb .
DDI-DrugBank.d434.s2.p1	AED	group	_	Felbatol	brand	_	false	the net effect of these interactions is summarized in the following table : druga drugn drugb
DDI-DrugBank.d434.s2.p2	AED	group	_	Felbatol	brand	_	false	the net effect of these interactions is summarized in the following table : drugn druga drugb
DDI-DrugBank.d434.s11.p0	Felbatol	brand	_	Antiepileptic Drugs	group	_	false	specific effects of druga on other drugb drugn : drugn causes an increase in steady-state drugn plasma concentrations .
DDI-DrugBank.d434.s11.p1	Felbatol	brand	_	Phenytoin	drug	_	false	specific effects of druga on other drugn drugb : drugn causes an increase in steady-state drugn plasma concentrations .
DDI-DrugBank.d434.s11.p4	Antiepileptic Drugs	group	_	Phenytoin	drug	_	false	specific effects of drugn on other druga drugb : drugn causes an increase in steady-state drugn plasma concentrations .
DDI-DrugBank.d434.s11.p5	Antiepileptic Drugs	group	_	Felbatol	brand	_	false	specific effects of drugn on other druga drugn : drugb causes an increase in steady-state drugn plasma concentrations .
DDI-DrugBank.d434.s11.p7	Phenytoin	drug	_	Felbatol	brand	_	false	specific effects of drugn on other drugn druga : drugb causes an increase in steady-state drugn plasma concentrations .
DDI-DrugBank.d434.s11.p9	Felbatol	brand	_	phenytoin	drug	_	mechanism	specific effects of drugn on other drugn drugn : druga causes an increase in steady-state drugb plasma concentrations .
DDI-DrugBank.d434.s14.p0	felbamate	drug	_	phenytoin	drug	_	mechanism	increasing the druga dose to # mg/day in six of these subjects increased the steady-state drugb cmin to # 7 micrograms/ml .
DDI-DrugBank.d434.s15.p0	phenytoin	drug	_	felbamate	drug	_	false	in order to maintain druga levels , limit adverse experiences , and achieve the drugb dose of # mg/day , a drugn dose reduction of approximately 40 % was necessary for eight of these # subjects .
DDI-DrugBank.d434.s15.p2	felbamate	drug	_	phenytoin	drug	_	advise	in order to maintain drugn levels , limit adverse experiences , and achieve the druga dose of # mg/day , a drugb dose reduction of approximately 40 % was necessary for eight of these # subjects .
DDI-DrugBank.d434.s16.p0	phenytoin	drug	_	Felbatol	brand	_	false	in a controlled clinical trial , a 20 % reduction of the druga dose at the initiation of drugb therapy resulted in drugn levels comparable to those prior to drugn administration .
DDI-DrugBank.d434.s16.p2	phenytoin	drug	_	Felbatol	brand	_	false	in a controlled clinical trial , a 20 % reduction of the druga dose at the initiation of drugn therapy resulted in drugn levels comparable to those prior to drugb administration .
DDI-DrugBank.d434.s16.p3	Felbatol	brand	_	phenytoin	drug	_	false	in a controlled clinical trial , a 20 % reduction of the drugn dose at the initiation of druga therapy resulted in drugb levels comparable to those prior to drugn administration .
DDI-DrugBank.d434.s16.p5	phenytoin	drug	_	Felbatol	brand	_	false	in a controlled clinical trial , a 20 % reduction of the drugn dose at the initiation of drugn therapy resulted in druga levels comparable to those prior to drugb administration .
DDI-DrugBank.d434.s17.p0	Carbamazepine	drug	_	Felbatol	brand	_	false	druga : drugb causes a decrease in the steady-state drugn plasma concentrations and an increase in the steady-state drugn plasma concentration .
DDI-DrugBank.d434.s17.p3	Felbatol	brand	_	carbamazepine	drug	_	mechanism	drugn : druga causes a decrease in the steady-state drugb plasma concentrations and an increase in the steady-state drugn plasma concentration .
DDI-DrugBank.d434.s17.p4	Felbatol	brand	_	carbamazepine epoxide	drug_n	_	false	drugn : druga causes a decrease in the steady-state drugn plasma concentrations and an increase in the steady-state drugb plasma concentration .
DDI-DrugBank.d434.s19.p0	carbamazepine	drug	_	felbamate	drug	_	mechanism	the druga steady-state cmin decreased 31 % to # 1 micrograms/ml when drugb -lcb- 3000 mg/day , divided into three doses -rcb- was coadministered .
DDI-DrugBank.d434.s20.p0	Carbamazepine epoxide	drug_n	_	felbamate	drug	_	false	druga steady-state cmin concentrations increased 57 % from # # to # # micrograms/ml with the addition of drugb .
DDI-DrugBank.d434.s22.p0	Valproate	drug	_	Felbatol	brand	_	false	druga : drugb causes an increase in steady-state drugn concentrations .
DDI-DrugBank.d434.s22.p2	Felbatol	brand	_	valproate	drug	_	mechanism	drugn : druga causes an increase in steady-state drugb concentrations .
DDI-DrugBank.d434.s25.p0	felbamate	drug	_	valproate	drug	_	mechanism	increasing the druga dose to # mg/day increased the steadystate drugb cmin to # 25 micrograms/ml .
DDI-DrugBank.d434.s26.p0	valproate	drug	_	Felbatol	brand	_	false	corresponding values for free druga cmin concentrations were # 3 , # 4 , and # 6 micrograms/ml for 0 , 1200 , and # mg/day drugb , respectively .
DDI-DrugBank.d434.s27.p1	valproate	drug	_	Felbatol	brand	_	false	the ratios of the aucs of unbound druga to the aucs of the total drugn were # % , # % , and # % , with coadministration of 0 , 1200 , and # mg/day of drugb , respectively .
DDI-DrugBank.d434.s27.p2	valproate	drug	_	Felbatol	brand	_	false	the ratios of the aucs of unbound drugn to the aucs of the total druga were # % , # % , and # % , with coadministration of 0 , 1200 , and # mg/day of drugb , respectively .
DDI-DrugBank.d434.s28.p0	Phenobarbital	drug	_	felbamate	drug	_	false	druga : coadministration of drugb with drugn causes an increase in drugn plasma concentrations , in # otherwise healthy male volunteers ingesting drugn , the steady-state trough -lcb- cmin -rcb- drugn concentration was # micrograms/ml .
DDI-DrugBank.d434.s28.p5	felbamate	drug	_	phenobarbital	drug	_	mechanism	drugn : coadministration of druga with drugb causes an increase in drugn plasma concentrations , in # otherwise healthy male volunteers ingesting drugn , the steady-state trough -lcb- cmin -rcb- drugn concentration was # micrograms/ml .
DDI-DrugBank.d434.s28.p6	felbamate	drug	_	phenobarbital	drug	_	false	drugn : coadministration of druga with drugn causes an increase in drugb plasma concentrations , in # otherwise healthy male volunteers ingesting drugn , the steady-state trough -lcb- cmin -rcb- drugn concentration was # micrograms/ml .
DDI-DrugBank.d434.s28.p7	felbamate	drug	_	phenobarbital	drug	_	false	drugn : coadministration of druga with drugn causes an increase in drugn plasma concentrations , in # otherwise healthy male volunteers ingesting drugb , the steady-state trough -lcb- cmin -rcb- drugn concentration was # micrograms/ml .
DDI-DrugBank.d434.s28.p8	felbamate	drug	_	phenobarbital	drug	_	false	drugn : coadministration of druga with drugn causes an increase in drugn plasma concentrations , in # otherwise healthy male volunteers ingesting drugn , the steady-state trough -lcb- cmin -rcb- drugb concentration was # micrograms/ml .
DDI-DrugBank.d434.s30.p0	Antiepileptic Drugs	group	_	Felbatol	brand	_	false	effects of other druga on drugb drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p1	Antiepileptic Drugs	group	_	Phenytoin	drug	_	false	effects of other druga on drugn drugb : drugn causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p8	Felbatol	brand	_	Phenytoin	drug	_	false	effects of other drugn on druga drugb : drugn causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p21	Phenytoin	drug	_	Felbatol	brand	_	mechanism	effects of other drugn on drugn drugn : druga causes an approximate doubling of the clearance of drugb -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p22	Phenytoin	drug	_	felbamate	drug	_	mechanism	effects of other drugn on drugn drugn : druga causes an approximate doubling of the clearance of drugn -lcb- drugb -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p24	Phenytoin	drug	_	Felbatol	brand	_	false	effects of other drugn on drugn drugn : druga causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugb as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p25	Phenytoin	drug	_	Felbatol	brand	_	false	effects of other drugn on drugn drugn : druga causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugb given as monotherapy .
DDI-DrugBank.d434.s30.p27	Felbatol	brand	_	phenytoin	drug	_	false	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of druga -lcb- drugn -rcb- at steady state and , therefore , the addition of drugb causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p30	felbamate	drug	_	phenytoin	drug	_	false	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- druga -rcb- at steady state and , therefore , the addition of drugb causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p31	felbamate	drug	_	Felbatol	brand	_	false	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- druga -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugb as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p32	felbamate	drug	_	Felbatol	brand	_	false	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- druga -rcb- at steady state and , therefore , the addition of drugn causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugb given as monotherapy .
DDI-DrugBank.d434.s30.p33	phenytoin	drug	_	Felbatol	brand	_	mechanism	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of druga causes an approximate 45 % decrease in the steady-state trough concentrations of drugb as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s30.p34	phenytoin	drug	_	Felbatol	brand	_	false	effects of other drugn on drugn drugn : drugn causes an approximate doubling of the clearance of drugn -lcb- drugn -rcb- at steady state and , therefore , the addition of druga causes an approximate 45 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugb given as monotherapy .
DDI-DrugBank.d434.s31.p5	Carbamazepine	drug	_	Felbatol	brand	_	mechanism	drugn : druga causes an approximate 50 % increase in the clearance of drugb at steady state and , therefore , the addition of drugn results in an approximate 40 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s31.p7	Carbamazepine	drug	_	Felbatol	brand	_	false	drugn : druga causes an approximate 50 % increase in the clearance of drugn at steady state and , therefore , the addition of drugn results in an approximate 40 % decrease in the steady-state trough concentrations of drugb as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s31.p8	Carbamazepine	drug	_	Felbatol	brand	_	false	drugn : druga causes an approximate 50 % increase in the clearance of drugn at steady state and , therefore , the addition of drugn results in an approximate 40 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugb given as monotherapy .
DDI-DrugBank.d434.s31.p9	Felbatol	brand	_	carbamazepine	drug	_	false	drugn : drugn causes an approximate 50 % increase in the clearance of druga at steady state and , therefore , the addition of drugb results in an approximate 40 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s31.p12	carbamazepine	drug	_	Felbatol	brand	_	mechanism	drugn : drugn causes an approximate 50 % increase in the clearance of drugn at steady state and , therefore , the addition of druga results in an approximate 40 % decrease in the steady-state trough concentrations of drugb as compared to the same dose of drugn given as monotherapy .
DDI-DrugBank.d434.s31.p13	carbamazepine	drug	_	Felbatol	brand	_	false	drugn : drugn causes an approximate 50 % increase in the clearance of drugn at steady state and , therefore , the addition of druga results in an approximate 40 % decrease in the steady-state trough concentrations of drugn as compared to the same dose of drugb given as monotherapy .
DDI-DrugBank.d434.s32.p5	valproate	drug	_	Felbatol	brand	_	false	drugn : available data suggest that there is no significant effect of druga on the clearance of drugb at steady state , therefore , the addition of drugn is not expected to cause a clinically important effect on drugn -lcb- drugn -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p7	valproate	drug	_	Felbatol	brand	_	false	drugn : available data suggest that there is no significant effect of druga on the clearance of drugn at steady state , therefore , the addition of drugn is not expected to cause a clinically important effect on drugb -lcb- drugn -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p8	valproate	drug	_	felbamate	drug	_	false	drugn : available data suggest that there is no significant effect of druga on the clearance of drugn at steady state , therefore , the addition of drugn is not expected to cause a clinically important effect on drugn -lcb- drugb -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p9	Felbatol	brand	_	valproate	drug	_	false	drugn : available data suggest that there is no significant effect of drugn on the clearance of druga at steady state , therefore , the addition of drugb is not expected to cause a clinically important effect on drugn -lcb- drugn -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p11	Felbatol	brand	_	felbamate	drug	_	false	drugn : available data suggest that there is no significant effect of drugn on the clearance of druga at steady state , therefore , the addition of drugn is not expected to cause a clinically important effect on drugn -lcb- drugb -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p12	valproate	drug	_	Felbatol	brand	_	false	drugn : available data suggest that there is no significant effect of drugn on the clearance of drugn at steady state , therefore , the addition of druga is not expected to cause a clinically important effect on drugb -lcb- drugn -rcb- plasma concentrations .
DDI-DrugBank.d434.s32.p13	valproate	drug	_	felbamate	drug	_	false	drugn : available data suggest that there is no significant effect of drugn on the clearance of drugn at steady state , therefore , the addition of druga is not expected to cause a clinically important effect on drugn -lcb- drugb -rcb- plasma concentrations .
DDI-DrugBank.d434.s33.p2	phenobarbital	drug	_	felbamate	drug	_	mechanism	drugn : it appears that druga may reduce plasma drugb concentrations .
DDI-DrugBank.d434.s35.p0	Antacids	group	_	Felbatol	brand	_	false	effects of druga on drugb the rate and extent of absorption of a # mg dose of drugn as monotherapy given as tablets was not affected when coadministered with drugn .
DDI-DrugBank.d434.s35.p1	Antacids	group	_	Felbatol	brand	_	false	effects of druga on drugn the rate and extent of absorption of a # mg dose of drugb as monotherapy given as tablets was not affected when coadministered with drugn .
DDI-DrugBank.d434.s35.p4	Felbatol	brand	_	antacids	group	_	false	effects of drugn on druga the rate and extent of absorption of a # mg dose of drugn as monotherapy given as tablets was not affected when coadministered with drugb .
DDI-DrugBank.d434.s35.p5	Felbatol	brand	_	antacids	group	_	false	effects of drugn on drugn the rate and extent of absorption of a # mg dose of druga as monotherapy given as tablets was not affected when coadministered with drugb .
DDI-DrugBank.d434.s36.p0	Erythromycin	drug	_	Felbatol	brand	_	false	effects of druga on drugb the coadministration of drugn -lcb- 1000 mg/day -rcb- for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at drugn daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .
DDI-DrugBank.d434.s36.p2	Erythromycin	drug	_	felbamate	drug	_	false	effects of druga on drugn the coadministration of drugn -lcb- 1000 mg/day -rcb- for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at drugb daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .
DDI-DrugBank.d434.s36.p3	Felbatol	brand	_	erythromycin	drug	_	false	effects of drugn on druga the coadministration of drugb -lcb- 1000 mg/day -rcb- for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at drugn daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .
DDI-DrugBank.d434.s36.p4	Felbatol	brand	_	felbamate	drug	_	false	effects of drugn on druga the coadministration of drugn -lcb- 1000 mg/day -rcb- for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at drugb daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .
DDI-DrugBank.d434.s36.p5	erythromycin	drug	_	felbamate	drug	_	false	effects of drugn on drugn the coadministration of druga -lcb- 1000 mg/day -rcb- for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at drugb daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .
DDI-DrugBank.d434.s37.p0	Felbatol	brand	_	Combination Oral Contraceptives	group	_	false	effects of druga on low-dose drugb a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p1	Felbatol	brand	_	contraceptive	group	_	false	effects of druga on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugb regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p2	Felbatol	brand	_	ethinyl estradiol	drug	_	false	effects of druga on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugb and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p3	Felbatol	brand	_	gestodene	drug	_	false	effects of druga on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugb for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p4	Felbatol	brand	_	felbamate	drug	_	false	effects of druga on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugb from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p5	Felbatol	brand	_	contraceptive	group	_	false	effects of druga on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugb cycles .
DDI-DrugBank.d434.s37.p7	Combination Oral Contraceptives	group	_	ethinyl estradiol	drug	_	false	effects of drugn on low-dose druga a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugb and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p8	Combination Oral Contraceptives	group	_	gestodene	drug	_	false	effects of drugn on low-dose druga a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugb for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p9	Combination Oral Contraceptives	group	_	felbamate	drug	_	false	effects of drugn on low-dose druga a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugb from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p11	contraceptive	group	_	ethinyl estradiol	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral druga regimen containing # mg drugb and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p12	contraceptive	group	_	gestodene	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral druga regimen containing # mg drugn and # mg drugb for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p13	contraceptive	group	_	felbamate	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral druga regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of drugb from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p15	ethinyl estradiol	drug	_	gestodene	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg druga and # mg drugb for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p16	ethinyl estradiol	drug	_	felbamate	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg druga and # mg drugn for at least # months received # mg/day of drugb from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p17	ethinyl estradiol	drug	_	contraceptive	group	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg druga and # mg drugn for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugb cycles .
DDI-DrugBank.d434.s37.p18	gestodene	drug	_	felbamate	drug	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg druga for at least # months received # mg/day of drugb from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugn cycles .
DDI-DrugBank.d434.s37.p19	gestodene	drug	_	contraceptive	group	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg druga for at least # months received # mg/day of drugn from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugb cycles .
DDI-DrugBank.d434.s37.p20	felbamate	drug	_	contraceptive	group	_	false	effects of drugn on low-dose drugn a group of # nonsmoking , healthy white female volunteers established on an oral drugn regimen containing # mg drugn and # mg drugn for at least # months received # mg/day of druga from midcycle -lcb- day 15 -rcb- to midcycle -lcb- day 14 -rcb- of two consecutive oral drugb cycles .
DDI-DrugBank.d434.s38.p0	Felbamate	drug	_	gestodene	drug	_	mechanism	druga treatment resulted in a 42 % decrease in the drugb auc 0-24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of drugn .
DDI-DrugBank.d434.s38.p1	Felbamate	drug	_	ethinyl estradiol	drug	_	false	druga treatment resulted in a 42 % decrease in the drugn auc 0-24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of drugb .
DDI-DrugBank.d434.s38.p2	gestodene	drug	_	ethinyl estradiol	drug	_	false	drugn treatment resulted in a 42 % decrease in the druga auc 0-24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of drugb .
DDI-DrugBank.d316.s1.p3	ketoconazole	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , druga , drugn , drugn , grapefruit juice , drugn -rcb- with drugb may lead to several - fold increases in the plasma levels of drugn , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p4	ketoconazole	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , druga , drugn , drugn , grapefruit juice , drugn -rcb- with drugn may lead to several - fold increases in the plasma levels of drugb , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p7	itraconazole	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , druga , drugn , grapefruit juice , drugn -rcb- with drugb may lead to several - fold increases in the plasma levels of drugn , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p8	itraconazole	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , druga , drugn , grapefruit juice , drugn -rcb- with drugn may lead to several - fold increases in the plasma levels of drugb , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p10	erythromycin	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , drugn , druga , grapefruit juice , drugn -rcb- with drugb may lead to several - fold increases in the plasma levels of drugn , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p11	erythromycin	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , drugn , druga , grapefruit juice , drugn -rcb- with drugn may lead to several - fold increases in the plasma levels of drugb , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p12	cimetidine	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , drugn , drugn , grapefruit juice , druga -rcb- with drugb may lead to several - fold increases in the plasma levels of drugn , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s1.p13	cimetidine	drug	_	felodipine	drug	_	false	co-administration of cyp3a4 inhibitors -lcb- eg , drugn , drugn , drugn , grapefruit juice , druga -rcb- with drugn may lead to several - fold increases in the plasma levels of drugb , either due to an increase in bioavailability or due to a decrease in metabolism .
DDI-DrugBank.d316.s4.p0	CYP3A4	drug	_	felodipine	drug	_	false	caution should be used when druga inhibitors are co-administered with drugb .
DDI-DrugBank.d316.s6.p0	felodipine	drug	_	itraconazole	drug	_	false	the following specific interactions have been reported : itraconazole co-administration of another extended release formulation of druga with drugb resulted in approximately 8-fold increase in the auc , more than 6 - fold increase in the cmax , and 2-fold prolongation in the half - life of drugn .
DDI-DrugBank.d316.s6.p2	itraconazole	drug	_	felodipine	drug	_	false	the following specific interactions have been reported : itraconazole co-administration of another extended release formulation of drugn with druga resulted in approximately 8-fold increase in the auc , more than 6 - fold increase in the cmax , and 2-fold prolongation in the half - life of drugb .
DDI-DrugBank.d316.s7.p1	felodipine	drug	_	erythromycin	drug	_	false	erythromycin co-administration of druga -lcb- drugn -rcb- with drugb resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of drugn .
DDI-DrugBank.d316.s7.p3	PLENDIL	drug	_	erythromycin	drug	_	false	erythromycin co-administration of drugn -lcb- druga -rcb- with drugb resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of drugn .
DDI-DrugBank.d316.s7.p4	PLENDIL	drug	_	felodipine	drug	_	false	erythromycin co-administration of drugn -lcb- druga -rcb- with drugn resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of drugb .
DDI-DrugBank.d316.s7.p5	erythromycin	drug	_	felodipine	drug	_	false	erythromycin co-administration of drugn -lcb- drugn -rcb- with druga resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of drugb .
DDI-DrugBank.d316.s9.p0	felodipine	drug	_	cimetidine	drug	_	false	cimetidine co-administration of druga with drugb -lcb- a non-specific cyp-450 inhibitor -rcb- resulted in an increase of approximately 50 % in the auc and the cmax , of drugn .
DDI-DrugBank.d316.s9.p2	cimetidine	drug	_	felodipine	drug	_	false	cimetidine co-administration of drugn with druga -lcb- a non-specific cyp-450 inhibitor -rcb- resulted in an increase of approximately 50 % in the auc and the cmax , of drugb .
DDI-DrugBank.d316.s10.p0	felodipine	drug	_	metoprolol	drug	_	false	beta-blocking agents a pharmacokinetic study of druga in conjunction with drugb demonstrated no significant effects on the pharmacokinetics of drugn .
DDI-DrugBank.d316.s10.p2	metoprolol	drug	_	felodipine	drug	_	false	beta-blocking agents a pharmacokinetic study of drugn in conjunction with druga demonstrated no significant effects on the pharmacokinetics of drugb .
DDI-DrugBank.d316.s12.p0	beta blockers	drug	_	metoprolol	drug	_	false	in controlled clinical trials , however , druga including drugb were concurrently administered with drugn and were well tolerated .
DDI-DrugBank.d316.s12.p1	beta blockers	drug	_	felodipine	drug	_	false	in controlled clinical trials , however , druga including drugn were concurrently administered with drugb and were well tolerated .
DDI-DrugBank.d316.s12.p2	metoprolol	drug	_	felodipine	drug	_	false	in controlled clinical trials , however , drugn including druga were concurrently administered with drugb and were well tolerated .
DDI-DrugBank.d316.s13.p0	PLENDIL	drug	_	digoxin	drug	_	false	digoxin when given concomitantly with druga the pharmacokinetics of drugb in patients with heart failure were not significantly altered .
DDI-DrugBank.d316.s14.p0	Anticonvulsants	group	_	felodipine	drug	_	false	druga : in a pharmacokinetic study , maximum plasma concentrations of drugb were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugn , drugn , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p2	Anticonvulsants	group	_	phenytoin	drug	_	false	druga : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugb , drugn , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p3	Anticonvulsants	group	_	carbamazepine	drug	_	false	druga : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugn , drugb , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p4	Anticonvulsants	group	_	phenobarbital	drug	_	false	druga : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugn , drugn , or drugb -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p5	felodipine	drug	_	anticonvulsant	group	_	mechanism	drugn : in a pharmacokinetic study , maximum plasma concentrations of druga were considerably lower in epileptic patients on long-term drugb therapy -lcb- eg , drugn , drugn , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p6	felodipine	drug	_	phenytoin	drug	_	mechanism	drugn : in a pharmacokinetic study , maximum plasma concentrations of druga were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugb , drugn , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p7	felodipine	drug	_	carbamazepine	drug	_	mechanism	drugn : in a pharmacokinetic study , maximum plasma concentrations of druga were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugn , drugb , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p8	felodipine	drug	_	phenobarbital	drug	_	mechanism	drugn : in a pharmacokinetic study , maximum plasma concentrations of druga were considerably lower in epileptic patients on long-term drugn therapy -lcb- eg , drugn , drugn , or drugb -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p9	anticonvulsant	group	_	phenytoin	drug	_	false	drugn : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term druga therapy -lcb- eg , drugb , drugn , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p10	anticonvulsant	group	_	carbamazepine	drug	_	false	drugn : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term druga therapy -lcb- eg , drugn , drugb , or drugn -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s14.p11	anticonvulsant	group	_	phenobarbital	drug	_	false	drugn : in a pharmacokinetic study , maximum plasma concentrations of drugn were considerably lower in epileptic patients on long-term druga therapy -lcb- eg , drugn , drugn , or drugb -rcb- than in healthy volunteers .
DDI-DrugBank.d316.s17.p0	Felodipine	drug	_	tacrolimus	drug	_	false	tacrolimus druga may increase the blood concentration of drugb .
DDI-DrugBank.d316.s18.p0	felodipine	drug	_	tacrolimus	drug	_	false	when given concomitantly with druga , the drugb blood concentration should be followed and the tacrolimus dose may need to be adjusted .
DDI-DrugBank.d316.s19.p0	felodipine	drug	_	indomethacin	drug	_	false	other concomitant therapy in healthy subjects there were no clinically significant interactions when druga was given concomitantly with drugb or drugn .
DDI-DrugBank.d316.s19.p1	felodipine	drug	_	spironolactone	drug	_	false	other concomitant therapy in healthy subjects there were no clinically significant interactions when druga was given concomitantly with drugn or drugb .
DDI-DrugBank.d316.s19.p2	indomethacin	drug	_	spironolactone	drug	_	false	other concomitant therapy in healthy subjects there were no clinically significant interactions when drugn was given concomitantly with druga or drugb .
DDI-DrugBank.d104.s0.p0	Fenfluramine	drug	_	antihypertensive drugs	group	_	effect	druga may increase slightly the effect of drugb , e , g , , drugn , drugn , drugn .
DDI-DrugBank.d104.s0.p1	Fenfluramine	drug	_	guanethidine	drug	_	effect	druga may increase slightly the effect of drugn , e , g , , drugb , drugn , drugn .
DDI-DrugBank.d104.s0.p2	Fenfluramine	drug	_	methyldopa	drug	_	effect	druga may increase slightly the effect of drugn , e , g , , drugn , drugb , drugn .
DDI-DrugBank.d104.s0.p3	Fenfluramine	drug	_	reserpine	drug	_	effect	druga may increase slightly the effect of drugn , e , g , , drugn , drugn , drugb .
DDI-DrugBank.d104.s0.p4	antihypertensive drugs	group	_	guanethidine	drug	_	false	drugn may increase slightly the effect of druga , e , g , , drugb , drugn , drugn .
DDI-DrugBank.d104.s0.p5	antihypertensive drugs	group	_	methyldopa	drug	_	false	drugn may increase slightly the effect of druga , e , g , , drugn , drugb , drugn .
DDI-DrugBank.d104.s0.p6	antihypertensive drugs	group	_	reserpine	drug	_	false	drugn may increase slightly the effect of druga , e , g , , drugn , drugn , drugb .
DDI-DrugBank.d104.s1.p0	CNS depressant drugs	group	_	fenfluramine	drug	_	advise	other druga should be used with caution in patients taking drugb , since the effects may be additive .
DDI-DrugBank.d283.s0.p1	Anticoagulants	group	_	TRICOR	brand	_	false	oral druga caution should be exercised when drugn are given in conjunction with drugb .
DDI-DrugBank.d283.s0.p2	COUMARIN ANTICOAGULANTS	group	_	TRICOR	brand	_	advise	oral drugn caution should be exercised when druga are given in conjunction with drugb .
DDI-DrugBank.d283.s3.p2	TRICOR	brand	_	HMG-CoA reductase inhibitors	group	_	advise	drugn : the combined use of druga and drugb should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination .
DDI-DrugBank.d283.s4.p3	bile acid sequestrants	group	_	TRICOR	brand	_	false	drugn : since druga may bind other drugs given concurrently , patients should take drugb at least # hour before or 4-6 hours after a drugn to avoid impeding its absorption .
DDI-DrugBank.d283.s4.p4	bile acid sequestrants	group	_	bile acid binding resin	group	_	false	drugn : since druga may bind other drugs given concurrently , patients should take drugn at least # hour before or 4-6 hours after a drugb to avoid impeding its absorption .
DDI-DrugBank.d283.s4.p5	TRICOR	brand	_	bile acid binding resin	group	_	mechanism	drugn : since drugn may bind other drugs given concurrently , patients should take druga at least # hour before or 4-6 hours after a drugb to avoid impeding its absorption .
DDI-DrugBank.d283.s5.p3	cyclosporine	drug	_	fibrate drugs	group	_	effect	drugn : because druga can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of drugb including drugn , there is a risk that an interaction will lead to deterioration .
DDI-DrugBank.d283.s5.p4	cyclosporine	drug	_	TRICOR	brand	_	effect	drugn : because druga can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of drugn including drugb , there is a risk that an interaction will lead to deterioration .
DDI-DrugBank.d283.s5.p5	fibrate drugs	group	_	TRICOR	brand	_	false	drugn : because drugn can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of druga including drugb , there is a risk that an interaction will lead to deterioration .
DDI-DrugBank.d283.s6.p0	TRICOR	brand	_	immunosuppressants	group	_	advise	the benefits and risks of using druga with drugb and other potentially nephrotoxic agents should be carefully considered , and the lowest effective dose employed
DDI-DrugBank.d283.s8.p0	fenofibrate	drug	_	fenofibric acid	drug_n	_	false	drug-drug interactions in vitro studies using human liver microsomes indicate that druga and drugb are not inhibitors of cytochrome -lcb- cyp -rcb- cyp2b6 isoforms cyp3a4 , cyp2d6 , cyp2e1 , or cyp1a2 .
DDI-DrugBank.d283.s12.p0	fenofibrate	drug	_	bile acid binding resin	group	_	advise	therefore , druga should be taken at least # hour before or 4-6 hours after a drugb to avoid impeding its absorption .
DDI-DrugBank.d283.s13.p0	fenofibrate	drug	_	TRICOR	brand	_	false	concomitant administration of druga -lcb- equivalent to 145mg drugb -rcb- with drugn -lcb- 40 mg -rcb- once daily for # days has been shown to increase the mean cmax and auc values for drugn by 36 % -lcb- range from 69 % decrease to 321 % increase -rcb- and 28 % -lcb- range from 54 % decrease to 128 % increase -rcb- , respectively , and for # - hydroxy-iso-pravastatin by 55 % -lcb- range from 32 % decrease to 314 % increase -rcb- and 39 % -lcb- range from 24 % decrease to 261 % increase -rcb- , respectively in # healthy adults .
DDI-DrugBank.d283.s13.p1	fenofibrate	drug	_	pravastatin	drug	_	mechanism	concomitant administration of druga -lcb- equivalent to 145mg drugn -rcb- with drugb -lcb- 40 mg -rcb- once daily for # days has been shown to increase the mean cmax and auc values for drugn by 36 % -lcb- range from 69 % decrease to 321 % increase -rcb- and 28 % -lcb- range from 54 % decrease to 128 % increase -rcb- , respectively , and for # - hydroxy-iso-pravastatin by 55 % -lcb- range from 32 % decrease to 314 % increase -rcb- and 39 % -lcb- range from 24 % decrease to 261 % increase -rcb- , respectively in # healthy adults .
DDI-DrugBank.d283.s13.p2	fenofibrate	drug	_	pravastatin	drug	_	false	concomitant administration of druga -lcb- equivalent to 145mg drugn -rcb- with drugn -lcb- 40 mg -rcb- once daily for # days has been shown to increase the mean cmax and auc values for drugb by 36 % -lcb- range from 69 % decrease to 321 % increase -rcb- and 28 % -lcb- range from 54 % decrease to 128 % increase -rcb- , respectively , and for # - hydroxy-iso-pravastatin by 55 % -lcb- range from 32 % decrease to 314 % increase -rcb- and 39 % -lcb- range from 24 % decrease to 261 % increase -rcb- , respectively in # healthy adults .
DDI-DrugBank.d283.s13.p3	TRICOR	brand	_	pravastatin	drug	_	mechanism	concomitant administration of drugn -lcb- equivalent to 145mg druga -rcb- with drugb -lcb- 40 mg -rcb- once daily for # days has been shown to increase the mean cmax and auc values for drugn by 36 % -lcb- range from 69 % decrease to 321 % increase -rcb- and 28 % -lcb- range from 54 % decrease to 128 % increase -rcb- , respectively , and for # - hydroxy-iso-pravastatin by 55 % -lcb- range from 32 % decrease to 314 % increase -rcb- and 39 % -lcb- range from 24 % decrease to 261 % increase -rcb- , respectively in # healthy adults .
DDI-DrugBank.d283.s13.p4	TRICOR	brand	_	pravastatin	drug	_	false	concomitant administration of drugn -lcb- equivalent to 145mg druga -rcb- with drugn -lcb- 40 mg -rcb- once daily for # days has been shown to increase the mean cmax and auc values for drugb by 36 % -lcb- range from 69 % decrease to 321 % increase -rcb- and 28 % -lcb- range from 54 % decrease to 128 % increase -rcb- , respectively , and for # - hydroxy-iso-pravastatin by 55 % -lcb- range from 32 % decrease to 314 % increase -rcb- and 39 % -lcb- range from 24 % decrease to 261 % increase -rcb- , respectively in # healthy adults .
DDI-DrugBank.d283.s14.p0	pravastatin	drug	_	fenofibric acid	drug_n	_	false	a single dose of druga had no clinically important effect on the pharmacokinetics of drugb .
DDI-DrugBank.d283.s15.p0	fenofibrate	drug	_	TRICOR	brand	_	false	concomitant administration of druga -lcb- equivalent to # mg drugb -rcb- with drugn -lcb- 20 mg -rcb- once daily for # days resulted in approximately 17 % decrease -lcb- range from 67 % decrease to 44 % increase -rcb- in drugn auc values in # healthy males .
DDI-DrugBank.d283.s15.p1	fenofibrate	drug	_	atorvastatin	drug	_	mechanism	concomitant administration of druga -lcb- equivalent to # mg drugn -rcb- with drugb -lcb- 20 mg -rcb- once daily for # days resulted in approximately 17 % decrease -lcb- range from 67 % decrease to 44 % increase -rcb- in drugn auc values in # healthy males .
DDI-DrugBank.d283.s15.p2	fenofibrate	drug	_	atorvastatin	drug	_	false	concomitant administration of druga -lcb- equivalent to # mg drugn -rcb- with drugn -lcb- 20 mg -rcb- once daily for # days resulted in approximately 17 % decrease -lcb- range from 67 % decrease to 44 % increase -rcb- in drugb auc values in # healthy males .
DDI-DrugBank.d283.s15.p3	TRICOR	brand	_	atorvastatin	drug	_	mechanism	concomitant administration of drugn -lcb- equivalent to # mg druga -rcb- with drugb -lcb- 20 mg -rcb- once daily for # days resulted in approximately 17 % decrease -lcb- range from 67 % decrease to 44 % increase -rcb- in drugn auc values in # healthy males .
DDI-DrugBank.d283.s15.p4	TRICOR	brand	_	atorvastatin	drug	_	false	concomitant administration of drugn -lcb- equivalent to # mg druga -rcb- with drugn -lcb- 20 mg -rcb- once daily for # days resulted in approximately 17 % decrease -lcb- range from 67 % decrease to 44 % increase -rcb- in drugb auc values in # healthy males .
DDI-DrugBank.d283.s16.p0	atorvastatin	drug	_	fenofibrate	drug	_	false	the druga cmax values were not significantly affected by drugb .
DDI-DrugBank.d283.s17.p0	fenofibric acid	drug_n	_	atorvastatin	drug	_	false	the pharmacokinetics of druga were not significantly affected by drugb
DDI-DrugBank.d546.s0.p0	Beta-Blockers	group	_	fenoldopam	drug	_	false	drug interactions with druga : concomitant use of drugb with drugn should be avoided .
DDI-DrugBank.d546.s0.p2	fenoldopam	drug	_	beta-blockers	group	_	advise	drug interactions with drugn : concomitant use of druga with drugb should be avoided .
DDI-DrugBank.d546.s2.p0	fenoldopam	drug	_	digitalis	group	_	false	drug interactions , general : although there have been no formal interaction studies , intravenous druga has been administered safely with drugs such as drugb and sublingual drugn .
DDI-DrugBank.d546.s2.p1	fenoldopam	drug	_	nitroglycerin	drug	_	false	drug interactions , general : although there have been no formal interaction studies , intravenous druga has been administered safely with drugs such as drugn and sublingual drugb .
DDI-DrugBank.d546.s2.p2	digitalis	group	_	nitroglycerin	drug	_	false	drug interactions , general : although there have been no formal interaction studies , intravenous drugn has been administered safely with drugs such as druga and sublingual drugb .
DDI-DrugBank.d546.s3.p0	antihypertensive agents	group	_	alpha-blockers	group	_	false	there is limited experience with concomitant druga such as drugb , drugn , drugn , and drugn -lcb- both drugn - like and loop -rcb- .
DDI-DrugBank.d546.s3.p1	antihypertensive agents	group	_	calcium channel-blockers	group	_	false	there is limited experience with concomitant druga such as drugn , drugb , drugn , and drugn -lcb- both drugn - like and loop -rcb- .
DDI-DrugBank.d546.s3.p2	antihypertensive agents	group	_	ACE inhibitors	group	_	false	there is limited experience with concomitant druga such as drugn , drugn , drugb , and drugn -lcb- both drugn - like and loop -rcb- .
DDI-DrugBank.d546.s3.p3	antihypertensive agents	group	_	diuretics	group	_	false	there is limited experience with concomitant druga such as drugn , drugn , drugn , and drugb -lcb- both drugn - like and loop -rcb- .
DDI-DrugBank.d546.s3.p4	antihypertensive agents	group	_	thiazide	group	_	false	there is limited experience with concomitant druga such as drugn , drugn , drugn , and drugn -lcb- both drugb - like and loop -rcb- .
DDI-DrugBank.d546.s3.p8	alpha-blockers	group	_	thiazide	group	_	false	there is limited experience with concomitant drugn such as druga , drugn , drugn , and drugn -lcb- both drugb - like and loop -rcb- .
DDI-DrugBank.d546.s3.p11	calcium channel-blockers	group	_	thiazide	group	_	false	there is limited experience with concomitant drugn such as drugn , druga , drugn , and drugn -lcb- both drugb - like and loop -rcb- .
DDI-DrugBank.d546.s3.p13	ACE inhibitors	group	_	thiazide	group	_	false	there is limited experience with concomitant drugn such as drugn , drugn , druga , and drugn -lcb- both drugb - like and loop -rcb- .
DDI-DrugBank.d546.s3.p14	diuretics	group	_	thiazide	group	_	false	there is limited experience with concomitant drugn such as drugn , drugn , drugn , and druga -lcb- both drugb - like and loop -rcb- .
DDI-DrugBank.d154.s0.p0	aspirin	brand	_	fenoprofen	drug	_	mechanism	the coadministration of druga decreases the biologic half-life of drugb because of an increase in metabolic clearance that results in a greater amount of drugn in the urine .
DDI-DrugBank.d154.s0.p1	aspirin	brand	_	hydroxylated fenoprofen	drug_n	_	false	the coadministration of druga decreases the biologic half-life of drugn because of an increase in metabolic clearance that results in a greater amount of drugb in the urine .
DDI-DrugBank.d154.s1.p0	fenoprofen	drug	_	aspirin	brand	_	mechanism	although the mechanism of interaction between druga and drugb is not totally known , enzyme induction and displacement of drugn from plasma alb binding sites are possibilities .
DDI-DrugBank.d154.s1.p2	aspirin	brand	_	fenoprofen	drug	_	false	although the mechanism of interaction between drugn and druga is not totally known , enzyme induction and displacement of drugb from plasma alb binding sites are possibilities .
DDI-DrugBank.d154.s2.p0	Nalfon	brand	_	aspirin	brand	_	false	because druga has not been shown to produce any additional effect beyond that obtained with drugb alone and because drugn increases the rate of excretion of drugn , the concomitant use of drugn and drugn is not recommended .
DDI-DrugBank.d154.s2.p1	Nalfon	brand	_	aspirin	brand	_	false	because druga has not been shown to produce any additional effect beyond that obtained with drugn alone and because drugb increases the rate of excretion of drugn , the concomitant use of drugn and drugn is not recommended .
DDI-DrugBank.d154.s2.p4	Nalfon	brand	_	salicylates	group	_	false	because druga has not been shown to produce any additional effect beyond that obtained with drugn alone and because drugn increases the rate of excretion of drugn , the concomitant use of drugn and drugb is not recommended .
DDI-DrugBank.d154.s2.p6	aspirin	brand	_	Nalfon	brand	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with druga alone and because drugn increases the rate of excretion of drugb , the concomitant use of drugn and drugn is not recommended .
DDI-DrugBank.d154.s2.p7	aspirin	brand	_	Nalfon	brand	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with druga alone and because drugn increases the rate of excretion of drugn , the concomitant use of drugb and drugn is not recommended .
DDI-DrugBank.d154.s2.p8	aspirin	brand	_	salicylates	group	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with druga alone and because drugn increases the rate of excretion of drugn , the concomitant use of drugn and drugb is not recommended .
DDI-DrugBank.d154.s2.p9	aspirin	brand	_	Nalfon	brand	_	mechanism	because drugn has not been shown to produce any additional effect beyond that obtained with drugn alone and because druga increases the rate of excretion of drugb , the concomitant use of drugn and drugn is not recommended .
DDI-DrugBank.d154.s2.p10	aspirin	brand	_	Nalfon	brand	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with drugn alone and because druga increases the rate of excretion of drugn , the concomitant use of drugb and drugn is not recommended .
DDI-DrugBank.d154.s2.p11	aspirin	brand	_	salicylates	group	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with drugn alone and because druga increases the rate of excretion of drugn , the concomitant use of drugn and drugb is not recommended .
DDI-DrugBank.d154.s2.p13	Nalfon	brand	_	salicylates	group	_	false	because drugn has not been shown to produce any additional effect beyond that obtained with drugn alone and because drugn increases the rate of excretion of druga , the concomitant use of drugn and drugb is not recommended .
DDI-DrugBank.d154.s2.p14	Nalfon	brand	_	salicylates	group	_	advise	because drugn has not been shown to produce any additional effect beyond that obtained with drugn alone and because drugn increases the rate of excretion of drugn , the concomitant use of druga and drugb is not recommended .
DDI-DrugBank.d154.s3.p0	phenobarbital	drug	_	fenoprofen	drug	_	mechanism	chronic administration of druga , a known enzyme inducer , may be associated with a decrease in the plasma half-life of drugb .
DDI-DrugBank.d154.s4.p0	phenobarbital	drug	_	Nalfon	brand	_	advise	when druga is added to or withdrawn from treatment , dosage adjustment of drugb may be required .
DDI-DrugBank.d154.s8.p0	coumarin-type anticoagulants	group	_	Nalfon	brand	_	effect	in patients receiving druga , the addition of drugb to therapy could prolong the prothrombin time .
DDI-DrugBank.d154.s10.p0	Nalfon	brand	_	loop diuretics	group	_	effect	patients treated with druga may be resistant to the effects of drugb .
DDI-DrugBank.d154.s11.p0	Nalfon	brand	_	steroid	group	_	advise	in patients receiving druga and a drugb concomitantly , any reduction in drugn dosage should be gradual in order to avoid the possible complications of sudden drugn withdrawal .
DDI-DrugBank.d154.s11.p1	Nalfon	brand	_	steroid	group	_	false	in patients receiving druga and a drugn concomitantly , any reduction in drugb dosage should be gradual in order to avoid the possible complications of sudden drugn withdrawal .
DDI-DrugBank.d154.s11.p2	Nalfon	brand	_	steroid	group	_	false	in patients receiving druga and a drugn concomitantly , any reduction in drugn dosage should be gradual in order to avoid the possible complications of sudden drugb withdrawal .
DDI-DrugBank.d170.s0.p0	Fentanyl	drug	_	DURAGESIC	brand	_	false	agents affecting cytochrome p450 3a4 isoenzyme system druga is metabolized mainly via the human cytochrome p450 3a4 isoenzyme system -lcb- cyp3a4 -rcb- , therefore potential interactions may occur when drugb is given concurrently with agents that affect cyp3a4 activity .
DDI-DrugBank.d170.s2.p0	fentanyl	drug	_	ritonavir	drug	_	mechanism	the concomitant use of transdermal druga with drugb or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p1	fentanyl	drug	_	ketoconazole	drug	_	mechanism	the concomitant use of transdermal druga with drugn or other potent 3a4 inhibitors such as drugb , drugn , drugn , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p2	fentanyl	drug	_	itraconazole	drug	_	mechanism	the concomitant use of transdermal druga with drugn or other potent 3a4 inhibitors such as drugn , drugb , drugn , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p3	fentanyl	drug	_	troleandomycin	drug	_	mechanism	the concomitant use of transdermal druga with drugn or other potent 3a4 inhibitors such as drugn , drugn , drugb , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p4	fentanyl	drug	_	clarithromycin	drug	_	mechanism	the concomitant use of transdermal druga with drugn or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugb , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p5	fentanyl	drug	_	nelfinavir	drug	_	mechanism	the concomitant use of transdermal druga with drugn or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugn , drugb , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p7	ritonavir	drug	_	ketoconazole	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugb , drugn , drugn , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p8	ritonavir	drug	_	itraconazole	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugn , drugb , drugn , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p9	ritonavir	drug	_	troleandomycin	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugn , drugn , drugb , drugn , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p10	ritonavir	drug	_	clarithromycin	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugb , drugn , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p11	ritonavir	drug	_	nelfinavir	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugn , drugb , and nefazadone may result in an increase in drugn plasma concentrations .
DDI-DrugBank.d170.s2.p12	ritonavir	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with druga or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugn , drugn , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s2.p17	ketoconazole	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with drugn or other potent 3a4 inhibitors such as druga , drugn , drugn , drugn , drugn , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s2.p21	itraconazole	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with drugn or other potent 3a4 inhibitors such as drugn , druga , drugn , drugn , drugn , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s2.p24	troleandomycin	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with drugn or other potent 3a4 inhibitors such as drugn , drugn , druga , drugn , drugn , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s2.p26	clarithromycin	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with drugn or other potent 3a4 inhibitors such as drugn , drugn , drugn , druga , drugn , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s2.p27	nelfinavir	drug	_	fentanyl	drug	_	false	the concomitant use of transdermal drugn with drugn or other potent 3a4 inhibitors such as drugn , drugn , drugn , drugn , druga , and nefazadone may result in an increase in drugb plasma concentrations .
DDI-DrugBank.d170.s3.p0	diltiazem	drug	_	erythromycin	drug	_	false	the concomitant use of other cyp3a4 inhibitors such as druga and drugb with transdermal drugn may also result in an increase in drugn plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .
DDI-DrugBank.d170.s3.p1	diltiazem	drug	_	fentanyl	drug	_	mechanism	the concomitant use of other cyp3a4 inhibitors such as druga and drugn with transdermal drugb may also result in an increase in drugn plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .
DDI-DrugBank.d170.s3.p2	diltiazem	drug	_	fentanyl	drug	_	false	the concomitant use of other cyp3a4 inhibitors such as druga and drugn with transdermal drugn may also result in an increase in drugb plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .
DDI-DrugBank.d170.s3.p3	erythromycin	drug	_	fentanyl	drug	_	mechanism	the concomitant use of other cyp3a4 inhibitors such as drugn and druga with transdermal drugb may also result in an increase in drugn plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .
DDI-DrugBank.d170.s3.p4	erythromycin	drug	_	fentanyl	drug	_	false	the concomitant use of other cyp3a4 inhibitors such as drugn and druga with transdermal drugn may also result in an increase in drugb plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .
DDI-DrugBank.d170.s5.p13	DURAGESIC	brand	_	central nervous system depressants	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugb , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p14	DURAGESIC	brand	_	opioids	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugb , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p15	DURAGESIC	brand	_	sedatives	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p16	DURAGESIC	brand	_	hypnotics	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p17	DURAGESIC	brand	_	tranquilizers	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p18	DURAGESIC	brand	_	benzodiazepines	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p19	DURAGESIC	brand	_	anesthetics	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugb , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p20	DURAGESIC	brand	_	phenothiazines	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugb , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p21	DURAGESIC	brand	_	skeletal muscle relaxants	group	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugb , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p22	DURAGESIC	brand	_	alcohol	drug	_	effect	drugn : the concomitant use of druga -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugb , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p23	fentanyl	drug	_	central nervous system depressants	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugb , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p24	fentanyl	drug	_	opioids	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugb , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p25	fentanyl	drug	_	sedatives	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p26	fentanyl	drug	_	hypnotics	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p27	fentanyl	drug	_	tranquilizers	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p28	fentanyl	drug	_	benzodiazepines	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p29	fentanyl	drug	_	anesthetics	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugb , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p30	fentanyl	drug	_	phenothiazines	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugb , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p31	fentanyl	drug	_	skeletal muscle relaxants	group	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugb , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p32	fentanyl	drug	_	alcohol	drug	_	effect	drugn : the concomitant use of drugn -lcb- druga transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugb , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p33	central nervous system depressants	group	_	opioids	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugb , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p34	central nervous system depressants	group	_	sedatives	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p35	central nervous system depressants	group	_	hypnotics	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugb , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p36	central nervous system depressants	group	_	tranquilizers	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p37	central nervous system depressants	group	_	benzodiazepines	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p38	central nervous system depressants	group	_	anesthetics	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugb , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p39	central nervous system depressants	group	_	phenothiazines	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugb , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p40	central nervous system depressants	group	_	skeletal muscle relaxants	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugb , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p41	central nervous system depressants	group	_	alcohol	drug	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other druga , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugb , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p42	opioids	group	_	sedatives	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other druga , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p51	sedatives	group	_	tranquilizers	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , druga , drugn , drugb -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p52	sedatives	group	_	benzodiazepines	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , druga , drugn , drugn -lcb- e , g , , drugb -rcb- , general drugn , drugn , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p62	hypnotics	group	_	alcohol	drug	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , druga , drugn -lcb- e , g , , drugn -rcb- , general drugn , drugn , drugn , and drugb , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p65	tranquilizers	group	_	phenothiazines	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , druga -lcb- e , g , , drugn -rcb- , general drugn , drugb , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p69	benzodiazepines	group	_	phenothiazines	group	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , druga -rcb- , general drugn , drugb , drugn , and drugn , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s5.p74	anesthetics	group	_	alcohol	drug	_	false	drugn : the concomitant use of drugn -lcb- drugn transdermal system -rcb- with other drugn , including but not limited to other drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , general druga , drugn , drugn , and drugb , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .
DDI-DrugBank.d170.s7.p0	MAO Inhibitors	group	_	DURAGESIC	brand	_	false	druga : drugb is not recommended for use in patients who have received drugn within # days because severe and unpredictable potentiation by drugn has been reported with drugn
DDI-DrugBank.d170.s7.p4	DURAGESIC	brand	_	MAOI	group	_	advise	drugn : druga is not recommended for use in patients who have received drugb within # days because severe and unpredictable potentiation by drugn has been reported with drugn
DDI-DrugBank.d170.s7.p5	DURAGESIC	brand	_	MAO inhibitors	group	_	false	drugn : druga is not recommended for use in patients who have received drugn within # days because severe and unpredictable potentiation by drugb has been reported with drugn
DDI-DrugBank.d170.s7.p6	DURAGESIC	brand	_	opioid analgesics	group	_	false	drugn : druga is not recommended for use in patients who have received drugn within # days because severe and unpredictable potentiation by drugn has been reported with drugb
DDI-DrugBank.d170.s7.p7	MAOI	group	_	MAO inhibitors	group	_	false	drugn : drugn is not recommended for use in patients who have received druga within # days because severe and unpredictable potentiation by drugb has been reported with drugn
DDI-DrugBank.d170.s7.p8	MAOI	group	_	opioid analgesics	group	_	false	drugn : drugn is not recommended for use in patients who have received druga within # days because severe and unpredictable potentiation by drugn has been reported with drugb
DDI-DrugBank.d170.s7.p9	MAO inhibitors	group	_	opioid analgesics	group	_	advise	drugn : drugn is not recommended for use in patients who have received drugn within # days because severe and unpredictable potentiation by druga has been reported with drugb
DDI-DrugBank.d466.s0.p0	Erythromycin	drug	_	Ketoconazole	drug	_	false	drug interaction with druga and drugb drugn has been shown to exhibit minimal -lcb- ca , 5 % -rcb- metabolism .
DDI-DrugBank.d466.s0.p1	Erythromycin	drug	_	Fexofenadine	drug	_	false	drug interaction with druga and drugn drugb has been shown to exhibit minimal -lcb- ca , 5 % -rcb- metabolism .
DDI-DrugBank.d466.s0.p2	Ketoconazole	drug	_	Fexofenadine	drug	_	false	drug interaction with drugn and druga drugb has been shown to exhibit minimal -lcb- ca , 5 % -rcb- metabolism .
DDI-DrugBank.d466.s1.p0	fexofenadine hydrochloride	drug	_	ketoconazole	drug	_	mechanism	however , co administration of druga with either drugb or drugn led to increased plasma concentrations of drugn .
DDI-DrugBank.d466.s1.p1	fexofenadine hydrochloride	drug	_	erythromycin	drug	_	mechanism	however , co administration of druga with either drugn or drugb led to increased plasma concentrations of drugn .
DDI-DrugBank.d466.s1.p3	ketoconazole	drug	_	erythromycin	drug	_	false	however , co administration of drugn with either druga or drugb led to increased plasma concentrations of drugn .
DDI-DrugBank.d466.s1.p4	ketoconazole	drug	_	fexofenadine	drug	_	false	however , co administration of drugn with either druga or drugn led to increased plasma concentrations of drugb .
DDI-DrugBank.d466.s1.p5	erythromycin	drug	_	fexofenadine	drug	_	false	however , co administration of drugn with either drugn or druga led to increased plasma concentrations of drugb .
DDI-DrugBank.d466.s2.p0	Fexofenadine	drug	_	erythromycin	drug	_	false	druga had no effect on the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d466.s2.p1	Fexofenadine	drug	_	ketoconazole	drug	_	false	druga had no effect on the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d466.s2.p2	erythromycin	drug	_	ketoconazole	drug	_	false	drugn had no effect on the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d466.s3.p0	fexofenadine hydrochloride	drug	_	erythromycin	drug	_	false	in # separate studies , druga # mg twice daily -lcb- 240 mg total daily dose -rcb- was co-administered with either drugb # mg every # hours or drugn # mg once daily under steady-state conditions to healthy volunteers -lcb- n = 24 , each study -rcb- .
DDI-DrugBank.d466.s3.p1	fexofenadine hydrochloride	drug	_	ketoconazole	drug	_	false	in # separate studies , druga # mg twice daily -lcb- 240 mg total daily dose -rcb- was co-administered with either drugn # mg every # hours or drugb # mg once daily under steady-state conditions to healthy volunteers -lcb- n = 24 , each study -rcb- .
DDI-DrugBank.d466.s3.p2	erythromycin	drug	_	ketoconazole	drug	_	false	in # separate studies , drugn # mg twice daily -lcb- 240 mg total daily dose -rcb- was co-administered with either druga # mg every # hours or drugb # mg once daily under steady-state conditions to healthy volunteers -lcb- n = 24 , each study -rcb- .
DDI-DrugBank.d466.s4.p0	fexofenadine hydrochloride	drug	_	erythromycin	drug	_	false	no differences in adverse events or qtc interval were observed when subjects were administered druga alone or in combination with either drugb or drugn .
DDI-DrugBank.d466.s4.p1	fexofenadine hydrochloride	drug	_	ketoconazole	drug	_	false	no differences in adverse events or qtc interval were observed when subjects were administered druga alone or in combination with either drugn or drugb .
DDI-DrugBank.d466.s4.p2	erythromycin	drug	_	ketoconazole	drug	_	false	no differences in adverse events or qtc interval were observed when subjects were administered drugn alone or in combination with either druga or drugb .
DDI-DrugBank.d466.s17.p0	ketoconazole	drug	_	erythromycin	drug	_	false	these studies indicate that druga or drugb co-administration enhances drugn gastrointestinal absorption .
DDI-DrugBank.d466.s17.p1	ketoconazole	drug	_	fexofenadine	drug	_	mechanism	these studies indicate that druga or drugn co-administration enhances drugb gastrointestinal absorption .
DDI-DrugBank.d466.s17.p2	erythromycin	drug	_	fexofenadine	drug	_	mechanism	these studies indicate that drugn or druga co-administration enhances drugb gastrointestinal absorption .
DDI-DrugBank.d466.s18.p0	fexofenadine	drug	_	ketoconazole	drug	_	false	this observed increase in the bioavailability of druga may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , drugb decreases drugn gastrointestinal secretion , while drugn may also decrease biliary excretion .
DDI-DrugBank.d466.s18.p2	fexofenadine	drug	_	erythromycin	drug	_	false	this observed increase in the bioavailability of druga may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , drugn decreases drugn gastrointestinal secretion , while drugb may also decrease biliary excretion .
DDI-DrugBank.d466.s18.p3	ketoconazole	drug	_	fexofenadine	drug	_	mechanism	this observed increase in the bioavailability of drugn may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , druga decreases drugb gastrointestinal secretion , while drugn may also decrease biliary excretion .
DDI-DrugBank.d466.s18.p4	ketoconazole	drug	_	erythromycin	drug	_	false	this observed increase in the bioavailability of drugn may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , druga decreases drugn gastrointestinal secretion , while drugb may also decrease biliary excretion .
DDI-DrugBank.d466.s18.p5	fexofenadine	drug	_	erythromycin	drug	_	false	this observed increase in the bioavailability of drugn may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , drugn decreases druga gastrointestinal secretion , while drugb may also decrease biliary excretion .
DDI-DrugBank.d466.s19.p0	Antacids	group	_	fexofenadine hydrochloride	drug	_	false	drug interactions with druga administration of # mg of drugb -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p1	Antacids	group	_	aluminum	drug	_	false	drug interactions with druga administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugb and drugn containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p2	Antacids	group	_	magnesium	drug	_	false	drug interactions with druga administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugb containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p4	Antacids	group	_	Maalox	brand	_	false	drug interactions with druga administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugn -lcb- drugb -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p5	Antacids	group	_	fexofenadine	drug	_	false	drug interactions with druga administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugn -lcb- drugn -rcb- decreased drugb auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p6	fexofenadine hydrochloride	drug	_	aluminum	drug	_	mechanism	drug interactions with drugn administration of # mg of druga -lcb- 2 x # mg capsule -rcb- within # minutes of an drugb and drugn containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p7	fexofenadine hydrochloride	drug	_	magnesium	drug	_	mechanism	drug interactions with drugn administration of # mg of druga -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugb containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p8	fexofenadine hydrochloride	drug	_	antacid	group	_	mechanism	drug interactions with drugn administration of # mg of druga -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugb -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p9	fexofenadine hydrochloride	drug	_	Maalox	brand	_	mechanism	drug interactions with drugn administration of # mg of druga -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugn -lcb- drugb -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p11	aluminum	drug	_	magnesium	drug	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an druga and drugb containing drugn -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p12	aluminum	drug	_	antacid	group	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an druga and drugn containing drugb -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p13	aluminum	drug	_	Maalox	brand	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an druga and drugn containing drugn -lcb- drugb -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p14	aluminum	drug	_	fexofenadine	drug	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an druga and drugn containing drugn -lcb- drugn -rcb- decreased drugb auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p15	magnesium	drug	_	antacid	group	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and druga containing drugb -lcb- drugn -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p16	magnesium	drug	_	Maalox	brand	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and druga containing drugn -lcb- drugb -rcb- decreased drugn auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p17	magnesium	drug	_	fexofenadine	drug	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and druga containing drugn -lcb- drugn -rcb- decreased drugb auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p19	antacid	group	_	fexofenadine	drug	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing druga -lcb- drugn -rcb- decreased drugb auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s19.p20	Maalox	brand	_	fexofenadine	drug	_	false	drug interactions with drugn administration of # mg of drugn -lcb- 2 x # mg capsule -rcb- within # minutes of an drugn and drugn containing drugn -lcb- druga -rcb- decreased drugb auc by 41 % and cmax by 43 % .
DDI-DrugBank.d466.s20.p0	ALLEGRA	brand	_	aluminum	drug	_	advise	druga should not be taken closely in time with drugb and drugn containing drugn .
DDI-DrugBank.d466.s20.p1	ALLEGRA	brand	_	magnesium	drug	_	advise	druga should not be taken closely in time with drugn and drugb containing drugn .
DDI-DrugBank.d466.s20.p2	ALLEGRA	brand	_	antacids	group	_	false	druga should not be taken closely in time with drugn and drugn containing drugb .
DDI-DrugBank.d466.s20.p3	aluminum	drug	_	magnesium	drug	_	false	drugn should not be taken closely in time with druga and drugb containing drugn .
DDI-DrugBank.d466.s20.p4	aluminum	drug	_	antacids	group	_	false	drugn should not be taken closely in time with druga and drugn containing drugb .
DDI-DrugBank.d466.s20.p5	magnesium	drug	_	antacids	group	_	false	drugn should not be taken closely in time with drugn and druga containing drugb .
DDI-DrugBank.d466.s27.p0	fexofenadine	drug	_	ALLEGRA	brand	_	false	therefore , to maximize the effects of druga , it is recommended that drugb should be taken with water
DDI-DrugBank.d209.s3.p0	finasteride	drug	_	acetaminophen	drug	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugb , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p1	finasteride	drug	_	acetylsalicylic acid	drug	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugb , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p2	finasteride	drug	_	analgesics	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugb , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p5	finasteride	drug	_	benzodiazepines	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugb , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p6	finasteride	drug	_	beta blockers	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugb , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p8	finasteride	drug	_	nitrates	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugb , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p9	finasteride	drug	_	diuretics	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugb , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p10	finasteride	drug	_	H2 antagonists	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugb , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p11	finasteride	drug	_	HMG-CoA reductase inhibitors	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugb , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p12	finasteride	drug	_	prostaglandin synthetase inhibitors	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugb -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p13	finasteride	drug	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p14	finasteride	drug	_	quinolone anti-infectives	group	_	false	other concomitant therapy although specific interaction studies were not performed , druga doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p20	acetaminophen	drug	_	beta blockers	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with druga , drugn , a-blockers , drugn , drugn , drugn , drugn , drugb , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p27	acetaminophen	drug	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with druga , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p33	acetylsalicylic acid	drug	_	beta blockers	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , druga , a-blockers , drugn , drugn , drugn , drugn , drugb , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p40	acetylsalicylic acid	drug	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , druga , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p45	analgesics	group	_	beta blockers	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , druga , drugn , drugn , drugn , drugb , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p52	analgesics	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , druga , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p63	angiotensin-converting enzyme (ACE) inhibitors	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , druga , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p70	anticonvulsants	group	_	H2 antagonists	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , druga , drugn , drugn , drugn , cardiac drugn , drugn , drugb , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p72	anticonvulsants	group	_	prostaglandin synthetase inhibitors	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , druga , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugb -lcb- also referred to as drugn -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p73	anticonvulsants	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , druga , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p74	anticonvulsants	group	_	quinolone anti-infectives	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , druga , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugn -rcb- , and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p82	benzodiazepines	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , druga , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p90	beta blockers	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , druga , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p97	calcium-channel blockers	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , druga , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p103	nitrates	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac druga , drugn , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p108	diuretics	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , druga , drugn , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p112	H2 antagonists	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , druga , drugn , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p115	HMG-CoA reductase inhibitors	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , druga , drugn -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p117	prostaglandin synthetase inhibitors	group	_	NSAIDs	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , druga -lcb- also referred to as drugb -rcb- , and drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d209.s3.p119	NSAIDs	group	_	quinolone anti-infectives	group	_	false	other concomitant therapy although specific interaction studies were not performed , drugn doses of # mg or more were concomitantly used in clinical studies with drugn , drugn , a-blockers , drugn , drugn , drugn , drugn , drugn , drugn , cardiac drugn , drugn , drugn , drugn , drugn -lcb- also referred to as druga -rcb- , and drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d87.s1.p0	TAMBOCOR	brand	_	digitalis preparations	group	_	false	druga has been administered to patients receiving drugb or drugn without adverse effects .
DDI-DrugBank.d87.s1.p1	TAMBOCOR	brand	_	beta-adrenergic blocking agents	group	_	false	druga has been administered to patients receiving drugn or drugb without adverse effects .
DDI-DrugBank.d87.s1.p2	digitalis preparations	group	_	beta-adrenergic blocking agents	group	_	false	drugn has been administered to patients receiving druga or drugb without adverse effects .
DDI-DrugBank.d87.s2.p0	TAMBOCOR	brand	_	digoxin	drug	_	mechanism	during administration of multiple oral doses of druga to healthy subjects stabilized on a maintenance dose of drugb , a 13 % -19 % increase in plasma drugn levels occurred at six hours postdose .
DDI-DrugBank.d87.s2.p1	TAMBOCOR	brand	_	digoxin	drug	_	false	during administration of multiple oral doses of druga to healthy subjects stabilized on a maintenance dose of drugn , a 13 % -19 % increase in plasma drugb levels occurred at six hours postdose .
DDI-DrugBank.d87.s3.p0	TAMBOCOR	brand	_	propranolol	drug	_	mechanism	in a study involving healthy subjects receiving druga and drugb concurrently , plasma drugn levels were increased about 20 % and drugn levels were increased about 30 % compared to control values .
DDI-DrugBank.d87.s3.p1	TAMBOCOR	brand	_	flecainide	drug	_	false	in a study involving healthy subjects receiving druga and drugn concurrently , plasma drugb levels were increased about 20 % and drugn levels were increased about 30 % compared to control values .
DDI-DrugBank.d87.s3.p2	TAMBOCOR	brand	_	propranolol	drug	_	false	in a study involving healthy subjects receiving druga and drugn concurrently , plasma drugn levels were increased about 20 % and drugb levels were increased about 30 % compared to control values .
DDI-DrugBank.d87.s3.p3	propranolol	drug	_	flecainide	drug	_	false	in a study involving healthy subjects receiving drugn and druga concurrently , plasma drugb levels were increased about 20 % and drugn levels were increased about 30 % compared to control values .
DDI-DrugBank.d87.s3.p5	flecainide	drug	_	propranolol	drug	_	false	in a study involving healthy subjects receiving drugn and drugn concurrently , plasma druga levels were increased about 20 % and drugb levels were increased about 30 % compared to control values .
DDI-DrugBank.d87.s4.p0	TAMBOCOR	brand	_	propranolol	drug	_	false	in this formal interaction study , druga and drugb were each found to have negative inotropic effects ;
DDI-DrugBank.d87.s6.p0	TAMBOCOR	brand	_	propranolol	drug	_	effect	the effects of concomitant administration of druga and drugb on the pr interval were less than additive .
DDI-DrugBank.d87.s7.p0	TAMBOCOR	brand	_	beta blockers	group	_	false	in druga clinical trials , patients who were receiving drugb concurrently did not experience an increased incidence of side effects .
DDI-DrugBank.d87.s8.p0	beta blockers	group	_	flecainide	drug	_	effect	nevertheless , the possibility of additive negative inotropic effects of druga and drugb should be recognized .
DDI-DrugBank.d87.s12.p0	TAMBOCOR	brand	_	diuretics	group	_	false	druga has been used in a large number of patients receiving drugb without apparent interaction .
DDI-DrugBank.d87.s13.p2	phenytoin	drug	_	flecainide	drug	_	mechanism	limited data in patients receiving known enzyme inducers -lcb- druga , drugn , drugn -rcb- indicate only a 30 % increase in the rate of drugb elimination .
DDI-DrugBank.d87.s13.p4	phenobarbital	drug	_	flecainide	drug	_	mechanism	limited data in patients receiving known enzyme inducers -lcb- drugn , druga , drugn -rcb- indicate only a 30 % increase in the rate of drugb elimination .
DDI-DrugBank.d87.s13.p5	carbamazepine	drug	_	flecainide	drug	_	mechanism	limited data in patients receiving known enzyme inducers -lcb- drugn , drugn , druga -rcb- indicate only a 30 % increase in the rate of drugb elimination .
DDI-DrugBank.d87.s14.p0	cimetidine	drug	_	flecainide	drug	_	mechanism	in healthy subjects receiving druga -lcb- 1 gm daily -rcb- for one week , plasma drugb levels increased by about 30 % and half-life increased by about 10 % .
DDI-DrugBank.d87.s15.p0	amiodarone	drug	_	flecainide	drug	_	mechanism	when druga is added to drugb therapy , plasma drugn levels may increase two-fold or more in some patients , if drugn dosage is not reduced .
DDI-DrugBank.d87.s15.p1	amiodarone	drug	_	flecainide	drug	_	false	when druga is added to drugn therapy , plasma drugb levels may increase two-fold or more in some patients , if drugn dosage is not reduced .
DDI-DrugBank.d87.s15.p2	amiodarone	drug	_	flecainide	drug	_	false	when druga is added to drugn therapy , plasma drugn levels may increase two-fold or more in some patients , if drugb dosage is not reduced .
DDI-DrugBank.d87.s16.p0	quinidine	drug	_	flecainide	drug	_	mechanism	drugs that inhibit cytochrome p450iid6 , such as druga , might increase the plasma concentrations of drugb in patients that are on chronic drugn therapy ;
DDI-DrugBank.d87.s16.p1	quinidine	drug	_	flecainide	drug	_	false	drugs that inhibit cytochrome p450iid6 , such as druga , might increase the plasma concentrations of drugn in patients that are on chronic drugb therapy ;
DDI-DrugBank.d87.s18.p0	TAMBOCOR	brand	_	disopyramide	drug	_	false	there has been little experience with the coadministration of druga and either drugb or drugn .
DDI-DrugBank.d87.s18.p1	TAMBOCOR	brand	_	verapamil	drug	_	false	there has been little experience with the coadministration of druga and either drugn or drugb .
DDI-DrugBank.d87.s18.p2	disopyramide	drug	_	verapamil	drug	_	false	there has been little experience with the coadministration of drugn and either druga or drugb .
DDI-DrugBank.d87.s19.p0	TAMBOCOR	brand	_	disopyramide	drug	_	false	because both of these drugs have negative inotropic properties and the effects of coadministration with druga are unknown , neither drugb nor drugn should be administered concurrently with drugn unless , in the judgment of the physician , the benefits of this combination outweigh the risks .
DDI-DrugBank.d87.s19.p1	TAMBOCOR	brand	_	verapamil	drug	_	false	because both of these drugs have negative inotropic properties and the effects of coadministration with druga are unknown , neither drugn nor drugb should be administered concurrently with drugn unless , in the judgment of the physician , the benefits of this combination outweigh the risks .
DDI-DrugBank.d87.s19.p3	disopyramide	drug	_	verapamil	drug	_	false	because both of these drugs have negative inotropic properties and the effects of coadministration with drugn are unknown , neither druga nor drugb should be administered concurrently with drugn unless , in the judgment of the physician , the benefits of this combination outweigh the risks .
DDI-DrugBank.d87.s19.p4	disopyramide	drug	_	TAMBOCOR	brand	_	advise	because both of these drugs have negative inotropic properties and the effects of coadministration with drugn are unknown , neither druga nor drugn should be administered concurrently with drugb unless , in the judgment of the physician , the benefits of this combination outweigh the risks .
DDI-DrugBank.d87.s19.p5	verapamil	drug	_	TAMBOCOR	brand	_	advise	because both of these drugs have negative inotropic properties and the effects of coadministration with drugn are unknown , neither drugn nor druga should be administered concurrently with drugb unless , in the judgment of the physician , the benefits of this combination outweigh the risks .
DDI-DrugBank.d87.s20.p0	TAMBOCOR	brand	_	nifedipine	drug	_	false	there has been too little experience with the coadministration of druga with drugb or drugn to recommend concomitant use .
DDI-DrugBank.d87.s20.p1	TAMBOCOR	brand	_	diltiazem	drug	_	false	there has been too little experience with the coadministration of druga with drugn or drugb to recommend concomitant use .
DDI-DrugBank.d87.s20.p2	nifedipine	drug	_	diltiazem	drug	_	false	there has been too little experience with the coadministration of drugn with druga or drugb to recommend concomitant use .
DDI-DrugBank.d453.s0.p0	Cytosine arabinoside	drug	_	cytostatic agent	group	_	false	druga , a drugb , has been reported to inactivate the antifungal activity of drugn by competitive inhibition .
DDI-DrugBank.d453.s0.p1	Cytosine arabinoside	drug	_	flucytosine	drug	_	effect	druga , a drugn , has been reported to inactivate the antifungal activity of drugb by competitive inhibition .
DDI-DrugBank.d453.s0.p2	cytostatic agent	group	_	flucytosine	drug	_	false	drugn , a druga , has been reported to inactivate the antifungal activity of drugb by competitive inhibition .
DDI-DrugBank.d444.s0.p0	FLUDARA	brand	_	pentostatin	drug	_	advise	the use of druga wwox injection in combination with drugb is not recommended due to the risk of severe pulmonary toxicity .
DDI-DrugBank.d526.s1.p0	Amphotericin B	drug	_	potassium-depleting diuretics	group	_	false	druga or drugb -lcb- drugn and related drugs , drugn and drugn -rcb- enhanced hypokalemia .
DDI-DrugBank.d526.s1.p1	Amphotericin B	drug	_	benzothiadiazines	group	_	false	druga or drugn -lcb- drugb and related drugs , drugn and drugn -rcb- enhanced hypokalemia .
DDI-DrugBank.d526.s1.p2	Amphotericin B	drug	_	ethacrynic acid	drug	_	false	druga or drugn -lcb- drugn and related drugs , drugb and drugn -rcb- enhanced hypokalemia .
DDI-DrugBank.d526.s1.p3	Amphotericin B	drug	_	furosemide	drug	_	false	druga or drugn -lcb- drugn and related drugs , drugn and drugb -rcb- enhanced hypokalemia .
DDI-DrugBank.d526.s14.p0	salicylate	group	_	steroids	group	_	false	rarely druga toxicity may occur in patients who discontinue drugb after concurrent high-dose drugn therapy .
DDI-DrugBank.d526.s14.p1	salicylate	group	_	aspirin	brand	_	false	rarely druga toxicity may occur in patients who discontinue drugn after concurrent high-dose drugb therapy .
DDI-DrugBank.d526.s14.p2	steroids	group	_	aspirin	brand	_	effect	rarely drugn toxicity may occur in patients who discontinue druga after concurrent high-dose drugb therapy .
DDI-DrugBank.d526.s15.p0	salicylate	group	_	aspirin	brand	_	false	monitor druga levels or the therapeutic effect for which drugb is given ;
DDI-DrugBank.d526.s17.p2	Barbiturates	group	_	fludrocortisone acetate	drug	_	mechanism	druga , drugn , or drugn increased metabolic clearance of drugb because of the induction of hepatic enzymes .
DDI-DrugBank.d526.s17.p4	phenytoin	drug	_	fludrocortisone acetate	drug	_	mechanism	drugn , druga , or drugn increased metabolic clearance of drugb because of the induction of hepatic enzymes .
DDI-DrugBank.d526.s17.p5	rifampin	drug	_	fludrocortisone acetate	drug	_	mechanism	drugn , drugn , or druga increased metabolic clearance of drugb because of the induction of hepatic enzymes .
DDI-DrugBank.d526.s24.p0	estrogen	group	_	corticosteroid	group	_	false	when druga therapy is initiated , a reduction in drugb dosage may be required , and increased amounts may be required when drugn is terminated .
DDI-DrugBank.d526.s24.p2	corticosteroid	group	_	estrogen	group	_	false	when drugn therapy is initiated , a reduction in druga dosage may be required , and increased amounts may be required when drugb is terminated .
DDI-DrugBank.d234.s0.p0	central nervous system depressants	group	_	benzodiazepines	group	_	false	interaction with druga other than drugb has not been specifically studied ;
DDI-DrugBank.d234.s1.p0	ROMAZICON	brand	_	narcotics	group	_	false	however , no deleterious interactions were seen when druga was administered after drugb , inhalational drugn , drugn and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .
DDI-DrugBank.d234.s1.p1	ROMAZICON	brand	_	anesthetics	group	_	false	however , no deleterious interactions were seen when druga was administered after drugn , inhalational drugb , drugn and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .
DDI-DrugBank.d234.s1.p2	ROMAZICON	brand	_	muscle relaxants	group	_	false	however , no deleterious interactions were seen when druga was administered after drugn , inhalational drugn , drugb and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .
DDI-DrugBank.d234.s2.p0	ROMAZICON	brand	_	cyclic antidepressants	group	_	effect	particular caution is necessary when using druga in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially drugb -rcb- may emerge with the reversal of the drugn effect by drugn .
DDI-DrugBank.d234.s2.p1	ROMAZICON	brand	_	benzodiazepine	group	_	false	particular caution is necessary when using druga in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially drugn -rcb- may emerge with the reversal of the drugb effect by drugn .
DDI-DrugBank.d234.s2.p2	ROMAZICON	brand	_	flumazenil	drug	_	false	particular caution is necessary when using druga in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially drugn -rcb- may emerge with the reversal of the drugn effect by drugb .
DDI-DrugBank.d234.s2.p3	cyclic antidepressants	group	_	benzodiazepine	group	_	false	particular caution is necessary when using drugn in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially druga -rcb- may emerge with the reversal of the drugb effect by drugn .
DDI-DrugBank.d234.s2.p4	cyclic antidepressants	group	_	flumazenil	drug	_	false	particular caution is necessary when using drugn in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially druga -rcb- may emerge with the reversal of the drugn effect by drugb .
DDI-DrugBank.d234.s2.p5	benzodiazepine	group	_	flumazenil	drug	_	false	particular caution is necessary when using drugn in cases of mixed drug overdosage since the toxic effects -lcb- such as convulsions and cardiac dysrhythmias -rcb- of other drugs taken in overdose -lcb- especially drugn -rcb- may emerge with the reversal of the druga effect by drugb .
DDI-DrugBank.d234.s6.p0	zopiclone	drug	_	ROMAZICON	brand	_	effect	the effects of nonbenzodiazepine agonists at benzodiazepine receptors , such as druga , triazolopyridazines and others , are also blocked by drugb .
DDI-DrugBank.d234.s7.p0	benzodiazepines	group	_	flumazenil	drug	_	false	the pharmacokinetics of druga are unaltered in the presence of drugb and vice versa .
DDI-DrugBank.d234.s8.p0	ethanol	drug	_	flumazenil	drug	_	false	there is no pharmacokinetic interaction between druga and drugb .
DDI-DrugBank.d234.s9.p0	ROMAZICON	brand	_	long-acting benzodiazepine	group	_	false	use in ambulatory patients the effects of druga may wear off before a drugb is completely cleared from the body .
DDI-DrugBank.d234.s11.p1	long-acting benzodiazepines	group	_	short-acting benzodiazepines	group	_	false	an adequate period of observation must be provided for any patient in whom either druga -lcb- such as drugn -rcb- or large doses of drugb -lcb- such as # mg of drugn -rcb- have been used .
DDI-DrugBank.d234.s11.p2	long-acting benzodiazepines	group	_	midazolam	drug	_	false	an adequate period of observation must be provided for any patient in whom either druga -lcb- such as drugn -rcb- or large doses of drugn -lcb- such as # mg of drugb -rcb- have been used .
DDI-DrugBank.d234.s11.p3	diazepam	drug	_	short-acting benzodiazepines	group	_	false	an adequate period of observation must be provided for any patient in whom either drugn -lcb- such as druga -rcb- or large doses of drugb -lcb- such as # mg of drugn -rcb- have been used .
DDI-DrugBank.d234.s11.p4	diazepam	drug	_	midazolam	drug	_	false	an adequate period of observation must be provided for any patient in whom either drugn -lcb- such as druga -rcb- or large doses of drugn -lcb- such as # mg of drugb -rcb- have been used .
DDI-DrugBank.d234.s11.p5	short-acting benzodiazepines	group	_	midazolam	drug	_	false	an adequate period of observation must be provided for any patient in whom either drugn -lcb- such as drugn -rcb- or large doses of druga -lcb- such as # mg of drugb -rcb- have been used .
DDI-DrugBank.d234.s12.p3	benzodiazepines	group	_	ROMAZICON	brand	_	false	because of the increased risk of adverse reactions in patients who have been taking druga on a regular basis , it is particularly important that physicians query patients or their guardians carefully about drugn , drugn and drugn use as part of the history prior to any procedure in which the use of drugb is planned .
DDI-DrugBank.d234.s12.p6	benzodiazepine	group	_	ROMAZICON	brand	_	false	because of the increased risk of adverse reactions in patients who have been taking drugn on a regular basis , it is particularly important that physicians query patients or their guardians carefully about druga , drugn and drugn use as part of the history prior to any procedure in which the use of drugb is planned .
DDI-DrugBank.d234.s12.p8	alcohol	drug	_	ROMAZICON	brand	_	false	because of the increased risk of adverse reactions in patients who have been taking drugn on a regular basis , it is particularly important that physicians query patients or their guardians carefully about drugn , druga and drugn use as part of the history prior to any procedure in which the use of drugb is planned .
DDI-DrugBank.d234.s12.p9	sedative	group	_	ROMAZICON	brand	_	false	because of the increased risk of adverse reactions in patients who have been taking drugn on a regular basis , it is particularly important that physicians query patients or their guardians carefully about drugn , drugn and druga use as part of the history prior to any procedure in which the use of drugb is planned .
DDI-DrugBank.d482.s1.p0	antibiotics	group	_	erythromycin	drug	_	false	talk to your doctor if you are taking certain druga such as drugb , drugn or drugn .
DDI-DrugBank.d482.s1.p1	antibiotics	group	_	clarithromycin	drug	_	false	talk to your doctor if you are taking certain druga such as drugn , drugb or drugn .
DDI-DrugBank.d482.s1.p2	antibiotics	group	_	azithromycin	drug	_	false	talk to your doctor if you are taking certain druga such as drugn , drugn or drugb .
DDI-DrugBank.d482.s3.p0	antibiotics	group	_	erythromycin	drug	_	false	caution should be exercised when taking this medicine certain druga , such as drugb , drugn , or drugn .
DDI-DrugBank.d482.s3.p1	antibiotics	group	_	clarithromycin	drug	_	false	caution should be exercised when taking this medicine certain druga , such as drugn , drugb , or drugn .
DDI-DrugBank.d482.s3.p2	antibiotics	group	_	azithromycin	drug	_	false	caution should be exercised when taking this medicine certain druga , such as drugn , drugn , or drugb .
DDI-DrugBank.d482.s9.p0	escitalopram	drug	_	non-selective MAO inhibitor	group	_	advise	wait # weeks after stopping druga before starting a drugb .
DDI-DrugBank.d482.s10.p0	MAO inhibitor	group	_	escitalopram	drug	_	advise	wait # weeks after stopping an druga before starting drugb .
DDI-DrugBank.d482.s14.p0	blood thinner	group	_	Coumadin	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugb -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p1	blood thinner	group	_	antidepressants	group	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugb drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p2	blood thinner	group	_	metoprolol	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugb drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p3	blood thinner	group	_	antihistamines	group	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugb drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p4	blood thinner	group	_	carbamazepine	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugb -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p5	blood thinner	group	_	Tegretol	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p6	blood thinner	group	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p7	blood thinner	group	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p8	blood thinner	group	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p9	blood thinner	group	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p10	blood thinner	group	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p11	blood thinner	group	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p12	blood thinner	group	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p13	blood thinner	group	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p14	blood thinner	group	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p15	blood thinner	group	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p16	blood thinner	group	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : druga s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p17	Coumadin	brand	_	antidepressants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugb drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p18	Coumadin	brand	_	metoprolol	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugb drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p19	Coumadin	brand	_	antihistamines	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugb drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p20	Coumadin	brand	_	carbamazepine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugb -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p21	Coumadin	brand	_	Tegretol	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p22	Coumadin	brand	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p23	Coumadin	brand	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p24	Coumadin	brand	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p25	Coumadin	brand	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p26	Coumadin	brand	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p27	Coumadin	brand	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p28	Coumadin	brand	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p29	Coumadin	brand	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p30	Coumadin	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p31	Coumadin	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p32	Coumadin	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- druga -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p33	antidepressants	group	_	metoprolol	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugb drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p34	antidepressants	group	_	antihistamines	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugb drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p35	antidepressants	group	_	carbamazepine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugb -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p36	antidepressants	group	_	Tegretol	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p37	antidepressants	group	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p38	antidepressants	group	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p39	antidepressants	group	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p40	antidepressants	group	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p41	antidepressants	group	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p42	antidepressants	group	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p43	antidepressants	group	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p44	antidepressants	group	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p45	antidepressants	group	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p46	antidepressants	group	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p47	antidepressants	group	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other druga drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p48	metoprolol	drug	_	antihistamines	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugb drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p49	metoprolol	drug	_	carbamazepine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugb -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p50	metoprolol	drug	_	Tegretol	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p51	metoprolol	drug	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p52	metoprolol	drug	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p53	metoprolol	drug	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p54	metoprolol	drug	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p55	metoprolol	drug	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p56	metoprolol	drug	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p57	metoprolol	drug	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p58	metoprolol	drug	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p59	metoprolol	drug	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p60	metoprolol	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p61	metoprolol	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn druga drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p62	antihistamines	group	_	carbamazepine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugb -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p63	antihistamines	group	_	Tegretol	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p64	antihistamines	group	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p65	antihistamines	group	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p66	antihistamines	group	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p67	antihistamines	group	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p68	antihistamines	group	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p69	antihistamines	group	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p70	antihistamines	group	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p71	antihistamines	group	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p72	antihistamines	group	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p73	antihistamines	group	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p74	antihistamines	group	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn druga drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p76	carbamazepine	drug	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p77	carbamazepine	drug	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p78	carbamazepine	drug	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p79	carbamazepine	drug	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p80	carbamazepine	drug	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p81	carbamazepine	drug	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p82	carbamazepine	drug	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p83	carbamazepine	drug	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p84	carbamazepine	drug	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p85	carbamazepine	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p86	carbamazepine	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn druga -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p87	Tegretol	brand	_	cimetidine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugb -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p88	Tegretol	brand	_	Tagamet	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugb -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p89	Tegretol	brand	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p90	Tegretol	brand	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p91	Tegretol	brand	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p92	Tegretol	brand	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p93	Tegretol	brand	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p94	Tegretol	brand	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p95	Tegretol	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p96	Tegretol	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p97	Tegretol	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p99	cimetidine	drug	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p100	cimetidine	drug	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p101	cimetidine	drug	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p102	cimetidine	drug	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p103	cimetidine	drug	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p104	cimetidine	drug	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p105	cimetidine	drug	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p106	cimetidine	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p107	cimetidine	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p108	Tagamet	brand	_	estrogens	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugb drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p109	Tagamet	brand	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p110	Tagamet	brand	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p111	Tagamet	brand	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p112	Tagamet	brand	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p113	Tagamet	brand	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p114	Tagamet	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p115	Tagamet	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p116	Tagamet	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p117	estrogens	group	_	fluoxetine	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugb -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p118	estrogens	group	_	Prozac	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugb -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p119	estrogens	group	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p120	estrogens	group	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p121	estrogens	group	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p122	estrogens	group	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p123	estrogens	group	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p124	estrogens	group	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p126	fluoxetine	drug	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p127	fluoxetine	drug	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p128	fluoxetine	drug	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p129	fluoxetine	drug	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p130	fluoxetine	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p131	fluoxetine	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p132	Prozac	brand	_	Sporanox	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugb -rcb- drugn -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p133	Prozac	brand	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugn -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p134	Prozac	brand	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p135	Prozac	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p136	Prozac	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p137	Prozac	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- druga -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p138	Sporanox	brand	_	ketoconazole	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- druga -rcb- drugb -lcb- drugn -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p139	Sporanox	brand	_	Nizoral	brand	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- druga -rcb- drugn -lcb- drugb -rcb- drugn drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p140	Sporanox	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p141	Sporanox	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p142	Sporanox	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- druga -rcb- drugn -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p144	ketoconazole	drug	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p145	ketoconazole	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p146	ketoconazole	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- druga -lcb- drugn -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p147	Nizoral	brand	_	levodopa	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugb drugn drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p148	Nizoral	brand	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p149	Nizoral	brand	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- druga -rcb- drugn drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p150	levodopa	drug	_	lithium	drug	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugb drugn birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p151	levodopa	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- druga drugn drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d482.s14.p152	lithium	drug	_	muscle relaxants	group	_	false	tell your doctor if you are taking any of the following drugs : drugn s -lcb- drugn -rcb- other drugn drugn drugn drugn -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn drugn -lcb- drugn -rcb- sporal -lcb- drugn -rcb- drugn -lcb- drugn -rcb- drugn druga drugb birth control pills sleeping pills thyroid medications
DDI-DrugBank.d355.s2.p0	oxyphenbutazone	drug	_	androgens	group	_	mechanism	concurrent administration of druga and drugb may result in elevated serum levels of drugn .
DDI-DrugBank.d355.s2.p2	androgens	group	_	oxyphenbutazone	drug	_	false	concurrent administration of drugn and druga may result in elevated serum levels of drugb .
DDI-DrugBank.d355.s3.p0	androgens	group	_	insulin	drug	_	effect	in diabetic patients , the metabolic effects of druga may decrease blood glucose and therefore , drugb requirements .
DDI-DrugBank.d13.s0.p0	Flupenthixol	drug	_	Monoamine oxidase inhibitors	group	_	int	drug interactions : druga may interact with some drugs , like drugb -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p1	Flupenthixol	drug	_	MAOI	group	_	int	drug interactions : druga may interact with some drugs , like drugn -lcb- drugb -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p30	MAOI	group	_	flupenthixol	drug	_	effect	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : druga could theoretically affect drugb pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p31	MAOI	group	_	Arecoline	drug_n	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : druga could theoretically affect drugn pharmacodynamics - drugb - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p32	MAOI	group	_	Ethanol	drug	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : druga could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugb : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p38	flupenthixol	drug	_	Arecoline	drug_n	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect druga pharmacodynamics - drugb - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p39	flupenthixol	drug	_	Ethanol	drug	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect druga pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugb : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p45	Arecoline	drug_n	_	Ethanol	drug	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - druga - jzqyavbxjcqsok_uhfffaoysa_n - drugb : drugn and drugn cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p56	Flupenthixol	drug	_	Ethanol	drug	_	effect	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : druga and drugb cause additive cns depression - drugn : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p57	Flupenthixol	drug	_	Tricyclic antidepressants	group	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : druga and drugn cause additive cns depression - drugb : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p60	Ethanol	drug	_	Tricyclic antidepressants	group	_	false	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and druga cause additive cns depression - drugb : drugn increases the effect of drugn
DDI-DrugBank.d13.s0.p65	Flupenthixol	drug	_	Tricyclic antidepressants	group	_	effect	drug interactions : drugn may interact with some drugs , like drugn -lcb- drugn -rcb- : drugn could theoretically affect drugn pharmacodynamics - drugn - jzqyavbxjcqsok_uhfffaoysa_n - drugn : drugn and drugn cause additive cns depression - drugn : druga increases the effect of drugb
DDI-DrugBank.d529.s0.p0	Antacids	group	_	flurbiprofen	drug	_	false	druga : administration of drugb to volunteers under fasting conditions , or with drugn suspension yielded similar serum drugn time profiles in young subjects -lcb- n = 12 -rcb- .
DDI-DrugBank.d529.s0.p2	Antacids	group	_	flurbiprofen	drug	_	false	druga : administration of drugn to volunteers under fasting conditions , or with drugn suspension yielded similar serum drugb time profiles in young subjects -lcb- n = 12 -rcb- .
DDI-DrugBank.d529.s0.p3	flurbiprofen	drug	_	antacid	group	_	false	drugn : administration of druga to volunteers under fasting conditions , or with drugb suspension yielded similar serum drugn time profiles in young subjects -lcb- n = 12 -rcb- .
DDI-DrugBank.d529.s0.p5	antacid	group	_	flurbiprofen	drug	_	false	drugn : administration of drugn to volunteers under fasting conditions , or with druga suspension yielded similar serum drugb time profiles in young subjects -lcb- n = 12 -rcb- .
DDI-DrugBank.d529.s2.p0	Anticoagulants	group	_	Flurbiprofen	drug	_	false	druga : drugb like other drugn , has been shown to affect bleeding parameters in patients receiving drugn , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s2.p1	Anticoagulants	group	_	nonsteroidal anti-inflammatory drugs	group	_	false	druga : drugn like other drugb , has been shown to affect bleeding parameters in patients receiving drugn , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s2.p2	Anticoagulants	group	_	anti-coagulants	group	_	false	druga : drugn like other drugn , has been shown to affect bleeding parameters in patients receiving drugb , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s2.p3	Flurbiprofen	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	drugn : druga like other drugb , has been shown to affect bleeding parameters in patients receiving drugn , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s2.p4	Flurbiprofen	drug	_	anti-coagulants	group	_	effect	drugn : druga like other drugn , has been shown to affect bleeding parameters in patients receiving drugb , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s2.p5	nonsteroidal anti-inflammatory drugs	group	_	anti-coagulants	group	_	effect	drugn : drugn like other druga , has been shown to affect bleeding parameters in patients receiving drugb , and serious clinical bleeding has been reported .
DDI-DrugBank.d529.s3.p0	flurbiprofen	drug	_	anticoagulants	group	_	advise	the physician should be cautious when administering druga to patients taking drugb .
DDI-DrugBank.d529.s4.p1	Aspirin	brand	_	flurbiprofen	drug	_	false	druga : concurrent administration of drugn and drugb resulted in 50 % lower serum drugn concentrations .
DDI-DrugBank.d529.s4.p2	Aspirin	brand	_	flurbiprofen	drug	_	false	druga : concurrent administration of drugn and drugn resulted in 50 % lower serum drugb concentrations .
DDI-DrugBank.d529.s4.p3	aspirin	brand	_	flurbiprofen	drug	_	mechanism	drugn : concurrent administration of druga and drugb resulted in 50 % lower serum drugn concentrations .
DDI-DrugBank.d529.s4.p4	aspirin	brand	_	flurbiprofen	drug	_	false	drugn : concurrent administration of druga and drugn resulted in 50 % lower serum drugb concentrations .
DDI-DrugBank.d529.s5.p0	aspirin	brand	_	nonsteroidal anti-inflammatory drugs	group	_	false	this effect of druga -lcb- which also lowers serum concentrations of other drugb given with it -rcb- has been demonstrated in patients with rheumatoid_arthritis -lcb- n = 15 -rcb- as well as normal volunteers -lcb- n = 16 -rcb- .
DDI-DrugBank.d529.s6.p0	flurbiprofen	drug	_	aspirin	brand	_	advise	concurrent use of druga and drugb is therefore not recommended .
DDI-DrugBank.d529.s7.p3	flurbiprofen	drug	_	propranolol	drug	_	false	drugn : the effect of druga on blood pressure response to drugb and drugn was evaluated in men with mild uncomplicated hypertension -lcb- n = 10 -rcb- .
DDI-DrugBank.d529.s7.p4	flurbiprofen	drug	_	atenolol	drug	_	false	drugn : the effect of druga on blood pressure response to drugn and drugb was evaluated in men with mild uncomplicated hypertension -lcb- n = 10 -rcb- .
DDI-DrugBank.d529.s7.p5	propranolol	drug	_	atenolol	drug	_	false	drugn : the effect of drugn on blood pressure response to druga and drugb was evaluated in men with mild uncomplicated hypertension -lcb- n = 10 -rcb- .
DDI-DrugBank.d529.s8.p0	Flurbiprofen	drug	_	propranolol	drug	_	effect	druga pretreatment attenuated the hypotensive effect of a single dose of drugb but not drugn .
DDI-DrugBank.d529.s8.p1	Flurbiprofen	drug	_	atenolol	drug	_	false	druga pretreatment attenuated the hypotensive effect of a single dose of drugn but not drugb .
DDI-DrugBank.d529.s8.p2	propranolol	drug	_	atenolol	drug	_	false	drugn pretreatment attenuated the hypotensive effect of a single dose of druga but not drugb .
DDI-DrugBank.d529.s10.p0	Flurbiprofen	drug	_	propranolol	drug	_	int	druga did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with drugb s hypotensive effect is unknown .
DDI-DrugBank.d529.s11.p0	flurbiprofen	drug	_	beta-blocker	group	_	advise	patients taking both druga and a drugb should be monitored to ensure that a satisfactory hypotensive effect is achieved .
DDI-DrugBank.d529.s12.p0	Cimetidine	drug	_	Ranitidine	drug	_	false	druga , drugb : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p2	Cimetidine	drug	_	ranitidine	drug	_	false	druga , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugb did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p3	Cimetidine	drug	_	flurbiprofen	drug	_	false	druga , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugb pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p4	Cimetidine	drug	_	flurbiprofen	drug	_	false	druga , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugb resulted with drugn .
DDI-DrugBank.d529.s12.p6	Ranitidine	drug	_	cimetidine	drug	_	false	drugn , druga : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugb or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p8	Ranitidine	drug	_	flurbiprofen	drug	_	false	drugn , druga : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugb pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p9	Ranitidine	drug	_	flurbiprofen	drug	_	false	drugn , druga : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugb resulted with drugn .
DDI-DrugBank.d529.s12.p10	Ranitidine	drug	_	cimetidine	drug	_	false	drugn , druga : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugb .
DDI-DrugBank.d529.s12.p11	cimetidine	drug	_	ranitidine	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with druga or drugb did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p12	cimetidine	drug	_	flurbiprofen	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with druga or drugn did not affect drugb pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p13	cimetidine	drug	_	flurbiprofen	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with druga or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugb resulted with drugn .
DDI-DrugBank.d529.s12.p15	ranitidine	drug	_	flurbiprofen	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or druga did not affect drugb pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugn .
DDI-DrugBank.d529.s12.p16	ranitidine	drug	_	flurbiprofen	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or druga did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugb resulted with drugn .
DDI-DrugBank.d529.s12.p17	ranitidine	drug	_	cimetidine	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or druga did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugb .
DDI-DrugBank.d529.s12.p19	flurbiprofen	drug	_	cimetidine	drug	_	false	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect druga pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of drugn resulted with drugb .
DDI-DrugBank.d529.s12.p20	flurbiprofen	drug	_	cimetidine	drug	_	mechanism	drugn , drugn : in normal volunteers -lcb- n = 9 -rcb- , pretreatment with drugn or drugn did not affect drugn pharmacokinetics except that a small -lcb- 13 % -rcb- but statistically significant increase in the area under the serum concentration curve of druga resulted with drugb .
DDI-DrugBank.d529.s13.p2	flurbiprofen	drug	_	digoxin	drug	_	false	drugn : studies of concomitant administration of druga and drugb to healthy men -lcb- n = 14 -rcb- did not show a change in the steady state serum levels of either drug .
DDI-DrugBank.d529.s14.p3	flurbiprofen	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	drugn : studies in normal volunteers have shown that druga like other drugb , can interfere with the effects of drugn .
DDI-DrugBank.d529.s14.p4	flurbiprofen	drug	_	furosemide	drug	_	effect	drugn : studies in normal volunteers have shown that druga like other drugn , can interfere with the effects of drugb .
DDI-DrugBank.d529.s14.p5	nonsteroidal anti-inflammatory drugs	group	_	furosemide	drug	_	effect	drugn : studies in normal volunteers have shown that drugn like other druga , can interfere with the effects of drugb .
DDI-DrugBank.d529.s16.p0	nonsteroidal anti-inflammatory drugs	group	_	thiazide diuretics	group	_	effect	other druga that inhibit prostaglandin synthesis have been shown to interfere with drugb in some studies and with drugn .
DDI-DrugBank.d529.s16.p1	nonsteroidal anti-inflammatory drugs	group	_	potassium-sparing diuretics	group	_	effect	other druga that inhibit prostaglandin synthesis have been shown to interfere with drugn in some studies and with drugb .
DDI-DrugBank.d529.s16.p2	thiazide diuretics	group	_	potassium-sparing diuretics	group	_	false	other drugn that inhibit prostaglandin synthesis have been shown to interfere with druga in some studies and with drugb .
DDI-DrugBank.d529.s18.p0	Hypoglycemic Agents	group	_	flurbiprofen	drug	_	false	oral druga : in one study , drugb was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p1	Hypoglycemic Agents	group	_	glyburide	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugb -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p2	Hypoglycemic Agents	group	_	metformin	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugb -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p3	Hypoglycemic Agents	group	_	chlorpropamide	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugb with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p4	Hypoglycemic Agents	group	_	phenformin	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugb -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p5	Hypoglycemic Agents	group	_	glyburide	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugb with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p6	Hypoglycemic Agents	group	_	phenformin	drug	_	false	oral druga : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p7	flurbiprofen	drug	_	glyburide	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugb -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p8	flurbiprofen	drug	_	metformin	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugb -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p9	flurbiprofen	drug	_	chlorpropamide	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugb with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p10	flurbiprofen	drug	_	phenformin	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugb -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p11	flurbiprofen	drug	_	glyburide	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugb with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p12	flurbiprofen	drug	_	phenformin	drug	_	false	oral drugn : in one study , druga was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p13	glyburide	drug	_	metformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving druga -lcb- n = 4 -rcb- , drugb -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p14	glyburide	drug	_	chlorpropamide	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving druga -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugb with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p15	glyburide	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving druga -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugb -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p17	glyburide	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving druga -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p18	metformin	drug	_	chlorpropamide	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , druga -lcb- n = 2 -rcb- drugb with drugn -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p19	metformin	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , druga -lcb- n = 2 -rcb- drugn with drugb -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p20	metformin	drug	_	glyburide	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , druga -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugb with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p21	metformin	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , druga -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or drugn with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p22	chlorpropamide	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- druga with drugb -lcb- n = 3 -rcb- or drugn with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p23	chlorpropamide	drug	_	glyburide	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- druga with drugn -lcb- n = 3 -rcb- or drugb with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p24	chlorpropamide	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- druga with drugn -lcb- n = 3 -rcb- or drugn with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p25	phenformin	drug	_	glyburide	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with druga -lcb- n = 3 -rcb- or drugb with drugn -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s18.p27	glyburide	drug	_	phenformin	drug	_	false	oral drugn : in one study , drugn was given to adult diabetics who were already receiving drugn -lcb- n = 4 -rcb- , drugn -lcb- n = 2 -rcb- drugn with drugn -lcb- n = 3 -rcb- or druga with drugb -lcb- n = 6 -rcb- .
DDI-DrugBank.d529.s19.p0	flurbiprofen	drug	_	hypoglycemic agents	group	_	effect	although there was a slight reduction in blood sugar concentrations during concomitant administration of druga and drugb , there were no signs or symptoms of hypoglycemia .
DDI-DrugBank.d442.s0.p0	warfarin	drug	_	flutamide	drug	_	effect	increases in prothrombin time have been noted in patients receiving long - term druga therapy after drugb was initiated .
DDI-DrugBank.d442.s1.p0	anticoagulant	group	_	EULEXIN	brand	_	false	therefore , close monitoring of prothrombin time is recommended and adjustment of the druga dose may be necessary when drugb capsules are administered concomitantly with drugn .
DDI-DrugBank.d442.s1.p1	anticoagulant	group	_	warfarin	drug	_	false	therefore , close monitoring of prothrombin time is recommended and adjustment of the druga dose may be necessary when drugn capsules are administered concomitantly with drugb .
DDI-DrugBank.d442.s1.p2	EULEXIN	brand	_	warfarin	drug	_	advise	therefore , close monitoring of prothrombin time is recommended and adjustment of the drugn dose may be necessary when druga capsules are administered concomitantly with drugb .
DDI-DrugBank.d76.s1.p0	serotonin reuptake inhibitor drug	group	_	monoamine oxidase inhibitors	group	_	effect	in patients receiving another druga in combination with drugb -lcb- drugn -rcb- , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .
DDI-DrugBank.d76.s1.p1	serotonin reuptake inhibitor drug	group	_	MAOI	group	_	effect	in patients receiving another druga in combination with drugn -lcb- drugb -rcb- , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .
DDI-DrugBank.d76.s4.p0	Fluvoxamine	drug	_	MAOIs	group	_	advise	therefore , it is recommended that druga tablets not be used in combination with drugb , or within # days of discontinuing treatment with a drugn .
DDI-DrugBank.d76.s4.p1	Fluvoxamine	drug	_	MAOI	group	_	advise	therefore , it is recommended that druga tablets not be used in combination with drugn , or within # days of discontinuing treatment with a drugb .
DDI-DrugBank.d76.s5.p0	Fluvoxamine	drug	_	MAOI	group	_	advise	after stopping druga tablets , at least # weeks should be allowed before starting a drugb .
DDI-DrugBank.d76.s6.p0	Terfenadine	drug	_	Astemizole	drug	_	false	potential druga , drugb , and drugn interactions
DDI-DrugBank.d76.s6.p1	Terfenadine	drug	_	Cisapride	drug	_	false	potential druga , drugn , and drugb interactions
DDI-DrugBank.d76.s6.p2	Astemizole	drug	_	Cisapride	drug	_	false	potential drugn , druga , and drugb interactions
DDI-DrugBank.d76.s7.p2	Terfenadine	drug	_	ketoconazole	drug	_	mechanism	druga , drugn and drugn are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that drugb , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .
DDI-DrugBank.d76.s7.p4	astemizole	drug	_	ketoconazole	drug	_	mechanism	drugn , druga and drugn are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that drugb , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .
DDI-DrugBank.d76.s7.p5	cisapride	drug	_	ketoconazole	drug	_	mechanism	drugn , drugn and druga are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that drugb , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .
DDI-DrugBank.d76.s9.p0	fluvoxamine	drug	_	alprazolam	drug	_	false	as noted below , a sub - for druga in combination with drugb , a drug that is known to be metabolized by the iiia4 isozyme .
DDI-DrugBank.d76.s10.p1	fluvoxamine	drug	_	alprazolam	drug	_	false	although it has not been definitively demonstrated that druga is a potent iiia4 inhibitor , it is likely to be , given the substantial interaction of drugn with drugb .
DDI-DrugBank.d76.s10.p2	fluvoxamine	drug	_	alprazolam	drug	_	int	although it has not been definitively demonstrated that drugn is a potent iiia4 inhibitor , it is likely to be , given the substantial interaction of druga with drugb .
DDI-DrugBank.d76.s11.p0	fluvoxamine	drug	_	terbinafine	drug	_	advise	consequently , it is recommended that druga not be used in combination with either drugb , drugn , or drugn .
DDI-DrugBank.d76.s11.p1	fluvoxamine	drug	_	astemizole	drug	_	advise	consequently , it is recommended that druga not be used in combination with either drugn , drugb , or drugn .
DDI-DrugBank.d76.s11.p2	fluvoxamine	drug	_	cisapride	drug	_	advise	consequently , it is recommended that druga not be used in combination with either drugn , drugn , or drugb .
DDI-DrugBank.d76.s12.p5	Benzodiazepines	group	_	alprazolam	drug	_	false	other potentially important drug interactions : drugn : druga metabolized by hepatic oxidation -lcb- e , g , , drugb , drugn , drugn elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugn .
DDI-DrugBank.d76.s12.p6	Benzodiazepines	group	_	midazolam	drug	_	false	other potentially important drug interactions : drugn : druga metabolized by hepatic oxidation -lcb- e , g , , drugn , drugb , drugn elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugn .
DDI-DrugBank.d76.s12.p7	Benzodiazepines	group	_	triazolam	drug	_	false	other potentially important drug interactions : drugn : druga metabolized by hepatic oxidation -lcb- e , g , , drugn , drugn , drugb elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugn .
DDI-DrugBank.d76.s12.p8	Benzodiazepines	group	_	fluvoxamine	drug	_	mechanism	other potentially important drug interactions : drugn : druga metabolized by hepatic oxidation -lcb- e , g , , drugn , drugn , drugn elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugb .
DDI-DrugBank.d76.s12.p11	alprazolam	drug	_	fluvoxamine	drug	_	mechanism	other potentially important drug interactions : drugn : drugn metabolized by hepatic oxidation -lcb- e , g , , druga , drugn , drugn elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugb .
DDI-DrugBank.d76.s12.p13	midazolam	drug	_	fluvoxamine	drug	_	mechanism	other potentially important drug interactions : drugn : drugn metabolized by hepatic oxidation -lcb- e , g , , drugn , druga , drugn elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugb .
DDI-DrugBank.d76.s12.p14	triazolam	drug	_	fluvoxamine	drug	_	mechanism	other potentially important drug interactions : drugn : drugn metabolized by hepatic oxidation -lcb- e , g , , drugn , drugn , druga elc , -rcb- should be used with caution because the clearance of these drugs is likely to be reduced by drugb .
DDI-DrugBank.d76.s13.p0	benzodiazepines	group	_	lorazepam	drug	_	false	the clearance of druga metabolized by glucuronidation -lcb- e , g , , drugb , drugn , drugn -rcb- is unlikely to be affected by drugn .
DDI-DrugBank.d76.s13.p1	benzodiazepines	group	_	oxazepam	drug	_	false	the clearance of druga metabolized by glucuronidation -lcb- e , g , , drugn , drugb , drugn -rcb- is unlikely to be affected by drugn .
DDI-DrugBank.d76.s13.p2	benzodiazepines	group	_	temazepam	drug	_	false	the clearance of druga metabolized by glucuronidation -lcb- e , g , , drugn , drugn , drugb -rcb- is unlikely to be affected by drugn .
DDI-DrugBank.d76.s13.p3	benzodiazepines	group	_	fluvoxamine	drug	_	false	the clearance of druga metabolized by glucuronidation -lcb- e , g , , drugn , drugn , drugn -rcb- is unlikely to be affected by drugb .
DDI-DrugBank.d76.s13.p6	lorazepam	drug	_	fluvoxamine	drug	_	false	the clearance of drugn metabolized by glucuronidation -lcb- e , g , , druga , drugn , drugn -rcb- is unlikely to be affected by drugb .
DDI-DrugBank.d76.s13.p8	oxazepam	drug	_	fluvoxamine	drug	_	false	the clearance of drugn metabolized by glucuronidation -lcb- e , g , , drugn , druga , drugn -rcb- is unlikely to be affected by drugb .
DDI-DrugBank.d76.s13.p9	temazepam	drug	_	fluvoxamine	drug	_	false	the clearance of drugn metabolized by glucuronidation -lcb- e , g , , drugn , drugn , druga -rcb- is unlikely to be affected by drugb .
DDI-DrugBank.d76.s14.p4	fluvoxamine maleate	drug	_	alprazolam	drug	_	mechanism	drugn : when druga -lcb- 100 mg qd -rcb- and drugb -lcb- 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters -lcb- auc , cmax , t1/2 , -rcb- of drugn were approximately twice those observed when drugn was administered alone ;
DDI-DrugBank.d76.s14.p5	fluvoxamine maleate	drug	_	alprazolam	drug	_	false	drugn : when druga -lcb- 100 mg qd -rcb- and drugn -lcb- 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters -lcb- auc , cmax , t1/2 , -rcb- of drugb were approximately twice those observed when drugn was administered alone ;
DDI-DrugBank.d76.s14.p6	fluvoxamine maleate	drug	_	alprazolam	drug	_	false	drugn : when druga -lcb- 100 mg qd -rcb- and drugn -lcb- 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters -lcb- auc , cmax , t1/2 , -rcb- of drugn were approximately twice those observed when drugb was administered alone ;
DDI-DrugBank.d76.s17.p7	alprazolam	drug	_	Fluvoxamine	drug	_	advise	this interaction , which has not been investigated using higher doses of drugn , may be more pronounced if a # mg daily dose is co-administered , particularly since drugn exhibits non-linear pharmacokinetics over the dosage range 100-300 mg , if druga is co-administered with drugb tablets , the initial drugn dosage should be at least halved and titration to the lowest effective dose is recommended .
DDI-DrugBank.d76.s17.p9	Fluvoxamine	drug	_	alprazolam	drug	_	false	this interaction , which has not been investigated using higher doses of drugn , may be more pronounced if a # mg daily dose is co-administered , particularly since drugn exhibits non-linear pharmacokinetics over the dosage range 100-300 mg , if drugn is co-administered with druga tablets , the initial drugb dosage should be at least halved and titration to the lowest effective dose is recommended .
DDI-DrugBank.d76.s19.p2	Fluvoxamine	drug	_	diazepam	drug	_	advise	drugn : the co-administration of druga tablets and drugb is generally not advisable .
DDI-DrugBank.d76.s20.p0	fluvoxamine	drug	_	diazepam	drug	_	mechanism	because druga reduces the clearance of both drugb and its active metabolite , drugn , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .
DDI-DrugBank.d76.s20.p1	fluvoxamine	drug	_	N-desmethyldiazepam	drug_n	_	mechanism	because druga reduces the clearance of both drugn and its active metabolite , drugb , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .
DDI-DrugBank.d76.s21.p0	fluvoxamine	drug	_	diazepam	drug	_	advise	evidence supporting the conclusion that it is inadvisable to co-administer druga and drugb is derived from a study in which healthy volunteers taking # mg/day of drugn were administered a single oral dose of # mg of drugn .
DDI-DrugBank.d76.s21.p2	fluvoxamine	drug	_	diazepam	drug	_	false	evidence supporting the conclusion that it is inadvisable to co-administer druga and drugn is derived from a study in which healthy volunteers taking # mg/day of drugn were administered a single oral dose of # mg of drugb .
DDI-DrugBank.d76.s21.p3	diazepam	drug	_	fluvoxamine	drug	_	false	evidence supporting the conclusion that it is inadvisable to co-administer drugn and druga is derived from a study in which healthy volunteers taking # mg/day of drugb were administered a single oral dose of # mg of drugn .
DDI-DrugBank.d76.s21.p5	fluvoxamine	drug	_	diazepam	drug	_	false	evidence supporting the conclusion that it is inadvisable to co-administer drugn and drugn is derived from a study in which healthy volunteers taking # mg/day of druga were administered a single oral dose of # mg of drugb .
DDI-DrugBank.d76.s24.p0	alprazolam	drug	_	fluvoxamine	drug	_	effect	moreover , as noted with druga , the effect of drugb may even be more pronounced when it is administered at higher doses .
DDI-DrugBank.d76.s25.p0	diazepam	drug	_	fluvoxamine	drug	_	advise	accordingly , druga and drugb should not ordinarily be co-administered .
DDI-DrugBank.d76.s26.p3	fluvoxamine	drug	_	Theophylline	drug	_	false	drugn : the effect of steady-state druga l50 mg bid on the pharmacokinetics of a single dose of drugb -lcb- 375 mg -rcb- as # mg drugn was evaluated in # healthy non-smoking , male volunteers .
DDI-DrugBank.d76.s26.p4	fluvoxamine	drug	_	aminophylline	drug	_	false	drugn : the effect of steady-state druga l50 mg bid on the pharmacokinetics of a single dose of drugn -lcb- 375 mg -rcb- as # mg drugb was evaluated in # healthy non-smoking , male volunteers .
DDI-DrugBank.d76.s26.p5	Theophylline	drug	_	aminophylline	drug	_	false	drugn : the effect of steady-state drugn l50 mg bid on the pharmacokinetics of a single dose of druga -lcb- 375 mg -rcb- as # mg drugb was evaluated in # healthy non-smoking , male volunteers .
DDI-DrugBank.d76.s28.p0	theophylline	drug	_	fluvoxamine maleate	drug	_	advise	therefore , if druga is co-administered with drugb , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drugn should to monitored .
DDI-DrugBank.d76.s28.p2	fluvoxamine maleate	drug	_	theophylline	drug	_	false	therefore , if drugn is co-administered with druga , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drugb should to monitored .
DDI-DrugBank.d76.s30.p3	fluvoxamine maleate	drug	_	warfarin	drug	_	mechanism	drugn : when druga -lcb- 50 mg tid -rcb- was administered concomitantly with drugb for two weeks , drugn plasma concentrations increased by 98 % and prothrombin times were prolonged .
DDI-DrugBank.d76.s30.p4	fluvoxamine maleate	drug	_	warfarin	drug	_	false	drugn : when druga -lcb- 50 mg tid -rcb- was administered concomitantly with drugn for two weeks , drugb plasma concentrations increased by 98 % and prothrombin times were prolonged .
DDI-DrugBank.d76.s31.p0	anticoagulants	group	_	Fluvoxamine	drug	_	advise	thus patients receiving oral druga and drugb tablets should have their prothrombin time monitored and their drugn dose adjusted accordingly .
DDI-DrugBank.d76.s31.p2	Fluvoxamine	drug	_	anticoagulant	group	_	false	thus patients receiving oral drugn and druga tablets should have their prothrombin time monitored and their drugb dose adjusted accordingly .
DDI-DrugBank.d425.s1.p2	anticonvulsant medications	group	_	metformin	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugb -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p3	anticonvulsant medications	group	_	sulfasalazine	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugb -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p4	anticonvulsant medications	group	_	triamterene	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugb -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p5	anticonvulsant medications	group	_	diuretic	group	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugb -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p6	anticonvulsant medications	group	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p7	anticonvulsant medications	group	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p8	anticonvulsant medications	group	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : druga -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p10	phenytoin	drug	_	metformin	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugb -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p11	phenytoin	drug	_	sulfasalazine	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugb -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p12	phenytoin	drug	_	triamterene	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugb -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p13	phenytoin	drug	_	diuretic	group	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugb -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p14	phenytoin	drug	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p15	phenytoin	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p16	phenytoin	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as druga , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p17	primidone	drug	_	metformin	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugb -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p18	primidone	drug	_	sulfasalazine	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugb -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p19	primidone	drug	_	triamterene	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugb -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p20	primidone	drug	_	diuretic	group	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugb -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p21	primidone	drug	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p22	primidone	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p23	primidone	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and druga -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p24	metformin	drug	_	sulfasalazine	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugb -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p25	metformin	drug	_	triamterene	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugb -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p26	metformin	drug	_	diuretic	group	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugb -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p27	metformin	drug	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p28	metformin	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p29	metformin	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- druga -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p30	sulfasalazine	drug	_	triamterene	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- druga -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugb -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p31	sulfasalazine	drug	_	diuretic	group	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- druga -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugb -rcb- drugn there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p32	sulfasalazine	drug	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- druga -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p33	sulfasalazine	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- druga -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p34	sulfasalazine	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- druga -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p36	triamterene	drug	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- druga -lcb- a drugn -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p37	triamterene	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- druga -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p38	triamterene	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- druga -lcb- a drugn -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p39	diuretic	group	_	Methotrexate	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a druga -rcb- drugb there has been concern about the interaction between drugn and drugn .
DDI-DrugBank.d425.s1.p40	diuretic	group	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a druga -rcb- drugn there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p41	diuretic	group	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a druga -rcb- drugn there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p42	Methotrexate	drug	_	vitamin B12	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- druga there has been concern about the interaction between drugb and drugn .
DDI-DrugBank.d425.s1.p43	Methotrexate	drug	_	folic acid	drug	_	false	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- druga there has been concern about the interaction between drugn and drugb .
DDI-DrugBank.d425.s1.p44	vitamin B12	drug	_	folic acid	drug	_	int	medications can interfere with folate utilization , including : drugn -lcb- such as drugn , and drugn -rcb- drugn -lcb- sometimes prescribed to control blood sugar in type # diabetes -rcb- drugn -lcb- used to control inflammation associated with crohn_disease and ulcerative colitis -rcb- drugn -lcb- a drugn -rcb- drugn there has been concern about the interaction between druga and drugb .
DDI-DrugBank.d425.s6.p0	folic acid	drug	_	vitamin B12	drug	_	false	it is important for older adults to be aware of the relationship between druga and drugb because they are at greater risk of having a vitamin b12 deficiency .
DDI-DrugBank.d228.s0.p0	Antizol	brand	_	ethanol	drug	_	mechanism	oral doses of druga -lcb- 10-20 mg/kg -rcb- , via akr1a1 inhibition , significantly reduced the rate of elimination of drugb -lcb- by approximately 40 % -rcb- given to healthy volunteers in moderate doses .
DDI-DrugBank.d228.s1.p0	ethanol	drug	_	Antizol	brand	_	mechanism	similarly , druga decreased the rate of elimination of drugb -lcb- by approximately 50 % -rcb- by the same mechanism .
DDI-DrugBank.d228.s2.p0	Antizol	brand	_	phenytoin	drug	_	mechanism	reciprocal interactions may occur with concomitant use of druga and drugs that increase or inhibit the cytochrome cyp2b6 system -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- , though this has not been studied
DDI-DrugBank.d228.s2.p1	Antizol	brand	_	carbamazepine	drug	_	mechanism	reciprocal interactions may occur with concomitant use of druga and drugs that increase or inhibit the cytochrome cyp2b6 system -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- , though this has not been studied
DDI-DrugBank.d228.s2.p2	Antizol	brand	_	cimetidine	drug	_	mechanism	reciprocal interactions may occur with concomitant use of druga and drugs that increase or inhibit the cytochrome cyp2b6 system -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- , though this has not been studied
DDI-DrugBank.d228.s2.p3	Antizol	brand	_	ketoconazole	drug	_	mechanism	reciprocal interactions may occur with concomitant use of druga and drugs that increase or inhibit the cytochrome cyp2b6 system -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- , though this has not been studied
DDI-DrugBank.d15.s0.p0	Fondaparinux	drug	_	anticoagulants	group	_	false	in clinical studies performed with druga , the concomitant use of oral drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p1	Fondaparinux	drug	_	warfarin	drug	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p2	Fondaparinux	drug	_	platelet inhibitors	group	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p3	Fondaparinux	drug	_	acetylsalicylic acid	drug	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p4	Fondaparinux	drug	_	NSAIDs	group	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p5	Fondaparinux	drug	_	piroxicam	drug	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p6	Fondaparinux	drug	_	digoxin	drug	_	false	in clinical studies performed with druga , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugb did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p9	anticoagulants	group	_	platelet inhibitors	group	_	false	in clinical studies performed with drugn , the concomitant use of oral druga -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p10	anticoagulants	group	_	acetylsalicylic acid	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral druga -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p14	anticoagulants	group	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p15	warfarin	drug	_	platelet inhibitors	group	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- druga -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p16	warfarin	drug	_	acetylsalicylic acid	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- druga -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugn .
DDI-DrugBank.d15.s0.p20	warfarin	drug	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p25	platelet inhibitors	group	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p29	acetylsalicylic acid	drug	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , drugn -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p32	NSAIDs	group	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , druga -lcb- drugn -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p34	piroxicam	drug	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- druga -rcb- , and drugn did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s0.p35	digoxin	drug	_	fondaparinux sodium	drug	_	false	in clinical studies performed with drugn , the concomitant use of oral drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and druga did not significantly affect the pharmacokinetics/pharmacodynamics of drugb .
DDI-DrugBank.d15.s1.p0	Fondaparinux	drug	_	warfarin	drug	_	false	in addition , druga neither influenced the pharmacodynamics of drugb , drugn , drugn , and drugn , nor the pharmacokinetics of drugn at steady state .
DDI-DrugBank.d15.s1.p1	Fondaparinux	drug	_	acetylsalicylic acid	drug	_	false	in addition , druga neither influenced the pharmacodynamics of drugn , drugb , drugn , and drugn , nor the pharmacokinetics of drugn at steady state .
DDI-DrugBank.d15.s1.p2	Fondaparinux	drug	_	piroxicam	drug	_	false	in addition , druga neither influenced the pharmacodynamics of drugn , drugn , drugb , and drugn , nor the pharmacokinetics of drugn at steady state .
DDI-DrugBank.d15.s1.p3	Fondaparinux	drug	_	digoxin	drug	_	false	in addition , druga neither influenced the pharmacodynamics of drugn , drugn , drugn , and drugb , nor the pharmacokinetics of drugn at steady state .
DDI-DrugBank.d15.s1.p4	Fondaparinux	drug	_	digoxin	drug	_	false	in addition , druga neither influenced the pharmacodynamics of drugn , drugn , drugn , and drugn , nor the pharmacokinetics of drugb at steady state .
DDI-DrugBank.d15.s1.p8	warfarin	drug	_	digoxin	drug	_	false	in addition , drugn neither influenced the pharmacodynamics of druga , drugn , drugn , and drugn , nor the pharmacokinetics of drugb at steady state .
DDI-DrugBank.d15.s1.p11	acetylsalicylic acid	drug	_	digoxin	drug	_	false	in addition , drugn neither influenced the pharmacodynamics of drugn , druga , drugn , and drugn , nor the pharmacokinetics of drugb at steady state .
DDI-DrugBank.d15.s1.p13	piroxicam	drug	_	digoxin	drug	_	false	in addition , drugn neither influenced the pharmacodynamics of drugn , drugn , druga , and drugn , nor the pharmacokinetics of drugb at steady state .
DDI-DrugBank.d15.s4.p0	coumarin	group	_	fondaparinux	drug	_	mechanism	in an in vitro study in human liver microsomes , inhibition of cyp2a6 hydroxylation of druga by drugb -lcb- 200 m.m. m i , e , , # mg/l -rcb- was 17-28 % .
DDI-DrugBank.d103.s0.p2	bronchodilators	group	_	formoterol	drug	_	false	drugn : aerosol druga of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using drugb .
DDI-DrugBank.d103.s2.p0	sympathomimetic agents	group	_	FORADIL	brand	_	effect	concomitant administration of other druga may potentiate the undesirable effects of drugb .
DDI-DrugBank.d103.s3.p0	Monoamine Oxidase Inhibitors	group	_	Tricyclic Antidepressants	group	_	false	druga and drugb : drugn should be administered with extreme caution in patients being treated with drugn or drugn because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p9	FORADIL	brand	_	monoamine oxidase inhibitors	group	_	advise	drugn and drugn : druga should be administered with extreme caution in patients being treated with drugb or drugn because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p10	FORADIL	brand	_	tricyclic antidepressants	group	_	advise	drugn and drugn : druga should be administered with extreme caution in patients being treated with drugn or drugb because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p11	FORADIL	brand	_	formoterol	drug	_	false	drugn and drugn : druga should be administered with extreme caution in patients being treated with drugn or drugn because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p12	monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	drugn and drugn : drugn should be administered with extreme caution in patients being treated with druga or drugb because the action of drugn on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p13	monoamine oxidase inhibitors	group	_	formoterol	drug	_	false	drugn and drugn : drugn should be administered with extreme caution in patients being treated with druga or drugn because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s3.p14	tricyclic antidepressants	group	_	formoterol	drug	_	false	drugn and drugn : drugn should be administered with extreme caution in patients being treated with drugn or druga because the action of drugb on the cardiovascular system may be potentiated by these agents .
DDI-DrugBank.d103.s4.p2	Corticosteroids	group	_	xanthine derivatives	group	_	false	druga , drugn and drugn : concomitant treatment with drugb , drugn , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p4	Corticosteroids	group	_	diuretics	group	_	false	druga , drugn and drugn : concomitant treatment with drugn , drugn , or drugb may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p5	Corticosteroids	group	_	beta2-agonists.	group	_	false	druga , drugn and drugn : concomitant treatment with drugn , drugn , or drugn may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s4.p6	Methylxanthines	group	_	Diuretics	group	_	false	drugn , druga and drugb : concomitant treatment with drugn , drugn , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p7	Methylxanthines	group	_	xanthine derivatives	group	_	false	drugn , druga and drugn : concomitant treatment with drugb , drugn , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p8	Methylxanthines	group	_	steroids	group	_	false	drugn , druga and drugn : concomitant treatment with drugn , drugb , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p9	Methylxanthines	group	_	diuretics	group	_	false	drugn , druga and drugn : concomitant treatment with drugn , drugn , or drugb may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p10	Methylxanthines	group	_	beta2-agonists.	group	_	false	drugn , druga and drugn : concomitant treatment with drugn , drugn , or drugn may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s4.p11	Diuretics	group	_	xanthine derivatives	group	_	false	drugn , drugn and druga : concomitant treatment with drugb , drugn , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p12	Diuretics	group	_	steroids	group	_	false	drugn , drugn and druga : concomitant treatment with drugn , drugb , or drugn may potentiate a possible hypokalemic effect of drugn
DDI-DrugBank.d103.s4.p14	Diuretics	group	_	beta2-agonists.	group	_	false	drugn , drugn and druga : concomitant treatment with drugn , drugn , or drugn may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s4.p17	xanthine derivatives	group	_	beta2-agonists.	group	_	effect	drugn , drugn and drugn : concomitant treatment with druga , drugn , or drugn may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s4.p19	steroids	group	_	beta2-agonists.	group	_	effect	drugn , drugn and drugn : concomitant treatment with drugn , druga , or drugn may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s4.p20	diuretics	group	_	beta2-agonists.	group	_	effect	drugn , drugn and drugn : concomitant treatment with drugn , drugn , or druga may potentiate a possible hypokalemic effect of drugb
DDI-DrugBank.d103.s15.p0	beta2-agonist	group	_	salbutamol	drug	_	false	acute symptoms should be treated with a short-acting , inhaled druga such as drugb -lcb- the physician should provide the patient with such medication and instruct the patient in how it should be used -rcb- .
DDI-DrugBank.d103.s20.p0	FORADIL	brand	_	corticosteroids	group	_	false	druga should not be used as a substitute for oral or inhaled drugb .
DDI-DrugBank.d103.s26.p0	FORADIL	brand	_	short-acting  beta2-agonists	group	_	false	guardians of children who have been prescribed druga should be alerted to the general concern regarding asthmas therapy compliance , especially neglect of anti-inflammatory therapy and overuse of drugb .
DDI-DrugBank.d511.s0.p0	FOSCAVIR	brand	_	pentamidine	drug	_	int	a possible drug interaction of druga and intravenous drugb has been described .
DDI-DrugBank.d511.s1.p0	FOSCAVIR	brand	_	pentamidine	drug	_	effect	concomitant treatment of four patients in the united kingdom with druga and intravenous drugb may have caused hypocalcemia ;
DDI-DrugBank.d511.s4.p0	foscarnet	drug	_	FOSCAVIR	brand	_	false	because of druga s tendency to cause renal impairment , the use of drugb should be avoided in combination with potentially nephrotoxic drugs such as drugn , drugn and intravenous drugn unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p1	foscarnet	drug	_	aminoglycosides	group	_	false	because of druga s tendency to cause renal impairment , the use of drugn should be avoided in combination with potentially nephrotoxic drugs such as drugb , drugn and intravenous drugn unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p2	foscarnet	drug	_	amphotericin B	drug	_	false	because of druga s tendency to cause renal impairment , the use of drugn should be avoided in combination with potentially nephrotoxic drugs such as drugn , drugb and intravenous drugn unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p3	foscarnet	drug	_	pentamidine	drug	_	false	because of druga s tendency to cause renal impairment , the use of drugn should be avoided in combination with potentially nephrotoxic drugs such as drugn , drugn and intravenous drugb unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p4	FOSCAVIR	brand	_	aminoglycosides	group	_	advise	because of drugn s tendency to cause renal impairment , the use of druga should be avoided in combination with potentially nephrotoxic drugs such as drugb , drugn and intravenous drugn unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p5	FOSCAVIR	brand	_	amphotericin B	drug	_	advise	because of drugn s tendency to cause renal impairment , the use of druga should be avoided in combination with potentially nephrotoxic drugs such as drugn , drugb and intravenous drugn unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s4.p6	FOSCAVIR	brand	_	pentamidine	drug	_	advise	because of drugn s tendency to cause renal impairment , the use of druga should be avoided in combination with potentially nephrotoxic drugs such as drugn , drugn and intravenous drugb unless the potential benefits outweigh the risks to the patient .
DDI-DrugBank.d511.s6.p2	foscarnet	drug	_	ganciclovir	drug	_	false	drugn : the pharmacokinetics of druga and drugb were not altered in # patients receiving either concomitant therapy or daily alternating therapy for maintenance of cmv disease .
DDI-DrugBank.d199.s0.p0	Metoclopramide	drug	_	MONUROL	brand	_	false	druga : when coadministered with drugb , drugn , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of drugn .
DDI-DrugBank.d199.s0.p2	Metoclopramide	drug	_	fosfomycin	drug	_	false	druga : when coadministered with drugn , drugn , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of drugb .
DDI-DrugBank.d199.s0.p3	MONUROL	brand	_	metoclopramide	drug	_	mechanism	drugn : when coadministered with druga , drugb , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of drugn .
DDI-DrugBank.d199.s0.p4	MONUROL	brand	_	fosfomycin	drug	_	false	drugn : when coadministered with druga , drugn , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of drugb .
DDI-DrugBank.d199.s0.p5	metoclopramide	drug	_	fosfomycin	drug	_	false	drugn : when coadministered with drugn , druga , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of drugb .
DDI-DrugBank.d199.s2.p3	Cimetidine	drug	_	fosfomycin	drug	_	false	drugn : druga does not affect the pharmacokinetics of drugb when coadministered with drugn .
DDI-DrugBank.d199.s2.p4	Cimetidine	drug	_	MONUROL	brand	_	false	drugn : druga does not affect the pharmacokinetics of drugn when coadministered with drugb .
DDI-DrugBank.d199.s2.p5	fosfomycin	drug	_	MONUROL	brand	_	false	drugn : drugn does not affect the pharmacokinetics of druga when coadministered with drugb .
DDI-DrugBank.d176.s0.p1	Diuretics	group	_	fosinopril sodium	drug	_	false	druga : patients on drugn , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb .
DDI-DrugBank.d176.s0.p2	diuretics	group	_	fosinopril sodium	drug	_	effect	drugn : patients on druga , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb .
DDI-DrugBank.d176.s1.p0	diuretic	group	_	fosinopril sodium	drug	_	effect	the possibility of hypotensive effects can be minimized by either discontinuing the druga or increasing salt intake prior to initiation of treatment with drugb .
DDI-DrugBank.d176.s3.p5	Fosinopril sodium	drug	_	thiazide diuretics	group	_	effect	drugn supplements and drugn : druga can attenuate potassium loss caused by drugb .
DDI-DrugBank.d176.s4.p6	spironolactone	drug	_	potassium	drug	_	false	drugn -lcb- druga , drugn , drugn , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d176.s4.p8	amiloride	drug	_	potassium	drug	_	false	drugn -lcb- drugn , druga , drugn , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d176.s4.p9	triamterene	drug	_	potassium	drug	_	false	drugn -lcb- drugn , drugn , druga , and others -rcb- or drugb supplements can increase the risk of hyperkalemia .
DDI-DrugBank.d176.s6.p2	Lithium	drug	_	ACE inhibitors	group	_	false	druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d176.s6.p5	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d176.s6.p7	lithium	drug	_	ACE inhibitors	group	_	false	drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving drugb during therapy with drugn .
DDI-DrugBank.d176.s6.p9	ACE inhibitors	group	_	lithium	drug	_	effect	drugn : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving druga during therapy with drugb .
DDI-DrugBank.d176.s9.p12	antacid	group	_	fosinopril	drug	_	mechanism	drugn : in a clinical pharmacology study , coadministration of an druga -lcb- drugn , drugn , and drugn -rcb- with drugb reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p13	antacid	group	_	fosinoprilat	drug_n	_	false	drugn : in a clinical pharmacology study , coadministration of an druga -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugb as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p14	antacid	group	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an druga -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugb administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p16	antacid	group	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an druga -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugb .
DDI-DrugBank.d176.s9.p19	aluminum hydroxide	drug	_	fosinopril	drug	_	mechanism	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- druga , drugn , and drugn -rcb- with drugb reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p20	aluminum hydroxide	drug	_	fosinoprilat	drug_n	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- druga , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugb as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p21	aluminum hydroxide	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- druga , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugb administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p22	aluminum hydroxide	drug	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- druga , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p23	aluminum hydroxide	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- druga , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugb .
DDI-DrugBank.d176.s9.p25	magnesium hydroxide	drug	_	fosinopril	drug	_	mechanism	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , druga , and drugn -rcb- with drugb reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p26	magnesium hydroxide	drug	_	fosinoprilat	drug_n	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , druga , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugb as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p27	magnesium hydroxide	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , druga , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugb administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p28	magnesium hydroxide	drug	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , druga , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p29	magnesium hydroxide	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , druga , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugb .
DDI-DrugBank.d176.s9.p30	simethicone	drug	_	fosinopril	drug	_	mechanism	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and druga -rcb- with drugb reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p31	simethicone	drug	_	fosinoprilat	drug_n	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and druga -rcb- with drugn reduced serum levels and urinary excretion of drugb as compared with drugn administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p32	simethicone	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and druga -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugb administered alone , suggesting that drugn may impair absorption of drugn .
DDI-DrugBank.d176.s9.p33	simethicone	drug	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and druga -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p34	simethicone	drug	_	fosinopril	drug	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and druga -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugn may impair absorption of drugb .
DDI-DrugBank.d176.s9.p37	fosinopril	drug	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and drugn -rcb- with druga reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p40	fosinoprilat	drug_n	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of druga as compared with drugn administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p42	fosinopril	drug	_	antacids	group	_	false	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with druga administered alone , suggesting that drugb may impair absorption of drugn .
DDI-DrugBank.d176.s9.p44	antacids	group	_	fosinopril	drug	_	mechanism	drugn : in a clinical pharmacology study , coadministration of an drugn -lcb- drugn , drugn , and drugn -rcb- with drugn reduced serum levels and urinary excretion of drugn as compared with drugn administered alone , suggesting that druga may impair absorption of drugb .
DDI-DrugBank.d176.s12.p8	chlorthalidone	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p9	chlorthalidone	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p17	nifedipine	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p18	nifedipine	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p25	propanolol	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p26	propanolol	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p32	hydrochlorothiazide	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p33	hydrochlorothiazide	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p38	cimetidine	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p39	cimetidine	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p43	metoclopramide	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p44	metoclopramide	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p47	propantheline	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p48	propantheline	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p50	digoxin	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p51	digoxin	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s12.p52	warfarin	drug	_	fosinoprilat	drug_n	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga , the bioavailability of drugb was not altered by coadministration of drugn with any one of these drugs .
DDI-DrugBank.d176.s12.p53	warfarin	drug	_	fosinopril	drug	_	false	in separate single or multiple dose pharmacokinetic interaction studies with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga , the bioavailability of drugn was not altered by coadministration of drugb with any one of these drugs .
DDI-DrugBank.d176.s13.p0	aspirin	brand	_	fosinopril sodium	drug	_	false	in a study with concomitant administration of druga and drugb , the bioavailability of unbound drugn was not altered .
DDI-DrugBank.d176.s13.p1	aspirin	brand	_	fosinoprilat	drug_n	_	false	in a study with concomitant administration of druga and drugn , the bioavailability of unbound drugb was not altered .
DDI-DrugBank.d176.s13.p2	fosinopril sodium	drug	_	fosinoprilat	drug_n	_	false	in a study with concomitant administration of drugn and druga , the bioavailability of unbound drugb was not altered .
DDI-DrugBank.d176.s15.p0	Fosinopril	drug	_	digoxin	drug	_	false	drug/laboratory test interaction druga may cause a false low measurement of serum drugb levels with the digi - tab ria kit for drugn .
DDI-DrugBank.d176.s15.p1	Fosinopril	drug	_	Digoxin	drug	_	false	drug/laboratory test interaction druga may cause a false low measurement of serum drugn levels with the digi - tab ria kit for drugb .
DDI-DrugBank.d40.s4.p2	fosphenytoin	drug	_	diazepam	drug	_	false	the pharmacokinetics and protein binding of druga , drugn , and drugn were not altered when drugb and drugn were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s4.p3	fosphenytoin	drug	_	Cerebyx	brand	_	false	the pharmacokinetics and protein binding of druga , drugn , and drugn were not altered when drugn and drugb were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s4.p5	phenytoin	drug	_	diazepam	drug	_	false	the pharmacokinetics and protein binding of drugn , druga , and drugn were not altered when drugb and drugn were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s4.p6	phenytoin	drug	_	Cerebyx	brand	_	false	the pharmacokinetics and protein binding of drugn , druga , and drugn were not altered when drugn and drugb were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s4.p8	diazepam	drug	_	Cerebyx	brand	_	false	the pharmacokinetics and protein binding of drugn , drugn , and druga were not altered when drugn and drugb were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s4.p9	diazepam	drug	_	Cerebyx	brand	_	false	the pharmacokinetics and protein binding of drugn , drugn , and drugn were not altered when druga and drugb were concurrently administered in single submaximal doses .
DDI-DrugBank.d40.s5.p0	Cerebyx	brand	_	phenytoin	drug	_	false	the most significant drug interactions following administration of druga are expected to occur with drugs that interact with drugb .
DDI-DrugBank.d40.s10.p0	phenytoin	drug	_	alcohol	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugb intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p1	phenytoin	drug	_	amiodarone	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugb , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p2	phenytoin	drug	_	chlordiazepoxide	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p3	phenytoin	drug	_	cimetidine	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p4	phenytoin	drug	_	diazepam	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p5	phenytoin	drug	_	dicumarol	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p6	phenytoin	drug	_	disulfiram	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p7	phenytoin	drug	_	estrogens	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p8	phenytoin	drug	_	ethosuximide	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p9	phenytoin	drug	_	fluoxetine	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p10	phenytoin	drug	_	H2-antagonists	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p11	phenytoin	drug	_	halothane	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p12	phenytoin	drug	_	isoniazid	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p13	phenytoin	drug	_	methylphenidate	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p14	phenytoin	drug	_	phenothiazines	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p15	phenytoin	drug	_	phenylbutazone	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p16	phenytoin	drug	_	salicylates	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p17	phenytoin	drug	_	succinimides	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p18	phenytoin	drug	_	sulfonamides	group	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn
DDI-DrugBank.d40.s10.p19	phenytoin	drug	_	tolbutamide	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn
DDI-DrugBank.d40.s10.p20	phenytoin	drug	_	trazodone	drug	_	mechanism	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma druga concentrations include : acute drugn intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb
DDI-DrugBank.d40.s10.p21	alcohol	drug	_	amiodarone	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugb , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p22	alcohol	drug	_	chlordiazepoxide	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p23	alcohol	drug	_	cimetidine	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p24	alcohol	drug	_	diazepam	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p25	alcohol	drug	_	dicumarol	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p26	alcohol	drug	_	disulfiram	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p27	alcohol	drug	_	estrogens	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p28	alcohol	drug	_	ethosuximide	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p29	alcohol	drug	_	fluoxetine	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p30	alcohol	drug	_	H2-antagonists	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p31	alcohol	drug	_	halothane	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p32	alcohol	drug	_	isoniazid	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p33	alcohol	drug	_	methylphenidate	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p34	alcohol	drug	_	phenothiazines	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p35	alcohol	drug	_	phenylbutazone	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p36	alcohol	drug	_	salicylates	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p37	alcohol	drug	_	succinimides	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn
DDI-DrugBank.d40.s10.p38	alcohol	drug	_	sulfonamides	group	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn
DDI-DrugBank.d40.s10.p39	alcohol	drug	_	tolbutamide	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn
DDI-DrugBank.d40.s10.p40	alcohol	drug	_	trazodone	drug	_	false	the most commonly occurring drug interactions are listed below : - drugs that may increase plasma drugn concentrations include : acute druga intake , drugn , chboramphenicol , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb
DDI-DrugBank.d40.s12.p0	phenytoin	drug	_	carbamazepine	drug	_	mechanism	- drugs that may decrease plasma druga concentrations include : drugb , chronic drugn abuse , drugn
DDI-DrugBank.d40.s12.p1	phenytoin	drug	_	alcohol	drug	_	mechanism	- drugs that may decrease plasma druga concentrations include : drugn , chronic drugb abuse , drugn
DDI-DrugBank.d40.s12.p2	phenytoin	drug	_	reserpine	drug	_	mechanism	- drugs that may decrease plasma druga concentrations include : drugn , chronic drugn abuse , drugb
DDI-DrugBank.d40.s12.p3	carbamazepine	drug	_	alcohol	drug	_	false	- drugs that may decrease plasma drugn concentrations include : druga , chronic drugb abuse , drugn
DDI-DrugBank.d40.s12.p4	carbamazepine	drug	_	reserpine	drug	_	false	- drugs that may decrease plasma drugn concentrations include : druga , chronic drugn abuse , drugb
DDI-DrugBank.d40.s12.p5	alcohol	drug	_	reserpine	drug	_	false	- drugs that may decrease plasma drugn concentrations include : drugn , chronic druga abuse , drugb
DDI-DrugBank.d40.s14.p0	phenytoin	drug	_	phenobarbital	drug	_	mechanism	- drugs that may either increase or decrease plasma druga concentrations include : drugb , vaiproic acid , and drugn .
DDI-DrugBank.d40.s14.p1	phenytoin	drug	_	sodium valproate	drug	_	mechanism	- drugs that may either increase or decrease plasma druga concentrations include : drugn , vaiproic acid , and drugb .
DDI-DrugBank.d40.s15.p0	phenytoin	drug	_	phenobarbital	drug	_	effect	similarly , the effects of druga on drugb , drugn and sodium plasma drugn concentrations are unpredictable
DDI-DrugBank.d40.s15.p1	phenytoin	drug	_	valproic acid	drug	_	effect	similarly , the effects of druga on drugn , drugb and sodium plasma drugn concentrations are unpredictable
DDI-DrugBank.d40.s15.p2	phenytoin	drug	_	valproate	drug	_	effect	similarly , the effects of druga on drugn , drugn and sodium plasma drugb concentrations are unpredictable
DDI-DrugBank.d40.s15.p4	phenobarbital	drug	_	valproate	drug	_	false	similarly , the effects of drugn on druga , drugn and sodium plasma drugb concentrations are unpredictable
DDI-DrugBank.d40.s15.p5	valproic acid	drug	_	valproate	drug	_	false	similarly , the effects of drugn on drugn , druga and sodium plasma drugb concentrations are unpredictable
DDI-DrugBank.d40.s17.p0	tricyclic antidepressants	group	_	Cerebyx	brand	_	effect	- although not a true drug interaction , druga may precipitate seizures in susceptible patients and drugb dosage may need to be adjusted
DDI-DrugBank.d40.s19.p0	phenytoin	drug	_	anticoagulants	group	_	effect	- drugs whose efficacy is impaired by druga include : drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p1	phenytoin	drug	_	corticosteroids	group	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p2	phenytoin	drug	_	coumarin	group	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p3	phenytoin	drug	_	digitoxin	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p4	phenytoin	drug	_	doxycycline	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p5	phenytoin	drug	_	estrogens	group	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p6	phenytoin	drug	_	furosemide	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p7	phenytoin	drug	_	contraceptives	group	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p8	phenytoin	drug	_	rifampin	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn , drugb , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p9	phenytoin	drug	_	quinidine	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugb , drugn , drugn .
DDI-DrugBank.d40.s19.p10	phenytoin	drug	_	theophylline	drug	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugb , drugn .
DDI-DrugBank.d40.s19.p11	phenytoin	drug	_	vitamin D	group	_	effect	- drugs whose efficacy is impaired by druga include : drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d40.s19.p27	corticosteroids	group	_	furosemide	drug	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugb , oral drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p28	corticosteroids	group	_	contraceptives	group	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugb , drugn , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p29	corticosteroids	group	_	rifampin	drug	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn , drugb , drugn , drugn , drugn .
DDI-DrugBank.d40.s19.p30	corticosteroids	group	_	quinidine	drug	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugb , drugn , drugn .
DDI-DrugBank.d40.s19.p31	corticosteroids	group	_	theophylline	drug	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugb , drugn .
DDI-DrugBank.d40.s19.p32	corticosteroids	group	_	vitamin D	group	_	false	- drugs whose efficacy is impaired by drugn include : drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d40.s24.p0	phenytoin	drug	_	Cerebyx	brand	_	false	care should be taken when using immunoanalytical methods to measure plasma druga concentrations following drugb administration .
DDI-DrugBank.d426.s1.p0	ergotamine	drug	_	ergot-type medications	group	_	false	due to a theoretical risk of a pharmacodynamic interaction , use of druga - containing or drugb -lcb- like drugn or drugn -rcb- and drugn within # hours of each other should be avoided -lcb- see a href = frova_od , htm #ci contraindications -rcb- .
DDI-DrugBank.d426.s1.p2	ergotamine	drug	_	methysergide	drug	_	false	due to a theoretical risk of a pharmacodynamic interaction , use of druga - containing or drugn -lcb- like drugn or drugb -rcb- and drugn within # hours of each other should be avoided -lcb- see a href = frova_od , htm #ci contraindications -rcb- .
DDI-DrugBank.d426.s1.p3	ergotamine	drug	_	FROVA	brand	_	advise	due to a theoretical risk of a pharmacodynamic interaction , use of druga - containing or drugn -lcb- like drugn or drugn -rcb- and drugb within # hours of each other should be avoided -lcb- see a href = frova_od , htm #ci contraindications -rcb- .
DDI-DrugBank.d426.s3.p5	Selective serotonin reuptake inhibitors	group	_	5-HT1 agonists	group	_	effect	druga -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s3.p10	SSRIs	group	_	5-HT1 agonists	group	_	effect	drugn -lcb- druga -rcb- -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s3.p14	fluoxetine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- -lcb- e , g , , druga , drugn , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s3.p17	fluvoxamine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , druga , drugn , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s3.p19	paroxetine	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , druga , drugn -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s3.p20	sertraline	drug	_	5-HT1 agonists	group	_	effect	drugn -lcb- drugn -rcb- -lcb- e , g , , drugn , drugn , drugn , druga -rcb- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
DDI-DrugBank.d426.s4.p0	frovatriptan	drug	_	SSRI	group	_	advise	if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d231.s0.p0	Furosemide	drug	_	aminoglycoside antibiotics	group	_	effect	druga may increase the ototoxic potential of drugb , especially in the presence of impaired renal function .
DDI-DrugBank.d231.s2.p0	Furosemide	drug	_	ethacrynic acid	drug	_	advise	druga should not be used concomitantly with drugb because of the possibility of ototoxicity .
DDI-DrugBank.d231.s3.p0	salicylates	group	_	furosemide	drug	_	effect	patients receiving high doses of druga concomitantly with drugb , as in rheumatic disease , may experience drugn toxicity at lower doses because of competitive renal excretory sites .
DDI-DrugBank.d231.s3.p2	furosemide	drug	_	salicylate	group	_	false	patients receiving high doses of drugn concomitantly with druga , as in rheumatic disease , may experience drugb toxicity at lower doses because of competitive renal excretory sites .
DDI-DrugBank.d231.s4.p0	Furosemide	drug	_	tubocurarine	drug	_	effect	druga has a tendency to antagonize the skeletal muscle relaxing effect of drugb and may potentiate the action of drugn .
DDI-DrugBank.d231.s4.p1	Furosemide	drug	_	succinylcholine	drug	_	effect	druga has a tendency to antagonize the skeletal muscle relaxing effect of drugn and may potentiate the action of drugb .
DDI-DrugBank.d231.s4.p2	tubocurarine	drug	_	succinylcholine	drug	_	false	drugn has a tendency to antagonize the skeletal muscle relaxing effect of druga and may potentiate the action of drugb .
DDI-DrugBank.d231.s5.p0	Lithium	drug	_	diuretics	group	_	advise	druga generally should not be given with drugb because they reduce drugn s renal clearance and add a high risk of drugn toxicity .
DDI-DrugBank.d231.s5.p3	diuretics	group	_	lithium	drug	_	false	drugn generally should not be given with druga because they reduce drugb s renal clearance and add a high risk of drugn toxicity .
DDI-DrugBank.d231.s5.p4	diuretics	group	_	lithium	drug	_	false	drugn generally should not be given with druga because they reduce drugn s renal clearance and add a high risk of drugb toxicity .
DDI-DrugBank.d231.s6.p0	Furosemide	drug	_	antihypertensive drugs	group	_	effect	druga may add to or potentiate the therapeutic effect of other drugb .
DDI-DrugBank.d231.s7.p0	ganglionic adrenergic blocking drugs	group	_	peripheral adrenergic blocking drugs	group	_	false	potentiation occurs with druga or drugb .
DDI-DrugBank.d231.s8.p0	Furosemide	drug	_	norepinephrine	drug	_	effect	druga may decrease arterial responsiveness to drugb .
DDI-DrugBank.d231.s10.p0	sucralfate	drug	_	furosemide	drug	_	effect	tablets simultaneous administration of druga and drugb tablets may reduce the natriuretic and antihypertensive effects of drugn .
DDI-DrugBank.d231.s10.p1	sucralfate	drug	_	furosemide	drug	_	false	tablets simultaneous administration of druga and drugn tablets may reduce the natriuretic and antihypertensive effects of drugb .
DDI-DrugBank.d231.s12.p0	furosemide	drug	_	sucralfate	drug	_	advise	the intake of druga and drugb should be separated by at least two hours .
DDI-DrugBank.d231.s13.p0	furosemide	drug	_	acetylsalicylic acid	drug	_	effect	tablets , injection , and oral solution one study in six subjects demonstrated that the combination of druga and drugb temporarily reduced creatinine clearance in patients with chronic renal insufficiency .
DDI-DrugBank.d231.s14.p0	furosemide	drug	_	NSAIDs	group	_	effect	there are case reports of patients who developed increased bun , serum creatinine and serum potassium levels , and weight gain when druga was used in conjunction with drugb .
DDI-DrugBank.d231.s15.p0	indomethacin	drug	_	furosemide	drug	_	effect	literature reports indicate that coadministration of druga may reduce the natriuretic and antihypertensive effects of drugb in some patients by inhibiting prostaglandin synthesis .
DDI-DrugBank.d231.s17.p0	indomethacin	drug	_	furosemide	drug	_	advise	patients receiving both druga and drugb should be observed closely to determine if the desired diuretic and/or antihypertensive effect of drugn is achieved .
DDI-DrugBank.d231.s17.p1	indomethacin	drug	_	furosemide	drug	_	false	patients receiving both druga and drugn should be observed closely to determine if the desired diuretic and/or antihypertensive effect of drugb is achieved .
DDI-DrugBank.d438.s5.p0	Gabapentin	drug	_	antiepileptic drugs	group	_	false	druga is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered drugb .
DDI-DrugBank.d438.s7.p6	Neurontin	brand	_	phenytoin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of druga in epileptic patients -lcb- n = 8 -rcb- maintained on drugb monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugn and drugn had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p7	Neurontin	brand	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of druga in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugb had no effect on the steady-state trough plasma concentrations of drugn and drugn had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p8	Neurontin	brand	_	phenytoin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of druga in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugb and drugn had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p9	Neurontin	brand	_	phenytoin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of druga in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugn and drugb had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p10	Neurontin	brand	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of druga in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugn and drugn had no effect on drugb pharmacokinetics .
DDI-DrugBank.d438.s7.p11	phenytoin	drug	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on druga monotherapy for at least # months , drugb had no effect on the steady-state trough plasma concentrations of drugn and drugn had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p14	phenytoin	drug	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on druga monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugn and drugn had no effect on drugb pharmacokinetics .
DDI-DrugBank.d438.s7.p15	gabapentin	drug	_	phenytoin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , druga had no effect on the steady-state trough plasma concentrations of drugb and drugn had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p16	gabapentin	drug	_	phenytoin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , druga had no effect on the steady-state trough plasma concentrations of drugn and drugb had no effect on drugn pharmacokinetics .
DDI-DrugBank.d438.s7.p19	phenytoin	drug	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of druga and drugn had no effect on drugb pharmacokinetics .
DDI-DrugBank.d438.s7.p20	phenytoin	drug	_	gabapentin	drug	_	false	drugn : in a single -lcb- 400 mg -rcb- and multiple dose -lcb- 400 mg tid -rcb- study of drugn in epileptic patients -lcb- n = 8 -rcb- maintained on drugn monotherapy for at least # months , drugn had no effect on the steady-state trough plasma concentrations of drugn and druga had no effect on drugb pharmacokinetics .
DDI-DrugBank.d438.s8.p4	carbamazepine	drug	_	gabapentin	drug	_	false	drugn : steady-state trough plasma druga and drugn concentrations were not affected by concomitant drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s8.p5	carbamazepine 10, 11 epoxide	drug_n	_	gabapentin	drug	_	false	drugn : steady-state trough plasma drugn and druga concentrations were not affected by concomitant drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s10.p0	gabapentin	drug	_	carbamazepine	drug	_	false	likewise , druga pharmacokinetics were unaltered by drugb administration .
DDI-DrugBank.d438.s11.p2	valproic acid	drug	_	gabapentin	drug	_	false	drugn : the mean steady-state trough serum druga concentrations prior to and during concomitant drugb administration -lcb- 400 mg tid ;
DDI-DrugBank.d438.s12.p0	gabapentin	drug	_	valproic acid	drug	_	false	n = 17 -rcb- were not different and neither were druga pharmacokinetic parameters affected by drugb .
DDI-DrugBank.d438.s13.p2	phenobarbital	drug	_	gabapentin	drug	_	false	drugn : estimates of steady-state pharmacokinetic parameters for druga or drugb -lcb- 300 mg tid ;
DDI-DrugBank.d438.s15.p1	Naproxen	drug	_	Neurontin	brand	_	false	druga : coadministration -lcb- n = 18 -rcb- of drugn capsules -lcb- 250 mg -rcb- with drugb -lcb- 125 mg -rcb- appears to increase the amount of drugn absorbed by 12 % to 15 % .
DDI-DrugBank.d438.s15.p2	Naproxen	drug	_	gabapentin	drug	_	false	druga : coadministration -lcb- n = 18 -rcb- of drugn capsules -lcb- 250 mg -rcb- with drugn -lcb- 125 mg -rcb- appears to increase the amount of drugb absorbed by 12 % to 15 % .
DDI-DrugBank.d438.s15.p3	naproxen sodium	drug	_	Neurontin	brand	_	mechanism	drugn : coadministration -lcb- n = 18 -rcb- of druga capsules -lcb- 250 mg -rcb- with drugb -lcb- 125 mg -rcb- appears to increase the amount of drugn absorbed by 12 % to 15 % .
DDI-DrugBank.d438.s15.p4	naproxen sodium	drug	_	gabapentin	drug	_	false	drugn : coadministration -lcb- n = 18 -rcb- of druga capsules -lcb- 250 mg -rcb- with drugn -lcb- 125 mg -rcb- appears to increase the amount of drugb absorbed by 12 % to 15 % .
DDI-DrugBank.d438.s15.p5	Neurontin	brand	_	gabapentin	drug	_	false	drugn : coadministration -lcb- n = 18 -rcb- of drugn capsules -lcb- 250 mg -rcb- with druga -lcb- 125 mg -rcb- appears to increase the amount of drugb absorbed by 12 % to 15 % .
DDI-DrugBank.d438.s16.p0	Gabapentin	drug	_	naproxen	drug	_	false	druga had no effect on drugb pharmacokinetic parameters .
DDI-DrugBank.d438.s19.p0	Hydrocodone	drug	_	Neurontin	brand	_	false	druga : coadministration of drugb -lcb- 125 to # mg ;
DDI-DrugBank.d438.s24.p0	Hydrocodone	drug	_	gabapentin	drug	_	mechanism	druga increases drugb auc values by 14 % .
DDI-DrugBank.d438.s26.p5	morphine	drug	_	Neurontin	brand	_	mechanism	drugn : a literature article reported that when a 60-mg controlled-release druga capsule was administered # hours prior to a 600-mg drugb capsule -lcb- n = 12 -rcb- , mean drugn auc increased by 44 % compared to drugn administered without drugn .
DDI-DrugBank.d438.s26.p6	morphine	drug	_	gabapentin	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release druga capsule was administered # hours prior to a 600-mg drugn capsule -lcb- n = 12 -rcb- , mean drugb auc increased by 44 % compared to drugn administered without drugn .
DDI-DrugBank.d438.s26.p7	morphine	drug	_	gabapentin	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release druga capsule was administered # hours prior to a 600-mg drugn capsule -lcb- n = 12 -rcb- , mean drugn auc increased by 44 % compared to drugb administered without drugn .
DDI-DrugBank.d438.s26.p9	Neurontin	brand	_	gabapentin	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release drugn capsule was administered # hours prior to a 600-mg druga capsule -lcb- n = 12 -rcb- , mean drugb auc increased by 44 % compared to drugn administered without drugn .
DDI-DrugBank.d438.s26.p10	Neurontin	brand	_	gabapentin	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release drugn capsule was administered # hours prior to a 600-mg druga capsule -lcb- n = 12 -rcb- , mean drugn auc increased by 44 % compared to drugb administered without drugn .
DDI-DrugBank.d438.s26.p11	Neurontin	brand	_	morphine	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release drugn capsule was administered # hours prior to a 600-mg druga capsule -lcb- n = 12 -rcb- , mean drugn auc increased by 44 % compared to drugn administered without drugb .
DDI-DrugBank.d438.s26.p13	gabapentin	drug	_	morphine	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release drugn capsule was administered # hours prior to a 600-mg drugn capsule -lcb- n = 12 -rcb- , mean druga auc increased by 44 % compared to drugn administered without drugb .
DDI-DrugBank.d438.s26.p14	gabapentin	drug	_	morphine	drug	_	false	drugn : a literature article reported that when a 60-mg controlled-release drugn capsule was administered # hours prior to a 600-mg drugn capsule -lcb- n = 12 -rcb- , mean drugn auc increased by 44 % compared to druga administered without drugb .
DDI-DrugBank.d438.s27.p0	Morphine	drug	_	Neurontin	brand	_	false	druga pharmacokinetic parameter values were not affected by administration of drugb # hours after drugn .
DDI-DrugBank.d438.s27.p2	Neurontin	brand	_	morphine	drug	_	false	drugn pharmacokinetic parameter values were not affected by administration of druga # hours after drugb .
DDI-DrugBank.d438.s29.p2	cimetidine	drug	_	gabapentin	drug	_	mechanism	drugn : in the presence of druga at # mg qid -lcb- n = 12 -rcb- the mean apparent oral clearance of drugb fell by 14 % and creatinine clearance fell by 10 % .
DDI-DrugBank.d438.s30.p0	cimetidine	drug	_	gabapentin	drug	_	mechanism	thus druga appeared to alter the renal excretion of both drugb and creatinine , an endogenous marker of renal function .
DDI-DrugBank.d438.s31.p0	gabapentin	drug	_	cimetidine	drug	_	mechanism	this small decrease in excretion of druga by drugb is not expected to be of clinical importance .
DDI-DrugBank.d438.s32.p0	gabapentin	drug	_	cimetidine	drug	_	false	the effect of druga on drugb was not evaluated .
DDI-DrugBank.d438.s33.p5	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of druga and drugb following administration of tablets containing # mg of drugn and # mcg of drugn were similar with and without coadministration of drugn -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p7	norethindrone	drug	_	ethinyl estradiol	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of druga and drugn following administration of tablets containing # mg of drugn and # mcg of drugb were similar with and without coadministration of drugn -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p8	norethindrone	drug	_	gabapentin	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of druga and drugn following administration of tablets containing # mg of drugn and # mcg of drugn were similar with and without coadministration of drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p9	ethinyl estradiol	drug	_	norethindrone acetate	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of drugn and druga following administration of tablets containing # mg of drugb and # mcg of drugn were similar with and without coadministration of drugn -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p11	ethinyl estradiol	drug	_	gabapentin	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of drugn and druga following administration of tablets containing # mg of drugn and # mcg of drugn were similar with and without coadministration of drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p12	norethindrone acetate	drug	_	ethinyl estradiol	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of drugn and drugn following administration of tablets containing # mg of druga and # mcg of drugb were similar with and without coadministration of drugn -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p13	norethindrone acetate	drug	_	gabapentin	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of drugn and drugn following administration of tablets containing # mg of druga and # mcg of drugn were similar with and without coadministration of drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s33.p14	ethinyl estradiol	drug	_	gabapentin	drug	_	false	oral drugn : based on auc and half-life , multiple-dose pharmacokinetic profiles of drugn and drugn following administration of tablets containing # mg of drugn and # mcg of druga were similar with and without coadministration of drugb -lcb- 400 mg tid ;
DDI-DrugBank.d438.s35.p0	norethindrone	drug	_	gabapentin	drug	_	mechanism	the cmax of druga was 13 % higher when it was coadministered with drugb ;
DDI-DrugBank.d438.s37.p5	Maalox	brand	_	gabapentin	drug	_	mechanism	drugn -lcb- drugn -rcb- : druga reduced the bioavailability of drugb -lcb- n = 16 -rcb- by about 20 % .
DDI-DrugBank.d438.s38.p0	gabapentin	drug	_	Maalox	brand	_	mechanism	this decrease in bioavailability was about 5 % when druga was administered # hours after drugb .
DDI-DrugBank.d438.s39.p0	gabapentin	drug	_	Maalox	brand	_	advise	it is recommended that druga be taken at least # hours following drugb administration .
DDI-DrugBank.d438.s41.p0	Gabapentin	drug	_	probenecid	drug	_	false	druga pharmacokinetic parameters without and with drugb were comparable .
DDI-DrugBank.d438.s42.p0	gabapentin	drug	_	probenecid	drug	_	false	this indicates that druga does not undergo renal tubular secretion by the pathway that is blocked by drugb .
DDI-DrugBank.d438.s43.p0	gabapentin	drug	_	antiepileptic drugs	group	_	false	drug/laboratory tests interactions because false positive readings were reported with the ames n-multistix sg dipstick test for urinary protein when druga was added to other drugb , the more specific sulfosalicylic_acid precipitation procedure is recommended to determine the presence of urine protein
DDI-DrugBank.d207.s1.p0	rifampicin	drug	_	phenytoin	drug	_	false	in patients receiving a potent cyp3a4 inducer such as druga or drugb , a dose increase to # mg daily should be considered in the absence of severe adverse drug reaction , and clinical response and adverse events should be carefully monitored -lcb- see clinical pharmacology-pharmacokinetics-drug-drug interactions and dosage and administration-dosage adjustment sections -rcb- .
DDI-DrugBank.d207.s2.p0	warfarin	drug	_	IRESSA	brand	_	effect	international normalized ratio -lcb- inr -rcb- elevations and/or bleeding events have been reported in some patients taking druga while on drugb therapy .
DDI-DrugBank.d207.s4.p1	ketoconazole	drug	_	gefitinib	drug	_	mechanism	substances that are potent inhibitors of cyp3a4 activity -lcb- eg , druga and drugn -rcb- decrease drugb metabolism and increase drugn plasma concentrations .
DDI-DrugBank.d207.s4.p2	ketoconazole	drug	_	gefitinib	drug	_	mechanism	substances that are potent inhibitors of cyp3a4 activity -lcb- eg , druga and drugn -rcb- decrease drugn metabolism and increase drugb plasma concentrations .
DDI-DrugBank.d207.s4.p3	itraconazole	drug	_	gefitinib	drug	_	mechanism	substances that are potent inhibitors of cyp3a4 activity -lcb- eg , drugn and druga -rcb- decrease drugb metabolism and increase drugn plasma concentrations .
DDI-DrugBank.d207.s4.p4	itraconazole	drug	_	gefitinib	drug	_	mechanism	substances that are potent inhibitors of cyp3a4 activity -lcb- eg , drugn and druga -rcb- decrease drugn metabolism and increase drugb plasma concentrations .
DDI-DrugBank.d207.s7.p2	histamine H2-receptor antagonists	group	_	IRESSA	brand	_	mechanism	drugs that cause significant sustained elevation in gastric ph -lcb- druga such as drugn or drugn -rcb- may reduce plasma concentrations of drugb and therefore potentially may reduce efficacy .
DDI-DrugBank.d207.s7.p4	ranitidine	drug	_	IRESSA	brand	_	mechanism	drugs that cause significant sustained elevation in gastric ph -lcb- drugn such as druga or drugn -rcb- may reduce plasma concentrations of drugb and therefore potentially may reduce efficacy .
DDI-DrugBank.d207.s7.p5	cimetidine	drug	_	IRESSA	brand	_	mechanism	drugs that cause significant sustained elevation in gastric ph -lcb- drugn such as drugn or druga -rcb- may reduce plasma concentrations of drugb and therefore potentially may reduce efficacy .
DDI-DrugBank.d207.s8.p0	IRESSA	brand	_	vinorelbine	drug	_	false	phase ii clinical trial data , where druga and drugb have been used concomitantly , indicate that drugn may exacerbate the neutropenic effect of drugn .
DDI-DrugBank.d207.s8.p2	IRESSA	brand	_	vinorelbine	drug	_	false	phase ii clinical trial data , where druga and drugn have been used concomitantly , indicate that drugn may exacerbate the neutropenic effect of drugb .
DDI-DrugBank.d207.s8.p3	vinorelbine	drug	_	IRESSA	brand	_	false	phase ii clinical trial data , where drugn and druga have been used concomitantly , indicate that drugb may exacerbate the neutropenic effect of drugn .
DDI-DrugBank.d207.s8.p5	IRESSA	brand	_	vinorelbine	drug	_	effect	phase ii clinical trial data , where drugn and drugn have been used concomitantly , indicate that druga may exacerbate the neutropenic effect of drugb .
DDI-DrugBank.d161.s1.p0	Gemzar	brand	_	cisplatin	drug	_	false	for information on the pharmacokinetics of druga and drugb in combination , see drug interactions under clinical pharmacology section .
DDI-DrugBank.d347.s0.p0	FACTIVE	brand	_	theophylline	drug	_	false	administration of repeat doses of druga had no effect on the repeat dose pharmacokinetics of drugb , drugn or an drugn / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p1	FACTIVE	brand	_	digoxin	drug	_	false	administration of repeat doses of druga had no effect on the repeat dose pharmacokinetics of drugn , drugb or an drugn / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p2	FACTIVE	brand	_	ethinylestradiol	drug	_	false	administration of repeat doses of druga had no effect on the repeat dose pharmacokinetics of drugn , drugn or an drugb / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p3	FACTIVE	brand	_	contraceptive product	group	_	false	administration of repeat doses of druga had no effect on the repeat dose pharmacokinetics of drugn , drugn or an drugn / levonorgestrol oral drugb in healthy subjects .
DDI-DrugBank.d347.s0.p4	theophylline	drug	_	digoxin	drug	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of druga , drugb or an drugn / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p5	theophylline	drug	_	ethinylestradiol	drug	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of druga , drugn or an drugb / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p6	theophylline	drug	_	contraceptive product	group	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of druga , drugn or an drugn / levonorgestrol oral drugb in healthy subjects .
DDI-DrugBank.d347.s0.p7	digoxin	drug	_	ethinylestradiol	drug	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of drugn , druga or an drugb / levonorgestrol oral drugn in healthy subjects .
DDI-DrugBank.d347.s0.p8	digoxin	drug	_	contraceptive product	group	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of drugn , druga or an drugn / levonorgestrol oral drugb in healthy subjects .
DDI-DrugBank.d347.s0.p9	ethinylestradiol	drug	_	contraceptive product	group	_	false	administration of repeat doses of drugn had no effect on the repeat dose pharmacokinetics of drugn , drugn or an druga / levonorgestrol oral drugb in healthy subjects .
DDI-DrugBank.d347.s1.p3	FACTIVE	brand	_	estrogen	group	_	mechanism	concomitant administration of druga and drugn , drugn , drugn , or an drugb / drugn oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p4	FACTIVE	brand	_	progesterone	drug	_	mechanism	concomitant administration of druga and drugn , drugn , drugn , or an drugn / drugb oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p5	FACTIVE	brand	_	contraceptive	group	_	mechanism	concomitant administration of druga and drugn , drugn , drugn , or an drugn / drugn oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p6	FACTIVE	brand	_	gemifloxacin	drug	_	false	concomitant administration of druga and drugn , drugn , drugn , or an drugn / drugn oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p9	calcium carbonate	drug	_	estrogen	group	_	false	concomitant administration of drugn and druga , drugn , drugn , or an drugb / drugn oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p10	calcium carbonate	drug	_	progesterone	drug	_	false	concomitant administration of drugn and druga , drugn , drugn , or an drugn / drugb oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p11	calcium carbonate	drug	_	contraceptive	group	_	false	concomitant administration of drugn and druga , drugn , drugn , or an drugn / drugn oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p12	calcium carbonate	drug	_	gemifloxacin	drug	_	false	concomitant administration of drugn and druga , drugn , drugn , or an drugn / drugn oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p14	cimetidine	drug	_	estrogen	group	_	false	concomitant administration of drugn and drugn , druga , drugn , or an drugb / drugn oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p15	cimetidine	drug	_	progesterone	drug	_	false	concomitant administration of drugn and drugn , druga , drugn , or an drugn / drugb oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p16	cimetidine	drug	_	contraceptive	group	_	false	concomitant administration of drugn and drugn , druga , drugn , or an drugn / drugn oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p17	cimetidine	drug	_	gemifloxacin	drug	_	false	concomitant administration of drugn and drugn , druga , drugn , or an drugn / drugn oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p18	omeprazole	drug	_	estrogen	group	_	false	concomitant administration of drugn and drugn , drugn , druga , or an drugb / drugn oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p19	omeprazole	drug	_	progesterone	drug	_	false	concomitant administration of drugn and drugn , drugn , druga , or an drugn / drugb oral drugn produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p20	omeprazole	drug	_	contraceptive	group	_	false	concomitant administration of drugn and drugn , drugn , druga , or an drugn / drugn oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p21	omeprazole	drug	_	gemifloxacin	drug	_	false	concomitant administration of drugn and drugn , drugn , druga , or an drugn / drugn oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p23	estrogen	group	_	contraceptive	group	_	false	concomitant administration of drugn and drugn , drugn , drugn , or an druga / drugn oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p24	estrogen	group	_	gemifloxacin	drug	_	false	concomitant administration of drugn and drugn , drugn , drugn , or an druga / drugn oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p25	progesterone	drug	_	contraceptive	group	_	false	concomitant administration of drugn and drugn , drugn , drugn , or an drugn / druga oral drugb produced minor changes in the pharmacokinetics of drugn , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p26	progesterone	drug	_	gemifloxacin	drug	_	false	concomitant administration of drugn and drugn , drugn , drugn , or an drugn / druga oral drugn produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s1.p27	contraceptive	group	_	gemifloxacin	drug	_	false	concomitant administration of drugn and drugn , drugn , drugn , or an drugn / drugn oral druga produced minor changes in the pharmacokinetics of drugb , which were considered to be without clinical significance .
DDI-DrugBank.d347.s2.p0	FACTIVE	brand	_	probenecid	drug	_	mechanism	concomitant administration of druga with drugb resulted in a 45 % increase in systemic exposure to drugn .
DDI-DrugBank.d347.s2.p1	FACTIVE	brand	_	gemifloxacin	drug	_	false	concomitant administration of druga with drugn resulted in a 45 % increase in systemic exposure to drugb .
DDI-DrugBank.d347.s2.p2	probenecid	drug	_	gemifloxacin	drug	_	false	concomitant administration of drugn with druga resulted in a 45 % increase in systemic exposure to drugb .
DDI-DrugBank.d347.s3.p0	FACTIVE	brand	_	warfarin	drug	_	false	druga had no significant effect on the anticoagulant effect of drugb in healthy subjects on stable drugn therapy .
DDI-DrugBank.d347.s3.p1	FACTIVE	brand	_	warfarin	drug	_	false	druga had no significant effect on the anticoagulant effect of drugn in healthy subjects on stable drugb therapy .
DDI-DrugBank.d347.s4.p0	quinolones	group	_	warfarin	drug	_	effect	however , because some druga have been reported to enhance the anticoagulant effects of drugb or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a drugn is administered concomitantly with drugn or its derivatives .
DDI-DrugBank.d347.s4.p1	quinolones	group	_	quinolone antimicrobial	group	_	false	however , because some druga have been reported to enhance the anticoagulant effects of drugn or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a drugb is administered concomitantly with drugn or its derivatives .
DDI-DrugBank.d347.s4.p2	quinolones	group	_	warfarin	drug	_	false	however , because some druga have been reported to enhance the anticoagulant effects of drugn or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a drugn is administered concomitantly with drugb or its derivatives .
DDI-DrugBank.d347.s4.p3	warfarin	drug	_	quinolone antimicrobial	group	_	false	however , because some drugn have been reported to enhance the anticoagulant effects of druga or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a drugb is administered concomitantly with drugn or its derivatives .
DDI-DrugBank.d347.s4.p5	quinolone antimicrobial	group	_	warfarin	drug	_	advise	however , because some drugn have been reported to enhance the anticoagulant effects of drugn or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a druga is administered concomitantly with drugb or its derivatives .
DDI-DrugBank.d347.s6.p0	gemifloxacin	drug	_	antacid	group	_	false	the absorption of oral druga is significantly reduced by the concomitant administration of an drugb containing drugn and drugn .
DDI-DrugBank.d347.s6.p1	gemifloxacin	drug	_	aluminum	drug	_	mechanism	the absorption of oral druga is significantly reduced by the concomitant administration of an drugn containing drugb and drugn .
DDI-DrugBank.d347.s6.p2	gemifloxacin	drug	_	magnesium	drug	_	mechanism	the absorption of oral druga is significantly reduced by the concomitant administration of an drugn containing drugn and drugb .
DDI-DrugBank.d347.s6.p3	antacid	group	_	aluminum	drug	_	false	the absorption of oral drugn is significantly reduced by the concomitant administration of an druga containing drugb and drugn .
DDI-DrugBank.d347.s6.p4	antacid	group	_	magnesium	drug	_	false	the absorption of oral drugn is significantly reduced by the concomitant administration of an druga containing drugn and drugb .
DDI-DrugBank.d347.s6.p5	aluminum	drug	_	magnesium	drug	_	false	the absorption of oral drugn is significantly reduced by the concomitant administration of an drugn containing druga and drugb .
DDI-DrugBank.d347.s7.p0	Magnesium	drug	_	aluminum	drug	_	false	druga - and/or drugb - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p1	Magnesium	drug	_	antacids	group	_	false	druga - and/or drugn - containing drugb , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p2	Magnesium	drug	_	ferrous sulfate	drug	_	false	druga - and/or drugn - containing drugn , products containing drugb -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p3	Magnesium	drug	_	iron	drug	_	false	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugb -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p4	Magnesium	drug	_	multivitamin preparations	group	_	false	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugb containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p5	Magnesium	drug	_	zinc	drug	_	false	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p6	Magnesium	drug	_	Videx	brand	_	false	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p7	Magnesium	drug	_	didanosine	drug	_	false	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p8	Magnesium	drug	_	FACTIVE	brand	_	advise	druga - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p9	aluminum	drug	_	antacids	group	_	false	drugn - and/or druga - containing drugb , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p10	aluminum	drug	_	ferrous sulfate	drug	_	false	drugn - and/or druga - containing drugn , products containing drugb -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p11	aluminum	drug	_	iron	drug	_	false	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugb -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p12	aluminum	drug	_	multivitamin preparations	group	_	false	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugn -rcb- , drugb containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p13	aluminum	drug	_	zinc	drug	_	false	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p14	aluminum	drug	_	Videx	brand	_	false	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p15	aluminum	drug	_	didanosine	drug	_	false	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p16	aluminum	drug	_	FACTIVE	brand	_	advise	drugn - and/or druga - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p17	antacids	group	_	ferrous sulfate	drug	_	false	drugn - and/or drugn - containing druga , products containing drugb -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p18	antacids	group	_	iron	drug	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugb -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p19	antacids	group	_	multivitamin preparations	group	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugn -rcb- , drugb containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p20	antacids	group	_	zinc	drug	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugn -rcb- , drugn containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p21	antacids	group	_	Videx	brand	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p22	antacids	group	_	didanosine	drug	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p23	antacids	group	_	FACTIVE	brand	_	false	drugn - and/or drugn - containing druga , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p25	ferrous sulfate	drug	_	multivitamin preparations	group	_	false	drugn - and/or drugn - containing drugn , products containing druga -lcb- drugn -rcb- , drugb containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p26	ferrous sulfate	drug	_	zinc	drug	_	false	drugn - and/or drugn - containing drugn , products containing druga -lcb- drugn -rcb- , drugn containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p27	ferrous sulfate	drug	_	Videx	brand	_	false	drugn - and/or drugn - containing drugn , products containing druga -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p28	ferrous sulfate	drug	_	didanosine	drug	_	false	drugn - and/or drugn - containing drugn , products containing druga -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p29	ferrous sulfate	drug	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing druga -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p30	iron	drug	_	multivitamin preparations	group	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- druga -rcb- , drugb containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p31	iron	drug	_	zinc	drug	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- druga -rcb- , drugn containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p32	iron	drug	_	Videx	brand	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- druga -rcb- , drugn containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p33	iron	drug	_	didanosine	drug	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- druga -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p34	iron	drug	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing drugn -lcb- druga -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p35	multivitamin preparations	group	_	zinc	drug	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , druga containing drugb or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p36	multivitamin preparations	group	_	Videx	brand	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , druga containing drugn or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p37	multivitamin preparations	group	_	didanosine	drug	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , druga containing drugn or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p38	multivitamin preparations	group	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , druga containing drugn or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p39	zinc	drug	_	Videx	brand	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing druga or other metal cations , or drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p40	zinc	drug	_	didanosine	drug	_	false	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing druga or other metal cations , or drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugn .
DDI-DrugBank.d347.s7.p41	zinc	drug	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing druga or other metal cations , or drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p43	Videx	brand	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or druga -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s7.p44	didanosine	drug	_	FACTIVE	brand	_	advise	drugn - and/or drugn - containing drugn , products containing drugn -lcb- drugn -rcb- , drugn containing drugn or other metal cations , or drugn -lcb- druga -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after drugb .
DDI-DrugBank.d347.s8.p0	Sucralfate	drug	_	FACTIVE	brand	_	advise	druga should not be taken within # hours of drugb .
DDI-DrugBank.d28.s1.p0	COPAXONE	brand	_	corticosteroids	group	_	false	results from existing clinical trials suggest no significant interactions between druga and other therapies commonly used in ms patients , including the concurrent use of drugb for up to # days .
DDI-DrugBank.d28.s2.p0	COPAXONE	brand	_	Interferon beta	drug	_	false	druga has not been formally evaluated in combination with drugb .
DDI-DrugBank.d28.s3.p0	Interferon beta	drug	_	COPAXONE	brand	_	false	however , # patients who switched from therapy with druga to drugb did not report any serious and unexpected adverse reactions thought to be related to treatment .
DDI-DrugBank.d178.s0.p0	sulfonylureas	group	_	nonsteroidal anti-inflammatory agents	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugb and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p1	sulfonylureas	group	_	salicylates	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p2	sulfonylureas	group	_	sulfonamides	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p3	sulfonylureas	group	_	chloramphenicol	drug	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p4	sulfonylureas	group	_	probenecid	drug	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p5	sulfonylureas	group	_	coumarins	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d178.s0.p6	sulfonylureas	group	_	monoamine oxidase inhibitors	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d178.s0.p7	sulfonylureas	group	_	beta adrenergic blocking agents	group	_	effect	the hypoglycemic action of druga may be potentiated by certain drugs including drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d178.s0.p8	nonsteroidal anti-inflammatory agents	group	_	salicylates	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p9	nonsteroidal anti-inflammatory agents	group	_	sulfonamides	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p10	nonsteroidal anti-inflammatory agents	group	_	chloramphenicol	drug	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p11	nonsteroidal anti-inflammatory agents	group	_	probenecid	drug	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d178.s0.p12	nonsteroidal anti-inflammatory agents	group	_	coumarins	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d178.s0.p13	nonsteroidal anti-inflammatory agents	group	_	monoamine oxidase inhibitors	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d178.s0.p14	nonsteroidal anti-inflammatory agents	group	_	beta adrenergic blocking agents	group	_	false	the hypoglycemic action of drugn may be potentiated by certain drugs including druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d178.s4.p0	thiazides	group	_	diuretics	group	_	false	these drugs include the druga and other drugb , drugn , phe-nothiazines , drugn , drugn , oral drugn , drugn , drugn , sympathomimet-ics , drugn , and drugn .
DDI-DrugBank.d178.s4.p1	thiazides	group	_	corticosteroids	group	_	false	these drugs include the druga and other drugn , drugb , phe-nothiazines , drugn , drugn , oral drugn , drugn , drugn , sympathomimet-ics , drugn , and drugn .
DDI-DrugBank.d178.s4.p9	diuretics	group	_	corticosteroids	group	_	false	these drugs include the drugn and other druga , drugb , phe-nothiazines , drugn , drugn , oral drugn , drugn , drugn , sympathomimet-ics , drugn , and drugn .
DDI-DrugBank.d178.s4.p18	corticosteroids	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , druga , phe-nothiazines , drugn , drugb , oral drugn , drugn , drugn , sympathomimet-ics , drugn , and drugn .
DDI-DrugBank.d178.s4.p24	thyroid products	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , drugn , phe-nothiazines , druga , drugb , oral drugn , drugn , drugn , sympathomimet-ics , drugn , and drugn .
DDI-DrugBank.d178.s7.p0	glyburide	drug	_	ciprofloxacin	drug	_	int	a possible interaction between druga and drugb , a drugn , has been reported , resulting in a potentiation of the hypoglycemic action of drugn .
DDI-DrugBank.d178.s7.p1	glyburide	drug	_	fluoroquinolone antibiotic	group	_	false	a possible interaction between druga and drugn , a drugb , has been reported , resulting in a potentiation of the hypoglycemic action of drugn .
DDI-DrugBank.d178.s7.p3	ciprofloxacin	drug	_	fluoroquinolone antibiotic	group	_	false	a possible interaction between drugn and druga , a drugb , has been reported , resulting in a potentiation of the hypoglycemic action of drugn .
DDI-DrugBank.d178.s7.p4	ciprofloxacin	drug	_	glyburide	drug	_	false	a possible interaction between drugn and druga , a drugn , has been reported , resulting in a potentiation of the hypoglycemic action of drugb .
DDI-DrugBank.d178.s7.p5	fluoroquinolone antibiotic	group	_	glyburide	drug	_	false	a possible interaction between drugn and drugn , a druga , has been reported , resulting in a potentiation of the hypoglycemic action of drugb .
DDI-DrugBank.d178.s9.p0	miconazole	drug	_	hypoglycemic agents	group	_	effect	a potential interaction between oral druga and oral drugb leading to severe hypoglycemia has been reported .
DDI-DrugBank.d521.s1.p0	glimepiride	drug	_	aspirin	brand	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugb or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p1	glimepiride	drug	_	salicylate	group	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugb such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p2	glimepiride	drug	_	magnesium/choline salicylate	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p3	glimepiride	drug	_	Trilisate	brand	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p4	glimepiride	drug	_	salsalate	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p5	glimepiride	drug	_	Disalcid	brand	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p6	glimepiride	drug	_	choline salicylate	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p7	glimepiride	drug	_	Arthropan	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p8	glimepiride	drug	_	magnesium salicylate	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p9	glimepiride	drug	_	Magan	brand	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p10	glimepiride	drug	_	bismuth subsalicylate	drug	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p11	glimepiride	drug	_	Pepto-Bismol	brand	_	advise	before taking druga , tell your doctor if you are taking any of the following medicines : - drugn or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s1.p12	aspirin	brand	_	salicylate	group	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugb such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p13	aspirin	brand	_	magnesium/choline salicylate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p14	aspirin	brand	_	Trilisate	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p15	aspirin	brand	_	salsalate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p16	aspirin	brand	_	Disalcid	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p17	aspirin	brand	_	choline salicylate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p18	aspirin	brand	_	Arthropan	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p19	aspirin	brand	_	magnesium salicylate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p20	aspirin	brand	_	Magan	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p21	aspirin	brand	_	bismuth subsalicylate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p22	aspirin	brand	_	Pepto-Bismol	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - druga or another drugn such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s1.p24	salicylate	group	_	Trilisate	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p25	salicylate	group	_	salsalate	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p26	salicylate	group	_	Disalcid	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p28	salicylate	group	_	Arthropan	drug	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p30	salicylate	group	_	Magan	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s1.p32	salicylate	group	_	Pepto-Bismol	brand	_	false	before taking drugn , tell your doctor if you are taking any of the following medicines : - drugn or another druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s2.p1	nonsteroidal anti-inflammatory drug	group	_	ibuprofen	drug	_	false	- a druga -lcb- drugn -rcb- such as drugb -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p2	nonsteroidal anti-inflammatory drug	group	_	Motrin	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugb , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p3	nonsteroidal anti-inflammatory drug	group	_	Advil	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugb , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p4	nonsteroidal anti-inflammatory drug	group	_	Nuprin	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugb , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p5	nonsteroidal anti-inflammatory drug	group	_	ketoprofen	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p6	nonsteroidal anti-inflammatory drug	group	_	Orudis	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p7	nonsteroidal anti-inflammatory drug	group	_	Orudis KT	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p8	nonsteroidal anti-inflammatory drug	group	_	Oruvail	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p9	nonsteroidal anti-inflammatory drug	group	_	diclofenac	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p10	nonsteroidal anti-inflammatory drug	group	_	Voltaren	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p11	nonsteroidal anti-inflammatory drug	group	_	Cataflam	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p12	nonsteroidal anti-inflammatory drug	group	_	etodolac	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p13	nonsteroidal anti-inflammatory drug	group	_	Lodine	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p14	nonsteroidal anti-inflammatory drug	group	_	indomethacin	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p15	nonsteroidal anti-inflammatory drug	group	_	Indocin	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p16	nonsteroidal anti-inflammatory drug	group	_	nabumetone	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p17	nonsteroidal anti-inflammatory drug	group	_	Relafen	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p18	nonsteroidal anti-inflammatory drug	group	_	oxaprozin	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p19	nonsteroidal anti-inflammatory drug	group	_	Daypro	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p20	nonsteroidal anti-inflammatory drug	group	_	naproxen	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugb -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p21	nonsteroidal anti-inflammatory drug	group	_	Anaprox	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugb , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p22	nonsteroidal anti-inflammatory drug	group	_	Naprosyn	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugb , drugn -rcb- ;
DDI-DrugBank.d521.s2.p23	nonsteroidal anti-inflammatory drug	group	_	Aleve	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugb -rcb- ;
DDI-DrugBank.d521.s2.p24	NSAID	group	_	ibuprofen	drug	_	false	- a drugn -lcb- druga -rcb- such as drugb -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p25	NSAID	group	_	Motrin	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugb , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p26	NSAID	group	_	Advil	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugb , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p27	NSAID	group	_	Nuprin	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugb , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p28	NSAID	group	_	ketoprofen	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugb -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p29	NSAID	group	_	Orudis	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugb , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p30	NSAID	group	_	Orudis KT	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugb , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p31	NSAID	group	_	Oruvail	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p32	NSAID	group	_	diclofenac	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p33	NSAID	group	_	Voltaren	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p34	NSAID	group	_	Cataflam	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p35	NSAID	group	_	etodolac	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p36	NSAID	group	_	Lodine	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p37	NSAID	group	_	indomethacin	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p38	NSAID	group	_	Indocin	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p39	NSAID	group	_	nabumetone	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p40	NSAID	group	_	Relafen	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p41	NSAID	group	_	oxaprozin	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p42	NSAID	group	_	Daypro	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , and drugn -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p43	NSAID	group	_	naproxen	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugb -lcb- drugn , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p44	NSAID	group	_	Anaprox	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugb , drugn , drugn -rcb- ;
DDI-DrugBank.d521.s2.p45	NSAID	group	_	Naprosyn	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugb , drugn -rcb- ;
DDI-DrugBank.d521.s2.p46	NSAID	group	_	Aleve	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn , drugn , drugn , others -rcb- , drugn -lcb- drugn , drugn , drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and drugn -lcb- drugn , drugn , drugb -rcb- ;
DDI-DrugBank.d521.s3.p0	sulfamethoxazole	drug	_	trimethoprim	drug	_	false	- a sulfa-based drug such as druga - drugb -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p1	sulfamethoxazole	drug	_	Bactrim	brand	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p2	sulfamethoxazole	drug	_	Septra	brand	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p3	sulfamethoxazole	drug	_	sulfisoxazole	drug	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p4	sulfamethoxazole	drug	_	Gantrisin	brand	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p5	sulfamethoxazole	drug	_	sulfasalazine	drug	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s3.p6	sulfamethoxazole	drug	_	Azulfidine	brand	_	false	- a sulfa-based drug such as druga - drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s4.p1	monoamine oxidase inhibitor	group	_	isocarboxazid	drug	_	false	- a druga -lcb- drugn -rcb- such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p2	monoamine oxidase inhibitor	group	_	Marplan	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p3	monoamine oxidase inhibitor	group	_	tranylcypromine	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p4	monoamine oxidase inhibitor	group	_	Parnate	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p5	monoamine oxidase inhibitor	group	_	phenelzine	drug	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p6	monoamine oxidase inhibitor	group	_	Nardil	brand	_	false	- a druga -lcb- drugn -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s4.p7	MAOI	group	_	isocarboxazid	drug	_	false	- a drugn -lcb- druga -rcb- such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p8	MAOI	group	_	Marplan	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p9	MAOI	group	_	tranylcypromine	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p10	MAOI	group	_	Parnate	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , or drugn -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p11	MAOI	group	_	phenelzine	drug	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugb -lcb- drugn -rcb- ;
DDI-DrugBank.d521.s4.p12	MAOI	group	_	Nardil	brand	_	false	- a drugn -lcb- druga -rcb- such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , or drugn -lcb- drugb -rcb- ;
DDI-DrugBank.d521.s5.p0	beta-blocker	group	_	propranolol	drug	_	false	- a druga such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p1	beta-blocker	group	_	Inderal	brand	_	false	- a druga such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p2	beta-blocker	group	_	atenolol	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p3	beta-blocker	group	_	Tenormin	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p4	beta-blocker	group	_	acebutolol	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p5	beta-blocker	group	_	Sectral	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p6	beta-blocker	group	_	metoprolol	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s5.p7	beta-blocker	group	_	Lopressor	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , and others ;
DDI-DrugBank.d521.s6.p0	diuretic	group	_	hydrochlorothiazide	drug	_	false	- a druga -lcb- water pill -rcb- such as drugb -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s6.p1	diuretic	group	_	HCTZ	drug	_	false	- a druga -lcb- water pill -rcb- such as drugn -lcb- drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s6.p2	diuretic	group	_	Hydrodiuril	brand	_	false	- a druga -lcb- water pill -rcb- such as drugn -lcb- drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s6.p3	diuretic	group	_	chlorothiazide	drug	_	false	- a druga -lcb- water pill -rcb- such as drugn -lcb- drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s6.p4	diuretic	group	_	Diuril	brand	_	false	- a druga -lcb- water pill -rcb- such as drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , and others ;
DDI-DrugBank.d521.s7.p0	steroid medicine	group	_	prednisone	drug	_	false	- a druga such as drugb -lcb- drugn , drugn , others -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p1	steroid medicine	group	_	Deltasone	brand	_	false	- a druga such as drugn -lcb- drugb , drugn , others -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p2	steroid medicine	group	_	Orasone	brand	_	false	- a druga such as drugn -lcb- drugn , drugb , others -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p3	steroid medicine	group	_	methylprednisolone	drug	_	false	- a druga such as drugn -lcb- drugn , drugn , others -rcb- , drugb -lcb- drugn , others -rcb- , drugn -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p4	steroid medicine	group	_	Medrol	brand	_	false	- a druga such as drugn -lcb- drugn , drugn , others -rcb- , drugn -lcb- drugb , others -rcb- , drugn -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p5	steroid medicine	group	_	prednisolone	drug	_	false	- a druga such as drugn -lcb- drugn , drugn , others -rcb- , drugn -lcb- drugn , others -rcb- , drugb -lcb- drugn , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p6	steroid medicine	group	_	Prelone	brand	_	false	- a druga such as drugn -lcb- drugn , drugn , others -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugb , drugn , others -rcb- , and others ;
DDI-DrugBank.d521.s7.p7	steroid medicine	group	_	Pediapred	brand	_	false	- a druga such as drugn -lcb- drugn , drugn , others -rcb- , drugn -lcb- drugn , others -rcb- , drugn -lcb- drugn , drugb , others -rcb- , and others ;
DDI-DrugBank.d521.s8.p0	phenothiazine	group	_	chlorpromazine	drug	_	false	- a druga such as drugb -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p1	phenothiazine	group	_	Thorazine	brand	_	false	- a druga such as drugn -lcb- drugb -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p2	phenothiazine	group	_	fluphenazine	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugb -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p3	phenothiazine	group	_	Prolixin	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugb , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p4	phenothiazine	group	_	Permitil	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugb -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p5	phenothiazine	group	_	prochlorperazine	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugb -lcb- drugn -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p6	phenothiazine	group	_	Compazine	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugb -rcb- , drugn -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p7	phenothiazine	group	_	promethazine	drug	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugb -lcb- drugn -rcb- , and others ;
DDI-DrugBank.d521.s8.p8	phenothiazine	group	_	Phenergan	brand	_	false	- a druga such as drugn -lcb- drugn -rcb- , drugn -lcb- drugn , drugn -rcb- , drugn -lcb- drugn -rcb- , drugn -lcb- drugb -rcb- , and others ;
DDI-DrugBank.d225.s0.p0	sulfonylureas	group	_	nonsteroidal anti-inflammatory agents	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugb , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p1	sulfonylureas	group	_	azoles	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugb and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p2	sulfonylureas	group	_	salicylates	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p3	sulfonylureas	group	_	sulfonamides	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p4	sulfonylureas	group	_	chloramphenicol	drug	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p5	sulfonylureas	group	_	probenecid	drug	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p6	sulfonylureas	group	_	coumarins	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d225.s0.p7	sulfonylureas	group	_	monoamine oxidase inhibitors	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d225.s0.p8	sulfonylureas	group	_	beta adrenergic blocking agents	group	_	effect	immediate and extended release tablets the hypoglycemic action of druga may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d225.s0.p9	nonsteroidal anti-inflammatory agents	group	_	azoles	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugb and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p10	nonsteroidal anti-inflammatory agents	group	_	salicylates	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p11	nonsteroidal anti-inflammatory agents	group	_	sulfonamides	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p12	nonsteroidal anti-inflammatory agents	group	_	chloramphenicol	drug	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p13	nonsteroidal anti-inflammatory agents	group	_	probenecid	drug	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p14	nonsteroidal anti-inflammatory agents	group	_	coumarins	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d225.s0.p15	nonsteroidal anti-inflammatory agents	group	_	monoamine oxidase inhibitors	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d225.s0.p16	nonsteroidal anti-inflammatory agents	group	_	beta adrenergic blocking agents	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including druga , some drugn and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d225.s0.p17	azoles	group	_	salicylates	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p18	azoles	group	_	sulfonamides	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p19	azoles	group	_	chloramphenicol	drug	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p20	azoles	group	_	probenecid	drug	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d225.s0.p21	azoles	group	_	coumarins	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d225.s0.p22	azoles	group	_	monoamine oxidase inhibitors	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d225.s0.p23	azoles	group	_	beta adrenergic blocking agents	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some druga and other drugs that are highly protein bound , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d225.s0.p34	sulfonamides	group	_	beta adrenergic blocking agents	group	_	false	immediate and extended release tablets the hypoglycemic action of drugn may be potentiated by certain drugs including drugn , some drugn and other drugs that are highly protein bound , drugn , druga , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d225.s3.p0	glipizide	drug	_	tolbutamide	drug	_	false	in vitro binding studies with human serum proteins indicate that druga binds differently than drugb and does not interact with drugn or drugn .
DDI-DrugBank.d225.s3.p1	glipizide	drug	_	salicylate	group	_	false	in vitro binding studies with human serum proteins indicate that druga binds differently than drugn and does not interact with drugb or drugn .
DDI-DrugBank.d225.s3.p2	glipizide	drug	_	dicumarol	drug	_	false	in vitro binding studies with human serum proteins indicate that druga binds differently than drugn and does not interact with drugn or drugb .
DDI-DrugBank.d225.s3.p3	tolbutamide	drug	_	salicylate	group	_	false	in vitro binding studies with human serum proteins indicate that drugn binds differently than druga and does not interact with drugb or drugn .
DDI-DrugBank.d225.s3.p4	tolbutamide	drug	_	dicumarol	drug	_	false	in vitro binding studies with human serum proteins indicate that drugn binds differently than druga and does not interact with drugn or drugb .
DDI-DrugBank.d225.s3.p5	salicylate	group	_	dicumarol	drug	_	false	in vitro binding studies with human serum proteins indicate that drugn binds differently than drugn and does not interact with druga or drugb .
DDI-DrugBank.d225.s6.p0	thiazides	group	_	diuretics	group	_	false	these drugs include the druga and other drugb , drugn , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s6.p1	thiazides	group	_	corticosteroids	group	_	false	these drugs include the druga and other drugn , drugb , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s6.p11	diuretics	group	_	corticosteroids	group	_	false	these drugs include the drugn and other druga , drugb , drugn , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s6.p12	diuretics	group	_	phenothiazines	group	_	false	these drugs include the drugn and other druga , drugn , drugb , drugn , drugn , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s6.p23	corticosteroids	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , druga , drugn , drugn , drugb , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s6.p38	thyroid products	group	_	estrogens	group	_	false	these drugs include the drugn and other drugn , drugn , drugn , druga , drugb , oral drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d225.s9.p0	miconazole	drug	_	hypoglycemic agents	group	_	int	a potential interaction between oral druga and oral drugb leading to severe hypoglycemia has been reported .
DDI-DrugBank.d225.s11.p0	fluconazole	drug	_	glipizide	drug	_	int	the effect of concomitant administration of druga and drugb has been demonstrated in a placebo-controlled crossover study in normal volunteers .
DDI-DrugBank.d225.s12.p0	glipizide	drug	_	fluconazole	drug	_	false	all subjects received druga alone and following treatment with # mg of drugb as a single daily oral dose for seven days .
DDI-DrugBank.d225.s13.p0	glipizide	drug	_	fluconazole	drug	_	mechanism	the mean percentage increase in the druga auc after drugb administration was # % -lcb- range : # to 81 -rcb- .
DDI-DrugBank.d510.s0.p0	Robinul	brand	_	anticholinergics	group	_	effect	the concurrent use of druga injection with other drugb or medications with anticholinergic activity , such as drugn , drugn , or drugn , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p1	Robinul	brand	_	phenothiazines	group	_	effect	the concurrent use of druga injection with other drugn or medications with anticholinergic activity , such as drugb , drugn , or drugn , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p2	Robinul	brand	_	antiparkinson drugs	group	_	effect	the concurrent use of druga injection with other drugn or medications with anticholinergic activity , such as drugn , drugb , or drugn , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p3	Robinul	brand	_	tricyclic antidepressants	group	_	effect	the concurrent use of druga injection with other drugn or medications with anticholinergic activity , such as drugn , drugn , or drugb , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p4	anticholinergics	group	_	phenothiazines	group	_	false	the concurrent use of drugn injection with other druga or medications with anticholinergic activity , such as drugb , drugn , or drugn , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p5	anticholinergics	group	_	antiparkinson drugs	group	_	false	the concurrent use of drugn injection with other druga or medications with anticholinergic activity , such as drugn , drugb , or drugn , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s0.p6	anticholinergics	group	_	tricyclic antidepressants	group	_	false	the concurrent use of drugn injection with other druga or medications with anticholinergic activity , such as drugn , drugn , or drugb , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .
DDI-DrugBank.d510.s1.p0	Robinul	brand	_	potassium chloride	drug	_	mechanism	concomitant administration of druga injection and drugb in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time .
DDI-DrugBank.d369.s2.p0	spironolactone	drug	_	levodopa	drug	_	false	the gonadotropin levels may be transiently elevated by druga , minimally elevated by drugb , and suppressed by oral drugn and drugn .
DDI-DrugBank.d369.s2.p1	spironolactone	drug	_	contraceptives	group	_	false	the gonadotropin levels may be transiently elevated by druga , minimally elevated by drugn , and suppressed by oral drugb and drugn .
DDI-DrugBank.d369.s2.p2	spironolactone	drug	_	digoxin	drug	_	false	the gonadotropin levels may be transiently elevated by druga , minimally elevated by drugn , and suppressed by oral drugn and drugb .
DDI-DrugBank.d369.s2.p3	levodopa	drug	_	contraceptives	group	_	false	the gonadotropin levels may be transiently elevated by drugn , minimally elevated by druga , and suppressed by oral drugb and drugn .
DDI-DrugBank.d369.s2.p4	levodopa	drug	_	digoxin	drug	_	false	the gonadotropin levels may be transiently elevated by drugn , minimally elevated by druga , and suppressed by oral drugn and drugb .
DDI-DrugBank.d369.s2.p5	contraceptives	group	_	digoxin	drug	_	false	the gonadotropin levels may be transiently elevated by drugn , minimally elevated by drugn , and suppressed by oral druga and drugb .
DDI-DrugBank.d369.s3.p0	Factrel	brand	_	phenothiazines	group	_	effect	the response to druga may be blunted by drugb and drugn which cause a rise in prolactin .
DDI-DrugBank.d369.s3.p1	Factrel	brand	_	dopamine antagonists	group	_	effect	the response to druga may be blunted by drugn and drugb which cause a rise in prolactin .
DDI-DrugBank.d369.s3.p2	phenothiazines	group	_	dopamine antagonists	group	_	false	the response to drugn may be blunted by druga and drugb which cause a rise in prolactin .
DDI-DrugBank.d78.s0.p0	Antacids	group	_	Sucralfate	drug	_	false	druga , drugb , metal cations , drugn drugn form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s0.p1	Antacids	group	_	Multivitamins	group	_	false	druga , drugn , metal cations , drugb drugn form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s0.p2	Antacids	group	_	Quinolones	group	_	false	druga , drugn , metal cations , drugn drugb form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s0.p3	Sucralfate	drug	_	Multivitamins	group	_	false	drugn , druga , metal cations , drugb drugn form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s0.p4	Sucralfate	drug	_	Quinolones	group	_	false	drugn , druga , metal cations , drugn drugb form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s0.p5	Multivitamins	group	_	Quinolones	group	_	false	drugn , drugn , metal cations , druga drugb form chelates with alkaline earth and transition metal cations .
DDI-DrugBank.d78.s1.p0	quinolones	group	_	antacids	group	_	false	administration of druga with drugb containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p1	quinolones	group	_	aluminum	drug	_	mechanism	administration of druga with drugn containing drugb , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p2	quinolones	group	_	magnesium	drug	_	mechanism	administration of druga with drugn containing drugn , drugb , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p3	quinolones	group	_	calcium	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugb , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p4	quinolones	group	_	sucralfate	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugb , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p5	quinolones	group	_	iron	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p6	quinolones	group	_	multivitamins	group	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p7	quinolones	group	_	iron	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p8	quinolones	group	_	zinc	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p9	quinolones	group	_	VIDEX	brand	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p10	quinolones	group	_	didanosine	drug	_	mechanism	administration of druga with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p12	antacids	group	_	aluminum	drug	_	false	administration of drugn with druga containing drugb , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p13	antacids	group	_	magnesium	drug	_	false	administration of drugn with druga containing drugn , drugb , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p14	antacids	group	_	calcium	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugb , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p15	antacids	group	_	sucralfate	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugb , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p16	antacids	group	_	iron	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p17	antacids	group	_	multivitamins	group	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p18	antacids	group	_	iron	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p19	antacids	group	_	zinc	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p20	antacids	group	_	VIDEX	brand	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p21	antacids	group	_	didanosine	drug	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p22	antacids	group	_	quinolones	group	_	false	administration of drugn with druga containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p25	aluminum	drug	_	sucralfate	drug	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugb , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p26	aluminum	drug	_	iron	drug	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p27	aluminum	drug	_	multivitamins	group	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p28	aluminum	drug	_	iron	drug	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p29	aluminum	drug	_	zinc	drug	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p30	aluminum	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p31	aluminum	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p32	aluminum	drug	_	quinolones	group	_	false	administration of drugn with drugn containing druga , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p34	magnesium	drug	_	sucralfate	drug	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugb , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p35	magnesium	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p36	magnesium	drug	_	multivitamins	group	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p37	magnesium	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p38	magnesium	drug	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p39	magnesium	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p40	magnesium	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p41	magnesium	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , druga , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p42	calcium	drug	_	sucralfate	drug	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugb , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p43	calcium	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p44	calcium	drug	_	multivitamins	group	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p45	calcium	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p46	calcium	drug	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p47	calcium	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p48	calcium	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p49	calcium	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or druga , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p50	sucralfate	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugb , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p51	sucralfate	drug	_	multivitamins	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p52	sucralfate	drug	_	iron	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugn containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p53	sucralfate	drug	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p54	sucralfate	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p55	sucralfate	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p56	sucralfate	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with druga , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p57	iron	drug	_	multivitamins	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as druga , or with drugb containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p59	iron	drug	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as druga , or with drugn containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p60	iron	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as druga , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p61	iron	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as druga , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p62	iron	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as druga , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p63	multivitamins	group	_	iron	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with druga containing drugb or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p64	multivitamins	group	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with druga containing drugn or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p65	multivitamins	group	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with druga containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p66	multivitamins	group	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with druga containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p67	multivitamins	group	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with druga containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p68	iron	drug	_	zinc	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing druga or drugb , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p69	iron	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing druga or drugn , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p70	iron	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing druga or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p71	iron	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing druga or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p72	zinc	drug	_	VIDEX	brand	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or druga , or with formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p73	zinc	drug	_	didanosine	drug	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or druga , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugn , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p74	zinc	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or druga , or with formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p76	VIDEX	brand	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as druga -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s1.p77	didanosine	drug	_	quinolones	group	_	false	administration of drugn with drugn containing drugn , drugn , or drugn , with drugn , with metal cations such as drugn , or with drugn containing drugn or drugn , or with formulations containing divalent and trivalent cations such as drugn -lcb- druga -rcb- chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drugb , resulting in systemic concentrations considerably lower than desired .
DDI-DrugBank.d78.s3.p0	Caffeine	drug	_	Theobromine	drug	_	false	druga drugb drugn , like other drugn , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p1	Caffeine	drug	_	Grepafloxacin	drug	_	false	druga drugn drugb , like other drugn , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p2	Caffeine	drug	_	quinolones	group	_	false	druga drugn drugn , like other drugb , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p4	Caffeine	drug	_	theobromine	drug	_	false	druga drugn drugn , like other drugn , may inhibit the metabolism of drugn and drugb .
DDI-DrugBank.d78.s3.p5	Theobromine	drug	_	Grepafloxacin	drug	_	false	drugn druga drugb , like other drugn , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p6	Theobromine	drug	_	quinolones	group	_	false	drugn druga drugn , like other drugb , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p7	Theobromine	drug	_	caffeine	drug	_	false	drugn druga drugn , like other drugn , may inhibit the metabolism of drugb and drugn .
DDI-DrugBank.d78.s3.p9	Grepafloxacin	drug	_	quinolones	group	_	false	drugn drugn druga , like other drugb , may inhibit the metabolism of drugn and drugn .
DDI-DrugBank.d78.s3.p10	Grepafloxacin	drug	_	caffeine	drug	_	mechanism	drugn drugn druga , like other drugn , may inhibit the metabolism of drugb and drugn .
DDI-DrugBank.d78.s3.p11	Grepafloxacin	drug	_	theobromine	drug	_	mechanism	drugn drugn druga , like other drugn , may inhibit the metabolism of drugn and drugb .
DDI-DrugBank.d78.s3.p12	quinolones	group	_	caffeine	drug	_	mechanism	drugn drugn drugn , like other druga , may inhibit the metabolism of drugb and drugn .
DDI-DrugBank.d78.s3.p13	quinolones	group	_	theobromine	drug	_	mechanism	drugn drugn drugn , like other druga , may inhibit the metabolism of drugn and drugb .
DDI-DrugBank.d78.s3.p14	caffeine	drug	_	theobromine	drug	_	false	drugn drugn drugn , like other drugn , may inhibit the metabolism of druga and drugb .
DDI-DrugBank.d78.s5.p0	caffeine	drug	_	theobromine	drug	_	false	in some patients , this may lead to reduced clearance , prolongation of plasma half-life , and enhanced effects of druga and drugb .
DDI-DrugBank.d78.s6.p2	Grepafloxacin	drug	_	theophylline	drug	_	mechanism	drugn : druga is a competitive inhibitor of the metabolism of drugb .
DDI-DrugBank.d78.s7.p0	theophylline	drug	_	grepafloxacin	drug	_	false	serum druga concentrations increase when drugb is initiated in a patient maintained on drugn .
DDI-DrugBank.d78.s7.p2	grepafloxacin	drug	_	theophylline	drug	_	mechanism	serum drugn concentrations increase when druga is initiated in a patient maintained on drugb .
DDI-DrugBank.d78.s8.p0	grepafloxacin	drug	_	theophylline	drug	_	false	when initiating a multi-day course of druga in a patient maintained on drugb , the drugn maintenance dose should be halved for the period of concurrent use of drugn and monitoring of serum drugn concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s8.p1	grepafloxacin	drug	_	theophylline	drug	_	false	when initiating a multi-day course of druga in a patient maintained on drugn , the drugb maintenance dose should be halved for the period of concurrent use of drugn and monitoring of serum drugn concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s8.p3	grepafloxacin	drug	_	theophylline	drug	_	false	when initiating a multi-day course of druga in a patient maintained on drugn , the drugn maintenance dose should be halved for the period of concurrent use of drugn and monitoring of serum drugb concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s8.p5	theophylline	drug	_	grepafloxacin	drug	_	false	when initiating a multi-day course of drugn in a patient maintained on druga , the drugn maintenance dose should be halved for the period of concurrent use of drugb and monitoring of serum drugn concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s8.p7	theophylline	drug	_	grepafloxacin	drug	_	advise	when initiating a multi-day course of drugn in a patient maintained on drugn , the druga maintenance dose should be halved for the period of concurrent use of drugb and monitoring of serum drugn concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s8.p9	grepafloxacin	drug	_	theophylline	drug	_	false	when initiating a multi-day course of drugn in a patient maintained on drugn , the drugn maintenance dose should be halved for the period of concurrent use of druga and monitoring of serum drugb concentrations should be initiated as a guide to further dosage adjustments .
DDI-DrugBank.d78.s9.p1	Warfarin	drug	_	grepafloxacin	drug	_	false	druga : in subjects receiving drugn , no significant change in clotting time was observed when drugb was coadministered .
DDI-DrugBank.d78.s9.p2	warfarin	drug	_	grepafloxacin	drug	_	false	drugn : in subjects receiving druga , no significant change in clotting time was observed when drugb was coadministered .
DDI-DrugBank.d78.s10.p0	quinolones	group	_	warfarin	drug	_	effect	however , because some druga have been reported to enhance the effects of drugb or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drugn is administered with drugn or its derivatives .
DDI-DrugBank.d78.s10.p1	quinolones	group	_	quinolone antimicrobial	group	_	false	however , because some druga have been reported to enhance the effects of drugn or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drugb is administered with drugn or its derivatives .
DDI-DrugBank.d78.s10.p2	quinolones	group	_	warfarin	drug	_	false	however , because some druga have been reported to enhance the effects of drugn or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drugn is administered with drugb or its derivatives .
DDI-DrugBank.d78.s10.p3	warfarin	drug	_	quinolone antimicrobial	group	_	false	however , because some drugn have been reported to enhance the effects of druga or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drugb is administered with drugn or its derivatives .
DDI-DrugBank.d78.s10.p5	quinolone antimicrobial	group	_	warfarin	drug	_	advise	however , because some drugn have been reported to enhance the effects of drugn or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a druga is administered with drugb or its derivatives .
DDI-DrugBank.d78.s11.p0	grepafloxacin	drug	_	theophylline	drug	_	false	drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of druga on drugb indicates that drugn inhibits drugn metabolism , which is mediated by cyp1a2 .
DDI-DrugBank.d78.s11.p2	grepafloxacin	drug	_	theophylline	drug	_	false	drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of druga on drugn indicates that drugn inhibits drugb metabolism , which is mediated by cyp1a2 .
DDI-DrugBank.d78.s11.p3	theophylline	drug	_	grepafloxacin	drug	_	false	drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of drugn on druga indicates that drugb inhibits drugn metabolism , which is mediated by cyp1a2 .
DDI-DrugBank.d78.s11.p5	grepafloxacin	drug	_	theophylline	drug	_	mechanism	drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of drugn on drugn indicates that druga inhibits drugb metabolism , which is mediated by cyp1a2 .
DDI-DrugBank.d78.s13.p0	grepafloxacin	drug	_	theophylline	drug	_	false	substrates , in vitro data suggest similar effects of druga in cyp3a4 mediated metabolism and drugb metabolism .
DDI-DrugBank.d78.s14.p0	quinolones	group	_	cyclosporine	drug	_	mechanism	in addition , other druga have been reported to decrease the cyp3a4-mediated metabolism of drugb .
DDI-DrugBank.d78.s19.p5	nonsteroidal anti inflammatory drug	group	_	quinolone	group	_	effect	drugn -lcb- drugn -rcb- : the concomitant administration of a druga with a drugb may increase the risks of cns stimulation and convulsions .
DDI-DrugBank.d78.s20.p0	Antidiabetic Agents	group	_	quinolones	group	_	false	druga : disturbances of blood glucose , including hyperglycemia and hypoglycemia , have been reported in patients treated concomitantly with drugb and an drugn .
DDI-DrugBank.d78.s20.p2	quinolones	group	_	antidiabetic agent	group	_	effect	drugn : disturbances of blood glucose , including hyperglycemia and hypoglycemia , have been reported in patients treated concomitantly with druga and an drugb .
DDI-DrugBank.d83.s0.p0	warfarin-type anticoagulant	group	_	griseofulvin	drug	_	advise	patients on druga therapy may require dosage adjustment of the anticoagulant during and after drugb therapy .
DDI-DrugBank.d83.s1.p0	barbiturates	group	_	griseofulvin	drug	_	effect	concomitant use of druga usually depresses drugb activity and may necessitate raising the dosage .
DDI-DrugBank.d83.s2.p0	griseofulvin	drug	_	contraceptives	group	_	effect	the concomitant administration of druga has been reported to reduce the efficacy of oral drugb and to increase the incidence of breakthrough bleeding .
DDI-DrugBank.d398.s0.p0	codeine	drug	_	alcohol	drug	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugb , drugn , drugn or other drugs that produce cns depression .
DDI-DrugBank.d398.s0.p1	codeine	drug	_	antihistamines	group	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugn , drugb , drugn or other drugs that produce cns depression .
DDI-DrugBank.d398.s0.p2	codeine	drug	_	psychotropics	group	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugn , drugn , drugb or other drugs that produce cns depression .
DDI-DrugBank.d398.s1.p0	dextromethorphan	drug	_	monoamine oxidase inhibitors	group	_	effect	serious toxicity may result if druga is coadministered with drugb -lcb- drugn -rcb- .
DDI-DrugBank.d398.s1.p1	dextromethorphan	drug	_	MAOIs	group	_	effect	serious toxicity may result if druga is coadministered with drugn -lcb- drugb -rcb- .
DDI-DrugBank.d398.s2.p0	dextromethorphan hydrobromide	drug	_	alcohol	drug	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugb , drugn , drugn or other drugs that produce cns depression .
DDI-DrugBank.d398.s2.p1	dextromethorphan hydrobromide	drug	_	antihistamines	group	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugn , drugb , drugn or other drugs that produce cns depression .
DDI-DrugBank.d398.s2.p2	dextromethorphan hydrobromide	drug	_	psychotropics	group	_	effect	the use of druga may result in additive cns depressant effects when coadministered with drugn , drugn , drugb or other drugs that produce cns depression .
DDI-DrugBank.d507.s0.p0	guanfacine	drug	_	CNS-depressant drug	group	_	effect	the potential for increased sedation when druga is given with other drugb should be appreciated .
DDI-DrugBank.d507.s1.p0	guanfacine	drug	_	phenobarbital	drug	_	mechanism	the administration of druga concomitantly with known microsomal enzyme inducer -lcb- drugb or drugn -rcb- to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .
DDI-DrugBank.d507.s1.p1	guanfacine	drug	_	phenytoin	drug	_	mechanism	the administration of druga concomitantly with known microsomal enzyme inducer -lcb- drugn or drugb -rcb- to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .
DDI-DrugBank.d507.s4.p0	TCAs	group	_	guanfacine	drug	_	effect	druga decrease the hypotensive effect of drugb .
DDI-DrugBank.d507.s5.p2	Noncardioselective beta-blockers	group	_	guanfacine	drug	_	effect	druga -lcb- drugn , porpranolol , drugn -rcb- may exacerbate rebound hypertension when drugb is withdrawn .
DDI-DrugBank.d507.s5.p4	nadolol	drug	_	guanfacine	drug	_	effect	drugn -lcb- druga , porpranolol , drugn -rcb- may exacerbate rebound hypertension when drugb is withdrawn .
DDI-DrugBank.d507.s5.p5	timolol	drug	_	guanfacine	drug	_	effect	drugn -lcb- drugn , porpranolol , druga -rcb- may exacerbate rebound hypertension when drugb is withdrawn .
DDI-DrugBank.d507.s7.p0	guafacine	drug	_	cardioselective beta-blocker	group	_	false	the gradual withdrawal of druga or a drugb could be substituted .
DDI-DrugBank.d507.s8.p2	anticoagulants	group	_	guanfacine	drug	_	false	drugn : ten patients who were stabilized on oral druga were given drugb , 1-2 mg/day , for # weeks .
DDI-DrugBank.d507.s10.p0	guanfacine	drug	_	diuretics	group	_	false	in several well-controlled studies , druga was administered together with drugb with no drug interactions reported .
DDI-DrugBank.d507.s12.p12	sedatives	group	_	coronary vasodilators	group	_	false	the principal drugs given -lcb- number of patients in parentheses -rcb- were : drugn -lcb- 115 -rcb- , druga and drugn -lcb- 103 -rcb- , drugb -lcb- 52 -rcb- , oral drugn -lcb- 45 -rcb- , cough and cold preparations -lcb- 45 -rcb- , drugn -lcb- 38 -rcb- , drugn -lcb- 29 -rcb- , drugn -lcb- 24 -rcb- , oral drugn -lcb- 18 -rcb- , drugn -lcb- 13 -rcb- , drugn -lcb- 10 -rcb- , and drugn -lcb- 10 -rcb- .
DDI-DrugBank.d507.s12.p14	sedatives	group	_	NSAIDs	group	_	false	the principal drugs given -lcb- number of patients in parentheses -rcb- were : drugn -lcb- 115 -rcb- , druga and drugn -lcb- 103 -rcb- , drugn -lcb- 52 -rcb- , oral drugn -lcb- 45 -rcb- , cough and cold preparations -lcb- 45 -rcb- , drugb -lcb- 38 -rcb- , drugn -lcb- 29 -rcb- , drugn -lcb- 24 -rcb- , oral drugn -lcb- 18 -rcb- , drugn -lcb- 13 -rcb- , drugn -lcb- 10 -rcb- , and drugn -lcb- 10 -rcb- .
DDI-DrugBank.d507.s12.p23	hypnotics	group	_	NSAIDs	group	_	false	the principal drugs given -lcb- number of patients in parentheses -rcb- were : drugn -lcb- 115 -rcb- , drugn and druga -lcb- 103 -rcb- , drugn -lcb- 52 -rcb- , oral drugn -lcb- 45 -rcb- , cough and cold preparations -lcb- 45 -rcb- , drugb -lcb- 38 -rcb- , drugn -lcb- 29 -rcb- , drugn -lcb- 24 -rcb- , oral drugn -lcb- 18 -rcb- , drugn -lcb- 13 -rcb- , drugn -lcb- 10 -rcb- , and drugn -lcb- 10 -rcb- .
DDI-DrugBank.d507.s12.p33	coronary vasodilators	group	_	antigout drugs	group	_	false	the principal drugs given -lcb- number of patients in parentheses -rcb- were : drugn -lcb- 115 -rcb- , drugn and drugn -lcb- 103 -rcb- , druga -lcb- 52 -rcb- , oral drugn -lcb- 45 -rcb- , cough and cold preparations -lcb- 45 -rcb- , drugn -lcb- 38 -rcb- , drugn -lcb- 29 -rcb- , drugb -lcb- 24 -rcb- , oral drugn -lcb- 18 -rcb- , drugn -lcb- 13 -rcb- , drugn -lcb- 10 -rcb- , and drugn -lcb- 10 -rcb- .
DDI-DrugBank.d507.s12.p46	NSAIDs	group	_	antigout drugs	group	_	false	the principal drugs given -lcb- number of patients in parentheses -rcb- were : drugn -lcb- 115 -rcb- , drugn and drugn -lcb- 103 -rcb- , drugn -lcb- 52 -rcb- , oral drugn -lcb- 45 -rcb- , cough and cold preparations -lcb- 45 -rcb- , druga -lcb- 38 -rcb- , drugn -lcb- 29 -rcb- , drugb -lcb- 24 -rcb- , oral drugn -lcb- 18 -rcb- , drugn -lcb- 13 -rcb- , drugn -lcb- 10 -rcb- , and drugn -lcb- 10 -rcb- .
DDI-DrugBank.d186.s0.p0	lithium	drug	_	HALDOL	brand	_	effect	an encephalopathic syndrome -lcb- characterized by weakness , lethargy , fever , tremulousness and confusion , extrapyramidal symptoms , leukocytosis , elevated serum enzymes , bun , and fbs -rcb- followed by irreversible brain damage has occurred in a few patients treated with druga plus drugb .
DDI-DrugBank.d186.s1.p0	lithium	drug	_	HALDOL	brand	_	false	a causal relationship between these events and the concomitant administration of druga and drugb has not been established ;
DDI-DrugBank.d186.s3.p0	antipsychotic agents	group	_	HALDOL	brand	_	false	as with other druga , it should be noted that drugb may be capable of potentiating drugn such as drugn , drugn , and drugn .
DDI-DrugBank.d186.s3.p1	antipsychotic agents	group	_	CNS depressants	group	_	effect	as with other druga , it should be noted that drugn may be capable of potentiating drugb such as drugn , drugn , and drugn .
DDI-DrugBank.d186.s3.p2	antipsychotic agents	group	_	anesthetics	group	_	effect	as with other druga , it should be noted that drugn may be capable of potentiating drugn such as drugb , drugn , and drugn .
DDI-DrugBank.d186.s3.p3	antipsychotic agents	group	_	opiates	group	_	effect	as with other druga , it should be noted that drugn may be capable of potentiating drugn such as drugn , drugb , and drugn .
DDI-DrugBank.d186.s3.p4	antipsychotic agents	group	_	alcohol	drug	_	effect	as with other druga , it should be noted that drugn may be capable of potentiating drugn such as drugn , drugn , and drugb .
DDI-DrugBank.d186.s3.p5	HALDOL	brand	_	CNS depressants	group	_	effect	as with other drugn , it should be noted that druga may be capable of potentiating drugb such as drugn , drugn , and drugn .
DDI-DrugBank.d186.s3.p6	HALDOL	brand	_	anesthetics	group	_	effect	as with other drugn , it should be noted that druga may be capable of potentiating drugn such as drugb , drugn , and drugn .
DDI-DrugBank.d186.s3.p7	HALDOL	brand	_	opiates	group	_	effect	as with other drugn , it should be noted that druga may be capable of potentiating drugn such as drugn , drugb , and drugn .
DDI-DrugBank.d186.s3.p8	HALDOL	brand	_	alcohol	drug	_	effect	as with other drugn , it should be noted that druga may be capable of potentiating drugn such as drugn , drugn , and drugb .
DDI-DrugBank.d186.s3.p9	CNS depressants	group	_	anesthetics	group	_	false	as with other drugn , it should be noted that drugn may be capable of potentiating druga such as drugb , drugn , and drugn .
DDI-DrugBank.d186.s3.p10	CNS depressants	group	_	opiates	group	_	false	as with other drugn , it should be noted that drugn may be capable of potentiating druga such as drugn , drugb , and drugn .
DDI-DrugBank.d186.s3.p11	CNS depressants	group	_	alcohol	drug	_	false	as with other drugn , it should be noted that drugn may be capable of potentiating druga such as drugn , drugn , and drugb .
DDI-DrugBank.d186.s4.p0	haloperidol	drug	_	rifampin	drug	_	mechanism	in a study of # schizophrenic patients coadministered oral druga and drugb , plasma drugn levels were decreased by a mean of 70 % and mean scores on the brief psychiatric rating scale were increased from baseline .
DDI-DrugBank.d186.s4.p2	rifampin	drug	_	haloperidol	drug	_	false	in a study of # schizophrenic patients coadministered oral drugn and druga , plasma drugb levels were decreased by a mean of 70 % and mean scores on the brief psychiatric rating scale were increased from baseline .
DDI-DrugBank.d186.s5.p0	haloperidol	drug	_	rifampin	drug	_	false	in # other schizophrenic patients treated with oral druga and drugb , discontinuation of drugn produced a mean # - fold increase in drugn concentrations .
DDI-DrugBank.d186.s5.p1	haloperidol	drug	_	rifampin	drug	_	false	in # other schizophrenic patients treated with oral druga and drugn , discontinuation of drugb produced a mean # - fold increase in drugn concentrations .
DDI-DrugBank.d186.s5.p4	rifampin	drug	_	haloperidol	drug	_	false	in # other schizophrenic patients treated with oral drugn and druga , discontinuation of drugn produced a mean # - fold increase in drugb concentrations .
DDI-DrugBank.d186.s5.p5	rifampin	drug	_	haloperidol	drug	_	mechanism	in # other schizophrenic patients treated with oral drugn and drugn , discontinuation of druga produced a mean # - fold increase in drugb concentrations .
DDI-DrugBank.d186.s6.p0	rifampin	drug	_	haloperidol	drug	_	advise	thus , careful monitoring of clinical status is warranted when druga is administered or discontinued in drugb - treated patients .
DDI-DrugBank.d74.s0.p0	FLUOTHANE	brand	_	non-depolarising muscle relaxant	group	_	effect	druga augments the action of drugb s and the muscle relaxant effects of drugn .
DDI-DrugBank.d74.s0.p1	FLUOTHANE	brand	_	aminoglycosides	group	_	effect	druga augments the action of drugn s and the muscle relaxant effects of drugb .
DDI-DrugBank.d74.s0.p2	non-depolarising muscle relaxant	group	_	aminoglycosides	group	_	false	drugn augments the action of druga s and the muscle relaxant effects of drugb .
DDI-DrugBank.d74.s1.p0	FLUOTHANE	brand	_	tubocurarine	drug	_	effect	druga may augment the hypotension caused by the ganglionic-blocking effect of drugb .
DDI-DrugBank.d74.s2.p0	adrenaline	drug	_	FLUOTHANE	brand	_	advise	caution should be exercised during the administration of druga to patients anaesthetised with drugb as arrhythmias may be precipitated .
DDI-DrugBank.d74.s3.p0	adrenaline	drug	_	antiarrhythmic agent	group	_	false	for this reason the dose of druga should be restricted and an drugb administered as appropriate .
DDI-DrugBank.d74.s4.p0	sympathomimetics	group	_	aminophylline	drug	_	false	caution should also be applied for other druga , and for drugb and drugn and drugn , which may also precipitate arrhythmias .
DDI-DrugBank.d74.s4.p1	sympathomimetics	group	_	theophylline	drug	_	false	caution should also be applied for other druga , and for drugn and drugb and drugn , which may also precipitate arrhythmias .
DDI-DrugBank.d74.s4.p2	sympathomimetics	group	_	tricyclic antidepressants	group	_	false	caution should also be applied for other druga , and for drugn and drugn and drugb , which may also precipitate arrhythmias .
DDI-DrugBank.d488.s0.p0	Heparin	drug	_	anticoagulants	group	_	false	drug interactions : a , drugs enhancing druga effect : oral drugb : drugn may prolong the one-stage prothrombin time .
DDI-DrugBank.d488.s1.p0	heparin sodium	drug	_	dicumarol	drug	_	advise	therefore , when druga is given with drugb or drugn , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .
DDI-DrugBank.d488.s1.p1	heparin sodium	drug	_	warfarin sodium	drug	_	advise	therefore , when druga is given with drugn or drugb , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .
DDI-DrugBank.d488.s1.p2	dicumarol	drug	_	warfarin sodium	drug	_	false	therefore , when drugn is given with druga or drugb , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .
DDI-DrugBank.d488.s2.p0	Platelet inhibitors	group	_	acetylsalicylic acid	drug	_	false	druga : drugs such as drugb , drugn , drugn , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p1	Platelet inhibitors	group	_	dextran	drug	_	false	druga : drugs such as drugn , drugb , drugn , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p2	Platelet inhibitors	group	_	phenylbutazone	drug	_	false	druga : drugs such as drugn , drugn , drugb , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p3	Platelet inhibitors	group	_	ibuprofen	drug	_	false	druga : drugs such as drugn , drugn , drugn , drugb , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p4	Platelet inhibitors	group	_	indomethacin	drug	_	false	druga : drugs such as drugn , drugn , drugn , drugn , drugb , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p5	Platelet inhibitors	group	_	dipyridamole	drug	_	false	druga : drugs such as drugn , drugn , drugn , drugn , drugn , drugb , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p6	Platelet inhibitors	group	_	hydroxychloroquine	drug	_	false	druga : drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugb and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugn .
DDI-DrugBank.d488.s2.p7	Platelet inhibitors	group	_	heparin sodium	drug	_	false	druga : drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p14	acetylsalicylic acid	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as druga , drugn , drugn , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p20	dextran	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , druga , drugn , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p25	phenylbutazone	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , drugn , druga , drugn , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p29	ibuprofen	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , drugn , drugn , druga , drugn , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p32	indomethacin	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , drugn , drugn , drugn , druga , drugn , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p34	dipyridamole	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , drugn , drugn , drugn , drugn , druga , drugn and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s2.p35	hydroxychloroquine	drug	_	heparin sodium	drug	_	effect	drugn : drugs such as drugn , drugn , drugn , drugn , drugn , drugn , druga and others that interfere with platelet-aggregation reactions -lcb- the main hemostatic defense of heparinized patients -rcb- may induce bleeding and should be used with caution in patients receiving drugb .
DDI-DrugBank.d488.s3.p0	heparin	drug	_	antithrombin III	drug	_	effect	the anticoagulant effect of druga is enhanced by concurrent treatment with drugb -lcb- human -rcb- in patients with hereditary antithrombin iii deficiency .
DDI-DrugBank.d488.s4.p0	heparin	drug	_	antithrombin III	drug	_	advise	thus in order to avoid bleeding , reduced dosage of druga is recommended during treatment with drugb -lcb- human -rcb- .
DDI-DrugBank.d488.s6.p0	Heparin	drug	_	Digitalis	group	_	false	drugs decreasing druga effect : drugb , drugn , drugn , or drugn may partially counteract the anticoagulant action of drugn .
DDI-DrugBank.d488.s6.p1	Heparin	drug	_	tetracyclines	group	_	false	drugs decreasing druga effect : drugn , drugb , drugn , or drugn may partially counteract the anticoagulant action of drugn .
DDI-DrugBank.d488.s6.p2	Heparin	drug	_	nicotine	drug	_	false	drugs decreasing druga effect : drugn , drugn , drugb , or drugn may partially counteract the anticoagulant action of drugn .
DDI-DrugBank.d488.s6.p3	Heparin	drug	_	antihistamines	group	_	false	drugs decreasing druga effect : drugn , drugn , drugn , or drugb may partially counteract the anticoagulant action of drugn .
DDI-DrugBank.d488.s6.p8	Digitalis	group	_	heparin sodium	drug	_	effect	drugs decreasing drugn effect : druga , drugn , drugn , or drugn may partially counteract the anticoagulant action of drugb .
DDI-DrugBank.d488.s6.p9	tetracyclines	group	_	nicotine	drug	_	false	drugs decreasing drugn effect : drugn , druga , drugb , or drugn may partially counteract the anticoagulant action of drugn .
DDI-DrugBank.d488.s6.p11	tetracyclines	group	_	heparin sodium	drug	_	effect	drugs decreasing drugn effect : drugn , druga , drugn , or drugn may partially counteract the anticoagulant action of drugb .
DDI-DrugBank.d488.s6.p13	nicotine	drug	_	heparin sodium	drug	_	effect	drugs decreasing drugn effect : drugn , drugn , druga , or drugn may partially counteract the anticoagulant action of drugb .
DDI-DrugBank.d488.s6.p14	antihistamines	group	_	heparin sodium	drug	_	effect	drugs decreasing drugn effect : drugn , drugn , drugn , or druga may partially counteract the anticoagulant action of drugb .
DDI-DrugBank.d488.s7.p0	Heparin Sodium	drug	_	doxorubicin	drug	_	false	druga injection should not be mixed with drugb , drugn , drugn , or drugn , since it has been reported that these drugs are incompatible with drugn and a precipitate may form .
DDI-DrugBank.d488.s7.p1	Heparin Sodium	drug	_	droperidol	drug	_	false	druga injection should not be mixed with drugn , drugb , drugn , or drugn , since it has been reported that these drugs are incompatible with drugn and a precipitate may form .
DDI-DrugBank.d488.s7.p2	Heparin Sodium	drug	_	ciprofloxacin	drug	_	false	druga injection should not be mixed with drugn , drugn , drugb , or drugn , since it has been reported that these drugs are incompatible with drugn and a precipitate may form .
DDI-DrugBank.d488.s7.p3	Heparin Sodium	drug	_	mitoxantrone	drug	_	false	druga injection should not be mixed with drugn , drugn , drugn , or drugb , since it has been reported that these drugs are incompatible with drugn and a precipitate may form .
DDI-DrugBank.d488.s7.p8	doxorubicin	drug	_	heparin	drug	_	false	drugn injection should not be mixed with druga , drugn , drugn , or drugn , since it has been reported that these drugs are incompatible with drugb and a precipitate may form .
DDI-DrugBank.d488.s7.p11	droperidol	drug	_	heparin	drug	_	false	drugn injection should not be mixed with drugn , druga , drugn , or drugn , since it has been reported that these drugs are incompatible with drugb and a precipitate may form .
DDI-DrugBank.d488.s7.p13	ciprofloxacin	drug	_	heparin	drug	_	false	drugn injection should not be mixed with drugn , drugn , druga , or drugn , since it has been reported that these drugs are incompatible with drugb and a precipitate may form .
DDI-DrugBank.d488.s7.p14	mitoxantrone	drug	_	heparin	drug	_	false	drugn injection should not be mixed with drugn , drugn , drugn , or druga , since it has been reported that these drugs are incompatible with drugb and a precipitate may form .
DDI-DrugBank.d514.s0.p0	Opioids	group	_	central nervous system depressants	group	_	false	druga are strong drugb , but regular users develop physiological tolerance allowing gradually increased dosages .
DDI-DrugBank.d514.s1.p0	central nervous system depressants	group	_	heroin	drug_n	_	effect	in combination with other druga , drugb may still kill even experienced users , particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased .
DDI-DrugBank.d514.s2.p0	heroin	drug_n	_	central nervous system depressants	group	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugb , including drugn , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p1	heroin	drug_n	_	alcohol	drug	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugn , including drugb , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p2	heroin	drug_n	_	benzodiazepines	group	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugn , including drugn , drugb such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p3	heroin	drug_n	_	diazepam	drug	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugn , including drugn , drugn such as drugb -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p4	heroin	drug_n	_	Valium	brand	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugn , including drugn , drugn such as drugn -lcb- drugb -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p5	heroin	drug_n	_	methadone	drug	_	effect	toxicology studies of druga - related deaths reveal frequent involvement of other drugn , including drugn , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s2.p6	central nervous system depressants	group	_	alcohol	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other druga , including drugb , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p7	central nervous system depressants	group	_	benzodiazepines	group	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other druga , including drugn , drugb such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p8	central nervous system depressants	group	_	diazepam	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other druga , including drugn , drugn such as drugb -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p9	central nervous system depressants	group	_	Valium	brand	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other druga , including drugn , drugn such as drugn -lcb- drugb -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p10	central nervous system depressants	group	_	methadone	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other druga , including drugn , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s2.p11	alcohol	drug	_	benzodiazepines	group	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including druga , drugb such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p12	alcohol	drug	_	diazepam	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including druga , drugn such as drugb -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p13	alcohol	drug	_	Valium	brand	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including druga , drugn such as drugn -lcb- drugb -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p14	alcohol	drug	_	methadone	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including druga , drugn such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s2.p15	benzodiazepines	group	_	diazepam	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including drugn , druga such as drugb -lcb- drugn -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p16	benzodiazepines	group	_	Valium	brand	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including drugn , druga such as drugn -lcb- drugb -rcb- , and , to a rising degree , drugn .
DDI-DrugBank.d514.s2.p17	benzodiazepines	group	_	methadone	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including drugn , druga such as drugn -lcb- drugn -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s2.p19	diazepam	drug	_	methadone	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including drugn , drugn such as druga -lcb- drugn -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s2.p20	Valium	brand	_	methadone	drug	_	false	toxicology studies of drugn - related deaths reveal frequent involvement of other drugn , including drugn , drugn such as drugn -lcb- druga -rcb- , and , to a rising degree , drugb .
DDI-DrugBank.d514.s3.p0	benzodiazepines	group	_	heroin	drug	_	false	ironically , druga are often used in the treatment of drugb addiction while they cause much more severe withdrawal symptoms .
DDI-DrugBank.d514.s4.p0	Cocaine	drug	_	heroin	drug_n	_	effect	druga sometimes proves to be fatal when used in combination with drugb .
DDI-DrugBank.d457.s0.p0	Barbiturates	group	_	contraceptives	group	_	effect	druga may decrease the effectiveness of oral drugb , certain drugn , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d457.s0.p1	Barbiturates	group	_	antibiotics	group	_	effect	druga may decrease the effectiveness of oral drugn , certain drugb , drugn , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d457.s0.p2	Barbiturates	group	_	quinidine	drug	_	effect	druga may decrease the effectiveness of oral drugn , certain drugn , drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d457.s0.p3	Barbiturates	group	_	theophylline	drug	_	effect	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d457.s0.p4	Barbiturates	group	_	corticosteroids	group	_	effect	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d457.s0.p5	Barbiturates	group	_	anticoagulants	group	_	effect	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d457.s0.p6	Barbiturates	group	_	beta blockers	group	_	effect	druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d31.s0.p0	MAO inhibitors	group	_	hydralazine	drug	_	advise	druga should be used with caution in patients receiving drugb .
DDI-DrugBank.d31.s1.p0	antihypertensive drugs	group	_	diazoxide	drug	_	effect	when other potent parental druga , such as drugb , are used in combination with drugn , patients should be continuously observed for several hours for any excessive fall in blood pressure .
DDI-DrugBank.d31.s1.p1	antihypertensive drugs	group	_	hydralazine	drug	_	effect	when other potent parental druga , such as drugn , are used in combination with drugb , patients should be continuously observed for several hours for any excessive fall in blood pressure .
DDI-DrugBank.d31.s1.p2	diazoxide	drug	_	hydralazine	drug	_	false	when other potent parental drugn , such as druga , are used in combination with drugb , patients should be continuously observed for several hours for any excessive fall in blood pressure .
DDI-DrugBank.d31.s2.p0	diazoxide	drug	_	hydralazine	drug	_	effect	profound hypotensive episodes may occur when druga infection and drugb are used concomitantly .
DDI-DrugBank.d31.s5.p0	Propranolol	drug	_	hydralazine	drug	_	mechanism	druga increases drugb s serum concentrations .
DDI-DrugBank.d31.s7.p0	NSAIDs	group	_	hydralazine	drug	_	effect	druga may decrease the hemodynamic effects of drugb ;
DDI-DrugBank.d162.s1.p0	Alcohol	drug	_	barbiturates	group	_	false	druga , drugb , or drugn : potentiation of orthostatic hypotension may occur .
DDI-DrugBank.d162.s2.p0	Antidiabetic drugs	group	_	insulin	drug	_	false	druga : -lcb- oral agents and drugb -rcb- - dosage adjustment of the drugn may be required .
DDI-DrugBank.d162.s2.p2	insulin	drug	_	antidiabetic drug	group	_	false	drugn : -lcb- oral agents and druga -rcb- - dosage adjustment of the drugb may be required .
DDI-DrugBank.d162.s4.p0	Cholestyramine	drug	_	colestipol	drug	_	false	druga and drugb drugn : absorption of drugn is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p1	Cholestyramine	drug	_	resins	group	_	false	druga and drugn drugb : absorption of drugn is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p2	Cholestyramine	drug	_	hydrochlorothiazide	drug	_	false	druga and drugn drugn : absorption of drugb is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p3	Cholestyramine	drug	_	anionic exchange resins	group	_	false	druga and drugn drugn : absorption of drugn is impaired in the presence of drugb .
DDI-DrugBank.d162.s4.p4	colestipol	drug	_	resins	group	_	false	drugn and druga drugb : absorption of drugn is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p5	colestipol	drug	_	hydrochlorothiazide	drug	_	false	drugn and druga drugn : absorption of drugb is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p6	colestipol	drug	_	anionic exchange resins	group	_	false	drugn and druga drugn : absorption of drugn is impaired in the presence of drugb .
DDI-DrugBank.d162.s4.p7	resins	group	_	hydrochlorothiazide	drug	_	false	drugn and drugn druga : absorption of drugb is impaired in the presence of drugn .
DDI-DrugBank.d162.s4.p9	hydrochlorothiazide	drug	_	anionic exchange resins	group	_	mechanism	drugn and drugn drugn : absorption of druga is impaired in the presence of drugb .
DDI-DrugBank.d162.s5.p0	cholestyramine	drug	_	colestipol	drug	_	false	single doses of either druga or drugb drugn bind the drugn and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s5.p1	cholestyramine	drug	_	resins	group	_	false	single doses of either druga or drugn drugb bind the drugn and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s5.p2	cholestyramine	drug	_	hydrochlorothiazide	drug	_	mechanism	single doses of either druga or drugn drugn bind the drugb and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s5.p3	colestipol	drug	_	resins	group	_	false	single doses of either drugn or druga drugb bind the drugn and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s5.p4	colestipol	drug	_	hydrochlorothiazide	drug	_	mechanism	single doses of either drugn or druga drugn bind the drugb and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s5.p5	resins	group	_	hydrochlorothiazide	drug	_	false	single doses of either drugn or drugn druga bind the drugb and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .
DDI-DrugBank.d162.s6.p0	Corticosteroids	group	_	ACTH	drug	_	false	druga , drugb : intensified electrolyte depletion , particularly hypokalemia .
DDI-DrugBank.d162.s8.p0	Skeletal muscle relaxants	group	_	tubocurarine	drug	_	false	druga , nondepolarizing -lcb- e , g , , drugb -rcb- : possible increased responsiveness to the drugn .
DDI-DrugBank.d162.s8.p2	tubocurarine	drug	_	muscle relaxant	group	_	false	drugn , nondepolarizing -lcb- e , g , , druga -rcb- : possible increased responsiveness to the drugb .
DDI-DrugBank.d162.s9.p0	Lithium	drug	_	diuretics	group	_	advise	druga : generally should not be given with drugb .
DDI-DrugBank.d162.s10.p0	Diuretic agents	group	_	lithium	drug	_	mechanism	druga reduce the renal clearance of drugb and add a high risk of drugn toxicity .
DDI-DrugBank.d162.s10.p1	Diuretic agents	group	_	lithium	drug	_	effect	druga reduce the renal clearance of drugn and add a high risk of drugb toxicity .
DDI-DrugBank.d162.s11.p0	lithium	drug	_	Hydrochlorothiazide	drug	_	advise	refer to the package insert for druga preparations before use of such preparations with drugb .
DDI-DrugBank.d162.s12.p0	Non-steroidal Anti-inflammatory Drugs	group	_	non-steroidal anti-inflammatory agent	group	_	false	druga : in some patients , the administration of a drugb can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugn .
DDI-DrugBank.d162.s12.p1	Non-steroidal Anti-inflammatory Drugs	group	_	loop diuretics	group	_	false	druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d162.s12.p2	Non-steroidal Anti-inflammatory Drugs	group	_	potassium-sparing diuretics	group	_	false	druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d162.s12.p3	Non-steroidal Anti-inflammatory Drugs	group	_	thiazide diuretics	group	_	false	druga : in some patients , the administration of a drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d162.s12.p4	non-steroidal anti-inflammatory agent	group	_	loop diuretics	group	_	effect	drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn and drugn .
DDI-DrugBank.d162.s12.p5	non-steroidal anti-inflammatory agent	group	_	potassium-sparing diuretics	group	_	effect	drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb and drugn .
DDI-DrugBank.d162.s12.p6	non-steroidal anti-inflammatory agent	group	_	thiazide diuretics	group	_	effect	drugn : in some patients , the administration of a druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn and drugb .
DDI-DrugBank.d162.s13.p0	Hydrochlorothiazide	drug	_	non-steroidal anti-inflammatory agents	group	_	advise	therefore , when druga and drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained .
DDI-DrugBank.d162.s13.p1	Hydrochlorothiazide	drug	_	diuretic	group	_	false	therefore , when druga and drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d162.s13.p2	non-steroidal anti-inflammatory agents	group	_	diuretic	group	_	false	therefore , when drugn and druga are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d396.s0.p2	narcotic analgesics	group	_	CNS depressants	group	_	false	patients receiving other druga , drugn , drugn , or other drugb -lcb- including drugn -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p3	narcotic analgesics	group	_	alcohol	drug	_	false	patients receiving other druga , drugn , drugn , or other drugn -lcb- including drugb -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p4	narcotic analgesics	group	_	hydrocodone	drug	_	effect	patients receiving other druga , drugn , drugn , or other drugn -lcb- including drugn -rcb- concomitantly with drugb and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p5	narcotic analgesics	group	_	acetaminophen	drug	_	false	patients receiving other druga , drugn , drugn , or other drugn -lcb- including drugn -rcb- concomitantly with drugn and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p7	antipsychotics	group	_	CNS depressants	group	_	false	patients receiving other drugn , druga , drugn , or other drugb -lcb- including drugn -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p8	antipsychotics	group	_	alcohol	drug	_	false	patients receiving other drugn , druga , drugn , or other drugn -lcb- including drugb -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p9	antipsychotics	group	_	hydrocodone	drug	_	effect	patients receiving other drugn , druga , drugn , or other drugn -lcb- including drugn -rcb- concomitantly with drugb and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p10	antipsychotics	group	_	acetaminophen	drug	_	false	patients receiving other drugn , druga , drugn , or other drugn -lcb- including drugn -rcb- concomitantly with drugn and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p11	antianxiety agents	group	_	CNS depressants	group	_	false	patients receiving other drugn , drugn , druga , or other drugb -lcb- including drugn -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p12	antianxiety agents	group	_	alcohol	drug	_	false	patients receiving other drugn , drugn , druga , or other drugn -lcb- including drugb -rcb- concomitantly with drugn and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p13	antianxiety agents	group	_	hydrocodone	drug	_	effect	patients receiving other drugn , drugn , druga , or other drugn -lcb- including drugn -rcb- concomitantly with drugb and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p14	antianxiety agents	group	_	acetaminophen	drug	_	false	patients receiving other drugn , drugn , druga , or other drugn -lcb- including drugn -rcb- concomitantly with drugn and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p16	CNS depressants	group	_	hydrocodone	drug	_	effect	patients receiving other drugn , drugn , drugn , or other druga -lcb- including drugn -rcb- concomitantly with drugb and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p17	CNS depressants	group	_	acetaminophen	drug	_	false	patients receiving other drugn , drugn , drugn , or other druga -lcb- including drugn -rcb- concomitantly with drugn and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p18	alcohol	drug	_	hydrocodone	drug	_	effect	patients receiving other drugn , drugn , drugn , or other drugn -lcb- including druga -rcb- concomitantly with drugb and drugn tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p19	alcohol	drug	_	acetaminophen	drug	_	false	patients receiving other drugn , drugn , drugn , or other drugn -lcb- including druga -rcb- concomitantly with drugn and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s0.p20	hydrocodone	drug	_	acetaminophen	drug	_	false	patients receiving other drugn , drugn , drugn , or other drugn -lcb- including drugn -rcb- concomitantly with druga and drugb tablets may exhibit an additive cns depression .
DDI-DrugBank.d396.s2.p0	MAO inhibitors	group	_	tricyclic antidepressants	group	_	false	the use of druga or drugb with drugn preparations may increase the effect of either the drugn or drugn .
DDI-DrugBank.d396.s2.p1	MAO inhibitors	group	_	hydrocodone	drug	_	effect	the use of druga or drugn with drugb preparations may increase the effect of either the drugn or drugn .
DDI-DrugBank.d396.s2.p2	MAO inhibitors	group	_	antidepressant	group	_	false	the use of druga or drugn with drugn preparations may increase the effect of either the drugb or drugn .
DDI-DrugBank.d396.s2.p3	MAO inhibitors	group	_	hydrocodone	drug	_	false	the use of druga or drugn with drugn preparations may increase the effect of either the drugn or drugb .
DDI-DrugBank.d396.s2.p4	tricyclic antidepressants	group	_	hydrocodone	drug	_	effect	the use of drugn or druga with drugb preparations may increase the effect of either the drugn or drugn .
DDI-DrugBank.d396.s2.p6	tricyclic antidepressants	group	_	hydrocodone	drug	_	false	the use of drugn or druga with drugn preparations may increase the effect of either the drugn or drugb .
DDI-DrugBank.d396.s2.p7	hydrocodone	drug	_	antidepressant	group	_	false	the use of drugn or drugn with druga preparations may increase the effect of either the drugb or drugn .
DDI-DrugBank.d396.s2.p9	antidepressant	group	_	hydrocodone	drug	_	false	the use of drugn or drugn with drugn preparations may increase the effect of either the druga or drugb .
DDI-DrugBank.d396.s3.p0	anticholinergics	group	_	hydrocodone	drug	_	effect	the concurrent use of druga with drugb may produce paralytic ileus .
DDI-DrugBank.d17.s6.p0	Antihypertensive medications	group	_	diazoxide	drug	_	false	druga , other , especially drugb , or pre drugn and anesthetic agents used in surgery or drugn , nondepolarizing , used in surgery
DDI-DrugBank.d17.s6.p1	Antihypertensive medications	group	_	anesthetic	group	_	false	druga , other , especially drugn , or pre drugb and anesthetic agents used in surgery or drugn , nondepolarizing , used in surgery
DDI-DrugBank.d17.s6.p2	Antihypertensive medications	group	_	skeletal-muscle relaxants	group	_	false	druga , other , especially drugn , or pre drugn and anesthetic agents used in surgery or drugb , nondepolarizing , used in surgery
DDI-DrugBank.d17.s6.p3	diazoxide	drug	_	anesthetic	group	_	false	drugn , other , especially druga , or pre drugb and anesthetic agents used in surgery or drugn , nondepolarizing , used in surgery
DDI-DrugBank.d17.s6.p4	diazoxide	drug	_	skeletal-muscle relaxants	group	_	false	drugn , other , especially druga , or pre drugn and anesthetic agents used in surgery or drugb , nondepolarizing , used in surgery
DDI-DrugBank.d17.s6.p5	anesthetic	group	_	skeletal-muscle relaxants	group	_	false	drugn , other , especially drugn , or pre druga and anesthetic agents used in surgery or drugb , nondepolarizing , used in surgery
DDI-DrugBank.d17.s12.p0	thiazide diuretics	group	_	digitalis	group	_	effect	-lcb- concurrent use with druga may enhance the possibility of drugb toxicity associated with hypokalemia .
DDI-DrugBank.d17.s18.p0	hypoglycemic medications	group	_	thiazide diuretic	group	_	advise	for adult-onset diabetics , dosage adjustment of druga may be necessary during and after drugb therapy ;
DDI-DrugBank.d17.s21.p0	thiazide diuretics	group	_	lithium	drug	_	false	-lcb- concurrent use with druga is not recommended , as they may provoke drugb toxicity because of reduced renal clearance .
DDI-DrugBank.d17.s25.p0	steroidal anti-inflammatory agent	group	_	loop diuretics	group	_	effect	-lcb- in some patients , the druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn , and drugn .
DDI-DrugBank.d17.s25.p1	steroidal anti-inflammatory agent	group	_	potassium sparing diuretics	group	_	effect	-lcb- in some patients , the druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb , and drugn .
DDI-DrugBank.d17.s25.p2	steroidal anti-inflammatory agent	group	_	thiazide diuretics	group	_	effect	-lcb- in some patients , the druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn , and drugb .
DDI-DrugBank.d17.s25.p4	loop diuretics	group	_	thiazide diuretics	group	_	false	-lcb- in some patients , the drugn can reduce the diuretic , natriuretic , and antihypertensive effects of druga , drugn , and drugb .
DDI-DrugBank.d17.s25.p5	potassium sparing diuretics	group	_	thiazide diuretics	group	_	false	-lcb- in some patients , the drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , druga , and drugb .
DDI-DrugBank.d17.s26.p0	hydroflumethiazide	drug	_	nonsteroidal anti-inflammatory agents	group	_	advise	therefore , when druga and drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained .
DDI-DrugBank.d17.s26.p1	hydroflumethiazide	drug	_	diuretic	group	_	false	therefore , when druga and drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d17.s26.p2	nonsteroidal anti-inflammatory agents	group	_	diuretic	group	_	false	therefore , when drugn and druga are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d17.s28.p0	Thiazides	group	_	norepinephrine	drug	_	effect	-lcb- druga may decrease arterial responsiveness to drugb .
DDI-DrugBank.d17.s31.p0	Thiazide drugs	group	_	tubocurarine	drug	_	effect	-lcb- druga may increase the responsiveness to drugb .
DDI-DrugBank.d26.s0.p1	narcotic analgesic	group	_	phenothiazines	group	_	false	patients receiving other druga s , general drugn , drugb , drugn , drugn , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugn may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p5	narcotic analgesic	group	_	CNS depressants	group	_	false	patients receiving other druga s , general drugn , drugn , drugn , drugn , drugn or other drugb -lcb- including drugn -rcb- concomitantly with drugn may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p6	narcotic analgesic	group	_	alcohol	drug	_	false	patients receiving other druga s , general drugn , drugn , drugn , drugn , drugn or other drugn -lcb- including drugb -rcb- concomitantly with drugn may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p7	narcotic analgesic	group	_	DILAUDID	brand	_	effect	patients receiving other druga s , general drugn , drugn , drugn , drugn , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p14	anesthetics	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general druga , drugn , drugn , drugn , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p20	phenothiazines	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , druga , drugn , drugn , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p25	tranquilizers	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , drugn , druga , drugn , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p29	sedative-hypnotics	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , drugn , drugn , druga , drugn or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p32	tricyclic antidepressants	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , drugn , drugn , drugn , druga or other drugn -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p34	CNS depressants	group	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , drugn , drugn , drugn , drugn or other druga -lcb- including drugn -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d26.s0.p35	alcohol	drug	_	DILAUDID	brand	_	effect	patients receiving other drugn s , general drugn , drugn , drugn , drugn , drugn or other drugn -lcb- including druga -rcb- concomitantly with drugb may exhibit an additive cns depression .
DDI-DrugBank.d16.s2.p0	hydroxyurea	drug	_	uricosuric medication	group	_	effect	since druga may raise the serum uric_acid level , dosage adjustment of drugb may be necessary
DDI-DrugBank.d308.s0.p0	HYDROXYZINE	drug	_	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	_	effect	the potentiating action of druga must be considered when the drug is used in conjunction with drugb such as drugn , drugn and drugn .
DDI-DrugBank.d308.s0.p1	HYDROXYZINE	drug	_	NARCOTICS	group	_	effect	the potentiating action of druga must be considered when the drug is used in conjunction with drugn such as drugb , drugn and drugn .
DDI-DrugBank.d308.s0.p2	HYDROXYZINE	drug	_	NON-NARCOTIC ANALGESICS	group	_	effect	the potentiating action of druga must be considered when the drug is used in conjunction with drugn such as drugn , drugb and drugn .
DDI-DrugBank.d308.s0.p3	HYDROXYZINE	drug	_	BARBITURATES	group	_	effect	the potentiating action of druga must be considered when the drug is used in conjunction with drugn such as drugn , drugn and drugb .
DDI-DrugBank.d308.s0.p4	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	_	NARCOTICS	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with druga such as drugb , drugn and drugn .
DDI-DrugBank.d308.s0.p5	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	_	NON-NARCOTIC ANALGESICS	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with druga such as drugn , drugb and drugn .
DDI-DrugBank.d308.s0.p6	CENTRAL NERVOUS SYSTEM DEPRESSANTS	group	_	BARBITURATES	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with druga such as drugn , drugn and drugb .
DDI-DrugBank.d308.s0.p7	NARCOTICS	group	_	NON-NARCOTIC ANALGESICS	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with drugn such as druga , drugb and drugn .
DDI-DrugBank.d308.s0.p8	NARCOTICS	group	_	BARBITURATES	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with drugn such as druga , drugn and drugb .
DDI-DrugBank.d308.s0.p9	NON-NARCOTIC ANALGESICS	group	_	BARBITURATES	group	_	false	the potentiating action of drugn must be considered when the drug is used in conjunction with drugn such as drugn , druga and drugb .
DDI-DrugBank.d308.s1.p0	central nervous system depressants	group	_	hydroxyzine	drug	_	advise	therefore when druga are administered concomitantly with drugb their dosage should be reduced .
DDI-DrugBank.d308.s3.p0	CNS depressant drugs	group	_	alcohol	drug	_	false	patients should be advised against the simultaneous use of other druga , and cautioned that the effect of drugb may be increased .
DDI-DrugBank.d142.s0.p0	LEVSIN	brand	_	antimuscarinics	group	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugb , drugn , drugn , drugn , drugn , drugn or some drugn .
DDI-DrugBank.d142.s0.p1	LEVSIN	brand	_	amantadine	drug	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugb , drugn , drugn , drugn , drugn or some drugn .
DDI-DrugBank.d142.s0.p2	LEVSIN	brand	_	haloperidol	drug	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugn , drugb , drugn , drugn , drugn or some drugn .
DDI-DrugBank.d142.s0.p3	LEVSIN	brand	_	phenothiazines	group	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugn , drugn , drugb , drugn , drugn or some drugn .
DDI-DrugBank.d142.s0.p4	LEVSIN	brand	_	monoamine oxidase (MAO) inhibitors	group	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugn , drugn , drugn , drugb , drugn or some drugn .
DDI-DrugBank.d142.s0.p5	LEVSIN	brand	_	tricyclic antidepressants	group	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugn , drugn , drugn , drugn , drugb or some drugn .
DDI-DrugBank.d142.s0.p6	LEVSIN	brand	_	antihistamines	group	_	effect	additive adverse effects resulting from cholinergic blockade may occur when druga is administered concomitantly with other drugn , drugn , drugn , drugn , drugn , drugn or some drugb .
DDI-DrugBank.d142.s0.p27	tricyclic antidepressants	group	_	antihistamines	group	_	false	additive adverse effects resulting from cholinergic blockade may occur when drugn is administered concomitantly with other drugn , drugn , drugn , drugn , drugn , druga or some drugb .
DDI-DrugBank.d142.s1.p0	Antacids	group	_	LEVSIN	brand	_	mechanism	druga may interfere with the absorption of drugb .
DDI-DrugBank.d440.s0.p0	Calcium	drug	_	Antacids	group	_	false	druga supplements / drugb
DDI-DrugBank.d440.s1.p0	calcium	drug	_	aluminum	drug	_	false	products containing druga and other multivalent cations -lcb- such as drugb , drugn , drugn -rcb- are likely to interfere with absorption of drugn .
DDI-DrugBank.d440.s1.p1	calcium	drug	_	magnesium	drug	_	false	products containing druga and other multivalent cations -lcb- such as drugn , drugb , drugn -rcb- are likely to interfere with absorption of drugn .
DDI-DrugBank.d440.s1.p2	calcium	drug	_	iron	drug	_	false	products containing druga and other multivalent cations -lcb- such as drugn , drugn , drugb -rcb- are likely to interfere with absorption of drugn .
DDI-DrugBank.d440.s1.p3	calcium	drug	_	Ibandronate	drug	_	mechanism	products containing druga and other multivalent cations -lcb- such as drugn , drugn , drugn -rcb- are likely to interfere with absorption of drugb .
DDI-DrugBank.d440.s1.p6	aluminum	drug	_	Ibandronate	drug	_	mechanism	products containing drugn and other multivalent cations -lcb- such as druga , drugn , drugn -rcb- are likely to interfere with absorption of drugb .
DDI-DrugBank.d440.s1.p8	magnesium	drug	_	Ibandronate	drug	_	mechanism	products containing drugn and other multivalent cations -lcb- such as drugn , druga , drugn -rcb- are likely to interfere with absorption of drugb .
DDI-DrugBank.d440.s1.p9	iron	drug	_	Ibandronate	drug	_	mechanism	products containing drugn and other multivalent cations -lcb- such as drugn , drugn , druga -rcb- are likely to interfere with absorption of drugb .
DDI-DrugBank.d440.s2.p0	Ibandronate	drug	_	antacids	group	_	advise	druga should be taken at least # minutes before any oral medications containing multivalent cations -lcb- including drugb , supplements or drugn -rcb- .
DDI-DrugBank.d440.s2.p1	Ibandronate	drug	_	vitamins	group	_	advise	druga should be taken at least # minutes before any oral medications containing multivalent cations -lcb- including drugn , supplements or drugb -rcb- .
DDI-DrugBank.d440.s3.p0	H2 Blockers	group	_	Proton Pump Inhibitors	group	_	false	druga and drugb -lcb- drugn -rcb-
DDI-DrugBank.d440.s3.p1	H2 Blockers	group	_	PPIs	group	_	false	druga and drugn -lcb- drugb -rcb-
DDI-DrugBank.d440.s4.p0	Ibandronate	drug	_	H2 blockers	group	_	false	of over # patients enrolled in the druga osteoporosis treatment and prevention studies , 15 % used anti-peptic agents -lcb- primarily drugb and drugn -rcb- .
DDI-DrugBank.d440.s4.p1	Ibandronate	drug	_	PPIs	group	_	false	of over # patients enrolled in the druga osteoporosis treatment and prevention studies , 15 % used anti-peptic agents -lcb- primarily drugn and drugb -rcb- .
DDI-DrugBank.d440.s8.p0	Aspirin	brand	_	Nonsteroidal Antiinflammatory Drug	group	_	false	druga / drugb s -lcb- drugn -rcb-
DDI-DrugBank.d440.s8.p1	Aspirin	brand	_	NSAIDs	group	_	false	druga / drugn s -lcb- drugb -rcb-
DDI-DrugBank.d440.s8.p2	Nonsteroidal Antiinflammatory Drug	group	_	NSAIDs	group	_	false	drugn / druga s -lcb- drugb -rcb-
DDI-DrugBank.d440.s9.p0	aspirin	brand	_	nonsteroidal anti-inflammatory drugs	group	_	false	in the large , placebo-controlled osteoporosis treatment study , druga and drugb were taken by 62 % of the # patients .
DDI-DrugBank.d440.s10.p0	aspirin	brand	_	NSAID	group	_	false	among druga or drugb users , the incidence of upper gastrointestinal adverse events in patients treated with drugn # mg daily -lcb- # % -rcb- was similar to that in placebo-treated patients -lcb- # % -rcb- .
DDI-DrugBank.d440.s10.p1	aspirin	brand	_	ibandronate	drug	_	false	among druga or drugn users , the incidence of upper gastrointestinal adverse events in patients treated with drugb # mg daily -lcb- # % -rcb- was similar to that in placebo-treated patients -lcb- # % -rcb- .
DDI-DrugBank.d440.s10.p2	NSAID	group	_	ibandronate	drug	_	false	among drugn or druga users , the incidence of upper gastrointestinal adverse events in patients treated with drugb # mg daily -lcb- # % -rcb- was similar to that in placebo-treated patients -lcb- # % -rcb- .
DDI-DrugBank.d440.s11.p0	aspirin	brand	_	nonsteroidal anti-inflammatory drugs	group	_	false	similarly , in the 1-year monthly comparison study , druga and drugb were taken by 39 % of the # patients .
DDI-DrugBank.d440.s12.p0	aspirin	brand	_	NSAIDs	group	_	false	the incidence of upper gastrointestinal events in patients concomitantly taking druga or drugb was similar in patients taking drugn # mg daily -lcb- # % -rcb- and # mg once monthly -lcb- # % -rcb- .
DDI-DrugBank.d440.s12.p1	aspirin	brand	_	ibandronate	drug	_	false	the incidence of upper gastrointestinal events in patients concomitantly taking druga or drugn was similar in patients taking drugb # mg daily -lcb- # % -rcb- and # mg once monthly -lcb- # % -rcb- .
DDI-DrugBank.d440.s12.p2	NSAIDs	group	_	ibandronate	drug	_	false	the incidence of upper gastrointestinal events in patients concomitantly taking drugn or druga was similar in patients taking drugb # mg daily -lcb- # % -rcb- and # mg once monthly -lcb- # % -rcb- .
DDI-DrugBank.d440.s13.p3	aspirin	brand	_	NSAIDs	group	_	false	however , since druga , drugn , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or drugb with drugn .
DDI-DrugBank.d440.s13.p4	aspirin	brand	_	Ibandronate	drug	_	false	however , since druga , drugn , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or drugn with drugb .
DDI-DrugBank.d440.s13.p6	NSAIDs	group	_	aspirin	brand	_	false	however , since drugn , druga , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugb or drugn with drugn .
DDI-DrugBank.d440.s13.p8	NSAIDs	group	_	Ibandronate	drug	_	false	however , since drugn , druga , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or drugn with drugb .
DDI-DrugBank.d440.s13.p9	bisphosphonates	group	_	aspirin	brand	_	false	however , since drugn , drugn , and druga are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugb or drugn with drugn .
DDI-DrugBank.d440.s13.p10	bisphosphonates	group	_	NSAIDs	group	_	false	however , since drugn , drugn , and druga are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or drugb with drugn .
DDI-DrugBank.d440.s13.p11	bisphosphonates	group	_	Ibandronate	drug	_	false	however , since drugn , drugn , and druga are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or drugn with drugb .
DDI-DrugBank.d440.s13.p12	aspirin	brand	_	NSAIDs	group	_	false	however , since drugn , drugn , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of druga or drugb with drugn .
DDI-DrugBank.d440.s13.p13	aspirin	brand	_	Ibandronate	drug	_	advise	however , since drugn , drugn , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of druga or drugn with drugb .
DDI-DrugBank.d440.s13.p14	NSAIDs	group	_	Ibandronate	drug	_	advise	however , since drugn , drugn , and drugn are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drugn or druga with drugb .
DDI-DrugBank.d415.s0.p2	ibuprofen	drug	_	coumarin-type anticoagulants	group	_	false	drugn : several short-term controlled studies failed to wshow that druga significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on drugb .
DDI-DrugBank.d415.s1.p0	ibuprofen	drug	_	nonsteroidal anti-inflammatory agents	group	_	false	however , because bleeding has been reported when druga and other drugb have been administered to patients on drugn , the physician should be cautious when administering drugn to patients on drugn .
DDI-DrugBank.d415.s1.p1	ibuprofen	drug	_	coumarin-type anticoagulants	group	_	effect	however , because bleeding has been reported when druga and other drugn have been administered to patients on drugb , the physician should be cautious when administering drugn to patients on drugn .
DDI-DrugBank.d415.s1.p3	ibuprofen	drug	_	anticoagulants	group	_	false	however , because bleeding has been reported when druga and other drugn have been administered to patients on drugn , the physician should be cautious when administering drugn to patients on drugb .
DDI-DrugBank.d415.s1.p4	nonsteroidal anti-inflammatory agents	group	_	coumarin-type anticoagulants	group	_	effect	however , because bleeding has been reported when drugn and other druga have been administered to patients on drugb , the physician should be cautious when administering drugn to patients on drugn .
DDI-DrugBank.d415.s1.p5	nonsteroidal anti-inflammatory agents	group	_	ibuprofen	drug	_	false	however , because bleeding has been reported when drugn and other druga have been administered to patients on drugn , the physician should be cautious when administering drugb to patients on drugn .
DDI-DrugBank.d415.s1.p6	nonsteroidal anti-inflammatory agents	group	_	anticoagulants	group	_	false	however , because bleeding has been reported when drugn and other druga have been administered to patients on drugn , the physician should be cautious when administering drugn to patients on drugb .
DDI-DrugBank.d415.s1.p7	coumarin-type anticoagulants	group	_	ibuprofen	drug	_	false	however , because bleeding has been reported when drugn and other drugn have been administered to patients on druga , the physician should be cautious when administering drugb to patients on drugn .
DDI-DrugBank.d415.s1.p9	ibuprofen	drug	_	anticoagulants	group	_	advise	however , because bleeding has been reported when drugn and other drugn have been administered to patients on drugn , the physician should be cautious when administering druga to patients on drugb .
DDI-DrugBank.d415.s2.p3	aspirin	brand	_	nonsteroidal anti-inflammatory agents	group	_	effect	drugn : animal studies wshow that druga given with drugb , including drugn , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .
DDI-DrugBank.d415.s2.p4	aspirin	brand	_	ibuprofen	drug	_	effect	drugn : animal studies wshow that druga given with drugn , including drugb , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .
DDI-DrugBank.d415.s2.p5	nonsteroidal anti-inflammatory agents	group	_	ibuprofen	drug	_	false	drugn : animal studies wshow that drugn given with druga , including drugb , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .
DDI-DrugBank.d415.s3.p0	aspirin	brand	_	ibuprofen	drug	_	false	single dose bioavailability studies in normal volunteers have failed to wshow an effect of druga on drugb blood levels .
DDI-DrugBank.d415.s5.p0	Methotrexate	drug	_	Ibuprofen	drug	_	false	druga : drugb , as well as other drugn , probably reduces the tubular secretion of drugn based on in vitro studies in rabbit kidney slices .
DDI-DrugBank.d415.s5.p1	Methotrexate	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	druga : drugn , as well as other drugb , probably reduces the tubular secretion of drugn based on in vitro studies in rabbit kidney slices .
DDI-DrugBank.d415.s5.p3	Ibuprofen	drug	_	nonsteroidal anti-inflammatory drugs	group	_	false	drugn : druga , as well as other drugb , probably reduces the tubular secretion of drugn based on in vitro studies in rabbit kidney slices .
DDI-DrugBank.d415.s5.p4	Ibuprofen	drug	_	methotrexate	drug	_	mechanism	drugn : druga , as well as other drugn , probably reduces the tubular secretion of drugb based on in vitro studies in rabbit kidney slices .
DDI-DrugBank.d415.s5.p5	nonsteroidal anti-inflammatory drugs	group	_	methotrexate	drug	_	mechanism	drugn : drugn , as well as other druga , probably reduces the tubular secretion of drugb based on in vitro studies in rabbit kidney slices .
DDI-DrugBank.d415.s6.p0	ibuprofen	drug	_	methotrexate	drug	_	effect	this may indicate that druga could enhance the toxicity of drugb .
DDI-DrugBank.d415.s7.p0	ibuprofen	drug	_	methotrexate	drug	_	advise	caution should be used if druga is administered concomitantly with drugb .
DDI-DrugBank.d415.s8.p0	cimetidine	drug	_	ranitidine	drug	_	false	h-2 antagonists : in studies with human volunteers , co-administration of druga or drugb with drugn had no substantive effect on drugn serum concentrations .
DDI-DrugBank.d415.s8.p1	cimetidine	drug	_	ibuprofen	drug	_	false	h-2 antagonists : in studies with human volunteers , co-administration of druga or drugn with drugb had no substantive effect on drugn serum concentrations .
DDI-DrugBank.d415.s8.p2	cimetidine	drug	_	ibuprofen	drug	_	false	h-2 antagonists : in studies with human volunteers , co-administration of druga or drugn with drugn had no substantive effect on drugb serum concentrations .
DDI-DrugBank.d415.s8.p3	ranitidine	drug	_	ibuprofen	drug	_	false	h-2 antagonists : in studies with human volunteers , co-administration of drugn or druga with drugb had no substantive effect on drugn serum concentrations .
DDI-DrugBank.d415.s8.p4	ranitidine	drug	_	ibuprofen	drug	_	false	h-2 antagonists : in studies with human volunteers , co-administration of drugn or druga with drugn had no substantive effect on drugb serum concentrations .
DDI-DrugBank.d415.s9.p0	Furosemide	drug	_	ibuprofen	drug	_	false	druga : clinical studies , as well as random observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d415.s9.p2	Furosemide	drug	_	thiazides	group	_	false	druga : clinical studies , as well as random observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d415.s9.p3	ibuprofen	drug	_	furosemide	drug	_	effect	drugn : clinical studies , as well as random observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d415.s9.p4	ibuprofen	drug	_	thiazides	group	_	effect	drugn : clinical studies , as well as random observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d415.s9.p5	furosemide	drug	_	thiazides	group	_	false	drugn : clinical studies , as well as random observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d415.s11.p0	ibuprofen	drug	_	diuretic	group	_	false	during concomitant therapy with druga , the patient should be observed closely for signs of renal failure , as well as to assure drugb efficacy .
DDI-DrugBank.d415.s12.p3	Ibuprofen	drug	_	lithium	drug	_	mechanism	drugn : druga produced an elevation of plasma drugb levels and a reduction in renal drugn clearance in a study of eleven normal volunteers .
DDI-DrugBank.d415.s12.p4	Ibuprofen	drug	_	lithium	drug	_	false	drugn : druga produced an elevation of plasma drugn levels and a reduction in renal drugb clearance in a study of eleven normal volunteers .
DDI-DrugBank.d415.s15.p0	ibuprofen	drug	_	lithium	drug	_	advise	thus , when druga and drugb are administered concurrently , subjects should be observed carefully for signs of drugn toxicity .
DDI-DrugBank.d415.s15.p1	ibuprofen	drug	_	lithium	drug	_	false	thus , when druga and drugn are administered concurrently , subjects should be observed carefully for signs of drugb toxicity .
DDI-DrugBank.d68.s3.p0	digoxin	drug	_	ibutilide	drug	_	false	coadministration of druga did not have effects on either the safety or efficacy of drugb in the clinical trials .
DDI-DrugBank.d68.s4.p0	Calcium channel blocking agents	group	_	calcium channel blockers	group	_	false	druga : coadministration of drugb did not have any effect on either the safety or efficacy of drugn in the clinical trials .
DDI-DrugBank.d68.s4.p1	Calcium channel blocking agents	group	_	ibutilide	drug	_	false	druga : coadministration of drugn did not have any effect on either the safety or efficacy of drugb in the clinical trials .
DDI-DrugBank.d68.s4.p2	calcium channel blockers	group	_	ibutilide	drug	_	false	drugn : coadministration of druga did not have any effect on either the safety or efficacy of drugb in the clinical trials .
DDI-DrugBank.d68.s5.p1	Beta-adrenergic blocking agents	group	_	ibutilide	drug	_	false	druga : coadministration of drugn did not have any effect on either the safety or efficacy of drugb in the clinical trials .
DDI-DrugBank.d68.s5.p2	beta-adrenergic blocking agents	group	_	ibutilide	drug	_	false	drugn : coadministration of druga did not have any effect on either the safety or efficacy of drugb in the clinical trials .
DDI-DrugBank.d501.s5.p5	EXTRANEAL	brand	_	insulin	drug	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of druga on drugb absorption from the peritoneal cavity or on drugn s ability to control blood glucose when drugn was administered intraperitoneally with drugn .
DDI-DrugBank.d501.s5.p6	EXTRANEAL	brand	_	insulin	drug	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of druga on drugn absorption from the peritoneal cavity or on drugb s ability to control blood glucose when drugn was administered intraperitoneally with drugn .
DDI-DrugBank.d501.s5.p7	EXTRANEAL	brand	_	insulin	drug	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of druga on drugn absorption from the peritoneal cavity or on drugn s ability to control blood glucose when drugb was administered intraperitoneally with drugn .
DDI-DrugBank.d501.s5.p11	insulin	drug	_	EXTRANEAL	brand	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of drugn on druga absorption from the peritoneal cavity or on drugn s ability to control blood glucose when drugn was administered intraperitoneally with drugb .
DDI-DrugBank.d501.s5.p13	insulin	drug	_	EXTRANEAL	brand	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of drugn on drugn absorption from the peritoneal cavity or on druga s ability to control blood glucose when drugn was administered intraperitoneally with drugb .
DDI-DrugBank.d501.s5.p14	insulin	drug	_	EXTRANEAL	brand	_	false	drugn : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of drugn on drugn absorption from the peritoneal cavity or on drugn s ability to control blood glucose when druga was administered intraperitoneally with drugb .
DDI-DrugBank.d501.s6.p0	EXTRANEAL	brand	_	insulin	drug	_	advise	however , appropriate monitoring of blood glucose should be performed when initiating druga in diabetic patients and drugb dosage should be adjusted if needed .
DDI-DrugBank.d501.s8.p0	heparin	drug	_	EXTRANEAL	brand	_	false	in vitro studies demonstrated no evidence of incompatibility of druga with drugb .
DDI-DrugBank.d501.s10.p6	vancomycin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of druga , drugn , drugn , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p7	vancomycin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of druga , drugn , drugn , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p13	cefazolin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , druga , drugn , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p14	cefazolin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , druga , drugn , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p19	ampicillin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , druga , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p20	ampicillin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , druga , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p24	ampicillin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , druga / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p25	ampicillin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , druga / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p28	ceftazidime	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , druga , drugn , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p29	ceftazidime	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , druga , drugn , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p31	gentamicin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , drugn , druga , and drugn demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p32	gentamicin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , drugn , druga , and drugn demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p33	amphotericin	drug	_	antibiotics	group	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , drugn , drugn , and druga demonstrated no evidence of incompatibility of these drugb with drugn .
DDI-DrugBank.d501.s10.p34	amphotericin	drug	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , drugn , drugn , and druga demonstrated no evidence of incompatibility of these drugn with drugb .
DDI-DrugBank.d501.s10.p35	antibiotics	group	_	EXTRANEAL	brand	_	false	in vitro studies evaluating the minimum inhibitory concentration -lcb- mic -rcb- of drugn , drugn , drugn , drugn / flucoxacillin , drugn , drugn , and drugn demonstrated no evidence of incompatibility of these druga with drugb .
DDI-DrugBank.d35.s0.p0	EPA	drug	_	aspirin	brand	_	int	interactions may occur between druga supplements and drugb and other drugn and herbs such as garlic -lcb- allium sativum -rcb- and drugn -lcb- drugn -rcb- .
DDI-DrugBank.d35.s0.p1	EPA	drug	_	non-steroidal anti-inflammatory drugs	group	_	int	interactions may occur between druga supplements and drugn and other drugb and herbs such as garlic -lcb- allium sativum -rcb- and drugn -lcb- drugn -rcb- .
DDI-DrugBank.d35.s0.p2	EPA	drug	_	ginkgo	drug	_	int	interactions may occur between druga supplements and drugn and other drugn and herbs such as garlic -lcb- allium sativum -rcb- and drugb -lcb- drugn -rcb- .
DDI-DrugBank.d35.s0.p3	EPA	drug	_	Ginkgo biloba	drug	_	int	interactions may occur between druga supplements and drugn and other drugn and herbs such as garlic -lcb- allium sativum -rcb- and drugn -lcb- drugb -rcb- .
DDI-DrugBank.d35.s0.p5	aspirin	brand	_	ginkgo	drug	_	false	interactions may occur between drugn supplements and druga and other drugn and herbs such as garlic -lcb- allium sativum -rcb- and drugb -lcb- drugn -rcb- .
DDI-DrugBank.d35.s0.p6	aspirin	brand	_	Ginkgo biloba	drug	_	false	interactions may occur between drugn supplements and druga and other drugn and herbs such as garlic -lcb- allium sativum -rcb- and drugn -lcb- drugb -rcb- .
DDI-DrugBank.d35.s0.p7	non-steroidal anti-inflammatory drugs	group	_	ginkgo	drug	_	false	interactions may occur between drugn supplements and drugn and other druga and herbs such as garlic -lcb- allium sativum -rcb- and drugb -lcb- drugn -rcb- .
DDI-DrugBank.d35.s0.p8	non-steroidal anti-inflammatory drugs	group	_	Ginkgo biloba	drug	_	false	interactions may occur between drugn supplements and drugn and other druga and herbs such as garlic -lcb- allium sativum -rcb- and drugn -lcb- drugb -rcb- .
DDI-DrugBank.d91.s2.p0	idoxuridine	drug	_	boric acid	drug	_	advise	when you are using druga , it is especially important that your health care professional know if you are using the following : eye product containing drugb .
DDI-DrugBank.d91.s3.p0	Boric acid	drug	_	idoxuridine	drug	_	mechanism	druga may interact with the drugb preparation causing a gritty substance to form or may interact with the preservative in the drugn preparation causing a toxic effect in the eye .
DDI-DrugBank.d91.s3.p1	Boric acid	drug	_	idoxuridine	drug	_	false	druga may interact with the drugn preparation causing a gritty substance to form or may interact with the preservative in the drugb preparation causing a toxic effect in the eye .
DDI-DrugBank.d549.s1.p0	iloprost	drug	_	vasodilators	group	_	effect	however , druga has the potential to increase the hypotensive effect of drugb and drugn .
DDI-DrugBank.d549.s1.p1	iloprost	drug	_	antihypertensive agents	group	_	effect	however , druga has the potential to increase the hypotensive effect of drugn and drugb .
DDI-DrugBank.d549.s1.p2	vasodilators	group	_	antihypertensive agents	group	_	false	however , drugn has the potential to increase the hypotensive effect of druga and drugb .
DDI-DrugBank.d549.s2.p0	iloprost	drug	_	anticoagulants	group	_	effect	since druga inhibits platelet function , there is a potential for increased risk of bleeding , particularly in patients maintained on drugb .
DDI-DrugBank.d549.s3.p0	iloprost	drug	_	anticoagulants	group	_	false	during clinical trials , druga was used concurrently with drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p1	iloprost	drug	_	diuretics	group	_	false	during clinical trials , druga was used concurrently with drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p2	iloprost	drug	_	cardiac glycosides	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p3	iloprost	drug	_	calcium channel blockers	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p4	iloprost	drug	_	analgesics	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p5	iloprost	drug	_	antipyretics	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and other medications .
DDI-DrugBank.d549.s3.p6	iloprost	drug	_	nonsteroidal antiinflammatories	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and other medications .
DDI-DrugBank.d549.s3.p7	iloprost	drug	_	corticosteroids	group	_	false	during clinical trials , druga was used concurrently with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and other medications .
DDI-DrugBank.d549.s4.p0	iloprost	drug	_	digoxin	drug	_	false	intravenous infusion of druga had no effect on the pharmacokinetics of drugb .
DDI-DrugBank.d549.s5.p0	Acetylsalicylic acid	drug	_	iloprost	drug	_	false	druga did not alter the clearance -lcb- pharmacokinetics -rcb- of drugb .
DDI-DrugBank.d115.s0.p1	imatinib	drug	_	Gleevec	brand	_	false	drugs that may alter druga plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering drugb with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p2	imatinib	drug	_	ketoconazole	drug	_	false	drugs that may alter druga plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p3	imatinib	drug	_	itraconazole	drug	_	false	drugs that may alter druga plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p4	imatinib	drug	_	erythromycin	drug	_	false	drugs that may alter druga plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d115.s0.p5	imatinib	drug	_	clarithromycin	drug	_	false	drugs that may alter druga plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d115.s0.p6	imatinib	drug	_	Gleevec	brand	_	false	drugs that may alter drugn plasma concentrations drugs that may increase druga plasma concentrations : caution is recommended when administering drugb with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p7	imatinib	drug	_	ketoconazole	drug	_	false	drugs that may alter drugn plasma concentrations drugs that may increase druga plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p8	imatinib	drug	_	itraconazole	drug	_	false	drugs that may alter drugn plasma concentrations drugs that may increase druga plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p9	imatinib	drug	_	erythromycin	drug	_	false	drugs that may alter drugn plasma concentrations drugs that may increase druga plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d115.s0.p10	imatinib	drug	_	clarithromycin	drug	_	false	drugs that may alter drugn plasma concentrations drugs that may increase druga plasma concentrations : caution is recommended when administering drugn with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d115.s0.p11	Gleevec	brand	_	ketoconazole	drug	_	advise	drugs that may alter drugn plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering druga with inhibitors of the cyp3a4 family -lcb- e , g , , drugb , drugn , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p12	Gleevec	brand	_	itraconazole	drug	_	advise	drugs that may alter drugn plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering druga with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugb , drugn , drugn -rcb- .
DDI-DrugBank.d115.s0.p13	Gleevec	brand	_	erythromycin	drug	_	advise	drugs that may alter drugn plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering druga with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugb , drugn -rcb- .
DDI-DrugBank.d115.s0.p14	Gleevec	brand	_	clarithromycin	drug	_	advise	drugs that may alter drugn plasma concentrations drugs that may increase drugn plasma concentrations : caution is recommended when administering druga with inhibitors of the cyp3a4 family -lcb- e , g , , drugn , drugn , drugn , drugb -rcb- .
DDI-DrugBank.d115.s2.p0	imatinib	drug	_	Gleevec	brand	_	false	there is a significant increase in exposure to druga when drugb is coadministered with drugn -lcb- cyp3a4 inhibitor -rcb- .
DDI-DrugBank.d115.s2.p1	imatinib	drug	_	ketoconazole	drug	_	false	there is a significant increase in exposure to druga when drugn is coadministered with drugb -lcb- cyp3a4 inhibitor -rcb- .
DDI-DrugBank.d115.s2.p2	Gleevec	brand	_	ketoconazole	drug	_	mechanism	there is a significant increase in exposure to drugn when druga is coadministered with drugb -lcb- cyp3a4 inhibitor -rcb- .
DDI-DrugBank.d115.s6.p0	rifampin	drug	_	Gleevec	brand	_	mechanism	pretreatment of healthy volunteers with multiple doses of druga followed by a single dose of drugb , increased drugn oral-dose clearance by # - fold , which significantly -lcb- p # -rcb- decreased mean cmax and auc -lcb- 0-8 -rcb- .
DDI-DrugBank.d115.s6.p1	rifampin	drug	_	Gleevec	brand	_	false	pretreatment of healthy volunteers with multiple doses of druga followed by a single dose of drugn , increased drugb oral-dose clearance by # - fold , which significantly -lcb- p # -rcb- decreased mean cmax and auc -lcb- 0-8 -rcb- .
DDI-DrugBank.d115.s8.p1	Gleevec	brand	_	simvastatin	drug	_	false	drugs that may have their plasma concentration altered by druga drugn increases the mean cmax and auc of drugb -lcb- cyp3a4 substrate -rcb- 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by drugn .
DDI-DrugBank.d115.s8.p3	Gleevec	brand	_	simvastatin	drug	_	mechanism	drugs that may have their plasma concentration altered by drugn druga increases the mean cmax and auc of drugb -lcb- cyp3a4 substrate -rcb- 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by drugn .
DDI-DrugBank.d115.s8.p5	simvastatin	drug	_	Gleevec	brand	_	false	drugs that may have their plasma concentration altered by drugn drugn increases the mean cmax and auc of druga -lcb- cyp3a4 substrate -rcb- 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by drugb .
DDI-DrugBank.d115.s9.p0	Gleevec	brand	_	cyclosporine	drug	_	advise	particular caution is recommended when administering druga with cyp3a4 substrates that have a narrow therapeutic window -lcb- e , g , , drugb or drugn -rcb- .
DDI-DrugBank.d115.s9.p1	Gleevec	brand	_	pimozide	drug	_	advise	particular caution is recommended when administering druga with cyp3a4 substrates that have a narrow therapeutic window -lcb- e , g , , drugn or drugb -rcb- .
DDI-DrugBank.d115.s10.p0	Gleevec	brand	_	benzodiazepines	group	_	mechanism	druga will increase plasmaconcentration of other cyp3a4 metabolized drugs -lcb- e , g , , triazolo - drugb , drugn , certain drugn , etc , -rcb- .
DDI-DrugBank.d115.s10.p1	Gleevec	brand	_	dihydropyridine calcium channel blockers	group	_	mechanism	druga will increase plasmaconcentration of other cyp3a4 metabolized drugs -lcb- e , g , , triazolo - drugn , drugb , certain drugn , etc , -rcb- .
DDI-DrugBank.d115.s10.p2	Gleevec	brand	_	HMG-CoA reductase inhibitors	group	_	mechanism	druga will increase plasmaconcentration of other cyp3a4 metabolized drugs -lcb- e , g , , triazolo - drugn , drugn , certain drugb , etc , -rcb- .
DDI-DrugBank.d115.s11.p0	warfarin	drug	_	heparin	drug	_	false	because druga is metabolized by cyp2c9 and cyp3a4 , patients who require anticoagulation should receive low-molecular weight or standard drugb .
DDI-DrugBank.d115.s16.p0	acetaminophen	drug	_	Gleevec	brand	_	mechanism	systemic exposure to druga is expected to be increased when coadministered with drugb .
DDI-DrugBank.d77.s2.p0	decongestants	group	_	anesthetics	group	_	false	avoid the use of preparations such as druga and local drugb which contain any drugn -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p1	decongestants	group	_	sympathomimetic amine	group	_	false	avoid the use of preparations such as druga and local drugn which contain any drugb -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p2	decongestants	group	_	epinephrine	drug	_	false	avoid the use of preparations such as druga and local drugn which contain any drugn -lcb- e , g , , drugb , drugn -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p3	decongestants	group	_	norepinephrine	drug	_	false	avoid the use of preparations such as druga and local drugn which contain any drugn -lcb- e , g , , drugn , drugb -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p4	decongestants	group	_	tricyclic antidepressants	group	_	advise	avoid the use of preparations such as druga and local drugn which contain any drugn -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugb can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p5	anesthetics	group	_	sympathomimetic amine	group	_	false	avoid the use of preparations such as drugn and local druga which contain any drugb -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p6	anesthetics	group	_	epinephrine	drug	_	false	avoid the use of preparations such as drugn and local druga which contain any drugn -lcb- e , g , , drugb , drugn -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p7	anesthetics	group	_	norepinephrine	drug	_	false	avoid the use of preparations such as drugn and local druga which contain any drugn -lcb- e , g , , drugn , drugb -rcb- , since it has been reported that drugn can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p8	anesthetics	group	_	tricyclic antidepressants	group	_	advise	avoid the use of preparations such as drugn and local druga which contain any drugn -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugb can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p11	sympathomimetic amine	group	_	tricyclic antidepressants	group	_	advise	avoid the use of preparations such as drugn and local drugn which contain any druga -lcb- e , g , , drugn , drugn -rcb- , since it has been reported that drugb can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p13	epinephrine	drug	_	tricyclic antidepressants	group	_	advise	avoid the use of preparations such as drugn and local drugn which contain any drugn -lcb- e , g , , druga , drugn -rcb- , since it has been reported that drugb can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s2.p14	norepinephrine	drug	_	tricyclic antidepressants	group	_	advise	avoid the use of preparations such as drugn and local drugn which contain any drugn -lcb- e , g , , drugn , druga -rcb- , since it has been reported that drugb can potentiate the effects of catecholamines .
DDI-DrugBank.d77.s4.p0	Imipramine hydrochloride	drug	_	CNS depressant drugs	group	_	effect	druga may potentiate the effects of drugb .
DDI-DrugBank.d77.s5.p0	imipramine	drug	_	cimetidine	drug	_	mechanism	the plasma concentration of druga may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugb , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p1	imipramine	drug	_	fluoxetine	drug	_	mechanism	the plasma concentration of druga may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , drugb -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p2	imipramine	drug	_	barbiturates	group	_	mechanism	the plasma concentration of druga may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p3	imipramine	drug	_	phenytoin	drug	_	mechanism	the plasma concentration of druga may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p6	cimetidine	drug	_	barbiturates	group	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p7	cimetidine	drug	_	phenytoin	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p8	cimetidine	drug	_	imipramine	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , druga , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and adjustment of the dosage of drugb may therefore be necessary .
DDI-DrugBank.d77.s5.p9	fluoxetine	drug	_	barbiturates	group	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugb , drugn -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p10	fluoxetine	drug	_	phenytoin	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugb -rcb- , and adjustment of the dosage of drugn may therefore be necessary .
DDI-DrugBank.d77.s5.p11	fluoxetine	drug	_	imipramine	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , druga -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , drugn -rcb- , and adjustment of the dosage of drugb may therefore be necessary .
DDI-DrugBank.d77.s5.p13	barbiturates	group	_	imipramine	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , druga , drugn -rcb- , and adjustment of the dosage of drugb may therefore be necessary .
DDI-DrugBank.d77.s5.p14	phenytoin	drug	_	imipramine	drug	_	false	the plasma concentration of drugn may increase when the drug is given concomitantly with hepatic enzyme inhibitors -lcb- e , g , , drugn , drugn -rcb- and decrease by concomitant administration of hepatic enzyme inducers -lcb- e , g , , drugn , druga -rcb- , and adjustment of the dosage of drugb may therefore be necessary .
DDI-DrugBank.d77.s14.p0	cimetidine	drug	_	antidepressants	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugb , drugn , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d77.s14.p1	cimetidine	drug	_	phenothiazines	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugb , and the drugn drugn and drugn -rcb- .
DDI-DrugBank.d77.s14.p2	cimetidine	drug	_	Type 1C antiarrhythmics	group	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugb drugn and drugn -rcb- .
DDI-DrugBank.d77.s14.p3	cimetidine	drug	_	propafenone	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugb and drugn -rcb- .
DDI-DrugBank.d77.s14.p4	cimetidine	drug	_	flecainide	drug	_	false	druga -rcb- and many that are substrates for cyp2b6 2d6 -lcb- many other drugn , drugn , and the drugn drugn and drugb -rcb- .
DDI-DrugBank.d77.s15.p1	selective serotonin reuptake inhibitors	group	_	fluoxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s15.p2	selective serotonin reuptake inhibitors	group	_	sertraline	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s15.p3	selective serotonin reuptake inhibitors	group	_	paroxetine	drug	_	false	while all the druga -lcb- drugn -rcb- , e , g , , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s15.p4	SSRIs	group	_	fluoxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugb , drugn , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s15.p5	SSRIs	group	_	sertraline	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugb , and drugn , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s15.p6	SSRIs	group	_	paroxetine	drug	_	false	while all the drugn -lcb- druga -rcb- , e , g , , drugn , drugn , and drugb , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .
DDI-DrugBank.d77.s16.p0	SSRI	group	_	TCA	group	_	int	the extent to which druga - drugb interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the drugn involved .
DDI-DrugBank.d77.s16.p2	TCA	group	_	SSRI	group	_	false	the extent to which drugn - druga interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the drugb involved .
DDI-DrugBank.d97.s4.p0	CRIXIVAN	brand	_	indinavir	drug	_	false	coadministration of druga and other drugs that inhibit cyp3a4 may decrease the clearance of drugb and may result in increased plasma concentrations of drugn .
DDI-DrugBank.d97.s4.p1	CRIXIVAN	brand	_	indinavir	drug	_	false	coadministration of druga and other drugs that inhibit cyp3a4 may decrease the clearance of drugn and may result in increased plasma concentrations of drugb .
DDI-DrugBank.d97.s8.p0	Antiarrhythmics	group	_	amiodarone	drug	_	false	druga : drugb
DDI-DrugBank.d97.s10.p2	dihydroergotamine	drug	_	methylergonovine	drug	_	false	ergot derivatives : druga , drugn , drugn , drugb
DDI-DrugBank.d97.s10.p5	ergotamine	drug	_	methylergonovine	drug	_	false	ergot derivatives : drugn , drugn , druga , drugb
DDI-DrugBank.d97.s12.p0	Sedative	group	_	hypnotics	group	_	false	druga / drugb : drugn , drugn
DDI-DrugBank.d97.s12.p1	Sedative	group	_	midazolam	drug	_	false	druga / drugn : drugb , drugn
DDI-DrugBank.d97.s12.p2	Sedative	group	_	triazolam	drug	_	false	druga / drugn : drugn , drugb
DDI-DrugBank.d97.s12.p3	hypnotics	group	_	midazolam	drug	_	false	drugn / druga : drugb , drugn
DDI-DrugBank.d97.s12.p4	hypnotics	group	_	triazolam	drug	_	false	drugn / druga : drugn , drugb
DDI-DrugBank.d97.s12.p5	midazolam	drug	_	triazolam	drug	_	false	drugn / drugn : druga , drugb
DDI-DrugBank.d97.s16.p0	Neuroleptic	group	_	pimozide	drug	_	false	druga : drugb
DDI-DrugBank.d97.s19.p0	CRIXIVAN	brand	_	protease inhibitors	group	_	false	may lead to loss of virologic response and possible resistance to druga or to the class of drugb .
DDI-DrugBank.d97.s20.p0	Antimycobacterial	group	_	rifampin	drug	_	false	druga : drugb
DDI-DrugBank.d97.s21.p0	CRIXIVAN	brand	_	protease inhibitors	group	_	false	may lead to loss of virologic response and possible resistance to druga or to the class of drugb or other coadministered drugn .
DDI-DrugBank.d97.s21.p1	CRIXIVAN	brand	_	antiretroviral agents	group	_	false	may lead to loss of virologic response and possible resistance to druga or to the class of drugn or other coadministered drugb .
DDI-DrugBank.d97.s21.p2	protease inhibitors	group	_	antiretroviral agents	group	_	false	may lead to loss of virologic response and possible resistance to drugn or to the class of druga or other coadministered drugb .
DDI-DrugBank.d97.s22.p0	HMG-CoA Reductase inhibitors	group	_	lovastatin	drug	_	false	druga : drugb , drugn
DDI-DrugBank.d97.s22.p1	HMG-CoA Reductase inhibitors	group	_	simvastatin	drug	_	false	druga : drugn , drugb
DDI-DrugBank.d97.s22.p2	lovastatin	drug	_	simvastatin	drug	_	false	drugn : druga , drugb
DDI-DrugBank.d97.s24.p0	Protease inhibitor	group	_	atazanavir	drug	_	false	druga : drugb
DDI-DrugBank.d97.s25.p0	CRIXIVAN	brand	_	atazanavir	drug	_	false	both druga and drugb are associated with indirect -lcb- unconjugated -rcb- hyperbilirubinemia .
DDI-DrugBank.d97.s26.p0	CRIXIVAN	brand	_	atazanavir	drug	_	advise	combinations of these drugs have not been studied and coadministration of druga and drugb is not recommended .
DDI-DrugBank.d97.s35.p0	CRIXIVAN	brand	_	delavirdine	drug	_	advise	dose reduction of druga to # mg every # hours should be considered when taking drugb # mg three times a day .
DDI-DrugBank.d97.s37.p0	Indinavir	drug	_	didanosine	drug	_	advise	druga and drugb formulations containing buffer should be administered at least one hour apart on an empty stomach .
DDI-DrugBank.d97.s40.p0	indinavir	drug	_	efavirenz	drug	_	false	the optimal dose of druga , when given in combination with drugb , is not known .
DDI-DrugBank.d97.s41.p1	indinavir	drug	_	efavirenz	drug	_	false	increasing the druga dose to # mg every # hours does not compensate for the increased drugn metabolism due to drugb .
DDI-DrugBank.d97.s41.p2	indinavir	drug	_	efavirenz	drug	_	mechanism	increasing the drugn dose to # mg every # hours does not compensate for the increased druga metabolism due to drugb .
DDI-DrugBank.d97.s47.p0	Indinavir	drug	_	nevirapine	drug	_	mechanism	druga concentrations may be decreased in the presence of drugb .
DDI-DrugBank.d97.s50.p0	indinavir	drug	_	ritonavir	drug	_	false	druga concentration drugb concentration
DDI-DrugBank.d97.s52.p0	indinavir	drug	_	ritonavir	drug	_	effect	preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving druga in combination with drugb than those receiving drugn # mg q8h .
DDI-DrugBank.d97.s52.p1	indinavir	drug	_	CRIXIVAN	brand	_	false	preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving druga in combination with drugn than those receiving drugb # mg q8h .
DDI-DrugBank.d97.s52.p2	ritonavir	drug	_	CRIXIVAN	brand	_	false	preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drugn in combination with druga than those receiving drugb # mg q8h .
DDI-DrugBank.d97.s57.p0	Antiarrhythmics	group	_	bepridil	drug	_	false	druga : drugb , drugn -lcb- systemic -rcb- and drugn
DDI-DrugBank.d97.s57.p1	Antiarrhythmics	group	_	lidocaine	drug	_	false	druga : drugn , drugb -lcb- systemic -rcb- and drugn
DDI-DrugBank.d97.s57.p2	Antiarrhythmics	group	_	quinidine	drug	_	false	druga : drugn , drugn -lcb- systemic -rcb- and drugb
DDI-DrugBank.d97.s59.p0	antiarrhythmics	group	_	CRIXIVAN	brand	_	advise	caution is warranted and therapeutic concentration monitoring is recommended for druga when coadministered with drugb .
DDI-DrugBank.d97.s60.p0	Anticonvulsants	group	_	carbamazepine	drug	_	false	druga : drugb , drugn , drugn
DDI-DrugBank.d97.s60.p1	Anticonvulsants	group	_	phenobarbital	drug	_	false	druga : drugn , drugb , drugn
DDI-DrugBank.d97.s60.p2	Anticonvulsants	group	_	phenytoin	drug	_	false	druga : drugn , drugn , drugb
DDI-DrugBank.d97.s60.p3	carbamazepine	drug	_	phenobarbital	drug	_	false	drugn : druga , drugb , drugn
DDI-DrugBank.d97.s60.p4	carbamazepine	drug	_	phenytoin	drug	_	false	drugn : druga , drugn , drugb
DDI-DrugBank.d97.s60.p5	phenobarbital	drug	_	phenytoin	drug	_	false	drugn : drugn , druga , drugb
DDI-DrugBank.d97.s63.p0	CRIXIVAN	brand	_	indinavir	drug	_	effect	druga may not be effective due to decreased drugb concentrations in patients taking these agents concomitantly .
DDI-DrugBank.d97.s64.p0	Calcium Channel Blockers	group	_	Dihydropyridine	group	_	false	druga , drugb : e , g , , drugn , drugn , drugn
DDI-DrugBank.d97.s64.p1	Calcium Channel Blockers	group	_	felodipine	drug	_	false	druga , drugn : e , g , , drugb , drugn , drugn
DDI-DrugBank.d97.s64.p2	Calcium Channel Blockers	group	_	nifedipine	drug	_	false	druga , drugn : e , g , , drugn , drugb , drugn
DDI-DrugBank.d97.s64.p3	Calcium Channel Blockers	group	_	nicardipine	drug	_	false	druga , drugn : e , g , , drugn , drugn , drugb
DDI-DrugBank.d97.s64.p4	Dihydropyridine	group	_	felodipine	drug	_	false	drugn , druga : e , g , , drugb , drugn , drugn
DDI-DrugBank.d97.s64.p5	Dihydropyridine	group	_	nifedipine	drug	_	false	drugn , druga : e , g , , drugn , drugb , drugn
DDI-DrugBank.d97.s64.p6	Dihydropyridine	group	_	nicardipine	drug	_	false	drugn , druga : e , g , , drugn , drugn , drugb
DDI-DrugBank.d97.s64.p7	felodipine	drug	_	nifedipine	drug	_	false	drugn , drugn : e , g , , druga , drugb , drugn
DDI-DrugBank.d97.s64.p8	felodipine	drug	_	nicardipine	drug	_	false	drugn , drugn : e , g , , druga , drugn , drugb
DDI-DrugBank.d97.s64.p9	nifedipine	drug	_	nicardipine	drug	_	false	drugn , drugn : e , g , , drugn , druga , drugb
DDI-DrugBank.d97.s68.p0	clarithromycin	drug	_	indinavir	drug	_	false	druga concentration drugb concentration
DDI-DrugBank.d97.s70.p0	HMG-CoA Reductase Inhibitor	group	_	atorvastatin	drug	_	false	druga : drugb
DDI-DrugBank.d97.s72.p0	atorvastatin	drug	_	HMG-CoA reductase inhibitors	group	_	false	use lowest possible dose of druga with careful monitoring , or consider drugb that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or drugn in combination with drugn .
DDI-DrugBank.d97.s72.p1	atorvastatin	drug	_	pravastatin	drug	_	false	use lowest possible dose of druga with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugb , drugn , or drugn in combination with drugn .
DDI-DrugBank.d97.s72.p2	atorvastatin	drug	_	fluvastatin	drug	_	false	use lowest possible dose of druga with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugn , drugb , or drugn in combination with drugn .
DDI-DrugBank.d97.s72.p3	atorvastatin	drug	_	rosuvastatin	drug	_	false	use lowest possible dose of druga with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or drugb in combination with drugn .
DDI-DrugBank.d97.s72.p4	atorvastatin	drug	_	CRIXIVAN	brand	_	advise	use lowest possible dose of druga with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or drugn in combination with drugb .
DDI-DrugBank.d97.s72.p5	HMG-CoA reductase inhibitors	group	_	pravastatin	drug	_	false	use lowest possible dose of drugn with careful monitoring , or consider druga that are not primarily metabolized by cyp3a4 , such as drugb , drugn , or drugn in combination with drugn .
DDI-DrugBank.d97.s72.p6	HMG-CoA reductase inhibitors	group	_	fluvastatin	drug	_	false	use lowest possible dose of drugn with careful monitoring , or consider druga that are not primarily metabolized by cyp3a4 , such as drugn , drugb , or drugn in combination with drugn .
DDI-DrugBank.d97.s72.p7	HMG-CoA reductase inhibitors	group	_	rosuvastatin	drug	_	false	use lowest possible dose of drugn with careful monitoring , or consider druga that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or drugb in combination with drugn .
DDI-DrugBank.d97.s72.p8	HMG-CoA reductase inhibitors	group	_	CRIXIVAN	brand	_	advise	use lowest possible dose of drugn with careful monitoring , or consider druga that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or drugn in combination with drugb .
DDI-DrugBank.d97.s72.p11	pravastatin	drug	_	CRIXIVAN	brand	_	false	use lowest possible dose of drugn with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as druga , drugn , or drugn in combination with drugb .
DDI-DrugBank.d97.s72.p13	fluvastatin	drug	_	CRIXIVAN	brand	_	false	use lowest possible dose of drugn with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugn , druga , or drugn in combination with drugb .
DDI-DrugBank.d97.s72.p14	rosuvastatin	drug	_	CRIXIVAN	brand	_	false	use lowest possible dose of drugn with careful monitoring , or consider drugn that are not primarily metabolized by cyp3a4 , such as drugn , drugn , or druga in combination with drugb .
DDI-DrugBank.d97.s73.p0	Immunosuppressants	group	_	cyclosporine	drug	_	false	druga : drugb , drugn , drugn
DDI-DrugBank.d97.s73.p1	Immunosuppressants	group	_	tacrolimus	drug	_	false	druga : drugn , drugb , drugn
DDI-DrugBank.d97.s73.p2	Immunosuppressants	group	_	sirolimus	drug	_	false	druga : drugn , drugn , drugb
DDI-DrugBank.d97.s73.p3	cyclosporine	drug	_	tacrolimus	drug	_	false	drugn : druga , drugb , drugn
DDI-DrugBank.d97.s73.p4	cyclosporine	drug	_	sirolimus	drug	_	false	drugn : druga , drugn , drugb
DDI-DrugBank.d97.s73.p5	tacrolimus	drug	_	sirolimus	drug	_	false	drugn : drugn , druga , drugb
DDI-DrugBank.d97.s78.p0	CRIXIVAN	brand	_	itraconazole	drug	_	advise	dose reduction of druga to # mg every # hours is recommended when administering drugb concurrently .
DDI-DrugBank.d97.s83.p0	indinavir	drug	_	rifabutin	drug	_	false	druga concentration drugb concentration
DDI-DrugBank.d97.s84.p0	rifabutin	drug	_	CRIXIVAN	brand	_	false	dose reduction of druga to half the standard dose and a dose increase of drugb to # mg -lcb- three 333-mg capsules -rcb- every # hours are recommended when drugn and drugn are coadministered .
DDI-DrugBank.d97.s84.p2	rifabutin	drug	_	CRIXIVAN	brand	_	false	dose reduction of druga to half the standard dose and a dose increase of drugn to # mg -lcb- three 333-mg capsules -rcb- every # hours are recommended when drugn and drugb are coadministered .
DDI-DrugBank.d97.s84.p3	CRIXIVAN	brand	_	rifabutin	drug	_	false	dose reduction of drugn to half the standard dose and a dose increase of druga to # mg -lcb- three 333-mg capsules -rcb- every # hours are recommended when drugb and drugn are coadministered .
DDI-DrugBank.d97.s84.p5	rifabutin	drug	_	CRIXIVAN	brand	_	advise	dose reduction of drugn to half the standard dose and a dose increase of drugn to # mg -lcb- three 333-mg capsules -rcb- every # hours are recommended when druga and drugb are coadministered .
DDI-DrugBank.d97.s87.p0	Sildenafil	drug	_	indinavir	drug	_	advise	druga dose should not exceed a maximum of # mg in a 48 - hour period in patients receiving concomitant drugb therapy .
DDI-DrugBank.d97.s90.p0	Tadalafil	drug	_	indinavir	drug	_	advise	druga dose should not exceed a maximum of # mg in a 72 - hour period in patients receiving concomitant drugb therapy .
DDI-DrugBank.d97.s93.p0	Vardenafil	drug	_	indinavir	drug	_	advise	druga dose should not exceed a maximum of # mg in a 24-hour period in patients receiving concomitant drugb therapy .
DDI-DrugBank.d82.s0.p0	indomethacin	drug	_	diflunisal	drug	_	false	in normal volunteers receiving druga , the administration of drugb decreased the renal clearance and significantly increased the plasma levels of drugn .
DDI-DrugBank.d82.s0.p2	diflunisal	drug	_	indomethacin	drug	_	mechanism	in normal volunteers receiving drugn , the administration of druga decreased the renal clearance and significantly increased the plasma levels of drugb .
DDI-DrugBank.d82.s1.p0	INDOCIN	brand	_	diflunisal	drug	_	effect	in some patients , combined use of druga and drugb has been associated with fatal gastrointestinal hemorrhage .
DDI-DrugBank.d82.s2.p0	diflunisal	drug	_	INDOCIN	brand	_	advise	therefore , druga and drugb should not be used concomitantly .
DDI-DrugBank.d82.s3.p0	aspirin	brand	_	indomethacin	drug	_	mechanism	in a study in normal volunteers , it was found that chronic concurrent administration of # g of druga per day decreases drugb blood levels approximately 20 % .
DDI-DrugBank.d82.s4.p0	INDOCIN	brand	_	NSAIDs	group	_	advise	the concomitant use of druga with other drugb is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .
DDI-DrugBank.d82.s5.p0	INDOCIN	brand	_	anticoagulants	group	_	false	clinical studies have shown that druga does not influence the hypoprothrombinemia produced by drugb .
DDI-DrugBank.d82.s6.p0	INDOCIN	brand	_	anticoagulant	group	_	advise	however , when any additional drug , including druga , is added to the treatment of patients on drugb therapy , the patients should be observed for alterations of the prothrombin time .
DDI-DrugBank.d82.s7.p0	anticoagulants	group	_	INDOCIN	brand	_	effect	in post-marketing experience , bleeding has been reported in patients on concomitant treatment with druga and drugb .
DDI-DrugBank.d82.s8.p0	INDOCIN	brand	_	anticoagulants	group	_	advise	caution should be exercised when druga and drugb are administered concomitantly .
DDI-DrugBank.d82.s9.p0	INDOCIN	brand	_	probenecid	drug	_	mechanism	when druga is given to patients receiving drugb , the plasma levels of drugn are likely to be increased .
DDI-DrugBank.d82.s9.p1	INDOCIN	brand	_	indomethacin	drug	_	false	when druga is given to patients receiving drugn , the plasma levels of drugb are likely to be increased .
DDI-DrugBank.d82.s9.p2	probenecid	drug	_	indomethacin	drug	_	false	when drugn is given to patients receiving druga , the plasma levels of drugb are likely to be increased .
DDI-DrugBank.d82.s12.p0	INDOCIN	brand	_	methotrexate	drug	_	advise	caution should be used if druga is administered simultaneously with drugb .
DDI-DrugBank.d82.s13.p0	INDOCIN	brand	_	methotrexate	drug	_	mechanism	druga has been reported to decrease the tubular secretion of drugb and to potentiate its toxicity .
DDI-DrugBank.d82.s14.p0	non-steroidal anti-inflammatory drugs	group	_	cyclosporine	drug	_	effect	administration of druga concomitantly with drugb has been associated with an increase in drugn - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .
DDI-DrugBank.d82.s14.p1	non-steroidal anti-inflammatory drugs	group	_	cyclosporine	drug	_	false	administration of druga concomitantly with drugn has been associated with an increase in drugb - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .
DDI-DrugBank.d82.s15.p0	NSAIDs	group	_	cyclosporine	drug	_	advise	druga should be used with caution in patients taking drugb , and renal function should be carefully monitored .
DDI-DrugBank.d82.s16.p0	INDOCIN	brand	_	lithium	drug	_	mechanism	capsules druga # mg t , i , d , produced a clinically relevant elevation of plasma drugb and reduction in renal drugn clearance in psychiatric patients and normal subjects with steady state plasma drugn concentrations .
DDI-DrugBank.d82.s16.p1	INDOCIN	brand	_	lithium	drug	_	false	capsules druga # mg t , i , d , produced a clinically relevant elevation of plasma drugn and reduction in renal drugb clearance in psychiatric patients and normal subjects with steady state plasma drugn concentrations .
DDI-DrugBank.d82.s16.p2	INDOCIN	brand	_	lithium	drug	_	false	capsules druga # mg t , i , d , produced a clinically relevant elevation of plasma drugn and reduction in renal drugn clearance in psychiatric patients and normal subjects with steady state plasma drugb concentrations .
DDI-DrugBank.d82.s18.p0	INDOCIN	brand	_	lithium	drug	_	advise	as a consequence , when druga and drugb are given concomitantly , the patient should be carefully observed for signs of drugn toxicity .
DDI-DrugBank.d82.s18.p1	INDOCIN	brand	_	lithium	drug	_	false	as a consequence , when druga and drugn are given concomitantly , the patient should be carefully observed for signs of drugb toxicity .
DDI-DrugBank.d82.s21.p0	INDOCIN	brand	_	digoxin	drug	_	mechanism	druga given concomitantly with drugb has been reported to increase the serum concentration and prolong the half-life of drugn .
DDI-DrugBank.d82.s21.p1	INDOCIN	brand	_	digoxin	drug	_	false	druga given concomitantly with drugn has been reported to increase the serum concentration and prolong the half-life of drugb .
DDI-DrugBank.d82.s22.p0	INDOCIN	brand	_	digoxin	drug	_	advise	therefore , when druga and drugb are used concomitantly , serum drugn levels should be closely monitored .
DDI-DrugBank.d82.s22.p1	INDOCIN	brand	_	digoxin	drug	_	false	therefore , when druga and drugn are used concomitantly , serum drugb levels should be closely monitored .
DDI-DrugBank.d82.s23.p0	INDOCIN	brand	_	loop diuretics	group	_	effect	in some patients , the administration of druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugb , drugn , and drugn .
DDI-DrugBank.d82.s23.p1	INDOCIN	brand	_	potassium-sparing diuretics	group	_	effect	in some patients , the administration of druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugb , and drugn .
DDI-DrugBank.d82.s23.p2	INDOCIN	brand	_	thiazide diuretics	group	_	effect	in some patients , the administration of druga can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , drugn , and drugb .
DDI-DrugBank.d82.s23.p4	loop diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of drugn can reduce the diuretic , natriuretic , and antihypertensive effects of druga , drugn , and drugb .
DDI-DrugBank.d82.s23.p5	potassium-sparing diuretics	group	_	thiazide diuretics	group	_	false	in some patients , the administration of drugn can reduce the diuretic , natriuretic , and antihypertensive effects of drugn , druga , and drugb .
DDI-DrugBank.d82.s25.p0	Indomethacin	drug	_	diuretics	group	_	false	-lcb- druga -rcb- drugb are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugn is obtained .
DDI-DrugBank.d82.s25.p1	Indomethacin	drug	_	diuretic	group	_	false	-lcb- druga -rcb- drugn are used concomitantly , the patient should be observed closely to determine if the desired effect of the drugb is obtained .
DDI-DrugBank.d82.s26.p0	INDOCIN	brand	_	furosemide	drug	_	false	druga reduces basal plasma renin activity -lcb- pra -rcb- , as well as those elevations of pra induced by drugb administration , or salt or volume depletion .
DDI-DrugBank.d82.s28.p0	triamterene	drug	_	INDOCIN	brand	_	effect	it has been reported that the addition of druga to a maintenance schedule of drugb resulted in reversible acute renal failure in two of four healthy volunteers .
DDI-DrugBank.d82.s29.p0	INDOCIN	brand	_	triamterene	drug	_	advise	druga and drugb should not be administered together .
DDI-DrugBank.d82.s30.p0	INDOCIN	brand	_	potassium-sparing diuretics	group	_	false	druga and drugb each may be associated with increased serum potassium levels .
DDI-DrugBank.d82.s31.p0	INDOCIN	brand	_	potassium-sparing diuretics	group	_	effect	the potential effects of druga and drugb on potassium kinetics and renal function should be considered when these agents are administered concurrently .
DDI-DrugBank.d82.s32.p0	diuretics	group	_	INDOCIN	brand	_	effect	most of the above effects concerning druga have been attributed , at least in part , to mechanisms involving inhibition of prostaglandin synthesis by drugb .
DDI-DrugBank.d82.s33.p0	beta-adrenoceptor blocking agents	group	_	non-steroidal antiinflammatory drugs	group	_	effect	blunting of the antihypertensive effect of druga by drugb including drugn has been reported .
DDI-DrugBank.d82.s33.p1	beta-adrenoceptor blocking agents	group	_	INDOCIN	brand	_	effect	blunting of the antihypertensive effect of druga by drugn including drugb has been reported .
DDI-DrugBank.d82.s33.p2	non-steroidal antiinflammatory drugs	group	_	INDOCIN	brand	_	false	blunting of the antihypertensive effect of drugn by druga including drugb has been reported .
DDI-DrugBank.d82.s35.p0	INDOCIN	brand	_	captopril	drug	_	effect	druga can reduce the antihypertensive effects of drugb and drugn .
DDI-DrugBank.d82.s35.p1	INDOCIN	brand	_	losartan	drug	_	effect	druga can reduce the antihypertensive effects of drugn and drugb .
DDI-DrugBank.d82.s35.p2	captopril	drug	_	losartan	drug	_	false	drugn can reduce the antihypertensive effects of druga and drugb .
DDI-DrugBank.d45.s0.p0	etanercept	drug	_	anakinra	drug	_	effect	concurrent administration of druga -lcb- another tnf - blocking agent -rcb- and drugb -lcb- an drugn -rcb- has been associated with an increased risk of serious infections , and increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d45.s0.p1	etanercept	drug	_	interleukin-1 antagonist	group	_	false	concurrent administration of druga -lcb- another tnf - blocking agent -rcb- and drugn -lcb- an drugb -rcb- has been associated with an increased risk of serious infections , and increased risk of neutropenia and no additional benefit compared to these medicinal products alone .
DDI-DrugBank.d45.s1.p1	TNFa-blocking agents	group	_	anakinra	drug	_	effect	other druga -lcb- including drugn -rcb- used in combination with drugb may also result in similar toxicities .
DDI-DrugBank.d45.s1.p2	REMICADE	brand	_	anakinra	drug	_	effect	other drugn -lcb- including druga -rcb- used in combination with drugb may also result in similar toxicities .
DDI-DrugBank.d45.s4.p0	MTX	drug	_	nonsteroidal anti-inflammatory agents	group	_	false	in rheumatoid arthritis , concomitant medications besides druga were drugb , drugn , drugn and/or drugn .
DDI-DrugBank.d45.s4.p1	MTX	drug	_	folic acid	drug	_	false	in rheumatoid arthritis , concomitant medications besides druga were drugn , drugb , drugn and/or drugn .
DDI-DrugBank.d45.s4.p2	MTX	drug	_	corticosteroids	group	_	false	in rheumatoid arthritis , concomitant medications besides druga were drugn , drugn , drugb and/or drugn .
DDI-DrugBank.d45.s4.p3	MTX	drug	_	narcotics	group	_	false	in rheumatoid arthritis , concomitant medications besides druga were drugn , drugn , drugn and/or drugb .
DDI-DrugBank.d45.s4.p6	nonsteroidal anti-inflammatory agents	group	_	narcotics	group	_	false	in rheumatoid arthritis , concomitant medications besides drugn were druga , drugn , drugn and/or drugb .
DDI-DrugBank.d45.s4.p8	folic acid	drug	_	narcotics	group	_	false	in rheumatoid arthritis , concomitant medications besides drugn were drugn , druga , drugn and/or drugb .
DDI-DrugBank.d45.s4.p9	corticosteroids	group	_	narcotics	group	_	false	in rheumatoid arthritis , concomitant medications besides drugn were drugn , drugn , druga and/or drugb .
DDI-DrugBank.d45.s5.p4	antivirals	group	_	corticosteroids	group	_	false	concomitant crohn s disease medications were drugn , druga , drugb , drugn / drugn and aminosalicylates .
DDI-DrugBank.d45.s6.p0	MTX	drug	_	nonsteroidal anti-inflammatory agents	group	_	false	in psoriatic arthritis clinical trials , concomitant medications included druga in approximately half of the patients as well as drugb , drugn and drugn .
DDI-DrugBank.d45.s6.p1	MTX	drug	_	folic acid	drug	_	false	in psoriatic arthritis clinical trials , concomitant medications included druga in approximately half of the patients as well as drugn , drugb and drugn .
DDI-DrugBank.d45.s6.p2	MTX	drug	_	corticosteroids	group	_	false	in psoriatic arthritis clinical trials , concomitant medications included druga in approximately half of the patients as well as drugn , drugn and drugb .
DDI-DrugBank.d45.s8.p0	infliximab	drug	_	corticosteroids	group	_	false	serum druga concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including drugb , drugn -lcb- drugn or drugn -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p1	infliximab	drug	_	antibiotics	group	_	false	serum druga concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including drugn , drugb -lcb- drugn or drugn -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p2	infliximab	drug	_	metronidazole	drug	_	false	serum druga concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including drugn , drugn -lcb- drugb or drugn -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p3	infliximab	drug	_	ciprofloxacin	drug	_	false	serum druga concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including drugn , drugn -lcb- drugn or drugb -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p4	corticosteroids	group	_	antibiotics	group	_	false	serum drugn concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including druga , drugb -lcb- drugn or drugn -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p5	corticosteroids	group	_	metronidazole	drug	_	false	serum drugn concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including druga , drugn -lcb- drugb or drugn -rcb- and aminosalicylates .
DDI-DrugBank.d45.s8.p6	corticosteroids	group	_	ciprofloxacin	drug	_	false	serum drugn concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including druga , drugn -lcb- drugn or drugb -rcb- and aminosalicylates .
DDI-DrugBank.d527.s1.p4	ACE inhibitors	group	_	propoxyphene	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d527.s1.p6	ACE inhibitors	group	_	somatostatin analog	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d527.s1.p7	ACE inhibitors	group	_	octreotide	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , drugn .
DDI-DrugBank.d527.s1.p8	ACE inhibitors	group	_	sulfonamide antibiotics	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb .
DDI-DrugBank.d527.s2.p0	insulin	drug	_	corticosteroids	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugb , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p1	insulin	drug	_	danazol	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugb , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p2	insulin	drug	_	diuretics	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugb , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p3	insulin	drug	_	sympathomimetic agents	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugb -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p4	insulin	drug	_	epinephrine	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugb , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p5	insulin	drug	_	albuterol	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugb , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p6	insulin	drug	_	terbutaline	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugb -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p7	insulin	drug	_	isoniazid	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugb , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p8	insulin	drug	_	phenothiazine derivatives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugb , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p9	insulin	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p10	insulin	drug	_	thyroid hormones	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p11	insulin	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p12	insulin	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p13	insulin	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of druga : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p25	corticosteroids	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : druga , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p26	corticosteroids	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : druga , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p34	danazol	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p36	danazol	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p37	danazol	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p38	danazol	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p45	diuretics	group	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p47	diuretics	group	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p48	diuretics	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p49	diuretics	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p55	sympathomimetic agents	group	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p56	sympathomimetic agents	group	_	thyroid hormones	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p57	sympathomimetic agents	group	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p58	sympathomimetic agents	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p59	sympathomimetic agents	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p64	epinephrine	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p65	epinephrine	drug	_	thyroid hormones	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p66	epinephrine	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p67	epinephrine	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p68	epinephrine	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p72	albuterol	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p73	albuterol	drug	_	thyroid hormones	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p74	albuterol	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p75	albuterol	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p76	albuterol	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p79	terbutaline	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p80	terbutaline	drug	_	thyroid hormones	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p81	terbutaline	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p82	terbutaline	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p83	terbutaline	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p85	isoniazid	drug	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p87	isoniazid	drug	_	estrogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugn , drugn , drugb , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p88	isoniazid	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p89	isoniazid	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p93	phenothiazine derivatives	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p94	phenothiazine derivatives	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p97	somatropin	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p98	somatropin	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p100	thyroid hormones	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d527.s2.p101	thyroid hormones	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p103	estrogens	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s2.p104	progestogens	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect of drugn : drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d527.s3.p3	Beta-blockers	group	_	insulin	drug	_	effect	druga , drugn , drugn salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d527.s3.p6	clonidine	drug	_	insulin	drug	_	effect	drugn , druga , drugn salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d527.s3.p8	lithium	drug	_	insulin	drug	_	effect	drugn , drugn , druga salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d527.s3.p9	alcohol	drug	_	insulin	drug	_	effect	drugn , drugn , drugn salts , and druga may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d313.s1.p0	antidiabetic products	group	_	ACE inhibitors	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p1	antidiabetic products	group	_	disopyramide	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p3	antidiabetic products	group	_	fluoxetine	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p4	antidiabetic products	group	_	monoamine oxidase (MAO) inhibitors	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p5	antidiabetic products	group	_	propoxyphene	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p7	antidiabetic products	group	_	somatostatin analog	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p8	antidiabetic products	group	_	octreotide	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , drugn .
DDI-DrugBank.d313.s1.p9	antidiabetic products	group	_	sulfonamide antibiotics	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb .
DDI-DrugBank.d313.s1.p14	ACE inhibitors	group	_	propoxyphene	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p16	ACE inhibitors	group	_	somatostatin analog	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , drugn -rcb- , drugn .
DDI-DrugBank.d313.s1.p17	ACE inhibitors	group	_	octreotide	drug	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugb -rcb- , drugn .
DDI-DrugBank.d313.s1.p18	ACE inhibitors	group	_	sulfonamide antibiotics	group	_	false	the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn -rcb- , drugb .
DDI-DrugBank.d313.s2.p9	corticosteroids	group	_	somatropin	drug	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : druga , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugb , drugn , drugn , drugn -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p12	corticosteroids	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : druga , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p13	corticosteroids	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : druga , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p25	niacin	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , druga , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p26	niacin	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , druga , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p37	danazol	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p38	danazol	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , druga , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p48	diuretics	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p49	diuretics	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , druga , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p58	sympathomimetic agents	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p59	sympathomimetic agents	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , druga -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p67	epinephrine	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p68	epinephrine	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p75	salbutamol	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p76	salbutamol	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p82	terbutaline	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p83	terbutaline	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugn , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p88	isoniazid	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p89	isoniazid	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , druga , drugn , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p93	phenothiazine derivatives	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p94	phenothiazine derivatives	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , druga , drugn , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p97	somatropin	drug	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p98	somatropin	drug	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , druga , drugn , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p100	thyroid hormones	group	_	progestogens	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugb -lcb- e , g , , in oral drugn -rcb- .
DDI-DrugBank.d313.s2.p101	thyroid hormones	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , druga , drugn , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p103	estrogens	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , druga , drugn -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s2.p104	progestogens	group	_	contraceptives	group	_	false	the following are examples of substances that may reduce the blood-glucose-lowering effect : drugn , drugn , drugn , drugn , drugn -lcb- e , g , , drugn , drugn , drugn -rcb- , drugn , drugn , drugn , drugn , drugn , druga -lcb- e , g , , in oral drugb -rcb- .
DDI-DrugBank.d313.s3.p3	Beta-blockers	group	_	insulin	drug	_	effect	druga , drugn , drugn salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d313.s3.p6	clonidine	drug	_	insulin	drug	_	effect	drugn , druga , drugn salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d313.s3.p8	lithium	drug	_	insulin	drug	_	effect	drugn , drugn , druga salts , and drugn may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d313.s3.p9	alcohol	drug	_	insulin	drug	_	effect	drugn , drugn , drugn salts , and druga may either potentiate or weaken the blood-glucose-lowering effect of drugb .
DDI-DrugBank.d313.s7.p0	NovoLog	brand	_	NPH human insulin	drug	_	false	a clinical study in healthy male volunteers -lcb- n = 24 -rcb- demonstrated that mixing druga with drugb immediately before injection produced some attenuation in the peak concentration of drugn , but that the time to peak and the total bioavailability of drugn were not significantly affected .
DDI-DrugBank.d313.s7.p3	NPH human insulin	drug	_	NovoLog	brand	_	false	a clinical study in healthy male volunteers -lcb- n = 24 -rcb- demonstrated that mixing drugn with druga immediately before injection produced some attenuation in the peak concentration of drugb , but that the time to peak and the total bioavailability of drugn were not significantly affected .
DDI-DrugBank.d313.s7.p4	NPH human insulin	drug	_	NovoLog	brand	_	false	a clinical study in healthy male volunteers -lcb- n = 24 -rcb- demonstrated that mixing drugn with druga immediately before injection produced some attenuation in the peak concentration of drugn , but that the time to peak and the total bioavailability of drugb were not significantly affected .
DDI-DrugBank.d313.s8.p0	NovoLog	brand	_	NPH human insulin	drug	_	false	if druga is mixed with drugb , drugn should be drawn into the syringe first .
DDI-DrugBank.d313.s8.p2	NPH human insulin	drug	_	NovoLog	brand	_	false	if drugn is mixed with druga , drugb should be drawn into the syringe first .
DDI-DrugBank.d313.s10.p0	NovoLog	brand	_	zinc insulin	drug	_	false	because there are no data on the compatibility of druga and crystalline drugb preparations , drugn should not be mixed with these preparations .
DDI-DrugBank.d313.s10.p2	zinc insulin	drug	_	NovoLog	brand	_	false	because there are no data on the compatibility of drugn and crystalline druga preparations , drugb should not be mixed with these preparations .
DDI-DrugBank.d313.s11.p0	NovoLog	brand	_	insulins	group	_	false	the effects of mixing druga with drugb of animal source or drugn preparations produced by other manufacturers have not been studied .
DDI-DrugBank.d313.s11.p1	NovoLog	brand	_	insulin	drug	_	false	the effects of mixing druga with drugn of animal source or drugb preparations produced by other manufacturers have not been studied .
DDI-DrugBank.d313.s13.p0	insulin	drug	_	NovoLog	brand	_	false	when used in external subcutaneous infusion pumps for druga , drugb should not be mixed with any other drugn or diluent .
DDI-DrugBank.d313.s13.p2	NovoLog	brand	_	insulins	group	_	false	when used in external subcutaneous infusion pumps for drugn , druga should not be mixed with any other drugb or diluent .
DDI-DrugBank.d10.s1.p0	corticosteroid	group	_	ACTH	drug	_	false	although studies designed to examine drug interactions have not been done , it was noted that druga or drugb treatment of relapses for periods of up to # days has been administered to patients -lcb- n = 180 -rcb- receiving drugn .
DDI-DrugBank.d10.s1.p1	corticosteroid	group	_	Betaseron	brand	_	false	although studies designed to examine drug interactions have not been done , it was noted that druga or drugn treatment of relapses for periods of up to # days has been administered to patients -lcb- n = 180 -rcb- receiving drugb .
DDI-DrugBank.d10.s1.p2	ACTH	drug	_	Betaseron	brand	_	false	although studies designed to examine drug interactions have not been done , it was noted that drugn or druga treatment of relapses for periods of up to # days has been administered to patients -lcb- n = 180 -rcb- receiving drugb .
DDI-DrugBank.d10.s2.p0	Betaseron	brand	_	antipyrine	drug	_	mechanism	druga administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of drugb elimination # the effect of alternate-day administration of # mg of drugn on drug metabolism in ms patients is unknown .
DDI-DrugBank.d10.s2.p2	antipyrine	drug	_	Betaseron	brand	_	false	drugn administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of druga elimination # the effect of alternate-day administration of # mg of drugb on drug metabolism in ms patients is unknown .
DDI-DrugBank.d51.s0.p0	ATROVENT	brand	_	sympathomimetic bronchodilators	group	_	false	druga inhalation aerosol has been used concomitantly with other drugs , including drugb , drugn , and drugn , commonly used in the treatment of chronic obstructive pulmonary disease .
DDI-DrugBank.d51.s0.p1	ATROVENT	brand	_	methylxanthines	group	_	false	druga inhalation aerosol has been used concomitantly with other drugs , including drugn , drugb , and drugn , commonly used in the treatment of chronic obstructive pulmonary disease .
DDI-DrugBank.d51.s0.p2	ATROVENT	brand	_	steroids	group	_	false	druga inhalation aerosol has been used concomitantly with other drugs , including drugn , drugn , and drugb , commonly used in the treatment of chronic obstructive pulmonary disease .
DDI-DrugBank.d51.s1.p0	albuterol	drug	_	ATROVENT	brand	_	false	with the exception of druga , there are no formal studies fully evaluating the interaction effects of drugb inhalation aerosol and these drugs with respect to effectiveness .
DDI-DrugBank.d51.s2.p2	ipratropium bromide	drug	_	anticholinergic medications	group	_	effect	drugn : although druga is minimally absorbed into the systemic circulation , there is some potential for an additive interaction with concomitantly used drugb .
DDI-DrugBank.d51.s3.p0	ATROVENT	brand	_	anticholinergic	group	_	advise	caution is therefore advised in the coadministration of druga inhalation aerosol with other drugb - containing drugs .
DDI-DrugBank.d27.s2.p0	irbesartan	drug	_	warfarin	drug	_	false	however , in clinical studies the consequences of concomitant druga on the pharmacodynamics of drugb were negligible .
DDI-DrugBank.d27.s4.p2	warfarin	drug	_	irbesartan	drug	_	false	in separate studies of patients receiving maintenance doses of druga , drugn , or drugn , drugb administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p4	warfarin	drug	_	digoxin	drug	_	false	in separate studies of patients receiving maintenance doses of druga , drugn , or drugn , drugn administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugb .
DDI-DrugBank.d27.s4.p6	hydrochlorothiazide	drug	_	irbesartan	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , druga , or drugn , drugb administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p7	hydrochlorothiazide	drug	_	warfarin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , druga , or drugn , drugn administration for # days had no effect on the pharmacodynamics of drugb -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p8	hydrochlorothiazide	drug	_	digoxin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , druga , or drugn , drugn administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugb .
DDI-DrugBank.d27.s4.p9	digoxin	drug	_	irbesartan	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , drugn , or druga , drugb administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p10	digoxin	drug	_	warfarin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , drugn , or druga , drugn administration for # days had no effect on the pharmacodynamics of drugb -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p12	irbesartan	drug	_	warfarin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , drugn , or drugn , druga administration for # days had no effect on the pharmacodynamics of drugb -lcb- prothrombin time -rcb- or pharmacokinetics of drugn .
DDI-DrugBank.d27.s4.p13	irbesartan	drug	_	digoxin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , drugn , or drugn , druga administration for # days had no effect on the pharmacodynamics of drugn -lcb- prothrombin time -rcb- or pharmacokinetics of drugb .
DDI-DrugBank.d27.s4.p14	warfarin	drug	_	digoxin	drug	_	false	in separate studies of patients receiving maintenance doses of drugn , drugn , or drugn , drugn administration for # days had no effect on the pharmacodynamics of druga -lcb- prothrombin time -rcb- or pharmacokinetics of drugb .
DDI-DrugBank.d27.s5.p0	irbesartan	drug	_	nifedipine	drug	_	false	the pharmacokinetics of druga were not affected by coadministration of drugb or drugn
DDI-DrugBank.d27.s5.p1	irbesartan	drug	_	hydrochlorothiazide	drug	_	false	the pharmacokinetics of druga were not affected by coadministration of drugn or drugb
DDI-DrugBank.d27.s5.p2	nifedipine	drug	_	hydrochlorothiazide	drug	_	false	the pharmacokinetics of drugn were not affected by coadministration of druga or drugb
DDI-DrugBank.d279.s0.p0	CAMPTOSAR	brand	_	antineoplastic agents	group	_	effect	the adverse effects of druga , such as myelosuppression and diarrhea , would be expected to be exacerbated by other drugb having similar adverse effects .
DDI-DrugBank.d279.s3.p0	CAMPTOSAR	brand	_	dexamethasone	drug	_	effect	lymphocytopenia has been reported in patients receiving druga , and it is possible that the administration of drugb as antiemetic prophylaxis may have enhanced the likelihood of this effect .
DDI-DrugBank.d279.s8.p0	prochlorperazine	drug	_	CAMPTOSAR	brand	_	effect	the incidence of akathisia in clinical trials of the weekly dosage schedule was greater -lcb- # % , 4/47 patients -rcb- when druga was administered on the same day as drugb than when these drugs were given on separate days -lcb- # % , 1/80 patients -rcb- .
DDI-DrugBank.d279.s10.p0	laxative	group	_	CAMPTOSAR	brand	_	effect	it would be expected that druga use during therapy with drugb would worsen the incidence or severity of diarrhea , but this has not been studied .
DDI-DrugBank.d279.s11.p0	CAMPTOSAR	brand	_	diuretics	group	_	false	in view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by druga , the physician may wish to withhold drugb during dosing with drugn and , certainly , during periods of active vomiting or diarrhea .
DDI-DrugBank.d279.s11.p2	diuretics	group	_	CAMPTOSAR	brand	_	effect	in view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by drugn , the physician may wish to withhold druga during dosing with drugb and , certainly , during periods of active vomiting or diarrhea .
DDI-DrugBank.d108.s0.p0	Isocarboxazid	drug	_	Antabuse	brand	_	advise	druga should be administered with caution to patients receiving drugb -lcb- drugn , wyeth-ayerst laboratories -rcb- .
DDI-DrugBank.d108.s0.p1	Isocarboxazid	drug	_	disulfiram	drug	_	advise	druga should be administered with caution to patients receiving drugn -lcb- drugb , wyeth-ayerst laboratories -rcb- .
DDI-DrugBank.d108.s1.p0	MAO inhibitor	group	_	disulfiram	drug	_	effect	in a single study , rats given high intraperitoneal doses of an druga plus drugb experienced severe toxicity , including convulsions and death .
DDI-DrugBank.d108.s2.p0	Isocarboxazid	drug	_	psychotropic agents	group	_	advise	concomitant use of druga and other drugb is generally not recommended because of possible potentiating effects .
DDI-DrugBank.d541.s0.p0	beta-adrenergic blocking agents	group	_	adrenergic bronchodilators	group	_	false	may interact with the following : druga -lcb- these medicines may make your condition worse and prevent the drugb from working properly -rcb- and drugn , drugn , drugn , and drugn -lcb- these medicines may increase the risk of heart problems -rcb- .
DDI-DrugBank.d541.s0.p5	adrenergic bronchodilators	group	_	disopyramide	drug	_	false	may interact with the following : drugn -lcb- these medicines may make your condition worse and prevent the druga from working properly -rcb- and drugb , drugn , drugn , and drugn -lcb- these medicines may increase the risk of heart problems -rcb- .
DDI-DrugBank.d541.s0.p6	adrenergic bronchodilators	group	_	quinidine	drug	_	false	may interact with the following : drugn -lcb- these medicines may make your condition worse and prevent the druga from working properly -rcb- and drugn , drugb , drugn , and drugn -lcb- these medicines may increase the risk of heart problems -rcb- .
DDI-DrugBank.d541.s0.p7	adrenergic bronchodilators	group	_	phenothiazines	group	_	false	may interact with the following : drugn -lcb- these medicines may make your condition worse and prevent the druga from working properly -rcb- and drugn , drugn , drugb , and drugn -lcb- these medicines may increase the risk of heart problems -rcb- .
DDI-DrugBank.d541.s0.p8	adrenergic bronchodilators	group	_	procainamide	drug	_	false	may interact with the following : drugn -lcb- these medicines may make your condition worse and prevent the druga from working properly -rcb- and drugn , drugn , drugn , and drugb -lcb- these medicines may increase the risk of heart problems -rcb- .
DDI-DrugBank.d227.s0.p0	Isoflurane	drug	_	muscle relaxants	group	_	effect	druga potentiates the muscle relaxant effect of all drugb , most notably drugn , and mac -lcb- minimum alveolar concentration -rcb- is reduced by concomitant administration of n 2o .
DDI-DrugBank.d227.s0.p1	Isoflurane	drug	_	nondepolarizing muscle relaxants	group	_	effect	druga potentiates the muscle relaxant effect of all drugn , most notably drugb , and mac -lcb- minimum alveolar concentration -rcb- is reduced by concomitant administration of n 2o .
DDI-DrugBank.d187.s2.p2	acetaminophen	drug	_	Isoniazid	drug	_	effect	drugn : a report of severe druga toxicity was reported in a patient receiving drugb .
DDI-DrugBank.d187.s3.p0	isoniazid	drug	_	acetaminophen	drug	_	effect	it is believed that the toxicity may have resulted from a previously unrecognized interaction between druga and drugb and a molecular basis for this interaction has been proposed .
DDI-DrugBank.d187.s5.p0	isoniazid	drug	_	acetaminophen	drug	_	mechanism	furthermore it has been proposed that druga resulted in induction of p-450iie1 in the patients liver which , in turn , resulted in a greater proportion of the ingested drugb being converted to the toxic metabolites .
DDI-DrugBank.d187.s7.p6	Isoniazid	drug	_	carbamazepine	drug	_	mechanism	drugn : druga is known to slow the metabolism of drugb and increase its serum levels drugn levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p7	Isoniazid	drug	_	Carbamazepine	drug	_	false	drugn : druga is known to slow the metabolism of drugn and increase its serum levels drugb levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p9	Isoniazid	drug	_	carbamazepine	drug	_	false	drugn : druga is known to slow the metabolism of drugn and increase its serum levels drugn levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugb toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p10	Isoniazid	drug	_	anticonvulsant	group	_	false	drugn : druga is known to slow the metabolism of drugn and increase its serum levels drugn levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugb should be made .
DDI-DrugBank.d187.s7.p12	carbamazepine	drug	_	isoniazid	drug	_	false	drugn : drugn is known to slow the metabolism of druga and increase its serum levels drugn levels should be determined prior to concurrent administration with drugb , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p14	carbamazepine	drug	_	anticonvulsant	group	_	false	drugn : drugn is known to slow the metabolism of druga and increase its serum levels drugn levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugb should be made .
DDI-DrugBank.d187.s7.p15	Carbamazepine	drug	_	isoniazid	drug	_	advise	drugn : drugn is known to slow the metabolism of drugn and increase its serum levels druga levels should be determined prior to concurrent administration with drugb , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p17	Carbamazepine	drug	_	anticonvulsant	group	_	false	drugn : drugn is known to slow the metabolism of drugn and increase its serum levels druga levels should be determined prior to concurrent administration with drugn , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugb should be made .
DDI-DrugBank.d187.s7.p18	isoniazid	drug	_	carbamazepine	drug	_	false	drugn : drugn is known to slow the metabolism of drugn and increase its serum levels drugn levels should be determined prior to concurrent administration with druga , signs and symptoms of drugb toxicity should be monitored closely , and appropriate dosage adjustment of the drugn should be made .
DDI-DrugBank.d187.s7.p19	isoniazid	drug	_	anticonvulsant	group	_	false	drugn : drugn is known to slow the metabolism of drugn and increase its serum levels drugn levels should be determined prior to concurrent administration with druga , signs and symptoms of drugn toxicity should be monitored closely , and appropriate dosage adjustment of the drugb should be made .
DDI-DrugBank.d187.s7.p20	carbamazepine	drug	_	anticonvulsant	group	_	false	drugn : drugn is known to slow the metabolism of drugn and increase its serum levels drugn levels should be determined prior to concurrent administration with drugn , signs and symptoms of druga toxicity should be monitored closely , and appropriate dosage adjustment of the drugb should be made .
DDI-DrugBank.d187.s8.p1	Ketoconazole	drug	_	Isoniazid	drug	_	false	druga : potential interaction of drugn and drugb may exist .
DDI-DrugBank.d187.s8.p2	Ketoconazole	drug	_	Isoniazid	drug	_	int	drugn : potential interaction of druga and drugb may exist .
DDI-DrugBank.d187.s9.p2	Isoniazid	drug	_	phenytoin	drug	_	mechanism	drugn : druga may increase serum levels of drugb .
DDI-DrugBank.d187.s10.p0	phenytoin	drug	_	anticonvulsant	group	_	false	to avoid druga intoxication , appropriate adjustment of the drugb should be made .
DDI-DrugBank.d187.s11.p0	isoniazid	drug	_	theophylline	drug	_	mechanism	therophylline : a recent study has shown that concomitan administration of druga and drugb may cause elevated plasma levels of drugn , and in some instances a slight decrease in the elimination of drugn .
DDI-DrugBank.d187.s11.p1	isoniazid	drug	_	theophylline	drug	_	false	therophylline : a recent study has shown that concomitan administration of druga and drugn may cause elevated plasma levels of drugb , and in some instances a slight decrease in the elimination of drugn .
DDI-DrugBank.d187.s11.p4	theophylline	drug	_	isoniazid	drug	_	false	therophylline : a recent study has shown that concomitan administration of drugn and druga may cause elevated plasma levels of drugn , and in some instances a slight decrease in the elimination of drugb .
DDI-DrugBank.d187.s11.p5	theophylline	drug	_	isoniazid	drug	_	false	therophylline : a recent study has shown that concomitan administration of drugn and drugn may cause elevated plasma levels of druga , and in some instances a slight decrease in the elimination of drugb .
DDI-DrugBank.d187.s13.p2	valproate	drug	_	isoniazid	drug	_	mechanism	drugn : a recent case study has shown a possible increase in the plasma level of druga when co administered with drugb .
DDI-DrugBank.d187.s14.p0	valproate	drug	_	isoniazid	drug	_	false	plasma druga concentration should be monitored when drugb and drugn are co administered , and appropriate dosage adjustments of drugn should be made .
DDI-DrugBank.d187.s14.p3	isoniazid	drug	_	valproate	drug	_	advise	plasma drugn concentration should be monitored when druga and drugb are co administered , and appropriate dosage adjustments of drugn should be made .
DDI-DrugBank.d187.s14.p4	isoniazid	drug	_	valproate	drug	_	false	plasma drugn concentration should be monitored when druga and drugn are co administered , and appropriate dosage adjustments of drugb should be made .
DDI-DrugBank.d55.s0.p0	Isoproterenol hydrochloride	drug	_	epinephrine	drug	_	advise	druga injection and drugb should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias .
DDI-DrugBank.d55.s2.p0	ISUPREL	brand	_	anesthetics	group	_	advise	druga should be used with caution , if at all , when potent inhalational drugb such as drugn are employed because of potential to sensitize the myocardium to effects of drugn .
DDI-DrugBank.d55.s2.p1	ISUPREL	brand	_	halothane	drug	_	advise	druga should be used with caution , if at all , when potent inhalational drugn such as drugb are employed because of potential to sensitize the myocardium to effects of drugn .
DDI-DrugBank.d55.s2.p2	ISUPREL	brand	_	sympathomimetic amines	group	_	false	druga should be used with caution , if at all , when potent inhalational drugn such as drugn are employed because of potential to sensitize the myocardium to effects of drugb .
DDI-DrugBank.d55.s2.p3	anesthetics	group	_	halothane	drug	_	false	drugn should be used with caution , if at all , when potent inhalational druga such as drugb are employed because of potential to sensitize the myocardium to effects of drugn .
DDI-DrugBank.d55.s2.p4	anesthetics	group	_	sympathomimetic amines	group	_	false	drugn should be used with caution , if at all , when potent inhalational druga such as drugn are employed because of potential to sensitize the myocardium to effects of drugb .
DDI-DrugBank.d55.s2.p5	halothane	drug	_	sympathomimetic amines	group	_	false	drugn should be used with caution , if at all , when potent inhalational drugn such as druga are employed because of potential to sensitize the myocardium to effects of drugb .
DDI-DrugBank.d465.s0.p0	isosorbide dinitrate	drug	_	vasodilators	group	_	effect	the vasodilating effects of druga may be additive with those of other drugb .
DDI-DrugBank.d479.s0.p0	isosorbide mononitrate	drug	_	vasodilators	group	_	effect	the vasodilating effects of druga may be additive with those of other drugb .
DDI-DrugBank.d479.s2.p0	calcium channel blockers	group	_	organic nitrates	group	_	effect	marked symptomatic orthostatic hypotension has been reported when druga and drugb were used in combination .
DDI-DrugBank.d163.s0.p4	Accutane	brand	_	vitamin A	group	_	effect	drugn : because of the relationship of druga to drugb , patients should be advised against taking drugn containing drugn to avoid additive toxic effects
DDI-DrugBank.d163.s0.p5	Accutane	brand	_	vitamin supplements	group	_	false	drugn : because of the relationship of druga to drugn , patients should be advised against taking drugb containing drugn to avoid additive toxic effects
DDI-DrugBank.d163.s0.p6	Accutane	brand	_	vitamin A	group	_	false	drugn : because of the relationship of druga to drugn , patients should be advised against taking drugn containing drugb to avoid additive toxic effects
DDI-DrugBank.d163.s0.p7	vitamin A	group	_	vitamin supplements	group	_	false	drugn : because of the relationship of drugn to druga , patients should be advised against taking drugb containing drugn to avoid additive toxic effects
DDI-DrugBank.d163.s0.p9	vitamin supplements	group	_	vitamin A	group	_	false	drugn : because of the relationship of drugn to drugn , patients should be advised against taking druga containing drugb to avoid additive toxic effects
DDI-DrugBank.d163.s2.p0	Tetracyclines	group	_	Accutane	brand	_	false	druga : concomitant treatment with drugb and drugn should be avoided because drugn use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugn
DDI-DrugBank.d163.s2.p2	Tetracyclines	group	_	Accutane	brand	_	false	druga : concomitant treatment with drugn and drugn should be avoided because drugb use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugn
DDI-DrugBank.d163.s2.p4	Accutane	brand	_	tetracyclines	group	_	advise	drugn : concomitant treatment with druga and drugb should be avoided because drugn use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugn
DDI-DrugBank.d163.s2.p6	Accutane	brand	_	tetracyclines	group	_	false	drugn : concomitant treatment with druga and drugn should be avoided because drugn use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugb
DDI-DrugBank.d163.s2.p7	tetracyclines	group	_	Accutane	brand	_	false	drugn : concomitant treatment with drugn and druga should be avoided because drugb use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugn
DDI-DrugBank.d163.s2.p9	Accutane	brand	_	tetracyclines	group	_	effect	drugn : concomitant treatment with drugn and drugn should be avoided because druga use has been associated with a number of cases of idiopathic_intracranial_hypertension -lcb- benign intracranial hypertension -rcb- , some of which involved concomitant use of drugb
DDI-DrugBank.d163.s4.p1	Progesterone	drug	_	estrogen	group	_	false	micro-dosed druga preparations : micro-dosed drugn preparations -lcb- minipills that do not contain an drugb -rcb- may be an inadequate method of contraception during drugn therapy .
DDI-DrugBank.d163.s4.p3	progesterone	drug	_	estrogen	group	_	false	micro-dosed drugn preparations : micro-dosed druga preparations -lcb- minipills that do not contain an drugb -rcb- may be an inadequate method of contraception during drugn therapy .
DDI-DrugBank.d163.s4.p4	progesterone	drug	_	Accutane	brand	_	effect	micro-dosed drugn preparations : micro-dosed druga preparations -lcb- minipills that do not contain an drugn -rcb- may be an inadequate method of contraception during drugb therapy .
DDI-DrugBank.d163.s4.p5	estrogen	group	_	Accutane	brand	_	false	micro-dosed drugn preparations : micro-dosed drugn preparations -lcb- minipills that do not contain an druga -rcb- may be an inadequate method of contraception during drugb therapy .
DDI-DrugBank.d163.s5.p0	hormonal contraceptives	group	_	combined oral contraceptives	group	_	false	although other druga are highly effective , there have been reports of pregnancy from women who have used drugb , as well as topical/injectable/implantable / insertable hormonal birth control products .
DDI-DrugBank.d163.s7.p0	hormonal contraceptives	group	_	Accutane	brand	_	false	it is not known if druga differ in their effectiveness when used with drugb .
DDI-DrugBank.d163.s10.p2	Accutane	brand	_	phenytoin	drug	_	false	drugn : druga has not been shown to alter the pharmacokinetics of drugb in a study in seven healthy volunteers .
DDI-DrugBank.d163.s13.p0	phenytoin	drug	_	Accutane	brand	_	false	no formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between druga and drugb .
DDI-DrugBank.d163.s17.p0	systemic corticosteroids	group	_	Accutane	brand	_	false	no formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between druga and drugb .
DDI-DrugBank.d81.s0.p1	Nitroglycerin	drug	_	isradipine	drug	_	false	druga : drugn -lcb- drugb -rcb- has been safely coadministered with drugn .
DDI-DrugBank.d81.s0.p4	DynaCirc	brand	_	nitroglycerin	drug	_	false	drugn : druga -lcb- drugn -rcb- has been safely coadministered with drugb .
DDI-DrugBank.d81.s0.p5	isradipine	drug	_	nitroglycerin	drug	_	false	drugn : drugn -lcb- druga -rcb- has been safely coadministered with drugb .
DDI-DrugBank.d81.s1.p4	DynaCirc	brand	_	hydrochlorothiazide	drug	_	false	drugn : a study in normal healthy volunteers has shown that concomitant administration of druga -lcb- drugn -rcb- and drugb does not result in altered pharmacoktnetics of either drug .
DDI-DrugBank.d81.s1.p5	isradipine	drug	_	hydrochlorothiazide	drug	_	false	drugn : a study in normal healthy volunteers has shown that concomitant administration of drugn -lcb- druga -rcb- and drugb does not result in altered pharmacoktnetics of either drug .
DDI-DrugBank.d81.s2.p0	isradipine	drug	_	hydrochlorothiazide	drug	_	false	in a study in hypertensive patients , addition of druga to existing drugb therapy did not result in any unexpected adverse effects , and drugn had an additional antihypertensive effect .
DDI-DrugBank.d81.s2.p2	hydrochlorothiazide	drug	_	isradipine	drug	_	false	in a study in hypertensive patients , addition of drugn to existing druga therapy did not result in any unexpected adverse effects , and drugb had an additional antihypertensive effect .
DDI-DrugBank.d81.s3.p2	propranolol	drug	_	isradipine	drug	_	false	drugn : in a single dose study in normal volunteers , coadministration of druga had a small effect on the rate but no effect on the extent of drugb bioavailability .
DDI-DrugBank.d81.s6.p0	propranolol	drug	_	isradipine	drug	_	false	druga to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between drugb given singly and in combination with drugn , and between drugn given singly and in combination with drugn .
DDI-DrugBank.d81.s6.p3	propranolol	drug	_	isradipine	drug	_	false	druga to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between drugn given singly and in combination with drugn , and between drugn given singly and in combination with drugb .
DDI-DrugBank.d81.s6.p4	isradipine	drug	_	propranolol	drug	_	false	drugn to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between druga given singly and in combination with drugb , and between drugn given singly and in combination with drugn .
DDI-DrugBank.d81.s6.p5	isradipine	drug	_	propranolol	drug	_	false	drugn to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between druga given singly and in combination with drugn , and between drugb given singly and in combination with drugn .
DDI-DrugBank.d81.s6.p8	propranolol	drug	_	isradipine	drug	_	false	drugn to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between drugn given singly and in combination with druga , and between drugn given singly and in combination with drugb .
DDI-DrugBank.d81.s6.p9	propranolol	drug	_	isradipine	drug	_	false	drugn to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between drugn given singly and in combination with drugn , and between druga given singly and in combination with drugb .
DDI-DrugBank.d81.s7.p3	cimetidine	drug	_	isradipine	drug	_	mechanism	drugn : in a study in healthy volunteers , a one-week course of druga at # mg b , i , d , with a single # mg dose of drugb on the sixth day showed an increase in drugn mean peak plasma concentrations -lcb- 36 % -rcb- and significant increase in area under the curve -lcb- 50 % -rcb- .
DDI-DrugBank.d81.s7.p4	cimetidine	drug	_	isradipine	drug	_	false	drugn : in a study in healthy volunteers , a one-week course of druga at # mg b , i , d , with a single # mg dose of drugn on the sixth day showed an increase in drugb mean peak plasma concentrations -lcb- 36 % -rcb- and significant increase in area under the curve -lcb- 50 % -rcb- .
DDI-DrugBank.d81.s8.p0	isradipine	drug	_	cimetidine	drug	_	advise	if druga therapy is initiated in a patient currently receiving drugb careful monitoring for adverse reactions is advised and downward dose adjustment may be required .
DDI-DrugBank.d81.s9.p3	rifampicin	drug	_	isradipine	drug	_	mechanism	drugn : in a study in healthy volunteers , a six-day course of druga at # mg/day followed by a single # mg dose of drugb resulted in a reduction in drugn levels to below detectable limits .
DDI-DrugBank.d81.s9.p4	rifampicin	drug	_	isradipine	drug	_	false	drugn : in a study in healthy volunteers , a six-day course of druga at # mg/day followed by a single # mg dose of drugn resulted in a reduction in drugb levels to below detectable limits .
DDI-DrugBank.d81.s10.p0	rifampicin	drug	_	isradipine	drug	_	mechanism	if druga therapy is required , drugb concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drugn .
DDI-DrugBank.d81.s10.p1	rifampicin	drug	_	isradipine	drug	_	false	if druga therapy is required , drugn concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drugb .
DDI-DrugBank.d81.s11.p4	isradipine	drug	_	warfarin	drug	_	false	drugn : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between druga and racemic drugb was seen when two single oral doses of drugn -lcb- # mg/kg body weight -rcb- were administered during # days of multipledose treatment with # mg b , i , d , drugn .
DDI-DrugBank.d81.s11.p5	isradipine	drug	_	warfarin	drug	_	false	drugn : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between druga and racemic drugn was seen when two single oral doses of drugb -lcb- # mg/kg body weight -rcb- were administered during # days of multipledose treatment with # mg b , i , d , drugn .
DDI-DrugBank.d81.s11.p8	warfarin	drug	_	isradipine	drug	_	false	drugn : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between drugn and racemic druga was seen when two single oral doses of drugn -lcb- # mg/kg body weight -rcb- were administered during # days of multipledose treatment with # mg b , i , d , drugb .
DDI-DrugBank.d81.s11.p9	warfarin	drug	_	isradipine	drug	_	false	drugn : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between drugn and racemic drugn was seen when two single oral doses of druga -lcb- # mg/kg body weight -rcb- were administered during # days of multipledose treatment with # mg b , i , d , drugb .
DDI-DrugBank.d81.s12.p0	warfarin	drug	_	isradipine	drug	_	false	neither racemic druga nor drugb binding to plasma proteins in vitro was altered by the addition of the other drug .
DDI-DrugBank.d81.s13.p5	DynaCirc	brand	_	digoxin	drug	_	false	drugn : the concomitant administration of druga -lcb- drugn -rcb- and drugb in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of drugn .
DDI-DrugBank.d81.s13.p6	DynaCirc	brand	_	digoxin	drug	_	false	drugn : the concomitant administration of druga -lcb- drugn -rcb- and drugn in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of drugb .
DDI-DrugBank.d81.s13.p7	isradipine	drug	_	digoxin	drug	_	false	drugn : the concomitant administration of drugn -lcb- druga -rcb- and drugb in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of drugn .
DDI-DrugBank.d81.s13.p8	isradipine	drug	_	digoxin	drug	_	false	drugn : the concomitant administration of drugn -lcb- druga -rcb- and drugn in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of drugb .
DDI-DrugBank.d81.s14.p1	Fentanyl	drug	_	beta blocker	group	_	false	druga anesthesia : severe hypotension has been reported during drugn anesthesia with concomitant use of a drugb and a drugn .
DDI-DrugBank.d81.s14.p2	Fentanyl	drug	_	calcium channel blocker	group	_	false	druga anesthesia : severe hypotension has been reported during drugn anesthesia with concomitant use of a drugn and a drugb .
DDI-DrugBank.d81.s14.p3	fentanyl	drug	_	beta blocker	group	_	effect	drugn anesthesia : severe hypotension has been reported during druga anesthesia with concomitant use of a drugb and a drugn .
DDI-DrugBank.d81.s14.p4	fentanyl	drug	_	calcium channel blocker	group	_	effect	drugn anesthesia : severe hypotension has been reported during druga anesthesia with concomitant use of a drugn and a drugb .
DDI-DrugBank.d81.s14.p5	beta blocker	group	_	calcium channel blocker	group	_	false	drugn anesthesia : severe hypotension has been reported during drugn anesthesia with concomitant use of a druga and a drugb .
DDI-DrugBank.d165.s3.p0	terfenadine	drug	_	Itraconazole	drug	_	mechanism	coadministration of druga with drugb has led to elevated plasma concentrations of drugn , resulting in rare instances of life - threatening cardiac dysrhythmias and one death .
DDI-DrugBank.d165.s3.p2	Itraconazole	drug	_	terfenadine	drug	_	false	coadministration of drugn with druga has led to elevated plasma concentrations of drugb , resulting in rare instances of life - threatening cardiac dysrhythmias and one death .
DDI-DrugBank.d165.s4.p0	azole antifungal	group	_	ketoconazole	drug	_	false	another oral druga , drugb , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of drugn and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d165.s4.p1	azole antifungal	group	_	astemizole	drug	_	false	another oral druga , drugn , inhibits the metabolism of drugb , resulting in elevated plasma concentrations of drugn and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d165.s4.p2	azole antifungal	group	_	astemizole	drug	_	false	another oral druga , drugn , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of drugb and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d165.s4.p3	azole antifungal	group	_	desmethylastermizole	drug_n	_	false	another oral druga , drugn , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of drugn and its active metabolite drugb which may prolong qt intervals .
DDI-DrugBank.d165.s4.p4	ketoconazole	drug	_	astemizole	drug	_	mechanism	another oral drugn , druga , inhibits the metabolism of drugb , resulting in elevated plasma concentrations of drugn and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d165.s4.p5	ketoconazole	drug	_	astemizole	drug	_	false	another oral drugn , druga , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of drugb and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d165.s4.p6	ketoconazole	drug	_	desmethylastermizole	drug_n	_	false	another oral drugn , druga , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of drugn and its active metabolite drugb which may prolong qt intervals .
DDI-DrugBank.d165.s4.p8	astemizole	drug	_	desmethylastermizole	drug_n	_	false	another oral drugn , drugn , inhibits the metabolism of druga , resulting in elevated plasma concentrations of drugn and its active metabolite drugb which may prolong qt intervals .
DDI-DrugBank.d165.s4.p9	astemizole	drug	_	desmethylastermizole	drug_n	_	false	another oral drugn , drugn , inhibits the metabolism of drugn , resulting in elevated plasma concentrations of druga and its active metabolite drugb which may prolong qt intervals .
DDI-DrugBank.d165.s5.p0	itraconazole	drug	_	ketoconazole	drug	_	false	in vitro data suggest that druga , when compared to drugb , has a less pronounced effect on the biotransformation system responsible for the metabolism of drugn .
DDI-DrugBank.d165.s5.p1	itraconazole	drug	_	astemizole	drug	_	mechanism	in vitro data suggest that druga , when compared to drugn , has a less pronounced effect on the biotransformation system responsible for the metabolism of drugb .
DDI-DrugBank.d165.s5.p2	ketoconazole	drug	_	astemizole	drug	_	false	in vitro data suggest that drugn , when compared to druga , has a less pronounced effect on the biotransformation system responsible for the metabolism of drugb .
DDI-DrugBank.d165.s6.p0	itraconazole	drug	_	ketoconazole	drug	_	false	based on the chemical resemblance of druga and drugb , coadministration of drugn with drugn is contraindicated .
DDI-DrugBank.d165.s6.p1	itraconazole	drug	_	astemizole	drug	_	false	based on the chemical resemblance of druga and drugn , coadministration of drugb with drugn is contraindicated .
DDI-DrugBank.d165.s6.p3	ketoconazole	drug	_	astemizole	drug	_	false	based on the chemical resemblance of drugn and druga , coadministration of drugb with drugn is contraindicated .
DDI-DrugBank.d165.s6.p4	ketoconazole	drug	_	itraconazole	drug	_	false	based on the chemical resemblance of drugn and druga , coadministration of drugn with drugb is contraindicated .
DDI-DrugBank.d165.s6.p5	astemizole	drug	_	itraconazole	drug	_	advise	based on the chemical resemblance of drugn and drugn , coadministration of druga with drugb is contraindicated .
DDI-DrugBank.d165.s7.p0	ketoconazole	drug	_	cisapride	drug	_	mechanism	human pharmacokinetics data indicate that oral druga potently inhibits the metabolism of drugb resulting in an eight-fold increase in the mean auc of drugn .
DDI-DrugBank.d165.s7.p1	ketoconazole	drug	_	cisapride	drug	_	false	human pharmacokinetics data indicate that oral druga potently inhibits the metabolism of drugn resulting in an eight-fold increase in the mean auc of drugb .
DDI-DrugBank.d165.s8.p0	ketoconazole	drug	_	cisapride	drug	_	effect	data suggest that coadministration of oral druga and drugb can result in prolongation of the qt interval on the ecg .
DDI-DrugBank.d165.s9.p0	itraconazole	drug	_	cisapride	drug	_	mechanism	in vitro data suggest that druga also markedly inhibits the biotransformation system mainly responsible for the metabolism of drugb ;
DDI-DrugBank.d165.s10.p0	Itraconazole	drug	_	cisapride	drug	_	advise	therefore concomitant administration of druga with drugb is contraindicated .
DDI-DrugBank.d165.s11.p0	Itraconazole	drug	_	midazolam	drug	_	mechanism	coadministration of druga with oral drugb or drugn has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d165.s11.p1	Itraconazole	drug	_	triazolam	drug	_	mechanism	coadministration of druga with oral drugn or drugb has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d165.s11.p2	midazolam	drug	_	triazolam	drug	_	false	coadministration of drugn with oral druga or drugb has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d165.s16.p2	Cyclosporine	drug	_	Itraconazole	drug	_	advise	druga , drugn and drugn concentrations should be monitored at the initiation of drugb therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .
DDI-DrugBank.d165.s16.p4	tacrolimus	drug	_	Itraconazole	drug	_	advise	drugn , druga and drugn concentrations should be monitored at the initiation of drugb therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .
DDI-DrugBank.d165.s16.p5	digoxin	drug	_	Itraconazole	drug	_	advise	drugn , drugn and druga concentrations should be monitored at the initiation of drugb therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .
DDI-DrugBank.d165.s17.p0	HMG-CoA reductase inhibitors	group	_	immunosuppressive drugs	group	_	effect	rhabdomyolysis has been observed in patients receiving druga administered alone -lcb- at recommended dosages -rcb- or concomitantly with drugb including drugn .
DDI-DrugBank.d165.s17.p1	HMG-CoA reductase inhibitors	group	_	cyclosporine	drug	_	effect	rhabdomyolysis has been observed in patients receiving druga administered alone -lcb- at recommended dosages -rcb- or concomitantly with drugn including drugb .
DDI-DrugBank.d165.s17.p2	immunosuppressive drugs	group	_	cyclosporine	drug	_	false	rhabdomyolysis has been observed in patients receiving drugn administered alone -lcb- at recommended dosages -rcb- or concomitantly with druga including drugb .
DDI-DrugBank.d165.s18.p0	Itraconazole	drug	_	phenytoin	drug	_	mechanism	when druga was coadministered with drugb , drugn , or h2antagonists , reduced plasma concentrations of drugn were reported .
DDI-DrugBank.d165.s18.p1	Itraconazole	drug	_	rifampin	drug	_	mechanism	when druga was coadministered with drugn , drugb , or h2antagonists , reduced plasma concentrations of drugn were reported .
DDI-DrugBank.d165.s18.p4	phenytoin	drug	_	itraconazole	drug	_	false	when drugn was coadministered with druga , drugn , or h2antagonists , reduced plasma concentrations of drugb were reported .
DDI-DrugBank.d165.s18.p5	rifampin	drug	_	itraconazole	drug	_	false	when drugn was coadministered with drugn , druga , or h2antagonists , reduced plasma concentrations of drugb were reported .
DDI-DrugBank.d165.s20.p0	Itraconazole	drug	_	phenytoin	drug	_	mechanism	although no studies have been conducted , concomitant administration of druga and drugb may alter the metabolism of drugn ;
DDI-DrugBank.d165.s20.p1	Itraconazole	drug	_	phenytoin	drug	_	false	although no studies have been conducted , concomitant administration of druga and drugn may alter the metabolism of drugb ;
DDI-DrugBank.d165.s21.p0	phenytoin	drug	_	Itraconazole	drug	_	advise	therefore , plasma concentrations of druga should also be monitored when it is given concurrently with drugb .
DDI-DrugBank.d165.s22.p0	Itraconazole	drug	_	coumarin	group	_	effect	it has been reported that druga enhances the anticoagulant effect of drugb - like drugs .
DDI-DrugBank.d165.s23.p0	Itraconazole	drug	_	coumarin	group	_	advise	therefore , prothrombin time should be carefully monitored in patients receiving druga and drugb - like drugs simultaneously .
DDI-DrugBank.d165.s24.p0	azole antifungal agents	group	_	isoniazid	drug	_	mechanism	plasma concentrations of druga are reduced when given concurrently with drugb .
DDI-DrugBank.d165.s25.p1	Itraconazole	drug	_	isoniazid	drug	_	false	druga plasma concentrations should be monitored when drugn and drugb are coadministered .
DDI-DrugBank.d165.s25.p2	Itraconazole	drug	_	isoniazid	drug	_	advise	drugn plasma concentrations should be monitored when druga and drugb are coadministered .
DDI-DrugBank.d165.s26.p0	azole antifungal agents	group	_	hypoglycemic agents	group	_	effect	severe hypoglycemia has been reported in patients concomitantly receiving druga and oral drugb .
DDI-DrugBank.d165.s27.p0	Itraconazole	drug	_	hypoglycemic agents	group	_	advise	blood glucose concentrations should be carefully monitored when druga and oral drugb are coadministered .
DDI-DrugBank.d165.s28.p0	Itraconazole	drug	_	quinidine	drug	_	effect	tinnitus and decreased hearing have been reported in patients concomitantly receiving druga and drugb .
DDI-DrugBank.d165.s29.p0	Itraconazole	drug	_	dihydropyridine calcium channel blockers	group	_	effect	edema has been reported in patients concomitantly receiving druga and drugb .
DDI-DrugBank.d165.s31.p1	zidovudine	drug	_	Itraconazole	drug	_	false	the results from a study in which eight hiv-infected individuals were treated with druga , # + / - # mg/kg/day , showed that the pharmacokinetics of drugn were not affected during concomitant administration of drugb , # mg b , i , d.
DDI-DrugBank.d165.s31.p2	zidovudine	drug	_	Itraconazole	drug	_	false	the results from a study in which eight hiv-infected individuals were treated with drugn , # + / - # mg/kg/day , showed that the pharmacokinetics of druga were not affected during concomitant administration of drugb , # mg b , i , d.
DDI-DrugBank.d57.s0.p0	aminoglycoside	group	_	antibiotics	group	_	effect	in vitro mixing of an druga with beta-lactamtype drugb -lcb- drugn or drugn -rcb- may result in a significant mutual inactivation .
DDI-DrugBank.d57.s0.p1	aminoglycoside	group	_	penicillins	group	_	effect	in vitro mixing of an druga with beta-lactamtype drugn -lcb- drugb or drugn -rcb- may result in a significant mutual inactivation .
DDI-DrugBank.d57.s0.p2	aminoglycoside	group	_	cephalosporins	group	_	effect	in vitro mixing of an druga with beta-lactamtype drugn -lcb- drugn or drugb -rcb- may result in a significant mutual inactivation .
DDI-DrugBank.d57.s1.p0	aminoglycoside	group	_	penicillin	group	_	mechanism	even when an druga and a drugb - type drug are administered separately by different routes , a reduction in drugn serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function .
DDI-DrugBank.d57.s1.p2	penicillin	group	_	aminoglycoside	group	_	false	even when an drugn and a druga - type drug are administered separately by different routes , a reduction in drugb serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function .
DDI-DrugBank.d518.s0.p0	barbiturates	group	_	narcotics	group	_	false	prolonged recovery time may occur if druga and/or drugb are used concurrently with drugn .
DDI-DrugBank.d518.s0.p1	barbiturates	group	_	ketamine	drug	_	effect	prolonged recovery time may occur if druga and/or drugn are used concurrently with drugb .
DDI-DrugBank.d518.s0.p2	narcotics	group	_	ketamine	drug	_	effect	prolonged recovery time may occur if drugn and/or druga are used concurrently with drugb .
DDI-DrugBank.d518.s1.p0	Ketamine	drug	_	anesthetic agents	group	_	false	druga is clinically compatible with the commonly used general and local drugb when an adequate respiratory exchange is maintained .
DDI-DrugBank.d458.s3.p3	Ketoconazole	drug	_	terfenadine	drug	_	mechanism	the following drug interactions have been identified involving drugn tablets and other drugs metabolized by the cyp3a4 enzyme system : druga tablets inhibit the metabolism of drugb , resulting in an increased plasma concentration of drugn and a delay in the elimination of its acid metabolite .
DDI-DrugBank.d458.s3.p4	Ketoconazole	drug	_	terfenadine	drug	_	false	the following drug interactions have been identified involving drugn tablets and other drugs metabolized by the cyp3a4 enzyme system : druga tablets inhibit the metabolism of drugn , resulting in an increased plasma concentration of drugb and a delay in the elimination of its acid metabolite .
DDI-DrugBank.d458.s5.p0	ketoconazole	drug	_	astemizole	drug	_	effect	pharmacokinetic data indicate that oral druga inhibits the metabolism of drugb , resulting in elevated plasma levels of drugn and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d458.s5.p1	ketoconazole	drug	_	astemizole	drug	_	false	pharmacokinetic data indicate that oral druga inhibits the metabolism of drugn , resulting in elevated plasma levels of drugb and its active metabolite drugn which may prolong qt intervals .
DDI-DrugBank.d458.s5.p2	ketoconazole	drug	_	desmethylastemizole	drug_n	_	false	pharmacokinetic data indicate that oral druga inhibits the metabolism of drugn , resulting in elevated plasma levels of drugn and its active metabolite drugb which may prolong qt intervals .
DDI-DrugBank.d458.s6.p0	astemizole	drug	_	ketoconazole	drug	_	advise	coadministration of druga with drugb tablets is therefore contraindicated .
DDI-DrugBank.d458.s7.p0	ketoconazole	drug	_	cisapride	drug	_	mechanism	human pharmacokinetics data indicate that oral druga potently inhibits the metabolism of drugb resulting in a mean eight-fold increase in auc of drugn .
DDI-DrugBank.d458.s7.p1	ketoconazole	drug	_	cisapride	drug	_	false	human pharmacokinetics data indicate that oral druga potently inhibits the metabolism of drugn resulting in a mean eight-fold increase in auc of drugb .
DDI-DrugBank.d458.s8.p0	ketoconazole	drug	_	cisapride	drug	_	effect	data suggest that coadministration of oral druga and drugb can result in prolongation of the qt interval on the ecg .
DDI-DrugBank.d458.s9.p0	ketoconazole	drug	_	cisapride	drug	_	advise	therefore concomitant administration of druga tablets with drugb is contraindicated .
DDI-DrugBank.d458.s10.p0	Ketoconazole	drug	_	cyclosporine	drug	_	mechanism	druga tablets may alter the metabolism of drugb , drugn , and drugn , resulting in elevated plasma concentrations of the latter drugs .
DDI-DrugBank.d458.s10.p1	Ketoconazole	drug	_	tacrolimus	drug	_	mechanism	druga tablets may alter the metabolism of drugn , drugb , and drugn , resulting in elevated plasma concentrations of the latter drugs .
DDI-DrugBank.d458.s10.p2	Ketoconazole	drug	_	methylprednisolone	drug	_	mechanism	druga tablets may alter the metabolism of drugn , drugn , and drugb , resulting in elevated plasma concentrations of the latter drugs .
DDI-DrugBank.d458.s11.p2	cyclosporine	drug	_	NIZORAL	brand	_	false	dosage adjustment may be required if druga , drugn , or drugn are given concomitantly with drugb tablets .
DDI-DrugBank.d458.s11.p4	tacrolimus	drug	_	NIZORAL	brand	_	false	dosage adjustment may be required if drugn , druga , or drugn are given concomitantly with drugb tablets .
DDI-DrugBank.d458.s11.p5	methylprednisolone	drug	_	NIZORAL	brand	_	false	dosage adjustment may be required if drugn , drugn , or druga are given concomitantly with drugb tablets .
DDI-DrugBank.d458.s12.p0	NIZORAL	brand	_	midazolam	drug	_	mechanism	coadministration of druga tablets with drugb or drugn has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d458.s12.p1	NIZORAL	brand	_	triazolam	drug	_	mechanism	coadministration of druga tablets with drugn or drugb has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d458.s12.p2	midazolam	drug	_	triazolam	drug	_	false	coadministration of drugn tablets with druga or drugb has resulted in elevated plasma concentrations of the latter two drugs .
DDI-DrugBank.d458.s18.p0	digoxin	drug	_	ketoconazole	drug	_	advise	it is , therefore , advisable to monitor druga concentrations in patients receiving drugb .
DDI-DrugBank.d458.s19.p0	imidazole compounds	group	_	ketoconazole	drug	_	false	when taken orally , druga like drugb may enhance the anticoagulant effect of drugn - like drugs .
DDI-DrugBank.d458.s19.p1	imidazole compounds	group	_	coumarin	group	_	effect	when taken orally , druga like drugn may enhance the anticoagulant effect of drugb - like drugs .
DDI-DrugBank.d458.s19.p2	ketoconazole	drug	_	coumarin	group	_	effect	when taken orally , drugn like druga may enhance the anticoagulant effect of drugb - like drugs .
DDI-DrugBank.d458.s20.p0	imidazole drugs	group	_	coumarin drugs	group	_	advise	in simultaneous treatment with druga and drugb , the anticoagulant effect should be carefully titrated and monitored .
DDI-DrugBank.d458.s21.p1	miconazole	drug	_	hypoglycemic agents	group	_	effect	because severe hypoglycemia has been reported in patients concomitantly receiving oral druga -lcb- an drugn -rcb- and oral drugb , such a potential interaction involving the latter agents when used concomitantly with drugn tablets -lcb- an drugn -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p2	miconazole	drug	_	ketoconazole	drug	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral druga -lcb- an drugn -rcb- and oral drugn , such a potential interaction involving the latter agents when used concomitantly with drugb tablets -lcb- an drugn -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p3	miconazole	drug	_	imidazole	group	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral druga -lcb- an drugn -rcb- and oral drugn , such a potential interaction involving the latter agents when used concomitantly with drugn tablets -lcb- an drugb -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p4	imidazole	group	_	hypoglycemic agents	group	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral drugn -lcb- an druga -rcb- and oral drugb , such a potential interaction involving the latter agents when used concomitantly with drugn tablets -lcb- an drugn -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p5	imidazole	group	_	ketoconazole	drug	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral drugn -lcb- an druga -rcb- and oral drugn , such a potential interaction involving the latter agents when used concomitantly with drugb tablets -lcb- an drugn -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p7	hypoglycemic agents	group	_	ketoconazole	drug	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral drugn -lcb- an drugn -rcb- and oral druga , such a potential interaction involving the latter agents when used concomitantly with drugb tablets -lcb- an drugn -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p8	hypoglycemic agents	group	_	imidazole	group	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral drugn -lcb- an drugn -rcb- and oral druga , such a potential interaction involving the latter agents when used concomitantly with drugn tablets -lcb- an drugb -rcb- can not be ruled out .
DDI-DrugBank.d458.s21.p9	ketoconazole	drug	_	imidazole	group	_	false	because severe hypoglycemia has been reported in patients concomitantly receiving oral drugn -lcb- an drugn -rcb- and oral drugn , such a potential interaction involving the latter agents when used concomitantly with druga tablets -lcb- an drugb -rcb- can not be ruled out .
DDI-DrugBank.d458.s22.p0	ketoconazole	drug	_	phenytoin	drug	_	mechanism	concomitant administration of druga tablets with drugb may alter the metabolism of one or both of the drugs .
DDI-DrugBank.d458.s23.p0	ketoconazole	drug	_	phenytoin	drug	_	advise	it is suggested to monitor both druga and drugb .
DDI-DrugBank.d458.s24.p0	rifampin	drug	_	ketoconazole	drug	_	mechanism	concomitant administration of druga with drugb tablets reduces the blood levels of the latter .
DDI-DrugBank.d458.s25.p1	INH	drug	_	ketoconazole	drug	_	mechanism	druga -lcb- drugn -rcb- is also reported to affect drugb concentrations adversely .
DDI-DrugBank.d458.s25.p2	Isoniazid	drug	_	ketoconazole	drug	_	mechanism	drugn -lcb- druga -rcb- is also reported to affect drugb concentrations adversely .
DDI-DrugBank.d458.s27.p0	ketoconazole	drug	_	loratadine	drug	_	mechanism	after the coadministration of # mg oral druga twice daily and one # mg dose of drugb to # subjects , the auc and cmax of drugn averaged 302 % -lcb- # s , d , -rcb- and 251 % -lcb- # s , d , -rcb- , respectively , of those obtained after co-treatment with placebo .
DDI-DrugBank.d458.s27.p1	ketoconazole	drug	_	loratadine	drug	_	false	after the coadministration of # mg oral druga twice daily and one # mg dose of drugn to # subjects , the auc and cmax of drugb averaged 302 % -lcb- # s , d , -rcb- and 251 % -lcb- # s , d , -rcb- , respectively , of those obtained after co-treatment with placebo .
DDI-DrugBank.d458.s30.p0	loratadine	drug	_	ketoconazole	drug	_	false	also , there were no clinically significant differences in adverse events when druga was administered with or without drugb .
DDI-DrugBank.d499.s1.p0	Orudis	brand	_	ketoprofen	drug	_	false	the possibility of increased interaction should be kept in mind when druga doses greater than # mg as a single dose or # mg of drugb per day are used concomitantly with highly bound drugs .
DDI-DrugBank.d499.s3.p0	Antacids	group	_	magnesium hydroxide	drug	_	false	druga : concomitant administration of drugb and drugn does not interfere with the rate or extent of the absorption of drugn administered as drugn .
DDI-DrugBank.d499.s3.p1	Antacids	group	_	aluminum hydroxide	drug	_	false	druga : concomitant administration of drugn and drugb does not interfere with the rate or extent of the absorption of drugn administered as drugn .
DDI-DrugBank.d499.s3.p2	Antacids	group	_	ketoprofen	drug	_	false	druga : concomitant administration of drugn and drugn does not interfere with the rate or extent of the absorption of drugb administered as drugn .
DDI-DrugBank.d499.s3.p3	Antacids	group	_	Orudis	brand	_	false	druga : concomitant administration of drugn and drugn does not interfere with the rate or extent of the absorption of drugn administered as drugb .
DDI-DrugBank.d499.s3.p4	magnesium hydroxide	drug	_	aluminum hydroxide	drug	_	false	drugn : concomitant administration of druga and drugb does not interfere with the rate or extent of the absorption of drugn administered as drugn .
DDI-DrugBank.d499.s3.p5	magnesium hydroxide	drug	_	ketoprofen	drug	_	false	drugn : concomitant administration of druga and drugn does not interfere with the rate or extent of the absorption of drugb administered as drugn .
DDI-DrugBank.d499.s3.p6	magnesium hydroxide	drug	_	Orudis	brand	_	false	drugn : concomitant administration of druga and drugn does not interfere with the rate or extent of the absorption of drugn administered as drugb .
DDI-DrugBank.d499.s3.p7	aluminum hydroxide	drug	_	ketoprofen	drug	_	false	drugn : concomitant administration of drugn and druga does not interfere with the rate or extent of the absorption of drugb administered as drugn .
DDI-DrugBank.d499.s3.p8	aluminum hydroxide	drug	_	Orudis	brand	_	false	drugn : concomitant administration of drugn and druga does not interfere with the rate or extent of the absorption of drugn administered as drugb .
DDI-DrugBank.d499.s3.p9	ketoprofen	drug	_	Orudis	brand	_	false	drugn : concomitant administration of drugn and drugn does not interfere with the rate or extent of the absorption of druga administered as drugb .
DDI-DrugBank.d499.s5.p2	Ketoprofen	drug	_	aspirin	brand	_	false	drugn : druga does not alter drugb absorption ;
DDI-DrugBank.d499.s6.p0	aspirin	brand	_	ketoprofen	drug	_	mechanism	however , in a study of # normal subjects , concurrent administration of druga decreased drugb protein binding and increased drugn plasma clearance from # l/kg/h without drugn to # l/kg/h with drugn .
DDI-DrugBank.d499.s6.p1	aspirin	brand	_	ketoprofen	drug	_	mechanism	however , in a study of # normal subjects , concurrent administration of druga decreased drugn protein binding and increased drugb plasma clearance from # l/kg/h without drugn to # l/kg/h with drugn .
DDI-DrugBank.d499.s6.p5	ketoprofen	drug	_	aspirin	brand	_	false	however , in a study of # normal subjects , concurrent administration of drugn decreased druga protein binding and increased drugn plasma clearance from # l/kg/h without drugb to # l/kg/h with drugn .
DDI-DrugBank.d499.s6.p6	ketoprofen	drug	_	aspirin	brand	_	false	however , in a study of # normal subjects , concurrent administration of drugn decreased druga protein binding and increased drugn plasma clearance from # l/kg/h without drugn to # l/kg/h with drugb .
DDI-DrugBank.d499.s6.p7	ketoprofen	drug	_	aspirin	brand	_	false	however , in a study of # normal subjects , concurrent administration of drugn decreased drugn protein binding and increased druga plasma clearance from # l/kg/h without drugb to # l/kg/h with drugn .
DDI-DrugBank.d499.s6.p8	ketoprofen	drug	_	aspirin	brand	_	false	however , in a study of # normal subjects , concurrent administration of drugn decreased drugn protein binding and increased druga plasma clearance from # l/kg/h without drugn to # l/kg/h with drugb .
DDI-DrugBank.d499.s8.p0	aspirin	brand	_	ketoprofen	drug	_	advise	therefore , concurrent use of druga and drugb is not recommended .
DDI-DrugBank.d499.s10.p0	Diuretic	group	_	Hydrochlorothiazide	drug	_	false	druga : drugb , given concomitantly with drugn , produces a reduction in urinary potassium and chloride excretion compared to drugn alone .
DDI-DrugBank.d499.s10.p1	Diuretic	group	_	ketoprofen	drug	_	false	druga : drugn , given concomitantly with drugb , produces a reduction in urinary potassium and chloride excretion compared to drugn alone .
DDI-DrugBank.d499.s10.p2	Diuretic	group	_	hydrochlorothiazide	drug	_	false	druga : drugn , given concomitantly with drugn , produces a reduction in urinary potassium and chloride excretion compared to drugb alone .
DDI-DrugBank.d499.s10.p3	Hydrochlorothiazide	drug	_	ketoprofen	drug	_	effect	drugn : druga , given concomitantly with drugb , produces a reduction in urinary potassium and chloride excretion compared to drugn alone .
DDI-DrugBank.d499.s10.p5	ketoprofen	drug	_	hydrochlorothiazide	drug	_	false	drugn : drugn , given concomitantly with druga , produces a reduction in urinary potassium and chloride excretion compared to drugb alone .
DDI-DrugBank.d499.s13.p4	ketoprofen	drug	_	digoxin	drug	_	false	drugn : in a study in # patients with congestive heart failure where druga and drugb were concomitantly administered , drugn did not alter the serum levels of drugn .
DDI-DrugBank.d499.s13.p6	ketoprofen	drug	_	digoxin	drug	_	false	drugn : in a study in # patients with congestive heart failure where druga and drugn were concomitantly administered , drugn did not alter the serum levels of drugb .
DDI-DrugBank.d499.s13.p7	digoxin	drug	_	ketoprofen	drug	_	false	drugn : in a study in # patients with congestive heart failure where drugn and druga were concomitantly administered , drugb did not alter the serum levels of drugn .
DDI-DrugBank.d499.s13.p9	ketoprofen	drug	_	digoxin	drug	_	false	drugn : in a study in # patients with congestive heart failure where drugn and drugn were concomitantly administered , druga did not alter the serum levels of drugb .
DDI-DrugBank.d499.s15.p2	ketoprofen	drug	_	warfarin	drug	_	false	drugn : in a short-term controlled study in # normal volunteers , druga did not significantly interfere with the effect of drugb on prothrombin time .
DDI-DrugBank.d499.s16.p0	warfarin	drug	_	ketoprofen	drug	_	false	bleeding from a number of sites may be a complication of druga treatment and gi bleeding a complication of drugb treatment .
DDI-DrugBank.d499.s17.p1	ketoprofen	drug	_	warfarin	drug	_	false	because prostaglandina play an important role in hemostasis and druga has an effect on platelet function as well , concurent therapy with drugn and drugb requires close monitoring of patients on both drugs .
DDI-DrugBank.d499.s17.p2	ketoprofen	drug	_	warfarin	drug	_	advise	because prostaglandina play an important role in hemostasis and drugn has an effect on platelet function as well , concurent therapy with druga and drugb requires close monitoring of patients on both drugs .
DDI-DrugBank.d499.s19.p3	Probenecid	drug	_	ketoprofen	drug	_	mechanism	drugn : druga increases both free and bound drugb by reducing the plasma clearance of drugn to about one-third , as well as decreasing its protein binding .
DDI-DrugBank.d499.s19.p4	Probenecid	drug	_	ketoprofen	drug	_	false	drugn : druga increases both free and bound drugn by reducing the plasma clearance of drugb to about one-third , as well as decreasing its protein binding .
DDI-DrugBank.d499.s20.p0	ketoprofen	drug	_	probenecid	drug	_	advise	therefore , the combination of druga and drugb is not recommended .
DDI-DrugBank.d499.s22.p0	Methotrexate	drug	_	Ketoprofen	drug	_	false	druga : drugb , like other drugn , may cause changes in the elimination of drugn leading to elevated serum levels of the drug and increased toxicity .
DDI-DrugBank.d499.s22.p1	Methotrexate	drug	_	NSAIDs	group	_	false	druga : drugn , like other drugb , may cause changes in the elimination of drugn leading to elevated serum levels of the drug and increased toxicity .
DDI-DrugBank.d499.s22.p3	Ketoprofen	drug	_	NSAIDs	group	_	false	drugn : druga , like other drugb , may cause changes in the elimination of drugn leading to elevated serum levels of the drug and increased toxicity .
DDI-DrugBank.d499.s22.p4	Ketoprofen	drug	_	methotrexate	drug	_	mechanism	drugn : druga , like other drugn , may cause changes in the elimination of drugb leading to elevated serum levels of the drug and increased toxicity .
DDI-DrugBank.d499.s22.p5	NSAIDs	group	_	methotrexate	drug	_	mechanism	drugn : drugn , like other druga , may cause changes in the elimination of drugb leading to elevated serum levels of the drug and increased toxicity .
DDI-DrugBank.d499.s24.p2	Nonsteroidal anti-inflammatory agents	group	_	lithium	drug	_	mechanism	drugn : druga have been reported to increase steadystate plasma drugb levels .
DDI-DrugBank.d499.s25.p0	lithium	drug	_	ketoprofen	drug	_	false	it is recommended that plasma druga levels be monitored when drugb is coadministered with drugn .
DDI-DrugBank.d499.s25.p2	ketoprofen	drug	_	lithium	drug	_	advise	it is recommended that plasma drugn levels be monitored when druga is coadministered with drugb .
DDI-DrugBank.d3.s1.p0	Warfarin	drug	_	Digoxin	drug	_	false	druga , drugb , drugn , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p2	Warfarin	drug	_	Heparin	drug	_	false	druga , drugn , drugn , and drugb the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p4	Warfarin	drug	_	ketorolac tromethamine	drug	_	false	druga , drugn , drugn , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugb -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p5	Warfarin	drug	_	ketorolac	drug	_	false	druga , drugn , drugn , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugb plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p7	Digoxin	drug	_	Heparin	drug	_	false	drugn , druga , drugn , and drugb the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p8	Digoxin	drug	_	warfarin	drug	_	false	drugn , druga , drugn , and drugn the in vitro binding of drugb to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p9	Digoxin	drug	_	ketorolac tromethamine	drug	_	false	drugn , druga , drugn , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugb -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p10	Digoxin	drug	_	ketorolac	drug	_	false	drugn , druga , drugn , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugb plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p11	Salicylate	group	_	Heparin	drug	_	false	drugn , drugn , druga , and drugb the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p12	Salicylate	group	_	warfarin	drug	_	false	drugn , drugn , druga , and drugn the in vitro binding of drugb to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p13	Salicylate	group	_	ketorolac tromethamine	drug	_	false	drugn , drugn , druga , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugb -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p14	Salicylate	group	_	ketorolac	drug	_	false	drugn , drugn , druga , and drugn the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugb plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p15	Heparin	drug	_	warfarin	drug	_	false	drugn , drugn , drugn , and druga the in vitro binding of drugb to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p16	Heparin	drug	_	ketorolac tromethamine	drug	_	false	drugn , drugn , drugn , and druga the in vitro binding of drugn to plasma proteins is only slightly reduced by drugb -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p17	Heparin	drug	_	ketorolac	drug	_	false	drugn , drugn , drugn , and druga the in vitro binding of drugn to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugb plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p18	warfarin	drug	_	ketorolac tromethamine	drug	_	mechanism	drugn , drugn , drugn , and drugn the in vitro binding of druga to plasma proteins is only slightly reduced by drugb -lcb- # % control vs # % -rcb- when drugn plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s1.p19	warfarin	drug	_	ketorolac	drug	_	false	drugn , drugn , drugn , and drugn the in vitro binding of druga to plasma proteins is only slightly reduced by drugn -lcb- # % control vs # % -rcb- when drugb plasma concentrations reach # to10 m g/ml .
DDI-DrugBank.d3.s2.p0	Ketorolac	drug	_	digoxin	drug	_	false	druga does not alter drugb protein binding .
DDI-DrugBank.d3.s3.p0	salicylate	group	_	ketorolac	drug	_	mechanism	in vitro studies indicate that , at therapeutic concentrations of druga -lcb- 300 m g/ml -rcb- , the binding of drugb was reduced from approximately # % to # % , representing a potential twofold increase in unbound drugn plasma levels .
DDI-DrugBank.d3.s3.p1	salicylate	group	_	ketorolac	drug	_	false	in vitro studies indicate that , at therapeutic concentrations of druga -lcb- 300 m g/ml -rcb- , the binding of drugn was reduced from approximately # % to # % , representing a potential twofold increase in unbound drugb plasma levels .
DDI-DrugBank.d3.s4.p6	digoxin	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of druga , drugn , drugn , drugn , drugn , drugn , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p12	warfarin	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , druga , drugn , drugn , drugn , drugn , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p17	ibuprofen	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , drugn , druga , drugn , drugn , drugn , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p21	naproxen	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , drugn , drugn , druga , drugn , drugn , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p24	piroxicam	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , drugn , drugn , drugn , druga , drugn , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p26	acetaminophen	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , drugn , drugn , drugn , drugn , druga , drugn andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s4.p27	phenytoin	drug	_	ketorolac tromethamine	drug	_	false	therapeutic concentrations of drugn , drugn , drugn , drugn , drugn , drugn , druga andtolbutamide did not alter drugb protein binding .
DDI-DrugBank.d3.s7.p3	TORADOL	brand	_	anticoagulants	group	_	false	although these results do not indicate a significant interaction between druga and drugn or drugn , the administration of drugn to patients taking drugb should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s7.p5	warfarin	drug	_	TORADOL	brand	_	false	although these results do not indicate a significant interaction between drugn and druga or drugn , the administration of drugb to patients taking drugn should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s7.p6	warfarin	drug	_	anticoagulants	group	_	false	although these results do not indicate a significant interaction between drugn and druga or drugn , the administration of drugn to patients taking drugb should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s7.p7	heparin	drug	_	TORADOL	brand	_	false	although these results do not indicate a significant interaction between drugn and drugn or druga , the administration of drugb to patients taking drugn should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s7.p8	heparin	drug	_	anticoagulants	group	_	false	although these results do not indicate a significant interaction between drugn and drugn or druga , the administration of drugn to patients taking drugb should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s7.p9	TORADOL	brand	_	anticoagulants	group	_	advise	although these results do not indicate a significant interaction between drugn and drugn or drugn , the administration of druga to patients taking drugb should be done extremely cautiously , and patients should be closely monitored .
DDI-DrugBank.d3.s8.p3	TORADOL	brand	_	diuretic	group	_	false	drugn : druga iv/im reduced the drugb response to drugn in normovolemic healthy subjects by approximately 20 % -lcb- mean sodium and urinary output decreased 17 % -rcb- .
DDI-DrugBank.d3.s8.p4	TORADOL	brand	_	furosemide	drug	_	effect	drugn : druga iv/im reduced the drugn response to drugb in normovolemic healthy subjects by approximately 20 % -lcb- mean sodium and urinary output decreased 17 % -rcb- .
DDI-DrugBank.d3.s8.p5	diuretic	group	_	furosemide	drug	_	false	drugn : drugn iv/im reduced the druga response to drugb in normovolemic healthy subjects by approximately 20 % -lcb- mean sodium and urinary output decreased 17 % -rcb- .
DDI-DrugBank.d3.s9.p0	Probenecid	drug	_	TORADOL	brand	_	false	druga : concomitant administration of drugb oral and drugn resulted in decreased clearance of drugn and significant increases in drugn plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p2	Probenecid	drug	_	ketorolac	drug	_	false	druga : concomitant administration of drugn oral and drugn resulted in decreased clearance of drugb and significant increases in drugn plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p3	Probenecid	drug	_	ketorolac	drug	_	false	druga : concomitant administration of drugn oral and drugn resulted in decreased clearance of drugn and significant increases in drugb plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p4	TORADOL	brand	_	probenecid	drug	_	mechanism	drugn : concomitant administration of druga oral and drugb resulted in decreased clearance of drugn and significant increases in drugn plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p5	TORADOL	brand	_	ketorolac	drug	_	false	drugn : concomitant administration of druga oral and drugn resulted in decreased clearance of drugb and significant increases in drugn plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p6	TORADOL	brand	_	ketorolac	drug	_	false	drugn : concomitant administration of druga oral and drugn resulted in decreased clearance of drugn and significant increases in drugb plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p7	probenecid	drug	_	ketorolac	drug	_	false	drugn : concomitant administration of drugn oral and druga resulted in decreased clearance of drugb and significant increases in drugn plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s9.p8	probenecid	drug	_	ketorolac	drug	_	false	drugn : concomitant administration of drugn oral and druga resulted in decreased clearance of drugn and significant increases in drugb plasma levels -lcb- total auc increased approximately threefold from # to # m g/h/ml -rcb- and terminal half-life increased approximately twofold from # to # hours .
DDI-DrugBank.d3.s10.p0	TORADOL	brand	_	probenecid	drug	_	advise	therefore , concomitant use of druga and drugb is contraindicated .
DDI-DrugBank.d3.s12.p0	TORADOL	brand	_	lithium	drug	_	false	the effect of druga on plasma drugb has not been studied , but cases of increased drugn plasma levels during drugn therapy have been reported .
DDI-DrugBank.d3.s12.p1	TORADOL	brand	_	lithium	drug	_	false	the effect of druga on plasma drugn has not been studied , but cases of increased drugb plasma levels during drugn therapy have been reported .
DDI-DrugBank.d3.s12.p4	lithium	drug	_	TORADOL	brand	_	false	the effect of drugn on plasma druga has not been studied , but cases of increased drugn plasma levels during drugb therapy have been reported .
DDI-DrugBank.d3.s12.p5	lithium	drug	_	TORADOL	brand	_	mechanism	the effect of drugn on plasma drugn has not been studied , but cases of increased druga plasma levels during drugb therapy have been reported .
DDI-DrugBank.d3.s13.p1	Methotrexate	drug	_	NSAIDs	group	_	false	druga : concomitant administration of drugn and some drugb has been reported to reduce the clearance of drugn , enhancing the toxicity of drugn .
DDI-DrugBank.d3.s13.p4	methotrexate	drug	_	NSAIDs	group	_	mechanism	drugn : concomitant administration of druga and some drugb has been reported to reduce the clearance of drugn , enhancing the toxicity of drugn .
DDI-DrugBank.d3.s13.p7	NSAIDs	group	_	methotrexate	drug	_	false	drugn : concomitant administration of drugn and some druga has been reported to reduce the clearance of drugb , enhancing the toxicity of drugn .
DDI-DrugBank.d3.s13.p8	NSAIDs	group	_	methotrexate	drug	_	false	drugn : concomitant administration of drugn and some druga has been reported to reduce the clearance of drugn , enhancing the toxicity of drugb .
DDI-DrugBank.d3.s14.p0	TORADOL	brand	_	methotrexate	drug	_	false	the effect of druga on drugb clearance has not been studied .
DDI-DrugBank.d3.s16.p0	TORADOL	brand	_	muscle relaxants	group	_	false	the concurrent use of druga with drugb has not been formally studied .
DDI-DrugBank.d3.s18.p4	TORADOL	brand	_	antiepileptic drugs	group	_	effect	drugn : sporadic cases of seizures have been reported during concomitant use of druga and drugb -lcb- drugn , drugn -rcb- .
DDI-DrugBank.d3.s18.p5	TORADOL	brand	_	phenytoin	drug	_	effect	drugn : sporadic cases of seizures have been reported during concomitant use of druga and drugn -lcb- drugb , drugn -rcb- .
DDI-DrugBank.d3.s18.p6	TORADOL	brand	_	carbamazepine	drug	_	effect	drugn : sporadic cases of seizures have been reported during concomitant use of druga and drugn -lcb- drugn , drugb -rcb- .
DDI-DrugBank.d3.s19.p5	TORADOL	brand	_	psychoactive drugs	group	_	effect	drugn : hallucinations have been reported when druga was used in patients taking drugb -lcb- drugn , drugn , drugn -rcb- .
DDI-DrugBank.d3.s19.p6	TORADOL	brand	_	fluoxetine	drug	_	effect	drugn : hallucinations have been reported when druga was used in patients taking drugn -lcb- drugb , drugn , drugn -rcb- .
DDI-DrugBank.d3.s19.p7	TORADOL	brand	_	thiothixene	drug	_	effect	drugn : hallucinations have been reported when druga was used in patients taking drugn -lcb- drugn , drugb , drugn -rcb- .
DDI-DrugBank.d3.s19.p8	TORADOL	brand	_	alprazolam	drug	_	effect	drugn : hallucinations have been reported when druga was used in patients taking drugn -lcb- drugn , drugn , drugb -rcb- .
DDI-DrugBank.d3.s21.p0	TORADOL	brand	_	morphine	drug	_	false	do not mix druga and drugb in the same syringe .
DDI-DrugBank.d95.s0.p0	Cyclosporine	drug	_	L-arginine	drug	_	false	druga - drugb may counteract the antinaturetic effect of drugn .
DDI-DrugBank.d95.s0.p2	L-arginine	drug	_	cyclosporin	drug	_	effect	drugn - druga may counteract the antinaturetic effect of drugb .
DDI-DrugBank.d95.s1.p0	Ibuprofen	drug	_	L-arginine	drug	_	false	druga - drugb may increase the absorption of drugn if taken concomitantly .
DDI-DrugBank.d95.s1.p2	L-arginine	drug	_	ibuprofen	drug	_	mechanism	drugn - druga may increase the absorption of drugb if taken concomitantly .
DDI-DrugBank.d95.s2.p0	nitrates	group	_	L-arginine	drug	_	false	organic druga - drugb supplements theoretically may potentiate the effects of organic drugn if taken concomitantly .
DDI-DrugBank.d95.s2.p2	L-arginine	drug	_	nitrates	drug	_	effect	organic drugn - druga supplements theoretically may potentiate the effects of organic drugb if taken concomitantly .
DDI-DrugBank.d95.s3.p0	Sildenafil citrate	drug	_	L-arginine	drug	_	false	druga - theoretically , drugb supplements taken concomitantly with drugn , may potentiate the effects of the drug .
DDI-DrugBank.d95.s3.p2	L-arginine	drug	_	sildenafil citrate	drug	_	effect	drugn - theoretically , druga supplements taken concomitantly with drugb , may potentiate the effects of the drug .
DDI-DrugBank.d66.s0.p0	Human growth hormone	drug	_	L-glutamine	drug	_	false	druga - concomitant use of drugb and drugn may enhance nutrient absorption in those with severe short bowel syndrome .
DDI-DrugBank.d66.s0.p2	L-glutamine	drug	_	human growth hormone	drug	_	mechanism	drugn - concomitant use of druga and drugb may enhance nutrient absorption in those with severe short bowel syndrome .
DDI-DrugBank.d66.s2.p0	Indomethacin	drug	_	L-glutamine	drug	_	false	druga - concomitant use of drugb and drugn may ameliorate increased intestinal permeability caused by drugn .
DDI-DrugBank.d66.s2.p3	L-glutamine	drug	_	indomethacin	drug	_	effect	drugn - concomitant use of druga and drugb may ameliorate increased intestinal permeability caused by drugn .
DDI-DrugBank.d66.s2.p4	L-glutamine	drug	_	indomethacin	drug	_	false	drugn - concomitant use of druga and drugn may ameliorate increased intestinal permeability caused by drugb .
DDI-DrugBank.d66.s5.p1	Methotrexate	drug	_	L-glutamine	drug	_	false	druga - there is one report that drugn may decrease the possible effectiveness of supplemental drugb for chemotherapy-induced mucositis .
DDI-DrugBank.d66.s5.p2	methotrexate	drug	_	L-glutamine	drug	_	effect	drugn - there is one report that druga may decrease the possible effectiveness of supplemental drugb for chemotherapy-induced mucositis .
DDI-DrugBank.d66.s6.p0	methotrexate	drug	_	L-glutamine	drug	_	effect	in another report , nine patients with breast cancer were reported to have decreased symptoms of druga - related toxicity when given supplemental drugb at a dose of # gram/kilogram/day .
DDI-DrugBank.d66.s7.p0	Paclitaxel	drug	_	L-glutamine	drug	_	false	druga - in one report , drugb at a dose of # grams three times daily , given # hours after receiving drugn , appeared to prevent the development of myalgia and arthralgia , adverse reactions of drugn .
DDI-DrugBank.d66.s7.p3	L-glutamine	drug	_	paclitaxel	drug	_	effect	drugn - in one report , druga at a dose of # grams three times daily , given # hours after receiving drugb , appeared to prevent the development of myalgia and arthralgia , adverse reactions of drugn .
DDI-DrugBank.d66.s7.p4	L-glutamine	drug	_	paclitaxel	drug	_	false	drugn - in one report , druga at a dose of # grams three times daily , given # hours after receiving drugn , appeared to prevent the development of myalgia and arthralgia , adverse reactions of drugb .
DDI-DrugBank.d365.s0.p0	Medroxyprogesterone Acetate	drug	_	L-histidine	drug	_	false	druga - drugb was observed to enhance -lcb- in tissue culture -rcb- the effect of drugn in reducing the number of human breast_cancer cells that were in the s phase .
DDI-DrugBank.d365.s0.p2	L-histidine	drug	_	medroxyprogesterone acetate	drug	_	effect	drugn - druga was observed to enhance -lcb- in tissue culture -rcb- the effect of drugb in reducing the number of human breast_cancer cells that were in the s phase .
DDI-DrugBank.d365.s1.p0	H1 Blockers	group	_	H2 Blockers	group	_	false	druga and drugb - although not reported , drugn , via its metabolism to histamine , might decrease the efficacy of drugn and drugn .
DDI-DrugBank.d365.s1.p1	H1 Blockers	group	_	L-histidine	drug	_	false	druga and drugn - although not reported , drugb , via its metabolism to histamine , might decrease the efficacy of drugn and drugn .
DDI-DrugBank.d365.s1.p3	H1 Blockers	group	_	H2 blockers	group	_	false	druga and drugn - although not reported , drugn , via its metabolism to histamine , might decrease the efficacy of drugn and drugb .
DDI-DrugBank.d365.s1.p4	H2 Blockers	group	_	L-histidine	drug	_	false	drugn and druga - although not reported , drugb , via its metabolism to histamine , might decrease the efficacy of drugn and drugn .
DDI-DrugBank.d365.s1.p5	H2 Blockers	group	_	H1 blockers	group	_	false	drugn and druga - although not reported , drugn , via its metabolism to histamine , might decrease the efficacy of drugb and drugn .
DDI-DrugBank.d365.s1.p7	L-histidine	drug	_	H1 blockers	group	_	effect	drugn and drugn - although not reported , druga , via its metabolism to histamine , might decrease the efficacy of drugb and drugn .
DDI-DrugBank.d365.s1.p8	L-histidine	drug	_	H2 blockers	group	_	effect	drugn and drugn - although not reported , druga , via its metabolism to histamine , might decrease the efficacy of drugn and drugb .
DDI-DrugBank.d365.s1.p9	H1 blockers	group	_	H2 blockers	group	_	false	drugn and drugn - although not reported , drugn , via its metabolism to histamine , might decrease the efficacy of druga and drugb .
DDI-DrugBank.d344.s0.p0	calcium	drug	_	L-lysine	drug	_	mechanism	concomitant use of druga supplements and drugb may increase drugn absorption
DDI-DrugBank.d344.s0.p2	L-lysine	drug	_	calcium	drug	_	false	concomitant use of drugn supplements and druga may increase drugb absorption
DDI-DrugBank.d528.s0.p0	Acetaminophen	drug	_	methotrexate	drug	_	false	druga and drugb - drugn may decrease hepatic toxicity in those with drugn overdosage or in those taking drugn .
DDI-DrugBank.d528.s0.p1	Acetaminophen	drug	_	L-methionine	drug	_	false	druga and drugn - drugb may decrease hepatic toxicity in those with drugn overdosage or in those taking drugn .
DDI-DrugBank.d528.s0.p3	Acetaminophen	drug	_	methotrexate	drug	_	false	druga and drugn - drugn may decrease hepatic toxicity in those with drugn overdosage or in those taking drugb .
DDI-DrugBank.d528.s0.p4	methotrexate	drug	_	L-methionine	drug	_	false	drugn and druga - drugb may decrease hepatic toxicity in those with drugn overdosage or in those taking drugn .
DDI-DrugBank.d528.s0.p5	methotrexate	drug	_	acetaminophen	drug	_	false	drugn and druga - drugn may decrease hepatic toxicity in those with drugb overdosage or in those taking drugn .
DDI-DrugBank.d528.s0.p7	L-methionine	drug	_	acetaminophen	drug	_	effect	drugn and drugn - druga may decrease hepatic toxicity in those with drugb overdosage or in those taking drugn .
DDI-DrugBank.d528.s0.p8	L-methionine	drug	_	methotrexate	drug	_	effect	drugn and drugn - druga may decrease hepatic toxicity in those with drugn overdosage or in those taking drugb .
DDI-DrugBank.d528.s0.p9	acetaminophen	drug	_	methotrexate	drug	_	false	drugn and drugn - drugn may decrease hepatic toxicity in those with druga overdosage or in those taking drugb .
DDI-DrugBank.d528.s2.p0	Gentamicin	drug	_	Methionine	drug	_	false	druga - drugb may protect against the ototoxic effects of drugn .
DDI-DrugBank.d528.s2.p2	Methionine	drug	_	gentamicin	drug	_	effect	drugn - druga may protect against the ototoxic effects of drugb .
DDI-DrugBank.d530.s0.p0	Non-selective monoamine oxidase (MAO) inhibitors	group	_	phenelzine sulfate	drug	_	false	druga - including drugb , drugn and drugn hc1 .
DDI-DrugBank.d530.s0.p1	Non-selective monoamine oxidase (MAO) inhibitors	group	_	tranylcypromine sulfate	drug	_	false	druga - including drugn , drugb and drugn hc1 .
DDI-DrugBank.d530.s0.p2	Non-selective monoamine oxidase (MAO) inhibitors	group	_	pargyline	drug	_	false	druga - including drugn , drugn and drugb hc1 .
DDI-DrugBank.d530.s1.p0	L-phenylalanine	drug	_	non-selective MAO inhibitors	group	_	effect	concomitant use of druga and drugb may cause hypertension .
DDI-DrugBank.d530.s2.p0	Selegiline	drug	_	L-phenylalanine	drug	_	false	druga - drugb and the drugn drugn may have synergistic antidepressant activity if used concomitantly .
DDI-DrugBank.d530.s2.p1	Selegiline	drug	_	selective MAO inhibitor	group	_	false	druga - drugn and the drugb drugn may have synergistic antidepressant activity if used concomitantly .
DDI-DrugBank.d530.s2.p3	L-phenylalanine	drug	_	selective MAO inhibitor	group	_	false	drugn - druga and the drugb drugn may have synergistic antidepressant activity if used concomitantly .
DDI-DrugBank.d530.s2.p4	L-phenylalanine	drug	_	selegiline	drug	_	effect	drugn - druga and the drugn drugb may have synergistic antidepressant activity if used concomitantly .
DDI-DrugBank.d530.s2.p5	selective MAO inhibitor	group	_	selegiline	drug	_	false	drugn - drugn and the druga drugb may have synergistic antidepressant activity if used concomitantly .
DDI-DrugBank.d530.s3.p0	Neuroleptic Drugs	group	_	L-phenylalanine	drug	_	effect	druga - drugb may potentiate the tardive dyskinesia side reactions of drugn if used concomitantly with them .
DDI-DrugBank.d530.s3.p2	L-phenylalanine	drug	_	neuroleptic drugs	group	_	false	drugn - druga may potentiate the tardive dyskinesia side reactions of drugb if used concomitantly with them .
DDI-DrugBank.d63.s0.p0	Monoamine oxidase (MAO) inhibitors	group	_	isocarboxazid	drug	_	false	druga such as drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p1	Monoamine oxidase (MAO) inhibitors	group	_	Marplan	brand	_	false	druga such as drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p2	Monoamine oxidase (MAO) inhibitors	group	_	phenelzine	drug	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p3	Monoamine oxidase (MAO) inhibitors	group	_	Nardil	brand	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p4	Monoamine oxidase (MAO) inhibitors	group	_	procarbazine	drug	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p5	Monoamine oxidase (MAO) inhibitors	group	_	Matulane	brand	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p6	Monoamine oxidase (MAO) inhibitors	group	_	selegiline	drug	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugb -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p7	Monoamine oxidase (MAO) inhibitors	group	_	Eldepryl	brand	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugb -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p8	Monoamine oxidase (MAO) inhibitors	group	_	tranylcypromine	drug	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugb -lcb- e , g , , drugn -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p9	Monoamine oxidase (MAO) inhibitors	group	_	Parnate	brand	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugb -rcb- : using these medicines with drugn may increase the chance of side effects .
DDI-DrugBank.d63.s0.p10	Monoamine oxidase (MAO) inhibitors	group	_	L-tryptophan	drug	_	false	druga such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p20	isocarboxazid	drug	_	L-tryptophan	drug	_	false	drugn such as druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p29	Marplan	brand	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p37	phenelzine	drug	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p44	Nardil	brand	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p50	procarbazine	drug	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p55	Matulane	brand	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p59	selegiline	drug	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , druga -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p62	Eldepryl	brand	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , druga -rcb- , and drugn -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p64	tranylcypromine	drug	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and druga -lcb- e , g , , drugn -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d63.s0.p65	Parnate	brand	_	L-tryptophan	drug	_	false	drugn such as drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , drugn -lcb- e , g , , drugn -rcb- , and drugn -lcb- e , g , , druga -rcb- : using these medicines with drugb may increase the chance of side effects .
DDI-DrugBank.d111.s0.p0	Non-selective MAO inhibitors	group	_	tranylcypromine sulfate	drug	_	false	druga including drugb , drugn , and drugn hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p1	Non-selective MAO inhibitors	group	_	phenelzine sulfate	drug	_	false	druga including drugn , drugb , and drugn hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p2	Non-selective MAO inhibitors	group	_	pargyline	drug	_	false	druga including drugn , drugn , and drugb hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p3	Non-selective MAO inhibitors	group	_	L-tyrosine	drug	_	false	druga including drugn , drugn , and drugn hc1 : concomitant use of drugb and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p5	tranylcypromine sulfate	drug	_	phenelzine sulfate	drug	_	false	drugn including druga , drugb , and drugn hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p6	tranylcypromine sulfate	drug	_	pargyline	drug	_	false	drugn including druga , drugn , and drugb hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p7	tranylcypromine sulfate	drug	_	L-tyrosine	drug	_	false	drugn including druga , drugn , and drugn hc1 : concomitant use of drugb and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p8	tranylcypromine sulfate	drug	_	MAO inhibitors	group	_	false	drugn including druga , drugn , and drugn hc1 : concomitant use of drugn and non-selective drugb may cause hypertension .
DDI-DrugBank.d111.s0.p9	phenelzine sulfate	drug	_	pargyline	drug	_	false	drugn including drugn , druga , and drugb hc1 : concomitant use of drugn and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p10	phenelzine sulfate	drug	_	L-tyrosine	drug	_	false	drugn including drugn , druga , and drugn hc1 : concomitant use of drugb and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p11	phenelzine sulfate	drug	_	MAO inhibitors	group	_	false	drugn including drugn , druga , and drugn hc1 : concomitant use of drugn and non-selective drugb may cause hypertension .
DDI-DrugBank.d111.s0.p12	pargyline	drug	_	L-tyrosine	drug	_	false	drugn including drugn , drugn , and druga hc1 : concomitant use of drugb and non-selective drugn may cause hypertension .
DDI-DrugBank.d111.s0.p13	pargyline	drug	_	MAO inhibitors	group	_	false	drugn including drugn , drugn , and druga hc1 : concomitant use of drugn and non-selective drugb may cause hypertension .
DDI-DrugBank.d111.s0.p14	L-tyrosine	drug	_	MAO inhibitors	group	_	effect	drugn including drugn , drugn , and drugn hc1 : concomitant use of druga and non-selective drugb may cause hypertension .
DDI-DrugBank.d412.s0.p0	labetalol HCl	drug	_	tricyclic antidepressants	group	_	effect	in one survey , # % of patients taking druga in combination with drugb experienced tremor , as compared to # % reported to occur with drugn alone .
DDI-DrugBank.d412.s0.p2	tricyclic antidepressants	group	_	labetalol HCl	drug	_	false	in one survey , # % of patients taking drugn in combination with druga experienced tremor , as compared to # % reported to occur with drugb alone .
DDI-DrugBank.d412.s4.p0	Cimetidine	drug	_	labetalol HCl	drug	_	mechanism	druga has been shown to increase the bioavailability of drugb .
DDI-DrugBank.d412.s6.p0	halothane	drug	_	labetalol HCl	drug	_	effect	synergism has been shown between druga anesthesia and intravenously administered drugb .
DDI-DrugBank.d412.s7.p0	labetalol HCl	drug	_	halothane	drug	_	effect	during controlled hypotensive anesthesia using druga in association with drugb , high concentrations -lcb- 3 % or above -rcb- of drugn should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure .
DDI-DrugBank.d412.s7.p1	labetalol HCl	drug	_	halothane	drug	_	false	during controlled hypotensive anesthesia using druga in association with drugn , high concentrations -lcb- 3 % or above -rcb- of drugb should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure .
DDI-DrugBank.d412.s9.p0	Labetalol HCl	drug	_	nitroglycerin	drug	_	effect	druga blunts the reflex tachycardia produced by drugb without preventing its hypotensive effect .
DDI-DrugBank.d412.s10.p0	labetalol HCl	drug	_	nitroglycerin	drug	_	effect	if druga is used with drugb in patients with angina pectoris , additional antihypertensive effects may occur .
DDI-DrugBank.d412.s11.p0	labetalol	drug	_	calcium antagonist	group	_	advise	care should be taken if druga is used concomitantly with drugb s of the drugn type .
DDI-DrugBank.d412.s11.p1	labetalol	drug	_	verapamil	drug	_	false	care should be taken if druga is used concomitantly with drugn s of the drugb type .
DDI-DrugBank.d412.s11.p2	calcium antagonist	group	_	verapamil	drug	_	false	care should be taken if drugn is used concomitantly with druga s of the drugb type .
DDI-DrugBank.d412.s16.p0	Labetalol HCl	drug	_	amphetamine	drug	_	false	druga has also been reported to produce a false positive test for drugb when screening urine for the presence of drugs using the commercially available assay methods toxi-lab a -lcb- thin-layer chromatographic assay -rcb- and emit-d , a , u , -lcb- radioenzymatic assay -rcb- .
DDI-DrugBank.d412.s17.p0	labetalol	drug	_	amphetamine	drug	_	false	when patients being treated with druga have a positive urine test for drugb using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique .
DDI-DrugBank.d206.s0.p0	antacids	group	_	lactulose	drug	_	mechanism	results of preliminary studies in humans and rats suggest that nonabsorbable druga given concurrently with drugb may inhibit the desired drugn - induced drop in colonic ph.
DDI-DrugBank.d206.s0.p1	antacids	group	_	lactulose	drug	_	false	results of preliminary studies in humans and rats suggest that nonabsorbable druga given concurrently with drugn may inhibit the desired drugb - induced drop in colonic ph.
DDI-DrugBank.d71.s3.p0	lamivudine	drug	_	TMP	drug	_	false	there is no information regarding the effect on druga pharmacokinetics of higher doses of drugb / drugn such as those used to treat pneumocystis carinii pneumonia .
DDI-DrugBank.d71.s3.p1	lamivudine	drug	_	SMX	drug	_	false	there is no information regarding the effect on druga pharmacokinetics of higher doses of drugn / drugb such as those used to treat pneumocystis carinii pneumonia .
DDI-DrugBank.d71.s5.p0	Lamivudine	drug	_	zalcitabine	drug	_	effect	druga and drugb may inhibit the intracellular phosphorylation of one another .
DDI-DrugBank.d71.s6.p0	lamivudine	drug	_	zalcitabine	drug	_	advise	therefore , use of druga in combination with drugb is not recommended
DDI-DrugBank.d431.s1.p0	lansoprazole	drug	_	warfarin	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p1	lansoprazole	drug	_	antipyrine	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p2	lansoprazole	drug	_	indomethacin	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p3	lansoprazole	drug	_	ibuprofen	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p4	lansoprazole	drug	_	phenytoin	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p5	lansoprazole	drug	_	propranolol	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p6	lansoprazole	drug	_	prednisone	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p7	lansoprazole	drug	_	diazepam	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p8	lansoprazole	drug	_	clarithromycin	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn in healthy subjects .
DDI-DrugBank.d431.s1.p9	lansoprazole	drug	_	terfenadine	drug	_	false	studies have shown that druga does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb in healthy subjects .
DDI-DrugBank.d431.s3.p0	lansoprazole	drug	_	theophylline	drug	_	mechanism	when druga was administered concomitantly with drugb -lcb- cyp1a2 , cyp3a -rcb- , a minor increase -lcb- 10 % -rcb- in the clearance of drugn was seen .
DDI-DrugBank.d431.s3.p1	lansoprazole	drug	_	theophylline	drug	_	false	when druga was administered concomitantly with drugn -lcb- cyp1a2 , cyp3a -rcb- , a minor increase -lcb- 10 % -rcb- in the clearance of drugb was seen .
DDI-DrugBank.d431.s5.p0	theophylline	drug	_	lansoprazole	drug	_	advise	nonetheless , individual patients may require additional titration of their druga dosage when drugb is started or stopped to ensure clinically effective blood levels .
DDI-DrugBank.d431.s6.p0	Lansoprazole	drug	_	amoxicillin	drug	_	false	druga has also been shown to have no clinically significant interaction with drugb .
DDI-DrugBank.d431.s7.p0	lansoprazole	drug	_	omeprazole	drug	_	false	in a single-dose crossover study examining druga # mg and drugb # mg each administered alone and concomitantly with drugn # gram , absorption of the drugn was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p1	lansoprazole	drug	_	sucralfate	drug	_	false	in a single-dose crossover study examining druga # mg and drugn # mg each administered alone and concomitantly with drugb # gram , absorption of the drugn was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p2	lansoprazole	drug	_	proton pump inhibitors	group	_	false	in a single-dose crossover study examining druga # mg and drugn # mg each administered alone and concomitantly with drugn # gram , absorption of the drugb was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p3	lansoprazole	drug	_	sucralfate	drug	_	false	in a single-dose crossover study examining druga # mg and drugn # mg each administered alone and concomitantly with drugn # gram , absorption of the drugn was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugb .
DDI-DrugBank.d431.s7.p4	omeprazole	drug	_	sucralfate	drug	_	false	in a single-dose crossover study examining drugn # mg and druga # mg each administered alone and concomitantly with drugb # gram , absorption of the drugn was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p5	omeprazole	drug	_	proton pump inhibitors	group	_	false	in a single-dose crossover study examining drugn # mg and druga # mg each administered alone and concomitantly with drugn # gram , absorption of the drugb was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p6	omeprazole	drug	_	sucralfate	drug	_	false	in a single-dose crossover study examining drugn # mg and druga # mg each administered alone and concomitantly with drugn # gram , absorption of the drugn was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugb .
DDI-DrugBank.d431.s7.p7	sucralfate	drug	_	proton pump inhibitors	group	_	false	in a single-dose crossover study examining drugn # mg and drugn # mg each administered alone and concomitantly with druga # gram , absorption of the drugb was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugn .
DDI-DrugBank.d431.s7.p9	proton pump inhibitors	group	_	sucralfate	drug	_	mechanism	in a single-dose crossover study examining drugn # mg and drugn # mg each administered alone and concomitantly with drugn # gram , absorption of the druga was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drugb .
DDI-DrugBank.d431.s8.p0	proton pump inhibitors	group	_	sucralfate	drug	_	advise	therefore , druga should be taken at least # minutes prior to drugb .
DDI-DrugBank.d431.s9.p0	antacids	group	_	lansoprazole	drug	_	false	in clinical trials , druga were administered concomitantly with drugb delayed-release capsules ;
DDI-DrugBank.d431.s12.p0	lansoprazole	drug	_	ketoconazole	drug	_	mechanism	therefore , it is theoretically possible that druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- e , g , drugb , drugn esters , drugn salts , drugn -rcb- .
DDI-DrugBank.d431.s12.p1	lansoprazole	drug	_	ampicillin	drug	_	mechanism	therefore , it is theoretically possible that druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- e , g , drugn , drugb esters , drugn salts , drugn -rcb- .
DDI-DrugBank.d431.s12.p2	lansoprazole	drug	_	iron	drug	_	mechanism	therefore , it is theoretically possible that druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- e , g , drugn , drugn esters , drugb salts , drugn -rcb- .
DDI-DrugBank.d431.s12.p3	lansoprazole	drug	_	digoxin	drug	_	mechanism	therefore , it is theoretically possible that druga may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability -lcb- e , g , drugn , drugn esters , drugn salts , drugb -rcb- .
DDI-DrugBank.d135.s7.p2	ketoconazole	drug	_	lapatinib	drug	_	mechanism	drugn : in healthy subjects receiving druga , a cyp3a4 inhibitor , at # mg twice daily for # days , systemic exposure -lcb- auc -rcb- to drugb was increased to approximately # - fold of control and half-life increased to # - fold of control .
DDI-DrugBank.d135.s8.p2	carbamazepine	drug	_	lapatinib	drug	_	mechanism	drugn : in healthy subjects receiving the cyp3a4 inducer , druga , at # mg twice daily for # days and # mg twice daily for # days , systemic exposure -lcb- auc -rcb- to drugb was decreased approximately 72 % .
DDI-DrugBank.d135.s10.p0	TYKERB	brand	_	lapatinib	drug	_	false	if druga is administered with drugs that inhibit pgp , increased concentrations of drugb are likely , and caution should be exercised .
DDI-DrugBank.d135.s11.p0	lapatinib	drug	_	capecitabine	drug	_	false	other chemotherapy agents in a separate study , concomitant administration of druga with drugb did not meaningfully alter the pharmacokinetics of either agent -lcb- or the metabolites of drugn -rcb- .
DDI-DrugBank.d135.s11.p1	lapatinib	drug	_	capecitabine	drug	_	false	other chemotherapy agents in a separate study , concomitant administration of druga with drugn did not meaningfully alter the pharmacokinetics of either agent -lcb- or the metabolites of drugb -rcb- .
DDI-DrugBank.d118.s0.p0	thimerosal	drug_n	_	latanoprost	drug	_	false	in vitro studies have shown that precipitation occurs when eye drops containing druga are mixed with drugb .
DDI-DrugBank.d41.s0.p0	Cholestyramine	drug	_	Charcoal	drug	_	false	druga and drugb administration of drugn or drugn in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugn -rcb- concentration .
DDI-DrugBank.d41.s0.p2	Cholestyramine	drug	_	activated charcoal	drug	_	false	druga and drugn administration of drugn or drugb in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugn -rcb- concentration .
DDI-DrugBank.d41.s0.p3	Cholestyramine	drug	_	leflunomide	drug	_	false	druga and drugn administration of drugn or drugn in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugb -rcb- concentration .
DDI-DrugBank.d41.s0.p4	Charcoal	drug	_	cholestyramine	drug	_	false	drugn and druga administration of drugb or drugn in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugn -rcb- concentration .
DDI-DrugBank.d41.s0.p6	Charcoal	drug	_	leflunomide	drug	_	false	drugn and druga administration of drugn or drugn in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugb -rcb- concentration .
DDI-DrugBank.d41.s0.p7	cholestyramine	drug	_	activated charcoal	drug	_	false	drugn and drugn administration of druga or drugb in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugn -rcb- concentration .
DDI-DrugBank.d41.s0.p8	cholestyramine	drug	_	leflunomide	drug	_	mechanism	drugn and drugn administration of druga or drugn in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugb -rcb- concentration .
DDI-DrugBank.d41.s0.p9	activated charcoal	drug	_	leflunomide	drug	_	mechanism	drugn and drugn administration of drugn or druga in patients -lcb- n = 13 -rcb- and volunteers -lcb- n = 96 -rcb- resulted in a rapid and significant decrease in plasma m1 -lcb- the active metabolite of drugb -rcb- concentration .
DDI-DrugBank.d41.s3.p0	ARAVA	brand	_	methotrexate	drug	_	effect	in a small -lcb- n = 30 -rcb- combination study of druga with drugb , a 2 - to 3-fold elevation in liver enzymes was seen in # of # patients .
DDI-DrugBank.d41.s9.p0	NSAIDs	group	_	diclofenac	drug	_	false	druga : in in vitro studies , m1 was shown to cause increases ranging from # - 50 % in the free fraction of drugb and drugn at concentrations in the clinical range .
DDI-DrugBank.d41.s9.p1	NSAIDs	group	_	ibuprofen	drug	_	false	druga : in in vitro studies , m1 was shown to cause increases ranging from # - 50 % in the free fraction of drugn and drugb at concentrations in the clinical range .
DDI-DrugBank.d41.s9.p2	diclofenac	drug	_	ibuprofen	drug	_	false	drugn : in in vitro studies , m1 was shown to cause increases ranging from # - 50 % in the free fraction of druga and drugb at concentrations in the clinical range .
DDI-DrugBank.d41.s14.p3	ARAVA	brand	_	rifampin	drug	_	mechanism	drugn : following concomitant administration of a single dose of druga to subjects receiving multiple doses of drugb , m1 peak levels were increased -lcb- ~ 40 % -rcb- over those seen when drugn was given alone .
DDI-DrugBank.d41.s14.p5	rifampin	drug	_	ARAVA	brand	_	false	drugn : following concomitant administration of a single dose of drugn to subjects receiving multiple doses of druga , m1 peak levels were increased -lcb- ~ 40 % -rcb- over those seen when drugb was given alone .
DDI-DrugBank.d41.s15.p1	ARAVA	brand	_	rifampin	drug	_	false	because of the potential for druga levels to continue to increase with multiple dosing , caution should be used if patients are to be receiving both drugn and drugb .
DDI-DrugBank.d41.s15.p2	ARAVA	brand	_	rifampin	drug	_	advise	because of the potential for drugn levels to continue to increase with multiple dosing , caution should be used if patients are to be receiving both druga and drugb .
DDI-DrugBank.d41.s16.p0	Warfarin	drug	_	ARAVA	brand	_	false	druga : increased inr -lcb- international normalized ratio -rcb- when drugb and drugn were co-administered has been rarely reported .
DDI-DrugBank.d41.s16.p2	ARAVA	brand	_	warfarin	drug	_	effect	drugn : increased inr -lcb- international normalized ratio -rcb- when druga and drugb were co-administered has been rarely reported .
DDI-DrugBank.d169.s0.p1	REVLIMID	brand	_	lenalidomide	drug	_	false	results from human in vitro metabolism studies and nonclinical studies show that druga -lcb- drugn -rcb- is neither metabolized by nor inhibits or induces the cytochrome cyp2b6 pathway suggesting that drugb is not likely to cause or be subject to p450-based metabolic drug interactions in man .
DDI-DrugBank.d169.s1.p0	lenalidomide	drug	_	R- warfarin	drug	_	false	co-administration of multiple doses of # mg of druga had no effect on the single dose pharmacokinetics of drugb and drugn .
DDI-DrugBank.d169.s1.p1	lenalidomide	drug	_	S- warfarin	drug	_	false	co-administration of multiple doses of # mg of druga had no effect on the single dose pharmacokinetics of drugn and drugb .
DDI-DrugBank.d169.s1.p2	R- warfarin	drug	_	S- warfarin	drug	_	false	co-administration of multiple doses of # mg of drugn had no effect on the single dose pharmacokinetics of druga and drugb .
DDI-DrugBank.d169.s2.p0	warfarin	drug	_	lenalidomide	drug	_	false	co-administration of single 25-mg dose druga had no effect on the pharmacokinetics of total drugb .
DDI-DrugBank.d169.s3.p0	warfarin	drug	_	lenalidomide	drug	_	false	expected changes in laboratory assessments of pt and inr were observed after druga administration , but these changes were not affected by concomitant drugb administration .
DDI-DrugBank.d52.s0.p1	thrombolytics	group	_	REFLUDAN	brand	_	false	concomitant treatment with druga -lcb- eg , rt-pa or drugn -rcb- may : - increase the risk of bleeding complications - considerably enhance the effect of drugb on aptt prolongation
DDI-DrugBank.d52.s0.p2	streptokinase	drug	_	REFLUDAN	brand	_	false	concomitant treatment with drugn -lcb- eg , rt-pa or druga -rcb- may : - increase the risk of bleeding complications - considerably enhance the effect of drugb on aptt prolongation
DDI-DrugBank.d157.s0.p0	cimetidine	drug	_	warfarin	drug	_	false	clinical interaction studies with druga and drugb indicated that the coadministration of drugn with these drugs does not result in clinically - significant drug interactions .
DDI-DrugBank.d157.s0.p1	cimetidine	drug	_	Femara	brand	_	false	clinical interaction studies with druga and drugn indicated that the coadministration of drugb with these drugs does not result in clinically - significant drug interactions .
DDI-DrugBank.d157.s0.p2	warfarin	drug	_	Femara	brand	_	false	clinical interaction studies with drugn and druga indicated that the coadministration of drugb with these drugs does not result in clinically - significant drug interactions .
DDI-DrugBank.d157.s1.p0	Femara	brand	_	tamoxifen	drug	_	mechanism	-lcb- see clinical pharmacology -rcb- coadministration of druga and drugb # mg daily resulted in a reduction of drugn plasma levels by 38 % on average .
DDI-DrugBank.d157.s1.p1	Femara	brand	_	letrozole	drug	_	false	-lcb- see clinical pharmacology -rcb- coadministration of druga and drugn # mg daily resulted in a reduction of drugb plasma levels by 38 % on average .
DDI-DrugBank.d157.s1.p2	tamoxifen	drug	_	letrozole	drug	_	false	-lcb- see clinical pharmacology -rcb- coadministration of drugn and druga # mg daily resulted in a reduction of drugb plasma levels by 38 % on average .
DDI-DrugBank.d151.s0.p0	Folic acid	drug	_	phenobarbital	drug	_	effect	druga in large amounts may counteract the antiepileptic effect of drugb , drugn and drugn , and increase the frequency of seizures in susceptible pediatric patients .
DDI-DrugBank.d151.s0.p1	Folic acid	drug	_	phenytoin	drug	_	effect	druga in large amounts may counteract the antiepileptic effect of drugn , drugb and drugn , and increase the frequency of seizures in susceptible pediatric patients .
DDI-DrugBank.d151.s0.p2	Folic acid	drug	_	primidone	drug	_	effect	druga in large amounts may counteract the antiepileptic effect of drugn , drugn and drugb , and increase the frequency of seizures in susceptible pediatric patients .
DDI-DrugBank.d151.s1.p0	leucovorin	drug	_	methotrexate	drug	_	false	preliminary animal and human studies have shown that small quantities of systemically administered druga enter the lamc2 primarily as 5-methyltetrahydro-folate and , in humans , remain # to # orders of magnitude lower than the usual drugb concentrations following intrathecal administration .
DDI-DrugBank.d151.s2.p0	leucovorin	drug	_	methotrexate	drug	_	effect	however , high doses of druga may reduce the efficacy of intrathecally administered drugb .
DDI-DrugBank.d151.s3.p0	Leucovorin	drug	_	5-fluorouracil	drug	_	effect	druga may enhance the toxicity of drugb .
DDI-DrugBank.d381.s0.p1	ERGAMISOL	brand	_	alcohol	drug	_	effect	druga -lcb- drugn -rcb- has been reported to produce antabuse-like side effects when given concomitantly with drugb .
DDI-DrugBank.d381.s0.p2	levamisole hydrochloride	drug	_	alcohol	drug	_	effect	drugn -lcb- druga -rcb- has been reported to produce antabuse-like side effects when given concomitantly with drugb .
DDI-DrugBank.d381.s2.p0	levamisole	drug	_	warfarin sodium	drug	_	advise	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent druga and drugb , it is suggested that the prothrombin time be monitored carefully , and the dose of drugn or other drugn - like drugs should be adjusted accordingly , in patients taking both drugs .
DDI-DrugBank.d381.s2.p1	levamisole	drug	_	warfarin sodium	drug	_	false	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent druga and drugn , it is suggested that the prothrombin time be monitored carefully , and the dose of drugb or other drugn - like drugs should be adjusted accordingly , in patients taking both drugs .
DDI-DrugBank.d381.s2.p2	levamisole	drug	_	coumarin	group	_	false	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent druga and drugn , it is suggested that the prothrombin time be monitored carefully , and the dose of drugn or other drugb - like drugs should be adjusted accordingly , in patients taking both drugs .
DDI-DrugBank.d381.s2.p4	warfarin sodium	drug	_	coumarin	group	_	false	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drugn and druga , it is suggested that the prothrombin time be monitored carefully , and the dose of drugn or other drugb - like drugs should be adjusted accordingly , in patients taking both drugs .
DDI-DrugBank.d381.s2.p5	warfarin sodium	drug	_	coumarin	group	_	false	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drugn and drugn , it is suggested that the prothrombin time be monitored carefully , and the dose of druga or other drugb - like drugs should be adjusted accordingly , in patients taking both drugs .
DDI-DrugBank.d212.s2.p0	levetiracetam	drug	_	valproic acid	drug	_	false	in addition , druga does not affect the in vitro glucuronidation of drugb .
DDI-DrugBank.d212.s6.p0	Keppra	brand	_	Antiepileptic Drugs	group	_	false	drug-drug interactions between druga and other drugb -lcb- drugn -rcb- drugn drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p1	Keppra	brand	_	AEDs	group	_	false	drug-drug interactions between druga and other drugn -lcb- drugb -rcb- drugn drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p2	Keppra	brand	_	Phenytoin	drug	_	false	drug-drug interactions between druga and other drugn -lcb- drugn -rcb- drugb drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p4	Keppra	brand	_	phenytoin	drug	_	false	drug-drug interactions between druga and other drugn -lcb- drugn -rcb- drugn drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugb in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p6	Antiepileptic Drugs	group	_	Phenytoin	drug	_	false	drug-drug interactions between drugn and other druga -lcb- drugn -rcb- drugb drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p7	Antiepileptic Drugs	group	_	Keppra	brand	_	false	drug-drug interactions between drugn and other druga -lcb- drugn -rcb- drugn drugb -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p8	Antiepileptic Drugs	group	_	phenytoin	drug	_	false	drug-drug interactions between drugn and other druga -lcb- drugn -rcb- drugn drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugb in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p9	AEDs	group	_	Phenytoin	drug	_	false	drug-drug interactions between drugn and other drugn -lcb- druga -rcb- drugb drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p10	AEDs	group	_	Keppra	brand	_	false	drug-drug interactions between drugn and other drugn -lcb- druga -rcb- drugn drugb -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p11	AEDs	group	_	phenytoin	drug	_	false	drug-drug interactions between drugn and other drugn -lcb- druga -rcb- drugn drugn -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugb in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p12	Phenytoin	drug	_	Keppra	brand	_	false	drug-drug interactions between drugn and other drugn -lcb- drugn -rcb- druga drugb -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugn in patients with refractory epilepsy .
DDI-DrugBank.d212.s6.p14	Keppra	brand	_	phenytoin	drug	_	false	drug-drug interactions between drugn and other drugn -lcb- drugn -rcb- drugn druga -lcb- 3000 mg daily -rcb- had no effect on the pharmacokinetic disposition of drugb in patients with refractory epilepsy .
DDI-DrugBank.d212.s7.p0	levetiracetam	drug	_	phenytoin	drug	_	false	pharmacokinetics of druga were also not affected by drugb .
DDI-DrugBank.d212.s8.p0	Valproate	drug	_	Keppra	brand	_	false	druga drugb -lcb- 1500 mg twice daily -rcb- did not alter the pharmacokinetics of drugn in healthy volunteers .
DDI-DrugBank.d212.s8.p2	Keppra	brand	_	valproate	drug	_	false	drugn druga -lcb- 1500 mg twice daily -rcb- did not alter the pharmacokinetics of drugb in healthy volunteers .
DDI-DrugBank.d212.s9.p0	Valproate	drug	_	levetiracetam	drug	_	false	druga # mg twice daily did not modify the rate or extent of drugb absorption or its plasma clearance or urinary excretion .
DDI-DrugBank.d212.s11.p0	Keppra	brand	_	AEDs	group	_	false	potential drug interactions between druga and other drugb -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p1	Keppra	brand	_	carbamazepine	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugb , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p2	Keppra	brand	_	gabapentin	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugb , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p3	Keppra	brand	_	lamotrigine	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugb , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p4	Keppra	brand	_	phenobarbital	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugb , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p5	Keppra	brand	_	phenytoin	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugn , drugb , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p6	Keppra	brand	_	primidone	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugb and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p7	Keppra	brand	_	valproate	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugb -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p8	Keppra	brand	_	levetiracetam	drug	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p9	Keppra	brand	_	AEDs	group	_	false	potential drug interactions between druga and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p17	AEDs	group	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other druga -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p25	carbamazepine	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p26	carbamazepine	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- druga , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p32	gabapentin	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p33	gabapentin	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , druga , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p38	lamotrigine	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p39	lamotrigine	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , druga , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p43	phenobarbital	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p44	phenobarbital	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , druga , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p47	phenytoin	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p48	phenytoin	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , druga , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p50	primidone	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga and drugn -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p51	primidone	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , druga and drugn -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p52	valproate	drug	_	levetiracetam	drug	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and druga -rcb- were also assessed by evaluating the serum concentrations of drugb and these drugn during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p53	valproate	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and druga -rcb- were also assessed by evaluating the serum concentrations of drugn and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s11.p54	levetiracetam	drug	_	AEDs	group	_	false	potential drug interactions between drugn and other drugn -lcb- drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- were also assessed by evaluating the serum concentrations of druga and these drugb during placebo-controlled clinical studies .
DDI-DrugBank.d212.s12.p0	levetiracetam	drug	_	AEDs	group	_	false	these data indicate that druga does not influence the plasma concentration of other drugb and that these drugn do not influence the pharmacokinetics of drugn .
DDI-DrugBank.d212.s12.p1	levetiracetam	drug	_	AEDs	group	_	false	these data indicate that druga does not influence the plasma concentration of other drugn and that these drugb do not influence the pharmacokinetics of drugn .
DDI-DrugBank.d212.s12.p4	AEDs	group	_	levetiracetam	drug	_	false	these data indicate that drugn does not influence the plasma concentration of other druga and that these drugn do not influence the pharmacokinetics of drugb .
DDI-DrugBank.d212.s12.p5	AEDs	group	_	levetiracetam	drug	_	false	these data indicate that drugn does not influence the plasma concentration of other drugn and that these druga do not influence the pharmacokinetics of drugb .
DDI-DrugBank.d212.s13.p0	AEDs	group	_	levetiracetam	drug	_	false	effect of druga in pediatric patients there was about a 22 % increase of apparent total body clearance of drugb when it was co-administered with enzyme-inducing drugn .
DDI-DrugBank.d212.s13.p2	levetiracetam	drug	_	AEDs	group	_	mechanism	effect of drugn in pediatric patients there was about a 22 % increase of apparent total body clearance of druga when it was co-administered with enzyme-inducing drugb .
DDI-DrugBank.d212.s14.p0	Levetiracetam	drug	_	carbamazepine	drug	_	false	dose adjustment is not recommended , druga had no effect on plasma concentrations of drugb , drugn , drugn , or drugn .
DDI-DrugBank.d212.s14.p1	Levetiracetam	drug	_	valproate	drug	_	false	dose adjustment is not recommended , druga had no effect on plasma concentrations of drugn , drugb , drugn , or drugn .
DDI-DrugBank.d212.s14.p2	Levetiracetam	drug	_	topiramate	drug	_	false	dose adjustment is not recommended , druga had no effect on plasma concentrations of drugn , drugn , drugb , or drugn .
DDI-DrugBank.d212.s14.p3	Levetiracetam	drug	_	lamotrigine	drug	_	false	dose adjustment is not recommended , druga had no effect on plasma concentrations of drugn , drugn , drugn , or drugb .
DDI-DrugBank.d212.s15.p0	Contraceptives	group	_	Keppra	brand	_	false	other drug interactions oral druga drugb -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg drugn and # mg drugn , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p2	Contraceptives	group	_	ethinyl estradiol	drug	_	false	other drug interactions oral druga drugn -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg drugb and # mg drugn , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p3	Contraceptives	group	_	levonorgestrel	drug	_	false	other drug interactions oral druga drugn -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg drugn and # mg drugb , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p4	Keppra	brand	_	contraceptive	group	_	false	other drug interactions oral drugn druga -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugb containing # mg drugn and # mg drugn , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p5	Keppra	brand	_	ethinyl estradiol	drug	_	false	other drug interactions oral drugn druga -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg drugb and # mg drugn , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p6	Keppra	brand	_	levonorgestrel	drug	_	false	other drug interactions oral drugn druga -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg drugn and # mg drugb , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p7	contraceptive	group	_	ethinyl estradiol	drug	_	false	other drug interactions oral drugn drugn -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral druga containing # mg drugb and # mg drugn , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p8	contraceptive	group	_	levonorgestrel	drug	_	false	other drug interactions oral drugn drugn -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral druga containing # mg drugn and # mg drugb , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s15.p9	ethinyl estradiol	drug	_	levonorgestrel	drug	_	false	other drug interactions oral drugn drugn -lcb- 500 mg twice daily -rcb- did not influence the pharmacokinetics of an oral drugn containing # mg druga and # mg drugb , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .
DDI-DrugBank.d212.s16.p0	contraceptive	group	_	levetiracetam	drug	_	false	coadministration of this oral druga did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d212.s17.p0	Digoxin	drug	_	Keppra	brand	_	false	druga drugb -lcb- 1000 mg twice daily -rcb- did not influence the pharmacokinetics and pharmacodynamics -lcb- ecg -rcb- of drugn given as a # mg dose every day .
DDI-DrugBank.d212.s17.p2	Keppra	brand	_	digoxin	drug	_	false	drugn druga -lcb- 1000 mg twice daily -rcb- did not influence the pharmacokinetics and pharmacodynamics -lcb- ecg -rcb- of drugb given as a # mg dose every day .
DDI-DrugBank.d212.s18.p0	digoxin	drug	_	levetiracetam	drug	_	false	coadministration of druga did not influence the pharmacokinetics of drugb .
DDI-DrugBank.d212.s19.p0	Warfarin	drug	_	Keppra	brand	_	false	druga drugb -lcb- 1000 mg twice daily -rcb- did not influence the pharmacokinetics of drugn and drugn .
DDI-DrugBank.d212.s19.p4	Keppra	brand	_	S warfarin	drug	_	false	drugn druga -lcb- 1000 mg twice daily -rcb- did not influence the pharmacokinetics of drugn and drugb .
DDI-DrugBank.d212.s19.p5	R warfarin	drug	_	S warfarin	drug	_	false	drugn drugn -lcb- 1000 mg twice daily -rcb- did not influence the pharmacokinetics of druga and drugb .
DDI-DrugBank.d212.s21.p0	warfarin	drug	_	levetiracetam	drug	_	false	coadministration of druga did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d212.s22.p1	Probenecid	drug	_	levetiracetam	drug	_	false	druga : drugn , a renal tubular secretion blocking agent , administered at a dose of # mg four times a day , did not change the pharmacokinetics of drugb # mg twice daily .
DDI-DrugBank.d212.s22.p2	Probenecid	drug	_	levetiracetam	drug	_	false	drugn : druga , a renal tubular secretion blocking agent , administered at a dose of # mg four times a day , did not change the pharmacokinetics of drugb # mg twice daily .
DDI-DrugBank.d212.s25.p0	Keppra	brand	_	probenecid	drug	_	false	the effect of druga on drugb was not studied .
DDI-DrugBank.d252.s0.p1	BETAGAN	brand	_	epinephrine	drug	_	false	although druga used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with drugn and drugb may occur .
DDI-DrugBank.d252.s0.p2	BETAGAN	brand	_	epinephrine	drug	_	effect	although drugn used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with druga and drugb may occur .
DDI-DrugBank.d252.s1.p0	beta-blocker	group	_	reserpine	drug	_	advise	close observation of the patient is recommended when a druga is administered to patients receiving catecholamine-depleting drugs such as drugb , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope or postural hypotension .
DDI-DrugBank.d252.s2.p0	beta-adrenergic blocking agents	group	_	calcium antagonists	group	_	advise	patients receiving druga along with either oral or intravenous drugb should be monitored for possible atrioventricular conduction disturbances , left ventricular failure and hypotension .
DDI-DrugBank.d252.s4.p0	beta-adrenergic blocking agents	group	_	digitalis	group	_	effect	the concomitant use of druga with drugb and drugn s may have additive effects on prolonging atrioventricular conduction time .
DDI-DrugBank.d252.s4.p1	beta-adrenergic blocking agents	group	_	calcium antagonist	group	_	effect	the concomitant use of druga with drugn and drugb s may have additive effects on prolonging atrioventricular conduction time .
DDI-DrugBank.d252.s4.p2	digitalis	group	_	calcium antagonist	group	_	false	the concomitant use of drugn with druga and drugb s may have additive effects on prolonging atrioventricular conduction time .
DDI-DrugBank.d252.s5.p0	Phenothiazine-related compounds	group	_	beta-adrenergic blocking agents	group	_	mechanism	druga and drugb may have additive hypotensite effects due to the inhibition of each other s metabolism .
DDI-DrugBank.d320.s0.p0	Chirocaine	brand	_	anesthetics	group	_	advise	druga should be used with caution in patients receiving other local drugb or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive .
DDI-DrugBank.d320.s1.p2	desbutyl levobupivacaine	drug_n	_	3-hydroxy levobupivacaine	drug_n	_	false	in vitro studies indicate cyp3a4 isoform and cyp1a2 isoform mediate the metabolism of drugn to druga and drugb , respectively .
DDI-DrugBank.d320.s3.p0	levobupivacaine	drug	_	phenytoin	drug	_	mechanism	although no clinical studies have been conducted , it is likely that the metabolism of druga may be affected by the known cyp3a4 inducers -lcb- such as drugb , drugn , drugn -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugn ;
DDI-DrugBank.d320.s3.p1	levobupivacaine	drug	_	phenobarbital	drug	_	mechanism	although no clinical studies have been conducted , it is likely that the metabolism of druga may be affected by the known cyp3a4 inducers -lcb- such as drugn , drugb , drugn -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugn ;
DDI-DrugBank.d320.s3.p2	levobupivacaine	drug	_	rifampin	drug	_	mechanism	although no clinical studies have been conducted , it is likely that the metabolism of druga may be affected by the known cyp3a4 inducers -lcb- such as drugn , drugn , drugb -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugn ;
DDI-DrugBank.d320.s3.p3	levobupivacaine	drug	_	ketoconazole	drug	_	mechanism	although no clinical studies have been conducted , it is likely that the metabolism of druga may be affected by the known cyp3a4 inducers -lcb- such as drugn , drugn , drugn -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugb ;
DDI-DrugBank.d320.s3.p6	phenytoin	drug	_	ketoconazole	drug	_	false	although no clinical studies have been conducted , it is likely that the metabolism of drugn may be affected by the known cyp3a4 inducers -lcb- such as druga , drugn , drugn -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugb ;
DDI-DrugBank.d320.s3.p8	phenobarbital	drug	_	ketoconazole	drug	_	false	although no clinical studies have been conducted , it is likely that the metabolism of drugn may be affected by the known cyp3a4 inducers -lcb- such as drugn , druga , drugn -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugb ;
DDI-DrugBank.d320.s3.p9	rifampin	drug	_	ketoconazole	drug	_	false	although no clinical studies have been conducted , it is likely that the metabolism of drugn may be affected by the known cyp3a4 inducers -lcb- such as drugn , drugn , druga -rcb- , cyp3a4 inhibitors -lcb- azole antimycotics e , g , , drugb ;
DDI-DrugBank.d320.s5.p0	macrolide antibiotics	group	_	erythromycin	drug	_	false	druga e , g , , drugb ;
DDI-DrugBank.d320.s6.p0	calcium channel antagonists	group	_	verapamil	drug	_	false	and druga e , g , , drugb -rcb- , cyp1a2 inducers -lcb- drugn -rcb- and cyp1a2 inhibitors -lcb- drugn and drugn -rcb- .
DDI-DrugBank.d320.s6.p1	calcium channel antagonists	group	_	omeprazole	drug	_	false	and druga e , g , , drugn -rcb- , cyp1a2 inducers -lcb- drugb -rcb- and cyp1a2 inhibitors -lcb- drugn and drugn -rcb- .
DDI-DrugBank.d320.s6.p2	calcium channel antagonists	group	_	furafylline	drug	_	false	and druga e , g , , drugn -rcb- , cyp1a2 inducers -lcb- drugn -rcb- and cyp1a2 inhibitors -lcb- drugb and drugn -rcb- .
DDI-DrugBank.d320.s6.p3	calcium channel antagonists	group	_	clarithromycin	drug	_	false	and druga e , g , , drugn -rcb- , cyp1a2 inducers -lcb- drugn -rcb- and cyp1a2 inhibitors -lcb- drugn and drugb -rcb- .
DDI-DrugBank.d320.s6.p4	verapamil	drug	_	omeprazole	drug	_	false	and drugn e , g , , druga -rcb- , cyp1a2 inducers -lcb- drugb -rcb- and cyp1a2 inhibitors -lcb- drugn and drugn -rcb- .
DDI-DrugBank.d320.s6.p5	verapamil	drug	_	furafylline	drug	_	false	and drugn e , g , , druga -rcb- , cyp1a2 inducers -lcb- drugn -rcb- and cyp1a2 inhibitors -lcb- drugb and drugn -rcb- .
DDI-DrugBank.d320.s6.p6	verapamil	drug	_	clarithromycin	drug	_	false	and drugn e , g , , druga -rcb- , cyp1a2 inducers -lcb- drugn -rcb- and cyp1a2 inhibitors -lcb- drugn and drugb -rcb- .
DDI-DrugBank.d320.s6.p7	omeprazole	drug	_	furafylline	drug	_	false	and drugn e , g , , drugn -rcb- , cyp1a2 inducers -lcb- druga -rcb- and cyp1a2 inhibitors -lcb- drugb and drugn -rcb- .
DDI-DrugBank.d320.s6.p8	omeprazole	drug	_	clarithromycin	drug	_	false	and drugn e , g , , drugn -rcb- , cyp1a2 inducers -lcb- druga -rcb- and cyp1a2 inhibitors -lcb- drugn and drugb -rcb- .
DDI-DrugBank.d242.s1.p0	quinolones	group	_	theophylline	drug	_	mechanism	however , the systemic administration of some druga has been shown to elevate plasma concentrations of drugb , interfere with the metabolism of drugn , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p1	quinolones	group	_	caffeine	drug	_	mechanism	however , the systemic administration of some druga has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugb , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p2	quinolones	group	_	anticoagulant	group	_	false	however , the systemic administration of some druga has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral drugb drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p3	quinolones	group	_	warfarin	drug	_	effect	however , the systemic administration of some druga has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral drugn drugb and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p4	quinolones	group	_	cyclosporine	drug	_	effect	however , the systemic administration of some druga has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugb concomitantly .
DDI-DrugBank.d242.s1.p5	theophylline	drug	_	caffeine	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of druga , interfere with the metabolism of drugb , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p6	theophylline	drug	_	anticoagulant	group	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of druga , interfere with the metabolism of drugn , and enhance the effects of the oral drugb drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p7	theophylline	drug	_	warfarin	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of druga , interfere with the metabolism of drugn , and enhance the effects of the oral drugn drugb and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p8	theophylline	drug	_	cyclosporine	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of druga , interfere with the metabolism of drugn , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugb concomitantly .
DDI-DrugBank.d242.s1.p9	caffeine	drug	_	anticoagulant	group	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of druga , and enhance the effects of the oral drugb drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p10	caffeine	drug	_	warfarin	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of druga , and enhance the effects of the oral drugn drugb and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p11	caffeine	drug	_	cyclosporine	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of druga , and enhance the effects of the oral drugn drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugb concomitantly .
DDI-DrugBank.d242.s1.p12	anticoagulant	group	_	warfarin	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral druga drugb and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugn concomitantly .
DDI-DrugBank.d242.s1.p13	anticoagulant	group	_	cyclosporine	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral druga drugn and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugb concomitantly .
DDI-DrugBank.d242.s1.p14	warfarin	drug	_	cyclosporine	drug	_	false	however , the systemic administration of some drugn has been shown to elevate plasma concentrations of drugn , interfere with the metabolism of drugn , and enhance the effects of the oral drugn druga and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drugb concomitantly .
DDI-DrugBank.d257.s0.p0	Levo-Dromoran	brand	_	central nervous system depressants	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugb -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p1	Levo-Dromoran	brand	_	alcohol	drug	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugb , drugn , drugn , other drugn , general drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p2	Levo-Dromoran	brand	_	sedatives	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugb , drugn , other drugn , general drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p3	Levo-Dromoran	brand	_	hypnotics	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugb , other drugn , general drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p4	Levo-Dromoran	brand	_	opioids	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugb , general drugn , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p5	Levo-Dromoran	brand	_	anesthetics	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugb , drugn , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p6	Levo-Dromoran	brand	_	barbiturates	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugb , drugn , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p7	Levo-Dromoran	brand	_	tricyclic antidepressants	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugb , drugn , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p8	Levo-Dromoran	brand	_	phenothiazines	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugn , drugb , drugn , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p9	Levo-Dromoran	brand	_	tranquilizers	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugn , drugn , drugb , drugn and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p10	Levo-Dromoran	brand	_	skeletal muscle relaxants	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugn , drugn , drugn , drugb and drugn -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s0.p11	Levo-Dromoran	brand	_	antihistamines	group	_	effect	interactions with other cns agents : concurrent use of druga with all drugn -lcb- eg , drugn , drugn , drugn , other drugn , general drugn , drugn , drugn , drugn , drugn , drugn and drugb -rcb- may result in additive central nervous system depressant effects .
DDI-DrugBank.d257.s3.p0	MAO inhibitors	group	_	Levo-Dromoran	brand	_	false	although no interaction between druga and drugb has been observed , it is not recommended for use with drugn .
DDI-DrugBank.d257.s3.p2	Levo-Dromoran	brand	_	MAO inhibitors	group	_	advise	although no interaction between drugn and druga has been observed , it is not recommended for use with drugb .
DDI-DrugBank.d257.s4.p0	Levo-Dromoran	brand	_	levorphanol	drug	_	false	most cases of serious or fatal adverse events involving druga reported to the manufacturer or the fda have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients , or the simultaneous administration of drugb with other drugs affecting respiration .
DDI-DrugBank.d257.s6.p1	Mixed Agonist/Antagonist Opioid Analgesics	group	_	pentazocine	drug	_	false	interactions with druga : drugn -lcb- eg , drugb , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugn .
DDI-DrugBank.d257.s6.p2	Mixed Agonist/Antagonist Opioid Analgesics	group	_	nalbuphine	drug	_	false	interactions with druga : drugn -lcb- eg , drugn , drugb , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugn .
DDI-DrugBank.d257.s6.p3	Mixed Agonist/Antagonist Opioid Analgesics	group	_	butorphanol	drug	_	false	interactions with druga : drugn -lcb- eg , drugn , drugn , drugb , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugn .
DDI-DrugBank.d257.s6.p4	Mixed Agonist/Antagonist Opioid Analgesics	group	_	dezocine	drug	_	false	interactions with druga : drugn -lcb- eg , drugn , drugn , drugn , drugb and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugn .
DDI-DrugBank.d257.s6.p5	Mixed Agonist/Antagonist Opioid Analgesics	group	_	buprenorphine	drug	_	false	interactions with druga : drugn -lcb- eg , drugn , drugn , drugn , drugn and drugb -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugn .
DDI-DrugBank.d257.s6.p13	Agonist/antagonist analgesics	group	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : druga -lcb- eg , drugn , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p14	Agonist/antagonist analgesics	group	_	Levo-Dromoran	brand	_	advise	interactions with drugn : druga -lcb- eg , drugn , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p19	pentazocine	drug	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : drugn -lcb- eg , druga , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p20	pentazocine	drug	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , druga , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p24	nalbuphine	drug	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : drugn -lcb- eg , drugn , druga , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p25	nalbuphine	drug	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , drugn , druga , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p28	butorphanol	drug	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : drugn -lcb- eg , drugn , drugn , druga , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p29	butorphanol	drug	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , drugn , drugn , druga , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p31	dezocine	drug	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : drugn -lcb- eg , drugn , drugn , drugn , druga and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p32	dezocine	drug	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , drugn , drugn , drugn , druga and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p33	buprenorphine	drug	_	pure agonist opioid analgesic	group	_	false	interactions with drugn : drugn -lcb- eg , drugn , drugn , drugn , drugn and druga -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugb such as drugn .
DDI-DrugBank.d257.s6.p34	buprenorphine	drug	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , drugn , drugn , drugn , drugn and druga -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a drugn such as drugb .
DDI-DrugBank.d257.s6.p35	pure agonist opioid analgesic	group	_	Levo-Dromoran	brand	_	advise	interactions with drugn : drugn -lcb- eg , drugn , drugn , drugn , drugn and drugn -rcb- should not be administered to a patient who has received or is receiving a course of therapy with a druga such as drugb .
DDI-DrugBank.d257.s7.p0	opioid	group	_	mixed agonist/antagonist analgesics	group	_	false	in druga - dependent patients , drugb may precipitate withdrawal symptoms .
DDI-DrugBank.d189.s0.p0	Levosimendan	drug	_	captopril	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p1	Levosimendan	drug	_	beta-blockers	group	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p2	Levosimendan	drug	_	felodipine	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p3	Levosimendan	drug	_	digoxin	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p4	Levosimendan	drug	_	warfarin	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p5	Levosimendan	drug	_	isosorbide mononitrate	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
DDI-DrugBank.d189.s0.p6	Levosimendan	drug	_	carvedilol	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
DDI-DrugBank.d189.s0.p7	Levosimendan	drug	_	ethanol	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
DDI-DrugBank.d189.s0.p8	Levosimendan	drug	_	itraconazole	drug	_	false	no important interactions to date druga does not have clinically important pharmacokinetic interactions with drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
DDI-DrugBank.d411.s2.p7	levothyroxine sodium	drug	_	aluminum hydoxide	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugb , drugn resin , drugn , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugn .
DDI-DrugBank.d411.s2.p8	levothyroxine sodium	drug	_	cholestyramine	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugn , drugb resin , drugn , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugn .
DDI-DrugBank.d411.s2.p9	levothyroxine sodium	drug	_	colestipol hydrochloride	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugn , drugn resin , drugb , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugn .
DDI-DrugBank.d411.s2.p10	levothyroxine sodium	drug	_	ferrous sulfate	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugn , drugn resin , drugn , drugb , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugn .
DDI-DrugBank.d411.s2.p11	levothyroxine sodium	drug	_	sodium polystyrene sulfonate	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugn , drugn resin , drugn , drugn , drugb , soybean flour -lcb- e , g , , infant formula -rcb- , drugn .
DDI-DrugBank.d411.s2.p12	levothyroxine sodium	drug	_	sucralfate	drug	_	mechanism	drugn absorption : the following agents may bind and decrease absorption of druga from the gastrointestinal tract : drugn , drugn resin , drugn , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s2.p17	aluminum hydoxide	drug	_	sucralfate	drug	_	false	drugn absorption : the following agents may bind and decrease absorption of drugn from the gastrointestinal tract : druga , drugn resin , drugn , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s2.p21	cholestyramine	drug	_	sucralfate	drug	_	false	drugn absorption : the following agents may bind and decrease absorption of drugn from the gastrointestinal tract : drugn , druga resin , drugn , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s2.p24	colestipol hydrochloride	drug	_	sucralfate	drug	_	false	drugn absorption : the following agents may bind and decrease absorption of drugn from the gastrointestinal tract : drugn , drugn resin , druga , drugn , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s2.p26	ferrous sulfate	drug	_	sucralfate	drug	_	false	drugn absorption : the following agents may bind and decrease absorption of drugn from the gastrointestinal tract : drugn , drugn resin , drugn , druga , drugn , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s2.p27	sodium polystyrene sulfonate	drug	_	sucralfate	drug	_	false	drugn absorption : the following agents may bind and decrease absorption of drugn from the gastrointestinal tract : drugn , drugn resin , drugn , drugn , druga , soybean flour -lcb- e , g , , infant formula -rcb- , drugb .
DDI-DrugBank.d411.s3.p0	levothyroxine sodium	drug	_	androgens	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugb and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p1	levothyroxine sodium	drug	_	anabolic hormones	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugb , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p2	levothyroxine sodium	drug	_	asparaginase	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugb , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p3	levothyroxine sodium	drug	_	clofibrate	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugb , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p4	levothyroxine sodium	drug	_	estrogens	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugb and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p5	levothyroxine sodium	drug	_	estrogen-containing compounds	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p6	levothyroxine sodium	drug	_	5-fluorouracil	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p7	levothyroxine sodium	drug	_	furosemide	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p8	levothyroxine sodium	drug	_	glucocorticoids	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p9	levothyroxine sodium	drug	_	meclofenamic acid	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p10	levothyroxine sodium	drug	_	mefenamic acid	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p11	levothyroxine sodium	drug	_	methadone	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p12	levothyroxine sodium	drug	_	perphenazine	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p13	levothyroxine sodium	drug	_	phenylbutazone	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p14	levothyroxine sodium	drug	_	phenytoin	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn .
DDI-DrugBank.d411.s3.p15	levothyroxine sodium	drug	_	salicylates	group	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn .
DDI-DrugBank.d411.s3.p16	levothyroxine sodium	drug	_	tamoxifen	drug	_	mechanism	binding to serum proteins : the following agents may either inhibit druga binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p20	androgens	group	_	estrogens	group	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugb and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p22	androgens	group	_	5-fluorouracil	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p23	androgens	group	_	furosemide	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p24	androgens	group	_	glucocorticoids	group	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p25	androgens	group	_	meclofenamic acid	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p26	androgens	group	_	mefenamic acid	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p27	androgens	group	_	methadone	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p28	androgens	group	_	perphenazine	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p29	androgens	group	_	phenylbutazone	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn .
DDI-DrugBank.d411.s3.p30	androgens	group	_	phenytoin	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn .
DDI-DrugBank.d411.s3.p31	androgens	group	_	salicylates	group	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn .
DDI-DrugBank.d411.s3.p32	androgens	group	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : druga and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p47	anabolic hormones	group	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related druga , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p61	asparaginase	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , druga , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p74	clofibrate	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , druga , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p86	estrogens	group	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , druga and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p97	estrogen-containing compounds	group	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p107	5-fluorouracil	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p116	furosemide	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p124	glucocorticoids	group	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p131	meclofenamic acid	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p137	mefenamic acid	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p142	methadone	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p146	perphenazine	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p149	phenylbutazone	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb .
DDI-DrugBank.d411.s3.p151	phenytoin	drug	_	tamoxifen	drug	_	false	binding to serum proteins : the following agents may either inhibit drugn binding to serum proteins or alter the concentrations of serum binding proteins : drugn and related drugn , drugn , drugn , drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb .
DDI-DrugBank.d411.s8.p9	insulin	drug	_	antidiabetic agents	group	_	false	drugn -lcb- drugn , drugn -rcb- : requirements for druga or oral drugb may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy .
DDI-DrugBank.d411.s13.p2	levothyroxine sodium	drug	_	ketamine	drug	_	effect	drugn : marked hypertension and tachycardia have been reported in association with concomitant administration of druga and drugb .
DDI-DrugBank.d411.s15.p0	Sodium Iodide	drug	_	Sodium Pertechnetate Tc99m	drug	_	false	druga -lcb- 123i and 131i -rcb- , drugb : uptake of radiolabeled ions may be decreased .
DDI-DrugBank.d411.s16.p0	Somatrem	drug	_	Somatropin	drug	_	false	druga / drugb : excessive concurrent use of drugn may accelerate epiphyseal closure .
DDI-DrugBank.d411.s16.p1	Somatrem	drug	_	thyroid hormone	group	_	false	druga / drugn : excessive concurrent use of drugb may accelerate epiphyseal closure .
DDI-DrugBank.d411.s16.p2	Somatropin	drug	_	thyroid hormone	group	_	false	drugn / druga : excessive concurrent use of drugb may accelerate epiphyseal closure .
DDI-DrugBank.d411.s17.p0	somatrem	drug	_	somatropin	drug	_	false	untreated hypothyroidism may interfere with the growth response to druga or drugb .
DDI-DrugBank.d564.s0.p0	anesthetic solutions	group	_	epinephrine	drug	_	false	the administration of local druga containing drugb or drugn to patients receiving drugn or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p1	anesthetic solutions	group	_	norepinephrine	drug	_	false	the administration of local druga containing drugn or drugb to patients receiving drugn or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p2	anesthetic solutions	group	_	monoamine oxidase inhibitors	group	_	false	the administration of local druga containing drugn or drugn to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p3	anesthetic solutions	group	_	tricyclic antidepressants	group	_	false	the administration of local druga containing drugn or drugn to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p5	epinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p6	epinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing druga or drugn to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p7	norepinephrine	drug	_	monoamine oxidase inhibitors	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugb or drugn may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p8	norepinephrine	drug	_	tricyclic antidepressants	group	_	effect	the administration of local drugn containing drugn or druga to patients receiving drugn or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s0.p9	monoamine oxidase inhibitors	group	_	tricyclic antidepressants	group	_	false	the administration of local drugn containing drugn or drugn to patients receiving druga or drugb may produce severe , prolonged hypertension .
DDI-DrugBank.d564.s1.p0	Phenothiazines	group	_	butyrophenones	group	_	false	druga and drugb may reduce or reverse the pressor effect of drugn .
DDI-DrugBank.d564.s1.p1	Phenothiazines	group	_	epinephrine	drug	_	effect	druga and drugn may reduce or reverse the pressor effect of drugb .
DDI-DrugBank.d564.s1.p2	butyrophenones	group	_	epinephrine	drug	_	effect	drugn and druga may reduce or reverse the pressor effect of drugb .
DDI-DrugBank.d564.s4.p0	vasopressor drugs	group	_	ergot-type oxytocic drugs	group	_	false	concurrent administration of druga -lcb- for the treatment of hypotension related to obstetric blocks -rcb- and drugb may cause severe , persistent hypertension or cerebrovascular accidents .
DDI-DrugBank.d130.s0.p0	Lincomycin	drug	_	neuromuscular blocking agents	group	_	effect	druga has been shown to have neuromuscular blocking properties that may enhance the action of other drugb .
DDI-DrugBank.d130.s2.p0	lincomycin	drug	_	erythromycin	drug	_	effect	antagonism between druga and drugb in vitro has been demonstrated .
DDI-DrugBank.d441.s1.p0	linezolid	drug	_	adrenergic	group	_	int	therefore , druga has the potential for interaction with drugb and drugn .
DDI-DrugBank.d441.s1.p1	linezolid	drug	_	serotonergic agents	group	_	int	therefore , druga has the potential for interaction with drugn and drugb .
DDI-DrugBank.d441.s1.p2	adrenergic	group	_	serotonergic agents	group	_	false	therefore , drugn has the potential for interaction with druga and drugb .
DDI-DrugBank.d441.s2.p0	Adrenergic Agents	group	_	ZYVOX	brand	_	false	druga : some individuals receiving drugb may experience a reversible enhancement of the pressor response to indirect-acting drugn , drugn or drugn .
DDI-DrugBank.d441.s2.p1	Adrenergic Agents	group	_	sympathomimetic agents	group	_	false	druga : some individuals receiving drugn may experience a reversible enhancement of the pressor response to indirect-acting drugb , drugn or drugn .
DDI-DrugBank.d441.s2.p2	Adrenergic Agents	group	_	vasopressor	group	_	false	druga : some individuals receiving drugn may experience a reversible enhancement of the pressor response to indirect-acting drugn , drugb or drugn .
DDI-DrugBank.d441.s2.p3	Adrenergic Agents	group	_	dopaminergic agents	group	_	false	druga : some individuals receiving drugn may experience a reversible enhancement of the pressor response to indirect-acting drugn , drugn or drugb .
DDI-DrugBank.d441.s2.p4	ZYVOX	brand	_	sympathomimetic agents	group	_	effect	drugn : some individuals receiving druga may experience a reversible enhancement of the pressor response to indirect-acting drugb , drugn or drugn .
DDI-DrugBank.d441.s2.p5	ZYVOX	brand	_	vasopressor	group	_	effect	drugn : some individuals receiving druga may experience a reversible enhancement of the pressor response to indirect-acting drugn , drugb or drugn .
DDI-DrugBank.d441.s2.p6	ZYVOX	brand	_	dopaminergic agents	group	_	effect	drugn : some individuals receiving druga may experience a reversible enhancement of the pressor response to indirect-acting drugn , drugn or drugb .
DDI-DrugBank.d441.s2.p8	sympathomimetic agents	group	_	dopaminergic agents	group	_	false	drugn : some individuals receiving drugn may experience a reversible enhancement of the pressor response to indirect-acting druga , drugn or drugb .
DDI-DrugBank.d441.s2.p9	vasopressor	group	_	dopaminergic agents	group	_	false	drugn : some individuals receiving drugn may experience a reversible enhancement of the pressor response to indirect-acting drugn , druga or drugb .
DDI-DrugBank.d441.s3.p0	phenylpropanolamine	drug	_	pseudoephedrine	drug	_	false	commonly used drugs such as druga and drugb have been specifically studied .
DDI-DrugBank.d441.s4.p0	adrenergic agents	group	_	dopamine	drug	_	false	initial doses of druga , such as drugb or drugn , should be reduced and titrated to achieve the desired response .
DDI-DrugBank.d441.s4.p1	adrenergic agents	group	_	epinephrine	drug	_	false	initial doses of druga , such as drugn or drugb , should be reduced and titrated to achieve the desired response .
DDI-DrugBank.d441.s4.p2	dopamine	drug	_	epinephrine	drug	_	false	initial doses of drugn , such as druga or drugb , should be reduced and titrated to achieve the desired response .
DDI-DrugBank.d441.s5.p0	Serotonergic Agents	group	_	linezolid	drug	_	false	druga : co-administration of drugb and drugn was not associated with serotonin syndrome in phase 1 , # or # studies .
DDI-DrugBank.d441.s5.p2	linezolid	drug	_	serotonergic agents	group	_	false	drugn : co-administration of druga and drugb was not associated with serotonin syndrome in phase 1 , # or # studies .
DDI-DrugBank.d441.s6.p0	ZYVOX	brand	_	serotonergic agents	group	_	effect	spontaneous reports of serotonin syndrome associated with co-administration of druga and drugb , including drugn such as drugn -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p1	ZYVOX	brand	_	antidepressants	group	_	effect	spontaneous reports of serotonin syndrome associated with co-administration of druga and drugn , including drugb such as drugn -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p2	ZYVOX	brand	_	selective serotonin reuptake inhibitors	group	_	effect	spontaneous reports of serotonin syndrome associated with co-administration of druga and drugn , including drugn such as drugb -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p3	ZYVOX	brand	_	SSRIs	group	_	effect	spontaneous reports of serotonin syndrome associated with co-administration of druga and drugn , including drugn such as drugn -lcb- drugb -rcb- , have been reported .
DDI-DrugBank.d441.s6.p4	serotonergic agents	group	_	antidepressants	group	_	false	spontaneous reports of serotonin syndrome associated with co-administration of drugn and druga , including drugb such as drugn -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p5	serotonergic agents	group	_	selective serotonin reuptake inhibitors	group	_	false	spontaneous reports of serotonin syndrome associated with co-administration of drugn and druga , including drugn such as drugb -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p6	serotonergic agents	group	_	SSRIs	group	_	false	spontaneous reports of serotonin syndrome associated with co-administration of drugn and druga , including drugn such as drugn -lcb- drugb -rcb- , have been reported .
DDI-DrugBank.d441.s6.p7	antidepressants	group	_	selective serotonin reuptake inhibitors	group	_	false	spontaneous reports of serotonin syndrome associated with co-administration of drugn and drugn , including druga such as drugb -lcb- drugn -rcb- , have been reported .
DDI-DrugBank.d441.s6.p8	antidepressants	group	_	SSRIs	group	_	false	spontaneous reports of serotonin syndrome associated with co-administration of drugn and drugn , including druga such as drugn -lcb- drugb -rcb- , have been reported .
DDI-DrugBank.d441.s7.p0	ZYVOX	brand	_	serotonergic agents	group	_	effect	patients who are treated with druga and concomitant drugb should be closely observed for signs and symptoms of serotonin syndrome -lcb- e , g , , cognitive dysfunction , hyperpyrexia , hyperreflexia , incoordination -rcb- .
DDI-DrugBank.d54.s2.p0	anticoagulants	group	_	thyroid	group	_	advise	patients stabilized on oral druga who are found to require drugb replacement therapy should be watched very closely when thyroid is started .
DDI-DrugBank.d54.s5.p0	Insulin	drug	_	Hypoglycemics	group	_	false	druga or oral drugb : initiating thyroid replacement therapy may cause increases in drugn or oral drugn requirements .
DDI-DrugBank.d54.s5.p2	Insulin	drug	_	hypoglycemic	group	_	false	druga or oral drugn : initiating thyroid replacement therapy may cause increases in drugn or oral drugb requirements .
DDI-DrugBank.d54.s5.p3	Hypoglycemics	group	_	insulin	drug	_	false	drugn or oral druga : initiating thyroid replacement therapy may cause increases in drugb or oral drugn requirements .
DDI-DrugBank.d54.s5.p5	insulin	drug	_	hypoglycemic	group	_	false	drugn or oral drugn : initiating thyroid replacement therapy may cause increases in druga or oral drugb requirements .
DDI-DrugBank.d54.s7.p0	insulin	drug	_	hypoglycemics	group	_	false	patients receiving druga or oral drugb should be closely watched during initiation of thyroid replacement therapy .
DDI-DrugBank.d54.s8.p4	Cholestyramine	drug	_	T4	drug	_	mechanism	drugn : druga binds both drugb and drugn in the intestine , thus impairing absorption of these drugn .
DDI-DrugBank.d54.s8.p5	Cholestyramine	drug	_	T3	drug	_	mechanism	drugn : druga binds both drugn and drugb in the intestine , thus impairing absorption of these drugn .
DDI-DrugBank.d54.s8.p6	Cholestyramine	drug	_	thyroid hormones	group	_	false	drugn : druga binds both drugn and drugn in the intestine , thus impairing absorption of these drugb .
DDI-DrugBank.d54.s8.p7	T4	drug	_	T3	drug	_	false	drugn : drugn binds both druga and drugb in the intestine , thus impairing absorption of these drugn .
DDI-DrugBank.d54.s8.p8	T4	drug	_	thyroid hormones	group	_	false	drugn : drugn binds both druga and drugn in the intestine , thus impairing absorption of these drugb .
DDI-DrugBank.d54.s8.p9	T3	drug	_	thyroid hormones	group	_	false	drugn : drugn binds both drugn and druga in the intestine , thus impairing absorption of these drugb .
DDI-DrugBank.d54.s10.p0	cholestyramine	drug	_	thyroid hormones	group	_	advise	therefore , # to # hours should elapse between administration of druga and drugb .
DDI-DrugBank.d54.s11.p0	Estrogen	group	_	Contraceptives	group	_	false	druga , oral drugb : drugn tend to increase serum serpina7 -lcb- tbg -rcb- .
DDI-DrugBank.d54.s12.p0	levothyroxine	drug	_	estrogens	group	_	mechanism	in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free druga may be decreased when drugb are started thus increasing drugn requirements .
DDI-DrugBank.d54.s12.p1	levothyroxine	drug	_	thyroid	group	_	false	in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free druga may be decreased when drugn are started thus increasing drugb requirements .
DDI-DrugBank.d54.s12.p2	estrogens	group	_	thyroid	group	_	false	in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free drugn may be decreased when druga are started thus increasing drugb requirements .
DDI-DrugBank.d54.s14.p0	thyroid	group	_	estrogens	group	_	advise	therefore , patients without a functioning druga gland who are on thyroid replacement therapy may need to increase their thyroid dose if drugb or drugn - containing oral drugn are given .
DDI-DrugBank.d54.s14.p1	thyroid	group	_	estrogen	group	_	false	therefore , patients without a functioning druga gland who are on thyroid replacement therapy may need to increase their thyroid dose if drugn or drugb - containing oral drugn are given .
DDI-DrugBank.d54.s14.p2	thyroid	group	_	contraceptives	group	_	advise	therefore , patients without a functioning druga gland who are on thyroid replacement therapy may need to increase their thyroid dose if drugn or drugn - containing oral drugb are given .
DDI-DrugBank.d54.s14.p4	estrogens	group	_	contraceptives	group	_	false	therefore , patients without a functioning drugn gland who are on thyroid replacement therapy may need to increase their thyroid dose if druga or drugn - containing oral drugb are given .
DDI-DrugBank.d54.s14.p5	estrogen	group	_	contraceptives	group	_	false	therefore , patients without a functioning drugn gland who are on thyroid replacement therapy may need to increase their thyroid dose if drugn or druga - containing oral drugb are given .
DDI-DrugBank.d54.s15.p0	Tricyclic Antidepressants	group	_	thyroid products	group	_	false	druga : use of drugb with drugn and other drugn may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .
DDI-DrugBank.d54.s15.p1	Tricyclic Antidepressants	group	_	imipramine	drug	_	false	druga : use of drugn with drugb and other drugn may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .
DDI-DrugBank.d54.s15.p3	thyroid products	group	_	imipramine	drug	_	effect	drugn : use of druga with drugb and other drugn may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .
DDI-DrugBank.d54.s15.p4	thyroid products	group	_	tricyclic antidepressants	group	_	effect	drugn : use of druga with drugn and other drugb may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .
DDI-DrugBank.d54.s15.p5	imipramine	drug	_	tricyclic antidepressants	group	_	false	drugn : use of drugn with druga and other drugb may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .
DDI-DrugBank.d54.s17.p2	Thyroid preparations	group	_	digitalis	group	_	effect	drugn : druga may potentiate the toxic effects of drugb .
DDI-DrugBank.d54.s19.p2	thyroid preparation	group	_	anesthetic	group	_	effect	drugn : when administered to patients on a druga , this parenteral drugb may cause hypertension and tachycardia .
DDI-DrugBank.d54.s21.p3	Thyroxine	drug	_	epinephrine	drug	_	effect	drugn s : druga increases the adrenergic effect of catecholamines such as drugb and drugn .
DDI-DrugBank.d54.s21.p4	Thyroxine	drug	_	norepinephrine	drug	_	effect	drugn s : druga increases the adrenergic effect of catecholamines such as drugn and drugb .
DDI-DrugBank.d54.s24.p0	thyroid hormone	group	_	androgens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugb , drugn , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p1	thyroid hormone	group	_	corticosteroids	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugb , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p2	thyroid hormone	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugn , drugb , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p3	thyroid hormone	group	_	contraceptives	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugn , drugn , oral drugb containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p4	thyroid hormone	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugn , drugn , oral drugn containing drugb , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p5	thyroid hormone	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugn , drugn , oral drugn containing drugn , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p6	thyroid hormone	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on druga therapy : drugn , drugn , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p7	androgens	group	_	corticosteroids	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugb , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p8	androgens	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugn , drugb , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p9	androgens	group	_	contraceptives	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugn , drugn , oral drugb containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p10	androgens	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugn , drugn , oral drugn containing drugb , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p11	androgens	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugn , drugn , oral drugn containing drugn , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p12	androgens	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : druga , drugn , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p13	corticosteroids	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , druga , drugb , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p14	corticosteroids	group	_	contraceptives	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , druga , drugn , oral drugb containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p15	corticosteroids	group	_	estrogens	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , druga , drugn , oral drugn containing drugb , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p16	corticosteroids	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , druga , drugn , oral drugn containing drugn , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p17	corticosteroids	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , druga , drugn , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p18	estrogens	group	_	contraceptives	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , druga , oral drugb containing drugn , drugn - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p20	estrogens	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , druga , oral drugn containing drugn , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p21	estrogens	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , druga , oral drugn containing drugn , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p23	contraceptives	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , drugn , oral druga containing drugn , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p24	contraceptives	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , drugn , oral druga containing drugn , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p25	estrogens	group	_	iodine	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , drugn , oral drugn containing druga , drugb - containing preparations and the numerous preparations containing drugn .
DDI-DrugBank.d54.s24.p26	estrogens	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , drugn , oral drugn containing druga , drugn - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s24.p27	iodine	group	_	salicylates	group	_	false	drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on drugn therapy : drugn , drugn , drugn , oral drugn containing drugn , druga - containing preparations and the numerous preparations containing drugb .
DDI-DrugBank.d54.s27.p1	estrogens	group	_	contraceptives	group	_	false	pregnancy druga and drugn - containing oral drugb increase tbg concentrations .
DDI-DrugBank.d54.s27.p2	estrogen	group	_	contraceptives	group	_	false	pregnancy drugn and druga - containing oral drugb increase tbg concentrations .
DDI-DrugBank.d54.s29.p0	androgen	group	_	corticosteroid	group	_	false	decreases in tbg concentrations are observed in nephrosis , acromegaly and after druga or drugb therapy .
DDI-DrugBank.d158.s0.p1	ammonium chloride	drug	_	amphetamine	drug	_	mechanism	urinary acidifying agents these agents -lcb- druga , drugn , etc , -rcb- increase the concentration of the ionized species of the drugb molecule , thereby increasing urinary excretion .
DDI-DrugBank.d158.s0.p2	sodium acid phosphate	drug	_	amphetamine	drug	_	mechanism	urinary acidifying agents these agents -lcb- drugn , druga , etc , -rcb- increase the concentration of the ionized species of the drugb molecule , thereby increasing urinary excretion .
DDI-DrugBank.d158.s2.p1	Adrenergic blockers	group	_	amphetamines	group	_	false	druga drugn are inhibited by drugb .
DDI-DrugBank.d158.s2.p2	Adrenergic blockers	group	_	amphetamines	group	_	effect	drugn druga are inhibited by drugb .
DDI-DrugBank.d158.s3.p0	Antidepressants	group	_	tricyclic	group	_	false	druga , drugb drugn may enhance the activity of drugn or drugn ;
DDI-DrugBank.d158.s3.p1	Antidepressants	group	_	Amphetamines	group	_	false	druga , drugn drugb may enhance the activity of drugn or drugn ;
DDI-DrugBank.d158.s3.p3	Antidepressants	group	_	sympathomimetic agents	group	_	false	druga , drugn drugn may enhance the activity of drugn or drugb ;
DDI-DrugBank.d158.s3.p4	tricyclic	group	_	Amphetamines	group	_	false	drugn , druga drugb may enhance the activity of drugn or drugn ;
DDI-DrugBank.d158.s3.p6	tricyclic	group	_	sympathomimetic agents	group	_	false	drugn , druga drugn may enhance the activity of drugn or drugb ;
DDI-DrugBank.d158.s3.p7	Amphetamines	group	_	tricyclic antidepressants	drug	_	effect	drugn , drugn druga may enhance the activity of drugb or drugn ;
DDI-DrugBank.d158.s3.p8	Amphetamines	group	_	sympathomimetic agents	group	_	effect	drugn , drugn druga may enhance the activity of drugn or drugb ;
DDI-DrugBank.d158.s3.p9	tricyclic antidepressants	drug	_	sympathomimetic agents	group	_	false	drugn , drugn drugn may enhance the activity of druga or drugb ;
DDI-DrugBank.d158.s4.p0	d-amphetamine	drug	_	desipramine	drug	_	mechanism	druga with drugb or drugn and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p1	d-amphetamine	drug	_	protriptyline	drug	_	mechanism	druga with drugn or drugb and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p2	d-amphetamine	drug	_	tricyclics	group	_	mechanism	druga with drugn or drugn and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p4	desipramine	drug	_	protriptyline	drug	_	false	drugn with druga or drugb and possibly other drugn cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p5	desipramine	drug	_	tricyclics	group	_	false	drugn with druga or drugn and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p6	desipramine	drug	_	d-amphetamine	drug	_	false	drugn with druga or drugn and possibly other drugn cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d158.s4.p7	protriptyline	drug	_	tricyclics	group	_	false	drugn with drugn or druga and possibly other drugb cause striking and sustained increases in the concentration of drugn in the brain ;
DDI-DrugBank.d158.s4.p8	protriptyline	drug	_	d-amphetamine	drug	_	false	drugn with drugn or druga and possibly other drugn cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d158.s4.p9	tricyclics	group	_	d-amphetamine	drug	_	false	drugn with drugn or drugn and possibly other druga cause striking and sustained increases in the concentration of drugb in the brain ;
DDI-DrugBank.d158.s6.p0	MAO inhibitors	group	_	MAOI antidepressants	group	_	false	druga drugb , as well as a metabolite of drugn , slow drugn metabolism .
DDI-DrugBank.d158.s6.p1	MAO inhibitors	group	_	furazolidone	drug	_	false	druga drugn , as well as a metabolite of drugb , slow drugn metabolism .
DDI-DrugBank.d158.s6.p2	MAO inhibitors	group	_	amphetamine	drug	_	false	druga drugn , as well as a metabolite of drugn , slow drugb metabolism .
DDI-DrugBank.d158.s6.p3	MAOI antidepressants	group	_	furazolidone	drug	_	false	drugn druga , as well as a metabolite of drugb , slow drugn metabolism .
DDI-DrugBank.d158.s6.p4	MAOI antidepressants	group	_	amphetamine	drug	_	mechanism	drugn druga , as well as a metabolite of drugn , slow drugb metabolism .
DDI-DrugBank.d158.s6.p5	furazolidone	drug	_	amphetamine	drug	_	mechanism	drugn drugn , as well as a metabolite of druga , slow drugb metabolism .
DDI-DrugBank.d158.s10.p2	Amphetamines	group	_	antihistamines	group	_	effect	drugn : druga may counteract the sedative effect of drugb .
DDI-DrugBank.d158.s11.p2	Amphetamines	group	_	antihypertensives	drug	_	effect	drugn : druga may antagonize the hypotensive effects of drugb .
DDI-DrugBank.d158.s12.p3	Chlorpromazine	drug	_	amphetamines	group	_	effect	drugn : druga blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of drugb and can be used to treat drugn poisoning .
DDI-DrugBank.d158.s12.p4	Chlorpromazine	drug	_	amphetamine	group	_	false	drugn : druga blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of drugn and can be used to treat drugb poisoning .
DDI-DrugBank.d158.s13.p2	Amphetamines	group	_	ethosuximide	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb .
DDI-DrugBank.d158.s14.p1	Haloperidol	drug	_	amphetamines	group	_	false	druga : drugn blocks dopamine receptors , thus inhibiting the central stimulant effects of drugb .
DDI-DrugBank.d158.s14.p2	Haloperidol	drug	_	amphetamines	group	_	effect	drugn : druga blocks dopamine receptors , thus inhibiting the central stimulant effects of drugb .
DDI-DrugBank.d158.s15.p2	amphetamines	group	_	lithium carbonate	drug	_	effect	drugn : the anorectic and stimulatory effects of druga may be inhibited by drugb .
DDI-DrugBank.d158.s16.p2	Amphetamines	group	_	meperidine	drug	_	effect	drugn : druga potentiate the analgesic effect of drugb .
DDI-DrugBank.d158.s17.p0	Methenamine	drug	_	amphetamines	group	_	false	druga therapy urinary excretion of drugb is increased , and efficacy is reduced by acidifying agents used in drugn therapy .
DDI-DrugBank.d158.s17.p2	amphetamines	group	_	methenamine	drug	_	mechanism	drugn therapy urinary excretion of druga is increased , and efficacy is reduced by acidifying agents used in drugb therapy .
DDI-DrugBank.d158.s18.p2	Amphetamines	group	_	norepinephrine	drug	_	effect	drugn : druga enhance the adrenergic effect of drugb .
DDI-DrugBank.d158.s19.p2	Amphetamines	group	_	phenobarbital	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb ;
DDI-DrugBank.d158.s21.p2	Amphetamines	group	_	phenytoin	drug	_	mechanism	drugn : druga may delay intestinal absorption of drugb ;
DDI-DrugBank.d158.s23.p2	propoxyphene	drug	_	amphetamine	drug	_	effect	drugn : in cases of druga overdosage , drugb cns stimulation is potentiated and fatal convulsions can occur .
DDI-DrugBank.d158.s24.p2	Amphetamines	group	_	veratrum alkaloids	group	_	effect	drugn : druga inhibit the hypotensive effect of drugb .
DDI-DrugBank.d334.s0.p0	diuretics	group	_	PRINIVIL	brand	_	effect	hypotension - patients on diuretic therapy : patients on druga , and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drugb .
DDI-DrugBank.d334.s1.p0	PRINIVIL	brand	_	diuretic	group	_	false	the possibility of hypotensive effects with druga can be minimized by either discontinuing the drugb or increasing the salt intake prior to initiation of treatment with drugn .
DDI-DrugBank.d334.s1.p2	diuretic	group	_	PRINIVIL	brand	_	effect	the possibility of hypotensive effects with drugn can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb .
DDI-DrugBank.d334.s2.p0	diuretic	group	_	PRINIVIL	brand	_	advise	if it is necessary to continue the druga , initiate therapy with drugb at a dose of # mg daily , and provide close medical supervision after the initial dose until blood pressure has stabilized .
DDI-DrugBank.d334.s3.p0	diuretic	group	_	PRINIVIL	brand	_	effect	when a druga is added to the therapy of a patient receiving drugb , an additional antihypertensive effect is usually observed .
DDI-DrugBank.d334.s4.p0	ACE inhibitors	group	_	diuretics	group	_	false	studies with druga in combination with drugb indicate that the dose of the drugn can be reduced when it is given with a drugn .
DDI-DrugBank.d334.s4.p2	ACE inhibitors	group	_	diuretic	group	_	false	studies with druga in combination with drugn indicate that the dose of the drugn can be reduced when it is given with a drugb .
DDI-DrugBank.d334.s4.p3	diuretics	group	_	ACE inhibitor	group	_	false	studies with drugn in combination with druga indicate that the dose of the drugb can be reduced when it is given with a drugn .
DDI-DrugBank.d334.s4.p5	ACE inhibitor	group	_	diuretic	group	_	advise	studies with drugn in combination with drugn indicate that the dose of the druga can be reduced when it is given with a drugb .
DDI-DrugBank.d334.s5.p2	non-steroidal anti-inflammatory drugs	group	_	lisinopril	drug	_	effect	drugn : in some patients with compromised renal function who are being treated with druga , the co-administration of drugb may result in a further deterioration of renal function .
DDI-DrugBank.d334.s7.p0	NSAIDs	group	_	ACE inhibitors	group	_	effect	reports suggest that druga may diminish the antihypertensive effect of drugb , including drugn .
DDI-DrugBank.d334.s7.p1	NSAIDs	group	_	lisinopril	drug	_	effect	reports suggest that druga may diminish the antihypertensive effect of drugn , including drugb .
DDI-DrugBank.d334.s7.p2	ACE inhibitors	group	_	lisinopril	drug	_	false	reports suggest that drugn may diminish the antihypertensive effect of druga , including drugb .
DDI-DrugBank.d334.s8.p0	NSAIDs	group	_	ACE inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d334.s9.p1	PRINIVIL	brand	_	indomethacin	drug	_	false	in a study in # patients with mild to moderate hypertension where the antihypertensive effects of druga alone were compared to drugn given concomitantly with drugb , the use of drugn was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .
DDI-DrugBank.d334.s9.p2	PRINIVIL	brand	_	indomethacin	drug	_	false	in a study in # patients with mild to moderate hypertension where the antihypertensive effects of druga alone were compared to drugn given concomitantly with drugn , the use of drugb was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .
DDI-DrugBank.d334.s9.p3	PRINIVIL	brand	_	indomethacin	drug	_	false	in a study in # patients with mild to moderate hypertension where the antihypertensive effects of drugn alone were compared to druga given concomitantly with drugb , the use of drugn was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .
DDI-DrugBank.d334.s9.p4	PRINIVIL	brand	_	indomethacin	drug	_	false	in a study in # patients with mild to moderate hypertension where the antihypertensive effects of drugn alone were compared to druga given concomitantly with drugn , the use of drugb was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .
DDI-DrugBank.d334.s10.p0	PRINIVIL	brand	_	nitrates	group	_	false	other agents : druga has been used concomitantly with drugb and/or drugn without evidence of clinically significant adverse interactions .
DDI-DrugBank.d334.s10.p1	PRINIVIL	brand	_	digoxin	drug	_	false	other agents : druga has been used concomitantly with drugn and/or drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d334.s10.p2	nitrates	group	_	digoxin	drug	_	false	other agents : drugn has been used concomitantly with druga and/or drugb without evidence of clinically significant adverse interactions .
DDI-DrugBank.d334.s12.p0	PRINIVIL	brand	_	propranolol	drug	_	false	no clinically important pharmacokinetic interactions occurred when druga was used concomitantly with drugb or drugn .
DDI-DrugBank.d334.s12.p1	PRINIVIL	brand	_	hydrochlorothiazide	drug	_	false	no clinically important pharmacokinetic interactions occurred when druga was used concomitantly with drugn or drugb .
DDI-DrugBank.d334.s12.p2	propranolol	drug	_	hydrochlorothiazide	drug	_	false	no clinically important pharmacokinetic interactions occurred when drugn was used concomitantly with druga or drugb .
DDI-DrugBank.d334.s14.p0	PRINIVIL	brand	_	thiazide-type diuretics	group	_	effect	agents increasing serum potassium : druga attenuates potassium loss caused by drugb .
DDI-DrugBank.d334.s15.p0	PRINIVIL	brand	_	potassium-sparing diuretics	group	_	effect	use of druga with drugb -lcb- e , g , , drugn , drugn , or drugn -rcb- , drugn supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p1	PRINIVIL	brand	_	spironolactone	drug	_	effect	use of druga with drugn -lcb- e , g , , drugb , drugn , or drugn -rcb- , drugn supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p2	PRINIVIL	brand	_	triamterene	drug	_	effect	use of druga with drugn -lcb- e , g , , drugn , drugb , or drugn -rcb- , drugn supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p3	PRINIVIL	brand	_	amiloride	drug	_	effect	use of druga with drugn -lcb- e , g , , drugn , drugn , or drugb -rcb- , drugn supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p4	PRINIVIL	brand	_	potassium	drug	_	effect	use of druga with drugn -lcb- e , g , , drugn , drugn , or drugn -rcb- , drugb supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p11	spironolactone	drug	_	potassium	drug	_	false	use of drugn with drugn -lcb- e , g , , druga , drugn , or drugn -rcb- , drugb supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p13	triamterene	drug	_	potassium	drug	_	false	use of drugn with drugn -lcb- e , g , , drugn , druga , or drugn -rcb- , drugb supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s15.p14	amiloride	drug	_	potassium	drug	_	false	use of drugn with drugn -lcb- e , g , , drugn , drugn , or druga -rcb- , drugb supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .
DDI-DrugBank.d334.s18.p4	Lithium	drug	_	ACE inhibitors	group	_	false	drugn : druga toxicity has been reported in patients receiving drugn concomitantly with drugs which cause elimination of sodium , including drugb .
DDI-DrugBank.d334.s18.p5	lithium	drug	_	ACE inhibitors	group	_	effect	drugn : drugn toxicity has been reported in patients receiving druga concomitantly with drugs which cause elimination of sodium , including drugb .
DDI-DrugBank.d334.s19.p1	Lithium	drug	_	ACE inhibitor	group	_	false	druga toxicity was usually reversible upon discontinuation of drugn and the drugb .
DDI-DrugBank.d334.s19.p2	lithium	drug	_	ACE inhibitor	group	_	effect	drugn toxicity was usually reversible upon discontinuation of druga and the drugb .
DDI-DrugBank.d334.s20.p0	lithium	drug	_	PRINIVIL	brand	_	false	it is recommended that serum druga levels be monitored frequently if drugb is administered concomitantly with drugn .
DDI-DrugBank.d334.s20.p2	PRINIVIL	brand	_	lithium	drug	_	advise	it is recommended that serum drugn levels be monitored frequently if druga is administered concomitantly with drugb .
DDI-DrugBank.d454.s0.p0	Lofexidine	drug	_	alcohol	drug	_	effect	- druga may enhance the cns depressive effects of drugb , drugn and other drugn
DDI-DrugBank.d454.s0.p1	Lofexidine	drug	_	barbiturates	group	_	effect	- druga may enhance the cns depressive effects of drugn , drugb and other drugn
DDI-DrugBank.d454.s0.p2	Lofexidine	drug	_	sedatives	group	_	effect	- druga may enhance the cns depressive effects of drugn , drugn and other drugb
DDI-DrugBank.d454.s2.p0	Lofexidine	drug	_	anti-hypertensive drug	group	_	effect	- druga may enhance the effects of drugb therapy
DDI-DrugBank.d454.s4.p0	tricyclic antidepressants	group	_	lofexidine	drug	_	effect	- concomitant use of druga may reduce the efficacy of drugb .
DDI-DrugBank.d516.s0.p2	theophylline	drug	_	lomefloxacin	drug	_	false	drugn : in three pharmacokinetic studies including # normal , healthy subjects , druga clearance and concentration were not significantly altered by the addition of drugb .
DDI-DrugBank.d516.s1.p0	theophylline	drug	_	lomefloxacin	drug	_	false	in clinical studies where patients were on chronic druga therapy , drugb had no measurable effect on the mean distribution of drugn concentrations or the mean estimates of drugn clearance .
DDI-DrugBank.d516.s1.p3	lomefloxacin	drug	_	theophylline	drug	_	false	in clinical studies where patients were on chronic drugn therapy , druga had no measurable effect on the mean distribution of drugb concentrations or the mean estimates of drugn clearance .
DDI-DrugBank.d516.s1.p4	lomefloxacin	drug	_	theophylline	drug	_	false	in clinical studies where patients were on chronic drugn therapy , druga had no measurable effect on the mean distribution of drugn concentrations or the mean estimates of drugb clearance .
DDI-DrugBank.d516.s3.p0	Antacids	group	_	sucralfate	drug	_	false	druga and drugb : drugn and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p15	Sucralfate	drug	_	antacids	group	_	false	drugn and drugn : druga and drugb containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p16	Sucralfate	drug	_	magnesium	drug	_	false	drugn and drugn : druga and drugn containing drugb or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p17	Sucralfate	drug	_	aluminum	drug	_	false	drugn and drugn : druga and drugn containing drugn or drugb , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p18	Sucralfate	drug	_	Videx	brand	_	false	drugn and drugn : druga and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p19	Sucralfate	drug	_	didanosine	drug	_	false	drugn and drugn : druga and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p20	Sucralfate	drug	_	lomefloxacin	drug	_	mechanism	drugn and drugn : druga and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p21	antacids	group	_	magnesium	drug	_	false	drugn and drugn : drugn and druga containing drugb or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p22	antacids	group	_	aluminum	drug	_	false	drugn and drugn : drugn and druga containing drugn or drugb , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p23	antacids	group	_	Videx	brand	_	false	drugn and drugn : drugn and druga containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p24	antacids	group	_	didanosine	drug	_	false	drugn and drugn : drugn and druga containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p25	antacids	group	_	lomefloxacin	drug	_	false	drugn and drugn : drugn and druga containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p26	magnesium	drug	_	aluminum	drug	_	false	drugn and drugn : drugn and drugn containing druga or drugb , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p27	magnesium	drug	_	Videx	brand	_	false	drugn and drugn : drugn and drugn containing druga or drugn , as well as formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p28	magnesium	drug	_	didanosine	drug	_	false	drugn and drugn : drugn and drugn containing druga or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p29	magnesium	drug	_	lomefloxacin	drug	_	mechanism	drugn and drugn : drugn and drugn containing druga or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p30	aluminum	drug	_	Videx	brand	_	false	drugn and drugn : drugn and drugn containing drugn or druga , as well as formulations containing divalent and trivalent cations such as drugb -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p31	aluminum	drug	_	didanosine	drug	_	false	drugn and drugn : drugn and drugn containing drugn or druga , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugb -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugn and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p32	aluminum	drug	_	lomefloxacin	drug	_	mechanism	drugn and drugn : drugn and drugn containing drugn or druga , as well as formulations containing divalent and trivalent cations such as drugn -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p34	Videx	brand	_	lomefloxacin	drug	_	mechanism	drugn and drugn : drugn and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as druga -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s3.p35	didanosine	drug	_	lomefloxacin	drug	_	mechanism	drugn and drugn : drugn and drugn containing drugn or drugn , as well as formulations containing divalent and trivalent cations such as drugn -lcb- druga -rcb- , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drugb and interfere with its bioavailability .
DDI-DrugBank.d516.s4.p0	Sucralfate	drug	_	lomefloxacin	drug	_	mechanism	druga administered # hours before drugb resulted in a slower absorption -lcb- mean c max decreased by 30 % and mean t max increased by # hour -rcb- and a lesser extent of absorption -lcb- mean auc decreased by approximately 25 % -rcb- .
DDI-DrugBank.d516.s5.p0	Magnesium	drug	_	aluminum	drug	_	false	druga - and drugb - containing drugn , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p1	Magnesium	drug	_	antacids	group	_	false	druga - and drugn - containing drugb , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p2	Magnesium	drug	_	lomefloxacin	drug	_	mechanism	druga - and drugn - containing drugn , administered concomitantly with drugb , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p3	Magnesium	drug	_	lomefloxacin	drug	_	false	druga - and drugn - containing drugn , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugb .
DDI-DrugBank.d516.s5.p4	aluminum	drug	_	antacids	group	_	false	drugn - and druga - containing drugb , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p5	aluminum	drug	_	lomefloxacin	drug	_	mechanism	drugn - and druga - containing drugn , administered concomitantly with drugb , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p6	aluminum	drug	_	lomefloxacin	drug	_	false	drugn - and druga - containing drugn , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugb .
DDI-DrugBank.d516.s5.p7	antacids	group	_	lomefloxacin	drug	_	mechanism	drugn - and drugn - containing druga , administered concomitantly with drugb , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugn .
DDI-DrugBank.d516.s5.p8	antacids	group	_	lomefloxacin	drug	_	false	drugn - and drugn - containing druga , administered concomitantly with drugn , significantly decreased the bioavailability -lcb- 48 % -rcb- of drugb .
DDI-DrugBank.d516.s6.p0	antacid	group	_	lomefloxacin	drug	_	mechanism	separating the doses of druga and drugb minimizes this decrease in bioavailability ;
DDI-DrugBank.d516.s8.p2	caffeine	drug	_	lomefloxacin	drug	_	false	drugn : two hundred mg of druga -lcb- equivalent to # to # cups of american coffee -rcb- was administered to # normal , healthy volunteers who had achieved steady-state blood concentrations of drugb after being dosed at # mg qd .
DDI-DrugBank.d516.s9.p0	caffeine	drug	_	paraxanthine	drug_n	_	false	this did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either druga or its major metabolite , drugb .
DDI-DrugBank.d516.s11.p0	quinolones	group	_	caffeine	drug	_	mechanism	other druga have demonstrated moderate to marked interference with the metabolism of drugb , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of drugn .
DDI-DrugBank.d516.s11.p1	quinolones	group	_	caffeine	drug	_	false	other druga have demonstrated moderate to marked interference with the metabolism of drugn , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of drugb .
DDI-DrugBank.d516.s12.p2	Cimetidine	drug	_	quinolones	group	_	mechanism	drugn : druga has been demonstrated to interfere with the elimination of other drugb .
DDI-DrugBank.d516.s14.p0	lomefloxacin	drug	_	cimetidine	drug	_	false	the interaction between druga and drugb has not been studied .
DDI-DrugBank.d516.s15.p2	Cyclosporine	drug	_	quinolone class	group	_	false	druga : elevated serum levels of drugn have been reported with concomitant use of drugn with other members of the drugb .
DDI-DrugBank.d516.s15.p4	cyclosporine	drug	_	quinolone class	group	_	false	drugn : elevated serum levels of druga have been reported with concomitant use of drugn with other members of the drugb .
DDI-DrugBank.d516.s15.p5	cyclosporine	drug	_	quinolone class	group	_	mechanism	drugn : elevated serum levels of drugn have been reported with concomitant use of druga with other members of the drugb .
DDI-DrugBank.d516.s16.p0	lomefloxacin	drug	_	cyclosporine	drug	_	false	interaction between druga and drugb has not been studied .
DDI-DrugBank.d516.s17.p4	lomefloxacin	drug	_	omeprazole	drug	_	false	drugn : no clinically significant changes in druga pharmacokinetics -lcb- auc , c max , or t max -rcb- were observed when a single dose of drugn # mg was given after multiple doses of drugb -lcb- 20 mg qd -rcb- in # healthy volunteers .
DDI-DrugBank.d516.s17.p5	lomefloxacin	drug	_	omeprazole	drug	_	false	drugn : no clinically significant changes in drugn pharmacokinetics -lcb- auc , c max , or t max -rcb- were observed when a single dose of druga # mg was given after multiple doses of drugb -lcb- 20 mg qd -rcb- in # healthy volunteers .
DDI-DrugBank.d516.s19.p4	phenytoin	drug	_	lomefloxacin	drug	_	false	drugn : no significant differences were observed in mean druga auc , c max , c min or t max -lcb- although c max increased by 11 % -rcb- when extended drugn capsules -lcb- 100 mg tid -rcb- were coadministered with drugb -lcb- 400 mg qd -rcb- for five days in # healthy males .
DDI-DrugBank.d516.s19.p5	phenytoin sodium	drug	_	lomefloxacin	drug	_	false	drugn : no significant differences were observed in mean drugn auc , c max , c min or t max -lcb- although c max increased by 11 % -rcb- when extended druga capsules -lcb- 100 mg tid -rcb- were coadministered with drugb -lcb- 400 mg qd -rcb- for five days in # healthy males .
DDI-DrugBank.d516.s20.p0	Lomefloxacin	drug	_	phenytoin	drug	_	false	druga is unlikely to have a significant effect on drugb metabolism .
DDI-DrugBank.d516.s23.p4	terfenadine	drug	_	lomefloxacin	drug	_	false	drugn : no clinically significant changes occurred in heart rate or corrected qt intervals , or in druga metabolite or drugb pharmacokinetics , during concurrent administration of drugn and drugn at steady-state in # healthy males .
DDI-DrugBank.d516.s23.p5	terfenadine	drug	_	lomefloxacin	drug	_	false	drugn : no clinically significant changes occurred in heart rate or corrected qt intervals , or in druga metabolite or drugn pharmacokinetics , during concurrent administration of drugb and drugn at steady-state in # healthy males .
DDI-DrugBank.d516.s23.p8	lomefloxacin	drug	_	terfenadine	drug	_	false	drugn : no clinically significant changes occurred in heart rate or corrected qt intervals , or in drugn metabolite or druga pharmacokinetics , during concurrent administration of drugn and drugb at steady-state in # healthy males .
DDI-DrugBank.d516.s23.p9	lomefloxacin	drug	_	terfenadine	drug	_	false	drugn : no clinically significant changes occurred in heart rate or corrected qt intervals , or in drugn metabolite or drugn pharmacokinetics , during concurrent administration of druga and drugb at steady-state in # healthy males .
DDI-DrugBank.d516.s24.p3	Quinolones	group	_	anticoagulant	group	_	effect	drugn : druga may enhance the effects of the oral drugb , drugn , or its derivatives .
DDI-DrugBank.d516.s24.p4	Quinolones	group	_	warfarin	drug	_	effect	drugn : druga may enhance the effects of the oral drugn , drugb , or its derivatives .
DDI-DrugBank.d516.s24.p5	anticoagulant	group	_	warfarin	drug	_	false	drugn : drugn may enhance the effects of the oral druga , drugb , or its derivatives .
DDI-DrugBank.d516.s26.p1	warfarin	drug	_	lomefloxacin	drug	_	false	however , no clinically or statistically significant differences in prothrombin time ratio or druga enantiomer pharmacokinetics were observed in a small study of # healthy males who received both drugn and drugb under steady-state conditions .
DDI-DrugBank.d516.s26.p2	warfarin	drug	_	lomefloxacin	drug	_	false	however , no clinically or statistically significant differences in prothrombin time ratio or drugn enantiomer pharmacokinetics were observed in a small study of # healthy males who received both druga and drugb under steady-state conditions .
DDI-DrugBank.d351.s0.p0	Probenecid	drug	_	b-lactam antibiotics	group	_	false	druga : as with other drugb , renal excretion of drugn is inhibited by drugn and resulted in an approximate 80 % increase in the auc for drugn .
DDI-DrugBank.d351.s0.p1	Probenecid	drug	_	loracarbef	drug	_	false	druga : as with other drugn , renal excretion of drugb is inhibited by drugn and resulted in an approximate 80 % increase in the auc for drugn .
DDI-DrugBank.d351.s0.p3	Probenecid	drug	_	loracarbef	drug	_	false	druga : as with other drugn , renal excretion of drugn is inhibited by drugn and resulted in an approximate 80 % increase in the auc for drugb .
DDI-DrugBank.d351.s0.p4	b-lactam antibiotics	group	_	loracarbef	drug	_	false	drugn : as with other druga , renal excretion of drugb is inhibited by drugn and resulted in an approximate 80 % increase in the auc for drugn .
DDI-DrugBank.d351.s0.p5	b-lactam antibiotics	group	_	probenecid	drug	_	mechanism	drugn : as with other druga , renal excretion of drugn is inhibited by drugb and resulted in an approximate 80 % increase in the auc for drugn .
DDI-DrugBank.d351.s0.p6	b-lactam antibiotics	group	_	loracarbef	drug	_	false	drugn : as with other druga , renal excretion of drugn is inhibited by drugn and resulted in an approximate 80 % increase in the auc for drugb .
DDI-DrugBank.d351.s0.p7	loracarbef	drug	_	probenecid	drug	_	mechanism	drugn : as with other drugn , renal excretion of druga is inhibited by drugb and resulted in an approximate 80 % increase in the auc for drugn .
DDI-DrugBank.d351.s0.p9	probenecid	drug	_	loracarbef	drug	_	false	drugn : as with other drugn , renal excretion of drugn is inhibited by druga and resulted in an approximate 80 % increase in the auc for drugb .
DDI-DrugBank.d258.s0.p0	Loratadine	drug	_	erythromycin	drug	_	false	druga -lcb- 10 mg once daily -rcb- has been coadministered with therapeutic doses of drugb , drugn , and drugn in controlled clinical pharmacology studies in adult volunteers .
DDI-DrugBank.d258.s0.p1	Loratadine	drug	_	cimetidine	drug	_	false	druga -lcb- 10 mg once daily -rcb- has been coadministered with therapeutic doses of drugn , drugb , and drugn in controlled clinical pharmacology studies in adult volunteers .
DDI-DrugBank.d258.s0.p2	Loratadine	drug	_	ketoconazole	drug	_	false	druga -lcb- 10 mg once daily -rcb- has been coadministered with therapeutic doses of drugn , drugn , and drugb in controlled clinical pharmacology studies in adult volunteers .
DDI-DrugBank.d258.s3.p0	cimetidine	drug	_	ketoconazole	drug	_	false	no effects on plasma concentrations of druga or drugb were observed .
DDI-DrugBank.d258.s4.p0	erythromycin	drug	_	loratadine	drug	_	mechanism	plasma concentrations -lcb- auc 0-24 hrs -rcb- of druga decreased 15 % with coadministration of drugb relative to that observed with drugn alone .
DDI-DrugBank.d258.s4.p2	loratadine	drug	_	erythromycin	drug	_	false	plasma concentrations -lcb- auc 0-24 hrs -rcb- of drugn decreased 15 % with coadministration of druga relative to that observed with drugb alone .
DDI-DrugBank.d258.s12.p0	contraceptives	group	_	loratadine	drug	_	false	there does not appear to be an increase in adverse events in subjects who received oral druga and drugb .
DDI-DrugBank.d18.s0.p0	benzodiazepines	group	_	lorazepam	drug	_	false	tablets : the druga , including drugb , produce cns-depressant effects when administered with such medications as drugn or drugn .
DDI-DrugBank.d18.s0.p1	benzodiazepines	group	_	barbiturates	group	_	effect	tablets : the druga , including drugn , produce cns-depressant effects when administered with such medications as drugb or drugn .
DDI-DrugBank.d18.s0.p2	benzodiazepines	group	_	alcohol	drug	_	effect	tablets : the druga , including drugn , produce cns-depressant effects when administered with such medications as drugn or drugb .
DDI-DrugBank.d18.s0.p3	lorazepam	drug	_	barbiturates	group	_	effect	tablets : the drugn , including druga , produce cns-depressant effects when administered with such medications as drugb or drugn .
DDI-DrugBank.d18.s0.p4	lorazepam	drug	_	alcohol	drug	_	effect	tablets : the drugn , including druga , produce cns-depressant effects when administered with such medications as drugn or drugb .
DDI-DrugBank.d18.s0.p5	barbiturates	group	_	alcohol	drug	_	false	tablets : the drugn , including drugn , produce cns-depressant effects when administered with such medications as druga or drugb .
DDI-DrugBank.d18.s1.p0	Lorazepam	drug	_	benzodiazepines	group	_	false	injection : druga injection , like other injectable drugb , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p1	Lorazepam	drug	_	ethyl alcohol	drug	_	effect	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugb , drugn , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p2	Lorazepam	drug	_	phenothiazines	group	_	effect	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugb , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p3	Lorazepam	drug	_	barbiturates	group	_	effect	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugb , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p4	Lorazepam	drug	_	MAO inhibitors	group	_	effect	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugb , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p5	Lorazepam	drug	_	antidepressants	group	_	effect	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p6	Lorazepam	drug	_	scopolamine	drug	_	false	injection : druga injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p8	benzodiazepines	group	_	ethyl alcohol	drug	_	effect	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugb , drugn , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p9	benzodiazepines	group	_	phenothiazines	group	_	effect	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugb , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p10	benzodiazepines	group	_	barbiturates	group	_	effect	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugn , drugb , drugn , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p11	benzodiazepines	group	_	MAO inhibitors	group	_	effect	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugb , and other drugn , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p12	benzodiazepines	group	_	antidepressants	group	_	effect	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p13	benzodiazepines	group	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p14	benzodiazepines	group	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable druga , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p18	ethyl alcohol	drug	_	antidepressants	group	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with druga , drugn , drugn , drugn , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p19	ethyl alcohol	drug	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with druga , drugn , drugn , drugn , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p20	ethyl alcohol	drug	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with druga , drugn , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p23	phenothiazines	group	_	antidepressants	group	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , druga , drugn , drugn , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p24	phenothiazines	group	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , druga , drugn , drugn , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p25	phenothiazines	group	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , druga , drugn , drugn , and other drugn , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p27	barbiturates	group	_	antidepressants	group	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , druga , drugn , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p28	barbiturates	group	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , druga , drugn , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p29	barbiturates	group	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , druga , drugn , and other drugn , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p30	MAO inhibitors	group	_	antidepressants	group	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , druga , and other drugb , when drugn is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p31	MAO inhibitors	group	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , druga , and other drugn , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p32	MAO inhibitors	group	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , druga , and other drugn , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p33	antidepressants	group	_	scopolamine	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other druga , when drugb is used concomitantly with injectable drugn , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p34	antidepressants	group	_	lorazepam	drug	_	false	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other druga , when drugn is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d18.s1.p35	scopolamine	drug	_	lorazepam	drug	_	effect	injection : drugn injection , like other injectable drugn , produces depression of the central nervous system when administered with drugn , drugn , drugn , drugn , and other drugn , when druga is used concomitantly with injectable drugb , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .
DDI-DrugBank.d30.s1.p0	Rifampin	drug	_	losartan	drug	_	mechanism	druga , an inducer of drug metabolism , decreased the concentrations of drugb and its active metabolite .
DDI-DrugBank.d30.s3.p0	Ketoconazole	drug	_	losartan	drug	_	false	druga did not affect the conversion of drugb to the active metabolite after intravenous administration of drugn , and drugn had no clinically significant effect after oral administration .
DDI-DrugBank.d30.s3.p1	Ketoconazole	drug	_	losartan	drug	_	false	druga did not affect the conversion of drugn to the active metabolite after intravenous administration of drugb , and drugn had no clinically significant effect after oral administration .
DDI-DrugBank.d30.s3.p2	Ketoconazole	drug	_	erythromycin	drug	_	false	druga did not affect the conversion of drugn to the active metabolite after intravenous administration of drugn , and drugb had no clinically significant effect after oral administration .
DDI-DrugBank.d30.s3.p4	losartan	drug	_	erythromycin	drug	_	false	drugn did not affect the conversion of druga to the active metabolite after intravenous administration of drugn , and drugb had no clinically significant effect after oral administration .
DDI-DrugBank.d30.s3.p5	losartan	drug	_	erythromycin	drug	_	false	drugn did not affect the conversion of drugn to the active metabolite after intravenous administration of druga , and drugb had no clinically significant effect after oral administration .
DDI-DrugBank.d30.s4.p0	Fluconazole	drug	_	losartan	drug	_	mechanism	druga , an inhibitor of cyp2b6 2c9 , decreased active metabolite concentration and increased drugb concentration .
DDI-DrugBank.d30.s8.p6	spironolactone	drug	_	potassium	drug	_	false	as with other drugs that block angiotensin ii or its effects , concomitant use of drugn -lcb- e , g , , druga , drugn , drugn -rcb- , drugb supplements , or salt substitutes containing potassium may lead to increases in serum potassium .
DDI-DrugBank.d30.s8.p8	triamterene	drug	_	potassium	drug	_	false	as with other drugs that block angiotensin ii or its effects , concomitant use of drugn -lcb- e , g , , drugn , druga , drugn -rcb- , drugb supplements , or salt substitutes containing potassium may lead to increases in serum potassium .
DDI-DrugBank.d30.s8.p9	amiloride	drug	_	potassium	drug	_	false	as with other drugs that block angiotensin ii or its effects , concomitant use of drugn -lcb- e , g , , drugn , drugn , druga -rcb- , drugb supplements , or salt substitutes containing potassium may lead to increases in serum potassium .
DDI-DrugBank.d30.s9.p0	antihypertensive agents	group	_	losartan	drug	_	false	as with other druga , the antihypertensive effect of drugb may be blunted by the drugn drugn
DDI-DrugBank.d30.s9.p1	antihypertensive agents	group	_	non-steroidal anti-inflammatory drug	group	_	false	as with other druga , the antihypertensive effect of drugn may be blunted by the drugb drugn
DDI-DrugBank.d30.s9.p2	antihypertensive agents	group	_	indomethacin	drug	_	false	as with other druga , the antihypertensive effect of drugn may be blunted by the drugn drugb
DDI-DrugBank.d30.s9.p3	losartan	drug	_	non-steroidal anti-inflammatory drug	group	_	false	as with other drugn , the antihypertensive effect of druga may be blunted by the drugb drugn
DDI-DrugBank.d30.s9.p4	losartan	drug	_	indomethacin	drug	_	effect	as with other drugn , the antihypertensive effect of druga may be blunted by the drugn drugb
DDI-DrugBank.d30.s9.p5	non-steroidal anti-inflammatory drug	group	_	indomethacin	drug	_	false	as with other drugn , the antihypertensive effect of drugn may be blunted by the druga drugb
DDI-DrugBank.d567.s5.p0	Itraconazole	drug	_	Ketoconazole	drug	_	false	druga drugb drugn drugn drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p1	Itraconazole	drug	_	Erythromycin	drug	_	false	druga drugn drugb drugn drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p2	Itraconazole	drug	_	Clarithromycin	drug	_	false	druga drugn drugn drugb drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p3	Itraconazole	drug	_	Telithromycin	drug	_	false	druga drugn drugn drugn drugb drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p4	Itraconazole	drug	_	HIV protease inhibitors	group	_	false	druga drugn drugn drugn drugn drugb drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p5	Itraconazole	drug	_	Nefazodone	drug	_	false	druga drugn drugn drugn drugn drugn drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p6	Itraconazole	drug	_	Cyclosporine	drug	_	false	druga drugn drugn drugn drugn drugn drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p7	Ketoconazole	drug	_	Erythromycin	drug	_	false	drugn druga drugb drugn drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p8	Ketoconazole	drug	_	Clarithromycin	drug	_	false	drugn druga drugn drugb drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p9	Ketoconazole	drug	_	Telithromycin	drug	_	false	drugn druga drugn drugn drugb drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p10	Ketoconazole	drug	_	HIV protease inhibitors	group	_	false	drugn druga drugn drugn drugn drugb drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p11	Ketoconazole	drug	_	Nefazodone	drug	_	false	drugn druga drugn drugn drugn drugn drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p12	Ketoconazole	drug	_	Cyclosporine	drug	_	false	drugn druga drugn drugn drugn drugn drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p13	Erythromycin	drug	_	Clarithromycin	drug	_	false	drugn drugn druga drugb drugn drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p14	Erythromycin	drug	_	Telithromycin	drug	_	false	drugn drugn druga drugn drugb drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p15	Erythromycin	drug	_	HIV protease inhibitors	group	_	false	drugn drugn druga drugn drugn drugb drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p16	Erythromycin	drug	_	Nefazodone	drug	_	false	drugn drugn druga drugn drugn drugn drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p17	Erythromycin	drug	_	Cyclosporine	drug	_	false	drugn drugn druga drugn drugn drugn drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p18	Clarithromycin	drug	_	Telithromycin	drug	_	false	drugn drugn drugn druga drugb drugn drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p19	Clarithromycin	drug	_	HIV protease inhibitors	group	_	false	drugn drugn drugn druga drugn drugb drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p20	Clarithromycin	drug	_	Nefazodone	drug	_	false	drugn drugn drugn druga drugn drugn drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p21	Clarithromycin	drug	_	Cyclosporine	drug	_	false	drugn drugn drugn druga drugn drugn drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p22	Telithromycin	drug	_	HIV protease inhibitors	group	_	false	drugn drugn drugn drugn druga drugb drugn drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p23	Telithromycin	drug	_	Nefazodone	drug	_	false	drugn drugn drugn drugn druga drugn drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p24	Telithromycin	drug	_	Cyclosporine	drug	_	false	drugn drugn drugn drugn druga drugn drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p25	HIV protease inhibitors	group	_	Nefazodone	drug	_	false	drugn drugn drugn drugn drugn druga drugb drugn large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p26	HIV protease inhibitors	group	_	Cyclosporine	drug	_	false	drugn drugn drugn drugn drugn druga drugn drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s5.p27	Nefazodone	drug	_	Cyclosporine	drug	_	false	drugn drugn drugn drugn drugn drugn druga drugb large quantities of grapefruit juice -lcb- # quart daily -rcb-
DDI-DrugBank.d567.s9.p0	Gemfibrozil	drug	_	fibrates	group	_	false	druga other drugb drugn -lcb- drugn -rcb- -lcb- = 1 g/day -rcb-
DDI-DrugBank.d567.s9.p1	Gemfibrozil	drug	_	Niacin	drug	_	false	druga other drugn drugb -lcb- drugn -rcb- -lcb- = 1 g/day -rcb-
DDI-DrugBank.d567.s9.p2	Gemfibrozil	drug	_	nicotinic acid	drug	_	false	druga other drugn drugn -lcb- drugb -rcb- -lcb- = 1 g/day -rcb-
DDI-DrugBank.d567.s9.p3	fibrates	group	_	Niacin	drug	_	false	drugn other druga drugb -lcb- drugn -rcb- -lcb- = 1 g/day -rcb-
DDI-DrugBank.d567.s9.p4	fibrates	group	_	nicotinic acid	drug	_	false	drugn other druga drugn -lcb- drugb -rcb- -lcb- = 1 g/day -rcb-
DDI-DrugBank.d567.s11.p2	danazol	drug	_	lovastatin	drug	_	effect	drugn : the risk of myopathy/rhabdomyolysis is increased by concomitant administration of druga particularly with higher doses of drugb -lcb- see warnings , myopathy/rhabdomyolysis -rcb- .
DDI-DrugBank.d567.s12.p0	Amiodarone	drug	_	Verapamil	drug	_	false	druga or drugb : the risk of myopathy/rhabdomyolysis is increased when either drugn or drugn is used concomitantly with a closely related member of the drugn -lcb- see warnings , myopathy/rhabdomyolysis -rcb- .
DDI-DrugBank.d567.s12.p7	amiodarone	drug	_	verapamil	drug	_	false	drugn or drugn : the risk of myopathy/rhabdomyolysis is increased when either druga or drugb is used concomitantly with a closely related member of the drugn -lcb- see warnings , myopathy/rhabdomyolysis -rcb- .
DDI-DrugBank.d567.s12.p8	amiodarone	drug	_	HMG-CoA reductase inhibitor class	group	_	effect	drugn or drugn : the risk of myopathy/rhabdomyolysis is increased when either druga or drugn is used concomitantly with a closely related member of the drugb -lcb- see warnings , myopathy/rhabdomyolysis -rcb- .
DDI-DrugBank.d567.s12.p9	verapamil	drug	_	HMG-CoA reductase inhibitor class	group	_	effect	drugn or drugn : the risk of myopathy/rhabdomyolysis is increased when either drugn or druga is used concomitantly with a closely related member of the drugb -lcb- see warnings , myopathy/rhabdomyolysis -rcb- .
DDI-DrugBank.d567.s13.p2	lovastatin	drug	_	warfarin	drug	_	false	drugn s : in a small clinical trial in which druga was administered to drugb treated patients , no effect on prothrombin time was detected .
DDI-DrugBank.d567.s14.p0	HMG-CoA reductase inhibitor	group	_	warfarin	drug	_	effect	however , another druga has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of drugb .
DDI-DrugBank.d567.s15.p0	coumarin anticoagulant	group	_	lovastatin	drug	_	effect	also , bleeding and/or increased prothrombin time have been reported in a few patients taking druga s concomitantly with drugb .
DDI-DrugBank.d567.s16.p0	anticoagulants	group	_	lovastatin	drug	_	advise	it is recommended that in patients taking druga , prothrombin time be determined before starting drugb and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs .
DDI-DrugBank.d567.s19.p0	Lovastatin	drug	_	anticoagulants	group	_	false	druga therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking drugb .
DDI-DrugBank.d567.s20.p0	Propranolol	drug	_	lovastatin	drug	_	false	druga : in normal volunteers , there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of drugb and drugn .
DDI-DrugBank.d567.s20.p2	lovastatin	drug	_	propranolol	drug	_	false	drugn : in normal volunteers , there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of druga and drugb .
DDI-DrugBank.d567.s21.p0	Digoxin	drug	_	lovastatin	drug	_	false	druga : in patients with hypercholesterolemia , concomitant administration of drugb and drugn resulted in no effect on drugn plasma concentrations .
DDI-DrugBank.d567.s21.p3	lovastatin	drug	_	digoxin	drug	_	false	drugn : in patients with hypercholesterolemia , concomitant administration of druga and drugb resulted in no effect on drugn plasma concentrations .
DDI-DrugBank.d567.s21.p4	lovastatin	drug	_	digoxin	drug	_	false	drugn : in patients with hypercholesterolemia , concomitant administration of druga and drugn resulted in no effect on drugb plasma concentrations .
DDI-DrugBank.d567.s22.p3	MEVACOR	brand	_	glipizide	drug	_	false	oral drugn : in pharmacokinetic studies of druga in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with drugb or with drugn
DDI-DrugBank.d567.s22.p4	MEVACOR	brand	_	chlorpropamide	drug	_	false	oral drugn : in pharmacokinetic studies of druga in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with drugn or with drugb
DDI-DrugBank.d567.s22.p5	glipizide	drug	_	chlorpropamide	drug	_	false	oral drugn : in pharmacokinetic studies of drugn in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with druga or with drugb
DDI-DrugBank.d504.s0.p0	loxapine	drug	_	lorazepam	drug	_	effect	there have been rare reports of significant respiratory depression , stupor and/or hypotension with the concomitant use of druga and drugb .
DDI-DrugBank.d79.s0.p0	lymecycline	drug	_	iron	drug	_	mechanism	the absorption of druga may be affected by the simultaneous administration of indigestion remedies , drugb or drugn supplements .
DDI-DrugBank.d79.s0.p1	lymecycline	drug	_	zinc	drug	_	mechanism	the absorption of druga may be affected by the simultaneous administration of indigestion remedies , drugn or drugb supplements .
DDI-DrugBank.d79.s0.p2	iron	drug	_	zinc	drug	_	false	the absorption of drugn may be affected by the simultaneous administration of indigestion remedies , druga or drugb supplements .
DDI-DrugBank.d79.s1.p0	contraceptives	group	_	lymecycline	drug	_	effect	oral druga may be less effective while you are taking drugb .
DDI-DrugBank.d113.s0.p2	Meclofenamate sodium	drug	_	warfarin	drug	_	false	drugn : druga enhances the effect of drugb .
DDI-DrugBank.d113.s1.p0	meclofenamate sodium	drug	_	warfarin	drug	_	advise	therefore , when druga is given to a patient receiving drugb , the dosage of drugn should be reduced to prevent excessive prolongation of the prothrombin time .
DDI-DrugBank.d113.s1.p1	meclofenamate sodium	drug	_	warfarin	drug	_	false	therefore , when druga is given to a patient receiving drugn , the dosage of drugb should be reduced to prevent excessive prolongation of the prothrombin time .
DDI-DrugBank.d113.s2.p1	Aspirin	brand	_	meclofenamate sodium	drug	_	false	druga : concurrent administration of drugn may lower drugb plasma levels , possibly by competing for protein-binding sites .
DDI-DrugBank.d113.s2.p2	aspirin	brand	_	meclofenamate sodium	drug	_	mechanism	drugn : concurrent administration of druga may lower drugb plasma levels , possibly by competing for protein-binding sites .
DDI-DrugBank.d113.s3.p0	meclofenamate sodium	drug	_	aspirin	brand	_	false	the urinary excretion of druga is unaffected by drugb , indicating no change in drugn absorption .
DDI-DrugBank.d113.s3.p2	aspirin	brand	_	meclofenamate sodium	drug	_	false	the urinary excretion of drugn is unaffected by druga , indicating no change in drugb absorption .
DDI-DrugBank.d113.s4.p0	Meclofenamate sodium	drug	_	salicylate	group	_	false	druga does not affect serum drugb levels .
DDI-DrugBank.d113.s6.p2	propoxyphene hydrochloride	drug	_	meclofenamate sodium	drug	_	false	drugn : the concurrent administration of druga does not affect the bioavailability of drugb .
DDI-DrugBank.d113.s7.p0	Antacids	group	_	aluminum hydroxide	drug	_	false	druga : concomitant administration of drugb s and drugn s does not interfere with absorption of drugn .
DDI-DrugBank.d113.s7.p1	Antacids	group	_	magnesium hydroxide	drug	_	false	druga : concomitant administration of drugn s and drugb s does not interfere with absorption of drugn .
DDI-DrugBank.d113.s7.p2	Antacids	group	_	meclofenamate sodium	drug	_	false	druga : concomitant administration of drugn s and drugn s does not interfere with absorption of drugb .
DDI-DrugBank.d113.s7.p3	aluminum hydroxide	drug	_	magnesium hydroxide	drug	_	false	drugn : concomitant administration of druga s and drugb s does not interfere with absorption of drugn .
DDI-DrugBank.d113.s7.p4	aluminum hydroxide	drug	_	meclofenamate sodium	drug	_	false	drugn : concomitant administration of druga s and drugn s does not interfere with absorption of drugb .
DDI-DrugBank.d113.s7.p5	magnesium hydroxide	drug	_	meclofenamate sodium	drug	_	false	drugn : concomitant administration of drugn s and druga s does not interfere with absorption of drugb .
DDI-DrugBank.d400.s0.p0	Aspirin	brand	_	NSAIDs	group	_	false	druga : as with other drugb , concomitant administration of drugn and drugn is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d400.s0.p1	Aspirin	brand	_	Ponstel	brand	_	false	druga : as with other drugn , concomitant administration of drugb and drugn is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d400.s0.p3	NSAIDs	group	_	Ponstel	brand	_	false	drugn : as with other druga , concomitant administration of drugb and drugn is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d400.s0.p4	NSAIDs	group	_	aspirin	brand	_	advise	drugn : as with other druga , concomitant administration of drugn and drugb is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d400.s0.p5	Ponstel	brand	_	aspirin	brand	_	advise	drugn : as with other drugn , concomitant administration of druga and drugb is not generally recommended because of the potential of increased adverse effects .
DDI-DrugBank.d400.s1.p2	NSAIDs	group	_	methotrexate	drug	_	mechanism	drugn : druga have been reported to competitively inhibit drugb accumulation in rabbit kidney slices .
DDI-DrugBank.d400.s3.p0	NSAIDs	group	_	methotrexate	drug	_	advise	caution should be used when druga are administered concomitantly with drugb .
DDI-DrugBank.d400.s4.p2	NSAIDs	group	_	ACE inhibitors	group	_	effect	drugn : reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d400.s5.p0	NSAIDs	group	_	ACE inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d400.s6.p0	Furosemide	drug	_	NSAIDs	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d400.s6.p2	Furosemide	drug	_	thiazides	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d400.s6.p3	NSAIDs	group	_	furosemide	drug	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d400.s6.p4	NSAIDs	group	_	thiazides	group	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d400.s6.p5	furosemide	drug	_	thiazides	group	_	false	drugn : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d400.s8.p0	Ponstel	brand	_	furosemide	drug	_	advise	during concomitant therapy of druga with drugb , the patient should be observed closely for signs of renal failure , as well as to assure diuretic efficacy .
DDI-DrugBank.d400.s9.p3	NSAIDs	group	_	lithium	drug	_	mechanism	drugn : druga have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
DDI-DrugBank.d400.s9.p4	NSAIDs	group	_	lithium	drug	_	mechanism	drugn : druga have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
DDI-DrugBank.d400.s12.p0	NSAIDs	group	_	lithium	drug	_	advise	thus , when druga and drugb are administered concurrently , subjects should be observed carefully for signs of drugn toxicity .
DDI-DrugBank.d400.s12.p1	NSAIDs	group	_	lithium	drug	_	false	thus , when druga and drugn are administered concurrently , subjects should be observed carefully for signs of drugb toxicity .
DDI-DrugBank.d400.s13.p2	warfarin	drug	_	NSAIDs	group	_	effect	drugn : the effects of druga and drugb on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than users of either drug alone .
DDI-DrugBank.d400.s14.p7	antacid	group	_	magnesium hydroxide	drug	_	false	drugn : in a single dose study -lcb- n = 6 -rcb- , ingestion of an druga containing # - gram of drugb with 500-mg of drugn increased the cmax and auc of drugn by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including drugn , drugn and drugn .
DDI-DrugBank.d400.s14.p8	antacid	group	_	mefenamic acid	drug	_	false	drugn : in a single dose study -lcb- n = 6 -rcb- , ingestion of an druga containing # - gram of drugn with 500-mg of drugb increased the cmax and auc of drugn by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including drugn , drugn and drugn .
DDI-DrugBank.d400.s14.p9	antacid	group	_	mefenamic acid	drug	_	false	drugn : in a single dose study -lcb- n = 6 -rcb- , ingestion of an druga containing # - gram of drugn with 500-mg of drugn increased the cmax and auc of drugb by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including drugn , drugn and drugn .
DDI-DrugBank.d400.s14.p13	magnesium hydroxide	drug	_	mefenamic acid	drug	_	mechanism	drugn : in a single dose study -lcb- n = 6 -rcb- , ingestion of an drugn containing # - gram of druga with 500-mg of drugb increased the cmax and auc of drugn by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including drugn , drugn and drugn .
DDI-DrugBank.d400.s14.p14	magnesium hydroxide	drug	_	mefenamic acid	drug	_	false	drugn : in a single dose study -lcb- n = 6 -rcb- , ingestion of an drugn containing # - gram of druga with 500-mg of drugn increased the cmax and auc of drugb by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including drugn , drugn and drugn .
DDI-DrugBank.d220.s4.p0	halofantrine	drug	_	Mefloquine	drug	_	advise	because of the danger of a potentially fatal prolongation of the qtc interval , druga must not be given simultaneously with or subsequent to drugb .
DDI-DrugBank.d220.s5.p0	Mefloquine	drug	_	quinine	drug	_	effect	concomitant administration of druga and other related compounds -lcb- eg , drugb , drugn and drugn -rcb- may produce electrocardiographic abnormalities and increase the risk of convulsions .
DDI-DrugBank.d220.s5.p1	Mefloquine	drug	_	quinidine	drug	_	effect	concomitant administration of druga and other related compounds -lcb- eg , drugn , drugb and drugn -rcb- may produce electrocardiographic abnormalities and increase the risk of convulsions .
DDI-DrugBank.d220.s5.p2	Mefloquine	drug	_	chloroquine	drug	_	effect	concomitant administration of druga and other related compounds -lcb- eg , drugn , drugn and drugb -rcb- may produce electrocardiographic abnormalities and increase the risk of convulsions .
DDI-DrugBank.d220.s9.p0	Mefloquine	drug	_	anti-arrhythmic	drug	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugb or drugn , drugn , drugn or drugn , drugn and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p1	Mefloquine	drug	_	beta-adrenergic blocking agents	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugb , drugn , drugn or drugn , drugn and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p2	Mefloquine	drug	_	calcium channel blockers	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugn , drugb , drugn or drugn , drugn and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p3	Mefloquine	drug	_	antihistamines	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugn , drugn , drugb or drugn , drugn and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p4	Mefloquine	drug	_	H1-blocking agents	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugn , drugn , drugn or drugb , drugn and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p5	Mefloquine	drug	_	tricyclic antidepressants	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugn , drugn , drugn or drugn , drugb and drugn -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s9.p6	Mefloquine	drug	_	phenothiazines	group	_	effect	this appears to be the only clinically relevant interaction of this kind with druga , although theoretically , coadministration of other drugs known to alter cardiac conduction -lcb- eg , drugn or drugn , drugn , drugn or drugn , drugn and drugb -rcb- might also contribute to a prolongation of the qtc interval .
DDI-DrugBank.d220.s11.p4	anticonvulsant	group	_	Mefloquine	drug	_	effect	in patients taking an druga -lcb- eg , drugn , drugn , drugn or drugn -rcb- , the concomitant use of drugb may reduce seizure control by lowering the plasma levels of the drugn .
DDI-DrugBank.d220.s11.p9	valproic acid	drug	_	Mefloquine	drug	_	effect	in patients taking an drugn -lcb- eg , druga , drugn , drugn or drugn -rcb- , the concomitant use of drugb may reduce seizure control by lowering the plasma levels of the drugn .
DDI-DrugBank.d220.s11.p10	valproic acid	drug	_	anticonvulsant	group	_	false	in patients taking an drugn -lcb- eg , druga , drugn , drugn or drugn -rcb- , the concomitant use of drugn may reduce seizure control by lowering the plasma levels of the drugb .
DDI-DrugBank.d220.s11.p13	carbamazepine	drug	_	Mefloquine	drug	_	effect	in patients taking an drugn -lcb- eg , drugn , druga , drugn or drugn -rcb- , the concomitant use of drugb may reduce seizure control by lowering the plasma levels of the drugn .
DDI-DrugBank.d220.s11.p14	carbamazepine	drug	_	anticonvulsant	group	_	false	in patients taking an drugn -lcb- eg , drugn , druga , drugn or drugn -rcb- , the concomitant use of drugn may reduce seizure control by lowering the plasma levels of the drugb .
DDI-DrugBank.d220.s11.p16	phenobarbital	drug	_	Mefloquine	drug	_	effect	in patients taking an drugn -lcb- eg , drugn , drugn , druga or drugn -rcb- , the concomitant use of drugb may reduce seizure control by lowering the plasma levels of the drugn .
DDI-DrugBank.d220.s11.p17	phenobarbital	drug	_	anticonvulsant	group	_	false	in patients taking an drugn -lcb- eg , drugn , drugn , druga or drugn -rcb- , the concomitant use of drugn may reduce seizure control by lowering the plasma levels of the drugb .
DDI-DrugBank.d220.s11.p18	phenytoin	drug	_	Mefloquine	drug	_	effect	in patients taking an drugn -lcb- eg , drugn , drugn , drugn or druga -rcb- , the concomitant use of drugb may reduce seizure control by lowering the plasma levels of the drugn .
DDI-DrugBank.d220.s11.p19	phenytoin	drug	_	anticonvulsant	group	_	false	in patients taking an drugn -lcb- eg , drugn , drugn , drugn or druga -rcb- , the concomitant use of drugn may reduce seizure control by lowering the plasma levels of the drugb .
DDI-DrugBank.d220.s11.p20	Mefloquine	drug	_	anticonvulsant	group	_	false	in patients taking an drugn -lcb- eg , drugn , drugn , drugn or drugn -rcb- , the concomitant use of druga may reduce seizure control by lowering the plasma levels of the drugb .
DDI-DrugBank.d220.s13.p0	Mefloquine	drug	_	live typhoid vaccines	group	_	effect	when druga is taken concurrently with oral drugb , attenuation of immunization can not be excluded .
DDI-DrugBank.d220.s16.p0	Mefloquine	drug	_	anticoagulants	group	_	advise	nevertheless , the effects of druga on travelers receiving comedication , particularly diabetics or patients using drugb , should be checked before departure .
DDI-DrugBank.d220.s17.p0	sulfadoxine	drug	_	pyrimethamine	drug	_	false	in clinical trials , the concomitant administration of druga and drugb did not alter the adverse reaction profile .
DDI-DrugBank.d139.s0.p1	Broad-Spectrum Antibiotics	group	_	vitamin K	group	_	false	druga - drugn may sterilize the bowel and decrease the drugb contribution to the body by the intestinal microflora .
DDI-DrugBank.d139.s0.p2	Broad-spectrum antibiotics	group	_	vitamin K	group	_	false	drugn - druga may sterilize the bowel and decrease the drugb contribution to the body by the intestinal microflora .
DDI-DrugBank.d139.s1.p1	Cephalosporins	group	_	cefmenoxime	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugb , drugn , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p2	Cephalosporins	group	_	cefoperazone	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugb , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p3	Cephalosporins	group	_	cefotetan	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugb , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p4	Cephalosporins	group	_	cefamandole	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugb , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p5	Cephalosporins	group	_	latamoxef	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugn , drugb -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p6	Cephalosporins	group	_	cefazolin	drug	_	false	druga - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p7	Cephalosporins	group	_	cefmenoxime	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugb , drugn , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p8	Cephalosporins	group	_	cefoperazone	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugn , drugb , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p9	Cephalosporins	group	_	cefotetan	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugb , drugn , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p10	Cephalosporins	group	_	cefamandole	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugb , drugn -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p11	Cephalosporins	group	_	latamoxef	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugn , drugb -rcb- or methylthiadiazole -lcb- drugn -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p12	Cephalosporins	group	_	cefazolin	drug	_	false	drugn - druga containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p17	cefmenoxime	drug	_	cefazolin	drug	_	false	drugn - drugn containing side chains of n-methylthiotetrazole -lcb- druga , drugn , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p21	cefoperazone	drug	_	cefazolin	drug	_	false	drugn - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , druga , drugn , drugn , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p24	cefotetan	drug	_	cefazolin	drug	_	false	drugn - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , druga , drugn , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p26	cefamandole	drug	_	cefazolin	drug	_	false	drugn - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , druga , drugn -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s1.p27	latamoxef	drug	_	cefazolin	drug	_	false	drugn - drugn containing side chains of n-methylthiotetrazole -lcb- drugn , drugn , drugn , drugn , druga -rcb- or methylthiadiazole -lcb- drugb -rcb- can cause vitamin_k_deficiency and hypoprothrombinemia .
DDI-DrugBank.d139.s3.p1	Cholestyramine	drug	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s3.p2	Cholestyramine	drug	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s3.p3	cholestyramine	drug	_	vitamin K	group	_	mechanism	drugn - concomitant intake of druga and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s3.p4	cholestyramine	drug	_	vitamin K	group	_	false	drugn - concomitant intake of druga and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s4.p1	Colestipol	drug	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s4.p2	Colestipol	drug	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s4.p3	colestipol	drug	_	vitamin K	group	_	mechanism	drugn - concomitant intake of druga and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s4.p4	colestipol	drug	_	vitamin K	group	_	false	drugn - concomitant intake of druga and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s5.p1	Mineral Oil	drug_n	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s5.p2	Mineral Oil	drug_n	_	vitamin K	group	_	false	druga - concomitant intake of drugn and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s5.p3	mineral oil	drug_n	_	vitamin K	group	_	mechanism	drugn - concomitant intake of druga and drugb may reduce the absorption of drugn .
DDI-DrugBank.d139.s5.p4	mineral oil	drug_n	_	vitamin K	group	_	false	drugn - concomitant intake of druga and drugn may reduce the absorption of drugb .
DDI-DrugBank.d139.s6.p1	Orlistat	drug	_	vitamin K	group	_	false	druga - drugn may decrease the absorption of drugb .
DDI-DrugBank.d139.s6.p2	Orlistat	drug	_	vitamin K	group	_	mechanism	drugn - druga may decrease the absorption of drugb .
DDI-DrugBank.d139.s8.p0	Warfarin	drug	_	Vitamin K	group	_	false	druga - drugb can antagonize the effect of drugn
DDI-DrugBank.d139.s8.p2	Vitamin K	group	_	warfarin	drug	_	effect	drugn - druga can antagonize the effect of drugb
DDI-DrugBank.d552.s0.p0	Nabilone	drug	_	psychoactive drugs	group	_	advise	druga should be administered with caution to patients who are taking other drugb or drugn , including drugn , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p1	Nabilone	drug	_	CNS depressants	group	_	advise	druga should be administered with caution to patients who are taking other drugn or drugb , including drugn , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p2	Nabilone	drug	_	alcohol	drug	_	advise	druga should be administered with caution to patients who are taking other drugn or drugn , including drugb , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p3	Nabilone	drug	_	barbiturates	group	_	advise	druga should be administered with caution to patients who are taking other drugn or drugn , including drugn , drugb and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p4	Nabilone	drug	_	narcotic analgesics	group	_	advise	druga should be administered with caution to patients who are taking other drugn or drugn , including drugn , drugn and drugb , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p5	psychoactive drugs	group	_	CNS depressants	group	_	false	drugn should be administered with caution to patients who are taking other druga or drugb , including drugn , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p6	psychoactive drugs	group	_	alcohol	drug	_	false	drugn should be administered with caution to patients who are taking other druga or drugn , including drugb , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p7	psychoactive drugs	group	_	barbiturates	group	_	false	drugn should be administered with caution to patients who are taking other druga or drugn , including drugn , drugb and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p8	psychoactive drugs	group	_	narcotic analgesics	group	_	false	drugn should be administered with caution to patients who are taking other druga or drugn , including drugn , drugn and drugb , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p9	CNS depressants	group	_	alcohol	drug	_	false	drugn should be administered with caution to patients who are taking other drugn or druga , including drugb , drugn and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p10	CNS depressants	group	_	barbiturates	group	_	false	drugn should be administered with caution to patients who are taking other drugn or druga , including drugn , drugb and drugn , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s0.p11	CNS depressants	group	_	narcotic analgesics	group	_	false	drugn should be administered with caution to patients who are taking other drugn or druga , including drugn , drugn and drugb , or to those with a history of psychiatric disorder -lcb- including manic-depressive illness and schizophrenia -rcb- .
DDI-DrugBank.d552.s1.p0	Nabilone	drug	_	diazepam	drug	_	effect	druga has been shown to have an additive cns depressant effect when given with either drugb , drugn , drugn or drugn .
DDI-DrugBank.d552.s1.p1	Nabilone	drug	_	secobarbitone sodium	brand	_	effect	druga has been shown to have an additive cns depressant effect when given with either drugn , drugb , drugn or drugn .
DDI-DrugBank.d552.s1.p2	Nabilone	drug	_	alcohol	drug	_	effect	druga has been shown to have an additive cns depressant effect when given with either drugn , drugn , drugb or drugn .
DDI-DrugBank.d552.s1.p3	Nabilone	drug	_	codeine	drug	_	effect	druga has been shown to have an additive cns depressant effect when given with either drugn , drugn , drugn or drugb .
DDI-DrugBank.d174.s1.p0	nabumetone	drug	_	warfarin	drug	_	advise	caution should be exercised when administering druga with drugb since interactions have been seen with other drugn .
DDI-DrugBank.d174.s1.p1	nabumetone	drug	_	NSAIDs	group	_	false	caution should be exercised when administering druga with drugn since interactions have been seen with other drugb .
DDI-DrugBank.d174.s1.p2	warfarin	drug	_	NSAIDs	group	_	int	caution should be exercised when administering drugn with druga since interactions have been seen with other drugb .
DDI-DrugBank.d174.s2.p0	aluminum	drug	_	antacid	group	_	false	concomitant administration of an druga - containing drugb had no significant effect in the bioavailability of drugn .
DDI-DrugBank.d174.s2.p1	aluminum	drug	_	6MNA	drug_n	_	false	concomitant administration of an druga - containing drugn had no significant effect in the bioavailability of drugb .
DDI-DrugBank.d174.s2.p2	antacid	group	_	6MNA	drug_n	_	false	concomitant administration of an drugn - containing druga had no significant effect in the bioavailability of drugb .
DDI-DrugBank.d204.s0.p0	beta-adrenergic receptor blocking agents	group	_	Anesthetics	group	_	int	when administered concurrently , the following drugs may interact with druga : drugb , general : exaggeration of the hypotension induced by general drugn .
DDI-DrugBank.d204.s0.p1	beta-adrenergic receptor blocking agents	group	_	anesthetics	group	_	false	when administered concurrently , the following drugs may interact with druga : drugn , general : exaggeration of the hypotension induced by general drugb .
DDI-DrugBank.d261.s0.p0	Tetracycline	drug	_	bacteriostatic antibiotic	group	_	false	druga , a drugb , may antagonize the bactericidal effect of drugn and concurrent use of these drugs should be avoided .
DDI-DrugBank.d261.s0.p1	Tetracycline	drug	_	penicillin	drug	_	effect	druga , a drugn , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d261.s0.p2	bacteriostatic antibiotic	group	_	penicillin	drug	_	false	drugn , a druga , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
DDI-DrugBank.d427.s0.p0	theophylline	drug	_	quinolone	group	_	mechanism	elevated plasma levels of druga have been reported with concomitant drugb use .
DDI-DrugBank.d427.s1.p0	theophylline	drug	_	quinolones	group	_	false	there have been reports of druga - related side effects in patients on concomitant therapy with drugb and drugn .
DDI-DrugBank.d427.s1.p2	quinolones	group	_	theophylline	drug	_	effect	there have been reports of drugn - related side effects in patients on concomitant therapy with druga and drugb .
DDI-DrugBank.d427.s3.p0	Quinolones	group	_	caffeine	drug	_	mechanism	druga have been shown to interfere with the metabolism of drugb .
DDI-DrugBank.d427.s5.p0	Quinolones	group	_	nalidixic acid	drug	_	false	druga , including drugb , may enhance the effects of the oral drugn drugn or its derivatives .
DDI-DrugBank.d427.s5.p1	Quinolones	group	_	anticoagulant	group	_	false	druga , including drugn , may enhance the effects of the oral drugb drugn or its derivatives .
DDI-DrugBank.d427.s5.p2	Quinolones	group	_	warfarin	drug	_	effect	druga , including drugn , may enhance the effects of the oral drugn drugb or its derivatives .
DDI-DrugBank.d427.s5.p3	nalidixic acid	drug	_	anticoagulant	group	_	false	drugn , including druga , may enhance the effects of the oral drugb drugn or its derivatives .
DDI-DrugBank.d427.s5.p4	nalidixic acid	drug	_	warfarin	drug	_	effect	drugn , including druga , may enhance the effects of the oral drugn drugb or its derivatives .
DDI-DrugBank.d427.s5.p5	anticoagulant	group	_	warfarin	drug	_	false	drugn , including drugn , may enhance the effects of the oral druga drugb or its derivatives .
DDI-DrugBank.d427.s7.p0	Nitrofurantoin	drug	_	nalidixic acid	drug	_	effect	druga interferes with the therapeutic action of drugb .
DDI-DrugBank.d427.s8.p0	Antacids	group	_	magnesium	drug	_	false	druga containing drugb , drugn , or drugn ;
DDI-DrugBank.d427.s8.p1	Antacids	group	_	aluminum	drug	_	false	druga containing drugn , drugb , or drugn ;
DDI-DrugBank.d427.s8.p2	Antacids	group	_	calcium	drug	_	false	druga containing drugn , drugn , or drugb ;
DDI-DrugBank.d427.s9.p0	sucralfate	drug	_	iron	drug	_	false	druga or divalent or trivalent cations such as drugb ;
DDI-DrugBank.d427.s10.p0	multivitamins	group	_	zinc	drug	_	false	druga containing drugb ;
DDI-DrugBank.d427.s11.p0	Videx	brand	_	Didanosine	drug	_	false	and druga , -lcb- drugb -rcb- , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drugn , resulting in systemic levels considerably lower than desired .
DDI-DrugBank.d427.s11.p1	Videx	brand	_	quinolones	group	_	mechanism	and druga , -lcb- drugn -rcb- , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drugb , resulting in systemic levels considerably lower than desired .
DDI-DrugBank.d427.s11.p2	Didanosine	drug	_	quinolones	group	_	mechanism	and drugn , -lcb- druga -rcb- , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drugb , resulting in systemic levels considerably lower than desired .
DDI-DrugBank.d427.s13.p0	cyclosporine	drug	_	quinolones	group	_	false	elevated serum levels of druga have been reported with the concomitant use of some drugb and drugn .
DDI-DrugBank.d427.s13.p2	quinolones	group	_	cyclosporine	drug	_	mechanism	elevated serum levels of drugn have been reported with the concomitant use of some druga and drugb .
DDI-DrugBank.d346.s0.p0	REVIA	brand	_	opiates	group	_	false	studies to evaluate possible interactions between druga and drugs other than drugb have not been performed .
DDI-DrugBank.d346.s2.p0	REVIA	brand	_	disulfiram	drug	_	effect	the safety and efficacy of concomitant use of druga and drugb is unknown , and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks .
DDI-DrugBank.d346.s3.p0	REVIA	brand	_	thioridazine	drug	_	effect	lethargy and somnolence have been reported following doses of druga and drugb .
DDI-DrugBank.d346.s4.p0	REVIA	brand	_	opioid	group	_	effect	patients taking druga may not benefit from drugb containing medicines , such as cough and cold preparations , antidiarrheal preparations , and drugn .
DDI-DrugBank.d346.s4.p1	REVIA	brand	_	opioid analgesics	group	_	effect	patients taking druga may not benefit from drugn containing medicines , such as cough and cold preparations , antidiarrheal preparations , and drugb .
DDI-DrugBank.d346.s5.p0	REVIA	brand	_	opioid	group	_	effect	in an emergency situation when opioid analgesia must be administered to a patient receiving druga , the amount of drugb required may be greater than usual , and the resulting respiratory_failure may be deeper and more prolonged .
DDI-DrugBank.d85.s0.p0	NSAIDs	group	_	ACE inhibitors	group	_	effect	the use of druga in patients who are receiving drugb may potentiate renal disease states .
DDI-DrugBank.d85.s6.p0	naproxen	drug	_	aspirin	brand	_	advise	concomitant administration of druga and drugb is not recommended because drugn is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations and peak plasma levels .
DDI-DrugBank.d85.s6.p2	naproxen	drug	_	aspirin	brand	_	false	concomitant administration of druga and drugn is not recommended because drugn is displaced from its binding sites during the concomitant administration of drugb , resulting in lower plasma concentrations and peak plasma levels .
DDI-DrugBank.d85.s6.p3	aspirin	brand	_	naproxen	drug	_	false	concomitant administration of drugn and druga is not recommended because drugb is displaced from its binding sites during the concomitant administration of drugn , resulting in lower plasma concentrations and peak plasma levels .
DDI-DrugBank.d85.s6.p5	naproxen	drug	_	aspirin	brand	_	advise	concomitant administration of drugn and drugn is not recommended because druga is displaced from its binding sites during the concomitant administration of drugb , resulting in lower plasma concentrations and peak plasma levels .
DDI-DrugBank.d85.s9.p0	Naproxen	drug	_	NSAIDs	group	_	false	druga and other drugb can reduce the antihypertensive effect of drugn and other drugn .
DDI-DrugBank.d85.s9.p1	Naproxen	drug	_	propranolol	drug	_	effect	druga and other drugn can reduce the antihypertensive effect of drugb and other drugn .
DDI-DrugBank.d85.s9.p2	Naproxen	drug	_	beta-blockers	group	_	effect	druga and other drugn can reduce the antihypertensive effect of drugn and other drugb .
DDI-DrugBank.d85.s9.p3	NSAIDs	group	_	propranolol	drug	_	effect	drugn and other druga can reduce the antihypertensive effect of drugb and other drugn .
DDI-DrugBank.d85.s9.p4	NSAIDs	group	_	beta-blockers	group	_	effect	drugn and other druga can reduce the antihypertensive effect of drugn and other drugb .
DDI-DrugBank.d85.s9.p5	propranolol	drug	_	beta-blockers	group	_	false	drugn and other drugn can reduce the antihypertensive effect of druga and other drugb .
DDI-DrugBank.d85.s10.p0	Probenecid	drug	_	naproxen	drug	_	mechanism	druga given concurrently increases drugb anion plasma levels and extends its plasma half-life significantly .
DDI-DrugBank.d85.s11.p0	naproxen	drug	_	methotrexate	drug	_	advise	caution should be used if druga is administered concomitantly with drugb .
DDI-DrugBank.d85.s12.p2	Naproxen	drug	_	methotrexate	drug	_	mechanism	druga , drugn and other drugn have been reported to reduce the tubular secretion of drugb in an animal model , possibly increasing the toxicity of drugn .
DDI-DrugBank.d85.s12.p3	Naproxen	drug	_	methotrexate	drug	_	false	druga , drugn and other drugn have been reported to reduce the tubular secretion of drugn in an animal model , possibly increasing the toxicity of drugb .
DDI-DrugBank.d85.s12.p5	naproxen sodium	drug	_	methotrexate	drug	_	mechanism	drugn , druga and other drugn have been reported to reduce the tubular secretion of drugb in an animal model , possibly increasing the toxicity of drugn .
DDI-DrugBank.d85.s12.p6	naproxen sodium	drug	_	methotrexate	drug	_	false	drugn , druga and other drugn have been reported to reduce the tubular secretion of drugn in an animal model , possibly increasing the toxicity of drugb .
DDI-DrugBank.d85.s12.p7	NSAIDs	group	_	methotrexate	drug	_	mechanism	drugn , drugn and other druga have been reported to reduce the tubular secretion of drugb in an animal model , possibly increasing the toxicity of drugn .
DDI-DrugBank.d85.s12.p8	NSAIDs	group	_	methotrexate	drug	_	false	drugn , drugn and other druga have been reported to reduce the tubular secretion of drugn in an animal model , possibly increasing the toxicity of drugb .
DDI-DrugBank.d478.s1.p0	ergotamine	drug	_	ergot-type medications	group	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugb -lcb- like drugn or drugn -rcb- and drugn within # hours is contraindicated .
DDI-DrugBank.d478.s1.p2	ergotamine	drug	_	methysergide	drug	_	false	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugb -rcb- and drugn within # hours is contraindicated .
DDI-DrugBank.d478.s1.p3	ergotamine	drug	_	naratriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of druga - containing or drugn -lcb- like drugn or drugn -rcb- and drugb within # hours is contraindicated .
DDI-DrugBank.d478.s1.p6	ergot-type medications	group	_	naratriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or druga -lcb- like drugn or drugn -rcb- and drugb within # hours is contraindicated .
DDI-DrugBank.d478.s1.p8	dihydroergotamine	drug	_	naratriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like druga or drugn -rcb- and drugb within # hours is contraindicated .
DDI-DrugBank.d478.s1.p9	methysergide	drug	_	naratriptan	drug	_	advise	because there is a theoretical basis that these effects may be additive , use of drugn - containing or drugn -lcb- like drugn or druga -rcb- and drugb within # hours is contraindicated .
DDI-DrugBank.d478.s2.p0	naratriptan	drug	_	5-HT1 agonists	group	_	false	the administration of druga with other drugb has not been evaluated in migraine patients .
DDI-DrugBank.d478.s3.p0	naratriptan	drug	_	5-HT1 agonists	group	_	advise	because their vasospastic effects may be additive , coadministration of druga and other drugb within # hours of each other is not recommended .
DDI-DrugBank.d478.s5.p0	naratriptan	drug	_	SSRI	group	_	advise	if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d232.s0.p0	interferon beta-1a	drug	_	AVONEX	brand	_	false	after multiple dosing , druga -lcb- drugb # mcg im once weekly -rcb- reduced drugn clearance by approximately 30 % .
DDI-DrugBank.d232.s0.p1	interferon beta-1a	drug	_	TYSABRI	brand	_	mechanism	after multiple dosing , druga -lcb- drugn # mcg im once weekly -rcb- reduced drugb clearance by approximately 30 % .
DDI-DrugBank.d232.s0.p2	AVONEX	brand	_	TYSABRI	brand	_	mechanism	after multiple dosing , drugn -lcb- druga # mcg im once weekly -rcb- reduced drugb clearance by approximately 30 % .
DDI-DrugBank.d232.s1.p0	TYSABRI	brand	_	AVONEX	brand	_	false	the similarity of the druga - associated adverse event profile between study # -lcb- without co-administered drugb -rcb- and study # -lcb- with co-administered drugn -rcb- indicates that this alteration in clearance does not necessitate reduction of the drugn dose to maintain safety , general -rcb- .
DDI-DrugBank.d232.s1.p1	TYSABRI	brand	_	AVONEX	brand	_	false	the similarity of the druga - associated adverse event profile between study # -lcb- without co-administered drugn -rcb- and study # -lcb- with co-administered drugb -rcb- indicates that this alteration in clearance does not necessitate reduction of the drugn dose to maintain safety , general -rcb- .
DDI-DrugBank.d232.s1.p4	AVONEX	brand	_	TYSABRI	brand	_	false	the similarity of the drugn - associated adverse event profile between study # -lcb- without co-administered druga -rcb- and study # -lcb- with co-administered drugn -rcb- indicates that this alteration in clearance does not necessitate reduction of the drugb dose to maintain safety , general -rcb- .
DDI-DrugBank.d232.s1.p5	AVONEX	brand	_	TYSABRI	brand	_	false	the similarity of the drugn - associated adverse event profile between study # -lcb- without co-administered drugn -rcb- and study # -lcb- with co-administered druga -rcb- indicates that this alteration in clearance does not necessitate reduction of the drugb dose to maintain safety , general -rcb- .
DDI-DrugBank.d232.s2.p1	TYSABRI	brand	_	AVONEX	brand	_	false	results of studies in multiple sclerosis patients taking druga and concomitant drugn -lcb- drugb # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugn or drugn .
DDI-DrugBank.d232.s2.p3	TYSABRI	brand	_	beta-interferon	drug	_	false	results of studies in multiple sclerosis patients taking druga and concomitant drugn -lcb- drugn # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugb or drugn .
DDI-DrugBank.d232.s2.p4	TYSABRI	brand	_	glatiramer acetate	drug	_	false	results of studies in multiple sclerosis patients taking druga and concomitant drugn -lcb- drugn # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugn or drugb .
DDI-DrugBank.d232.s2.p5	interferon beta-1a	drug	_	AVONEX	brand	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant druga -lcb- drugb # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugn or drugn .
DDI-DrugBank.d232.s2.p7	interferon beta-1a	drug	_	beta-interferon	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant druga -lcb- drugn # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugb or drugn .
DDI-DrugBank.d232.s2.p8	interferon beta-1a	drug	_	glatiramer acetate	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant druga -lcb- drugn # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugn or drugb .
DDI-DrugBank.d232.s2.p9	AVONEX	brand	_	glatiramer acetate	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant drugn -lcb- druga # mcg im once weekly -rcb- or drugb were inconclusive with regard to the need for dose adjustment of the drugn or drugn .
DDI-DrugBank.d232.s2.p10	AVONEX	brand	_	beta-interferon	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant drugn -lcb- druga # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugb or drugn .
DDI-DrugBank.d232.s2.p11	AVONEX	brand	_	glatiramer acetate	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant drugn -lcb- druga # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the drugn or drugb .
DDI-DrugBank.d232.s2.p12	glatiramer acetate	drug	_	beta-interferon	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant drugn -lcb- drugn # mcg im once weekly -rcb- or druga were inconclusive with regard to the need for dose adjustment of the drugb or drugn .
DDI-DrugBank.d232.s2.p14	beta-interferon	drug	_	glatiramer acetate	drug	_	false	results of studies in multiple sclerosis patients taking drugn and concomitant drugn -lcb- drugn # mcg im once weekly -rcb- or drugn were inconclusive with regard to the need for dose adjustment of the druga or drugb .
DDI-DrugBank.d460.s1.p0	Starlix	brand	_	tolbutamide	drug	_	mechanism	druga is a potential inhibitor of the cyp2c9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of drugb .
DDI-DrugBank.d460.s3.p0	Glyburide	drug	_	Starlix	brand	_	false	druga : in a randomized , multiple-dose crossover study , patients with type # diabetes were administered # mg drugb three times a day before meals for # day in combination with drugn # mg daily .
DDI-DrugBank.d460.s3.p2	Starlix	brand	_	glyburide	drug	_	false	drugn : in a randomized , multiple-dose crossover study , patients with type # diabetes were administered # mg druga three times a day before meals for # day in combination with drugb # mg daily .
DDI-DrugBank.d460.s5.p2	Starlix	brand	_	metformin	drug	_	false	drugn : when druga # mg three times daily before meals was administered in combination with drugb # mg three times daily to patients with type # diabetes , there were no clinically relevant changes in the pharmacokinetics of either agent .
DDI-DrugBank.d460.s6.p2	Starlix	brand	_	digoxin	drug	_	false	drugn : when druga # mg before meals was administered in combination with a single 1-mg dose of drugb to healthy volunteers , there were no clinically relevant changes in the pharmacokinetics of either agent .
DDI-DrugBank.d460.s7.p2	Starlix	brand	_	warfarin	drug	_	false	drugn : when healthy subjects were administered druga # mg three times daily before meals for four days in combination with a single dose of drugb # mg on day 2 , there were no alterations in the pharmacokinetics of either agent .
DDI-DrugBank.d460.s9.p0	Diclofenac	drug	_	Starlix	brand	_	false	druga : administration of morning and lunch doses of drugb # mg in combination with a single 75-mg dose of drugn in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent .
DDI-DrugBank.d460.s9.p2	Starlix	brand	_	diclofenac	drug	_	false	drugn : administration of morning and lunch doses of druga # mg in combination with a single 75-mg dose of drugb in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent .
DDI-DrugBank.d460.s11.p10	furosemide	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p20	propranolol	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p29	captopril	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p37	nicardipine	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p44	pravastatin	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p50	glyburide	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p55	warfarin	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p59	phenytoin	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p62	acetylsalicylic acid	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p64	tolbutamide	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s11.p65	metformin	drug	_	nateglinide	drug	_	false	in vitro displacement studies with highly protein-bound drugs such as drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga showed no influence on the extent of drugb protein binding .
DDI-DrugBank.d460.s12.p0	nateglinide	drug	_	propranolol	drug	_	false	similarly , druga had no influence on the serum protein binding of drugb , drugn , drugn , drugn , drugn , drugn , and drugn in vitro .
DDI-DrugBank.d460.s12.p1	nateglinide	drug	_	glyburide	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugb , drugn , drugn , drugn , drugn , and drugn in vitro .
DDI-DrugBank.d460.s12.p2	nateglinide	drug	_	nicardipine	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugn , drugb , drugn , drugn , drugn , and drugn in vitro .
DDI-DrugBank.d460.s12.p3	nateglinide	drug	_	warfarin	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugn , drugn , drugb , drugn , drugn , and drugn in vitro .
DDI-DrugBank.d460.s12.p4	nateglinide	drug	_	phenytoin	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugn , drugn , drugn , drugb , drugn , and drugn in vitro .
DDI-DrugBank.d460.s12.p5	nateglinide	drug	_	acetylsalicylic acid	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugn , drugn , drugn , drugn , drugb , and drugn in vitro .
DDI-DrugBank.d460.s12.p6	nateglinide	drug	_	tolbutamide	drug	_	false	similarly , druga had no influence on the serum protein binding of drugn , drugn , drugn , drugn , drugn , drugn , and drugb in vitro .
DDI-DrugBank.d460.s14.p4	nonsteroidal anti-inflammatory agents	group	_	Starlix	brand	_	effect	certain drugs , including druga -lcb- drugn -rcb- , drugn , drugn , and drugn may potentiate the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s14.p5	nonsteroidal anti-inflammatory agents	group	_	antidiabetic drugs	group	_	effect	certain drugs , including druga -lcb- drugn -rcb- , drugn , drugn , and drugn may potentiate the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s14.p9	NSAIDs	group	_	Starlix	brand	_	effect	certain drugs , including drugn -lcb- druga -rcb- , drugn , drugn , and drugn may potentiate the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s14.p10	NSAIDs	group	_	antidiabetic drugs	group	_	effect	certain drugs , including drugn -lcb- druga -rcb- , drugn , drugn , and drugn may potentiate the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s14.p13	salicylates	group	_	Starlix	brand	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , druga , drugn , and drugn may potentiate the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s14.p14	salicylates	group	_	antidiabetic drugs	group	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , druga , drugn , and drugn may potentiate the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s14.p16	monoamine oxidase inhibitors	group	_	Starlix	brand	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , drugn , druga , and drugn may potentiate the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s14.p17	monoamine oxidase inhibitors	group	_	antidiabetic drugs	group	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , drugn , druga , and drugn may potentiate the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s14.p18	non-selective beta-adrenergic-blocking agents	group	_	Starlix	brand	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , drugn , drugn , and druga may potentiate the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s14.p19	non-selective beta-adrenergic-blocking agents	group	_	antidiabetic drugs	group	_	effect	certain drugs , including drugn -lcb- drugn -rcb- , drugn , drugn , and druga may potentiate the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s14.p20	Starlix	brand	_	antidiabetic drugs	group	_	false	certain drugs , including drugn -lcb- drugn -rcb- , drugn , drugn , and drugn may potentiate the hypoglycemic action of druga and other oral drugb .
DDI-DrugBank.d460.s15.p3	thiazides	group	_	Starlix	brand	_	effect	certain drugs including druga , drugn , drugn , and drugn may reduce the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s15.p4	thiazides	group	_	antidiabetic drugs	group	_	effect	certain drugs including druga , drugn , drugn , and drugn may reduce the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s15.p7	corticosteroids	group	_	Starlix	brand	_	effect	certain drugs including drugn , druga , drugn , and drugn may reduce the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s15.p8	corticosteroids	group	_	antidiabetic drugs	group	_	effect	certain drugs including drugn , druga , drugn , and drugn may reduce the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s15.p10	thyroid products	group	_	Starlix	brand	_	effect	certain drugs including drugn , drugn , druga , and drugn may reduce the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s15.p11	thyroid products	group	_	antidiabetic drugs	group	_	effect	certain drugs including drugn , drugn , druga , and drugn may reduce the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s15.p12	sympathomimetics	group	_	Starlix	brand	_	effect	certain drugs including drugn , drugn , drugn , and druga may reduce the hypoglycemic action of drugb and other oral drugn .
DDI-DrugBank.d460.s15.p13	sympathomimetics	group	_	antidiabetic drugs	group	_	effect	certain drugs including drugn , drugn , drugn , and druga may reduce the hypoglycemic action of drugn and other oral drugb .
DDI-DrugBank.d460.s15.p14	Starlix	brand	_	antidiabetic drugs	group	_	false	certain drugs including drugn , drugn , drugn , and drugn may reduce the hypoglycemic action of druga and other oral drugb .
DDI-DrugBank.d61.s0.p0	Tilade	brand	_	bronchodilators	group	_	false	in clinical studies , druga has been co-administered with other anti-asthma medications , including inhaled and oral drugb , and inhaled drugn , with no evidence of increased frequency of adverse events or laboratory abnormalities .
DDI-DrugBank.d61.s0.p1	Tilade	brand	_	corticosteroids	group	_	false	in clinical studies , druga has been co-administered with other anti-asthma medications , including inhaled and oral drugn , and inhaled drugb , with no evidence of increased frequency of adverse events or laboratory abnormalities .
DDI-DrugBank.d61.s0.p2	bronchodilators	group	_	corticosteroids	group	_	false	in clinical studies , drugn has been co-administered with other anti-asthma medications , including inhaled and oral druga , and inhaled drugb , with no evidence of increased frequency of adverse events or laboratory abnormalities .
DDI-DrugBank.d340.s1.p0	VIRACEPT	brand	_	dihydropyridine calcium channel blockers	group	_	false	coadministration of druga and drugs primarily metabolized by cytochrome_p450_family_3_subfamily_a -lcb- e , g , , drugb -rcb- may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects .
DDI-DrugBank.d340.s3.p0	VIRACEPT	brand	_	nelfinavir	drug	_	false	coadministration of druga and drugs that induce cytochrome_p450_family_3_subfamily_a may decrease drugb plasma concentrations and reduce its therapeutic effect .
DDI-DrugBank.d340.s4.p0	VIRACEPT	brand	_	nelfinavir	drug	_	false	coadministration of druga and drugs that inhibit cytochrome_p450_family_3_subfamily_a may increase drugb plasma concentrations .
DDI-DrugBank.d340.s6.p0	VIRACEPT	brand	_	Antiarrhythmics	group	_	advise	drugs that should not be coadministered with druga drugb : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p1	VIRACEPT	brand	_	amiodarone	drug	_	advise	drugs that should not be coadministered with druga drugn : drugb , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p2	VIRACEPT	brand	_	quinidine	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugb drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p3	VIRACEPT	brand	_	Antihistamines	group	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugb : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p4	VIRACEPT	brand	_	astemizole	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugb , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p5	VIRACEPT	brand	_	terfenadine	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p6	VIRACEPT	brand	_	ergot derivatives	group	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p7	VIRACEPT	brand	_	Antimycobacterial agents	group	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p8	VIRACEPT	brand	_	rifampin	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p9	VIRACEPT	brand	_	Benzodiazepines	group	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p10	VIRACEPT	brand	_	midazolam	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p11	VIRACEPT	brand	_	triazolam	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p12	VIRACEPT	brand	_	cisapride	drug	_	advise	drugs that should not be coadministered with druga drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p13	Antiarrhythmics	group	_	amiodarone	drug	_	false	drugs that should not be coadministered with drugn druga : drugb , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p14	Antiarrhythmics	group	_	quinidine	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugb drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p15	Antiarrhythmics	group	_	Antihistamines	group	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugb : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p16	Antiarrhythmics	group	_	astemizole	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugb , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p17	Antiarrhythmics	group	_	terfenadine	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p18	Antiarrhythmics	group	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p19	Antiarrhythmics	group	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p20	Antiarrhythmics	group	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p21	Antiarrhythmics	group	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p22	Antiarrhythmics	group	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p23	Antiarrhythmics	group	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p24	Antiarrhythmics	group	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn druga : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p25	amiodarone	drug	_	quinidine	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugb drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p26	amiodarone	drug	_	Antihistamines	group	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugb : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p27	amiodarone	drug	_	astemizole	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugb , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p28	amiodarone	drug	_	terfenadine	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p29	amiodarone	drug	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p30	amiodarone	drug	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p31	amiodarone	drug	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p32	amiodarone	drug	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p33	amiodarone	drug	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p34	amiodarone	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p35	amiodarone	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : druga , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p36	quinidine	drug	_	Antihistamines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugb : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p37	quinidine	drug	_	astemizole	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugb , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p38	quinidine	drug	_	terfenadine	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p39	quinidine	drug	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p40	quinidine	drug	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p41	quinidine	drug	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p42	quinidine	drug	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p43	quinidine	drug	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p44	quinidine	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p45	quinidine	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , druga drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p46	Antihistamines	group	_	astemizole	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugb , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p47	Antihistamines	group	_	terfenadine	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p48	Antihistamines	group	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p49	Antihistamines	group	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p50	Antihistamines	group	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p51	Antihistamines	group	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p52	Antihistamines	group	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p53	Antihistamines	group	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p54	Antihistamines	group	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn druga : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p55	astemizole	drug	_	terfenadine	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugb antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p56	astemizole	drug	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p57	astemizole	drug	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p58	astemizole	drug	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p59	astemizole	drug	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p60	astemizole	drug	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p61	astemizole	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p62	astemizole	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : druga , drugn antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p63	terfenadine	drug	_	ergot derivatives	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugb drugn : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p64	terfenadine	drug	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p65	terfenadine	drug	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p66	terfenadine	drug	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p67	terfenadine	drug	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p68	terfenadine	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p69	terfenadine	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , druga antimigraine : drugn drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p70	ergot derivatives	group	_	Antimycobacterial agents	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugb : drugn drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p71	ergot derivatives	group	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugn : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p72	ergot derivatives	group	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugn : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p73	ergot derivatives	group	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugn : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p74	ergot derivatives	group	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugn : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p75	ergot derivatives	group	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : druga drugn : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p76	Antimycobacterial agents	group	_	rifampin	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn druga : drugb drugn drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p77	Antimycobacterial agents	group	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn druga : drugn drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p78	Antimycobacterial agents	group	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn druga : drugn drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p79	Antimycobacterial agents	group	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn druga : drugn drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p80	Antimycobacterial agents	group	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn druga : drugn drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p81	rifampin	drug	_	Benzodiazepines	group	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : druga drugb drugn , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p82	rifampin	drug	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : druga drugn drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p83	rifampin	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : druga drugn drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p84	rifampin	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : druga drugn drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p85	Benzodiazepines	group	_	midazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn druga drugb , drugn gi motility agents : drugn
DDI-DrugBank.d340.s6.p86	Benzodiazepines	group	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn druga drugn , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p87	Benzodiazepines	group	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn druga drugn , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p88	midazolam	drug	_	triazolam	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn druga , drugb gi motility agents : drugn
DDI-DrugBank.d340.s6.p89	midazolam	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn druga , drugn gi motility agents : drugb
DDI-DrugBank.d340.s6.p90	triazolam	drug	_	cisapride	drug	_	false	drugs that should not be coadministered with drugn drugn : drugn , drugn drugn : drugn , drugn antimigraine : drugn drugn : drugn drugn drugn , druga gi motility agents : drugb
DDI-DrugBank.d340.s7.p0	VIRACEPT	brand	_	Antimycobacterial agents	group	_	advise	drugs which require a dose reduction when coadminstered with druga drugb : drugn
DDI-DrugBank.d340.s7.p1	VIRACEPT	brand	_	rifabutin	drug	_	advise	drugs which require a dose reduction when coadminstered with druga drugn : drugb
DDI-DrugBank.d340.s7.p2	Antimycobacterial agents	group	_	rifabutin	drug	_	false	drugs which require a dose reduction when coadminstered with drugn druga : drugb
DDI-DrugBank.d340.s8.p0	VIRACEPT	brand	_	nelfinavir	drug	_	false	* this table is not all inclusive ** druga may not be effective due to decreased drugb plasma concentrations in patients taking these agents concomitantly
DDI-DrugBank.d340.s10.p1	Terfenadine	drug	_	VIRACEPT	brand	_	false	druga : administration of drugn with drugb resulted in the appearance of unchanged drugn in plasma ;
DDI-DrugBank.d340.s10.p3	terfenadine	drug	_	VIRACEPT	brand	_	false	drugn : administration of druga with drugb resulted in the appearance of unchanged drugn in plasma ;
DDI-DrugBank.d340.s10.p5	VIRACEPT	brand	_	terfenadine	drug	_	false	drugn : administration of drugn with druga resulted in the appearance of unchanged drugb in plasma ;
DDI-DrugBank.d340.s11.p0	VIRACEPT	brand	_	terfenadine	drug	_	advise	therefore , druga should not be administered concurrently with drugb because of the potential for serious and/or life-threatening cardiac arrhythmias .
DDI-DrugBank.d340.s12.p0	VIRACEPT	brand	_	astemizole	drug	_	advise	because a similar interaction is likely , druga should also not be administered concurrently with drugb .
DDI-DrugBank.d340.s14.p1	Indinavir	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn with drugb resulted in an 83 % increase in drugn plasma auc and a 51 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s14.p2	Indinavir	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn with drugn resulted in an 83 % increase in drugb plasma auc and a 51 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s14.p4	indinavir	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga with drugb resulted in an 83 % increase in drugn plasma auc and a 51 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s14.p5	indinavir	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga with drugn resulted in an 83 % increase in drugb plasma auc and a 51 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s14.p7	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn with druga resulted in an 83 % increase in drugb plasma auc and a 51 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s14.p8	VIRACEPT	brand	_	indinavir	drug	_	false	drugn : coadministration of drugn with druga resulted in an 83 % increase in drugn plasma auc and a 51 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s14.p9	nelfinavir	drug	_	indinavir	drug	_	false	drugn : coadministration of drugn with drugn resulted in an 83 % increase in druga plasma auc and a 51 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s16.p1	Ritonavir	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn with drugb resulted in a 152 % increase in drugn plasma auc and very little change in drugn plasma a , c.
DDI-DrugBank.d340.s16.p2	Ritonavir	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn with drugn resulted in a 152 % increase in drugb plasma auc and very little change in drugn plasma a , c.
DDI-DrugBank.d340.s16.p4	ritonavir	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga with drugb resulted in a 152 % increase in drugn plasma auc and very little change in drugn plasma a , c.
DDI-DrugBank.d340.s16.p5	ritonavir	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga with drugn resulted in a 152 % increase in drugb plasma auc and very little change in drugn plasma a , c.
DDI-DrugBank.d340.s16.p7	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn with druga resulted in a 152 % increase in drugb plasma auc and very little change in drugn plasma a , c.
DDI-DrugBank.d340.s16.p8	VIRACEPT	brand	_	ritonavir	drug	_	false	drugn : coadministration of drugn with druga resulted in a 152 % increase in drugn plasma auc and very little change in drugb plasma a , c.
DDI-DrugBank.d340.s16.p9	nelfinavir	drug	_	ritonavir	drug	_	false	drugn : coadministration of drugn with drugn resulted in a 152 % increase in druga plasma auc and very little change in drugb plasma a , c.
DDI-DrugBank.d340.s18.p2	Saquinavir	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with drugb resulted in an 18 % increase in drugn plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p3	Saquinavir	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with drugn resulted in an 18 % increase in drugb plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p6	saquinavir	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with drugb resulted in an 18 % increase in drugn plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p7	saquinavir	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with drugn resulted in an 18 % increase in drugb plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p9	saquinavir	drug	_	VIRACEPT	brand	_	false	drugn : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of druga 1200mg -rcb- with drugb resulted in an 18 % increase in drugn plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p10	saquinavir	drug	_	nelfinavir	drug	_	false	drugn : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of druga 1200mg -rcb- with drugn resulted in an 18 % increase in drugb plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p12	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with druga resulted in an 18 % increase in drugb plasma auc and a 4-fold increase in drugn plasma a , c.
DDI-DrugBank.d340.s18.p13	VIRACEPT	brand	_	saquinavir	drug	_	false	drugn : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with druga resulted in an 18 % increase in drugn plasma auc and a 4-fold increase in drugb plasma a , c.
DDI-DrugBank.d340.s18.p14	nelfinavir	drug	_	saquinavir	drug	_	false	drugn : coadministration of drugn -lcb- using an experimental soft-gelatin capsule formulation of drugn 1200mg -rcb- with drugn resulted in an 18 % increase in druga plasma auc and a 4-fold increase in drugb plasma a , c.
DDI-DrugBank.d340.s22.p1	Ketoconazole	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn with drugb resulted in a 35 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s22.p2	Ketoconazole	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn with drugn resulted in a 35 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s22.p3	ketoconazole	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga with drugb resulted in a 35 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s22.p4	ketoconazole	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga with drugn resulted in a 35 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s22.p5	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn with druga resulted in a 35 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s23.p0	ketoconazole	drug	_	VIRACEPT	brand	_	false	this change was not considered clinically significant and no dose adjustment is needed when druga and drugb are coadministered .
DDI-DrugBank.d340.s26.p0	nelfinavir	drug	_	didanosine	drug	_	advise	therefore , druga should be administered -lcb- with food -rcb- one hour after or more than two hours before drugb .
DDI-DrugBank.d340.s27.p0	zidovudine	drug	_	VIRACEPT	brand	_	advise	a dose adjustment is not needed when druga is administered with drugb .
DDI-DrugBank.d340.s28.p0	VIRACEPT	brand	_	lamivudine	drug	_	false	little or no change in the pharmacokinetics of either drug was observed when druga was coadministered with drugb or drugn .
DDI-DrugBank.d340.s28.p1	VIRACEPT	brand	_	stavudine	drug	_	false	little or no change in the pharmacokinetics of either drug was observed when druga was coadministered with drugn or drugb .
DDI-DrugBank.d340.s28.p2	lamivudine	drug	_	stavudine	drug	_	false	little or no change in the pharmacokinetics of either drug was observed when drugn was coadministered with druga or drugb .
DDI-DrugBank.d340.s30.p1	Rifabutin	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn and drugb resulted in a 32 % decrease in drugn plasma auc and a 207 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s30.p2	Rifabutin	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn and drugn resulted in a 32 % decrease in drugb plasma auc and a 207 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s30.p4	rifabutin	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga and drugb resulted in a 32 % decrease in drugn plasma auc and a 207 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s30.p5	rifabutin	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga and drugn resulted in a 32 % decrease in drugb plasma auc and a 207 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s30.p7	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn and druga resulted in a 32 % decrease in drugb plasma auc and a 207 % increase in drugn plasma a , c.
DDI-DrugBank.d340.s30.p8	VIRACEPT	brand	_	rifabutin	drug	_	false	drugn : coadministration of drugn and druga resulted in a 32 % decrease in drugn plasma auc and a 207 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s30.p9	nelfinavir	drug	_	rifabutin	drug	_	false	drugn : coadministration of drugn and drugn resulted in a 32 % decrease in druga plasma auc and a 207 % increase in drugb plasma a , c.
DDI-DrugBank.d340.s31.p0	rifabutin	drug	_	VIRACEPT	brand	_	advise	it is recommended that the dose of druga be reduced to one-half the usual dose when administered with drugb .
DDI-DrugBank.d340.s32.p1	Rifampin	drug	_	VIRACEPT	brand	_	false	druga : coadministration of drugn and drugb resulted in an 82 % decrease in drugn plasma a , c.
DDI-DrugBank.d340.s32.p2	Rifampin	drug	_	nelfinavir	drug	_	false	druga : coadministration of drugn and drugn resulted in an 82 % decrease in drugb plasma a , c.
DDI-DrugBank.d340.s32.p3	rifampin	drug	_	VIRACEPT	brand	_	mechanism	drugn : coadministration of druga and drugb resulted in an 82 % decrease in drugn plasma a , c.
DDI-DrugBank.d340.s32.p4	rifampin	drug	_	nelfinavir	drug	_	false	drugn : coadministration of druga and drugn resulted in an 82 % decrease in drugb plasma a , c.
DDI-DrugBank.d340.s32.p5	VIRACEPT	brand	_	nelfinavir	drug	_	false	drugn : coadministration of drugn and druga resulted in an 82 % decrease in drugb plasma a , c.
DDI-DrugBank.d340.s33.p0	VIRACEPT	brand	_	rifampin	drug	_	advise	druga and drugb should not be coadministered .
DDI-DrugBank.d340.s35.p0	Ethinyl Estradiol	drug	_	Norethindrone	drug	_	false	druga and drugb : coadministration of drugn with drugn resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p1	Ethinyl Estradiol	drug	_	VIRACEPT	brand	_	false	druga and drugn : coadministration of drugb with drugn resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p2	Ethinyl Estradiol	drug	_	OVCON-35	brand	_	false	druga and drugn : coadministration of drugn with drugb resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p4	Ethinyl Estradiol	drug	_	norethindrone	drug	_	false	druga and drugn : coadministration of drugn with drugn resulted in a 47 % decrease in drugn and an 18 % decrease in drugb plasma concentrations .
DDI-DrugBank.d340.s35.p5	Norethindrone	drug	_	VIRACEPT	brand	_	false	drugn and druga : coadministration of drugb with drugn resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p6	Norethindrone	drug	_	OVCON-35	brand	_	false	drugn and druga : coadministration of drugn with drugb resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p7	Norethindrone	drug	_	ethinyl estradiol	drug	_	false	drugn and druga : coadministration of drugn with drugn resulted in a 47 % decrease in drugb and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p9	VIRACEPT	brand	_	OVCON-35	brand	_	mechanism	drugn and drugn : coadministration of druga with drugb resulted in a 47 % decrease in drugn and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p10	VIRACEPT	brand	_	ethinyl estradiol	drug	_	false	drugn and drugn : coadministration of druga with drugn resulted in a 47 % decrease in drugb and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p11	VIRACEPT	brand	_	norethindrone	drug	_	false	drugn and drugn : coadministration of druga with drugn resulted in a 47 % decrease in drugn and an 18 % decrease in drugb plasma concentrations .
DDI-DrugBank.d340.s35.p12	OVCON-35	brand	_	ethinyl estradiol	drug	_	false	drugn and drugn : coadministration of drugn with druga resulted in a 47 % decrease in drugb and an 18 % decrease in drugn plasma concentrations .
DDI-DrugBank.d340.s35.p13	OVCON-35	brand	_	norethindrone	drug	_	false	drugn and drugn : coadministration of drugn with druga resulted in a 47 % decrease in drugn and an 18 % decrease in drugb plasma concentrations .
DDI-DrugBank.d340.s35.p14	ethinyl estradiol	drug	_	norethindrone	drug	_	false	drugn and drugn : coadministration of drugn with drugn resulted in a 47 % decrease in druga and an 18 % decrease in drugb plasma concentrations .
DDI-DrugBank.d330.s1.p0	aminoglycosides	group	_	polymyxins	group	_	false	caution should also be taken in concurrent or serial use of other druga and drugb because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate drugn neuromuscular blocking effects .
DDI-DrugBank.d330.s1.p1	aminoglycosides	group	_	neomycin sulfate	drug	_	false	caution should also be taken in concurrent or serial use of other druga and drugn because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate drugb neuromuscular blocking effects .
DDI-DrugBank.d330.s1.p2	polymyxins	group	_	neomycin sulfate	drug	_	false	caution should also be taken in concurrent or serial use of other drugn and druga because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate drugb neuromuscular blocking effects .
DDI-DrugBank.d330.s2.p0	neomycin	drug	_	penicillin V	drug	_	mechanism	oral druga inhibits the gastrointestinal absorption of drugb , oral drugn , drugn and drugn .
DDI-DrugBank.d330.s2.p1	neomycin	drug	_	vitamin B-12	drug	_	mechanism	oral druga inhibits the gastrointestinal absorption of drugn , oral drugb , drugn and drugn .
DDI-DrugBank.d330.s2.p2	neomycin	drug	_	methotrexate	drug	_	mechanism	oral druga inhibits the gastrointestinal absorption of drugn , oral drugn , drugb and drugn .
DDI-DrugBank.d330.s2.p3	neomycin	drug	_	5-fluorouracil	drug	_	mechanism	oral druga inhibits the gastrointestinal absorption of drugn , oral drugn , drugn and drugb .
DDI-DrugBank.d330.s5.p0	neomycin sulfate	drug	_	coumarin	group	_	effect	oral druga may enhance the effect of drugb in drugn by decreasing vitamin k availability .
DDI-DrugBank.d330.s5.p1	neomycin sulfate	drug	_	anticoagulants	group	_	effect	oral druga may enhance the effect of drugn in drugb by decreasing vitamin k availability .
DDI-DrugBank.d330.s5.p2	coumarin	group	_	anticoagulants	group	_	false	oral drugn may enhance the effect of druga in drugb by decreasing vitamin k availability .
DDI-DrugBank.d498.s1.p0	antibiotics	group	_	anticholinesterase	group	_	advise	these druga should be used in the myasthenic patient only where definitely indicated , and then careful adjustment should be made of adjunctive drugb dosage .
DDI-DrugBank.d239.s2.p0	Natrecor	brand	_	vasodilators	group	_	false	the co-administration of druga with iv drugb such as drugn , drugn , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p1	Natrecor	brand	_	nitroglycerin	drug	_	false	the co-administration of druga with iv drugn such as drugb , drugn , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p2	Natrecor	brand	_	nitroprusside	drug	_	false	the co-administration of druga with iv drugn such as drugn , drugb , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p3	Natrecor	brand	_	milrinone	drug	_	false	the co-administration of druga with iv drugn such as drugn , drugn , drugb , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p4	Natrecor	brand	_	ACE inhibitors	group	_	false	the co-administration of druga with iv drugn such as drugn , drugn , drugn , or iv drugb has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p6	vasodilators	group	_	nitroglycerin	drug	_	false	the co-administration of drugn with iv druga such as drugb , drugn , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p7	vasodilators	group	_	nitroprusside	drug	_	false	the co-administration of drugn with iv druga such as drugn , drugb , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p8	vasodilators	group	_	milrinone	drug	_	false	the co-administration of drugn with iv druga such as drugn , drugn , drugb , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p9	vasodilators	group	_	ACE inhibitors	group	_	false	the co-administration of drugn with iv druga such as drugn , drugn , drugn , or iv drugb has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p10	vasodilators	group	_	Natrecor	brand	_	false	the co-administration of drugn with iv druga such as drugn , drugn , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugb in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p13	nitroglycerin	drug	_	ACE inhibitors	group	_	false	the co-administration of drugn with iv drugn such as druga , drugn , drugn , or iv drugb has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p14	nitroglycerin	drug	_	Natrecor	brand	_	false	the co-administration of drugn with iv drugn such as druga , drugn , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugb in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p16	nitroprusside	drug	_	ACE inhibitors	group	_	false	the co-administration of drugn with iv drugn such as drugn , druga , drugn , or iv drugb has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p17	nitroprusside	drug	_	Natrecor	brand	_	false	the co-administration of drugn with iv drugn such as drugn , druga , drugn , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugb in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p18	milrinone	drug	_	ACE inhibitors	group	_	false	the co-administration of drugn with iv drugn such as drugn , drugn , druga , or iv drugb has not been evaluated -lcb- these drugs were not co-administered with drugn in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p19	milrinone	drug	_	Natrecor	brand	_	false	the co-administration of drugn with iv drugn such as drugn , drugn , druga , or iv drugn has not been evaluated -lcb- these drugs were not co-administered with drugb in clinical trials -rcb- .
DDI-DrugBank.d239.s2.p20	ACE inhibitors	group	_	Natrecor	brand	_	false	the co-administration of drugn with iv drugn such as drugn , drugn , drugn , or iv druga has not been evaluated -lcb- these drugs were not co-administered with drugb in clinical trials -rcb- .
DDI-DrugBank.d417.s0.p0	Netilmicin	drug	_	loop diuretics	group	_	advise	druga should not be administered concomitantly with potent drugb such as drugn and drugn as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d417.s0.p1	Netilmicin	drug	_	furosemide	drug	_	advise	druga should not be administered concomitantly with potent drugn such as drugb and drugn as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d417.s0.p2	Netilmicin	drug	_	ethacrynic acid	drug	_	advise	druga should not be administered concomitantly with potent drugn such as drugn and drugb as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d417.s0.p3	loop diuretics	group	_	furosemide	drug	_	false	drugn should not be administered concomitantly with potent druga such as drugb and drugn as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d417.s0.p4	loop diuretics	group	_	ethacrynic acid	drug	_	false	drugn should not be administered concomitantly with potent druga such as drugn and drugb as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d417.s0.p5	furosemide	drug	_	ethacrynic acid	drug	_	false	drugn should not be administered concomitantly with potent drugn such as druga and drugb as the potential for ototoxicity is enhanced by the combination .
DDI-DrugBank.d270.s9.p0	nevirapine	drug	_	antithrombotic agent	group	_	false	the in vitro interaction between druga and the drugb drugn is complex .
DDI-DrugBank.d270.s9.p1	nevirapine	drug	_	warfarin	drug	_	int	the in vitro interaction between druga and the drugn drugb is complex .
DDI-DrugBank.d270.s9.p2	antithrombotic agent	group	_	warfarin	drug	_	false	the in vitro interaction between drugn and the druga drugb is complex .
DDI-DrugBank.d270.s11.p0	warfarin	drug	_	nevirapine	drug	_	advise	when druga is co-administered with drugb , anticoagulation levels should be monitored frequently .
DDI-DrugBank.d270.s18.p0	Clarithromycin	drug	_	nevirapine	drug	_	mechanism	druga exposure was significantly decreased by drugb ;
DDI-DrugBank.d270.s20.p0	clarithromycin	drug	_	azithromycin	drug	_	false	alternatives to druga , such as drugb , should be considered .
DDI-DrugBank.d270.s24.p0	Ethinyl estradiol	drug	_	Norethindrone	drug	_	false	druga and drugb
DDI-DrugBank.d270.s25.p0	Ethinyl estradiol	drug	_	Norethindrone	drug	_	false	druga drugb
DDI-DrugBank.d270.s26.p0	contraceptives	group	_	nevirapine	drug	_	advise	oral druga and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking drugb , since nevirapinemay lower the plasma levels of thesemedications .
DDI-DrugBank.d270.s36.p0	Nevirapine	drug	_	ketoconazole	drug	_	advise	druga and drugb should not beadministered concomitantly becausedecreases in drugn plasmaconcentrations may reduce the efficacy of the drug .
DDI-DrugBank.d270.s36.p1	Nevirapine	drug	_	ketoconazole	drug	_	false	druga and drugn should not beadministered concomitantly becausedecreases in drugb plasmaconcentrations may reduce the efficacy of the drug .
DDI-DrugBank.d270.s37.p0	Lopinavir	drug	_	Ritonavir	drug	_	false	druga / drugb
DDI-DrugBank.d270.s39.p1	lopinavir	drug	_	nevirapine	drug	_	advise	a dose increase of druga / drugn to 533/133 mg twice daily with food isrecommended in combination with drugb .
DDI-DrugBank.d270.s39.p2	ritonavir	drug	_	nevirapine	drug	_	advise	a dose increase of drugn / druga to 533/133 mg twice daily with food isrecommended in combination with drugb .
DDI-DrugBank.d270.s42.p0	Methadone	drug	_	opiate	group	_	false	druga levels may be decreased ; increased dosages may be required to prevent symptoms of drugb withdrawal , drugn maintained patients beginning drugn therapy should be monitored forevidence of withdrawal and drugn dose should be adjusted accordingly .
DDI-DrugBank.d270.s42.p7	Methadone	drug	_	nevirapine	drug	_	advise	drugn levels may be decreased ; increased dosages may be required to prevent symptoms of drugn withdrawal , druga maintained patients beginning drugb therapy should be monitored forevidence of withdrawal and drugn dose should be adjusted accordingly .
DDI-DrugBank.d270.s42.p9	nevirapine	drug	_	methadone	drug	_	false	drugn levels may be decreased ; increased dosages may be required to prevent symptoms of drugn withdrawal , drugn maintained patients beginning druga therapy should be monitored forevidence of withdrawal and drugb dose should be adjusted accordingly .
DDI-DrugBank.d270.s45.p0	nelfinavir	drug	_	nevirapine	drug	_	false	the appropriate dose for druga incombination with drugb , with respectto safety and efficacy , has not been established .
DDI-DrugBank.d270.s53.p0	Nevirapine	drug	_	rifampin	drug	_	advise	druga and drugb should not beadministered concomitantly becausedecreases in drugn plasmaconcentrations may reduce the efficacy ofthe drug .
DDI-DrugBank.d270.s53.p2	rifampin	drug	_	nevirapine	drug	_	false	drugn and druga should not beadministered concomitantly becausedecreases in drugb plasmaconcentrations may reduce the efficacy ofthe drug .
DDI-DrugBank.d270.s54.p0	nevirapine	drug	_	rifabutin	drug	_	false	physicians needing to treatpatients co-infected with tuberculosis andusing a druga containing regimen mayuse drugb instead .
DDI-DrugBank.d270.s58.p0	nevirapine	drug	_	methadone	drug	_	effect	abased on reports of narcotic withdrawal syndrome in patients treated with druga and drugb concurrently , and evidence of decreased plasma concentrations of drugn .
DDI-DrugBank.d270.s58.p1	nevirapine	drug	_	methadone	drug	_	false	abased on reports of narcotic withdrawal syndrome in patients treated with druga and drugn concurrently , and evidence of decreased plasma concentrations of drugb .
DDI-DrugBank.d270.s63.p0	Amiodarone	drug	_	disopyramide	drug	_	false	druga , drugb , drugn
DDI-DrugBank.d270.s63.p1	Amiodarone	drug	_	lidocaine	drug	_	false	druga , drugn , drugb
DDI-DrugBank.d270.s63.p2	disopyramide	drug	_	lidocaine	drug	_	false	drugn , druga , drugb
DDI-DrugBank.d270.s65.p0	Carbamazepine	drug	_	clonazepam	drug	_	false	druga , drugb , drugn
DDI-DrugBank.d270.s65.p1	Carbamazepine	drug	_	ethosuximide	drug	_	false	druga , drugn , drugb
DDI-DrugBank.d270.s65.p2	clonazepam	drug	_	ethosuximide	drug	_	false	drugn , druga , drugb
DDI-DrugBank.d270.s69.p0	Diltiazem	drug	_	nifedipine	drug	_	false	druga , drugb , drugn
DDI-DrugBank.d270.s69.p1	Diltiazem	drug	_	verapamil	drug	_	false	druga , drugn , drugb
DDI-DrugBank.d270.s69.p2	nifedipine	drug	_	verapamil	drug	_	false	drugn , druga , drugb
DDI-DrugBank.d270.s75.p0	Cyclosporin	drug	_	tacrolimus	drug	_	false	druga , drugb , drugn
DDI-DrugBank.d270.s75.p1	Cyclosporin	drug	_	sirolimus	drug	_	false	druga , drugn , drugb
DDI-DrugBank.d270.s75.p2	tacrolimus	drug	_	sirolimus	drug	_	false	drugn , druga , drugb
DDI-DrugBank.d542.s0.p1	Vitamin B3	drug	_	Antihypertensive	group	_	false	interactions for druga -lcb- drugn -rcb- : drugb therapy : drugn may potentiate the effects of drugn and vasoactive drugs resulting in postural hypotension .
DDI-DrugBank.d542.s0.p4	Niacin	drug	_	Antihypertensive	group	_	false	interactions for drugn -lcb- druga -rcb- : drugb therapy : drugn may potentiate the effects of drugn and vasoactive drugs resulting in postural hypotension .
DDI-DrugBank.d542.s0.p9	Nicotinic acid	drug	_	ganglionic blocking agents	group	_	effect	interactions for drugn -lcb- drugn -rcb- : drugn therapy : druga may potentiate the effects of drugb and vasoactive drugs resulting in postural hypotension .
DDI-DrugBank.d542.s1.p1	Aspirin	brand	_	nicotinic acid	drug	_	false	druga : concomitant drugn may decrease the metabolic clearance of drugb .
DDI-DrugBank.d542.s1.p2	aspirin	brand	_	nicotinic acid	drug	_	mechanism	drugn : concomitant druga may decrease the metabolic clearance of drugb .
DDI-DrugBank.d468.s0.p0	Beta-Blockers	group	_	adrenergic beta-receptor blockers	group	_	false	druga : in controlled clinical studies , drugb have been frequently administered concomitantly with drugn .
DDI-DrugBank.d468.s0.p1	Beta-Blockers	group	_	nicardipine HCl	drug	_	false	druga : in controlled clinical studies , drugn have been frequently administered concomitantly with drugb .
DDI-DrugBank.d468.s0.p2	adrenergic beta-receptor blockers	group	_	nicardipine HCl	drug	_	false	drugn : in controlled clinical studies , druga have been frequently administered concomitantly with drugb .
DDI-DrugBank.d468.s2.p2	Cimetidine	drug	_	nicardipine HCl	drug	_	mechanism	drugn : druga increases drugb plasma levels .
DDI-DrugBank.d468.s4.p2	calcium blockers	group	_	digitalis preparations	group	_	mechanism	drugn : some druga may increase the concentration of drugb in the blood .
DDI-DrugBank.d468.s5.p0	Nicardipine HCl	drug	_	digoxin	drug	_	false	druga usually does not alter the plasma levels of drugb , however , serum drugn levels should be evaluated after concomitant therapy with drugn is initiated .
DDI-DrugBank.d468.s5.p1	Nicardipine HCl	drug	_	digoxin	drug	_	false	druga usually does not alter the plasma levels of drugn , however , serum drugb levels should be evaluated after concomitant therapy with drugn is initiated .
DDI-DrugBank.d468.s5.p4	digoxin	drug	_	nicardipine HCl	drug	_	false	drugn usually does not alter the plasma levels of druga , however , serum drugn levels should be evaluated after concomitant therapy with drugb is initiated .
DDI-DrugBank.d468.s5.p5	digoxin	drug	_	nicardipine HCl	drug	_	advise	drugn usually does not alter the plasma levels of drugn , however , serum druga levels should be evaluated after concomitant therapy with drugb is initiated .
DDI-DrugBank.d468.s6.p1	Maalox	brand	_	nicardipine HCl	drug	_	false	druga * coadministration of drugn had no effect on drugb absorption .
DDI-DrugBank.d468.s6.p2	Maalox TC	brand	_	nicardipine HCl	drug	_	false	drugn * coadministration of druga had no effect on drugb absorption .
DDI-DrugBank.d468.s8.p0	Cyclosporine	drug	_	nicardipine	drug	_	false	druga : concomitant administration of drugb and drugn levels .
DDI-DrugBank.d468.s8.p2	nicardipine	drug	_	cyclosporine	drug	_	false	drugn : concomitant administration of druga and drugb levels .
DDI-DrugBank.d468.s9.p0	cyclosporine	drug	_	nicardipine	drug	_	advise	plasma concentrations of druga should therefore be closely monitored , and its dosage reduced accordingly , in patients treated with drugb .
DDI-DrugBank.d468.s10.p5	furosemide	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of druga , drugn , drugn , drugn , drugn , or drugn were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d468.s10.p10	propranolol	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of drugn , druga , drugn , drugn , drugn , or drugn were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d468.s10.p14	dipyridamole	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of drugn , drugn , druga , drugn , drugn , or drugn were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d468.s10.p17	warfarin	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of drugn , drugn , drugn , druga , drugn , or drugn were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d468.s10.p19	quinidine	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of drugn , drugn , drugn , drugn , druga , or drugn were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d468.s10.p20	naproxen	drug	_	nicardipine HCl	drug	_	false	when therapeutic concentrations of drugn , drugn , drugn , drugn , drugn , or druga were added to human plasma -lcb- in vitro -rcb- , the plasma protein binding of drugb was not altered .
DDI-DrugBank.d271.s0.p0	nicotine	drug	_	tricyclic antidepressants	group	_	false	physiological changes resulting from smoking cessation , with or without druga replacement , may alter the pharmacokinetics of certain concomitant medications , such as drugb and drugn .
DDI-DrugBank.d271.s0.p1	nicotine	drug	_	theophylline	drug	_	false	physiological changes resulting from smoking cessation , with or without druga replacement , may alter the pharmacokinetics of certain concomitant medications , such as drugn and drugb .
DDI-DrugBank.d271.s0.p2	tricyclic antidepressants	group	_	theophylline	drug	_	false	physiological changes resulting from smoking cessation , with or without drugn replacement , may alter the pharmacokinetics of certain concomitant medications , such as druga and drugb .
DDI-DrugBank.d373.s0.p0	Beta-adrenergic Blocking Agents	group	_	nifedipine	drug	_	false	druga : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of drugb and drugn is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .
DDI-DrugBank.d373.s0.p1	Beta-adrenergic Blocking Agents	group	_	beta-blocking agents	group	_	false	druga : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of drugn and drugb is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .
DDI-DrugBank.d373.s0.p2	nifedipine	drug	_	beta-blocking agents	group	_	effect	drugn : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of druga and drugb is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .
DDI-DrugBank.d373.s1.p2	Nifedipine	drug	_	nitrates	group	_	false	long acting drugn : druga may be safely co-administered with drugb , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination .
DDI-DrugBank.d373.s2.p6	digoxin	drug	_	nifedipine	drug	_	false	drugn : immediate release capsules : since there have been isolated reports of patients with elevated druga levels , and there is a possible interaction between drugn and drugb , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugn to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s2.p8	digoxin	drug	_	nifedipine	drug	_	false	drugn : immediate release capsules : since there have been isolated reports of patients with elevated druga levels , and there is a possible interaction between drugn and drugn , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugb to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s2.p9	digoxin	drug	_	nifedipine	drug	_	int	drugn : immediate release capsules : since there have been isolated reports of patients with elevated drugn levels , and there is a possible interaction between druga and drugb , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugn to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s2.p11	digoxin	drug	_	nifedipine	drug	_	false	drugn : immediate release capsules : since there have been isolated reports of patients with elevated drugn levels , and there is a possible interaction between druga and drugn , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugb to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s2.p12	nifedipine	drug	_	digoxin	drug	_	false	drugn : immediate release capsules : since there have been isolated reports of patients with elevated drugn levels , and there is a possible interaction between drugn and druga , it is recommended that drugb levels be monitored when initiating , adjusting , and discontinuing drugn to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s2.p14	digoxin	drug	_	nifedipine	drug	_	advise	drugn : immediate release capsules : since there have been isolated reports of patients with elevated drugn levels , and there is a possible interaction between drugn and drugn , it is recommended that druga levels be monitored when initiating , adjusting , and discontinuing drugb to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s3.p0	nifedipine	drug	_	digoxin	drug	_	false	extended release tablets : administration of druga with drugb increased drugn levels in # of # normal volunteers .
DDI-DrugBank.d373.s3.p1	nifedipine	drug	_	digoxin	drug	_	false	extended release tablets : administration of druga with drugn increased drugb levels in # of # normal volunteers .
DDI-DrugBank.d373.s7.p1	digoxin	drug	_	nifedipine	drug	_	false	since there have been isolated reports of patients with elevated druga levels , it is recommended that drugn levels be monitored when initiating , adjusting , and discontinuing drugb to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s7.p2	digoxin	drug	_	nifedipine	drug	_	advise	since there have been isolated reports of patients with elevated drugn levels , it is recommended that druga levels be monitored when initiating , adjusting , and discontinuing drugb to avoid possible over - or under-digitalization .
DDI-DrugBank.d373.s8.p3	quinidine	drug	_	nifedipine	drug	_	mechanism	drugn : immediate release capsules : there have been rare reports of an interaction between druga and drugb -lcb- with a decreased plasma level of drugn -rcb- .
DDI-DrugBank.d373.s8.p5	nifedipine	drug	_	quinidine	drug	_	false	drugn : immediate release capsules : there have been rare reports of an interaction between drugn and druga -lcb- with a decreased plasma level of drugb -rcb- .
DDI-DrugBank.d373.s9.p2	coumarin anticoagulants	group	_	nifedipine	drug	_	effect	drugn : there have been rare reports of increased prothrombin time in patients taking druga to whom drugb was administered .
DDI-DrugBank.d373.s11.p3	nifedipine	drug	_	cimetidine	drug	_	false	drugn : a study in # healthy volunteers has shown a significant increase in peak druga plasma levels -lcb- 80 % -rcb- and area-under-the-curve -lcb- 74 % -rcb- after a # week course of drugb at # mg per day and drugn at # mg per day .
DDI-DrugBank.d373.s11.p5	cimetidine	drug	_	nifedipine	drug	_	mechanism	drugn : a study in # healthy volunteers has shown a significant increase in peak drugn plasma levels -lcb- 80 % -rcb- and area-under-the-curve -lcb- 74 % -rcb- after a # week course of druga at # mg per day and drugb at # mg per day .
DDI-DrugBank.d373.s13.p0	cimetidine	drug	_	nifedipine	drug	_	false	the effect may be mediated by the known inhibition of druga on hepatic cytochrome p-450 , the enzyme system probably responsible for the first-pass metabolism of drugb .
DDI-DrugBank.d373.s14.p0	nifedipine	drug	_	cimetidine	drug	_	advise	if druga therapy is initiated in a patient currently receiving drugb , cautious titration is advised .
DDI-DrugBank.d177.s3.p0	vitamin K antagonists	group	_	nilutamide	drug	_	advise	for example , when druga are administered concomitantly with drugb , prothrombin time should be carefully monitored and if necessary , the dosage of drugn should be reduced .
DDI-DrugBank.d177.s3.p2	nilutamide	drug	_	vitamin K antagonists	group	_	false	for example , when drugn are administered concomitantly with druga , prothrombin time should be carefully monitored and if necessary , the dosage of drugb should be reduced .
DDI-DrugBank.d310.s0.p0	calcium channel blockers	group	_	Nimotop	brand	_	effect	it is possible that the cardiovascular action of other druga could be enhanced by the addition of drugb .
DDI-DrugBank.d310.s1.p0	Nimotop	brand	_	antihypertensive compounds	group	_	effect	in europe , druga was observed to occasionally intensify the effect of drugb taken concomitantly by patients suffering from hypertension ;
DDI-DrugBank.d310.s3.p0	nimodipine	drug	_	cimetidine	drug	_	false	a study in eight healthy volunteers has shown a 50 % increase in mean peak druga plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of drugb at 1,000 mg/day and drugn at # mg/day .
DDI-DrugBank.d310.s3.p2	cimetidine	drug	_	nimodipine	drug	_	mechanism	a study in eight healthy volunteers has shown a 50 % increase in mean peak drugn plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of druga at 1,000 mg/day and drugb at # mg/day .
DDI-DrugBank.d310.s4.p0	cimetidine	drug	_	nimodipine	drug	_	false	this effect may be mediated by the known inhibition of hepatic cytochrome p - # by druga , which could decrease first pass metabolism of drugb .
DDI-DrugBank.d106.s0.p0	nisoldipine	drug	_	cimetidine 400 mg	drug	_	mechanism	a # to 45 % increase in auc and cmax of druga was observed with concomitant administration of drugb twice daily .
DDI-DrugBank.d106.s1.p0	Ranitidine	drug	_	nisoldipine	drug	_	false	druga # mg twice daily did not interact significantly with drugb -lcb- auc was decreased by 15-20 % -rcb- .
DDI-DrugBank.d106.s3.p0	phenytoin	drug	_	SULAR	brand	_	mechanism	coadministration of druga with # mg drugb tablets in epileptic patients lowered the drugn plasma concentrations to undetectable levels .
DDI-DrugBank.d106.s3.p1	phenytoin	drug	_	nisoldipine	drug	_	false	coadministration of druga with # mg drugn tablets in epileptic patients lowered the drugb plasma concentrations to undetectable levels .
DDI-DrugBank.d106.s3.p2	SULAR	brand	_	nisoldipine	drug	_	false	coadministration of drugn with # mg druga tablets in epileptic patients lowered the drugb plasma concentrations to undetectable levels .
DDI-DrugBank.d106.s4.p0	SULAR	brand	_	phenytoin	drug	_	advise	coadministration of druga with drugb or any known cyp3a4 inducer should be avoided and alternative drugn therapy should be considered .
DDI-DrugBank.d106.s4.p1	SULAR	brand	_	antihypertensive	group	_	false	coadministration of druga with drugn or any known cyp3a4 inducer should be avoided and alternative drugb therapy should be considered .
DDI-DrugBank.d106.s4.p2	phenytoin	drug	_	antihypertensive	group	_	false	coadministration of drugn with druga or any known cyp3a4 inducer should be avoided and alternative drugb therapy should be considered .
DDI-DrugBank.d106.s5.p0	nisoldipine	drug	_	beta-blockers	group	_	false	pharmacokinetic interactions between druga and drugb -lcb- drugn , drugn -rcb- were variable and not significant .
DDI-DrugBank.d106.s5.p1	nisoldipine	drug	_	atenolol	drug	_	false	pharmacokinetic interactions between druga and drugn -lcb- drugb , drugn -rcb- were variable and not significant .
DDI-DrugBank.d106.s5.p2	nisoldipine	drug	_	propranolol	drug	_	false	pharmacokinetic interactions between druga and drugn -lcb- drugn , drugb -rcb- were variable and not significant .
DDI-DrugBank.d106.s6.p0	Propranolol	drug	_	nisoldipine	drug	_	effect	druga attenuated the heart rate increase following administration of immediate release drugb .
DDI-DrugBank.d106.s7.p0	SULAR	brand	_	atenolol	drug	_	effect	the blood pressure effect of druga tended to be greater in patients on drugb than in patients on no other drugn therapy .
DDI-DrugBank.d106.s7.p1	SULAR	brand	_	antihypertensive	group	_	false	the blood pressure effect of druga tended to be greater in patients on drugn than in patients on no other drugb therapy .
DDI-DrugBank.d106.s7.p2	atenolol	drug	_	antihypertensive	group	_	false	the blood pressure effect of drugn tended to be greater in patients on druga than in patients on no other drugb therapy .
DDI-DrugBank.d106.s8.p0	Quinidine	drug	_	nisoldipine	drug	_	mechanism	druga at # mg bid decreased the bioavailability -lcb- auc -rcb- of drugb by 26 % , but not the peak concentration .
DDI-DrugBank.d106.s9.p0	nisoldipine	drug	_	quinidine	drug	_	mechanism	the immediate release , but not the coat-core formulation of druga increased plasma drugb concentrations by about 20 % .
DDI-DrugBank.d354.s1.p0	nitazoxanide	drug	_	warfarin	drug	_	mechanism	therefore , caution should be used when administering druga concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices , as competition for binding sites may occur -lcb- e , g , , drugb -rcb- .
DDI-DrugBank.d183.s1.p0	INOmax	brand	_	tolazoline	drug	_	false	druga has been administered with drugb , drugn , drugn , drugn , drugn , and high-frequency ventilation .
DDI-DrugBank.d183.s1.p1	INOmax	brand	_	dopamine	drug	_	false	druga has been administered with drugn , drugb , drugn , drugn , drugn , and high-frequency ventilation .
DDI-DrugBank.d183.s1.p2	INOmax	brand	_	dobutamine	drug	_	false	druga has been administered with drugn , drugn , drugb , drugn , drugn , and high-frequency ventilation .
DDI-DrugBank.d183.s1.p3	INOmax	brand	_	steroids	group	_	false	druga has been administered with drugn , drugn , drugn , drugb , drugn , and high-frequency ventilation .
DDI-DrugBank.d183.s1.p4	INOmax	brand	_	surfactant	drug	_	false	druga has been administered with drugn , drugn , drugn , drugn , drugb , and high-frequency ventilation .
DDI-DrugBank.d183.s2.p0	nitric oxide donor compounds	group	_	sodium nitroprusside	drug	_	false	although there are no study data to evaluate the possibility , druga , including drugb and drugn , may have an additive effect with drugn on the risk of developing methemoglobinemia .
DDI-DrugBank.d183.s2.p1	nitric oxide donor compounds	group	_	nitroglycerin	drug	_	false	although there are no study data to evaluate the possibility , druga , including drugn and drugb , may have an additive effect with drugn on the risk of developing methemoglobinemia .
DDI-DrugBank.d183.s2.p2	nitric oxide donor compounds	group	_	INOmax	brand	_	effect	although there are no study data to evaluate the possibility , druga , including drugn and drugn , may have an additive effect with drugb on the risk of developing methemoglobinemia .
DDI-DrugBank.d183.s2.p3	sodium nitroprusside	drug	_	nitroglycerin	drug	_	false	although there are no study data to evaluate the possibility , drugn , including druga and drugb , may have an additive effect with drugn on the risk of developing methemoglobinemia .
DDI-DrugBank.d183.s2.p4	sodium nitroprusside	drug	_	INOmax	brand	_	effect	although there are no study data to evaluate the possibility , drugn , including druga and drugn , may have an additive effect with drugb on the risk of developing methemoglobinemia .
DDI-DrugBank.d183.s2.p5	nitroglycerin	drug	_	INOmax	brand	_	effect	although there are no study data to evaluate the possibility , drugn , including drugn and druga , may have an additive effect with drugb on the risk of developing methemoglobinemia .
DDI-DrugBank.d276.s0.p0	Antacids	group	_	magnesium trisilicate	drug	_	false	druga containing drugb , when administered concomitantly with drugn , reduce both the rate and extent of absorption .
DDI-DrugBank.d276.s0.p1	Antacids	group	_	nitrofurantoin	drug	_	false	druga containing drugn , when administered concomitantly with drugb , reduce both the rate and extent of absorption .
DDI-DrugBank.d276.s0.p2	magnesium trisilicate	drug	_	nitrofurantoin	drug	_	mechanism	drugn containing druga , when administered concomitantly with drugb , reduce both the rate and extent of absorption .
DDI-DrugBank.d276.s1.p0	nitrofurantoin	drug	_	magnesium trisilicate	drug	_	mechanism	the mechanism for this interaction probably is adsorption of druga onto the surface of drugb .
DDI-DrugBank.d276.s2.p0	Uricosuric drugs	group	_	probenecid	drug	_	false	druga , such as drugb and drugn , can inhibit renal tubular secretion of drugn .
DDI-DrugBank.d276.s2.p1	Uricosuric drugs	group	_	sulfinpyrazone	drug	_	false	druga , such as drugn and drugb , can inhibit renal tubular secretion of drugn .
DDI-DrugBank.d276.s2.p2	Uricosuric drugs	group	_	nitrofurantoin	drug	_	mechanism	druga , such as drugn and drugn , can inhibit renal tubular secretion of drugb .
DDI-DrugBank.d276.s2.p3	probenecid	drug	_	sulfinpyrazone	drug	_	false	drugn , such as druga and drugb , can inhibit renal tubular secretion of drugn .
DDI-DrugBank.d276.s2.p4	probenecid	drug	_	nitrofurantoin	drug	_	mechanism	drugn , such as druga and drugn , can inhibit renal tubular secretion of drugb .
DDI-DrugBank.d276.s2.p5	sulfinpyrazone	drug	_	nitrofurantoin	drug	_	mechanism	drugn , such as drugn and druga , can inhibit renal tubular secretion of drugb .
DDI-DrugBank.d276.s3.p0	nitrofurantoin	drug	_	antibacterial	group	_	false	the resulting increase in druga serum levels may increase toxicity , and the decreased urinary levels could lessen its efficacy as a urinary tract drugb .
DDI-DrugBank.d14.s0.p0	nitroglycerin	drug	_	vasodilators	group	_	effect	the vasodilating effects of druga may be additive with those of other drugb .
DDI-DrugBank.d14.s2.p0	calcium channel blockers	group	_	nitrates	group	_	effect	marked symptomatic orthostatic hypotension has been reported when druga and organic drugb were used in combination .
DDI-DrugBank.d394.s0.p0	sodium nitroprusside	drug	_	hypotensive drugs	group	_	effect	the hypotensive effect of druga is augmented by that of most other drugb , including drugn , negative inotropic agents , and inhaled drugn .
DDI-DrugBank.d394.s0.p1	sodium nitroprusside	drug	_	ganglionic blocking agents	group	_	effect	the hypotensive effect of druga is augmented by that of most other drugn , including drugb , negative inotropic agents , and inhaled drugn .
DDI-DrugBank.d394.s0.p2	sodium nitroprusside	drug	_	anesthetics	group	_	effect	the hypotensive effect of druga is augmented by that of most other drugn , including drugn , negative inotropic agents , and inhaled drugb .
DDI-DrugBank.d394.s0.p3	hypotensive drugs	group	_	ganglionic blocking agents	group	_	false	the hypotensive effect of drugn is augmented by that of most other druga , including drugb , negative inotropic agents , and inhaled drugn .
DDI-DrugBank.d394.s0.p4	hypotensive drugs	group	_	anesthetics	group	_	false	the hypotensive effect of drugn is augmented by that of most other druga , including drugn , negative inotropic agents , and inhaled drugb .
DDI-DrugBank.d394.s0.p5	ganglionic blocking agents	group	_	anesthetics	group	_	false	the hypotensive effect of drugn is augmented by that of most other drugn , including druga , negative inotropic agents , and inhaled drugb .
DDI-DrugBank.d475.s3.p0	aspirin	brand	_	salicylate	group	_	false	in patients given very high doses -lcb- 3900 mg -rcb- of druga daily , increases in serum drugb levels were seen when drugn , # mg b , i , d , , was administered concurrently .
DDI-DrugBank.d475.s3.p1	aspirin	brand	_	nizatidine	drug	_	mechanism	in patients given very high doses -lcb- 3900 mg -rcb- of druga daily , increases in serum drugn levels were seen when drugb , # mg b , i , d , , was administered concurrently .
DDI-DrugBank.d475.s3.p2	salicylate	group	_	nizatidine	drug	_	false	in patients given very high doses -lcb- 3900 mg -rcb- of drugn daily , increases in serum druga levels were seen when drugb , # mg b , i , d , , was administered concurrently .
DDI-DrugBank.d306.s0.p0	progestin	group	_	anticonvulsants	group	_	false	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugb drugn , drugn , and drugn , and the drugn drugn .
DDI-DrugBank.d306.s0.p1	progestin	group	_	phenytoin	drug	_	effect	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugb , drugn , and drugn , and the drugn drugn .
DDI-DrugBank.d306.s0.p2	progestin	group	_	carbamazepine	drug	_	effect	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugb , and drugn , and the drugn drugn .
DDI-DrugBank.d306.s0.p3	progestin	group	_	barbiturates	group	_	effect	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and drugb , and the drugn drugn .
DDI-DrugBank.d306.s0.p4	progestin	group	_	antituberculosis drug	group	_	false	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and drugn , and the drugb drugn .
DDI-DrugBank.d306.s0.p5	progestin	group	_	rifampin	drug	_	effect	the effectiveness of druga - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and drugn , and the drugn drugb .
DDI-DrugBank.d306.s0.p6	anticonvulsants	group	_	phenytoin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the druga drugb , drugn , and drugn , and the drugn drugn .
DDI-DrugBank.d306.s0.p7	anticonvulsants	group	_	carbamazepine	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the druga drugn , drugb , and drugn , and the drugn drugn .
DDI-DrugBank.d306.s0.p8	anticonvulsants	group	_	barbiturates	group	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the druga drugn , drugn , and drugb , and the drugn drugn .
DDI-DrugBank.d306.s0.p9	anticonvulsants	group	_	antituberculosis drug	group	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the druga drugn , drugn , and drugn , and the drugb drugn .
DDI-DrugBank.d306.s0.p10	anticonvulsants	group	_	rifampin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the druga drugn , drugn , and drugn , and the drugn drugb .
DDI-DrugBank.d306.s0.p13	phenytoin	drug	_	antituberculosis drug	group	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn druga , drugn , and drugn , and the drugb drugn .
DDI-DrugBank.d306.s0.p14	phenytoin	drug	_	rifampin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn druga , drugn , and drugn , and the drugn drugb .
DDI-DrugBank.d306.s0.p16	carbamazepine	drug	_	antituberculosis drug	group	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , druga , and drugn , and the drugb drugn .
DDI-DrugBank.d306.s0.p17	carbamazepine	drug	_	rifampin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , druga , and drugn , and the drugn drugb .
DDI-DrugBank.d306.s0.p18	barbiturates	group	_	antituberculosis drug	group	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and druga , and the drugb drugn .
DDI-DrugBank.d306.s0.p19	barbiturates	group	_	rifampin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and druga , and the drugn drugb .
DDI-DrugBank.d306.s0.p20	antituberculosis drug	group	_	rifampin	drug	_	false	the effectiveness of drugn - only pills is reduced by hepatic enzyme-inducing drugs such as the drugn drugn , drugn , and drugn , and the druga drugb .
DDI-DrugBank.d217.s0.p0	theophylline	drug	_	quinolone	group	_	mechanism	elevated plasma levels of druga have been reported with concomitant drugb use .
DDI-DrugBank.d217.s1.p0	theophylline	drug	_	norfloxacin	drug	_	false	there have been reports of druga - related side effects in patients on concomitant therapy with drugb and drugn .
DDI-DrugBank.d217.s1.p2	norfloxacin	drug	_	theophylline	drug	_	effect	there have been reports of drugn - related side effects in patients on concomitant therapy with druga and drugb .
DDI-DrugBank.d217.s3.p1	cyclosporine	drug	_	norfloxacin	drug	_	false	elevated serum levels of druga have been reported with concomitant use of drugn with drugb .
DDI-DrugBank.d217.s3.p2	cyclosporine	drug	_	norfloxacin	drug	_	mechanism	elevated serum levels of drugn have been reported with concomitant use of druga with drugb .
DDI-DrugBank.d217.s5.p0	Quinolones	group	_	norfloxacin	drug	_	false	druga , including drugb , may enhance the effects of oral drugn , including drugn or its derivatives or similar agents .
DDI-DrugBank.d217.s5.p1	Quinolones	group	_	anticoagulants	group	_	effect	druga , including drugn , may enhance the effects of oral drugb , including drugn or its derivatives or similar agents .
DDI-DrugBank.d217.s5.p2	Quinolones	group	_	warfarin	drug	_	effect	druga , including drugn , may enhance the effects of oral drugn , including drugb or its derivatives or similar agents .
DDI-DrugBank.d217.s5.p3	norfloxacin	drug	_	anticoagulants	group	_	effect	drugn , including druga , may enhance the effects of oral drugb , including drugn or its derivatives or similar agents .
DDI-DrugBank.d217.s5.p4	norfloxacin	drug	_	warfarin	drug	_	effect	drugn , including druga , may enhance the effects of oral drugn , including drugb or its derivatives or similar agents .
DDI-DrugBank.d217.s5.p5	anticoagulants	group	_	warfarin	drug	_	false	drugn , including drugn , may enhance the effects of oral druga , including drugb or its derivatives or similar agents .
DDI-DrugBank.d217.s7.p0	quinolones	group	_	norfloxacin	drug	_	false	the concomitant administration of druga including drugb with drugn -lcb- a drugn -rcb- has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d217.s7.p1	quinolones	group	_	glyburide	drug	_	effect	the concomitant administration of druga including drugn with drugb -lcb- a drugn -rcb- has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d217.s7.p2	quinolones	group	_	sulfonylurea agent	group	_	false	the concomitant administration of druga including drugn with drugn -lcb- a drugb -rcb- has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d217.s7.p3	norfloxacin	drug	_	glyburide	drug	_	effect	the concomitant administration of drugn including druga with drugb -lcb- a drugn -rcb- has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d217.s7.p4	norfloxacin	drug	_	sulfonylurea agent	group	_	false	the concomitant administration of drugn including druga with drugn -lcb- a drugb -rcb- has , on rare occasions , resulted in severe hypoglycemia .
DDI-DrugBank.d217.s9.p0	norfloxacin	drug	_	probenecid	drug	_	false	diminished urinary excretion of druga has been reported during the concomitant administration of drugb and drugn .
DDI-DrugBank.d217.s9.p2	probenecid	drug	_	norfloxacin	drug	_	mechanism	diminished urinary excretion of drugn has been reported during the concomitant administration of druga and drugb .
DDI-DrugBank.d217.s10.p1	nitrofurantoin	drug	_	Norfloxacin	drug	_	false	the concomitant use of druga is not recommended since drugn may antagonize the antibacterial effect of drugb in the urinary tract .
DDI-DrugBank.d217.s10.p2	nitrofurantoin	drug	_	Norfloxacin	drug	_	effect	the concomitant use of drugn is not recommended since druga may antagonize the antibacterial effect of drugb in the urinary tract .
DDI-DrugBank.d217.s11.p0	Multivitamins	group	_	iron	drug	_	false	druga , or other products containing drugb or drugn , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p1	Multivitamins	group	_	zinc	drug	_	false	druga , or other products containing drugn or drugb , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p2	Multivitamins	group	_	antacids	group	_	false	druga , or other products containing drugn or drugn , drugb or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p3	Multivitamins	group	_	sucralfate	drug	_	false	druga , or other products containing drugn or drugn , drugn or drugb should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p4	Multivitamins	group	_	norfloxacin	drug	_	advise	druga , or other products containing drugn or drugn , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugb , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p5	Multivitamins	group	_	norfloxacin	drug	_	false	druga , or other products containing drugn or drugn , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s11.p9	iron	drug	_	norfloxacin	drug	_	advise	drugn , or other products containing druga or drugn , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugb , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p10	iron	drug	_	norfloxacin	drug	_	false	drugn , or other products containing druga or drugn , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s11.p13	zinc	drug	_	norfloxacin	drug	_	advise	drugn , or other products containing drugn or druga , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugb , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p14	zinc	drug	_	norfloxacin	drug	_	false	drugn , or other products containing drugn or druga , drugn or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s11.p16	antacids	group	_	norfloxacin	drug	_	advise	drugn , or other products containing drugn or drugn , druga or drugn should not be administered concomitantly with , or within # hours of , the administration of drugb , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p17	antacids	group	_	norfloxacin	drug	_	false	drugn , or other products containing drugn or drugn , druga or drugn should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s11.p18	sucralfate	drug	_	norfloxacin	drug	_	advise	drugn , or other products containing drugn or drugn , drugn or druga should not be administered concomitantly with , or within # hours of , the administration of drugb , because they may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s11.p19	sucralfate	drug	_	norfloxacin	drug	_	false	drugn , or other products containing drugn or drugn , drugn or druga should not be administered concomitantly with , or within # hours of , the administration of drugn , because they may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s12.p1	Videx	brand	_	norfloxacin	drug	_	advise	druga -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of drugb , because these products may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s12.p2	Videx	brand	_	norfloxacin	drug	_	false	druga -lcb- drugn -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of drugn , because these products may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s12.p3	Didanosine	drug	_	norfloxacin	drug	_	advise	drugn -lcb- druga -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of drugb , because these products may interfere with absorption resulting in lower serum and urine levels of drugn .
DDI-DrugBank.d217.s12.p4	Didanosine	drug	_	norfloxacin	drug	_	false	drugn -lcb- druga -rcb- chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of drugn , because these products may interfere with absorption resulting in lower serum and urine levels of drugb .
DDI-DrugBank.d217.s13.p0	quinolones	group	_	caffeine	drug	_	mechanism	some druga have also been shown to interfere with the metabolism of drugb .
DDI-DrugBank.d360.s1.p5	barbiturates	group	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with druga , drugn , drugn , drugn , drugn , drugn , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p6	barbiturates	group	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with druga , drugn , drugn , drugn , drugn , drugn , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p11	phenylbutazone	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , druga , drugn , drugn , drugn , drugn , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p12	phenylbutazone	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , druga , drugn , drugn , drugn , drugn , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p16	phenytoin sodium	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , drugn , druga , drugn , drugn , drugn , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p17	phenytoin sodium	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , drugn , druga , drugn , drugn , drugn , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p20	carbamazepine	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , druga , drugn , drugn , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p21	carbamazepine	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , druga , drugn , drugn , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p23	griseofulvin	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , drugn , druga , drugn , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p24	griseofulvin	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , drugn , druga , drugn , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p25	topiramate	drug	_	ampicillin	drug	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , drugn , drugn , druga , and possibly with drugb and drugn 72 .
DDI-DrugBank.d360.s1.p26	topiramate	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , drugn , drugn , druga , and possibly with drugn and drugb 72 .
DDI-DrugBank.d360.s1.p27	ampicillin	drug	_	tetracyclines	group	_	false	a similar association , though less marked , has been suggested with drugn , drugn , drugn , drugn , drugn , drugn , and possibly with druga and drugb 72 .
DDI-DrugBank.d202.s0.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	mechanism	steady-state serum concentrations of druga are reported to fluctuate significantly when drugb is either added or deleted from the drug regimen .
DDI-DrugBank.d202.s1.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	effect	serious anticholinergic symptoms -lcb- severe dry mouth , urinary retention , blurred vision -rcb- have been associated with elevations in the serum levels of druga when drugb is added to the drug regimen .
DDI-DrugBank.d202.s2.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	mechanism	in addition , higher-than expected steady-state serum concentrations of druga have been observed when therapy is initiated in patients already taking drugb .
DDI-DrugBank.d202.s3.p0	cimetidine	drug	_	tricyclic antidepressants	group	_	mechanism	in well-controlled patients undergoing concurrent therapy with druga , a decrease in the steady-state serum concentrations of drugb may occur when cime-tidine therapy is discontinued .
DDI-DrugBank.d202.s4.p0	tricyclic antidepressants	group	_	cimetidine	drug	_	effect	the therapeutic efficacy of druga may be compromised in these patients when drugb is discontinued .
DDI-DrugBank.d202.s6.p0	antidepressants	group	_	nortriptyline	drug	_	false	there have been greater than 2-fold increases in previously stable plasma levels of other druga , including drugb , when drugn has been administered in combination with these agents .
DDI-DrugBank.d202.s6.p1	antidepressants	group	_	fluoxetine hydrochloride	drug	_	mechanism	there have been greater than 2-fold increases in previously stable plasma levels of other druga , including drugn , when drugb has been administered in combination with these agents .
DDI-DrugBank.d202.s6.p2	nortriptyline	drug	_	fluoxetine hydrochloride	drug	_	mechanism	there have been greater than 2-fold increases in previously stable plasma levels of other drugn , including druga , when drugb has been administered in combination with these agents .
DDI-DrugBank.d202.s8.p0	reserpine	drug	_	tricyclic antidepressant	group	_	effect	administration of druga during therapy with a drugb has been shown to produce a stimulating effect in some depressed patients .
DDI-DrugBank.d202.s9.p0	nortriptyline hydrochloride	drug	_	anticholinergic drugs	group	_	advise	close supervision and careful adjustment of the dosage are required when druga is used with other drugb or drugn .
DDI-DrugBank.d202.s9.p1	nortriptyline hydrochloride	drug	_	sympathomimetic drugs	group	_	advise	close supervision and careful adjustment of the dosage are required when druga is used with other drugn or drugb .
DDI-DrugBank.d202.s9.p2	anticholinergic drugs	group	_	sympathomimetic drugs	group	_	false	close supervision and careful adjustment of the dosage are required when drugn is used with other druga or drugb .
DDI-DrugBank.d202.s12.p0	debrisoquin	drug	_	dextromethorphan	drug	_	false	such individuals are referred to as poor metabolizers of drugs such as druga , drugb , and the drugn .
DDI-DrugBank.d202.s12.p1	debrisoquin	drug	_	tricyclic antidepressants	group	_	false	such individuals are referred to as poor metabolizers of drugs such as druga , drugn , and the drugb .
DDI-DrugBank.d202.s12.p2	dextromethorphan	drug	_	tricyclic antidepressants	group	_	false	such individuals are referred to as poor metabolizers of drugs such as drugn , druga , and the drugb .
DDI-DrugBank.d202.s16.p1	tricyclic antidepressants	group	_	phenothiazines	group	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugb , drugn , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p2	tricyclic antidepressants	group	_	carbamazepine	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugb , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p3	tricyclic antidepressants	group	_	Type 1C antiarrhythmics	group	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugb -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p4	tricyclic antidepressants	group	_	propafenone	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugb , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p5	tricyclic antidepressants	group	_	flecainide	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugn , drugb , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p6	tricyclic antidepressants	group	_	encainide	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugn , drugn , and drugb -rcb- , or that inhibit this enzyme -lcb- eg , drugn -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p7	tricyclic antidepressants	group	_	quinidine	drug	_	advise	therefore , co-administration of druga with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p14	antidepressants	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other druga , drugn , drugn , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p20	phenothiazines	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , druga , drugn , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p25	carbamazepine	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , druga , and drugn -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p29	Type 1C antiarrhythmics	group	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and druga -lcb- eg , drugn , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p32	propafenone	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , druga , drugn , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p34	flecainide	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugn , druga , and drugn -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d202.s16.p35	encainide	drug	_	quinidine	drug	_	false	therefore , co-administration of drugn with other drugs that are metabolized by this isoenzyme , including other drugn , drugn , drugn , and drugn -lcb- eg , drugn , drugn , and druga -rcb- , or that inhibit this enzyme -lcb- eg , drugb -rcb- , should be approached with caution .
DDI-DrugBank.d307.s1.p0	AED	group	_	oxcarbazepine	drug	_	mechanism	in addition , several druga s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of drugb and drugn .
DDI-DrugBank.d307.s1.p1	AED	group	_	MHD	drug_n	_	false	in addition , several druga s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of drugn and drugb .
DDI-DrugBank.d307.s1.p2	oxcarbazepine	drug	_	MHD	drug_n	_	false	in addition , several drugn s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of druga and drugb .
DDI-DrugBank.d307.s3.p0	oxcarbazepine	drug	_	MHD	drug_n	_	false	results demonstrate that druga and its pharmacologically active 10-monohydroxy metabolite -lcb- drugb -rcb- have little or no capacity to function as inhibitors for most of the human cytochrome cyp2b6 enzymes evaluated -lcb- cyp1a2 , cyp2a6 , cyp2c9 , cyp2d6 , cyp2e1 , cyp4a9 and cyp4a11 -rcb- with the exception of cyp2c19 and cyp3a4/5 .
DDI-DrugBank.d307.s4.p0	OXC	drug	_	MHD	drug_n	_	false	although inhibition of cyp 3a4/5 by druga and drugb did occur at high concentrations , it is not likely to be of clinical significance .
DDI-DrugBank.d307.s5.p0	OXC	drug	_	MHD	drug_n	_	false	the inhibition of cyp-2c19 by druga and drugb , however , is clinically relevant .
DDI-DrugBank.d307.s7.p0	MHD	drug_n	_	oxcarbazepine	drug	_	false	increases of 22 % with druga and 47 % with drugb were observed .
DDI-DrugBank.d307.s8.p0	MHD	drug_n	_	valproic acid	drug	_	false	as druga , the predominant plasma substrate , is only a weak inducer of udp-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through udp-glucuronyl transferase -lcb- e , g , , drugb , drugn -rcb- .
DDI-DrugBank.d307.s8.p1	MHD	drug_n	_	lamotrigine	drug	_	false	as druga , the predominant plasma substrate , is only a weak inducer of udp-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through udp-glucuronyl transferase -lcb- e , g , , drugn , drugb -rcb- .
DDI-DrugBank.d307.s9.p0	oxcarbazepine	drug	_	MHD	drug_n	_	false	in addition , druga and drugb induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of drugn and oral drugn , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s9.p1	oxcarbazepine	drug	_	dihydropyridine calcium antagonists	group	_	false	in addition , druga and drugn induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of drugb and oral drugn , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s9.p2	oxcarbazepine	drug	_	contraceptives	group	_	false	in addition , druga and drugn induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of drugn and oral drugb , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s9.p3	MHD	drug_n	_	dihydropyridine calcium antagonists	group	_	false	in addition , drugn and druga induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of drugb and oral drugn , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s9.p4	MHD	drug_n	_	contraceptives	group	_	false	in addition , drugn and druga induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of drugn and oral drugb , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s9.p5	dihydropyridine calcium antagonists	group	_	contraceptives	group	_	false	in addition , drugn and drugn induce a subgroup of the cytochrome cyp2b6 3a family -lcb- cyp3a4 and cyp3a5 -rcb- responsible for the metabolism of druga and oral drugb , resulting in a lower plasma concentration of these drugs .
DDI-DrugBank.d307.s11.p0	Antiepileptic drugs	group	_	Trileptal	brand	_	false	druga : potential interactions between drugb and other drugn were assessed in clinical studies .
DDI-DrugBank.d307.s11.p1	Antiepileptic drugs	group	_	AEDs	group	_	false	druga : potential interactions between drugn and other drugb were assessed in clinical studies .
DDI-DrugBank.d307.s11.p2	Trileptal	brand	_	AEDs	group	_	false	drugn : potential interactions between druga and other drugb were assessed in clinical studies .
DDI-DrugBank.d307.s16.p0	Trileptal	brand	_	AED	group	_	false	influence of druga on drugb concentration -lcb- mean change , 90 % confidence interval -rcb-
DDI-DrugBank.d307.s17.p0	AED	group	_	MHD	drug_n	_	false	influence of druga on drugb concentration -lcb- mean change , 90 % confidence interval -rcb-
DDI-DrugBank.d307.s35.p0	Trileptal	brand	_	phenytoin	drug	_	false	1 - nc denotes a mean change of less than 10 % 2 - pediatrics 3 - mean increase in adults at high druga doses in vivo , the plasma levels of drugb increased by up to 40 % , when drugn was given at doses above # mg/day .
DDI-DrugBank.d307.s35.p2	phenytoin	drug	_	Trileptal	brand	_	mechanism	1 - nc denotes a mean change of less than 10 % 2 - pediatrics 3 - mean increase in adults at high drugn doses in vivo , the plasma levels of druga increased by up to 40 % , when drugb was given at doses above # mg/day .
DDI-DrugBank.d307.s36.p0	Trileptal	brand	_	phenytoin	drug	_	advise	therefore , when using doses of druga greater than # mg/day during adjunctive therapy , a decrease in the dose of drugb may be required .
DDI-DrugBank.d307.s37.p0	phenobarbital	drug	_	Trileptal	brand	_	mechanism	the increase of druga level , however , is small -lcb- 15 % -rcb- when given with drugb .
DDI-DrugBank.d307.s38.p2	carbamazepine	drug	_	MHD	drug_n	_	false	strong inducers of cytochrome p450 enzymes -lcb- i , e , druga , drugn and drugn -rcb- have been shown to decrease the plasma levels of drugb -lcb- 29-40 % -rcb- .
DDI-DrugBank.d307.s38.p4	phenytoin	drug	_	MHD	drug_n	_	false	strong inducers of cytochrome p450 enzymes -lcb- i , e , drugn , druga and drugn -rcb- have been shown to decrease the plasma levels of drugb -lcb- 29-40 % -rcb- .
DDI-DrugBank.d307.s38.p5	phenobarbital	drug	_	MHD	drug_n	_	false	strong inducers of cytochrome p450 enzymes -lcb- i , e , drugn , drugn and druga -rcb- have been shown to decrease the plasma levels of drugb -lcb- 29-40 % -rcb- .
DDI-DrugBank.d307.s40.p0	contraceptives	group	_	Trileptal	brand	_	false	hormonal druga co-administration of drugb with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , drugn -lcb- ee -rcb- and drugn -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p2	contraceptives	group	_	ethinylestradiol	drug	_	false	hormonal druga co-administration of drugn with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , drugb -lcb- ee -rcb- and drugn -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p3	contraceptives	group	_	levonorgestrel	drug	_	false	hormonal druga co-administration of drugn with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , drugn -lcb- ee -rcb- and drugb -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p4	Trileptal	brand	_	contraceptive	group	_	mechanism	hormonal drugn co-administration of druga with an oral drugb has been shown to influence the plasma concentrations of the two hormonal components , drugn -lcb- ee -rcb- and drugn -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p5	Trileptal	brand	_	ethinylestradiol	drug	_	false	hormonal drugn co-administration of druga with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , drugb -lcb- ee -rcb- and drugn -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p6	Trileptal	brand	_	levonorgestrel	drug	_	false	hormonal drugn co-administration of druga with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , drugn -lcb- ee -rcb- and drugb -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p7	contraceptive	group	_	ethinylestradiol	drug	_	false	hormonal drugn co-administration of drugn with an oral druga has been shown to influence the plasma concentrations of the two hormonal components , drugb -lcb- ee -rcb- and drugn -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p8	contraceptive	group	_	levonorgestrel	drug	_	false	hormonal drugn co-administration of drugn with an oral druga has been shown to influence the plasma concentrations of the two hormonal components , drugn -lcb- ee -rcb- and drugb -lcb- lng -rcb- .
DDI-DrugBank.d307.s40.p9	ethinylestradiol	drug	_	levonorgestrel	drug	_	false	hormonal drugn co-administration of drugn with an oral drugn has been shown to influence the plasma concentrations of the two hormonal components , druga -lcb- ee -rcb- and drugb -lcb- lng -rcb- .
DDI-DrugBank.d307.s43.p0	Trileptal	brand	_	hormonal contraceptives	group	_	effect	therefore , concurrent use of druga with drugb may render these drugn less effective .
DDI-DrugBank.d307.s43.p1	Trileptal	brand	_	contraceptives	group	_	false	therefore , concurrent use of druga with drugn may render these drugb less effective .
DDI-DrugBank.d307.s45.p2	Trileptal	brand	_	felodipine	drug	_	mechanism	drugn s : after repeated co-administration of druga , the auc of drugb was lowered by 28 % -lsb- 90 % ci : 20-33 -rsb- .
DDI-DrugBank.d307.s46.p0	Verapamil	drug	_	MHD	drug_n	_	false	druga produced a decrease of 20 % -lsb- 90 % ci : 18-27 -rsb- of the plasma levels of drugb .
DDI-DrugBank.d307.s47.p2	Cimetidine	drug	_	MHD	drug_n	_	false	other drug interactions druga , drugn and drugn had no effect on the pharmacokinetics of drugb .
DDI-DrugBank.d307.s47.p4	erythromycin	drug	_	MHD	drug_n	_	false	other drug interactions drugn , druga and drugn had no effect on the pharmacokinetics of drugb .
DDI-DrugBank.d307.s47.p5	dextropropoxyphene	drug	_	MHD	drug_n	_	false	other drug interactions drugn , drugn and druga had no effect on the pharmacokinetics of drugb .
DDI-DrugBank.d307.s48.p0	warfarin	drug	_	Trileptal	brand	_	false	results with druga wshow no evidence of interaction with either single or repeated doses of drugb .
DDI-DrugBank.d288.s0.p0	TAXOL	brand	_	cisplatin	drug	_	false	in a phase i trial using escalating doses of druga -lcb- 110-200 mg/m2 -rcb- and drugb -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after drugn than with the alternate sequence -lcb- ie , drugn before drugn -rcb- .
DDI-DrugBank.d288.s0.p2	TAXOL	brand	_	cisplatin	drug	_	false	in a phase i trial using escalating doses of druga -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after drugb than with the alternate sequence -lcb- ie , drugn before drugn -rcb- .
DDI-DrugBank.d288.s0.p4	TAXOL	brand	_	cisplatin	drug	_	false	in a phase i trial using escalating doses of druga -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after drugn than with the alternate sequence -lcb- ie , drugn before drugb -rcb- .
DDI-DrugBank.d288.s0.p5	cisplatin	drug	_	TAXOL	brand	_	false	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and druga -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugb was given after drugn than with the alternate sequence -lcb- ie , drugn before drugn -rcb- .
DDI-DrugBank.d288.s0.p7	cisplatin	drug	_	TAXOL	brand	_	false	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and druga -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after drugn than with the alternate sequence -lcb- ie , drugb before drugn -rcb- .
DDI-DrugBank.d288.s0.p9	TAXOL	brand	_	cisplatin	drug	_	effect	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when druga was given after drugb than with the alternate sequence -lcb- ie , drugn before drugn -rcb- .
DDI-DrugBank.d288.s0.p11	TAXOL	brand	_	cisplatin	drug	_	false	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when druga was given after drugn than with the alternate sequence -lcb- ie , drugn before drugb -rcb- .
DDI-DrugBank.d288.s0.p12	cisplatin	drug	_	TAXOL	brand	_	false	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after druga than with the alternate sequence -lcb- ie , drugb before drugn -rcb- .
DDI-DrugBank.d288.s0.p14	TAXOL	brand	_	cisplatin	drug	_	false	in a phase i trial using escalating doses of drugn -lcb- 110-200 mg/m2 -rcb- and drugn -lcb- 50 or # mg/m2 -rcb- given as sequential infusions , myelosuppression was more profound when drugn was given after drugn than with the alternate sequence -lcb- ie , druga before drugb -rcb- .
DDI-DrugBank.d288.s1.p0	paclitaxel	drug	_	TAXOL	brand	_	false	pharmacokinetic data from these patients demonstrated a decrease in druga clearance of approximately 33 % when drugb was administered following drugn .
DDI-DrugBank.d288.s1.p1	paclitaxel	drug	_	cisplatin	drug	_	false	pharmacokinetic data from these patients demonstrated a decrease in druga clearance of approximately 33 % when drugn was administered following drugb .
DDI-DrugBank.d288.s1.p2	TAXOL	brand	_	cisplatin	drug	_	mechanism	pharmacokinetic data from these patients demonstrated a decrease in drugn clearance of approximately 33 % when druga was administered following drugb .
DDI-DrugBank.d288.s4.p0	TAXOL	brand	_	protease inhibitors	group	_	false	potential interactions between druga , a substrate of cyp3a4 , and drugb -lcb- drugn , drugn , drugn , and drugn -rcb- , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .
DDI-DrugBank.d288.s4.p1	TAXOL	brand	_	ritonavir	drug	_	false	potential interactions between druga , a substrate of cyp3a4 , and drugn -lcb- drugb , drugn , drugn , and drugn -rcb- , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .
DDI-DrugBank.d288.s4.p2	TAXOL	brand	_	saquinavir	drug	_	false	potential interactions between druga , a substrate of cyp3a4 , and drugn -lcb- drugn , drugb , drugn , and drugn -rcb- , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .
DDI-DrugBank.d288.s4.p3	TAXOL	brand	_	indinavir	drug	_	false	potential interactions between druga , a substrate of cyp3a4 , and drugn -lcb- drugn , drugn , drugb , and drugn -rcb- , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .
DDI-DrugBank.d288.s4.p4	TAXOL	brand	_	nelfinavir	drug	_	false	potential interactions between druga , a substrate of cyp3a4 , and drugn -lcb- drugn , drugn , drugn , and drugb -rcb- , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .
DDI-DrugBank.d288.s5.p1	doxorubicin	drug	_	paclitaxel	drug	_	false	reports in the literature suggest that plasma levels of druga -lcb- and its active metabolite drugn -rcb- may be increased when drugb and drugn are used in combination .
DDI-DrugBank.d288.s5.p3	doxorubicinol	drug_n	_	paclitaxel	drug	_	false	reports in the literature suggest that plasma levels of drugn -lcb- and its active metabolite druga -rcb- may be increased when drugb and drugn are used in combination .
DDI-DrugBank.d288.s5.p5	paclitaxel	drug	_	doxorubicin	drug	_	mechanism	reports in the literature suggest that plasma levels of drugn -lcb- and its active metabolite drugn -rcb- may be increased when druga and drugb are used in combination .
DDI-DrugBank.d288.s11.p0	cyclosporin	drug	_	teniposide	drug	_	false	hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el -lcb- eg , druga for injection concentrate and drugb for injection concentrate -rcb- should not be treated with drugn .
DDI-DrugBank.d288.s11.p1	cyclosporin	drug	_	TAXOL	brand	_	advise	hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el -lcb- eg , druga for injection concentrate and drugn for injection concentrate -rcb- should not be treated with drugb .
DDI-DrugBank.d288.s11.p2	teniposide	drug	_	TAXOL	brand	_	advise	hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el -lcb- eg , drugn for injection concentrate and druga for injection concentrate -rcb- should not be treated with drugb .
DDI-DrugBank.d288.s12.p0	TAXOL	brand	_	corticosteroids	group	_	false	in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with druga should be premedicated with drugb -lcb- such as drugn -rcb- , diphen-hydramine and drugn -lcb- such as drugn or drugn -rcb- .
DDI-DrugBank.d288.s12.p1	TAXOL	brand	_	dexamethasone	drug	_	false	in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with druga should be premedicated with drugn -lcb- such as drugb -rcb- , diphen-hydramine and drugn -lcb- such as drugn or drugn -rcb- .
DDI-DrugBank.d288.s12.p2	TAXOL	brand	_	H2 antagonists	group	_	false	in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with druga should be premedicated with drugn -lcb- such as drugn -rcb- , diphen-hydramine and drugb -lcb- such as drugn or drugn -rcb- .
DDI-DrugBank.d288.s12.p3	TAXOL	brand	_	cimetidine	drug	_	false	in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with druga should be premedicated with drugn -lcb- such as drugn -rcb- , diphen-hydramine and drugn -lcb- such as drugb or drugn -rcb- .
DDI-DrugBank.d288.s12.p4	TAXOL	brand	_	ranitidine	drug	_	false	in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with druga should be premedicated with drugn -lcb- such as drugn -rcb- , diphen-hydramine and drugn -lcb- such as drugn or drugb -rcb- .
DDI-DrugBank.d288.s14.p0	bronchodilators	group	_	TAXOL	brand	_	false	however , severe reactions , such as hypotension requiring treatment , dyspnea requiring druga , angioedema , or generalized urticaria require immediate discontinuation of drugb and aggressive symptomatic therapy .
DDI-DrugBank.d196.s0.p0	PEGASYS	brand	_	theophylline	drug	_	mechanism	treatment with druga once weekly for # weeks in healthy subjects was associated with an inhibition of cyp2b6 1a2 and a 25 % increase in drugb auc .
DDI-DrugBank.d196.s1.p1	Theophylline	drug	_	PEGASYS	brand	_	false	druga serum levels should be monitored and appropriate dose adjustments considered for patients given both drugn and drugb .
DDI-DrugBank.d196.s1.p2	theophylline	drug	_	PEGASYS	brand	_	advise	drugn serum levels should be monitored and appropriate dose adjustments considered for patients given both druga and drugb .
DDI-DrugBank.d196.s3.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	in patients with chronic hepatitis c treated with druga in combination with drugb , drugn treatment did not affect drugn distribution or clearance .
DDI-DrugBank.d196.s3.p2	PEGASYS	brand	_	ribavirin	drug	_	false	in patients with chronic hepatitis c treated with druga in combination with drugn , drugn treatment did not affect drugb distribution or clearance .
DDI-DrugBank.d196.s3.p3	COPEGUS	brand	_	PEGASYS	brand	_	false	in patients with chronic hepatitis c treated with drugn in combination with druga , drugb treatment did not affect drugn distribution or clearance .
DDI-DrugBank.d196.s3.p4	COPEGUS	brand	_	ribavirin	drug	_	false	in patients with chronic hepatitis c treated with drugn in combination with druga , drugn treatment did not affect drugb distribution or clearance .
DDI-DrugBank.d196.s3.p5	PEGASYS	brand	_	ribavirin	drug	_	false	in patients with chronic hepatitis c treated with drugn in combination with drugn , druga treatment did not affect drugb distribution or clearance .
DDI-DrugBank.d196.s4.p0	Didanosine	drug	_	COPEGUS	brand	_	false	nucleoside analogues druga co-administration of drugb and drugn is not recommended .
DDI-DrugBank.d196.s4.p2	COPEGUS	brand	_	didanosine	drug	_	advise	nucleoside analogues drugn co-administration of druga and drugb is not recommended .
DDI-DrugBank.d196.s6.p0	Stavudine	drug	_	Zidovudine	drug	_	false	druga and drugb drugn can antagonize the in vitro antiviral activity of drugn and drugn against hiv .
DDI-DrugBank.d196.s6.p1	Stavudine	drug	_	Ribavirin	drug	_	false	druga and drugn drugb can antagonize the in vitro antiviral activity of drugn and drugn against hiv .
DDI-DrugBank.d196.s6.p3	Stavudine	drug	_	zidovudine	drug	_	false	druga and drugn drugn can antagonize the in vitro antiviral activity of drugn and drugb against hiv .
DDI-DrugBank.d196.s6.p4	Zidovudine	drug	_	Ribavirin	drug	_	false	drugn and druga drugb can antagonize the in vitro antiviral activity of drugn and drugn against hiv .
DDI-DrugBank.d196.s6.p5	Zidovudine	drug	_	stavudine	drug	_	false	drugn and druga drugn can antagonize the in vitro antiviral activity of drugb and drugn against hiv .
DDI-DrugBank.d196.s6.p7	Ribavirin	drug	_	stavudine	drug	_	effect	drugn and drugn druga can antagonize the in vitro antiviral activity of drugb and drugn against hiv .
DDI-DrugBank.d196.s6.p8	Ribavirin	drug	_	zidovudine	drug	_	effect	drugn and drugn druga can antagonize the in vitro antiviral activity of drugn and drugb against hiv .
DDI-DrugBank.d196.s6.p9	stavudine	drug	_	zidovudine	drug	_	false	drugn and drugn drugn can antagonize the in vitro antiviral activity of druga and drugb against hiv .
DDI-DrugBank.d196.s33.p0	peginterferon	drug	_	ribavirin	drug	_	false	the effect of orally ingested druga or drugb from breast milk on the nursing infant has not been evaluated .
DDI-DrugBank.d196.s34.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	because of the potential for adverse reactions from the drugs in nursing infants , a decision must be made whether to discontinue nursing or discontinue druga and drugb treatment .
DDI-DrugBank.d196.s35.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	pediatric use the safety and effectiveness of druga , alone or in combination with drugb in patients below the age of # years have not been established .
DDI-DrugBank.d196.s36.p0	PEGASYS	brand	_	benzyl alcohol	drug_n	_	false	druga contains drugb .
DDI-DrugBank.d196.s39.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	clinical studies of druga alone or in combination with drugb did not include sufficient numbers of subjects aged # or over to determine whether they respond differently from younger subjects .
DDI-DrugBank.d196.s40.p0	alpha interferon	drug	_	PEGASYS	brand	_	false	adverse reactions related to druga s , such as cns , cardiac , and systemic -lcb- eg , flu-like -rcb- effects may be more severe in the elderly and caution should be exercised in the use of drugb in this population .
DDI-DrugBank.d196.s41.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	druga and drugb are excreted by the kidney , and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function .
DDI-DrugBank.d196.s43.p0	PEGASYS	brand	_	COPEGUS	brand	_	false	druga should be used with caution in patients with creatinine clearance # ml/min and drugb should not be administered to patients with creatinine clearance # ml/min
DDI-DrugBank.d462.s0.p3	piperacillin	drug	_	aminoglycoside	group	_	effect	drugn : the mixing of druga with an drugb in vitro can result in substantial inactivation of the drugn .
DDI-DrugBank.d462.s0.p4	piperacillin	drug	_	aminoglycoside	group	_	false	drugn : the mixing of druga with an drugn in vitro can result in substantial inactivation of the drugb .
DDI-DrugBank.d462.s1.p2	piperacillin	drug	_	vecuronium	drug	_	effect	drugn : when used in the perioperative period , druga has been implicated in the prolongation of the neuromuscular blockade of drugb .
DDI-DrugBank.d462.s3.p0	piperacillin	drug	_	vecuronium	drug	_	effect	in one controlled clinical study , the ureidopenicillins , including druga , were reported to prolong the action of drugb .
DDI-DrugBank.d462.s4.p0	non-depolarizing muscle relaxants	group	_	piperacillin	drug	_	effect	due to their similar mechanism of action , it is expected that the neuromuscular blockade produced by any of the druga could be prolonged in the presence of drugb .
DDI-DrugBank.d462.s5.p3	probenecid	drug	_	PIPRACIL	brand	_	mechanism	drugn : the oral combination of druga before intramuscular injection of drugb produces an increase in drugn peak serum level of about 30 % .
DDI-DrugBank.d462.s5.p4	probenecid	drug	_	piperacillin	drug	_	false	drugn : the oral combination of druga before intramuscular injection of drugn produces an increase in drugb peak serum level of about 30 % .
DDI-DrugBank.d462.s5.p5	PIPRACIL	brand	_	piperacillin	drug	_	false	drugn : the oral combination of drugn before intramuscular injection of druga produces an increase in drugb peak serum level of about 30 % .
DDI-DrugBank.d462.s6.p2	heparin	drug	_	anticoagulants	group	_	false	drugn : coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of druga , oral drugb , or other drugs that may affect the blood coagulation system or the thrombocyte function .
DDI-DrugBank.d462.s7.p2	Piperacillin sodium	drug	_	methotrexate	drug	_	mechanism	drugn : druga may reduce the excretion of drugb .
DDI-DrugBank.d462.s9.p0	penicillins	drug	_	PIPRACIL	brand	_	false	drug/laboratory test interactions as with other druga , the administration of drugb may result in a false-positive reaction for glucose in the urine using a copper-reduction method .
DDI-DrugBank.d326.s0.p0	Phenothiazines	group	_	piperazine	drug	_	false	druga - taking drugb and a drugn together may increase the risk of convulsions -lcb- seizures -rcb- .
DDI-DrugBank.d326.s0.p2	piperazine	drug	_	phenothiazine	group	_	effect	drugn - taking druga and a drugb together may increase the risk of convulsions -lcb- seizures -rcb- .
DDI-DrugBank.d326.s1.p1	Pyrantel	drug	_	piperazine	drug	_	false	druga -lcb- e , g , , drugn -rcb- - taking drugb and drugn together may decrease the effects of drugn .
DDI-DrugBank.d326.s1.p3	Pyrantel	drug	_	piperazine	drug	_	false	druga -lcb- e , g , , drugn -rcb- - taking drugn and drugn together may decrease the effects of drugb .
DDI-DrugBank.d326.s1.p4	Antiminth	drug	_	piperazine	drug	_	false	drugn -lcb- e , g , , druga -rcb- - taking drugb and drugn together may decrease the effects of drugn .
DDI-DrugBank.d326.s1.p5	Antiminth	drug	_	pyrantel	drug	_	false	drugn -lcb- e , g , , druga -rcb- - taking drugn and drugb together may decrease the effects of drugn .
DDI-DrugBank.d326.s1.p6	Antiminth	drug	_	piperazine	drug	_	false	drugn -lcb- e , g , , druga -rcb- - taking drugn and drugn together may decrease the effects of drugb .
DDI-DrugBank.d326.s1.p7	piperazine	drug	_	pyrantel	drug	_	effect	drugn -lcb- e , g , , drugn -rcb- - taking druga and drugb together may decrease the effects of drugn .
DDI-DrugBank.d326.s1.p9	pyrantel	drug	_	piperazine	drug	_	false	drugn -lcb- e , g , , drugn -rcb- - taking drugn and druga together may decrease the effects of drugb .
DDI-DrugBank.d210.s0.p2	NSAIDs	group	_	Angiotensin Converting Enzyme (ACE) inhibitors	group	_	effect	drugn : reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d210.s1.p0	VIOXX	brand	_	ACE inhibitor	group	_	false	in patients with mild to moderate hypertension , administration of # mg daily of druga with the drugb drugn , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to drugn alone .
DDI-DrugBank.d210.s1.p1	VIOXX	brand	_	benazepril	drug	_	effect	in patients with mild to moderate hypertension , administration of # mg daily of druga with the drugn drugb , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to drugn alone .
DDI-DrugBank.d210.s1.p2	VIOXX	brand	_	ACE inhibitor	group	_	false	in patients with mild to moderate hypertension , administration of # mg daily of druga with the drugn drugn , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to drugb alone .
DDI-DrugBank.d210.s1.p3	ACE inhibitor	group	_	benazepril	drug	_	false	in patients with mild to moderate hypertension , administration of # mg daily of drugn with the druga drugb , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to drugn alone .
DDI-DrugBank.d210.s1.p5	benazepril	drug	_	ACE inhibitor	group	_	false	in patients with mild to moderate hypertension , administration of # mg daily of drugn with the drugn druga , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to drugb alone .
DDI-DrugBank.d210.s2.p0	VIOXX	brand	_	ACE inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d210.s3.p1	Aspirin	brand	_	VIOXX	brand	_	false	druga : concomitant administration of low-dose drugn with drugb may result in an increased rate of gi ulceration or other complications , compared to use of drugn alone .
DDI-DrugBank.d210.s3.p2	Aspirin	brand	_	VIOXX	brand	_	false	druga : concomitant administration of low-dose drugn with drugn may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d210.s3.p3	aspirin	brand	_	VIOXX	brand	_	effect	drugn : concomitant administration of low-dose druga with drugb may result in an increased rate of gi ulceration or other complications , compared to use of drugn alone .
DDI-DrugBank.d210.s3.p4	aspirin	brand	_	VIOXX	brand	_	false	drugn : concomitant administration of low-dose druga with drugn may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
DDI-DrugBank.d210.s4.p0	aspirin	brand	_	VIOXX	brand	_	false	in a 12-week endoscopy study conducted in oa patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose -lcb- 81 mg -rcb- enteric coated druga plus drugb # mg daily , as compared to those taking drugn # mg daily alone .
DDI-DrugBank.d210.s4.p1	aspirin	brand	_	ibuprofen	drug	_	false	in a 12-week endoscopy study conducted in oa patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose -lcb- 81 mg -rcb- enteric coated druga plus drugn # mg daily , as compared to those taking drugb # mg daily alone .
DDI-DrugBank.d210.s4.p2	VIOXX	brand	_	ibuprofen	drug	_	false	in a 12-week endoscopy study conducted in oa patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose -lcb- 81 mg -rcb- enteric coated drugn plus druga # mg daily , as compared to those taking drugb # mg daily alone .
DDI-DrugBank.d210.s5.p0	aspirin	brand	_	ibuprofen	drug	_	false	patients taking low-dose druga plus drugb were not studied .
DDI-DrugBank.d210.s6.p0	VIOXX	brand	_	aspirin	brand	_	false	at steady state , druga # mg once daily had no effect on the anti-platelet activity of low-dose -lcb- 81 mg once daily -rcb- drugb , as assessed by ex vivo platelet aggregation and serum thromboxane_b2 generation in clotting blood .
DDI-DrugBank.d210.s7.p0	VIOXX	brand	_	aspirin	brand	_	false	because of its lack of platelet effects , druga is not a substitute for drugb for cardiovascular prophylaxis .
DDI-DrugBank.d210.s9.p0	VIOXX	brand	_	aspirin	brand	_	false	prospective , long-term studies on concomitant administration of druga and drugb have not been conducted .
DDI-DrugBank.d210.s10.p1	Cimetidine	drug	_	rofecoxib	drug	_	false	druga : co-administration with high doses of drugn -lsb- 800 mg twice daily -rsb- increased the cmax of drugb by 21 % , the auc0-120hr by 23 % and the t1/2 by 15 % .
DDI-DrugBank.d210.s10.p2	cimetidine	drug	_	rofecoxib	drug	_	mechanism	drugn : co-administration with high doses of druga -lsb- 800 mg twice daily -rsb- increased the cmax of drugb by 21 % , the auc0-120hr by 23 % and the t1/2 by 15 % .
DDI-DrugBank.d210.s12.p2	Rofecoxib	drug	_	digoxin	drug	_	false	drugn : druga # mg once daily for # days does not alter the plasma concentration profile or renal elimination of drugb after a single # mg oral dose .
DDI-DrugBank.d210.s13.p0	Furosemide	drug	_	NSAIDs	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d210.s13.p2	Furosemide	drug	_	thiazides	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d210.s13.p3	NSAIDs	group	_	furosemide	drug	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d210.s13.p4	NSAIDs	group	_	thiazides	group	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d210.s13.p5	furosemide	drug	_	thiazides	group	_	false	drugn : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d210.s15.p2	Ketoconazole	drug	_	rofecoxib	drug	_	false	drugn : druga # mg daily did not have any clinically important effect on the pharmacokinetics of drugb .
DDI-DrugBank.d210.s16.p3	NSAIDs	group	_	lithium	drug	_	mechanism	drugn : druga have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
DDI-DrugBank.d210.s16.p4	NSAIDs	group	_	lithium	drug	_	false	drugn : druga have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
DDI-DrugBank.d210.s18.p0	VIOXX	brand	_	lithium	drug	_	advise	thus , when druga and drugb are administered concurrently , subjects should be observed carefully for signs of drugn toxicity .
DDI-DrugBank.d210.s18.p1	VIOXX	brand	_	lithium	drug	_	false	thus , when druga and drugn are administered concurrently , subjects should be observed carefully for signs of drugb toxicity .
DDI-DrugBank.d210.s19.p0	Methotrexate	drug	_	VIOXX	brand	_	false	druga drugb # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of drugn as measured by auc0-24hr in patients receiving single weekly drugn doses of # to # mg for rheumatoid arthritis .
DDI-DrugBank.d210.s19.p3	VIOXX	brand	_	methotrexate	drug	_	false	drugn druga # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of drugb as measured by auc0-24hr in patients receiving single weekly drugn doses of # to # mg for rheumatoid arthritis .
DDI-DrugBank.d210.s19.p4	VIOXX	brand	_	methotrexate	drug	_	false	drugn druga # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of drugn as measured by auc0-24hr in patients receiving single weekly drugb doses of # to # mg for rheumatoid arthritis .
DDI-DrugBank.d210.s20.p0	VIOXX	brand	_	methotrexate	drug	_	mechanism	at higher than recommended doses , druga # mg administered once daily for # days increased plasma concentrations by 23 % as measured by auc0-24hr in patients receiving drugb # to # mg/week for rheumatoid arthritis .
DDI-DrugBank.d210.s21.p1	methotrexate	drug	_	rofecoxib	drug	_	false	at # hours postdose , a similar proportion of patients treated with druga alone -lcb- 94 % -rcb- and subsequently treated with drugn co-administered with # mg of drugb -lcb- 88 % -rcb- had drugn plasma concentrations below the measurable limit -lcb- 5 ng/ml -rcb- .
DDI-DrugBank.d210.s21.p3	methotrexate	drug	_	rofecoxib	drug	_	mechanism	at # hours postdose , a similar proportion of patients treated with drugn alone -lcb- 94 % -rcb- and subsequently treated with druga co-administered with # mg of drugb -lcb- 88 % -rcb- had drugn plasma concentrations below the measurable limit -lcb- 5 ng/ml -rcb- .
DDI-DrugBank.d210.s21.p5	rofecoxib	drug	_	methotrexate	drug	_	false	at # hours postdose , a similar proportion of patients treated with drugn alone -lcb- 94 % -rcb- and subsequently treated with drugn co-administered with # mg of druga -lcb- 88 % -rcb- had drugb plasma concentrations below the measurable limit -lcb- 5 ng/ml -rcb- .
DDI-DrugBank.d210.s22.p0	methotrexate	drug	_	VIOXX	brand	_	false	standard monitoring of druga - related toxicity should be continued if drugb and drugn are administered concomitantly .
DDI-DrugBank.d210.s22.p2	VIOXX	brand	_	methotrexate	drug	_	advise	standard monitoring of drugn - related toxicity should be continued if druga and drugb are administered concomitantly .
DDI-DrugBank.d210.s23.p0	Contraceptives	group	_	Rofecoxib	drug	_	false	oral druga drugb did not have any clinically important effect on the pharmacokinetics of drugn and drugn .
DDI-DrugBank.d210.s23.p1	Contraceptives	group	_	ethinyl estradiol	drug	_	false	oral druga drugn did not have any clinically important effect on the pharmacokinetics of drugb and drugn .
DDI-DrugBank.d210.s23.p2	Contraceptives	group	_	norethindrone	drug	_	false	oral druga drugn did not have any clinically important effect on the pharmacokinetics of drugn and drugb .
DDI-DrugBank.d210.s23.p3	Rofecoxib	drug	_	ethinyl estradiol	drug	_	false	oral drugn druga did not have any clinically important effect on the pharmacokinetics of drugb and drugn .
DDI-DrugBank.d210.s23.p4	Rofecoxib	drug	_	norethindrone	drug	_	false	oral drugn druga did not have any clinically important effect on the pharmacokinetics of drugn and drugb .
DDI-DrugBank.d210.s23.p5	ethinyl estradiol	drug	_	norethindrone	drug	_	false	oral drugn drugn did not have any clinically important effect on the pharmacokinetics of druga and drugb .
DDI-DrugBank.d210.s24.p0	Prednisone	drug	_	prednisolone	drug	_	false	druga / drugb : drugn did not have any clinically important effect on the pharmacokinetics of drugn or drugn .
DDI-DrugBank.d210.s24.p7	Rofecoxib	drug	_	prednisolone	drug	_	false	drugn / drugn : druga did not have any clinically important effect on the pharmacokinetics of drugb or drugn .
DDI-DrugBank.d210.s24.p8	Rofecoxib	drug	_	prednisone	drug	_	false	drugn / drugn : druga did not have any clinically important effect on the pharmacokinetics of drugn or drugb .
DDI-DrugBank.d210.s24.p9	prednisolone	drug	_	prednisone	drug	_	false	drugn / drugn : drugn did not have any clinically important effect on the pharmacokinetics of druga or drugb .
DDI-DrugBank.d210.s25.p0	Rifampin	drug	_	VIOXX	brand	_	false	druga : co-administration of drugb with drugn # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drugn plasma concentrations .
DDI-DrugBank.d210.s25.p2	Rifampin	drug	_	rofecoxib	drug	_	false	druga : co-administration of drugn with drugn # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drugb plasma concentrations .
DDI-DrugBank.d210.s25.p3	VIOXX	brand	_	rifampin	drug	_	mechanism	drugn : co-administration of druga with drugb # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drugn plasma concentrations .
DDI-DrugBank.d210.s25.p4	VIOXX	brand	_	rofecoxib	drug	_	false	drugn : co-administration of druga with drugn # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drugb plasma concentrations .
DDI-DrugBank.d210.s25.p5	rifampin	drug	_	rofecoxib	drug	_	false	drugn : co-administration of drugn with druga # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drugb plasma concentrations .
DDI-DrugBank.d210.s27.p0	Theophylline	drug	_	VIOXX	brand	_	false	druga drugb # , 25 , and # mg administered once daily for # days increased plasma drugn concentrations -lcb- auc -lcb- 0 - -rcb- -rcb- by # to 60 % in healthy subjects administered a single 300-mg dose of drugn .
DDI-DrugBank.d210.s27.p3	VIOXX	brand	_	theophylline	drug	_	mechanism	drugn druga # , 25 , and # mg administered once daily for # days increased plasma drugb concentrations -lcb- auc -lcb- 0 - -rcb- -rcb- by # to 60 % in healthy subjects administered a single 300-mg dose of drugn .
DDI-DrugBank.d210.s27.p4	VIOXX	brand	_	theophylline	drug	_	false	drugn druga # , 25 , and # mg administered once daily for # days increased plasma drugn concentrations -lcb- auc -lcb- 0 - -rcb- -rcb- by # to 60 % in healthy subjects administered a single 300-mg dose of drugb .
DDI-DrugBank.d210.s28.p0	theophylline	drug	_	VIOXX	brand	_	false	adequate monitoring of druga plasma concentrations should be considered when therapy with drugb is initiated or changed in patients receiving drugn .
DDI-DrugBank.d210.s28.p2	VIOXX	brand	_	theophylline	drug	_	advise	adequate monitoring of drugn plasma concentrations should be considered when therapy with druga is initiated or changed in patients receiving drugb .
DDI-DrugBank.d210.s31.p2	VIOXX	brand	_	warfarin	drug	_	advise	drugn : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing druga therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding complications .
DDI-DrugBank.d210.s32.p0	warfarin	drug	_	rofecoxib	drug	_	effect	in single and multiple dose studies in healthy subjects receiving both druga and drugb , prothrombin time -lcb- measured as inr -rcb- was increased by approximately 8 % to 11 % .
DDI-DrugBank.d210.s33.p0	VIOXX	brand	_	warfarin	drug	_	effect	in post-marketing experience , bleeding events have been reported , predominantly in the elderly , in association with increases in prothrombin time in patients receiving druga concurrently with drugb .
DDI-DrugBank.d124.s1.p0	INVIRASE	brand	_	FORTOVASE	brand	_	false	several drug interaction studies have been completed with both druga and drugb .
DDI-DrugBank.d124.s2.p0	FORTOVASE	brand	_	INVIRASE	brand	_	false	observations from drug interaction studies with druga may not be predictive for drugb .
DDI-DrugBank.d124.s9.p0	INVIRASE	brand	_	ritonavir	drug	_	false	additional drugs that are not recommended for coadministration with druga and drugb are included below .
DDI-DrugBank.d124.s14.p0	Antiarrhythmics	group	_	Amiodarone	drug	_	false	druga : drugb , drugn , drugn , drugn , drugn contraindicated due to potential for serious and/or life-threatening reactions .
DDI-DrugBank.d124.s14.p1	Antiarrhythmics	group	_	bepridil	drug	_	false	druga : drugn , drugb , drugn , drugn , drugn contraindicated due to potential for serious and/or life-threatening reactions .
DDI-DrugBank.d124.s14.p2	Antiarrhythmics	group	_	flecainide	drug	_	false	druga : drugn , drugn , drugb , drugn , drugn contraindicated due to potential for serious and/or life-threatening reactions .
DDI-DrugBank.d124.s14.p3	Antiarrhythmics	group	_	propafenone	drug	_	false	druga : drugn , drugn , drugn , drugb , drugn contraindicated due to potential for serious and/or life-threatening reactions .
DDI-DrugBank.d124.s14.p4	Antiarrhythmics	group	_	quinidine	drug	_	false	druga : drugn , drugn , drugn , drugn , drugb contraindicated due to potential for serious and/or life-threatening reactions .
DDI-DrugBank.d124.s15.p0	Antihistamines	drug	_	astemizole	drug	_	false	druga : drugb * , drugn * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .
DDI-DrugBank.d124.s15.p1	Antihistamines	drug	_	terfenadine	drug	_	false	druga : drugn * , drugb * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .
DDI-DrugBank.d124.s15.p2	astemizole	drug	_	terfenadine	drug	_	false	drugn : druga * , drugb * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .
DDI-DrugBank.d124.s16.p0	Ergot Derivatives	group	_	Dihydroergotamine	drug	_	false	druga : drugb , drugn , drugn , drugn contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p1	Ergot Derivatives	group	_	ergonovine	drug	_	false	druga : drugn , drugb , drugn , drugn contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p2	Ergot Derivatives	group	_	ergotamine	drug	_	false	druga : drugn , drugn , drugb , drugn contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p3	Ergot Derivatives	group	_	methylergonovine	drug	_	false	druga : drugn , drugn , drugn , drugb contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p7	Dihydroergotamine	drug	_	methylergonovine	drug	_	false	drugn : druga , drugn , drugn , drugb contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p11	ergonovine	drug	_	ergot	group	_	false	drugn : drugn , druga , drugn , drugn contraindicated due to potential for serious and life-threatening reactions such as acute drugb toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p12	ergotamine	drug	_	methylergonovine	drug	_	false	drugn : drugn , drugn , druga , drugb contraindicated due to potential for serious and life-threatening reactions such as acute drugn toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s16.p14	methylergonovine	drug	_	ergot	group	_	false	drugn : drugn , drugn , drugn , druga contraindicated due to potential for serious and life-threatening reactions such as acute drugb toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .
DDI-DrugBank.d124.s17.p0	Antimycobacterial Agents	group	_	rifampin	drug	_	false	druga : drugb contraindicated since the coadministration of this product with drugn in an drugn regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p1	Antimycobacterial Agents	group	_	saquinavir	drug	_	false	druga : drugn contraindicated since the coadministration of this product with drugb in an drugn regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p2	Antimycobacterial Agents	group	_	antiretroviral	group	_	false	druga : drugn contraindicated since the coadministration of this product with drugn in an drugb regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p3	Antimycobacterial Agents	group	_	saquinavir	drug	_	false	druga : drugn contraindicated since the coadministration of this product with drugn in an drugn regimen reduces the plasma concentrations of drugb .
DDI-DrugBank.d124.s17.p4	rifampin	drug	_	saquinavir	drug	_	false	drugn : druga contraindicated since the coadministration of this product with drugb in an drugn regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p5	rifampin	drug	_	antiretroviral	group	_	false	drugn : druga contraindicated since the coadministration of this product with drugn in an drugb regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p6	rifampin	drug	_	saquinavir	drug	_	false	drugn : druga contraindicated since the coadministration of this product with drugn in an drugn regimen reduces the plasma concentrations of drugb .
DDI-DrugBank.d124.s17.p7	saquinavir	drug	_	antiretroviral	group	_	false	drugn : drugn contraindicated since the coadministration of this product with druga in an drugb regimen reduces the plasma concentrations of drugn .
DDI-DrugBank.d124.s17.p9	antiretroviral	group	_	saquinavir	drug	_	false	drugn : drugn contraindicated since the coadministration of this product with drugn in an druga regimen reduces the plasma concentrations of drugb .
DDI-DrugBank.d124.s18.p1	saquinavir	drug	_	protease inhibitor	group	_	false	garlic capsules garlic capsules should not be used while taking druga -lcb- drugn -rcb- as the sole drugb due to the risk of decreased drugn plasma concentrations .
DDI-DrugBank.d124.s18.p3	FORTOVASE	brand	_	protease inhibitor	group	_	false	garlic capsules garlic capsules should not be used while taking drugn -lcb- druga -rcb- as the sole drugb due to the risk of decreased drugn plasma concentrations .
DDI-DrugBank.d124.s18.p4	FORTOVASE	brand	_	saquinavir	drug	_	false	garlic capsules garlic capsules should not be used while taking drugn -lcb- druga -rcb- as the sole drugn due to the risk of decreased drugb plasma concentrations .
DDI-DrugBank.d124.s18.p5	protease inhibitor	group	_	saquinavir	drug	_	false	garlic capsules garlic capsules should not be used while taking drugn -lcb- drugn -rcb- as the sole druga due to the risk of decreased drugb plasma concentrations .
DDI-DrugBank.d124.s22.p0	HMG-CoA Reductase Inhibitors	group	_	lovastatin	drug	_	false	druga : drugb , drugn warning potential for serious reactions such as risk of myopathy including rhabdomyolysis .
DDI-DrugBank.d124.s22.p1	HMG-CoA Reductase Inhibitors	group	_	simvastatin	drug	_	false	druga : drugn , drugb warning potential for serious reactions such as risk of myopathy including rhabdomyolysis .
DDI-DrugBank.d124.s22.p2	lovastatin	drug	_	simvastatin	drug	_	false	drugn : druga , drugb warning potential for serious reactions such as risk of myopathy including rhabdomyolysis .
DDI-DrugBank.d124.s23.p0	Sedatives	group	_	Hypnotics	group	_	false	druga / drugb : drugn , drugn contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s23.p1	Sedatives	group	_	triazolam	drug	_	false	druga / drugn : drugb , drugn contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s23.p2	Sedatives	group	_	midazolam	drug	_	false	druga / drugn : drugn , drugb contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s23.p3	Hypnotics	group	_	triazolam	drug	_	false	drugn / druga : drugb , drugn contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s23.p4	Hypnotics	group	_	midazolam	drug	_	false	drugn / druga : drugn , drugb contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s23.p5	triazolam	drug	_	midazolam	drug	_	false	drugn / drugn : druga , drugb contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .
DDI-DrugBank.d124.s26.p15	calcium channel blockers	group	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p30	dapsone	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p44	disopyramide	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p57	quinine	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p69	amiodarone	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p80	quinidine	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p90	warfarin	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p99	tacrolimus	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p107	cyclosporine	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p114	ergot derivatives	group	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p120	pimozide	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p125	carbamazepine	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p129	fentanyl	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p132	alfentanyl	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p134	alprazolam	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s26.p135	triazolam	drug	_	saquinavir	drug	_	mechanism	although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 -lcb- eg , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga -rcb- may have elevated plasma concentrations when coadministered with drugb ;
DDI-DrugBank.d124.s28.p0	INVIRASE	brand	_	ritonavir	drug	_	advise	since druga is coadministered with drugb , the drugn label should be reviewed for additional drugs that should not be coadministered .
DDI-DrugBank.d124.s28.p1	INVIRASE	brand	_	ritonavir	drug	_	false	since druga is coadministered with drugn , the drugb label should be reviewed for additional drugs that should not be coadministered .
DDI-DrugBank.d124.s30.p3	phenobarbital	drug	_	saquinavir	drug	_	mechanism	coadministration with compounds that are potent inducers of cyp3a4 -lcb- eg , druga , drugn , drugn , drugn -rcb- may result in decreased plasma levels of drugb .
DDI-DrugBank.d124.s30.p6	phenytoin	drug	_	saquinavir	drug	_	mechanism	coadministration with compounds that are potent inducers of cyp3a4 -lcb- eg , drugn , druga , drugn , drugn -rcb- may result in decreased plasma levels of drugb .
DDI-DrugBank.d124.s30.p8	dexamethasone	drug	_	saquinavir	drug	_	mechanism	coadministration with compounds that are potent inducers of cyp3a4 -lcb- eg , drugn , drugn , druga , drugn -rcb- may result in decreased plasma levels of drugb .
DDI-DrugBank.d124.s30.p9	carbamazepine	drug	_	saquinavir	drug	_	mechanism	coadministration with compounds that are potent inducers of cyp3a4 -lcb- eg , drugn , drugn , drugn , druga -rcb- may result in decreased plasma levels of drugb .
DDI-DrugBank.d65.s0.p0	Sulfacetamide	drug	_	silver	drug	_	int	druga preparations are incompatible with drugb preparations .
DDI-DrugBank.d179.s1.p0	Sulfapyridine	drug	_	Acetaminophen	drug	_	int	druga may interact with any of the following : - drugb -lcb- e , g , , drugn -rcb- -lcb- with long-term , high-dose use -rcb- or
DDI-DrugBank.d179.s1.p1	Sulfapyridine	drug	_	Tylenol	brand	_	int	druga may interact with any of the following : - drugn -lcb- e , g , , drugb -rcb- -lcb- with long-term , high-dose use -rcb- or
DDI-DrugBank.d179.s19.p0	contraceptives	group	_	estrogen	group	_	false	- oral druga -lcb- birth control pills -rcb- containing drugb or
DDI-DrugBank.d179.s23.p1	Valproic acid	drug	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn -rcb- use of drugb with these medicines may increase the chance of side effects affecting the liver
DDI-DrugBank.d179.s23.p2	Depakene	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugb with these medicines may increase the chance of side effects affecting the liver
DDI-DrugBank.d179.s33.p2	Vitamin K	group	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn , drugn -rcb- use of drugb with these medicines may increase the chance of side effects affecting the blood
DDI-DrugBank.d179.s33.p4	AquaMEPHYTON	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga , drugn -rcb- use of drugb with these medicines may increase the chance of side effects affecting the blood
DDI-DrugBank.d179.s33.p5	Synkayvite	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , drugn , druga -rcb- use of drugb with these medicines may increase the chance of side effects affecting the blood
DDI-DrugBank.d179.s36.p1	Mephenytoin	drug	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn -rcb- use of drugb with these medicines may increase the chance of side effects of these medicines
DDI-DrugBank.d179.s36.p2	Mesantoin	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugb with these medicines may increase the chance of side effects of these medicines
DDI-DrugBank.d179.s37.p1	Antidiabetics	group	_	sulfapyridine	drug	_	false	- druga , oral -lcb- diabetes medicine you take by mouth -rcb- use of oral drugn with drugb may increase the chance of side effects affecting the blood and/or the side effects or oral drugn
DDI-DrugBank.d179.s37.p3	antidiabetics	group	_	sulfapyridine	drug	_	effect	- drugn , oral -lcb- diabetes medicine you take by mouth -rcb- use of oral druga with drugb may increase the chance of side effects affecting the blood and/or the side effects or oral drugn
DDI-DrugBank.d179.s37.p5	sulfapyridine	drug	_	antidiabetics	group	_	false	- drugn , oral -lcb- diabetes medicine you take by mouth -rcb- use of oral drugn with druga may increase the chance of side effects affecting the blood and/or the side effects or oral drugb
DDI-DrugBank.d179.s38.p2	Methotrexate	drug	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s38.p4	Mexate	brand	_	methotrexate	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugb with drugn may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s38.p5	Mexate	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s38.p6	Mexate	brand	_	methotrexate	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugn with drugn may increase the chance of side effects affecting the liver and/or the side effects of drugb
DDI-DrugBank.d179.s38.p7	methotrexate	drug	_	sulfapyridine	drug	_	effect	- drugn -lcb- e , g , , drugn -rcb- use of druga with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s38.p9	sulfapyridine	drug	_	methotrexate	drug	_	false	- drugn -lcb- e , g , , drugn -rcb- use of drugn with druga may increase the chance of side effects affecting the liver and/or the side effects of drugb
DDI-DrugBank.d179.s39.p2	Methyldopa	drug	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s39.p3	Aldomet	brand	_	methyldopa	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugb with drugn may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s39.p4	Aldomet	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s39.p5	methyldopa	drug	_	sulfapyridine	drug	_	effect	- drugn -lcb- e , g , , drugn -rcb- use of druga with drugb may increase the chance of side effects affecting the liver and/or the blood
DDI-DrugBank.d179.s40.p2	Phenytoin	drug	_	sulfapyridine	drug	_	false	- druga -lcb- e , g , , drugn -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s40.p4	Dilantin	brand	_	phenytoin	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugb with drugn may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s40.p5	Dilantin	brand	_	sulfapyridine	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugn with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s40.p6	Dilantin	brand	_	phenytoin	drug	_	false	- drugn -lcb- e , g , , druga -rcb- use of drugn with drugn may increase the chance of side effects affecting the liver and/or the side effects of drugb
DDI-DrugBank.d179.s40.p7	phenytoin	drug	_	sulfapyridine	drug	_	effect	- drugn -lcb- e , g , , drugn -rcb- use of druga with drugb may increase the chance of side effects affecting the liver and/or the side effects of drugn
DDI-DrugBank.d179.s40.p9	sulfapyridine	drug	_	phenytoin	drug	_	false	- drugn -lcb- e , g , , drugn -rcb- use of drugn with druga may increase the chance of side effects affecting the liver and/or the side effects of drugb
DDI-DrugBank.d277.s2.p0	valproate	drug	_	gabapentin	drug	_	false	druga and drugb are not .
DDI-DrugBank.d277.s3.p0	GABITRIL	brand	_	AED	group	_	false	druga is considered to be a non-enzyme inducing drugb .
DDI-DrugBank.d277.s5.p0	GABITRIL	brand	_	AEDs	group	_	false	effects of druga on other antiepilepsy drugs -lcb- drugb -rcb- : drugn : drugn had no effect on the steady-state plasma concentrations of drugn in patients with epilepsy .
DDI-DrugBank.d277.s5.p1	GABITRIL	brand	_	Phenytoin	drug	_	false	effects of druga on other antiepilepsy drugs -lcb- drugn -rcb- : drugb : drugn had no effect on the steady-state plasma concentrations of drugn in patients with epilepsy .
DDI-DrugBank.d277.s5.p4	AEDs	group	_	Phenytoin	drug	_	false	effects of drugn on other antiepilepsy drugs -lcb- druga -rcb- : drugb : drugn had no effect on the steady-state plasma concentrations of drugn in patients with epilepsy .
DDI-DrugBank.d277.s5.p9	Tiagabine	drug	_	phenytoin	drug	_	false	effects of drugn on other antiepilepsy drugs -lcb- drugn -rcb- : drugn : druga had no effect on the steady-state plasma concentrations of drugb in patients with epilepsy .
DDI-DrugBank.d277.s6.p2	Tiagabine	drug	_	carbamazepine	drug	_	false	drugn : druga had no effect on the steady-state plasma concentrations of drugb or its epoxide metabolite in patients with epilepsy .
DDI-DrugBank.d277.s7.p2	Tiagabine	drug	_	valproate	drug	_	mechanism	drugn : druga causes a slight decrease -lcb- about 10 % -rcb- in steady-state drugb concentrations .
DDI-DrugBank.d277.s8.p0	Phenobarbital	drug	_	Primidone	drug	_	false	druga or drugb : no formal pharmacokinetic studies have been performed examining the addition of drugn to regimens containing drugn or drugn .
DDI-DrugBank.d277.s8.p7	tiagabine	drug	_	phenobarbital	drug	_	false	drugn or drugn : no formal pharmacokinetic studies have been performed examining the addition of druga to regimens containing drugb or drugn .
DDI-DrugBank.d277.s8.p8	tiagabine	drug	_	primidone	drug	_	false	drugn or drugn : no formal pharmacokinetic studies have been performed examining the addition of druga to regimens containing drugn or drugb .
DDI-DrugBank.d277.s8.p9	phenobarbital	drug	_	primidone	drug	_	false	drugn or drugn : no formal pharmacokinetic studies have been performed examining the addition of drugn to regimens containing druga or drugb .
DDI-DrugBank.d277.s9.p0	tiagabine	drug	_	phenobarbital	drug	_	false	the addition of druga in a limited number of patients in three well-controlled studies caused no systematic changes in drugb or drugn concentrations when compared to placebo .
DDI-DrugBank.d277.s9.p1	tiagabine	drug	_	primidone	drug	_	false	the addition of druga in a limited number of patients in three well-controlled studies caused no systematic changes in drugn or drugb concentrations when compared to placebo .
DDI-DrugBank.d277.s9.p2	phenobarbital	drug	_	primidone	drug	_	false	the addition of drugn in a limited number of patients in three well-controlled studies caused no systematic changes in druga or drugb concentrations when compared to placebo .
DDI-DrugBank.d277.s10.p0	AEDs	group	_	GABITRIL	brand	_	false	effects of other antiepilepsy drugs -lcb- druga -rcb- on drugb : drugn : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking drugn with or without other enzyme - inducing drugn .
DDI-DrugBank.d277.s10.p1	AEDs	group	_	Carbamazepine	drug	_	false	effects of other antiepilepsy drugs -lcb- druga -rcb- on drugn : drugb : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking drugn with or without other enzyme - inducing drugn .
DDI-DrugBank.d277.s10.p5	GABITRIL	brand	_	Carbamazepine	drug	_	false	effects of other antiepilepsy drugs -lcb- drugn -rcb- on druga : drugb : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking drugn with or without other enzyme - inducing drugn .
DDI-DrugBank.d277.s10.p12	tiagabine	drug	_	carbamazepine	drug	_	mechanism	effects of other antiepilepsy drugs -lcb- drugn -rcb- on drugn : drugn : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugb with or without other enzyme - inducing drugn .
DDI-DrugBank.d277.s10.p13	tiagabine	drug	_	AEDs	group	_	false	effects of other antiepilepsy drugs -lcb- drugn -rcb- on drugn : drugn : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugn with or without other enzyme - inducing drugb .
DDI-DrugBank.d277.s10.p14	carbamazepine	drug	_	AEDs	group	_	false	effects of other antiepilepsy drugs -lcb- drugn -rcb- on drugn : drugn : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking druga with or without other enzyme - inducing drugb .
DDI-DrugBank.d277.s11.p3	tiagabine	drug	_	phenytoin	drug	_	mechanism	drugn : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugb with or without other enzyme - inducing drugn .
DDI-DrugBank.d277.s11.p4	tiagabine	drug	_	AEDs	group	_	false	drugn : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugn with or without other enzyme - inducing drugb .
DDI-DrugBank.d277.s11.p5	phenytoin	drug	_	AEDs	group	_	false	drugn : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking druga with or without other enzyme - inducing drugb .
DDI-DrugBank.d277.s12.p9	tiagabine	drug	_	phenobarbital	drug	_	mechanism	drugn -lcb- drugn -rcb- : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugb -lcb- drugn -rcb- with or without other enzyme-inducing drugn .
DDI-DrugBank.d277.s12.p10	tiagabine	drug	_	primidone	drug	_	mechanism	drugn -lcb- drugn -rcb- : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugn -lcb- drugb -rcb- with or without other enzyme-inducing drugn .
DDI-DrugBank.d277.s12.p11	tiagabine	drug	_	AEDs	group	_	false	drugn -lcb- drugn -rcb- : population pharmacokinetic analyses indicate that druga clearance is 60 % greater in patients taking drugn -lcb- drugn -rcb- with or without other enzyme-inducing drugb .
DDI-DrugBank.d277.s12.p13	phenobarbital	drug	_	AEDs	group	_	false	drugn -lcb- drugn -rcb- : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking druga -lcb- drugn -rcb- with or without other enzyme-inducing drugb .
DDI-DrugBank.d277.s12.p14	primidone	drug	_	AEDs	group	_	false	drugn -lcb- drugn -rcb- : population pharmacokinetic analyses indicate that drugn clearance is 60 % greater in patients taking drugn -lcb- druga -rcb- with or without other enzyme-inducing drugb .
DDI-DrugBank.d277.s13.p5	tiagabine	drug	_	valproate	drug	_	false	drugn : the addition of druga to patients taking drugb chronically had no effect on drugn pharmacokinetics , but drugn significantly decreased drugn binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s13.p7	tiagabine	drug	_	valproate	drug	_	false	drugn : the addition of druga to patients taking drugn chronically had no effect on drugn pharmacokinetics , but drugb significantly decreased drugn binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s13.p9	valproate	drug	_	tiagabine	drug	_	false	drugn : the addition of drugn to patients taking druga chronically had no effect on drugb pharmacokinetics , but drugn significantly decreased drugn binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s13.p11	valproate	drug	_	tiagabine	drug	_	false	drugn : the addition of drugn to patients taking druga chronically had no effect on drugn pharmacokinetics , but drugn significantly decreased drugb binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s13.p12	tiagabine	drug	_	valproate	drug	_	false	drugn : the addition of drugn to patients taking drugn chronically had no effect on druga pharmacokinetics , but drugb significantly decreased drugn binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s13.p14	valproate	drug	_	tiagabine	drug	_	mechanism	drugn : the addition of drugn to patients taking drugn chronically had no effect on drugn pharmacokinetics , but druga significantly decreased drugb binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .
DDI-DrugBank.d277.s15.p0	GABITRIL	brand	_	Cimetidine	drug	_	false	interaction of druga with other drugs : drugb : co-administration of drugn -lcb- 800 mg/day -rcb- to patients taking drugn chronically had no effect on drugn pharmacokinetics .
DDI-DrugBank.d277.s15.p1	GABITRIL	brand	_	cimetidine	drug	_	false	interaction of druga with other drugs : drugn : co-administration of drugb -lcb- 800 mg/day -rcb- to patients taking drugn chronically had no effect on drugn pharmacokinetics .
DDI-DrugBank.d277.s15.p2	GABITRIL	brand	_	tiagabine	drug	_	false	interaction of druga with other drugs : drugn : co-administration of drugn -lcb- 800 mg/day -rcb- to patients taking drugb chronically had no effect on drugn pharmacokinetics .
DDI-DrugBank.d277.s15.p3	GABITRIL	brand	_	tiagabine	drug	_	false	interaction of druga with other drugs : drugn : co-administration of drugn -lcb- 800 mg/day -rcb- to patients taking drugn chronically had no effect on drugb pharmacokinetics .
DDI-DrugBank.d277.s15.p5	Cimetidine	drug	_	tiagabine	drug	_	false	interaction of drugn with other drugs : druga : co-administration of drugn -lcb- 800 mg/day -rcb- to patients taking drugb chronically had no effect on drugn pharmacokinetics .
DDI-DrugBank.d277.s15.p6	Cimetidine	drug	_	tiagabine	drug	_	false	interaction of drugn with other drugs : druga : co-administration of drugn -lcb- 800 mg/day -rcb- to patients taking drugn chronically had no effect on drugb pharmacokinetics .
DDI-DrugBank.d277.s15.p7	cimetidine	drug	_	tiagabine	drug	_	false	interaction of drugn with other drugs : drugn : co-administration of druga -lcb- 800 mg/day -rcb- to patients taking drugb chronically had no effect on drugn pharmacokinetics .
DDI-DrugBank.d277.s15.p8	cimetidine	drug	_	tiagabine	drug	_	false	interaction of drugn with other drugs : drugn : co-administration of druga -lcb- 800 mg/day -rcb- to patients taking drugn chronically had no effect on drugb pharmacokinetics .
DDI-DrugBank.d277.s16.p2	tiagabine	drug	_	theophylline	drug	_	false	drugn : a single # mg dose of druga did not affect the pharmacokinetics of drugb at steady state .
DDI-DrugBank.d277.s17.p3	R-warfarin	drug	_	S-warfarin	drug	_	false	drugn : no significant differences were observed in the steady-state pharmacokinetics of druga or drugb with the addition of drugn given as a single dose .
DDI-DrugBank.d277.s17.p4	R-warfarin	drug	_	tiagabine	drug	_	false	drugn : no significant differences were observed in the steady-state pharmacokinetics of druga or drugn with the addition of drugb given as a single dose .
DDI-DrugBank.d277.s17.p5	S-warfarin	drug	_	tiagabine	drug	_	false	drugn : no significant differences were observed in the steady-state pharmacokinetics of drugn or druga with the addition of drugb given as a single dose .
DDI-DrugBank.d277.s19.p0	Digoxin	drug	_	tiagabine	drug	_	false	druga : concomitant administration of drugb did not affect the steady-state pharmacokinetics of drugn or the mean daily trough serum level of drugn .
DDI-DrugBank.d277.s19.p3	tiagabine	drug	_	digoxin	drug	_	false	drugn : concomitant administration of druga did not affect the steady-state pharmacokinetics of drugb or the mean daily trough serum level of drugn .
DDI-DrugBank.d277.s19.p4	tiagabine	drug	_	digoxin	drug	_	false	drugn : concomitant administration of druga did not affect the steady-state pharmacokinetics of drugn or the mean daily trough serum level of drugb .
DDI-DrugBank.d277.s20.p0	Ethanol	drug	_	Triazolam	drug	_	false	druga or drugb : no significant differences were observed in the pharmacokinetics of drugn -lcb- # mg -rcb- and drugn -lcb- 10 mg -rcb- when given together as a single dose .
DDI-DrugBank.d277.s20.p5	triazolam	drug	_	tiagabine	drug	_	false	drugn or drugn : no significant differences were observed in the pharmacokinetics of druga -lcb- # mg -rcb- and drugb -lcb- 10 mg -rcb- when given together as a single dose .
DDI-DrugBank.d277.s21.p0	ethanol	drug	_	tiagabine	drug	_	false	the pharmacokinetics of druga were not affected by multiple-dose administration of drugb .
DDI-DrugBank.d277.s22.p0	Tiagabine	drug	_	alcohol	drug	_	false	druga has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or drugb .
DDI-DrugBank.d277.s23.p0	ethanol	drug	_	triazolam	drug	_	false	because of the possible additive effects of drugs that may depress the nervous system , druga or drugb should be used cautiously in combination with drugn .
DDI-DrugBank.d277.s23.p1	ethanol	drug	_	tiagabine	drug	_	advise	because of the possible additive effects of drugs that may depress the nervous system , druga or drugn should be used cautiously in combination with drugb .
DDI-DrugBank.d277.s23.p2	triazolam	drug	_	tiagabine	drug	_	advise	because of the possible additive effects of drugs that may depress the nervous system , drugn or druga should be used cautiously in combination with drugb .
DDI-DrugBank.d277.s24.p2	tiagabine	drug	_	contraceptives	group	_	false	oral drugn : multiple dose administration of druga -lcb- 8 mg/day monotherapy -rcb- did not alter the pharmacokinetics of oral drugb in healthy women of childbearing age .
DDI-DrugBank.d277.s25.p2	Antipyrine	drug	_	tiagabine	drug	_	false	drugn : druga pharmacokinetics were not significantly different before and after drugb multiple-dose regimens .
DDI-DrugBank.d277.s26.p0	tiagabine	drug	_	antipyrine	drug	_	false	this indicates that druga does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of drugb .
DDI-DrugBank.d328.s4.p1	Aspirin	brand	_	valdecoxib	drug	_	false	druga : concomitant administration of drugn with drugb may result in an increased risk of gi ulceration and complications compared to drugn alone .
DDI-DrugBank.d328.s4.p2	Aspirin	brand	_	valdecoxib	drug	_	false	druga : concomitant administration of drugn with drugn may result in an increased risk of gi ulceration and complications compared to drugb alone .
DDI-DrugBank.d328.s4.p3	aspirin	brand	_	valdecoxib	drug	_	effect	drugn : concomitant administration of druga with drugb may result in an increased risk of gi ulceration and complications compared to drugn alone .
DDI-DrugBank.d328.s4.p4	aspirin	brand	_	valdecoxib	drug	_	false	drugn : concomitant administration of druga with drugn may result in an increased risk of gi ulceration and complications compared to drugb alone .
DDI-DrugBank.d328.s5.p0	valdecoxib	drug	_	aspirin	brand	_	false	because of its lack of anti-platelet effect druga is not a substitute for drugb for cardiovascular prophylaxis .
DDI-DrugBank.d328.s6.p1	valdecoxib	drug	_	aspirin	brand	_	false	in a parallel group drug interaction study comparing the intravenous prodrug form of druga at # mg bid -lcb- n = 10 -rcb- vs placebo -lcb- n = 9 -rcb- , drugn had no effect on in vitro drugb - mediated inhibition of arachidonate - or collagen-stimulated platelet aggregation .
DDI-DrugBank.d328.s6.p2	valdecoxib	drug	_	aspirin	brand	_	false	in a parallel group drug interaction study comparing the intravenous prodrug form of drugn at # mg bid -lcb- n = 10 -rcb- vs placebo -lcb- n = 9 -rcb- , druga had no effect on in vitro drugb - mediated inhibition of arachidonate - or collagen-stimulated platelet aggregation .
DDI-DrugBank.d328.s7.p2	Valdecoxib 10 mg	drug	_	methotrexate	drug	_	false	drugn : druga bid did not show a significant effect on the plasma exposure or renal clearance of drugb .
DDI-DrugBank.d328.s8.p0	ACE-inhibitors	group	_	NSAIDs	group	_	false	druga : reports suggest that drugb may diminish the antihypertensive effect of drugn .
DDI-DrugBank.d328.s8.p2	NSAIDs	group	_	ACE-inhibitors	group	_	effect	drugn : reports suggest that druga may diminish the antihypertensive effect of drugb .
DDI-DrugBank.d328.s9.p0	BEXTRA	brand	_	ACE-inhibitors	group	_	advise	this interaction should be given consideration in patients taking druga concomitantly with drugb .
DDI-DrugBank.d328.s10.p0	Furosemide	drug	_	NSAIDs	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
DDI-DrugBank.d328.s10.p2	Furosemide	drug	_	thiazides	group	_	false	druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d328.s10.p3	NSAIDs	group	_	furosemide	drug	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
DDI-DrugBank.d328.s10.p4	NSAIDs	group	_	thiazides	group	_	effect	drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
DDI-DrugBank.d328.s10.p5	furosemide	drug	_	thiazides	group	_	false	drugn : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
DDI-DrugBank.d328.s12.p5	valdecoxib	drug	_	phenytoin	drug	_	mechanism	drugn -lcb- drugn -rcb- : steady state plasma exposure -lcb- auc -rcb- of druga -lcb- 40 mg bid for # days -rcb- was decreased by 27 % when co-administered with multiple doses -lcb- 300 mg qd for # days -rcb- of drugb -lcb- a ppig 3a4 inducer -rcb- .
DDI-DrugBank.d328.s13.p0	valdecoxib	drug	_	phenytoin	drug	_	advise	patients already stabilized on druga should be closely monitored for loss of symptom control with drugb coadministration .
DDI-DrugBank.d328.s14.p0	Valdecoxib	drug	_	phenytoin	drug	_	false	druga did not have a statistically significant effect on the pharmacokinetics of drugb -lcb- a ppig 2c9 and cyp 2c19 substrate -rcb- .
DDI-DrugBank.d328.s18.p0	valdecoxib	drug	_	dextromethorphan	drug	_	mechanism	coadministration with druga -lcb- 40 mg bid for # days -rcb- resulted in a significant increase in drugb plasma levels suggesting that , at these doses , drugn is a weak inhibitor of 2d6 .
DDI-DrugBank.d328.s18.p2	dextromethorphan	drug	_	valdecoxib	drug	_	false	coadministration with drugn -lcb- 40 mg bid for # days -rcb- resulted in a significant increase in druga plasma levels suggesting that , at these doses , drugb is a weak inhibitor of 2d6 .
DDI-DrugBank.d328.s19.p0	dextromethorphan	drug	_	valdecoxib	drug	_	mechanism	even so druga plasma concentrations in the presence of high doses of drugb were almost 5-fold lower than those seen in ppig 2d6 poor metabolizers suggesting that dose adjustment is not necessary .
DDI-DrugBank.d328.s20.p3	Valdecoxib	drug	_	lithium	drug	_	mechanism	drugn : druga # mg bid for # days produced significant decreases in drugb serum clearance -lcb- 25 % -rcb- and renal clearance -lcb- 30 % -rcb- with a 34 % higher serum exposure compared to drugn alone .
DDI-DrugBank.d328.s20.p4	Valdecoxib	drug	_	lithium	drug	_	false	drugn : druga # mg bid for # days produced significant decreases in drugn serum clearance -lcb- 25 % -rcb- and renal clearance -lcb- 30 % -rcb- with a 34 % higher serum exposure compared to drugb alone .
DDI-DrugBank.d328.s21.p0	Lithium	drug	_	BEXTRA	brand	_	false	druga serum concentrations should be monitored closely when initiating or changing therapy with drugb in patients receiving drugn .
DDI-DrugBank.d328.s21.p2	BEXTRA	brand	_	lithium	drug	_	advise	drugn serum concentrations should be monitored closely when initiating or changing therapy with druga in patients receiving drugb .
DDI-DrugBank.d328.s22.p0	Lithium carbonate	drug	_	valdecoxib	drug	_	false	druga -lcb- 450 mg bid for # days -rcb- had no effect on drugb pharmacokinetics .
DDI-DrugBank.d328.s23.p3	valdecoxib	drug	_	warfarin	drug	_	false	drugn : the effect of druga on the anticoagulant effect of drugb -lcb- 1 - # mg/day -rcb- was studied in healthy subjects by coadministration of drugn # mg bid for # days .
DDI-DrugBank.d328.s23.p4	valdecoxib	drug	_	BEXTRA	brand	_	false	drugn : the effect of druga on the anticoagulant effect of drugn -lcb- 1 - # mg/day -rcb- was studied in healthy subjects by coadministration of drugb # mg bid for # days .
DDI-DrugBank.d328.s23.p5	warfarin	drug	_	BEXTRA	brand	_	false	drugn : the effect of drugn on the anticoagulant effect of druga -lcb- 1 - # mg/day -rcb- was studied in healthy subjects by coadministration of drugb # mg bid for # days .
DDI-DrugBank.d328.s24.p0	Valdecoxib	drug	_	R-warfarin	drug	_	mechanism	druga caused a statistically significant increase in plasma exposures of drugb and drugn -lcb- 12 % and 15 % , respectively -rcb- , and in the pharmacodynamic effects -lcb- prothrombin time , measured as inr -rcb- of drugn .
DDI-DrugBank.d328.s24.p1	Valdecoxib	drug	_	S-warfarin	drug	_	mechanism	druga caused a statistically significant increase in plasma exposures of drugn and drugb -lcb- 12 % and 15 % , respectively -rcb- , and in the pharmacodynamic effects -lcb- prothrombin time , measured as inr -rcb- of drugn .
DDI-DrugBank.d328.s24.p2	Valdecoxib	drug	_	warfarin	drug	_	effect	druga caused a statistically significant increase in plasma exposures of drugn and drugn -lcb- 12 % and 15 % , respectively -rcb- , and in the pharmacodynamic effects -lcb- prothrombin time , measured as inr -rcb- of drugb .
DDI-DrugBank.d328.s24.p3	R-warfarin	drug	_	S-warfarin	drug	_	false	drugn caused a statistically significant increase in plasma exposures of druga and drugb -lcb- 12 % and 15 % , respectively -rcb- , and in the pharmacodynamic effects -lcb- prothrombin time , measured as inr -rcb- of drugn .
DDI-DrugBank.d328.s26.p0	Anticoagulant	brand	_	BEXTRA	brand	_	false	druga therapy should be monitored , particularly during the first few weeks , after initiating therapy with drugb in patients receiving drugn or similar agents .
DDI-DrugBank.d328.s26.p1	Anticoagulant	brand	_	warfarin	drug	_	false	druga therapy should be monitored , particularly during the first few weeks , after initiating therapy with drugn in patients receiving drugb or similar agents .
DDI-DrugBank.d328.s26.p2	BEXTRA	brand	_	warfarin	drug	_	advise	drugn therapy should be monitored , particularly during the first few weeks , after initiating therapy with druga in patients receiving drugb or similar agents .
DDI-DrugBank.d328.s27.p0	Fluconazole	drug	_	Ketoconazole	drug	_	false	druga and drugb : drugn and drugn are predominantly ppig 3a4 and 2c9 inhibitors , respectively .
DDI-DrugBank.d328.s27.p5	Ketoconazole	drug	_	fluconazole	drug	_	false	drugn and drugn : druga and drugb are predominantly ppig 3a4 and 2c9 inhibitors , respectively .
DDI-DrugBank.d328.s28.p0	valdecoxib	drug	_	ketoconazole	drug	_	mechanism	concomitant single dose administration of druga # mg with multiple doses of drugb and drugn produced a significant increase in exposure of drugn .
DDI-DrugBank.d328.s28.p1	valdecoxib	drug	_	fluconazole	drug	_	mechanism	concomitant single dose administration of druga # mg with multiple doses of drugn and drugb produced a significant increase in exposure of drugn .
DDI-DrugBank.d328.s28.p3	ketoconazole	drug	_	fluconazole	drug	_	false	concomitant single dose administration of drugn # mg with multiple doses of druga and drugb produced a significant increase in exposure of drugn .
DDI-DrugBank.d328.s28.p4	ketoconazole	drug	_	valdecoxib	drug	_	false	concomitant single dose administration of drugn # mg with multiple doses of druga and drugn produced a significant increase in exposure of drugb .
DDI-DrugBank.d328.s28.p5	fluconazole	drug	_	valdecoxib	drug	_	false	concomitant single dose administration of drugn # mg with multiple doses of drugn and druga produced a significant increase in exposure of drugb .
DDI-DrugBank.d328.s29.p0	valdecoxib	drug	_	fluconazole	drug	_	mechanism	plasma exposure -lcb- auc -rcb- to druga was increased 62 % when coadministered with drugb and 38 % when coadministered with drugn .
DDI-DrugBank.d328.s29.p1	valdecoxib	drug	_	ketoconazole	drug	_	mechanism	plasma exposure -lcb- auc -rcb- to druga was increased 62 % when coadministered with drugn and 38 % when coadministered with drugb .
DDI-DrugBank.d328.s29.p2	fluconazole	drug	_	ketoconazole	drug	_	false	plasma exposure -lcb- auc -rcb- to drugn was increased 62 % when coadministered with druga and 38 % when coadministered with drugb .
DDI-DrugBank.d328.s31.p0	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 10 mg bid for # days -rcb- with drugb -lcb- 5 mg qd or # mg bid -rcb- did not affect the pharmacokinetics -lcb- exposure -rcb- of drugn .
DDI-DrugBank.d328.s31.p1	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 10 mg bid for # days -rcb- with drugn -lcb- 5 mg qd or # mg bid -rcb- did not affect the pharmacokinetics -lcb- exposure -rcb- of drugb .
DDI-DrugBank.d328.s32.p0	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugb -lcb- 5 mg qd -rcb- did not affect either the pharmacokinetics -lcb- exposure -rcb- or the pharmacodynamics -lcb- blood glucose and insulin levels -rcb- of drugn .
DDI-DrugBank.d328.s32.p1	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugn -lcb- 5 mg qd -rcb- did not affect either the pharmacokinetics -lcb- exposure -rcb- or the pharmacodynamics -lcb- blood glucose and insulin levels -rcb- of drugb .
DDI-DrugBank.d328.s33.p0	valdecoxib	drug	_	glyburide	drug	_	mechanism	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugb -lcb- 10 mg drugn bid -rcb- resulted in 21 % increase in drugn auc0-12 and a 16 % increase in drugn cmax leading to a 16 % decrease in glucose auc0-24 .
DDI-DrugBank.d328.s33.p1	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugn -lcb- 10 mg drugb bid -rcb- resulted in 21 % increase in drugn auc0-12 and a 16 % increase in drugn cmax leading to a 16 % decrease in glucose auc0-24 .
DDI-DrugBank.d328.s33.p2	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugn -lcb- 10 mg drugn bid -rcb- resulted in 21 % increase in drugb auc0-12 and a 16 % increase in drugn cmax leading to a 16 % decrease in glucose auc0-24 .
DDI-DrugBank.d328.s33.p3	valdecoxib	drug	_	glyburide	drug	_	false	coadministration of druga -lcb- 40 mg bid -lcb- day 1 -rcb- and # mg qd -lcb- days 2-7 -rcb- -rcb- with drugn -lcb- 10 mg drugn bid -rcb- resulted in 21 % increase in drugn auc0-12 and a 16 % increase in drugb cmax leading to a 16 % decrease in glucose auc0-24 .
DDI-DrugBank.d328.s35.p0	valdecoxib	drug	_	glyburide	drug	_	false	because changes in glucose concentrations with druga coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dl , dose adjustment for drugb -lcb- 5 mg qd and # mg bid -rcb- with drugn coadministration -lcb- up to # mg qd -rcb- is not indicated .
DDI-DrugBank.d328.s35.p2	glyburide	drug	_	valdecoxib	drug	_	advise	because changes in glucose concentrations with drugn coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dl , dose adjustment for druga -lcb- 5 mg qd and # mg bid -rcb- with drugb coadministration -lcb- up to # mg qd -rcb- is not indicated .
DDI-DrugBank.d328.s36.p0	glyburide	drug	_	valdecoxib	drug	_	false	coadministration of druga with doses higher than # mg drugb -lcb- e , g , , # mg bid -rcb- have not been studied .
DDI-DrugBank.d328.s38.p0	Valdecoxib	drug	_	omeprazole	drug	_	false	druga steady state plasma concentrations -lcb- 40 mg bid -rcb- were not affected significantly with multiple doses of drugb -lcb- 40 mg qd -rcb- .
DDI-DrugBank.d328.s39.p0	valdecoxib	drug	_	omeprazole	drug	_	mechanism	coadministration with druga increased exposure of drugb -lcb- auc -rcb- by 46 % .
DDI-DrugBank.d328.s40.p0	omeprazole	drug	_	valdecoxib	drug	_	false	drugs whose absorption is sensitive to ph may be negatively impacted by concomitant administration of druga and drugb .
DDI-DrugBank.d328.s42.p0	valdecoxib	drug	_	omeprazole	drug	_	false	coadministration of druga with doses higher than # mg qd drugb has not been studied .
DDI-DrugBank.d328.s43.p5	Valdecoxib	drug	_	contraceptive	group	_	false	oral drugn : druga -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugb drugn / drugn -lcb- 1 mg / 35 mcg combination , drugn 1/35 -rcb- .
DDI-DrugBank.d328.s43.p6	Valdecoxib	drug	_	norethindrone	drug	_	false	oral drugn : druga -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugn drugb / drugn -lcb- 1 mg / 35 mcg combination , drugn 1/35 -rcb- .
DDI-DrugBank.d328.s43.p7	Valdecoxib	drug	_	ethinyl estradiol	drug	_	false	oral drugn : druga -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugn drugn / drugb -lcb- 1 mg / 35 mcg combination , drugn 1/35 -rcb- .
DDI-DrugBank.d328.s43.p8	Valdecoxib	drug	_	Ortho-Novum	brand	_	false	oral drugn : druga -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugn drugn / drugn -lcb- 1 mg / 35 mcg combination , drugb 1/35 -rcb- .
DDI-DrugBank.d328.s43.p9	contraceptive	group	_	norethindrone	drug	_	false	oral drugn : drugn -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral druga drugb / drugn -lcb- 1 mg / 35 mcg combination , drugn 1/35 -rcb- .
DDI-DrugBank.d328.s43.p10	contraceptive	group	_	ethinyl estradiol	drug	_	false	oral drugn : drugn -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral druga drugn / drugb -lcb- 1 mg / 35 mcg combination , drugn 1/35 -rcb- .
DDI-DrugBank.d328.s43.p11	contraceptive	group	_	Ortho-Novum	brand	_	false	oral drugn : drugn -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral druga drugn / drugn -lcb- 1 mg / 35 mcg combination , drugb 1/35 -rcb- .
DDI-DrugBank.d328.s43.p13	norethindrone	drug	_	Ortho-Novum	brand	_	false	oral drugn : drugn -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugn druga / drugn -lcb- 1 mg / 35 mcg combination , drugb 1/35 -rcb- .
DDI-DrugBank.d328.s43.p14	ethinyl estradiol	drug	_	Ortho-Novum	brand	_	false	oral drugn : drugn -lcb- 40 mg bid -rcb- did not induce the metabolism of the combination oral drugn drugn / druga -lcb- 1 mg / 35 mcg combination , drugb 1/35 -rcb- .
DDI-DrugBank.d328.s44.p0	valdecoxib	drug	_	Ortho-Novum	brand	_	mechanism	coadministration of druga and drugb 1/35 increased the exposure of drugn and drugn by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s44.p1	valdecoxib	drug	_	norethindrone	drug	_	false	coadministration of druga and drugn 1/35 increased the exposure of drugb and drugn by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s44.p2	valdecoxib	drug	_	ethinyl estradiol	drug	_	false	coadministration of druga and drugn 1/35 increased the exposure of drugn and drugb by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s44.p3	Ortho-Novum	brand	_	norethindrone	drug	_	false	coadministration of drugn and druga 1/35 increased the exposure of drugb and drugn by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s44.p4	Ortho-Novum	brand	_	ethinyl estradiol	drug	_	false	coadministration of drugn and druga 1/35 increased the exposure of drugn and drugb by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s44.p5	norethindrone	drug	_	ethinyl estradiol	drug	_	false	coadministration of drugn and drugn 1/35 increased the exposure of druga and drugb by 20 % and 34 % , respectively .
DDI-DrugBank.d328.s46.p0	norethindrone	drug	_	ethinyl estradiol	drug	_	false	these increased exposures of druga and drugb should be taken into consideration when selecting an oral drugn for women taking drugn .
DDI-DrugBank.d328.s46.p1	norethindrone	drug	_	contraceptive	group	_	false	these increased exposures of druga and drugn should be taken into consideration when selecting an oral drugb for women taking drugn .
DDI-DrugBank.d328.s46.p2	norethindrone	drug	_	valdecoxib	drug	_	false	these increased exposures of druga and drugn should be taken into consideration when selecting an oral drugn for women taking drugb .
DDI-DrugBank.d328.s46.p3	ethinyl estradiol	drug	_	contraceptive	group	_	false	these increased exposures of drugn and druga should be taken into consideration when selecting an oral drugb for women taking drugn .
DDI-DrugBank.d328.s46.p4	ethinyl estradiol	drug	_	valdecoxib	drug	_	false	these increased exposures of drugn and druga should be taken into consideration when selecting an oral drugn for women taking drugb .
DDI-DrugBank.d328.s46.p5	contraceptive	group	_	valdecoxib	drug	_	advise	these increased exposures of drugn and drugn should be taken into consideration when selecting an oral druga for women taking drugb .
DDI-DrugBank.d328.s48.p0	diazepam	drug	_	valdecoxib	drug	_	mechanism	plasma exposure of druga -lcb- 10 mg bid -rcb- was increased by 28 % following administration of drugb -lcb- 40 mg bid -rcb- for # days , while plasma exposure of drugn -lcb- 40 mg bid -rcb- was not substantially increased following administration of drugn -lcb- 10 mg bid -rcb- for # days .
DDI-DrugBank.d328.s48.p1	diazepam	drug	_	valdecoxib	drug	_	false	plasma exposure of druga -lcb- 10 mg bid -rcb- was increased by 28 % following administration of drugn -lcb- 40 mg bid -rcb- for # days , while plasma exposure of drugb -lcb- 40 mg bid -rcb- was not substantially increased following administration of drugn -lcb- 10 mg bid -rcb- for # days .
DDI-DrugBank.d328.s48.p4	valdecoxib	drug	_	diazepam	drug	_	false	plasma exposure of drugn -lcb- 10 mg bid -rcb- was increased by 28 % following administration of druga -lcb- 40 mg bid -rcb- for # days , while plasma exposure of drugn -lcb- 40 mg bid -rcb- was not substantially increased following administration of drugb -lcb- 10 mg bid -rcb- for # days .
DDI-DrugBank.d328.s48.p5	valdecoxib	drug	_	diazepam	drug	_	false	plasma exposure of drugn -lcb- 10 mg bid -rcb- was increased by 28 % following administration of drugn -lcb- 40 mg bid -rcb- for # days , while plasma exposure of druga -lcb- 40 mg bid -rcb- was not substantially increased following administration of drugb -lcb- 10 mg bid -rcb- for # days .
DDI-DrugBank.d328.s49.p0	diazepam	drug	_	valdecoxib	drug	_	false	although the magnitude of changes in druga plasma exposure when coadministered with drugb were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of drugn under this circumstance .
DDI-DrugBank.d328.s49.p2	valdecoxib	drug	_	diazepam	drug	_	effect	although the magnitude of changes in drugn plasma exposure when coadministered with druga were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of drugb under this circumstance .
DDI-DrugBank.d198.s4.p0	Cimetidine	drug	_	vardenafil	drug	_	false	druga -lcb- 400 mg b , i , d , -rcb- had no effect on drugb bioavailability -lcb- auc -rcb- and maximum concentration -lcb- cmax -rcb- of drugn when co-administered with # mg drugn in healthy volunteers .
DDI-DrugBank.d198.s4.p1	Cimetidine	drug	_	vardenafil	drug	_	false	druga -lcb- 400 mg b , i , d , -rcb- had no effect on drugn bioavailability -lcb- auc -rcb- and maximum concentration -lcb- cmax -rcb- of drugb when co-administered with # mg drugn in healthy volunteers .
DDI-DrugBank.d198.s4.p2	Cimetidine	drug	_	Vardenafil	drug	_	false	druga -lcb- 400 mg b , i , d , -rcb- had no effect on drugn bioavailability -lcb- auc -rcb- and maximum concentration -lcb- cmax -rcb- of drugn when co-administered with # mg drugb in healthy volunteers .
DDI-DrugBank.d198.s5.p0	Erythromycin	drug	_	vardenafil	drug	_	mechanism	druga -lcb- 500 mg t , i , d -rcb- produced a 4-fold increase in drugb auc and a 3-fold increase in cmax when co-administered with drugn # mg in healthy volunteers .
DDI-DrugBank.d198.s5.p1	Erythromycin	drug	_	Vardenafil	drug	_	false	druga -lcb- 500 mg t , i , d -rcb- produced a 4-fold increase in drugn auc and a 3-fold increase in cmax when co-administered with drugb # mg in healthy volunteers .
DDI-DrugBank.d198.s6.p0	Vardenafil	drug	_	erythromycin	drug	_	advise	it is recommended not to exceed a single # mg dose of druga in a 24-hour period when used in combination with drugb .
DDI-DrugBank.d198.s7.p0	Ketoconazole	drug	_	vardenafil	drug	_	mechanism	druga -lcb- 200 mg once daily -rcb- produced a 10-fold increase in drugb auc and a 4-fold increase in cmax when co-administered with drugn -lcb- 5 mg -rcb- in healthy volunteers .
DDI-DrugBank.d198.s7.p1	Ketoconazole	drug	_	Vardenafil	drug	_	false	druga -lcb- 200 mg once daily -rcb- produced a 10-fold increase in drugn auc and a 4-fold increase in cmax when co-administered with drugb -lcb- 5 mg -rcb- in healthy volunteers .
DDI-DrugBank.d198.s8.p0	Vardenafil	drug	_	ketoconazole	drug	_	advise	a 5-mg druga dose should not be exceeded when used in combination with # mg once daily drugb .
DDI-DrugBank.d198.s9.p0	ketoconazole	drug	_	Vardenafil	drug	_	false	since higher doses of druga -lcb- 400 mg daily -rcb- may result in higher increases in cmax and auc , a single # mg dose of drugb should not be exceeded in a 24-hour period when used in combination with drugn # mg daily .
DDI-DrugBank.d198.s9.p2	Vardenafil	drug	_	ketoconazole	drug	_	advise	since higher doses of drugn -lcb- 400 mg daily -rcb- may result in higher increases in cmax and auc , a single # mg dose of druga should not be exceeded in a 24-hour period when used in combination with drugb # mg daily .
DDI-DrugBank.d198.s10.p5	Indinavir	drug	_	Vardenafil	drug	_	mechanism	drugn : druga -lcb- 800 mg t , i , d , -rcb- co-administered with drugb # mg resulted in a 16-fold increase in drugn auc , a 7-fold increase in drugn cmax and a 2-fold increase in drugn half-life .
DDI-DrugBank.d198.s10.p6	Indinavir	drug	_	vardenafil	drug	_	false	drugn : druga -lcb- 800 mg t , i , d , -rcb- co-administered with drugn # mg resulted in a 16-fold increase in drugb auc , a 7-fold increase in drugn cmax and a 2-fold increase in drugn half-life .
DDI-DrugBank.d198.s10.p7	Indinavir	drug	_	vardenafil	drug	_	false	drugn : druga -lcb- 800 mg t , i , d , -rcb- co-administered with drugn # mg resulted in a 16-fold increase in drugn auc , a 7-fold increase in drugb cmax and a 2-fold increase in drugn half-life .
DDI-DrugBank.d198.s10.p8	Indinavir	drug	_	vardenafil	drug	_	false	drugn : druga -lcb- 800 mg t , i , d , -rcb- co-administered with drugn # mg resulted in a 16-fold increase in drugn auc , a 7-fold increase in drugn cmax and a 2-fold increase in drugb half-life .
DDI-DrugBank.d198.s11.p0	Vardenafil	drug	_	indinavir	drug	_	advise	it is recommended not to exceed a single # mg druga dose in a 24-hour period when used in combination with drugb .
DDI-DrugBank.d198.s12.p0	Ritonavir	drug	_	Vardenafil	drug	_	mechanism	druga -lcb- 600 mg b , i , d , -rcb- co-administered with drugb # mg resulted in a 49-fold increase in drugn auc and a 13-fold increase in drugn cmax .
DDI-DrugBank.d198.s12.p1	Ritonavir	drug	_	vardenafil	drug	_	false	druga -lcb- 600 mg b , i , d , -rcb- co-administered with drugn # mg resulted in a 49-fold increase in drugb auc and a 13-fold increase in drugn cmax .
DDI-DrugBank.d198.s12.p2	Ritonavir	drug	_	vardenafil	drug	_	false	druga -lcb- 600 mg b , i , d , -rcb- co-administered with drugn # mg resulted in a 49-fold increase in drugn auc and a 13-fold increase in drugb cmax .
DDI-DrugBank.d198.s13.p0	vardenafil	drug	_	ritonavir	drug	_	mechanism	the interaction is a consequence of blocking hepatic metabolism of druga by drugb , a highly potent cyp3a4 inhibitor , which also inhibits cyp2c9 .
DDI-DrugBank.d198.s14.p0	Ritonavir	drug	_	vardenafil	drug	_	mechanism	druga significantly prolonged the half-life of drugb to # hours .
DDI-DrugBank.d198.s15.p0	Vardenafil	drug	_	ritonavir	drug	_	advise	consequently , it is recommended not to exceed a single # mg druga dose in a 72-hour period when used in combination with drugb .
DDI-DrugBank.d198.s16.p0	vardenafil	drug	_	glyburide	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between druga and the following drugs : drugb , drugn , drugn , drugn , and drugn .
DDI-DrugBank.d198.s16.p1	vardenafil	drug	_	warfarin	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between druga and the following drugs : drugn , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d198.s16.p2	vardenafil	drug	_	digoxin	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between druga and the following drugs : drugn , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d198.s16.p3	vardenafil	drug	_	Maalox	brand	_	false	other drug interactions : no pharmacokinetic interactions were observed between druga and the following drugs : drugn , drugn , drugn , drugb , and drugn .
DDI-DrugBank.d198.s16.p4	vardenafil	drug	_	ranitidine	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between druga and the following drugs : drugn , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d198.s16.p5	glyburide	drug	_	warfarin	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : druga , drugb , drugn , drugn , and drugn .
DDI-DrugBank.d198.s16.p6	glyburide	drug	_	digoxin	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : druga , drugn , drugb , drugn , and drugn .
DDI-DrugBank.d198.s16.p8	glyburide	drug	_	ranitidine	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : druga , drugn , drugn , drugn , and drugb .
DDI-DrugBank.d198.s16.p9	warfarin	drug	_	digoxin	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : drugn , druga , drugb , drugn , and drugn .
DDI-DrugBank.d198.s16.p11	warfarin	drug	_	ranitidine	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : drugn , druga , drugn , drugn , and drugb .
DDI-DrugBank.d198.s16.p13	digoxin	drug	_	ranitidine	drug	_	false	other drug interactions : no pharmacokinetic interactions were observed between drugn and the following drugs : drugn , drugn , druga , drugn , and drugb .
DDI-DrugBank.d198.s17.p0	warfarin	drug	_	vardenafil	drug	_	false	in the druga study , drugb had no effect on the prothrombin time or other pharmacodynamic parameters .
DDI-DrugBank.d198.s22.p3	nitrates	group	_	vardenafil	drug	_	mechanism	in vivo studies : drugn : the blood pressure lowering effects of sublingual druga -lcb- # mg -rcb- taken # and # hours after drugb and increases in heart rate when taken at 1 , # and # hours were potentiated by a # mg dose of drugn in healthy middle-aged subjects .
DDI-DrugBank.d198.s22.p4	nitrates	group	_	Vardenafil	drug	_	false	in vivo studies : drugn : the blood pressure lowering effects of sublingual druga -lcb- # mg -rcb- taken # and # hours after drugn and increases in heart rate when taken at 1 , # and # hours were potentiated by a # mg dose of drugb in healthy middle-aged subjects .
DDI-DrugBank.d198.s23.p0	Vardenafil	drug	_	NTG	drug	_	false	these effects were not observed when druga # mg was taken # hours before the drugb .
DDI-DrugBank.d198.s24.p0	nitrates	group	_	Vardenafil	drug	_	false	potentiation of the hypotensive effects of druga for patients with ischemic_heart_disease has not been evaluated , and concomitant use of drugb and drugn is contraindicated .
DDI-DrugBank.d198.s24.p2	Vardenafil	drug	_	nitrates	group	_	advise	potentiation of the hypotensive effects of drugn for patients with ischemic_heart_disease has not been evaluated , and concomitant use of druga and drugb is contraindicated .
DDI-DrugBank.d198.s25.p0	Nifedipine	drug	_	Vardenafil	drug	_	false	druga : drugb # mg , when co-administered with slow-release drugn # mg or # mg once daily , did not affect the relative bioavailability -lcb- auc -rcb- or maximum concentration -lcb- cmax -rcb- of drugn , a drug that is metabolized via cyp3a4 .
DDI-DrugBank.d198.s25.p3	Vardenafil	drug	_	nifedipine	drug	_	false	drugn : druga # mg , when co-administered with slow-release drugb # mg or # mg once daily , did not affect the relative bioavailability -lcb- auc -rcb- or maximum concentration -lcb- cmax -rcb- of drugn , a drug that is metabolized via cyp3a4 .
DDI-DrugBank.d198.s25.p4	Vardenafil	drug	_	nifedipine	drug	_	false	drugn : druga # mg , when co-administered with slow-release drugn # mg or # mg once daily , did not affect the relative bioavailability -lcb- auc -rcb- or maximum concentration -lcb- cmax -rcb- of drugb , a drug that is metabolized via cyp3a4 .
DDI-DrugBank.d198.s26.p0	Nifedipine	drug	_	Vardenafil	drug	_	false	druga did not alter the plasma levels of drugb when taken in combination .
DDI-DrugBank.d198.s27.p0	nifedipine	drug	_	Vardenafil	drug	_	effect	in these patients whose hypertension was controlled with druga , drugb # mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm hg compared to placebo .
DDI-DrugBank.d198.s28.p2	Vardenafil	drug	_	terazosin	drug	_	effect	drugn : when druga # or # mg was given to healthy volunteers either simultaneously or # hours after a # mg dose of drugb , significant hypotension developed in a substantial number of subjects .
DDI-DrugBank.d198.s29.p0	Vardenafil	drug	_	terazosin	drug	_	effect	with simultaneous dosing of druga # mg and drugb # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .
DDI-DrugBank.d198.s30.p0	Vardenafil	drug	_	terazosin	drug	_	effect	with simultaneous dosing of druga # mg and drugb # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .
DDI-DrugBank.d198.s31.p0	Vardenafil	drug	_	terazosin	drug	_	effect	when druga dosing was separated from drugb # mg by # hours , # of # subjects who received # mg of drugn experienced a decrease in standing systolic blood pressure below # mm hg .
DDI-DrugBank.d198.s31.p2	terazosin	drug	_	Vardenafil	drug	_	false	when drugn dosing was separated from druga # mg by # hours , # of # subjects who received # mg of drugb experienced a decrease in standing systolic blood pressure below # mm hg .
DDI-DrugBank.d198.s32.p0	tamsulosin	drug	_	Vardenafil	drug	_	false	in a similar study with druga in healthy volunteers , # of # subjects dosed with drugb # mg and drugn # mg separated by # hours experienced a standing systolic blood pressure below # mm hg .
DDI-DrugBank.d198.s32.p2	Vardenafil	drug	_	tamsulosin	drug	_	effect	in a similar study with drugn in healthy volunteers , # of # subjects dosed with druga # mg and drugb # mg separated by # hours experienced a standing systolic blood pressure below # mm hg .
DDI-DrugBank.d198.s33.p0	Vardenafil	drug	_	tamsulosin	drug	_	effect	two of # subjects dosed simultaneously with druga # mg and drugb # mg experienced a standing systolic blood pressure below # mm hg .
DDI-DrugBank.d198.s34.p0	Vardenafil	drug	_	alpha-blockers	group	_	false	the administration of lower doses of druga with drugb has not been completely evaluated to determine if they can be safely administered together .
DDI-DrugBank.d198.s35.p0	Vardenafil	drug	_	alpha-blocker	group	_	advise	based on these data , druga should not be used in patients on drugb therapy .
DDI-DrugBank.d198.s36.p0	Ritonavir	drug	_	indinavir	drug	_	false	druga and drugb : upon concomitant administration of # mg of drugn with # mg bid drugn , the cmax and auc of drugn were reduced by approximately 20 % .
DDI-DrugBank.d198.s36.p7	Vardenafil	drug	_	ritonavir	drug	_	mechanism	drugn and drugn : upon concomitant administration of # mg of druga with # mg bid drugb , the cmax and auc of drugn were reduced by approximately 20 % .
DDI-DrugBank.d198.s36.p8	Vardenafil	drug	_	ritonavir	drug	_	false	drugn and drugn : upon concomitant administration of # mg of druga with # mg bid drugn , the cmax and auc of drugb were reduced by approximately 20 % .
DDI-DrugBank.d198.s37.p0	Vardenafil	drug	_	indinavir	drug	_	mechanism	upon administration of # mg of druga with # mg tid drugb , the cmax and auc of drugn were reduced by 40 % and 30 % , respectively .
DDI-DrugBank.d198.s37.p1	Vardenafil	drug	_	indinavir	drug	_	false	upon administration of # mg of druga with # mg tid drugn , the cmax and auc of drugb were reduced by 40 % and 30 % , respectively .
DDI-DrugBank.d198.s38.p2	Alcohol	drug	_	vardenafil	drug	_	false	drugn : druga -lcb- # g/kg body weight : approximately # ml of absolute alcohol in a # kg person -rcb- and drugb plasma levels were not altered when dosed simultaneously .
DDI-DrugBank.d198.s39.p0	Vardenafil	drug	_	alcohol	drug	_	false	druga -lcb- 20 mg -rcb- did not potentiate the hypotensive effects of drugb during the 4-hour observation period in healthy volunteers when administered with drugn -lcb- # g/kg body weight -rcb- .
DDI-DrugBank.d198.s39.p1	Vardenafil	drug	_	alcohol	drug	_	false	druga -lcb- 20 mg -rcb- did not potentiate the hypotensive effects of drugn during the 4-hour observation period in healthy volunteers when administered with drugb -lcb- # g/kg body weight -rcb- .
DDI-DrugBank.d198.s40.p2	Vardenafil	drug	_	aspirin	brand	_	false	drugn : druga -lcb- 10 mg and # mg -rcb- did not potentiate the increase in bleeding time caused by drugb -lcb- two # mg tablets -rcb- .
DDI-DrugBank.d198.s41.p0	Vardenafil	drug	_	glyburide	drug	_	false	other interactions : druga had no effect on the pharmacodynamics of drugb -lcb- glucose and irdn concentrations -rcb- and drugn -lcb- prothrombin time or other pharmacodynamic parameters -rcb- .
DDI-DrugBank.d198.s41.p1	Vardenafil	drug	_	warfarin	drug	_	false	other interactions : druga had no effect on the pharmacodynamics of drugn -lcb- glucose and irdn concentrations -rcb- and drugb -lcb- prothrombin time or other pharmacodynamic parameters -rcb- .
DDI-DrugBank.d198.s41.p2	glyburide	drug	_	warfarin	drug	_	false	other interactions : drugn had no effect on the pharmacodynamics of druga -lcb- glucose and irdn concentrations -rcb- and drugb -lcb- prothrombin time or other pharmacodynamic parameters -rcb- .
DDI-DrugBank.d263.s0.p2	ZDV	drug	_	zalcitabine	drug	_	false	drugn : there is no significant pharmacokinetic interaction between druga and drugb which has been confirmed clinically .
DDI-DrugBank.d263.s1.p0	Zalcitabine	drug	_	ZDV	drug	_	effect	druga also has no significant effect on the intracellular phosphorylation of drugb , as shown in vitro in peripheral blood mononuclear cells or in two other cell_line -lcb- u937 and molt-4 -rcb- .
DDI-DrugBank.d263.s2.p0	didanosine	drug	_	stavudine	drug	_	false	in the same study it was shown that druga and drugb had no significant effect on the intracellular phosphorylation of drugn in peripheral blood mononuclear cells .
DDI-DrugBank.d263.s2.p1	didanosine	drug	_	zalcitabine	drug	_	false	in the same study it was shown that druga and drugn had no significant effect on the intracellular phosphorylation of drugb in peripheral blood mononuclear cells .
DDI-DrugBank.d263.s2.p2	stavudine	drug	_	zalcitabine	drug	_	false	in the same study it was shown that drugn and druga had no significant effect on the intracellular phosphorylation of drugb in peripheral blood mononuclear cells .
DDI-DrugBank.d263.s3.p2	lamivudine	drug	_	zalcitabine	drug	_	effect	drugn : in vitro studies in peripheral blood mononuclear cells , u937 and molt-4 cells revealed that druga significantly inhibited drugb phosphorylation in a dose dependent manner .
DDI-DrugBank.d263.s5.p0	Zalcitabine	drug	_	lamivudine	drug	_	effect	druga inhibited drugb phosphorylation at high concentration ratios -lcb- 10 and 100 -rcb- ;
DDI-DrugBank.d263.s6.p1	lamivudine	drug	_	zalcitabine	drug	_	false	however , it is considered to be unlikely that this decrease of phosphorylated druga concentration is of clinical significance , as drugn is a more efficient substrate for dck than drugb .
DDI-DrugBank.d263.s6.p2	lamivudine	drug	_	zalcitabine	drug	_	false	however , it is considered to be unlikely that this decrease of phosphorylated drugn concentration is of clinical significance , as druga is a more efficient substrate for dck than drugb .
DDI-DrugBank.d263.s7.p0	zalcitabine	drug	_	lamivudine	drug	_	effect	these in vitro studies suggest that concomitant administration of druga and drugb in humans may result in sub-therapeutic concentrations of active phosphorylated drugn , which may lead to a decreased drugn effect of drugn .
DDI-DrugBank.d263.s7.p2	zalcitabine	drug	_	antiretroviral	group	_	false	these in vitro studies suggest that concomitant administration of druga and drugn in humans may result in sub-therapeutic concentrations of active phosphorylated drugn , which may lead to a decreased drugb effect of drugn .
DDI-DrugBank.d263.s7.p4	lamivudine	drug	_	zalcitabine	drug	_	false	these in vitro studies suggest that concomitant administration of drugn and druga in humans may result in sub-therapeutic concentrations of active phosphorylated drugb , which may lead to a decreased drugn effect of drugn .
DDI-DrugBank.d263.s7.p5	lamivudine	drug	_	antiretroviral	group	_	false	these in vitro studies suggest that concomitant administration of drugn and druga in humans may result in sub-therapeutic concentrations of active phosphorylated drugn , which may lead to a decreased drugb effect of drugn .
DDI-DrugBank.d263.s7.p6	lamivudine	drug	_	zalcitabine	drug	_	false	these in vitro studies suggest that concomitant administration of drugn and druga in humans may result in sub-therapeutic concentrations of active phosphorylated drugn , which may lead to a decreased drugn effect of drugb .
DDI-DrugBank.d263.s7.p7	zalcitabine	drug	_	antiretroviral	group	_	false	these in vitro studies suggest that concomitant administration of drugn and drugn in humans may result in sub-therapeutic concentrations of active phosphorylated druga , which may lead to a decreased drugb effect of drugn .
DDI-DrugBank.d263.s7.p9	antiretroviral	group	_	zalcitabine	drug	_	false	these in vitro studies suggest that concomitant administration of drugn and drugn in humans may result in sub-therapeutic concentrations of active phosphorylated drugn , which may lead to a decreased druga effect of drugb .
DDI-DrugBank.d263.s9.p0	zalcitabine	drug	_	lamivudine	drug	_	advise	concomitant use of druga and drugb is not recommended .
DDI-DrugBank.d263.s10.p0	Saquinavir	drug	_	HIVID	drug	_	false	druga : the combination of drugb , drugn , and drugn has been studied -lcb- as triple combination -rcb- in adults .
DDI-DrugBank.d263.s10.p2	Saquinavir	drug	_	ZDV	drug	_	false	druga : the combination of drugn , drugn , and drugb has been studied -lcb- as triple combination -rcb- in adults .
DDI-DrugBank.d263.s14.p0	HIVID	drug	_	didanosine	drug	_	advise	concomitant use of druga with drugb is not recommended .
DDI-DrugBank.d263.s15.p0	Pentamidine	drug	_	HIVID	drug	_	false	intravenous druga : treatment with drugb should be interrupted when the use of a drug that has the potential to cause pancreatitis is required .
DDI-DrugBank.d263.s16.p0	pentamidine	drug	_	HIVID	drug	_	effect	death due to fulminant pancreatitis possibly related to intravenous druga and drugb has been reported .
DDI-DrugBank.d263.s17.p0	pentamidine	drug	_	HIVID	drug	_	advise	if intravenous druga is required to treat pneumocystis carinii pneumonia , treatment with drugb should be interrupted .
DDI-DrugBank.d263.s18.p1	Amphotericin	drug	_	Aminoglycosides	group	_	false	druga , drugn , and drugb : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p3	Amphotericin	drug	_	foscarnet	drug	_	false	druga , drugn , and drugn : drugs such as drugn , drugb , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p4	Amphotericin	drug	_	aminoglycosides	group	_	false	druga , drugn , and drugn : drugs such as drugn , drugn , and drugb may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p5	Amphotericin	drug	_	HIVID	drug	_	false	druga , drugn , and drugn : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p6	Amphotericin	drug	_	zalcitabine	drug	_	false	druga , drugn , and drugn : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p8	Foscarnet	drug	_	amphotericin	drug	_	false	drugn , druga , and drugn : drugs such as drugb , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p10	Foscarnet	drug	_	aminoglycosides	group	_	false	drugn , druga , and drugn : drugs such as drugn , drugn , and drugb may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p11	Foscarnet	drug	_	HIVID	drug	_	false	drugn , druga , and drugn : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p12	Foscarnet	drug	_	zalcitabine	drug	_	false	drugn , druga , and drugn : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p13	Aminoglycosides	group	_	amphotericin	drug	_	false	drugn , drugn , and druga : drugs such as drugb , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p14	Aminoglycosides	group	_	foscarnet	drug	_	false	drugn , drugn , and druga : drugs such as drugn , drugb , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p16	Aminoglycosides	group	_	HIVID	drug	_	false	drugn , drugn , and druga : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p17	Aminoglycosides	group	_	zalcitabine	drug	_	false	drugn , drugn , and druga : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p20	amphotericin	drug	_	HIVID	drug	_	effect	drugn , drugn , and drugn : drugs such as druga , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p21	amphotericin	drug	_	zalcitabine	drug	_	mechanism	drugn , drugn , and drugn : drugs such as druga , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p23	foscarnet	drug	_	HIVID	drug	_	effect	drugn , drugn , and drugn : drugs such as drugn , druga , and drugn may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p24	foscarnet	drug	_	zalcitabine	drug	_	mechanism	drugn , drugn , and drugn : drugs such as drugn , druga , and drugn may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p25	aminoglycosides	group	_	HIVID	drug	_	effect	drugn , drugn , and drugn : drugs such as drugn , drugn , and druga may increase the risk of developing peripheral_neuropathies or other drugb - associated adverse events by interfering with the renal clearance of drugn -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p26	aminoglycosides	group	_	zalcitabine	drug	_	mechanism	drugn , drugn , and drugn : drugs such as drugn , drugn , and druga may increase the risk of developing peripheral_neuropathies or other drugn - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s18.p27	HIVID	drug	_	zalcitabine	drug	_	false	drugn , drugn , and drugn : drugs such as drugn , drugn , and drugn may increase the risk of developing peripheral_neuropathies or other druga - associated adverse events by interfering with the renal clearance of drugb -lcb- thereby raising systemic exposure -rcb- .
DDI-DrugBank.d263.s20.p0	Probenecid	drug	_	Cimetidine	drug	_	false	druga or drugb : concomitant administration of drugn or drugn decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p2	Probenecid	drug	_	cimetidine	drug	_	false	druga or drugn : concomitant administration of drugn or drugb decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p3	Probenecid	drug	_	zalcitabine	drug	_	false	druga or drugn : concomitant administration of drugn or drugn decreases the elimination of drugb , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p4	Probenecid	drug	_	zalcitabine	drug	_	false	druga or drugn : concomitant administration of drugn or drugn decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugb .
DDI-DrugBank.d263.s20.p5	Cimetidine	drug	_	probenecid	drug	_	false	drugn or druga : concomitant administration of drugb or drugn decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p7	Cimetidine	drug	_	zalcitabine	drug	_	false	drugn or druga : concomitant administration of drugn or drugn decreases the elimination of drugb , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p8	Cimetidine	drug	_	zalcitabine	drug	_	false	drugn or druga : concomitant administration of drugn or drugn decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugb .
DDI-DrugBank.d263.s20.p9	probenecid	drug	_	cimetidine	drug	_	false	drugn or drugn : concomitant administration of druga or drugb decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p10	probenecid	drug	_	zalcitabine	drug	_	mechanism	drugn or drugn : concomitant administration of druga or drugn decreases the elimination of drugb , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p11	probenecid	drug	_	zalcitabine	drug	_	false	drugn or drugn : concomitant administration of druga or drugn decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugb .
DDI-DrugBank.d263.s20.p12	cimetidine	drug	_	zalcitabine	drug	_	mechanism	drugn or drugn : concomitant administration of drugn or druga decreases the elimination of drugb , most likely by inhibition of renal tubular secretion of drugn .
DDI-DrugBank.d263.s20.p13	cimetidine	drug	_	zalcitabine	drug	_	false	drugn or drugn : concomitant administration of drugn or druga decreases the elimination of drugn , most likely by inhibition of renal tubular secretion of drugb .
DDI-DrugBank.d263.s22.p0	Magnesium	drug	_	Aluminum	drug	_	false	druga / drugb - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p1	Magnesium	drug	_	Antacid Products	group	_	false	druga / drugn - containing drugb : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p2	Magnesium	drug	_	zalcitabine	drug	_	false	druga / drugn - containing drugn : absorption of drugb is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p4	Magnesium	drug	_	aluminum	drug	_	false	druga / drugn - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugb - containing drugn .
DDI-DrugBank.d263.s22.p5	Magnesium	drug	_	antacid products	group	_	false	druga / drugn - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugb .
DDI-DrugBank.d263.s22.p6	Aluminum	drug	_	Antacid Products	group	_	false	drugn / druga - containing drugb : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p7	Aluminum	drug	_	zalcitabine	drug	_	false	drugn / druga - containing drugn : absorption of drugb is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p8	Aluminum	drug	_	magnesium	drug	_	false	drugn / druga - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugb / drugn - containing drugn .
DDI-DrugBank.d263.s22.p10	Aluminum	drug	_	antacid products	group	_	false	drugn / druga - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugb .
DDI-DrugBank.d263.s22.p11	Antacid Products	group	_	zalcitabine	drug	_	false	drugn / drugn - containing druga : absorption of drugb is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugn .
DDI-DrugBank.d263.s22.p12	Antacid Products	group	_	magnesium	drug	_	false	drugn / drugn - containing druga : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugb / drugn - containing drugn .
DDI-DrugBank.d263.s22.p13	Antacid Products	group	_	aluminum	drug	_	false	drugn / drugn - containing druga : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugb - containing drugn .
DDI-DrugBank.d263.s22.p15	zalcitabine	drug	_	magnesium	drug	_	false	drugn / drugn - containing drugn : absorption of druga is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugb / drugn - containing drugn .
DDI-DrugBank.d263.s22.p16	zalcitabine	drug	_	aluminum	drug	_	false	drugn / drugn - containing drugn : absorption of druga is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugb - containing drugn .
DDI-DrugBank.d263.s22.p17	zalcitabine	drug	_	antacid products	group	_	false	drugn / drugn - containing drugn : absorption of druga is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / drugn - containing drugb .
DDI-DrugBank.d263.s22.p19	magnesium	drug	_	antacid products	group	_	false	drugn / drugn - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with druga / drugn - containing drugb .
DDI-DrugBank.d263.s22.p20	aluminum	drug	_	antacid products	group	_	false	drugn / drugn - containing drugn : absorption of drugn is moderately reduced -lcb- approximately 25 % -rcb- when coadministered with drugn / druga - containing drugb .
DDI-DrugBank.d263.s23.p0	zalcitabine	drug	_	magnesium	drug	_	advise	the clinical significance of this reduction is not known , hence druga is not recommended to be ingested simultaneously with drugb / drugn - containing drugn .
DDI-DrugBank.d263.s23.p1	zalcitabine	drug	_	aluminum	drug	_	advise	the clinical significance of this reduction is not known , hence druga is not recommended to be ingested simultaneously with drugn / drugb - containing drugn .
DDI-DrugBank.d263.s23.p2	zalcitabine	drug	_	antacids	group	_	advise	the clinical significance of this reduction is not known , hence druga is not recommended to be ingested simultaneously with drugn / drugn - containing drugb .
DDI-DrugBank.d263.s23.p4	magnesium	drug	_	antacids	group	_	false	the clinical significance of this reduction is not known , hence drugn is not recommended to be ingested simultaneously with druga / drugn - containing drugb .
DDI-DrugBank.d263.s23.p5	aluminum	drug	_	antacids	group	_	false	the clinical significance of this reduction is not known , hence drugn is not recommended to be ingested simultaneously with drugn / druga - containing drugb .
DDI-DrugBank.d263.s24.p2	zalcitabine	drug	_	metoclopramide	drug	_	mechanism	drugn : bioavailability is mildly reduced -lcb- approximately 10 % -rcb- when druga and drugb are coadministered .
DDI-DrugBank.d263.s25.p2	Doxorubicin	drug	_	zalcitabine	drug	_	effect	drugn : druga caused a decrease in drugb phosphorylation -lcb- 50 % inhibition of total phosphate formation -rcb- in u937/molt # cells .
DDI-DrugBank.d324.s1.p4	Sonata	brand	_	ethanol	drug	_	effect	cns-active drugs drugn : druga # mg potentiated the cns-impairing effects of drugb # g/kg on balance testing and reaction time for # hour after drugn administration and on the digit symbol substitution test -lcb- dsst -rcb- , symbol copying test , and the variability component of the divided attention test for # hours after drugn administration .
DDI-DrugBank.d324.s1.p5	Sonata	brand	_	ethanol	drug	_	false	cns-active drugs drugn : druga # mg potentiated the cns-impairing effects of drugn # g/kg on balance testing and reaction time for # hour after drugb administration and on the digit symbol substitution test -lcb- dsst -rcb- , symbol copying test , and the variability component of the divided attention test for # hours after drugn administration .
DDI-DrugBank.d324.s1.p6	Sonata	brand	_	ethanol	drug	_	false	cns-active drugs drugn : druga # mg potentiated the cns-impairing effects of drugn # g/kg on balance testing and reaction time for # hour after drugn administration and on the digit symbol substitution test -lcb- dsst -rcb- , symbol copying test , and the variability component of the divided attention test for # hours after drugb administration .
DDI-DrugBank.d324.s3.p0	zaleplon	drug	_	ethanol	drug	_	false	druga did not affect the pharmacokinetics of drugb .
DDI-DrugBank.d324.s4.p0	Imipramine	drug	_	Sonata	brand	_	false	druga : coadministration of single doses of drugb # mg and drugn # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .
DDI-DrugBank.d324.s4.p2	Sonata	brand	_	imipramine	drug	_	effect	drugn : coadministration of single doses of druga # mg and drugb # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .
DDI-DrugBank.d324.s6.p0	Paroxetine	drug	_	Sonata	brand	_	false	druga : coadministration of a single dose of drugb # mg and drugn # mg daily for # days did not produce any interaction on psychomotor performance .
DDI-DrugBank.d324.s6.p2	Sonata	brand	_	paroxetine	drug	_	false	drugn : coadministration of a single dose of druga # mg and drugb # mg daily for # days did not produce any interaction on psychomotor performance .
DDI-DrugBank.d324.s7.p0	paroxetine	drug	_	Sonata	brand	_	false	additionally , druga did not alter the pharmacokinetics of drugb , reflecting the absence of a role of cyp2d6 in drugn s metabolism .
DDI-DrugBank.d324.s7.p1	paroxetine	drug	_	zaleplon	drug	_	false	additionally , druga did not alter the pharmacokinetics of drugn , reflecting the absence of a role of cyp2d6 in drugb s metabolism .
DDI-DrugBank.d324.s7.p2	Sonata	brand	_	zaleplon	drug	_	false	additionally , drugn did not alter the pharmacokinetics of druga , reflecting the absence of a role of cyp2d6 in drugb s metabolism .
DDI-DrugBank.d324.s8.p0	Thioridazine	drug	_	Sonata	brand	_	false	druga : coadministration of single doses of drugb # mg and drugn # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .
DDI-DrugBank.d324.s8.p2	Sonata	brand	_	thioridazine	drug	_	effect	drugn : coadministration of single doses of druga # mg and drugb # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .
DDI-DrugBank.d324.s10.p0	Venlafaxine	drug	_	zaleplon	drug	_	false	druga : coadministration of a single dose of drugb # mg and multiple doses of drugn er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d324.s10.p2	Venlafaxine	drug	_	zaleplon	drug	_	false	druga : coadministration of a single dose of drugn # mg and multiple doses of drugn er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d324.s10.p4	zaleplon	drug	_	venlafaxine	drug	_	false	drugn : coadministration of a single dose of druga # mg and multiple doses of drugb er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either drugn or drugn .
DDI-DrugBank.d324.s10.p6	zaleplon	drug	_	venlafaxine	drug	_	false	drugn : coadministration of a single dose of druga # mg and multiple doses of drugn er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either drugn or drugb .
DDI-DrugBank.d324.s10.p7	venlafaxine	drug	_	zaleplon	drug	_	false	drugn : coadministration of a single dose of drugn # mg and multiple doses of druga er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either drugb or drugn .
DDI-DrugBank.d324.s10.p9	zaleplon	drug	_	venlafaxine	drug	_	false	drugn : coadministration of a single dose of drugn # mg and multiple doses of drugn er -lcb- extended release -rcb- # mg did not result in any significant changes in the pharmacokinetics of either druga or drugb .
DDI-DrugBank.d324.s11.p0	zaleplon	drug	_	venlafaxine	drug	_	false	in addition , there was no pharmacodynamic interaction as a result of coadministration of druga and drugb er .
DDI-DrugBank.d324.s12.p0	Promethazine	drug	_	zaleplon	drug	_	false	druga : coadministration of a single dose of drugb and drugn -lcb- 10 and # mg , respectively -rcb- resulted in a 15 % decrease in maximal plasma concentrations of drugn , but no change in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s12.p2	Promethazine	drug	_	zaleplon	drug	_	false	druga : coadministration of a single dose of drugn and drugn -lcb- 10 and # mg , respectively -rcb- resulted in a 15 % decrease in maximal plasma concentrations of drugb , but no change in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s12.p3	zaleplon	drug	_	promethazine	drug	_	mechanism	drugn : coadministration of a single dose of druga and drugb -lcb- 10 and # mg , respectively -rcb- resulted in a 15 % decrease in maximal plasma concentrations of drugn , but no change in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s12.p5	promethazine	drug	_	zaleplon	drug	_	false	drugn : coadministration of a single dose of drugn and druga -lcb- 10 and # mg , respectively -rcb- resulted in a 15 % decrease in maximal plasma concentrations of drugb , but no change in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s13.p0	zaleplon	drug	_	promethazine	drug	_	false	however , the pharmacodynamics of coadministration of druga and drugb have not been evaluated .
DDI-DrugBank.d324.s16.p0	rifampin	drug	_	zaleplon	drug	_	mechanism	multiple-dose administration of the potent cyp3a4 inducer druga -lcb- 600 mg every # hours , q24h , for # days -rcb- , however , reduced drugb cmax and auc by approximately 80 % .
DDI-DrugBank.d324.s18.p0	hypnotic agent	group	_	rifampin	drug	_	false	an alternative non-cyp3a4 substrate druga may be considered in patients taking cyp3a4 inducers such as drugb , drugn , drugn , and drugn .
DDI-DrugBank.d324.s18.p1	hypnotic agent	group	_	phenytoin	drug	_	false	an alternative non-cyp3a4 substrate druga may be considered in patients taking cyp3a4 inducers such as drugn , drugb , drugn , and drugn .
DDI-DrugBank.d324.s18.p2	hypnotic agent	group	_	carbamazepine	drug	_	false	an alternative non-cyp3a4 substrate druga may be considered in patients taking cyp3a4 inducers such as drugn , drugn , drugb , and drugn .
DDI-DrugBank.d324.s18.p3	hypnotic agent	group	_	phenobarbital	drug	_	false	an alternative non-cyp3a4 substrate druga may be considered in patients taking cyp3a4 inducers such as drugn , drugn , drugn , and drugb .
DDI-DrugBank.d324.s20.p0	zaleplon	drug	_	erythromycin	drug	_	mechanism	coadministration of single , oral doses of druga with drugb -lcb- 10 mg and # mg , respectively -rcb- , a strong , selective cyp3a4 inhibitor produced a 34 % increase in drugn s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s20.p2	erythromycin	drug	_	zaleplon	drug	_	false	coadministration of single , oral doses of drugn with druga -lcb- 10 mg and # mg , respectively -rcb- , a strong , selective cyp3a4 inhibitor produced a 34 % increase in drugb s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .
DDI-DrugBank.d324.s22.p0	ketoconazole	drug	_	zaleplon	drug	_	mechanism	other strong selective cyp3a4 inhibitors such as druga can also be expected to increase the exposure of drugb .
DDI-DrugBank.d324.s26.p0	zaleplon	drug	_	diphenhydramine	drug	_	false	there is no pharmacokinetic interaction between druga and drugb following the administration of a single dose -lcb- 10 mg and # mg , respectively -rcb- of each drug .
DDI-DrugBank.d324.s28.p2	Cimetidine	drug	_	zaleplon	drug	_	mechanism	drugs that inhibit both aldehyde oxidase and cyp3a4 drugn : druga inhibits both aox1 -lcb- in vitro -rcb- and cyp3a4 -lcb- in vitro and in vivo -rcb- , the primary and secondary enzymes , respectively , responsible for drugb metabolism .
DDI-DrugBank.d324.s29.p0	Sonata	brand	_	cimetidine	drug	_	mechanism	concomitant administration of druga -lcb- 10 mg -rcb- and drugb -lcb- 800 mg -rcb- produced an 85 % increase in the mean cmax and auc of drugn .
DDI-DrugBank.d324.s29.p1	Sonata	brand	_	zaleplon	drug	_	false	concomitant administration of druga -lcb- 10 mg -rcb- and drugn -lcb- 800 mg -rcb- produced an 85 % increase in the mean cmax and auc of drugb .
DDI-DrugBank.d324.s29.p2	cimetidine	drug	_	zaleplon	drug	_	false	concomitant administration of drugn -lcb- 10 mg -rcb- and druga -lcb- 800 mg -rcb- produced an 85 % increase in the mean cmax and auc of drugb .
DDI-DrugBank.d324.s34.p2	Sonata	brand	_	digoxin	drug	_	false	drugs with a narrow therapeutic index drugn : druga -lcb- 10 mg -rcb- did not affect the pharmacokinetic or pharmacodynamic profile of drugb -lcb- # mg q24h for # days -rcb- .
DDI-DrugBank.d324.s35.p3	Sonata	brand	_	warfarin	drug	_	false	drugn : multiple oral doses of druga -lcb- 20 mg q24h for # days -rcb- did not affect the pharmacokinetics of drugb -lcb- r + -rcb- - or -lcb- s - -rcb- - enantiomers or the pharmacodynamics -lcb- prothrombin time -rcb- following a single 25-mg oral dose of drugn .
DDI-DrugBank.d324.s35.p4	Sonata	brand	_	warfarin	drug	_	false	drugn : multiple oral doses of druga -lcb- 20 mg q24h for # days -rcb- did not affect the pharmacokinetics of drugn -lcb- r + -rcb- - or -lcb- s - -rcb- - enantiomers or the pharmacodynamics -lcb- prothrombin time -rcb- following a single 25-mg oral dose of drugb .
DDI-DrugBank.d324.s37.p0	zaleplon	drug	_	ibuprofen	drug	_	false	there was no apparent pharmacokinetic interaction between druga and drugb following single dose administration -lcb- 10 mg and # mg , respectively -rcb- of each drug .
